<SEC-DOCUMENT>0001657312-23-000006.txt : 20230307
<SEC-HEADER>0001657312-23-000006.hdr.sgml : 20230307
<ACCEPTANCE-DATETIME>20230307084714
ACCESSION NUMBER:		0001657312-23-000006
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		86
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230307
DATE AS OF CHANGE:		20230307

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Verona Pharma plc
		CENTRAL INDEX KEY:			0001657312
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38067
		FILM NUMBER:		23711133

	BUSINESS ADDRESS:	
		STREET 1:		3 MORE LONDON RIVERSIDE
		CITY:			LONDON
		STATE:			X0
		ZIP:			SE1 2RE
		BUSINESS PHONE:		011-44-0-2032834200

	MAIL ADDRESS:	
		STREET 1:		3 MORE LONDON RIVERSIDE
		CITY:			LONDON
		STATE:			X0
		ZIP:			SE1 2RE
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>vrna-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:3c4b6351-9dd7-43ec-8a74-8bad3a93c534,g:ba5c393f-9b46-4696-9211-0bc9a20ff330,d:c8555b0a0e574cdcb5428a00447fe322--><html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:vrna="http://veronapharma.com/20221231" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>vrna-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl80L2ZyYWc6MzA1MTAyYzY2OTAxNDAyM2EzYzczNjNjNjgxMzFlMmEvdGFibGU6N2U4YTZkNzQyZTQ1NDk4NTkyY2ZjZGQ0MTkwM2FkZTAvdGFibGVyYW5nZTo3ZThhNmQ3NDJlNDU0OTg1OTJjZmNkZDQxOTAzYWRlMF8zLTEtMS0xLTU5MTI3_eb8d78c5-84fb-4fc6-a805-ef769838fbe1">false</ix:nonNumeric><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl80L2ZyYWc6MzA1MTAyYzY2OTAxNDAyM2EzYzczNjNjNjgxMzFlMmEvdGFibGU6N2U4YTZkNzQyZTQ1NDk4NTkyY2ZjZGQ0MTkwM2FkZTAvdGFibGVyYW5nZTo3ZThhNmQ3NDJlNDU0OTg1OTJjZmNkZDQxOTAzYWRlMF80LTEtMS0xLTU5MTI3_a70ddbae-cc59-48d9-a04a-e072b80b486c">2022</ix:nonNumeric><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl80L2ZyYWc6MzA1MTAyYzY2OTAxNDAyM2EzYzczNjNjNjgxMzFlMmEvdGFibGU6N2U4YTZkNzQyZTQ1NDk4NTkyY2ZjZGQ0MTkwM2FkZTAvdGFibGVyYW5nZTo3ZThhNmQ3NDJlNDU0OTg1OTJjZmNkZDQxOTAzYWRlMF81LTEtMS0xLTU5MTI3_e291100e-79c0-4cef-94e0-25814e56ab5c">FY</ix:nonNumeric><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl80L2ZyYWc6MzA1MTAyYzY2OTAxNDAyM2EzYzczNjNjNjgxMzFlMmEvdGFibGU6N2U4YTZkNzQyZTQ1NDk4NTkyY2ZjZGQ0MTkwM2FkZTAvdGFibGVyYW5nZTo3ZThhNmQ3NDJlNDU0OTg1OTJjZmNkZDQxOTAzYWRlMF82LTEtMS0xLTU5MTI3_d8c9ed14-4f05-49b0-b8c8-c014a9f043f9">0001657312</ix:nonNumeric><ix:nonNumeric contextRef="icf154344047d460588bc54417f0e3d9b_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzQ1MDg_ff010e70-9a6d-4e4c-a482-a7e0d106f1e3">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="ie22e6682054147c4961ab22e3d0b6106_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzgyMg_06949a37-1fa3-4277-8388-a28ff5d09dc6">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="vrna-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8686e244a6e42d3a8ac63e71fe128c3_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="iaade0201ae634843939c414628a28829_I20230303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i46f03490e9ee4cdfbbb33910795928d1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id40f0f069eba45cba259ca5e4029e3c6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="gbpPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i914d9cdf65d04c2f90fe005e7472a193_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i628f4c337d8a4907b099660435d9a654_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7f0ec0ed1784d75a7a6870bf8e210e8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bcd9fdf0b49455fbda9ed3d6b4ffe6a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f35aecd3e8247dab76bb02c4f16b0fc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if80b5e08771841e98a3888a3388c32e2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if823f7d8c92d4955b417d2877d92cf1e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i380ad8bec02d4cef80ab1e2a0293509c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrna:AtTheMarketSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i375548ad8ff84bd0982f3bccb9de8503_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrna:AtTheMarketSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i442b161bf35c4276ac36992d05e23115_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrna:AtTheMarketSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2541a30ef7e84fc1925bf03d916e97a2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8a8c7eae65b43e9a11fdf51f5b2d5d8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib56e759a9ec24aa88f41a41be62db95d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia773a9ee14f34d1a8dc7c9d57c7401e1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ece18e799b840598f8450de9ee4fb80_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8f5a4cc91e843d384ab12b09f91edb8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i609c9125fe4c4df8b724395ec47768f6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2df52cddbf6047d99bc4c33dc209f75a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i079c0a66af1a4b4f8579073c30a06c55_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrna:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibab55600f3bc40aa902c283296c411ce_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrna:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d11dce15ffe46c5a3f318667309b215_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrna:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2af5163aa9d84dad89a011496414bdd2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrna:AtTheMarketSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i111533997c354eed8392ec995f25323f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrna:AtTheMarketSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i979239b8c81f4ce297052fdb5fcfb029_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrna:AtTheMarketSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6d783db1d43419d8f15b7dc0a5bcb2d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1aae0c0ff8a846889a7cab3fe123941d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9ea6a1e50f743c7b2706c4f275812bf_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91456de939c649aabb7986b2e37d0859_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25dfa9d20fe64551adbf52bf5cde91b6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica49ccad51694417b0ecd16ca773ee2b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79d67ed1de10489aa0bb85ba9c0ec74a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9383bef872e64838b59e60f52963eea3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="subsidiary"><xbrli:measure>vrna:subsidiary</xbrli:measure></xbrli:unit><xbrli:context id="ie238e662ca594fb8b2c61e9a8e7cc2b7_D20220815-20220815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vrna:AmericanDepositorySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrna:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-15</xbrli:startDate><xbrli:endDate>2022-08-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice1cf713bbb6461a9be47f13e6cb343f_I20220815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-08-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ieb1aa532b71f489d849b821859d2f380_I20220815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vrna:AmericanDepositorySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrna:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i184e0ab9d5a54b338f38f20780281582_D20220815-20220815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vrna:AmericanDepositorySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-15</xbrli:startDate><xbrli:endDate>2022-08-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bd8f835b5424f209ef20622393563fe_D20220815-20220815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrna:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-15</xbrli:startDate><xbrli:endDate>2022-08-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia867c724f1754d6b8ce8489a52865172_I20221014"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:OxfordTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6f1e5c7e48647c0920bd6e598622618_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:TermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5b573c06bda4d9abf4c5788689f8267_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vrna:AmericanDepositorySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i527c9fac13d64a47b9bf9214236f60e2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vrna:AmericanDepositorySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6695925fbed543f894ece49ef4cdea3a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vrna:AmericanDepositorySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51dfe19fdb8b4c94be7f8c486773856a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vrna:AmericanDepositorySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic554433105b34f27be03700dabfb47f7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vrna:AmericanDepositorySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8aef53e83ae8405d96c0bb866c6a4b44_D20230101-20230303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a0e931dedec4d268138428467b28255_D20230101-20230303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vrna:AmericanDepositorySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i947febb528b2492baff336d20285fda1_I20230303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icff757a8f7aa4258a984848491ccbe0b_I20230303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vrna:AmericanDepositorySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf154344047d460588bc54417f0e3d9b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12dbdc5aaf3b4090a92274f569107ad3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>vrna:segment</xbrli:measure></xbrli:unit><xbrli:context id="i1ffe1b3cbbcb48709153748921695a17_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i562a8171ec384150b25fc8dac4d3d04a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vrna:LondonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id194ff6c8cf4476bad35353399857ce0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vrna:LondonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie824d87e23bd49a6b8466e65062ab474_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8b9d9c7ed4d45b39aee6fc8c9e89a1e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia06c5918648040c2b8e5e55554c67cb2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vrna:MeasurementInputAnnualizedVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc128abfb89243b6bb31d0ca13db2070_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30e7bb276e12407b8476499428f6f60a_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:TermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90f55e89f14448548416cbd47cfb6cf9_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:TermBLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie69772c787fa46e283c35e0159c9ed3b_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:TermCLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10a520855ec54e2da16ba70468d0a51b_I20221014"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:OxfordTermALoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="loanadvance"><xbrli:measure>vrna:loanAdvance</xbrli:measure></xbrli:unit><xbrli:context id="i3541a8c38127458ba1aae3fdc52c63d5_I20221014"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:OxfordTermBCDELoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic244fa4c95204e0e8dcfaefb2e6b8237_I20221014"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:OxfordTermBLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22eac3eaf4ba4678a0eb3d0971d09767_I20221014"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:OxfordTermCLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48aaa74363db4fc7b8d8426a1eff5049_I20221014"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:OxfordTermDLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id04385f9e7774756bbf90a20930f80ec_I20221014"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:OxfordTermELoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbe1ef2d7eb14330b2e19597ed9f08da_D20221014-20221014"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:OxfordTermALoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="vrna:InterestRatePeriodAxis">vrna:DebtInstrumentInterestRatePeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-14</xbrli:startDate><xbrli:endDate>2022-10-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic419bc3e647a4ca9a2757dc9edc5107d_D20221014-20221014"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:OxfordTermALoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="vrna:InterestRatePeriodAxis">vrna:DebtInstrumentInterestRatePeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-14</xbrli:startDate><xbrli:endDate>2022-10-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i428494c244664464882b178b3d34c37f_D20221014-20221014"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:OxfordTermALoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="vrna:InterestRatePeriodAxis">vrna:DebtInstrumentInterestRatePeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-14</xbrli:startDate><xbrli:endDate>2022-10-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d4b040098df4fc3a356ffafd5e4b830_D20221014-20221014"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:OxfordTermALoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="vrna:InterestRatePeriodAxis">vrna:DebtInstrumentInterestRatePeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-14</xbrli:startDate><xbrli:endDate>2022-10-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77e399a94d574a9c9520217f5ebd6515_D20221014-20221014"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:OxfordTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-14</xbrli:startDate><xbrli:endDate>2022-10-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ad954ea881e4224a373e39507e05382_D20221014-20221014"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:OxfordTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-14</xbrli:startDate><xbrli:endDate>2022-10-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife6bb65a13724831ab4e8d78c473f147_D20221014-20221014"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:OxfordTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-14</xbrli:startDate><xbrli:endDate>2022-10-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d76374535984c8fbfde48cfb17a2b35_D20221014-20221014"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:OxfordTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-14</xbrli:startDate><xbrli:endDate>2022-10-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2014cf02dad94153af60f28551c0469c_D20220301-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrna:LigandUKDevelopmentLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa2a4633d09c407a94ff8f3507d2318d_D20220301-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="vrna:BenchmarkAchievementAxis">vrna:FirstCommercialSaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrna:LigandUKDevelopmentLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="tradingday"><xbrli:measure>vrna:tradingDay</xbrli:measure></xbrli:unit><xbrli:context id="ia63bdd4aff86454a9544c5c56ab3a539_D20220301-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrna:LigandUKDevelopmentLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44405a18d6cc405cab4ed043524c8fde_I20210609"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrna:NuanceShanghaiPharmaCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ed4c5f1e427439596625fc8558417f6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrna:NuanceShanghaiPharmaCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib45dfb15713741578ce57657f76c641a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrna:NuanceShanghaiPharmaCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbecaaa2e50f422788c7776146b6f738_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrna:NuanceShanghaiPharmaCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie22e6682054147c4961ab22e3d0b6106_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9abfa929c414b3a8a9f9e7a5436d4f3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ef7ac44600e4b82bd5f7115b1d6d54d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01712b818a734e4a92734201de78b797_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7233af3af0bd4811889a59bfd4f27031_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i119cc232d51e4fbb9e1d846ac2bd0d41_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26d09ecdd3a64d1a8904a12f454da71e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a6b7ded42314692aa873d8195ffbd32_I20060918"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrna:EMIOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2006-09-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20dbfdab854c46fdaca99b937c1a2004_I20120724"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrna:PreIPOOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-07-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ce1126e308447edb0ce8f68eda07d48_D20170401-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrna:PreIPOOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-04-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4854c977bffc4921b1f1611822527f5d_D20170401-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrna:EMIOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-04-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd6f70b91dd0435991ce621ce894613c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrna:EMIOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5476c2b57bb84c3c9a60aba57bb6d479_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrna:PreIPOOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fd6a66dcd33401c900f14a24e099e1b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrna:A2017IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="rate"><xbrli:measure>utr:Rate</xbrli:measure></xbrli:unit><xbrli:context id="ic23d87e5f60a4b6cbb480b4fd31b6c15_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28bc6028d27549bdbe82ed5d76e8a4d3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47d19bc9bec84458b044241464c4ca53_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i659b636bd9904c8884a0708f012c5d76_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0887a875bbe3456c88ad04cb88647ce3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic01569d19cb64fe9a0f5cf16691732dd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b874456201746c6bb2d1caa6f13eeed_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cb073618a12467ebf16ed58054c7606_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b5ab64a3a124f8683b6125306368d23_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00a363abd6ea427e834a199f24664952_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vrna:RestrictedStockUnitTimeBasedVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1754f1ba19694c9bb318a7a84afebbe8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vrna:RestrictedStockUnitTimeBasedVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i280f6b8ea0fa434cb722279e0e05373e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vrna:RestrictedStockUnitMilestoneBasedVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f452df8cc584b6c9688098f4a50632f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vrna:RestrictedStockUnitMilestoneBasedVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9240e12e8374554928914a1dfb017fb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c61487d635a4696b64cde5303229764_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a63b0b903ee4acab0480335043b47f5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i709ea29e7e7249da99a23ab89c643290_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1b945830df8444a9ed8c6acd123c8b9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001657312</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ic8555b0a0e574cdcb5428a00447fe322_1"></div><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Washington, D.C. 20549 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGV4dHJlZ2lvbjpiM2ZiNDFlMGQ5OTU0ZjVkODkwZWYzNDdjYTRmMzRiOV80MDQz_ff200151-8460-4932-8d09-2c8629af66e0">10-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGV4dHJlZ2lvbjpiM2ZiNDFlMGQ5OTU0ZjVkODkwZWYzNDdjYTRmMzRiOV80MDM2_dd8a964b-1705-49a7-b715-a78291b70152">&#9746;</ix:nonNumeric>&#160;&#160;&#160;&#160;ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGV4dHJlZ2lvbjpiM2ZiNDFlMGQ5OTU0ZjVkODkwZWYzNDdjYTRmMzRiOV8yMDQ_fe7f2e2d-4eae-418e-b56e-79cc516e28df"><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGV4dHJlZ2lvbjpiM2ZiNDFlMGQ5OTU0ZjVkODkwZWYzNDdjYTRmMzRiOV8yMDQ_20368bcd-00cc-459b-a92d-118a6fc04597">December 31</ix:nonNumeric>, 2022</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">OR </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGV4dHJlZ2lvbjpiM2ZiNDFlMGQ5OTU0ZjVkODkwZWYzNDdjYTRmMzRiOV80MDQ1_989b70a8-3da4-4e10-b90e-f10cd51e7af2">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">FOR THE TRANSITION PERIOD FROM __________ TO __________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGV4dHJlZ2lvbjpiM2ZiNDFlMGQ5OTU0ZjVkODkwZWYzNDdjYTRmMzRiOV80MDQ4_0db8e31b-8fc0-44e3-a7f6-176573ac5ec8">001-38067</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGV4dHJlZ2lvbjpiM2ZiNDFlMGQ5OTU0ZjVkODkwZWYzNDdjYTRmMzRiOV80MDUy_4ef3e30f-e260-4b73-879a-34d648f9d12a">Verona Pharma plc</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of Registrant as specified in its Charter) </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGFibGU6NTk1ODYxMTFjNTY5NDhiMDk2YWQ4MTJjOTI4OTYxZWMvdGFibGVyYW5nZTo1OTU4NjExMWM1Njk0OGIwOTZhZDgxMmM5Mjg5NjFlY18wLTAtMS0xLTU5MTI3_362f94fb-a56a-4c5f-b273-c5b7042d85d9">United Kingdom</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGFibGU6NTk1ODYxMTFjNTY5NDhiMDk2YWQ4MTJjOTI4OTYxZWMvdGFibGVyYW5nZTo1OTU4NjExMWM1Njk0OGIwOTZhZDgxMmM5Mjg5NjFlY18wLTMtMS0xLTU5MTI3_73a8aae0-006b-4498-8d7f-1dbf5c34efd3">98-1489389</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(I.R.S. Employer Identification No.)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGFibGU6NTk1ODYxMTFjNTY5NDhiMDk2YWQ4MTJjOTI4OTYxZWMvdGFibGVyYW5nZTo1OTU4NjExMWM1Njk0OGIwOTZhZDgxMmM5Mjg5NjFlY18zLTAtMS0xLTU5MTI3L3RleHRyZWdpb246ZGI2MDYyYTZhNWIwNDBmNjkzNDg5Yzc0MzEzNmVmMGNfNQ_e7dd8cd6-65ab-4e53-952c-30d442a3e1ca">3 More London Riverside</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGFibGU6NTk1ODYxMTFjNTY5NDhiMDk2YWQ4MTJjOTI4OTYxZWMvdGFibGVyYW5nZTo1OTU4NjExMWM1Njk0OGIwOTZhZDgxMmM5Mjg5NjFlY18zLTAtMS0xLTU5MTI3L3RleHRyZWdpb246ZGI2MDYyYTZhNWIwNDBmNjkzNDg5Yzc0MzEzNmVmMGNfOA_a8bce48f-6663-403e-b436-e2618f55040d">London</ix:nonNumeric> <ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGFibGU6NTk1ODYxMTFjNTY5NDhiMDk2YWQ4MTJjOTI4OTYxZWMvdGFibGVyYW5nZTo1OTU4NjExMWM1Njk0OGIwOTZhZDgxMmM5Mjg5NjFlY18zLTAtMS0xLTU5MTI3L3RleHRyZWdpb246ZGI2MDYyYTZhNWIwNDBmNjkzNDg5Yzc0MzEzNmVmMGNfMTE_a775d6e6-f394-41e2-a847-c613ed5a13a9">SE1 2RE</ix:nonNumeric> <ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGFibGU6NTk1ODYxMTFjNTY5NDhiMDk2YWQ4MTJjOTI4OTYxZWMvdGFibGVyYW5nZTo1OTU4NjExMWM1Njk0OGIwOTZhZDgxMmM5Mjg5NjFlY18zLTAtMS0xLTU5MTI3L3RleHRyZWdpb246ZGI2MDYyYTZhNWIwNDBmNjkzNDg5Yzc0MzEzNmVmMGNfMTQ_e7095e92-fcf7-4a2f-a3d6-36b6c4a366ea">United Kingdom</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(Address of principal executive offices)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(Zip Code)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: +<ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="dei:CountryRegion" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGV4dHJlZ2lvbjpiM2ZiNDFlMGQ5OTU0ZjVkODkwZWYzNDdjYTRmMzRiOV80MDM3_be4e8ae5-f053-462f-8538-1757a783ec0e">44</ix:nonNumeric> <ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGV4dHJlZ2lvbjpiM2ZiNDFlMGQ5OTU0ZjVkODkwZWYzNDdjYTRmMzRiOV80MDQ5_1f0a5415-10a1-4a0e-8c73-a766f8d4913b">203</ix:nonNumeric> <ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGV4dHJlZ2lvbjpiM2ZiNDFlMGQ5OTU0ZjVkODkwZWYzNDdjYTRmMzRiOV80MDUw_dd0776b9-4b4b-4a62-b737-ccf7c31cb3b1">283 4200</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:42.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.882%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGFibGU6YjFiMWEyZGEyY2FlNDkxNDljMTIzNjRjYmEzYzEwOWIvdGFibGVyYW5nZTpiMWIxYTJkYTJjYWU0OTE0OWMxMjM2NGNiYTNjMTA5Yl8xLTAtMS0xLTU5MTI3_21b9034d-2b40-4e9c-926a-93fc71e2ca0d">Ordinary shares, nominal value &#163;0.05 per share*</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGFibGU6YjFiMWEyZGEyY2FlNDkxNDljMTIzNjRjYmEzYzEwOWIvdGFibGVyYW5nZTpiMWIxYTJkYTJjYWU0OTE0OWMxMjM2NGNiYTNjMTA5Yl8xLTEtMS0xLTU5MTI3_a293c042-5737-4a10-9062-88b3f8676aee">VRNA</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The Nasdaq Stock Market LLC (<ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGFibGU6YjFiMWEyZGEyY2FlNDkxNDljMTIzNjRjYmEzYzEwOWIvdGFibGVyYW5nZTpiMWIxYTJkYTJjYWU0OTE0OWMxMjM2NGNiYTNjMTA5Yl8xLTItMS0xLTU5MTI3L3RleHRyZWdpb246MmFmZTQ3ODM0NmI5NGM5NDkzMWY2MGFjNjk4OGQ4ZGVfMzM_71837bdc-8e3d-45f1-9702-77f630186aca">Nasdaq Global Market</ix:nonNumeric>)</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* The ordinary shares are represented by American Depositary Shares (each representing 8 ordinary shares), which are exempt from the operation of Section 12(a) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 12a-8 thereunder.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(g) of the Act:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">None</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. <ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGV4dHJlZ2lvbjpiM2ZiNDFlMGQ5OTU0ZjVkODkwZWYzNDdjYTRmMzRiOV8yNDczOTAxMTYyOTUzNw_dfb163f9-1b8f-407b-99bf-c5fc8cd03752">Yes</ix:nonNumeric> &#9746; No &#9744;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes &#9744; <ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGV4dHJlZ2lvbjpiM2ZiNDFlMGQ5OTU0ZjVkODkwZWYzNDdjYTRmMzRiOV80MDM4_862c8b01-ba3d-4d9a-b092-11e65d373ea0">No</ix:nonNumeric> &#9746;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGV4dHJlZ2lvbjpiM2ZiNDFlMGQ5OTU0ZjVkODkwZWYzNDdjYTRmMzRiOV80MDQ2_ce655380-bb6d-448d-84a2-74339959f98b">Yes</ix:nonNumeric> &#9746; No &#9744;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGV4dHJlZ2lvbjpiM2ZiNDFlMGQ5OTU0ZjVkODkwZWYzNDdjYTRmMzRiOV80MDQ3_0ea40d34-4251-47c6-887f-d16882b7be4b">Yes</ix:nonNumeric> &#9746; No &#9744;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.397%"><tr><td style="width:1.0%"></td><td style="width:43.036%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.808%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.808%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.036%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.812%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated filer&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGFibGU6MDhmMjNiNzQ5NjI1NGJjYTg4MjA2MmMzNjllOGNkZTcvdGFibGVyYW5nZTowOGYyM2I3NDk2MjU0YmNhODgyMDYyYzM2OWU4Y2RlN18xLTAtMS0xLTU5MTI3_bc8f5fd2-4297-4d02-bc97-844b713a379a">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Small reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGFibGU6MDhmMjNiNzQ5NjI1NGJjYTg4MjA2MmMzNjllOGNkZTcvdGFibGVyYW5nZTowOGYyM2I3NDk2MjU0YmNhODgyMDYyYzM2OWU4Y2RlN18xLTQtMS0xLTU5MTI3_5642daba-1025-4bb6-89a5-86d4f87c301c">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGFibGU6MDhmMjNiNzQ5NjI1NGJjYTg4MjA2MmMzNjllOGNkZTcvdGFibGVyYW5nZTowOGYyM2I3NDk2MjU0YmNhODgyMDYyYzM2OWU4Y2RlN18yLTQtMS0xLTU5MTI3_34c69152-34bf-46d0-a2fb-1dad2b6cb0e9">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  &#9744;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  <ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGV4dHJlZ2lvbjpiM2ZiNDFlMGQ5OTU0ZjVkODkwZWYzNDdjYTRmMzRiOV80MDQw_304291f8-9fd8-48ef-b0f6-dcea7e87b311">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes &#9744;    No <ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGV4dHJlZ2lvbjpiM2ZiNDFlMGQ5OTU0ZjVkODkwZWYzNDdjYTRmMzRiOV8yNDczOTAxMTYyOTYxNw_109f2697-fa65-46fc-b796-6b78db4dc297">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The aggregate market value of the registrant's voting and non-voting common equity held by non-affiliates was approximately $<ix:nonFraction unitRef="usd" contextRef="id8686e244a6e42d3a8ac63e71fe128c3_I20220630" decimals="-5" name="dei:EntityPublicFloat" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGV4dHJlZ2lvbjpiM2ZiNDFlMGQ5OTU0ZjVkODkwZWYzNDdjYTRmMzRiOV8zMDQ3_7c4915fc-7de9-48b5-af8c-1ed06c7a6699">212.1</ix:nonFraction> million as of June 30, 2022, the last business day of the registrant's most recently completed second fiscal quarter. Solely for purposes of this disclosure, shares held by executive officers, directors and certain shareholders of the registrant as of such date have been excluded because such persons or entities may be deemed to be affiliates of the registrant. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As of March 3, 2023, the registrant had <ix:nonFraction unitRef="shares" contextRef="iaade0201ae634843939c414628a28829_I20230303" decimals="0" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGV4dHJlZ2lvbjpiM2ZiNDFlMGQ5OTU0ZjVkODkwZWYzNDdjYTRmMzRiOV8zNDU1_4a049a84-c1eb-4260-89c7-ae4ce171f594">631,904,598</ix:nonFraction> ordinary shares, nominal value &#163;0.05 per share, outstanding, which if all held in ADS form, would be represented by 78,988,075 American Depositary Shares, each representing eight (8) ordinary shares.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGV4dHJlZ2lvbjpiM2ZiNDFlMGQ5OTU0ZjVkODkwZWYzNDdjYTRmMzRiOV80MDQy_ab7a42a5-b730-430a-ba32-1898100066c9" escape="true">Portions of the registrant&#8217;s definitive proxy statement that the registrant intends to file with the Securities and Exchange Commission pursuant to Regulation 14A in connection with the registrant&#8217;s 2023 Annual Meeting of Shareholders are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.</ix:nonNumeric> </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="ic8555b0a0e574cdcb5428a00447fe322_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">GENERAL INFORMATION</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">All references in this Annual Report on Form 10-K (the &#8220;Annual Report&#8221;), to &#8220;Verona,&#8221; the &#8220;company,&#8221; the "group", &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Verona Pharma plc and its consolidated subsidiaries. In this Annual Report, the U.S. Securities and Exchange Commission is referred to as the &#8220;SEC&#8221;, the Securities Act of 1933, as amended, is referred to as the &#8220;Securities Act&#8221; and the Securities Exchange Act of 1934, as amended, is referred to as the &#8220;Exchange Act.&#8221;</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">TRADEMARKS, TRADENAMES AND SERVICE MARKS</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">This Annual Report may include trademarks, tradenames and service marks that are the property of other organizations. Solely for convenience, trademarks and tradenames referred to in this Annual Report appear without the &#174; and &#8482; symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner will not assert its rights, to these trademarks and tradenames.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">This Annual Report contains statements that constitute forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. All statements other than statements of historical facts contained in this Annual Report, including without limitation statements regarding our future results of operations and financial position, business strategy and plans and objectives of management for future operations, the development of ensifentrine or any other product candidates, including statements regarding the expected initiation, timing, progress and availability of data from our clinical trials and potential regulatory approvals and the expected regulations applicable to ensifentrine, research and development costs, timing and likelihood of success, potential collaborations, the duration of our patent portfolio, our estimates regarding expenses, future revenues, capital requirements, debt service obligations and our need for additional financing, the funding we expect to become available under the Oxford Term Loan and from cash receipts from U.K. tax credits, and the sufficiency of our cash and cash equivalents to fund operations, are forward-looking statements. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The forward-looking statements in this Annual Report are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Annual Report and are subject to a number of known and unknown risks, uncertainties and assumptions, including the important factors described under the sections in this Annual Report entitled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and in our other filings with the SEC.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. We intend the forward-looking statements contained in this Annual Report to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">This Annual Report contains market data and industry forecasts that were obtained from industry publications. These data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. We have not independently verified any third-party information. While we believe the market position, market opportunity and market size information included in this Annual Report is generally reliable, such information is inherently imprecise.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">SUMMARY RISK FACTORS</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our business is subject to numerous risks and uncertainties, including those described in Part I, Item 1A. &#8220;Risk Factors&#8221; in this Annual Report. You should carefully consider these risks and uncertainties when investing in our ADSs. The principal risks and uncertainties affecting our business include the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">We have a limited operating history and have never generated any product revenue;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">We may need additional funding to complete development of and commercialize ensifentrine and any future product candidates, if approved, or develop and commercialize other formulations or target indications of ensifentrine, if approved;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">The advances under the $150.0 million Oxford Term Loan are contingent upon achievement of certain clinical and regulatory milestones and other specified conditions. If we fail to meet those conditions, we will need to find alternative sources of funding;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Changes in our tax rates, unavailability of certain tax credits or reliefs or exposure to additional tax liabilities or assessments could affect our profitability, and audits by tax authorities could result in additional tax payments for prior periods;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">We depend solely on the success of ensifentrine, our only product candidate under development;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Ensifentrine may have serious adverse, undesirable or unacceptable side effects which may delay or prevent marketing approval;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">If we are unable to enroll patients in our clinical trials, or enrollment is slower than anticipated, our research and development efforts could be adversely affected;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">We may become exposed to costly and damaging liability claims, either when testing ensifentrine in the clinic or at the commercial stage, and our product liability insurance may not cover all damages from such claims;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Regulatory approval processes are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for ensifentrine, our business will be substantially harmed;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize ensifentrine and may affect the prices we may set;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">We operate in a highly competitive and rapidly changing industry, which may result in others discovering, developing or commercializing competing products before or more successfully than we do;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">We rely, and expect to continue to rely, on third parties, including independent clinical investigators and clinical research organizations, to conduct our pre-clinical studies and clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">The collaboration and license agreement with Nuance Pharma is important to our business. If Nuance Pharma is unable to develop and commercialize products containing ensifentrine in Greater China, if we or Nuance Pharma fail to adequately perform under the Nuance Agreement, or if we or Nuance Pharma terminate the Nuance Agreement, our business would be adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">If we fail to enter into new strategic relationships for ensifentrine, our business, research and development and commercialization prospects could be adversely affected;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">We currently rely on third-party manufacturers and suppliers for production of the active pharmaceutical ingredient ensifentrine and its derived formulated products. Our dependence on these third parties may impair the advancement of our research and development programs and the development of ensifentrine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">We rely on patents and other intellectual property rights to protect ensifentrine, the enforcement, defense and maintenance of which may be challenging and costly;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent which might adversely affect our ability to develop, manufacture and market ensifentrine;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">We may be involved in lawsuits to protect or enforce patents covering ensifentrine, which could be expensive, time consuming and unsuccessful, and issued patents could be found invalid or unenforceable if challenged in court;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Our future growth and ability to compete depends on our ability to retain our key personnel and recruit additional qualified personnel;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">We expect to expand our development, regulatory and sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">The price of our American Depositary Shares may be volatile and may fluctuate due to factors beyond our control; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">We will continue to incur increased costs as a result of operating as a public company in the United States, and our senior management are required to devote substantial time to new compliance initiatives and corporate governance practices.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="ic8555b0a0e574cdcb5428a00447fe322_13"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.516%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Table of Contents</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Part I</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_16">Item 1.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_16">Business</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic8555b0a0e574cdcb5428a00447fe322_16">1</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_19">Item 1A.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_19">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic8555b0a0e574cdcb5428a00447fe322_19">34</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_22">Item 1B.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_22">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic8555b0a0e574cdcb5428a00447fe322_22">80</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_25">Item 2.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_25">Properties</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic8555b0a0e574cdcb5428a00447fe322_25">80</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_28">Item 3.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_28">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic8555b0a0e574cdcb5428a00447fe322_28">81</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_31">Item 4.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_31">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic8555b0a0e574cdcb5428a00447fe322_31">81</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Part II</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_37">Item 5.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_37">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic8555b0a0e574cdcb5428a00447fe322_37">82</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_40">Item 6.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_40">[Reserved]</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic8555b0a0e574cdcb5428a00447fe322_40">82</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_43">Item 7.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_43">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic8555b0a0e574cdcb5428a00447fe322_43">82</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_49">Item 7A.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_49">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_52">Item 8.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_52">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic8555b0a0e574cdcb5428a00447fe322_52">93</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_55">Item 9.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_55">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic8555b0a0e574cdcb5428a00447fe322_55">93</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_58">Item 9A.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_58">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic8555b0a0e574cdcb5428a00447fe322_58">93</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_61">Item 9B.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_61">Other Information</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic8555b0a0e574cdcb5428a00447fe322_61">94</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_64">Item 9C.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_64">Disclosures Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic8555b0a0e574cdcb5428a00447fe322_64">94</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Part III</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_70">Item 10.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_70">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic8555b0a0e574cdcb5428a00447fe322_70">95</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_73">Item 11.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_73">Executive Compensation</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic8555b0a0e574cdcb5428a00447fe322_73">95</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_76">Item 12.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_76">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic8555b0a0e574cdcb5428a00447fe322_76">95</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_79">Item 13.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_79">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic8555b0a0e574cdcb5428a00447fe322_79">95</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_82">Item 14.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_82">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic8555b0a0e574cdcb5428a00447fe322_82">95</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Part IV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_88">Item 15.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_88">Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic8555b0a0e574cdcb5428a00447fe322_88">96</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_91">Item 16.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_94">Form 10-K Summary</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic8555b0a0e574cdcb5428a00447fe322_91">97</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_94">Signatures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic8555b0a0e574cdcb5428a00447fe322_94">98</a></span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="ic8555b0a0e574cdcb5428a00447fe322_16"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 1.&#160;&#160;&#160;&#160;Business</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">OVERVIEW</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical need. Our product candidate, ensifentrine, is an investigational, first-in-class, inhaled, selective, dual inhibitor of the enzymes phosphodiesterase 3 and 4 (&#8220;PDE3&#8221; and &#8220;PDE4&#8221;), combining bronchodilator and non-steroidal anti-inflammatory activities in one compound. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Initially, we are developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (&#8220;COPD&#8221;), a common, chronic, progressive, and life-threatening respiratory disease without a cure. If successfully developed, ensifentrine would be the first therapeutic with a novel mode of action for COPD in over a decade.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">During 2022, we reported positive top-line results from both of our Phase 3 ENHANCE (&#8220;Ensifentrine as a Novel inHAled Nebulized COPD thErapy&#8221;) trials evaluating nebulized ensifentrine for the maintenance treatment of COPD. Ensifentrine met the primary endpoint in both the ENHANCE-1 and ENHANCE-2 trials demonstrating statistically significant and clinically meaningful improvements in measures of lung function. In addition, ensifentrine substantially reduced the rate and risk of COPD exacerbations in ENHANCE-1 and ENHANCE-2. Ensifentrine was well tolerated in both trials.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Based on the results from our ENHANCE program, we believe ensifentrine, if approved, has the potential to change the treatment paradigm for COPD. The totality of data from clinical trials, in particular top-line results from the ENHANCE program, support our belief. We plan to submit a New Drug Application (&#8220;NDA&#8221;) to the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in the second quarter of 2023 for inhaled ensifentrine for the maintenance treatment of COPD.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If approved, we intend to commercialize inhaled ensifentrine for the maintenance treatment of COPD in the United States (&#8220;U.S.&#8221;). Although we believe ensifentrine will not be regulated as a drug device combination, patients use a readily available standard jet nebulizer to take ensifentrine. Outside the US, we intend to license ensifentrine to companies with expertise and experience in developing and commercializing products in those regions. To that end, we have entered into a strategic collaboration with Nuance Pharma Limited, a Shanghai-based specialty pharmaceutical company (&#8220;Nuance Pharma&#8221;), to develop and commercialize ensifentrine in Greater China.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In Phase 2 clinical trials, ensifentrine has demonstrated positive results in patients with COPD, asthma and cystic fibrosis (&#8220;CF&#8221;). Two additional formulations of ensifentrine have been evaluated in Phase 2 trials for the treatment of COPD: dry powder inhaler (&#8220;DPI&#8221;) and pressurized metered-dose inhaler (&#8220;pMDI&#8221;). </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Overview of COPD and current treatments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">COPD is a common, progressive, life-threatening respiratory disease without a cure. It causes loss of lung function, leading to debilitating breathlessness, hospitalizations, and death. COPD has a major impact on everyday life. Patients struggle with basic activities such as getting out of bed, showering, eating, and walking. Worldwide, COPD affects approximately 384 million people and is the third leading cause of death, according to the Global Initiative for Chronic Obstructive Lung Disease.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The goal of COPD pharmacological therapy is to improve patients&#8217; quality of life by reducing symptoms, decreasing the quantity and severity of exacerbations (often an escalation of symptoms) and to improve patients&#8217; ability to function.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">For approximately 40 years, the treatment of COPD has been dominated by three classes of inhaled therapies approved for use by the FDA and the European Commission based on the European Medicines Agency&#8217;s (&#8220;EMA&#8221;) opinion: anti-muscarinics, beta-agonists and inhaled corticosteroids (&#8220;ICSs&#8221;). COPD patients are frequently treated with bronchodilators, including long-acting anti-muscarinics (&#8220;LAMAs&#8221;) and long-acting beta-agonists (&#8220;LABAs&#8221;), to relieve airway constriction and make it easier to breathe. In addition, patients at risk for exacerbations may be prescribed ICSs to prevent them. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Certain COPD patients are treated with the oral PDE4 inhibitor, roflumilast (Daliresp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">), which has demonstrated a reduction in exacerbation risk in patients with severe chronic bronchitis. However, oral PDE4 therapy results in systemic exposure, which has been associated with unfavorable gastrointestinal side-effects such as nausea, emesis, diarrhea, abdominal pain, loss of appetite and weight loss.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Approximately 8.5 million COPD patients in the U.S. receive LAMA, LABA, or ICS treatments alone or in combination regardless of COPD severity. Despite these medications and the earlier use of dual (LAMA/LABA) and triple (LAMA/LABA/ICS) therapies, many patients continue to suffer debilitating symptoms. According to a December 2022 study by Phreesia, 45% of patients continue to have symptoms more than 24 days a month. This burden leaves a significant opportunity for new inhaled therapies that offer additional benefit added to the three main classes of treatment. New treatment options are urgently needed to help improve lung function and symptoms, reduce exacerbations and improve overall quality of life in these patients.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Ensifentrine</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Ensifentrine is an investigational, first-in-class, inhaled, small molecule and selective, dual PDE3 and PDE4 inhibitor. This dual inhibition enables it to act as a bronchodilator and a non-steroidal anti-inflammatory agent in a single compound. Importantly, ensifentrine&#8217;s therapeutic profile differentiates it from existing classes of bronchodilator and anti-inflammatory treatments. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are not aware of any other single compound in clinical development in the U.S. or Europe or approved by the FDA nor the European Commission for the treatm</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">ent of respiratory diseases that acts both as a bronchodilator and anti-inflammatory agent. If successfully developed and approved, ensifentrine has the potential to be the first novel class of therapeutic in COPD in over 10 years and to become the only bronchodilator option that could be added to existing classes of inhaled therapies including LAMA, LABA and ICS.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Safety profile</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Ensifentrine has been well tolerated in clinical trials involving approximately 3,000 subjects to date. Additionally, ensifentrine did not prolong the QT interval or impact other cardiac conduction parameters in a thorough QT study in healthy volunteers. It is delivered directly to the lungs by inhalation to maximize pulmonary exposure to ensifentrine while minimizing systemic exposure. This feature minimizes any systemic side-effects such as the gastrointestinal disturbance associated with oral PDE4 inhibitors. In addition, in non-clinical trials ensifentrine has demonstrated high selectivity for PDE3 and PDE4 over other enzymes and receptors, which is believed to minimize off-target effects.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Differentiated profile</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">By selectively inhibiting PDE3 and PDE4, ensifentrine impacts three key mechanisms in respiratory disease: bronchodilation, inflammation and mucociliary clearance. Ensifentrine is designed to increase the levels of cellular cAMP and cGMP in smooth muscle cells and inflammatory cells, resulting in bronchodilator and anti-inflammatory effects. Ensifentrine has also been shown to stimulate the cystic fibrosis transmembrane conductance regulator (&#8220;CFTR&#8221;), which is an ion channel in the epithelial cells lining the airways. Mutations in the CFTR protein result in poorly or non-functioning ion channels, which cause CF. CFTR dysfunction is also potentially important in COPD. CFTR stimulation leads to improved electrolyte balance in the lung and thinning of the mucus, which facilitates mucociliary clearance and leads to improved lung function and potentially a reduction in lung infections. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Dual inhibition of PDE3 and PDE4 has shown enhanced or synergistic effects compared with inhibition of either PDE alone on contraction of airway smooth muscle and suppression of inflammatory mediator release in several preclinical studies. We believe these enhanced effects may increase the utility of ensifentrine in the treatment of respiratory diseases including COPD, asthma and CF. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><img src="vrna-20221231_g1.jpg" alt="vrna-20221231_g1.jpg" style="height:388px;margin-bottom:5pt;vertical-align:text-bottom;width:725px"/></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Clinical data</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Phase 2b</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Ensifentrine has demonstrated improvements in lung function, symptoms and quality of life with or without background therapy in two 4-week, Phase 2b dose-ranging clinical trials in moderate to severe COPD patients. In both studies ensifentrine was well tolerated at all doses with an adverse event profile similar to placebo:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">In March 2018, we reported positive top-line results with ensifentrine as monotherapy from our first Phase 2b trial in 403 patients. The trial evaluated four doses of nebulized ensifentrine (0.75 mg, 1.5 mg, 3 mg and 6 mg) or placebo twice daily over 4 weeks. Patients withheld use of regular long-acting bronchodilator therapy for the duration of the study. The trial met its primary endpoint of improved lung function with ensifentrine demonstrating a clinically and statistically significant increase in peak forced expiratory volume in 1 second (&#8220;FEV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:1.41pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221;) at week 4 compared to placebo. In addition, clinically relevant secondary endpoints were met including significant progressive improvements in COPD symptoms. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">In January 2020, we reported positive top-line results with ensifentrine added on to background therapy from our second Phase 2b trial in 413 patients. This trial evaluated four doses of nebulized ensifentrine (0.375 mg, 0.75 mg, 1.5 mg and 3 mg) or placebo added on to treatment with once-daily tiotropium (Spiriva</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> Respimat</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">), a commonly used LAMA bronchodilator, in symptomatic patients with moderate to severe COPD who required additional treatment. The trial met its primary endpoint of improved lung function, with ensifentrine plus tiotropium demonstrating a clinically and statistically significant dose-dependent improvement in peak FEV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:1.41pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> and FEV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:1.41pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> over 12 hours with ensifentrine at week 4, compared to placebo plus tiotropium. Additionally, clinically meaningful and statistically significant improvements in health-related quality of life were observed with ensifentrine added on to tiotropium. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><img src="vrna-20221231_g2.jpg" alt="vrna-20221231_g2.jpg" style="height:422px;margin-bottom:5pt;vertical-align:text-bottom;width:750px"/></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Phase 3 ENHANCE program</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Ensifentrine has successfully met the primary endpoints in two randomized, double-blind, placebo-controlled Phase 3 trials, ENHANCE-1 and ENHANCE-2, demonstrating statistically significant and clinically meaningful improvements in measures of lung function in moderate to severe COPD patients. Improvements in symptoms and quality of life measures were shown in both trials, which reached statistical significance in ENHANCE-1. Ensifentrine substantially reduced the rate and risk of moderate to severe COPD exacerbations in both trials. Ensifentrine was well tolerated in both trials.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The ENHANCE trials were designed to evaluate ensifentrine as monotherapy and added onto a single bronchodilator with approximately 50% of subjects receiving either a LAMA or a LABA. Additionally, approximately 20% of subjects received ICSs with their concomitant LAMA or LABA.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Each trial enrolled approximately 800 subjects, for a total of approximately 1,600 subjects, at sites primarily in the U.S. and Europe. The two trials provided replicate evidence of efficacy and safety data over 24 weeks and ENHANCE-1 also evaluated longer-term safety in approximately 400 subjects over 48 weeks.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><img src="vrna-20221231_g3.jpg" alt="vrna-20221231_g3.jpg" style="height:480px;margin-bottom:5pt;vertical-align:text-bottom;width:700px"/></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject demographics and disease characteristics were well balanced between treatment groups in both trials.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">In ENHANCE-1 approximately 69% of subjects received background COPD therapy, either LAMA or a LABA. Additionally, approximately 20% of all subjects received ICS with concomitant LAMA or LABA.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">In ENHANCE-2 approximately 55% of subjects received background COPD therapy, either a LAMA or a LABA. Additionally, approximately 15% of all subjects received ICS with concomitant LAMA or LABA.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><img src="vrna-20221231_g4.jpg" alt="vrna-20221231_g4.jpg" style="height:397px;margin-bottom:5pt;vertical-align:text-bottom;width:750px"/></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We reported positive top-line results from ENHANCE-2 and ENHANCE-1, in August and December 2022, respectively. Ensifentrine successfully met the primary endpoints in both trials, demonstrating statistically significant and clinically meaningful improvements in measures of lung function in moderate to severe COPD patients. Improvements in symptoms and quality of life measures were shown in both trials, which reached statistical significance in ENHANCE-1. Ensifentrine substantially reduced the rate and risk of moderate to severe COPD exacerbations and was well tolerated in both trials.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Highlights</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Primary endpoint met (FEV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AUC 0-12 hr)</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Placebo corrected, change from baseline in average FEV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:1.41pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> area under the curve 0-12 hours post dose at week 12 was 87 mL (p&lt;0.0001) for ensifentrine in ENHANCE-1 and 94 mL (p&lt;0.0001) for ensifentrine in ENHANCE-2.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Demonstrated consistent improvements with ensifentrine in all subgroups including gender, age, smoking status, COPD severity, background medication, ICS use, chronic bronchitis, FEV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:1.41pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> reversibility and geographic region.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Secondary endpoints evaluating lung function met:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Placebo corrected, increase in peak FEV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:1.41pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> of 147 mL (p&lt;0.0001) 0-4 hours post dose at week 12 in ENHANCE-1 and 146 mL (p&lt;0.0001) in ENHANCE-2.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Placebo corrected, increase in morning trough FEV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:1.41pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> of 35 mL (p=0.0413) at week 12 in ENHANCE-1 and 49 mL (p=0.0016) in ENHANCE-2, supporting twice daily dosing regimen.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><img src="vrna-20221231_g5.jpg" alt="vrna-20221231_g5.jpg" style="height:376px;margin-bottom:5pt;vertical-align:text-bottom;width:750px"/></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exacerbation rate and risk reduced</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Subjects receiving ensifentrine demonstrated a 36% reduction in the rate of moderate to severe COPD exacerbations over 24 weeks (p=0.0503) compared to those receiving placebo in ENHANCE-1 and a 43% reduction (p=0.0090) in ENHANCE-2.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><img src="vrna-20221231_g6.jpg" alt="vrna-20221231_g6.jpg" style="height:372px;margin-bottom:5pt;vertical-align:text-bottom;width:750px"/></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="padding-right:-18pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">In pooled exacerbation data from ENHANCE-1 and ENHANCE-2, ensifentrine demonstrated a 40% reduction in the rate of moderate to severe COPD exacerbations over 24 weeks (p=0.0012) compared to those receiving placebo. </span></div><div style="text-align:center"><img src="vrna-20221231_g7.jpg" alt="vrna-20221231_g7.jpg" style="height:264px;margin-bottom:5pt;vertical-align:text-bottom;width:700px"/></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Treatment with ensifentrine significantly decreased the risk of a moderate/severe exacerbation as measured by time to first exacerbation when compared with placebo by 38% (p=0.0382) in ENHANCE-1 and by 42% (p=0.0089) in ENHANCE-2.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="text-align:center"><img src="vrna-20221231_g8.jpg" alt="vrna-20221231_g8.jpg" style="height:458px;margin-bottom:5pt;vertical-align:text-bottom;width:750px"/></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">In pooled exacerbation data from ENHANCE-1 and ENHANCE-2, ensifentrine significantly decreased the risk of a moderate/severe exacerbation as measured by time to first exacerbation when compared with placebo by 41% (p=0.0009).</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><img src="vrna-20221231_g9.jpg" alt="vrna-20221231_g9.jpg" style="height:398px;margin-bottom:5pt;vertical-align:text-bottom;width:700px"/></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COPD symptoms and Quality of Life </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;QOL&#8221;)</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">In ENHANCE-1, daily symptoms as measured by E-RS* Total Score in the ensifentrine group improved from baseline to greater than the minimal clinically important difference (&#8220;MCID&#8221;) of -2 units with a statistically significant improvement compared to placebo at week 24. Improvements in symptoms were early and sustained with statistical significance versus placebo at weeks 6, 12 and 24. Similar improvements were demonstrated in ENHANCE-2 but statistical significance was not achieved due to improvements observed in the placebo group over time.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><img src="vrna-20221231_g10.jpg" alt="vrna-20221231_g10.jpg" style="height:362px;margin-bottom:5pt;vertical-align:text-bottom;width:700px"/></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">In ENHANCE-1, QOL as measured by SGRQ* Total Score in the ensifentrine group improved from baseline to greater than the MCID of -4 units with a statistically significant improvement compared to placebo at week 24. Improvements in QOL were early and sustained with statistical significance versus placebo at weeks 6, 12 and 24. In ENHANCE-2, QOL as measured by SGRQ* Total Score in the ensifentrine group also improved from baseline to greater than the MCID of -4 units at weeks 12 and 24, numerically exceeding placebo at each measurement, but statistical significance was not achieved due to improvements observed in the placebo group over time.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">*E-RS, Evaluating Respiratory Symptoms, and SGRQ, St. George&#8217;s Respiratory Questionnaire, are validated patient reported outcome tools</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><img src="vrna-20221231_g11.jpg" alt="vrna-20221231_g11.jpg" style="height:377px;margin-bottom:5pt;vertical-align:text-bottom;width:700px"/></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Favorable safety profile</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Ensifentrine was well tolerated with very few adverse events occurring in more than 1% of subjects and greater than placebo over 24 and 48 weeks.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><img src="vrna-20221231_g12.jpg" alt="vrna-20221231_g12.jpg" style="height:376px;margin-bottom:5pt;vertical-align:text-bottom;width:800px"/></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We believe ensifentrine, if approved, has the potential to change the treatment paradigm for COPD. The totality of data from clinical trials, in particular the top-line results from the ENHANCE program, including improvements in measures of lung function, symptoms, quality of life measures, and exacerbation reductions, coupled with the consistent safety results, support our belief. We plan to submit an NDA to the FDA in the second quarter of 2023.</span></div><div style="text-align:center"><img src="vrna-20221231_g13.jpg" alt="vrna-20221231_g13.jpg" style="height:395px;margin-bottom:5pt;vertical-align:text-bottom;width:750px"/></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Formulations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Verona Pharma has developed formulations of ensifentrine for the three most widely used inhalation devices: nebulizer, DPI and pMDI. The nebulized formulation of ensifentrine is designed to be suitable for use in a standard jet nebulizer, not a proprietary device. Delivery of COPD medications by nebulizer is important because such medications can be used by adults of almost any age and dexterity and regardless of peak inspiratory flow, offering advantages to patients who struggle to operate handheld inhaler devices or have low peak inspiratory flow. DPI and pMDI handheld inhaler formats are relatively portable and convenient and are also important delivery mechanisms.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">While we continue to focus on development of the nebulized formulation of ensifentrine, we believe the development of pMDI and DPI formulations of ensifentrine provides additional lifecycle opportunities including new potential indications, formulation combinations and collaborations. In February 2021, we reported positive results from the second, multiple dose part of a Phase 2 trial with pMDI ensifentrine in patients with moderate to severe COPD. Ensifentrine delivered by pMDI met all of the primary and secondary lung function endpoints. The improvement in lung function was dose-ordered and statistically significant at peak and over the 12-hour dosing interval compared with placebo, and supports twice-daily dosing of ensifentrine via pMDI for the treatment of COPD. Data from the single dose part of the study were reported in March 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Verona Pharma has successfully demonstrated proof of concept in Phase 2 COPD trials with all three formulations. In addition, the data from Phase 2 trials were consistent across the three formulations. All three dosage forms have demonstrated statistically significant and clinically meaningful improvements in lung function and duration of action, supporting twice-daily dosing and a safety profile similar to placebo. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Pipeline</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table summarizes our development programs.</span></div><div style="text-align:center"><img src="vrna-20221231_g14.jpg" alt="vrna-20221231_g14.jpg" style="height:385px;margin-bottom:5pt;vertical-align:text-bottom;width:700px"/></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Potential additional indications for ensifentrine</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Cystic fibrosis and asthma</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In addition to COPD, we believe ensifentrine has potential applications in other respiratory diseases including CF and asthma.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">CF is a progressive, fatal genetic disease without a cure and a median age of death of 46 years. The condition is characterized by thick, sticky mucus that damages many of the body&#8217;s organs. It causes repeat and persistent lung infections that result in frequent exacerbations and hospitalizations. Other symptoms include malnutrition, constipation and diarrhea, and some adults develop diabetes, arthritis and liver problems.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">CF is the most common fatal inherited disease in the U.S. and Europe. Approximately 40,000 people in the U.S. and an estimated 105,000 people worldwide have been diagnosed with CF across more than 90 countries and approximately 1,000 new cases are diagnosed each year, according to the Cystic Fibrosis Foundation. The U.S. and European regulatory authorities consider CF to be a rare, or orphan, disease and provide incentives to encourage development of effective new treatments.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">CF patients endure multiple daily medications, frequent exacerbations and hospitalizations. Ultimately, selected patients have lung transplants.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In a Phase 2a clinical trial, a single dose of nebulized ensifentrine demonstrated an improvement in lung function in patients with CF. In addition, in preclinical studies, ensifentrine activated the cystic fibrosis transmembrane conductance regulator (&#8220;CFTR&#8221;), which is beneficial in reducing mucous viscosity and improving mucociliary clearance. We believe these data support the continued development of ensifentrine as a potential therapy for CF.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Asthma is a common chronic inflammatory lung condition that causes sporadic breathing difficulties. The disease causes narrowing and swelling of the airways leading to symptoms including difficulty breathing, wheezing, coughing and tightness in the chest. Exposure to triggers such as allergens or irritants can lead to asthma attacks.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Asthma attacks vary in severity and frequency. More than 260 million people worldwide suffer from asthma and it is the most common chronic disease among children, according to estimates from the World Health Organization. Approximately 60% of adult asthmatics in the U.S. have uncontrolled asthma despite regularly taking medication. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Although there is no cure, symptoms may be prevented by avoiding triggers and through established maintenance therapies including bronchodilators, ICS, anti-IgE agents and leukotriene inhibitors.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Ensifentrine has shown potential in a Phase 2a clinical trial in asthma. The data from this trial, published in October 2019 in the journal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Pulmonary Pharmacology &amp; Therapeutic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">s, demonstrated that ensifentrine produced dose-dependent improvements in lung function that were comparable to current rescue medication, high dose nebulized albuterol. Importantly, ensifentrine was well tolerated and patients experienced fewer systemic effects than those receiving albuterol.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Our team</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our expert team has decades of experience in developing and commercializing respiratory therapeutics including the following COPD therapeutics: Advair</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">; Anoro Ellipta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">; Breo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">; Flovent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">; Flutiform</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">; Incruse Ellipta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">; Serevent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">; Symbicort</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">; Tudorza Pressair</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> and Ventolin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">MANUFACTURING </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We do not have manufacturing facilities and rely on, and expect to continue to rely on, third-party contract manufacturing organizations (&#8220;CMOs&#8221;) for the supply of current good manufacturing practices (&#8220;cGMP&#8221;) compliant clinical trial materials of ensifentrine, and any future product candidates, as well as for commercial quantities of ensifentrine and any future product candidates, if approved. We currently do not have any agreements for the long-term commercial production of ensifentrine. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">While we may contract with other CMOs in the future, we currently have one CMO for the manufacture of ensifentrine drug substance and one CMO for each formulation of ensifentrine.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">All of our current CMOs have commercial scale manufacturing capabilities. We believe that the ensifentrine drug substance and drug product manufacturing processes can be transferred to other CMOs to produce clinical and commercial supplies in the ordinary course of business.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">COMMERCIALIZATION</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">United States</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the United States, we are preparing to commercialize nebulized ensifentrine ourselves, if approved. Current maintenance COPD treatments in the U.S. generate approximately $10 billion in sales. In the US, approximately 8.5 million patients receive chronic maintenance treatment for COPD. These patients receive LAMAs, LABAs, and ICS products alone or in combination across all COPD severities. Despite the use of these therapies, approximately 50% of patients report having symptoms for more than 24 days a month. This burden is significant and highlights the need for new and novel mechanisms of actions to treat COPD patients. These patients need therapies that can help improve their lung function and symptoms. In addition to the number of patients that remain symptomatic, COPD places a tremendous burden on the U.S. healthcare system with approximately $50 billion in direct and indirect costs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Based on our market research, conducted with U.S. healthcare providers and payers, we believe ensifentrine would be widely adopted with use as an add on therapy across all symptomatic patients regardless of COPD severity and treatment. Most of ensifentrine&#8217;s use would be as an add on therapy to current patients who are on LAMA LABA / ICS, LAMA/LABA, or triple therapy. This is due to the urgent unmet need for new therapies to help improve lung function, symptoms and quality of life in these patients. Our market research also suggests the majority of ensifentrine usage would be initially commenced by pulmonologists. Due to this focused prescriber base, we anticipate a field sales force of approximately 100 representatives would be able to reach the potential ensifentrine opportunity. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">International</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">COPD affects over 384 million people worldwide with many patients remaining undiagnosed. Our strategy outside of the U.S. including Asia, Europe and Latin America, is to establish partnerships with leading companies that can support the further development and commercialization of ensifentrine in those regions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In June 2021, we executed on this strategy by entering into a strategic collaboration with Nuance Pharma, a Shanghai-based specialty pharmaceutical company, with a potential value of up to $219.0 million to develop and commercialize ensifentrine in Greater China. Under the terms of the agreement, we granted Nuance Pharma the exclusive rights to develop and commercialize ensifentrine in Greater China. In return, we received an aggregate $40.0 million upfront payment consisting of $25.0 million in cash and an equity interest valued at $15.0 million, as of June 9, 2021, in Nuance Biotech, the parent company of Nuance Pharma. We are eligible to receive further milestone payments of up to $179.0 million that are triggered upon achievement of certain clinical, regulatory and commercial milestones as well as tiered double-digit royalties on net sales in Greater China.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Nuance Pharma is responsible for all costs related to clinical development and commercialization in Greater China. A joint steering committee has been established to ensure ensifentrine&#8217;s clinical development in the region aligns with our global development and commercialization strategy. In August 2022, Nuance Pharma, received clearance from China&#8217;s Center for Drug Evaluation to begin Phase 1 and Phase 3 studies of ensifentrine for COPD in mainland China. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">COMPETITION</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The pharmaceutical industry is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary drugs. We face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions. If successfully developed and commercialized, ensifentrine will compete with existing treatments and new treatments that may become available in the future.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Ensifentrine is a unique, first-in-class therapeutic candidate with both bronchodilator and non-steroidal anti-inflammatory properties in a single compound. As far as we are aware, no other dual PDE3 and PDE4 inhibitor is on the market nor in clinical development in the U.S. or Europe. Based on our market research, we expect ensifentrine to be used across the patient spectrum regardless of severity. We expect it will mainly be used as an add on therapy in symptomatic patients across all existing classes of therapies (LAMA, LABA, ICS). Some healthcare providers have indicated that they would use ensifentrine as a monotherapy based on ensifentrine&#8217;s clinical profile. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Consequently, we believe that, if approved, nebulized ensifentrine&#8217;s unique profile will enable it to compete with all approved COPD therapies including nebulized and handheld inhaler formulations, DPI and pMDI. Furthermore, because ensifentrine&#8217;s mechanism of action is complementary to available therapies, we believe it could be used in addition to these treatments.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Within the currently approved nebulizer products for the maintenance treatment of COPD, we consider ensifentrine's potential competitors in the U.S. market to be LABAs (Brovana</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> and Perforomist</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">) and LAMAs (Yupelri</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> and Lonhala</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Magnair</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">). </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the DPI/pMDI maintenance treatment of COPD market, ensifentrine&#8217;s current closest potential competitors are Symbicort</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">, a combination of a long-acting beta2-agonist bronchodilator and ICS marketed by AstraZeneca plc, Spiriva</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">, a long-acting anti-muscarinic bronchodilator marketed by Boehringer Ingelheim GmbH, Advair</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">, a combination of a long-acting beta2-agonist bronchodilator and ICS marketed by GlaxoSmithKline plc, Utibron Neohaler</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">, a combination of a long-acting beta2-agonist and long-acting anti-muscarinic bronchodilator marketed by Novartis International AG, Breo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">, a combination of a long-acting beta2-agonist bronchodilator and ICS marketed by GlaxoSmithKline, and Anoro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">, a combination of a long-acting beta2-agonist bronchodilator and long-acting anti-muscarinic bronchodilator marketed by GlaxoSmithKline. A triple-combination therapy of a LAMA, a LABA and ICS, developed by GlaxoSmithKline and Chiesi Farmaceutici S.p.A., Trelegy Ellipta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">, has been approved in the U.S. and the European Union and AstraZeneca also has a triple-therapy combination product (LAMA / LABA / ICS), Breztri Aerosphere</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> that was approved in the U.S. in July 2020, in the European Union in December 2020 and in China in December 2019. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Other potential therapies in clinical development for the prevention of COPD exacerbations include injectable biologics. Sanofi&#8217;s anti-IL4, Dupixent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">, AstraZeneca&#8217;s anti-IL5, Fasenra</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">, GlaxoSmithKline&#8217;s anti-IL5, Nucala</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">, and Chiesi&#8217;s PDE4 inhibitor, tanimilast, are in Phase 3 trials. We are also aware of several anti-inflammatories and bronchodilators that are in Phase 2 clinical trials for the treatment of COPD.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">INTELLECTUAL PROPERTY</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We strive to protect and enhance the proprietary technologies, inventions and improvements that we believe are important to our business, including seeking, maintaining and defending patent rights, whether developed internally or licensed from third parties. Our policy is to seek to protect our proprietary position by, among other methods, pursuing and obtaining patent protection in the U.S. and in jurisdictions outside of the U.S. related to our proprietary technology, inventions, improvements, platforms and our product candidates that are important to the development and implementation of our business. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As of December 31, 2022, our patent portfolio consisted of ten issued U.S. patents, eight pending U.S. patent applications (including four U.S. provisional patent applications), 70 issued foreign patents and 76 pending foreign applications. These patents and patent applications include claims directed to certain respirable formulations comprising ensifentrine, a crystalline form of ensifentrine, combinations of ensifentrine with certain respiratory drugs, certain salts of ensifentrine, ensifentrine for use in the treatment of cystic fibrosis and for use in the treatment of certain aspects of some other respiratory disorders, and a method of making ensifentrine, with expected expiry dates up to 2042. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Individual patents extend for varying periods depending on the date of filing of the patent application or the date of patent issuance and the legal term of patents in the countries in which they are obtained. Generally, patents issued for regularly filed applications in the United States are granted a term of 20 years from the earliest effective non&#8209;provisional filing date. In addition, in certain instances, a patent term can be extended to recapture a portion of the U.S. Patent and Trademark Office, or the USPTO, delay in issuing the patent as well as a portion of the term effectively lost as a result of the FDA regulatory review period. However, as to the FDA component, the restoration period cannot be longer than five years and the total patent term including the restoration period must not exceed 14 years following FDA approval. The duration of foreign patents varies in accordance with provisions of applicable local law, but typically is also 20 years from the earliest effective filing date. However, the actual protection afforded by a patent varies on a product-by-product basis, from country to country and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory&#8209;related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Furthermore, we rely upon trade secrets and know&#8209;how and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary information, in part, using confidentiality agreements with our collaborators, employees and consultants and invention assignment agreements with our employees. We also have confidentiality agreements or invention assignment agreements with our collaborators and selected consultants. These agreements are designed to protect our proprietary information and, in the case of the invention assignment agreements, to grant us ownership of technologies that are developed through a relationship with a third party. These agreements may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our collaborators, employees and consultants use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know&#8209;how and inventions. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our commercial success will also depend in part on not infringing upon the proprietary rights of third parties. It is uncertain whether the issuance of any third&#8209;party patent would require us to alter our development or commercial strategies, or our drugs or processes, obtain licenses or cease certain activities. Our breach of any license agreements or failure to obtain a license to proprietary rights that we may require to develop or commercialize our future drugs may have an adverse impact on us. If third parties have prepared and filed patent applications prior to March 16, 2013 in the United States that also claim technology to which we have rights, we may have to participate in interference proceedings in the USPTO, to determine priority of invention. For more information, please see &#8220;Item 1A. Risk Factors - Risks Related to Intellectual Property and Information Technology.&#8221;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">License agreement with Ligand (formerly Vernalis)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In February 2005, Rhinopharma Limited (&#8220;Rhinopharma&#8221;) entered into an assignment and license agreement with Ligand UK Development Limited (formerly Vernalis Development Limited) (&#8220;Ligand&#8221;), which since October 2018 has been a wholly owned subsidiary of Ligand Pharmaceuticals, Inc. In 2006, we acquired Rhinopharma and all its rights and liabilities under the assignment and license agreement. On March 24, 2022, we entered into an agreement with Ligand to amend the assignment and license agreement. We refer to the assignment and license agreement and the amendment agreement together as the Ligand Agreement. Pursuant to the Ligand Agreement, Ligand has assigned to us all its rights to certain patents and patent applications relating to ensifentrine and related compounds, or the Ligand Patents. We cannot further assign the Ligand Patents to a third party without Ligand's prior consent. Ligand also granted to us an exclusive, worldwide, royalty-bearing license under certain Ligand know-how to </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">develop, manufacture and commercialize products, or the Licensed Products, based on PDE inhibitors developed using Ligand Patents, Ligand know-how and the physical stock of certain compounds, including ensifentrine, which we refer to as the Program IP, in the treatment of human or animal allergic or inflammatory disorders. Pursuant to the Ligand Agreement, we must maintain the Ligand Patents and use commercially reasonable and diligent efforts to develop and commercialize the Licensed Products. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In March 2022, we entered into an Amendment Agreement (the &#8220;Amendment&#8221;) with Ligand whereby the Ligand Agreement was amended to clarify certain ambiguous terms in the Ligand Agreement. Pursuant to the Amendment:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;&#160;&#160;&#160;&#160;we agreed to pay to Ligand (i) $2.0 million within five business days of the date of the Amendment and (ii) $15.0 million upon the first commercial sale of ensifentrine by us or a sub-licensee, which amount is payable in cash or, at the our discretion, by the issuance of Company equity of equivalent value, as determined based on the volume-weighted average price of the our American Depositary Shares on the Nasdaq Global Market over the ten (10) trading days including and prior to such milestone event;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;&#160;&#160;&#160;&#160;the milestone payment may be paid in cash or, at our discretion, by issuing to Ligand shares in the Company of equivalent value; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We paid the $2.0 million to Ligand in March, 2022 and accounted for the $2.0 million payment at execution as selling, general and administrative expense in the consolidated statements of operations as the payment is related to a contract modification.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Ligand Agreement expires on March 24, 2042, unless terminated earlier by either party in accordance with its terms. Either party may terminate the Ligand Agreement for bankruptcy or insolvency of the other party, or for an uncured material breach of the other party, conditional upon the party seeking to terminate obtaining a final judgment of the English High Court declaring that the other party is in material breach of its obligations under the Ligand Agreement. We may terminate the Ligand Agreement upon 90 days' prior written notice. Ligand may terminate the Ligand Agreement if we notify Ligand of our intention to abandon any Ligand Patents or allow any Ligand Patents to lapse. Upon termination of the Ligand Agreement, we must cease use of any Program IP and assign the Ligand Patents and any improvements thereto back to Ligand, provided however, that any of our sublicensees shall have the right to enter into a direct license agreement with Ligand for the portion of the Program IP that was sub-licensed by such sub-licensee.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">GOVERNMENT REGULATION</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The FDA and comparable regulatory authorities in state and local jurisdictions and in other countries impose substantial and burdensome requirements upon companies involved in the clinical development, manufacture, marketing and distribution of drugs such as those we are developing. These agencies and other federal, state and local and foreign entities regulate, among other things, the research and development, testing, manufacture, quality control, safety, effectiveness, labeling, storage, record keeping, approval, advertising and promotion, distribution, post-approval monitoring and reporting, sampling and export and import of our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">FDA drug approval process </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the U.S., the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;) and its implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA's refusal to file an application for review or non-approval of a pending new drug applications (&#8220;NDA&#8221;), withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The process required by the FDA before a drug may be marketed in the United States generally involves the following: </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Completion of non-clinical laboratory tests, animal studies and formulation studies in compliance with the FDA's good laboratory practice (&#8220;GLP&#8221;) regulations; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Submission to the FDA of an investigational new drug application (&#8220;IND&#8221;), which must become effective before human clinical trials may begin in the U.S.;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Approval by an independent institutional review board (&#8220;IRB&#8221;) or ethics committee at each clinical site before each trial may be initiated; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Performance of adequate and well-controlled human clinical trials in accordance with good clinical practice (&#8220;GCP&#8221;) requirements to establish the safety and efficacy of the proposed drug product for each indication;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Submission to the FDA of an NDA after completion of all pivotal trials; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Completion of an FDA advisory committee review, if required by the FDA;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with current good manufacturing practice (&#8220;cGMP&#8221;) requirements and to assure that the facilities, methods and controls are adequate to preserve the drug's identity, strength, quality and purity, and of selected clinical investigation sites to assess compliance with GCP; and </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">FDA review and approval of the NDA and U.S. Prescribing Information to permit commercial marketing of the product for particular indications for use in the U.S.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Non-clinical Studies </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Non-clinical studies include laboratory evaluation of product chemistry, toxicity and formulation, as well as animal studies to assess potential safety and efficacy. An IND sponsor must submit the results of the non-clinical tests, together with manufacturing information, analytical data and any available clinical data or literature, among other things, to the FDA as part of an IND. An IND is a request for authorization from the FDA to ship in interstate commerce and administer an investigational new drug product to humans. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Clinical Trials </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Clinical trials involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include the requirement that all research subjects or a legal representative provide their informed consent in writing for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives or endpoints of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB at each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which reviews the data and recommends whether or not a study may move forward at designated checkpoints. It may halt the clinical trial if it determines that there is an unacceptable safety risk or on other grounds, such as no demonstration of efficacy. Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health, or NIH, for public dissemination on their www.clinicaltrials.gov website. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Human clinical trials are typically conducted in three phases, which may overlap or be combined: </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Phase 1: The drug candidate is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Phase 2: The drug candidate is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Phase 3: The drug candidate is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Post-approval trials, sometimes referred to as Phase 4 studies, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">During the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points may be prior to submission of an IND, at the end of Phase 2, and before an NDA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice, and for the sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use the meetings at the end of the Phase 2 trial to discuss Phase 2 clinical results and present plans for the pivotal Phase 3 clinical trials that they believe will support approval of the new drug. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug. In addition, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Marketing Approval </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Assuming successful completion of the required clinical testing, the results of the pre-clinical studies and clinical trials, together with detailed information relating to the product's chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. In most cases, the submission of an NDA is subject to a substantial application user fee.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective and whether the facility in which it is manufactured, processed, packaged or held meets standards designed to assure the product's continued safety, quality and purity. Under the Prescription Drug User Fee Act guidelines that are currently in effect, the FDA has a goal of ten months from the date of &#8220;filing&#8221; of a standard NDA for a new molecular entity to review and act on the submission. This review typically takes twelve months from the date the NDA is submitted to FDA because the FDA has approximately two months to make a &#8220;filing&#8221; decision after it the application is submitted.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">After evaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a complete response letter. A complete response letter generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA and may require additional clinical or pre-clinical testing in order for FDA to reconsider the application. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA's satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the NDA with a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a medicine and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries, and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. The FDA may also require one or more Phase 4 post-market studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing studies. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In addition, the Pediatric Research Equity Act (&#8220;PREA&#8221;) requires a sponsor to conduct pediatric clinical trials for most drugs, for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under PREA, original NDAs and supplements must contain a pediatric assessment unless the sponsor has received a deferral or waiver from the FDA. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The FDA offers a number of expedited development and review programs for qualifying product candidates. For example, the fast track program is intended to expedite or facilitate the process for reviewing new products that are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product candidate and the specific indication for which it is being studied. The sponsor of a fast track product candidate has opportunities for more frequent interactions with the applicable FDA review team during product development and, once an NDA is submitted, the product candidate may be eligible for priority review. A fast track product candidate may also be eligible for rolling review, where the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">A product candidate intended to treat a serious or life-threatening disease or condition may also be eligible for breakthrough therapy designation to expedite its development and review. A product candidate can receive breakthrough therapy designation if preliminary clinical evidence indicates that the product candidate, alone or in combination with one or more other drugs or biologics, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product candidate, including involvement of senior managers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Any marketing application for a drug submitted to the FDA for approval, including a product candidate with a fast track designation and/or breakthrough therapy designation, may be eligible for other types of FDA programs to expedite the FDA review and approval process, such as priority review and accelerated approval. An NDA is eligible for priority review if the product candidate is designed to treat a serious or life-threatening disease or condition, and if approved, would provide a significant improvement in safety or effectiveness compared to available alternatives for such disease or condition. For new molecular entity NDAs, priority review designation means the FDA&#8217;s goal is to take action on the marketing application within six months of the 60-day filing date (as compared to ten months under standard review). </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Additionally, product candidates studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well-controlled confirmatory clinical studies to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. Products receiving accelerated approval may be subject to expedited withdrawal procedures if the sponsor fails to conduct the required studies in a timely manner or if such studies fail to verify the predicted clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Fast track designation, breakthrough therapy designation, priority review, and accelerated approval do not change the standards for approval but may expedite the development or approval process. Even if a product candidate qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Orphan drug designation and exclusivity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 individuals in the United States and when there is no reasonable expectation that the cost of developing and making available the drug or biologic in the United States will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting an NDA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If a product that has orphan drug designation subsequently receives the first FDA approval for a particular active ingredient for the disease or condition for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a full NDA, to market the same drug for the same disease or condition for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or if the FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the NDA application user fee.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">A designated orphan drug many not receive orphan drug exclusivity if it is approved for a use that is broader than the disease or condition for which it received orphan designation. In addition, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or, as noted above, if a second applicant demonstrates that its product is clinically superior to the approved product with orphan exclusivity or the manufacturer of the approved product is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Post-Approval Requirements </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims are subject to prior FDA review and approval. There also are continuing, annual user fee requirements for any marketed products under which NDA applicants must pay a substantial &#8220;program fee&#8221; for each prescription drug product approved in an NDA. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Fines, warning letters or holds on post-approval clinical trials; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Product seizure or detention, or refusal to permit the import or export of products; or </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Injunctions or the imposition of civil or criminal penalties. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Drug Product Marketing Exclusivity </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Market exclusivity provisions authorized under the FDCA can delay the submission or the approval of certain marketing applications. For example, the FDCA provides a five-year period of non-patent data exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not approve or even accept for review an abbreviated new drug application (&#8220;ANDA&#8221;) or an NDA submitted under Section 505(b)(2) (a &#8220;505(b)(2) NDA&#8221;), submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovative drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The FDCA alternatively provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to any preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Foreign regulation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In order to market any medicinal product outside of the U.S., similar regulatory requirements, including adherence to GLP, Good Clinical Practices (&#8220;GCP&#8221;) and Good Manufacturing Practice (&#8220;GMP&#8221;), to initiate clinical trials and, subsequently, to obtain marketing approval of a new pharmaceutical product are in place in each jurisdiction and vary country to country.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Each jurisdiction will apply these regulations in their assessment of clinical trial applications and marketing authorization applications. The foreign regulatory approval process includes all of the risks associated with FDA approval set forth above, as well as additional country-specific regulation. The foreign regulatory approval process includes all of the risks associated with FDA approval set forth above, as well as additional country-specific regulation. Whether or not we obtain FDA approval for a product, we must obtain approval of a product by the comparable regulatory authorities of foreign countries before we can commence clinical trials or marketing of the product in those countries. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another. In addition, a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others. Failure to comply with applicable foreign regulatory requirements, may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Non-clinical studies and clinical trials</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Similarly to the United States, the various phases of non-clinical and clinical research in the European Union (&#8220;EU&#8221;) are subject to significant regulatory controls.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Non-clinical studies are performed to demonstrate the health or environmental safety of new biological substances. Non-clinical studies (pharmaco-toxicological) must be conducted in compliance with the principles of GLP, as set forth in EU Directive 2004/10/EC (unless otherwise justified for certain particular medicinal products - e.g., radio-pharmaceutical precursors for radio-labelling purposes). In particular, non-clinical studies, both in vitro and in vivo, must be planned, performed, monitored, recorded, reported and archived in accordance with the GLP principles, which define a set of rules and criteria for a quality system for the organizational process and the conditions for non-clinical studies. These GLP standards reflect the Organization for Economic Co-operation and Development requirements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Clinical trials of medicinal products in the EU must be conducted in accordance with EU and national regulations and the International Conference on Harmonization (&#8220;ICH&#8221;) guidelines on GCP as well as the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. If the sponsor of the clinical trial is not established within the EU, it must appoint an EU entity to act as its legal representative. The sponsor must take out a clinical trial insurance policy, and in most EU countries, the sponsor is liable to provide &#8216;no fault&#8217; compensation to any study subject injured in the clinical trial.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The regulatory landscape related to clinical trials in the EU has been subject to recent changes. The EU Clinical Trials Regulation (&#8220;CTR&#8221;) which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on January 31, 2022. Unlike directives, the CTR is directly applicable in all EU member states without the need for member states to further implement it into national law. The CTR notably harmonizes the assessment and supervision processes for clinical trials throughout the EU via a Clinical Trials Information System, which contains a centralized EU portal and database.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">While the Clinical Trials Directive required a separate clinical trial application (&#8220;CTA&#8221;) to be submitted in each member state in which the clinical trial takes place, to both the competent national health authority and an independent ethics committee, much like the FDA and IRB respectively, the CTR introduces a centralized process and only requires the submission of a single application for multi-center trials. The CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The CTA must include, among other things, a copy of the trial protocol and an investigational medicinal product dossier containing information about the manufacture and quality of the medicinal product under investigation. The assessment procedure of the CTA has been harmonized as well, including a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state&#8217;s decision is communicated to the sponsor via the centralized EU portal. Once the CTA is approved, clinical study development may proceed. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The CTR foresees a three-year transition period. The extent to which ongoing and new clinical trials will be governed by the CTR varies. Clinical trials for which an application was submitted (i) prior to January 31, 2022 under the Clinical Trials Directive, or (ii) between January 31, 2022 and January 31, 2023 and for which the sponsor has opted for the application of the EU Clinical Trials Directive remain governed by said Directive until January 31, 2025. After this date, all clinical trials (including those which are ongoing) will become subject to the provisions of the CTR.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Medicines used in clinical trials must be manufactured in accordance with GMP. Other national and EU-wide regulatory requirements may also apply.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Marketing authorization</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the EU, medicinal products can only be placed on the market after obtaining a marketing authorization (&#8220;MA&#8221;). To obtain regulatory approval of a product candidate under EU regulatory systems, we must submit a MA, or MAA. The process for doing this depends, among other things, on the nature of the medicinal product. There are two types of MAs:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">&#8220;Centralized MAs&#8221; are issued by the European Commission through the centralized procedure, based on the opinion of the Committee for Medicinal Products for Human Use (&#8220;CHMP&#8221;) of the EMA, and are valid throughout the entire territory of the EU. The centralized procedure is mandatory for certain types of medicinal products, such as (i) medicines derived from biotechnology processes, (ii) advanced therapy medicinal products (such as gene therapy, somatic cell therapy and tissue engineered products), (iii) orphan designated medicinal products, and (iv) products that contain a new active substance indicated for the treatment of certain diseases such as HIV/AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral diseases. The centralized procedure is optional for products containing a new active substance not yet authorized in the EU, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">&#8220;National MAs&#8221; are issued by the competent authorities of the member states of the EU and only cover their respective territory, and are available for products not falling within the mandatory scope of the centralized procedure. Where a product has already been authorized for marketing in a member state of the EU, this national MA can be recognized in another member state through the mutual recognition procedure. If the product has not received a national MA in any member state at the time of application, it can be approved simultaneously in various member states through the decentralized procedure. Under the decentralized procedure an identical dossier is submitted to the competent authorities of each of the member states in which the MA is sought, one of which is selected by the applicant as the reference member state.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Under the above described procedures, in order to grant the MA, the EMA or the competent authorities of the member states of the EU make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy. MAs have an initial duration of five years. After these five years, the authorization may be renewed on the basis of a reevaluation of the risk-benefit balance. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Under the centralized procedure the maximum timeframe for the evaluation of a MAA by the EMA is 210 days. In exceptional cases, the CHMP might perform an accelerated assessment of a MAA in no more than 150 days (not including clock stops). Innovative products that target an unmet medical need and are expected to be of major public health interest may be eligible for a number of expedited development and review programs, such as the Priority Medicines (&#8220;PRIME&#8221;) scheme, which provides incentives similar to the breakthrough therapy designation in the U.S. In March 2016, the EMA launched an initiative, the PRIME scheme, a voluntary scheme aimed at enhancing the EMA&#8217;s support for the development of medicines that target unmet medical needs. It is based on increased interaction and early dialogue with companies developing promising medicines, to optimize their product development plans and speed up their evaluation to help them reach patients earlier. Product developers that benefit from PRIME designation can expect to be eligible for accelerated assessment but this is not guaranteed. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and accelerated MAA assessment once a dossier has been submitted. Importantly, a dedicated contact and rapporteur from the CHMP is appointed early in the PRIME scheme facilitating increased understanding of the product at EMA&#8217;s committee level. An initial meeting initiates these relationships and includes a team of multidisciplinary experts at the EMA to provide guidance on the overall development and regulatory strategies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Data and marketing exclusivity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the EEA, new products authorized for marketing, (i.e., reference products), generally receive eight years of data exclusivity and an additional two years of market exclusivity upon MA. If granted, the data exclusivity period prevents generic or biosimilar applicants from relying on the pre-clinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar MA in the EU during a period of eight years from the date on which the reference product was first authorized in the EU. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until 10 years have elapsed from the initial authorization of the reference product in the EU. The overall 10-year market exclusivity period can be extended to a maximum of eleven years if, during the first eight years of those 10 years, the MA holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. However, there is no guarantee that a product will be considered by the EU&#8217;s regulatory authorities to be a new active substance, and products may not qualify for data exclusivity.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Pediatric development</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the EEA, MAAs for new medicinal products have to include the results of studies conducted in the pediatric population, in compliance with a pediatric investigation plan (&#8220;PIP&#8221;), agreed with the EMA's Pediatric Committee (&#8220;PDCO&#8221;). The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the drug for which MA is being sought. The PDCO can grant a deferral of the obligation to implement some or all of the measures of the PIP until there are sufficient data to demonstrate the efficacy and safety of the product in adults. Further, the obligation to provide pediatric clinical trial data can be waived by the PDCO when these data are not needed or appropriate because the product is likely to be ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product does not represent a significant therapeutic benefit over existing treatments for pediatric patients. We have received a waiver for pediatric data in COPD.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Orphan Medicinal Products</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The criteria for designating an &#8220;orphan medicinal product&#8221; in the EU are similar in principle to those in the United States. A medicinal product may be designated as orphan if its sponsor can establish that: (1) the product is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition; (2) either (a) such condition affects no more than five in 10,000 persons in the EU when the application is made, or (b) the product, without the benefits derived from orphan status, would not generate sufficient return in the EU to justify investment; and (3) there exists no satisfactory method of diagnosis, prevention or treatment of such condition that has been authorized for marketing in the EU, or if such a method exists, the product will be of significant benefit to those affected by the condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Orphan drug designation must be requested before submitting an MAA. An EU orphan designation entitles a party to incentives such as reduction of fees or fee waivers, protocol assistance, and access to the centralized procedure. Upon grant of a MA, orphan medicinal products are entitled to ten years of market exclusivity for the approved therapeutic indication which means that the EU regulatory authorities cannot accept another MAA, or grant an MA, or accept an application to extend a MA for a similar product for the same indication for a period of ten years. The period of market exclusivity is extended by two years for orphan medicinal products that have also complied with an agreed PIP. No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications. Orphan designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The orphan exclusivity period may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity, or where the prevalence of the condition has increased above the threshold. Additionally, MA may be granted to a similar product for the same indication at any time if (1) the second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior; (2) the applicant consents to a second orphan medicinal product application; or (3) the applicant cannot supply enough orphan medicinal product.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Post-Approval Requirements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Similar to the United States, both MA holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the EMA, the European Commission and/or the competent regulatory authorities of the EU member states. The holder of a MA must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance (&#8220;QPPV&#8221;) who is responsible for the establishment and maintenance of that system, and oversees the safety profiles of medicinal products and any emerging safety concerns. Key obligations include expedited reporting of suspected serious adverse reactions and submission of periodic safety update reports (&#8220;PSURs&#8221;).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">All new MAA must include a risk management plan (&#8220;RMP&#8221;) describing the risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. The regulatory authorities may also impose specific obligations as a condition of the MA. Such risk-minimization measures or post-authorization obligations may include additional safety monitoring, more frequent submission of PSURs, or the conduct of additional clinical trials or post-authorization safety studies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The advertising and promotion of medicinal products is also subject to laws concerning promotion of medicinal products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. All advertising and promotional activities for the product must be consistent with the approved summary of product characteristics, and therefore all off-label promotion is prohibited. Direct-to-consumer advertising of prescription medicines is also prohibited in the EU. Although general requirements for advertising and promotion of medicinal products are established under EU directives, the details are governed by regulations in each member state and can differ from one country to another.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The aforementioned EU rules are generally applicable in the European Economic Area (&#8220;EEA&#8221;) which consists of the 27 EU member states plus Norway, Liechtenstein and Iceland.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Failure by us or by any of our third-party partners, including suppliers, manufacturers and distributors to comply with EU and EU member state laws that apply to the conduct of clinical trials, manufacturing approval, MA of medicinal products and marketing of such products, both before and after grant of the MA, manufacturing of medicinal products, statutory health insurance, bribery and anti-corruption or with other applicable regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials or to grant MA, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the marketing authorization, total or partial suspension of production, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Brexit and the Regulatory Framework in the United Kingdom</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Since the end of the Brexit transition period on January 1, 2021, Great Britain (England, Scotland and Wales) has not been directly subject to EU laws, however under the terms of the Ireland/Northern Ireland Protocol, EU laws generally apply to Northern Ireland. The EU laws that have been transposed into UK law through secondary legislation remain applicable in Great Britain. However, under the Retained EU Law (Revocation and Reform) Bill 2022, which is currently before the UK parliament, any retained EU law not expressly preserved and &#8220;assimilated&#8221; into domestic law or extended by ministerial regulations (to no later than June 23, 2026) will automatically expire and be revoked by December 31, 2023. However, new legislation such as the EU CTR is not applicable in Great Britain (&#8220;GB&#8221;).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Under the Medicines and Medical Devices Act 2021, the Secretary of State or an &#8216;appropriate authority&#8217; has delegated powers to amend or supplement existing regulations in the area of medicinal products and medical devices. This allows new rules to be introduced in the future by way of secondary legislation, which aims to allow flexibility in addressing regulatory gaps and future changes in the fields of human medicines, clinical trials and medical devices.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Since January 1, 2021, the Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;) has been the UK&#8217;s standalone medicines and medical devices regulator. As a result of the Northern Ireland protocol, different rules will apply in Northern Ireland than in England, Wales, and Scotland, together, GB; broadly, Northern Ireland will continue to follow the EU regulatory regime, but its national competent authority will remain the MHRA. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The UK regulatory framework in relation to clinical trials is derived from existing EU legislation (as implemented into UK law, through secondary legislation). On January 17, 2022, the MHRA launched an eight-week consultation on reframing the UK legislation for clinical trials. The consultation closed on March 14, 2022 and aims to streamline clinical trials approvals, enable innovation, enhance clinical trials transparency, enable greater risk proportionality, and promote patient and public involvement in clinical trials. The outcome of the consultation is being closely watched and will determine whether the UK chooses to align with the CTR or diverge from it to maintain regulatory flexibility. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The MHRA has introduced changes to national licensing procedures, including procedures to prioritize access to new medicines that will benefit patients, including a 150-day assessment and a rolling review procedure. All existing EU MAs for centrally authorized products were automatically converted or grandfathered into UK MAs, effective in GB (only), free of charge on January 1, 2021, unless the MA holder has opted out. In order to use the centralized procedure to obtain a MA that will be valid throughout the EEA, companies must be established in the EEA. Therefore since Brexit, without first establishing an EEA entity, companies established in the UK can no longer use the EU centralized procedure and instead an EEA entity must hold any centralized MAs . In order to obtain a UK MA to commercialize products in the UK, an applicant must be established in the UK and must follow one of the UK national authorization procedures or one of the remaining post-Brexit international cooperation procedures to obtain an MA to commercialize products in the UK. The MHRA may rely on a decision taken by the European Commission on the approval of a new (centralized procedure) MA when determining an application for a GB authorization; or use the MHRA&#8217;s decentralized or mutual recognition procedures which enable MAs approved in EU member states (or Iceland, Liechtenstein, Norway) to be granted in GB.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">There is no pre-MA orphan designation. Instead, the MHRA will review applications for orphan designation in parallel to the corresponding MA application. The criteria are essentially the same, but have been tailored for the market, i.e., the prevalence of the condition in GB, rather than the EU, must not be more than five in 10,000. Should an orphan designation be granted, the period of market exclusivity will be set from the date of first approval of the product in GB.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Other Healthcare Laws </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In addition to FDA restrictions on marketing of pharmaceutical and biological products, other U.S. federal and state healthcare regulatory laws restrict business practices in the pharmaceutical industry, which include, but are not limited to, state and federal anti-kickback, false claims and physician payment and drug pricing transparency laws. Similar laws exist in foreign jurisdictions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The U.S. federal Anti-Kickback Statute prohibits, among other things, any person or entity from knowingly and willfully offering, paying, soliciting, receiving or providing any remuneration, directly or indirectly, overtly or covertly, to induce or in return for purchasing, leasing, ordering, or arranging for or recommending the purchase, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">lease, or order of any good, facility, item or service reimbursable, in whole or in part, under Medicare, Medicaid or other federal healthcare programs. The term "remuneration" has been broadly interpreted to include anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, formulary managers and beneficiaries on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions and safe harbors are drawn narrowly. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases, or recommendations may be subject to scrutiny if they do not meet the requirements of a statutory or regulatory exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the U.S. federal Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all its facts and circumstances. Several courts have interpreted the statute's intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the statute has been violated. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In addition, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The federal false claims laws, including the civil False Claims Act, prohibit any person or entity from, among other things, knowingly presenting, or causing to be presented, a false, fictitious or fraudulent claim for payment to, or approval by, the federal government, knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. A claim includes "any request or demand" for money or property presented to the U.S. government. Actions under the civil False Claims Act may be brought by the Attorney General or as a qui tam action by a private individual in the name of the government. Violations of the civil False Claims Act can result in very significant monetary penalties and treble damages. Several pharmaceutical and other healthcare companies have been prosecuted under these laws for, among other things, allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the companies' marketing of products for unapproved, or off-label, uses. Moreover, a claim including items or services resulting from a violation of the U.S. federal Anti-Kickback Statue constitutes a false or fraudulent claim for the purposes of the federal civil False Claims Act. In addition, the civil monetary penalties statute imposes penalties against any person who is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent. Many states also have similar fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created additional federal criminal statutes that prohibit, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In addition, there has been a recent trend of increased federal and state regulation of payments made to physicians and certain other healthcare providers. The Physician Payments Sunshine Act imposes, among other things, annual reporting requirements for covered manufacturers for certain payments and "transfers of value" provided to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain non-physician practitioners (physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiology assistants and certified nurse-midwives) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Failure to submit timely, accurately and completely the required information for all payments, transfers of value and ownership or investment interests may result in significant civil monetary penalties and additional penalties for "knowing failures." Covered manufacturers must submit reports by the 90th day of each subsequent calendar year. In addition, certain states require implementation of compliance programs and compliance with the pharmaceutical industry's voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, impose restrictions on marketing practices and/or tracking and reporting of gifts, compensation and other remuneration or items of value provided to physicians and other healthcare professionals and entities. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Violations of any such laws or any other governmental regulations that apply may result in significant criminal, civil and administrative penalties, including damages, fines, the possibility of exclusion from federal healthcare programs (including Medicare and Medicaid), disgorgement and corporate integrity agreements, which impose, among other things, rigorous operational and monitoring requirements on companies to resolve allegations of non-compliance with these laws. Similar sanctions and penalties, as well as imprisonment, also can be imposed upon executive officers and employees of such companies. Given the significant size of actual and potential settlements, it is expected that the government authorities will continue to devote substantial resources to investigating healthcare providers' and manufacturers' compliance with applicable fraud and abuse laws. Moreover, analogous state and foreign laws and regulations may be broader in scope than the provisions described above and may apply regardless of payor. These laws and regulations may differ from one another in significant ways, thus further complicating compliance efforts. For instance, in the EU, many EU member states have adopted specific anti-gift statutes that further limit commercial practices for medicinal products, in particular vis-&#224;-vis healthcare professionals and organizations. Additionally, there has been a recent trend of increased regulation of payments and transfers of value provided to healthcare professionals or entities and many EU member states have adopted national &#8220;Sunshine Acts&#8221; which impose reporting and transparency requirements (often on an annual basis), similar to the requirements in the United States, on pharmaceutical companies. Certain countries also mandate implementation of commercial compliance programs, or require disclosure of marketing expenditures and pricing information. Violation of any of such laws or any other governmental regulations that apply may result in penalties, including, without limitation, significant administrative, civil and criminal penalties, damages, fines, disgorgement, additional reporting obligations and oversight if a manufacturer becomes subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, the curtailment or restructuring of operations, exclusion from participation in governmental healthcare programs and imprisonment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Coverage and Reimbursement </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological products for which we obtain regulatory approval. In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our products. Sales of any products for which we receive regulatory approval for commercial sale will therefore depend, in part, on the availability of coverage and adequate reimbursement from third-party payors. Third-party payors include government authorities, managed care plans, private health insurers and other organizations. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the United States, the process for determining whether a third-party payor will provide coverage for a pharmaceutical or biological product typically is separate from the process for setting the price of such product or for establishing the reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the FDA-approved products for a particular indication. A decision by a third-party payor not to cover our product candidates could reduce physician utilization of our products once approved and have a material adverse effect on our sales, results of operations and financial condition. Moreover, a third-party payor's decision to provide coverage for a pharmaceutical or biological product does not imply that an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. Additionally, coverage and reimbursement for products can differ significantly from payor to payor. One third-party payor's decision to cover a particular medical product or service does not ensure that other payors will also provide coverage for the medical product or service, or will provide coverage at an adequate reimbursement rate. As a result, the coverage determination process will require us to provide scientific and clinical support for the use of our products to each payor separately and will be a time-consuming process. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In international markets, reimbursement and healthcare payment systems vary significantly by country. In the EU, governments influence the price of products through their pricing and reimbursement rules and control of national health care systems that fund a large part of the cost of those products to consumers. Member states are free to restrict the range of pharmaceutical products for which their national health insurance systems provide reimbursement, and to control the prices and reimbursement levels of pharmaceutical products for human use. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed to by the government. Member states may approve a specific price or level of reimbursement for the pharmaceutical product, or alternatively adopt a system of direct or indirect controls on the profitability of the company responsible for placing the pharmaceutical product on the market, including volume-based arrangements, caps and reference pricing mechanisms. To obtain reimbursement or pricing approval, some of </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines, but monitor and control company profits. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. The downward pressure on health care costs in general, particularly prescription products, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross border imports from low-priced markets exert a commercial pressure on pricing within a country. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of pharmaceutical or biological products have been a focus in this effort. Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost-effectiveness of pharmaceutical or biological products, medical devices and medical services, in addition to questioning safety and efficacy. If these third-party payors do not consider our products to be cost-effective compared to other available therapies, they may not cover our products after FDA approval or, if they do, the level of payment may not be sufficient to allow us to sell our products at a profit. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Healthcare Reform </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medical products. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA, was enacted, which, among other things, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program; introduced a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed care plans; imposed mandatory discounts for certain Medicare Part D beneficiaries as a condition for manufacturers' outpatient drugs coverage under Medicare Part D.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#8217;s decision, President Biden issued an executive order initiating a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Additionally, on August 2, 2011, the Budget Control Act of 2011 created measures for spending reductions was enacted, which, among other things, included aggregate reductions of Medicare payments to providers, which went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute, will stay in effect through 2032, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022, unless additional action is taken by Congress. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. In addition, in March 2021, the American Rescue Plan Act of 2021 was signed into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, beginning January 1, 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">More recently, there has been heightened governmental scrutiny recently over the manner in which manufacturers set prices for their marketed products, which have resulted in several recent Congressional inquiries and proposed and enacted legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. On August 16, 2022, the Inflation Reduction Act of 2022, or IRA, was signed into law. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023), and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of the Department of Health and Human Services (HHS) to implement many of these provisions through guidance, as opposed to regulation, for the initial years. For that and other reasons, it is currently unclear how the IRA will be effectuated.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We expect that additional state, federal and foreign healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products, once approved, or additional price increases. In particular, we anticipate that Medicare Part B will play an important role in the reimbursement of ensifentrine. Changes in how products are reimbursed through Medicare Part B may affect the overall coverage for ensifentrine, if approved. Any reduction in reimbursement from Medicare or other government-funded programs may result in a similar reduction in payments from private payors.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Data Privacy and Security Laws</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Numerous state, federal and foreign laws, regulations and standards govern the collection, use, access to, confidentiality and security of health-related and other personal information, and could apply now or in the future to our operations or the operations of our partners. In the United States, numerous federal and state laws and regulations, including data breach notification laws, health information privacy and security laws and consumer protection laws and regulations govern the collection, use, disclosure, and protection of health-related and other personal information. In addition, certain foreign laws govern the privacy and security of personal data, including health-related data. For example, the General Data Protection Regulation (&#8220;GDPR&#8221;) imposes strict requirements for processing the personal data of individuals within the European Economic Area. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. Further, from January 1, 2021, companies have had to comply with the GDPR and also the United Kingdom GDPR (&#8220;UK GDPR&#8221;), which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law. The UK GDPR mirrors the fines under the GDPR, i.e., fines up to the greater of &#8364;20 million (&#163;17.5 million) or 4% of global turnover. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Additional regulation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservation and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws govern the use, handling and disposal of various biologic, chemical and radioactive substances used in, and wastes generated by, operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines. Equivalent laws have been adopted in certain other countries that impose similar obligations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">U.S. Foreign Corrupt Practices Act</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The U.S. Foreign Corrupt Practices Act ("FCPA"), prohibits U.S. corporations and individuals from engaging in certain activities to obtain or retain business abroad or to influence a person working in an official capacity. It is illegal to pay, offer to pay or authorize the payment of anything of value to any foreign government official, government staff member, political party or political candidate in an attempt to obtain or retain business or to otherwise influence a person working in an official capacity. The scope of the FCPA includes interactions with certain healthcare professionals in many countries. Equivalent laws have been adopted in other foreign countries that impose similar obligations.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">EMPLOYEES</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As of December 31, 2022, we had 35 full-time and 1 part time employees. None of our employees is party to a collective bargaining agreement or represented by a trade union or labor union. We consider our relationship with our employees to be good.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">ADDITIONAL INFORMATION</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We were incorporated in February 2005 as Isis Resources plc under the laws of England and Wales. In September 2006, we acquired Rhinopharma Limited, a private company incorporated in Canada, and changed our name to Verona Pharma plc. Our principal office is located at 3 More London Riverside, London, SE1 2RE, United Kingdom. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We make available our public filings, including annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and any amendments to those reports, with the SEC free of charge through our website at www.veronapharma.com in the &#8220;Investors&#8221; section as soon as reasonably practicable after we electronically file such material with, or furnish such material to, the SEC. The information contained in, or accessible through, our website does not constitute a part of this Annual Report.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="ic8555b0a0e574cdcb5428a00447fe322_19"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 1A.&#160;&#160;&#160;&#160;Risk Factors</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Investing in our ADSs involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Annual Report, including our consolidated financial statements and the related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;. The occurrence of any of the events or developments described below could adversely affect our business, financial condition, results of operations and growth prospects. In such an event, the market price of our ADSs could decline, and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Risks Related to Our Business and Industry</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We have a limited operating history and have never generated any product revenue.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are a clinical-stage biopharmaceutical company with a limited operating history, and have incurred significant operating losses since our inception. We had net losses of $68.7 million and $55.6 million for the years ended December 31, 2022 and 2021, respectively. As of December 31, 2022, we had an accumulated deficit of $333.1 million. Our losses have resulted principally from expenses incurred in research and development of ensifentrine, our only product candidate, and from general and administrative costs that we have incurred while building our business infrastructure. We expect to continue to incur significant operating losses for the foreseeable future as we expand our research and development efforts, advance our clinical development of ensifentrine, and seek to obtain regulatory approval for and commercialize ensifentrine. We anticipate that our expenses will increase substantially as we:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">initiate and conduct clinical trials of ensifentrine for the treatment of cystic fibrosis (&#8220;CF&#8221;), asthma or other indications;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">initiate and conduct other future clinical trials of ensifentrine in other formulations, including in combination with other active ingredients, for the treatment of COPD or other indications;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">initiate and conduct clinical pharmacology studies with any formulation;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">seek to discover and develop or in-license additional respiratory product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">conduct pre-clinical studies to support ensifentrine and potentially other future product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">develop the manufacturing processes and produce clinical and commercial supplies of the ensifentrine active pharmaceutical ingredient and formulated drug products derived from it;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">seek regulatory approvals of ensifentrine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">grow commercial infrastructure to support the potential commercialization of ensifentrine, including sales, marketing, operations, reimbursement and distribution infrastructure and scale-up manufacturing capabilities to commercialize ensifentrine, if approved;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">maintain, expand and protect our intellectual property portfolio;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">secure, maintain or obtain freedom to operate for our in-licensed technologies and products;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">add clinical, scientific, operational, financial and management information systems and personnel, including personnel to support our product development and potential future commercialization efforts; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">expand our operations in the United States, the United Kingdom (&#8220;UK&#8221;) and possibly elsewhere.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our expenses may also increase substantially if we experience any delays or encounter any issues with any of the above, including, but not limited to, failed pre-clinical studies or clinical trials, complex results, safety issues or regulatory challenges.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We have devoted substantially all of our financial resources and efforts to the research and development and pre-clinical studies and clinical trials of ensifentrine. We are continuing development of ensifentrine, and we have not completed development of any product candidate or any drugs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">To become and remain profitable, we must succeed in developing, and eventually commercializing, products that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing clinical trials of ensifentrine, discovering and developing additional product candidates, obtaining regulatory approval for ensifentrine and any future product candidates that successfully complete clinical trials, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">establishing manufacturing, commercial and marketing capabilities and ultimately distributing and selling any products for which we may obtain regulatory approval. We are only in the preliminary stages of many of these activities. We may never succeed in these activities and, even if we do, we may never generate revenue that is significant enough to achieve profitability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. If we are required by the FDA, the European Medicines Agency (&#8220;EMA&#8221;), or other regulatory authorities to perform studies in addition to those we currently anticipate, or if there are any delays in completing our clinical trials or the development of ensifentrine or any other product candidates, our expenses could increase and revenue could be further delayed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Even if we do generate product royalties or product sales, we may never achieve or sustain profitability on a quarterly or annual basis. Our failure to sustain profitability would depress the market price of our ADSs and could impair our ability to raise capital, expand our business, diversify our product offerings or continue our operations. A decline in the market price of our ADSs also could cause our ADS holders to lose all or a part of their investment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We will need additional funding to complete development and commercialization of any future product candidates, or development and commercialization of other formulations or target indications of ensifentrine, if approved. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We expect our expenses to increase in connection with our ongoing and planned activities, particularly as we conduct clinical trials of ensifentrine, and develop ensifentrine in other formulations or for other indications. In addition, if we obtain regulatory approval for ensifentrine or any other product candidates, we expect to incur significant commercialization expenses related to activities including product positioning studies, product manufacturing, medical affairs, marketing, sales and distribution. Furthermore, we expect to incur ongoing costs associated with operating as a public company in the United States and maintaining a listing on the Nasdaq Global Market, or Nasdaq. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If we obtain regulatory approval for ensifentrine for the treatment of COPD in the US, we estimate that our existing cash resources, expected cash receipts from the UK tax credit program and funding expected to become available under the $150.0 million debt facility will enable the Company to fund planned operating expenses and capital expenditure requirements through at least the end of 2025 including the commercial launch of ensifentrine. Future advances under the Oxford Term Loan are contingent upon achievement of certain clinical and regulatory milestones and other specified conditions. We have based this estimate on assumptions that may prove to be incorrect, and we could use our available capital resources sooner than we currently expect. In addition, our operating plan may change as a result of many factors unknown to us. These factors, among others, may necessitate that we seek additional capital sooner than currently planned. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our future capital requirements will depend on many factors, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the costs, progress and results of our ongoing Phase 3 clinical trials for the maintenance treatment of COPD;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the costs, timing and outcome of the regulatory submission and review of ensifentrine, including any post-marketing studies that could be required by regulatory authorities, if regulatory approval is received;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the cost, progress and results of any other studies required to support the commercial positioning of ensifentrine for the treatment of COPD, if regulatory approval is received;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the cost, progress and results of any clinical trials for the treatment of CF, asthma or other indications, or for other formulations of ensifentrine including fixed-dose combination products;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the cost of manufacturing clinical and, if approved, commercial supplies of the ensifentrine active ingredient and derived formulated drug products;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the scope, progress, results and costs of pre-clinical development, laboratory testing and clinical trials for ensifentrine in other indications and of the development of DPI and pMDI formulations of ensifentrine, or fixed-dose combination formulations of ensifentrine for the maintenance treatment of COPD and potentially asthma and other respiratory diseases;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the costs, timing and outcome of potential future commercialization activities, including manufacturing, marketing, sales and distribution, for ensifentrine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims, including any claims by third parties that we are infringing upon their intellectual property rights;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the timing and amount of revenue, if any, received from commercial sales of ensifentrine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the sales price and availability of adequate third-party coverage and reimbursement for ensifentrine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the effect of competing technological and market developments; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the extent to which we acquire or invest in businesses, products and technologies, including entering into licensing or collaboration arrangements for ensifentrine, although we currently have no commitments or agreements to complete any such transactions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize ensifentrine. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect our business, the holdings or the rights of our shareholders, or the value of our ordinary shares or ADSs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue our research and development programs relating to ensifentrine or any commercialization efforts, be unable to expand our operations, or be unable to otherwise capitalize on our business opportunities, as desired, which could harm our business and potentially cause us to discontinue operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We depend solely on the success of ensifentrine, our only product candidate under development. We cannot give any assurance that ensifentrine will receive regulatory approval for any indication, which is necessary before it can be commercialized. If we, and any collaborators with whom we have entered or may enter into agreements for the development and commercialization of ensifentrine, are unable to commercialize ensifentrine, or experience significant delays in doing so, our ability to generate revenue and our financial condition will be adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We do not currently generate any revenues from sales of any products, and we may never be able to develop or commercialize a marketable product. We have invested substantially all of our efforts and financial resources in the development of ensifentrine, and we do not have any other product candidate currently under development. Our ability to generate royalty and product revenues, which we do not expect will occur for at least the next few years, if ever, will depend heavily on the successful development and eventual commercialization of ensifentrine, if approved, which may never occur. Ensifentrine will require regulatory approval, procurement of manufacturing supply, commercialization, substantial additional investment and significant marketing efforts before we generate any revenues from product sales. We are not permitted to market or promote ensifentrine or any product candidates in the United States, Europe or other countries before we receive regulatory approval from the FDA, the European Commission or comparable foreign regulatory authorities, and we may never receive such regulatory approval for ensifentrine or any future product candidate. We have not submitted an NDA to the FDA, a marketing authorization application (&#8220;MAA&#8221;) to the EMA or comparable applications to other regulatory authorities. The success of ensifentrine will depend on many factors, including the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">we may not be able to demonstrate that ensifentrine is safe and effective as a treatment for our targeted indications to the satisfaction of the applicable regulatory authorities;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the applicable regulatory authorities may require additional pre-clinical or clinical trials, which would increase our costs and prolong our development;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the results of clinical trials of ensifentrine may not meet the level of statistical or clinical significance required by the applicable regulatory authorities for marketing approval;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the applicable regulatory authorities may disagree with the number, design, size, conduct or implementation of our clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the contract research organizations (&#8220;CROs&#8221;) that we retain to conduct clinical trials may take actions outside of our control that materially adversely impact our clinical trials;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the applicable regulatory authorities may not find the data from pre-clinical studies and clinical trials sufficient to demonstrate that the clinical and other benefits of ensifentrine outweigh its safety risks or may disagree with our interpretation of data;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">our ability to demonstrate a non-clinical safety profile that is acceptable to the applicable regulatory authorities;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">unexpected operational or clinical issues may prevent completion or interpretation of clinical study results;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">unexpected manufacturing issues, product performance issues or stability issues may delay or otherwise adversely affect the progress of our clinical development program;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">if FDA or other regulatory authorities determine that inspections of the manufacturing facilities or clinical sites for our product candidates are required in connection with a marketing application, and such regulatory authorities are unable to conduct such inspections, whether due to geopolitical conflict, such as the ongoing Russia-Ukraine conflict, or travel restrictions, such as those imposed during the COVID-19 pandemic;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the applicable regulatory authorities may not accept data generated at our clinical trial sites due to GCP compliance issues, misconduct, or other reasons;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">if we submit an NDA to the FDA, and it is reviewed by an advisory committee, the FDA may have difficulties scheduling an advisory committee meeting in a timely manner or the advisory committee may recommend against approval of our application or may recommend that the FDA require, as a condition of approval, additional pre-clinical studies or clinical trials, limitations on approved labeling or distribution and use restrictions;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the applicable regulatory authorities may require development of a risk evaluation and mitigation strategy, or REMS, or similar risk management measures as a condition of approval;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the applicable regulatory authorities may identify deficiencies in the manufacturing processes or facilities of our third-party manufacturers;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the applicable regulatory authorities may change their approval policies or adopt new regulations;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">if we license ensifentrine to others, the efforts of those parties in completing clinical trials of, receiving regulatory approval for, and commercializing ensifentrine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">through our clinical trials, we may discover factors that limit the commercial viability of ensifentrine or make the commercialization of ensifentrine unfeasible;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">if we retain rights under a collaboration agreement for ensifentrine, our efforts in completing pre-clinical studies and clinical trials of, receiving marketing approvals for, establishing commercial manufacturing capabilities for, and commercializing ensifentrine; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">if approved, acceptance of ensifentrine by patients, the medical community and third-party payors, effectively competing with other therapies, a continued acceptable safety profile following approval and qualifying for, maintaining, enforcing and defending our intellectual property rights and claims.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">An unfavorable outcome in any of these factors could result in our experiencing significant delays or an inability to successfully commercialize ensifentrine. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We cannot be certain that ensifentrine or any future product candidates will be successful in clinical trials or receive regulatory approval. Further, ensifentrine or any future product candidates may not receive regulatory approval even if they are successful in clinical trials. If we do not receive regulatory approvals for ensifentrine or any future product candidates, we may not be able to continue our operations. Even if we successfully obtain regulatory approvals to manufacture and market ensifentrine or any future product candidates, our revenues will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval and have commercial rights. If the markets for patient subsets that we are targeting are not as significant as we estimate, we may not generate significant revenues from sales of such products, if approved.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We plan to seek regulatory approval to commercialize ensifentrine in the United States, and potentially in the European Union (&#8220;EU&#8221;) and additional foreign countries. While the scope of regulatory approval is similar in many countries, to obtain separate regulatory approval in multiple countries requires us to comply with the numerous and varying regulatory requirements of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and distribution of ensifentrine, and we cannot predict success in these jurisdictions.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">The COVID-19 pandemic has and may continue to adversely impact our business, including our plans to commercialize ensifentrine in the United States, if approved, and plans for the development and commercialization of ensifentrine in other countries.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The COVID-19 pandemic continues to rapidly evolve, including in countries where we have operations, have conducted our ENHANCE clinical trial program and are planning to develop and commercialize ensifentrine, if approved. For example, the COVID-19 pandemic continues to impact Greater China where we have granted a license to a third party for the development and commercialization of products containing ensifentrine. The pandemic and government measures taken in response have had and continue to have a significant impact, both direct and indirect, on businesses and commerce, as worker shortages continue to occur; supply chains continue to be disrupted; and demand for and costs of certain goods and services, such as medical services and supplies, has spiked. If the COVID-19 pandemic continues for a significant length of time, or if new government measures are introduced, we may experience additional disruptions that could severely impact our business, including in particular the approval of and commercialization of ensifentrine. The extent to which the pandemic impacts our business will depend on future developments, which are highly uncertain and cannot be predicted with confidence.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Our limited operating history may make it difficult for investors to evaluate the success of our business to date and to assess our future viability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Since our inception in 2005, we have devoted substantially all of our resources to developing ensifentrine, building our intellectual property portfolio, developing our supply chain, planning our business, raising capital and providing general and administrative support for these operations. We have completed multiple Phase 1 and 2 clinical trials for ensifentrine, and we have two registrational Phase 3 clinical trials nearing completion. We have not yet successfully obtained regulatory approvals, manufactured a commercial-scale product or arranged for a third party to do so on our behalf or conducted sales and marketing activities necessary for successful product commercialization. Additionally, we are not profitable and have incurred losses in each year since our inception, and we expect our financial condition and operating results to continue to fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Consequently, any predictions investors make about our future success or viability may not be as accurate as they could be if we had a longer operating history.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">The terms of our credit facility place restrictions on our operating and financial flexibility, and our existing and any future indebtedness could adversely affect our ability to operate our business, and our existing and any future indebtedness could adversely affect our ability to operate our business, and our existing and any future indebtedness could adversely affect our ability to operate our business. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In October 2022, we and Verona Pharma, Inc. (&#8220;Verona U.S.&#8221;) entered into a loan and security agreement (the &#8220;Loan Agreement&#8221;), with Oxford Finance Luxembourg S.&#192; R.L. (&#8220;Oxford&#8221;), pursuant to which a term loan facility in an aggregate amount of up to $150.0 million (the &#8220;Term Loan&#8221;) is available to us in five tranches. We received the first tranche of $10.0 million (the &#8220;Term A Loan&#8221;) at closing. Each advance under the Term Loan accrues interest at a floating per annum rate equal to (a) the greater of (i) the 1-Month CME Term SOFR reference rate on the last business day of the month that immediately precedes the month in which the interest will accrue and (ii) 2.38%, plus (b) 5.50% (the &#8220;Basic Rate&#8221;); provided, however, that in no event shall the Basic Rate (x) for the Term A Loan be less than 7.88% and (y) for each other advance be less than the Basic Rate on the business day immediately prior to the funding date of such advance.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our outstanding indebtedness, including any additional indebtedness beyond our borrowings from Oxford, combined with our other financial obligations and contractual commitments could have significant adverse consequences, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">requiring us to dedicate a portion of our cash resources to the payment of interest and principal, reducing money available to fund working capital, capital expenditures, product candidate development and other general corporate purposes;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">increasing our vulnerability to adverse changes in general economic, industry and market conditions;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">subjecting us to restrictive covenants that may reduce our ability to take certain corporate actions or obtain further debt or equity financing;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">limiting our flexibility in planning for, or reacting to, changes in our business and the industry in which we compete; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">placing us at a competitive disadvantage compared to our competitors that have less debt or better debt servicing options.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We intend to satisfy our current and future debt service obligations with our then existing cash and cash equivalents. However, we may not have sufficient funds, and may be unable to arrange for additional financing, to pay the amounts due under the Loan Agreement or any other debt instruments. Failure to make payments or comply with other covenants under the Loan Agreement or such other debt instruments could result in an event of default and acceleration of amounts due. For example, the affirmative covenants under our Loan Agreement include, among others, covenants requiring us (and us to cause our subsidiaries) to maintain our legal existence and governmental approvals, deliver certain financial reports and notifications, maintain proper books of record and account, timely file and pay tax returns, and maintain inventory and insurance coverage. Under the Loan Agreement, the occurrence of a material adverse change in our business, operations, or condition is an event of default. If an event of default occurs and Oxford accelerates the amounts due, we may not be able to make accelerated payments and Oxford could seek to enforce security interests in the collateral securing such indebtedness, which could potentially require us to renegotiate our agreement on terms less favorable to us or to immediately cease operations. Further, if we are liquidated, the lenders&#8217; right to repayment would be senior to the rights of holders of our American Depositary Shares (&#8220;ADS&#8221;) or of our shareholders to receive any proceeds from the liquidation. Any declaration by Oxford of an event of default could significantly harm our business and prospects and could cause the price of our ADSs to decline. In addition, the covenants under the Loan Agreement, the pledge of our assets as collateral and the negative pledge with respect to our intellectual property could limit our ability to obtain additional debt financing. If we raise any additional debt financing, the terms of such additional debt could further restrict our operating and financial flexibility.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Raising additional capital may cause dilution to our holders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of securities offerings, debt financings, license and collaboration agreements and research grants. If we raise capital through securities offerings, the ownership interest of our ADS holders and shareholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect these holders&#8217; rights as holders of our ADSs. Debt financing, if available, could result in fixed payment obligations, and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, to acquire, sell or license intellectual property rights, to make capital expenditures, or to declare dividends, or other operating restrictions. If we raise additional funds through collaboration or licensing agreements, we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. In addition, we could also be required to seek funds through arrangements with collaborators or others at an earlier stage than otherwise would be desirable. If we raise funds through research grants, we may be subject to certain requirements, which may limit our ability to use the funds or require us to share information from our research and development. Raising additional capital through any of these or other means could adversely affect our business and the holdings or rights of our ADS holders and shareholders, and may cause the market price of our ADSs to decline.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Our business may become subject to economic, political, regulatory and other risks associated with international operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As a company based in the United Kingdom and listed on Nasdaq, our business is subject to risks associated with conducting business internationally. Many of our suppliers and collaborative and clinical trial relationships are located outside the United Kingdom and the United States. Accordingly, our future results could be harmed by a variety of factors, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">economic weakness, including inflation, or political instability in particular non-U.S. economies and markets;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">differing regulatory requirements for drug approvals in non-U.S. countries;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">differing jurisdictions could present different issues for securing, maintaining or obtaining freedom to operate in such jurisdictions;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">potentially reduced protection for intellectual property rights;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">difficulties in compliance with non-U.S. laws and regulations;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">changes in non-U.S. regulations and customs, tariffs and trade barriers;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">changes in non-U.S. currency exchange rates of the euro and currency controls;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">changes in a specific country&#8217;s or region&#8217;s political or economic environment;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">trade protection measures, import or export licensing requirements or other restrictive actions by U.S. or non-U.S. governments;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">differing reimbursement regimes and price controls in certain non-U.S. markets;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">negative consequences from changes in tax laws;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">difficulties associated with staffing and managing international operations, including differing labor relations;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">business interruptions resulting from geopolitical actions, including war and terrorism, such as the ongoing conflict between Russia and Ukraine, or natural disasters including earthquakes, typhoons, floods and fires, or public health emergencies, such as the COVID-19 pandemic.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Exchange rate fluctuations may materially affect our results of operations and financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Although we are based in the United Kingdom, our financial statements are denominated in U.S dollars and many of our business activities are carried out with partners outside the U.S. and United Kingdom and these transactions may be denominated in another currency. As a result, our business and the price of our ADSs may be affected by fluctuations in foreign exchange rates not only between the pound sterling and the U.S. dollar, but also the currencies of other countries, which may have a significant impact on our results of operations and cash flows from period to period. Currently, we do not have any exchange rate hedging arrangements in place.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Risks Related to Development, Clinical Testing and Regulatory Approval</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Clinical drug development involves a lengthy and expensive process, with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our only product candidate, ensifentrine, is in clinical development. Clinical drug development is a lengthy and expensive process with uncertain timelines and uncertain outcomes. If clinical trials of ensifentrine are prolonged or delayed, or if ensifentrine in later stage clinical trials fails to show the safety and efficacy required by regulatory authorities, we or our collaborators may be unable to obtain required regulatory approvals and be unable to commercialize ensifentrine on a timely basis, or at all.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">To obtain the requisite regulatory approvals to market and sell ensifentrine, we or any collaborator for ensifentrine must demonstrate through extensive pre-clinical studies and clinical trials that ensifentrine is safe and effective in humans. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of pre-clinical studies and early-stage clinical trials of ensifentrine may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through pre-clinical studies and initial clinical trials. Regulators interpretations of results may differ from our own, and expectations can change over time while a product is in clinical development. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Our future clinical trial results may not be successful.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We may experience delays in our ongoing clinical trials and we do not know whether planned clinical trials will begin on time, need to be redesigned, enroll patients on time or be completed on schedule, if at all. Our clinical trials can be delayed, suspended, or terminated, or the utility of data from these trials may be compromised, for a variety of reasons, including the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">inability to generate sufficient preclinical, toxicology or other in vivo or in vitro data to support the initiation or continuation of clinical trials; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">delays in or failure to obtain regulatory agreement on clinical trial design or implementation, including dose and frequency of administration;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">delays in or failure to obtain regulatory authorization to commence a trial;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">delays in or failure to reach agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">inability of a CRO to meet their contracted obligations regarding subject enrollment, data collection, data monitoring, laboratory sample management, programming and analysis or other activities;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">delays in or failure to obtain institutional review board (&#8220;IRB&#8221;), or ethics committee approval or positive opinion at each site;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">delays in or failure to recruit suitable patients to participate in a trial;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">failure to have patients complete a trial or return for post-treatment follow-up;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">clinical sites deviating from trial protocol or dropping out of a trial or committing gross misconduct or fraud;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">delays to the addition of new clinical trial sites;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">inability to achieve or maintain double blinding of ensifentrine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">unexpected technical issues during manufacture of ensifentrine and the corresponding drug products;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">variability in drug product performance and/or stability;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">discoveries that may reduce the commercial viability of ensifentrine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">inability to manufacture sufficient quantities of ensifentrine for use in clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the quality or stability of ensifentrine falling below acceptable standards for either safety or efficacy;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">third-party actions claiming infringement by ensifentrine in clinical trials and obtaining injunctions interfering with our progress;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">business interruptions resulting from geo-political actions, including war and terrorism, such as the ongoing conflict between Russia and Ukraine, or natural disasters including earthquakes, typhoons, floods and fires;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">trade sanctions imposed by the United States or other governments impacting our ability to transfer money to certain countries, such as Russia, to pay clinical trials sites in those countries;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">safety or tolerability concerns causing us or our collaborators, as applicable, to suspend or terminate a trial if we or our collaborators find that the participants are being exposed to unacceptable health risks;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">changes in regulatory requirements, policies and guidelines;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">lower than anticipated retention rates of patients and volunteers in clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">failure of our third-party research contractors to comply with regulatory requirements or to meet their contractual obligations to us in a timely manner, or at all; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">difficulty in certain countries in identifying the sub-populations that we are trying to evaluate in a particular trial, which may delay enrollment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We could encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by the Data Review Committee or Data Safety Monitoring Board for such trial or by the FDA or other regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, failure of our clinical trials to demonstrate adequate efficacy and safety, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or other regulatory authority. The FDA or other regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or other regulatory authority may therefore </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or other regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of ensifentrine.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If we experience delays in the completion of any clinical trial of ensifentrine or any clinical trial of ensifentrine is terminated, the commercial prospects of ensifentrine may be harmed, and our ability to generate product revenues from ensifentrine, if any, will be delayed. Moreover, any delays in completing our clinical trials will increase our costs, slow down the development and approval process of ensifentrine and jeopardize our ability to commence product sales and generate revenue, if any. Significant clinical trial delays could also allow our competitors to bring products to market before we do or shorten any periods during which we have the exclusive right to commercialize ensifentrine and could impair our ability to commercialize ensifentrine. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of ensifentrine.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Clinical trials must be conducted in accordance with the laws and regulations of the FDA, EU rules and regulations and other applicable regulatory authorities&#8217; legal requirements, regulations or guidelines, and are subject to oversight by these governmental agencies and IRBs (or other ethics committees) at the medical institutions where the clinical trials are conducted. In addition, clinical trials must be conducted with supplies of ensifentrine produced under current good manufacturing practice, or cGMP, and similar foreign requirements and other regulations. Furthermore, we rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and while we have agreements governing their committed activities, we have limited influence over their actual performance. We depend on our collaborators and on medical institutions and CROs to conduct our clinical trials in compliance with good clinical practice, or GCP, requirements. To the extent our collaborators or the CROs fail to enroll participants for our clinical trials, fail to conduct the study to GCP standards or are delayed for a significant time in the execution of trials, including achieving full enrollment, we may be affected by increased costs, program delays or both. In addition, clinical trials that are conducted in countries outside the EU and the United States may subject us to further delays and expenses as a result of increased shipment costs, additional regulatory requirements and the engagement of non-EU and non-U.S. CROs, as well as expose us to risks associated with clinical investigators who are unknown to the FDA or the EMA, and different standards of diagnosis, screening and medical care.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In addition, the FDA&#8217;s and other regulatory authorities&#8217; policies with respect to clinical trials may change and additional government regulations may be enacted. For instance, the regulatory landscape related to clinical trials in the EU recently evolved. The EU Clinical Trials Regulation (&#8220;CTR&#8221;), which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on January 31, 2022. While the Clinical Trials Directive required a separate clinical trial application (&#8220;CTA&#8221;), to be submitted in each member state in which the clinical trial takes place, to both the competent national health authority and an independent ethics committee, the CTR introduces a centralized process and only requires the submission of a single application for multi-center trials. The CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The assessment procedure of the CTA has been harmonized as well, including a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state&#8217;s decision is communicated to the sponsor via the centralized EU portal. Once the CTA is approved, clinical study development may proceed. The CTR foresees a three-year transition period. The extent to which ongoing and new clinical trials will be governed by the CTR varies. Clinical trials for which an application was submitted (i) prior to January 31, 2022 under the Clinical Trials Directive, or (ii) between January 31, 2022 and January 31, 2023 and for which the sponsor has opted for the application of the EU Clinical Trials Directive remain governed by said Directive until January 31, 2025. After this date, all clinical trials (including those which are ongoing) will become subject to the provisions of the CTR. Compliance with the CTR requirements by us and our third-party service providers, such as CROs, may impact our developments plans. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">It is currently unclear to what extent the UK, will seek to align its regulations with the EU. The UK regulatory framework in relation to clinical trials is derived from existing EU legislation (as implemented into UK law, through secondary legislation).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">On January 17, 2022, the UK Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;), launched an eight-week consultation on reframing the UK legislation for clinical trials. The consultation closed on March 14, 2022 and aims to streamline clinical trials approvals, enable innovation, enhance clinical trials transparency, enable greater risk proportionality, and promote patient and public involvement in clinical trials. The outcome of the consultation will be closely watched and will determine whether the UK chooses to align with the (EU) CTR or diverge from it to maintain regulatory flexibility. Under the terms of the Protocol on Ireland/Northern Ireland, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">provisions of the (EU) CTR which relate to the manufacture and import of investigational medicinal products and auxiliary medicinal products apply in Northern Ireland. A decision by the UK Government not to closely align its regulations with the new approach that has been adopted in the EU may have an effect on the cost of conducting clinical trials in the UK as opposed to other countries.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Ensifentrine may have serious adverse, undesirable or unacceptable side effects which may delay or prevent marketing approval. If such side effects are identified during the development of ensifentrine or following approval, if any, we may need to abandon our development of ensifentrine, the commercial profile of any approved label may be limited, or we may be subject to other significant negative consequences following marketing approval, if any.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Undesirable side effects that may be caused by ensifentrine could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. During the conduct of clinical trials, patients report changes in their health, including illnesses, injuries, and discomforts, to their study doctor. Often, it is not possible to determine whether or not the product candidate being studied caused these conditions. It is possible that as we test our product candidates in larger, longer and more extensive clinical trials, or as use of these product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in previous trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by patients. Many times, side effects are only detectable after investigational products are tested in large-scale clinical trials or, in some cases, after they are made available to patients on a commercial scale following approval. We have completed 20 Phase 1, 2 and nearly completed two Phase 3 clinical trials of ensifentrine. In these trials, some patients have experienced mild to moderate adverse reactions, including headache, cough, worsening of COPD, nasopharyngitis and hypertension.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Results of our future clinical trials could reveal a high and unacceptable severity and prevalence of adverse side effects. In such an event, our trials could be suspended or terminated and the FDA or other comparable foreign regulatory authorities could order us to cease further development of or deny approval of ensifentrine for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Additionally, if ensifentrine receives marketing approval and we or others later identify undesirable or unacceptable side effects caused by ensifentrine, a number of potentially significant negative consequences could result, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">regulatory authorities may withdraw approvals of such products and require us to take ensifentrine off the market;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and pharmacies;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">regulatory authorities may require a medication guide outlining the risks of such side effects for distribution to patients, or that we implement a REMS plan or similar risk management measures to ensure that the benefits of ensifentrine outweigh its risks;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">we may be required to change the way ensifentrine is administered, conduct additional clinical trials or change the labeling of ensifentrine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">we may be subject to limitations on how we may promote ensifentrine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">sales of ensifentrine may decrease significantly;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">we may be subject to litigation or product liability claims; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">our reputation may suffer.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Any of these events could prevent us or any collaborators from achieving or maintaining market acceptance of ensifentrine or could substantially increase commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenue from the sale of ensifentrine.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We may not be successful in our efforts to develop ensifentrine for multiple indications, including asthma, CF or other respiratory diseases.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Part of our strategy is to continue to develop ensifentrine in indications other than COPD, such as CF and asthma and other formulations including fixed-dose combinations, MDI and DPI. Although our research and development efforts to date have suggested that ensifentrine has the potential to treat CF and asthma, we may not be able to develop ensifentrine in these indications or any other disease, or development may not be successful. In addition, the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">potential use of ensifentrine in other diseases may not be suitable for clinical development, including as a result of difficulties enrolling patients in any clinical studies we plan to initiate or the potential for harmful side effects or other characteristics that might suggest marketing approval and market acceptance are unlikely. If we do not continue to successfully develop and begin to commercialize ensifentrine for multiple indications or formulations, we will face difficulty in obtaining product revenues in future periods, which could significantly harm our financial position.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We depend on enrollment of patients in our clinical trials for ensifentrine. If we are unable to enroll patients in our clinical trials, or enrollment is slower than anticipated, our research and development efforts could be adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Successful and timely completion of clinical trials for ensifentrine will require that we enroll a sufficient number of patient candidates. Trials may be subject to delays as a result of patient enrollment taking longer than anticipated or patient withdrawal and other external factors including COVID-19. Patient enrollment depends on many factors, including the size and nature of the patient population, the severity of the disease under investigation, eligibility criteria for the trial, the proximity of patients to clinical sites, the design of the clinical protocol, the ability to obtain and maintain patient consents, the risk that enrolled patients will drop out of a trial, the availability of competing clinical trials, the availability of new drugs approved for the indication the clinical trial is investigating and clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the drug being studied in relation to other available therapies. These factors may make it difficult for us to enroll enough patients to complete our clinical trials in a timely and cost-effective manner. Higher than expected numbers of patients could also discontinue participation in the clinical trials. Delays in the completion of any clinical trial of ensifentrine will increase our costs, slow down our development and approval of ensifentrine and delay or potentially jeopardize our ability to commence product sales and generate revenue. In addition, some of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of ensifentrine.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We may become exposed to costly and damaging liability claims, either when testing ensifentrine in the clinic or at the commercial stage, and our product liability insurance may not cover all damages from such claims.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing, marketing and use of pharmaceutical products. Currently, we have no products that have been approved for commercial sale; however, the current and future use of ensifentrine by us and any collaborators in clinical trials, and the sale of ensifentrine, if approved, in the future, may expose us to liability claims. These claims might be made by patients that use the product, healthcare providers, pharmaceutical companies, our collaborators or others selling ensifentrine. Any claims against us, regardless of their merit, could be difficult and costly to defend and could adversely affect the market for ensifentrine or any prospects for commercialization of ensifentrine. In addition, regardless of the merits or eventual outcome, liability claims may result in:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">decreased demand for ensifentrine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">injury to our reputation;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">withdrawal of clinical trial participants;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">costs to defend related litigation;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">diversion of management&#8217;s time and our resources;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">substantial monetary awards to trial participants or patients;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">regulatory investigation, product recalls or withdrawals, or labeling, marketing or promotional restrictions;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">loss of revenue; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the inability to commercialize or promote ensifentrine.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Although the clinical trial process is designed to identify and assess potential side effects, it is always possible that a drug, even after regulatory approval, may exhibit unforeseen side effects. If ensifentrine were to cause adverse side effects during clinical trials or after approval, we may be exposed to substantial liabilities. Physicians and patients may not comply with any warnings that identify known potential adverse effects and patients who should not use ensifentrine.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Although we maintain product liability insurance for ensifentrine, it is possible that our liabilities could exceed our insurance coverage. We intend to expand our insurance coverage to include the sale of commercial products if we </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">obtain marketing approval for ensifentrine. However, we may not be able to maintain insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that may arise. If a successful product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">The regulatory approval processes of the FDA, the EMA and comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for ensifentrine, our business will be substantially harmed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The time required to obtain approval by the FDA, the European Commission and comparable foreign regulatory authorities is unpredictable, but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for ensifentrine and it is possible that ensifentrine or any product candidates we may develop in the future will never obtain regulatory approval.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we or our collaborators must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA or foreign regulatory agencies, that such product candidate is safe and effective for its intended uses. Results from nonclinical studies and clinical trials can be interpreted in different ways. Even if we believe the nonclinical or clinical data for our product candidate are promising, such data may not be sufficient to support approval by the FDA and other regulatory authorities. The FDA or foreign regulatory agencies may also require us to conduct additional preclinical studies or clinical trials for ensifentrine either prior to or post-approval, or it may object to elements of our clinical development program.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Ensifentrine could fail to receive regulatory approval for many reasons, including the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">we may be unable to demonstrate to the satisfaction of the FDA, the EMA or comparable foreign regulatory authorities that ensifentrine is safe and effective, with the required level of statistical significance, for its proposed indication;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">we may be unable to demonstrate that ensifentrine&#8217;s benefits outweigh its safety risks;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the FDA, the EMA or comparable foreign regulatory authorities may disagree with our interpretation of data from pre-clinical studies or clinical trials or may find the data to be unacceptable;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the FDA, the EMA or comparable foreign regulatory authorities may find that the dose or doses evaluated in Phase 3 clinical trials or the way in which double blinding was effected to be unacceptable;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the data collected from clinical trials of ensifentrine may, for various reasons, be insufficient to support the submission or approval of an NDA in the United States, a marketing authorization application (&#8220;MAA&#8221;) in the EU, or other comparable submission to obtain regulatory approval in other countries;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">FDA or comparable regulatory authorities may identify issues of GCP noncompliance or unacceptable practices at clinical sites or CROs participating in our clinical studies, rendering clinical data insufficient to support approval;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the FDA, the EMA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the FDA, the EMA or comparable foreign regulatory authorities may disagree with our proposed product specifications and performance characteristics.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">This lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market ensifentrine. The FDA, the EMA and other regulatory authorities have substantial discretion in the approval process, and determining when or whether regulatory approval will be obtained </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">for ensifentrine. Even if we believe the data collected from clinical trials of ensifentrine are promising, such data may not be sufficient to support approval by the FDA, the European Commission or any other regulatory authority.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In addition, even if we were to obtain approval for any jurisdiction, regulatory authorities may approve ensifentrine for fewer or more limited indications than we request, may not approve the price we intend to charge for ensifentrine, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve ensifentrine with a label that does not include the labeling claims necessary or desirable for the successful commercialization of ensifentrine. Any of the foregoing scenarios could materially harm the commercial prospects for ensifentrine.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In addition, FDA and foreign regulatory authorities may change their approval policies and new regulations may be enacted. For instance, the EU pharmaceutical legislation is currently undergoing a complete review process, in the context of the Pharmaceutical Strategy for Europe initiative, launched by the European Commission in November 2020. The European Commission&#8217;s proposal for revision of several legislative instruments related to medicinal products (potentially revising the duration of regulatory exclusivity, eligibility for expedited pathways, etc.) is currently expected during the first quarter of 2023. The proposed revisions, once they are agreed and adopted by the European Parliament and European Council (not expected before the end of 2024 or early 2025) may have a significant impact on the biopharmaceutical industry in the long term.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The ability of the FDA and foreign regulatory authorities to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s or foreign regulatory authorities&#8217; ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s or foreign regulatory authorities&#8217; ability to perform routine functions. Average review times at the FDA and foreign regulatory authorities have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies, such as the EMA following its relocation to Amsterdam and resulting staff changes, may also slow the time necessary for new drugs, or modifications to cleared or approved drugs, to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Separately, in response to the COVID-19 pandemic, the FDA postponed most inspections of domestic and foreign manufacturing facilities at various points. Even though the FDA has since resumed standard inspection operations of domestic facilities where feasible, the FDA has continued to monitor and implement changes to its inspectional activities to ensure the safety of its employees and those of the firms it regulates as it adapts to the evolving COVID-19 pandemic, and any resurgence of the virus or emergence of new variants may lead to further inspectional delays. Regulatory authorities outside the United States have adopted similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Even if ensifentrine obtains regulatory approval, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense. Additionally, ensifentrine, if approved, could be subject to labeling and other restrictions and market withdrawal and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with ensifentrine.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If the FDA or a comparable foreign regulatory authority approves ensifentrine, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and record keeping for ensifentrine will be subject to extensive and ongoing regulatory requirements. These requirements include payment of annual user fees, submissions of safety and other post-marketing information and reports, facility registration and drug listing, as well as continued compliance with cGMP and similar foreign requirements for the manufacture of ensifentrine and GCP requirements for any clinical trials that we conduct post-approval, all of which may result in significant expense and limit our ability to commercialize ensifentrine. In addition, any approval we may obtain for ensifentrine may contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">requirements. For example, the FDA may require a REMS in order to approve our product candidates, which could entail requirements for a medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We and our contract manufacturers will also be subject to periodic inspection by the FDA and other regulatory authorities to monitor compliance with these requirements and the terms of any product approval we may obtain. If we or a regulatory authority discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facilities where the product is manufactured, a regulatory authority may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. In addition, failure to comply with FDA and other comparable foreign regulatory requirements may subject our company to administrative or judicially imposed sanctions, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">delays in or the rejection of product approvals;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">restrictions on the products, manufacturers or manufacturing process;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">warning or untitled letters;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">civil and criminal penalties;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">injunctions;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">suspension or withdrawal of regulatory approvals;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">product seizures, detentions or import bans;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">voluntary or mandatory product recalls and publicity requirements;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">total or partial suspension of production; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">imposition of restrictions on operations, including costly new manufacturing requirements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The occurrence of any event or penalty described above may inhibit our ability to commercialize ensifentrine and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In addition, the policies of the FDA and of other regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may be subject to enforcement action and we may not achieve or sustain profitability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">The FDA and other foreign regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If ensifentrine is approved for any indication and we are found to have improperly promoted off-label uses for ensifentrine, we may become subject to significant liability. The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products, such as our product candidates, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&#8217;s approved labeling. If we receive marketing approval for a product candidate, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability. The U.S. federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of ensifentrine, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In Europe, off-label use is not per se regulated by the EU pharmaceutical legislation and a difference is made between the strict regulation of medicinal product and the use of medicinal products in medical practice. Off-label use is deferred to national regulation and may vary depending on the EU Member State(s).</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Even if we obtain marketing approval of ensifentrine for any indication in a major pharmaceutical market such as the United States or EU, we may never obtain approval or commercialize ensifentrine in other major markets, which would limit our ability to realize its full market potential.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In order to market any products in a country or territory, we must establish and comply with numerous and varying regulatory requirements of such country or territory regarding safety and efficacy. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval procedures vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking regulatory approvals in all major markets could result in significant delays, difficulties and costs for us and may require additional pre-clinical studies or clinical trials which would be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of ensifentrine in those countries. Satisfying these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. In addition, our failure to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory approval in other countries. We currently do not have any product candidates approved for sale in any jurisdiction, whether in the EU, the United States or any other international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, our target market will be reduced and our ability to realize the full market potential of ensifentrine will be compromised.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Our employees and independent contractors, including principal investigators, CROs, consultants, vendors and collaboration partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are exposed to the risk that our employees and independent contractors, including principal investigators, CROs, consultants, vendors and collaboration partners may engage in fraudulent conduct or other illegal activities. Misconduct by these parties could include intentional, reckless or negligent conduct or unauthorized activities that violate: (i) the laws and regulations of the FDA, the EU and other similar regulatory bodies and the EU, including those laws that require the reporting of true, complete and accurate information to such authorities; (ii) manufacturing standards; (iii) federal and state data privacy, security, fraud and abuse and other healthcare laws and regulations in the United States and abroad; or (iv) laws that require the reporting of true, complete and accurate financial information and data. Specifically, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws could also involve the improper use or misrepresentation of information obtained in the course of clinical trials, creating fraudulent data in our pre-clinical studies or clinical trials or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid and other U.S. federal healthcare programs or healthcare programs in other jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Interim, &#8220;top-line,&#8221; or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">From time to time, we may publicly disclose top-line or preliminary data from our clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the top-line or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Top-line or preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the top-line or preliminary data we previously published. As a result, top-line and preliminary data should be viewed with caution until the final data are available.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between interim data and final data could significantly harm our business prospects. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If the interim, top-line or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Risks Related to Healthcare Laws and Other Legal Compliance Matters</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize ensifentrine and may affect the prices we may set.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the United States, the EU and other foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, was enacted, which substantially changes the way healthcare is financed by both governmental and private insurers. Among the provisions of the ACA, those of greatest importance to the pharmaceutical and biotechnology industries include the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">an annual, non-deductible fee payable by any entity that manufactures or imports certain branded prescription drugs and biologic agents, which is apportioned among these entities according to their market share in certain government healthcare programs;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13.0% of the average manufacturer price for branded and generic drugs, respectively;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">extension of a manufacturer&#8217;s Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#8217;s Medicaid rebate liability;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">establishment of a Center for Medicare and Medicaid Innovation at the Centers for Medicare and Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#8217;s decision, President Biden issued an executive order initiating a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, the Budget Control Act of 2011 has, among other things, led to aggregate reductions of Medicare payments to providers, which, due to subsequent legislative amendments to the statute, will remain in effect through 2032, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022, unless additional action is taken by Congress. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. In addition, the American Rescue Plan Act of 2021 was signed into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, beginning January 1, 2024. These laws and any laws enacted in the future may result in additional reductions in Medicare and other health care funding, which could have a material adverse effect on our customers and accordingly, our financial operations.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products. Most recently, on August 16, 2022, the Inflation Reduction Act of 2022, or IRA, was signed into law. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of the Department of Health and Human Services, or HHS, to implement many of these provisions through guidance, as opposed to regulation, for the initial years. For that and other reasons, it is currently unclear how the IRA will be effectuated. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for ensifentrine or additional pricing pressures.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for ensifentrine or put pressure on our product pricing.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the EU, similar political, economic and regulatory developments may affect our ability to profitably commercialize ensifentrine, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the EU or member state level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of health care in the EU, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than EU, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing EU and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of ensifentrine, restrict or regulate post-approval activities and affect our ability to commercialize ensifentrine, if approved. In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">On December 13, 2021, Regulation No 2021/2282 on Health Technology Assessment (&#8220;HTA&#8221;) amending Directive 2011/24/EU, was adopted. While the Regulation entered into force in January 2022, it will only begin to apply from January 2025 onwards, with preparatory and implementation-related steps to take place in the interim. Once the Regulation becomes applicable, it will have a phased implementation depending on the concerned products. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">While the Regulation entered into force in January 2022, it will only begin to apply from January 2025 onwards, with preparatory and implementation-related steps to take place in the interim. Once the Regulation becomes applicable, it will have a phased implementation depending on the concerned products. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">This regulation intends to boost cooperation among EU member states in assessing health technologies, including new medicinal products, and providing the basis for cooperation at the EU level for joint clinical assessments in these areas. The regulation will permit EU member states to use common HTA tools, methodologies, and procedures across the EU, working together in four main areas, including joint clinical assessment of the innovative health technologies with the most potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual EU member states will continue to be responsible for assessing non-clinical (e.g., economic, social, ethical) aspects of health technology, and making decisions on pricing and reimbursement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we or our collaborators are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or our collaborators are </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">not able to maintain regulatory compliance, ensifentrine may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors and customers, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute ensifentrine, if approved. Such laws include:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the U.S. federal false claims and civil monetary penalties laws, including the civil False Claims Act, which, among other things, impose criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services; similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the U.S. federal legislation commonly referred to as Physician Payments Sunshine Act, enacted as part of the ACA, and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to the government information related to certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain non-physician practitioners (physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiology assistants and certified nurse-midwives), and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">analogous state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; and state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">in the EU, interactions between pharmaceutical companies and health care professionals and health care organizations, are also governed by strict laws, regulations, industry self-regulation codes of conduct and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">physicians&#8217; codes of professional conduct both at EU level and in the individual EU member states. The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of pharmaceutical products is prohibited in the EU. Relationships with healthcare professionals and associations are subject to stringent anti-gift statutes and anti-bribery laws, the scope of which differs across the EU. In addition, national &#8220;Sunshine Acts&#8221; may require pharmaceutical companies to report/publish transfers of value provided to health care professionals and associations on a regular (e.g. annual) basis. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Ensuring that our internal operations and business arrangements with third parties comply with applicable healthcare laws and regulations involves substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from U.S. government funded healthcare programs, such as Medicare and Medicaid, or similar programs in other countries or jurisdictions, a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment, which could affect our ability to operate our business. Further, defending against any such actions can be costly, time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The global data protection landscape is rapidly evolving, and we are or may become subject to numerous state, federal and foreign laws, requirements and regulations governing the collection, use, disclosure, retention, and security of personal information, such as information that we may collect in connection with clinical trials. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business, affect our ability to operate in certain jurisdictions or to collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us to comply with federal, state or foreign laws or regulations, our internal policies and procedures or our contracts governing our processing of personal information could result in negative publicity, government investigations and enforcement actions, claims by third parties and damage to our reputation, any of which could have a material adverse effect on our business, results of operation, and financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As our operations and business grow, we may become subject to or affected by new or additional data protection laws and regulations and face increased scrutiny or attention from regulatory authorities. In the United States, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and regulations implemented thereunder, or collectively HIPAA, imposes, among other things, certain standards relating to the privacy, security, transmission and breach reporting of individually identifiable health information. Most healthcare providers, including research institutions from which we obtain patient health information, are subject to privacy and security regulations promulgated under HIPAA. We do not believe that we are currently acting as a covered entity or business associate under HIPAA and thus are not directly subject to its requirements or penalties. However, depending on the facts and circumstances, we could face substantial criminal penalties if we knowingly receive individually identifiable health information from a HIPAA-covered healthcare provider or research institution that has not satisfied HIPAA&#8217;s requirements for disclosure of individually identifiable health information. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Certain states have also adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. For example, California enacted the California Consumer Privacy Act, (&#8220;CCPA&#8221;), which went into effect on January 1, 2020. The CCPA, among other things, creates data privacy obligations for covered companies and provides privacy rights to California consumers, including rights to access and delete their information, to opt out of certain information sharing, and receive detailed information about how their personal </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">information is used. The CCPA also creates a private right of action with statutory damages for certain data breaches, thereby potentially increasing risks associated with a data breach. Although the law includes limited exceptions for health-related information, it may regulate or impact our processing of personal information depending on the context. Further, the California Privacy Rights Act (&#8220;CPRA&#8221;) generally went into effect on January 1, 2023 and significantly amends the CCPA. It imposes additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It also creates a new California data protection agency authorized to issue substantive regulations and will likely result in increased privacy and information security enforcement. Additional compliance investment and potential business process changes may be required. Similar laws have passed in Virginia, Connecticut, Utah and Colorado, and have been proposed in other states and at the federal level, reflecting a trend toward more stringent privacy legislation in the United States. The enactment of such laws could have potentially conflicting requirements that would make compliance challenging. In the event that we are subject to or affected by HIPAA, the CCPA, the CPRA or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are also subject to diverse laws and regulations relating to data privacy and security in the EU and the EEA, including the GDPR. The GDPR went into effect in May 2018 and imposes strict requirements for processing the personal data of individuals within the EEA. The GDPR imposes strict obligations on the ability to process health-related and other personal data of individuals within the EEA, including in relation to use, collection, analysis, and transfer (including cross-border transfer) of such personal data. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. The law is also developing rapidly and in July 2020, the Court of Justice of the EU limited how organizations could lawfully transfer personal data from the EEA to the U.S. by invalidating the Privacy Shield for purposes of international transfers and imposing further restrictions on the used of standard contractual clauses. In March 2022, the U.S. and EU announced a new regulatory regime intended to replace the invalidated regulations; however, this new EU-U.S. Data Privacy Framework has not been implemented beyond an executive order signed by President Biden on October 7, 2022 on Enhancing Safeguards for United States Signals Intelligence Activities. European court and regulatory decisions subset to the CJEU decision of July 2020 have taken a restrictive approach to international data transfers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Relatedly, since the beginning of 2021, following the United Kingdom&#8217;s withdrawal from the EEA and the European Union, and the expiry of the transition period, companies have had to comply with both the GDPR and the GDPR as incorporated into United Kingdom national law, the latter regime having the ability to separately fine up to the greater of &#163;17.5 million or 4% of global turnover. The relationship between the United Kingdom and the European Union in relation to certain aspects of data protection law remains unclear, for example around how data can lawfully be transferred between each jurisdiction, which exposes us to further compliance risk. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Compliance with applicable data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure by us or our collaborators and third-party providers to comply with applicable data protection laws and regulations could result in government enforcement actions (which could include civil or criminal penalties), private litigation and/or adverse publicity and could negatively affect our operating results and business. Moreover, clinical trial subjects about whom we or our potential collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose such information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws or breached our contractual obligations, even if we are not found liable, could be expensive and time consuming to defend, could result in adverse publicity and could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">The increasing focus on environmental sustainability and social initiatives could increase our costs, harm our, reputation and adversely impact our financial results. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">There has been increasing public focus by investors, environmental activists, the media and governmental and nongovernmental organizations on a variety of environmental, social and other sustainability matters. We may experience pressure to make commitments relating to sustainability matters that affect us, including the design and implementation of specific risk mitigation strategic initiatives relating to sustainability. If we are not effective in addressing environmental, social and other sustainability matters affecting our business, or setting and meeting relevant sustainability goals, our reputation and financial results may suffer. In addition, we may experience </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">increased costs in order to execute upon our sustainability goals and measure achievement of those goals, which could have an adverse impact on our business and financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In addition, this emphasis on environmental, social and other sustainability matters has resulted and may result in the adoption of new laws and regulations, including new reporting requirements. If we fail to comply with new laws, regulations or reporting requirements, our reputation and business could be adversely impacted.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We are subject to environmental, health and safety laws and regulations, and we may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our sub-contracted operations, including our research, development, testing and manufacturing activities, are subject to numerous environmental, health and safety laws and regulations. These laws and regulations govern, among other things, the controlled use, handling, release and disposal of and the maintenance of a registry for, hazardous materials and biological materials, such as chemical solvents, human cells, carcinogenic compounds, mutagenic compounds and compounds that have a toxic effect on reproduction, laboratory procedures and exposure to blood-borne pathogens. If we fail to comply with such laws and regulations, we could be subject to fines or other sanctions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As with other companies engaged in activities similar to ours, we face a risk of environmental liability inherent in our current and historical activities, including liability relating to releases of or exposure to hazardous or biological materials. Environmental, health and safety laws and regulations are becoming more stringent. We may be required to incur substantial expenses in connection with future environmental compliance or remediation activities, in which case, our production and development efforts may be interrupted or delayed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We are subject to anti-corruption laws, as well as export control laws, customs laws, sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures and legal expenses.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our operations are subject to anti-corruption laws, including the U.K. Bribery Act 2010, or Bribery Act, the U.S. Foreign Corrupt Practices Act, or FCPA, and other anti-corruption laws that apply in countries where we do business and may do business in the future. The Bribery Act, FCPA and these other laws generally prohibit us, our officers and our employees and intermediaries from bribing, being bribed or making other prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage. We may in the future operate in jurisdictions that pose a high risk of potential Bribery Act or FCPA violations, and we may participate in collaborations and relationships with third parties whose actions could potentially subject us to liability under the Bribery Act, FCPA or local anti-corruption laws. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which any of our international operations might be subject or the manner in which existing laws might be administered or interpreted.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We also are subject to other laws and regulations governing any international operations, including regulations administered by the governments of the United Kingdom and the United States, and authorities in the EU, including applicable export control regulations, economic sanctions on countries and persons, customs requirements and currency exchange regulations, or, collectively, the Trade Control laws. In particular, we engaged a number of clinical trial sites in Russia in connection with our Phase 3 ENHANCE clinical program and, with the ongoing conflict between Russia and Ukraine, and resulting sanctions imposed by the United States and other governments, there is an increased risk that our ability to pay clinical sites or conduct clinical trials in Russia, may be impacted.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">There is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the Bribery Act, the FCPA or other legal requirements, including Trade Control laws. If we are not in compliance with the Bribery Act, the FCPA and other anti-corruption laws or Trade Control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures and legal expenses. Any investigation of any potential violations of the Bribery Act, the FCPA, other anti-corruption laws or Trade Control laws by U.K., U.S. or other authorities, even if it is ultimately determined that we did not violate such laws, could be costly and time consuming, require significant personnel resources and harm our reputation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We will seek to build and continuously improve our systems of internal controls and to remedy any weaknesses identified. There can be no assurance, however, that the policies and procedures will be followed at all times or effectively detect and prevent violations of the applicable laws by one or more of our employees, consultants, agents or collaborators and, as a result, we could be subject to fines, penalties or prosecution.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Risks Related to Commercialization</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We operate in a highly competitive and rapidly changing industry, which may result in others discovering, developing or commercializing competing products before or more successfully than we do.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The biopharmaceutical and pharmaceutical industries are highly competitive and subject to significant and rapid technological change. Our success is highly dependent on our ability to discover, develop and obtain marketing approval for new products on a cost-effective basis and to market them successfully. If ensifentrine is approved for any indication, we will face intense competition from a variety of businesses, including large, fully integrated pharmaceutical companies, specialty pharmaceutical companies and biopharmaceutical companies, academic institutions, government agencies and other private and public research institutions in Europe, the United States and other jurisdictions. These organizations may have significantly greater resources than we do and conduct similar research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and marketing of products that may compete with ensifentrine.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Given the number of products already on the market to treat COPD, asthma and CF, we expect to face intense competition if ensifentrine is approved for these indications. Companies including Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca, Novartis, Vertex, Viatris, Theravance, Gilead, Genentech and Sunovion currently have treatments on the market for COPD, CF and asthma, and we anticipate that new companies will enter these markets in the future. If we successfully develop and commercialize ensifentrine, it will compete with existing therapies and new therapies that may become available in the future. The highly competitive nature of, and rapid technological changes in, the biopharmaceutical and pharmaceutical industries could render ensifentrine obsolete, less competitive or uneconomical. Our competitors may, among other things:</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">have significantly greater name recognition, financial, manufacturing, marketing, drug development, technical and human resources than we do, and future mergers and acquisitions in the biopharmaceutical and pharmaceutical industries may result in even more resources being concentrated in our competitors;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">develop and commercialize products that are safer, more effective, less expensive, more convenient or easier to administer, or have fewer or less severe side effects;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">obtain quicker regulatory approval;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">establish superior proprietary positions covering our products and technologies;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">implement more effective approaches to sales and marketing; or</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">form more advantageous strategic alliances.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Smaller and other early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. In addition, any collaborators we may have may decide to market and sell products that compete with ensifentrine. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are more effective, have fewer or less severe side effects, are more convenient or are less expensive than ensifentrine. Our competitors may also obtain FDA or other regulatory approval for their product candidates more rapidly than we may obtain approval for ours, which could result in our competitors establishing or strengthening their market position before we are able to enter the market.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We may be unable to obtain orphan drug designation from the FDA or similar foreign authorities for ensifentrine for the treatment of CF, and even if we do obtain such designations, we may be unable to obtain or maintain the benefits associated with orphan drug designation, including the potential for orphan drug exclusivity.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is intended to treat a rare disease or condition, defined as one occurring in a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the EU, orphan designation may be granted by the European Commission after receiving the opinion of the EMA&#8217;s Committee for Orphan Medicinal Products to promote the development of products (1) that are intended for the diagnosis, prevention or treatment that is life-threatening or chronically debilitating, and (2) either (a) such condition affects no more than five in 10,000 persons in the EU when the application is made, or (b) the product, without the benefits derived from orphan status, would be unlikely to generate sufficient returns in the EU to justify the necessary investment, and (3) there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU, or, if such a method exists, the medicine must be of significant benefit to those affected by the condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding toward clinical trial costs, tax credits for qualified clinical testing and application fee waivers. In addition, if a product receives the first FDA approval of that drug for the indication for which it has orphan designation, the product is entitled to orphan drug exclusivity, which means the FDA may not approve any other application to market the same drug for the same indication for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity or where the manufacturer is unable to assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the rare disease or condition. Under the FDA&#8217;s regulations, the FDA will deny orphan drug exclusivity to a designated drug upon approval if the FDA has already approved another drug with the same active ingredient for the same indication, unless the drug is demonstrated to be clinically superior to the previously approved drug. In the EU, orphan drug designation entitles a party to financial incentives such as reduction of fees or fee waivers. Upon grant of a marketing authorization, orphan medicinal products are entitled to ten years of market exclusivity for the approved therapeutic indication, during which time no similar medicinal product for the same indication may be placed on the market. However, during such period, marketing authorizations may be granted to a similar medicinal product with the same orphan indication if: (i) the applicant can establish that the second medicinal product, although similar to the orphan medicinal product already authorized is safer, more effective or otherwise clinically superior to the orphan medicinal product already authorized; (ii) the marketing authorization holder for the orphan medicinal product is unable to supply sufficient quantities of product. The European exclusivity period may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the orphan designation criteria, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity, or when the prevalence of the condition has increased above the orphan designation threshold.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We may seek orphan drug designation from the FDA and the European Commission (and comparable authorities) for ensifentrine for the treatment of CF. Even if we are able to obtain orphan designation for ensifentrine in the United States and/or the EU (and/or other foreign jurisdictions), we may not be the first to obtain marketing approval for any particular orphan indication due to the uncertainties associated with developing pharmaceutical products, which could prevent us from marketing ensifentrine if another company is able to obtain orphan drug exclusivity before we do. In addition, exclusive marketing rights in the United States and/or the EU may be unavailable if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA and/or foreign regulatory authorities later determine that the request for designation was materially defective or if we are unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition following approval. Further, even if we obtain orphan drug exclusivity for ensifentrine, that exclusivity may not effectively protect ensifentrine from competition because different drugs with different active moieties can be approved for the same condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In addition, the FDA or foreign regulatory authorities can subsequently approve products with the same active moiety for the same condition if the FDA or foreign regulatory authorities conclude that the later drug is clinically superior on the basis of greater safety, greater effectiveness, or a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. In addition, while we intend to seek orphan drug designation for ensifentrine for the treatment of CF, we may never receive such designation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">The successful commercialization of ensifentrine will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels and pricing policies for ensifentrine. Failure to obtain or maintain adequate coverage and reimbursement for ensifentrine, if approved, could limit our ability to market ensifentrine and decrease our ability to generate revenue.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The availability and adequacy of coverage and reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford prescription medications such as ensifentrine, assuming approval. Our ability to achieve acceptable levels of coverage and reimbursement by governmental authorities, private health insurers and other organizations will have an effect on our ability to successfully commercialize ensifentrine. Assuming we obtain coverage for ensifentrine by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. Moreover, for drugs and biologics administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such products. We cannot be sure that coverage and reimbursement in the United States, the EU or elsewhere will be available for ensifentrine or any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs when an equivalent generic drug or a less expensive therapy is available. It is possible that a third-party payor may consider ensifentrine as substitutable and only offer to reimburse patients for the less expensive product. Even if we show improved efficacy or improved convenience of administration with ensifentrine, pricing of existing drugs may limit the amount we will be able to charge for ensifentrine. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in ensifentrine. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize ensifentrine, and may not be able to obtain a satisfactory financial return on ensifentrine.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and biologics will be covered. The Medicare and Medicaid programs increasingly are used as models for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for ensifentrine.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Obtaining and maintaining reimbursement status is time consuming and costly. No uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of ensifentrine to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases at short notice, and we believe that changes in these rules and regulations are likely. Specifically, we believe that Medicare Part B will play an important role in the reimbursement of ensifentrine. Changes within how products are reimbursed through Medicare Part B could occur and those changes may affect the overall coverage of ensifentrine in the future. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe and other countries has and will continue to put pressure on the pricing and usage of ensifentrine. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for ensifentrine. Accordingly, in markets outside the United States, the reimbursement for ensifentrine may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for ensifentrine. We expect to experience pricing pressures in connection with the sale of ensifentrine due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In addition, even if a pharmaceutical product obtains a marketing authorization in the EU, there can be no assurance that reimbursement for such product will be secured on a timely basis or at all. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Ensifentrine may not gain market acceptance, in which case our ability to generate product revenues will be compromised.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Even if the FDA or any other regulatory authority approves the marketing of ensifentrine, whether developed on our own or with a collaborator, physicians, healthcare providers, patients or the medical community may not accept or use ensifentrine. If ensifentrine does not achieve an adequate level of acceptance, we may not generate significant product revenues or any profits from operations. The degree of market acceptance of ensifentrine will depend on a variety of factors, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the timing of market introduction;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the number and clinical profile of competing products;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the clinical indications for which ensifentrine is approved;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">our ability to provide acceptable evidence of safety and efficacy;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the prevalence and severity of any side effects;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">relative convenience, frequency, and ease of administration;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">cost effectiveness;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">marketing, sales, and distribution support;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">availability of adequate coverage, reimbursement and adequate payment from health maintenance organizations and other insurers, both public and private; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">other potential advantages over alternative treatment methods</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If ensifentrine fails to gain market acceptance, this will adversely impact our ability to generate revenues. Even if ensifentrine achieves market acceptance, the market may prove not to be large enough to allow us to generate significant revenues.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We currently have limited commercial capabilities and infrastructure, including sales, marketing, operations, distribution, and reimbursement infrastructure. If we are unable to develop commercial capabilities and infrastructure, including sales, marketing, operations, distribution and reimbursement capabilities on our own or through collaborations, we may not be successful in commercializing ensifentrine.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We have limited sales, marketing, or operations, distribution or reimbursement capabilities and infrastructure and we have not previously marketed, sold or distributed pharmaceutical products. The establishment of commercial capabilities and infrastructure, including sales, marketing, operations, distribution, and reimbursement with technical expertise and supporting distribution capabilities to commercialize ensifentrine, is expensive and time consuming. Some or all of these costs may be incurred in advance of any approval of ensifentrine. In addition, we may not be able to hire a sales force that is sufficient in size or has adequate expertise in the medical markets that we intend to target. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of ensifentrine.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">To the extent that we enter into collaboration agreements with respect to marketing, sales or distribution, our product revenue may be lower than if we directly marketed or sold ensifentrine, if approved. In addition, any revenue we receive will depend in whole or in part upon the efforts of these third-party collaborators, which may not be successful and are generally not within our control. If we are unable to enter into these arrangements on acceptable terms or at all, we may not be able to successfully commercialize ensifentrine. If we are not successful in commercializing ensifentrine, either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we may incur significant additional losses.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Risks Related to Our Dependence on Third Parties</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We rely, and expect to continue to rely, on third parties, including independent clinical investigators and CROs, to conduct our pre-clinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize ensifentrine and our business could be substantially harmed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We have relied upon and plan to continue to rely upon third parties, including independent clinical investigators and CROs, to conduct our pre-clinical studies and clinical trials and to monitor and manage data for our ongoing pre-clinical and clinical programs. We rely on these parties for execution of our pre-clinical studies and clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. We and our third-party contractors and CROs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA, and comparable foreign regulatory authorities for all of our products in clinical development. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, principal investigators and trial sites. If we fail to exercise adequate oversight over any of our CROs or if we or any of our CROs fail to comply with applicable GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, the EMA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot provide assurance that upon a regulatory inspection of us or our CROs or other third parties performing services in connection with our clinical trials, such regulatory authority will determine that any of our clinical trials complies with GCP regulations. In addition, our clinical trials must be conducted with product produced under applicable cGMP and similar foreign regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Further, these investigators and CROs are not our employees and we will not be able to control, other than by contract, the amount of resources, including time, which they devote to ensifentrine and clinical trials. If independent investigators or CROs fail to devote sufficient resources to the development of ensifentrine, or if their performance is substandard, it may delay or compromise the prospects for approval and commercialization of ensifentrine. In addition, the use of third-party service providers requires us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our existing and future CROs have or may have the right to terminate their agreements with us in the event of an uncured material breach. In addition, some of our CROs have an ability to terminate their respective agreements with us if it can be reasonably demonstrated that the safety of the subjects participating in our clinical trials warrants such termination, if we make a general assignment for the benefit of our creditors or if we are liquidated.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or to do so on commercially reasonable terms. Switching or adding CROs involves additional cost and requires management&#8217;s time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays could occur, which could materially impact our ability to meet our desired clinical development timelines. In addition, if our CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for, or commercialize, ensifentrine. As a result, our results of operations and the commercial prospects for ensifentrine would be harmed, our costs could increase and our ability to generate revenues could be delayed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">The collaboration and license agreement with Nuance Pharma is important to our business. If Nuance Pharma is unable to develop and commercialize products containing ensifentrine in Greater China, if we or Nuance Pharma fail to adequately perform under the Nuance Agreement, or if we or Nuance Pharma terminate the Nuance Agreement, our business would be adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We entered into a collaboration and license agreement with Nuance Pharma effective June 9, 2021 (the &#8220;Nuance Agreement&#8221;) under which we granted Nuance Pharma the exclusive rights to develop and commercialize products containing ensifentrine (the &#8220;Nuance Licensed Products&#8221;) in Greater China (China, Taiwan, Hong Kong and Macau).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Nuance Agreement will continue on a jurisdiction-by-jurisdiction and product-by-product basis until the expiration of royalty payment obligations with respect to such product in such jurisdiction unless earlier terminated by the parties. Either party may terminate the Nuance Agreement for an uncured material breach or bankruptcy of the other party. Nuance Pharma may also terminate the Nuance Agreement at will upon 90 days' prior written notice.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Termination of the Nuance Agreement could cause significant setbacks in our ability to develop and commercialize the Nuance Licensed Products in Greater China. Any suitable alternative collaboration or license agreement would take considerable time to negotiate and could also be on less favorable terms to us. In addition, under the Nuance Agreement, Nuance Pharma agreed to assume all costs related to clinical development and commercialization of the Nuance Licensed Products in Greater China. If the Nuance Agreement were to be terminated, and whether or not we identify another suitable collaborator, we may need to seek additional financing to support the clinical development and commercialization of the Nuance Licensed Products in Greater China, which could have a material adverse effect on our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Under the Nuance Agreement, we are dependent upon Nuance Pharma to successfully develop and commercialize Nuance Licensed Products. Although we have formed a joint steering committee with Nuance Pharma to oversee and coordinate the overall conduct of the clinical development and commercialization of the Nuance Licensed Products in Greater China, we do not control all aspects of Nuance Pharma&#8217;s development and commercialization or the resources it allocates to the development of the Nuance Licensed Products identified under the Nuance Agreement. Our interests and Nuance Pharma&#8217;s interests may differ or conflict from time to time, or we may disagree with Nuance Pharma&#8217;s level of effort or resource allocation. Nuance Pharma may internally prioritize programs under development within the collaboration differently than we would, or it may not allocate sufficient resources to effectively or optimally develop or commercialize the Nuance Licensed Products. If these events were to occur, our ability to receive revenue from the commercialization of the Nuance Licensed Products would be reduced, and our business would be adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">If we fail to enter into new strategic relationships for ensifentrine, our business, research and development and commercialization prospects could be adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our development program for ensifentrine and the potential commercialization of ensifentrine will require substantial additional cash to fund expenses. Therefore, we may decide to enter into collaborations with pharmaceutical or biopharmaceutical companies for the development and potential commercialization of ensifentrine. For example, we may seek a collaborator for development of our DPI or pMDI formulation of ensifentrine for the maintenance treatment of COPD and potentially asthma and other respiratory diseases.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We face significant competition in seeking appropriate collaborators. Collaborations are complex and time consuming to negotiate and document. We may also be restricted under existing and future collaboration agreements from entering into agreements on certain terms with other potential collaborators. We may not be able to negotiate collaborations on acceptable terms, or at all. If that were to occur, we may have to curtail the development of ensifentrine, reduce or delay its development program, delay its potential commercialization or reduce the scope of our sales or marketing activities, or increase our expenditures and undertake development or commercialization </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we will not be able to bring ensifentrine to market and generate product revenue. If we do enter into a collaboration agreement, we could be subject to the following risks, among others, any of which could adversely affect our ability to develop and commercialize ensifentrine:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">we may not be able to control the amount and timing of resources that the collaborator devotes to the development of ensifentrine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the collaborator may experience financial difficulties;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">we may be required to relinquish important rights such as marketing, distribution and intellectual property rights;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">a collaborator could move forward with a competing product developed either independently or in collaboration with third parties, including our competitors;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">safety and/or efficacy data from a collaborator&#8217;s clinical development activities may conflict with our data and could potentially impact our global clinical development activities;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">a collaborator may unlawfully use or disclose confidential information and materials in breach of confidentiality obligations to us;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">business combinations or significant changes in a collaborator&#8217;s business strategy may adversely affect our willingness to complete our obligations under any arrangement;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">we or a collaborator could fail to adequately perform our obligations under the agreement and/or the agreement could fall into dispute;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">we may be involved in lawsuits to protect or enforce patents covering ensifentrine, or relating to the terms of our collaborations, which could be expensive, time consuming and unsuccessful; or</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the collaboration may not provide sufficient funds to be profitable for us after we fulfill our payment liabilities under our agreement with Ligand Pharmaceuticals, Inc., or Ligand, which acquired Vernalis Development Limited, or Vernalis, in October 2018.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We currently rely on third-party manufacturers and suppliers for production of the active pharmaceutical ingredient ensifentrine and its derived formulated products. Our dependence on these third parties may impair the advancement of our research and development programs and the development of ensifentrine. Moreover, we intend to rely on third parties to produce commercial supplies of ensifentrine, if approved, and commercialization could be stopped, delayed or made less profitable if those third parties fail to obtain the necessary approvals from the FDA or comparable regulatory authorities, fail to provide us with sufficient quantities of product in a timely manner or fail to do so at acceptable quality levels or prices or fail to otherwise complete their duties in compliance with their obligations to us or other parties.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We have limited personnel with experience in manufacturing, and we do not own facilities for manufacturing ensifentrine and its derived formulated products. Instead, we rely on and expect to continue to rely on third-party contract manufacturing organizations (&#8220;CMOs&#8221;), for the supply of cGMP- or GMP-grade clinical trial materials and commercial quantities of ensifentrine and its derived formulated products, if approved. While we may contract with other CMOs in the future, we currently have one CMO for the manufacture of ensifentrine drug substance and one CMO for each formulation of ensifentrine. The facilities used to manufacture ensifentrine and its derived formulated products must be approved by the FDA pursuant to inspections that will be conducted after we submit an NDA to the FDA, and by comparable foreign regulatory authorities for approvals outside the United States. While we provide sponsor oversight of manufacturing activities, we do not and will not directly control the manufacturing process of, and are or will be essentially dependent on, our CMOs for compliance with cGMP and similar foreign requirements for the manufacture of ensifentrine and its derived formulated products. If a CMO cannot successfully manufacture material that conforms to our specifications and the regulatory requirements of the FDA or a comparable foreign regulatory authority, it will not be able to secure or maintain regulatory approval for the manufacture of ensifentrine and its derived formulated products in its manufacturing facilities. In addition, we have little direct control over the ability of a CMO to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of ensifentrine and its derived formulated products or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would delay our development program and significantly impact our ability to develop, obtain regulatory approval for or market ensifentrine and its derived </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">formulated products, if approved. In addition, any failure to achieve and maintain compliance with these laws, regulations and standards could subject us to the risk that we may have to suspend the manufacture of ensifentrine and its derived formulated products or that obtained approvals could be revoked. Furthermore, third-party providers may breach existing agreements they have with us because of factors beyond our control. They may also terminate or refuse to renew their agreement because of their own financial difficulties or business priorities, at a time that is costly or otherwise inconvenient for us. If we were unable to find an adequate replacement or another acceptable solution in time, our clinical trials could be delayed or our commercial activities could be harmed. In addition, the fact that we are dependent on our suppliers, CMOs and other third parties for the manufacture, storage and distribution of ensifentrine and its derived formulated products means that we are subject to the risk that ensifentrine and its derived formulated products may have manufacturing defects that we have limited ability to prevent, detect or control.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We rely on and will continue to rely on CMOs to purchase from third-party suppliers the materials necessary to produce ensifentrine and its derived formulated products and the inhalation and nebulization devices to deliver ensifentrine. We do not and will not have any direct control over the process or timing of the acquisition and delivery of these supplies by any CMO or its third-party suppliers, or the quality or quantity of such supplies. These supplies could be interrupted from time to time and, if interrupted, we cannot be certain that alternative supplies could be obtained within a reasonable timeframe, at an acceptable cost or quality, or at all. There are a limited number of suppliers for the raw materials that we may use to manufacture ensifentrine and for the drug delivery devices (e.g. nebulizers) that we use for clinical trials with ensifentrine, and we will need to assess alternate suppliers to prevent a possible disruption to our clinical trials, and if approved, ultimately to commercial sales. Although we generally do not begin a clinical trial unless we believe we have on hand, or will be able to obtain, a sufficient supply of ensifentrine to complete the clinical trial, any significant delay in the supply of ensifentrine drug products, or the raw material components needed to produce, or devices needed to deliver, ensifentrine, for an ongoing clinical trial due to our CMOs or their third-party suppliers could considerably delay completion of our clinical trials, product testing and potential regulatory approval of ensifentrine. If our CMOs, their third-party supplies, or we are unable to purchase these supplies after regulatory approval has been obtained for ensifentrine, the commercial launch of ensifentrine would be delayed or there would be a shortage in supply, which would impair our ability to generate revenues from the sale of ensifentrine. In addition, growth in the costs and expenses of these supplies may impair our ability to cost-effectively manufacture ensifentrine. Additionally, CMOs are experiencing labor constraints which could impact their ability to manufacture and deliver ensifentrine.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We rely and will continue to rely on CMOs and third-party suppliers to comply with and respect the proprietary rights of others in conducting their contractual obligations for us. If a CMO or third-party suppliers fails to acquire the proper licenses or otherwise infringes third-party proprietary rights in the course of providing services to us, we may have to find alternative CMOs or third-party suppliers, or defend against claims of infringement, either of which would significantly impact our ability to develop, obtain regulatory approval for, or market ensifentrine and any of its derived formulated products, if approved.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Risks Related to Intellectual Property and Information Technology</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We rely on patents and other intellectual property rights to protect ensifentrine, the enforcement, defense and maintenance of which may be challenging and costly. Failure to enforce or protect these rights adequately could harm our ability to compete and impair our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our commercial success depends in part on obtaining and maintaining patents and other forms of intellectual property rights for ensifentrine, formulations of ensifentrine, polymorphs, salts and analogs of ensifentrine, methods used to manufacture ensifentrine, methods for manufacturing of final drug product for different inhalation devices such as nebulizer, DPI, pMDI, and the methods for treating patients with respiratory diseases using ensifentrine alone or in combination with other available products, or on in-licensing such rights. The registrations of the assignment of each of these patents and patent applications with the relevant authorities in certain jurisdictions in which the patent and patent applications are registered have been granted, but there is no assurance that any additional registrations will be effected in a timely manner or at all. Failure to protect or to obtain, maintain or extend adequate patent and other intellectual property rights could adversely affect our ability to develop and market ensifentrine.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The patent prosecution process is expensive and time-consuming, and we or our licensors, licensees or collaborators may not be able to prepare, file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions. It is also possible that we or our licensors, licensees or collaborators will fail to identify patentable aspects of inventions made in the course of development and commercialization activities </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">before it is too late to obtain patent protection on them. Moreover, depending on the terms of any future in-licenses to which we may become a party, in some circumstances we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology in-licensed from third parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. Further, the issuance, scope, validity, enforceability and commercial value of our and our current or future licensors&#8217;, licensees&#8217; or collaborators&#8217; patent rights are highly uncertain. Our and our licensors&#8217; pending and future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. The patent examination process may require us or our licensors, licensees or collaborators to narrow the scope of the claims of our or our licensors&#8217;, licensees&#8217; or collaborators&#8217; pending and future patent applications, which may limit the scope of patent protection that may be obtained. We cannot provide assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found. If such prior art exists, it can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue and even if such patents cover ensifentrine, third parties may initiate an opposition, interference, re-examination, post-grant review, inter partes review, nullification or derivation action in court or before patent offices, or similar proceedings challenging the validity, enforceability or scope of such patents, which may result in the patent claims being narrowed or invalidated. Our and our licensors&#8217;, licensees&#8217; or collaborators&#8217; patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications, and then only to the extent the issued claims cover the technology.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Because patent applications are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we or our licensors were the first to file any patent application related to ensifentrine. Furthermore, if third parties have filed such patent applications on or before March 15, 2013, the date on which the U.S. patent filing system changed from a first-to-invent to a first-to-file standard, an interference proceeding can be initiated by such third parties to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. If third parties have filed such applications after March 15, 2013, a derivation proceeding can be initiated by such third parties to determine whether our invention was derived from theirs. Even where we have a valid and enforceable patent, we may not be able to exclude others from practicing our invention where the other party can show that they used the invention in commerce before our filing date or the other party benefits from a compulsory license.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent which might adversely affect our ability to develop, manufacture and market ensifentrine.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We cannot guarantee that any of our or our licensors&#8217; patent searches or analyses, including but not limited to the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of ensifentrine in any jurisdiction. For example, U.S. applications filed before November 29, 2000 and certain U.S. applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Patent applications in the United States and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering ensifentrine could have been filed by others without our knowledge. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover ensifentrine or the use of ensifentrine. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market ensifentrine. We may incorrectly determine that ensifentrine is not covered by a third-party patent or may incorrectly predict whether a third party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market ensifentrine. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market ensifentrine.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If we fail to identify and correctly interpret relevant patents, we may be subject to infringement claims. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing ensifentrine. We might, if possible, also be forced to redesign ensifentrine so that we no longer infringe the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We may be involved in lawsuits to protect or enforce patents covering ensifentrine, which could be expensive, time consuming and unsuccessful, and issued patents could be found invalid or unenforceable if challenged in court.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">To protect our competitive position, we may from time to time need to resort to litigation in order to enforce or defend any patents or other intellectual property rights owned by or licensed to us, or to determine or challenge the scope or validity of patents or other intellectual property rights of third parties. As enforcement of intellectual property rights is difficult, unpredictable, time consuming and expensive, we may fail in enforcing our rights&#8201;&#8212;&#8201;in which case our competitors may be permitted to use our technology without being required to pay us any license fees. In addition, however, litigation involving our patents carries the risk that one or more of our patents will be held invalid (in whole or in part, on a claim-by-claim basis) or held unenforceable. Such an adverse court ruling could allow third parties to commercialize ensifentrine, and then compete directly with us, without payment to us. If we in-license intellectual property rights, our agreements may give our licensors the first right to control claims of third-party infringement, or to defend validity challenges. Therefore, these patents and patent applications may not be enforced or defended in a manner consistent with the best interests of our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If we were to initiate legal proceedings against a third party to enforce a patent covering one of our products, the defendant could counterclaim that our patent is invalid or unenforceable. In patent litigation in the United States or in Europe, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the U.S. Patent and Trademark Office, or USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on ensifentrine. Patents and other intellectual property rights also will not protect our technology if competitors design around our protected technology without infringing our patents or other intellectual property rights.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts, industry commentators or investors perceive these results to be negative, it could have an adverse effect on the price of our ADSs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a negative impact on the success of our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our commercial success depends, in part, upon our ability, and the ability of our future collaborators, to develop, manufacture, market and sell our product candidates without alleged or actual infringement, misappropriation or other violation of the patents and proprietary rights of third parties. There have been many lawsuits and other proceedings involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions and reexamination proceedings before the USPTO and corresponding foreign patent offices. The various markets in which we plan to operate are subject to frequent and extensive litigation regarding patents and other intellectual property rights. In addition, many companies in intellectual property-dependent industries, including the biopharmaceutical and pharmaceutical industries, have employed intellectual property litigation as a means to gain an advantage over their competitors. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing ensifentrine. Some claimants may have substantially greater resources than we do and may be able to sustain the costs of complex intellectual property litigation to a greater degree and for longer periods of time than we could. In addition, patent holding companies that focus solely on extracting royalties and settlements by enforcing patent rights may target us. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that ensifentrine may be subject to claims of infringement of the intellectual property rights of third parties.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We may in the future become party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to ensifentrine and any future product candidates, including interference or derivation proceedings, post grant review and inter partes review before the USPTO or similar adversarial proceedings or litigation in other jurisdictions. Similarly, we or our licensors or collaborators may initiate such proceedings or litigation against third parties, for example, to challenge the validity or scope of intellectual property </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">rights controlled by third parties. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of their merit. There is a risk that third parties may choose to engage in litigation with us to enforce or to otherwise assert their patent rights against us. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, and the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire or are finally determined to be invalid or unenforceable. Similarly, if any third-party patents were held by a court of competent jurisdiction to cover aspects of our compositions, formulations, or methods of treatment, prevention or use, the holders of any such patents may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a license or until such patent expires or is finally determined to be invalid or unenforceable. Such licenses may not be available on reasonable terms, or at all, or may be non-exclusive thereby giving our competitors access to the same technologies licensed to us.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If we fail in any such dispute, we may be forced to pay damages, including the possibility of treble damages in a patent case if a court finds us to have willfully infringed certain intellectual property rights. We or our licensees may be temporarily or permanently prohibited from commercializing ensifentrine or from selling, incorporating, manufacturing or using our products in the United States and/or other jurisdictions that use the subject intellectual property. We might, if possible, also be forced to redesign ensifentrine so that we no longer infringe the third-party intellectual property rights, which may result in significant cost or delay to us, or which redesign could be technically infeasible. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In addition, if the breadth or strength of protection provided by our or our licensors&#8217; or collaborators&#8217; patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We may be subject to claims challenging the inventorship of our patents and other intellectual property.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Although we are not currently experiencing any claims challenging the inventorship of our patents or ownership of our intellectual property, we may in the future be subject to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor. While it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. For example, the assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached, or we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, such perceptions could have a substantial adverse effect on the price of our ADSs. Such litigation or proceedings could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have an adverse effect on our ability to compete in the marketplace.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">If we fail to comply with our obligations under our existing and any future intellectual property licenses with third parties, we could lose license rights that are important to our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are party to a license agreement with Ligand, under which we in-license certain intellectual property and were assigned certain patents and patent applications related to our business. We may enter into additional license agreements in the future. We expect that any future license agreements would impose various diligence, milestone </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">payment, royalty, insurance and other obligations on us. Any uncured, material breach under these license agreements could result in our loss of rights to practice the patent rights and other intellectual property licensed to us under these agreements, and could compromise our development and commercialization efforts for ensifentrine or any future product candidates. Under our agreement with Ligand, we may not abandon any of the assigned patents or allow any of the assigned patents to lapse without consent from Ligand, which is not to be unreasonably delayed or withheld. If we do not obtain such consent in a timely manner or at all and such assigned patent rights lapse or are abandoned, our agreement with Ligand may be terminated in its entirety. For example, if we decide for commercial reasons to let an assigned patent lapse in a country of little commercial importance, but Ligand does not provide consent and such patent rights lapse, we may lose all intellectual property rights covering ensifentrine in multiple markets. Moreover, our future licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor&#8217;s rights.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We may not be successful in maintaining the necessary rights to ensifentrine or obtaining other intellectual property rights important to our business through acquisitions and in-licenses.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We currently own and have in-licensed rights to intellectual property, including patents, patent applications and know-how, relating to ensifentrine, and our success will likely depend on maintaining these rights. Because our programs may require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, in-license, maintain or use these proprietary rights. In addition, ensifentrine may require specific formulations to work effectively and the rights to these formulations may be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes, or other third-party intellectual property rights that we identify as necessary for ensifentrine. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies also are pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We may also be unable to license or acquire third-party intellectual property rights on a timely basis, on terms that would allow us to make an appropriate return on our investment, or at all. Even if we are able to obtain a license to intellectual property of interest, we may not be able to secure exclusive rights, in which case others could use the same rights and compete with us. If we are unable to successfully obtain a license to third-party intellectual property rights necessary for the development of ensifentrine or a development program on acceptable terms, we may have to abandon development of ensifentrine or that development program.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our competitive position may be adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We have registered trademarks in some territories and made applications to register the trademarks in other territories for potential trade names for our business and proposed drug products. We may not be able to obtain trademark protection for our trade names in territories that we consider of significant importance to us. If we register trademarks, our trademark applications may be rejected during trademark registration proceedings. Although we will be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, any of our trademarks or trade names, whether registered or unregistered, may be challenged, opposed, infringed, cancelled, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition by potential collaborators or customers in our markets of interest. Over the long-term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. If other entities use trademarks similar to ours in different jurisdictions, or have senior rights to ours, it could interfere with our use of our current trademarks throughout the world.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">If we do not obtain protection under the Hatch-Waxman Amendments and similar non-U.S. legislation for extending the term of patents covering ensifentrine and any other product candidates, our ability to compete effectively could be impaired.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. The issued patents covering the composition of matter for ensifentrine expired in 2020, and our other issued patents will expire in 2031 to 2041, subject to any patent extensions that may be available for such patents. If patents are issued on our pending patent applications, the resulting patents are projected to expire on dates ranging from 2031 to 2036. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">ensifentrine are obtained, once the patent life has expired for a product, we may be open to competition from competitive medications, including generic medications. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Depending upon the timing, duration and conditions of the FDA marketing approval of ensifentrine, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments, and similar legislation in the EU. The Hatch-Waxman Amendments permit a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened and our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced, possibly materially.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We enjoy only limited geographical protection with respect to certain patents and may face difficulties in certain jurisdictions, which may diminish the value of our intellectual property rights in those jurisdictions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We generally file our first patent application, or priority filing, at the United Kingdom Intellectual Property Office. International applications under the Patent Cooperation Treaty, or PCT, are usually filed within 12 months after the priority filing. Based on the PCT filing, national and regional patent applications may be filed in additional jurisdictions where we believe a product candidate may be marketed or manufactured. We have so far not filed for patent protection for ensifentrine in all national and regional jurisdictions where such protection may be available. Filing, prosecuting and defending patents in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, we may decide to abandon national and regional patent applications before grant. The grant proceeding of each national or regional patent is an independent proceeding which may lead to situations in which applications might in some jurisdictions be refused by the relevant patent offices, while granted by others. For example, unlike other countries, China has a heightened requirement for patentability, and specifically requires a detailed description of medical uses of a claimed drug. Furthermore, generic drug manufacturers or other competitors may challenge the scope, validity or enforceability of our or our licensors&#8217; patents, requiring us or our licensors to engage in complex, lengthy and costly litigation or other proceedings. Generic drug manufacturers may develop, seek approval for and launch generic versions of our products. It is also quite common that depending on the country, the scope of patent protection may vary for the same product candidate or technology.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Competitors may use our or our licensors&#8217; or collaborators&#8217; technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we or our licensors or collaborators have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our product candidates, and our and our licensors&#8217; or collaborators&#8217; patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws or rules and regulations in the United States and the EU, and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. Furthermore, while we intend to protect our intellectual property rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our product candidates. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate, which may have an adverse effect on our ability to successfully commercialize our product candidates in all of our expected significant foreign markets. If we or our licensors encounter difficulties in protecting, or are otherwise </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished and we may face additional competition from others in those jurisdictions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Some countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, some countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Others may be able to make compounds that are the same as or similar to our product candidates but that are not covered by the claims of the patents that we own or have exclusively licensed;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">The patents of third parties may impair our ability to develop or commercialize our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">We or our licensors or any future strategic collaborators might not have been the first to conceive or reduce to practice the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">We or our licensors or any future collaborators might not have been the first to file patent applications covering certain of our inventions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">It is possible that our pending patent applications will not lead to issued patents.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Issued patents that we own or have exclusively licensed may not provide us with any competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by our competitors.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">Third parties performing manufacturing or testing for us using our product candidates or technologies could use the intellectual property of others without obtaining a proper license.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">We may not develop additional technologies that are patentable.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect ensifentrine or any future product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological complexity and legal complexity. Therefore, obtaining and enforcing biopharmaceutical patents is costly, time consuming and inherently uncertain. In addition, the America Invents Act, or the AIA, which was passed on September 16, 2011, resulted in significant changes to the U.S. patent system.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">An important change introduced by the AIA is that, as of March 16, 2013, the United States transitioned to a &#8220;first-to-file&#8221; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. A third party that files a patent application in the USPTO, after that date but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by the third party. This requires us to be cognizant of the time from invention to filing of a patent application, but circumstances could prevent us from promptly filing patent applications on our inventions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Among some of the other changes introduced by the AIA are changes that limit where a patentee may file a patent infringement suit and providing opportunities for third parties to challenge any issued patent in the USPTO. This applies to all of our U.S. patents, even those issued before March 16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. It is not clear what, if any, impact the AIA will have on the operation of our business. However, the AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of our or our licensors&#8217; or collaboration partners&#8217; patent applications and the enforcement or defense of our or our licensors&#8217; or collaboration partners&#8217; issued patents.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Additionally, the U.S. Supreme Court has ruled on several patent cases in recent years either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. Similarly, the complexity and uncertainty of European patent laws has also increased in recent years. In addition, the European patent system is relatively stringent in the type of amendments that are allowed during prosecution. Complying with these laws and regulations could limit our ability to obtain new patents in the future that may be important for our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Confidentiality agreements with employees and others may not adequately prevent disclosure of trade secrets and protect other proprietary information.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We consider proprietary trade secrets and confidential know-how and unpatented know-how to be important to our business. We may rely on trade secrets or confidential know-how to protect our technology, especially where patent protection is believed to be of limited value. However, trade secrets and confidential know-how are difficult to maintain as confidential.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">To protect this type of information against disclosure or appropriation by competitors, our policy is to require our employees, consultants, contractors and advisors to enter into confidentiality agreements with us. We also seek to preserve the integrity and confidentiality of our data, trade secrets and know-how by maintaining physical security of our premises and physical and electronic security of our information technology systems. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. We cannot guarantee that our trade secrets and other proprietary and confidential information will not be disclosed or that competitors will not otherwise gain access to our trade secrets. However, current or former employees, consultants, contractors and advisors may unintentionally or willfully disclose our confidential information to competitors, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. Enforcing a claim that a third party obtained illegally and is using trade secrets and/or confidential know-how is expensive, time consuming and unpredictable. The enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction. Furthermore, if a competitor lawfully obtained or independently developed any of our trade secrets, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Failure to obtain or maintain trade secrets and confidential know-how trade protection could adversely affect our competitive position. Moreover, our competitors may independently develop substantially equivalent proprietary information and may even apply for patent protection in respect of the same. If successful in obtaining such patent protection, our competitors could limit our use of our trade secrets and/or confidential know-how.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Many of our employees, including our senior management, were previously employed at universities or at other biopharmaceutical companies, including our competitors or potential competitors. Some of these employees executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these employees have used or disclosed confidential information or intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s former employer. Litigation may be necessary to defend against these claims.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel or sustain damages. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products. Such a license may not be available on commercially reasonable terms or at all. Even if we successfully prosecute or defend against such claims, litigation could result in substantial costs and distract management.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Periodic maintenance and annuity fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or our licensors or collaboration partners fail to maintain the patents and patent applications covering our product candidates, our competitors might be able to enter the market, which would hurt our competitive position and could impair our ability to successfully commercialize any product candidate.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Our information technology systems, and those of our manufacturers, suppliers and other third parties that we use to conduct our pre-clinical and clinical trials or otherwise collaborate with, may fail or suffer security breaches, which could distract our operations and cause delays in our research and development work, and may adversely affect our business, operations and financial performance. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the ordinary course of our business, we and our manufacturers, suppliers and third parties that we use to conduct our pre-clinical and clinical trials or otherwise collaborate with, collect and store sensitive data, including intellectual property, clinical trial data, proprietary business information and personally identifiable information of our clinical trial subjects and employees, in our and third-party data centers and on our and third-party networks. The secure processing, maintenance and transmission of this information is critical to our operations. Our information technology and other internal infrastructure systems, including corporate firewalls, servers, leased lines and connection to the Internet, and that of our manufacturers, suppliers and other third parties that we use to conduct our pre-clinical and clinical trials or otherwise collaborate with, face the risk of systemic failure that could disrupt our operations. A significant disruption in the availability of these information technology and other internal infrastructure systems could cause interruptions in our collaborations and delays in our research and development work. Further, our information technology systems and those of our third-party service providers, strategic partners and other contractors or consultants are vulnerable to damage, attack or interruption from computer viruses, malware (e.g ransomware), natural disasters, terrorism, war, telecommunication and electrical failures, hacking, cyberattacks, phishing attacks and other social engineering schemes, malicious code, employee theft or misuse, human error, fraud, denial or degradation of service attacks, sophisticated nation-state and nation-state-supported actors or unauthorized access or use by persons inside our organization, or persons with access to systems inside our organization. Attacks upon information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. As a result of the COVID-19 pandemic and continued hybrid working environment, we may also face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage or disrupt, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. Even if identified, we may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Despite security measures that we and our critical third parties (e.g., collaborators) implement, our information technology and infrastructure may be vulnerable to attacks by hackers or internal bad actors, breaches due to human error, technical vulnerabilities, malfeasance or other disruptions. We and certain of our service providers are from time to time subject to cyberattacks and security incidents. Although to our knowledge we have not experienced any </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">significant security breach to date, any such breach could compromise our networks and the information stored there could be accessed, publicly disclosed, lost or stolen. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal data, regulatory penalties, disrupt our operations, damage our reputation, and cause a loss of confidence in us and our ability to conduct clinical trials, which could adversely affect our reputation and delay clinical development of our product candidates. Any losses, costs or liabilities may not be covered by, or may exceed the coverage limits of, any or all applicable insurance policies.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Risks Related to Employee Matters and Managing Growth</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Our future growth and ability to compete depends on our ability to retain our key personnel and recruit additional qualified personnel.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our success depends upon the contributions of our key management, scientific and technical personnel, many of whom have been instrumental for us and have substantial experience with ensifentrine and related technologies. Our key management individuals include our chief executive officer, David Zaccardelli, our chief financial officer, Mark Hahn, our general counsel, Claire Poll, our chief medical officer, Kathleen Rickard, our senior vice president, chemistry manufacturing and controls, Peter Spargo, our senior vice president, regulatory affairs, Caroline Diaz, our senior vice president of commercial, Christopher Martin, and our senior vice president, R&amp;D, Tara Rheault. The loss of key managers and senior scientists could delay our research and development activities. In addition, the competition for qualified personnel in the biopharmaceutical and pharmaceutical field is intense, and our future success depends upon our ability to attract, retain and motivate highly skilled scientific, technical and managerial employees. We face competition for personnel from other companies, universities, public and private research institutions and other organizations. If our recruitment and retention efforts are unsuccessful in the future, it may be difficult for us to achieve our product candidate development objectives, raise additional capital and implement our business strategy.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We expect to expand our development, regulatory and sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of drug development, regulatory affairs and sales and marketing. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Risks Related to Our ADSs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Certain of our shareholders, members of our board of directors, and senior management own a majority of our ordinary shares (including ordinary shares represented by ADSs) and as a result, are be able to exercise significant control over us.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As of December 31, 2022, our senior management, board of directors and greater than 5% shareholders and their respective affiliates, in the aggregate, owned approximately 32% of our outstanding voting ordinary shares (including ordinary shares represented by ADSs) assuming no exercise of outstanding options. Depending on the level of attendance at our general meetings of shareholders, these shareholders either alone or voting together as a group may be in a position to determine or significantly influence the outcome of decisions taken at any such general meeting. Any shareholder or group of shareholders controlling more than 50% of the share capital present and voting at our general meetings of shareholders may control any shareholder resolution requiring a simple majority, including the appointment of board members, certain decisions relating to our capital structure, and the approval of certain significant corporate transactions. Among other consequences, this concentration of ownership may have the effect of delaying or preventing a change in control and might therefore negatively affect the market price of our ADSs and ordinary shares.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Because we do not anticipate paying any cash dividends on our ADSs or ordinary shares in the foreseeable future, capital appreciation, if any, will be our ADS holders&#8217; and shareholders&#8217; sole source of gains and they may never receive a return on their investment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Under current English law, a company&#8217;s accumulated realized profits must exceed its accumulated realized losses (on a non-consolidated basis) before dividends can be paid. Therefore, we must have distributable profits before issuing a dividend. We have not paid dividends in the past on our ordinary shares. We intend to retain earnings, if any, for use in our business and do not anticipate paying any cash dividends in the foreseeable future. As a result, capital appreciation, if any, on our ADSs or ordinary shares will be our ADS holders&#8217; and shareholders&#8217; sole source of gain for the foreseeable future, and they will suffer a loss on their investment if they are unable to sell their ADSs </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">or ordinary shares at or above the price at which they were purchased. Investors seeking cash dividends should not purchase our ADSs or ordinary shares.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Holders of our ADSs may not have the same voting rights as the holders of our ordinary shares and may not receive voting materials in time to be able to exercise their right to vote.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Holders of our ADSs are not be able to exercise voting rights attaching to the ordinary shares evidenced by our ADSs on an individual basis. Holders of our ADSs have appointed a depositary as their representative to exercise the voting rights attaching to the ordinary shares represented by their ADSs. Holders of our ADSs may not receive voting materials in time to instruct the depositary to vote, and it is possible that they, or persons who hold their ADSs through brokers, dealers or other third parties, will not have the opportunity to exercise a right to vote. Furthermore, the depositary will not be liable for any failure to carry out any instructions to vote, for the manner in which any vote is cast or for the effect of any such vote. As a result, holders of our ADSs may not be able to exercise voting rights and may lack recourse if their ADSs are not voted as requested. In addition, holders of our ADSs will not be able to call a shareholders&#8217; meeting.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Holders of our ADSs may not receive distributions on our ordinary shares represented by our ADSs or any value for them if it is illegal or impractical to make them available to them.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The depositary for our ADSs has agreed to pay to holders of our ADSs the cash dividends or other distributions it or the custodian receives on our ordinary shares or other deposited securities after deducting its fees and expenses. Holders of our ADSs will receive these distributions in proportion to the number of our ordinary shares their ADSs represent. However, in accordance with the limitations set forth in the deposit agreement entered into with the depositary, it may be unlawful or impractical to make a distribution available to holders of our ADSs. We have no obligation to take any other action to permit the distribution of our ADSs, ordinary shares, rights or anything else to holders of our ADSs. This means that holders of our ADSs may not receive the distributions we make on our ordinary shares or any value from them if it is unlawful or impractical to make the distributions available to them. These restrictions may have a material adverse effect on the value of our ADSs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Holders of our ADSs may be subject to limitations on transfer of their ADSs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">ADSs are transferable on the books of the depositary. However, the depositary may close its transfer books at any time or from time to time when it deems expedient in connection with the performance of its duties. In addition, the depositary may refuse to deliver, transfer or register transfers of ADSs generally when our books or the books of the depositary are closed, or at any time if we or the depositary deems it advisable to do so because of any requirement of law or of any government or governmental body, or under any provision of the deposit agreement, or for any other reason in accordance with the terms of the deposit agreement. These limitations on transfer may have a material adverse effect on the value of our ADSs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">The rights of our shareholders may differ from the rights typically offered to shareholders of a U.S. corporation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are incorporated under English law. The rights of holders of ordinary shares and, therefore, certain of the rights of holders of ADSs, are governed by English law, including the provisions of the Companies Act 2006, and by our Articles of Association. These rights differ in certain material respects from the rights of shareholders in typical U.S. corporations. As a result, investors in our ordinary shares or ADSs may not have the same protections or rights as they would if they had invested in a U.S. corporation. This may make our ADSs less attractive to such investors, which could harm the value of our ADSs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Claims of U.S. civil liabilities may not be enforceable against us.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are incorporated under English law. Substantially all of our assets are located outside the United States. The majority of our senior management and board of directors reside outside the United States. As a result, it may not be possible for investors to effect service of process within the United States upon such persons or to enforce judgments obtained in U.S. courts against them or us, including judgments predicated upon the civil liability provisions of the U.S. federal securities laws.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The United States and the United Kingdom do not currently have a treaty providing for recognition and enforcement of judgments (other than arbitration awards) in civil and commercial matters. Consequently, a final judgment for payment given by a court in the United States, whether or not predicated solely upon U.S. securities laws, would not automatically be recognized or enforceable in the United Kingdom. In addition, uncertainty exists as to whether U.K. courts would entertain original actions brought in the United Kingdom against us or our directors or senior management predicated upon the securities laws of the United States or any state in the United States. Any final and conclusive monetary judgment for a definite sum obtained against us in U.S. courts would be treated by the courts of the United Kingdom as a cause of action in itself and sued upon as a debt at common law so that no retrial of the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">issues would be necessary, provided that certain requirements are met. Whether these requirements are met in respect of a judgment based upon the civil liability provisions of the U.S. securities laws, including whether the award of monetary damages under such laws would constitute a penalty, is an issue for the court making such decision. If an English court gives judgment for the sum payable under a U.S. judgment, the English judgment will be enforceable by methods generally available for this purpose. These methods generally permit the English court discretion to prescribe the manner of enforcement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As a result, U.S. investors may not be able to enforce against us or our senior management, board of directors or certain experts named herein who are residents of the United Kingdom or countries other than the United States any judgments obtained in U.S. courts in civil and commercial matters, including judgments under the U.S. federal securities laws.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, shareholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our ADSs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section 404, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inadequate internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our ADSs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Management will be required to assess the effectiveness of our internal controls annually. However, for as long as we are a non-accelerated filer, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal controls over financial reporting pursuant to Section 404. An independent assessment of the effectiveness of our internal controls could detect problems that our management&#8217;s assessment might not. Undetected material weaknesses in our internal controls could lead to financial statement restatements requiring us to incur the expense of remediation and could also result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We may have inadvertently violated Section 13(k) of the Exchange Act (implementing Section 402 of the Sarbanes-Oxley Act of 2002) and may be subject to sanctions as a result.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Section 13(k) of the Exchange Act provides that it is unlawful for a company, such as ours, that has a class of securities registered under Section 12 of the Exchange Act to, directly or indirectly, including through any subsidiary, extend or maintain credit in the form of a personal loan to or for any director or executive officer of the company. In August 2018, a receivable arose with respect to taxes due upon the vesting of restricted share units held by one of our directors and two of our executive officers, which may have violated Section 13(k) of the Exchange Act. The receivable was repaid, with interest, in March 2019, as soon as management became aware of the possible violation. Issuers that are found to have violated Section 13(k) of the Exchange Act may be subject to civil sanctions, including injunctive remedies and monetary penalties, as well as criminal sanctions. The imposition of any of such sanctions on us could have a material adverse effect on our business, financial position, results of operations or cash flows.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Risks Related to Taxation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Changes in our tax rates, unavailability of certain tax credits or reliefs or exposure to additional tax liabilities or assessments could affect our profitability, and audits by tax authorities could result in additional tax payments for prior periods.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">New income, sales use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, or interpreted, changed, modified or applied adversely to us, any of which could adversely affect our business operations and financial performance. We are currently unable to predict whether such changes will occur and, if so, the ultimate impact on our business. To the extent that such changes have a negative impact on us, including as a result of related uncertainty, these changes may materially and adversely impact our business, financial condition, results of operations and cash flows. For example, beginning in 2022, the Tax Cuts and Jobs Act of 2017 eliminates the option to deduct research and development expenditures and requires taxpayers to amortize them over five years pursuant to Section 174 of the U.S. Internal Revenue Code of 1986, as amended, or the Code, or 15 years for expenditures attributable to research and development conducted outside the United States. If the requirement is not modified or deferred, it may materially reduce our cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We carry out research and development activities including, but not limited to, developing ensifentrine for various indications and delivery methods, and as a result we benefit in the U.K. from the HM Revenue and Customs, or HMRC, small and medium sized enterprises research and development relief, or SME R&amp;D Relief, which provides relief against U.K. Corporation Tax.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Broadly, SME R&amp;D Relief comprises two elements, (a) allowing qualifying SMEs to deduct a total of 230% expected to reduce to 186% for expenditure incurred on or after April 1, 2023 of their qualifying expenditure from their yearly profit for U.K. Corporation Tax purposes (the deduction is given by allowing an additional 130% deduction (expected to reduce to 86% for expenditure incurred after April 1, 2023) plus the usual 100% deduction), </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">or the SME R&amp;D Additional Deduction and, (b) where there are not sufficient profits for U.K. Corporation Tax purposes to fully utilize the SME R&amp;D Additional Deduction, the excess (&#8220;surrenderable losses&#8221;) can be carried forward to offset against future taxable profits, or a tax credit currently equal to 14.5% (expected to reduce to 10% from April 1, 2023) of such surrenderable loss can be claimed in cash, or the SME R&amp;D Tax Credit.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Based on criteria established by HMRC a portion of expenditure incurred in relation to our research and development activities including, but not limited to, operating clinical trials, manufacturing, consultant and salary and related costs, is eligible for the SME R&amp;D Additional Deduction. Our consequential surrenderable losses are currently eligible for the SME R&amp;D Tax Credit, in accordance with HMRC criteria.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the financial statements for the year ended December 31, 2021, we recorded an SME R&amp;D Tax Credit of $15.6 million which was subsequently received in cash in the year ended December 31, 2022. For the year ended December 31, 2022, we recorded an SME R&amp;D Tax Credit of $9.6 million, which we expect to receive in the year ending December 31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Changes to the UK&#8217;s SME R&amp;D Relief regime may adversely affect our financial condition. In particular, HM Treasury and HMRC launched a consultation in January 2023 entitled &#8220;R&amp;D Tax Reliefs Review, Consultation on a single scheme&#8221; which seeks views on the possible merger of the SME R&amp;D Relief scheme and the &#8220;RDEC&#8221; scheme applicable to &#8220;large&#8221; companies, the outcome of which is currently uncertain. If it is decided to merge the schemes, any new regime is expected to apply with effect from April 1, 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">If we were classified as a passive foreign investment company, it would result in adverse U.S. federal income tax consequences to U.S. holders.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">A non-U.S. company will be considered a passive foreign investment company, or PFIC, for any taxable year in which (i) 75% or more of its gross income consists of passive income or (ii) 50% or more of the average quarterly value of its assets consists of assets that produce, or are held for the production of, passive income. For purposes of these tests, passive income includes dividends, interest, gains from the sale or exchange of investment property and certain rents and royalties. In addition, for purposes of the above calculations, a non-U.S. corporation that directly or indirectly owns at least 25% by value of the shares of another corporation is treated as holding and receiving directly its proportionate share of assets and income of such corporation. If we are classified as a PFIC for any taxable year during which a U.S. Holder holds our ordinary shares or ADSs, certain adverse U.S. federal income tax consequences could apply to such U.S. Holder, including (i) the treatment of all or a portion of any gain on disposition as ordinary income, (ii) the application of a deferred interest charge on such gain and the receipt of certain dividends and (iii) the obligation to comply with certain reporting requirements. A &#8220;U.S. Holder&#8221; is a holder who, for U.S. federal income tax purposes, is a beneficial owner of our ordinary shares or ADSs who is a citizen or individual resident of the United States, a corporation, or other entity taxable as a corporation, created or organized in or under the laws of the United States, any state therein or the District of Columbia; an estate the income of which is subject to U.S. federal income taxation regardless of its source; or a trust that (i) is subject to the supervision of a U.S. court and all substantial decisions of which are subject to the control of one or more &#8220;United States persons&#8221; (within the meaning of Section 7701(a)(30) of the Code), or (ii) has a valid election in effect to be treated as a United States person. No assurances regarding our PFIC status can be provided for the current taxable year or any future taxable years. The determination of whether we are a PFIC is a fact-intensive determination made on an annual basis applying principles and methodologies that in some circumstances are unclear and subject to varying interpretation. Under the income test, our status as a PFIC depends on the composition of our income which will depend on the transactions we enter into in the future and our corporate structure. The composition of our income and assets is also affected by the spending of the cash we raise in any offering. Each U.S. Holder should consult its own tax advisors with respect to the potential adverse U.S. tax consequences to it if we are or were to become a PFIC.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If we are classified as a PFIC in any year with respect to which a U.S. Holder owns our ordinary shares or ADSs, we will continue to be treated as a PFIC with respect to such U.S. Holder in all succeeding years during which the U.S. Holder owns our ordinary shares or ADSs, regardless of whether we continue to meet the PFIC test described above, unless the U.S. Holder makes a specified election once we cease to be a PFIC.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Based on the current and expected composition of our income and assets and the value of our assets, we believe that we were not a PFIC for U.S. federal income tax purposes for our taxable year ended December 31, 2022. However, no assurances regarding our PFIC status can be provided for any past taxable years, the taxable year ending December 31, 2022, or any future taxable years.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">If a U.S. Holder is treated as owning at least 10% of our ordinary shares or ADSs, such holder may be subject to adverse U.S. federal income tax consequences.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If a U.S. Holder (as defined above) is treated as owning, directly, indirectly or constructively, at least 10% of the value or voting power of our ordinary shares or ADSs, such U.S. Holder may be treated as a &#8220;United States shareholder&#8221; with respect to each &#8220;controlled foreign corporation&#8221; or &#8220;CFC&#8221; in our group, if any. Because our group includes one or more U.S. subsidiaries, certain of our non-U.S. subsidiaries could be treated as CFCs, regardless of whether we are treated as a CFC. A United States shareholder of a controlled foreign corporation may be required to annually report and include in its U.S. taxable income its pro rata share of &#8220;Subpart F income,&#8221; &#8220;global intangible low-taxed income&#8221; and investments in U.S. property by CFCs, regardless of whether we make any distributions. An individual that is a United States shareholder with respect to a CFC generally would not be allowed certain tax deductions or foreign tax credits that would be allowed to a United States shareholder that is a U.S. corporation. Failure to comply with these reporting obligations may subject a United States shareholder to significant monetary penalties and may prevent the statute of limitations with respect to such shareholder&#8217;s U.S. federal income tax return for the year for which reporting was due from starting. We cannot provide any assurances that we will assist our investors in determining whether we or any of our non-U.S. subsidiaries are treated as a CFC or whether such investor is treated as a United States shareholder with respect to any of such CFCs. Further, we cannot provide any assurances that we will furnish to any United States shareholder information that may be necessary to comply with the reporting and tax paying obligations described in this risk factor. U.S. Holders should consult their tax advisors regarding the potential application of these rules to their investment in our ordinary shares or ADSs.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">General Risks</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">The price of our ADSs may be volatile and may fluctuate due to factors beyond our control.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The trading market for publicly traded emerging biopharmaceutical and drug discovery and development companies has been highly volatile and is likely to remain highly volatile in the future. The market price of our ADSs may fluctuate significantly due to a variety of factors, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">positive or negative results from, or delays in, clinical trials of ensifentrine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">developments in our competitors&#8217; businesses;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">delays in entering into collaborations and strategic relationships with respect to development or commercialization of ensifentrine or entry into collaborations and strategic relationships on terms that are not deemed to be favorable to us;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">technological innovations or commercial product introductions by us or competitors;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">changes in government regulations;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">developments concerning proprietary rights, including patents and litigation matters;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">public concern relating to the commercial value or safety of ensifentrine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">financing or other corporate transactions;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">publication of research reports or comments by securities or industry analysts or commentators;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">general market conditions in the pharmaceutical industry or in the economy as a whole;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the loss of any of our key scientific or senior management personnel;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">sales of our ADSs by us, our senior management or board members, and significant holders of our ADSs; or</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">other events and factors, many of which are beyond our control.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">These and other market and industry factors may cause the market price and demand for our ADSs to fluctuate substantially, regardless of our actual operating performance, which may limit or prevent investors from readily selling their ADSs and may otherwise negatively affect the liquidity of our ADSs. In addition, the stock market in general, and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. In the past, when the market price of a stock has been volatile, holders of that stock have sometimes instituted securities class action litigation against the issuer. If any of the holders of our ADSs were to bring such a lawsuit against us, we could incur substantial costs defending the lawsuit and the attention of our senior management would be diverted from the operation of our business. Any adverse determination in litigation could also subject us to significant liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Future sales, or the possibility of future sales, of a substantial number of our ADSs or ordinary shares could adversely affect the price of our ADSs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Future sales of a substantial number of our ADSs or ordinary shares, or the perception that such sales will occur, could cause a decline in the market price of our ADSs. Sales in the United States of our ADSs and ordinary shares held by our directors, officers and affiliated shareholders are subject to restrictions. If these shareholders sell substantial amounts of ordinary shares or ADSs in the public market, or the market perceives that such sales may occur, the market price of our ADSs and our ability to raise capital through an issue of equity securities in the future could be adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Unstable market and economic conditions may have serous adverse consequences on our business and financial condition and the price of our ADSs. The global economy, including credit and financial markets, has recently experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, rising interest and inflation rates, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. If the equity and credit markets continue to deteriorate or the United Kingdom or the United States enters a recession, it may make any necessary debt or equity financing more difficult to obtain in a timely manner or on favorable terms, more costly or more dilutive. In addition, there is a risk that one or more of our CROs, suppliers or other third-party providers may not survive an economic downturn or recession. As a result, our business, results of operations and price of our ADSs may be adversely affected.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">If securities or industry analysts or commentators publish inaccurate or unfavorable research, about our business, the price of our ADSs and ordinary shares and our trading volume could decline.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The trading market for our ADSs and ordinary shares depends in part on the research and reports that securities or industry analysts or commentators publish about us or our business. If one or more of the analysts who cover us downgrade our ADSs or if they or other industry commentators publish inaccurate or unfavorable research or comments about our business, the price of our ADSs and ordinary shares would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, demand for our ADSs could decrease, which might cause the price of our ADSs and ordinary shares and trading volume to decline.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">We have incurred and expect to continue to incur increased costs as a result of operating as a public company in the United States, and our senior management are required to devote substantial time to new compliance initiatives and corporate governance practices.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As a U.S. public company, we have incurred and expect to continue to incur significant legal, accounting and other expenses that we did not incur prior to becoming a U.S. public company. The Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of Nasdaq and other applicable securities rules and regulations impose various requirements on non-U.S. reporting public companies, including the establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our senior management and other personnel have devoted and will need to continue to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will continue to increase our legal and financial compliance costs and will make some activities more time-consuming and costly.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, or Section 404, we are required to furnish a report by our senior management on our internal control over financial reporting. However, while we remain a non-accelerated filer, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To prepare for eventual compliance with Section 404, once we are no longer a non-accelerated filer, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed time frame or at all, that our internal control over financial reporting is effective as required by Section 404. If we identify one or more material weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div id="ic8555b0a0e574cdcb5428a00447fe322_22"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 1B.&#160;&#160;&#160;&#160;Unresolved Staff Comments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">None.</span></div><div id="ic8555b0a0e574cdcb5428a00447fe322_25"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 2.&#160;&#160;&#160;&#160;Properties</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our corporate headquarters is in leased office space at 3 More London Riverside, London, U.K. The leases on the offices expire in the first quarter of 2024. We also have office space at 8045 Arco Corporate Drive, Suite 130, Raleigh, North Carolina 27617, USA, which expires in the second quarter of 2024, and 33 Park of Commerce, Suite 300, Savanna, Georgia, 31405, which expires in the forth quarter of 2025. We believe that these facilities are adequate to meet our current and near term needs.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><div id="ic8555b0a0e574cdcb5428a00447fe322_28"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 3.&#160;&#160;&#160;&#160;Legal Proceedings</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. We are not currently subject to any material legal proceedings.</span></div><div id="ic8555b0a0e574cdcb5428a00447fe322_31"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 4.&#160;&#160;&#160;&#160;Mine Safety Disclosures</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Not applicable.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><div id="ic8555b0a0e574cdcb5428a00447fe322_34"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART II</span></div><div id="ic8555b0a0e574cdcb5428a00447fe322_37"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 5.&#160;&#160;&#160;&#160;Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Market Information and Holders</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Prior to October 30, 2020, our ordinary shares were traded on the AIM Market of the London Stock Exchange under the symbol &#8220;VRP&#8221;. We canceled the admission of the ordinary shares to trading on AIM on October 30, 2020 and our ordinary shares are now not publicly traded. Our American Depositary Shares (&#8220;ADSs&#8221;) have been publicly traded on the Nasdaq Global Market under the symbol &#8220;VRNA&#8221; since April 27, 2017.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Each ADS represents eight ordinary shares of Verona Pharma plc.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As of February 13, 2023, 99.9% of our voting ordinary shares are held in ADS form, between 7,869 registered holders. The 0.1% balance of our ordinary voting shares are held as unlisted voting ordinary shares. We also have 48,088,896 unlisted non-voting ordinary shares.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Dividends</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We have never declared or paid any dividends on our common stock. We anticipate that we will retain all of our future earnings, if any, for use in the operation and expansion of our business and do not anticipate paying cash dividends in the foreseeable future.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Recent Sales of Unregistered Securities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">None.</span></div><div id="ic8555b0a0e574cdcb5428a00447fe322_40"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 6.&#160;&#160;&#160;&#160;[Reserved]</span></div><div id="ic8555b0a0e574cdcb5428a00447fe322_43"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 7.&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the consolidated financial statements and the related notes to those statements included later in this Annual Report on Form 10-K. In addition to historical financial information, the following discussion contains forward-looking statements that reflect our plans, estimates, beliefs and expectations that involve risks and uncertainties. Our actual results and the timing of events could differ materially from those discussed in these forward-looking statements. Important factors that could cause or contribute to these differences include those discussed below and elsewhere in this Annual Report on Form 10-K, particularly in Part I, Item 1A. &#8220;Risk Factors&#8221; and the section entitled &#8220;Cautionary Note Regarding Forward-Looking Statements.&#8221;</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Overview</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical need. Our product candidate, ensifentrine, is an investigational, first-in-class, inhaled, selective, small molecule and dual inhibitor of the enzymes phosphodiesterase 3 and 4 (&#8220;PDE3&#8221; and &#8220;PDE4&#8221;), combining bronchodilator and non-steroidal anti-inflammatory activities in one compound.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">During 2022, we reported positive top-line results from both of our Phase 3 ENHANCE (&#8220;Ensifentrine as a Novel inHAled Nebulized COPD thErapy&#8221;) trials evaluating nebulized ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease (&#8220;COPD&#8221;). Ensifentrine met the primary endpoint in both the ENHANCE-1 and ENHANCE-2 trials demonstrating statistically significant and clinically meaningful improvements in measures of lung function. In addition, ensifentrine substantially reduced the rate and risk of COPD exacerbations in ENHANCE-1 and ENHANCE-2. Ensifentrine was well tolerated in both trials.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Based on the results from our ENHANCE program, we believe ensifentrine, if approved, has the potential to change the treatment paradigm for COPD, if approved. The totality of data from clinical trials, in particular top-line results from the ENHANCE program, support our belief. We plan to submit a New Drug Application (&#8220;NDA&#8221;) to the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in the second quarter of 2023 for inhaled ensifentrine for the maintenance treatment of COPD.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In Phase 2 clinical trials, ensifentrine has demonstrated positive results in patients with COPD, asthma and cystic fibrosis (&#8220;CF&#8221;). Two additional formulations of ensifentrine have been evaluated in Phase 2 studies for the treatment of COPD: dry powder inhaler (&#8220;DPI&#8221;) and pressurized metered-dose inhaler (&#8220;pMDI&#8221;). Ensifentrine has shown positive Phase 2 data in COPD trials when delivered by each of these formulations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If approved, we intend to commercialize ensifentrine for the maintenance treatment of COPD in the United States (&#8220;US&#8221;). Although we believe ensifentrine will not be regulated as a drug device combination, patients use a readily available standard jet nebulizer to take ensifentrine. Outside the US, we intend to license ensifentrine to companies with expertise and experience in developing and commercializing products in those regions. To that end, we have entered a strategic collaboration with Nuance Pharma Limited (&#8220;Nuance Pharma&#8221;), a Shanghai-based specialty pharmaceutical company, to develop and commercialize ensifentrine in Greater China.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We have incurred recurring losses and negative cash flows from operations since inception, and have an accumulated deficit of $333.1 million as of December 31, 2022. We expect to incur additional losses and negative cash flows from operations until our product candidates potentially gain regulatory approval and reach commercial profitability, if at all.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We anticipate significant expenses in connection with our ongoing activities, as we:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">build out commercial infrastructure and prepare for potential commercial launch;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">continue to invest in the clinical development of ensifentrine for the treatment of COPD or other indications;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">manufacture ensifentrine and engage in other Chemistry, Manufacturing and Controls activities; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">maintain, expand and protect our intellectual property portfolio</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We believe that our cash and cash equivalents as of December 31, 2022, expected cash receipts from the UK tax credit program and funding expected to become available under the $150.0 million debt financing facility secured in October 2022, will enable us to fund our planned operating expenses and capital expenditure requirements through at least the end of 2025 including the planned commercial launch of ensifentrine in the US, if approved. The advances under the $150.0 million debt financing facility are contingent upon the achievement of certain clinical and regulatory milestones and other specified conditions. See &#8220;Indebtedness&#8221; for additional information.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Significant agreements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Ligand agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In 2006 we acquired Rhinopharma and assumed contingent liabilities owed to Ligand UK Development Limited (&#8220;Ligand&#8221;) (formerly Vernalis Development Limited). We refer to the assignment and license agreement as the Ligand Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Ligand&#160;assigned to us all of its rights to certain patents and patent applications relating to ensifentrine and related compounds (the &#8220;Ligand Patents&#8221;) and an exclusive, worldwide, royalty-bearing license under certain Ligand know-how to develop, manufacture and commercialize products (the &#8220;Licensed Products&#8221;) developed using Ligand Patents, Ligand know-how and the physical stock of certain compounds.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The contingent liability comprises a milestone payment on obtaining the first approval of any regulatory authority for the commercialization of a Licensed Product, low single digit royalties based on the future sales performance of all Licensed Products and a portion equal to a mid-twenty percent of any consideration received from any sub-licensees for the Ligand Patents and for Ligand know-how.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">At time of the acquisition the contingent liability was not recognized as part of the acquisition accounting as it was immaterial. We will therefore record as a research and development expense the milestone payment or royalties when they are probable.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In March 2022 we entered into an Amendment Agreement (the &#8220;Amendment&#8221;) with Ligand whereby the Ligand Agreement was amended to clarify certain ambiguous terms in the Ligand Agreement. Pursuant to the Amendment:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;&#160;&#160;&#160;&#160;we agreed to pay to Ligand (i) $2.0 million within five business days of the date of the Amendment and (ii) $15.0 million upon the first commercial sale of ensifentrine by us or a sub-licensee, which amount is payable in cash or, at the our discretion, by the issuance of Company equity of equivalent value, as determined based on the volume-weighted average price of the our American Depositary Shares on the Nasdaq Global Market over the ten (10) trading days including and prior to such milestone event;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;&#160;&#160;&#160;&#160;the Ligand Agreement shall expire on March 24, 2042 unless terminated earlier by either party in accordance with its terms;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;&#160;&#160;&#160;&#160;upon termination of the Ligand Agreement, any Sub-licensee (as defined in the Amendment) shall have the right to enter into a direct license agreement with Ligand for the portion of the Program IP (as defined in the Amendment) that was sub-licensed by such Sub-licensee;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;&#160;&#160;&#160;&#160;the Milestone Payment may be paid in cash or, at our discretion, by issuing to Ligand shares in the Company of equivalent value; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;&#160;&#160;&#160;&#160;each party&#8217;s right to terminate the Ligand Agreement is conditioned upon such party obtaining a final judgment of the English High Court declaring that the other party is in material breach of its obligations under the Ligand Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">For the year ended December 31, 2022 we paid the $2.0 million to Ligand and accounted for the $2.0 million payment at execution as selling, general and administrative expense in the consolidated statements of operations as the payment is related to a contract modification.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Nuance agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We entered into a collaboration and license agreement (the &#8220;Nuance Agreement&#8221;) with Nuance Pharma effective June 9, 2021 (the &#8220;Effective Date&#8221;) under which we granted Nuance Pharma the exclusive rights to develop and commercialize ensifentrine in Greater China (China, Taiwan, Hong Kong and Macau). In return, we received an unconditional right to consideration aggregating $40.0 million consisting of $25.0 million in cash and an equity interest valued at $15.0 million as of the Effective Date in Nuance Biotech, the parent company of Nuance Pharma. We are eligible to receive future milestone payments of up to $179.0 million, triggered upon achievement of certain clinical, regulatory, and commercial milestones as well as tiered double-digit royalties on net sales in Greater China.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As of December 31, 2022, the $25.0&#160;million cash payment and $15.0&#160;million equity interest had been received and the holding in Nuance Biotech was recorded as Equity interest on the Consolidated Balance Sheet, included elsewhere in this Annual Report on Form 10-K. The Equity interest is recorded at cost as the Company has elected to use the measurement alternative for equity investments without readily determinable fair values. The Company will evaluate this investment for indicators of impairment quarterly. The Company did not identify events or changes in circumstances that may have a significant effect on the fair value of the investment during the year ended December 31, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Nuance Pharma will be responsible for all costs related to clinical development and commercialization of ensifentrine in Greater China. In August 2022, Nuance Pharma, received clearance from China&#8217;s Center for Drug Evaluation to begin Phase 1 and Phase 3 studies with ensifentrine for COPD in mainland China. A joint steering committee has been established between us and Nuance Pharma to oversee and coordinate the overall conduct of such clinical development and commercialization. We intend to use the joint steering committee to help ensure the clinical development of ensifentrine in Greater China aligns with our overall global development and commercialization strategy.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Under the terms of the Nuance Agreement, at any time until three months prior to the expected submission of the first New Drug Application in Greater China, if (i) a third party is interested in partnering with us, either globally or in territory covering at least the United States or Europe, for the development and/or commercialization of ensifentrine or (ii) we undergo a change of control, we will have an exclusive option right to buy back the license granted to Nuance Pharma and all related assets. The price is agreed to be equal to the aggregate of (i) all prior amounts paid by Nuance Pharma to us in cash under the agreement and (ii) all development and regulatory costs incurred and paid by Nuance Pharma in connection with the development and commercialization of the ensifentrine under the Nuance Agreement multiplied by a single-digit factor range dependent upon achievement of certain milestones, subject to a specified maximum amount.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Nuance Agreement will continue on a jurisdiction-by-jurisdiction and product-by-product basis until the expiration of royalty payment obligations with respect to such product in such jurisdiction unless earlier terminated by the parties. Either party may terminate the Nuance Agreement for an uncured material breach or bankruptcy of the other party. Nuance Pharma may also terminate the Nuance Agreement at will upon 90 days' prior written notice. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We reviewed the buy-back option and determined that because it is conditional on a third party we do not have the practical ability to exercise it and, accordingly, the contract is accounted for under ASC 606.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The transaction price at the Effective Date of the Nuance Agreement was $40.0 million consisting of the $25.0 million upfront cash payment and $15.0 million equity interest. Developmental and regulatory milestones, and the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">manufacture and supply of ensifentrine drug product, were not included in the transaction price as we determined that it is not probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Commercial milestones and sales royalties were also excluded and will be recognized when the milestones are achieved or the sales occur in Greater China.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The performance obligations in the Nuance Agreement include the grant of the license (including the right to commercialize ensifentrine until the end of the term, the sharing of certain know how, and the sharing of certain clinical and regulatory data), and manufacture and supply of ensifentrine drug product. We have determined that the manufacturing and supply was not at a discount.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We have determined that the license and the know how shared with Nuance Pharma constitutes functional intellectual property and that revenue relating to this should be recognized at a point in time. Consequently, we have determined that we fulfilled our obligations to Nuance Pharma when we delivered the know how that will allow Nuance Pharma to file an investigational new drug application in Greater China. We delivered this know how in the year ended December 31, 2021, and, as such, recorded the $40.0 million as revenue in the year then ended.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">On the Effective Date, $4.0&#160;million of costs of obtaining the contract were recorded as a contract asset. In the year ended December 31, 2021, the entire cost was recognized as Selling, General and Administrative expense in the Consolidated Statement of Operations, in line with recognition of the revenue relating to the contract.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">On April 13, 2022, we entered into an Agreement for the Manufacture and Supply of ensifentrine (&#8220;Nuance Supply Agreement&#8221;) with Nuance Pharma. We determined that the manufacturing and supply of ensifentrine to Nuance represents a distinct and separate performance obligation, for which consideration to be received is variable based on the quantities to be ordered by Nuance. Revenue earned with the manufacture and supply of the licensed product is, and will be, recognized as the supply is delivered to Nuance. We have determined we are acting as principal in relation to the manufacture and supply under the Agreement. In its capacity as principal, the Company will recognize the associated revenue on a gross basis. As of December 31, 2022, we have recognized $0.5 million in relation to the clinical supply of ensifentrine to Nuance Pharma.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">For additional information regarding the Nuance Agreement, see Note 8 to our consolidated financial statements and related notes included elsewhere in this Annual Report.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Warrants</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">On July 29, 2016, as part of a private placement we issued warrants to investors. The warrant holders could subscribe for an ordinary share at a per share exercise price of &#163;1.7238. They could also opt for a cashless exercise of their warrants whereby they could choose to exchange the warrants held for a reduced number of warrants exercisable at nil consideration.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If, after a transaction, should the warrants have been exercisable for unlisted securities, the warrant holders were able to demand a cash payment instead of the delivery of the underlying securities. Accordingly, they were accounted for as a liability under ASC 480 &#8220;Distinguishing Liabilities from Equity&#8221; and recorded at fair value </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">using the Black-Scholes valuation methodology, on recognition and at each reporting date. The warrants expired </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">May 2, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Term loans</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In November 2020, we and Verona Pharma Inc. entered into a term loan facility of up to $30.0 million with Silicon Valley Bank (the &#8220;Term Loan&#8221;). On October 14, 2022, we and Verona Pharma, Inc. entered into a term loan (the &#8220;Oxford Term Loan&#8221;) of up to $150.0 million with Oxford Finance Luxembourg which replaced the Company&#8217;s existing Term Loan. See &#8220;Indebtedness&#8221; for additional information.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Critical accounting estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP"). The preparation of these financial statements requires us to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities as of the dates of the balance sheets and the reported amounts of expenses during the reporting periods. In accordance with U.S. GAAP, we evaluate our estimates and judgments on an ongoing basis.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">While our significant accounting policies are described in more detail in the notes to our consolidated financial statements included elsewhere in this Annual Report, we believe that the following accounting policy is most critical to the judgments and estimates used in the preparation of our consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Research and development costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Research and development (&#8220;R&amp;D&#8221;) costs are charged to the consolidated statements of operations and comprehensive loss, as incurred. We are required to estimate our expenses resulting from our obligation under contracts with vendors and consultants and clinical site agreements in connection with our R&amp;D efforts. The financial terms of these contracts are subject to negotiations which vary contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. Our objective is to reflect the appropriate clinical trial expenses in our financial statements by matching those expenses with the period in which services and efforts are expended. We account for these expenses according to the progress of the trials and other development activities measured by patient progression and the timing of various aspects of the trial. We also determine prepaid and accrual estimates through discussions with applicable personnel and outside service providers as to the progress of clinical trials, or other services completed. During the course of a clinical trial, we may adjust our rate of clinical trial expense recognition if actual results differ from its estimates. We make estimates of its prepaid and accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known at that time. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in us reporting amounts that are too high or too low for any particular period. Our clinical trial prepaid and accrual expense is dependent upon the timely and accurate reporting of study recruitment from contract research organizations and activities carried out by other third-party vendors as well as the timely processing of any change orders from the contract research organizations.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Components of results of operations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We anticipate that our expenses will increase substantially if and as we:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">establish a sales, marketing and distribution infrastructure and scale-up manufacturing capabilities to potentially commercialize any products for which we may obtain regulatory approval;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">continue the clinical development of our DPI and pMDI formulations of ensifentrine and research and develop other formulations of ensifentrine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">initiate and conduct further clinical trials for ensifentrine for the treatment of acute COPD, cystic fibrosis (&#8220;CF&#8221;) or any other indication;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">initiate and progress pre-clinical studies relating to other potential indications of ensifentrine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">seek to discover and develop additional product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">seek regulatory approvals for any of our product candidates that successfully complete clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">maintain, expand and protect our intellectual property portfolio;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">add clinical, scientific, operational, financial and management information systems and personnel, including personnel to support our product development and potential future commercialization efforts and to support our continuing operations as a U.S. public company; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">experience any delays or encounter any issues from any of the above, including but not limited to failed studies, complex results, safety issues or other regulatory challenges.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Revenue</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">To date, we have not generated revenue from the sale of any products. All revenue to date has been derived from the receipt of up-front proceeds and supply of ensifentrine under the Nuance Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the future, we anticipate generating revenue from a combination of sales of our products, if approved, whether through our own or a third-party sales force, and license fees, milestone payments and royalties in connection with strategic collaborations regarding ensifentrine or other potential products. We expect that any revenue we generate will fluctuate from quarter to quarter. If we or our strategic partners fail to complete the development of ensifentrine in a timely manner or obtain regulatory approval for them, or if we fail to develop our own sales force or find one or more strategic partners for the commercialization of approved products, our ability to generate future revenue, and our financial condition and results of operations would be materially adversely affected.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Operating expenses</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Research and development costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Research and development costs consist of salary and personnel related costs and third party costs for our research and development activities for ensifentrine. Personnel related costs include a share based compensation charge relating to our stock option plan. The largest component of third party costs is for clinical trials, as well as manufacturing for clinical supplies and associated development, and pre-clinical studies. Research and development costs are expensed as incurred.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As the Phase 3 ENHANCE program is nearing completion, we expect our research and development costs to decrease over the next several quarters until we add new compounds or develop ensifentrine further in other delivery methods or indications. Due to the nature of research and development, the expected costs are inherently uncertain and may vary significantly from our current expectations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Selling, general and administrative costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Selling, general and administrative costs consist of salary and personnel related costs, including share based expense, expenses relating to operating as a public company, including professional fees, insurance, and commercial related costs, as well as other operating expenses.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We expect commercial costs to increase as we continue to develop our commercial operations, prepare for a potential launch, and, in the event of successful regulatory approval, incur sales force, marketing and other launch </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">related costs. As we develop our knowledge of the market and refine our commercialization plans, expected costs may vary significantly from our current expectations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Other income/(expense)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Other income/(expense) are driven by interest income and expense, foreign exchange movements on cash and cash equivalents and taxes receivable, the U.K. research and development tax credits and other non-operating income and loss items.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We participate in the U.K. Small and Medium Enterprises R&amp;D tax relief program. The tax credits are calculated as a percentage of qualifying research and development expenditure and are payable in cash by the U.K. government to us. Credits recorded in the 2022 financial year are expected to be received in the 2023 financial year.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Taxation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are subject to corporate taxation in the United States and the United Kingdom. We have generated losses since inception and have therefore not paid United Kingdom corporation tax. The income taxes presented in our consolidated statements of operations and comprehensive loss represents the tax impact from our operating activities in the United States, which generates taxable income based on intercompany service arrangements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">United Kingdom losses may be carried forward indefinitely to be offset against future taxable profits, subject to various utilization criteria and restrictions. The amount that can be offset each year is limited to &#163;5.0 million plus an incremental 50% of U.K. taxable profits.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Results of operations for the years ended December 31, 2022 and 2021</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows our statements of operations for the years ended December 31, 2022 and 2021 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.476%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.243%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Variance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,542)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(346)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(346)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,888)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,123)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 4pt;text-align:left;text-indent:9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,328)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,862&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,451)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75,750)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73,313)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,437)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other income/(expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,996)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(815)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(815)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,807&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(521)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(340)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(181)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value movement on warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,246)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange (loss)/gain</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,817)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,993)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total other income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,302&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,726&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,424)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68,448)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,587)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,861)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense)/income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(253)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(271)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68,701)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,569)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,132)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Revenue</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Revenue was $0.5 million for the year ended December 31, 2022 compared to $40.0 million for the year ended December 31, 2021 a decrease of $39.5 million. The decrease is due to different revenue streams in each year with 2022 revenue related to sales of clinical supply materials to Nuance Pharma and 2021 revenue related to upfront consideration received under the Nuance Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Cost of sales</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Cost of sales of $0.3 million for the year ended December 31, 2022 related to the manufacture of the clinical supply materials sold to Nuance Pharma.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Research and development costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Research and development costs were $49.3 million for the year ended December 31, 2022, compared to $79.4 million for the year ended December 31, 2021, a decrease of $30.1 million. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">This decrease was primarily due to a reduction in clinical trial and other development costs of $27.9 million as we were nearing completion of the ENHANCE studies at the end of 2022 and a $4.2 million decrease in share-based compensation charges.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Selling, general and administrative costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Selling, general and administrative costs were </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">$26.6 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> for the year ended December 31, 2022 compared to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">$33.9 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> for the year ended December 31, 2021, a decrease of $7.3 million. This decrease was driven primarily by a $7.1 million decrease in share-based compensation charges.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Other income / (expense)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The R&amp;D tax credit for the year ended December 31, 2022 was $9.6 million compared to a credit of $15.6 million for the year ended December 31, 2021, a decrease of $6.0 million.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> This decrease is attributable to our lower qualifying expenditure on research and development in 2022 compared to 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The foreign exchange loss of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">$3.8 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> in 2022 and gain of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">$0.2 million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">in 2021 relate to the foreign exchange movements on the cash held in pound sterling and our research and development tax credit, which is a receivable in pound sterling. In 2022, the pound sterling weakened against the U.S. dollar causing the loss.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Cash flows</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table summarizes our cash flows for the years ended December 31, 2022 and 2021 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.476%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.243%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Variance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents at beginning of the year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,986&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,606)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,862)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,254)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,608)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by/(used in) financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,818&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,117)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,480)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(223)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,257)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents at end of the year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,827&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,380&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,447&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Operating activities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Operating activities used $59.9 million of cash during the year ended December 31, 2022, primarily for clinical development costs related to the ENHANCE program, employee related expenses and a decrease in payables and accruals. Operating cash flows also included office operational expenses, recruiting and legal fees.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Operating activities used $33.3 million of cash during the year ended December 31, 2021, primarily for clinical development costs related to the ENHANCE program, employee related expenses, $4.0 million commission paid to a financial advisor partially offset by the receipt of a $25.0 million net upfront payment related to our Nuance Agreement and an increase in payables and accruals. Operating cash flows also included office operational expenses, recruiting and legal fees.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Financing activities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">For the year ended December 31, 2022, financing activities provided $140.8 million of net cash, related to $140.2 million net from a public offering, $3.9 million net from a new debt agreement with Oxford finance and termination of the SVB loan, $1.4 million of proceeds from share options offset by $4.7 million payments of withholding taxes from share-based awards.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">For the year ended December 31, 2021, financing activities used $6.1 million of net cash, related to $6.8 million payments of withholding taxes from share-based awards offset by $0.7 million of proceeds from the ATM sales agreement.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Liquidity and capital resources</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We do not currently have any approved products and have never generated any revenue from product sales. To date, we have financed our operations primarily through the issuances of our equity securities, including warrants, from borrowings under the term loan facilities and from upfront payments received under the Nuance Agreement. See &#8220;Significant Agreements&#8221; and &#8220;Indebtedness&#8221; for additional information.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We have incurred recurring losses since inception, including net losses of $68.7 million, and $55.6 million for the years ended December 31, 2022, and 2021, respectively. In addition, as of December 31, 2022, we had an accumulated deficit of $333.1 million. We expect to continue to generate operating losses for the foreseeable future.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">August 2022 follow-on equity offering</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In August 2022, we completed an upsized public offering of 14,260,000 ADSs, each representing eight of our ordinary shares, nominal value &#163;0.05 per share, at a price to the public of $10.50 per ADS, which includes the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">exercise in full by the underwriters of their option to purchase an additional 1,860,000 ADSs. The aggregate net proceeds from the offering were $140.2 million after deducting underwriting discounts and offering expenses.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Open market sale agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In March 2021, we entered into an open market sale agreement with Jefferies LLC (&#8220;Jefferies&#8221;) to sell shares of our ordinary shares, in the form of ADSs, with aggregate gross sales proceeds of up to $100.0 million, from time to time, through an &#8220;at the market&#8221; equity offering program under which Jefferies will act as sales agent (the &#8220;ATM Program&#8221;). We provided Jefferies with customary indemnification rights, and Jefferies is entitled to a commission at a fixed commission rate of 3.0% of the gross proceeds. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">During the year ended December 31, 2021, we sold 873,104 ordinary shares (equivalent to 109,138 ADSs) under the ATM Program, at an average price of approximately $0.86 per share (equivalent to $6.91 per ADS), raising aggregate net proceeds of $0.7 million after deducting issuance costs. As of December 31, 2021, $99.2 million of ordinary shares, in the form of ADSs, remained available for sale under the ATM Program.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">During the year ended December 31, 2022, we sold 80,696 ordinary shares (equivalent to 10,087 ADSs) under the ATM Program, at an average price of approximately $0.86 per share (equivalent to $6.86 per ADS), raising aggregate net proceeds of $0.1 million after deducting issuance costs. As of December 31, 2022, $99.2 million of ordinary shares, in the form of ADSs, remained available for sale under the ATM Program.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Additionally, between January 1, 2023 and March&#160;3, 2023, the Company sold 20,321,384 ordinary shares (equivalent to 2,540,173 ADSs) under the ATM Program, at an average price of approximately $2.88 per share (equivalent to $23.08 per ADS), raising aggregate net proceeds of $56.9 million after deducting issuance costs. As of March&#160;3, 2023, there remained $40.6 million&#160;of ordinary shares, in the form of ADSs, available for sale under the ATM Program.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We have no ongoing material financing commitments, such as lines of credit or guarantees, that are expected to affect our liquidity over the next five years, other than leases and the Oxford Term Loan.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Indebtedness</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In November, 2020, we and Verona Pharma, Inc. (&#8220;Verona U.S.&#8221;, and together with us, the &#8220;Borrowers&#8221;) entered into the Term Loan facility of up to $30.0 million, consisting of term loan advances in an aggregate amount of $5.0 million funded at closing, a term loan advance available subject to certain terms and conditions in an aggregate amount of $10.0 million (the &#8220;Term B Loan&#8221;) and a term loan advance available subject to certain terms and conditions in an aggregate amount of $15.0 million (the &#8220;Term C Loan&#8221;), with Silicon Valley Bank (&#8220;SVB&#8221;), the proceeds of which will be used for general corporate and working capital purposes.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">On October 14, 2022 (the &#8220;Effective Date&#8221;), we and Verona Pharma, Inc. (&#8220;Verona U.S.&#8221; and together with us, the &#8220;Borrowers&#8221;) entered into the Debt Facility with Oxford Finance Luxembourg S.&#192; R.L. (&#8220;Oxford&#8221;) for an aggregate amount of up to $150.0 million (the &#8220;Oxford Term Loan&#8221;). The Oxford Term Loan provides for an initial term loan advance in an aggregate amount of $10.0 million to be funded on the Effective Date (the &#8220;Oxford Term A Loan&#8221;), and up to four additional term loan advances in an aggregate amount of $140.0 million, which are available as described below and subject to terms of the loan and security agreement (&#8220;Loan Agreement&#8221;). The proceeds from the Oxford Term Loan will be used for general corporate and working capital purposes, and a portion of the proceeds of the Oxford Term A Loan has been used to repay in full the existing outstanding indebtedness owed to SVB as discussed in Note</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">7 &#8211; Term Loan. The Oxford Term Loan has a maturity date of October 1, 2027.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The four additional term loan advances under the Oxford Term Loan consists of a $10.0 million term loan advance (the &#8220;Oxford Term B Loan&#8221;) which is available at the option of Company from the Effective Date up to and including March 31, 2023; a $20.0 million term loan advance (the &#8220;Oxford Term C Loan&#8221;) available during the period commencing on the later of January 1, 2024 and the date on which we receive positive ENHANCE-1 data in the Phase 3 clinical trial for ensifentrine sufficient to support the submission of a New Drug Application (&#8220;NDA&#8221;) with the United States Food and Drug Administration (the &#8220;FDA&#8221;) for ensifentrine through and including March 29, 2024; a $60.0 million term loan advance (the &#8220;Oxford Term D Loan&#8221;) available during the period commencing on the later of October 1, 2024 and the date on which we receive final approval from the FDA for our NDA for ensifentrine up to and including December 31, 2024; and a $50.0 million term loan advance (the &#8220;Oxford Term E Loan&#8221;) available during the interest-only period at our request and at Oxford&#8217;s sole discretion.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Each advance under the Oxford Term Loan accrues interest at a floating per annum rate equal to (a) the greater of (i) the 1-Month CME Term SOFR reference rate on the last business day of the month that immediately precedes the month in which the interest will accrue and (ii) 2.38%, plus (b) 5.50% (the &#8220;Basic Rate&#8221;). In no event shall the Basic Rate (x) for the Term A Loan be less than 7.88% and (y) for each other term loan be less than the Basic Rate on the business day immediately prior to the funding date of such term loan. The Basic Rate for the Term A Loan for the period from the Effective Date through and including October 31, 2022 shall be 8.54205% and the Basic Rate for each Term Loan shall not increase by more than 2.00% above the applicable Basic Rate as of the funding date of each such term loan. The Oxford Term Loan provides for interest-only payments on a monthly basis until the payment date immediately preceding December 1, 2025, if the Term D Loan is not made, and December 1, 2026, if the Term D Loan is made. Thereafter, amortization payments will be payable monthly in equal installments of principal plus accrued interest.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Upon repayment, whether at maturity, upon acceleration or by prepayment or otherwise, we shall make a final payment to the lenders in an amount ranging from 1.30% to 3.00% of the aggregate principal balance, depending on the advances received under the Oxford Term Loan. We may prepay the Oxford Term Loan in full, or in part, in accordance with the terms of the Loan Agreement, which is subject to a prepayment fee of up to 2.00%, depending on the timing of the prepayment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Oxford Term Loan is secured by a lien on substantially all our assets, other than intellectual property, but including any rights to payments and proceeds from the sale, licensing or disposition of intellectual property. We have also granted Oxford a negative pledge with respect to our intellectual property. The Loan Agreement contains customary covenants and representations, including but not limited to financial reporting obligations and limitations on dividends, dispositions, indebtedness, collateral, investments, distributions, transfers, mergers or acquisitions, taxes, corporate changes, deposit accounts, transactions with affiliates and subsidiaries. The Loan Agreement also contains other customary provisions, such as expense reimbursement, non-disclosure obligations as well as indemnification rights for the benefit of Oxford.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Funding requirements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We believe that our cash and cash equivalents as of December 31, 2022, together with, expected cash receipts from U.K. tax credits and additional funding expected to become available under the Oxford Term Loan, will enable us to fund our planned operating expenses and capital expenditure requirements through at least the end of 2025, including the planned commercial launch of nebulized ensifentrine for COPD maintenance treatment in the U.S. Future advances under the Oxford Term Loan are contingent upon achievement of certain clinical and regulatory milestones and other specified conditions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We may require additional capital to commercialize ensifentrine, to continue the clinical development of our DPI and pMDI formulations of ensifentrine and to research and develop additional formulations of or with ensifentrine. In addition, we may seek to initiate or conduct preclinical or clinical studies with ensifentrine in additional indications or to discover or in-license and develop additional product candidates. We may need to seek additional funding through public or private financings, debt financing, collaboration or licensing agreements and other arrangements. However, there is no guarantee that we will be successful in securing additional capital on acceptable terms, or at all.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our shareholders and ADS holders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect such holders&#8217; rights as a shareholder or ADS holder. Any future debt financing or preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends and may require the issuance of warrants, which could potentially dilute our security holders&#8217; ownership interests.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our future capital requirements for ensifentrine or any future product candidates will depend on many factors, including:</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">the progress, timing and completion of pre-clinical testing and clinical trials for ensifentrine or any future product candidates and the potential that we may be required to conduct additional clinical trials for ensifentrine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">the number of potential new product candidates we decide to in-license and develop;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">the costs involved in growing our organization to the size needed to allow for the research, development and potential commercialization of ensifentrine or any future product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">the costs involved in filing patent applications and maintaining and enforcing patents or defending against claims or infringements raised by third parties;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">the time and costs involved in obtaining regulatory approvals for ensifentrine or any future product candidate we develop and any delays we may encounter as a result of evolving regulatory requirements or adverse results with respect to ensifentrine or any future product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">any licensing or milestone fees we might have to pay during future development of ensifentrine or any future product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">selling and marketing activities undertaken in connection with the anticipated commercialization of ensifentrine or any future product candidates, if approved, and costs involved in the creation of an effective sales and marketing organization; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">the amount of revenue, if any, we may derive either directly or in the form of royalty payments from future sales of ensifentrine or any future product candidates, if approved.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our commercial revenue, if any, will be derived from sales of products that we do not expect to be commercially available for several years, if ever. Accordingly, we may need to obtain substantial additional funds to achieve our business objectives. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Recent accounting pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">For a discussion of pending and recently adopted accounting pronouncements, see Note 2 to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K</span></div><div id="ic8555b0a0e574cdcb5428a00447fe322_49"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 7A.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We are a smaller reporting company as defined in Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this Item 7A.</span></div><div id="ic8555b0a0e574cdcb5428a00447fe322_52"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 8.&#160;&#160;&#160;&#160;Financial Statements and Supplementary Data</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The information required by this Item is set forth in the consolidated financial statements and notes as referenced in Item 15 of Part IV of this Annual Report.</span></div><div id="ic8555b0a0e574cdcb5428a00447fe322_55"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 9.&#160;&#160;&#160;&#160;Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">None</span></div><div id="ic8555b0a0e574cdcb5428a00447fe322_58"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 9A.&#160;&#160;&#160;&#160;Controls and Procedures</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Disclosure Controls and Procedures</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Limitations on Effectiveness of Controls and Procedures</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Disclosure Controls and Procedures</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a- 15(e) and 15d- 15(e) under the Exchange Act), as of the end of the period covered by this Annual Report. Based on such evaluation, our principal executive officer and principal financial officer have concluded that as of December 31, 2022, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our management is responsible for establishing and maintaining adequate internal control over our financial reporting, as such term is defined in Rule 13a-15(f) under the Exchange Act.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our management conducted an assessment of the effectiveness of our internal control over financial reporting based on the criteria set forth in &#8220;Internal Control &#8211; Integrated Framework (2013)&#8221; issued by the Committee of Sponsoring Organizations of the Treadway Commission.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Based on this assessment, our management concluded that, as of December&#160;31, 2022, our internal control over financial reporting was effective.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Attestation Report of the Registered Public Accounting Firm</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">This Annual Report does not include an attestation report of our registered public accounting firm because we are a non-accelerated filer.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">There was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) under the Exchange Act) that occurred during the fourth quarter of fiscal year ended December 31, 2022, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="ic8555b0a0e574cdcb5428a00447fe322_61"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 9B.&#160;&#160;&#160;&#160;Other Information</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">None.</span></div><div id="ic8555b0a0e574cdcb5428a00447fe322_64"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 9C.&#160;&#160;&#160;&#160;Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Not applicable.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><div id="ic8555b0a0e574cdcb5428a00447fe322_67"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART III</span></div><div id="ic8555b0a0e574cdcb5428a00447fe322_70"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 10.&#160;&#160;&#160;&#160;Directors, Executive Officers and Corporate Governance</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Code of Ethics</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our board of directors has adopted a written Code of Business Conduct and Ethics applicable to all officers, directors and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. We have posted a current copy of our Code of Business Conduct and Ethics on our website at www.veronapharma.com in the &#8220;Investors&#8221; section under &#8220;Corporate Governance.&#8221; We intend to satisfy the disclosure requirement under Item 5.05 of Form 8-K regarding amendment to, or waiver from, a provision of our Code of Business Conduct and Ethics, as well as Nasdaq&#8217;s requirement to disclose waivers with respect to directors and executive officers, by posting such information on our website at the address and location specified above. The information contained on our website is not incorporated by reference into this Annual Report.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The remaining information required by this item will be included in our definitive proxy statement for the 2023 Annual General Meeting of Stockholders and is incorporated herein by reference to such proxy statement.</span></div><div id="ic8555b0a0e574cdcb5428a00447fe322_73"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 11. Executive Compensation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The information required by this item will be included in our definitive proxy statement for the 2023 Annual General Meeting of Shareholders and is incorporated herein by reference to such proxy statement.</span></div><div id="ic8555b0a0e574cdcb5428a00447fe322_76"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The information required by this item will be included in our definitive proxy statement for the 2023 Annual General Meeting of Shareholders and is incorporated herein by reference to such proxy statement.</span></div><div id="ic8555b0a0e574cdcb5428a00447fe322_79"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 13. Certain Relationships and Related Transactions, and Director Independence</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The information required by this item will be included in our definitive proxy statement for the 2023 Annual General Meeting of Shareholders and is incorporated herein by reference to such proxy statement.</span></div><div id="ic8555b0a0e574cdcb5428a00447fe322_82"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 14.&#160;&#160;&#160;&#160;Principal Accountant Fees and Services</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The information required by this item will be included in our definitive proxy statement for the 2023 Annual General Meeting of Shareholders and is incorporated herein by reference to such proxy statement.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><div id="ic8555b0a0e574cdcb5428a00447fe322_85"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART IV</span></div><div id="ic8555b0a0e574cdcb5428a00447fe322_88"></div><div style="-sec-extract:summary;margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 15. Exhibits and Financial Statement Schedule</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">s</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">(a)(1) Financial Statements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following financial statements and the Report of Independent Registered Accounting Firm are filed as part of this Annual Report:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.074%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_100">Report of Independent Registered Public Accounting Firm (PCAOB ID: </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl84OC9mcmFnOjU1YThmNGRlNDEyODRiYmRhNDY2MGUwNjE1MDhhOTRhL3RhYmxlOjM0OWY3NGEzZGU1OTRhY2JhY2I3ZDg2ZTIyMjBiNjA2L3RhYmxlcmFuZ2U6MzQ5Zjc0YTNkZTU5NGFjYmFjYjdkODZlMjIyMGI2MDZfMC0wLTEtMS01OTEyNy90ZXh0cmVnaW9uOjI3Zjg4MzA0MzhiMDRkOTZhNWUyMDNmNWQ5YzRlYTAxXzcx_ec816228-267b-45c5-ab87-2e81b16e128d">876</ix:nonNumeric>)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic8555b0a0e574cdcb5428a00447fe322_100">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_103">Consolidated Balance Sheets as of December 31, 2022 and 2021</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic8555b0a0e574cdcb5428a00447fe322_103">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_106">Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2022 and 2021</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic8555b0a0e574cdcb5428a00447fe322_106">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_109">Consolidated Statements of Changes in Shareholders&#8217; Equity for the years ended December 31, 2022 and 2021</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic8555b0a0e574cdcb5428a00447fe322_109">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_112">Consolidated Statements of Cash Flows for the years ended December 31, 2022 and 2021</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic8555b0a0e574cdcb5428a00447fe322_112">7</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_115">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic8555b0a0e574cdcb5428a00447fe322_115">8</a></span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">(a)(2) Financial Statement Schedules.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">All financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the financial statements or the notes thereto.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">(a)(3) Exhibits.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following is a list of exhibits filed as part of this Annual Report.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:8.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.253%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.922%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.189%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by Reference to Filings Indicated </span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit&#160;Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">File No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit No. </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filing date</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed / Furnished Herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000110465920140541/tm2039594d1_ex1.htm">Articles of Association, as amended and as currently in effect</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38067</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/30/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000165731218000006/exhibit21depositagreemen.htm">Deposit Agreement</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20-F</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38067</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/27/2018</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000165731218000006/exhibit21depositagreemen.htm">Form of American Depositary Receipt (included in Exhibit 4.1)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20-F</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38067</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/27/2018</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000104746917002313/a2231519zex-4_3.htm">Form of Warrant issued to each of the investors named in Schedule A thereto</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-217124</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/3/2017</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000104746917002313/a2231519zex-4_4.htm">Warrant Instrument issued to NPlus1 Singer LLP</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-217124</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/3/2017</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000165731221000004/vrna-descriptionofsecuriti.htm">Description of Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38067</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/25/2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">* </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000104746917002313/a2231519zex-10_1.htm">Registration Rights Agreement, dated July 29, 2016, by and among Verona Pharma plc and the investors set forth therein</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-217124</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/3/2017</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000110465920085620/tm2025101d2_ex2.htm">Registration Rights Agreement, dated July 16, 2020, by and among Verona Pharma plc and the investors set forth therein</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38067</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/22/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3.1&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000104746917002313/a2231519zex-10_2.htm">Intellectual Property Assignment and Licence Agreement between Vernalis Development Limited and Rhinopharma Limited, as predecessor to Verona Pharma plc, dated February 7, 2005</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-217124</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/3/2017</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000110465922040140/tm2210807d1_ex10-1.htm">Amendment Agreement by and between Verona Pharma plc and Ligand UK Development Limited dated March 23, 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38067</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/30/2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000165731220000019/ex433reguslease13914316s.htm">Renewal Agreement to Lease by and between the Verona Pharma plc and Regus Management (UK) Limited dated September 16, 2017#1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20-F</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38067</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/27/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000165731220000019/ex434reguslease14214416s.htm">Renewal Agreement to Lease by and between the Verona Pharma plc and Regus Management (UK) Limited dated September 16, 2017#2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20-F</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38067</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/27/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000165731220000019/ex435reguslease145a15116.htm">Renewal Agreement to Lease by and between the Verona Pharma plc and Regus Management (UK) Limited dated September 16, 2017#3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20-F</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38067</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/27/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000165731220000019/ex436regushudsonyardslea.htm">Renewal Agreement to Lease by and between the Verona Pharma Inc. and Regus Management Group LLC dated July 16, 2019</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20-F</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38067</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/27/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4.7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000165731222000010/reguslease_139142144xend.htm">Renewal Agreement to Lease by and between the Verona Pharma Plc. and Regus Management (UK) Limited dated November 9, 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38067</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4.7</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/7/2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4.8</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000165731222000010/reguslease_145a151xendin.htm">Renewal Agreement to Lease by and between the Verona Pharma Plc. and Regus Management (UK) Limited dated December 7, 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38067</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4.8</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/7/2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4.9</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000165731222000010/veronapharmaincbriercree.htm">Agreement to Lease by and between the Verona Pharma Inc. and Brier Creek Office #4, LLC dated March 6, 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38067</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4.9</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/7/2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000104746917002313/a2231519zex-10_4.htm">EMI Option Scheme</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-217124</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/3/2017</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000104746917002313/a2231519zex-10_5.htm">Unapproved Share Option Scheme, as amended</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-217124</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/3/2017</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000165731218000006/exhibit462017plan.htm">2017 Incentive Award Plan and forms of award agreements thereunder</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-8</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-237926</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/30/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000165731220000019/a47dzaccarrelliemploymen.htm">Employment Agreement, dated January 28, 2020, between Verona Pharma Inc. and David Zaccardelli, Pharm. D.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20-F</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38067</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/27/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000165731219000007/kathyrickardemploymentag.htm">Employment Agreement, dated December 21, 2019, between Verona Pharma plc and Kathleen Rickard</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20-F</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38067</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/19/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000104746917002313/a2231519zex-10_9.htm">Employment Agreement, dated October 1, 2016, between Verona Pharma plc and Claire Poll</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-217124</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/3/2017</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000110465920095810/tm2027314d2_ex10-12.htm">Employment Agreement, dated February 1, 2020, between Verona Pharma Inc. and Mark Hahn</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-247928</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/17/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000104746917002697/a2231786zex-10_111.htm">Form of Indemnification Agreement for board members</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-217124</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/18/2017</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000104746917002697/a2231786zex-10_112.htm">Form of Indemnification Agreement for executive officers</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-217124</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/18/2017</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000110465921103493/tm2124824d1_ex10-1.htm">Employee Change in Control Severance Benefit Plan</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-39067</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/11/2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000104746917002313/a2231519zex-10_12.htm">Relationship Agreement relating to Verona Pharma plc, dated July 29, 2016, by and among the Verona Pharma plc, OrbiMed Private Investments VI, LP and NPlus1 Singer Advisory LLP</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-217124</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/3/2017</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000104746917002313/a2231519zex-10_13.htm">Relationship Agreement relating to Verona Pharma plc, dated July 29, 2016, by and among the Verona Pharma plc, Abingworth Bioventures VI LP and NPlus1 Singer Advisory LLP</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-217124</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/3/2017</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000104746917002313/a2231519zex-10_14.htm">Relationship Agreement relating to Verona Pharma plc, dated July 29, 2016, by and among the Verona Pharma plc, Vivo Ventures Fund VII, L.P., Vivo Ventures VII Affiliates Fund, L.P., Vivo Ventures Fund VI, L.P., Vivo Ventures VI Affiliates Fund, L.P. and NPlus1 Singer Advisory LLP</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-217124</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/3/2017</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000110465920085620/tm2025101d2_ex1.htm">Relationship Agreement relating to Verona Pharma plc, dated July 29, 2016, by and among the Verona Pharma plc, Vivo Ventures Fund VII, L.P., Vivo Ventures VII Affiliates Fund, L.P., Vivo Ventures Fund VI, L.P., Vivo Ventures VI Affiliates Fund, L.P. and NPlus1 Singer Advisory LLP</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38067</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/22/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000110465920128643/tm2036424d1_ex1-1.htm">Loan and Security Agreement, dated as of November 19, 2020, by and among Silicon Valley Bank, Verona Pharma plc and Verona Pharma, Inc.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38067</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/24/2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000165731221000004/non-executicedirectorappoi.htm">Form of Non-Executive Director letter of appointment</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38067</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/25/2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1657312/000165731221000018/exhibit101q221.htm">Collaboration and License Agreement, effective as of June 9, 2021, by and between Verona Pharma plc, Nuance Pharma Limited and Nuance (Shanghai) Pharma Co Ltd</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38067</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/5/2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit211q422.htm">List of Subsidiaries of Verona Pharma plc </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="consentletter-fy22.htm">Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311q422.htm">Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312q422.htm">Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321q422.htm">Section 1350 Certification of Chief Executive Officer</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit322q422.htm">Section 1350 Certification of Chief Financial Officer</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">*        Filed herewith.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">**      Furnished herewith.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">#         Indicates management contract or compensatory plan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8224;         Portions of this exhibit (indicated by asterisks) have been omitted pursuant to Regulation S-K, Item 601(b)(10). Such omitted information is not material and the registrant customarily and actually treats such information as private or confidential. Additionally, schedules and attachments to this exhibit have been omitted pursuant to Regulation S-K, Items 601(a)(5).</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><div id="ic8555b0a0e574cdcb5428a00447fe322_91"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Item 16.&#160;&#160;&#160;&#160;Form 10-K Summary</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">None</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><div id="ic8555b0a0e574cdcb5428a00447fe322_94"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.664%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">VERONA PHARMA PLC</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date: March 7, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ David Zaccardelli</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">David Zaccardelli, Pharm. D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">President and Chief Executive Officer</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:30.029%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.061%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.934%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ David Zaccardelli</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">President and Chief Executive Officer</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(principal executive officer)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 7, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">David Zaccardelli, Pharm. D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ Mark W. Hahn</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Financial Officer</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(principal financial and accounting officer)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 7, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Mark W. Hahn</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ David Ebsworth, Ph.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chairperson of the Board of Directors</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 7, 2023</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">David Ebsworth, Ph.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ James Brady</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 7, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">James Brady</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ Ken Cunningham, M.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 7, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Ken Cunningham, M.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ Lisa Deschamps</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 7, 2023</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Lisa Deschamps</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ Martin Edwards, M.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 7, 2023</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Martin Edwards, M.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ Rishi Gupta</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 7, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Rishi Gupta</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ Mahendra Shah, Ph.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 7, 2023</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Mahendra Shah, Ph.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ Vikas Sinha</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 7, 2023</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Vikas Sinha</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ Anders Ullman, M.D., Ph.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 7, 2023</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Anders Ullman, M.D., Ph.D.</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><div id="ic8555b0a0e574cdcb5428a00447fe322_97"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Index</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.074%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_100">Report of Independent Registered Public Accounting Firm (PCAOB ID:</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> <ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl85Ny9mcmFnOmE5NWMyMmJhMDAyNDQ4Y2E4YzI2MGM5ZjgwY2YwNmVjL3RhYmxlOmEyODViNjkwZjg0NDQ4MzU4MjMwYjlmMjkyYzQ2ZmQyL3RhYmxlcmFuZ2U6YTI4NWI2OTBmODQ0NDgzNTgyMzBiOWYyOTJjNDZmZDJfMC0wLTEtMS01OTEyNy90ZXh0cmVnaW9uOjAwYTYyZjcxZDdmYjQ4NWFiNzZhMDk1ODFlZTI1NDRhXzcx_ec816228-267b-45c5-ab87-2e81b16e128d">876</ix:nonNumeric>)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic8555b0a0e574cdcb5428a00447fe322_100">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_103">Consolidated Balance Sheets as of December 31, 2022 and 2021</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic8555b0a0e574cdcb5428a00447fe322_103">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_106">Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2022 and 2021</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic8555b0a0e574cdcb5428a00447fe322_106">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_109">Consolidated Statements of Changes in Shareholders&#8217; Equity for the years ended December 31, 2022 and 2021</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic8555b0a0e574cdcb5428a00447fe322_109">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_112">Consolidated Statements of Cash Flows for the years ended December 31, 2022 and 2021</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic8555b0a0e574cdcb5428a00447fe322_112">7</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic8555b0a0e574cdcb5428a00447fe322_115">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ic8555b0a0e574cdcb5428a00447fe322_115">8</a></span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-1</span></div></div></div><div id="ic8555b0a0e574cdcb5428a00447fe322_100"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To the Board of Directors and Shareholders of Verona Pharma plc</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Opinion on the Financial Statements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We have audited the accompanying consolidated balance sheets of Verona Pharma plc and its subsidiary (the &#8220;Company&#8221;) as of December 31, 2022 and 2021, and the related consolidated statements of operations and comprehensive loss, of shareholders&#8217; equity and of cash flows for the years then ended, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Basis for Opinion</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Critical Audit Matters</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Recognition of Research and Development Expenditures Related to Clinical Trial Costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As described in Note 2 to the consolidated financial statements, the company carries out research and development activities including contracts with clinical research organizations and contract manufacturers. Research and Development expenditure for the year ended December 31, 2022 was $49,283 thousand, of which a significant portion is made up of research and development costs from contracts with clinical research organizations and contract manufacturers. Management estimates expenses resulting from obligations under contracts with vendors and consultants and clinical site agreements by matching expenses with the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of the trials and other development activities which requires management to apply judgment in developing assumptions related to patient progression and the timing of various aspects of the trial.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The principal considerations for our determination that performing procedures relating to recognition of research and development expenditures related to clinical trial costs is a critical audit matter are the judgment required by management in estimating the cost based upon the progress of clinical trial activities, which in turn led to a high degree of auditor judgment, subjectivity and effort in performing procedures and evaluating evidence of assumptions related to patient progression and the timing of various aspects of the trial. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included, among others, (i) testing management&#8217;s process for developing estimated expenses related to clinical trial activities; (ii) evaluating the appropriateness of the method used by management to develop the estimates; (iii) testing the completeness and accuracy of the underlying data used by management; and (iv) evaluating the reasonableness of significant assumptions related to patient progression and the timing of various aspects of the trial. Evaluating management&#8217;s assumptions involved considering the associated clinical trial timelines, patient progression, invoicing to date, and the provisions of the related contracts.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDAvZnJhZzo1MGJhNWMxMmQ0Mjk0MWRjYjg5YzEzNjM1MmViYzYyYS90ZXh0cmVnaW9uOjUwYmE1YzEyZDQyOTQxZGNiODljMTM2MzUyZWJjNjJhXzMxMTg_2e18f9f5-32e7-45ae-b9f0-f6b4fc541fbf">PricewaterhouseCoopers LLP</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDAvZnJhZzo1MGJhNWMxMmQ0Mjk0MWRjYjg5YzEzNjM1MmViYzYyYS90ZXh0cmVnaW9uOjUwYmE1YzEyZDQyOTQxZGNiODljMTM2MzUyZWJjNjJhXzMxMTc_257a4e38-beb0-48a5-bdf8-72cc2ea6e519">Reading, United Kingdom</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 7, 2023</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company's auditor since 2015.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-3</span></div></div></div><div id="ic8555b0a0e574cdcb5428a00447fe322_103"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share amounts, per share amounts and par value of shares)</span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzQtMi0xLTEtNTkxMjc_765e1a0c-41cf-49d3-bd98-75707fd75822">227,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzQtNC0xLTEtNTkxMjc_dd6decb0-24f7-446a-9b47-62be528accb1">148,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzctMi0xLTEtNTkxMjc_f34e5d9d-a60c-4baf-a672-e1ad8c0b13d3">2,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzctNC0xLTEtNTkxMjc_cc43a569-8bba-4ca2-88f2-ab46313c9472">4,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax incentive receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="vrna:TaxCreditAndIncomeTaxesReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzgtMi0xLTEtNTkxMjc_81bb735b-138d-485f-b274-ca86357817d7">9,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" name="vrna:TaxCreditAndIncomeTaxesReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzgtNC0xLTEtNTkxMjc_ee3fdd81-e4bf-4273-8cdd-6b37e683898e">15,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzExLTItMS0xLTU5MTI3_92807c6c-26f5-4f7b-9c41-fa0808e3fc85">3,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzExLTQtMS0xLTU5MTI3_84894ffe-a4a4-4abc-a36a-2d099df4ad8c">2,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzEyLTItMS0xLTU5MTI3_96252286-c91f-43d5-80ef-a28477698b5a">242,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzEyLTQtMS0xLTU5MTI3_e2b418b3-3d37-4584-be86-2edc6a9d1bf1">170,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzE1LTItMS0xLTU5MTI3_79d430d9-a66d-43c0-b0b2-eaa57bc96b36">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzE1LTQtMS0xLTU5MTI3_332da618-610f-40bf-8c5d-cc2c6f338a5b">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzE2LTItMS0xLTU5MTI3_1b55113e-5a16-457b-ab92-ab5942301666">545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzE2LTQtMS0xLTU5MTI3_a6eed54f-5f47-4746-8bea-fe076d400285">545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzE3LTItMS0xLTU5MTI3_f6670fd5-5268-4dac-a0bf-25ae3bbbe515">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzE3LTQtMS0xLTU5MTI3_c45df30c-d938-4402-90bb-378e1e53a333">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzE4LTItMS0xLTU5MTI3_d2574b62-872e-42ae-ad1e-75205673af8d">854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzE4LTQtMS0xLTU5MTI3_0b84cc12-71b2-4e30-852f-10dd954a8ac8">899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total non-current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzE5LTItMS0xLTU5MTI3_fcfee9df-2b16-4f5c-8bd0-84646e598af0">16,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzE5LTQtMS0xLTU5MTI3_90e0271b-33de-4e9a-802b-5f104056c2b8">16,524</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzIwLTItMS0xLTU5MTI3_e0e4301a-9a12-494c-a998-f20caf7e1786">259,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzIwLTQtMS0xLTU5MTI3_7d1a1732-de3c-42c7-8c3a-a678de918842">186,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzI0LTItMS0xLTU5MTI3_b67e607c-2a33-41c8-8892-dfd84b246ca9">2,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzI0LTQtMS0xLTU5MTI3_e684063f-ead5-4083-8174-147ad653631c">10,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzI1LTItMS0xLTU5MTI3_dbb52186-36fb-451e-9f7e-228e91064190">13,752</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzI1LTQtMS0xLTU5MTI3_3f20433c-d5f1-4e02-9372-93dbbc353c2d">22,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzI3LTItMS0xLTU5MTI3_057b8d39-625e-4553-a3e8-bc6fe4b9c538">675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzI3LTQtMS0xLTU5MTI3_43f86712-74bc-4169-ae36-8b91012664f5">648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="us-gaap:TaxesPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzI5LTItMS0xLTU5MTI3_867138c8-3533-44e4-8fda-bab374840ddc">283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" name="us-gaap:TaxesPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzI5LTQtMS0xLTU5MTI3_3d8bb306-da18-42e7-a3a3-1eca2ca067a5">147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzMwLTItMS0xLTU5MTI3_99019260-54ef-4348-99c6-cb075803487e">1,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzMwLTQtMS0xLTU5MTI3_f7258857-3599-42d3-bfb7-cd48cbe6c23f">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzMxLTItMS0xLTU5MTI3_315c4f75-9a64-4490-b9df-2ddeaa5fdd0f">19,029</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzMxLTQtMS0xLTU5MTI3_2d15fb4c-b6f1-48e9-868b-92baa1eb584b">33,422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzM1LTItMS0xLTU5MTI3_03db1c67-f742-4284-85e8-4863d50461a2">9,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzM1LTQtMS0xLTU5MTI3_800bcaac-ad8a-4bbb-8862-afeede87d2cf">4,874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzM2LTItMS0xLTU5MTI3_c1104ed7-8df1-40f3-9ce3-dddc7d03fb94">205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzM2LTQtMS0xLTU5MTI3_7bdeab6a-7f08-41b7-81ac-007cf88ea229">286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzM3LTItMS0xLTU5MTI3_d71ec89a-835c-4679-82ee-487b2091ce0f">9,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzM3LTQtMS0xLTU5MTI3_b6ca69b6-9c98-4b09-b5a2-36cc71064e08">5,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzM4LTItMS0xLTU5MTI3_e6bbd066-1b10-4e28-b101-911951d4cbb5">29,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzM4LTQtMS0xLTU5MTI3_8df090bd-852b-4f21-acfd-589d0237ef34">38,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commitments and contingencies </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzQwLTItMS0xLTU5MTI3_f163d427-f9d1-4247-abff-ae56786cc294"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzQwLTQtMS0xLTU5MTI3_c057b8e2-811b-4e2c-8ef5-6e351e89aa32"></ix:nonFraction></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shareholders' equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ordinary &#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="2" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzQzLTAtMS0xLTU5MTI3L3RleHRyZWdpb246NDEwM2EyZDI2NDVhNGQwMGE0MjY2YWU0Nzc0ODllM2RfMTM_249dbafe-c5df-4a7a-9e26-613b18a3fdbe"><ix:nonFraction unitRef="gbpPerShare" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="2" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzQzLTAtMS0xLTU5MTI3L3RleHRyZWdpb246NDEwM2EyZDI2NDVhNGQwMGE0MjY2YWU0Nzc0ODllM2RfMTM_af5c73c5-146a-4d84-94bc-288da41cabdb">0.05</ix:nonFraction></ix:nonFraction> par value shares: <ix:nonFraction unitRef="shares" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="0" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzQzLTAtMS0xLTU5MTI3L3RleHRyZWdpb246NDEwM2EyZDI2NDVhNGQwMGE0MjY2YWU0Nzc0ODllM2RfMzQ_feaa870e-9f48-42fe-bc1d-6b9afa757316">631,338,246</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="0" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzQzLTAtMS0xLTU5MTI3L3RleHRyZWdpb246NDEwM2EyZDI2NDVhNGQwMGE0MjY2YWU0Nzc0ODllM2RfNDE_1e7c495d-85ae-4f28-a284-299875e04548">489,177,550</ix:nonFraction> issued, and <ix:nonFraction unitRef="shares" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzQzLTAtMS0xLTU5MTI3L3RleHRyZWdpb246NDEwM2EyZDI2NDVhNGQwMGE0MjY2YWU0Nzc0ODllM2RfNTY_12a5fe37-0d73-4ccd-9f96-94dd49ae47a2">606,301,054</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzQzLTAtMS0xLTU5MTI3L3RleHRyZWdpb246NDEwM2EyZDI2NDVhNGQwMGE0MjY2YWU0Nzc0ODllM2RfNjM_2aabeb57-be9c-41fc-9cca-1ed11fa76422">480,082,966</ix:nonFraction> outstanding, at December 31, 2022 and 2021, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzQzLTItMS0xLTU5MTI3_34553d7e-02da-464d-aece-42d718e361c8">40,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzQzLTQtMS0xLTU5MTI3_13ef434f-e993-4ba1-b714-b5d828e44c5a">31,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzQ0LTItMS0xLTU5MTI3_fc76a5d8-8568-47bf-b874-79cd994ee312">529,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzQ0LTQtMS0xLTU5MTI3_6ba4ca40-3a10-4a8d-960b-741ec1a73aec">385,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ordinary shares held in treasury</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzQ1LTItMS0xLTU5MTI3_b6e398b0-00f0-4ac4-ac58-ab27561ee01f">1,549</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" name="us-gaap:TreasuryStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzQ1LTQtMS0xLTU5MTI3_11226d7a-11d7-416c-9a68-c3c7bd2d2d6e">603</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzQ2LTItMS0xLTU5MTI3_02b4a503-be2e-4731-bae6-ca916333cdc5">4,601</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzQ2LTQtMS0xLTU5MTI3_03774e0b-1e74-4f34-a2ad-41d2b5cb54d4">4,601</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzQ3LTItMS0xLTU5MTI3_844fa8d5-b7e0-4927-85cd-2d3a5bd85a20">333,097</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzQ3LTQtMS0xLTU5MTI3_ca265a6b-3298-4060-97fc-9046487535d6">263,716</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total shareholders' equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzQ4LTItMS0xLTU5MTI3_dcb5dd94-2881-4ad7-ae3b-70fd14a8aa78">230,466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzQ4LTQtMS0xLTU5MTI3_a49401a7-07ee-4083-933b-f23782e6d01a">148,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and shareholders' equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzQ5LTItMS0xLTU5MTI3_1ecbb9cc-ecbd-407f-8e00-35b5c7d6be78">259,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzQ5LTQtMS0xLTU5MTI3_fe584c46-d0d0-42f4-8e6f-b9ca066c04fe">186,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-4</span></div></div></div><div id="ic8555b0a0e574cdcb5428a00447fe322_106"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share amounts)</span></div></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzItMi0xLTEtNTkxMjc_04daaa4c-92e4-4715-9040-498d2e842c80">458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzItNC0xLTEtNTkxMjc_6cda5271-5c9a-471d-b8f9-b32cbfa40654">40,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="us-gaap:CostOfRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzMtMi0xLTEtNTkxMjc_62642537-ad70-4924-b333-b2de2fdae05c">346</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzMtNC0xLTEtNTkxMjc_6702c0df-711c-4eaa-b874-6e173a681c6a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzQtMi0xLTEtNTkxMjc_720e8d7e-d28a-4a91-8636-ddf7bf494f4f">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzQtNC0xLTEtNTkxMjc_200d2810-08e7-4f0b-bc74-2d946efcd4ff">40,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzYtMi0xLTEtNTkxMjc_71d30870-bfce-4dcc-842b-aa877fff6fdc">49,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzYtNC0xLTEtNTkxMjc_8b57c4e9-277c-40ae-b470-fec8640c6010">79,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzctMi0xLTEtNTkxMjc_e50fee84-48ac-4682-9e1d-457eed164e23">26,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzctNC0xLTEtNTkxMjc_acbcf422-0e93-4530-a2de-9613456d07fb">33,907</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzgtMi0xLTEtNTkxMjc_ed9820d9-6121-4131-8c19-68c0a8593fc2">75,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzgtNC0xLTEtNTkxMjc_89d5be54-a1af-41a5-90bc-6b929e63262f">113,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzktMi0xLTEtNTkxMjc_7335aa25-174d-4d95-9f4e-01bf4c72a6d7">75,750</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzktNC0xLTEtNTkxMjc_a7b041e7-633c-4bf9-b11f-4c54b232b020">73,313</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other income/(expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="vrna:GainLossFromResearchAndDevelopmentTaxCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzExLTItMS0xLTU5MTI3_f4649fa6-486b-412a-8896-4e08b070bde3">9,634</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="vrna:GainLossFromResearchAndDevelopmentTaxCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzExLTQtMS0xLTU5MTI3_8379b371-4738-4af3-8c8f-371817e05597">15,630</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzEyLTItMS0xLTU5MTY0_76ddb656-35a9-49e1-ae6f-d5aef45fc63e">815</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzEyLTQtMS0xLTU5MTY0_d9bc4fc8-dcd3-4a9a-8efb-40262016ea2f">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzEyLTItMS0xLTU5MTI3_29021942-0d27-4cb1-b744-b8b883889814">2,821</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzEyLTQtMS0xLTU5MTI3_81b54ac3-13ad-4675-957a-ebceac2d25bd">14</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzEzLTItMS0xLTU5MTI3_57f62e5f-7aca-4683-9b00-6ce8a66850f9">521</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzEzLTQtMS0xLTU5MTI3_281279d3-91e4-45a7-a88f-cd6dfbac7f0a">340</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value movement on warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="vrna:UnrealizedGainLossOnWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzE0LTItMS0xLTU5MTI3_4907f05f-4424-418d-9c61-b172806e8497">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="vrna:UnrealizedGainLossOnWarrants" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzE0LTQtMS0xLTU5MTI3_08bf8ef4-c22c-490b-9cf1-8a3712729d83">2,246</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange (loss)/gain</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzE1LTItMS0xLTU5MTI3_d1bf539a-fad8-485c-bb93-0b134dd1b5e5">3,817</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzE1LTQtMS0xLTU5MTI3_92497c84-a4f6-4cc1-a385-41fd80f8ab8f">176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total other income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzE2LTItMS0xLTU5MTI3_77e09019-35d9-4c6a-9685-0efab40bda47">7,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzE2LTQtMS0xLTU5MTI3_1b0e7220-1059-4aa5-8cc3-059f7a01de96">17,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzE3LTItMS0xLTU5MTI3_464ad949-d9da-4558-88d7-a5997af639c1">68,448</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzE3LTQtMS0xLTU5MTI3_f4afa9d7-ceb3-4212-93d8-82786a964aad">55,587</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense)/income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzE4LTItMS0xLTU5MTI3_d13eef67-8713-44b3-8d2c-f0991f45f0a8">253</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzE4LTQtMS0xLTU5MTI3_f4e30076-a8d6-4496-b556-4e2330b71bf3">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzE5LTItMS0xLTU5MTI3_b1f13fbf-99d9-4b9c-ade9-675d4193b0cd">68,701</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzE5LTQtMS0xLTU5MTI3_795f12cb-4286-4e08-b821-ed78b19ea57f">55,569</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per ordinary share &#8212; basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzIzLTItMS0xLTU5MTI3_0a7e9201-6ec0-4172-91fa-89b900474441"><ix:nonFraction unitRef="usdPerShare" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzIzLTItMS0xLTU5MTI3_36ba8915-9bcf-47d3-a672-087b4ae9afb2">0.13</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzIzLTQtMS0xLTU5MTI3_6a5f1077-3559-4095-896a-c60a37b100f5"><ix:nonFraction unitRef="usdPerShare" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzIzLTQtMS0xLTU5MTI3_e0a11042-d08d-4522-949a-20dd118a311c">0.12</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-5</span></div></div></div><div id="ic8555b0a0e574cdcb5428a00447fe322_109"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Shareholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands except share data)</span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"></td><td style="width:20.317%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.434%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.078%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.561%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.460%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.337%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Ordinary shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additional paid-in capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Ordinary shares held in treasury</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total shareholders' equity</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i914d9cdf65d04c2f90fe005e7472a193_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzItMi0xLTEtNTkxMjc_44105498-d4e9-47d1-92b7-0a2dad101498">488,304,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914d9cdf65d04c2f90fe005e7472a193_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzItNC0xLTEtNTkxMjc_7764a667-7fd8-4d27-b866-66faf04b93c6">31,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628f4c337d8a4907b099660435d9a654_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzItNi0xLTEtNTkxMjc_1572d66f-7272-4304-a5a8-7043f7fc4b9d">366,411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib7f0ec0ed1784d75a7a6870bf8e210e8_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzItOC0xLTEtNTkxMjc_b97862cc-69ed-403b-b22a-3ae2a270d6e4">1,700</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bcd9fdf0b49455fbda9ed3d6b4ffe6a_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzItMTAtMS0xLTU5MTI3_201d1b5d-2d67-4246-9271-0f350c555467">4,601</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f35aecd3e8247dab76bb02c4f16b0fc_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzItMTItMS0xLTU5MTI3_7e85dc61-54b0-45fc-8fef-3b4635e6cd12">207,050</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if80b5e08771841e98a3888a3388c32e2_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzItMTQtMS0xLTU5MTI3_e7475005-db7c-4a66-bafe-1bb570ae660d">184,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if823f7d8c92d4955b417d2877d92cf1e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzMtMTItMS0xLTU5MTI3_5e3c24a6-8547-4b6a-a8b4-3817f2eb09cf">55,569</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzMtMTQtMS0xLTU5MTI3_943a29ed-94d3-490e-b7be-df9434a6a8cc">55,569</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common shares under at-the-market sales agreement</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i380ad8bec02d4cef80ab1e2a0293509c_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzUtMi0xLTEtNTkyMjg_46c14e4b-7f0a-47fb-b6c2-ab30dd038f8c">873,104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i380ad8bec02d4cef80ab1e2a0293509c_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzUtNC0xLTEtNTkyMjg_128aff55-f767-4be4-9c22-d9d203baca66">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i375548ad8ff84bd0982f3bccb9de8503_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzUtNi0xLTEtNTkyMjg_73ec496d-ffc7-42f8-9f5e-99444a294aee">672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i442b161bf35c4276ac36992d05e23115_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzUtMTQtMS0xLTU5MjI4_8a351799-7539-4495-8001-e55f37366d9f">733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted share units vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2541a30ef7e84fc1925bf03d916e97a2_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzctOC0xLTEtNTk0MzI_e440f8ab-8953-493c-a67d-2c3c43d57988">1,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if823f7d8c92d4955b417d2877d92cf1e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzctMTItMS0xLTU5NDMy_594bf020-e764-47a0-be5d-e57b9f909fd4">1,097</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8a8c7eae65b43e9a11fdf51f5b2d5d8_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzgtNi0xLTEtNTkzNDQ_255de6fd-8512-4c24-9a9d-d99057676227">25,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzgtMTQtMS0xLTU5MzQ0_73b0c6b2-c835-4ccd-93d8-a52bf4beba45">25,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares withheld for taxes on vested stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8a8c7eae65b43e9a11fdf51f5b2d5d8_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzktNi0xLTEtNTk0MzI_fd158733-f343-4b1d-bc16-a3e420ca9ced">6,850</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzktMTQtMS0xLTU5NDMy_44d6eff8-3574-4d67-a379-ebe02052fa0a">6,850</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity settled share-based compensation reclassified as cash-settled</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8a8c7eae65b43e9a11fdf51f5b2d5d8_D20210101-20211231" decimals="-3" name="vrna:AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzEwLTYtMS0xLTU5NDMy_628fa5aa-389c-460e-96d7-10394d4d64ef">588</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="vrna:AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzEwLTE0LTEtMS01OTQzMg_cb69f546-c6ab-49d6-9c0c-4135fac49cae">588</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib56e759a9ec24aa88f41a41be62db95d_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzEwLTItMS0xLTU5MTI3_6c0d1d42-75d3-4816-91ae-f4e58b0d3c8b">489,177,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56e759a9ec24aa88f41a41be62db95d_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzEwLTQtMS0xLTU5MTI3_b6928d67-a0a2-4585-99a3-ea0aab2584fa">31,855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia773a9ee14f34d1a8dc7c9d57c7401e1_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzEwLTYtMS0xLTU5MTI3_54f72f85-5eb3-46ba-a07b-3d3b02b8b33b">385,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ece18e799b840598f8450de9ee4fb80_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzEwLTgtMS0xLTU5MTI3_991d6998-fc2c-4ff8-bdec-bc5550e5e340">603</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8f5a4cc91e843d384ab12b09f91edb8_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzEwLTEwLTEtMS01OTEyNw_5a86e3cf-6e11-4758-9e5c-f7cc3681f8eb">4,601</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i609c9125fe4c4df8b724395ec47768f6_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzEwLTEyLTEtMS01OTEyNw_3013fe08-27f9-4ae3-9aeb-acbb31b8b46f">263,716</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzEwLTE0LTEtMS01OTEyNw_41cbaae7-a1f1-4dc6-9469-836b34848c2e">148,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2df52cddbf6047d99bc4c33dc209f75a_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzExLTEyLTEtMS01OTEyNw_d9d1a12c-77f7-4fa5-a141-85aa9501f7e7">68,701</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzExLTE0LTEtMS01OTEyNw_589c6e08-e0f8-4d24-b4e9-1233d61517c6">68,701</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of ordinary shares, net of issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i079c0a66af1a4b4f8579073c30a06c55_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzEzLTItMS0xLTU5MjY2_78c38e91-9aae-4b31-886d-de81c2b022f0">114,080,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i079c0a66af1a4b4f8579073c30a06c55_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzEzLTQtMS0xLTU5MjY2_e720ac5f-1006-46d5-927a-ebb3aa4e6852">6,918</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibab55600f3bc40aa902c283296c411ce_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzEzLTYtMS0xLTU5MjY2_66a128b9-6cd0-410d-b53b-89bb479a2a68">133,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d11dce15ffe46c5a3f318667309b215_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzEzLTE0LTEtMS01OTI2Ng_ec36b814-d0f5-4980-a1da-5729f5a8b6c6">140,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common shares under at-the-market sales agreement</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2af5163aa9d84dad89a011496414bdd2_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzEyLTItMS0xLTU5MTI3_bb4ab586-afb9-4ef9-9fee-0f46ee74b925">80,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af5163aa9d84dad89a011496414bdd2_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzEyLTQtMS0xLTU5MTI3_eed6d343-eb76-4e3f-a4fd-9029934f3ef1">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i111533997c354eed8392ec995f25323f_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzEyLTYtMS0xLTU5MTI3_7e2def35-1837-4cd2-9a24-5d960966722c">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i979239b8c81f4ce297052fdb5fcfb029_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzEyLTE0LTEtMS01OTEyNw_7d83be96-dea0-49dd-829b-eb907940222c">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of ordinary shares to treasury</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie6d783db1d43419d8f15b7dc0a5bcb2d_D20220101-20221231" decimals="INF" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzEzLTItMS0xLTU5MTI3_93ac81fd-95e5-4618-b6e0-00d01df5fc2f">28,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6d783db1d43419d8f15b7dc0a5bcb2d_D20220101-20221231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzEzLTQtMS0xLTU5MTI3_cf8219a5-2fda-4d4d-830b-1f61672091df">1,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1aae0c0ff8a846889a7cab3fe123941d_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzEzLTgtMS0xLTU5MTI3_53515dbf-48f1-4d70-a5e7-d7060868cb7b">1,748</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzEzLTE0LTEtMS01OTEyNw_65200643-cae4-4c58-8d3c-e01765e9de35">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted share units vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1aae0c0ff8a846889a7cab3fe123941d_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzE3LTgtMS0xLTU5NDkx_a3bf3a24-5dc1-48a7-8c65-24d2e5ab0f6f">680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2df52cddbf6047d99bc4c33dc209f75a_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzE3LTEyLTEtMS01OTQ5MQ_732e802d-7945-41e1-8f9e-38fb820ee80e">680</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share options exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9ea6a1e50f743c7b2706c4f275812bf_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzE4LTYtMS0xLTU5NDU0_ced646b4-7f93-4bc6-845d-59b08232182f">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1aae0c0ff8a846889a7cab3fe123941d_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzE4LTgtMS0xLTU5NDU0_f30dc5ee-ec02-48b2-b5c0-96fd3a75af67">122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzE4LTE0LTEtMS01OTQ1NA_ebe4d095-5375-4ba3-b214-34493c350832">1,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9ea6a1e50f743c7b2706c4f275812bf_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzE0LTYtMS0xLTU5MTI3_f257b956-3211-46b5-b598-da182689181d">14,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzE0LTE0LTEtMS01OTEyNw_961208eb-1211-4942-a380-30f7664f2e52">14,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares withheld for taxes on vested stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9ea6a1e50f743c7b2706c4f275812bf_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzE1LTYtMS0xLTU5MTI3_4eac42fc-8065-4e33-8163-f85302f544ce">4,723</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzE1LTE0LTEtMS01OTEyNw_683ad21b-43e2-4ace-85ec-117ec0b05124">4,723</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity settled share-based compensation reclassified as cash-settled</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9ea6a1e50f743c7b2706c4f275812bf_D20220101-20221231" decimals="-3" sign="-" name="vrna:AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzIwLTYtMS0xLTU5MTI3_756bd2e0-4b5b-4cbd-9fbe-58ec8367df86">128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" sign="-" name="vrna:AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzIwLTE0LTEtMS01OTEyNw_8051eb74-5b01-4e05-b361-bd650facb4f4">128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i91456de939c649aabb7986b2e37d0859_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzIxLTItMS0xLTU5MTI3_269b9a1a-1b52-444c-a64a-c262e9e1af28">631,338,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91456de939c649aabb7986b2e37d0859_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzIxLTQtMS0xLTU5MTI3_0c9dda61-b8fb-4f7d-a37d-d89f759248d1">40,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25dfa9d20fe64551adbf52bf5cde91b6_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzIxLTYtMS0xLTU5MTI3_e1688bc8-d2a7-407b-b50e-574f4fd2d6fe">529,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica49ccad51694417b0ecd16ca773ee2b_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzIxLTgtMS0xLTU5MTI3_c5d3e2bb-ed08-4bfd-a799-570bb0bfa450">1,549</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79d67ed1de10489aa0bb85ba9c0ec74a_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzIxLTEwLTEtMS01OTEyNw_bdcc17be-74bc-4d3a-a587-52ea15066a5b">4,601</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9383bef872e64838b59e60f52963eea3_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzIxLTEyLTEtMS01OTEyNw_09ed7493-89d5-4064-a075-56ffce9e2058">333,097</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzIxLTE0LTEtMS01OTEyNw_e08935ec-8a04-4888-86d6-fe3f74ab66ef">230,466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-6</span></div></div></div><div id="ic8555b0a0e574cdcb5428a00447fe322_112"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzMtMi0xLTEtNTkxMjc_1f24ed5d-4ce0-4e0b-bd38-ea8bb12e4de5">68,701</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzMtNC0xLTEtNTkxMjc_3f9e62f1-abea-4211-b7ba-c02a97b9840e">55,569</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange loss/(gain)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzUtMi0xLTEtNTkxMjc_6f2adc97-36c1-4036-9302-7d6fad619c63">3,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzUtNC0xLTEtNTkxMjc_f20598c9-cf3a-4509-b27e-e9836c7291d2">176</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issue costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzYtMi0xLTEtNTkxMjc_42d8e36e-f77d-448b-9b0f-c6af67b3a257">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzYtNC0xLTEtNTkxMjc_fc31ebcd-9595-4908-94cb-229191a11628">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of redemption premium on debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzctMi0xLTEtNTkxMjc_80a0b479-7cf2-4dd5-ad1a-1feec9d99974">108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzctNC0xLTEtNTkxMjc_73901c89-4cf5-4866-a6bf-1dce9d4e32e7">125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzgtMi0xLTEtNTk1MzA_851a76cd-dc69-41b5-8af4-b1538b4c23a8">815</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzgtNC0xLTEtNTk1MzA_d8190015-bdb4-43c6-9b13-9790f8ecf6f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value movement on warrants </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzgtMi0xLTEtNTkxMjc_dbda9887-43a3-4fab-ad3d-370855140531">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzgtNC0xLTEtNTkxMjc_d42acac5-6347-4f4e-97d5-b00ae42bab51">2,246</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzEwLTItMS0xLTU5MTI3_4540b060-250f-4225-be71-02cfb3667932">14,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzEwLTQtMS0xLTU5MTI3_ad6581a9-d17b-4457-96dd-498dd3f545ce">25,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzExLTItMS0xLTU5MTI3_02ffc5b7-34d1-4e74-bad5-ae2efe80ccce">636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzExLTQtMS0xLTU5MTI3_9951f210-beb9-49d0-9e59-785f8e896303">629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity interest recognized as revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="vrna:IncreaseDecreaseInEquityInterestReceivable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzEyLTItMS0xLTU5MTI3_3b436057-e674-40cb-a9b1-e1445fd18cec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="vrna:IncreaseDecreaseInEquityInterestReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzEyLTQtMS0xLTU5MTI3_a5cb6b1f-5fe9-407f-8d77-17809189c20e">15,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzE2LTItMS0xLTU5MTI3_30402302-5839-474c-ba11-4b1e44e1d3d7">1,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzE2LTQtMS0xLTU5MTI3_6b6cf190-0863-4043-abc4-cc88df64f0a7">501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax incentive receivables</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" sign="-" name="vrna:IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzE3LTItMS0xLTU5MTI3_e4254633-259f-4307-ab66-04f9924a2cfe">3,964</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="vrna:IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzE3LTQtMS0xLTU5MTI3_575cac2c-5751-44f9-be13-6bb2de7fae4f">6,924</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzE4LTItMS0xLTU5MTI3_90399fa9-f016-49fb-ac7a-5810332d7ff6">1,325</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzE4LTQtMS0xLTU5MTI3_be91bd09-3ca6-4598-9105-b6b0b19624f0">343</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzE5LTItMS0xLTU5MTI3_aeacbebe-9117-4422-b5d2-b4bce982a920">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzE5LTQtMS0xLTU5MTI3_040997d8-7978-4a35-9a35-b5a9a4891951">440</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzIwLTItMS0xLTU5MTI3_bbcab77e-9d7a-4983-840b-466d2bb8d1f4">7,146</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzIwLTQtMS0xLTU5MTI3_ea55bd19-7c47-4d54-9bb3-7b9dad67b7ec">9,866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzIxLTItMS0xLTU5MTI3_e8125572-1c4e-4711-8d13-cef1e6441eef">8,504</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzIxLTQtMS0xLTU5MTI3_47d02767-bc94-4bbb-a7bf-b314572cfc0f">11,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" sign="-" name="vrna:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzIyLTItMS0xLTU5MTI3_3b3ad075-b28d-4304-8360-928b21e97ada">597</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" sign="-" name="vrna:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzIyLTQtMS0xLTU5MTI3_48e46e1f-3364-4c82-9207-81b390245d8f">373</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedTaxesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzIzLTItMS0xLTU5MTI3_cfc066ad-73d4-4b3d-b776-90d70b1c8597">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedTaxesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzIzLTQtMS0xLTU5MTI3_2e2744ca-22ab-4e88-bdd7-86972ad9140f">147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzI0LTItMS0xLTU5MTI3_37162e05-efc2-4380-a016-7f9983fa0081">1,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzI0LTQtMS0xLTU5MTI3_69b9b126-458c-48be-bebc-027b19550ec9">379</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzI1LTItMS0xLTU5MTI3_9b46d596-14e8-47fd-a8dc-a30f14f7a06f">59,862</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzI1LTQtMS0xLTU5MTI3_ca1143ba-f2fb-464c-981e-444905135166">33,254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of furniture and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzI3LTItMS0xLTU5MTI3_71bdb539-6a7d-4caf-934d-7db120a1842c">29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzI3LTQtMS0xLTU5MTI3_a70f4ce1-4bec-44e8-a0b1-95e9f7f4d7ef">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzI5LTItMS0xLTU5MTI3_98aa91c8-d22f-463b-bf61-707c0f07ad05">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzI5LTQtMS0xLTU5MTI3_4db20a38-004b-4d77-bcc4-0dfc7ad1dd90">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of ordinary shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzMxLTItMS0xLTU5MTI3_c89add5d-76e8-403a-a87b-9c48ac5e97e0">149,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzMxLTQtMS0xLTU5MTI3_f5072336-6b7e-4e42-9ad6-1476becd84ff">733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of offering costs in connection with the issuance of ordinary shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzMyLTItMS0xLTU5MTI3_437565c1-841d-47ea-889e-ee2b134893b7">9,533</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzMyLTQtMS0xLTU5MTI3_3eb0d110-f555-439f-bb70-4ab5f443046c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of Oxford Term Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzMzLTItMS0xLTU5MTI3_1d4cd6d7-63e1-46fd-9bd3-264b956c2fdf">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzMzLTQtMS0xLTU5MTI3_e49144f7-871e-4177-85e5-e81f7d112693">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oxford Term Loan issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzM0LTItMS0xLTU5MTI3_e3805715-0615-4100-802b-b2acd52ba10a">245</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzM0LTQtMS0xLTU5MTI3_a52ae838-fa8a-4faa-8531-ea950c902f93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of SVB Term Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzM2LTItMS0xLTY5MTY3_9bece2ba-a636-4508-b178-011a4453a3a5">5,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzM2LTQtMS0xLTY5MTY3_6b2763c8-8df2-4463-8d0e-f04011058607">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SVB Term Loan repayment costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsOfLoanCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzM3LTItMS0xLTY5MTY3_3cd6a545-f285-4ecf-b69e-4bd00face73c">850</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsOfLoanCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzM3LTQtMS0xLTY5MTY3_b482e804-8068-495e-86bf-1929c5590b2a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments of withholding taxes from share-based awards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzM1LTItMS0xLTU5MTI3_3ec303d7-3f78-4613-ad5a-cae4d479abfd">4,723</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzM1LTQtMS0xLTU5MTI3_f3f9351b-3322-4da1-bc52-c48b3f9b30f7">6,850</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of share options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzM2LTItMS0xLTU5MTI3_add54e1a-516f-4cf4-b496-a5a50d5d0384">1,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzM2LTQtMS0xLTU5MTI3_dc827a20-4e0f-468a-8125-42a92eb3f903">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by/(used in) financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzM4LTItMS0xLTU5MTI3_c819b3fc-6f34-4299-9948-ee5f3ddb3a55">140,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzM4LTQtMS0xLTU5MTI3_f1154390-3283-426e-95a2-886b1cf0a9f9">6,117</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzM5LTItMS0xLTU5MTI3_5ebdf782-2857-4376-9ee2-4ed8c741b09b">1,480</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzM5LTQtMS0xLTU5MTI3_553720e9-7a55-4f9d-a98d-6b8bf4bc73b0">223</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzQwLTItMS0xLTU5MTI3_cbb9fab3-68cb-4e44-a122-f03be82f34ca">79,447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzQwLTQtMS0xLTU5MTI3_c424077d-fee7-49a5-9c28-fad9caf00f26">39,606</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents at beginning of the year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzQxLTItMS0xLTU5MTI3_450f994a-73e7-457b-84de-d5df15581ca2">148,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if80b5e08771841e98a3888a3388c32e2_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzQxLTQtMS0xLTU5MTI3_eb3b388a-bc37-4d4f-9c33-89cb8c5172ac">187,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents at end of the year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzQyLTItMS0xLTU5MTI3_1d443dbf-b083-401e-af25-6ef3d89b3a7a">227,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzQyLTQtMS0xLTU5MTI3_36c2db9d-6e03-45a6-a02a-901ba3905028">148,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes paid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzQ0LTItMS0xLTU5MTI3_6032a8c5-bc51-4eb0-9124-26d2c61bfe75">120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzQ0LTQtMS0xLTU5MTI3_fd9b4e7c-89fa-402e-82db-97db81326f31">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzQ1LTItMS0xLTU5MTI3_4cdd2c60-d539-4436-b280-a173ade8c1d0">348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzQ1LTQtMS0xLTU5MTI3_71062625-5e56-4f64-aa07-a55b2777c499">215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-7</span></div></div></div><div id="ic8555b0a0e574cdcb5428a00447fe322_115"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements&#160;&#160;&#160;&#160;</span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 1 - <ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="vrna:OrganizationAndBusinessDescriptionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzMzMzg_5824c86b-37bd-43e3-b851-c58da915fca4" continuedAt="ic093a18696ae47a78f3c6281be61ba91" escape="true">Organization and description of business operations </ix:nonNumeric></span></div><ix:continuation id="ic093a18696ae47a78f3c6281be61ba91"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Verona Pharma plc (the "Company") is incorporated and domiciled in the United Kingdom. Verona Pharma plc has <ix:nonFraction unitRef="subsidiary" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="INF" name="vrna:NumberOfWhollyOwnedSubsidiaries" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzE3Ng_b4ba8c58-705e-43e1-a106-190c53057fce">one</ix:nonFraction> wholly-owned subsidiary, Verona Pharma, Inc., a Delaware corporation. Rhinopharma Limited (&#8220;Rhinopharma&#8221;), a Canadian company that was previously a non-operating, wholly-owned subsidiary, was dissolved in June 2021. The address of the registered office is 1 Central Square, Cardiff, CF10 1FS, United Kingdom.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company is a clinical-stage biopharmaceutical group focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. The Company&#8217;s American Depositary Shares (&#8220;ADSs&#8221;) are listed on the Nasdaq Global Market (&#8220;Nasdaq&#8221;) and trade under the symbol &#8220;VRNA&#8221;. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Liquidity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company has incurred recurring losses and negative cashflows from operations since inception, and has an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzIxOTkwMjMyNjg2NTc_4550bdff-e665-4ea3-9c3e-69f1590e96f2">333.1</ix:nonFraction>&#160;million as of December 31, 2022. The Company expects to incur additional losses and negative cash flows from operations until its products potentially gain regulatory approval and reach commercial profitability, if at all.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company expects that its cash and cash equivalents as of December 31, 2022, will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months from the date of issuance.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In August 2022, the Company completed an upsized public offering of <ix:nonFraction unitRef="shares" contextRef="ie238e662ca594fb8b2c61e9a8e7cc2b7_D20220815-20220815" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzI0NzM5MDExNjM3NjIx_c87d2f10-f52f-426b-b263-29928d34712a">14,260,000</ix:nonFraction> ADSs, each representing <ix:nonFraction unitRef="number" contextRef="ice1cf713bbb6461a9be47f13e6cb343f_I20220815" decimals="0" name="dei:EntityListingDepositoryReceiptRatio" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzI0NzM5MDExNjM3NzA1_c2826258-d8f6-40f1-b261-7bdb37d14835">eight</ix:nonFraction> ordinary shares of the Company, nominal value &#163;<ix:nonFraction unitRef="usdPerShare" contextRef="ice1cf713bbb6461a9be47f13e6cb343f_I20220815" decimals="2" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzI0NzM5MDExNjM3Njk5_d6f69e28-35fb-41f5-aa35-411d0b792465">0.05</ix:nonFraction> per share, at a price to the public of $<ix:nonFraction unitRef="usdPerShare" contextRef="ieb1aa532b71f489d849b821859d2f380_I20220815" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzI0NzM5MDExNjM3NjMz_a51339ae-d0e9-4adb-9fb1-fe538d902d15">10.50</ix:nonFraction> per ADS, which includes the exercise in full by the underwriters of their option to purchase an additional <ix:nonFraction unitRef="shares" contextRef="i184e0ab9d5a54b338f38f20780281582_D20220815-20220815" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzI0NzM5MDExNjM3NjQx_c709f81e-ce3c-4be4-b837-77204ac88db6">1,860,000</ix:nonFraction> ADSs. The aggregate net proceeds from the offering were $<ix:nonFraction unitRef="usd" contextRef="i7bd8f835b5424f209ef20622393563fe_D20220815-20220815" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzI0NzM5MDExNjM3NjUy_c5e5770e-5c62-4d13-80ca-746212da8b29">140.2</ix:nonFraction>&#160;million after deducting underwriting discounts and commissions and estimated offering expenses payable.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In October 2022, the Company entered into a term loan of up to $<ix:nonFraction unitRef="usd" contextRef="ia867c724f1754d6b8ce8489a52865172_I20221014" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzI0NzM5MDExNjM3NjY4_3d84a1e5-f414-4bbb-91a6-1e09980e1431">150.0</ix:nonFraction>&#160;million (the &#8220;Oxford Term Loan&#8221;) with Oxford Finance Luxembourg S.&#192; R.L. (&#8220;Oxford&#8221;). This Oxford Term Loan replaced the Company&#8217;s existing $<ix:nonFraction unitRef="usd" contextRef="ib6f1e5c7e48647c0920bd6e598622618_I20201130" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzI0NzM5MDExNjM3Njg0_2fb246ea-1144-4d44-9331-aa6add372e25">30.0</ix:nonFraction>&#160;million facility with Silicon Valley Bank. See Note 7 for further details.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In March, 2021, the Company entered into an open market sale agreement with respect to an at-the-market offering program (the &#8220;ATM Program&#8221;) under which the Company may issue and sell its ordinary shares in the form of ADSs, with an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="ic5b573c06bda4d9abf4c5788689f8267_I20210331" decimals="-5" name="vrna:SaleOfStockMaximumAggregateOfferingPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzIwMjU_a4340ccf-2cd8-470e-bdbb-f9d33d60537d">100.0</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">During the year ended December 31, 2021, the Company sold <ix:nonFraction unitRef="shares" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzI0MTg5MjU1ODIzMzY3_fb0a8734-641c-4825-9d72-fd3a3558eb58">873,104</ix:nonFraction> ordinary shares (equivalent to <ix:nonFraction unitRef="shares" contextRef="i527c9fac13d64a47b9bf9214236f60e2_D20210101-20211231" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzI0MTg5MjU1ODIzNDAy_f98d3561-ec47-4d99-a65b-1124966bc4d3">109,138</ix:nonFraction> ADSs) under the ATM Program, at an average price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzI0MTg5MjU1ODIzNDcy_1d2dc7f1-7176-4ad2-b1a8-b7f1988cd9a9">0.86</ix:nonFraction> per share (equivalent to $<ix:nonFraction unitRef="usdPerShare" contextRef="i6695925fbed543f894ece49ef4cdea3a_I20211231" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzI0MTg5MjU1ODIzNTAx_7184858a-fdab-4ff7-81a4-9d9cb8ff956a">6.91</ix:nonFraction> per ADS), raising aggregate net proceeds of $<ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzI0MTg5MjU1ODIzNTYz_6e4f2ff9-b15a-4d3a-b5e2-228c6349f919">0.7</ix:nonFraction>&#160;million after deducting issuance costs. As of December 31, 2021, there remained $<ix:nonFraction unitRef="usd" contextRef="i6695925fbed543f894ece49ef4cdea3a_I20211231" decimals="-3" name="vrna:CommonStockSharesAvailableForSaleValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzI0MTg5MjU1ODIzNjM5_bac242d6-fa41-40cd-a45d-b8546212300e">99.3</ix:nonFraction>&#160;million of ordinary shares, in the form of ADSs, available for sale under the ATM Program.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">During the year ended December 31, 2022, the Company sold <ix:nonFraction unitRef="shares" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzM4NDgyOTA3MDEwNTE_5b2371f5-973f-4f54-abfa-9b94a9e21110">80,696</ix:nonFraction> ordinary shares (equivalent to <ix:nonFraction unitRef="shares" contextRef="i51dfe19fdb8b4c94be7f8c486773856a_D20220101-20221231" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzM4NDgyOTA3MDEwNzA_3e697fdd-5279-4782-a0fd-07ec0d5d38ba">10,087</ix:nonFraction> ADSs) under the ATM Program, at an average price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzM4NDgyOTA3MDEwODY_1ff9a70e-6492-4ab8-9702-f6a2ce04d0c9">0.86</ix:nonFraction> per share (equivalent to $<ix:nonFraction unitRef="usdPerShare" contextRef="ic554433105b34f27be03700dabfb47f7_I20221231" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzM4NDgyOTA3MDEwOTk_112c030c-19ed-4e21-8875-d67f99507c32">6.86</ix:nonFraction> per ADS), raising aggregate net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzM4NDgyOTA3MDExMjE_e22bf46e-413e-4f10-8e19-9c304d42661f">0.1</ix:nonFraction>&#160;million after deducting issuance costs. As of December 31, 2022, there remained $<ix:nonFraction unitRef="usd" contextRef="ic554433105b34f27be03700dabfb47f7_I20221231" decimals="-3" name="vrna:CommonStockSharesAvailableForSaleValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzM4NDgyOTA3MDExNTI_3b480fa9-9900-4351-8543-66567b53509b">99.2</ix:nonFraction>&#160;million of ordinary shares, in the form of ADSs, available for sale under the ATM Program.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Additionally, between January 1, 2023 and March 3, 2023, the Company sold <ix:nonFraction unitRef="shares" contextRef="i8aef53e83ae8405d96c0bb866c6a4b44_D20230101-20230303" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzEzMDYy_d97a1354-b612-4901-b86c-9e394ed10ac8">20,321,384</ix:nonFraction> ordinary shares (equivalent to <ix:nonFraction unitRef="shares" contextRef="i7a0e931dedec4d268138428467b28255_D20230101-20230303" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzEzMDc4_59ccf274-f257-4616-8de8-88e75af8571e">2,540,173</ix:nonFraction> ADSs) under the ATM Program, at an average price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i947febb528b2492baff336d20285fda1_I20230303" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzEzMDY2_5eadfad8-b989-484f-9127-e5c9985ebcb0">2.88</ix:nonFraction> per share (equivalent to $<ix:nonFraction unitRef="usdPerShare" contextRef="icff757a8f7aa4258a984848491ccbe0b_I20230303" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzEzMDc0_3310fbc0-8bff-411c-a408-592bec39cd85">23.08</ix:nonFraction> per ADS), raising aggregate net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i8aef53e83ae8405d96c0bb866c6a4b44_D20230101-20230303" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzEzMDgy_3e0e26e9-6551-4f23-b2db-9cdd923d7fce">56.9</ix:nonFraction> million after deducting issuance costs. As of March&#160;3, 2023, there remained $<ix:nonFraction unitRef="usd" contextRef="icff757a8f7aa4258a984848491ccbe0b_I20230303" decimals="-3" name="vrna:CommonStockSharesAvailableForSaleValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzEzMDcw_cced559d-0f79-42ca-b64d-5cb91af1d670">40.6</ix:nonFraction> million&#160;of ordinary shares, in the form of ADSs, available for sale under the ATM Program.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company&#8217;s commercial revenue, if any, will be derived from sales of products that we do not expect to be commercially available within the next year, if ever. Additionally, we may enter into out-licensing transactions from time to time but there can be no assurance that the company can secure such transactions in the future. Accordingly, we may need to obtain substantial additional funds to achieve our business objectives including to further advance clinical and regulatory activities, to fund prelaunch and launch related costs and to create an effective sales and marketing organization to commercialize ensifentrine. Any such additional funding will need to be obtained through public or private financings, debt financing, collaboration or licensing agreements and other arrangements. However, there is no guarantee that we will be successful in securing additional capital on acceptable terms, or at all.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-8</span></div></div></div><div id="ic8555b0a0e574cdcb5428a00447fe322_118"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements&#160;&#160;&#160;&#160;</span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 2 - <ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzIzOTA2_29295754-e2dc-48bb-8746-3dae9e9e4d4d" continuedAt="i5d40444f720e4aadacd0755f6f08e3d2" escape="true">Basis of Presentation and Summary of Significant Accounting policies</ix:nonNumeric></span></div><ix:continuation id="i5d40444f720e4aadacd0755f6f08e3d2" continuedAt="ice81230e82a04f1d82b0704728913446"><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzIzODk3_10b5b295-c9cb-48fb-a2a3-899c5ba125e5" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Basis of presentation and consolidation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The consolidated financial statements include the accounts of Verona Pharma plc and its wholly-owned subsidiaries Verona Pharma, Inc. and Rhinopharma through to its dissolution in June 2021. All inter-company balances and transactions have been eliminated. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") and the following accounting policies have been consistently applied.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">At the end of the second quarter of 2020, the Company determined that it no longer qualified as a Foreign Private Issuer under SEC rules. As a result, beginning January 1, 2021, the Company was required to report with the SEC on domestic forms and comply with domestic company rules in the United States. The transition to U.S. GAAP was made retrospectively for all periods from the Company&#8217;s inception.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzIzOTA4_1310afd3-d363-4c85-b091-cca25a40c9be" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Use of estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual and prepayment of research and development expenses and the fair value of share-based compensation. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from the Company&#8217;s estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzIzOTA5_25cbef5b-b5ea-417f-bf6c-6884438f9d2b" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Business combinations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company applies the acquisition method to account for business combinations. The consideration transferred for the acquisition of a subsidiary is the fair value of the assets transferred, the liabilities incurred to the former owners of the acquiree and the equity interests issued by the Company. The consideration transferred includes the fair value of any asset or liability resulting from a contingent consideration arrangement. The excess of the cost of acquisition over the fair value of the Company's share of the identifiable net assets acquired is recorded as goodwill. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Identifiable ass</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">ets acquired and liabilities and contingent liabilities assumed in a business combination are measured initially at their fair values at the acquisition date. Acquisition-related costs are expensed as incurred and included in administrative expenses.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzIzOTEw_028f006c-ad2b-4f46-afed-9a10416df8cb" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Cash and cash equivalents</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company considers all highly liquid investments purchased with original maturities of ninety days or less at acquisition to be cash equivalents. Cash and cash equivalents includes deposits held at call with banks, and in money market funds investing in U.S. and U.K. government debt and liquid securities from highly rated institutions.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzIzOTEx_4909fab0-fe68-4f65-80bb-2dedcb7a51a1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Equity interest</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As part of the Nuance Agreement, the Company received an equity interest in Nuance Biotech, the parent company of Nuance Pharma (see Note 8). As Nuance Biotech&#8217;s securities are not publicly traded the equity interest&#8217;s fair value is not readily determinable. The Company therefore follows guidance from ASC 321-10-35-2 and uses the fair value measurement alternative and measures the securities at cost, which is deemed to be the value indicated by the last observable transaction in Nuance Biotech's stock, subject to impairment. The valuation will be adjusted for any observable price changes in orderly transactions for an identical or similar investment in Nuance Biotech, or if there is an indicator of impairment.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzIzOTAy_af158b7d-0fb8-4109-a5e8-ac8e468602f5" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Furniture and equipment, net</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Furniture and equipment comprise office furniture and computer equipment and are stated at cost less accumulated depreciation, which is calculated on a straight-line basis over the expected useful economic lives, generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzQ1MDg_ff010e70-9a6d-4e4c-a482-a7e0d106f1e3">two</span> to <ix:nonNumeric contextRef="i12dbdc5aaf3b4090a92274f569107ad3_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzQ1MTQ_1fe556f8-e30d-44c8-af93-78c4c0864b22">five years</ix:nonNumeric>.</span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements&#160;&#160;&#160;&#160;</span></div></div><ix:continuation id="ice81230e82a04f1d82b0704728913446" continuedAt="i0c2c48ee6a5943898028c2f64a48c62d"><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzIzOTAz_8c8dbc78-c3fd-4bb3-8458-698de3fc3524" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Goodwill</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Goodwill consists of goodwill related to the acquisition of Rhinopharma. Goodwill is not amortized but periodically tested for impairment.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzIzODk4_ac2bf854-fbbc-4f3e-b5ad-29838c61f29f" continuedAt="i960503407d334c5b8f4a816295edfd8a" escape="true">Impairment of long-lived assets</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"><ix:continuation id="i960503407d334c5b8f4a816295edfd8a">The Company reviews long-lived assets for impairment annually or whenever events or changes in circumstances indicate that the carrying amount of assets may not be fully recoverable.</ix:continuation> </span></div><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzIzOTEz_d0bc2003-146b-4889-aa15-c2cf3c16dbe4" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Revenue recognition</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company&#8217;s revenue consists of revenue from the Company&#8217;s strategic agreements for the development and commercialization of ensifentrine. The terms of the agreements typically include non-refundable upfront fees, payments based upon achievement of milestones and eventually revenue from the commercialized product. These agreements usually have both fixed and variable consideration. Non-refundable upfront fees are considered fixed, while milestone payments and revenue from the commercialized product are identified as variable consideration.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under agreements within the scope of ASC Topic 606, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic 606. The Company&#8217;s performance obligations include intellectual property rights, (which include the license, patents and developmental and regulatory data) and manufacturing and supply. Management are required to judge when performance obligations are satisfied and consequently when revenue is recognized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company allocates the total transaction price to each performance obligation based on the estimated relative standalone selling prices of the promised goods or service underlying each performance obligation. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied. If the right to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the right when the right is transferred to the customer, and the customer can use and benefit from the right.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">At the inception of the arrangement, the Company evaluates whether the development milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company, such as approvals from regulators, are not considered probable of being achieved until those approvals are received.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzIzOTAx_d10f8b66-02e9-4a58-859c-e82ce811b30a" continuedAt="i98bad4393e404bf795316e9e398a1757" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Research and development costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Research and development (&#8220;R&amp;D&#8221;) costs are expensed as incurred. Research and development expenses include salaries, share-based compensation and benefits of employees, and other costs related to the Company&#8217;s R&amp;D activities, including contracts with clinical research organizations and contract manufacturers. The Company is required to estimate its expenses resulting from its obligations under contracts with vendors and consultants and clinical site agreements in connection with its R&amp;D efforts. The financial terms of these contracts are subject to negotiations which vary contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts. The Company&#8217;s objective is to reflect the appropriate clinical trial expenses in its consolidated financial statements by matching those expenses with the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of the trials and other development activities. Judgment is applied in determining assumptions related to patient progression and the timing of various aspects of the trial used to measure progress. The Company determines prepaid and accrual estimates through discussions with applicable personnel and outside service providers as to the progress of clinical trials, or other services completed. During the course of a clinical trial, the Company adjusts its </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements&#160;&#160;&#160;&#160;</span></div></div><ix:continuation id="i0c2c48ee6a5943898028c2f64a48c62d" continuedAt="ia5fc56afa74946da8bec8cd32ef4c845"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"><ix:continuation id="i98bad4393e404bf795316e9e398a1757">rate of clinical trial expense recognition if actual results differ from its estimates. The Company makes estimates of its prepaid and accrued expenses as of each balance sheet date in its consolidated financial statements based on facts and circumstances known at that time. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in the Company reporting amounts that are too high or too low for any particular period. The Company&#8217;s clinical trial prepaid and accrual expense is dependent upon the timely and accurate reporting of study recruitment from contract research organizations and activities carried out by other third-party vendors as well as the timely processing of any change orders from the contract research organizations.</ix:continuation></span></div><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzIzODk5_5acb3774-20e1-468c-93b0-5a74f614123f" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Share-based compensation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company has a share-based compensation plan under which various types of equity-based awards may be granted, including stock options and restricted stock units (RSUs). The fair value of share options and RSUs, which are subject to milestone or service conditions with graded vesting, are recognized as compensation expense on a straight-line basis using the graded-vesting method; f</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">orfeitures are recognized as they occur.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company uses the fair-value based method to determine compensation for all arrangements under which employees receive shares. The fair value of each option and RSU is estimated on the date of grant using the Black-Scholes valuation model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate. Expected volatility is based on the historical volatility of the Company&#8217;s ordinary shares over the expected term of the options. The expected term of options granted is derived using the simplified method, which computes the expected term as the average of the sum of the vesting term plus the contract term. Historically the risk-free rate has been based on the appropriate U.K. government debt yield. After delisting its Ordinary shares from AIM on October 30, 2020, the Company used U.S. government debt yields.</span></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Details of the assumptions used are set out in Note 9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">to the consolidated financial statements.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements&#160;&#160;&#160;&#160;</span></div></div><ix:continuation id="ia5fc56afa74946da8bec8cd32ef4c845" continuedAt="i9e2a7a1db9cc4150bf382cdf8c140ba5"><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="vrna:GovernmentTaxCreditsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzIzOTEy_63ed354e-c882-4ac1-beb5-ba762dc02395" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Other income - United Kingdom R&amp;D tax credits </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Other income relates to R&amp;D tax credits receivable in the UK. As a company that carries out extensive research and development activities, Verona is subject to the UK R&amp;D Small and Medium Enterprise (&#8220;SME&#8221;) Program. Qualifying expenditures largely comprise employment costs for research staff, consumables, a proportion of relevant, permitted sub-contract costs and certain internal overhead costs incurred as part of research projects for which it does not receive income. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Tax credits related to the SME Program are received as cash and are recorded as other income, as they are akin to grant income, in the consolidated statements of operations and comprehensive loss.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzIzODk1_c45632ac-5591-49bf-8592-627fe1573d10" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Income taxes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company accounts for income taxes in accordance with ASC 740, &#8220;Income Taxes&#8221; (&#8220;ASC 740&#8221;). ASC 740 prescribes the use of the liability method, whereby deferred tax assets and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. ASC 740 establishes a single model to address accounting for uncertain tax positions. ASC 740 clarified the accounting for income taxes by prescribing the minimum recognition threshold a tax position is required to meet before being recognized in the financial statements. The Company has no uncertain tax positions.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzIzOTE0_32c64ecb-406b-4429-b349-9dc285ce3785" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Comprehensive loss</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company accounts for comprehensive loss in accordance with ASC 220, &#8220;Income Statement - Reporting Comprehensive Income&#8221;. Comprehensive income represents all changes in stockholders&#8217; equity during the period except those resulting from investments by, or distributions to, stockholders.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzIzOTA3_528f726d-6270-41f8-b4e1-a01629d05081" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Segment Reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company has <ix:nonFraction unitRef="segment" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="0" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzE1NjE2_6d6a9e83-1c40-487b-a156-d82d026a8e4f"><ix:nonFraction unitRef="segment" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="0" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzE1NjE2_bebe3fdb-3461-4b27-a078-dffd3405f91f">one</ix:nonFraction></ix:nonFraction> operating and reportable segment, pharmaceutical development. The Company&#8217;s long-lived assets are held in the United Kingdom.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzIzODk2_07ad4b3f-be23-4fa6-acd6-5a9e04d30de5" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Foreign Currencies</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Reporting and functional currencies</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The consolidated financial statements are reported in U.S. dollars, which is also the functional currency of our subsidiary. Transactions in foreign currencies are remeasured into our functional currency at the rate of exchange prevailing at the date of the transaction. Any monetary assets and liabilities arising from these transactions are remeasured into our functional currency at exchange rates prevailing at the balance sheet date or on settlement. Resulting gains and losses are recorded in foreign exchange loss in our consolidated statements of operations.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements&#160;&#160;&#160;&#160;</span></div></div><ix:continuation id="i9e2a7a1db9cc4150bf382cdf8c140ba5" continuedAt="if67213f9838e4995a457f55b19135614"><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="us-gaap:StockholdersEquityPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzIzOTE2_7357c90c-9e25-423e-a182-1cb78fee4bbb" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Treasury shares</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the year ended December 31, 2020, the Company incorporated a trust to facilitate the acquisition of shares, by or for the benefit of employees and former employees. In the year ended December 31, 2022, the Company issued <ix:nonFraction unitRef="shares" contextRef="ie6d783db1d43419d8f15b7dc0a5bcb2d_D20220101-20221231" decimals="-6" name="vrna:StockIssuedDuringPeriodSharesHeldInTreasury" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzE3OTMy_9538706d-a40c-480d-a1c8-4c598b3a4815">28.0</ix:nonFraction>&#160;million ordinary shares (equivalent to <ix:nonFraction unitRef="shares" contextRef="ie6d783db1d43419d8f15b7dc0a5bcb2d_D20220101-20221231" decimals="-5" name="vrna:StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzE3OTY2_26e8d226-e006-403b-a44f-c91c26177084">3.5</ix:nonFraction>&#160;million ADSs) to cover expected shares issued upon the vesting of share awards to employees. The Company issued <ix:nonFraction unitRef="shares" contextRef="i1ffe1b3cbbcb48709153748921695a17_D20210101-20211231" decimals="-6" name="vrna:StockIssuedDuringPeriodSharesHeldInTreasury" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzI0NzM5MDExNjc1MzU5_8a046c61-6ab2-4ba7-a498-2b9bb14d8d73">no</ix:nonFraction> ordinary shares in the year ended December 31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company has the indirect ability to control the trust as trustees are required to act in accordance with the trust deed and because the Company controls the issuance of shares to cover awards. As a consequence, the trust is consolidated into the Company&#8217;s consolidated financial statements. The shares that were issued to the trust that have not been issued to employees to satisfy vesting of share awards are included in the Consolidated Balance Sheets as treasury shares.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzIzOTE3_e3c18a80-7bc0-4d2d-8936-5886622d0ebf" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Fair value of financial instruments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">US GAAP defines fair value and requires companies to establish a framework for measuring fair value and disclosure about fair value measurements using a three-tier approach. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our financial instruments include cash equivalents, an equity interest, other assets, accounts payable and accrued expenses and other liabilities. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgement and therefore cannot be determined with precision. The equity interest is held at cost subject to impairment, following </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">guidance from ASC 321-10-35-2</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. The carrying amounts of the other instruments are considered to be representative of their fair values because of their short-term nature.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzIzOTE4_b57880bb-e3a6-42cf-ab4d-6b14bef299d6" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Concentration of credit risk</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Financial instruments that potentially subject the Company to concentration of credit risk consist of principally cash and cash equivalents, bank deposits and certain receivables. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company holds cash and cash equivalents with highly rated financial institutions and in highly rated money market funds and the Company has not experienced any significant credit losses in these accounts and does not believe the Company is exposed to any significant credit risk on these instruments.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzI0NzM5MDExNjc1MzU4_5744fb6f-e583-4f26-a8c6-c6b59d40792b" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Lease accounting </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The company accounts for leases in accordance with ASU No. 2016-02, &#8220;Leases&#8221; (Topic 842) (&#8220;ASC 842&#8221;). The standard requires lessees to recognize almost all leases on the balance sheet as right-of-use (&#8220;ROU&#8221;) assets and lease liabilities, and requires leases to be classified as either operating or finance type leases. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Under ASC 842, the Company determines if an arrangement is a lease at inception. ROU ass</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">ets and liabilities are recognized at the commencement date based on the present value of remaining lease payments. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As the Company's leases do not provide an implicit rate, the Company determines the incremental borrowing rate in calculating the present value of lease payments. The ROU assets also include any lease payments made prior to commencement and are recorded net of any lease incentives received. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company&#8217;s lease terms may include options to extend or terminate the lease. When it is reasonably certain the Company will exercise such options the lease will be recognized as a liability and a corresponding ROU asset also recognized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Operating leases are included in Right-of-use assets and in Current and non-current operating lease liabilities on the Company's Consolidated Balance Sheets.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements&#160;&#160;&#160;&#160;</span></div></div><ix:continuation id="if67213f9838e4995a457f55b19135614"><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzIzOTA1_fd917c47-402b-494a-a5e8-4d76c33bc3e6" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Recently issued accounting pronouncements, not yet adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326)-Measurement of Credit Losses on Financial Instruments. This guidance replaces the current incurred loss impairment methodology. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Under the new guidance, on initial recognition and at each reporting period, an entity is required to recognize an allowance that reflects its current estimate of credit losses expected to be incurred over the life of the financial instrument based on historical experience, current conditions and reasonable and supportable forecasts. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates (&#8220;ASU 2019-10&#8221;). The purpose of this amendment is to create a two tier rollout of major updates, staggering the effective dates between larger public companies and all other entities. This granted certain classes of companies, including Smaller Reporting Companies (&#8220;SRCs&#8221;), additional time to implement major FASB standards, including ASU 2016-13. Larger public companies will have an effective date for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. All other entities are permitted to defer adoption of ASU 2016-13, and its related amendments, until fiscal periods beginning after December 15, 2022. Under the current SEC definitions, we meet the definition of an SRC as of the ASU 2019-10 issuance date and are deferring adoption for ASU 2016-13. The guidance requires a modified retrospective transition approach through a cumulative-effect adjustment to retained earnings as of the beginning of the period of adoption. We are currently evaluating the impact of the adoption of ASU 2016-13 on our consolidated financial statements, but do not believe the adoption of this standard will have a material impact on our consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Other accounting standards that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company&#8217;s financial statements upon adoption.</span></div></ix:nonNumeric></ix:continuation><div id="ic8555b0a0e574cdcb5428a00447fe322_121"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 3 - <ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="vrna:PrepaidExpenseDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjEvZnJhZzo5YTgxODRhNmVkMWY0ODRiOTFkNGZjZGU0YjA3MDgwYy90ZXh0cmVnaW9uOjlhODE4NGE2ZWQxZjQ4NGI5MWQ0ZmNkZTRiMDcwODBjXzky_bd20446a-8ec0-4ba8-afa3-898d9b7df575" continuedAt="i95325543f6b8400f9bdbb0a89f204e98" escape="true">Prepaid expenses </ix:nonNumeric></span></div><ix:continuation id="i95325543f6b8400f9bdbb0a89f204e98"><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjEvZnJhZzo5YTgxODRhNmVkMWY0ODRiOTFkNGZjZGU0YjA3MDgwYy90ZXh0cmVnaW9uOjlhODE4NGE2ZWQxZjQ4NGI5MWQ0ZmNkZTRiMDcwODBjXzkz_64eb3181-74ee-44c8-b722-02b207131458" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Prepaid expenses consisted of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial and other development costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="vrna:PrepaidResearchAndDevelopmentFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjEvZnJhZzo5YTgxODRhNmVkMWY0ODRiOTFkNGZjZGU0YjA3MDgwYy90YWJsZTozODMzZTdhMjg1ZGE0MjBiYjkzNjg1YmY3ZmM1M2RhOC90YWJsZXJhbmdlOjM4MzNlN2EyODVkYTQyMGJiOTM2ODViZjdmYzUzZGE4XzItMi0xLTEtNTkxMjc_7b18741f-031d-4ebe-a47d-93a8fe4b8583">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" name="vrna:PrepaidResearchAndDevelopmentFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjEvZnJhZzo5YTgxODRhNmVkMWY0ODRiOTFkNGZjZGU0YjA3MDgwYy90YWJsZTozODMzZTdhMjg1ZGE0MjBiYjkzNjg1YmY3ZmM1M2RhOC90YWJsZXJhbmdlOjM4MzNlN2EyODVkYTQyMGJiOTM2ODViZjdmYzUzZGE4XzItNC0xLTEtNTkxMjc_775692ea-35da-4afd-8fb5-1f5feff306dd">2,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="us-gaap:PrepaidInsurance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjEvZnJhZzo5YTgxODRhNmVkMWY0ODRiOTFkNGZjZGU0YjA3MDgwYy90YWJsZTozODMzZTdhMjg1ZGE0MjBiYjkzNjg1YmY3ZmM1M2RhOC90YWJsZXJhbmdlOjM4MzNlN2EyODVkYTQyMGJiOTM2ODViZjdmYzUzZGE4XzMtMi0xLTEtNTkxMjc_74728fc2-8ff0-4e65-8a01-ebfb4c74d233">2,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" name="us-gaap:PrepaidInsurance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjEvZnJhZzo5YTgxODRhNmVkMWY0ODRiOTFkNGZjZGU0YjA3MDgwYy90YWJsZTozODMzZTdhMjg1ZGE0MjBiYjkzNjg1YmY3ZmM1M2RhOC90YWJsZXJhbmdlOjM4MzNlN2EyODVkYTQyMGJiOTM2ODViZjdmYzUzZGE4XzMtNC0xLTEtNTkxMjc_787e718c-41a3-41c3-b3ca-8f8297e18b52">1,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjEvZnJhZzo5YTgxODRhNmVkMWY0ODRiOTFkNGZjZGU0YjA3MDgwYy90YWJsZTozODMzZTdhMjg1ZGE0MjBiYjkzNjg1YmY3ZmM1M2RhOC90YWJsZXJhbmdlOjM4MzNlN2EyODVkYTQyMGJiOTM2ODViZjdmYzUzZGE4XzQtMi0xLTEtNTkxMjc_07418532-d1a2-44ce-85ba-c840eb43cfda">434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjEvZnJhZzo5YTgxODRhNmVkMWY0ODRiOTFkNGZjZGU0YjA3MDgwYy90YWJsZTozODMzZTdhMjg1ZGE0MjBiYjkzNjg1YmY3ZmM1M2RhOC90YWJsZXJhbmdlOjM4MzNlN2EyODVkYTQyMGJiOTM2ODViZjdmYzUzZGE4XzQtNC0xLTEtNTkxMjc_b89f8e4c-dfe2-48c0-8c6a-903e899818da">313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total prepaid expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjEvZnJhZzo5YTgxODRhNmVkMWY0ODRiOTFkNGZjZGU0YjA3MDgwYy90YWJsZTozODMzZTdhMjg1ZGE0MjBiYjkzNjg1YmY3ZmM1M2RhOC90YWJsZXJhbmdlOjM4MzNlN2EyODVkYTQyMGJiOTM2ODViZjdmYzUzZGE4XzUtMi0xLTEtNTkxMjc_17b1dc53-fd77-49e0-989d-770e808fbf4f">2,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjEvZnJhZzo5YTgxODRhNmVkMWY0ODRiOTFkNGZjZGU0YjA3MDgwYy90YWJsZTozODMzZTdhMjg1ZGE0MjBiYjkzNjg1YmY3ZmM1M2RhOC90YWJsZXJhbmdlOjM4MzNlN2EyODVkYTQyMGJiOTM2ODViZjdmYzUzZGE4XzUtNC0xLTEtNTkxMjc_74e9a320-a9c6-4091-b078-f8c5ce98abf3">4,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-14</span></div></div></div><div id="ic8555b0a0e574cdcb5428a00447fe322_127"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements&#160;&#160;&#160;&#160;</span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 4 - <ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjcvZnJhZzpjYWRiMzlhODQ3ZWI0NGUzYWIzOTczYTVlYTU0MDU5OS90ZXh0cmVnaW9uOmNhZGIzOWE4NDdlYjQ0ZTNhYjM5NzNhNWVhNTQwNTk5XzkxMQ_c013619c-b2c1-4258-a270-fb9126cdc6cb" continuedAt="i61fcb776698e4027a680ca4d811b27be" escape="true">Property leases</ix:nonNumeric></span></div><ix:continuation id="i61fcb776698e4027a680ca4d811b27be"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The right-of-use assets (&#8220;ROU&#8221;) relate to rented office space in London, North Carolina and Georgia with leases ending in 2023, 2024 and 2025, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the year ended December 31, 2022, the Company entered into a lease arrangement in Georgia for office space and extended its existing London lease and recognized lease liability and corresponding ROU asset of $<ix:nonFraction unitRef="usd" contextRef="i562a8171ec384150b25fc8dac4d3d04a_D20220101-20221231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjcvZnJhZzpjYWRiMzlhODQ3ZWI0NGUzYWIzOTczYTVlYTU0MDU5OS90ZXh0cmVnaW9uOmNhZGIzOWE4NDdlYjQ0ZTNhYjM5NzNhNWVhNTQwNTk5XzM4NDgyOTA3MDA1MTA_577515aa-d384-4821-bfb6-4cf7ca6f3d50">0.7</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the year ended December 31, 2021, the Company extended its existing London lease. As a consequence it modified its accounting for the lease and recorded $<ix:nonFraction unitRef="usd" contextRef="id194ff6c8cf4476bad35353399857ce0_D20210101-20211231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjcvZnJhZzpjYWRiMzlhODQ3ZWI0NGUzYWIzOTczYTVlYTU0MDU5OS90ZXh0cmVnaW9uOmNhZGIzOWE4NDdlYjQ0ZTNhYjM5NzNhNWVhNTQwNTk5XzMyOQ_982aad5c-9481-4cbc-a9c7-3f3e154d4d15">0.6</ix:nonFraction>&#160;million lease liability and corresponding ROU asset.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">To calculate lease liabilities the Company used a weighted average discount rate of <ix:nonFraction unitRef="number" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="2" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjcvZnJhZzpjYWRiMzlhODQ3ZWI0NGUzYWIzOTczYTVlYTU0MDU5OS90ZXh0cmVnaW9uOmNhZGIzOWE4NDdlYjQ0ZTNhYjM5NzNhNWVhNTQwNTk5XzI0NzM5MDExNjI4ODk2_31e86302-ff5b-4011-9676-afe2065109df">4</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="2" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjcvZnJhZzpjYWRiMzlhODQ3ZWI0NGUzYWIzOTczYTVlYTU0MDU5OS90ZXh0cmVnaW9uOmNhZGIzOWE4NDdlYjQ0ZTNhYjM5NzNhNWVhNTQwNTk5XzI0NzM5MDExNjI4OTAw_8cf173c5-2d53-4ae2-914b-e43b4f656c2e">8</ix:nonFraction>% for the years ended December 31, 2022 and December 31, 2021, respectively. The weighted average remaining lease term as of December 31, 2022 and December 31, 2021 was <ix:nonNumeric contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjcvZnJhZzpjYWRiMzlhODQ3ZWI0NGUzYWIzOTczYTVlYTU0MDU5OS90ZXh0cmVnaW9uOmNhZGIzOWE4NDdlYjQ0ZTNhYjM5NzNhNWVhNTQwNTk5XzU0OTc1NTgxNjgyMw_662dd611-7be5-4014-9178-208ed907b6eb">1.5</ix:nonNumeric> and <ix:nonNumeric contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjcvZnJhZzpjYWRiMzlhODQ3ZWI0NGUzYWIzOTczYTVlYTU0MDU5OS90ZXh0cmVnaW9uOmNhZGIzOWE4NDdlYjQ0ZTNhYjM5NzNhNWVhNTQwNTk5XzI0NzM5MDExNjI4ODkz_598985f9-43c6-4045-8f4e-0045880c51da">1.8</ix:nonNumeric> years, respectively.</span></div><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjcvZnJhZzpjYWRiMzlhODQ3ZWI0NGUzYWIzOTczYTVlYTU0MDU5OS90ZXh0cmVnaW9uOmNhZGIzOWE4NDdlYjQ0ZTNhYjM5NzNhNWVhNTQwNTk5XzkxMg_1a9d0d77-803a-411e-bec8-744e9d8ffda8" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Minimum annual payments over the remaining lease periods as of December 31, 2022 are as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.926%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjcvZnJhZzpjYWRiMzlhODQ3ZWI0NGUzYWIzOTczYTVlYTU0MDU5OS90YWJsZTpjNmI5NTY1Mzc3NGI0MDZlOGZkNGNkMWIzYjVhOWRhMC90YWJsZXJhbmdlOmM2Yjk1NjUzNzc0YjQwNmU4ZmQ0Y2QxYjNiNWE5ZGEwXzEtMi0xLTEtNTkxMjc_515b1faa-76db-4eff-8328-d0928597856b">675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjcvZnJhZzpjYWRiMzlhODQ3ZWI0NGUzYWIzOTczYTVlYTU0MDU5OS90YWJsZTpjNmI5NTY1Mzc3NGI0MDZlOGZkNGNkMWIzYjVhOWRhMC90YWJsZXJhbmdlOmM2Yjk1NjUzNzc0YjQwNmU4ZmQ0Y2QxYjNiNWE5ZGEwXzItMi0xLTEtNTkxMjc_0d6d684a-ba3d-4089-9851-0cac8763537c">215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjcvZnJhZzpjYWRiMzlhODQ3ZWI0NGUzYWIzOTczYTVlYTU0MDU5OS90YWJsZTpjNmI5NTY1Mzc3NGI0MDZlOGZkNGNkMWIzYjVhOWRhMC90YWJsZXJhbmdlOmM2Yjk1NjUzNzc0YjQwNmU4ZmQ0Y2QxYjNiNWE5ZGEwXzMtMi0xLTEtNjYzNTE_1fe473ff-ce9d-4b7a-b1d2-9f0f3855d3f9">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum future lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjcvZnJhZzpjYWRiMzlhODQ3ZWI0NGUzYWIzOTczYTVlYTU0MDU5OS90YWJsZTpjNmI5NTY1Mzc3NGI0MDZlOGZkNGNkMWIzYjVhOWRhMC90YWJsZXJhbmdlOmM2Yjk1NjUzNzc0YjQwNmU4ZmQ0Y2QxYjNiNWE5ZGEwXzMtMi0xLTEtNTkxMjc_06d7b09c-15a2-4482-982d-aa6218dabf63">907</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjcvZnJhZzpjYWRiMzlhODQ3ZWI0NGUzYWIzOTczYTVlYTU0MDU5OS90YWJsZTpjNmI5NTY1Mzc3NGI0MDZlOGZkNGNkMWIzYjVhOWRhMC90YWJsZXJhbmdlOmM2Yjk1NjUzNzc0YjQwNmU4ZmQ0Y2QxYjNiNWE5ZGEwXzQtMi0xLTEtNTkxMjc_b907144b-9eb4-45fd-8e0b-bb675acab5dd">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjcvZnJhZzpjYWRiMzlhODQ3ZWI0NGUzYWIzOTczYTVlYTU0MDU5OS90YWJsZTpjNmI5NTY1Mzc3NGI0MDZlOGZkNGNkMWIzYjVhOWRhMC90YWJsZXJhbmdlOmM2Yjk1NjUzNzc0YjQwNmU4ZmQ0Y2QxYjNiNWE5ZGEwXzUtMi0xLTEtNTkxMjc_36d00d92-9269-4a81-b12a-45844f5c7d16">880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The total operating lease expense included in selling, general and administrative costs was $<ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjcvZnJhZzpjYWRiMzlhODQ3ZWI0NGUzYWIzOTczYTVlYTU0MDU5OS90ZXh0cmVnaW9uOmNhZGIzOWE4NDdlYjQ0ZTNhYjM5NzNhNWVhNTQwNTk5XzU0OTc1NTgxNjgyOQ_e4c0a909-b306-41fb-9442-213911fbcc00">0.6</ix:nonFraction>&#160;million.</span></div></ix:continuation><div id="ic8555b0a0e574cdcb5428a00447fe322_130"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 5 - <ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzAvZnJhZzpjMzM1ODVlMDhhMGY0Nzk3YTcxZTMyMWExOWJmNjkxMC90ZXh0cmVnaW9uOmMzMzU4NWUwOGEwZjQ3OTdhNzFlMzIxYTE5YmY2OTEwXzkx_50fc4ad1-8379-4e00-976b-8ba761e8020a" continuedAt="i10c9fa7d6cb845a3b62e8e19ebd56d06" escape="true">Accrued expenses</ix:nonNumeric></span></div><ix:continuation id="i10c9fa7d6cb845a3b62e8e19ebd56d06"><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzAvZnJhZzpjMzM1ODVlMDhhMGY0Nzk3YTcxZTMyMWExOWJmNjkxMC90ZXh0cmVnaW9uOmMzMzU4NWUwOGEwZjQ3OTdhNzFlMzIxYTE5YmY2OTEwXzky_a67e5a3c-0010-4876-9358-b4ff3d059388" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial and other development costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="vrna:AccruedResearchAndDevelopmentFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzAvZnJhZzpjMzM1ODVlMDhhMGY0Nzk3YTcxZTMyMWExOWJmNjkxMC90YWJsZTo2MTc4NDY4OWNhYjA0OTI4YTUxZmM3Y2JkOTkwZjNiZS90YWJsZXJhbmdlOjYxNzg0Njg5Y2FiMDQ5MjhhNTFmYzdjYmQ5OTBmM2JlXzItMi0xLTEtNTkxMjc_f7114742-880a-4a1a-8b02-89658bfa476b">12,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" name="vrna:AccruedResearchAndDevelopmentFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzAvZnJhZzpjMzM1ODVlMDhhMGY0Nzk3YTcxZTMyMWExOWJmNjkxMC90YWJsZTo2MTc4NDY4OWNhYjA0OTI4YTUxZmM3Y2JkOTkwZjNiZS90YWJsZXJhbmdlOjYxNzg0Njg5Y2FiMDQ5MjhhNTFmYzdjYmQ5OTBmM2JlXzItNC0xLTEtNTkxMjc_96caedb0-2da6-4a59-b6ef-782b407f321b">21,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees, listing and general corporate costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="vrna:AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzAvZnJhZzpjMzM1ODVlMDhhMGY0Nzk3YTcxZTMyMWExOWJmNjkxMC90YWJsZTo2MTc4NDY4OWNhYjA0OTI4YTUxZmM3Y2JkOTkwZjNiZS90YWJsZXJhbmdlOjYxNzg0Njg5Y2FiMDQ5MjhhNTFmYzdjYmQ5OTBmM2JlXzMtMi0xLTEtNTkxMjc_7779ead1-71d2-48c4-a9a7-8b1286d105d2">1,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" name="vrna:AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzAvZnJhZzpjMzM1ODVlMDhhMGY0Nzk3YTcxZTMyMWExOWJmNjkxMC90YWJsZTo2MTc4NDY4OWNhYjA0OTI4YTUxZmM3Y2JkOTkwZjNiZS90YWJsZXJhbmdlOjYxNzg0Njg5Y2FiMDQ5MjhhNTFmYzdjYmQ5OTBmM2JlXzMtNC0xLTEtNTkxMjc_c6d3e8a0-afe0-4240-9032-9a4229aaacef">919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">People related costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzAvZnJhZzpjMzM1ODVlMDhhMGY0Nzk3YTcxZTMyMWExOWJmNjkxMC90YWJsZTo2MTc4NDY4OWNhYjA0OTI4YTUxZmM3Y2JkOTkwZjNiZS90YWJsZXJhbmdlOjYxNzg0Njg5Y2FiMDQ5MjhhNTFmYzdjYmQ5OTBmM2JlXzQtMi0xLTEtNTkxMjc_340fcbec-1d8f-4480-8724-2c6c414692f1">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzAvZnJhZzpjMzM1ODVlMDhhMGY0Nzk3YTcxZTMyMWExOWJmNjkxMC90YWJsZTo2MTc4NDY4OWNhYjA0OTI4YTUxZmM3Y2JkOTkwZjNiZS90YWJsZXJhbmdlOjYxNzg0Njg5Y2FiMDQ5MjhhNTFmYzdjYmQ5OTBmM2JlXzQtNC0xLTEtNTkxMjc_6213187f-15d1-4c32-9f57-b2ef3ebdb127">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzAvZnJhZzpjMzM1ODVlMDhhMGY0Nzk3YTcxZTMyMWExOWJmNjkxMC90YWJsZTo2MTc4NDY4OWNhYjA0OTI4YTUxZmM3Y2JkOTkwZjNiZS90YWJsZXJhbmdlOjYxNzg0Njg5Y2FiMDQ5MjhhNTFmYzdjYmQ5OTBmM2JlXzUtMi0xLTEtNTkxMjc_e6636196-eb90-4565-843a-7f7f72aebcb2">13,752</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzAvZnJhZzpjMzM1ODVlMDhhMGY0Nzk3YTcxZTMyMWExOWJmNjkxMC90YWJsZTo2MTc4NDY4OWNhYjA0OTI4YTUxZmM3Y2JkOTkwZjNiZS90YWJsZXJhbmdlOjYxNzg0Njg5Y2FiMDQ5MjhhNTFmYzdjYmQ5OTBmM2JlXzUtNC0xLTEtNTkxMjc_bd5eb446-1b04-442e-9a79-5a2da4298ec2">22,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-15</span></div></div></div><div id="ic8555b0a0e574cdcb5428a00447fe322_133"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements&#160;&#160;&#160;&#160;</span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 6 - <ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="vrna:WarrantAndRightsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzMvZnJhZzowN2ZiZGVhY2JmZjg0OTU2YjI3ZmQwOGMzNzhkOGVhOC90ZXh0cmVnaW9uOjA3ZmJkZWFjYmZmODQ5NTZiMjdmZDA4YzM3OGQ4ZWE4XzE5NDc_bcbadc12-1056-48a3-97a5-5905182b73a1" continuedAt="i51903cf506cf446192188e959a9291e0" escape="true">Warrants</ix:nonNumeric></span></div><ix:continuation id="i51903cf506cf446192188e959a9291e0"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">On May 2, 2022 all remaining warrants expired. <ix:nonFraction unitRef="shares" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="0" name="vrna:ClassOfWarrantOrRightNumberOfExercisedOrForfeited" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzMvZnJhZzowN2ZiZGVhY2JmZjg0OTU2YjI3ZmQwOGMzNzhkOGVhOC90ZXh0cmVnaW9uOjA3ZmJkZWFjYmZmODQ5NTZiMjdmZDA4YzM3OGQ4ZWE4XzI0NzM5MDExNjMyMzI0_19c032ea-9f5c-4dd6-b1e9-79e53c0ddcfc"><ix:nonFraction unitRef="shares" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="0" name="vrna:ClassOfWarrantOrRightNumberOfExercisedOrForfeited" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzMvZnJhZzowN2ZiZGVhY2JmZjg0OTU2YjI3ZmQwOGMzNzhkOGVhOC90ZXh0cmVnaW9uOjA3ZmJkZWFjYmZmODQ5NTZiMjdmZDA4YzM3OGQ4ZWE4XzI0NzM5MDExNjMyMzI0_894cec93-7ee2-435d-b470-b03564ede4d9">No</ix:nonFraction></ix:nonFraction> warrants were exercised or forfeited in the years ended December 31, 2022 and 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In 2016, the Company issued <ix:nonFraction unitRef="shares" contextRef="ie824d87e23bd49a6b8466e65062ab474_I20161231" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzMvZnJhZzowN2ZiZGVhY2JmZjg0OTU2YjI3ZmQwOGMzNzhkOGVhOC90ZXh0cmVnaW9uOjA3ZmJkZWFjYmZmODQ5NTZiMjdmZDA4YzM3OGQ4ZWE4XzUx_f2b5bb4c-3a59-478b-a3fe-61dbac60e50d">31,115,926</ix:nonFraction> units to new and existing investors at the placing price of &#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="ie824d87e23bd49a6b8466e65062ab474_I20161231" decimals="4" name="vrna:ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzMvZnJhZzowN2ZiZGVhY2JmZjg0OTU2YjI3ZmQwOGMzNzhkOGVhOC90ZXh0cmVnaW9uOjA3ZmJkZWFjYmZmODQ5NTZiMjdmZDA4YzM3OGQ4ZWE4XzExNA_00c0bddd-c5b1-4a6a-98eb-ba8f77b297b0">1.4365</ix:nonFraction> per unit. Each unit comprised one ordinary share and one warrant. The warrant holders could subscribe for <ix:nonFraction unitRef="shares" contextRef="ie824d87e23bd49a6b8466e65062ab474_I20161231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzMvZnJhZzowN2ZiZGVhY2JmZjg0OTU2YjI3ZmQwOGMzNzhkOGVhOC90ZXh0cmVnaW9uOjA3ZmJkZWFjYmZmODQ5NTZiMjdmZDA4YzM3OGQ4ZWE4XzIyMQ_7564ded8-b01f-4857-aa6f-1ce77dc394e0">0.4</ix:nonFraction> of an ordinary share at a per share exercise price of &#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="ie824d87e23bd49a6b8466e65062ab474_I20161231" decimals="4" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzMvZnJhZzowN2ZiZGVhY2JmZjg0OTU2YjI3ZmQwOGMzNzhkOGVhOC90ZXh0cmVnaW9uOjA3ZmJkZWFjYmZmODQ5NTZiMjdmZDA4YzM3OGQ4ZWE4XzI3OA_e8412b84-94fa-4460-bca1-e359926c740d">1.7238</ix:nonFraction> until May 2, 2022. The warrant holders could opt for a cashless exercise of their warrants, whereby the warrant holders could choose to exchange the warrants held for a reduced number of warrants exercisable at nil consideration. The reduced number of warrants was calculated based on a formula considering the share price and the exercise price of the warrants.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If, after a transaction, should the warrants be exercisable for unlisted securities, the warrant holders were able to demand a cash payment instead of the delivery of the underlying securities. Accordingly, the warrants were accounted for as a liability under ASC 480 &#8220;Distinguishing Liabilities from Equity&#8221;. The warrants were measured at fair value, classified as Level 3 in the fair value hierarchy, with movements recorded in other income/(expense) in the Consolidated Statements of Operations and Comprehensive Loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">At December 31, 2021, <ix:nonFraction unitRef="shares" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzMvZnJhZzowN2ZiZGVhY2JmZjg0OTU2YjI3ZmQwOGMzNzhkOGVhOC90ZXh0cmVnaW9uOjA3ZmJkZWFjYmZmODQ5NTZiMjdmZDA4YzM3OGQ4ZWE4XzY2MQ_b025399d-a07a-4722-8a63-cad96b205ef8">31,003,155</ix:nonFraction> warrants remained outstanding and entitled the investors to subscribe for, in aggregate, a maximum of <ix:nonFraction unitRef="shares" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzMvZnJhZzowN2ZiZGVhY2JmZjg0OTU2YjI3ZmQwOGMzNzhkOGVhOC90ZXh0cmVnaW9uOjA3ZmJkZWFjYmZmODQ5NTZiMjdmZDA4YzM3OGQ4ZWE4Xzc2Mw_f39095b2-de7d-4acf-946d-8496ee4dcddb">12,401,262</ix:nonFraction> ordinary shares.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The warrants had <ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="INF" name="vrna:ClassOfWarrantOrRightIntrinsicValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzMvZnJhZzowN2ZiZGVhY2JmZjg0OTU2YjI3ZmQwOGMzNzhkOGVhOC90ZXh0cmVnaW9uOjA3ZmJkZWFjYmZmODQ5NTZiMjdmZDA4YzM3OGQ4ZWE4XzE0MDE_71c759dd-9a7d-43d3-8982-778f3fa1dd22">no</ix:nonFraction> intrinsic value as at December 31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">There have been no changes in valuation techniques or transfers between fair value measurement levels during the years ended December 31, 2022 and 2021. There has been no change in fair value between December 31, 2021, and May 2, 2022 (expiration). <ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzMvZnJhZzowN2ZiZGVhY2JmZjg0OTU2YjI3ZmQwOGMzNzhkOGVhOC90ZXh0cmVnaW9uOjA3ZmJkZWFjYmZmODQ5NTZiMjdmZDA4YzM3OGQ4ZWE4XzE5NDg_df4d6d1f-adf0-4889-96b3-8c5796532c06" continuedAt="icf03ac3edb1c4423a8bc6a4d0c1c1de5" escape="true">The warrants were valued using the Black-Scholes model and the table below presents the assumptions used:</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><ix:continuation id="icf03ac3edb1c4423a8bc6a4d0c1c1de5"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price in pounds sterling</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#163;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="gbpPerShare" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="4" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzMvZnJhZzowN2ZiZGVhY2JmZjg0OTU2YjI3ZmQwOGMzNzhkOGVhOC90YWJsZTo1YTM3ZTBkNGMyN2Q0YTFmYjEwY2UzZTU0ZDQwNDBmYS90YWJsZXJhbmdlOjVhMzdlMGQ0YzI3ZDRhMWZiMTBjZTNlNTRkNDA0MGZhXzMtNC0xLTEtNTkxMjc_be93ba18-b259-4ba6-916f-96537868e7f1">1.7238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia8b9d9c7ed4d45b39aee6fc8c9e89a1e_I20211231" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzMvZnJhZzowN2ZiZGVhY2JmZjg0OTU2YjI3ZmQwOGMzNzhkOGVhOC90YWJsZTo1YTM3ZTBkNGMyN2Q0YTFmYjEwY2UzZTU0ZDQwNDBmYS90YWJsZXJhbmdlOjVhMzdlMGQ0YzI3ZDRhMWZiMTBjZTNlNTRkNDA0MGZhXzQtNC0xLTEtNTkxMjc_f0821470-c8f8-41b6-bcc9-807186b29342">0.07</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term to exercise</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzMvZnJhZzowN2ZiZGVhY2JmZjg0OTU2YjI3ZmQwOGMzNzhkOGVhOC90YWJsZTo1YTM3ZTBkNGMyN2Q0YTFmYjEwY2UzZTU0ZDQwNDBmYS90YWJsZXJhbmdlOjVhMzdlMGQ0YzI3ZDRhMWZiMTBjZTNlNTRkNDA0MGZhXzUtNC0xLTEtNTkxMjc_df6e980b-be73-4c75-8b1a-440b5fcd7fc1">0.33</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annualized volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia06c5918648040c2b8e5e55554c67cb2_I20211231" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzMvZnJhZzowN2ZiZGVhY2JmZjg0OTU2YjI3ZmQwOGMzNzhkOGVhOC90YWJsZTo1YTM3ZTBkNGMyN2Q0YTFmYjEwY2UzZTU0ZDQwNDBmYS90YWJsZXJhbmdlOjVhMzdlMGQ0YzI3ZDRhMWZiMTBjZTNlNTRkNDA0MGZhXzYtNC0xLTEtNTkxMjc_9c56781b-32bf-4996-8d07-de80fb4c537f">51.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibc128abfb89243b6bb31d0ca13db2070_I20211231" decimals="INF" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzMvZnJhZzowN2ZiZGVhY2JmZjg0OTU2YjI3ZmQwOGMzNzhkOGVhOC90YWJsZTo1YTM3ZTBkNGMyN2Q0YTFmYjEwY2UzZTU0ZDQwNDBmYS90YWJsZXJhbmdlOjVhMzdlMGQ0YzI3ZDRhMWZiMTBjZTNlNTRkNDA0MGZhXzctNC0xLTEtNTkxMjc_c22a1bc0-d9c8-44da-87ee-18b376788705">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Calculated value of the warrants, in thousands of U.S. dollars</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" name="vrna:WarrantLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzMvZnJhZzowN2ZiZGVhY2JmZjg0OTU2YjI3ZmQwOGMzNzhkOGVhOC90YWJsZTo1YTM3ZTBkNGMyN2Q0YTFmYjEwY2UzZTU0ZDQwNDBmYS90YWJsZXJhbmdlOjVhMzdlMGQ0YzI3ZDRhMWZiMTBjZTNlNTRkNDA0MGZhXzgtNC0xLTEtNTkxMjc_a566de86-f018-46f6-8790-efa318f37db1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzMvZnJhZzowN2ZiZGVhY2JmZjg0OTU2YjI3ZmQwOGMzNzhkOGVhOC90ZXh0cmVnaW9uOjA3ZmJkZWFjYmZmODQ5NTZiMjdmZDA4YzM3OGQ4ZWE4XzE5NDk_49cd62f7-fc20-4478-aa4f-a33b09c14806" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows the movement of the value of the warrants (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">At January 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if80b5e08771841e98a3888a3388c32e2_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzMvZnJhZzowN2ZiZGVhY2JmZjg0OTU2YjI3ZmQwOGMzNzhkOGVhOC90YWJsZTo1OTY0MGFkNmFhMGM0NDBmYjU0OGZmNjQyNmU2MzE3OC90YWJsZXJhbmdlOjU5NjQwYWQ2YWEwYzQ0MGZiNTQ4ZmY2NDI2ZTYzMTc4XzItNC0xLTEtNTkxMjc_14064eb8-5e8c-4bdc-a15d-0dc7b59bb17a">2,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" sign="-" name="vrna:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzMvZnJhZzowN2ZiZGVhY2JmZjg0OTU2YjI3ZmQwOGMzNzhkOGVhOC90YWJsZTo1OTY0MGFkNmFhMGM0NDBmYjU0OGZmNjQyNmU2MzE3OC90YWJsZXJhbmdlOjU5NjQwYWQ2YWEwYzQ0MGZiNTQ4ZmY2NDI2ZTYzMTc4XzQtNC0xLTEtNTkxMjc_a2d0b826-fe30-45ad-818c-2960df857b74">2,246</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">At December 31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzMvZnJhZzowN2ZiZGVhY2JmZjg0OTU2YjI3ZmQwOGMzNzhkOGVhOC90YWJsZTo1OTY0MGFkNmFhMGM0NDBmYjU0OGZmNjQyNmU2MzE3OC90YWJsZXJhbmdlOjU5NjQwYWQ2YWEwYzQ0MGZiNTQ4ZmY2NDI2ZTYzMTc4XzctNC0xLTEtNTkxMjc_5626c211-3823-4ed5-92c7-72c654d74dc3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-16</span></div></div></div><div id="ic8555b0a0e574cdcb5428a00447fe322_136"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements&#160;&#160;&#160;&#160;</span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 7 - <ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzYvZnJhZzplMGZlM2Q3MGM0NDk0ZDkwOGE2ZWU2MTlmMTBlZTQ3OS90ZXh0cmVnaW9uOmUwZmUzZDcwYzQ0OTRkOTA4YTZlZTYxOWYxMGVlNDc5XzY3MDY_2a4f70d2-fd00-4809-9617-d27308013dff" continuedAt="ife6f1515a9fb44a08eeafa5aa5356f60" escape="true">Term loan</ix:nonNumeric></span></div><ix:continuation id="ife6f1515a9fb44a08eeafa5aa5356f60"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In November 2020, the Company entered into a term loan facility of up to $<ix:nonFraction unitRef="usd" contextRef="ib6f1e5c7e48647c0920bd6e598622618_I20201130" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzYvZnJhZzplMGZlM2Q3MGM0NDk0ZDkwOGE2ZWU2MTlmMTBlZTQ3OS90ZXh0cmVnaW9uOmUwZmUzZDcwYzQ0OTRkOTA4YTZlZTYxOWYxMGVlNDc5XzU0OTc1NTgzNDM1NQ_4e846ba0-d856-4a8d-8dd7-76fd557145f3">30.0</ix:nonFraction>&#160;million (the &#8220;SVB Term Loan&#8221;), consisting of advances of $<ix:nonFraction unitRef="usd" contextRef="i30e7bb276e12407b8476499428f6f60a_D20201101-20201130" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzYvZnJhZzplMGZlM2Q3MGM0NDk0ZDkwOGE2ZWU2MTlmMTBlZTQ3OS90ZXh0cmVnaW9uOmUwZmUzZDcwYzQ0OTRkOTA4YTZlZTYxOWYxMGVlNDc5XzU0OTc1NTgzNDQwOA_45b4cf18-cf62-45af-96c7-4bf7a63fe16c">5.0</ix:nonFraction>&#160;million funded at closing and $<ix:nonFraction unitRef="usd" contextRef="i90f55e89f14448548416cbd47cfb6cf9_I20201130" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzYvZnJhZzplMGZlM2Q3MGM0NDk0ZDkwOGE2ZWU2MTlmMTBlZTQ3OS90ZXh0cmVnaW9uOmUwZmUzZDcwYzQ0OTRkOTA4YTZlZTYxOWYxMGVlNDc5XzU0OTc1NTgzNDQzNA_78b0ca62-6ea4-4b9c-8cad-1902ef1a9ab5">10.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ie69772c787fa46e283c35e0159c9ed3b_I20201130" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzYvZnJhZzplMGZlM2Q3MGM0NDk0ZDkwOGE2ZWU2MTlmMTBlZTQ3OS90ZXh0cmVnaW9uOmUwZmUzZDcwYzQ0OTRkOTA4YTZlZTYxOWYxMGVlNDc5XzU0OTc1NTgzNDQ0Mg_bf4e8699-cfe1-438a-bdbe-3eac553374b7">15.0</ix:nonFraction>&#160;million&#160;contingent upon achievement of certain clinical development milestones and other specified conditions. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The SVB Term Loan was categorized within Level 3 of the fair value hierarchy and the carrying amount of the debt approximated its fair value based on prevailing interest rates as of December 31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">On October 14, 2022 (the &#8220;Effective Date&#8221;), the Company entered into a loan and security agreement (the &#8220;Loan Agreement&#8221;) with Oxford Finance Luxembourg S.&#192; R.L. (&#8220;Oxford&#8221;) for an aggregate amount of up to $<ix:nonFraction unitRef="usd" contextRef="ia867c724f1754d6b8ce8489a52865172_I20221014" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzYvZnJhZzplMGZlM2Q3MGM0NDk0ZDkwOGE2ZWU2MTlmMTBlZTQ3OS90ZXh0cmVnaW9uOmUwZmUzZDcwYzQ0OTRkOTA4YTZlZTYxOWYxMGVlNDc5XzU0OTc1NTgyOTk4OA_36879990-beef-414a-8c86-8d4ea1a155d1">150.0</ix:nonFraction>&#160;million (the &#8220;Oxford Term Loan&#8221;). The Oxford Term Loan provides for an initial term loan advance in an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="i10a520855ec54e2da16ba70468d0a51b_I20221014" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzYvZnJhZzplMGZlM2Q3MGM0NDk0ZDkwOGE2ZWU2MTlmMTBlZTQ3OS90ZXh0cmVnaW9uOmUwZmUzZDcwYzQ0OTRkOTA4YTZlZTYxOWYxMGVlNDc5XzU0OTc1NTgzMDEwNw_e0cded6d-49b5-4f40-8fbb-6e56a91ee397">10.0</ix:nonFraction>&#160;million funded on the Effective Date (the &#8220;Oxford Term A Loan&#8221;), and up to <ix:nonFraction unitRef="loanadvance" contextRef="ia867c724f1754d6b8ce8489a52865172_I20221014" decimals="INF" name="vrna:LineOfCreditFacilityNumberOfLoanAdvances" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzYvZnJhZzplMGZlM2Q3MGM0NDk0ZDkwOGE2ZWU2MTlmMTBlZTQ3OS90ZXh0cmVnaW9uOmUwZmUzZDcwYzQ0OTRkOTA4YTZlZTYxOWYxMGVlNDc5XzU0OTc1NTgzMDE3OA_15ca25bb-4f43-4671-97f1-4864a4c0b20c">four</ix:nonFraction> additional term loan advances in an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="i3541a8c38127458ba1aae3fdc52c63d5_I20221014" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzYvZnJhZzplMGZlM2Q3MGM0NDk0ZDkwOGE2ZWU2MTlmMTBlZTQ3OS90ZXh0cmVnaW9uOmUwZmUzZDcwYzQ0OTRkOTA4YTZlZTYxOWYxMGVlNDc5XzU0OTc1NTgzMDIzOA_d60f307e-98dc-4883-b9df-25998db69860">140.0</ix:nonFraction>&#160;million, which are available as described below and subject to terms of the Loan Agreement. The proceeds from the Oxford Term Loan will be used for general corporate and working capital purposes, and a portion of the proceeds of the Oxford Term A Loan have been used to repay in full the existing outstanding indebtedness owed to SVB.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The <ix:nonFraction unitRef="loanadvance" contextRef="ia867c724f1754d6b8ce8489a52865172_I20221014" decimals="INF" name="vrna:LineOfCreditFacilityNumberOfLoanAdvances" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzYvZnJhZzplMGZlM2Q3MGM0NDk0ZDkwOGE2ZWU2MTlmMTBlZTQ3OS90ZXh0cmVnaW9uOmUwZmUzZDcwYzQ0OTRkOTA4YTZlZTYxOWYxMGVlNDc5XzU0OTc1NTgzMDY3MA_aadfbd38-f588-4c34-92f0-c37abd8a1b80">four</ix:nonFraction> additional term loan advances under the Oxford Term Loan consist of: a $<ix:nonFraction unitRef="usd" contextRef="ic244fa4c95204e0e8dcfaefb2e6b8237_I20221014" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzYvZnJhZzplMGZlM2Q3MGM0NDk0ZDkwOGE2ZWU2MTlmMTBlZTQ3OS90ZXh0cmVnaW9uOmUwZmUzZDcwYzQ0OTRkOTA4YTZlZTYxOWYxMGVlNDc5XzU0OTc1NTgzMDc0Ng_206993bd-59b8-4368-923a-4a1a66964b32">10.0</ix:nonFraction>&#160;million term loan advance (the &#8220;Oxford Term B Loan&#8221;) which is available at the option of the Company from the Effective Date up to and including March 31, 2023; a $<ix:nonFraction unitRef="usd" contextRef="i22eac3eaf4ba4678a0eb3d0971d09767_I20221014" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzYvZnJhZzplMGZlM2Q3MGM0NDk0ZDkwOGE2ZWU2MTlmMTBlZTQ3OS90ZXh0cmVnaW9uOmUwZmUzZDcwYzQ0OTRkOTA4YTZlZTYxOWYxMGVlNDc5XzU0OTc1NTgzMDkwNQ_01bd81f4-f60c-417e-8f44-b95f4c7be403">20.0</ix:nonFraction>&#160;million term loan advance (the &#8220;Oxford Term C Loan&#8221;) available during the period commencing on the later of January 1, 2024 and the date on which the Company receives positive ENHANCE-1 data in the Phase 3 clinical trial for ensifentrine sufficient to support the submission of a New Drug Application (&#8220;NDA&#8221;) with the United States Food and Drug Administration (the &#8220;FDA&#8221;) for ensifentrine through and including March 29, 2024; a $<ix:nonFraction unitRef="usd" contextRef="i48aaa74363db4fc7b8d8426a1eff5049_I20221014" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzYvZnJhZzplMGZlM2Q3MGM0NDk0ZDkwOGE2ZWU2MTlmMTBlZTQ3OS90ZXh0cmVnaW9uOmUwZmUzZDcwYzQ0OTRkOTA4YTZlZTYxOWYxMGVlNDc5XzU0OTc1NTgzMTMzMQ_0f21561f-56a8-4e72-885f-34636a89d7c6">60.0</ix:nonFraction>&#160;million term loan advance (the &#8220;Oxford Term D Loan&#8221;) available during the period commencing on the later of October 1, 2024 and the date on which the Company receives final approval from the FDA for the Company&#8217;s NDA for ensifentrine up to and including December 31, 2024; and a $<ix:nonFraction unitRef="usd" contextRef="id04385f9e7774756bbf90a20930f80ec_I20221014" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzYvZnJhZzplMGZlM2Q3MGM0NDk0ZDkwOGE2ZWU2MTlmMTBlZTQ3OS90ZXh0cmVnaW9uOmUwZmUzZDcwYzQ0OTRkOTA4YTZlZTYxOWYxMGVlNDc5XzU0OTc1NTgzMTYwNg_0ec5b12c-d7f7-4db9-ba70-77ae5575f9b5">50.0</ix:nonFraction>&#160;million term loan advance (the &#8220;Oxford Term E Loan&#8221;) available during the interest-only period at the Company&#8217;s request and at Oxford&#8217;s sole discretion.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Each advance under the Oxford Term Loan accrues interest at a floating per annum rate equal to (a) the greater of (i) the 1-Month CME Term SOFR reference rate on the last business day of the month that immediately precedes the month in which the interest will accrue and (ii) <ix:nonFraction unitRef="number" contextRef="ibbe1ef2d7eb14330b2e19597ed9f08da_D20221014-20221014" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzYvZnJhZzplMGZlM2Q3MGM0NDk0ZDkwOGE2ZWU2MTlmMTBlZTQ3OS90ZXh0cmVnaW9uOmUwZmUzZDcwYzQ0OTRkOTA4YTZlZTYxOWYxMGVlNDc5XzU0OTc1NTgzMjAzMQ_b34bc036-1948-4764-a687-386c47b79f6e">2.38</ix:nonFraction>%, plus (b) <ix:nonFraction unitRef="number" contextRef="ic419bc3e647a4ca9a2757dc9edc5107d_D20221014-20221014" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzYvZnJhZzplMGZlM2Q3MGM0NDk0ZDkwOGE2ZWU2MTlmMTBlZTQ3OS90ZXh0cmVnaW9uOmUwZmUzZDcwYzQ0OTRkOTA4YTZlZTYxOWYxMGVlNDc5XzU0OTc1NTgzMjA0NQ_22a6e600-70bf-4fe7-a059-6cb64e9cd50d">5.50</ix:nonFraction>% (the &#8220;Basic Rate&#8221;). In no event shall the Basic Rate (x) for the Oxford Term A Loan be less than <ix:nonFraction unitRef="number" contextRef="i428494c244664464882b178b3d34c37f_D20221014-20221014" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzYvZnJhZzplMGZlM2Q3MGM0NDk0ZDkwOGE2ZWU2MTlmMTBlZTQ3OS90ZXh0cmVnaW9uOmUwZmUzZDcwYzQ0OTRkOTA4YTZlZTYxOWYxMGVlNDc5XzU0OTc1NTgzMjE0Ng_805f1301-c561-4225-bcf6-3390745df374">7.88</ix:nonFraction>% and (y) for each other advance be less than the Basic Rate on the business day immediately prior to the funding date of such term advance. The Basic Rate for the Term A Loan for the period from the Effective Date through and including October 31, 2022 shall be <ix:nonFraction unitRef="number" contextRef="i3d4b040098df4fc3a356ffafd5e4b830_D20221014-20221014" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzYvZnJhZzplMGZlM2Q3MGM0NDk0ZDkwOGE2ZWU2MTlmMTBlZTQ3OS90ZXh0cmVnaW9uOmUwZmUzZDcwYzQ0OTRkOTA4YTZlZTYxOWYxMGVlNDc5XzU0OTc1NTgzMjQxMQ_3745bb5c-65c7-49b0-b459-8688e1defefb">8.54205</ix:nonFraction>% and the Basic Rate for each Term Loan shall not increase by more than <ix:nonFraction unitRef="number" contextRef="i77e399a94d574a9c9520217f5ebd6515_D20221014-20221014" decimals="4" name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzYvZnJhZzplMGZlM2Q3MGM0NDk0ZDkwOGE2ZWU2MTlmMTBlZTQ3OS90ZXh0cmVnaW9uOmUwZmUzZDcwYzQ0OTRkOTA4YTZlZTYxOWYxMGVlNDc5XzU0OTc1NTgzMjQ4NQ_563c09e1-850d-4f6f-9455-dc1370a27dc5">2.00</ix:nonFraction>% above the applicable Basic Rate as of the funding date of each such term loan. The Oxford Term Loan provides for interest-only payments on a monthly basis until the payment date immediately preceding December 1, 2025, if the Oxford Term D Loan is not made, and December 1, 2026, if the Oxford Term D Loan is made. Thereafter, amortization payments will be payable monthly in equal installments of principal plus accrued interest. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Upon repayment, whether at maturity, upon acceleration or by prepayment or otherwise, the Company shall make a final payment to the lenders in an amount ranging from <ix:nonFraction unitRef="number" contextRef="i7ad954ea881e4224a373e39507e05382_D20221014-20221014" decimals="4" name="vrna:DebtInstrumentFinalPaymentPercentageOfPrincipalAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzYvZnJhZzplMGZlM2Q3MGM0NDk0ZDkwOGE2ZWU2MTlmMTBlZTQ3OS90ZXh0cmVnaW9uOmUwZmUzZDcwYzQ0OTRkOTA4YTZlZTYxOWYxMGVlNDc5XzU0OTc1NTgzMzA4Ng_5dc96197-eb6f-40ab-a751-31803f8301c1">1.30</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ife6bb65a13724831ab4e8d78c473f147_D20221014-20221014" decimals="4" name="vrna:DebtInstrumentFinalPaymentPercentageOfPrincipalAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzYvZnJhZzplMGZlM2Q3MGM0NDk0ZDkwOGE2ZWU2MTlmMTBlZTQ3OS90ZXh0cmVnaW9uOmUwZmUzZDcwYzQ0OTRkOTA4YTZlZTYxOWYxMGVlNDc5XzU0OTc1NTgzMzA5Mw_cbff71f4-9832-4d69-a11d-36a9c7ec4444">3.00</ix:nonFraction>% of the aggregate principal balance, depending on the advances received under the Oxford Term Loan. The Company may prepay the Oxford Term Loan in full, or in part, in accordance with the terms of the Loan Agreement, which is subject to a prepayment fee of up to <ix:nonFraction unitRef="number" contextRef="i7d76374535984c8fbfde48cfb17a2b35_D20221014-20221014" decimals="4" name="vrna:DebtInstrumentPrepaymentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzYvZnJhZzplMGZlM2Q3MGM0NDk0ZDkwOGE2ZWU2MTlmMTBlZTQ3OS90ZXh0cmVnaW9uOmUwZmUzZDcwYzQ0OTRkOTA4YTZlZTYxOWYxMGVlNDc5XzU0OTc1NTgzMzM1OQ_baca5f6c-ff54-44b2-918a-0f6490db94b9">2.00</ix:nonFraction>%, depending on the timing of the prepayment. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Oxford Term Loan is secured by a lien on substantially all of the assets of the Company, other than intellectual property, but including any rights to payments and proceeds from the sale, licensing or disposition of intellectual property. The Company has also granted Oxford a negative pledge with respect to its intellectual property. The Loan Agreement contains customary covenants and representations, including but not limited to financial reporting obligations and limitations on dividends, dispositions, indebtedness, collateral, investments, distributions, transfers, mergers or acquisitions, taxes, corporate changes, deposit accounts, transactions with affiliates and subsidiaries. The Loan Agreement also contains other customary provisions, such as expense reimbursement, non-disclosure obligations as well as indemnification rights for the benefit of Oxford.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-17</span></div></div></div><div id="ic8555b0a0e574cdcb5428a00447fe322_139"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements&#160;&#160;&#160;&#160;</span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 8 - <ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzkvZnJhZzowYmM2NDE1MGIwNGU0YjdiOGNjMDE5MDY3ZGQ0MzVmNC90ZXh0cmVnaW9uOjBiYzY0MTUwYjA0ZTRiN2I4Y2MwMTkwNjdkZDQzNWY0XzU2MzQ_f06e45a3-2e31-4674-a2df-79f63c63c0a3" continuedAt="id282454c0e3d48e7835dfab7146c516d" escape="true">Significant agreements</ix:nonNumeric></span></div><ix:continuation id="id282454c0e3d48e7835dfab7146c516d" continuedAt="ideda84c614c149d581a0e2a89cb4dab1"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Ligand agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In 2006 the Company acquired Rhinopharma and assumed contingent liabilities owed to Ligand UK Development Limited (&#8220;Ligand&#8221;) (formerly Vernalis Development Limited). The Company refers to the assignment and license agreement as the Ligand Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Ligand assigned to the Company all of its rights to certain patents and patent applications relating to ensifentrine and related compounds (the "Ligand Patents") and an exclusive, worldwide, royalty-bearing license under certain Ligand know-how to develop, manufacture and commercialize products (the "Ligand Licensed Products") developed using Ligand Patents, Ligand know-how and the physical stock of certain compounds.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company is obligated to pay a milestone payment on obtaining the first approval of any regulatory authority for the commercialization of a Ligand Licensed Product, low single digit royalties based on the future sales performance of all Ligand Licensed Products and a portion equal to a mid-twenty percent of any consideration received from any sub-licensees for the Ligand Patents and for Ligand know-how. Royalties payable are based on the future sales performance so the amount payable is unlimited.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">At the time each contingency is resolved, the Company will record the contingent consideration payment (or payable) in connection with the Ligand Agreement as an expense and will classify it within R&amp;D expenses.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In March 2022, the Company entered into an Amendment Agreement (the &#8220;Amendment&#8221;) with Ligand whereby the Ligand Agreement was amended to clarify certain ambiguous terms in the Ligand Agreement. Pursuant to the Amendment:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">the Company agreed to pay to Ligand (i) $<ix:nonFraction unitRef="usd" contextRef="i2014cf02dad94153af60f28551c0469c_D20220301-20220331" decimals="-3" name="vrna:SublicensePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzkvZnJhZzowYmM2NDE1MGIwNGU0YjdiOGNjMDE5MDY3ZGQ0MzVmNC90ZXh0cmVnaW9uOjBiYzY0MTUwYjA0ZTRiN2I4Y2MwMTkwNjdkZDQzNWY0XzI0NzM5MDExNjM4MzQz_9c7178d3-783d-4dcb-8dc3-90d9acc55747">2.0</ix:nonFraction>&#160;million within five business days of the date of the Amendment and (ii) $<ix:nonFraction unitRef="usd" contextRef="ifa2a4633d09c407a94ff8f3507d2318d_D20220301-20220331" decimals="-3" name="vrna:SublicensePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzkvZnJhZzowYmM2NDE1MGIwNGU0YjdiOGNjMDE5MDY3ZGQ0MzVmNC90ZXh0cmVnaW9uOjBiYzY0MTUwYjA0ZTRiN2I4Y2MwMTkwNjdkZDQzNWY0XzI0NzM5MDExNjM4MzU3_f94b9d65-9477-41d6-b2b0-a2b7d529eb56">15.0</ix:nonFraction>&#160;million upon the first commercial sale of ensifentrine by the Company or a sub-licensee, which amount is payable in cash or, at the Company's discretion, by the issuance of Company equity of equivalent value, as determined based on the volume-weighted average price of the Company's American Depositary Shares on the Nasdaq Global Market over the ten (<ix:nonFraction unitRef="tradingday" contextRef="i2014cf02dad94153af60f28551c0469c_D20220301-20220331" decimals="INF" name="vrna:SublicensePaymentEquityIssuanceThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzkvZnJhZzowYmM2NDE1MGIwNGU0YjdiOGNjMDE5MDY3ZGQ0MzVmNC90ZXh0cmVnaW9uOjBiYzY0MTUwYjA0ZTRiN2I4Y2MwMTkwNjdkZDQzNWY0XzI0NzM5MDExNjM4Mzcy_baa9d696-753a-4e70-a95b-16334e00a243">10</ix:nonFraction>) trading days including and prior to such milestone event;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">the Ligand Agreement shall expire on March 24, 2042 unless terminated earlier by either party in accordance with its terms;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">upon termination of the Ligand Agreement, any Sub-licensee (as defined in the Amendment) shall have the right to enter into a direct license agreement with Ligand for the portion of the Program IP (as defined in the Amendment) that was sub-licensed by such Sub-licensee;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">the milestone payment may be paid in cash or, at the Company&#8217;s discretion, by issuing to Ligand shares in the Company of equivalent value; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">each party&#8217;s right to terminate the Ligand Agreement is conditioned upon such party obtaining a final judgment of the English High Court declaring that the other party is in material breach of its obligations under the Ligand Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company accounted for the $<ix:nonFraction unitRef="usd" contextRef="ia63bdd4aff86454a9544c5c56ab3a539_D20220301-20220331" decimals="-5" name="vrna:SublicensePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzkvZnJhZzowYmM2NDE1MGIwNGU0YjdiOGNjMDE5MDY3ZGQ0MzVmNC90ZXh0cmVnaW9uOjBiYzY0MTUwYjA0ZTRiN2I4Y2MwMTkwNjdkZDQzNWY0XzI0NzM5MDExNjM4Mzc2_bd6129e6-2633-473a-a184-a1ca5b91afb9">2.0</ix:nonFraction>&#160;million payment at execution of the Amendment as selling, general and administrative expense in the consolidated statements of operations as the payment is related to a contract modification.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Nuance agreement </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company entered into a collaboration and license agreement (the &#8220;Nuance Agreement&#8221;) with Nuance Pharma Limited (&#8220;Nuance Pharma&#8221;) effective June 9, 2021 (the &#8220;Effective Date&#8221;), under which the Company granted Nuance Pharma the exclusive rights to develop and commercialize ensifentrine in Greater China (China, Taiwan, Hong Kong and Macau). In return, the Company received an unconditional right to consideration aggregating $<ix:nonFraction unitRef="usd" contextRef="i44405a18d6cc405cab4ed043524c8fde_I20210609" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzkvZnJhZzowYmM2NDE1MGIwNGU0YjdiOGNjMDE5MDY3ZGQ0MzVmNC90ZXh0cmVnaW9uOjBiYzY0MTUwYjA0ZTRiN2I4Y2MwMTkwNjdkZDQzNWY0XzU0MQ_11596286-a2fd-4f91-8e87-1ad618c4a5b2">40.0</ix:nonFraction>&#160;million consisting of $<ix:nonFraction unitRef="usd" contextRef="i44405a18d6cc405cab4ed043524c8fde_I20210609" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzkvZnJhZzowYmM2NDE1MGIwNGU0YjdiOGNjMDE5MDY3ZGQ0MzVmNC90ZXh0cmVnaW9uOjBiYzY0MTUwYjA0ZTRiN2I4Y2MwMTkwNjdkZDQzNWY0XzU1OA_a262d9ef-46d3-46f6-b86d-966d395fb4b6">25.0</ix:nonFraction>&#160;million in cash and an equity interest, valued at $<ix:nonFraction unitRef="usd" contextRef="i44405a18d6cc405cab4ed043524c8fde_I20210609" decimals="-5" name="vrna:EquityInterestReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzkvZnJhZzowYmM2NDE1MGIwNGU0YjdiOGNjMDE5MDY3ZGQ0MzVmNC90ZXh0cmVnaW9uOjBiYzY0MTUwYjA0ZTRiN2I4Y2MwMTkwNjdkZDQzNWY0XzYwMw_f299a3a9-8814-4941-9be4-9f33da875d77">15.0</ix:nonFraction>&#160;million as of the Effective Date, in Nuance Biotech, the parent company of Nuance Pharma. The Company is eligible to receive future milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="i44405a18d6cc405cab4ed043524c8fde_I20210609" decimals="-5" name="vrna:ContractWithCustomerFutureEligibleMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzkvZnJhZzowYmM2NDE1MGIwNGU0YjdiOGNjMDE5MDY3ZGQ0MzVmNC90ZXh0cmVnaW9uOjBiYzY0MTUwYjA0ZTRiN2I4Y2MwMTkwNjdkZDQzNWY0Xzc1OA_798d543b-97b9-4890-9608-6266ee4e15ae">179.0</ix:nonFraction>&#160;million triggered upon achievement of certain clinical, regulatory, and commercial milestones, as well as tiered double-digit royalties as a percentage of net sales of the products in Greater China. The Company will recognize these milestones when it is probable that a significant revenue reversal would not occur.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As of December 31, 2022, the $<ix:nonFraction unitRef="usd" contextRef="i2ed4c5f1e427439596625fc8558417f6_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzkvZnJhZzowYmM2NDE1MGIwNGU0YjdiOGNjMDE5MDY3ZGQ0MzVmNC90ZXh0cmVnaW9uOjBiYzY0MTUwYjA0ZTRiN2I4Y2MwMTkwNjdkZDQzNWY0XzEwOTg_41e36a87-86a6-4637-95db-0494cb48e625">25.0</ix:nonFraction>&#160;million cash payment and $<ix:nonFraction unitRef="usd" contextRef="i2ed4c5f1e427439596625fc8558417f6_I20221231" decimals="-5" name="vrna:EquityInterestReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzkvZnJhZzowYmM2NDE1MGIwNGU0YjdiOGNjMDE5MDY3ZGQ0MzVmNC90ZXh0cmVnaW9uOjBiYzY0MTUwYjA0ZTRiN2I4Y2MwMTkwNjdkZDQzNWY0XzExMTg_17766514-85a8-43fe-a7e8-b6da2ca8dbe3">15.0</ix:nonFraction>&#160;million equity interest had been received and the holding in Nuance Biotech was recorded as Equity interest on the Consolidated Balance Sheet. The Equity </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements&#160;&#160;&#160;&#160;</span></div></div><ix:continuation id="ideda84c614c149d581a0e2a89cb4dab1"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">interest is recorded at cost as the Company has elected to use the measurement alternative for equity investments without readily determinable fair values. The Company will evaluate this investment for indicators of impairment quarterly. The Company did not identify events or changes in circumstances that may have a significant effect on the fair value of the investment during the year ended December 31, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Under the terms of the Nuance Agreement, at any time until three months prior to the expected submission of the first New Drug Application in Greater China, if (i) a third party is interested in partnering with the Company, either globally or in territory covering at least the United States or Europe, for the development and/or commercialization of ensifentrine or (ii) the Company undergoes a change of control, the Company will have an exclusive option right to buy back the license granted to Nuance Pharma and all related assets. The price is agreed to be equal to the aggregate of (i) all prior amounts paid by Nuance Pharma to the Company in cash under the agreement and (ii) all development and regulatory costs incurred and paid by Nuance Pharma in connection with the development and commercialization of ensifentrine under the Nuance Agreement multiplied by a single-digit factor range dependent upon achievement of certain milestones, subject to a specified maximum amount.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Nuance Agreement will continue on a jurisdiction-by-jurisdiction and product-by-product basis until the expiration of royalty payment obligations with respect to such product in such jurisdiction unless earlier terminated by the parties. Either party may terminate the Nuance Agreement for an uncured material breach or bankruptcy of the other party. Nuance Pharma may also terminate the Nuance Agreement at will upon 90 days' prior written notice. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company reviewed the buy-back option and determined that because it is conditional on a third party the Company does not have the practical ability to exercise it and, accordingly, the contract is accounted for under ASC 606.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The transaction price at the Effective Date of the Nuance Agreement was $<ix:nonFraction unitRef="usd" contextRef="i44405a18d6cc405cab4ed043524c8fde_I20210609" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzkvZnJhZzowYmM2NDE1MGIwNGU0YjdiOGNjMDE5MDY3ZGQ0MzVmNC90ZXh0cmVnaW9uOjBiYzY0MTUwYjA0ZTRiN2I4Y2MwMTkwNjdkZDQzNWY0XzMzMjI_ccf24bdd-6c36-49ea-8650-2eed789add5b">40.0</ix:nonFraction>&#160;million consisting of the $<ix:nonFraction unitRef="usd" contextRef="i44405a18d6cc405cab4ed043524c8fde_I20210609" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzkvZnJhZzowYmM2NDE1MGIwNGU0YjdiOGNjMDE5MDY3ZGQ0MzVmNC90ZXh0cmVnaW9uOjBiYzY0MTUwYjA0ZTRiN2I4Y2MwMTkwNjdkZDQzNWY0XzMzNDM_5e2e2c79-036d-4e74-8439-4d50a9700be7">25.0</ix:nonFraction>&#160;million upfront cash payment and $<ix:nonFraction unitRef="usd" contextRef="i44405a18d6cc405cab4ed043524c8fde_I20210609" decimals="-5" name="vrna:EquityInterestReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzkvZnJhZzowYmM2NDE1MGIwNGU0YjdiOGNjMDE5MDY3ZGQ0MzVmNC90ZXh0cmVnaW9uOjBiYzY0MTUwYjA0ZTRiN2I4Y2MwMTkwNjdkZDQzNWY0XzMzNzE_c6365473-cae6-4371-9382-232bf79e1479">15.0</ix:nonFraction>&#160;million equity interest. Developmental and regulatory milestones, and the manufacture and supply of ensifentrine drug product, were not included in the transaction price as management determined that it is not probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Commercial milestones and sales royalties were also excluded and will be recognized when the milestones are achieved or the sales occur in Greater China.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The performance obligations in the Nuance Agreement include the grant of the license (including the right to commercialize ensifentrine until the end of the term, the sharing of certain know how, and the sharing of certain clinical and regulatory data), and manufacture and supply of ensifentrine drug product. The Company has determined that the manufacturing and supply was not at a discount.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company has determined that the license and the know how shared with Nuance Pharma constitutes functional intellectual property and that revenue relating to this should be recognized at a point in time. Consequently, the Company determined that it fulfilled its obligations to Nuance Pharma after it delivered the know how that will allow Nuance Pharma to file an investigational new drug application in Greater China. This know how was delivered in the year ended December 31, 2021, and the $<ix:nonFraction unitRef="usd" contextRef="ib45dfb15713741578ce57657f76c641a_I20211231" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzkvZnJhZzowYmM2NDE1MGIwNGU0YjdiOGNjMDE5MDY3ZGQ0MzVmNC90ZXh0cmVnaW9uOjBiYzY0MTUwYjA0ZTRiN2I4Y2MwMTkwNjdkZDQzNWY0XzQ3MjI_3978242e-fbe8-409c-827d-2a5a8115cb3b">40.0</ix:nonFraction>&#160;million revenue was therefore recognized as revenue in this period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">On the Effective Date, $<ix:nonFraction unitRef="usd" contextRef="i44405a18d6cc405cab4ed043524c8fde_I20210609" decimals="-5" name="us-gaap:CapitalizedContractCostNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzkvZnJhZzowYmM2NDE1MGIwNGU0YjdiOGNjMDE5MDY3ZGQ0MzVmNC90ZXh0cmVnaW9uOjBiYzY0MTUwYjA0ZTRiN2I4Y2MwMTkwNjdkZDQzNWY0XzM4NDgyOTA3MDc5MjM_3bd2129c-5c91-48be-b7ae-6a950f426a2a">4.0</ix:nonFraction>&#160;million of costs of obtaining the contract were recorded as a contract asset. As of December 31, 2021, the entire cost had been recognized in the Consolidated Statements of Operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">On April 13, 2022, the Company formalized the Agreement for the Manufacture and Supply of ensifentrine (&#8220;Nuance Supply Agreement&#8221;) with Nuance Pharma. The Company determined that the manufacturing and supply of ensifentrine to Nuance represents a distinct and separate performance obligation, for which consideration to be received is variable based on the quantities to be ordered by Nuance. Revenue earned with the manufacture and supply of the licensed product is, and will be, recognized as the supply is delivered to Nuance. The Company has determined it is acting as principal in relation to the manufacture and supply under the Agreement. In its capacity as principal, the Company will recognize the associated revenue on a gross basis. As of December 31, 2022, the Company has recognized $<ix:nonFraction unitRef="usd" contextRef="idbecaaa2e50f422788c7776146b6f738_D20220101-20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzkvZnJhZzowYmM2NDE1MGIwNGU0YjdiOGNjMDE5MDY3ZGQ0MzVmNC90ZXh0cmVnaW9uOjBiYzY0MTUwYjA0ZTRiN2I4Y2MwMTkwNjdkZDQzNWY0XzI0NzM5MDExNjM4Mzkw_8f91d9c8-435d-4eff-b765-027f14a0428b">0.5</ix:nonFraction>&#160;million in relation to the clinical supply of ensifentrine to Nuance Pharma.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-19</span></div></div></div><div id="ic8555b0a0e574cdcb5428a00447fe322_148"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements&#160;&#160;&#160;&#160;</span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 9 - <ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzUwMzI_2fc7c26a-d8dd-4ebc-9279-bdbf0e6f6c44" continuedAt="i57c44cf30309431c8918188ca096cfcf" escape="true">Share-based compensation</ix:nonNumeric></span></div><ix:continuation id="i57c44cf30309431c8918188ca096cfcf" continuedAt="i353122aefd424fbc9e381b8109954b3f"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company operates various share based incentive plans for its staff and issues ordinary shares or ADSs when share-based awards are exercised.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company records share-based compensation expense related to share options and RSUs granted to employees and directors. The expense is included in research and development and selling, general and administrative costs, based on the nature of individual employees&#8217; functions, and represents the relevant year's allocation of the expense. The costs of share-based compensation to employees are recognized in the consolidated statements of operations and comprehensive loss, together with a corresponding increase in equity over the vesting period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Options are issued with an exercise price of the closing market price on the day before the grant and generally vest over a period of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzgyMg_06949a37-1fa3-4277-8388-a28ff5d09dc6">one</span> to <ix:nonNumeric contextRef="ic9abfa929c414b3a8a9f9e7a5436d4f3_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzgyOA_4f62dcb2-e5ef-4c44-92d0-4ff3bd989bd3">four years</ix:nonNumeric> and the contractual life of all options is <ix:nonNumeric contextRef="i6ef7ac44600e4b82bd5f7115b1d6d54d_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzg3NA_10c50313-7650-4ee2-92d1-b14fb4dbd832">ten years</ix:nonNumeric>. </span></div><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzUwMjk_1612f5f4-bf9a-4a6b-a0d5-361c890553ce" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows the allocation of share-based compensation between research and development and selling, general and administrative costs (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01712b818a734e4a92734201de78b797_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTo4ZWU3MTE3MGZlMDA0MDUzYTgwZjY4NWNlN2E0M2VmNC90YWJsZXJhbmdlOjhlZTcxMTcwZmUwMDQwNTNhODBmNjg1Y2U3YTQzZWY0XzItMi0xLTEtNTkxMjc_4dadab6e-0ded-4aff-b1fd-f0412772d226">5,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7233af3af0bd4811889a59bfd4f27031_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTo4ZWU3MTE3MGZlMDA0MDUzYTgwZjY4NWNlN2E0M2VmNC90YWJsZXJhbmdlOjhlZTcxMTcwZmUwMDQwNTNhODBmNjg1Y2U3YTQzZWY0XzItNC0xLTEtNTkxMjc_ed9f984e-cb22-4aad-ab6e-2ba0cf491a3d">9,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i119cc232d51e4fbb9e1d846ac2bd0d41_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTo4ZWU3MTE3MGZlMDA0MDUzYTgwZjY4NWNlN2E0M2VmNC90YWJsZXJhbmdlOjhlZTcxMTcwZmUwMDQwNTNhODBmNjg1Y2U3YTQzZWY0XzMtMi0xLTEtNTkxMjc_fb091897-654d-4cd6-9932-ac345b99c4a5">8,701</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d09ecdd3a64d1a8904a12f454da71e_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTo4ZWU3MTE3MGZlMDA0MDUzYTgwZjY4NWNlN2E0M2VmNC90YWJsZXJhbmdlOjhlZTcxMTcwZmUwMDQwNTNhODBmNjg1Y2U3YTQzZWY0XzMtNC0xLTEtNTkxMjc_d42e8c90-c4d2-407b-a96a-c6ba0f450ac6">15,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTo4ZWU3MTE3MGZlMDA0MDUzYTgwZjY4NWNlN2E0M2VmNC90YWJsZXJhbmdlOjhlZTcxMTcwZmUwMDQwNTNhODBmNjg1Y2U3YTQzZWY0XzQtMi0xLTEtNTkxMjc_d415ce97-7767-40ec-814b-07d5e4e9f9e2">14,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTo4ZWU3MTE3MGZlMDA0MDUzYTgwZjY4NWNlN2E0M2VmNC90YWJsZXJhbmdlOjhlZTcxMTcwZmUwMDQwNTNhODBmNjg1Y2U3YTQzZWY0XzQtNC0xLTEtNTkxMjc_30d2218a-d2c5-4e12-8b17-d12973dc058e">25,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">EMI Option Plan and Pre-IPO Option Plan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The EMI Option Plan and the Pre-IPO Option Plan were adopted by our board of directors on September 18, 2006, and July 24, 2012, respectively. The total number of shares that may be issued under these plans is the current number of outstanding options over <ix:nonFraction unitRef="shares" contextRef="i2a6b7ded42314692aa873d8195ffbd32_I20060918" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzU0OTc1NTgxOTgwOA_402b15cf-e0ca-4a6a-be78-d9c06065b9d0">114,000</ix:nonFraction> ordinary shares, or <ix:nonFraction unitRef="shares" contextRef="i2a6b7ded42314692aa873d8195ffbd32_I20060918" decimals="0" name="vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzU0OTc1NTgxOTgxNA_8ac9cf85-569d-4692-a837-3d696b037d24">14,250</ix:nonFraction> ADSs, for the EMI Option Plan and <ix:nonFraction unitRef="shares" contextRef="i20dbfdab854c46fdaca99b937c1a2004_I20120724" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzU0OTc1NTgxOTgxOA_2939ce67-12bb-4eb7-a363-58343ce68928">1,860,000</ix:nonFraction> ordinary shares, or <ix:nonFraction unitRef="shares" contextRef="i20dbfdab854c46fdaca99b937c1a2004_I20120724" decimals="0" name="vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzU0OTc1NTgxOTgyMg_7d4ddc17-70c1-44d6-8c58-d4c21d944317">232,500</ix:nonFraction> ADSs, for the Pre-IPO Option Plan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"><ix:nonFraction unitRef="shares" contextRef="i7ce1126e308447edb0ce8f68eda07d48_D20170401-20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzE0NDI_091dbc15-dd1b-42da-a001-d38df2ebda99"><ix:nonFraction unitRef="shares" contextRef="i4854c977bffc4921b1f1611822527f5d_D20170401-20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzE0NDI_5ea8ede0-4018-467a-ab57-d398a943f0a6">No</ix:nonFraction></ix:nonFraction> further awards have been granted under either plan since the 2017 Incentive Plan was adopted, and <ix:nonFraction unitRef="shares" contextRef="icd6f70b91dd0435991ce621ce894613c_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzE1MjU_1283bd8d-8c81-4909-aba1-444f08eb8746"><ix:nonFraction unitRef="shares" contextRef="i5476c2b57bb84c3c9a60aba57bb6d479_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzE1MjU_e74e8406-2d13-4bd1-b45f-654550c33be2">no</ix:nonFraction></ix:nonFraction> further awards will be granted under them.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">2017 Incentive Plan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The 2017 Incentive Plan was adopted by our board of directors and became effective on April 26, 2017, in order to grant share based compensation to certain of the Company&#8217;s directors and employees. It provides for the grant of stock options, RSUs, and other share-based awards to Company&#8217;s directors, officers, employees and non-employee directors.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the year ended December 31, 2019, the Company modified the terms of all RSUs issued prior to January 1, 2019 to include a market based condition, which was also included in the terms of RSUs issued during 2019. The Company's stock price must be maintained above the equivalent of &#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="i2fd6a66dcd33401c900f14a24e099e1b_D20190101-20191231" decimals="2" name="vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzIyMjM_b52cbb7a-c29f-401f-b6a4-d09151f7b7a4">2</ix:nonFraction> per ordinary share for <ix:nonNumeric contextRef="i2fd6a66dcd33401c900f14a24e099e1b_D20190101-20191231" name="vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzIyNDk_b63fd677-2572-4dc5-b73f-9530af31a516">thirty days</ix:nonNumeric> for the RSUs to vest, in addition to the existing service condition. The RSUs vest <ix:nonNumeric contextRef="i2fd6a66dcd33401c900f14a24e099e1b_D20190101-20191231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzIzMzU_682b0cc4-314b-464f-80da-0c19d915602e">five years</ix:nonNumeric> after the date of grant irrespective of whether the &#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="i2fd6a66dcd33401c900f14a24e099e1b_D20190101-20191231" decimals="2" name="vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzIzOTA_465e2068-f70e-42ba-9928-c721e5fe5ab3">2</ix:nonFraction> market condition was met. This modification did not result in an increase in the fair value of the RSUs.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements&#160;&#160;&#160;&#160;</span></div></div><ix:continuation id="i353122aefd424fbc9e381b8109954b3f" continuedAt="ic3d1aad28acc4311a0ba0eabb8391dfc"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Share option activity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The number of options, the weighted average grant date fair value per stock option, and the weighted average exercise price are all shown below on a per ordinary shares basis. The Company&#8217;s ADSs that are listed on the Nasdaq Global Market each represent <ix:nonFraction unitRef="rate" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="0" name="dei:EntityListingDepositoryReceiptRatio" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzI3NzQ_e5107e02-954c-4f59-9bb2-97f8fea445cf">eight</ix:nonFraction> ordinary shares.</span></div><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzUwMzM_c16ec94b-5467-4583-8869-adefe0d8a7df" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows share option activity and includes the options outstanding from all three plans :</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.335%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.244%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of share options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average exercise price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average remaining contractual term (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate intrinsic value (thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at January 1, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if80b5e08771841e98a3888a3388c32e2_I20201231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzEtMi0xLTEtNTkxMjc_8c5191ab-64c2-4391-9294-cc14b3889924">13,125,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if80b5e08771841e98a3888a3388c32e2_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzEtNC0xLTEtNTkxMjc_025267b0-24d4-48ad-947f-8388ca58f5b7">1.41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic23d87e5f60a4b6cbb480b4fd31b6c15_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzEtNi0xLTEtNzI1NTk_58e940d3-4c86-4a24-9ba1-bd93eb5d1e42">7.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzItMi0xLTEtNTkxMjc_1c9fafa6-2035-4f9c-a478-7c4ab27f311e">1,696,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzItNC0xLTEtNTkxMjc_1f44f93c-223a-412d-b29c-78dbc386d36f">0.72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzMtMi0xLTEtNTkxMjc_bb4e2225-271f-477d-92f7-1166b6a07f63">2,126,472</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzMtNC0xLTEtNTkxMjc_ce7f8c0f-e3de-471f-bcf4-2efefc7ed5ed">1.06</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December 31, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzYtMi0xLTEtNTkxMjc_efc95e9c-c75b-4d77-a37e-84e8f6a476a0">12,695,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzYtNC0xLTEtNTkxMjc_78b39277-2f85-4292-93de-7a7cb6f214da">1.38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzYtNi0xLTEtNTkxMjc_75b2bc76-3dc8-42e1-9571-2739ae2e8ece">6.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzYtOC0xLTEtNTkxMjc_92efc256-5064-4305-b4f0-e1322618cf9e">950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzctMi0xLTEtNTkxMjc_930a2512-d2ae-4ec7-b6d0-f9c9fba67b9a">9,024,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzctNC0xLTEtNTkxMjc_be635205-aef1-47b5-a19c-f5845c639081">0.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzgtMi0xLTEtNTkxMjc_fe20d2b5-ebf5-4131-b77c-9a995b37abfc">620,016</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzgtNC0xLTEtNTkxMjc_cd86f403-479b-4575-b458-b5b240e63b6b">1.04</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzEwLTItMS0xLTU5MTI3_546c34db-b751-4634-8b45-b5c57dccfff8">1,822,688</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzEwLTQtMS0xLTU5MTI3_2bcecc3f-7127-43c4-a1ef-b348faf606b5">0.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December 31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzExLTItMS0xLTU5MTI3_5aaec7ff-bf5f-4524-b40f-9f736a2923f3">19,276,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzExLTQtMS0xLTU5MTI3_41cf6ab5-d122-465a-85bd-318e1ef9e85b">1.22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzExLTYtMS0xLTU5MTI3_b381bbf1-4f9f-4c3a-97dc-c3c88d204b69">7.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzExLTgtMS0xLTU5MTI3_2817ece7-dee4-4471-aab6-089be5d36792">39,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercisable at December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzEyLTItMS0xLTU5MTI3_224a813f-fbd0-4755-b42f-5c2417ab42f1">10,382,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzEyLTQtMS0xLTU5MTI3_cb12c66b-0468-45a4-a4b1-95459484ed52">1.48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzEyLTYtMS0xLTU5MTI3_3a5a4d3d-73e4-486b-8641-fed0fbf6db15">5.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzEyLTgtMS0xLTU5MTI3_e6105fb6-4473-4d8d-8d98-f9da331a6636">18,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline"> (1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The exercise prices relate to the equivalent price for an ordinary share, calculated as one <ix:nonFraction unitRef="rate" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="0" name="dei:EntityListingDepositoryReceiptRatio" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzMwMDE_5070474b-cc55-4501-9ee4-9fb416f9b2e6">eight</ix:nonFraction>h of the ADS price.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following summarizes the aggregate intrinsic value and cash receipts related to stock option exercise activity for the years ended December 31:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.938%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.241%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">($ in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate intrinsic value of stock options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToxNzA0NzE1OTM1ZWM0NzQ4YjZiNDk3MWU4Zjg0YzY3ZS90YWJsZXJhbmdlOjE3MDQ3MTU5MzVlYzQ3NDhiNmI0OTcxZThmODRjNjdlXzEtMi0xLTEtNzUxNjU_8b78629f-8630-42e2-a59c-6384988c6037">2,413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToxNzA0NzE1OTM1ZWM0NzQ4YjZiNDk3MWU4Zjg0YzY3ZS90YWJsZXJhbmdlOjE3MDQ3MTU5MzVlYzQ3NDhiNmI0OTcxZThmODRjNjdlXzEtNC0xLTEtNzM5MDg_22af085a-be2c-4acb-91d1-92151b629f6d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash receipts from stock options exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToxNzA0NzE1OTM1ZWM0NzQ4YjZiNDk3MWU4Zjg0YzY3ZS90YWJsZXJhbmdlOjE3MDQ3MTU5MzVlYzQ3NDhiNmI0OTcxZThmODRjNjdlXzItMi0xLTEtNzUxNjU_3f4202c8-af13-4588-8244-9c0efc4cd167">1,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToxNzA0NzE1OTM1ZWM0NzQ4YjZiNDk3MWU4Zjg0YzY3ZS90YWJsZXJhbmdlOjE3MDQ3MTU5MzVlYzQ3NDhiNmI0OTcxZThmODRjNjdlXzItNC0xLTEtNzUxNjU_40ce3e50-9ff2-4567-9852-80a42216820a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Determining the fair value of share options and RSUs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The total fair values of the options and RSUs were estimated using the Black-Scholes option-pricing model for equity-settled compensation, amounted to $<ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-5" name="vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzU0OTc1NTgxOTk1NQ_ea916f2e-75c7-4e5f-b259-a6d8c570c896">19.6</ix:nonFraction>&#160;million for instruments granted in the year ended December 31, 2022 and $<ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-5" name="vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzU0OTc1NTgxOTk0Ng_fbbd6606-a907-4a08-ade4-f5dd56f4304a">3.1</ix:nonFraction>&#160;million for instruments granted in the year ended December 31, 2021. The cost is amortized over the vesting period of the options and RSUs on a straight-line basis using the graded-vesting method. The following assumptions were used for the Black-Scholes valuation of share options granted in 2022 and 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Expected volatility</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Volatility is calculated using historical weekly averages of the Company's share price over a period that is in line with the expected life of the options and RSUs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Fair value of ordinary shares.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The fair value of ordinary shares has been based on the share price of the Company&#8217;s shares on AIM on the evening before the date of grant up until October 20, 2020 when the company delisted from AIM. Post this the fair value has been based on the ADS&#8217;s traded on Nasdaq on the evening before the date of grant.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Risk-free interest rate</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The risk-free interest rate has been based on U.K. Government debt yield for the relevant term at the time of grant up until October 20, 2020 when the company delisted from AIM. After this appropriate U.S Treasury yield rates were used.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Expected term.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As the Company does not have sufficient history to estimate its expected term, the Company applied the simplified method of estimating the expected term of the options, as described in the SEC&#8217;s Staff Accounting Bulletins 107 and </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements&#160;&#160;&#160;&#160;</span></div></div><ix:continuation id="ic3d1aad28acc4311a0ba0eabb8391dfc"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">110. The expected term, calculated under the simplified method, is applied to all stock options which have similar contractual terms. Using this method, the expected term is determined using the average of the vesting period and the contractual life of the stock options granted</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Expected dividend</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">There are no expected dividends.</span></div><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzUwMzQ_8cf31ba8-e5d9-42e3-84bc-22357c0915ef" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">A summary of the weighted-average assumptions applicable to the share options granted in the applicable years is as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6ef7ac44600e4b82bd5f7115b1d6d54d_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTplMTk4YTBjYzRhM2Q0ZDgyODFjYjJkYjE3NTk5MTc5Yy90YWJsZXJhbmdlOmUxOThhMGNjNGEzZDRkODI4MWNiMmRiMTc1OTkxNzljXzItMi0xLTEtNTkxMjcvdGV4dHJlZ2lvbjo5ZWQ2OWJmNWU0ZTc0NDg0YmRhNzcyOTJjNmJkZGJkYV80_49815520-73cf-41fa-bc66-dc62548c5f4b">2.09</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i6ef7ac44600e4b82bd5f7115b1d6d54d_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTplMTk4YTBjYzRhM2Q0ZDgyODFjYjJkYjE3NTk5MTc5Yy90YWJsZXJhbmdlOmUxOThhMGNjNGEzZDRkODI4MWNiMmRiMTc1OTkxNzljXzItMi0xLTEtNTkxMjcvdGV4dHJlZ2lvbjo5ZWQ2OWJmNWU0ZTc0NDg0YmRhNzcyOTJjNmJkZGJkYV85_ca330215-46c4-4fc5-a3cb-0624aac27239">4.20</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i28bc6028d27549bdbe82ed5d76e8a4d3_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTplMTk4YTBjYzRhM2Q0ZDgyODFjYjJkYjE3NTk5MTc5Yy90YWJsZXJhbmdlOmUxOThhMGNjNGEzZDRkODI4MWNiMmRiMTc1OTkxNzljXzItNC0xLTEtNTkxMjcvdGV4dHJlZ2lvbjo2NTE5OTA0NDBjOWY0NzkzOGYwNmU1MzVhNWIyZDhiYV80_b3967105-0222-454a-88ad-9b85ebc51894">0.79</ix:nonFraction>% -<ix:nonFraction unitRef="number" contextRef="i28bc6028d27549bdbe82ed5d76e8a4d3_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTplMTk4YTBjYzRhM2Q0ZDgyODFjYjJkYjE3NTk5MTc5Yy90YWJsZXJhbmdlOmUxOThhMGNjNGEzZDRkODI4MWNiMmRiMTc1OTkxNzljXzItNC0xLTEtNTkxMjcvdGV4dHJlZ2lvbjo2NTE5OTA0NDBjOWY0NzkzOGYwNmU1MzVhNWIyZDhiYV84_92d26efa-4540-4fca-94ce-763c8711cc3b">1.32</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected lives, years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie22e6682054147c4961ab22e3d0b6106_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTplMTk4YTBjYzRhM2Q0ZDgyODFjYjJkYjE3NTk5MTc5Yy90YWJsZXJhbmdlOmUxOThhMGNjNGEzZDRkODI4MWNiMmRiMTc1OTkxNzljXzMtMi0xLTEtNTkxMjcvdGV4dHJlZ2lvbjo3Mjc5MTE3MjQ2ODA0NWFlOTA3NzAzZjBkMmI2MmI2OF80_03ede85d-d26c-4901-bf71-2989c06636fb">5</ix:nonNumeric>-<ix:nonNumeric contextRef="ic9abfa929c414b3a8a9f9e7a5436d4f3_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTplMTk4YTBjYzRhM2Q0ZDgyODFjYjJkYjE3NTk5MTc5Yy90YWJsZXJhbmdlOmUxOThhMGNjNGEzZDRkODI4MWNiMmRiMTc1OTkxNzljXzMtMi0xLTEtNTkxMjcvdGV4dHJlZ2lvbjo3Mjc5MTE3MjQ2ODA0NWFlOTA3NzAzZjBkMmI2MmI2OF83_1b4fdbdd-3ae8-448f-9e28-257acf6b4fcd">7</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i47d19bc9bec84458b044241464c4ca53_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTplMTk4YTBjYzRhM2Q0ZDgyODFjYjJkYjE3NTk5MTc5Yy90YWJsZXJhbmdlOmUxOThhMGNjNGEzZDRkODI4MWNiMmRiMTc1OTkxNzljXzMtNC0xLTEtNTkxMjcvdGV4dHJlZ2lvbjplNDc4NTQ3MjIyMDE0NDE5YTU2YjA1NDk2ODhlYTY4Nl80_5430f08c-5e4e-41a0-8eb8-4e19334e8209">5</ix:nonNumeric>-<ix:nonNumeric contextRef="i659b636bd9904c8884a0708f012c5d76_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTplMTk4YTBjYzRhM2Q0ZDgyODFjYjJkYjE3NTk5MTc5Yy90YWJsZXJhbmdlOmUxOThhMGNjNGEzZDRkODI4MWNiMmRiMTc1OTkxNzljXzMtNC0xLTEtNTkxMjcvdGV4dHJlZ2lvbjplNDc4NTQ3MjIyMDE0NDE5YTU2YjA1NDk2ODhlYTY4Nl83_d16cd075-b756-43b1-bde6-1a421558b332">7</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6ef7ac44600e4b82bd5f7115b1d6d54d_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTplMTk4YTBjYzRhM2Q0ZDgyODFjYjJkYjE3NTk5MTc5Yy90YWJsZXJhbmdlOmUxOThhMGNjNGEzZDRkODI4MWNiMmRiMTc1OTkxNzljXzQtMi0xLTEtNTkxMjcvdGV4dHJlZ2lvbjoxM2MzMGJhOWQzZjA0NWNiYmYzOWQ1YjljYTdkODZjYl80_c8d11c69-d94b-4f2f-a13f-36e08c40272f">82.50</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i6ef7ac44600e4b82bd5f7115b1d6d54d_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTplMTk4YTBjYzRhM2Q0ZDgyODFjYjJkYjE3NTk5MTc5Yy90YWJsZXJhbmdlOmUxOThhMGNjNGEzZDRkODI4MWNiMmRiMTc1OTkxNzljXzQtMi0xLTEtNTkxMjcvdGV4dHJlZ2lvbjoxM2MzMGJhOWQzZjA0NWNiYmYzOWQ1YjljYTdkODZjYl85_42d24a7c-f75b-415f-bfdd-b7f38303995a">84.27</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i28bc6028d27549bdbe82ed5d76e8a4d3_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTplMTk4YTBjYzRhM2Q0ZDgyODFjYjJkYjE3NTk5MTc5Yy90YWJsZXJhbmdlOmUxOThhMGNjNGEzZDRkODI4MWNiMmRiMTc1OTkxNzljXzQtNC0xLTEtNTkxMjcvdGV4dHJlZ2lvbjo1Mzk5OTM0MjVkMDg0MTBmODMzYWE3MzRjYThiODI3M180_61993ab0-6032-4a99-b70c-e68fddae9552">85.35</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i28bc6028d27549bdbe82ed5d76e8a4d3_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTplMTk4YTBjYzRhM2Q0ZDgyODFjYjJkYjE3NTk5MTc5Yy90YWJsZXJhbmdlOmUxOThhMGNjNGEzZDRkODI4MWNiMmRiMTc1OTkxNzljXzQtNC0xLTEtNTkxMjcvdGV4dHJlZ2lvbjo1Mzk5OTM0MjVkMDg0MTBmODMzYWE3MzRjYThiODI3M185_7ca3f529-2a41-40a1-a96a-2ed3f7c9ce21">87.68</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6ef7ac44600e4b82bd5f7115b1d6d54d_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTplMTk4YTBjYzRhM2Q0ZDgyODFjYjJkYjE3NTk5MTc5Yy90YWJsZXJhbmdlOmUxOThhMGNjNGEzZDRkODI4MWNiMmRiMTc1OTkxNzljXzUtMi0xLTEtNTkxMjc_28b70659-8b52-4255-be61-f23039b50a0f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i28bc6028d27549bdbe82ed5d76e8a4d3_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTplMTk4YTBjYzRhM2Q0ZDgyODFjYjJkYjE3NTk5MTc5Yy90YWJsZXJhbmdlOmUxOThhMGNjNGEzZDRkODI4MWNiMmRiMTc1OTkxNzljXzUtNC0xLTEtNTkxMjc_0922309c-a53e-4990-8218-969fae5ba1b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant date fair value (per share)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ie22e6682054147c4961ab22e3d0b6106_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTplMTk4YTBjYzRhM2Q0ZDgyODFjYjJkYjE3NTk5MTc5Yy90YWJsZXJhbmdlOmUxOThhMGNjNGEzZDRkODI4MWNiMmRiMTc1OTkxNzljXzYtMi0xLTEtNTkxMjcvdGV4dHJlZ2lvbjoyZWQ5NmI4NjdiNGQ0MDZjOWJkYmIwNmEyOGUxN2Q2M180_b9856461-7daa-497f-9f7a-d79f2cad1668">0.34</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="ic9abfa929c414b3a8a9f9e7a5436d4f3_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTplMTk4YTBjYzRhM2Q0ZDgyODFjYjJkYjE3NTk5MTc5Yy90YWJsZXJhbmdlOmUxOThhMGNjNGEzZDRkODI4MWNiMmRiMTc1OTkxNzljXzYtMi0xLTEtNTkxMjcvdGV4dHJlZ2lvbjoyZWQ5NmI4NjdiNGQ0MDZjOWJkYmIwNmEyOGUxN2Q2M185_31f61793-6677-4a07-a556-b7356ad3344d">1.33</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i47d19bc9bec84458b044241464c4ca53_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTplMTk4YTBjYzRhM2Q0ZDgyODFjYjJkYjE3NTk5MTc5Yy90YWJsZXJhbmdlOmUxOThhMGNjNGEzZDRkODI4MWNiMmRiMTc1OTkxNzljXzYtNC0xLTEtNTkxMjcvdGV4dHJlZ2lvbjoxMjdhMDljNGUwYTM0NTNkYmQ2MTE1YzJiMjcwNmVlY180_763c16c1-4952-4bcc-85d9-e29e1a2604e2">0.62</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="i659b636bd9904c8884a0708f012c5d76_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTplMTk4YTBjYzRhM2Q0ZDgyODFjYjJkYjE3NTk5MTc5Yy90YWJsZXJhbmdlOmUxOThhMGNjNGEzZDRkODI4MWNiMmRiMTc1OTkxNzljXzYtNC0xLTEtNTkxMjcvdGV4dHJlZ2lvbjoxMjdhMDljNGUwYTM0NTNkYmQ2MTE1YzJiMjcwNmVlY185_972f40d7-66c1-47ce-8e21-c48fb0e88d12">0.78</ix:nonFraction></span></div></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Restricted stock units activity</span></div><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzUwMzA_6bc6e8bd-b3e7-4bb0-89f3-12d828ddb3ee" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows RSU activity:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average grant date fair value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average remaining contractual term (years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at January 1, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0887a875bbe3456c88ad04cb88647ce3_I20201231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTpmYjdkZjIyMzM5ZjU0NWRlYTIxNTgxMzM2N2MwNzRiNi90YWJsZXJhbmdlOmZiN2RmMjIzMzlmNTQ1ZGVhMjE1ODEzMzY3YzA3NGI2XzEtMi0xLTEtNTkxMjc_ef6efcf9-edd6-419c-bdee-686fea942ad1">61,992,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if80b5e08771841e98a3888a3388c32e2_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTpmYjdkZjIyMzM5ZjU0NWRlYTIxNTgxMzM2N2MwNzRiNi90YWJsZXJhbmdlOmZiN2RmMjIzMzlmNTQ1ZGVhMjE1ODEzMzY3YzA3NGI2XzEtNC0xLTEtNzUxMjI_7c64fc0b-9994-4017-ad50-93879d5e4419">0.98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic01569d19cb64fe9a0f5cf16691732dd_D20210101-20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTpmYjdkZjIyMzM5ZjU0NWRlYTIxNTgxMzM2N2MwNzRiNi90YWJsZXJhbmdlOmZiN2RmMjIzMzlmNTQ1ZGVhMjE1ODEzMzY3YzA3NGI2XzItMi0xLTEtNTkxMjc_f96c9f42-7c7a-4c1a-a916-7e5595ccad14">3,030,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTpmYjdkZjIyMzM5ZjU0NWRlYTIxNTgxMzM2N2MwNzRiNi90YWJsZXJhbmdlOmZiN2RmMjIzMzlmNTQ1ZGVhMjE1ODEzMzY3YzA3NGI2XzItNC0xLTEtNzUxMjI_278a9114-a8d5-473a-b82f-104233d284db">0.73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic01569d19cb64fe9a0f5cf16691732dd_D20210101-20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTpmYjdkZjIyMzM5ZjU0NWRlYTIxNTgxMzM2N2MwNzRiNi90YWJsZXJhbmdlOmZiN2RmMjIzMzlmNTQ1ZGVhMjE1ODEzMzY3YzA3NGI2XzMtMi0xLTEtNTkxMjc_53897699-9ef6-40cd-94d1-3bf56879225f">2,002,584</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTpmYjdkZjIyMzM5ZjU0NWRlYTIxNTgxMzM2N2MwNzRiNi90YWJsZXJhbmdlOmZiN2RmMjIzMzlmNTQ1ZGVhMjE1ODEzMzY3YzA3NGI2XzMtNC0xLTEtNzUxMjI_c8c70d03-a179-4a91-8c8c-7936cf13873e">1.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic01569d19cb64fe9a0f5cf16691732dd_D20210101-20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTpmYjdkZjIyMzM5ZjU0NWRlYTIxNTgxMzM2N2MwNzRiNi90YWJsZXJhbmdlOmZiN2RmMjIzMzlmNTQ1ZGVhMjE1ODEzMzY3YzA3NGI2XzQtMi0xLTEtNTkxMjc_1f3db49a-22b0-4a27-b303-d8b25ba2c36e">24,673,352</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTpmYjdkZjIyMzM5ZjU0NWRlYTIxNTgxMzM2N2MwNzRiNi90YWJsZXJhbmdlOmZiN2RmMjIzMzlmNTQ1ZGVhMjE1ODEzMzY3YzA3NGI2XzQtNC0xLTEtNzUxMjI_df736a27-e855-406d-bc4e-5fe04dc8b611">0.97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December 31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6b874456201746c6bb2d1caa6f13eeed_I20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTpmYjdkZjIyMzM5ZjU0NWRlYTIxNTgxMzM2N2MwNzRiNi90YWJsZXJhbmdlOmZiN2RmMjIzMzlmNTQ1ZGVhMjE1ODEzMzY3YzA3NGI2XzUtMi0xLTEtNTkxMjc_959c64d4-f9a7-493f-b56f-78cdfc661952">38,347,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTpmYjdkZjIyMzM5ZjU0NWRlYTIxNTgxMzM2N2MwNzRiNi90YWJsZXJhbmdlOmZiN2RmMjIzMzlmNTQ1ZGVhMjE1ODEzMzY3YzA3NGI2XzUtNC0xLTEtNzUxMjI_a93a78cd-d1ba-45a3-93c2-8d56e47e2506">0.97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic01569d19cb64fe9a0f5cf16691732dd_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTpmYjdkZjIyMzM5ZjU0NWRlYTIxNTgxMzM2N2MwNzRiNi90YWJsZXJhbmdlOmZiN2RmMjIzMzlmNTQ1ZGVhMjE1ODEzMzY3YzA3NGI2XzUtNC0xLTEtNTkxMjc_2e59def4-7c06-4765-b1b1-00891240fb4e">1.2</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0cb073618a12467ebf16ed58054c7606_D20220101-20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTpmYjdkZjIyMzM5ZjU0NWRlYTIxNTgxMzM2N2MwNzRiNi90YWJsZXJhbmdlOmZiN2RmMjIzMzlmNTQ1ZGVhMjE1ODEzMzY3YzA3NGI2XzYtMi0xLTEtNTkxMjc_ecc4e9cb-aceb-46c6-9603-786b749ced91">12,877,864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTpmYjdkZjIyMzM5ZjU0NWRlYTIxNTgxMzM2N2MwNzRiNi90YWJsZXJhbmdlOmZiN2RmMjIzMzlmNTQ1ZGVhMjE1ODEzMzY3YzA3NGI2XzYtNC0xLTEtNzUxMjI_3a71c31a-724d-43d5-9486-01fb43b5dc5d">1.07</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0cb073618a12467ebf16ed58054c7606_D20220101-20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTpmYjdkZjIyMzM5ZjU0NWRlYTIxNTgxMzM2N2MwNzRiNi90YWJsZXJhbmdlOmZiN2RmMjIzMzlmNTQ1ZGVhMjE1ODEzMzY3YzA3NGI2XzctMi0xLTEtNTkxMjc_cc234585-53e1-479e-8122-90f2e869bf30">1,006,264</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTpmYjdkZjIyMzM5ZjU0NWRlYTIxNTgxMzM2N2MwNzRiNi90YWJsZXJhbmdlOmZiN2RmMjIzMzlmNTQ1ZGVhMjE1ODEzMzY3YzA3NGI2XzctNC0xLTEtNzUxMjI_dd5925a5-663f-42d0-a3db-122fde107012">1.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0cb073618a12467ebf16ed58054c7606_D20220101-20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTpmYjdkZjIyMzM5ZjU0NWRlYTIxNTgxMzM2N2MwNzRiNi90YWJsZXJhbmdlOmZiN2RmMjIzMzlmNTQ1ZGVhMjE1ODEzMzY3YzA3NGI2XzgtMi0xLTEtNTkxMjc_45393270-7e13-4716-8e2a-8a8cb4be2a0d">15,676,608</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTpmYjdkZjIyMzM5ZjU0NWRlYTIxNTgxMzM2N2MwNzRiNi90YWJsZXJhbmdlOmZiN2RmMjIzMzlmNTQ1ZGVhMjE1ODEzMzY3YzA3NGI2XzgtNC0xLTEtNzUxMjI_226c9693-2c3e-4f9e-a09b-cd8aeb9ebd2c">0.96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0b5ab64a3a124f8683b6125306368d23_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTpmYjdkZjIyMzM5ZjU0NWRlYTIxNTgxMzM2N2MwNzRiNi90YWJsZXJhbmdlOmZiN2RmMjIzMzlmNTQ1ZGVhMjE1ODEzMzY3YzA3NGI2XzktMi0xLTEtNTkxMjc_8d2faa6b-966d-43cd-8cb6-5c4e66104f06">34,542,344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTpmYjdkZjIyMzM5ZjU0NWRlYTIxNTgxMzM2N2MwNzRiNi90YWJsZXJhbmdlOmZiN2RmMjIzMzlmNTQ1ZGVhMjE1ODEzMzY3YzA3NGI2XzktNC0xLTEtNzUxMjI_70af3ddc-a29f-4efd-8dbd-7a6897283e15">1.01</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0cb073618a12467ebf16ed58054c7606_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTpmYjdkZjIyMzM5ZjU0NWRlYTIxNTgxMzM2N2MwNzRiNi90YWJsZXJhbmdlOmZiN2RmMjIzMzlmNTQ1ZGVhMjE1ODEzMzY3YzA3NGI2XzktNC0xLTEtNTkxMjc_ce23c3cd-b729-4742-951d-8f8f00f12a9c">1.2</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.476%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.243%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of RSUs outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average remaining vesting Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Period in which the target must be achieved</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs subject to time based vesting</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i00a363abd6ea427e834a199f24664952_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTplMDMxNGIzNTQzODk0MTgxODc3MDlhNGJkYzQwNmYxZS90YWJsZXJhbmdlOmUwMzE0YjM1NDM4OTQxODE4NzcwOWE0YmRjNDA2ZjFlXzEtMi0xLTEtNTkxMjc_3710a35e-6de6-4509-883e-c0eff0b9482f">34,028,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1754f1ba19694c9bb318a7a84afebbe8_D20220101-20221231" name="vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTplMDMxNGIzNTQzODk0MTgxODc3MDlhNGJkYzQwNmYxZS90YWJsZXJhbmdlOmUwMzE0YjM1NDM4OTQxODE4NzcwOWE0YmRjNDA2ZjFlXzEtNC0xLTEtNTkxMjc_b063e1a9-d3fa-4d44-aac1-3ad695f11ed7">1.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs subject to milestone based vesting</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i280f6b8ea0fa434cb722279e0e05373e_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTplMDMxNGIzNTQzODk0MTgxODc3MDlhNGJkYzQwNmYxZS90YWJsZXJhbmdlOmUwMzE0YjM1NDM4OTQxODE4NzcwOWE0YmRjNDA2ZjFlXzItMi0xLTEtNTkxMjc_12574f48-8253-4a57-9dbd-d8515193219a">513,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4f452df8cc584b6c9688098f4a50632f_D20220101-20221231" name="vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTplMDMxNGIzNTQzODk0MTgxODc3MDlhNGJkYzQwNmYxZS90YWJsZXJhbmdlOmUwMzE0YjM1NDM4OTQxODE4NzcwOWE0YmRjNDA2ZjFlXzItNC0xLTEtNTkxMjc_f0397238-a2c6-48e0-be4a-c5396b4ac904">0.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 - 2024</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The intrinsic and fair value of RSUs that vested in the years ended December 31, 2022 and 2021, was $<ix:nonFraction unitRef="usd" contextRef="i0cb073618a12467ebf16ed58054c7606_D20220101-20221231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzI3NDg3NzkwNzU5NDg_3a35dcdf-ba33-48f8-ba47-b6d557a4456a">14.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ic01569d19cb64fe9a0f5cf16691732dd_D20210101-20211231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzI3NDg3NzkwNzU5NTY_6d0244f7-76da-4d87-adce-05448bb821f2">20.2</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As of December 31, 2022, total compensation cost related to share options and RSUs granted but not yet recognized was $<ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzU0OTc1NTgyMDUyNw_851b9006-03c1-46bd-84c4-d310f913fd76">20.5</ix:nonFraction>&#160;million. This cost will be amortized to expense over a weighted average remaining period of <ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzI0NzM5MDExNjMyMjQ4_6ac9b7b8-d8bf-4a70-860c-a62819c1e497">1.0</ix:nonNumeric> years and will be adjusted for subsequent forfeitures.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-22</span></div></div></div><div id="ic8555b0a0e574cdcb5428a00447fe322_142"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements&#160;&#160;&#160;&#160;</span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 10 - <ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="us-gaap:DefinedContributionPlanTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDIvZnJhZzpmZDg3MzE1ZjU5MGE0MWEwYTU5NWRmZjg0MjQyYWUyNy90ZXh0cmVnaW9uOmZkODczMTVmNTkwYTQxYTBhNTk1ZGZmODQyNDJhZTI3XzU0OA_6d120cc4-6c3c-4d1a-9a1a-df5af6314761" continuedAt="i7ae50c87ad9041f0a8011e5beff79116" escape="true">Benefit plans</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"><ix:continuation id="i7ae50c87ad9041f0a8011e5beff79116" continuedAt="i180d19f7bf8f466baeeaa90f4af39f41">The Company maintains a 401(k) defined contribution retirement plan in the U.S. and a defined contribution plan in the U.K. for its employees and executive directors. The assets of the plans are held separately from those of the Company in independently administered funds.</ix:continuation></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><ix:continuation id="i180d19f7bf8f466baeeaa90f4af39f41" continuedAt="i0f94a094586a445d8f8412a531ff9038"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The retirement plan cost charge represents the contributions payable by the Company to the plans during the year. Defined contribution costs during the years ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">December 31, 2022</span></ix:continuation><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"><ix:continuation id="i0f94a094586a445d8f8412a531ff9038"> and 2021 amounted to $<ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="us-gaap:DefinedContributionPlanCostRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDIvZnJhZzpmZDg3MzE1ZjU5MGE0MWEwYTU5NWRmZjg0MjQyYWUyNy90ZXh0cmVnaW9uOmZkODczMTVmNTkwYTQxYTBhNTk1ZGZmODQyNDJhZTI3XzUwNg_12debe06-e6d3-4640-ba86-751df0a1818e">319</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="us-gaap:DefinedContributionPlanCostRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDIvZnJhZzpmZDg3MzE1ZjU5MGE0MWEwYTU5NWRmZjg0MjQyYWUyNy90ZXh0cmVnaW9uOmZkODczMTVmNTkwYTQxYTBhNTk1ZGZmODQyNDJhZTI3XzUyMg_0813930a-2ea2-423f-87e1-288c2c6ae286">274</ix:nonFraction> thousand, respectively.</ix:continuation> </span></div><div id="ic8555b0a0e574cdcb5428a00447fe322_145"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 11 - <ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90ZXh0cmVnaW9uOjc1MmU0YmUxMzczODQ3ODFhN2FlYzRhNTM5ZDk5NDI1XzE4NDU_86a5986d-a12c-40e7-a27f-cb95cba37423" continuedAt="i333dd17dc2554d5d96251b1d0e3ea7cd" escape="true">Taxation</ix:nonNumeric></span></div><ix:continuation id="i333dd17dc2554d5d96251b1d0e3ea7cd" continuedAt="i89fb4167ffe947a88c5a01032ec7e5ab"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Verona Pharma plc operates in the United Kingdom and Verona Pharma, Inc. in the United States and they are subject to income taxes in those countries. U.K. corporation tax is charged at 19% and the U.S. Federal Income tax rate is 21%.</span></div><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90ZXh0cmVnaW9uOjc1MmU0YmUxMzczODQ3ODFhN2FlYzRhNTM5ZDk5NDI1XzE4NDY_9592f4b0-d88b-4493-ad70-896646024402" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The components of (profit)/loss before income taxes are as follows (in thousands): </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTplZTBiMmMxNGVhNzc0YTRiOTA3ZTZmODkwNDVmOTkxNi90YWJsZXJhbmdlOmVlMGIyYzE0ZWE3NzRhNGI5MDdlNmY4OTA0NWY5OTE2XzItMi0xLTEtNTkxMjc_56f8e697-a1e5-4f37-b275-c4e601c67e28">3,868</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTplZTBiMmMxNGVhNzc0YTRiOTA3ZTZmODkwNDVmOTkxNi90YWJsZXJhbmdlOmVlMGIyYzE0ZWE3NzRhNGI5MDdlNmY4OTA0NWY5OTE2XzItNC0xLTEtNTkxMjc_fb1262cd-7c29-4820-8840-842f9cc0c670">4,850</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTplZTBiMmMxNGVhNzc0YTRiOTA3ZTZmODkwNDVmOTkxNi90YWJsZXJhbmdlOmVlMGIyYzE0ZWE3NzRhNGI5MDdlNmY4OTA0NWY5OTE2XzMtMi0xLTEtNTkxMjc_da6060bc-1f5f-4687-b943-a450521b4088">72,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTplZTBiMmMxNGVhNzc0YTRiOTA3ZTZmODkwNDVmOTkxNi90YWJsZXJhbmdlOmVlMGIyYzE0ZWE3NzRhNGI5MDdlNmY4OTA0NWY5OTE2XzMtNC0xLTEtNTkxMjc_a3ef6e4e-2092-4755-b966-b86adfc7d4c4">60,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTplZTBiMmMxNGVhNzc0YTRiOTA3ZTZmODkwNDVmOTkxNi90YWJsZXJhbmdlOmVlMGIyYzE0ZWE3NzRhNGI5MDdlNmY4OTA0NWY5OTE2XzQtMi0xLTEtNTkxMjc_f99dcfc2-e559-4745-bb11-7b12aeb395d0">68,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTplZTBiMmMxNGVhNzc0YTRiOTA3ZTZmODkwNDVmOTkxNi90YWJsZXJhbmdlOmVlMGIyYzE0ZWE3NzRhNGI5MDdlNmY4OTA0NWY5OTE2XzQtNC0xLTEtNTkxMjc_fba7fdf8-d6a2-4714-a387-499b5b937338">55,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90ZXh0cmVnaW9uOjc1MmU0YmUxMzczODQ3ODFhN2FlYzRhNTM5ZDk5NDI1XzE4NDc_abe5d335-bb00-4eb4-8d5b-f318c52e607c" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The components of income tax expense are as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTowYWE0NWJiYWRiODQ0ZTNhYWUwYmVlOTVhODEyNWMyYS90YWJsZXJhbmdlOjBhYTQ1YmJhZGI4NDRlM2FhZTBiZWU5NWE4MTI1YzJhXzItMi0xLTEtNTkxMjc_7f8b0b38-bf22-4849-857f-150167d3d079">253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTowYWE0NWJiYWRiODQ0ZTNhYWUwYmVlOTVhODEyNWMyYS90YWJsZXJhbmdlOjBhYTQ1YmJhZGI4NDRlM2FhZTBiZWU5NWE4MTI1YzJhXzItNC0xLTEtNTkxMjc_fca14f52-71ac-43e2-a177-368d6a2828ba">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTowYWE0NWJiYWRiODQ0ZTNhYWUwYmVlOTVhODEyNWMyYS90YWJsZXJhbmdlOjBhYTQ1YmJhZGI4NDRlM2FhZTBiZWU5NWE4MTI1YzJhXzMtMi0xLTEtNTkxMjc_7704ca2c-aee7-41d1-a2c4-b360ed7a634f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTowYWE0NWJiYWRiODQ0ZTNhYWUwYmVlOTVhODEyNWMyYS90YWJsZXJhbmdlOjBhYTQ1YmJhZGI4NDRlM2FhZTBiZWU5NWE4MTI1YzJhXzMtNC0xLTEtNTkxMjc_62d5c5ff-7b4e-4bfd-bf31-a07ca72b2af5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current tax expense/(credit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTowYWE0NWJiYWRiODQ0ZTNhYWUwYmVlOTVhODEyNWMyYS90YWJsZXJhbmdlOjBhYTQ1YmJhZGI4NDRlM2FhZTBiZWU5NWE4MTI1YzJhXzQtMi0xLTEtNTkxMjc_ac489c5d-6674-4dd2-b031-c4d67b386fba">253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTowYWE0NWJiYWRiODQ0ZTNhYWUwYmVlOTVhODEyNWMyYS90YWJsZXJhbmdlOjBhYTQ1YmJhZGI4NDRlM2FhZTBiZWU5NWE4MTI1YzJhXzQtNC0xLTEtNTkxMjc_06b0a1c2-906b-47b1-b689-e17c01c01057">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTowYWE0NWJiYWRiODQ0ZTNhYWUwYmVlOTVhODEyNWMyYS90YWJsZXJhbmdlOjBhYTQ1YmJhZGI4NDRlM2FhZTBiZWU5NWE4MTI1YzJhXzYtMi0xLTEtNTkxMjc_d56534eb-0c6a-4523-a0de-d1450cbc7d3d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTowYWE0NWJiYWRiODQ0ZTNhYWUwYmVlOTVhODEyNWMyYS90YWJsZXJhbmdlOjBhYTQ1YmJhZGI4NDRlM2FhZTBiZWU5NWE4MTI1YzJhXzYtNC0xLTEtNTkxMjc_76255688-6814-43c2-81d4-2949a0192d86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTowYWE0NWJiYWRiODQ0ZTNhYWUwYmVlOTVhODEyNWMyYS90YWJsZXJhbmdlOjBhYTQ1YmJhZGI4NDRlM2FhZTBiZWU5NWE4MTI1YzJhXzctMi0xLTEtNTkxMjc_cf215cc6-fb57-4fa0-a5b4-88763e60506b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTowYWE0NWJiYWRiODQ0ZTNhYWUwYmVlOTVhODEyNWMyYS90YWJsZXJhbmdlOjBhYTQ1YmJhZGI4NDRlM2FhZTBiZWU5NWE4MTI1YzJhXzctNC0xLTEtNTkxMjc_952eb9ce-0830-4c74-853b-c3071f5facd5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total deferred tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTowYWE0NWJiYWRiODQ0ZTNhYWUwYmVlOTVhODEyNWMyYS90YWJsZXJhbmdlOjBhYTQ1YmJhZGI4NDRlM2FhZTBiZWU5NWE4MTI1YzJhXzgtMi0xLTEtNTkxMjc_9e9d8051-101a-4649-887b-d83045b49e37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTowYWE0NWJiYWRiODQ0ZTNhYWUwYmVlOTVhODEyNWMyYS90YWJsZXJhbmdlOjBhYTQ1YmJhZGI4NDRlM2FhZTBiZWU5NWE4MTI1YzJhXzgtNC0xLTEtNTkxMjc_e95caeaa-7062-4fe8-b52c-1fa13b494226">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total income tax expense/(credit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTowYWE0NWJiYWRiODQ0ZTNhYWUwYmVlOTVhODEyNWMyYS90YWJsZXJhbmdlOjBhYTQ1YmJhZGI4NDRlM2FhZTBiZWU5NWE4MTI1YzJhXzktMi0xLTEtNTkxMjc_072754a3-0499-4837-934a-2a67e26b3c3b">253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTowYWE0NWJiYWRiODQ0ZTNhYWUwYmVlOTVhODEyNWMyYS90YWJsZXJhbmdlOjBhYTQ1YmJhZGI4NDRlM2FhZTBiZWU5NWE4MTI1YzJhXzktNC0xLTEtNTkxMjc_daef3212-96de-4610-8505-b6045ecad0b2">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90ZXh0cmVnaW9uOjc1MmU0YmUxMzczODQ3ODFhN2FlYzRhNTM5ZDk5NDI1XzE4NDg_a4efea69-96ad-430f-8c06-8260275cfb9a" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">A reconciliation of the U.K. statutory income tax rate to our effective income tax rate is as follows (in percentages):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.K. tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTo4NTgzMWRmOTMyZGQ0M2ZmYTBlYWU1ZDRkMTg4YTM0MS90YWJsZXJhbmdlOjg1ODMxZGY5MzJkZDQzZmZhMGVhZTVkNGQxODhhMzQxXzItMi0xLTEtNTkxMjc_a32520ae-1443-465c-96fc-93b8b108dbe9">19.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTo4NTgzMWRmOTMyZGQ0M2ZmYTBlYWU1ZDRkMTg4YTM0MS90YWJsZXJhbmdlOjg1ODMxZGY5MzJkZDQzZmZhMGVhZTVkNGQxODhhMzQxXzItNC0xLTEtNTkxMjc_cb03f2d6-7196-4564-93c1-3baef198845f">19.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTo4NTgzMWRmOTMyZGQ0M2ZmYTBlYWU1ZDRkMTg4YTM0MS90YWJsZXJhbmdlOjg1ODMxZGY5MzJkZDQzZmZhMGVhZTVkNGQxODhhMzQxXzMtMi0xLTEtNTkxMjc_9cc21f68-91c0-4ac0-8545-28f1bdae00a4">1.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTo4NTgzMWRmOTMyZGQ0M2ZmYTBlYWU1ZDRkMTg4YTM0MS90YWJsZXJhbmdlOjg1ODMxZGY5MzJkZDQzZmZhMGVhZTVkNGQxODhhMzQxXzMtNC0xLTEtNTkxMjc_299ecfd7-db0c-43dd-be14-e677514899c4">7.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development incentive</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTo4NTgzMWRmOTMyZGQ0M2ZmYTBlYWU1ZDRkMTg4YTM0MS90YWJsZXJhbmdlOjg1ODMxZGY5MzJkZDQzZmZhMGVhZTVkNGQxODhhMzQxXzQtMi0xLTEtNTkxMjc_d64e7694-85db-416a-9caf-abf4930c45d6">8.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTo4NTgzMWRmOTMyZGQ0M2ZmYTBlYWU1ZDRkMTg4YTM0MS90YWJsZXJhbmdlOjg1ODMxZGY5MzJkZDQzZmZhMGVhZTVkNGQxODhhMzQxXzQtNC0xLTEtNTkxMjc_b6d768d6-8d8f-4132-bf33-a5384295ea86">10.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share options exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTo4NTgzMWRmOTMyZGQ0M2ZmYTBlYWU1ZDRkMTg4YTM0MS90YWJsZXJhbmdlOjg1ODMxZGY5MzJkZDQzZmZhMGVhZTVkNGQxODhhMzQxXzUtMi0xLTEtNTkxMjc_1286b7cc-3af7-4284-ba54-72076105a6c5">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTo4NTgzMWRmOTMyZGQ0M2ZmYTBlYWU1ZDRkMTg4YTM0MS90YWJsZXJhbmdlOjg1ODMxZGY5MzJkZDQzZmZhMGVhZTVkNGQxODhhMzQxXzUtNC0xLTEtNTkxMjc_f9eeca54-2738-4ea7-8bb6-e260426075a1">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred tax valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTo4NTgzMWRmOTMyZGQ0M2ZmYTBlYWU1ZDRkMTg4YTM0MS90YWJsZXJhbmdlOjg1ODMxZGY5MzJkZDQzZmZhMGVhZTVkNGQxODhhMzQxXzYtMi0xLTEtNTkxMjc_50d42c29-fa81-471f-9e61-48cca6ef4822">11.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTo4NTgzMWRmOTMyZGQ0M2ZmYTBlYWU1ZDRkMTg4YTM0MS90YWJsZXJhbmdlOjg1ODMxZGY5MzJkZDQzZmZhMGVhZTVkNGQxODhhMzQxXzYtNC0xLTEtNTkxMjc_28c65552-6145-4342-8841-108568da3767">3.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other differences</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="3" sign="-" name="vrna:EffectiveIncomeTaxRateReconciliationCapitalAllowancesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTo4NTgzMWRmOTMyZGQ0M2ZmYTBlYWU1ZDRkMTg4YTM0MS90YWJsZXJhbmdlOjg1ODMxZGY5MzJkZDQzZmZhMGVhZTVkNGQxODhhMzQxXzctMi0xLTEtNTkxMjc_2a8d405d-cce9-42ae-910d-28fcaf0dc733">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="3" sign="-" name="vrna:EffectiveIncomeTaxRateReconciliationCapitalAllowancesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTo4NTgzMWRmOTMyZGQ0M2ZmYTBlYWU1ZDRkMTg4YTM0MS90YWJsZXJhbmdlOjg1ODMxZGY5MzJkZDQzZmZhMGVhZTVkNGQxODhhMzQxXzctNC0xLTEtNTkxMjc_145a3c29-8fb7-4cc3-8869-cc56c98e27ce">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effective income tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTo4NTgzMWRmOTMyZGQ0M2ZmYTBlYWU1ZDRkMTg4YTM0MS90YWJsZXJhbmdlOjg1ODMxZGY5MzJkZDQzZmZhMGVhZTVkNGQxODhhMzQxXzgtMi0xLTEtNTkxMjc_88057f7b-b1e4-4b08-af2e-6489e268ad34">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTo4NTgzMWRmOTMyZGQ0M2ZmYTBlYWU1ZDRkMTg4YTM0MS90YWJsZXJhbmdlOjg1ODMxZGY5MzJkZDQzZmZhMGVhZTVkNGQxODhhMzQxXzgtNC0xLTEtNTkxMjc_14d8d0d2-6c5d-48ea-be13-023937f343cf">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements&#160;&#160;&#160;&#160;</span></div></div><ix:continuation id="i89fb4167ffe947a88c5a01032ec7e5ab"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">C<ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90ZXh0cmVnaW9uOjc1MmU0YmUxMzczODQ3ODFhN2FlYzRhNTM5ZDk5NDI1XzE4NDk_44351669-6012-446d-845f-15d194832312" continuedAt="iabd7bbaa39734a9280bb91c8268fbc39" escape="true">omponents of the Company&#8217;s deferred tax assets and liabilities are as follows (in thousands):</ix:nonNumeric></span></div><ix:continuation id="iabd7bbaa39734a9280bb91c8268fbc39"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="vrna:DeferredTaxLiabilitiesContingentLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzMtMi0xLTEtNTkxMjc_a705910a-9bac-49ab-a86f-e0b088e001fb">34,565</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" name="vrna:DeferredTaxLiabilitiesContingentLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzMtNC0xLTEtNTkxMjc_d8317946-a78f-4f84-9783-02b25e98fc4d">8,903</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzUtMi0xLTEtNTkxMjc_72c68c47-0a07-43ba-97e8-a9f06229bc0d">34,565</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzUtNC0xLTEtNTkxMjc_698ef4b9-d9ad-4233-974f-5f56873e4ba5">8,903</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzgtMi0xLTEtNTkxMjc_2321cc48-236c-40f7-ad27-0ef6dacdf427">38,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzgtNC0xLTEtNTkxMjc_773ed204-ff16-44fa-8888-d083d16efa7c">26,931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D asset</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzktMi0xLTEtNTkxMjc_72b54460-eee5-40f9-b932-8f794d0e797d">32,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzktNC0xLTEtNTkxMjc_3a65d071-4601-424d-a3ed-62f4be6c761c">7,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Future exercisable shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzEwLTItMS0xLTU5MTI3_53ad51b3-c57d-4d61-bc31-3764e66afc9b">11,964</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzEwLTQtMS0xLTU5MTI3_d406205f-13e6-4e7c-947d-5c69978164c5">4,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" sign="-" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzExLTItMS0xLTU5MTI3_e8ee61be-b6d5-4078-bcff-fca3dc32cf4e">516</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzExLTQtMS0xLTU5MTI3_9fd120a0-0a88-4ad1-95a2-6389952609dd">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzEyLTItMS0xLTU5MTI3_4b202e11-0975-41d4-a171-3df48280397a">83,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzEyLTQtMS0xLTU5MTI3_4eb73552-1873-45b5-a143-c70b88e42d2f">39,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzEzLTItMS0xLTU5MTI3_b340798d-5c9d-4e9c-95c2-ee8773e3ccf8">48,476</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzEzLTQtMS0xLTU5MTI3_5150fd4e-d992-42c3-9268-4f786595819c">30,252</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets, net of valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzE0LTItMS0xLTU5MTI3_fb5c7804-d7b1-4eb7-806e-7e26e7492faa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzE0LTQtMS0xLTU5MTI3_5290556f-a39d-4ae9-a459-cc81ca9e8926">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Movements in the deferred tax valuation allowance </span></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation allowance at January 1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9240e12e8374554928914a1dfb017fb_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzE4LTItMS0xLTU5MTI3_725960e5-e5bc-48e1-b840-ee2f1addd49f">30,252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c61487d635a4696b64cde5303229764_I20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzE4LTQtMS0xLTU5MTI3_a596d6cb-b02f-45c0-a4ab-f08276044555">30,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a63b0b903ee4acab0480335043b47f5_D20220101-20221231" decimals="-3" name="vrna:SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzE5LTItMS0xLTU5MTI3_db590d5b-4f15-43b7-be91-dfb43e996181">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i709ea29e7e7249da99a23ab89c643290_D20210101-20211231" decimals="-3" name="vrna:SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzE5LTQtMS0xLTU5MTI3_eb1d1117-50ed-426a-bc9a-5cd01ab751ab">7,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase/(decrease) in valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a63b0b903ee4acab0480335043b47f5_D20220101-20221231" decimals="-3" name="vrna:SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzIwLTItMS0xLTU5MTI3_929b90b5-dd4d-4b78-b644-b6a3e4753ac9">18,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i709ea29e7e7249da99a23ab89c643290_D20210101-20211231" decimals="-3" sign="-" name="vrna:SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzIwLTQtMS0xLTU5MTI3_e52d14e4-a049-4862-89c6-4c4e25bc71f7">7,422</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation allowance at December 31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1b945830df8444a9ed8c6acd123c8b9_I20221231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzIyLTItMS0xLTU5MTI3_8ebf6627-0612-4d1b-86a4-06ca0994e03a">48,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9240e12e8374554928914a1dfb017fb_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzIyLTQtMS0xLTU5MTI3_691747d5-5fde-44ba-9a7f-09abd4140c20">30,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">These relate to the difference in the tax base of the IP R&amp;D asset and assumed contingent liability and the financial reporting base, which is nil under U.S. GAAP.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Management has reviewed cumulative tax losses and projections of future taxable losses and determined that it is not more likely than not that they will be realized. Accordingly, valuation allowances have been provided over deferred tax assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">At December 31, 2022 and December 31, 2021, the Company had U.K. net operating losses (&#8220;NOLs&#8221;) of $<ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90ZXh0cmVnaW9uOjc1MmU0YmUxMzczODQ3ODFhN2FlYzRhNTM5ZDk5NDI1XzExNDI_e9e8e664-f138-4d3b-ab59-19f0f3bbb7b5">155.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90ZXh0cmVnaW9uOjc1MmU0YmUxMzczODQ3ODFhN2FlYzRhNTM5ZDk5NDI1XzM4NDgyOTA3MDI3ODI_795be1a7-f3b4-4d50-bea5-9c7dd1f70176">104.3</ix:nonFraction>&#160;million, respectively. The NOLs can be carried forward indefinitely to be offset against future taxable profits, but this is restricted to an annual &#163;5&#160;million allowance after which there will be a 50% restriction in the profits that can be covered by losses brought forward.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company files separate income tax returns in the U.K. and the U.S. All necessary income tax filings have been completed for all years up to and including December 31, 2021, and there are no ongoing tax examinations in any jurisdiction. <ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="INF" name="us-gaap:IncomeTaxExaminationPenaltiesAccrued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90ZXh0cmVnaW9uOjc1MmU0YmUxMzczODQ3ODFhN2FlYzRhNTM5ZDk5NDI1XzE2NjA_2f534f47-73df-4f5b-9031-d46ceaeb575f"><ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="INF" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90ZXh0cmVnaW9uOjc1MmU0YmUxMzczODQ3ODFhN2FlYzRhNTM5ZDk5NDI1XzE2NjA_5bca1714-bb34-49eb-9415-e488a48feeaa"><ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="INF" name="us-gaap:IncomeTaxExaminationPenaltiesAccrued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90ZXh0cmVnaW9uOjc1MmU0YmUxMzczODQ3ODFhN2FlYzRhNTM5ZDk5NDI1XzE2NjA_5f6e1f60-5940-43a8-9f58-f918dfa6c637"><ix:nonFraction unitRef="usd" contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231" decimals="INF" name="us-gaap:IncomeTaxExaminationInterestAccrued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90ZXh0cmVnaW9uOjc1MmU0YmUxMzczODQ3ODFhN2FlYzRhNTM5ZDk5NDI1XzE2NjA_a58e6c3c-7c90-4618-bb89-af4628c24c74"><ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="INF" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90ZXh0cmVnaW9uOjc1MmU0YmUxMzczODQ3ODFhN2FlYzRhNTM5ZDk5NDI1XzE2NjA_c214cc1e-765c-4616-9260-5ff0ecd14c2f"><ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="INF" name="us-gaap:IncomeTaxExaminationInterestAccrued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90ZXh0cmVnaW9uOjc1MmU0YmUxMzczODQ3ODFhN2FlYzRhNTM5ZDk5NDI1XzE2NjA_d00377b1-25cf-42f6-9552-998b04ea129f">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> interest or penalties were recognized in the consolidated statements of operations or consolidated balance sheets. As of December 31, 2022, the Company has no uncertain tax positions.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-24</span></div></div></div><div id="ic8555b0a0e574cdcb5428a00447fe322_151"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Verona Pharma plc</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements&#160;&#160;&#160;&#160;</span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 12 - <ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNTEvZnJhZzo1MDgwNTRmOGYwYjM0MzQ1OGI1NmQwMjNiNjlhMzIxMy90ZXh0cmVnaW9uOjUwODA1NGY4ZjBiMzQzNDU4YjU2ZDAyM2I2OWEzMjEzXzU5MQ_4a08edb3-f552-4450-b2d4-1fbc792f6b5c" continuedAt="i8304f59c079044798088298acc48a63e" escape="true">Net loss per share </ix:nonNumeric></span></div><ix:continuation id="i8304f59c079044798088298acc48a63e"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Net loss per share is calculated on an ordinary share basis. The Company&#8217;s ADSs that are listed on the Nasdaq Global Market each represent <ix:nonFraction unitRef="rate" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="0" name="dei:EntityListingDepositoryReceiptRatio" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNTEvZnJhZzo1MDgwNTRmOGYwYjM0MzQ1OGI1NmQwMjNiNjlhMzIxMy90ZXh0cmVnaW9uOjUwODA1NGY4ZjBiMzQzNDU4YjU2ZDAyM2I2OWEzMjEzXzI0NzM5MDExNjI1NjU5_9b78198f-0421-4e68-a170-d3def61ffcdf">eight</ix:nonFraction> ordinary shares. <ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNTEvZnJhZzo1MDgwNTRmOGYwYjM0MzQ1OGI1NmQwMjNiNjlhMzIxMy90ZXh0cmVnaW9uOjUwODA1NGY4ZjBiMzQzNDU4YjU2ZDAyM2I2OWEzMjEzXzU5Mg_f4d9611a-5472-4e52-8dad-07b5b64aef93" continuedAt="id03373c10efd4720bc63589713512eef" escape="true">The following table shows the computation of basic and diluted earnings per share for 2022 and 2021 (net loss in thousands, loss per share in dollars):</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><ix:continuation id="id03373c10efd4720bc63589713512eef"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNTEvZnJhZzo1MDgwNTRmOGYwYjM0MzQ1OGI1NmQwMjNiNjlhMzIxMy90YWJsZTpiMmQwM2UxNmU5MjQ0MDJiOTcxODljYjBhNGY0YjcwZC90YWJsZXJhbmdlOmIyZDAzZTE2ZTkyNDQwMmI5NzE4OWNiMGE0ZjRiNzBkXzMtMi0xLTEtNTkxMjc_a11c1af4-0489-4f88-b9b6-21f67f2fa074">68,701</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNTEvZnJhZzo1MDgwNTRmOGYwYjM0MzQ1OGI1NmQwMjNiNjlhMzIxMy90YWJsZTpiMmQwM2UxNmU5MjQ0MDJiOTcxODljYjBhNGY0YjcwZC90YWJsZXJhbmdlOmIyZDAzZTE2ZTkyNDQwMmI5NzE4OWNiMGE0ZjRiNzBkXzMtNC0xLTEtNTkxMjc_2880f779-4707-45c6-88b9-a5077f13da4a">55,569</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss available to ordinary shareholders - basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNTEvZnJhZzo1MDgwNTRmOGYwYjM0MzQ1OGI1NmQwMjNiNjlhMzIxMy90YWJsZTpiMmQwM2UxNmU5MjQ0MDJiOTcxODljYjBhNGY0YjcwZC90YWJsZXJhbmdlOmIyZDAzZTE2ZTkyNDQwMmI5NzE4OWNiMGE0ZjRiNzBkXzQtMi0xLTEtNTkxMjc_2835996a-5d87-489e-95ab-9c6f05792fc3"><ix:nonFraction unitRef="usd" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNTEvZnJhZzo1MDgwNTRmOGYwYjM0MzQ1OGI1NmQwMjNiNjlhMzIxMy90YWJsZTpiMmQwM2UxNmU5MjQ0MDJiOTcxODljYjBhNGY0YjcwZC90YWJsZXJhbmdlOmIyZDAzZTE2ZTkyNDQwMmI5NzE4OWNiMGE0ZjRiNzBkXzQtMi0xLTEtNTkxMjc_c9c4110d-ae83-4712-b8f4-0c9d55bfc6da">68,701</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNTEvZnJhZzo1MDgwNTRmOGYwYjM0MzQ1OGI1NmQwMjNiNjlhMzIxMy90YWJsZTpiMmQwM2UxNmU5MjQ0MDJiOTcxODljYjBhNGY0YjcwZC90YWJsZXJhbmdlOmIyZDAzZTE2ZTkyNDQwMmI5NzE4OWNiMGE0ZjRiNzBkXzQtNC0xLTEtNTkxMjc_23c0bdf5-f9b6-466a-a002-d6085ea2c60d"><ix:nonFraction unitRef="usd" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNTEvZnJhZzo1MDgwNTRmOGYwYjM0MzQ1OGI1NmQwMjNiNjlhMzIxMy90YWJsZTpiMmQwM2UxNmU5MjQ0MDJiOTcxODljYjBhNGY0YjcwZC90YWJsZXJhbmdlOmIyZDAzZTE2ZTkyNDQwMmI5NzE4OWNiMGE0ZjRiNzBkXzQtNC0xLTEtNTkxMjc_8e454b6e-d57a-4021-afb5-b488040896d2">55,569</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding - basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="INF" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNTEvZnJhZzo1MDgwNTRmOGYwYjM0MzQ1OGI1NmQwMjNiNjlhMzIxMy90YWJsZTpiMmQwM2UxNmU5MjQ0MDJiOTcxODljYjBhNGY0YjcwZC90YWJsZXJhbmdlOmIyZDAzZTE2ZTkyNDQwMmI5NzE4OWNiMGE0ZjRiNzBkXzYtMi0xLTEtNTkxMjc_6a5d22a0-0456-4d4a-b582-33c00dccdf49"><ix:nonFraction unitRef="shares" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="INF" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNTEvZnJhZzo1MDgwNTRmOGYwYjM0MzQ1OGI1NmQwMjNiNjlhMzIxMy90YWJsZTpiMmQwM2UxNmU5MjQ0MDJiOTcxODljYjBhNGY0YjcwZC90YWJsZXJhbmdlOmIyZDAzZTE2ZTkyNDQwMmI5NzE4OWNiMGE0ZjRiNzBkXzYtMi0xLTEtNTkxMjc_dc4fc896-cb58-45be-a3f7-cb5fc6b6a4b9">529,071,526</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="INF" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNTEvZnJhZzo1MDgwNTRmOGYwYjM0MzQ1OGI1NmQwMjNiNjlhMzIxMy90YWJsZTpiMmQwM2UxNmU5MjQ0MDJiOTcxODljYjBhNGY0YjcwZC90YWJsZXJhbmdlOmIyZDAzZTE2ZTkyNDQwMmI5NzE4OWNiMGE0ZjRiNzBkXzYtNC0xLTEtNTkxMjc_99d91f01-2053-4d8f-a781-b966cb4b3d30"><ix:nonFraction unitRef="shares" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="INF" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNTEvZnJhZzo1MDgwNTRmOGYwYjM0MzQ1OGI1NmQwMjNiNjlhMzIxMy90YWJsZTpiMmQwM2UxNmU5MjQ0MDJiOTcxODljYjBhNGY0YjcwZC90YWJsZXJhbmdlOmIyZDAzZTE2ZTkyNDQwMmI5NzE4OWNiMGE0ZjRiNzBkXzYtNC0xLTEtNTkxMjc_cd1ebf1d-0171-4853-b3c2-fa3a0ebb3bef">473,188,457</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss per share - basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNTEvZnJhZzo1MDgwNTRmOGYwYjM0MzQ1OGI1NmQwMjNiNjlhMzIxMy90YWJsZTpiMmQwM2UxNmU5MjQ0MDJiOTcxODljYjBhNGY0YjcwZC90YWJsZXJhbmdlOmIyZDAzZTE2ZTkyNDQwMmI5NzE4OWNiMGE0ZjRiNzBkXzctMi0xLTEtNTkxMjc_0a7e9201-6ec0-4172-91fa-89b900474441"><ix:nonFraction unitRef="usdPerShare" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNTEvZnJhZzo1MDgwNTRmOGYwYjM0MzQ1OGI1NmQwMjNiNjlhMzIxMy90YWJsZTpiMmQwM2UxNmU5MjQ0MDJiOTcxODljYjBhNGY0YjcwZC90YWJsZXJhbmdlOmIyZDAzZTE2ZTkyNDQwMmI5NzE4OWNiMGE0ZjRiNzBkXzctMi0xLTEtNTkxMjc_36ba8915-9bcf-47d3-a672-087b4ae9afb2">0.13</ix:nonFraction></ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNTEvZnJhZzo1MDgwNTRmOGYwYjM0MzQ1OGI1NmQwMjNiNjlhMzIxMy90YWJsZTpiMmQwM2UxNmU5MjQ0MDJiOTcxODljYjBhNGY0YjcwZC90YWJsZXJhbmdlOmIyZDAzZTE2ZTkyNDQwMmI5NzE4OWNiMGE0ZjRiNzBkXzctNC0xLTEtNTkxMjc_6a5f1077-3559-4095-896a-c60a37b100f5"><ix:nonFraction unitRef="usdPerShare" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNTEvZnJhZzo1MDgwNTRmOGYwYjM0MzQ1OGI1NmQwMjNiNjlhMzIxMy90YWJsZTpiMmQwM2UxNmU5MjQ0MDJiOTcxODljYjBhNGY0YjcwZC90YWJsZXJhbmdlOmIyZDAzZTE2ZTkyNDQwMmI5NzE4OWNiMGE0ZjRiNzBkXzctNC0xLTEtNTkxMjc_e0a11042-d08d-4522-949a-20dd118a311c">0.12</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">During the years ended December 31, 2022 and 2021, outstanding share options, RSUs and warrants of <ix:nonFraction unitRef="shares" contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNTEvZnJhZzo1MDgwNTRmOGYwYjM0MzQ1OGI1NmQwMjNiNjlhMzIxMy90ZXh0cmVnaW9uOjUwODA1NGY4ZjBiMzQzNDU4YjU2ZDAyM2I2OWEzMjEzXzM4NDgyOTA2OTc4NTg_6dd2216b-5e1b-4faa-8ee3-cee0b45a616d">53,818,840</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNTEvZnJhZzo1MDgwNTRmOGYwYjM0MzQ1OGI1NmQwMjNiNjlhMzIxMy90ZXh0cmVnaW9uOjUwODA1NGY4ZjBiMzQzNDU4YjU2ZDAyM2I2OWEzMjEzXzM4NDgyOTA2OTc4NjI_db6b3adf-586e-4ec7-a9da-9b1733147152">63,443,814</ix:nonFraction>, respectively, were not included in the computation of diluted earnings per ordinary share, because to do so would be antidilutive.</span></div></ix:continuation><div id="ic8555b0a0e574cdcb5428a00447fe322_157"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 13 - <ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNTcvZnJhZzo4N2Q5YjM5ZDhiZTM0ZjdkYmY4ZjY5YjYyNzZlY2I4NS90ZXh0cmVnaW9uOjg3ZDliMzlkOGJlMzRmN2RiZjhmNjliNjI3NmVjYjg1XzI0NzM5MDExNjI3MTc0_bc4e10e2-99d4-4f6a-be8b-9f3ea0f8c1d2" continuedAt="i3de197af071f4a5c8d12c94e55644edc" escape="true">Commitments and contingencies</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"><ix:continuation id="i3de197af071f4a5c8d12c94e55644edc">Management is currently negotiating a matter with a supplier that has an estimated exposure of approximately $<ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="-5" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNTcvZnJhZzo4N2Q5YjM5ZDhiZTM0ZjdkYmY4ZjY5YjYyNzZlY2I4NS90ZXh0cmVnaW9uOjg3ZDliMzlkOGJlMzRmN2RiZjhmNjliNjI3NmVjYjg1XzIxOTkwMjMyNTY4MzE_608be0c0-c174-4a53-acda-94134e9a612b">1.5</ix:nonFraction>&#160;million. Management does not currently consider it probable that a payment will be made and therefore <ix:nonFraction unitRef="usd" contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231" decimals="INF" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNTcvZnJhZzo4N2Q5YjM5ZDhiZTM0ZjdkYmY4ZjY5YjYyNzZlY2I4NS90ZXh0cmVnaW9uOjg3ZDliMzlkOGJlMzRmN2RiZjhmNjliNjI3NmVjYjg1XzI0NzM5MDExNjI3MTc1_f384b627-9498-42b9-b9c6-b73c17bad2a1">no</ix:nonFraction> accrual is recorded at December 31, 2022. This matter is expected to be resolved within the next 12 months.</ix:continuation></span></div><div id="ic8555b0a0e574cdcb5428a00447fe322_440"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Note 14 - <ix:nonNumeric contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl80NDAvZnJhZzpiZjBlYjlmMzdiZmE0N2Y2OTZlYzZkNTkxNjY2MTE0Mi90ZXh0cmVnaW9uOmJmMGViOWYzN2JmYTQ3ZjY5NmVjNmQ1OTE2NjYxMTQyXzI0NzM5MDExNjI1MjUz_22c150d7-7cbd-4624-b5f5-ca64ace21360" continuedAt="if169dd15d6b74d2cb602e94afb6f2b85" escape="true">Related party transactions and other shareholder matters</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"><ix:continuation id="if169dd15d6b74d2cb602e94afb6f2b85">In the years ended December 31, 2022 and 2021 there were no related party transactions.</ix:continuation></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F-25</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>exhibit211q422.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i448663ef6e9f4beda152bd94e6959aa3_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.1</font></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUBSIDIARIES OF VERONA PHARMA PLC</font></div><div style="margin-top:12pt;text-indent:24.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.880%"><tr><td style="width:1.0%"></td><td style="width:48.317%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.319%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Legal Name of Subsidiary</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Verona Pharma, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Delaware</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>consentletter-fy22.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i62ac98f604fd437fa3ceae1dd2cf2241_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:112%">We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-268389, 333-248199, 333-237926, 333-217521) and Form S-3 (No. 333-254530) of Verona Pharma plc of our report dated March 7, 2023 relating to the financial statements, which appears in this Form 10-K.</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt"><font><br></font></div><div><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; PricewaterhouseCoopers LLP</font></div><div><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:120%">Reading, United Kingdom</font></div><div><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:120%">March 7, 2023</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>exhibit311q422.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ie74c36f703cd4e7eb01bfe130a756c4c_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, David Zaccardelli, Pharm.D., certify that&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Annual Report on Form 10-K of Verona Pharma plc&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in&#160;Exchange Act Rules 13a-15(e)&#160;and&#160;15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="padding-left:24.5pt;text-indent:-24.5pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.215%"><tr><td style="width:1.0%"></td><td style="width:36.253%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.102%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.345%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Date&#58; March 7, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47;&#160;David Zaccardelli, Pharm.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">David Zaccardelli, Pharm.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer </font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(principal executive officer)</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>exhibit312q422.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i6ca9046855324efca0d9cbdc267e89e6_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Mark W. Hahn, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Annual Report on Form 10-K of Verona Pharma plc&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in&#160;Exchange Act Rules 13a-15(e)&#160;and&#160;15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="padding-left:24.5pt;text-indent:-24.5pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.381%"><tr><td style="width:1.0%"></td><td style="width:26.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.251%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Date&#58; March 7, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47;&#160;Mark W. Hahn</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Mark W. Hahn</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer (</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">principal financial officer</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>exhibit321q422.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ic7676361a9f545f1aeaeccd1669797df_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report on Form 10-K of Verona Pharma plc (the &#8220;Company&#8221;) for the period ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge&#58;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="padding-left:24.5pt;text-indent:-24.5pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.215%"><tr><td style="width:1.0%"></td><td style="width:36.253%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.102%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.345%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Date&#58; March 7, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47; David Zaccardelli, Pharm.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">David Zaccardelli, Pharm.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">principal executive officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>exhibit322q422.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ib2ed855a9bf0435c9cbd1ae3a76bbfff_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report on Form 10-K of Verona Pharma plc (the &#8220;Company&#8221;) for the period ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge&#58;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="padding-left:24.5pt;text-indent:-24.5pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.381%"><tr><td style="width:1.0%"></td><td style="width:26.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.251%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Date&#58; March 7, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47;&#160;Mark W. Hahn</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Mark W. Hahn</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer (</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">principal financial officer)</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>vrna-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:3c4b6351-9dd7-43ec-8a74-8bad3a93c534,g:ba5c393f-9b46-4696-9211-0bc9a20ff330-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:vrna="http://veronapharma.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://veronapharma.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vrna-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vrna-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vrna-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vrna-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://veronapharma.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://veronapharma.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://veronapharma.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://veronapharma.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>0000005 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofShareholdersEquity" roleURI="http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity">
        <link:definition>0000006 - Statement - Consolidated Statements of Shareholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://veronapharma.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000007 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Organizationanddescriptionofbusinessoperations" roleURI="http://veronapharma.com/role/Organizationanddescriptionofbusinessoperations">
        <link:definition>0000008 - Disclosure - Organization and description of business operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingpolicies" roleURI="http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpolicies">
        <link:definition>0000009 - Disclosure - Basis of Presentation and Summary of Significant Accounting policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Prepaidexpenses" roleURI="http://veronapharma.com/role/Prepaidexpenses">
        <link:definition>0000010 - Disclosure - Prepaid expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Propertyleases" roleURI="http://veronapharma.com/role/Propertyleases">
        <link:definition>0000011 - Disclosure - Property leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Accruedexpenses" roleURI="http://veronapharma.com/role/Accruedexpenses">
        <link:definition>0000012 - Disclosure - Accrued expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Warrants" roleURI="http://veronapharma.com/role/Warrants">
        <link:definition>0000013 - Disclosure - Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Termloan" roleURI="http://veronapharma.com/role/Termloan">
        <link:definition>0000014 - Disclosure - Term loan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Significantagreements" roleURI="http://veronapharma.com/role/Significantagreements">
        <link:definition>0000015 - Disclosure - Significant agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Benefitplans" roleURI="http://veronapharma.com/role/Benefitplans">
        <link:definition>0000016 - Disclosure - Benefit plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Taxation" roleURI="http://veronapharma.com/role/Taxation">
        <link:definition>0000017 - Disclosure - Taxation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Sharebasedcompensation" roleURI="http://veronapharma.com/role/Sharebasedcompensation">
        <link:definition>0000018 - Disclosure - Share based compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Netlosspershare" roleURI="http://veronapharma.com/role/Netlosspershare">
        <link:definition>0000019 - Disclosure - Net loss per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Commitmentsandcontingencies" roleURI="http://veronapharma.com/role/Commitmentsandcontingencies">
        <link:definition>0000020 - Disclosure - Commitments and contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Relatedpartytransactionsandothershareholdermatters" roleURI="http://veronapharma.com/role/Relatedpartytransactionsandothershareholdermatters">
        <link:definition>0000021 - Disclosure - Related party transactions and other shareholder matters</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies" roleURI="http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies">
        <link:definition>0000022 - Disclosure - Basis of Presentation and Summary of Significant Accounting policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidexpensesTables" roleURI="http://veronapharma.com/role/PrepaidexpensesTables">
        <link:definition>0000023 - Disclosure - Prepaid expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyleasesTables" roleURI="http://veronapharma.com/role/PropertyleasesTables">
        <link:definition>0000024 - Disclosure - Property leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedexpensesTables" roleURI="http://veronapharma.com/role/AccruedexpensesTables">
        <link:definition>0000025 - Disclosure - Accrued expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsTables" roleURI="http://veronapharma.com/role/WarrantsTables">
        <link:definition>0000026 - Disclosure - Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxationTables" roleURI="http://veronapharma.com/role/TaxationTables">
        <link:definition>0000027 - Disclosure - Taxation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedcompensationTables" roleURI="http://veronapharma.com/role/SharebasedcompensationTables">
        <link:definition>0000028 - Disclosure - Share based compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetlosspershareTables" roleURI="http://veronapharma.com/role/NetlosspershareTables">
        <link:definition>0000029 - Disclosure - Net loss per share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationanddescriptionofbusinessoperationsDetails" roleURI="http://veronapharma.com/role/OrganizationanddescriptionofbusinessoperationsDetails">
        <link:definition>0000030 - Disclosure - Organization and description of business operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails" roleURI="http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails">
        <link:definition>0000031 - Disclosure - Basis of Presentation and Summary of Significant Accounting policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidexpensesDetails" roleURI="http://veronapharma.com/role/PrepaidexpensesDetails">
        <link:definition>0000032 - Disclosure - Prepaid expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyleasesNarrativeDetails" roleURI="http://veronapharma.com/role/PropertyleasesNarrativeDetails">
        <link:definition>0000033 - Disclosure - Property leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyleasesMaturityDetails" roleURI="http://veronapharma.com/role/PropertyleasesMaturityDetails">
        <link:definition>0000034 - Disclosure - Property leases - Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyleasesMaturityDetails_1" roleURI="http://veronapharma.com/role/PropertyleasesMaturityDetails_1">
        <link:definition>0000034 - Disclosure - Property leases - Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedexpensesDetails" roleURI="http://veronapharma.com/role/AccruedexpensesDetails">
        <link:definition>0000035 - Disclosure - Accrued expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsNarrativeDetails" roleURI="http://veronapharma.com/role/WarrantsNarrativeDetails">
        <link:definition>0000036 - Disclosure - Warrants - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsFairValueAssumptionsDetails" roleURI="http://veronapharma.com/role/WarrantsFairValueAssumptionsDetails">
        <link:definition>0000037 - Disclosure - Warrants - Fair Value Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsMovementinValueDetails" roleURI="http://veronapharma.com/role/WarrantsMovementinValueDetails">
        <link:definition>0000038 - Disclosure - Warrants - Movement in Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TermloanDetails" roleURI="http://veronapharma.com/role/TermloanDetails">
        <link:definition>0000039 - Disclosure - Term loan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantagreementsDetails" roleURI="http://veronapharma.com/role/SignificantagreementsDetails">
        <link:definition>0000040 - Disclosure - Significant agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BenefitplansDetails" roleURI="http://veronapharma.com/role/BenefitplansDetails">
        <link:definition>0000041 - Disclosure - Benefit plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxationLossBeforeTaxDetails" roleURI="http://veronapharma.com/role/TaxationLossBeforeTaxDetails">
        <link:definition>0000042 - Disclosure - Taxation - Loss Before Tax (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxationTaxExpenseBenefitDetails" roleURI="http://veronapharma.com/role/TaxationTaxExpenseBenefitDetails">
        <link:definition>0000043 - Disclosure - Taxation - Tax Expense (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxationReconciliationofStatutoryRateDetails" roleURI="http://veronapharma.com/role/TaxationReconciliationofStatutoryRateDetails">
        <link:definition>0000044 - Disclosure - Taxation - Reconciliation of Statutory Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxationDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>0000045 - Disclosure - Taxation - Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxationNarrativeDetails" roleURI="http://veronapharma.com/role/TaxationNarrativeDetails">
        <link:definition>0000046 - Disclosure - Taxation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedcompensationShareBasedCompensationExpenseDetails" roleURI="http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails">
        <link:definition>0000047 - Disclosure - Share based compensation - Share-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedcompensationNarrativeDetails" roleURI="http://veronapharma.com/role/SharebasedcompensationNarrativeDetails">
        <link:definition>0000048 - Disclosure - Share based compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedcompensationShareOptionActivityDetails" roleURI="http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails">
        <link:definition>0000049 - Disclosure - Share based compensation - Share Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedcompensationWeightedAverageAssumptionsDetails" roleURI="http://veronapharma.com/role/SharebasedcompensationWeightedAverageAssumptionsDetails">
        <link:definition>0000050 - Disclosure - Share based compensation - Weighted-Average Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedcompensationRSUActivityDetails" roleURI="http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails">
        <link:definition>0000051 - Disclosure - Share based compensation - RSU Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetlosspershareComputationDetails" roleURI="http://veronapharma.com/role/NetlosspershareComputationDetails">
        <link:definition>0000052 - Disclosure - Net loss per share - Computation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandcontingenciesDetails" roleURI="http://veronapharma.com/role/CommitmentsandcontingenciesDetails">
        <link:definition>0000053 - Disclosure - Commitments and contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="vrna_RestrictedStockUnitTimeBasedVestingMember" abstract="true" name="RestrictedStockUnitTimeBasedVestingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" abstract="false" name="IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_ContractWithCustomerFutureEligibleMilestonePayments" abstract="false" name="ContractWithCustomerFutureEligibleMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_SublicensePayment" abstract="false" name="SublicensePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_TermBLoanMember" abstract="true" name="TermBLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_UnrealizedGainLossOnWarrants" abstract="false" name="UnrealizedGainLossOnWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_GovernmentTaxCreditsPolicyPolicyTextBlock" abstract="false" name="GovernmentTaxCreditsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="vrna_OxfordTermCLoanMember" abstract="true" name="OxfordTermCLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_DebtInstrumentInterestRatePeriodTwoMember" abstract="true" name="DebtInstrumentInterestRatePeriodTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_EffectiveIncomeTaxRateReconciliationCapitalAllowancesPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationCapitalAllowancesPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vrna_InterestRatePeriodDomain" abstract="true" name="InterestRatePeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_PrepaidExpenseDisclosureTextBlock" abstract="false" name="PrepaidExpenseDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vrna_OxfordTermELoanMember" abstract="true" name="OxfordTermELoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_AtTheMarketSalesAgreementMember" abstract="true" name="AtTheMarketSalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_PreIPOOptionPlanMember" abstract="true" name="PreIPOOptionPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="vrna_OxfordTermALoanMember" abstract="true" name="OxfordTermALoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_TermCLoanMember" abstract="true" name="TermCLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_AmericanDepositorySharesMember" abstract="true" name="AmericanDepositorySharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_PublicStockOfferingMember" abstract="true" name="PublicStockOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_DebtInstrumentInterestRatePeriodOneMember" abstract="true" name="DebtInstrumentInterestRatePeriodOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_FirstCommercialSaleMember" abstract="true" name="FirstCommercialSaleMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="vrna_PrepaidResearchAndDevelopmentFeesCurrent" abstract="false" name="PrepaidResearchAndDevelopmentFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates" abstract="false" name="SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_SublicensePaymentEquityIssuanceThresholdTradingDays" abstract="false" name="SublicensePaymentEquityIssuanceThresholdTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vrna_LineOfCreditFacilityNumberOfLoanAdvances" abstract="false" name="LineOfCreditFacilityNumberOfLoanAdvances" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vrna_A2017IncentivePlanMember" abstract="true" name="A2017IncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_DebtInstrumentPrepaymentFeePercentage" abstract="false" name="DebtInstrumentPrepaymentFeePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vrna_ClassOfWarrantOrRightNumberOfExercisedOrForfeited" abstract="false" name="ClassOfWarrantOrRightNumberOfExercisedOrForfeited" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="vrna_NumberOfWhollyOwnedSubsidiaries" abstract="false" name="NumberOfWhollyOwnedSubsidiaries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vrna_NuanceShanghaiPharmaCoLtdMember" abstract="true" name="NuanceShanghaiPharmaCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" abstract="false" name="AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_BenchmarkAchievementAxis" abstract="true" name="BenchmarkAchievementAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="vrna_EquityInterestReceivable" abstract="false" name="EquityInterestReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_OxfordTermBLoanMember" abstract="true" name="OxfordTermBLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_EMIOptionPlanMember" abstract="true" name="EMIOptionPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_LondonMember" abstract="true" name="LondonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vrna_GainLossFromResearchAndDevelopmentTaxCredit" abstract="false" name="GainLossFromResearchAndDevelopmentTaxCredit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_TaxCreditAndIncomeTaxesReceivableCurrent" abstract="false" name="TaxCreditAndIncomeTaxesReceivableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_CommonStockSharesAvailableForSaleValue" abstract="false" name="CommonStockSharesAvailableForSaleValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_LigandUKDevelopmentLimitedMember" abstract="true" name="LigandUKDevelopmentLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares" abstract="false" name="StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="vrna_DeferredTaxLiabilitiesContingentLiability" abstract="false" name="DeferredTaxLiabilitiesContingentLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_IncreaseDecreaseInOperatingLeaseLiabilities" abstract="false" name="IncreaseDecreaseInOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_OxfordTermBCDELoanMember" abstract="true" name="OxfordTermBCDELoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_WarrantAndRightsDisclosureTextBlock" abstract="false" name="WarrantAndRightsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="vrna_TermLoanFacilityMember" abstract="true" name="TermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustment" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_BenchmarkAchievementDomain" abstract="true" name="BenchmarkAchievementDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_AccruedResearchAndDevelopmentFeesCurrent" abstract="false" name="AccruedResearchAndDevelopmentFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance" abstract="false" name="SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_DebtInstrumentFinalPaymentPercentageOfPrincipalAmount" abstract="false" name="DebtInstrumentFinalPaymentPercentageOfPrincipalAmount" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vrna_WarrantLiabilityCurrent" abstract="false" name="WarrantLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_MeasurementInputAnnualizedVolatilityMember" abstract="true" name="MeasurementInputAnnualizedVolatilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_SaleOfStockMaximumAggregateOfferingPrice" abstract="false" name="SaleOfStockMaximumAggregateOfferingPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_RestrictedStockUnitMilestoneBasedVestingMember" abstract="true" name="RestrictedStockUnitMilestoneBasedVestingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights" abstract="false" name="ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="vrna_OrganizationAndBusinessDescriptionTextBlock" abstract="false" name="OrganizationAndBusinessDescriptionTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_IncreaseDecreaseInEquityInterestReceivable" abstract="false" name="IncreaseDecreaseInEquityInterestReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vrna_StockIssuedDuringPeriodSharesHeldInTreasury" abstract="false" name="StockIssuedDuringPeriodSharesHeldInTreasury" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="vrna_OxfordTermDLoanMember" abstract="true" name="OxfordTermDLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vrna_OxfordTermLoanMember" abstract="true" name="OxfordTermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vrna_InterestRatePeriodAxis" abstract="true" name="InterestRatePeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="vrna_ClassOfWarrantOrRightIntrinsicValue" abstract="false" name="ClassOfWarrantOrRightIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>vrna-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:3c4b6351-9dd7-43ec-8a74-8bad3a93c534,g:ba5c393f-9b46-4696-9211-0bc9a20ff330-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="vrna-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e0a38c2c-4bb2-487f-aafb-212deadfe3fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_58f6316c-d016-4634-af73-d27687e1412b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e0a38c2c-4bb2-487f-aafb-212deadfe3fd" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_58f6316c-d016-4634-af73-d27687e1412b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8770cc2a-0727-4807-8f68-a16564332cab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e0a38c2c-4bb2-487f-aafb-212deadfe3fd" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_8770cc2a-0727-4807-8f68-a16564332cab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_69b4f6ef-eada-458e-b09d-641f2cccb710" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e0a38c2c-4bb2-487f-aafb-212deadfe3fd" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_69b4f6ef-eada-458e-b09d-641f2cccb710" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_042e77b0-880c-46d0-944f-8083fc8195e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e0a38c2c-4bb2-487f-aafb-212deadfe3fd" xlink:to="loc_us-gaap_TaxesPayableCurrent_042e77b0-880c-46d0-944f-8083fc8195e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a86ae406-1d6c-426c-bfc9-f3b5f8f187ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e0a38c2c-4bb2-487f-aafb-212deadfe3fd" xlink:to="loc_us-gaap_AccountsPayableCurrent_a86ae406-1d6c-426c-bfc9-f3b5f8f187ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2f87fe14-5a10-4d4c-a5c4-b846396e0d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9389ffe5-089b-4f1a-982a-6d9d78899776" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2f87fe14-5a10-4d4c-a5c4-b846396e0d1b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9389ffe5-089b-4f1a-982a-6d9d78899776" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_4d1bbe1c-ec83-43b2-812a-5a192955932e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2f87fe14-5a10-4d4c-a5c4-b846396e0d1b" xlink:to="loc_us-gaap_OtherAssetsCurrent_4d1bbe1c-ec83-43b2-812a-5a192955932e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TaxCreditAndIncomeTaxesReceivableCurrent_cc228683-e3e4-4fa9-88aa-23b619b1b776" xlink:href="vrna-20221231.xsd#vrna_TaxCreditAndIncomeTaxesReceivableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2f87fe14-5a10-4d4c-a5c4-b846396e0d1b" xlink:to="loc_vrna_TaxCreditAndIncomeTaxesReceivableCurrent_cc228683-e3e4-4fa9-88aa-23b619b1b776" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_1ed4454e-854b-44d8-80a3-7c642d736c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2f87fe14-5a10-4d4c-a5c4-b846396e0d1b" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_1ed4454e-854b-44d8-80a3-7c642d736c5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_7fdec0e3-5b0c-4afd-b5db-b0ff41959426" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_17592627-159a-439f-9962-c6be9908acd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_7fdec0e3-5b0c-4afd-b5db-b0ff41959426" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_17592627-159a-439f-9962-c6be9908acd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_f2357c00-fda7-4db2-9fe4-6056e7da2cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_7fdec0e3-5b0c-4afd-b5db-b0ff41959426" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_f2357c00-fda7-4db2-9fe4-6056e7da2cb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f65236a4-7de9-4de3-b345-b9051febc8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_7fdec0e3-5b0c-4afd-b5db-b0ff41959426" xlink:to="loc_us-gaap_Goodwill_f65236a4-7de9-4de3-b345-b9051febc8c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_22f6f742-18a6-42a8-8859-8af5ffe4422e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_7fdec0e3-5b0c-4afd-b5db-b0ff41959426" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_22f6f742-18a6-42a8-8859-8af5ffe4422e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_2dbb6c0f-8b85-437d-ab28-7b584e3f27a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_783ff910-4967-40df-a5b6-100a3bea933e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2dbb6c0f-8b85-437d-ab28-7b584e3f27a7" xlink:to="loc_us-gaap_AssetsNoncurrent_783ff910-4967-40df-a5b6-100a3bea933e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9b995481-23db-422b-80e5-ee0fc10818bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2dbb6c0f-8b85-437d-ab28-7b584e3f27a7" xlink:to="loc_us-gaap_AssetsCurrent_9b995481-23db-422b-80e5-ee0fc10818bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_fca55ffd-668f-4eea-9fcd-b8d85d704e65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_955fd5ee-fccd-4705-8ef4-d76dc38cb880" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_fca55ffd-668f-4eea-9fcd-b8d85d704e65" xlink:to="loc_us-gaap_Liabilities_955fd5ee-fccd-4705-8ef4-d76dc38cb880" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_71ac72d2-633a-4051-8b4b-4f572485f0e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_fca55ffd-668f-4eea-9fcd-b8d85d704e65" xlink:to="loc_us-gaap_CommitmentsAndContingencies_71ac72d2-633a-4051-8b4b-4f572485f0e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_59aa2b36-c2fc-47eb-8dcb-2c965184be7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_fca55ffd-668f-4eea-9fcd-b8d85d704e65" xlink:to="loc_us-gaap_StockholdersEquity_59aa2b36-c2fc-47eb-8dcb-2c965184be7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_3dadf543-c3e7-409e-a635-8cfef916f335" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a6075073-83a9-4bb5-b249-f3f7432c7168" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_3dadf543-c3e7-409e-a635-8cfef916f335" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a6075073-83a9-4bb5-b249-f3f7432c7168" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_d5d246f5-d4ed-44e5-a7ed-42e2a56166e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_3dadf543-c3e7-409e-a635-8cfef916f335" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_d5d246f5-d4ed-44e5-a7ed-42e2a56166e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1e4ac1ce-b6f0-4782-a767-a89bae30e1cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7573eed1-91e2-4ff0-bdad-572581a83e4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1e4ac1ce-b6f0-4782-a767-a89bae30e1cb" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7573eed1-91e2-4ff0-bdad-572581a83e4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_5e1e46f0-628d-4c64-a82b-a26daaf09488" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1e4ac1ce-b6f0-4782-a767-a89bae30e1cb" xlink:to="loc_us-gaap_AdditionalPaidInCapital_5e1e46f0-628d-4c64-a82b-a26daaf09488" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_bd687c16-d6bb-4730-91c0-224ddf22b01d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1e4ac1ce-b6f0-4782-a767-a89bae30e1cb" xlink:to="loc_us-gaap_TreasuryStockValue_bd687c16-d6bb-4730-91c0-224ddf22b01d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_5ddfeac3-1ba7-410a-854d-657ff7c54583" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1e4ac1ce-b6f0-4782-a767-a89bae30e1cb" xlink:to="loc_us-gaap_CommonStockValue_5ddfeac3-1ba7-410a-854d-657ff7c54583" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4d3b7fc5-6a57-471e-9623-733b3e8e9eef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1e4ac1ce-b6f0-4782-a767-a89bae30e1cb" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4d3b7fc5-6a57-471e-9623-733b3e8e9eef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_61f5d1d5-867c-48a3-b2a8-2dee39baddf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_c42b1ac5-049d-4dd0-a770-d39307f1aefd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_61f5d1d5-867c-48a3-b2a8-2dee39baddf8" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_c42b1ac5-049d-4dd0-a770-d39307f1aefd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_cfdda09f-81ba-4edb-97f8-8cc7c4ad57a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_61f5d1d5-867c-48a3-b2a8-2dee39baddf8" xlink:to="loc_us-gaap_LiabilitiesCurrent_cfdda09f-81ba-4edb-97f8-8cc7c4ad57a0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="vrna-20221231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_770a987e-e0d7-475c-93c3-1a77fca8ec53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_18341c38-50d6-4bc0-9652-6b5f5397c416" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_770a987e-e0d7-475c-93c3-1a77fca8ec53" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_18341c38-50d6-4bc0-9652-6b5f5397c416" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7ccf08da-739e-4dde-a791-857e67433281" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_770a987e-e0d7-475c-93c3-1a77fca8ec53" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7ccf08da-739e-4dde-a791-857e67433281" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_6159f614-24ea-450a-b23d-df7d13cf6e54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_d017729d-bf2a-415b-b8ad-381d07362634" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_6159f614-24ea-450a-b23d-df7d13cf6e54" xlink:to="loc_us-gaap_Revenues_d017729d-bf2a-415b-b8ad-381d07362634" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_98ba5e0f-e8af-47e8-a307-094f3b148469" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_6159f614-24ea-450a-b23d-df7d13cf6e54" xlink:to="loc_us-gaap_CostOfRevenue_98ba5e0f-e8af-47e8-a307-094f3b148469" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_4ff2cdce-cfe4-42ac-9041-3a506907cd84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_48cb1b0f-378b-4bc6-8fad-559fe8dd2cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_4ff2cdce-cfe4-42ac-9041-3a506907cd84" xlink:to="loc_us-gaap_InvestmentIncomeNet_48cb1b0f-378b-4bc6-8fad-559fe8dd2cc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_ddaa192b-9bf4-4e7b-9726-ca9669536dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_4ff2cdce-cfe4-42ac-9041-3a506907cd84" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_ddaa192b-9bf4-4e7b-9726-ca9669536dbf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_GainLossFromResearchAndDevelopmentTaxCredit_72eaf858-f9f0-49f3-bf7c-85b9c6ca0440" xlink:href="vrna-20221231.xsd#vrna_GainLossFromResearchAndDevelopmentTaxCredit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_4ff2cdce-cfe4-42ac-9041-3a506907cd84" xlink:to="loc_vrna_GainLossFromResearchAndDevelopmentTaxCredit_72eaf858-f9f0-49f3-bf7c-85b9c6ca0440" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_46191114-077a-4ec2-a560-5f86d6417745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_4ff2cdce-cfe4-42ac-9041-3a506907cd84" xlink:to="loc_us-gaap_InterestExpense_46191114-077a-4ec2-a560-5f86d6417745" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_UnrealizedGainLossOnWarrants_069968bc-b429-401a-95b6-0a4063da8e89" xlink:href="vrna-20221231.xsd#vrna_UnrealizedGainLossOnWarrants"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_4ff2cdce-cfe4-42ac-9041-3a506907cd84" xlink:to="loc_vrna_UnrealizedGainLossOnWarrants_069968bc-b429-401a-95b6-0a4063da8e89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_13ad5be0-6743-4cad-ba7b-bb1b087a1f59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_4ff2cdce-cfe4-42ac-9041-3a506907cd84" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_13ad5be0-6743-4cad-ba7b-bb1b087a1f59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b175e68c-31e2-444c-b9b6-9d13bb8b7bce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_537093e7-87a5-4931-9e90-2b24a18317b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_b175e68c-31e2-444c-b9b6-9d13bb8b7bce" xlink:to="loc_us-gaap_GrossProfit_537093e7-87a5-4931-9e90-2b24a18317b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_1fe2f9e6-9251-4518-8e4e-1c76ff14ded0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_b175e68c-31e2-444c-b9b6-9d13bb8b7bce" xlink:to="loc_us-gaap_OperatingExpenses_1fe2f9e6-9251-4518-8e4e-1c76ff14ded0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_610b9829-05da-470c-8624-d026658ad621" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_da757dfe-e786-4058-8fa5-d3f6ad4ce0b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_610b9829-05da-470c-8624-d026658ad621" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_da757dfe-e786-4058-8fa5-d3f6ad4ce0b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_fbce67e6-0806-47c8-a23e-5d7992f395de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_610b9829-05da-470c-8624-d026658ad621" xlink:to="loc_us-gaap_OperatingIncomeLoss_fbce67e6-0806-47c8-a23e-5d7992f395de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_08e19d21-4fbb-44cd-a6ae-a441ac850e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_87e425f7-c960-40a4-8049-8eea7fac1330" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_08e19d21-4fbb-44cd-a6ae-a441ac850e0b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_87e425f7-c960-40a4-8049-8eea7fac1330" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_c5e6eb50-f650-4a35-aff3-2c37478646f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_08e19d21-4fbb-44cd-a6ae-a441ac850e0b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_c5e6eb50-f650-4a35-aff3-2c37478646f3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="vrna-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c83ac1e9-ea69-4fc3-ad91-49f46feeb742" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_75a54dd2-78d9-459d-a01e-c8b9bd90dd31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c83ac1e9-ea69-4fc3-ad91-49f46feeb742" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_75a54dd2-78d9-459d-a01e-c8b9bd90dd31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_150b6c86-dced-40bc-ab6b-611dd11bb2b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c83ac1e9-ea69-4fc3-ad91-49f46feeb742" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_150b6c86-dced-40bc-ab6b-611dd11bb2b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_32f381be-1612-4ebe-907a-f23a8eb94648" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c83ac1e9-ea69-4fc3-ad91-49f46feeb742" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_32f381be-1612-4ebe-907a-f23a8eb94648" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_b6d78054-9d20-4281-a518-ab472873818b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c83ac1e9-ea69-4fc3-ad91-49f46feeb742" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_b6d78054-9d20-4281-a518-ab472873818b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfLoanCosts_14d7c041-b11b-454a-b4f7-2ffe6a0f2eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfLoanCosts"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c83ac1e9-ea69-4fc3-ad91-49f46feeb742" xlink:to="loc_us-gaap_PaymentsOfLoanCosts_14d7c041-b11b-454a-b4f7-2ffe6a0f2eb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_8c2fa4ae-4453-42c7-8769-eee9c3bdc7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c83ac1e9-ea69-4fc3-ad91-49f46feeb742" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_8c2fa4ae-4453-42c7-8769-eee9c3bdc7d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_ef44b248-9506-4f43-99b9-a686de71f327" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c83ac1e9-ea69-4fc3-ad91-49f46feeb742" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_ef44b248-9506-4f43-99b9-a686de71f327" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_79a1d218-9e17-4bc8-a22a-3758e5299ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c83ac1e9-ea69-4fc3-ad91-49f46feeb742" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_79a1d218-9e17-4bc8-a22a-3758e5299ec6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bfbe9420-52e8-489e-8ab4-8131d4e99de9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_fa3c8ceb-86de-42be-831a-28982af6fbd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bfbe9420-52e8-489e-8ab4-8131d4e99de9" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_fa3c8ceb-86de-42be-831a-28982af6fbd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_ba54e03f-8b8d-4f90-a76c-ac65035e85b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bfbe9420-52e8-489e-8ab4-8131d4e99de9" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_ba54e03f-8b8d-4f90-a76c-ac65035e85b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_4098c7fa-e221-4783-8f0a-6d0d2a98670d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedTaxesPayable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bfbe9420-52e8-489e-8ab4-8131d4e99de9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_4098c7fa-e221-4783-8f0a-6d0d2a98670d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_b1c3e4b0-1e51-42cb-b01c-36a6d692c71a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bfbe9420-52e8-489e-8ab4-8131d4e99de9" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_b1c3e4b0-1e51-42cb-b01c-36a6d692c71a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_16dc82f0-e5f8-4a46-82b0-006acc92e931" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bfbe9420-52e8-489e-8ab4-8131d4e99de9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_16dc82f0-e5f8-4a46-82b0-006acc92e931" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_d4993b37-bc44-4675-bd2d-0dc4c43a8d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bfbe9420-52e8-489e-8ab4-8131d4e99de9" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_d4993b37-bc44-4675-bd2d-0dc4c43a8d6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_984a7166-2181-4e6a-a73a-63a9b0d34d04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bfbe9420-52e8-489e-8ab4-8131d4e99de9" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_984a7166-2181-4e6a-a73a-63a9b0d34d04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_73114598-b4e0-4447-8bea-b6ff066ba353" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bfbe9420-52e8-489e-8ab4-8131d4e99de9" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_73114598-b4e0-4447-8bea-b6ff066ba353" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_475925af-bf0b-460e-8d76-e1714c5289f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bfbe9420-52e8-489e-8ab4-8131d4e99de9" xlink:to="loc_us-gaap_NetIncomeLoss_475925af-bf0b-460e-8d76-e1714c5289f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_fb188a43-ac3e-4b3d-b4f0-13c54e736a05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bfbe9420-52e8-489e-8ab4-8131d4e99de9" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_fb188a43-ac3e-4b3d-b4f0-13c54e736a05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_IncreaseDecreaseInEquityInterestReceivable_9c571588-088f-48ab-aab7-05e03c5c00b7" xlink:href="vrna-20221231.xsd#vrna_IncreaseDecreaseInEquityInterestReceivable"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bfbe9420-52e8-489e-8ab4-8131d4e99de9" xlink:to="loc_vrna_IncreaseDecreaseInEquityInterestReceivable_9c571588-088f-48ab-aab7-05e03c5c00b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent_84c34622-5158-426b-8742-da102529385d" xlink:href="vrna-20221231.xsd#vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bfbe9420-52e8-489e-8ab4-8131d4e99de9" xlink:to="loc_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent_84c34622-5158-426b-8742-da102529385d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_322850e4-0670-456a-8320-c5693d80591c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bfbe9420-52e8-489e-8ab4-8131d4e99de9" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_322850e4-0670-456a-8320-c5693d80591c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_846ddce6-73f3-4619-8a16-e4e9ed287698" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bfbe9420-52e8-489e-8ab4-8131d4e99de9" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_846ddce6-73f3-4619-8a16-e4e9ed287698" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_IncreaseDecreaseInOperatingLeaseLiabilities_cdcb98c0-b250-4448-96b1-560ee3d14a07" xlink:href="vrna-20221231.xsd#vrna_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bfbe9420-52e8-489e-8ab4-8131d4e99de9" xlink:to="loc_vrna_IncreaseDecreaseInOperatingLeaseLiabilities_cdcb98c0-b250-4448-96b1-560ee3d14a07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_4cb5cfc7-3a70-4179-bbe7-50a4fdaa02aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bfbe9420-52e8-489e-8ab4-8131d4e99de9" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_4cb5cfc7-3a70-4179-bbe7-50a4fdaa02aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_ba285aed-3adc-4677-a385-f09bc10f9801" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bfbe9420-52e8-489e-8ab4-8131d4e99de9" xlink:to="loc_us-gaap_ShareBasedCompensation_ba285aed-3adc-4677-a385-f09bc10f9801" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ed18743e-9072-4629-b9b1-740b8fecb170" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bfbe9420-52e8-489e-8ab4-8131d4e99de9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ed18743e-9072-4629-b9b1-740b8fecb170" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_618759bc-f91f-4070-be49-8203986749f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_633d2f6a-0150-467b-980a-788a71084686" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_618759bc-f91f-4070-be49-8203986749f2" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_633d2f6a-0150-467b-980a-788a71084686" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d65cbfb4-a603-4953-99b9-778b8f503f66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6bb4a35f-f16d-429f-ac53-7e2b180f84ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d65cbfb4-a603-4953-99b9-778b8f503f66" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6bb4a35f-f16d-429f-ac53-7e2b180f84ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_783be24c-993e-49bb-9334-23adb2a15be2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d65cbfb4-a603-4953-99b9-778b8f503f66" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_783be24c-993e-49bb-9334-23adb2a15be2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9fde8b8f-38b1-4f0f-9219-765d0619123d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d65cbfb4-a603-4953-99b9-778b8f503f66" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9fde8b8f-38b1-4f0f-9219-765d0619123d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_450017db-98c9-437f-9ded-5cb0f8847cb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d65cbfb4-a603-4953-99b9-778b8f503f66" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_450017db-98c9-437f-9ded-5cb0f8847cb9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/PrepaidexpensesDetails" xlink:type="simple" xlink:href="vrna-20221231.xsd#PrepaidexpensesDetails"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/PrepaidexpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_41840cd3-0f7c-466a-91c1-2a1f0d7a8e74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_4a4acaf3-98af-48a9-bbee-6bc91d644562" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_41840cd3-0f7c-466a-91c1-2a1f0d7a8e74" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_4a4acaf3-98af-48a9-bbee-6bc91d644562" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_PrepaidResearchAndDevelopmentFeesCurrent_c11175d7-b410-483d-8d25-0271cfd6923d" xlink:href="vrna-20221231.xsd#vrna_PrepaidResearchAndDevelopmentFeesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_41840cd3-0f7c-466a-91c1-2a1f0d7a8e74" xlink:to="loc_vrna_PrepaidResearchAndDevelopmentFeesCurrent_c11175d7-b410-483d-8d25-0271cfd6923d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_c14f6b5d-83ee-4bec-8bf7-4f43b120bc57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_41840cd3-0f7c-466a-91c1-2a1f0d7a8e74" xlink:to="loc_us-gaap_PrepaidInsurance_c14f6b5d-83ee-4bec-8bf7-4f43b120bc57" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/PropertyleasesMaturityDetails" xlink:type="simple" xlink:href="vrna-20221231.xsd#PropertyleasesMaturityDetails"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/PropertyleasesMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8bd74a7e-e81a-4af5-8d3c-8d1d8aa115ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c33c988a-66b8-488e-aa5c-428393c5be4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8bd74a7e-e81a-4af5-8d3c-8d1d8aa115ae" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c33c988a-66b8-488e-aa5c-428393c5be4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_ae11aeef-4fc3-48aa-8d20-51f86699da0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8bd74a7e-e81a-4af5-8d3c-8d1d8aa115ae" xlink:to="loc_us-gaap_OperatingLeaseLiability_ae11aeef-4fc3-48aa-8d20-51f86699da0b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/PropertyleasesMaturityDetails_1" xlink:type="simple" xlink:href="vrna-20221231.xsd#PropertyleasesMaturityDetails_1"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/PropertyleasesMaturityDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b53833c9-5cde-4623-b578-3014321cbafd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ee78985d-7b63-45fe-8ce3-14adeef61876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b53833c9-5cde-4623-b578-3014321cbafd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ee78985d-7b63-45fe-8ce3-14adeef61876" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_aaedc542-510c-4579-920d-e00a121eb1e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b53833c9-5cde-4623-b578-3014321cbafd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_aaedc542-510c-4579-920d-e00a121eb1e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_50ec2cfc-8e96-4ca2-8d3a-3e46b893253e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b53833c9-5cde-4623-b578-3014321cbafd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_50ec2cfc-8e96-4ca2-8d3a-3e46b893253e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/AccruedexpensesDetails" xlink:type="simple" xlink:href="vrna-20221231.xsd#AccruedexpensesDetails"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/AccruedexpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_0fc5bbc1-90d6-408d-bf20-92e42b27eed4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent_bebe6a60-cc9e-472c-9481-c08ebad1d617" xlink:href="vrna-20221231.xsd#vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_0fc5bbc1-90d6-408d-bf20-92e42b27eed4" xlink:to="loc_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent_bebe6a60-cc9e-472c-9481-c08ebad1d617" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AccruedResearchAndDevelopmentFeesCurrent_cfc221ed-a6f0-45e2-b4c3-03fbeef813e5" xlink:href="vrna-20221231.xsd#vrna_AccruedResearchAndDevelopmentFeesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_0fc5bbc1-90d6-408d-bf20-92e42b27eed4" xlink:to="loc_vrna_AccruedResearchAndDevelopmentFeesCurrent_cfc221ed-a6f0-45e2-b4c3-03fbeef813e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d222f445-0590-40e8-a342-ae58af85355e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_0fc5bbc1-90d6-408d-bf20-92e42b27eed4" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d222f445-0590-40e8-a342-ae58af85355e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/TaxationLossBeforeTaxDetails" xlink:type="simple" xlink:href="vrna-20221231.xsd#TaxationLossBeforeTaxDetails"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/TaxationLossBeforeTaxDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5bbe77df-1dbe-46bf-8bef-736822126351" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_cf386ade-9156-46e6-a00c-becd5669a617" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5bbe77df-1dbe-46bf-8bef-736822126351" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_cf386ade-9156-46e6-a00c-becd5669a617" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_913b877e-fed8-439f-b882-ee2566ad2478" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5bbe77df-1dbe-46bf-8bef-736822126351" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_913b877e-fed8-439f-b882-ee2566ad2478" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/TaxationTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="vrna-20221231.xsd#TaxationTaxExpenseBenefitDetails"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/TaxationTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d17301ba-1076-49d0-93c6-873ea2c91763" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_f3d52001-beb7-4052-bf83-e71eed2c5c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d17301ba-1076-49d0-93c6-873ea2c91763" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_f3d52001-beb7-4052-bf83-e71eed2c5c9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_29e4e54d-e7d7-4655-ae99-89511a549d63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d17301ba-1076-49d0-93c6-873ea2c91763" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_29e4e54d-e7d7-4655-ae99-89511a549d63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c6b0484c-b581-4aa7-8e04-f568a1fef517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e215bb88-a89f-4d4b-bcd2-c604eea6804a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_c6b0484c-b581-4aa7-8e04-f568a1fef517" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e215bb88-a89f-4d4b-bcd2-c604eea6804a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_35b1f73f-5a27-4633-90ba-3040b497ce30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_c6b0484c-b581-4aa7-8e04-f568a1fef517" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_35b1f73f-5a27-4633-90ba-3040b497ce30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5af887d4-9180-4de6-91ea-6d5a0cd7fa9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_85e9e4f3-205a-40e8-b5c4-4d98a1507ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5af887d4-9180-4de6-91ea-6d5a0cd7fa9b" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_85e9e4f3-205a-40e8-b5c4-4d98a1507ad1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_17c5fcdf-a3c8-4b16-affc-1bf7799b156a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5af887d4-9180-4de6-91ea-6d5a0cd7fa9b" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_17c5fcdf-a3c8-4b16-affc-1bf7799b156a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/TaxationReconciliationofStatutoryRateDetails" xlink:type="simple" xlink:href="vrna-20221231.xsd#TaxationReconciliationofStatutoryRateDetails"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/TaxationReconciliationofStatutoryRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa8770f6-4955-4758-88d1-7cf4dd8113a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_EffectiveIncomeTaxRateReconciliationCapitalAllowancesPercent_592e4e6d-12a7-40dc-9d18-b569aa15a51c" xlink:href="vrna-20221231.xsd#vrna_EffectiveIncomeTaxRateReconciliationCapitalAllowancesPercent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa8770f6-4955-4758-88d1-7cf4dd8113a5" xlink:to="loc_vrna_EffectiveIncomeTaxRateReconciliationCapitalAllowancesPercent_592e4e6d-12a7-40dc-9d18-b569aa15a51c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_ce2f35b5-408d-492d-941a-bea5c30e177e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa8770f6-4955-4758-88d1-7cf4dd8113a5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_ce2f35b5-408d-492d-941a-bea5c30e177e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_2118d175-02be-42e0-9cb1-e88acbfa0b21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa8770f6-4955-4758-88d1-7cf4dd8113a5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_2118d175-02be-42e0-9cb1-e88acbfa0b21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_af5f1ade-6e7a-4a59-91cf-a2556d17242a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa8770f6-4955-4758-88d1-7cf4dd8113a5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_af5f1ade-6e7a-4a59-91cf-a2556d17242a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c9bbc105-e052-441e-9fda-1e3f40f7f074" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa8770f6-4955-4758-88d1-7cf4dd8113a5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c9bbc105-e052-441e-9fda-1e3f40f7f074" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_10f23a98-04df-4837-a332-74f4dce831a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa8770f6-4955-4758-88d1-7cf4dd8113a5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_10f23a98-04df-4837-a332-74f4dce831a9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="vrna-20221231.xsd#TaxationDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_30aca4f2-f729-4271-9a05-7a672cb723f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_1670e1bd-035b-4a76-8222-1d24f7b2e6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_30aca4f2-f729-4271-9a05-7a672cb723f0" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_1670e1bd-035b-4a76-8222-1d24f7b2e6b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0708e5fa-b424-4158-972c-c936a17618a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_30aca4f2-f729-4271-9a05-7a672cb723f0" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0708e5fa-b424-4158-972c-c936a17618a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_4e39fcfc-b4f7-42be-9d07-f623457ad2ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_30aca4f2-f729-4271-9a05-7a672cb723f0" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_4e39fcfc-b4f7-42be-9d07-f623457ad2ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0832f713-4fac-4573-abfc-6fea573c8558" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_30aca4f2-f729-4271-9a05-7a672cb723f0" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0832f713-4fac-4573-abfc-6fea573c8558" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_c2d01df1-e36b-480c-882e-570d856df670" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_34a55aa4-5370-4837-9c94-fb5c879cb2e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_c2d01df1-e36b-480c-882e-570d856df670" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_34a55aa4-5370-4837-9c94-fb5c879cb2e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_56b4a804-ab04-46dc-bd64-778c605de4be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_c2d01df1-e36b-480c-882e-570d856df670" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_56b4a804-ab04-46dc-bd64-778c605de4be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_8ab61a63-d376-4e11-8cbb-74fc935f1578" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_c2d01df1-e36b-480c-882e-570d856df670" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_8ab61a63-d376-4e11-8cbb-74fc935f1578" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_059bfcba-ecfc-4304-b8bb-094a89cc0ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DeferredTaxLiabilitiesContingentLiability_b5e6cd29-3184-414f-9a77-3393e9af1b63" xlink:href="vrna-20221231.xsd#vrna_DeferredTaxLiabilitiesContingentLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_059bfcba-ecfc-4304-b8bb-094a89cc0ed0" xlink:to="loc_vrna_DeferredTaxLiabilitiesContingentLiability_b5e6cd29-3184-414f-9a77-3393e9af1b63" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>vrna-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:3c4b6351-9dd7-43ec-8a74-8bad3a93c534,g:ba5c393f-9b46-4696-9211-0bc9a20ff330-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="vrna-20221231.xsd#ConsolidatedStatementsofShareholdersEquity"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="extended" id="i3b32ae20e3cd4dffadb3be02937bb847_ConsolidatedStatementsofShareholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2398be22-2d77-4bc7-9f9a-38685c055458" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c80a78c1-7a69-47ed-906b-ba53146f242f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2398be22-2d77-4bc7-9f9a-38685c055458" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c80a78c1-7a69-47ed-906b-ba53146f242f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_384443b2-b7ec-4234-b6f5-b4d6dfb41ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c80a78c1-7a69-47ed-906b-ba53146f242f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_384443b2-b7ec-4234-b6f5-b4d6dfb41ed1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_da1e5bb0-1b35-4887-b287-ffa5a055e353" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c80a78c1-7a69-47ed-906b-ba53146f242f" xlink:to="loc_us-gaap_StockholdersEquity_da1e5bb0-1b35-4887-b287-ffa5a055e353" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c49005bf-9086-40de-a85a-e051aff341eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c80a78c1-7a69-47ed-906b-ba53146f242f" xlink:to="loc_us-gaap_NetIncomeLoss_c49005bf-9086-40de-a85a-e051aff341eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_68e895bc-024b-4378-adf9-f74cae1017b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c80a78c1-7a69-47ed-906b-ba53146f242f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_68e895bc-024b-4378-adf9-f74cae1017b2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2db586b5-eee0-4cde-9323-efc1b75f5965" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c80a78c1-7a69-47ed-906b-ba53146f242f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2db586b5-eee0-4cde-9323-efc1b75f5965" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_b830694e-2cba-4052-9192-a1893f061f90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c80a78c1-7a69-47ed-906b-ba53146f242f" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_b830694e-2cba-4052-9192-a1893f061f90" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_7a0b9cb5-c056-450a-ad49-03628dd586d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c80a78c1-7a69-47ed-906b-ba53146f242f" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_7a0b9cb5-c056-450a-ad49-03628dd586d1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_5316a04f-899e-497f-a6a1-43f84e9e347e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c80a78c1-7a69-47ed-906b-ba53146f242f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_5316a04f-899e-497f-a6a1-43f84e9e347e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_09e8fe44-6df3-4d41-b62c-c38050e10310" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c80a78c1-7a69-47ed-906b-ba53146f242f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_09e8fe44-6df3-4d41-b62c-c38050e10310" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2fc92f1c-5410-4746-a260-f18b9b0d9a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c80a78c1-7a69-47ed-906b-ba53146f242f" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2fc92f1c-5410-4746-a260-f18b9b0d9a6d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_e48e8fb3-edd1-4dc6-944a-f0f01cead9cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c80a78c1-7a69-47ed-906b-ba53146f242f" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_e48e8fb3-edd1-4dc6-944a-f0f01cead9cc" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation_123778a1-a620-4c88-80d4-02d4898e31bd" xlink:href="vrna-20221231.xsd#vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c80a78c1-7a69-47ed-906b-ba53146f242f" xlink:to="loc_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation_123778a1-a620-4c88-80d4-02d4898e31bd" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_13d97d2b-ffb7-4a2a-88ae-ee4bfb2eb1e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_48f4481c-3e0e-4437-bc78-be284817604b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ec43c86c-f8f9-4bc8-ac75-76d503c86fca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2398be22-2d77-4bc7-9f9a-38685c055458" xlink:to="loc_us-gaap_StatementTable_ec43c86c-f8f9-4bc8-ac75-76d503c86fca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d5dc533c-9206-455e-90b7-7cfd8f350fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ec43c86c-f8f9-4bc8-ac75-76d503c86fca" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d5dc533c-9206-455e-90b7-7cfd8f350fe4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d5dc533c-9206-455e-90b7-7cfd8f350fe4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d5dc533c-9206-455e-90b7-7cfd8f350fe4" xlink:to="loc_us-gaap_EquityComponentDomain_d5dc533c-9206-455e-90b7-7cfd8f350fe4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a5cbfc17-cd24-4244-9351-d8a331518197" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d5dc533c-9206-455e-90b7-7cfd8f350fe4" xlink:to="loc_us-gaap_EquityComponentDomain_a5cbfc17-cd24-4244-9351-d8a331518197" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c78f41ea-11c0-4408-891e-a7d6deaaf4aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a5cbfc17-cd24-4244-9351-d8a331518197" xlink:to="loc_us-gaap_CommonStockMember_c78f41ea-11c0-4408-891e-a7d6deaaf4aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_8a896888-ed0d-48f0-9300-ba2231c7efdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a5cbfc17-cd24-4244-9351-d8a331518197" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_8a896888-ed0d-48f0-9300-ba2231c7efdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_3a2d6e86-8a42-4032-a8e5-aed599901c26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a5cbfc17-cd24-4244-9351-d8a331518197" xlink:to="loc_us-gaap_TreasuryStockMember_3a2d6e86-8a42-4032-a8e5-aed599901c26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_94ab9181-c10b-4849-9a2c-e7cecf1aa5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a5cbfc17-cd24-4244-9351-d8a331518197" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_94ab9181-c10b-4849-9a2c-e7cecf1aa5c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d40bf9cf-ab6f-44c4-8f24-ec7487f9ac0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a5cbfc17-cd24-4244-9351-d8a331518197" xlink:to="loc_us-gaap_RetainedEarningsMember_d40bf9cf-ab6f-44c4-8f24-ec7487f9ac0c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_4215e52b-2e5f-4fdf-aefa-4d0b8eed1f35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ec43c86c-f8f9-4bc8-ac75-76d503c86fca" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_4215e52b-2e5f-4fdf-aefa-4d0b8eed1f35" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4215e52b-2e5f-4fdf-aefa-4d0b8eed1f35_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4215e52b-2e5f-4fdf-aefa-4d0b8eed1f35" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4215e52b-2e5f-4fdf-aefa-4d0b8eed1f35_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_73a0f71b-6b02-4890-a587-92988b4ac9b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4215e52b-2e5f-4fdf-aefa-4d0b8eed1f35" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_73a0f71b-6b02-4890-a587-92988b4ac9b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AtTheMarketSalesAgreementMember_2dd6b799-05e6-429b-a0e5-b0f470c78150" xlink:href="vrna-20221231.xsd#vrna_AtTheMarketSalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_73a0f71b-6b02-4890-a587-92988b4ac9b2" xlink:to="loc_vrna_AtTheMarketSalesAgreementMember_2dd6b799-05e6-429b-a0e5-b0f470c78150" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_PublicStockOfferingMember_a43b91c7-8285-44a4-8a24-97d2073746f8" xlink:href="vrna-20221231.xsd#vrna_PublicStockOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_73a0f71b-6b02-4890-a587-92988b4ac9b2" xlink:to="loc_vrna_PublicStockOfferingMember_a43b91c7-8285-44a4-8a24-97d2073746f8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://veronapharma.com/role/OrganizationanddescriptionofbusinessoperationsDetails" xlink:type="simple" xlink:href="vrna-20221231.xsd#OrganizationanddescriptionofbusinessoperationsDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/OrganizationanddescriptionofbusinessoperationsDetails" xlink:type="extended" id="ic58bca681636444ca3303a7f21ff1ff9_OrganizationanddescriptionofbusinessoperationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_b360c39a-903a-43e8-b114-3e0e0f34d131" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2fa0bf6d-dba7-438d-9ef9-6fa5af4eb4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b360c39a-903a-43e8-b114-3e0e0f34d131" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2fa0bf6d-dba7-438d-9ef9-6fa5af4eb4e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SaleOfStockMaximumAggregateOfferingPrice_df485adc-fed8-4778-ad95-d6443430b3a1" xlink:href="vrna-20221231.xsd#vrna_SaleOfStockMaximumAggregateOfferingPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b360c39a-903a-43e8-b114-3e0e0f34d131" xlink:to="loc_vrna_SaleOfStockMaximumAggregateOfferingPrice_df485adc-fed8-4778-ad95-d6443430b3a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8aee0378-397c-42e9-8ce8-f0759b1ef1d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b360c39a-903a-43e8-b114-3e0e0f34d131" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8aee0378-397c-42e9-8ce8-f0759b1ef1d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingDepositoryReceiptRatio_dcff0dbd-375e-4d29-a5b2-7bac7f337701" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityListingDepositoryReceiptRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b360c39a-903a-43e8-b114-3e0e0f34d131" xlink:to="loc_dei_EntityListingDepositoryReceiptRatio_dcff0dbd-375e-4d29-a5b2-7bac7f337701" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_a47aa578-9b94-4c36-813a-ba97ee803d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b360c39a-903a-43e8-b114-3e0e0f34d131" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_a47aa578-9b94-4c36-813a-ba97ee803d0e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_ef9e1507-649b-4636-aca1-49e46afe911a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b360c39a-903a-43e8-b114-3e0e0f34d131" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_ef9e1507-649b-4636-aca1-49e46afe911a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_18d3e619-c440-43de-909a-db99ea986097" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b360c39a-903a-43e8-b114-3e0e0f34d131" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_18d3e619-c440-43de-909a-db99ea986097" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_f8f14148-2462-491d-99d6-c8c8ba357646" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b360c39a-903a-43e8-b114-3e0e0f34d131" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_f8f14148-2462-491d-99d6-c8c8ba357646" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_bf0ac5c1-d8e1-4aba-804e-07f230c9ca9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b360c39a-903a-43e8-b114-3e0e0f34d131" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_bf0ac5c1-d8e1-4aba-804e-07f230c9ca9a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_CommonStockSharesAvailableForSaleValue_6b5f736b-ad73-4772-8668-6326afe1b03f" xlink:href="vrna-20221231.xsd#vrna_CommonStockSharesAvailableForSaleValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b360c39a-903a-43e8-b114-3e0e0f34d131" xlink:to="loc_vrna_CommonStockSharesAvailableForSaleValue_6b5f736b-ad73-4772-8668-6326afe1b03f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_41428f2e-b6b0-4d30-acb7-38b90d6fb99a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_b360c39a-903a-43e8-b114-3e0e0f34d131" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_41428f2e-b6b0-4d30-acb7-38b90d6fb99a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3fed211f-cb3a-4b52-8e15-df5a9c42d9d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_41428f2e-b6b0-4d30-acb7-38b90d6fb99a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3fed211f-cb3a-4b52-8e15-df5a9c42d9d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3fed211f-cb3a-4b52-8e15-df5a9c42d9d7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3fed211f-cb3a-4b52-8e15-df5a9c42d9d7" xlink:to="loc_us-gaap_ClassOfStockDomain_3fed211f-cb3a-4b52-8e15-df5a9c42d9d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_852b57da-0f9a-4d4c-a630-44b94db55667" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3fed211f-cb3a-4b52-8e15-df5a9c42d9d7" xlink:to="loc_us-gaap_ClassOfStockDomain_852b57da-0f9a-4d4c-a630-44b94db55667" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AmericanDepositorySharesMember_552814fe-882b-4247-a95b-5a113e4f9ae2" xlink:href="vrna-20221231.xsd#vrna_AmericanDepositorySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_852b57da-0f9a-4d4c-a630-44b94db55667" xlink:to="loc_vrna_AmericanDepositorySharesMember_552814fe-882b-4247-a95b-5a113e4f9ae2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_10b36a19-7533-4efb-aec8-e338a0fce9b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_41428f2e-b6b0-4d30-acb7-38b90d6fb99a" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_10b36a19-7533-4efb-aec8-e338a0fce9b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_10b36a19-7533-4efb-aec8-e338a0fce9b3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_10b36a19-7533-4efb-aec8-e338a0fce9b3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_10b36a19-7533-4efb-aec8-e338a0fce9b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1e4a73c7-39c1-45bd-9ac4-340220463273" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_10b36a19-7533-4efb-aec8-e338a0fce9b3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1e4a73c7-39c1-45bd-9ac4-340220463273" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_PublicStockOfferingMember_ddfa8f0d-aa4c-43b1-9965-a67c93005022" xlink:href="vrna-20221231.xsd#vrna_PublicStockOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1e4a73c7-39c1-45bd-9ac4-340220463273" xlink:to="loc_vrna_PublicStockOfferingMember_ddfa8f0d-aa4c-43b1-9965-a67c93005022" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_08a15f36-576f-4434-9456-ca01cde89c75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1e4a73c7-39c1-45bd-9ac4-340220463273" xlink:to="loc_us-gaap_OverAllotmentOptionMember_08a15f36-576f-4434-9456-ca01cde89c75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_d305de64-e467-4504-9156-21245f74dc61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_41428f2e-b6b0-4d30-acb7-38b90d6fb99a" xlink:to="loc_us-gaap_CreditFacilityAxis_d305de64-e467-4504-9156-21245f74dc61" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_d305de64-e467-4504-9156-21245f74dc61_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_d305de64-e467-4504-9156-21245f74dc61" xlink:to="loc_us-gaap_CreditFacilityDomain_d305de64-e467-4504-9156-21245f74dc61_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_cb680267-b54a-4718-99ca-f5a0d235befc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_d305de64-e467-4504-9156-21245f74dc61" xlink:to="loc_us-gaap_CreditFacilityDomain_cb680267-b54a-4718-99ca-f5a0d235befc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_0bb169cc-867a-4641-85e2-44790876abaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_cb680267-b54a-4718-99ca-f5a0d235befc" xlink:to="loc_us-gaap_LineOfCreditMember_0bb169cc-867a-4641-85e2-44790876abaf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a94fd374-476e-49dd-b41d-bce0bd8c58a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_41428f2e-b6b0-4d30-acb7-38b90d6fb99a" xlink:to="loc_us-gaap_DebtInstrumentAxis_a94fd374-476e-49dd-b41d-bce0bd8c58a8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a94fd374-476e-49dd-b41d-bce0bd8c58a8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_a94fd374-476e-49dd-b41d-bce0bd8c58a8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a94fd374-476e-49dd-b41d-bce0bd8c58a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_94096699-cf2b-41d5-95da-0aa673f5d4bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_a94fd374-476e-49dd-b41d-bce0bd8c58a8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_94096699-cf2b-41d5-95da-0aa673f5d4bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_OxfordTermLoanMember_950b45ae-2e86-4fb6-9437-fd0778d91cf7" xlink:href="vrna-20221231.xsd#vrna_OxfordTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_94096699-cf2b-41d5-95da-0aa673f5d4bf" xlink:to="loc_vrna_OxfordTermLoanMember_950b45ae-2e86-4fb6-9437-fd0778d91cf7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TermLoanFacilityMember_664b41c3-535d-4bb9-ad03-fbfcdeb91c86" xlink:href="vrna-20221231.xsd#vrna_TermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_94096699-cf2b-41d5-95da-0aa673f5d4bf" xlink:to="loc_vrna_TermLoanFacilityMember_664b41c3-535d-4bb9-ad03-fbfcdeb91c86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3d6b17f8-d621-4ba3-811f-b0a43dcba166" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_41428f2e-b6b0-4d30-acb7-38b90d6fb99a" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_3d6b17f8-d621-4ba3-811f-b0a43dcba166" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3d6b17f8-d621-4ba3-811f-b0a43dcba166_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3d6b17f8-d621-4ba3-811f-b0a43dcba166" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3d6b17f8-d621-4ba3-811f-b0a43dcba166_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fa14d024-622e-4537-9c3d-d85b8a9f2745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3d6b17f8-d621-4ba3-811f-b0a43dcba166" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fa14d024-622e-4537-9c3d-d85b8a9f2745" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_aa0ff32d-fb58-4762-8e3c-5ba2e69cf4d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_fa14d024-622e-4537-9c3d-d85b8a9f2745" xlink:to="loc_us-gaap_SubsequentEventMember_aa0ff32d-fb58-4762-8e3c-5ba2e69cf4d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6b863285-abf7-4a6c-944c-3d4c3ad50724" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_41428f2e-b6b0-4d30-acb7-38b90d6fb99a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6b863285-abf7-4a6c-944c-3d4c3ad50724" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6b863285-abf7-4a6c-944c-3d4c3ad50724_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6b863285-abf7-4a6c-944c-3d4c3ad50724" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6b863285-abf7-4a6c-944c-3d4c3ad50724_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b57b6711-5e64-41fa-9f3b-a9813904d24c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6b863285-abf7-4a6c-944c-3d4c3ad50724" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b57b6711-5e64-41fa-9f3b-a9813904d24c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_5eaeb449-7789-4528-b228-fa997de22106" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b57b6711-5e64-41fa-9f3b-a9813904d24c" xlink:to="loc_us-gaap_SecuredDebtMember_5eaeb449-7789-4528-b228-fa997de22106" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails" xlink:type="simple" xlink:href="vrna-20221231.xsd#BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails" xlink:type="extended" id="ic6c4985b540d4cde81d799ff3b639c67_BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a0351727-12ff-4500-8b4d-87dd63b39f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_bdadb038-e644-4652-a2a7-01a59e61cb08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a0351727-12ff-4500-8b4d-87dd63b39f6d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_bdadb038-e644-4652-a2a7-01a59e61cb08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_0396b9ea-ae01-4036-a2d2-c45eabf1b50e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a0351727-12ff-4500-8b4d-87dd63b39f6d" xlink:to="loc_us-gaap_NumberOfOperatingSegments_0396b9ea-ae01-4036-a2d2-c45eabf1b50e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_665653b3-54da-4edb-972f-ce06b22011a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a0351727-12ff-4500-8b4d-87dd63b39f6d" xlink:to="loc_us-gaap_NumberOfReportableSegments_665653b3-54da-4edb-972f-ce06b22011a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_StockIssuedDuringPeriodSharesHeldInTreasury_d501818e-785d-4e3f-b32a-ec7c268c1676" xlink:href="vrna-20221231.xsd#vrna_StockIssuedDuringPeriodSharesHeldInTreasury"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a0351727-12ff-4500-8b4d-87dd63b39f6d" xlink:to="loc_vrna_StockIssuedDuringPeriodSharesHeldInTreasury_d501818e-785d-4e3f-b32a-ec7c268c1676" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares_3eb18a62-f5f4-43ad-a13a-2fc4b84ade8c" xlink:href="vrna-20221231.xsd#vrna_StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a0351727-12ff-4500-8b4d-87dd63b39f6d" xlink:to="loc_vrna_StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares_3eb18a62-f5f4-43ad-a13a-2fc4b84ade8c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_85b7a08c-a81e-4841-8ef4-9676966ebbaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a0351727-12ff-4500-8b4d-87dd63b39f6d" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_85b7a08c-a81e-4841-8ef4-9676966ebbaf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8dd32f47-c7ca-4982-8491-b7af99a0e194" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_85b7a08c-a81e-4841-8ef4-9676966ebbaf" xlink:to="loc_srt_RangeAxis_8dd32f47-c7ca-4982-8491-b7af99a0e194" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8dd32f47-c7ca-4982-8491-b7af99a0e194_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8dd32f47-c7ca-4982-8491-b7af99a0e194" xlink:to="loc_srt_RangeMember_8dd32f47-c7ca-4982-8491-b7af99a0e194_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e88efda1-88bf-4626-b141-a50e77190dc5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8dd32f47-c7ca-4982-8491-b7af99a0e194" xlink:to="loc_srt_RangeMember_e88efda1-88bf-4626-b141-a50e77190dc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_81f87c36-d551-4ffc-ac80-9b251b0581e2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e88efda1-88bf-4626-b141-a50e77190dc5" xlink:to="loc_srt_MinimumMember_81f87c36-d551-4ffc-ac80-9b251b0581e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_13868d26-3b35-4c79-9b44-1afec1f534ac" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e88efda1-88bf-4626-b141-a50e77190dc5" xlink:to="loc_srt_MaximumMember_13868d26-3b35-4c79-9b44-1afec1f534ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fa9411b3-d4ac-432b-b103-cee08620f341" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_85b7a08c-a81e-4841-8ef4-9676966ebbaf" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fa9411b3-d4ac-432b-b103-cee08620f341" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fa9411b3-d4ac-432b-b103-cee08620f341_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fa9411b3-d4ac-432b-b103-cee08620f341" xlink:to="loc_us-gaap_EquityComponentDomain_fa9411b3-d4ac-432b-b103-cee08620f341_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_391675d6-f50d-40d7-b349-c2fb7f5ca520" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fa9411b3-d4ac-432b-b103-cee08620f341" xlink:to="loc_us-gaap_EquityComponentDomain_391675d6-f50d-40d7-b349-c2fb7f5ca520" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f38aec1f-85df-42fb-9dcf-5ffb9ae201fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_391675d6-f50d-40d7-b349-c2fb7f5ca520" xlink:to="loc_us-gaap_CommonStockMember_f38aec1f-85df-42fb-9dcf-5ffb9ae201fa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://veronapharma.com/role/PropertyleasesNarrativeDetails" xlink:type="simple" xlink:href="vrna-20221231.xsd#PropertyleasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/PropertyleasesNarrativeDetails" xlink:type="extended" id="i9515657dd86d4c0e87577a2b9c2f8052_PropertyleasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_3769f4e2-0cfb-41c4-bce4-32bf23ab3ff1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_268156cb-73ba-4fcd-baeb-e31b5b19ed20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3769f4e2-0cfb-41c4-bce4-32bf23ab3ff1" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_268156cb-73ba-4fcd-baeb-e31b5b19ed20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_1194b945-0289-441e-93fc-9345914c1dce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3769f4e2-0cfb-41c4-bce4-32bf23ab3ff1" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_1194b945-0289-441e-93fc-9345914c1dce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_4b3db9b5-3642-4dcf-b74c-a209399e703c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3769f4e2-0cfb-41c4-bce4-32bf23ab3ff1" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_4b3db9b5-3642-4dcf-b74c-a209399e703c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_319e2745-ba53-4589-9bec-7cb865e78d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3769f4e2-0cfb-41c4-bce4-32bf23ab3ff1" xlink:to="loc_us-gaap_OperatingLeaseExpense_319e2745-ba53-4589-9bec-7cb865e78d6a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_c90e43fe-49a1-4175-825f-6e7c6bd992c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3769f4e2-0cfb-41c4-bce4-32bf23ab3ff1" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_c90e43fe-49a1-4175-825f-6e7c6bd992c4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e41ee588-e881-4a85-8f07-92c3517f7ccf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_c90e43fe-49a1-4175-825f-6e7c6bd992c4" xlink:to="loc_srt_StatementGeographicalAxis_e41ee588-e881-4a85-8f07-92c3517f7ccf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e41ee588-e881-4a85-8f07-92c3517f7ccf_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_e41ee588-e881-4a85-8f07-92c3517f7ccf" xlink:to="loc_srt_SegmentGeographicalDomain_e41ee588-e881-4a85-8f07-92c3517f7ccf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9cb55621-5699-40dd-8667-6b48b0aafe5b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_e41ee588-e881-4a85-8f07-92c3517f7ccf" xlink:to="loc_srt_SegmentGeographicalDomain_9cb55621-5699-40dd-8667-6b48b0aafe5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_LondonMember_9a0fae7d-7e4a-47ef-9b90-ca9424b38425" xlink:href="vrna-20221231.xsd#vrna_LondonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_9cb55621-5699-40dd-8667-6b48b0aafe5b" xlink:to="loc_vrna_LondonMember_9a0fae7d-7e4a-47ef-9b90-ca9424b38425" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_92f07ccc-05c2-481d-a54d-b53653c06afd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_c90e43fe-49a1-4175-825f-6e7c6bd992c4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_92f07ccc-05c2-481d-a54d-b53653c06afd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_92f07ccc-05c2-481d-a54d-b53653c06afd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_92f07ccc-05c2-481d-a54d-b53653c06afd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_92f07ccc-05c2-481d-a54d-b53653c06afd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5ac08799-06c3-4188-8f7d-fda712964853" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_92f07ccc-05c2-481d-a54d-b53653c06afd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5ac08799-06c3-4188-8f7d-fda712964853" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_5c3d50d6-5d3d-49ba-bc93-9a76dd2d8022" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5ac08799-06c3-4188-8f7d-fda712964853" xlink:to="loc_us-gaap_BuildingMember_5c3d50d6-5d3d-49ba-bc93-9a76dd2d8022" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://veronapharma.com/role/WarrantsFairValueAssumptionsDetails" xlink:type="simple" xlink:href="vrna-20221231.xsd#WarrantsFairValueAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/WarrantsFairValueAssumptionsDetails" xlink:type="extended" id="ic23032cbad3c49aea63068b63c1be284_WarrantsFairValueAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_161e0581-11c4-4305-a82e-f246a57997cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_f6623b6c-09bd-4f6c-b4ad-464132272a00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_161e0581-11c4-4305-a82e-f246a57997cc" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_f6623b6c-09bd-4f6c-b4ad-464132272a00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b0d46271-a326-4fc3-9ee9-875c7962af06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_161e0581-11c4-4305-a82e-f246a57997cc" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b0d46271-a326-4fc3-9ee9-875c7962af06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_6a1109f5-b5ae-423a-8b65-a8a6d3e5d66f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_161e0581-11c4-4305-a82e-f246a57997cc" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_6a1109f5-b5ae-423a-8b65-a8a6d3e5d66f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_b4ab26ca-c700-4159-9d91-c7be9ff9ba1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_161e0581-11c4-4305-a82e-f246a57997cc" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_b4ab26ca-c700-4159-9d91-c7be9ff9ba1b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_WarrantLiabilityCurrent_3f40adf7-c2ae-4585-9454-603bc124c09b" xlink:href="vrna-20221231.xsd#vrna_WarrantLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_161e0581-11c4-4305-a82e-f246a57997cc" xlink:to="loc_vrna_WarrantLiabilityCurrent_3f40adf7-c2ae-4585-9454-603bc124c09b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_6a261f91-6b29-41a5-a264-4bf48ae7a6b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_161e0581-11c4-4305-a82e-f246a57997cc" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_6a261f91-6b29-41a5-a264-4bf48ae7a6b7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_b9fcd5ea-6564-424f-9b19-78a597f90ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_6a261f91-6b29-41a5-a264-4bf48ae7a6b7" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_b9fcd5ea-6564-424f-9b19-78a597f90ab3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_b9fcd5ea-6564-424f-9b19-78a597f90ab3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_b9fcd5ea-6564-424f-9b19-78a597f90ab3" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_b9fcd5ea-6564-424f-9b19-78a597f90ab3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_0546a1fb-9d87-417d-a51c-6efae23595cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_b9fcd5ea-6564-424f-9b19-78a597f90ab3" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_0546a1fb-9d87-417d-a51c-6efae23595cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_8864f275-e62b-471b-b7ab-25be8930b3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0546a1fb-9d87-417d-a51c-6efae23595cc" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_8864f275-e62b-471b-b7ab-25be8930b3dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_MeasurementInputAnnualizedVolatilityMember_ba0fd1ab-8fb1-4ea7-a1ba-bed06ad49013" xlink:href="vrna-20221231.xsd#vrna_MeasurementInputAnnualizedVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0546a1fb-9d87-417d-a51c-6efae23595cc" xlink:to="loc_vrna_MeasurementInputAnnualizedVolatilityMember_ba0fd1ab-8fb1-4ea7-a1ba-bed06ad49013" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_56ced0d3-ec38-4289-b024-db9f957d4093" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0546a1fb-9d87-417d-a51c-6efae23595cc" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_56ced0d3-ec38-4289-b024-db9f957d4093" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://veronapharma.com/role/TermloanDetails" xlink:type="simple" xlink:href="vrna-20221231.xsd#TermloanDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/TermloanDetails" xlink:type="extended" id="i5acbbd12382746eca59e6b0d4d320193_TermloanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_d98f5fcf-10a8-43ce-b8b2-c38e8d3db0f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_49218764-56e6-44fa-a797-5be275d1f019" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d98f5fcf-10a8-43ce-b8b2-c38e8d3db0f3" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_49218764-56e6-44fa-a797-5be275d1f019" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_f84eaac4-b07c-4325-81c8-be0b2ad536a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d98f5fcf-10a8-43ce-b8b2-c38e8d3db0f3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_f84eaac4-b07c-4325-81c8-be0b2ad536a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_884bf0f0-645d-4992-9b4e-54e6f6b6a0e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d98f5fcf-10a8-43ce-b8b2-c38e8d3db0f3" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_884bf0f0-645d-4992-9b4e-54e6f6b6a0e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_LineOfCreditFacilityNumberOfLoanAdvances_5590b1f4-57d0-4df4-81ad-18be55aa6966" xlink:href="vrna-20221231.xsd#vrna_LineOfCreditFacilityNumberOfLoanAdvances"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d98f5fcf-10a8-43ce-b8b2-c38e8d3db0f3" xlink:to="loc_vrna_LineOfCreditFacilityNumberOfLoanAdvances_5590b1f4-57d0-4df4-81ad-18be55aa6966" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_c94ded21-8885-4242-b198-39d77d4d9650" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d98f5fcf-10a8-43ce-b8b2-c38e8d3db0f3" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_c94ded21-8885-4242-b198-39d77d4d9650" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_cb700fdb-316d-4e99-8488-19eaa9446c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d98f5fcf-10a8-43ce-b8b2-c38e8d3db0f3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_cb700fdb-316d-4e99-8488-19eaa9446c4d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentFinalPaymentPercentageOfPrincipalAmount_56660ed6-de0e-4ed5-aa0a-87aee2e1bb11" xlink:href="vrna-20221231.xsd#vrna_DebtInstrumentFinalPaymentPercentageOfPrincipalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d98f5fcf-10a8-43ce-b8b2-c38e8d3db0f3" xlink:to="loc_vrna_DebtInstrumentFinalPaymentPercentageOfPrincipalAmount_56660ed6-de0e-4ed5-aa0a-87aee2e1bb11" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentPrepaymentFeePercentage_5598d0fe-1b6b-4ce9-bfe0-8e7d60e0d796" xlink:href="vrna-20221231.xsd#vrna_DebtInstrumentPrepaymentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d98f5fcf-10a8-43ce-b8b2-c38e8d3db0f3" xlink:to="loc_vrna_DebtInstrumentPrepaymentFeePercentage_5598d0fe-1b6b-4ce9-bfe0-8e7d60e0d796" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_921ea9cf-1306-4119-aeb4-c8278d1278a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d98f5fcf-10a8-43ce-b8b2-c38e8d3db0f3" xlink:to="loc_us-gaap_DebtInstrumentTable_921ea9cf-1306-4119-aeb4-c8278d1278a0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a4033d07-ec22-420f-a005-8ca91cc5e00c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_921ea9cf-1306-4119-aeb4-c8278d1278a0" xlink:to="loc_us-gaap_DebtInstrumentAxis_a4033d07-ec22-420f-a005-8ca91cc5e00c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a4033d07-ec22-420f-a005-8ca91cc5e00c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_a4033d07-ec22-420f-a005-8ca91cc5e00c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a4033d07-ec22-420f-a005-8ca91cc5e00c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9b182c51-260f-4235-9e33-7f7ae2e0fae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_a4033d07-ec22-420f-a005-8ca91cc5e00c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9b182c51-260f-4235-9e33-7f7ae2e0fae2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TermLoanFacilityMember_98aedd30-0b8a-4c0d-8fa0-0134655ebfe0" xlink:href="vrna-20221231.xsd#vrna_TermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9b182c51-260f-4235-9e33-7f7ae2e0fae2" xlink:to="loc_vrna_TermLoanFacilityMember_98aedd30-0b8a-4c0d-8fa0-0134655ebfe0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TermBLoanMember_50f9243e-985c-40b9-9cbb-60ebd6df92a1" xlink:href="vrna-20221231.xsd#vrna_TermBLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9b182c51-260f-4235-9e33-7f7ae2e0fae2" xlink:to="loc_vrna_TermBLoanMember_50f9243e-985c-40b9-9cbb-60ebd6df92a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TermCLoanMember_858cf955-ea97-426b-a3d1-23094f9844e7" xlink:href="vrna-20221231.xsd#vrna_TermCLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9b182c51-260f-4235-9e33-7f7ae2e0fae2" xlink:to="loc_vrna_TermCLoanMember_858cf955-ea97-426b-a3d1-23094f9844e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_OxfordTermLoanMember_d89c4037-8278-4af7-ba00-ab3fc8e74c57" xlink:href="vrna-20221231.xsd#vrna_OxfordTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9b182c51-260f-4235-9e33-7f7ae2e0fae2" xlink:to="loc_vrna_OxfordTermLoanMember_d89c4037-8278-4af7-ba00-ab3fc8e74c57" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_OxfordTermALoanMember_6dc60ecf-aca0-4885-9aca-298d66333624" xlink:href="vrna-20221231.xsd#vrna_OxfordTermALoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9b182c51-260f-4235-9e33-7f7ae2e0fae2" xlink:to="loc_vrna_OxfordTermALoanMember_6dc60ecf-aca0-4885-9aca-298d66333624" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_OxfordTermBCDELoanMember_2c89f691-b7c5-4d1b-bc61-d15949a1b152" xlink:href="vrna-20221231.xsd#vrna_OxfordTermBCDELoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9b182c51-260f-4235-9e33-7f7ae2e0fae2" xlink:to="loc_vrna_OxfordTermBCDELoanMember_2c89f691-b7c5-4d1b-bc61-d15949a1b152" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_OxfordTermBLoanMember_ac67d703-6dcc-454b-8275-3f625cae9f1f" xlink:href="vrna-20221231.xsd#vrna_OxfordTermBLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9b182c51-260f-4235-9e33-7f7ae2e0fae2" xlink:to="loc_vrna_OxfordTermBLoanMember_ac67d703-6dcc-454b-8275-3f625cae9f1f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_OxfordTermCLoanMember_cfa6f4c6-9b50-4f9c-9a2b-477d06cf783b" xlink:href="vrna-20221231.xsd#vrna_OxfordTermCLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9b182c51-260f-4235-9e33-7f7ae2e0fae2" xlink:to="loc_vrna_OxfordTermCLoanMember_cfa6f4c6-9b50-4f9c-9a2b-477d06cf783b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_OxfordTermDLoanMember_147255ad-30ab-41fe-a08d-39b147d3de5e" xlink:href="vrna-20221231.xsd#vrna_OxfordTermDLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9b182c51-260f-4235-9e33-7f7ae2e0fae2" xlink:to="loc_vrna_OxfordTermDLoanMember_147255ad-30ab-41fe-a08d-39b147d3de5e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_OxfordTermELoanMember_f52dea48-d286-4ecd-969d-7ceedfb5b21d" xlink:href="vrna-20221231.xsd#vrna_OxfordTermELoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9b182c51-260f-4235-9e33-7f7ae2e0fae2" xlink:to="loc_vrna_OxfordTermELoanMember_f52dea48-d286-4ecd-969d-7ceedfb5b21d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_aaab26df-3719-4d22-9d72-1384bd2be762" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_921ea9cf-1306-4119-aeb4-c8278d1278a0" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_aaab26df-3719-4d22-9d72-1384bd2be762" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_aaab26df-3719-4d22-9d72-1384bd2be762_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_aaab26df-3719-4d22-9d72-1384bd2be762" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_aaab26df-3719-4d22-9d72-1384bd2be762_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d5268fc2-6ca8-4bfc-b501-f00b3a9ea6aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_aaab26df-3719-4d22-9d72-1384bd2be762" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d5268fc2-6ca8-4bfc-b501-f00b3a9ea6aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_39d874fb-5e4b-4092-8d49-d04562a960cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d5268fc2-6ca8-4bfc-b501-f00b3a9ea6aa" xlink:to="loc_us-gaap_SecuredDebtMember_39d874fb-5e4b-4092-8d49-d04562a960cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_856135b8-9ff3-4898-b21e-669d8e04c35e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_921ea9cf-1306-4119-aeb4-c8278d1278a0" xlink:to="loc_us-gaap_CreditFacilityAxis_856135b8-9ff3-4898-b21e-669d8e04c35e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_856135b8-9ff3-4898-b21e-669d8e04c35e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_856135b8-9ff3-4898-b21e-669d8e04c35e" xlink:to="loc_us-gaap_CreditFacilityDomain_856135b8-9ff3-4898-b21e-669d8e04c35e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_0eb4ac57-f9e8-40f4-bbb3-019cc700d426" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_856135b8-9ff3-4898-b21e-669d8e04c35e" xlink:to="loc_us-gaap_CreditFacilityDomain_0eb4ac57-f9e8-40f4-bbb3-019cc700d426" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_2b96a049-a110-4f81-82ba-14e0e896d93e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_0eb4ac57-f9e8-40f4-bbb3-019cc700d426" xlink:to="loc_us-gaap_LineOfCreditMember_2b96a049-a110-4f81-82ba-14e0e896d93e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_InterestRatePeriodAxis_c66d71a1-71ea-485d-aa59-5d8b5837df89" xlink:href="vrna-20221231.xsd#vrna_InterestRatePeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_921ea9cf-1306-4119-aeb4-c8278d1278a0" xlink:to="loc_vrna_InterestRatePeriodAxis_c66d71a1-71ea-485d-aa59-5d8b5837df89" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_InterestRatePeriodDomain_c66d71a1-71ea-485d-aa59-5d8b5837df89_default" xlink:href="vrna-20221231.xsd#vrna_InterestRatePeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_vrna_InterestRatePeriodAxis_c66d71a1-71ea-485d-aa59-5d8b5837df89" xlink:to="loc_vrna_InterestRatePeriodDomain_c66d71a1-71ea-485d-aa59-5d8b5837df89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_InterestRatePeriodDomain_66fefd97-23b1-4fd4-9719-3d95ade99528" xlink:href="vrna-20221231.xsd#vrna_InterestRatePeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_vrna_InterestRatePeriodAxis_c66d71a1-71ea-485d-aa59-5d8b5837df89" xlink:to="loc_vrna_InterestRatePeriodDomain_66fefd97-23b1-4fd4-9719-3d95ade99528" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentInterestRatePeriodOneMember_54511c18-80d6-41a9-b0f1-718a17dbc934" xlink:href="vrna-20221231.xsd#vrna_DebtInstrumentInterestRatePeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vrna_InterestRatePeriodDomain_66fefd97-23b1-4fd4-9719-3d95ade99528" xlink:to="loc_vrna_DebtInstrumentInterestRatePeriodOneMember_54511c18-80d6-41a9-b0f1-718a17dbc934" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentInterestRatePeriodTwoMember_3e4602f2-76ca-4b06-aa96-a1614d3de2dd" xlink:href="vrna-20221231.xsd#vrna_DebtInstrumentInterestRatePeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vrna_InterestRatePeriodDomain_66fefd97-23b1-4fd4-9719-3d95ade99528" xlink:to="loc_vrna_DebtInstrumentInterestRatePeriodTwoMember_3e4602f2-76ca-4b06-aa96-a1614d3de2dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c4ba488c-aa90-4c7f-b1ea-e624fc74d93c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_921ea9cf-1306-4119-aeb4-c8278d1278a0" xlink:to="loc_srt_RangeAxis_c4ba488c-aa90-4c7f-b1ea-e624fc74d93c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c4ba488c-aa90-4c7f-b1ea-e624fc74d93c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c4ba488c-aa90-4c7f-b1ea-e624fc74d93c" xlink:to="loc_srt_RangeMember_c4ba488c-aa90-4c7f-b1ea-e624fc74d93c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5f265139-8d00-4953-9b3a-0cab129373e2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c4ba488c-aa90-4c7f-b1ea-e624fc74d93c" xlink:to="loc_srt_RangeMember_5f265139-8d00-4953-9b3a-0cab129373e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_72663ea2-3de6-4bc2-9976-1175b2daf7eb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5f265139-8d00-4953-9b3a-0cab129373e2" xlink:to="loc_srt_MinimumMember_72663ea2-3de6-4bc2-9976-1175b2daf7eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_47ac4608-fe42-4873-be02-18f5dc7ca2cc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5f265139-8d00-4953-9b3a-0cab129373e2" xlink:to="loc_srt_MaximumMember_47ac4608-fe42-4873-be02-18f5dc7ca2cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_d6d2fe26-9c46-465f-ae3a-0a39597ef5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_921ea9cf-1306-4119-aeb4-c8278d1278a0" xlink:to="loc_us-gaap_VariableRateAxis_d6d2fe26-9c46-465f-ae3a-0a39597ef5f1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_d6d2fe26-9c46-465f-ae3a-0a39597ef5f1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_d6d2fe26-9c46-465f-ae3a-0a39597ef5f1" xlink:to="loc_us-gaap_VariableRateDomain_d6d2fe26-9c46-465f-ae3a-0a39597ef5f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_10d20749-fe46-4117-bbec-90dfea748d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_d6d2fe26-9c46-465f-ae3a-0a39597ef5f1" xlink:to="loc_us-gaap_VariableRateDomain_10d20749-fe46-4117-bbec-90dfea748d8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_bd36c65b-6e20-470d-aae1-b3c43454ddb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_10d20749-fe46-4117-bbec-90dfea748d8f" xlink:to="loc_us-gaap_BaseRateMember_bd36c65b-6e20-470d-aae1-b3c43454ddb2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://veronapharma.com/role/SignificantagreementsDetails" xlink:type="simple" xlink:href="vrna-20221231.xsd#SignificantagreementsDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/SignificantagreementsDetails" xlink:type="extended" id="id03b59d009434719a2a7a75068124707_SignificantagreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostLineItems_e56b8a70-fa70-4940-97fb-4e4d6818c5e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SublicensePayment_c3be259b-490c-4cf1-867d-e50778cb264c" xlink:href="vrna-20221231.xsd#vrna_SublicensePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_e56b8a70-fa70-4940-97fb-4e4d6818c5e2" xlink:to="loc_vrna_SublicensePayment_c3be259b-490c-4cf1-867d-e50778cb264c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SublicensePaymentEquityIssuanceThresholdTradingDays_7c0128ed-6ffe-4cad-9392-5549954811f8" xlink:href="vrna-20221231.xsd#vrna_SublicensePaymentEquityIssuanceThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_e56b8a70-fa70-4940-97fb-4e4d6818c5e2" xlink:to="loc_vrna_SublicensePaymentEquityIssuanceThresholdTradingDays_7c0128ed-6ffe-4cad-9392-5549954811f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_a9fb0e81-d20d-4c25-a2de-ed9c37eb0664" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_e56b8a70-fa70-4940-97fb-4e4d6818c5e2" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_a9fb0e81-d20d-4c25-a2de-ed9c37eb0664" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_1926118a-76dc-40c1-b1f8-acf2233d55aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_e56b8a70-fa70-4940-97fb-4e4d6818c5e2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_1926118a-76dc-40c1-b1f8-acf2233d55aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_EquityInterestReceivable_0406d368-a6b3-4e86-9f0c-0ac25785ddca" xlink:href="vrna-20221231.xsd#vrna_EquityInterestReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_e56b8a70-fa70-4940-97fb-4e4d6818c5e2" xlink:to="loc_vrna_EquityInterestReceivable_0406d368-a6b3-4e86-9f0c-0ac25785ddca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ContractWithCustomerFutureEligibleMilestonePayments_e02a5870-2c8a-49a6-8e30-d8eb4c158a5f" xlink:href="vrna-20221231.xsd#vrna_ContractWithCustomerFutureEligibleMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_e56b8a70-fa70-4940-97fb-4e4d6818c5e2" xlink:to="loc_vrna_ContractWithCustomerFutureEligibleMilestonePayments_e02a5870-2c8a-49a6-8e30-d8eb4c158a5f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_416588e6-141d-49bc-b8b0-2ece21b28add" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_e56b8a70-fa70-4940-97fb-4e4d6818c5e2" xlink:to="loc_us-gaap_ContractWithCustomerLiability_416588e6-141d-49bc-b8b0-2ece21b28add" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNet_d3b2ae1d-d635-476b-b5b4-262c602161a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_e56b8a70-fa70-4940-97fb-4e4d6818c5e2" xlink:to="loc_us-gaap_CapitalizedContractCostNet_d3b2ae1d-d635-476b-b5b4-262c602161a1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_c1ba25d4-65b4-4806-a2a8-97f368f1db4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_e56b8a70-fa70-4940-97fb-4e4d6818c5e2" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_c1ba25d4-65b4-4806-a2a8-97f368f1db4a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostTable_2021eba8-a2fd-452b-8ead-a2dac7e6ece7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_e56b8a70-fa70-4940-97fb-4e4d6818c5e2" xlink:to="loc_us-gaap_CapitalizedContractCostTable_2021eba8-a2fd-452b-8ead-a2dac7e6ece7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1073e276-797f-4cb8-a252-76d9a222b85f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_CapitalizedContractCostTable_2021eba8-a2fd-452b-8ead-a2dac7e6ece7" xlink:to="loc_srt_CounterpartyNameAxis_1073e276-797f-4cb8-a252-76d9a222b85f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1073e276-797f-4cb8-a252-76d9a222b85f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_1073e276-797f-4cb8-a252-76d9a222b85f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1073e276-797f-4cb8-a252-76d9a222b85f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_45a64cff-0797-47fd-856d-c400a409c6de" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_1073e276-797f-4cb8-a252-76d9a222b85f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_45a64cff-0797-47fd-856d-c400a409c6de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_LigandUKDevelopmentLimitedMember_9ef3c008-ae1c-4f04-8a4e-d94d317df0c4" xlink:href="vrna-20221231.xsd#vrna_LigandUKDevelopmentLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_45a64cff-0797-47fd-856d-c400a409c6de" xlink:to="loc_vrna_LigandUKDevelopmentLimitedMember_9ef3c008-ae1c-4f04-8a4e-d94d317df0c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_NuanceShanghaiPharmaCoLtdMember_eca7f557-a18d-4f66-9d00-82be1153f6d9" xlink:href="vrna-20221231.xsd#vrna_NuanceShanghaiPharmaCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_45a64cff-0797-47fd-856d-c400a409c6de" xlink:to="loc_vrna_NuanceShanghaiPharmaCoLtdMember_eca7f557-a18d-4f66-9d00-82be1153f6d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_BenchmarkAchievementAxis_0076039f-5ae6-4499-8627-287db57753cc" xlink:href="vrna-20221231.xsd#vrna_BenchmarkAchievementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_CapitalizedContractCostTable_2021eba8-a2fd-452b-8ead-a2dac7e6ece7" xlink:to="loc_vrna_BenchmarkAchievementAxis_0076039f-5ae6-4499-8627-287db57753cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_BenchmarkAchievementDomain_0076039f-5ae6-4499-8627-287db57753cc_default" xlink:href="vrna-20221231.xsd#vrna_BenchmarkAchievementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_vrna_BenchmarkAchievementAxis_0076039f-5ae6-4499-8627-287db57753cc" xlink:to="loc_vrna_BenchmarkAchievementDomain_0076039f-5ae6-4499-8627-287db57753cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_BenchmarkAchievementDomain_606b9b8b-14aa-474a-b4a7-a2bee0f73bb2" xlink:href="vrna-20221231.xsd#vrna_BenchmarkAchievementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_vrna_BenchmarkAchievementAxis_0076039f-5ae6-4499-8627-287db57753cc" xlink:to="loc_vrna_BenchmarkAchievementDomain_606b9b8b-14aa-474a-b4a7-a2bee0f73bb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_FirstCommercialSaleMember_54532a21-635f-4ee7-b9f7-93bbcb86bdf3" xlink:href="vrna-20221231.xsd#vrna_FirstCommercialSaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vrna_BenchmarkAchievementDomain_606b9b8b-14aa-474a-b4a7-a2bee0f73bb2" xlink:to="loc_vrna_FirstCommercialSaleMember_54532a21-635f-4ee7-b9f7-93bbcb86bdf3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a84fb3c0-e310-4889-ab2a-33419b4ce1bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_CapitalizedContractCostTable_2021eba8-a2fd-452b-8ead-a2dac7e6ece7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a84fb3c0-e310-4889-ab2a-33419b4ce1bc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a84fb3c0-e310-4889-ab2a-33419b4ce1bc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a84fb3c0-e310-4889-ab2a-33419b4ce1bc" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a84fb3c0-e310-4889-ab2a-33419b4ce1bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_56fbdcb8-8b4b-4f0f-968f-1467568525fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a84fb3c0-e310-4889-ab2a-33419b4ce1bc" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_56fbdcb8-8b4b-4f0f-968f-1467568525fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d7fbf651-012d-417d-934d-1e31f58444a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_56fbdcb8-8b4b-4f0f-968f-1467568525fe" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d7fbf651-012d-417d-934d-1e31f58444a9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="vrna-20221231.xsd#TaxationDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended" id="i6168908a26364defbc9d9a1e5e0f134d_TaxationDeferredTaxAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_d6609f2c-f073-49a8-b55d-f697fb863055" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_59f5342f-c639-468b-99e4-b5c6fd0b10f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_d6609f2c-f073-49a8-b55d-f697fb863055" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_59f5342f-c639-468b-99e4-b5c6fd0b10f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_1234ac4a-efe1-48fc-91ec-61926e157832" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_59f5342f-c639-468b-99e4-b5c6fd0b10f7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_1234ac4a-efe1-48fc-91ec-61926e157832" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates_370b238d-a930-4b37-b018-6064b53fd06e" xlink:href="vrna-20221231.xsd#vrna_SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_59f5342f-c639-468b-99e4-b5c6fd0b10f7" xlink:to="loc_vrna_SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates_370b238d-a930-4b37-b018-6064b53fd06e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance_84434cb6-5210-4be7-878c-cdeb1a028ebd" xlink:href="vrna-20221231.xsd#vrna_SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_59f5342f-c639-468b-99e4-b5c6fd0b10f7" xlink:to="loc_vrna_SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance_84434cb6-5210-4be7-878c-cdeb1a028ebd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_c796a02c-d516-4e7c-9163-f81ee1d65875" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_8363834e-060e-4333-9c9e-02ba7755deda" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_d6609f2c-f073-49a8-b55d-f697fb863055" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_8363834e-060e-4333-9c9e-02ba7755deda" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_412a661a-a422-4b1d-bdbe-4c4a83690576" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_8363834e-060e-4333-9c9e-02ba7755deda" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_412a661a-a422-4b1d-bdbe-4c4a83690576" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_412a661a-a422-4b1d-bdbe-4c4a83690576_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_412a661a-a422-4b1d-bdbe-4c4a83690576" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_412a661a-a422-4b1d-bdbe-4c4a83690576_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_8ffd0e39-0ccb-4e2f-9ef5-5249047beba4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_412a661a-a422-4b1d-bdbe-4c4a83690576" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_8ffd0e39-0ccb-4e2f-9ef5-5249047beba4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_0c003351-917d-4834-8f6a-c7454d7d5251" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8ffd0e39-0ccb-4e2f-9ef5-5249047beba4" xlink:to="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_0c003351-917d-4834-8f6a-c7454d7d5251" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="vrna-20221231.xsd#SharebasedcompensationShareBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails" xlink:type="extended" id="i6fb57dad4159497190fcbaacd4ef0519_SharebasedcompensationShareBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e82eb099-9fa4-40df-99aa-e2518d050785" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_4205f85a-6927-426b-8bea-2ada805fc367" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e82eb099-9fa4-40df-99aa-e2518d050785" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_4205f85a-6927-426b-8bea-2ada805fc367" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8f0cadc1-bdfb-4a5d-a1b4-c17faa3184e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e82eb099-9fa4-40df-99aa-e2518d050785" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8f0cadc1-bdfb-4a5d-a1b4-c17faa3184e9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ff0e9d7e-d99b-49c3-abd4-1e4c7bed2e51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8f0cadc1-bdfb-4a5d-a1b4-c17faa3184e9" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ff0e9d7e-d99b-49c3-abd4-1e4c7bed2e51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ff0e9d7e-d99b-49c3-abd4-1e4c7bed2e51_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ff0e9d7e-d99b-49c3-abd4-1e4c7bed2e51" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ff0e9d7e-d99b-49c3-abd4-1e4c7bed2e51_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_337f27a7-43bd-46e9-99da-fbdbbe3875f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ff0e9d7e-d99b-49c3-abd4-1e4c7bed2e51" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_337f27a7-43bd-46e9-99da-fbdbbe3875f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ddda2d04-bee1-4349-a709-75ba2573b9ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_337f27a7-43bd-46e9-99da-fbdbbe3875f3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ddda2d04-bee1-4349-a709-75ba2573b9ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c8c1e5ef-03dc-4903-8f08-7ab0eb12e1db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_337f27a7-43bd-46e9-99da-fbdbbe3875f3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c8c1e5ef-03dc-4903-8f08-7ab0eb12e1db" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://veronapharma.com/role/SharebasedcompensationNarrativeDetails" xlink:type="simple" xlink:href="vrna-20221231.xsd#SharebasedcompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/SharebasedcompensationNarrativeDetails" xlink:type="extended" id="i27e4d63cae0948c7affc164699a5b810_SharebasedcompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6af08090-f70f-49df-a078-8ddd87a4a2f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5ed0907d-d5d4-41c3-8f1a-3492d18ccc2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6af08090-f70f-49df-a078-8ddd87a4a2f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5ed0907d-d5d4-41c3-8f1a-3492d18ccc2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_73227ce4-1b9e-4fa3-85ae-a4edc034daa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6af08090-f70f-49df-a078-8ddd87a4a2f1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_73227ce4-1b9e-4fa3-85ae-a4edc034daa7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_59f3d3b2-416c-4cb1-95ad-ca65edf057f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6af08090-f70f-49df-a078-8ddd87a4a2f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_59f3d3b2-416c-4cb1-95ad-ca65edf057f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized_461e02d6-6b8f-4f9d-b34c-69e1f8f805ba" xlink:href="vrna-20221231.xsd#vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6af08090-f70f-49df-a078-8ddd87a4a2f1" xlink:to="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized_461e02d6-6b8f-4f9d-b34c-69e1f8f805ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0d02ff68-12ec-45eb-a29a-94218e6b6b00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6af08090-f70f-49df-a078-8ddd87a4a2f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0d02ff68-12ec-45eb-a29a-94218e6b6b00" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_ef74e0ac-d175-4021-a2de-4f08e41dfe02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6af08090-f70f-49df-a078-8ddd87a4a2f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_ef74e0ac-d175-4021-a2de-4f08e41dfe02" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired_433d661b-8972-4487-b67d-977bb09b7b78" xlink:href="vrna-20221231.xsd#vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6af08090-f70f-49df-a078-8ddd87a4a2f1" xlink:to="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired_433d661b-8972-4487-b67d-977bb09b7b78" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod_f37d8765-4d8e-4260-aa36-73d9617409a2" xlink:href="vrna-20221231.xsd#vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6af08090-f70f-49df-a078-8ddd87a4a2f1" xlink:to="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod_f37d8765-4d8e-4260-aa36-73d9617409a2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingDepositoryReceiptRatio_8771f9a4-c2ad-4bfe-91c2-1ed376772c23" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityListingDepositoryReceiptRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6af08090-f70f-49df-a078-8ddd87a4a2f1" xlink:to="loc_dei_EntityListingDepositoryReceiptRatio_8771f9a4-c2ad-4bfe-91c2-1ed376772c23" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue_01d47faf-6de5-48f3-a443-a21ccceacdf6" xlink:href="vrna-20221231.xsd#vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6af08090-f70f-49df-a078-8ddd87a4a2f1" xlink:to="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue_01d47faf-6de5-48f3-a443-a21ccceacdf6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_e45f2d27-9eba-49bb-946b-5334c134c237" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6af08090-f70f-49df-a078-8ddd87a4a2f1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_e45f2d27-9eba-49bb-946b-5334c134c237" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_2ad5f9ff-c358-4cfd-8bb3-8e552242bef3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6af08090-f70f-49df-a078-8ddd87a4a2f1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_2ad5f9ff-c358-4cfd-8bb3-8e552242bef3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1e93da97-f8b1-47a0-9282-58852dc2b879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6af08090-f70f-49df-a078-8ddd87a4a2f1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1e93da97-f8b1-47a0-9282-58852dc2b879" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1caf82b5-0e93-456d-b9bd-d0ff90c278a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6af08090-f70f-49df-a078-8ddd87a4a2f1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1caf82b5-0e93-456d-b9bd-d0ff90c278a8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0e2ab3bc-3e6f-4863-b101-5cdac4416e70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1caf82b5-0e93-456d-b9bd-d0ff90c278a8" xlink:to="loc_us-gaap_AwardTypeAxis_0e2ab3bc-3e6f-4863-b101-5cdac4416e70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e2ab3bc-3e6f-4863-b101-5cdac4416e70_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0e2ab3bc-3e6f-4863-b101-5cdac4416e70" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e2ab3bc-3e6f-4863-b101-5cdac4416e70_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9c5949a7-1d3c-4a6a-84f5-5a03ffb3b87c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0e2ab3bc-3e6f-4863-b101-5cdac4416e70" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9c5949a7-1d3c-4a6a-84f5-5a03ffb3b87c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_24ca378e-7bea-4699-a8ae-c6f5e10c28ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9c5949a7-1d3c-4a6a-84f5-5a03ffb3b87c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_24ca378e-7bea-4699-a8ae-c6f5e10c28ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6567004c-fc1a-4198-b87d-ed06e412ba60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9c5949a7-1d3c-4a6a-84f5-5a03ffb3b87c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6567004c-fc1a-4198-b87d-ed06e412ba60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_2a8ad870-4d32-420f-8d6e-40269c6a3010" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1caf82b5-0e93-456d-b9bd-d0ff90c278a8" xlink:to="loc_us-gaap_PlanNameAxis_2a8ad870-4d32-420f-8d6e-40269c6a3010" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_2a8ad870-4d32-420f-8d6e-40269c6a3010_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_2a8ad870-4d32-420f-8d6e-40269c6a3010" xlink:to="loc_us-gaap_PlanNameDomain_2a8ad870-4d32-420f-8d6e-40269c6a3010_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0fbcff94-41a9-4f88-a163-7e0ec8399083" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_2a8ad870-4d32-420f-8d6e-40269c6a3010" xlink:to="loc_us-gaap_PlanNameDomain_0fbcff94-41a9-4f88-a163-7e0ec8399083" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_EMIOptionPlanMember_e7c4b1f8-b5da-4321-a1a6-904a6dd5151c" xlink:href="vrna-20221231.xsd#vrna_EMIOptionPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_0fbcff94-41a9-4f88-a163-7e0ec8399083" xlink:to="loc_vrna_EMIOptionPlanMember_e7c4b1f8-b5da-4321-a1a6-904a6dd5151c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_PreIPOOptionPlanMember_2bdc636c-f4c6-42e8-8216-bbb8a13aa583" xlink:href="vrna-20221231.xsd#vrna_PreIPOOptionPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_0fbcff94-41a9-4f88-a163-7e0ec8399083" xlink:to="loc_vrna_PreIPOOptionPlanMember_2bdc636c-f4c6-42e8-8216-bbb8a13aa583" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_A2017IncentivePlanMember_4f549677-3d81-45be-b035-bd0fd1b59c7a" xlink:href="vrna-20221231.xsd#vrna_A2017IncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_0fbcff94-41a9-4f88-a163-7e0ec8399083" xlink:to="loc_vrna_A2017IncentivePlanMember_4f549677-3d81-45be-b035-bd0fd1b59c7a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5f0eae50-0aea-4259-ac1b-73b65cf258d9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1caf82b5-0e93-456d-b9bd-d0ff90c278a8" xlink:to="loc_srt_RangeAxis_5f0eae50-0aea-4259-ac1b-73b65cf258d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5f0eae50-0aea-4259-ac1b-73b65cf258d9_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5f0eae50-0aea-4259-ac1b-73b65cf258d9" xlink:to="loc_srt_RangeMember_5f0eae50-0aea-4259-ac1b-73b65cf258d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_66a219eb-90c4-48bb-8399-ee198eb7e49e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5f0eae50-0aea-4259-ac1b-73b65cf258d9" xlink:to="loc_srt_RangeMember_66a219eb-90c4-48bb-8399-ee198eb7e49e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5cabc3e4-36c2-43ab-b7bb-f67371702dda" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_66a219eb-90c4-48bb-8399-ee198eb7e49e" xlink:to="loc_srt_MinimumMember_5cabc3e4-36c2-43ab-b7bb-f67371702dda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b9320f53-93c2-4c80-9e8b-e253d8fac6e7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_66a219eb-90c4-48bb-8399-ee198eb7e49e" xlink:to="loc_srt_MaximumMember_b9320f53-93c2-4c80-9e8b-e253d8fac6e7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://veronapharma.com/role/SharebasedcompensationWeightedAverageAssumptionsDetails" xlink:type="simple" xlink:href="vrna-20221231.xsd#SharebasedcompensationWeightedAverageAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/SharebasedcompensationWeightedAverageAssumptionsDetails" xlink:type="extended" id="i4a0a9afdccee4bb4ab66d31482c5cbfc_SharebasedcompensationWeightedAverageAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f179693b-fd4a-4e33-b9e0-608991c395ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_18b3599f-fb35-407d-af9a-4c36b4eaf00b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f179693b-fd4a-4e33-b9e0-608991c395ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_18b3599f-fb35-407d-af9a-4c36b4eaf00b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_57daec93-35ed-4128-844d-fb32c48c9891" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f179693b-fd4a-4e33-b9e0-608991c395ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_57daec93-35ed-4128-844d-fb32c48c9891" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5ca5ac7c-b200-470c-8b12-5a487757997b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f179693b-fd4a-4e33-b9e0-608991c395ef" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5ca5ac7c-b200-470c-8b12-5a487757997b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_38fa007b-c377-4405-9190-d4d12493e67b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f179693b-fd4a-4e33-b9e0-608991c395ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_38fa007b-c377-4405-9190-d4d12493e67b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_b188b1cc-3976-414a-bf50-de86fd2d7a40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f179693b-fd4a-4e33-b9e0-608991c395ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_b188b1cc-3976-414a-bf50-de86fd2d7a40" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_85246846-33ee-4f53-b825-76e780c874b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f179693b-fd4a-4e33-b9e0-608991c395ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_85246846-33ee-4f53-b825-76e780c874b7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_39df730e-89f7-41bd-a60d-527247af05b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f179693b-fd4a-4e33-b9e0-608991c395ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_39df730e-89f7-41bd-a60d-527247af05b8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9b21257f-65cc-4d1f-a864-9f7d3bfe6c08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f179693b-fd4a-4e33-b9e0-608991c395ef" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9b21257f-65cc-4d1f-a864-9f7d3bfe6c08" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_486e41c4-2c58-408a-9149-c17cde37d7b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9b21257f-65cc-4d1f-a864-9f7d3bfe6c08" xlink:to="loc_us-gaap_AwardTypeAxis_486e41c4-2c58-408a-9149-c17cde37d7b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_486e41c4-2c58-408a-9149-c17cde37d7b7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_486e41c4-2c58-408a-9149-c17cde37d7b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_486e41c4-2c58-408a-9149-c17cde37d7b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c3248f81-514a-4444-b1d6-8298134de4c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_486e41c4-2c58-408a-9149-c17cde37d7b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c3248f81-514a-4444-b1d6-8298134de4c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5ae01c83-b405-4df1-b2bc-16bdc9b6d550" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c3248f81-514a-4444-b1d6-8298134de4c2" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5ae01c83-b405-4df1-b2bc-16bdc9b6d550" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_55c38c54-54c6-4cc0-867e-8b9c0a0f80f3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9b21257f-65cc-4d1f-a864-9f7d3bfe6c08" xlink:to="loc_srt_RangeAxis_55c38c54-54c6-4cc0-867e-8b9c0a0f80f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_55c38c54-54c6-4cc0-867e-8b9c0a0f80f3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_55c38c54-54c6-4cc0-867e-8b9c0a0f80f3" xlink:to="loc_srt_RangeMember_55c38c54-54c6-4cc0-867e-8b9c0a0f80f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_34e69f59-5cbf-46fb-8279-8c3938d5638e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_55c38c54-54c6-4cc0-867e-8b9c0a0f80f3" xlink:to="loc_srt_RangeMember_34e69f59-5cbf-46fb-8279-8c3938d5638e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8700f913-ffc8-4964-a5e3-05d67b140b1f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_34e69f59-5cbf-46fb-8279-8c3938d5638e" xlink:to="loc_srt_MinimumMember_8700f913-ffc8-4964-a5e3-05d67b140b1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_76e38050-9c87-4d2c-8860-3f087692e7b4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_34e69f59-5cbf-46fb-8279-8c3938d5638e" xlink:to="loc_srt_MaximumMember_76e38050-9c87-4d2c-8860-3f087692e7b4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails" xlink:type="simple" xlink:href="vrna-20221231.xsd#SharebasedcompensationRSUActivityDetails"/>
  <link:definitionLink xlink:role="http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails" xlink:type="extended" id="i9ac4b1bd0d604b56b9ea6ee5ccd51461_SharebasedcompensationRSUActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13e25830-f5dd-47d1-afb5-a27735a553cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_3a6090cb-12bc-460f-a9b4-17ff8d62e799" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13e25830-f5dd-47d1-afb5-a27735a553cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_3a6090cb-12bc-460f-a9b4-17ff8d62e799" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_41d24fea-6705-41f7-8e17-a96229adf4d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_3a6090cb-12bc-460f-a9b4-17ff8d62e799" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_41d24fea-6705-41f7-8e17-a96229adf4d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4b2e08fe-bd54-4832-b942-39958bd6a058" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_3a6090cb-12bc-460f-a9b4-17ff8d62e799" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4b2e08fe-bd54-4832-b942-39958bd6a058" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_624fee9e-87d2-4902-aff2-32e70aeef93f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_3a6090cb-12bc-460f-a9b4-17ff8d62e799" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_624fee9e-87d2-4902-aff2-32e70aeef93f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_483bcced-abdd-494c-aa7c-32457fec8181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_3a6090cb-12bc-460f-a9b4-17ff8d62e799" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_483bcced-abdd-494c-aa7c-32457fec8181" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_29c7f654-bb49-4740-b04b-61cb973cc9c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_90f353f1-e074-4520-a908-08de45648fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13e25830-f5dd-47d1-afb5-a27735a553cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_90f353f1-e074-4520-a908-08de45648fb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bb0cab01-6125-4efe-a856-d7f608a461c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_90f353f1-e074-4520-a908-08de45648fb0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bb0cab01-6125-4efe-a856-d7f608a461c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d8276f0a-cba3-43de-9e7f-3ed73eb1859d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_90f353f1-e074-4520-a908-08de45648fb0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d8276f0a-cba3-43de-9e7f-3ed73eb1859d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_adf28524-bc51-41f4-809d-493d91bd35bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_90f353f1-e074-4520-a908-08de45648fb0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_adf28524-bc51-41f4-809d-493d91bd35bf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_6724e17d-ceb3-4bb6-a452-56f75f8488db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_90f353f1-e074-4520-a908-08de45648fb0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_6724e17d-ceb3-4bb6-a452-56f75f8488db" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a78e887e-2f99-4c8a-8878-bf1ae570d43b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_a1180290-4a85-45b8-bb91-3654a4441503" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13e25830-f5dd-47d1-afb5-a27735a553cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_a1180290-4a85-45b8-bb91-3654a4441503" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3094e0c4-68a9-45bc-adb1-cdb6041740c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod_46b79d3d-0920-4cca-9fee-4d1743b929d5" xlink:href="vrna-20221231.xsd#vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13e25830-f5dd-47d1-afb5-a27735a553cf" xlink:to="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod_46b79d3d-0920-4cca-9fee-4d1743b929d5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a0abaa2-ff81-4809-af2e-3e3de7308260" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13e25830-f5dd-47d1-afb5-a27735a553cf" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a0abaa2-ff81-4809-af2e-3e3de7308260" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_07f5baf7-d7ed-473d-9475-8c376c9375b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a0abaa2-ff81-4809-af2e-3e3de7308260" xlink:to="loc_us-gaap_AwardTypeAxis_07f5baf7-d7ed-473d-9475-8c376c9375b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_07f5baf7-d7ed-473d-9475-8c376c9375b4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_07f5baf7-d7ed-473d-9475-8c376c9375b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_07f5baf7-d7ed-473d-9475-8c376c9375b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_82764404-afc7-47a1-ba1c-fc9e927dac35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_07f5baf7-d7ed-473d-9475-8c376c9375b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_82764404-afc7-47a1-ba1c-fc9e927dac35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5e02f3ec-55ef-4c9c-a134-366aca639c78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_82764404-afc7-47a1-ba1c-fc9e927dac35" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5e02f3ec-55ef-4c9c-a134-366aca639c78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_RestrictedStockUnitTimeBasedVestingMember_b76c5e20-8507-4fdf-8120-be8c5632c65e" xlink:href="vrna-20221231.xsd#vrna_RestrictedStockUnitTimeBasedVestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_5e02f3ec-55ef-4c9c-a134-366aca639c78" xlink:to="loc_vrna_RestrictedStockUnitTimeBasedVestingMember_b76c5e20-8507-4fdf-8120-be8c5632c65e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_RestrictedStockUnitMilestoneBasedVestingMember_eeee5011-1ed4-4145-bc42-fc7f8e52a0a3" xlink:href="vrna-20221231.xsd#vrna_RestrictedStockUnitMilestoneBasedVestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_5e02f3ec-55ef-4c9c-a134-366aca639c78" xlink:to="loc_vrna_RestrictedStockUnitMilestoneBasedVestingMember_eeee5011-1ed4-4145-bc42-fc7f8e52a0a3" xlink:type="arc" order="2"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>vrna-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:3c4b6351-9dd7-43ec-8a74-8bad3a93c534,g:ba5c393f-9b46-4696-9211-0bc9a20ff330-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_561148a7-ff81-4a9d-989e-7a5e35e53587_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_1a0a4217-b55d-4f7b-b92b-d5db242fbbb0_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e63443b9-bbbc-4ee0-b701-0d033b793f35_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total minimum future lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_c6ac4189-c9db-4483-bab8-9f55d6e92748_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currencies</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_OxfordTermALoanMember_273c63db-b4bb-4bb6-849e-796c85cb7a97_terseLabel_en-US" xlink:label="lab_vrna_OxfordTermALoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Term A Loan</link:label>
    <link:label id="lab_vrna_OxfordTermALoanMember_label_en-US" xlink:label="lab_vrna_OxfordTermALoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Term A Loan [Member]</link:label>
    <link:label id="lab_vrna_OxfordTermALoanMember_documentation_en-US" xlink:label="lab_vrna_OxfordTermALoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Term A Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_OxfordTermALoanMember" xlink:href="vrna-20221231.xsd#vrna_OxfordTermALoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_OxfordTermALoanMember" xlink:to="lab_vrna_OxfordTermALoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_d885e3f7-d770-4dbd-928e-f4423fbd99bc_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent_ee689bc2-43ce-4fa7-ac7c-a794e960f5e5_negatedTerseLabel_en-US" xlink:label="lab_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax incentive receivables</link:label>
    <link:label id="lab_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent_label_en-US" xlink:label="lab_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Tax And Tax Credit Receivables, Current</link:label>
    <link:label id="lab_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent_documentation_en-US" xlink:label="lab_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Tax And Tax Credit Receivables, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" xlink:href="vrna-20221231.xsd#vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" xlink:to="lab_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired_e73ae425-eb95-42bf-ac53-35b8dedf7bac_terseLabel_en-US" xlink:label="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum stock price required to vest (in pound sterling per share)</link:label>
    <link:label id="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired_label_en-US" xlink:label="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Award Vesting Rights, Minimum Stock Price Required</link:label>
    <link:label id="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired_documentation_en-US" xlink:label="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Award Vesting Rights, Minimum Stock Price Required</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired" xlink:href="vrna-20221231.xsd#vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired" xlink:to="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_0ac214c4-b314-49e9-93f5-83dedaf2ece9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_b37ca0c3-efae-4361-bb70-fe6ab84b4869_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_31f3b4c9-4b4c-4f47-903e-48d348830b30_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates_23edf560-2be1-4a3e-8aec-f993e0036718_terseLabel_en-US" xlink:label="lab_vrna_SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in tax rates</link:label>
    <link:label id="lab_vrna_SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates_label_en-US" xlink:label="lab_vrna_SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule 12-09, Valuation Allowances and Reserves, Change In Tax Rates</link:label>
    <link:label id="lab_vrna_SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates_documentation_en-US" xlink:label="lab_vrna_SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule 12-09, Valuation Allowances and Reserves, Change In Tax Rates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates" xlink:href="vrna-20221231.xsd#vrna_SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates" xlink:to="lab_vrna_SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_a782353f-1e50-41b5-a338-75f773dab9f5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of financial instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_ff0e19a7-03a6-429a-a2b0-c3a7c7c4b5b3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income/(expense):</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_1de6fd1b-5621-44c2-9ab7-62dc2a1fe98f_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized_29fd69bf-eaa0-4d52-915b-2c98dbb03adb_terseLabel_en-US" xlink:label="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of American Depository Shares authorized</link:label>
    <link:label id="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized_label_en-US" xlink:label="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of American Depositary Shares Authorized</link:label>
    <link:label id="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized_documentation_en-US" xlink:label="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of American Depositary Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized" xlink:href="vrna-20221231.xsd#vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized" xlink:to="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_OxfordTermBCDELoanMember_a53b8bd7-0134-4846-ba37-55a17d797d91_terseLabel_en-US" xlink:label="lab_vrna_OxfordTermBCDELoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Term B, C, D, E Loan</link:label>
    <link:label id="lab_vrna_OxfordTermBCDELoanMember_label_en-US" xlink:label="lab_vrna_OxfordTermBCDELoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Term B, C, D, E Loan [Member]</link:label>
    <link:label id="lab_vrna_OxfordTermBCDELoanMember_documentation_en-US" xlink:label="lab_vrna_OxfordTermBCDELoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Term B, C, D, E Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_OxfordTermBCDELoanMember" xlink:href="vrna-20221231.xsd#vrna_OxfordTermBCDELoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_OxfordTermBCDELoanMember" xlink:to="lab_vrna_OxfordTermBCDELoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_fd5445b1-0a3d-4119-b255-21a530f4629b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_bdc28191-8177-4166-8071-0bed0e64685b_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_439f949a-f378-41cf-b942-80b6733d14a1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate (in percent)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_23bb9a5f-a042-4ba8-8066-10e6ae76b862_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_06a9fc56-fcd6-43a3-9c10-09cec1186916_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_5ac67d89-9e6d-4df1-b33d-5d5b954e7d2d_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of ordinary shares to treasury</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_c65694d9-30b9-49f8-bede-7fef9264eb80_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_ec426da0-3228-4b71-8caf-f6a9a9d2cecd_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_b803d308-8017-4ddd-9839-2a1b320f41bb_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_0d370c17-75c1-4cbf-b0d3-04b3d190dace_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_bc03f878-92cb-478d-a957-c37f2e2377cb_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_OxfordTermCLoanMember_7fb2c92a-914a-4f10-b012-1c01228b3c11_terseLabel_en-US" xlink:label="lab_vrna_OxfordTermCLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Term C Loan</link:label>
    <link:label id="lab_vrna_OxfordTermCLoanMember_label_en-US" xlink:label="lab_vrna_OxfordTermCLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Term C Loan [Member]</link:label>
    <link:label id="lab_vrna_OxfordTermCLoanMember_documentation_en-US" xlink:label="lab_vrna_OxfordTermCLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Term C Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_OxfordTermCLoanMember" xlink:href="vrna-20221231.xsd#vrna_OxfordTermCLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_OxfordTermCLoanMember" xlink:to="lab_vrna_OxfordTermCLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_AmericanDepositorySharesMember_87728e93-9e39-4ceb-b87b-2aa96994af5a_terseLabel_en-US" xlink:label="lab_vrna_AmericanDepositorySharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">American Depository Shares</link:label>
    <link:label id="lab_vrna_AmericanDepositorySharesMember_label_en-US" xlink:label="lab_vrna_AmericanDepositorySharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">American Depository Shares [Member]</link:label>
    <link:label id="lab_vrna_AmericanDepositorySharesMember_documentation_en-US" xlink:label="lab_vrna_AmericanDepositorySharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">American Depository Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AmericanDepositorySharesMember" xlink:href="vrna-20221231.xsd#vrna_AmericanDepositorySharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_AmericanDepositorySharesMember" xlink:to="lab_vrna_AmericanDepositorySharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_8396f4bd-616f-4fec-bec5-565766570360_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_IncreaseDecreaseInOperatingLeaseLiabilities_3a6d5991-37af-4c72-aa46-2f85596a095b_terseLabel_en-US" xlink:label="lab_vrna_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_vrna_IncreaseDecreaseInOperatingLeaseLiabilities_label_en-US" xlink:label="lab_vrna_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Liabilities</link:label>
    <link:label id="lab_vrna_IncreaseDecreaseInOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_vrna_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:href="vrna-20221231.xsd#vrna_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="lab_vrna_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidInsurance_608864e6-48c4-4e4f-b598-37fa570e2fc8_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance</link:label>
    <link:label id="lab_us-gaap_PrepaidInsurance_label_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_815dfbef-e2e5-45ee-b2e7-dc7abe7a586c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_5d12a407-3eed-4919-93c2-223e31aab3a4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_53303bc1-b6e8-4a7e-a296-a9256509d701_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_3a7dd06f-e30c-4151-bdfa-149be7e65ca0_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_167594f8-f6e7-43ec-86a9-da99b731fac6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_c593fb1b-2964-4bbf-8415-949040a3279f_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_e26f3a67-c07c-48fa-bf0c-19e00c63622f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_EMIOptionPlanMember_31ba840d-1246-41e8-8c2c-e858ba70daa3_terseLabel_en-US" xlink:label="lab_vrna_EMIOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EMI Option Plan</link:label>
    <link:label id="lab_vrna_EMIOptionPlanMember_label_en-US" xlink:label="lab_vrna_EMIOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EMI Option Plan [Member]</link:label>
    <link:label id="lab_vrna_EMIOptionPlanMember_documentation_en-US" xlink:label="lab_vrna_EMIOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EMI Option Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_EMIOptionPlanMember" xlink:href="vrna-20221231.xsd#vrna_EMIOptionPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_EMIOptionPlanMember" xlink:to="lab_vrna_EMIOptionPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_ece72261-ca2c-4fe2-80e0-a5ab8b71ac4e_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_2e53a702-fefe-49de-835e-696da2fa3778_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_6ca0c51a-305c-4088-8253-88c6c71b4341_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e393576f-2d75-4861-8f49-8bfe89340b5c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited, Weight average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_50e5c056-35fc-42b9-8660-77583153078a_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_7661c006-c55f-4d51-a185-76e80afa3937_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostNet_63efe889-5886-46dd-a7a1-bcb76c3d07d7_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Net</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostNet_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostNet" xlink:to="lab_us-gaap_CapitalizedContractCostNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_79473727-8d6c-42f3-948f-49643e70f8a1_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_RestrictedStockUnitTimeBasedVestingMember_5d8ca52c-8e6a-4918-9812-bc18b83ea058_terseLabel_en-US" xlink:label="lab_vrna_RestrictedStockUnitTimeBasedVestingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time-Based Vesting</link:label>
    <link:label id="lab_vrna_RestrictedStockUnitTimeBasedVestingMember_label_en-US" xlink:label="lab_vrna_RestrictedStockUnitTimeBasedVestingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Unit, Time-Based Vesting [Member]</link:label>
    <link:label id="lab_vrna_RestrictedStockUnitTimeBasedVestingMember_documentation_en-US" xlink:label="lab_vrna_RestrictedStockUnitTimeBasedVestingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Unit, Time-Based Vesting</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_RestrictedStockUnitTimeBasedVestingMember" xlink:href="vrna-20221231.xsd#vrna_RestrictedStockUnitTimeBasedVestingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_RestrictedStockUnitTimeBasedVestingMember" xlink:to="lab_vrna_RestrictedStockUnitTimeBasedVestingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_edc9b253-1c5c-4112-9ec6-451e97295ede_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Weighted average remaining contractual term (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_BenchmarkAchievementDomain_d89ff359-103d-4dd7-b260-05115d2815fe_terseLabel_en-US" xlink:label="lab_vrna_BenchmarkAchievementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benchmark Achievement [Domain]</link:label>
    <link:label id="lab_vrna_BenchmarkAchievementDomain_label_en-US" xlink:label="lab_vrna_BenchmarkAchievementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benchmark Achievement [Domain]</link:label>
    <link:label id="lab_vrna_BenchmarkAchievementDomain_documentation_en-US" xlink:label="lab_vrna_BenchmarkAchievementDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benchmark Achievement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_BenchmarkAchievementDomain" xlink:href="vrna-20221231.xsd#vrna_BenchmarkAchievementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_BenchmarkAchievementDomain" xlink:to="lab_vrna_BenchmarkAchievementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_35c5b8af-9f9b-417c-b093-dda2cf7ddce5_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_9c593075-1aaa-4797-bb57-9be394121020_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Increase (Decrease)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:to="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_12abb6d7-4b97-4d0b-b8f8-264dc135349b_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_FirstCommercialSaleMember_0154cd79-5425-4447-a820-fda6d972cf26_terseLabel_en-US" xlink:label="lab_vrna_FirstCommercialSaleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Commercial Sale</link:label>
    <link:label id="lab_vrna_FirstCommercialSaleMember_label_en-US" xlink:label="lab_vrna_FirstCommercialSaleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Commercial Sale [Member]</link:label>
    <link:label id="lab_vrna_FirstCommercialSaleMember_documentation_en-US" xlink:label="lab_vrna_FirstCommercialSaleMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Commercial Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_FirstCommercialSaleMember" xlink:href="vrna-20221231.xsd#vrna_FirstCommercialSaleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_FirstCommercialSaleMember" xlink:to="lab_vrna_FirstCommercialSaleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_d1156eab-31e2-4b44-8bbc-a24ad427a419_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_a3995fed-c500-46d1-b9b7-4f365fca01ec_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_bdacddd8-628c-485f-a73b-67ff2cd6e8de_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_26587a92-39c2-44dd-9f55-7074679e32ec_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_213e8333-6886-443b-a319-d6a5035320f2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Unit Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_0b19f810-cae4-46a5-8b8c-05a4324c34b6_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_OrganizationAndBusinessDescriptionTextBlock_a16e285b-0332-4076-a807-4e557987f8eb_terseLabel_en-US" xlink:label="lab_vrna_OrganizationAndBusinessDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and description of business operations</link:label>
    <link:label id="lab_vrna_OrganizationAndBusinessDescriptionTextBlock_label_en-US" xlink:label="lab_vrna_OrganizationAndBusinessDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Business Description [Text Block]</link:label>
    <link:label id="lab_vrna_OrganizationAndBusinessDescriptionTextBlock_documentation_en-US" xlink:label="lab_vrna_OrganizationAndBusinessDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Business Description</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_OrganizationAndBusinessDescriptionTextBlock" xlink:href="vrna-20221231.xsd#vrna_OrganizationAndBusinessDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_OrganizationAndBusinessDescriptionTextBlock" xlink:to="lab_vrna_OrganizationAndBusinessDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_a8776aea-a58f-41db-a810-9d00baed68f2_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible expenses</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d05710b9-0ced-44df-a009-8b00fbef02a5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAccrued_20d8b689-70ba-4071-aef8-04e23478904c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Penalties accrued</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAccrued_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination, Penalties Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationPenaltiesAccrued" xlink:to="lab_us-gaap_IncomeTaxExaminationPenaltiesAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_e167c1d5-f2df-4e13-a9fb-c21ad9950223_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_5d09c1f3-0651-4d4a-8639-cca0620315dd_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_5cf15d95-7cfe-417e-bacb-76f3e702b565_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1279045c-22ee-4945-a2ec-b740e3e5d2ca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_OxfordTermELoanMember_dadf2da6-6e0c-46a8-8b6a-88ca58b178e6_terseLabel_en-US" xlink:label="lab_vrna_OxfordTermELoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Term E Loan</link:label>
    <link:label id="lab_vrna_OxfordTermELoanMember_label_en-US" xlink:label="lab_vrna_OxfordTermELoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Term E Loan [Member]</link:label>
    <link:label id="lab_vrna_OxfordTermELoanMember_documentation_en-US" xlink:label="lab_vrna_OxfordTermELoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Term E Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_OxfordTermELoanMember" xlink:href="vrna-20221231.xsd#vrna_OxfordTermELoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_OxfordTermELoanMember" xlink:to="lab_vrna_OxfordTermELoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_0b18d796-8c03-4120-baef-b8b5383a3271_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d81a3ac6-aae3-4643-b043-7b688912595c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_82fb771e-3f32-4a33-8c76-f9675c0cf49f_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of ordinary shares, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_b34c892d-7e6f-42fb-91ef-569456bf445e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic and fair value, vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_a1dec0a9-c55b-4324-bb35-139667092947_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_d0e62435-c151-4ca2-8ff3-8db6d9dd6b80_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f24ff584-46d5-49fd-95ba-f7fd339e30e0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_5373a730-1577-4919-9795-6b82263ad471_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CountryRegion_b2fdf8d8-b882-4d45-996b-79bff49d9c67_terseLabel_en-US" xlink:label="lab_dei_CountryRegion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Country Region</link:label>
    <link:label id="lab_dei_CountryRegion_label_en-US" xlink:label="lab_dei_CountryRegion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Country Region</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CountryRegion" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CountryRegion" xlink:to="lab_dei_CountryRegion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_394461a8-f363-4149-9a65-2cac45a925bd_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d2f59d20-72cf-4dc3-beff-df3a2fdd9361_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_9ee6f223-81a8-4b75-83d0-e080f8d7ecb6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_2e164333-dc8f-4bdc-af88-a803a7ca428f_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_1e466697-d612-4f80-9b62-a4c0c49fa342_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax expense</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_WarrantAndRightsDisclosureTextBlock_0692eba4-f236-41a1-aef3-b11486daf0f9_terseLabel_en-US" xlink:label="lab_vrna_WarrantAndRightsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_vrna_WarrantAndRightsDisclosureTextBlock_label_en-US" xlink:label="lab_vrna_WarrantAndRightsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant And Rights Disclosure [Text Block]</link:label>
    <link:label id="lab_vrna_WarrantAndRightsDisclosureTextBlock_documentation_en-US" xlink:label="lab_vrna_WarrantAndRightsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant And Rights Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_WarrantAndRightsDisclosureTextBlock" xlink:href="vrna-20221231.xsd#vrna_WarrantAndRightsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_WarrantAndRightsDisclosureTextBlock" xlink:to="lab_vrna_WarrantAndRightsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_4c210e1c-7d84-4280-99d4-02fc85b29206_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_80fee924-fc38-44d5-abd2-2429ade94f6e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_EquityInterestReceivable_de30eb3d-d138-4129-8b1b-3e9fa4d1a643_terseLabel_en-US" xlink:label="lab_vrna_EquityInterestReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity interest receivable</link:label>
    <link:label id="lab_vrna_EquityInterestReceivable_label_en-US" xlink:label="lab_vrna_EquityInterestReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Interest Receivable</link:label>
    <link:label id="lab_vrna_EquityInterestReceivable_documentation_en-US" xlink:label="lab_vrna_EquityInterestReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Interest Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_EquityInterestReceivable" xlink:href="vrna-20221231.xsd#vrna_EquityInterestReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_EquityInterestReceivable" xlink:to="lab_vrna_EquityInterestReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_TermCLoanMember_ce963b3b-102a-466d-acb5-abb6907fc81c_terseLabel_en-US" xlink:label="lab_vrna_TermCLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term C Loan</link:label>
    <link:label id="lab_vrna_TermCLoanMember_label_en-US" xlink:label="lab_vrna_TermCLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term C Loan [Member]</link:label>
    <link:label id="lab_vrna_TermCLoanMember_documentation_en-US" xlink:label="lab_vrna_TermCLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term C Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TermCLoanMember" xlink:href="vrna-20221231.xsd#vrna_TermCLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_TermCLoanMember" xlink:to="lab_vrna_TermCLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_3ab7d608-7568-4ef0-8080-39b9e390a287_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_224e96fa-cc9b-40a0-b202-7305ed1f3421_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_21b3b5c3-00bd-4426-9243-eff08be93476_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_b0326fb7-d2cf-429f-8de0-ccd0fff2a8de_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_2d28bcb1-8a37-4953-8665-62738bb531fd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_DeferredTaxLiabilitiesContingentLiability_2b72e7b3-bf01-4c74-bcd8-68b6e783804f_negatedTerseLabel_en-US" xlink:label="lab_vrna_DeferredTaxLiabilitiesContingentLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent liability</link:label>
    <link:label id="lab_vrna_DeferredTaxLiabilitiesContingentLiability_label_en-US" xlink:label="lab_vrna_DeferredTaxLiabilitiesContingentLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Contingent Liability</link:label>
    <link:label id="lab_vrna_DeferredTaxLiabilitiesContingentLiability_documentation_en-US" xlink:label="lab_vrna_DeferredTaxLiabilitiesContingentLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Contingent Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DeferredTaxLiabilitiesContingentLiability" xlink:href="vrna-20221231.xsd#vrna_DeferredTaxLiabilitiesContingentLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_DeferredTaxLiabilitiesContingentLiability" xlink:to="lab_vrna_DeferredTaxLiabilitiesContingentLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_InterestRatePeriodDomain_ee4e7049-d8cc-493a-b02d-ee03b85db1cf_terseLabel_en-US" xlink:label="lab_vrna_InterestRatePeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Period [Domain]</link:label>
    <link:label id="lab_vrna_InterestRatePeriodDomain_label_en-US" xlink:label="lab_vrna_InterestRatePeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Period [Domain]</link:label>
    <link:label id="lab_vrna_InterestRatePeriodDomain_documentation_en-US" xlink:label="lab_vrna_InterestRatePeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_InterestRatePeriodDomain" xlink:href="vrna-20221231.xsd#vrna_InterestRatePeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_InterestRatePeriodDomain" xlink:to="lab_vrna_InterestRatePeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_120e97fa-932a-4e58-9708-a623fbcb8c1b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and penalties recognized</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination, Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_e09fe683-e23e-4c0a-b9bc-f79932a57bb1_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_483af4c3-8c11-41ea-9490-ef710f46978e_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_6b27f674-6183-4315-9c96-06230b9ff897_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised, Weight average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_74cde6ff-e199-44e3-ab2a-38470d54546b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by/(used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_f2de135e-948a-401e-994f-4d75dffa91d6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">People related costs</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_1e59cd55-3a9d-4777-96bd-ef2be8ab2fbb_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_00d616d2-eea6-453f-85c2-9f0e275bda95_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_50394d53-3e95-4d29-8e6e-a280a5ed1f7c_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_35866846-b73c-4519-bc47-452f1062c74e_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_a1b4a6aa-5658-4da2-804b-fa981df7a2db_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_b65c171e-af2d-46b9-ae47-b510016d1e63_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted-Average Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent_35abdee4-176d-414c-8460-53587f8f6597_terseLabel_en-US" xlink:label="lab_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fees, listing and general corporate costs</link:label>
    <link:label id="lab_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent_label_en-US" xlink:label="lab_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Listing, And General Corporate Costs, Current</link:label>
    <link:label id="lab_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent_documentation_en-US" xlink:label="lab_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Listing, And General Corporate Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" xlink:href="vrna-20221231.xsd#vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" xlink:to="lab_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_a34d9a63-d977-406f-b318-326106713a5f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_2e572bf9-2986-4bfd-ac55-2220cf125f9b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of income tax expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65ceb018-2787-4383-800f-51edc906ca00_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_d910a441-0b39-43fe-9238-4190355aa9aa_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in deferred tax valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_f6ccaf88-add8-4caf-872a-9ca378704f23_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3ec5ef4b-1346-488a-a75e-276c10f943a6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_97914b9c-3ac6-4219-93ed-04f444bd68a4_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_24f2ab19-af05-4b02-86f6-dcd6850cfa06_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_c0013963-d92f-452a-b60a-ee4ca922a7f6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, Weighted average remaining contractual term (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_f03c5a0c-8ed5-4604-a3be-283a6aebf9c9_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_c51d9291-f975-4f0a-967e-48fce1e82a67_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9efd8aa2-a119-437a-9121-3b9ebfa62a1c_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of ordinary shares, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_LondonMember_2a210275-71a6-4742-9aba-a2d153706fc8_terseLabel_en-US" xlink:label="lab_vrna_LondonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London</link:label>
    <link:label id="lab_vrna_LondonMember_label_en-US" xlink:label="lab_vrna_LondonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London [Member]</link:label>
    <link:label id="lab_vrna_LondonMember_documentation_en-US" xlink:label="lab_vrna_LondonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_LondonMember" xlink:href="vrna-20221231.xsd#vrna_LondonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_LondonMember" xlink:to="lab_vrna_LondonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_ee602197-8f82-4293-8b89-c8a61400e241_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_ef782ccd-6cc4-4674-b216-a836296f6a4d_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3f7ba664-d0e8-4dbc-b9cb-a2120d2b66dd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_7d6cb41e-f4b4-4626-86dd-1bf47b383047_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityListingDepositoryReceiptRatio_8ec6b504-801d-4d03-9caf-397e64cb630b_terseLabel_en-US" xlink:label="lab_dei_EntityListingDepositoryReceiptRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of ordinary shares per ADS</link:label>
    <link:label id="lab_dei_EntityListingDepositoryReceiptRatio_label_en-US" xlink:label="lab_dei_EntityListingDepositoryReceiptRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Listing, Depository Receipt Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingDepositoryReceiptRatio" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityListingDepositoryReceiptRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityListingDepositoryReceiptRatio" xlink:to="lab_dei_EntityListingDepositoryReceiptRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_010bcff0-0f16-459b-b030-33e797d42ce2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_c0bce2df-6b22-4ecd-81bc-e2b05f8cff47_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted share units vested</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_44d4dc83-10c9-421a-83ee-820842b9af3f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating losses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_151dc2bf-3446-466d-a467-02395a7dbaee_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of presentation and consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_05129bd4-a9d4-428f-88a7-287bdd9c5332_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_InterestRatePeriodAxis_eb37c8d7-e1de-4533-8712-b0a07e98606d_terseLabel_en-US" xlink:label="lab_vrna_InterestRatePeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Period [Axis]</link:label>
    <link:label id="lab_vrna_InterestRatePeriodAxis_label_en-US" xlink:label="lab_vrna_InterestRatePeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Period [Axis]</link:label>
    <link:label id="lab_vrna_InterestRatePeriodAxis_documentation_en-US" xlink:label="lab_vrna_InterestRatePeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_InterestRatePeriodAxis" xlink:href="vrna-20221231.xsd#vrna_InterestRatePeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_InterestRatePeriodAxis" xlink:to="lab_vrna_InterestRatePeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_a50ff8b0-6656-42ed-8349-ae6ea2077736_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_6d8ec1d3-da51-4c3a-a149-f6949fb0721a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in pounds sterling per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_5775cd1d-d11c-49b6-baaa-26437f4d9dc4_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_d436403a-f9d3-4578-9575-4b067c286616_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_33980093-1fd0-49dd-8403-608fc2421e1e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_f9be480e-e2f7-4f73-a9e9-fddcdfec19b5_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_9f3cf9ab-1be9-47d4-a70c-4870459d62c0_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_6374cd92-aff9-4f50-a012-1a6845d2f18f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development incentive</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_SublicensePaymentEquityIssuanceThresholdTradingDays_28ca17c4-9a7e-4e06-a4ad-6933a6ba2208_terseLabel_en-US" xlink:label="lab_vrna_SublicensePaymentEquityIssuanceThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublicense Payment, Equity Issuance, Threshold Trading Days</link:label>
    <link:label id="lab_vrna_SublicensePaymentEquityIssuanceThresholdTradingDays_label_en-US" xlink:label="lab_vrna_SublicensePaymentEquityIssuanceThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublicense Payment, Equity Issuance, Threshold Trading Days</link:label>
    <link:label id="lab_vrna_SublicensePaymentEquityIssuanceThresholdTradingDays_documentation_en-US" xlink:label="lab_vrna_SublicensePaymentEquityIssuanceThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublicense Payment, Equity Issuance, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SublicensePaymentEquityIssuanceThresholdTradingDays" xlink:href="vrna-20221231.xsd#vrna_SublicensePaymentEquityIssuanceThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_SublicensePaymentEquityIssuanceThresholdTradingDays" xlink:to="lab_vrna_SublicensePaymentEquityIssuanceThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_28d86019-a58b-4f55-9013-8002b5de7ac4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_41cc44a4-b395-4e74-8871-a6c22e8c366f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_60ab3733-0344-4b47-8f32-46b05a57c4bc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_75938c85-7bc6-463e-bd03-4b96e3f4412e_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_048ffe1d-1c8d-4815-b0c1-f752481d8278_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_6c54f492-1e81-49a7-9512-5ddc3abac97f_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_e03a6f48-3f1c-4af3-a849-54e569b95340_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_ca16843b-8f80-4eee-a8f5-08b35d390f1f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_54fd0265-8829-4290-b04d-73f470c5734e_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At January 1</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3c0a3187-26e0-466e-821d-ce624c75de35_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At December 31</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_7ce8b217-17b1-4a4e-b682-c482a86ed2ad_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_91530382-5892-476f-942c-bfadfc16ae98_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_AuditInformationAbstract_label_en-US" xlink:label="lab_vrna_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_vrna_AuditInformationAbstract_documentation_en-US" xlink:label="lab_vrna_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AuditInformationAbstract" xlink:href="vrna-20221231.xsd#vrna_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_AuditInformationAbstract" xlink:to="lab_vrna_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_b5d8c821-e48b-4039-a2d8-5356fc1bd670_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet" xlink:to="lab_us-gaap_InvestmentIncomeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_4ca5a263-850a-43d6-b129-75a44dd3ee9e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_b03c4822-2f29-4699-9c45-366bc650eaaf_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7c06daf0-3462-477a-94fe-007f496f006b_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of stock warrant (in pound sterling per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_58b04106-3734-4ae2-8632-b9a7d61c3924_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_3c35f433-a50d-4fcc-8fb0-f3e8e69138df_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per ordinary share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9ac13138-8fcc-44c5-b67a-dd54842c8d2a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_e4215e36-3e55-4ecb-a7cb-f2bf4b923754_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_392338d8-63c5-4613-858a-715e275107c2_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_398f5dfd-213c-438b-84bf-a59bbab69094_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary shares held in treasury</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_7d5344d4-07c6-4be0-aa0f-314183bbc116_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_0d974f44-dcd7-4de3-b7a4-ec910ab73a56_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_a36ee91b-a9bf-4f7c-b5e8-8c9aaf79454f_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_4a5c18f9-aefc-41e3-87ff-b748e830f98c_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_50b6c0fe-d447-47ca-a1d9-1e1c6fb01378_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9ca4936b-af0b-448d-a721-43e2ddf24d0b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation_b6fa0f72-0ca6-406a-8dc3-8878575001e1_negatedTerseLabel_en-US" xlink:label="lab_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity settled share-based compensation reclassified as cash-settled</link:label>
    <link:label id="lab_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation_label_en-US" xlink:label="lab_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Reclassification from Share-based Compensation</link:label>
    <link:label id="lab_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation_documentation_en-US" xlink:label="lab_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Reclassification from Share-based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation" xlink:href="vrna-20221231.xsd#vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation" xlink:to="lab_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_d2c7d0dc-cdf7-4a4e-9703-8565a1e32f46_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_5bf52c35-e30d-4bc1-a0aa-aac3c796e5cb_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_40fd9ce4-b26e-4f0c-b40d-7cbe80d42fe2_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued in sale (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_BenchmarkAchievementAxis_1dc5c759-69f1-4cfb-b818-ff48c941600e_terseLabel_en-US" xlink:label="lab_vrna_BenchmarkAchievementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benchmark Achievement [Axis]</link:label>
    <link:label id="lab_vrna_BenchmarkAchievementAxis_label_en-US" xlink:label="lab_vrna_BenchmarkAchievementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benchmark Achievement [Axis]</link:label>
    <link:label id="lab_vrna_BenchmarkAchievementAxis_documentation_en-US" xlink:label="lab_vrna_BenchmarkAchievementAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benchmark Achievement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_BenchmarkAchievementAxis" xlink:href="vrna-20221231.xsd#vrna_BenchmarkAchievementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_BenchmarkAchievementAxis" xlink:to="lab_vrna_BenchmarkAchievementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b3ace027-73f3-4473-95dd-5980860206c7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_54f2f977-b519-454d-8eb7-c7e403dec24d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Movement of the Value of the Warrants</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_866b530b-d31e-44c6-8a3a-8f2b29c082d6_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_a0e3ab62-a233-4f7b-89ef-2beea96a637b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary shares</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_5838471d-8221-4c46-bc06-e0f1a90456db_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocation of Share Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_9ebb47a0-51df-43ce-ac17-4ce89b838e2e_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4ad07488-819e-4a64-8220-642c452ac3ca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Further awards to be granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_cb964188-b7a6-47ff-b810-a9000e4a3543_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_3c3ccdd9-0318-4255-ae9f-c3cbee908415_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_c3003f0a-48e4-4b73-b3bd-a7e6de6150d8_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_57655dd1-676e-4aa9-815e-21c705bb98ae_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_4b345612-9421-49de-8e80-c55284058c98_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_StockIssuedDuringPeriodSharesHeldInTreasury_ccf60c1f-a019-4f6f-bf5b-7765f08ef5fb_terseLabel_en-US" xlink:label="lab_vrna_StockIssuedDuringPeriodSharesHeldInTreasury" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of ordinary shares to treasury (in shares)</link:label>
    <link:label id="lab_vrna_StockIssuedDuringPeriodSharesHeldInTreasury_label_en-US" xlink:label="lab_vrna_StockIssuedDuringPeriodSharesHeldInTreasury" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Held In Treasury</link:label>
    <link:label id="lab_vrna_StockIssuedDuringPeriodSharesHeldInTreasury_documentation_en-US" xlink:label="lab_vrna_StockIssuedDuringPeriodSharesHeldInTreasury" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Held In Treasury</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_StockIssuedDuringPeriodSharesHeldInTreasury" xlink:href="vrna-20221231.xsd#vrna_StockIssuedDuringPeriodSharesHeldInTreasury"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_StockIssuedDuringPeriodSharesHeldInTreasury" xlink:to="lab_vrna_StockIssuedDuringPeriodSharesHeldInTreasury" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_863af1cd-75df-4878-b2c6-60266abbafe1_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_b0bd8709-cfb0-46a7-af59-da7e44727866_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_27128b11-5dc9-4699-b97a-4c0607f9416c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_ce808256-f96e-4c93-a58c-e0c747ddc302_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Valuation Assumptions of Warrants</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_5c3af61d-0503-4b8d-b63c-2bca605d3c53_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution cost</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_920d698b-5e25-455d-ac2c-51189da58d15_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_432034db-7cec-4cb0-b175-0c24e71aa91c_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of ordinary shares to treasury (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_cf0c6390-fb0e-4f24-995d-0e506fbc999f_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_068c7c80-eb2c-4bf9-9e6d-5b27830d77cc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_82170135-db17-4b14-9bce-630aee41d7bb_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity interest</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights_b0fddc7f-fca2-4015-a925-517c28be47f6_terseLabel_en-US" xlink:label="lab_vrna_ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issue price of warrants (in pounds sterling per share)</link:label>
    <link:label id="lab_vrna_ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights_label_en-US" xlink:label="lab_vrna_ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Issue Price of Warrants or Rights</link:label>
    <link:label id="lab_vrna_ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights_documentation_en-US" xlink:label="lab_vrna_ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Issue Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights" xlink:href="vrna-20221231.xsd#vrna_ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights" xlink:to="lab_vrna_ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_EffectiveIncomeTaxRateReconciliationCapitalAllowancesPercent_5e769322-5fb1-4bfa-b0b0-869468d19bfb_terseLabel_en-US" xlink:label="lab_vrna_EffectiveIncomeTaxRateReconciliationCapitalAllowancesPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other differences</link:label>
    <link:label id="lab_vrna_EffectiveIncomeTaxRateReconciliationCapitalAllowancesPercent_label_en-US" xlink:label="lab_vrna_EffectiveIncomeTaxRateReconciliationCapitalAllowancesPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Capital Allowances, Percent</link:label>
    <link:label id="lab_vrna_EffectiveIncomeTaxRateReconciliationCapitalAllowancesPercent_documentation_en-US" xlink:label="lab_vrna_EffectiveIncomeTaxRateReconciliationCapitalAllowancesPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Capital Allowances, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_EffectiveIncomeTaxRateReconciliationCapitalAllowancesPercent" xlink:href="vrna-20221231.xsd#vrna_EffectiveIncomeTaxRateReconciliationCapitalAllowancesPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_EffectiveIncomeTaxRateReconciliationCapitalAllowancesPercent" xlink:to="lab_vrna_EffectiveIncomeTaxRateReconciliationCapitalAllowancesPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_a45d72f8-a836-45cc-94ec-81cf4ec9a4cc_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_cf134de3-fd1b-4163-b116-06ae34853de6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5278c255-3277-4ff6-b9c9-a45cfa49e9cf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, Weight average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_efb16749-e6d2-418c-8d67-6f971371a81c_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party transactions and other shareholder matters</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_0d790eae-93a9-4f8d-b186-6bdb57c0221a_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_35458248-9666-40c4-b636-87c53640ef28_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_LigandUKDevelopmentLimitedMember_2991a8e4-08c3-45a3-b3e7-3b97f79af847_terseLabel_en-US" xlink:label="lab_vrna_LigandUKDevelopmentLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ligand UK Development Limited</link:label>
    <link:label id="lab_vrna_LigandUKDevelopmentLimitedMember_label_en-US" xlink:label="lab_vrna_LigandUKDevelopmentLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ligand UK Development Limited [Member]</link:label>
    <link:label id="lab_vrna_LigandUKDevelopmentLimitedMember_documentation_en-US" xlink:label="lab_vrna_LigandUKDevelopmentLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ligand UK Development Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_LigandUKDevelopmentLimitedMember" xlink:href="vrna-20221231.xsd#vrna_LigandUKDevelopmentLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_LigandUKDevelopmentLimitedMember" xlink:to="lab_vrna_LigandUKDevelopmentLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_a3951c8e-4733-4ea7-a9b0-eb8b40c431ad_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b1ce08a0-973d-4935-b603-a3e7cce43d19_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_09e6de81-122b-4dd9-bed5-00eb19fc8b21_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_227e2c46-6f07-4652-a82b-bebcbfd3c013_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term to exercise</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_cf585611-3698-4da8-abf5-4b0775d80917_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2f376baf-268d-4ce5-854e-6ea16828af9f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d8d3ec28-7943-411e-954a-c7542b857d41_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of RSUs outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_21538ea6-feb9-4a66-9453-8087b75d8a00_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_aca3b026-2559-4edb-bcf1-c56d1b761931_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod_1077b07c-0456-43d9-af8d-c16a65e2b5ff_terseLabel_en-US" xlink:label="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period to maintain minimum stock price</link:label>
    <link:label id="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod_label_en-US" xlink:label="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Award Vesting Rights, Minimum Stock Price Required, Period</link:label>
    <link:label id="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod_documentation_en-US" xlink:label="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Award Vesting Rights, Minimum Stock Price Required, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod" xlink:href="vrna-20221231.xsd#vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod" xlink:to="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_bf0aad4a-ed16-49c7-a612-e01ba3c98661_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current tax expense/(credit)</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_00f54434-82d1-4ec7-a4b1-51dbd00576a1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6b403e89-5ce4-4196-8b40-ffd7d05f9c18_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_NumberOfWhollyOwnedSubsidiaries_0f0613c5-3a86-437a-916f-fecaf1ddb9ef_terseLabel_en-US" xlink:label="lab_vrna_NumberOfWhollyOwnedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of wholly owned subsidiaries</link:label>
    <link:label id="lab_vrna_NumberOfWhollyOwnedSubsidiaries_label_en-US" xlink:label="lab_vrna_NumberOfWhollyOwnedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Wholly Owned Subsidiaries</link:label>
    <link:label id="lab_vrna_NumberOfWhollyOwnedSubsidiaries_documentation_en-US" xlink:label="lab_vrna_NumberOfWhollyOwnedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Wholly Owned Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_NumberOfWhollyOwnedSubsidiaries" xlink:href="vrna-20221231.xsd#vrna_NumberOfWhollyOwnedSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_NumberOfWhollyOwnedSubsidiaries" xlink:to="lab_vrna_NumberOfWhollyOwnedSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_5b6f83bb-d984-4085-aa2f-4b8068688c35_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_f884a048-96cf-472f-955c-7109c0793aa1_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares called by each warrant</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_75c86645-6dc1-4893-8a7b-531dc4c7ac6f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_bf1da613-7e2c-498e-9993-5cfe1aa4d0cd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_f94d4530-f80f-43fb-8131-6cbfdb061610_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_803b5feb-2f8a-4f5b-b633-35fe4774434a_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_LineOfCreditFacilityNumberOfLoanAdvances_42f7cbaf-0432-445e-a737-f8114f78232e_terseLabel_en-US" xlink:label="lab_vrna_LineOfCreditFacilityNumberOfLoanAdvances" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Number of Loan Advances</link:label>
    <link:label id="lab_vrna_LineOfCreditFacilityNumberOfLoanAdvances_label_en-US" xlink:label="lab_vrna_LineOfCreditFacilityNumberOfLoanAdvances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Number of Loan Advances</link:label>
    <link:label id="lab_vrna_LineOfCreditFacilityNumberOfLoanAdvances_documentation_en-US" xlink:label="lab_vrna_LineOfCreditFacilityNumberOfLoanAdvances" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Number of Loan Advances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_LineOfCreditFacilityNumberOfLoanAdvances" xlink:href="vrna-20221231.xsd#vrna_LineOfCreditFacilityNumberOfLoanAdvances"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_LineOfCreditFacilityNumberOfLoanAdvances" xlink:to="lab_vrna_LineOfCreditFacilityNumberOfLoanAdvances" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_e0ba2487-9d6b-447e-9da9-8fec2e4ea0ea_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_c79e95cc-a838-4cdb-ad64-7a945807f8f6_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6ab4c100-ef92-4ce4-a661-49727efd6a6e_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently issued accounting pronouncements, not yet adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_87697097-1eab-4ea3-82fb-610021ac2fd8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future exercisable shares</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_317f77e4-fc15-4545-b223-c5131ea0589f_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_ce6ed42e-e4ab-48c1-be66-2a90f734dd5a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_7a9b2aa4-5d26-4705-85a7-a12ba45c3897_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_3e7907d1-3269-4601-8194-2b22f84d0fe9_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_816e06b8-3d1f-4b92-9bc2-121b5a37c275_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cda5c8e2-afc5-4534-9eb1-be053ea7726f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_361f6c3a-8090-41e3-8ad3-c087e06d5218_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_2aab1ac7-c552-431d-a2cc-bc372e4dfe6b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_ce3402e6-b154-420c-b831-7323ce00cfe1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (expense)/income</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_648da769-37f3-4030-9abd-d8500aad6c8d_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total income tax expense/(credit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_f87719b1-3ef9-40b3-ad40-571008a088b0_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_b18f88ae-0e9c-466f-9a75-d2542a2ae942_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_5763999b-3bbb-40ff-bdf7-2e761b77bc44_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom</link:label>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_8442c581-dc9c-4ed0-9d51-22cb9bb0a5ce_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c6299990-7f29-4853-97b1-d2c426c51b17_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d0c386c4-0615-46cb-9eee-6ae0bedc2cfd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_7a1f4b57-16a5-4b51-82cc-ddc200714c39_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_de454a85-b896-44c3-bbbf-a08b3c775172_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_9289ae2d-3e69-4d7e-b7b0-0597441506f2_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_89f10f07-b68e-4274-b80d-362e0dc66ba4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of stock options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f9f1b3c9-56de-46b2-ad5a-d038578a49a0_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_0cf8ab9b-7cb6-41fe-8f59-77df906845d6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8f9b94cd-3185-4340-83f5-a076e43995d9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected lives, years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_866a6c76-b21a-4b55-aee5-c0a6055b7262_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_be157862-598f-4926-a8b9-9670582955b3_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_PrepaidExpenseDisclosureTextBlock_841fbba5-798f-45da-a098-89ce83bbc75d_terseLabel_en-US" xlink:label="lab_vrna_PrepaidExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_vrna_PrepaidExpenseDisclosureTextBlock_label_en-US" xlink:label="lab_vrna_PrepaidExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Disclosure [Text Block]</link:label>
    <link:label id="lab_vrna_PrepaidExpenseDisclosureTextBlock_documentation_en-US" xlink:label="lab_vrna_PrepaidExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_PrepaidExpenseDisclosureTextBlock" xlink:href="vrna-20221231.xsd#vrna_PrepaidExpenseDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_PrepaidExpenseDisclosureTextBlock" xlink:to="lab_vrna_PrepaidExpenseDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_WarrantLiabilityCurrent_d198c6f8-65f8-4479-95e6-9102d7e740ed_verboseLabel_en-US" xlink:label="lab_vrna_WarrantLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Calculated value of the warrants, in thousands of U.S. dollars</link:label>
    <link:label id="lab_vrna_WarrantLiabilityCurrent_label_en-US" xlink:label="lab_vrna_WarrantLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liability, Current</link:label>
    <link:label id="lab_vrna_WarrantLiabilityCurrent_documentation_en-US" xlink:label="lab_vrna_WarrantLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_WarrantLiabilityCurrent" xlink:href="vrna-20221231.xsd#vrna_WarrantLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_WarrantLiabilityCurrent" xlink:to="lab_vrna_WarrantLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_AccruedResearchAndDevelopmentFeesCurrent_a32c5528-b929-45f9-8708-2e211232cd01_terseLabel_en-US" xlink:label="lab_vrna_AccruedResearchAndDevelopmentFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical trial and other development costs</link:label>
    <link:label id="lab_vrna_AccruedResearchAndDevelopmentFeesCurrent_label_en-US" xlink:label="lab_vrna_AccruedResearchAndDevelopmentFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Fees, Current</link:label>
    <link:label id="lab_vrna_AccruedResearchAndDevelopmentFeesCurrent_documentation_en-US" xlink:label="lab_vrna_AccruedResearchAndDevelopmentFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AccruedResearchAndDevelopmentFeesCurrent" xlink:href="vrna-20221231.xsd#vrna_AccruedResearchAndDevelopmentFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_AccruedResearchAndDevelopmentFeesCurrent" xlink:to="lab_vrna_AccruedResearchAndDevelopmentFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_17b82718-d4ab-463b-a813-e3db44c3a59d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary &#163;0.05 par value shares: 631,338,246 and 489,177,550 issued, and 606,301,054 and 480,082,966 outstanding, at December 31, 2022 and 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares_b9d1672a-b2d2-473d-9dde-eef4c051ec90_terseLabel_en-US" xlink:label="lab_vrna_StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of ordinary shares to treasury as ADS equivalent (in shares)</link:label>
    <link:label id="lab_vrna_StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares_label_en-US" xlink:label="lab_vrna_StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Held In Treasury (American Depository Shares)</link:label>
    <link:label id="lab_vrna_StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares_documentation_en-US" xlink:label="lab_vrna_StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Held In Treasury (American Depository Shares)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares" xlink:href="vrna-20221231.xsd#vrna_StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares" xlink:to="lab_vrna_StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_cca6fd9a-d57e-4f15-944f-6cc8045045de_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_c8ce1c20-96e7-4726-b2d4-9cbfe80761a3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a03ea734-c6fd-47ec-aabe-fd3118af1e02_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_OxfordTermBLoanMember_e3d22fde-8819-4aa8-a645-1aafa0b09b35_terseLabel_en-US" xlink:label="lab_vrna_OxfordTermBLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Term B Loan</link:label>
    <link:label id="lab_vrna_OxfordTermBLoanMember_label_en-US" xlink:label="lab_vrna_OxfordTermBLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Term B Loan [Member]</link:label>
    <link:label id="lab_vrna_OxfordTermBLoanMember_documentation_en-US" xlink:label="lab_vrna_OxfordTermBLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Term B Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_OxfordTermBLoanMember" xlink:href="vrna-20221231.xsd#vrna_OxfordTermBLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_OxfordTermBLoanMember" xlink:to="lab_vrna_OxfordTermBLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustment_d4db5e10-8807-4a81-aa45-bf99aa3b29a3_terseLabel_en-US" xlink:label="lab_vrna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value adjustment</link:label>
    <link:label id="lab_vrna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustment_label_en-US" xlink:label="lab_vrna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Fair Value Adjustment</link:label>
    <link:label id="lab_vrna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustment_documentation_en-US" xlink:label="lab_vrna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Fair Value Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustment" xlink:href="vrna-20221231.xsd#vrna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustment" xlink:to="lab_vrna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c743b82f-0f04-4272-ad60-096bcb68b9c9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, Aggregate intrinsic value (in dollars)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_IncreaseDecreaseInEquityInterestReceivable_12546124-cd68-4dd9-b206-92aa250c3c3d_negatedTerseLabel_en-US" xlink:label="lab_vrna_IncreaseDecreaseInEquityInterestReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity interest recognized as revenue</link:label>
    <link:label id="lab_vrna_IncreaseDecreaseInEquityInterestReceivable_label_en-US" xlink:label="lab_vrna_IncreaseDecreaseInEquityInterestReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Equity Interest Receivable</link:label>
    <link:label id="lab_vrna_IncreaseDecreaseInEquityInterestReceivable_documentation_en-US" xlink:label="lab_vrna_IncreaseDecreaseInEquityInterestReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Equity Interest Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_IncreaseDecreaseInEquityInterestReceivable" xlink:href="vrna-20221231.xsd#vrna_IncreaseDecreaseInEquityInterestReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_IncreaseDecreaseInEquityInterestReceivable" xlink:to="lab_vrna_IncreaseDecreaseInEquityInterestReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a3f08e33-b171-4c20-a56d-b7fa04818b8a_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of the year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_50058e9b-11e0-4376-ba9a-8c9cd12ed727_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of the year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_GainLossFromResearchAndDevelopmentTaxCredit_3621ab1b-422f-4b1a-9f6d-7f7aab1eed88_terseLabel_en-US" xlink:label="lab_vrna_GainLossFromResearchAndDevelopmentTaxCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development tax credit</link:label>
    <link:label id="lab_vrna_GainLossFromResearchAndDevelopmentTaxCredit_label_en-US" xlink:label="lab_vrna_GainLossFromResearchAndDevelopmentTaxCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) From Research And Development Tax Credit</link:label>
    <link:label id="lab_vrna_GainLossFromResearchAndDevelopmentTaxCredit_documentation_en-US" xlink:label="lab_vrna_GainLossFromResearchAndDevelopmentTaxCredit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) From Research And Development Tax Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_GainLossFromResearchAndDevelopmentTaxCredit" xlink:href="vrna-20221231.xsd#vrna_GainLossFromResearchAndDevelopmentTaxCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_GainLossFromResearchAndDevelopmentTaxCredit" xlink:to="lab_vrna_GainLossFromResearchAndDevelopmentTaxCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_69f84335-a223-4797-a6e6-4dca23befec8_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_67a7fa53-a89e-47ae-a905-3d21de4a0098_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_988791d1-8093-478f-837f-509f91c0c964_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_b92d64ac-2b7d-4ea1-b1ed-1f2eeef7c8b5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_aa3ee0f2-8cc3-470f-8da8-3bb354df2809_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss available to ordinary shareholders - basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_6642ad61-f681-4119-ab28-dc9b273df6ae_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of share options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_33d35938-e4e7-4121-a78a-99bbd55ef504_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of Oxford Term Loan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_e250c47b-3202-4844-b01c-e482fe8bd3c6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_fb1969e8-8fab-43bd-a54a-c71385322035_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange (loss)/gain</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_9fe79a60-5fd5-42e0-9aa6-57580155667a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange loss/(gain)</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_3e14f084-dda8-4171-ace9-c20d7f6b1093_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_861c4227-b588-4838-8abd-31fa805e7e2d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Weighted average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_e7da5b32-85b5-41d4-9857-8afcea64f628_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_3ded28ad-be88-49a5-872b-78ba057624c0_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_AtTheMarketSalesAgreementMember_6ed6fe41-2a32-4607-8c3a-15f6bf27a100_terseLabel_en-US" xlink:label="lab_vrna_AtTheMarketSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-The-Market Sales Agreement</link:label>
    <link:label id="lab_vrna_AtTheMarketSalesAgreementMember_label_en-US" xlink:label="lab_vrna_AtTheMarketSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-The-Market Sales Agreement [Member]</link:label>
    <link:label id="lab_vrna_AtTheMarketSalesAgreementMember_documentation_en-US" xlink:label="lab_vrna_AtTheMarketSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-The-Market Sales Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AtTheMarketSalesAgreementMember" xlink:href="vrna-20221231.xsd#vrna_AtTheMarketSalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_AtTheMarketSalesAgreementMember" xlink:to="lab_vrna_AtTheMarketSalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_d225a6e6-726f-4f09-ad5f-c1b803033089_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_584838f9-29d8-4a4a-8978-ca4d2baef000_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short term investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_88bb1057-6210-46fd-95a4-5d7058502016_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_481b0494-22c5-4079-9b0a-566a92e1d574_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_0ce700e1-896f-4576-a2d1-11387983a42a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4f975c1f-ec93-48fa-977b-7316b182172c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option activity, additional disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_73523fc0-cb8b-4242-90cc-7fa1beba4dc7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_ClassOfWarrantOrRightNumberOfExercisedOrForfeited_672ecd82-6595-4079-bf91-6d25ec2f7a25_terseLabel_en-US" xlink:label="lab_vrna_ClassOfWarrantOrRightNumberOfExercisedOrForfeited" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants exercised and forfeited</link:label>
    <link:label id="lab_vrna_ClassOfWarrantOrRightNumberOfExercisedOrForfeited_label_en-US" xlink:label="lab_vrna_ClassOfWarrantOrRightNumberOfExercisedOrForfeited" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Number Of Exercised Or Forfeited</link:label>
    <link:label id="lab_vrna_ClassOfWarrantOrRightNumberOfExercisedOrForfeited_documentation_en-US" xlink:label="lab_vrna_ClassOfWarrantOrRightNumberOfExercisedOrForfeited" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Number Of Exercised Or Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ClassOfWarrantOrRightNumberOfExercisedOrForfeited" xlink:href="vrna-20221231.xsd#vrna_ClassOfWarrantOrRightNumberOfExercisedOrForfeited"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_ClassOfWarrantOrRightNumberOfExercisedOrForfeited" xlink:to="lab_vrna_ClassOfWarrantOrRightNumberOfExercisedOrForfeited" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_0b1d4116-94b2-4869-8f50-a3eed033fe9b_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_9b083233-b92f-4c28-bccc-3c84354be0bb_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.K. tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_ContractWithCustomerFutureEligibleMilestonePayments_6e1017f0-11e3-4300-bd12-5c9d8d3b1294_terseLabel_en-US" xlink:label="lab_vrna_ContractWithCustomerFutureEligibleMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future eligible milestone payments</link:label>
    <link:label id="lab_vrna_ContractWithCustomerFutureEligibleMilestonePayments_label_en-US" xlink:label="lab_vrna_ContractWithCustomerFutureEligibleMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Future Eligible Milestone Payments</link:label>
    <link:label id="lab_vrna_ContractWithCustomerFutureEligibleMilestonePayments_documentation_en-US" xlink:label="lab_vrna_ContractWithCustomerFutureEligibleMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Future Eligible Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ContractWithCustomerFutureEligibleMilestonePayments" xlink:href="vrna-20221231.xsd#vrna_ContractWithCustomerFutureEligibleMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_ContractWithCustomerFutureEligibleMilestonePayments" xlink:to="lab_vrna_ContractWithCustomerFutureEligibleMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_34bb76b8-3004-4648-8d19-b86838cda20d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_7f9d40b7-3a31-4334-b003-2f439b43b254_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_25cfcfa1-038b-46cd-a705-7f1c7dd34e52_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_654b80a6-e0f1-4074-a0c6-3feff3f40979_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_60bd9abb-ef11-478c-a1e6-623437689bf6_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share options exercised</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_c5683886-1fff-4404-aa17-18679f153150_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_a5fdeb30-36cd-457f-ab35-c1c52525dfc8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom</link:label>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_16f1efaa-0b09-4639-9f33-ae96d9b006bc_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_d14afcea-2f50-4cbc-a2d9-ef4919167a7d_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSU Activity</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c8170b7d-e191-4d7a-929d-77a77681abca_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_dbd5ed7e-d35c-4ec5-8f2e-5734c185b1fd_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_a516b1d0-fa05-44a5-88bf-b8a8649c32a9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of SVB Term Loan</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_9c5e8b93-9bb1-419e-a459-4f7e984accf6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_4a50233b-6861-4547-a09b-0949da46ec59_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_aabd452b-106a-45c0-89e6-bebefd305ba4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary shares held in treasury</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_41d6b1ad-7b2f-4c64-8899-954bc924f04b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share options exercised</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b1349d71-62f4-452b-a507-148c287efabd_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_196e219c-4c91-4ab6-ac65-d693b61e8784_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_ed9836dc-5565-458f-b0fd-877b085e87ff_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_6960ecfa-ea78-4c82-9713-927fd5452398_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_029a56af-87a3-4914-9531-a53898f5363a_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_60fcd9b4-8fd9-442f-931b-b6e169f8713b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_TermBLoanMember_327eacb4-a780-4deb-9322-fd132335207e_terseLabel_en-US" xlink:label="lab_vrna_TermBLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term B Loan</link:label>
    <link:label id="lab_vrna_TermBLoanMember_label_en-US" xlink:label="lab_vrna_TermBLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term B Loan [Member]</link:label>
    <link:label id="lab_vrna_TermBLoanMember_documentation_en-US" xlink:label="lab_vrna_TermBLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term B Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TermBLoanMember" xlink:href="vrna-20221231.xsd#vrna_TermBLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_TermBLoanMember" xlink:to="lab_vrna_TermBLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_6f6afcb2-4f42-4e7e-a000-0d8a12dc527d_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_NuanceShanghaiPharmaCoLtdMember_1e014d5b-2192-4bb9-acae-21be85a40542_terseLabel_en-US" xlink:label="lab_vrna_NuanceShanghaiPharmaCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nuance (Shanghai) Pharma Co Ltd</link:label>
    <link:label id="lab_vrna_NuanceShanghaiPharmaCoLtdMember_label_en-US" xlink:label="lab_vrna_NuanceShanghaiPharmaCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nuance (Shanghai) Pharma Co Ltd [Member]</link:label>
    <link:label id="lab_vrna_NuanceShanghaiPharmaCoLtdMember_documentation_en-US" xlink:label="lab_vrna_NuanceShanghaiPharmaCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nuance (Shanghai) Pharma Co Ltd</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_NuanceShanghaiPharmaCoLtdMember" xlink:href="vrna-20221231.xsd#vrna_NuanceShanghaiPharmaCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_NuanceShanghaiPharmaCoLtdMember" xlink:to="lab_vrna_NuanceShanghaiPharmaCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_DebtInstrumentFinalPaymentPercentageOfPrincipalAmount_e053c1c6-b883-4ec9-b2e1-83168dc0971c_terseLabel_en-US" xlink:label="lab_vrna_DebtInstrumentFinalPaymentPercentageOfPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Final Payment, Percentage of Principal Amount</link:label>
    <link:label id="lab_vrna_DebtInstrumentFinalPaymentPercentageOfPrincipalAmount_label_en-US" xlink:label="lab_vrna_DebtInstrumentFinalPaymentPercentageOfPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Final Payment, Percentage of Principal Amount</link:label>
    <link:label id="lab_vrna_DebtInstrumentFinalPaymentPercentageOfPrincipalAmount_documentation_en-US" xlink:label="lab_vrna_DebtInstrumentFinalPaymentPercentageOfPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Final Payment, Percentage of Principal Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentFinalPaymentPercentageOfPrincipalAmount" xlink:href="vrna-20221231.xsd#vrna_DebtInstrumentFinalPaymentPercentageOfPrincipalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_DebtInstrumentFinalPaymentPercentageOfPrincipalAmount" xlink:to="lab_vrna_DebtInstrumentFinalPaymentPercentageOfPrincipalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_19a2711e-0586-42d1-9a05-9bd5fab6e718_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_ded6698c-dfc5-4f97-ba0f-6e07d8a0ce73_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_7a211c03-ddbb-4c9f-9fb4-64f45165db87_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_fa7d8064-33df-4389-b97b-6ca7bac90e27_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_58bbc588-c015-4cd7-bb23-82e32920fb53_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_7c625735-691b-42c1-917c-7a0157e8eb96_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_2aaedd23-614b-4b84-8475-3c97dfdf53f0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost related to share options and RSUs granted but not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ac827c55-3a52-49dd-bbee-02b3cdd3f551_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_791452d6-963c-4f34-8162-06e6a5fc16b3_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_2a5a1cbf-2e6a-4b10-9116-a50e47c38c7b_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of redemption premium on debt</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_d74f2a3f-44b1-4875-b344-fe32f3fd2a9b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Aggregate intrinsic value (in dollars)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_5649fc6e-67d4-4468-a940-55f38e544160_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_60ab459c-e4bd-448f-b235-788e8ad30e5f_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_MeasurementInputAnnualizedVolatilityMember_b082d91a-ffc0-4e29-8856-75fb13d64585_terseLabel_en-US" xlink:label="lab_vrna_MeasurementInputAnnualizedVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annualized volatility</link:label>
    <link:label id="lab_vrna_MeasurementInputAnnualizedVolatilityMember_label_en-US" xlink:label="lab_vrna_MeasurementInputAnnualizedVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Annualized Volatility [Member]</link:label>
    <link:label id="lab_vrna_MeasurementInputAnnualizedVolatilityMember_documentation_en-US" xlink:label="lab_vrna_MeasurementInputAnnualizedVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Annualized Volatility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_MeasurementInputAnnualizedVolatilityMember" xlink:href="vrna-20221231.xsd#vrna_MeasurementInputAnnualizedVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_MeasurementInputAnnualizedVolatilityMember" xlink:to="lab_vrna_MeasurementInputAnnualizedVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod_41ade6c9-fb23-4a62-a801-1284538bb383_terseLabel_en-US" xlink:label="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining vesting Period</link:label>
    <link:label id="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod_label_en-US" xlink:label="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Vesting Period</link:label>
    <link:label id="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod_documentation_en-US" xlink:label="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod" xlink:href="vrna-20221231.xsd#vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod" xlink:to="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_74169855-9480-451e-8bfc-aadf602f8a70_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_efcdae24-4836-45f3-93b6-e606d2167cdc_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_d4a3b7ad-6c83-4de9-a2ef-a82806a7dbb2_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_612c6789-d9e5-47f3-abcd-3ee02d677853_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Term Loan issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_d4958a7d-4ec7-42a9-8412-b22c00e100a2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_6e68cc88-e17e-47b0-b9ac-ef3e6bbad5cd_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance at January 1</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_0f0068ef-2ade-48ed-a370-66418aba8b0e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance at December 31</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_47802ae8-6750-46c2-9947-0201e2acc487_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_76ca8cac-bf06-41be-9a50-8c91739ecf5f_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_2f2bdc4b-1696-4308-a6b4-0b2407cdef6f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_PublicStockOfferingMember_fa39a405-3dff-440e-a510-7b2334db29f2_terseLabel_en-US" xlink:label="lab_vrna_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering</link:label>
    <link:label id="lab_vrna_PublicStockOfferingMember_label_en-US" xlink:label="lab_vrna_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering [Member]</link:label>
    <link:label id="lab_vrna_PublicStockOfferingMember_documentation_en-US" xlink:label="lab_vrna_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_PublicStockOfferingMember" xlink:href="vrna-20221231.xsd#vrna_PublicStockOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_PublicStockOfferingMember" xlink:to="lab_vrna_PublicStockOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f152a2cc-c443-4c4e-9a88-823d06d65e51_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_PrepaidResearchAndDevelopmentFeesCurrent_378dfc26-d630-4e35-b624-2bf1ab4176be_terseLabel_en-US" xlink:label="lab_vrna_PrepaidResearchAndDevelopmentFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical trial and other development costs</link:label>
    <link:label id="lab_vrna_PrepaidResearchAndDevelopmentFeesCurrent_label_en-US" xlink:label="lab_vrna_PrepaidResearchAndDevelopmentFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Research And Development Fees, Current</link:label>
    <link:label id="lab_vrna_PrepaidResearchAndDevelopmentFeesCurrent_documentation_en-US" xlink:label="lab_vrna_PrepaidResearchAndDevelopmentFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Research And Development Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_PrepaidResearchAndDevelopmentFeesCurrent" xlink:href="vrna-20221231.xsd#vrna_PrepaidResearchAndDevelopmentFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_PrepaidResearchAndDevelopmentFeesCurrent" xlink:to="lab_vrna_PrepaidResearchAndDevelopmentFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanTextBlock_f6909720-97a5-49c9-a604-5d163a5d8bf2_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits plans</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanTextBlock_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanTextBlock" xlink:to="lab_us-gaap_DefinedContributionPlanTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2973ed34-b8c2-4bf6-a905-11b11e421487_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted, Weight average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_OxfordTermDLoanMember_1b979315-be4f-4e98-be8e-bc5d14d90c9e_terseLabel_en-US" xlink:label="lab_vrna_OxfordTermDLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Term D Loan</link:label>
    <link:label id="lab_vrna_OxfordTermDLoanMember_label_en-US" xlink:label="lab_vrna_OxfordTermDLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Term D Loan [Member]</link:label>
    <link:label id="lab_vrna_OxfordTermDLoanMember_documentation_en-US" xlink:label="lab_vrna_OxfordTermDLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Term D Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_OxfordTermDLoanMember" xlink:href="vrna-20221231.xsd#vrna_OxfordTermDLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_OxfordTermDLoanMember" xlink:to="lab_vrna_OxfordTermDLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2bb7b4ee-34fc-478e-8e6b-1821237e30ce_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration received from sale of stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_718446fd-2b8a-4485-bcf1-be3ac8d8cb4a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_SublicensePayment_aaa6acd4-7756-44d5-8c80-f17b1c5f1cd4_terseLabel_en-US" xlink:label="lab_vrna_SublicensePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublicense Payment</link:label>
    <link:label id="lab_vrna_SublicensePayment_label_en-US" xlink:label="lab_vrna_SublicensePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublicense Payment</link:label>
    <link:label id="lab_vrna_SublicensePayment_documentation_en-US" xlink:label="lab_vrna_SublicensePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublicense Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SublicensePayment" xlink:href="vrna-20221231.xsd#vrna_SublicensePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_SublicensePayment" xlink:to="lab_vrna_SublicensePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_TermLoanFacilityMember_1e7bb2e3-83a4-46f7-963b-b85b67ca64a5_terseLabel_en-US" xlink:label="lab_vrna_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility</link:label>
    <link:label id="lab_vrna_TermLoanFacilityMember_label_en-US" xlink:label="lab_vrna_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility [Member]</link:label>
    <link:label id="lab_vrna_TermLoanFacilityMember_documentation_en-US" xlink:label="lab_vrna_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TermLoanFacilityMember" xlink:href="vrna-20221231.xsd#vrna_TermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_TermLoanFacilityMember" xlink:to="lab_vrna_TermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_d0fac1b8-3449-4439-93ec-28106ca79a6f_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_SaleOfStockMaximumAggregateOfferingPrice_21998fa7-ef95-4a19-82f3-ae2e080b51d3_terseLabel_en-US" xlink:label="lab_vrna_SaleOfStockMaximumAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum aggregate offering price</link:label>
    <link:label id="lab_vrna_SaleOfStockMaximumAggregateOfferingPrice_label_en-US" xlink:label="lab_vrna_SaleOfStockMaximumAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Aggregate Offering Price</link:label>
    <link:label id="lab_vrna_SaleOfStockMaximumAggregateOfferingPrice_documentation_en-US" xlink:label="lab_vrna_SaleOfStockMaximumAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Aggregate Offering Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SaleOfStockMaximumAggregateOfferingPrice" xlink:href="vrna-20221231.xsd#vrna_SaleOfStockMaximumAggregateOfferingPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_SaleOfStockMaximumAggregateOfferingPrice" xlink:to="lab_vrna_SaleOfStockMaximumAggregateOfferingPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_ba3258ff-0289-4587-92f8-48eb45b22ed5_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cf5b7df6-ef1f-48e0-ad10-a2e366bc3c36_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_6b2fa66e-34da-43a9-ba94-94f650dcaf15_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of ordinary shares</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_DebtInstrumentInterestRatePeriodOneMember_0b0205b2-1b85-4807-99e0-0c429cc90ea4_terseLabel_en-US" xlink:label="lab_vrna_DebtInstrumentInterestRatePeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Rate, Period One</link:label>
    <link:label id="lab_vrna_DebtInstrumentInterestRatePeriodOneMember_label_en-US" xlink:label="lab_vrna_DebtInstrumentInterestRatePeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Rate, Period One [Member]</link:label>
    <link:label id="lab_vrna_DebtInstrumentInterestRatePeriodOneMember_documentation_en-US" xlink:label="lab_vrna_DebtInstrumentInterestRatePeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Rate, Period One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentInterestRatePeriodOneMember" xlink:href="vrna-20221231.xsd#vrna_DebtInstrumentInterestRatePeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_DebtInstrumentInterestRatePeriodOneMember" xlink:to="lab_vrna_DebtInstrumentInterestRatePeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_4488579d-e347-4f62-b585-6f379a0037fa_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_dfeea34c-6a92-4f48-b9ec-dc3d1a6ce876_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total share-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_c336f388-301d-41c6-b342-90cb3f7c0605_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_b2346f09-5e0f-4ddb-9da9-a2ebb5633b3d_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6ac6bf33-8242-487a-b362-7956356c550c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Beginning Balance, Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8d5dce0b-d7ca-4a8e-817f-8d6f6026f2a9_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Ending Balance, Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_1274649e-64b0-4b79-9b40-139412a710be_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_e3d51064-75f1-4e7e-843e-fe06487a6e2f_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_GovernmentTaxCreditsPolicyPolicyTextBlock_5ef022c6-256d-4939-9e0d-e3b9d4653180_terseLabel_en-US" xlink:label="lab_vrna_GovernmentTaxCreditsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income - U.K. R&amp;D tax credits</link:label>
    <link:label id="lab_vrna_GovernmentTaxCreditsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_vrna_GovernmentTaxCreditsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Tax Credits, Policy [Policy Text Block]</link:label>
    <link:label id="lab_vrna_GovernmentTaxCreditsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_vrna_GovernmentTaxCreditsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Tax Credits, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_GovernmentTaxCreditsPolicyPolicyTextBlock" xlink:href="vrna-20221231.xsd#vrna_GovernmentTaxCreditsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_GovernmentTaxCreditsPolicyPolicyTextBlock" xlink:to="lab_vrna_GovernmentTaxCreditsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_7aeb2d54-4f67-458d-b977-3936d192b331_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:to="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfLoanCosts_923f246a-c693-45cb-9005-93999317eecf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfLoanCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SVB Term Loan repayment costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfLoanCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfLoanCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Loan Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfLoanCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfLoanCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfLoanCosts" xlink:to="lab_us-gaap_PaymentsOfLoanCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_8e3ef7f8-3139-409a-b42d-b98f488f4d36_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_7cf9ba58-7b2e-48ef-b0ac-0fc56868debd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_202956ad-082e-4425-80fa-813ccdd76a72_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease accounting</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrent_cb6efd43-4d09-4aac-853e-fd5954f805d5_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="lab_us-gaap_AssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_62e10682-c1b7-4c69-9d61-2d976b883b2c_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_OxfordTermLoanMember_4469e173-e431-4950-8024-b3853b491500_terseLabel_en-US" xlink:label="lab_vrna_OxfordTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Term Loan</link:label>
    <link:label id="lab_vrna_OxfordTermLoanMember_label_en-US" xlink:label="lab_vrna_OxfordTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Term Loan [Member]</link:label>
    <link:label id="lab_vrna_OxfordTermLoanMember_documentation_en-US" xlink:label="lab_vrna_OxfordTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Term Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_OxfordTermLoanMember" xlink:href="vrna-20221231.xsd#vrna_OxfordTermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_OxfordTermLoanMember" xlink:to="lab_vrna_OxfordTermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_35bbcbcb-8c3a-47cf-983f-fca3532c26f0_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_UnrealizedGainLossOnWarrants_47c7c189-78be-482b-80e6-6b13d4ee5fb9_terseLabel_en-US" xlink:label="lab_vrna_UnrealizedGainLossOnWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value movement on warrants</link:label>
    <link:label id="lab_vrna_UnrealizedGainLossOnWarrants_label_en-US" xlink:label="lab_vrna_UnrealizedGainLossOnWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) On Warrants</link:label>
    <link:label id="lab_vrna_UnrealizedGainLossOnWarrants_documentation_en-US" xlink:label="lab_vrna_UnrealizedGainLossOnWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) On Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_UnrealizedGainLossOnWarrants" xlink:href="vrna-20221231.xsd#vrna_UnrealizedGainLossOnWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_UnrealizedGainLossOnWarrants" xlink:to="lab_vrna_UnrealizedGainLossOnWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_0a267bc9-0283-4fb3-8d70-9c2b098ed39a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant agreements</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_DebtInstrumentInterestRatePeriodTwoMember_efd3abd0-e82f-41cf-a746-86378bbcaee1_terseLabel_en-US" xlink:label="lab_vrna_DebtInstrumentInterestRatePeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Rate, Period Two</link:label>
    <link:label id="lab_vrna_DebtInstrumentInterestRatePeriodTwoMember_label_en-US" xlink:label="lab_vrna_DebtInstrumentInterestRatePeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Rate, Period Two [Member]</link:label>
    <link:label id="lab_vrna_DebtInstrumentInterestRatePeriodTwoMember_documentation_en-US" xlink:label="lab_vrna_DebtInstrumentInterestRatePeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Rate, Period Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentInterestRatePeriodTwoMember" xlink:href="vrna-20221231.xsd#vrna_DebtInstrumentInterestRatePeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_DebtInstrumentInterestRatePeriodTwoMember" xlink:to="lab_vrna_DebtInstrumentInterestRatePeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_805a1c9d-f52a-4252-86ee-cfe8a8454955_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d4eaaa6e-6a2b-400c-85bd-677da2ad8aa5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of withholding taxes from share-based awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_353fbd25-ace3-4152-a4fa-03102d08f89b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_5f450671-b700-4e4a-9385-4e9873755ef6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_48fb30d8-89d1-4e65-9d30-0b068600555e_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issue costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_b4a9308a-8503-4ce6-9514-63f6a56300c0_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_RestrictedStockUnitMilestoneBasedVestingMember_86571374-9350-4b01-b4a0-a9b1f8e57291_terseLabel_en-US" xlink:label="lab_vrna_RestrictedStockUnitMilestoneBasedVestingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone-Based Vesting</link:label>
    <link:label id="lab_vrna_RestrictedStockUnitMilestoneBasedVestingMember_label_en-US" xlink:label="lab_vrna_RestrictedStockUnitMilestoneBasedVestingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Unit, Milestone-Based Vesting [Member]</link:label>
    <link:label id="lab_vrna_RestrictedStockUnitMilestoneBasedVestingMember_documentation_en-US" xlink:label="lab_vrna_RestrictedStockUnitMilestoneBasedVestingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Unit, Milestone-Based Vesting</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_RestrictedStockUnitMilestoneBasedVestingMember" xlink:href="vrna-20221231.xsd#vrna_RestrictedStockUnitMilestoneBasedVestingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_RestrictedStockUnitMilestoneBasedVestingMember" xlink:to="lab_vrna_RestrictedStockUnitMilestoneBasedVestingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_4af0df3d-f1a4-48b8-9377-19916d67f342_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_cdd29ae8-7ae8-4755-9e50-c418231ba648_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_7f07d85b-29cd-439f-bfa0-3d27edc0aca2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of loss before income taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_320fd19e-3635-4f01-a8b9-4aca8fb88e85_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_CommonStockSharesAvailableForSaleValue_cc95ebcb-9255-48bb-8869-b204b58a171f_terseLabel_en-US" xlink:label="lab_vrna_CommonStockSharesAvailableForSaleValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining ordinary shares available for sale</link:label>
    <link:label id="lab_vrna_CommonStockSharesAvailableForSaleValue_label_en-US" xlink:label="lab_vrna_CommonStockSharesAvailableForSaleValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Available For Sale, Value</link:label>
    <link:label id="lab_vrna_CommonStockSharesAvailableForSaleValue_documentation_en-US" xlink:label="lab_vrna_CommonStockSharesAvailableForSaleValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Available For Sale, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_CommonStockSharesAvailableForSaleValue" xlink:href="vrna-20221231.xsd#vrna_CommonStockSharesAvailableForSaleValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_CommonStockSharesAvailableForSaleValue" xlink:to="lab_vrna_CommonStockSharesAvailableForSaleValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_d6b1d7fc-2686-4d0c-a7bb-574210b0beb9_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_3b05d8aa-2d31-4273-9ad1-971ffe4439bc_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d083e6c4-34d2-4cf4-a2ea-089cdd53b9e5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_9c1d70d8-2e4a-4c51-be64-4acbf75ed030_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss available to ordinary shareholders - diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_3eba3637-936b-4872-8a31-ab35125f2a30_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per ordinary share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_ClassOfWarrantOrRightIntrinsicValue_2050ec01-5103-41b0-a966-e77ebc31f647_terseLabel_en-US" xlink:label="lab_vrna_ClassOfWarrantOrRightIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value</link:label>
    <link:label id="lab_vrna_ClassOfWarrantOrRightIntrinsicValue_label_en-US" xlink:label="lab_vrna_ClassOfWarrantOrRightIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Intrinsic Value</link:label>
    <link:label id="lab_vrna_ClassOfWarrantOrRightIntrinsicValue_documentation_en-US" xlink:label="lab_vrna_ClassOfWarrantOrRightIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ClassOfWarrantOrRightIntrinsicValue" xlink:href="vrna-20221231.xsd#vrna_ClassOfWarrantOrRightIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_ClassOfWarrantOrRightIntrinsicValue" xlink:to="lab_vrna_ClassOfWarrantOrRightIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_73e44840-ccf4-47bf-bd2b-f905666a8a70_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0f14bf09-b709-4356-b8fb-8a83fa4727c8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_e5157cf1-d0ea-4791-b396-f3e67e7edd3a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of offering costs in connection with the issuance of ordinary shares</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance_6122cfa1-8bff-46d6-a326-84285cb137bc_terseLabel_en-US" xlink:label="lab_vrna_SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase/(decrease) in valuation allowance</link:label>
    <link:label id="lab_vrna_SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance_label_en-US" xlink:label="lab_vrna_SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule 12-09, Valuation Allowances and Reserves, Increase In Valuation Allowance</link:label>
    <link:label id="lab_vrna_SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance_documentation_en-US" xlink:label="lab_vrna_SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule 12-09, Valuation Allowances and Reserves, Increase In Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance" xlink:href="vrna-20221231.xsd#vrna_SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance" xlink:to="lab_vrna_SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ab8dc17f-c3c5-4305-a9a1-07584595f4d0_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_fc17cce5-4643-4cd5-b1f3-56e7b4711f9e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value adjustment</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_e4df363d-7b21-4f7d-9ae3-5f3e19b7d02f_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_a4d09977-69ec-4445-9602-121d9ed4eaab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_576e4090-b499-49c0-b3c8-a88c8c57524a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_416afcb9-1001-45bb-b477-7dadf31705e0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_TaxCreditAndIncomeTaxesReceivableCurrent_730f2150-0047-4a7c-8d6e-23f34cd93c15_verboseLabel_en-US" xlink:label="lab_vrna_TaxCreditAndIncomeTaxesReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax incentive receivables</link:label>
    <link:label id="lab_vrna_TaxCreditAndIncomeTaxesReceivableCurrent_label_en-US" xlink:label="lab_vrna_TaxCreditAndIncomeTaxesReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit And Income Taxes Receivable, Current</link:label>
    <link:label id="lab_vrna_TaxCreditAndIncomeTaxesReceivableCurrent_documentation_en-US" xlink:label="lab_vrna_TaxCreditAndIncomeTaxesReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit And Income Taxes Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TaxCreditAndIncomeTaxesReceivableCurrent" xlink:href="vrna-20221231.xsd#vrna_TaxCreditAndIncomeTaxesReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_TaxCreditAndIncomeTaxesReceivableCurrent" xlink:to="lab_vrna_TaxCreditAndIncomeTaxesReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_72707151-8703-4606-b208-2494db3756f2_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net of valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_9dc26eb4-b0b1-4c3d-8888-50172676c825_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_201ddcea-ef11-4f0e-9282-469885e700f3_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction price</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_6f8da99e-6c7e-42fa-bb06-8266584afd95_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationInterestAccrued_bae06127-51d1-4e6b-bdd1-0221b9e5ac53_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest accrued</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationInterestAccrued_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination, Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationInterestAccrued" xlink:to="lab_us-gaap_IncomeTaxExaminationInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_13e72ecc-6c80-4ba6-a138-0bdcf8169350_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_953a949a-472c-46d2-9d85-7e787a859a7b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Annual Operating Lease Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_782f64c4-e81b-439d-b591-69689607a728_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_57b4638a-a12f-452c-99cb-00d10a87ec13_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_3f4b5faa-2075-4e21-ab10-3269ba9fac50_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_99f82d41-e9ac-4a46-aa81-8a22cca79f41_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_A2017IncentivePlanMember_7ba5927b-b26f-4cec-9719-6fc6d2268e4d_terseLabel_en-US" xlink:label="lab_vrna_A2017IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Incentive Plan</link:label>
    <link:label id="lab_vrna_A2017IncentivePlanMember_label_en-US" xlink:label="lab_vrna_A2017IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Incentive Plan [Member]</link:label>
    <link:label id="lab_vrna_A2017IncentivePlanMember_documentation_en-US" xlink:label="lab_vrna_A2017IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_A2017IncentivePlanMember" xlink:href="vrna-20221231.xsd#vrna_A2017IncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_A2017IncentivePlanMember" xlink:to="lab_vrna_A2017IncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_fe5a158f-ad18-4bc5-9a44-b6c4dfb30a7f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_d43381d6-7a95-4f10-b71a-4aeedfae4973_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_d1428dd4-fd9c-4fc3-91fe-0edd5a7c9fd7_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_6d9e1a00-5c7f-4477-8a01-415469691722_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_3ce996ca-00f5-4f6f-80f5-4221177fd831_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_cb2ab04d-54db-4626-bb10-f723ecb08c69_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_e2be138d-6ffd-43c1-aec3-3fe1509cf793_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_89039d31-609d-4e84-bf05-c0241238d6c9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostTable_1bdf67f4-f890-4e6a-a1a6-11283236a606_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Table]</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostTable_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostTable" xlink:to="lab_us-gaap_CapitalizedContractCostTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_e175ee48-f156-47f2-81b2-1fccaeb1bd76_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_PreIPOOptionPlanMember_c5725837-ac8d-4024-b003-60dd249a5a38_terseLabel_en-US" xlink:label="lab_vrna_PreIPOOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-IPO Option Plan</link:label>
    <link:label id="lab_vrna_PreIPOOptionPlanMember_label_en-US" xlink:label="lab_vrna_PreIPOOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-IPO Option Plan [Member]</link:label>
    <link:label id="lab_vrna_PreIPOOptionPlanMember_documentation_en-US" xlink:label="lab_vrna_PreIPOOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-IPO Option Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_PreIPOOptionPlanMember" xlink:href="vrna-20221231.xsd#vrna_PreIPOOptionPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_PreIPOOptionPlanMember" xlink:to="lab_vrna_PreIPOOptionPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_37528f49-e557-4a88-a198-dd168509d54f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Activity</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_2575142a-4b32-440f-808d-ab722921199b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of the U.K. statutory income tax rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f94ce699-674f-46d1-ad28-1b0358f45346_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue_c33d7790-140b-47bc-a18f-6defb8a3d93d_terseLabel_en-US" xlink:label="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value for instruments granted during period</link:label>
    <link:label id="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue_label_en-US" xlink:label="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period, Grant Date Fair Value</link:label>
    <link:label id="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue_documentation_en-US" xlink:label="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period, Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue" xlink:href="vrna-20221231.xsd#vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue" xlink:to="lab_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_c87ab73d-08eb-492d-a0c9-a3b53075c678_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_9e0d3a62-4f35-4cf3-854f-ea8398621ccd_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_0c56b52f-d675-4238-9481-0c1cded97f71_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8a789ff1-f908-4e17-957c-f86549cd4b96_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_54171b73-6b1c-43f4-95e3-16d295de56e5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares withheld for taxes on vested stock awards</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_62b0fb14-7516-471a-8358-1200b5e40dd2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_vrna_DebtInstrumentPrepaymentFeePercentage_e71d9680-8570-4e87-a5f6-6beb4e0c5732_terseLabel_en-US" xlink:label="lab_vrna_DebtInstrumentPrepaymentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Fee, Percentage</link:label>
    <link:label id="lab_vrna_DebtInstrumentPrepaymentFeePercentage_label_en-US" xlink:label="lab_vrna_DebtInstrumentPrepaymentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Fee, Percentage</link:label>
    <link:label id="lab_vrna_DebtInstrumentPrepaymentFeePercentage_documentation_en-US" xlink:label="lab_vrna_DebtInstrumentPrepaymentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Fee, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentPrepaymentFeePercentage" xlink:href="vrna-20221231.xsd#vrna_DebtInstrumentPrepaymentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vrna_DebtInstrumentPrepaymentFeePercentage" xlink:to="lab_vrna_DebtInstrumentPrepaymentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_803f5042-5f1d-4ae4-8f06-8183183fbae4_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of credit risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_730cd717-8656-485b-ac4d-ff95b296fe96_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_0cba7469-b7ea-4223-91d5-b4800a484a06_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_fc92e0a5-9859-4fbe-bc78-fa2ab3af477f_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_75ec568d-a97c-46ee-9326-15b0a30abd21_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_6aefe11b-f041-4ada-a369-55a14ad9f137_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_abf0b372-34e1-4203-afe5-aaf10eb668dc_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_877b8e7f-cb91-4e94-a4f1-eb5b5a7b1197_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_b252c9c4-77c9-4695-bf1d-66d44db9e88f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_984b223e-7d9d-475b-a42f-8615b18d595a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostLineItems_2ee91fd7-b332-4cb2-9129-427ddad2ab98_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostLineItems_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems" xlink:to="lab_us-gaap_CapitalizedContractCostLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_f27cbc1b-a071-4f02-93ee-ce351e4b7c02_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Prepaid Expenses</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_061a3d8d-0cf9-4786-9c27-c16c2a11d9a2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e32343a5-42aa-418f-9762-5117acf3073b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_edbd5f9d-868e-451a-9fc1-79e6c0d76bb0_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_e96abc86-01cf-49cf-8f72-59122d98f66f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of outstanding warrants</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ba9f2383-25be-4863-8f84-0a042fd6e2d4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of furniture and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_434764fd-104f-4403-8f92-40046f1900f4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0ba568bf-e687-4838-b6a1-068022c65592_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computation of Basic and Diluted Earning Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1e05a549-b59f-4026-bb13-dadecfb8da09_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets recognized with associated liability</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>vrna-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:3c4b6351-9dd7-43ec-8a74-8bad3a93c534,g:ba5c393f-9b46-4696-9211-0bc9a20ff330-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://veronapharma.com/role/Cover" xlink:type="simple" xlink:href="vrna-20221231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_c8e3baad-3330-4c9a-b455-f221bac718b3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_d8e5e7e7-9b4a-475b-952d-3d27048e0199" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8e3baad-3330-4c9a-b455-f221bac718b3" xlink:to="loc_dei_DocumentType_d8e5e7e7-9b4a-475b-952d-3d27048e0199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_9669ff47-1cb6-4986-b9f2-994dc6e7adb8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8e3baad-3330-4c9a-b455-f221bac718b3" xlink:to="loc_dei_DocumentAnnualReport_9669ff47-1cb6-4986-b9f2-994dc6e7adb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_6abcee6e-ef1f-44c1-8fc0-db4c9678abc9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8e3baad-3330-4c9a-b455-f221bac718b3" xlink:to="loc_dei_DocumentPeriodEndDate_6abcee6e-ef1f-44c1-8fc0-db4c9678abc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_4b7132d1-d76e-4673-b500-2f04fbec0821" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8e3baad-3330-4c9a-b455-f221bac718b3" xlink:to="loc_dei_CurrentFiscalYearEndDate_4b7132d1-d76e-4673-b500-2f04fbec0821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_e00bb0e7-a3d0-4cfe-b52b-9cfbcdf0bb17" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8e3baad-3330-4c9a-b455-f221bac718b3" xlink:to="loc_dei_DocumentTransitionReport_e00bb0e7-a3d0-4cfe-b52b-9cfbcdf0bb17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_b7aa4246-8274-4621-8850-7a64ee5805d6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8e3baad-3330-4c9a-b455-f221bac718b3" xlink:to="loc_dei_EntityFileNumber_b7aa4246-8274-4621-8850-7a64ee5805d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_4e177077-e659-485f-abf9-1b42ea6017e8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8e3baad-3330-4c9a-b455-f221bac718b3" xlink:to="loc_dei_EntityRegistrantName_4e177077-e659-485f-abf9-1b42ea6017e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_067a3a62-e581-4058-98f8-26d9e73882dc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8e3baad-3330-4c9a-b455-f221bac718b3" xlink:to="loc_dei_EntityIncorporationStateCountryCode_067a3a62-e581-4058-98f8-26d9e73882dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_6105a62b-61d1-4e8f-8ff6-2b0433526d7a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8e3baad-3330-4c9a-b455-f221bac718b3" xlink:to="loc_dei_EntityTaxIdentificationNumber_6105a62b-61d1-4e8f-8ff6-2b0433526d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_55f7252d-bed9-4250-9daf-28a5867aa302" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8e3baad-3330-4c9a-b455-f221bac718b3" xlink:to="loc_dei_EntityAddressAddressLine1_55f7252d-bed9-4250-9daf-28a5867aa302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_4c63f279-ba46-4248-b79a-c1a8fc2d5f0b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8e3baad-3330-4c9a-b455-f221bac718b3" xlink:to="loc_dei_EntityAddressCityOrTown_4c63f279-ba46-4248-b79a-c1a8fc2d5f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_7064e69e-4de8-4f48-993b-156f3d27cf0b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8e3baad-3330-4c9a-b455-f221bac718b3" xlink:to="loc_dei_EntityAddressPostalZipCode_7064e69e-4de8-4f48-993b-156f3d27cf0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_152ee016-718f-41b4-b887-78e2f2bf37cd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8e3baad-3330-4c9a-b455-f221bac718b3" xlink:to="loc_dei_EntityAddressCountry_152ee016-718f-41b4-b887-78e2f2bf37cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CountryRegion_aa1c36a3-2d05-4fb7-9fc2-6a28b9323cba" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8e3baad-3330-4c9a-b455-f221bac718b3" xlink:to="loc_dei_CountryRegion_aa1c36a3-2d05-4fb7-9fc2-6a28b9323cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_44375a15-7f06-4ed8-92a4-65a56fb6f2b7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8e3baad-3330-4c9a-b455-f221bac718b3" xlink:to="loc_dei_CityAreaCode_44375a15-7f06-4ed8-92a4-65a56fb6f2b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_8b4fd2b6-7f14-4d6e-a532-1d4b53d523db" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8e3baad-3330-4c9a-b455-f221bac718b3" xlink:to="loc_dei_LocalPhoneNumber_8b4fd2b6-7f14-4d6e-a532-1d4b53d523db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_53957329-b3d5-4ee7-9983-86a070f4fa55" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8e3baad-3330-4c9a-b455-f221bac718b3" xlink:to="loc_dei_Security12bTitle_53957329-b3d5-4ee7-9983-86a070f4fa55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_f005b3ec-e848-4777-8457-200cdbd01ed7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8e3baad-3330-4c9a-b455-f221bac718b3" xlink:to="loc_dei_TradingSymbol_f005b3ec-e848-4777-8457-200cdbd01ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_c5780dde-5829-4686-ba57-393118591ec6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8e3baad-3330-4c9a-b455-f221bac718b3" xlink:to="loc_dei_SecurityExchangeName_c5780dde-5829-4686-ba57-393118591ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_fb3f1c66-f8a4-4946-bd10-0bc1b849486b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8e3baad-3330-4c9a-b455-f221bac718b3" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_fb3f1c66-f8a4-4946-bd10-0bc1b849486b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_2dfcdef4-f1d2-4468-aa00-993233da3861" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8e3baad-3330-4c9a-b455-f221bac718b3" xlink:to="loc_dei_EntityVoluntaryFilers_2dfcdef4-f1d2-4468-aa00-993233da3861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_1aeba618-ef0e-4422-823f-0e6f06e33fe2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8e3baad-3330-4c9a-b455-f221bac718b3" xlink:to="loc_dei_EntityCurrentReportingStatus_1aeba618-ef0e-4422-823f-0e6f06e33fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_eea58393-37a2-4088-9ff1-d46f9c2bc06b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8e3baad-3330-4c9a-b455-f221bac718b3" xlink:to="loc_dei_EntityInteractiveDataCurrent_eea58393-37a2-4088-9ff1-d46f9c2bc06b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_6b6167e8-4be1-45b3-b115-8b1cc521e328" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8e3baad-3330-4c9a-b455-f221bac718b3" xlink:to="loc_dei_EntityFilerCategory_6b6167e8-4be1-45b3-b115-8b1cc521e328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_68e81ede-643b-43ff-b283-47f12f564094" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8e3baad-3330-4c9a-b455-f221bac718b3" xlink:to="loc_dei_EntitySmallBusiness_68e81ede-643b-43ff-b283-47f12f564094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c683bd19-4945-4225-9e17-bdd2a36b3672" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8e3baad-3330-4c9a-b455-f221bac718b3" xlink:to="loc_dei_EntityEmergingGrowthCompany_c683bd19-4945-4225-9e17-bdd2a36b3672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_462db69b-66b9-4e77-a1ca-db98ee0c645c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8e3baad-3330-4c9a-b455-f221bac718b3" xlink:to="loc_dei_IcfrAuditorAttestationFlag_462db69b-66b9-4e77-a1ca-db98ee0c645c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_0969c9a6-1286-448c-be0b-c34578c21181" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8e3baad-3330-4c9a-b455-f221bac718b3" xlink:to="loc_dei_EntityShellCompany_0969c9a6-1286-448c-be0b-c34578c21181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_e4154a5b-2552-410f-8248-acb6a8707169" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8e3baad-3330-4c9a-b455-f221bac718b3" xlink:to="loc_dei_EntityPublicFloat_e4154a5b-2552-410f-8248-acb6a8707169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_78471fad-fa96-43d8-81b4-884b22dd1a2c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8e3baad-3330-4c9a-b455-f221bac718b3" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_78471fad-fa96-43d8-81b4-884b22dd1a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_d959466c-19b2-43f0-a6c9-58a2405fb16e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8e3baad-3330-4c9a-b455-f221bac718b3" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_d959466c-19b2-43f0-a6c9-58a2405fb16e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_00bea96d-958a-4728-b2a9-238516d08597" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8e3baad-3330-4c9a-b455-f221bac718b3" xlink:to="loc_dei_AmendmentFlag_00bea96d-958a-4728-b2a9-238516d08597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_42fc4ba9-4f3e-486f-b570-cdcd5f78ea94" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8e3baad-3330-4c9a-b455-f221bac718b3" xlink:to="loc_dei_DocumentFiscalYearFocus_42fc4ba9-4f3e-486f-b570-cdcd5f78ea94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_5fc2d963-63f6-4883-aa2a-af08204da8b8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8e3baad-3330-4c9a-b455-f221bac718b3" xlink:to="loc_dei_DocumentFiscalPeriodFocus_5fc2d963-63f6-4883-aa2a-af08204da8b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_e068eecb-f928-4531-83b6-25bf4b52f601" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c8e3baad-3330-4c9a-b455-f221bac718b3" xlink:to="loc_dei_EntityCentralIndexKey_e068eecb-f928-4531-83b6-25bf4b52f601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/AuditInformation" xlink:type="simple" xlink:href="vrna-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AuditInformationAbstract_b1e0e1d0-9fd6-46aa-b7cb-193b935cf32a" xlink:href="vrna-20221231.xsd#vrna_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_7626b91e-a1b5-46d6-a753-d4dc213bab64" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrna_AuditInformationAbstract_b1e0e1d0-9fd6-46aa-b7cb-193b935cf32a" xlink:to="loc_dei_AuditorName_7626b91e-a1b5-46d6-a753-d4dc213bab64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_bdb7f421-950c-49a7-bfd8-c3f9424dffd0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrna_AuditInformationAbstract_b1e0e1d0-9fd6-46aa-b7cb-193b935cf32a" xlink:to="loc_dei_AuditorFirmId_bdb7f421-950c-49a7-bfd8-c3f9424dffd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_8bc1378e-469d-4c62-a093-ff7802dc6e08" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrna_AuditInformationAbstract_b1e0e1d0-9fd6-46aa-b7cb-193b935cf32a" xlink:to="loc_dei_AuditorLocation_8bc1378e-469d-4c62-a093-ff7802dc6e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="vrna-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1017985a-9d9f-462f-8b38-07abc412edf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_840d1893-1bf4-4ffe-a409-b0261f134c48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1017985a-9d9f-462f-8b38-07abc412edf3" xlink:to="loc_us-gaap_AssetsAbstract_840d1893-1bf4-4ffe-a409-b0261f134c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_0d0be587-f9cf-40b9-98d7-3a67642fb04d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_840d1893-1bf4-4ffe-a409-b0261f134c48" xlink:to="loc_us-gaap_AssetsCurrentAbstract_0d0be587-f9cf-40b9-98d7-3a67642fb04d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bca72489-baf5-4694-a241-1db545be91fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0d0be587-f9cf-40b9-98d7-3a67642fb04d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bca72489-baf5-4694-a241-1db545be91fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_d3c02181-3440-4d90-8080-df0891ea6883" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0d0be587-f9cf-40b9-98d7-3a67642fb04d" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_d3c02181-3440-4d90-8080-df0891ea6883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TaxCreditAndIncomeTaxesReceivableCurrent_5827f84b-883a-47b1-ac50-c8880178911d" xlink:href="vrna-20221231.xsd#vrna_TaxCreditAndIncomeTaxesReceivableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0d0be587-f9cf-40b9-98d7-3a67642fb04d" xlink:to="loc_vrna_TaxCreditAndIncomeTaxesReceivableCurrent_5827f84b-883a-47b1-ac50-c8880178911d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_eb64a41c-6793-4bce-8795-e97e45361081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0d0be587-f9cf-40b9-98d7-3a67642fb04d" xlink:to="loc_us-gaap_OtherAssetsCurrent_eb64a41c-6793-4bce-8795-e97e45361081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1d2181eb-a1c0-46a3-b10a-6686590c58f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0d0be587-f9cf-40b9-98d7-3a67642fb04d" xlink:to="loc_us-gaap_AssetsCurrent_1d2181eb-a1c0-46a3-b10a-6686590c58f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_57917709-2fc2-445d-be12-d926db4e3ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_840d1893-1bf4-4ffe-a409-b0261f134c48" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_57917709-2fc2-445d-be12-d926db4e3ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8f501750-1c55-4460-89b5-cd306a5932d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_57917709-2fc2-445d-be12-d926db4e3ba8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8f501750-1c55-4460-89b5-cd306a5932d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a3be11f6-20c5-4191-9e1a-d4595c9df09a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_57917709-2fc2-445d-be12-d926db4e3ba8" xlink:to="loc_us-gaap_Goodwill_a3be11f6-20c5-4191-9e1a-d4595c9df09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_b656bbc7-5a90-408d-ad9f-47acaca6ec8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_57917709-2fc2-445d-be12-d926db4e3ba8" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_b656bbc7-5a90-408d-ad9f-47acaca6ec8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_50f9047d-c690-434a-bd83-c6eccf451aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_57917709-2fc2-445d-be12-d926db4e3ba8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_50f9047d-c690-434a-bd83-c6eccf451aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_2d4e03f5-222c-477e-84e8-7eaefcad6af9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_57917709-2fc2-445d-be12-d926db4e3ba8" xlink:to="loc_us-gaap_AssetsNoncurrent_2d4e03f5-222c-477e-84e8-7eaefcad6af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_4327ea18-0942-4579-9b53-6cca3ce85303" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_840d1893-1bf4-4ffe-a409-b0261f134c48" xlink:to="loc_us-gaap_Assets_4327ea18-0942-4579-9b53-6cca3ce85303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c9e228a2-4580-4f87-9735-d636870e09a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1017985a-9d9f-462f-8b38-07abc412edf3" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c9e228a2-4580-4f87-9735-d636870e09a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_96ea047e-38cb-47fc-a62a-b2ba5dcd0861" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c9e228a2-4580-4f87-9735-d636870e09a5" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_96ea047e-38cb-47fc-a62a-b2ba5dcd0861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_ddfcd948-7513-4c1b-9514-ba2be19ea1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_96ea047e-38cb-47fc-a62a-b2ba5dcd0861" xlink:to="loc_us-gaap_AccountsPayableCurrent_ddfcd948-7513-4c1b-9514-ba2be19ea1d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_dfaf588a-5825-46b1-a0dd-98fcd2f4690f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_96ea047e-38cb-47fc-a62a-b2ba5dcd0861" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_dfaf588a-5825-46b1-a0dd-98fcd2f4690f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4004292b-dde8-47b2-840f-83a65c4c1d21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_96ea047e-38cb-47fc-a62a-b2ba5dcd0861" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4004292b-dde8-47b2-840f-83a65c4c1d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_fb18e84e-24a9-4cd0-8bff-54bea08c6d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_96ea047e-38cb-47fc-a62a-b2ba5dcd0861" xlink:to="loc_us-gaap_TaxesPayableCurrent_fb18e84e-24a9-4cd0-8bff-54bea08c6d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_d455814c-5e11-4844-8d8f-11b91e1af4a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_96ea047e-38cb-47fc-a62a-b2ba5dcd0861" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_d455814c-5e11-4844-8d8f-11b91e1af4a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3e220d6d-da90-4265-85c9-a79a0b6ba4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_96ea047e-38cb-47fc-a62a-b2ba5dcd0861" xlink:to="loc_us-gaap_LiabilitiesCurrent_3e220d6d-da90-4265-85c9-a79a0b6ba4b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_583282a1-0806-46c8-889f-3110ab0d38ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c9e228a2-4580-4f87-9735-d636870e09a5" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_583282a1-0806-46c8-889f-3110ab0d38ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_9baa7f04-db40-4296-8a71-1269485a0154" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_583282a1-0806-46c8-889f-3110ab0d38ff" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_9baa7f04-db40-4296-8a71-1269485a0154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2d619b8f-4c49-463d-ba16-04b4a0372c72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_583282a1-0806-46c8-889f-3110ab0d38ff" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2d619b8f-4c49-463d-ba16-04b4a0372c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_79ba9abd-ece1-4217-8388-cff386e7c244" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_583282a1-0806-46c8-889f-3110ab0d38ff" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_79ba9abd-ece1-4217-8388-cff386e7c244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_44b694dc-c547-4161-96ec-1a8dea4d82ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c9e228a2-4580-4f87-9735-d636870e09a5" xlink:to="loc_us-gaap_Liabilities_44b694dc-c547-4161-96ec-1a8dea4d82ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_8797b6ec-3099-4778-9e6e-b9b867c79aba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c9e228a2-4580-4f87-9735-d636870e09a5" xlink:to="loc_us-gaap_CommitmentsAndContingencies_8797b6ec-3099-4778-9e6e-b9b867c79aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_8e3657b1-01e3-4408-be71-4bbf8d0d98de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c9e228a2-4580-4f87-9735-d636870e09a5" xlink:to="loc_us-gaap_StockholdersEquityAbstract_8e3657b1-01e3-4408-be71-4bbf8d0d98de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_644e7d31-8c9f-4a3b-8e06-3fe566e9c62c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8e3657b1-01e3-4408-be71-4bbf8d0d98de" xlink:to="loc_us-gaap_CommonStockValue_644e7d31-8c9f-4a3b-8e06-3fe566e9c62c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_ddca4239-7bd9-4b01-a521-a01a02ce7abd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8e3657b1-01e3-4408-be71-4bbf8d0d98de" xlink:to="loc_us-gaap_AdditionalPaidInCapital_ddca4239-7bd9-4b01-a521-a01a02ce7abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_44c64df3-05b4-4120-9bd4-09346d6ac923" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8e3657b1-01e3-4408-be71-4bbf8d0d98de" xlink:to="loc_us-gaap_TreasuryStockValue_44c64df3-05b4-4120-9bd4-09346d6ac923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d50c05dc-b761-42f2-b775-f80797e96fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8e3657b1-01e3-4408-be71-4bbf8d0d98de" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d50c05dc-b761-42f2-b775-f80797e96fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_686e1a90-ec75-4899-a075-c169c9e2c938" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8e3657b1-01e3-4408-be71-4bbf8d0d98de" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_686e1a90-ec75-4899-a075-c169c9e2c938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_75ff68fc-8b64-4942-b7ca-d7b504d53250" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8e3657b1-01e3-4408-be71-4bbf8d0d98de" xlink:to="loc_us-gaap_StockholdersEquity_75ff68fc-8b64-4942-b7ca-d7b504d53250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d5c88c6d-cca8-4d52-929e-1c021b16203c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c9e228a2-4580-4f87-9735-d636870e09a5" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_d5c88c6d-cca8-4d52-929e-1c021b16203c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="vrna-20221231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_b1b48414-2ad6-40a7-962e-9857e6f8d568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_669fd663-7b39-4cd5-acc6-bd8adff1b290" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b1b48414-2ad6-40a7-962e-9857e6f8d568" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_669fd663-7b39-4cd5-acc6-bd8adff1b290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_2a56b72f-7929-46b1-a23a-fb3e891be22d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b1b48414-2ad6-40a7-962e-9857e6f8d568" xlink:to="loc_us-gaap_CommonStockSharesIssued_2a56b72f-7929-46b1-a23a-fb3e891be22d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_84928065-ab27-463f-9d7d-1f2e522803be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b1b48414-2ad6-40a7-962e-9857e6f8d568" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_84928065-ab27-463f-9d7d-1f2e522803be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="vrna-20221231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_e745c2c4-a560-4b5c-a6ad-08b775ab30c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_70e3a2d0-562b-4d91-a13f-845f713bdd98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e745c2c4-a560-4b5c-a6ad-08b775ab30c6" xlink:to="loc_us-gaap_Revenues_70e3a2d0-562b-4d91-a13f-845f713bdd98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_1fce33ec-dc67-4943-a718-3875302956ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e745c2c4-a560-4b5c-a6ad-08b775ab30c6" xlink:to="loc_us-gaap_CostOfRevenue_1fce33ec-dc67-4943-a718-3875302956ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_07d142d5-7ecf-4f54-aa9f-ab296d036cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e745c2c4-a560-4b5c-a6ad-08b775ab30c6" xlink:to="loc_us-gaap_GrossProfit_07d142d5-7ecf-4f54-aa9f-ab296d036cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_b398398a-fe86-492d-9d72-221d855b1c10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e745c2c4-a560-4b5c-a6ad-08b775ab30c6" xlink:to="loc_us-gaap_OperatingExpensesAbstract_b398398a-fe86-492d-9d72-221d855b1c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f6f0d27d-bab3-4462-9f96-49f12446eeca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b398398a-fe86-492d-9d72-221d855b1c10" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f6f0d27d-bab3-4462-9f96-49f12446eeca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_51e7b332-c773-4b62-8801-7aa7fd2e2fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b398398a-fe86-492d-9d72-221d855b1c10" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_51e7b332-c773-4b62-8801-7aa7fd2e2fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_afc95a7c-9934-4361-80cf-e71cf9bada9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b398398a-fe86-492d-9d72-221d855b1c10" xlink:to="loc_us-gaap_OperatingExpenses_afc95a7c-9934-4361-80cf-e71cf9bada9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_98df3019-8d0e-44a1-b3d5-20644719f76b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b398398a-fe86-492d-9d72-221d855b1c10" xlink:to="loc_us-gaap_OperatingIncomeLoss_98df3019-8d0e-44a1-b3d5-20644719f76b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_119f6d62-6080-415b-b769-7ea6dd3d361d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e745c2c4-a560-4b5c-a6ad-08b775ab30c6" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_119f6d62-6080-415b-b769-7ea6dd3d361d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_GainLossFromResearchAndDevelopmentTaxCredit_5c91c3af-1867-4b3b-b606-5c2518d1f93d" xlink:href="vrna-20221231.xsd#vrna_GainLossFromResearchAndDevelopmentTaxCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_119f6d62-6080-415b-b769-7ea6dd3d361d" xlink:to="loc_vrna_GainLossFromResearchAndDevelopmentTaxCredit_5c91c3af-1867-4b3b-b606-5c2518d1f93d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8d20e553-45ec-4056-a125-0d82ab93d71d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_119f6d62-6080-415b-b769-7ea6dd3d361d" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8d20e553-45ec-4056-a125-0d82ab93d71d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_7fa0e2e7-79f8-4b53-8c05-6cd2b782a882" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_119f6d62-6080-415b-b769-7ea6dd3d361d" xlink:to="loc_us-gaap_InvestmentIncomeNet_7fa0e2e7-79f8-4b53-8c05-6cd2b782a882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_daec5552-0183-4f53-b853-a29d62146244" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_119f6d62-6080-415b-b769-7ea6dd3d361d" xlink:to="loc_us-gaap_InterestExpense_daec5552-0183-4f53-b853-a29d62146244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_UnrealizedGainLossOnWarrants_77f6d155-ada1-4bf6-b4d7-626985087668" xlink:href="vrna-20221231.xsd#vrna_UnrealizedGainLossOnWarrants"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_119f6d62-6080-415b-b769-7ea6dd3d361d" xlink:to="loc_vrna_UnrealizedGainLossOnWarrants_77f6d155-ada1-4bf6-b4d7-626985087668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_e00f469b-21a4-4b3c-bb6c-83378189c344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_119f6d62-6080-415b-b769-7ea6dd3d361d" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_e00f469b-21a4-4b3c-bb6c-83378189c344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_68cb18b6-9aef-4444-8475-30930fc5dec9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_119f6d62-6080-415b-b769-7ea6dd3d361d" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_68cb18b6-9aef-4444-8475-30930fc5dec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f4dc15da-272c-4f81-b40d-0f96f3b794fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e745c2c4-a560-4b5c-a6ad-08b775ab30c6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f4dc15da-272c-4f81-b40d-0f96f3b794fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1a03af05-c387-43ac-a99f-45c33b0fc5c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e745c2c4-a560-4b5c-a6ad-08b775ab30c6" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1a03af05-c387-43ac-a99f-45c33b0fc5c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b9757b3c-dbef-42e1-8b03-fb9eb56a41de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e745c2c4-a560-4b5c-a6ad-08b775ab30c6" xlink:to="loc_us-gaap_NetIncomeLoss_b9757b3c-dbef-42e1-8b03-fb9eb56a41de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_b4e1df79-b270-454f-9a9b-cc9d0b9cde8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e745c2c4-a560-4b5c-a6ad-08b775ab30c6" xlink:to="loc_us-gaap_EarningsPerShareBasic_b4e1df79-b270-454f-9a9b-cc9d0b9cde8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_a78c7ac9-bf62-4c23-be67-4042721bdf46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e745c2c4-a560-4b5c-a6ad-08b775ab30c6" xlink:to="loc_us-gaap_EarningsPerShareDiluted_a78c7ac9-bf62-4c23-be67-4042721bdf46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="vrna-20221231.xsd#ConsolidatedStatementsofShareholdersEquity"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_dcf71a18-91d8-492f-b0a5-fe0b48a1f4d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ec43c86c-f8f9-4bc8-ac75-76d503c86fca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_dcf71a18-91d8-492f-b0a5-fe0b48a1f4d0" xlink:to="loc_us-gaap_StatementTable_ec43c86c-f8f9-4bc8-ac75-76d503c86fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d5dc533c-9206-455e-90b7-7cfd8f350fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ec43c86c-f8f9-4bc8-ac75-76d503c86fca" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d5dc533c-9206-455e-90b7-7cfd8f350fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a5cbfc17-cd24-4244-9351-d8a331518197" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d5dc533c-9206-455e-90b7-7cfd8f350fe4" xlink:to="loc_us-gaap_EquityComponentDomain_a5cbfc17-cd24-4244-9351-d8a331518197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c78f41ea-11c0-4408-891e-a7d6deaaf4aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a5cbfc17-cd24-4244-9351-d8a331518197" xlink:to="loc_us-gaap_CommonStockMember_c78f41ea-11c0-4408-891e-a7d6deaaf4aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_8a896888-ed0d-48f0-9300-ba2231c7efdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a5cbfc17-cd24-4244-9351-d8a331518197" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_8a896888-ed0d-48f0-9300-ba2231c7efdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_3a2d6e86-8a42-4032-a8e5-aed599901c26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a5cbfc17-cd24-4244-9351-d8a331518197" xlink:to="loc_us-gaap_TreasuryStockMember_3a2d6e86-8a42-4032-a8e5-aed599901c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_94ab9181-c10b-4849-9a2c-e7cecf1aa5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a5cbfc17-cd24-4244-9351-d8a331518197" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_94ab9181-c10b-4849-9a2c-e7cecf1aa5c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d40bf9cf-ab6f-44c4-8f24-ec7487f9ac0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a5cbfc17-cd24-4244-9351-d8a331518197" xlink:to="loc_us-gaap_RetainedEarningsMember_d40bf9cf-ab6f-44c4-8f24-ec7487f9ac0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_4215e52b-2e5f-4fdf-aefa-4d0b8eed1f35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ec43c86c-f8f9-4bc8-ac75-76d503c86fca" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_4215e52b-2e5f-4fdf-aefa-4d0b8eed1f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_73a0f71b-6b02-4890-a587-92988b4ac9b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4215e52b-2e5f-4fdf-aefa-4d0b8eed1f35" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_73a0f71b-6b02-4890-a587-92988b4ac9b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AtTheMarketSalesAgreementMember_2dd6b799-05e6-429b-a0e5-b0f470c78150" xlink:href="vrna-20221231.xsd#vrna_AtTheMarketSalesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_73a0f71b-6b02-4890-a587-92988b4ac9b2" xlink:to="loc_vrna_AtTheMarketSalesAgreementMember_2dd6b799-05e6-429b-a0e5-b0f470c78150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_PublicStockOfferingMember_a43b91c7-8285-44a4-8a24-97d2073746f8" xlink:href="vrna-20221231.xsd#vrna_PublicStockOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_73a0f71b-6b02-4890-a587-92988b4ac9b2" xlink:to="loc_vrna_PublicStockOfferingMember_a43b91c7-8285-44a4-8a24-97d2073746f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2398be22-2d77-4bc7-9f9a-38685c055458" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ec43c86c-f8f9-4bc8-ac75-76d503c86fca" xlink:to="loc_us-gaap_StatementLineItems_2398be22-2d77-4bc7-9f9a-38685c055458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c80a78c1-7a69-47ed-906b-ba53146f242f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2398be22-2d77-4bc7-9f9a-38685c055458" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c80a78c1-7a69-47ed-906b-ba53146f242f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_384443b2-b7ec-4234-b6f5-b4d6dfb41ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c80a78c1-7a69-47ed-906b-ba53146f242f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_384443b2-b7ec-4234-b6f5-b4d6dfb41ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_da1e5bb0-1b35-4887-b287-ffa5a055e353" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c80a78c1-7a69-47ed-906b-ba53146f242f" xlink:to="loc_us-gaap_StockholdersEquity_da1e5bb0-1b35-4887-b287-ffa5a055e353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c49005bf-9086-40de-a85a-e051aff341eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c80a78c1-7a69-47ed-906b-ba53146f242f" xlink:to="loc_us-gaap_NetIncomeLoss_c49005bf-9086-40de-a85a-e051aff341eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_68e895bc-024b-4378-adf9-f74cae1017b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c80a78c1-7a69-47ed-906b-ba53146f242f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_68e895bc-024b-4378-adf9-f74cae1017b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2db586b5-eee0-4cde-9323-efc1b75f5965" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c80a78c1-7a69-47ed-906b-ba53146f242f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2db586b5-eee0-4cde-9323-efc1b75f5965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_b830694e-2cba-4052-9192-a1893f061f90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c80a78c1-7a69-47ed-906b-ba53146f242f" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_b830694e-2cba-4052-9192-a1893f061f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_7a0b9cb5-c056-450a-ad49-03628dd586d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c80a78c1-7a69-47ed-906b-ba53146f242f" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_7a0b9cb5-c056-450a-ad49-03628dd586d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_5316a04f-899e-497f-a6a1-43f84e9e347e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c80a78c1-7a69-47ed-906b-ba53146f242f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_5316a04f-899e-497f-a6a1-43f84e9e347e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_09e8fe44-6df3-4d41-b62c-c38050e10310" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c80a78c1-7a69-47ed-906b-ba53146f242f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_09e8fe44-6df3-4d41-b62c-c38050e10310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2fc92f1c-5410-4746-a260-f18b9b0d9a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c80a78c1-7a69-47ed-906b-ba53146f242f" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2fc92f1c-5410-4746-a260-f18b9b0d9a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_e48e8fb3-edd1-4dc6-944a-f0f01cead9cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c80a78c1-7a69-47ed-906b-ba53146f242f" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_e48e8fb3-edd1-4dc6-944a-f0f01cead9cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation_123778a1-a620-4c88-80d4-02d4898e31bd" xlink:href="vrna-20221231.xsd#vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c80a78c1-7a69-47ed-906b-ba53146f242f" xlink:to="loc_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation_123778a1-a620-4c88-80d4-02d4898e31bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_13d97d2b-ffb7-4a2a-88ae-ee4bfb2eb1e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c80a78c1-7a69-47ed-906b-ba53146f242f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_13d97d2b-ffb7-4a2a-88ae-ee4bfb2eb1e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_48f4481c-3e0e-4437-bc78-be284817604b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c80a78c1-7a69-47ed-906b-ba53146f242f" xlink:to="loc_us-gaap_StockholdersEquity_48f4481c-3e0e-4437-bc78-be284817604b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="vrna-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0a85348b-0bd3-4d42-bda7-6159e895f34b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b9cef17f-c7e1-4a39-9367-9bfa3f5fa9ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0a85348b-0bd3-4d42-bda7-6159e895f34b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b9cef17f-c7e1-4a39-9367-9bfa3f5fa9ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8685bc71-128e-4708-9121-658b124f5d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b9cef17f-c7e1-4a39-9367-9bfa3f5fa9ae" xlink:to="loc_us-gaap_NetIncomeLoss_8685bc71-128e-4708-9121-658b124f5d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8b0d0c77-ddae-48e0-9f49-af295ed0f26d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b9cef17f-c7e1-4a39-9367-9bfa3f5fa9ae" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8b0d0c77-ddae-48e0-9f49-af295ed0f26d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_f92a968e-f340-4757-b3ba-98fc0cc9477b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8b0d0c77-ddae-48e0-9f49-af295ed0f26d" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_f92a968e-f340-4757-b3ba-98fc0cc9477b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_d9f31069-f997-428f-a22a-98c2ddc60164" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8b0d0c77-ddae-48e0-9f49-af295ed0f26d" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_d9f31069-f997-428f-a22a-98c2ddc60164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_8e0ad952-d0e7-4760-98ff-6d6b39d96247" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8b0d0c77-ddae-48e0-9f49-af295ed0f26d" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_8e0ad952-d0e7-4760-98ff-6d6b39d96247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7eebf517-b0e7-461b-a16e-315720367da2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8b0d0c77-ddae-48e0-9f49-af295ed0f26d" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7eebf517-b0e7-461b-a16e-315720367da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_58fb6e68-7dab-459c-9a01-9363a1df4791" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8b0d0c77-ddae-48e0-9f49-af295ed0f26d" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_58fb6e68-7dab-459c-9a01-9363a1df4791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_9fb5fdb9-cb59-4268-a02c-02420e1ab298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8b0d0c77-ddae-48e0-9f49-af295ed0f26d" xlink:to="loc_us-gaap_ShareBasedCompensation_9fb5fdb9-cb59-4268-a02c-02420e1ab298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_a7e1c40d-85d9-4580-986e-25776eea1050" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8b0d0c77-ddae-48e0-9f49-af295ed0f26d" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_a7e1c40d-85d9-4580-986e-25776eea1050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_IncreaseDecreaseInEquityInterestReceivable_9caea850-14a1-4139-8122-7f604c329c0e" xlink:href="vrna-20221231.xsd#vrna_IncreaseDecreaseInEquityInterestReceivable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8b0d0c77-ddae-48e0-9f49-af295ed0f26d" xlink:to="loc_vrna_IncreaseDecreaseInEquityInterestReceivable_9caea850-14a1-4139-8122-7f604c329c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dca218cc-3b03-4ead-bf9d-48a5df4980c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8b0d0c77-ddae-48e0-9f49-af295ed0f26d" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dca218cc-3b03-4ead-bf9d-48a5df4980c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_0bc285f6-6e26-4c0f-b91c-1d4a34e576f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dca218cc-3b03-4ead-bf9d-48a5df4980c3" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_0bc285f6-6e26-4c0f-b91c-1d4a34e576f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent_60cd5fbf-83b8-4c8c-ad7c-e888fabb79b5" xlink:href="vrna-20221231.xsd#vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dca218cc-3b03-4ead-bf9d-48a5df4980c3" xlink:to="loc_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent_60cd5fbf-83b8-4c8c-ad7c-e888fabb79b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_77c0b025-adbf-4e9c-9c91-0ab0cbe0367d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dca218cc-3b03-4ead-bf9d-48a5df4980c3" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_77c0b025-adbf-4e9c-9c91-0ab0cbe0367d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_56eb77f5-cad8-4428-82ab-04e8f0b566dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dca218cc-3b03-4ead-bf9d-48a5df4980c3" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_56eb77f5-cad8-4428-82ab-04e8f0b566dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a04e5a66-3e82-4def-aa3d-c5d2fa5eb6f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dca218cc-3b03-4ead-bf9d-48a5df4980c3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a04e5a66-3e82-4def-aa3d-c5d2fa5eb6f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c5e17aa0-0af1-4379-9b4b-347d66a7f392" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dca218cc-3b03-4ead-bf9d-48a5df4980c3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c5e17aa0-0af1-4379-9b4b-347d66a7f392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_IncreaseDecreaseInOperatingLeaseLiabilities_e36eb64e-c454-4646-9fe5-e19eff42bf73" xlink:href="vrna-20221231.xsd#vrna_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dca218cc-3b03-4ead-bf9d-48a5df4980c3" xlink:to="loc_vrna_IncreaseDecreaseInOperatingLeaseLiabilities_e36eb64e-c454-4646-9fe5-e19eff42bf73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_02948033-c063-45fe-b7e2-bb18a216de1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedTaxesPayable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dca218cc-3b03-4ead-bf9d-48a5df4980c3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_02948033-c063-45fe-b7e2-bb18a216de1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_b2c31776-2d60-4af5-b7ea-603e75f2cc1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dca218cc-3b03-4ead-bf9d-48a5df4980c3" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_b2c31776-2d60-4af5-b7ea-603e75f2cc1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1330dfa6-0e95-410e-806c-7e944fe5ee88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b9cef17f-c7e1-4a39-9367-9bfa3f5fa9ae" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1330dfa6-0e95-410e-806c-7e944fe5ee88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0e7b8bc3-209e-4096-a2f4-dba0f677e743" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0a85348b-0bd3-4d42-bda7-6159e895f34b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0e7b8bc3-209e-4096-a2f4-dba0f677e743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a2076a13-d118-4dca-a899-f1b284187c64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0e7b8bc3-209e-4096-a2f4-dba0f677e743" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a2076a13-d118-4dca-a899-f1b284187c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fd2dc9d9-788f-4011-9afe-76e0de1a7381" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0e7b8bc3-209e-4096-a2f4-dba0f677e743" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fd2dc9d9-788f-4011-9afe-76e0de1a7381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8bd288e2-92d4-4718-b2ee-73aa5c2e283b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0a85348b-0bd3-4d42-bda7-6159e895f34b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8bd288e2-92d4-4718-b2ee-73aa5c2e283b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1c0d4070-a4b9-4e29-a12b-09bd33915a64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8bd288e2-92d4-4718-b2ee-73aa5c2e283b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1c0d4070-a4b9-4e29-a12b-09bd33915a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_f5e7f4ff-b752-4807-b9b2-81adfe70e34c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8bd288e2-92d4-4718-b2ee-73aa5c2e283b" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_f5e7f4ff-b752-4807-b9b2-81adfe70e34c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_e37611f6-3987-49ef-974c-e8123f5534b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8bd288e2-92d4-4718-b2ee-73aa5c2e283b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_e37611f6-3987-49ef-974c-e8123f5534b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_8c0e4bbf-8c8c-47b3-b332-911bfdbee046" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8bd288e2-92d4-4718-b2ee-73aa5c2e283b" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_8c0e4bbf-8c8c-47b3-b332-911bfdbee046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_387cc48b-1ef0-4ef2-a669-a0c0be211b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8bd288e2-92d4-4718-b2ee-73aa5c2e283b" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_387cc48b-1ef0-4ef2-a669-a0c0be211b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfLoanCosts_05c8fe8e-1238-48cf-aaca-b09bd6ca151f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfLoanCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8bd288e2-92d4-4718-b2ee-73aa5c2e283b" xlink:to="loc_us-gaap_PaymentsOfLoanCosts_05c8fe8e-1238-48cf-aaca-b09bd6ca151f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_e05e7547-77c6-4f33-8d6f-c62c18084970" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8bd288e2-92d4-4718-b2ee-73aa5c2e283b" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_e05e7547-77c6-4f33-8d6f-c62c18084970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_bf67732a-e38f-401a-8e28-88d3e69f095f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8bd288e2-92d4-4718-b2ee-73aa5c2e283b" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_bf67732a-e38f-401a-8e28-88d3e69f095f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ab4b8414-1a51-4231-9fd7-b7276fa75d35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8bd288e2-92d4-4718-b2ee-73aa5c2e283b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ab4b8414-1a51-4231-9fd7-b7276fa75d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d504fe32-65da-4f97-a769-8a7cf7925973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0a85348b-0bd3-4d42-bda7-6159e895f34b" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d504fe32-65da-4f97-a769-8a7cf7925973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_205a9ea1-84f0-42d6-b1d6-abf60b73c1bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0a85348b-0bd3-4d42-bda7-6159e895f34b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_205a9ea1-84f0-42d6-b1d6-abf60b73c1bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9899315b-5f31-4707-9e36-e224f254fde3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0a85348b-0bd3-4d42-bda7-6159e895f34b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9899315b-5f31-4707-9e36-e224f254fde3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_63752323-8adc-4372-9d82-8e1d26d39094" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0a85348b-0bd3-4d42-bda7-6159e895f34b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_63752323-8adc-4372-9d82-8e1d26d39094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_6e68be12-8fe0-499c-91ed-abfb3e47d4f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0a85348b-0bd3-4d42-bda7-6159e895f34b" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_6e68be12-8fe0-499c-91ed-abfb3e47d4f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_ca4192cb-ad01-4f1b-893b-6513115589cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6e68be12-8fe0-499c-91ed-abfb3e47d4f1" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_ca4192cb-ad01-4f1b-893b-6513115589cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_cd9a2fca-3402-41bf-a2a7-e7f79ad49f42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6e68be12-8fe0-499c-91ed-abfb3e47d4f1" xlink:to="loc_us-gaap_InterestPaidNet_cd9a2fca-3402-41bf-a2a7-e7f79ad49f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Organizationanddescriptionofbusinessoperations" xlink:type="simple" xlink:href="vrna-20221231.xsd#Organizationanddescriptionofbusinessoperations"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Organizationanddescriptionofbusinessoperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f5046bb8-0f72-4bc4-9478-536bd0b60b43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_OrganizationAndBusinessDescriptionTextBlock_9d450fc2-a372-4514-bc2a-cb752d168e75" xlink:href="vrna-20221231.xsd#vrna_OrganizationAndBusinessDescriptionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f5046bb8-0f72-4bc4-9478-536bd0b60b43" xlink:to="loc_vrna_OrganizationAndBusinessDescriptionTextBlock_9d450fc2-a372-4514-bc2a-cb752d168e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpolicies" xlink:type="simple" xlink:href="vrna-20221231.xsd#BasisofPresentationandSummaryofSignificantAccountingpolicies"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c8856845-b218-4129-aea2-198b2548565b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_0a5bb49d-f25e-4363-ac85-160766c7eff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c8856845-b218-4129-aea2-198b2548565b" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_0a5bb49d-f25e-4363-ac85-160766c7eff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Prepaidexpenses" xlink:type="simple" xlink:href="vrna-20221231.xsd#Prepaidexpenses"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Prepaidexpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_d04cd125-ed5f-4a5b-8fdf-06470e03ce4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_PrepaidExpenseDisclosureTextBlock_79e24f7f-a6df-4c5f-9312-f6a8c84fa825" xlink:href="vrna-20221231.xsd#vrna_PrepaidExpenseDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_d04cd125-ed5f-4a5b-8fdf-06470e03ce4c" xlink:to="loc_vrna_PrepaidExpenseDisclosureTextBlock_79e24f7f-a6df-4c5f-9312-f6a8c84fa825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Propertyleases" xlink:type="simple" xlink:href="vrna-20221231.xsd#Propertyleases"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Propertyleases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_067ac69d-f24f-4556-b54c-7c24a5b6d433" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_bcb0bda4-1306-43ec-bb65-57f5426341ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_067ac69d-f24f-4556-b54c-7c24a5b6d433" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_bcb0bda4-1306-43ec-bb65-57f5426341ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Accruedexpenses" xlink:type="simple" xlink:href="vrna-20221231.xsd#Accruedexpenses"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Accruedexpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_61e8a18d-d44d-4010-b5f5-22d6cd8a8dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_5e266106-6c87-421f-96f4-f8139a08016c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_61e8a18d-d44d-4010-b5f5-22d6cd8a8dd6" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_5e266106-6c87-421f-96f4-f8139a08016c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Warrants" xlink:type="simple" xlink:href="vrna-20221231.xsd#Warrants"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Warrants" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_bb66c8a6-c2c3-48e2-9ffc-240a979f8e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_WarrantAndRightsDisclosureTextBlock_04c3e850-074e-44ba-a835-4b47f0aacd43" xlink:href="vrna-20221231.xsd#vrna_WarrantAndRightsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_bb66c8a6-c2c3-48e2-9ffc-240a979f8e1f" xlink:to="loc_vrna_WarrantAndRightsDisclosureTextBlock_04c3e850-074e-44ba-a835-4b47f0aacd43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Termloan" xlink:type="simple" xlink:href="vrna-20221231.xsd#Termloan"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Termloan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_dbac87a5-bc40-4737-9e9a-c7bc5ac6ee78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_e532df4c-b741-41cf-a730-bb97ab829298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_dbac87a5-bc40-4737-9e9a-c7bc5ac6ee78" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_e532df4c-b741-41cf-a730-bb97ab829298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Significantagreements" xlink:type="simple" xlink:href="vrna-20221231.xsd#Significantagreements"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Significantagreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2b0ba851-8349-4b81-ab40-4fb8d3383d34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_879e6a7a-b589-4e3e-aa03-fef49bff7609" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2b0ba851-8349-4b81-ab40-4fb8d3383d34" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_879e6a7a-b589-4e3e-aa03-fef49bff7609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Benefitplans" xlink:type="simple" xlink:href="vrna-20221231.xsd#Benefitplans"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Benefitplans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_009574cb-f767-4540-9a76-a8d601da22d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTextBlock_82d908f2-4040-4cc2-b0e1-802b5bc64c26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_009574cb-f767-4540-9a76-a8d601da22d1" xlink:to="loc_us-gaap_DefinedContributionPlanTextBlock_82d908f2-4040-4cc2-b0e1-802b5bc64c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Taxation" xlink:type="simple" xlink:href="vrna-20221231.xsd#Taxation"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Taxation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_cac13045-84b2-4efa-9cfb-dd7090be191e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_cdd4d562-9596-4504-84ac-309461bce838" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cac13045-84b2-4efa-9cfb-dd7090be191e" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_cdd4d562-9596-4504-84ac-309461bce838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Sharebasedcompensation" xlink:type="simple" xlink:href="vrna-20221231.xsd#Sharebasedcompensation"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Sharebasedcompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9ea0e595-ba14-4be4-891c-4e2a62103492" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_812cbb2a-6787-4839-8e39-2bed4ffb7190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9ea0e595-ba14-4be4-891c-4e2a62103492" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_812cbb2a-6787-4839-8e39-2bed4ffb7190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Netlosspershare" xlink:type="simple" xlink:href="vrna-20221231.xsd#Netlosspershare"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Netlosspershare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_84f40e31-28d5-4b16-a08e-d6201c30ef49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_9065db90-b110-46a2-9f8e-816a437f3176" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_84f40e31-28d5-4b16-a08e-d6201c30ef49" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_9065db90-b110-46a2-9f8e-816a437f3176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Commitmentsandcontingencies" xlink:type="simple" xlink:href="vrna-20221231.xsd#Commitmentsandcontingencies"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Commitmentsandcontingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3a0806a2-0650-4d63-84b3-8706ad1156ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f6bca104-180d-4e47-a6ba-00c3412e2cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3a0806a2-0650-4d63-84b3-8706ad1156ca" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f6bca104-180d-4e47-a6ba-00c3412e2cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/Relatedpartytransactionsandothershareholdermatters" xlink:type="simple" xlink:href="vrna-20221231.xsd#Relatedpartytransactionsandothershareholdermatters"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/Relatedpartytransactionsandothershareholdermatters" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_1bb1324c-6ce9-4e2a-809f-64a12ed1bf87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_81390885-6146-4f4b-bc5d-55de4bf524cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_1bb1324c-6ce9-4e2a-809f-64a12ed1bf87" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_81390885-6146-4f4b-bc5d-55de4bf524cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies" xlink:type="simple" xlink:href="vrna-20221231.xsd#BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4a6a0f6d-9ba0-497e-97a3-bf5516c498bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_8988f6ce-4164-401c-9736-3adfd56b6065" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a6a0f6d-9ba0-497e-97a3-bf5516c498bb" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_8988f6ce-4164-401c-9736-3adfd56b6065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_59c5ac13-7c98-454e-80cb-7ad900384eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a6a0f6d-9ba0-497e-97a3-bf5516c498bb" xlink:to="loc_us-gaap_UseOfEstimates_59c5ac13-7c98-454e-80cb-7ad900384eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_905ababc-1064-49aa-85b1-1fbfe71b3193" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a6a0f6d-9ba0-497e-97a3-bf5516c498bb" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_905ababc-1064-49aa-85b1-1fbfe71b3193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_2bf4bcac-078b-4b8d-b532-cd5af10885e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a6a0f6d-9ba0-497e-97a3-bf5516c498bb" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_2bf4bcac-078b-4b8d-b532-cd5af10885e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_b509fb3f-aabd-4a06-b5df-04afdf625103" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a6a0f6d-9ba0-497e-97a3-bf5516c498bb" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_b509fb3f-aabd-4a06-b5df-04afdf625103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4c864e70-5b0b-4aee-afc5-96a4397a663c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a6a0f6d-9ba0-497e-97a3-bf5516c498bb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4c864e70-5b0b-4aee-afc5-96a4397a663c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_3a586bed-b054-4575-8091-d9658c4762d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a6a0f6d-9ba0-497e-97a3-bf5516c498bb" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_3a586bed-b054-4575-8091-d9658c4762d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_5a51c0df-38fd-4371-a00a-b922fe6249c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a6a0f6d-9ba0-497e-97a3-bf5516c498bb" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_5a51c0df-38fd-4371-a00a-b922fe6249c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_6aa84fa3-d61d-428c-9439-f805377ce3d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a6a0f6d-9ba0-497e-97a3-bf5516c498bb" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_6aa84fa3-d61d-428c-9439-f805377ce3d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_547a81a7-174d-4010-9172-e19b03ea554b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a6a0f6d-9ba0-497e-97a3-bf5516c498bb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_547a81a7-174d-4010-9172-e19b03ea554b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_f5eed8a1-738a-4bf9-90c7-7ba188a5e85d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a6a0f6d-9ba0-497e-97a3-bf5516c498bb" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_f5eed8a1-738a-4bf9-90c7-7ba188a5e85d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_GovernmentTaxCreditsPolicyPolicyTextBlock_73303a3e-58b0-4969-b909-9a5b90a93806" xlink:href="vrna-20221231.xsd#vrna_GovernmentTaxCreditsPolicyPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a6a0f6d-9ba0-497e-97a3-bf5516c498bb" xlink:to="loc_vrna_GovernmentTaxCreditsPolicyPolicyTextBlock_73303a3e-58b0-4969-b909-9a5b90a93806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_0ecec9a8-20b7-4f4b-bff0-00fb6197e880" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a6a0f6d-9ba0-497e-97a3-bf5516c498bb" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_0ecec9a8-20b7-4f4b-bff0-00fb6197e880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_2c37c796-6468-4a10-850d-4209f1c4869c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a6a0f6d-9ba0-497e-97a3-bf5516c498bb" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_2c37c796-6468-4a10-850d-4209f1c4869c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_6b065641-c1ba-4f5b-89fd-e28d4898fe83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a6a0f6d-9ba0-497e-97a3-bf5516c498bb" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_6b065641-c1ba-4f5b-89fd-e28d4898fe83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_2f5ce453-a406-4d0a-92ff-c2fc26711c08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a6a0f6d-9ba0-497e-97a3-bf5516c498bb" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_2f5ce453-a406-4d0a-92ff-c2fc26711c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock_98525c8e-e244-43ad-9764-9e2ba1be0c41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a6a0f6d-9ba0-497e-97a3-bf5516c498bb" xlink:to="loc_us-gaap_StockholdersEquityPolicyTextBlock_98525c8e-e244-43ad-9764-9e2ba1be0c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_be082536-46d9-472f-b1d8-1c54691e6843" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a6a0f6d-9ba0-497e-97a3-bf5516c498bb" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_be082536-46d9-472f-b1d8-1c54691e6843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_b7376f84-9f75-4de6-aa86-4c7a603aab4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a6a0f6d-9ba0-497e-97a3-bf5516c498bb" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_b7376f84-9f75-4de6-aa86-4c7a603aab4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_dd86adc8-4f95-4bbf-ac3b-a07fc8a018b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a6a0f6d-9ba0-497e-97a3-bf5516c498bb" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_dd86adc8-4f95-4bbf-ac3b-a07fc8a018b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0ce686ce-eaec-4916-b283-178e09498e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a6a0f6d-9ba0-497e-97a3-bf5516c498bb" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0ce686ce-eaec-4916-b283-178e09498e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/PrepaidexpensesTables" xlink:type="simple" xlink:href="vrna-20221231.xsd#PrepaidexpensesTables"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/PrepaidexpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_3e0c04cd-07f6-409a-b960-9157817a7117" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_18f39e0b-e4ac-472d-9696-fe3e2b417232" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_3e0c04cd-07f6-409a-b960-9157817a7117" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_18f39e0b-e4ac-472d-9696-fe3e2b417232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/PropertyleasesTables" xlink:type="simple" xlink:href="vrna-20221231.xsd#PropertyleasesTables"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/PropertyleasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f0332a89-793a-4905-ab36-4e45d1bb7006" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_8864dbb0-9939-4789-898f-67658ea9488e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f0332a89-793a-4905-ab36-4e45d1bb7006" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_8864dbb0-9939-4789-898f-67658ea9488e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/AccruedexpensesTables" xlink:type="simple" xlink:href="vrna-20221231.xsd#AccruedexpensesTables"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/AccruedexpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_dab763c3-6819-48a2-a17e-17daca23543b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_43175682-eeba-4ef6-a36c-dcb16479bd35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_dab763c3-6819-48a2-a17e-17daca23543b" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_43175682-eeba-4ef6-a36c-dcb16479bd35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/WarrantsTables" xlink:type="simple" xlink:href="vrna-20221231.xsd#WarrantsTables"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/WarrantsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_025e634f-93b1-4d67-a8a5-4ccd89979105" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_42c1952c-485e-4299-babf-324eb6ad1446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_025e634f-93b1-4d67-a8a5-4ccd89979105" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_42c1952c-485e-4299-babf-324eb6ad1446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_7f645330-da52-47cc-aae6-6df09393b1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_025e634f-93b1-4d67-a8a5-4ccd89979105" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_7f645330-da52-47cc-aae6-6df09393b1e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/TaxationTables" xlink:type="simple" xlink:href="vrna-20221231.xsd#TaxationTables"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/TaxationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7f7d815f-d082-4abb-b69d-7a35d6b81a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_d02d81da-4688-48b8-ae9b-4ee5018d4b61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7f7d815f-d082-4abb-b69d-7a35d6b81a8d" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_d02d81da-4688-48b8-ae9b-4ee5018d4b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_4d47eb42-644c-4920-8a82-cb3e47e7c7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7f7d815f-d082-4abb-b69d-7a35d6b81a8d" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_4d47eb42-644c-4920-8a82-cb3e47e7c7a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_c099c6f7-3b71-42ed-b9ae-9c7d44d49473" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7f7d815f-d082-4abb-b69d-7a35d6b81a8d" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_c099c6f7-3b71-42ed-b9ae-9c7d44d49473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_e0e3112f-dfe4-46b9-beec-857501edc76f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7f7d815f-d082-4abb-b69d-7a35d6b81a8d" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_e0e3112f-dfe4-46b9-beec-857501edc76f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/SharebasedcompensationTables" xlink:type="simple" xlink:href="vrna-20221231.xsd#SharebasedcompensationTables"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/SharebasedcompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0ae507d8-1b96-46c8-b7ac-e79607a56b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_93b6577b-bcdd-41ec-811d-f77488da7be0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0ae507d8-1b96-46c8-b7ac-e79607a56b0c" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_93b6577b-bcdd-41ec-811d-f77488da7be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ce959fa0-5b15-4b14-a5cd-7b1efffac4ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0ae507d8-1b96-46c8-b7ac-e79607a56b0c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ce959fa0-5b15-4b14-a5cd-7b1efffac4ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_a037b830-f0f9-43b4-b687-67eb470fba0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0ae507d8-1b96-46c8-b7ac-e79607a56b0c" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_a037b830-f0f9-43b4-b687-67eb470fba0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_b591b1b3-1a7b-4695-9c12-d29f7fc25185" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0ae507d8-1b96-46c8-b7ac-e79607a56b0c" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_b591b1b3-1a7b-4695-9c12-d29f7fc25185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/NetlosspershareTables" xlink:type="simple" xlink:href="vrna-20221231.xsd#NetlosspershareTables"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/NetlosspershareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_893c3da1-c755-4bf5-a99a-615035d8057d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0030890e-ba21-44cf-a7a9-e5c7e4ad30b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_893c3da1-c755-4bf5-a99a-615035d8057d" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0030890e-ba21-44cf-a7a9-e5c7e4ad30b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/OrganizationanddescriptionofbusinessoperationsDetails" xlink:type="simple" xlink:href="vrna-20221231.xsd#OrganizationanddescriptionofbusinessoperationsDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/OrganizationanddescriptionofbusinessoperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_72399a4d-2d0f-49eb-9fa5-11f89b9a9de2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_NumberOfWhollyOwnedSubsidiaries_ef756c27-7ab1-4430-a4f9-cf000afe9410" xlink:href="vrna-20221231.xsd#vrna_NumberOfWhollyOwnedSubsidiaries"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_72399a4d-2d0f-49eb-9fa5-11f89b9a9de2" xlink:to="loc_vrna_NumberOfWhollyOwnedSubsidiaries_ef756c27-7ab1-4430-a4f9-cf000afe9410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_41428f2e-b6b0-4d30-acb7-38b90d6fb99a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_72399a4d-2d0f-49eb-9fa5-11f89b9a9de2" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_41428f2e-b6b0-4d30-acb7-38b90d6fb99a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3fed211f-cb3a-4b52-8e15-df5a9c42d9d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_41428f2e-b6b0-4d30-acb7-38b90d6fb99a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3fed211f-cb3a-4b52-8e15-df5a9c42d9d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_852b57da-0f9a-4d4c-a630-44b94db55667" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3fed211f-cb3a-4b52-8e15-df5a9c42d9d7" xlink:to="loc_us-gaap_ClassOfStockDomain_852b57da-0f9a-4d4c-a630-44b94db55667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AmericanDepositorySharesMember_552814fe-882b-4247-a95b-5a113e4f9ae2" xlink:href="vrna-20221231.xsd#vrna_AmericanDepositorySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_852b57da-0f9a-4d4c-a630-44b94db55667" xlink:to="loc_vrna_AmericanDepositorySharesMember_552814fe-882b-4247-a95b-5a113e4f9ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_10b36a19-7533-4efb-aec8-e338a0fce9b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_41428f2e-b6b0-4d30-acb7-38b90d6fb99a" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_10b36a19-7533-4efb-aec8-e338a0fce9b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1e4a73c7-39c1-45bd-9ac4-340220463273" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_10b36a19-7533-4efb-aec8-e338a0fce9b3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1e4a73c7-39c1-45bd-9ac4-340220463273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_PublicStockOfferingMember_ddfa8f0d-aa4c-43b1-9965-a67c93005022" xlink:href="vrna-20221231.xsd#vrna_PublicStockOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1e4a73c7-39c1-45bd-9ac4-340220463273" xlink:to="loc_vrna_PublicStockOfferingMember_ddfa8f0d-aa4c-43b1-9965-a67c93005022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_08a15f36-576f-4434-9456-ca01cde89c75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1e4a73c7-39c1-45bd-9ac4-340220463273" xlink:to="loc_us-gaap_OverAllotmentOptionMember_08a15f36-576f-4434-9456-ca01cde89c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_d305de64-e467-4504-9156-21245f74dc61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_41428f2e-b6b0-4d30-acb7-38b90d6fb99a" xlink:to="loc_us-gaap_CreditFacilityAxis_d305de64-e467-4504-9156-21245f74dc61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_cb680267-b54a-4718-99ca-f5a0d235befc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_d305de64-e467-4504-9156-21245f74dc61" xlink:to="loc_us-gaap_CreditFacilityDomain_cb680267-b54a-4718-99ca-f5a0d235befc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_0bb169cc-867a-4641-85e2-44790876abaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_cb680267-b54a-4718-99ca-f5a0d235befc" xlink:to="loc_us-gaap_LineOfCreditMember_0bb169cc-867a-4641-85e2-44790876abaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a94fd374-476e-49dd-b41d-bce0bd8c58a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_41428f2e-b6b0-4d30-acb7-38b90d6fb99a" xlink:to="loc_us-gaap_DebtInstrumentAxis_a94fd374-476e-49dd-b41d-bce0bd8c58a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_94096699-cf2b-41d5-95da-0aa673f5d4bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_a94fd374-476e-49dd-b41d-bce0bd8c58a8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_94096699-cf2b-41d5-95da-0aa673f5d4bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_OxfordTermLoanMember_950b45ae-2e86-4fb6-9437-fd0778d91cf7" xlink:href="vrna-20221231.xsd#vrna_OxfordTermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_94096699-cf2b-41d5-95da-0aa673f5d4bf" xlink:to="loc_vrna_OxfordTermLoanMember_950b45ae-2e86-4fb6-9437-fd0778d91cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TermLoanFacilityMember_664b41c3-535d-4bb9-ad03-fbfcdeb91c86" xlink:href="vrna-20221231.xsd#vrna_TermLoanFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_94096699-cf2b-41d5-95da-0aa673f5d4bf" xlink:to="loc_vrna_TermLoanFacilityMember_664b41c3-535d-4bb9-ad03-fbfcdeb91c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3d6b17f8-d621-4ba3-811f-b0a43dcba166" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_41428f2e-b6b0-4d30-acb7-38b90d6fb99a" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_3d6b17f8-d621-4ba3-811f-b0a43dcba166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fa14d024-622e-4537-9c3d-d85b8a9f2745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3d6b17f8-d621-4ba3-811f-b0a43dcba166" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fa14d024-622e-4537-9c3d-d85b8a9f2745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_aa0ff32d-fb58-4762-8e3c-5ba2e69cf4d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_fa14d024-622e-4537-9c3d-d85b8a9f2745" xlink:to="loc_us-gaap_SubsequentEventMember_aa0ff32d-fb58-4762-8e3c-5ba2e69cf4d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6b863285-abf7-4a6c-944c-3d4c3ad50724" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_41428f2e-b6b0-4d30-acb7-38b90d6fb99a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6b863285-abf7-4a6c-944c-3d4c3ad50724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b57b6711-5e64-41fa-9f3b-a9813904d24c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6b863285-abf7-4a6c-944c-3d4c3ad50724" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b57b6711-5e64-41fa-9f3b-a9813904d24c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_5eaeb449-7789-4528-b228-fa997de22106" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b57b6711-5e64-41fa-9f3b-a9813904d24c" xlink:to="loc_us-gaap_SecuredDebtMember_5eaeb449-7789-4528-b228-fa997de22106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_b360c39a-903a-43e8-b114-3e0e0f34d131" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_41428f2e-b6b0-4d30-acb7-38b90d6fb99a" xlink:to="loc_us-gaap_ClassOfStockLineItems_b360c39a-903a-43e8-b114-3e0e0f34d131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2fa0bf6d-dba7-438d-9ef9-6fa5af4eb4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b360c39a-903a-43e8-b114-3e0e0f34d131" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2fa0bf6d-dba7-438d-9ef9-6fa5af4eb4e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SaleOfStockMaximumAggregateOfferingPrice_df485adc-fed8-4778-ad95-d6443430b3a1" xlink:href="vrna-20221231.xsd#vrna_SaleOfStockMaximumAggregateOfferingPrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b360c39a-903a-43e8-b114-3e0e0f34d131" xlink:to="loc_vrna_SaleOfStockMaximumAggregateOfferingPrice_df485adc-fed8-4778-ad95-d6443430b3a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8aee0378-397c-42e9-8ce8-f0759b1ef1d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b360c39a-903a-43e8-b114-3e0e0f34d131" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8aee0378-397c-42e9-8ce8-f0759b1ef1d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingDepositoryReceiptRatio_dcff0dbd-375e-4d29-a5b2-7bac7f337701" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityListingDepositoryReceiptRatio"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b360c39a-903a-43e8-b114-3e0e0f34d131" xlink:to="loc_dei_EntityListingDepositoryReceiptRatio_dcff0dbd-375e-4d29-a5b2-7bac7f337701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_a47aa578-9b94-4c36-813a-ba97ee803d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b360c39a-903a-43e8-b114-3e0e0f34d131" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_a47aa578-9b94-4c36-813a-ba97ee803d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_ef9e1507-649b-4636-aca1-49e46afe911a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b360c39a-903a-43e8-b114-3e0e0f34d131" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_ef9e1507-649b-4636-aca1-49e46afe911a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_18d3e619-c440-43de-909a-db99ea986097" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b360c39a-903a-43e8-b114-3e0e0f34d131" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_18d3e619-c440-43de-909a-db99ea986097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_f8f14148-2462-491d-99d6-c8c8ba357646" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b360c39a-903a-43e8-b114-3e0e0f34d131" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_f8f14148-2462-491d-99d6-c8c8ba357646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_bf0ac5c1-d8e1-4aba-804e-07f230c9ca9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b360c39a-903a-43e8-b114-3e0e0f34d131" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_bf0ac5c1-d8e1-4aba-804e-07f230c9ca9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_CommonStockSharesAvailableForSaleValue_6b5f736b-ad73-4772-8668-6326afe1b03f" xlink:href="vrna-20221231.xsd#vrna_CommonStockSharesAvailableForSaleValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b360c39a-903a-43e8-b114-3e0e0f34d131" xlink:to="loc_vrna_CommonStockSharesAvailableForSaleValue_6b5f736b-ad73-4772-8668-6326afe1b03f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails" xlink:type="simple" xlink:href="vrna-20221231.xsd#BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_844a0608-536f-497f-a364-d965ee383afd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_85b7a08c-a81e-4841-8ef4-9676966ebbaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_844a0608-536f-497f-a364-d965ee383afd" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_85b7a08c-a81e-4841-8ef4-9676966ebbaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8dd32f47-c7ca-4982-8491-b7af99a0e194" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_85b7a08c-a81e-4841-8ef4-9676966ebbaf" xlink:to="loc_srt_RangeAxis_8dd32f47-c7ca-4982-8491-b7af99a0e194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e88efda1-88bf-4626-b141-a50e77190dc5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8dd32f47-c7ca-4982-8491-b7af99a0e194" xlink:to="loc_srt_RangeMember_e88efda1-88bf-4626-b141-a50e77190dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_81f87c36-d551-4ffc-ac80-9b251b0581e2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e88efda1-88bf-4626-b141-a50e77190dc5" xlink:to="loc_srt_MinimumMember_81f87c36-d551-4ffc-ac80-9b251b0581e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_13868d26-3b35-4c79-9b44-1afec1f534ac" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e88efda1-88bf-4626-b141-a50e77190dc5" xlink:to="loc_srt_MaximumMember_13868d26-3b35-4c79-9b44-1afec1f534ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fa9411b3-d4ac-432b-b103-cee08620f341" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_85b7a08c-a81e-4841-8ef4-9676966ebbaf" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fa9411b3-d4ac-432b-b103-cee08620f341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_391675d6-f50d-40d7-b349-c2fb7f5ca520" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fa9411b3-d4ac-432b-b103-cee08620f341" xlink:to="loc_us-gaap_EquityComponentDomain_391675d6-f50d-40d7-b349-c2fb7f5ca520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f38aec1f-85df-42fb-9dcf-5ffb9ae201fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_391675d6-f50d-40d7-b349-c2fb7f5ca520" xlink:to="loc_us-gaap_CommonStockMember_f38aec1f-85df-42fb-9dcf-5ffb9ae201fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a0351727-12ff-4500-8b4d-87dd63b39f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_85b7a08c-a81e-4841-8ef4-9676966ebbaf" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a0351727-12ff-4500-8b4d-87dd63b39f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_bdadb038-e644-4652-a2a7-01a59e61cb08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a0351727-12ff-4500-8b4d-87dd63b39f6d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_bdadb038-e644-4652-a2a7-01a59e61cb08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_0396b9ea-ae01-4036-a2d2-c45eabf1b50e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a0351727-12ff-4500-8b4d-87dd63b39f6d" xlink:to="loc_us-gaap_NumberOfOperatingSegments_0396b9ea-ae01-4036-a2d2-c45eabf1b50e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_665653b3-54da-4edb-972f-ce06b22011a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a0351727-12ff-4500-8b4d-87dd63b39f6d" xlink:to="loc_us-gaap_NumberOfReportableSegments_665653b3-54da-4edb-972f-ce06b22011a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_StockIssuedDuringPeriodSharesHeldInTreasury_d501818e-785d-4e3f-b32a-ec7c268c1676" xlink:href="vrna-20221231.xsd#vrna_StockIssuedDuringPeriodSharesHeldInTreasury"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a0351727-12ff-4500-8b4d-87dd63b39f6d" xlink:to="loc_vrna_StockIssuedDuringPeriodSharesHeldInTreasury_d501818e-785d-4e3f-b32a-ec7c268c1676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares_3eb18a62-f5f4-43ad-a13a-2fc4b84ade8c" xlink:href="vrna-20221231.xsd#vrna_StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a0351727-12ff-4500-8b4d-87dd63b39f6d" xlink:to="loc_vrna_StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares_3eb18a62-f5f4-43ad-a13a-2fc4b84ade8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/PrepaidexpensesDetails" xlink:type="simple" xlink:href="vrna-20221231.xsd#PrepaidexpensesDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/PrepaidexpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_be170272-2945-478d-9b46-a4c7371f99ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_PrepaidResearchAndDevelopmentFeesCurrent_3194057b-a8d5-408b-a429-5543c0e0cf60" xlink:href="vrna-20221231.xsd#vrna_PrepaidResearchAndDevelopmentFeesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_be170272-2945-478d-9b46-a4c7371f99ec" xlink:to="loc_vrna_PrepaidResearchAndDevelopmentFeesCurrent_3194057b-a8d5-408b-a429-5543c0e0cf60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_8c63a928-24a3-4255-a140-9cdf7d353017" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_be170272-2945-478d-9b46-a4c7371f99ec" xlink:to="loc_us-gaap_PrepaidInsurance_8c63a928-24a3-4255-a140-9cdf7d353017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_6ae8c02f-f763-4ead-9659-c81fc808aa03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_be170272-2945-478d-9b46-a4c7371f99ec" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_6ae8c02f-f763-4ead-9659-c81fc808aa03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_b549e0bc-8fd2-48e0-a05a-d61c2a4b3967" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_be170272-2945-478d-9b46-a4c7371f99ec" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_b549e0bc-8fd2-48e0-a05a-d61c2a4b3967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/PropertyleasesNarrativeDetails" xlink:type="simple" xlink:href="vrna-20221231.xsd#PropertyleasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/PropertyleasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_03fc9d6c-5cc3-4f73-97a2-759dff7b593a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_c90e43fe-49a1-4175-825f-6e7c6bd992c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_03fc9d6c-5cc3-4f73-97a2-759dff7b593a" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_c90e43fe-49a1-4175-825f-6e7c6bd992c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e41ee588-e881-4a85-8f07-92c3517f7ccf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_c90e43fe-49a1-4175-825f-6e7c6bd992c4" xlink:to="loc_srt_StatementGeographicalAxis_e41ee588-e881-4a85-8f07-92c3517f7ccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9cb55621-5699-40dd-8667-6b48b0aafe5b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_e41ee588-e881-4a85-8f07-92c3517f7ccf" xlink:to="loc_srt_SegmentGeographicalDomain_9cb55621-5699-40dd-8667-6b48b0aafe5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_LondonMember_9a0fae7d-7e4a-47ef-9b90-ca9424b38425" xlink:href="vrna-20221231.xsd#vrna_LondonMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_9cb55621-5699-40dd-8667-6b48b0aafe5b" xlink:to="loc_vrna_LondonMember_9a0fae7d-7e4a-47ef-9b90-ca9424b38425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_92f07ccc-05c2-481d-a54d-b53653c06afd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_c90e43fe-49a1-4175-825f-6e7c6bd992c4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_92f07ccc-05c2-481d-a54d-b53653c06afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5ac08799-06c3-4188-8f7d-fda712964853" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_92f07ccc-05c2-481d-a54d-b53653c06afd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5ac08799-06c3-4188-8f7d-fda712964853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_5c3d50d6-5d3d-49ba-bc93-9a76dd2d8022" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5ac08799-06c3-4188-8f7d-fda712964853" xlink:to="loc_us-gaap_BuildingMember_5c3d50d6-5d3d-49ba-bc93-9a76dd2d8022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_3769f4e2-0cfb-41c4-bce4-32bf23ab3ff1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_c90e43fe-49a1-4175-825f-6e7c6bd992c4" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_3769f4e2-0cfb-41c4-bce4-32bf23ab3ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_268156cb-73ba-4fcd-baeb-e31b5b19ed20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3769f4e2-0cfb-41c4-bce4-32bf23ab3ff1" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_268156cb-73ba-4fcd-baeb-e31b5b19ed20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_1194b945-0289-441e-93fc-9345914c1dce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3769f4e2-0cfb-41c4-bce4-32bf23ab3ff1" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_1194b945-0289-441e-93fc-9345914c1dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_4b3db9b5-3642-4dcf-b74c-a209399e703c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3769f4e2-0cfb-41c4-bce4-32bf23ab3ff1" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_4b3db9b5-3642-4dcf-b74c-a209399e703c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_319e2745-ba53-4589-9bec-7cb865e78d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3769f4e2-0cfb-41c4-bce4-32bf23ab3ff1" xlink:to="loc_us-gaap_OperatingLeaseExpense_319e2745-ba53-4589-9bec-7cb865e78d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/PropertyleasesMaturityDetails" xlink:type="simple" xlink:href="vrna-20221231.xsd#PropertyleasesMaturityDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/PropertyleasesMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_36d42a2d-4109-4f02-ac06-ae6a96a8c0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3258568a-2285-43ca-95f7-73adfe1a9f61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_36d42a2d-4109-4f02-ac06-ae6a96a8c0ed" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3258568a-2285-43ca-95f7-73adfe1a9f61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_6d4626c3-9223-40fb-ba43-a2c3fae5c137" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_36d42a2d-4109-4f02-ac06-ae6a96a8c0ed" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_6d4626c3-9223-40fb-ba43-a2c3fae5c137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1c865b16-4511-4e52-b086-6f2398774fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_36d42a2d-4109-4f02-ac06-ae6a96a8c0ed" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1c865b16-4511-4e52-b086-6f2398774fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d3126866-02f4-4b24-83ab-375931245b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_36d42a2d-4109-4f02-ac06-ae6a96a8c0ed" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d3126866-02f4-4b24-83ab-375931245b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a877c048-554b-4a2c-b0a4-dcec84f17447" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_36d42a2d-4109-4f02-ac06-ae6a96a8c0ed" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a877c048-554b-4a2c-b0a4-dcec84f17447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_1793c84f-e5ff-4ec4-b999-d1174bbb421e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_36d42a2d-4109-4f02-ac06-ae6a96a8c0ed" xlink:to="loc_us-gaap_OperatingLeaseLiability_1793c84f-e5ff-4ec4-b999-d1174bbb421e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/PropertyleasesMaturityDetails_1" xlink:type="simple" xlink:href="vrna-20221231.xsd#PropertyleasesMaturityDetails_1"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/PropertyleasesMaturityDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://veronapharma.com/role/AccruedexpensesDetails" xlink:type="simple" xlink:href="vrna-20221231.xsd#AccruedexpensesDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/AccruedexpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_55583e19-fc1c-4b24-8daf-1ec28079e443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AccruedResearchAndDevelopmentFeesCurrent_441b2e79-b541-4792-aefc-7157cdf6f379" xlink:href="vrna-20221231.xsd#vrna_AccruedResearchAndDevelopmentFeesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_55583e19-fc1c-4b24-8daf-1ec28079e443" xlink:to="loc_vrna_AccruedResearchAndDevelopmentFeesCurrent_441b2e79-b541-4792-aefc-7157cdf6f379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent_5ab27c8b-af4d-40c4-ad88-0e31b61e37fb" xlink:href="vrna-20221231.xsd#vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_55583e19-fc1c-4b24-8daf-1ec28079e443" xlink:to="loc_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent_5ab27c8b-af4d-40c4-ad88-0e31b61e37fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_20bef136-4fd6-492c-a307-d8735c754c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_55583e19-fc1c-4b24-8daf-1ec28079e443" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_20bef136-4fd6-492c-a307-d8735c754c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1e27ca9c-ae78-48e9-80a0-aff8622dd942" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_55583e19-fc1c-4b24-8daf-1ec28079e443" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1e27ca9c-ae78-48e9-80a0-aff8622dd942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/WarrantsNarrativeDetails" xlink:type="simple" xlink:href="vrna-20221231.xsd#WarrantsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/WarrantsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_ff41abed-5c36-4677-9a22-0bfe44285a47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ClassOfWarrantOrRightNumberOfExercisedOrForfeited_7ba68e02-3da3-4e8e-93d0-d525e974a903" xlink:href="vrna-20221231.xsd#vrna_ClassOfWarrantOrRightNumberOfExercisedOrForfeited"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_ff41abed-5c36-4677-9a22-0bfe44285a47" xlink:to="loc_vrna_ClassOfWarrantOrRightNumberOfExercisedOrForfeited_7ba68e02-3da3-4e8e-93d0-d525e974a903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_f44ea575-869d-463a-b76d-9cbb5cc43b37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_ff41abed-5c36-4677-9a22-0bfe44285a47" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_f44ea575-869d-463a-b76d-9cbb5cc43b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights_5376de7c-e275-4730-be50-81915216430c" xlink:href="vrna-20221231.xsd#vrna_ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_ff41abed-5c36-4677-9a22-0bfe44285a47" xlink:to="loc_vrna_ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights_5376de7c-e275-4730-be50-81915216430c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_fc006d6b-3e83-433f-aee3-8e6c4eadb864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_ff41abed-5c36-4677-9a22-0bfe44285a47" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_fc006d6b-3e83-433f-aee3-8e6c4eadb864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_542a68df-e5d1-4627-9189-79cc83b67e91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_ff41abed-5c36-4677-9a22-0bfe44285a47" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_542a68df-e5d1-4627-9189-79cc83b67e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_c6a315c8-3537-4c58-99f7-8eee8da7772b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_ff41abed-5c36-4677-9a22-0bfe44285a47" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_c6a315c8-3537-4c58-99f7-8eee8da7772b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ClassOfWarrantOrRightIntrinsicValue_30ff11c4-14b0-4a65-9c8a-5a838ebb66b8" xlink:href="vrna-20221231.xsd#vrna_ClassOfWarrantOrRightIntrinsicValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_ff41abed-5c36-4677-9a22-0bfe44285a47" xlink:to="loc_vrna_ClassOfWarrantOrRightIntrinsicValue_30ff11c4-14b0-4a65-9c8a-5a838ebb66b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/WarrantsFairValueAssumptionsDetails" xlink:type="simple" xlink:href="vrna-20221231.xsd#WarrantsFairValueAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/WarrantsFairValueAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_92e3ab01-d3c2-4687-9a2d-2a586f3af28d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_6a261f91-6b29-41a5-a264-4bf48ae7a6b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_92e3ab01-d3c2-4687-9a2d-2a586f3af28d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_6a261f91-6b29-41a5-a264-4bf48ae7a6b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_b9fcd5ea-6564-424f-9b19-78a597f90ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_6a261f91-6b29-41a5-a264-4bf48ae7a6b7" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_b9fcd5ea-6564-424f-9b19-78a597f90ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_0546a1fb-9d87-417d-a51c-6efae23595cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_b9fcd5ea-6564-424f-9b19-78a597f90ab3" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_0546a1fb-9d87-417d-a51c-6efae23595cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_8864f275-e62b-471b-b7ab-25be8930b3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0546a1fb-9d87-417d-a51c-6efae23595cc" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_8864f275-e62b-471b-b7ab-25be8930b3dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_MeasurementInputAnnualizedVolatilityMember_ba0fd1ab-8fb1-4ea7-a1ba-bed06ad49013" xlink:href="vrna-20221231.xsd#vrna_MeasurementInputAnnualizedVolatilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0546a1fb-9d87-417d-a51c-6efae23595cc" xlink:to="loc_vrna_MeasurementInputAnnualizedVolatilityMember_ba0fd1ab-8fb1-4ea7-a1ba-bed06ad49013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_56ced0d3-ec38-4289-b024-db9f957d4093" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0546a1fb-9d87-417d-a51c-6efae23595cc" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_56ced0d3-ec38-4289-b024-db9f957d4093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_161e0581-11c4-4305-a82e-f246a57997cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_6a261f91-6b29-41a5-a264-4bf48ae7a6b7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_161e0581-11c4-4305-a82e-f246a57997cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_f6623b6c-09bd-4f6c-b4ad-464132272a00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_161e0581-11c4-4305-a82e-f246a57997cc" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_f6623b6c-09bd-4f6c-b4ad-464132272a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b0d46271-a326-4fc3-9ee9-875c7962af06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_161e0581-11c4-4305-a82e-f246a57997cc" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b0d46271-a326-4fc3-9ee9-875c7962af06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_6a1109f5-b5ae-423a-8b65-a8a6d3e5d66f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_161e0581-11c4-4305-a82e-f246a57997cc" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_6a1109f5-b5ae-423a-8b65-a8a6d3e5d66f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_b4ab26ca-c700-4159-9d91-c7be9ff9ba1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_161e0581-11c4-4305-a82e-f246a57997cc" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_b4ab26ca-c700-4159-9d91-c7be9ff9ba1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_WarrantLiabilityCurrent_3f40adf7-c2ae-4585-9454-603bc124c09b" xlink:href="vrna-20221231.xsd#vrna_WarrantLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_161e0581-11c4-4305-a82e-f246a57997cc" xlink:to="loc_vrna_WarrantLiabilityCurrent_3f40adf7-c2ae-4585-9454-603bc124c09b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/WarrantsMovementinValueDetails" xlink:type="simple" xlink:href="vrna-20221231.xsd#WarrantsMovementinValueDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/WarrantsMovementinValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_e2004be7-52e4-42be-b7b0-2cef6548e98d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8c75b78f-9514-4fc3-84ad-7b0c6c7c82d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_e2004be7-52e4-42be-b7b0-2cef6548e98d" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8c75b78f-9514-4fc3-84ad-7b0c6c7c82d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1cb4d1c3-0103-4d3c-8422-d2aa2cb2abd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8c75b78f-9514-4fc3-84ad-7b0c6c7c82d7" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1cb4d1c3-0103-4d3c-8422-d2aa2cb2abd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustment_99145f9a-8b1d-43b7-a9ce-9d75db158be3" xlink:href="vrna-20221231.xsd#vrna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8c75b78f-9514-4fc3-84ad-7b0c6c7c82d7" xlink:to="loc_vrna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustment_99145f9a-8b1d-43b7-a9ce-9d75db158be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_813c6b8e-7570-4d39-b4a9-be141241b279" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8c75b78f-9514-4fc3-84ad-7b0c6c7c82d7" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_813c6b8e-7570-4d39-b4a9-be141241b279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/TermloanDetails" xlink:type="simple" xlink:href="vrna-20221231.xsd#TermloanDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/TermloanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_6f950505-5e93-45f2-b4c6-082d18d0ffa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_921ea9cf-1306-4119-aeb4-c8278d1278a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6f950505-5e93-45f2-b4c6-082d18d0ffa3" xlink:to="loc_us-gaap_DebtInstrumentTable_921ea9cf-1306-4119-aeb4-c8278d1278a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a4033d07-ec22-420f-a005-8ca91cc5e00c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_921ea9cf-1306-4119-aeb4-c8278d1278a0" xlink:to="loc_us-gaap_DebtInstrumentAxis_a4033d07-ec22-420f-a005-8ca91cc5e00c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9b182c51-260f-4235-9e33-7f7ae2e0fae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_a4033d07-ec22-420f-a005-8ca91cc5e00c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9b182c51-260f-4235-9e33-7f7ae2e0fae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TermLoanFacilityMember_98aedd30-0b8a-4c0d-8fa0-0134655ebfe0" xlink:href="vrna-20221231.xsd#vrna_TermLoanFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9b182c51-260f-4235-9e33-7f7ae2e0fae2" xlink:to="loc_vrna_TermLoanFacilityMember_98aedd30-0b8a-4c0d-8fa0-0134655ebfe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TermBLoanMember_50f9243e-985c-40b9-9cbb-60ebd6df92a1" xlink:href="vrna-20221231.xsd#vrna_TermBLoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9b182c51-260f-4235-9e33-7f7ae2e0fae2" xlink:to="loc_vrna_TermBLoanMember_50f9243e-985c-40b9-9cbb-60ebd6df92a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_TermCLoanMember_858cf955-ea97-426b-a3d1-23094f9844e7" xlink:href="vrna-20221231.xsd#vrna_TermCLoanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9b182c51-260f-4235-9e33-7f7ae2e0fae2" xlink:to="loc_vrna_TermCLoanMember_858cf955-ea97-426b-a3d1-23094f9844e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_OxfordTermLoanMember_d89c4037-8278-4af7-ba00-ab3fc8e74c57" xlink:href="vrna-20221231.xsd#vrna_OxfordTermLoanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9b182c51-260f-4235-9e33-7f7ae2e0fae2" xlink:to="loc_vrna_OxfordTermLoanMember_d89c4037-8278-4af7-ba00-ab3fc8e74c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_OxfordTermALoanMember_6dc60ecf-aca0-4885-9aca-298d66333624" xlink:href="vrna-20221231.xsd#vrna_OxfordTermALoanMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9b182c51-260f-4235-9e33-7f7ae2e0fae2" xlink:to="loc_vrna_OxfordTermALoanMember_6dc60ecf-aca0-4885-9aca-298d66333624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_OxfordTermBCDELoanMember_2c89f691-b7c5-4d1b-bc61-d15949a1b152" xlink:href="vrna-20221231.xsd#vrna_OxfordTermBCDELoanMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9b182c51-260f-4235-9e33-7f7ae2e0fae2" xlink:to="loc_vrna_OxfordTermBCDELoanMember_2c89f691-b7c5-4d1b-bc61-d15949a1b152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_OxfordTermBLoanMember_ac67d703-6dcc-454b-8275-3f625cae9f1f" xlink:href="vrna-20221231.xsd#vrna_OxfordTermBLoanMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9b182c51-260f-4235-9e33-7f7ae2e0fae2" xlink:to="loc_vrna_OxfordTermBLoanMember_ac67d703-6dcc-454b-8275-3f625cae9f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_OxfordTermCLoanMember_cfa6f4c6-9b50-4f9c-9a2b-477d06cf783b" xlink:href="vrna-20221231.xsd#vrna_OxfordTermCLoanMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9b182c51-260f-4235-9e33-7f7ae2e0fae2" xlink:to="loc_vrna_OxfordTermCLoanMember_cfa6f4c6-9b50-4f9c-9a2b-477d06cf783b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_OxfordTermDLoanMember_147255ad-30ab-41fe-a08d-39b147d3de5e" xlink:href="vrna-20221231.xsd#vrna_OxfordTermDLoanMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9b182c51-260f-4235-9e33-7f7ae2e0fae2" xlink:to="loc_vrna_OxfordTermDLoanMember_147255ad-30ab-41fe-a08d-39b147d3de5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_OxfordTermELoanMember_f52dea48-d286-4ecd-969d-7ceedfb5b21d" xlink:href="vrna-20221231.xsd#vrna_OxfordTermELoanMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9b182c51-260f-4235-9e33-7f7ae2e0fae2" xlink:to="loc_vrna_OxfordTermELoanMember_f52dea48-d286-4ecd-969d-7ceedfb5b21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_aaab26df-3719-4d22-9d72-1384bd2be762" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_921ea9cf-1306-4119-aeb4-c8278d1278a0" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_aaab26df-3719-4d22-9d72-1384bd2be762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d5268fc2-6ca8-4bfc-b501-f00b3a9ea6aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_aaab26df-3719-4d22-9d72-1384bd2be762" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d5268fc2-6ca8-4bfc-b501-f00b3a9ea6aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_39d874fb-5e4b-4092-8d49-d04562a960cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d5268fc2-6ca8-4bfc-b501-f00b3a9ea6aa" xlink:to="loc_us-gaap_SecuredDebtMember_39d874fb-5e4b-4092-8d49-d04562a960cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_856135b8-9ff3-4898-b21e-669d8e04c35e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_921ea9cf-1306-4119-aeb4-c8278d1278a0" xlink:to="loc_us-gaap_CreditFacilityAxis_856135b8-9ff3-4898-b21e-669d8e04c35e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_0eb4ac57-f9e8-40f4-bbb3-019cc700d426" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_856135b8-9ff3-4898-b21e-669d8e04c35e" xlink:to="loc_us-gaap_CreditFacilityDomain_0eb4ac57-f9e8-40f4-bbb3-019cc700d426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_2b96a049-a110-4f81-82ba-14e0e896d93e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_0eb4ac57-f9e8-40f4-bbb3-019cc700d426" xlink:to="loc_us-gaap_LineOfCreditMember_2b96a049-a110-4f81-82ba-14e0e896d93e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_InterestRatePeriodAxis_c66d71a1-71ea-485d-aa59-5d8b5837df89" xlink:href="vrna-20221231.xsd#vrna_InterestRatePeriodAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_921ea9cf-1306-4119-aeb4-c8278d1278a0" xlink:to="loc_vrna_InterestRatePeriodAxis_c66d71a1-71ea-485d-aa59-5d8b5837df89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_InterestRatePeriodDomain_66fefd97-23b1-4fd4-9719-3d95ade99528" xlink:href="vrna-20221231.xsd#vrna_InterestRatePeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrna_InterestRatePeriodAxis_c66d71a1-71ea-485d-aa59-5d8b5837df89" xlink:to="loc_vrna_InterestRatePeriodDomain_66fefd97-23b1-4fd4-9719-3d95ade99528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentInterestRatePeriodOneMember_54511c18-80d6-41a9-b0f1-718a17dbc934" xlink:href="vrna-20221231.xsd#vrna_DebtInstrumentInterestRatePeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrna_InterestRatePeriodDomain_66fefd97-23b1-4fd4-9719-3d95ade99528" xlink:to="loc_vrna_DebtInstrumentInterestRatePeriodOneMember_54511c18-80d6-41a9-b0f1-718a17dbc934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentInterestRatePeriodTwoMember_3e4602f2-76ca-4b06-aa96-a1614d3de2dd" xlink:href="vrna-20221231.xsd#vrna_DebtInstrumentInterestRatePeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrna_InterestRatePeriodDomain_66fefd97-23b1-4fd4-9719-3d95ade99528" xlink:to="loc_vrna_DebtInstrumentInterestRatePeriodTwoMember_3e4602f2-76ca-4b06-aa96-a1614d3de2dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c4ba488c-aa90-4c7f-b1ea-e624fc74d93c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_921ea9cf-1306-4119-aeb4-c8278d1278a0" xlink:to="loc_srt_RangeAxis_c4ba488c-aa90-4c7f-b1ea-e624fc74d93c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5f265139-8d00-4953-9b3a-0cab129373e2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c4ba488c-aa90-4c7f-b1ea-e624fc74d93c" xlink:to="loc_srt_RangeMember_5f265139-8d00-4953-9b3a-0cab129373e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_72663ea2-3de6-4bc2-9976-1175b2daf7eb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5f265139-8d00-4953-9b3a-0cab129373e2" xlink:to="loc_srt_MinimumMember_72663ea2-3de6-4bc2-9976-1175b2daf7eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_47ac4608-fe42-4873-be02-18f5dc7ca2cc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5f265139-8d00-4953-9b3a-0cab129373e2" xlink:to="loc_srt_MaximumMember_47ac4608-fe42-4873-be02-18f5dc7ca2cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_d6d2fe26-9c46-465f-ae3a-0a39597ef5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_921ea9cf-1306-4119-aeb4-c8278d1278a0" xlink:to="loc_us-gaap_VariableRateAxis_d6d2fe26-9c46-465f-ae3a-0a39597ef5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_10d20749-fe46-4117-bbec-90dfea748d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_d6d2fe26-9c46-465f-ae3a-0a39597ef5f1" xlink:to="loc_us-gaap_VariableRateDomain_10d20749-fe46-4117-bbec-90dfea748d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_bd36c65b-6e20-470d-aae1-b3c43454ddb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_10d20749-fe46-4117-bbec-90dfea748d8f" xlink:to="loc_us-gaap_BaseRateMember_bd36c65b-6e20-470d-aae1-b3c43454ddb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_d98f5fcf-10a8-43ce-b8b2-c38e8d3db0f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_921ea9cf-1306-4119-aeb4-c8278d1278a0" xlink:to="loc_us-gaap_DebtInstrumentLineItems_d98f5fcf-10a8-43ce-b8b2-c38e8d3db0f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_49218764-56e6-44fa-a797-5be275d1f019" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d98f5fcf-10a8-43ce-b8b2-c38e8d3db0f3" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_49218764-56e6-44fa-a797-5be275d1f019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_f84eaac4-b07c-4325-81c8-be0b2ad536a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d98f5fcf-10a8-43ce-b8b2-c38e8d3db0f3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_f84eaac4-b07c-4325-81c8-be0b2ad536a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_884bf0f0-645d-4992-9b4e-54e6f6b6a0e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d98f5fcf-10a8-43ce-b8b2-c38e8d3db0f3" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_884bf0f0-645d-4992-9b4e-54e6f6b6a0e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_LineOfCreditFacilityNumberOfLoanAdvances_5590b1f4-57d0-4df4-81ad-18be55aa6966" xlink:href="vrna-20221231.xsd#vrna_LineOfCreditFacilityNumberOfLoanAdvances"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d98f5fcf-10a8-43ce-b8b2-c38e8d3db0f3" xlink:to="loc_vrna_LineOfCreditFacilityNumberOfLoanAdvances_5590b1f4-57d0-4df4-81ad-18be55aa6966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_c94ded21-8885-4242-b198-39d77d4d9650" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d98f5fcf-10a8-43ce-b8b2-c38e8d3db0f3" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_c94ded21-8885-4242-b198-39d77d4d9650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_cb700fdb-316d-4e99-8488-19eaa9446c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d98f5fcf-10a8-43ce-b8b2-c38e8d3db0f3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_cb700fdb-316d-4e99-8488-19eaa9446c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentFinalPaymentPercentageOfPrincipalAmount_56660ed6-de0e-4ed5-aa0a-87aee2e1bb11" xlink:href="vrna-20221231.xsd#vrna_DebtInstrumentFinalPaymentPercentageOfPrincipalAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d98f5fcf-10a8-43ce-b8b2-c38e8d3db0f3" xlink:to="loc_vrna_DebtInstrumentFinalPaymentPercentageOfPrincipalAmount_56660ed6-de0e-4ed5-aa0a-87aee2e1bb11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DebtInstrumentPrepaymentFeePercentage_5598d0fe-1b6b-4ce9-bfe0-8e7d60e0d796" xlink:href="vrna-20221231.xsd#vrna_DebtInstrumentPrepaymentFeePercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d98f5fcf-10a8-43ce-b8b2-c38e8d3db0f3" xlink:to="loc_vrna_DebtInstrumentPrepaymentFeePercentage_5598d0fe-1b6b-4ce9-bfe0-8e7d60e0d796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/SignificantagreementsDetails" xlink:type="simple" xlink:href="vrna-20221231.xsd#SignificantagreementsDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/SignificantagreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_38edb720-1abf-410d-9d40-6368e86a5a87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostTable_2021eba8-a2fd-452b-8ead-a2dac7e6ece7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_38edb720-1abf-410d-9d40-6368e86a5a87" xlink:to="loc_us-gaap_CapitalizedContractCostTable_2021eba8-a2fd-452b-8ead-a2dac7e6ece7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1073e276-797f-4cb8-a252-76d9a222b85f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostTable_2021eba8-a2fd-452b-8ead-a2dac7e6ece7" xlink:to="loc_srt_CounterpartyNameAxis_1073e276-797f-4cb8-a252-76d9a222b85f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_45a64cff-0797-47fd-856d-c400a409c6de" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_1073e276-797f-4cb8-a252-76d9a222b85f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_45a64cff-0797-47fd-856d-c400a409c6de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_LigandUKDevelopmentLimitedMember_9ef3c008-ae1c-4f04-8a4e-d94d317df0c4" xlink:href="vrna-20221231.xsd#vrna_LigandUKDevelopmentLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_45a64cff-0797-47fd-856d-c400a409c6de" xlink:to="loc_vrna_LigandUKDevelopmentLimitedMember_9ef3c008-ae1c-4f04-8a4e-d94d317df0c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_NuanceShanghaiPharmaCoLtdMember_eca7f557-a18d-4f66-9d00-82be1153f6d9" xlink:href="vrna-20221231.xsd#vrna_NuanceShanghaiPharmaCoLtdMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_45a64cff-0797-47fd-856d-c400a409c6de" xlink:to="loc_vrna_NuanceShanghaiPharmaCoLtdMember_eca7f557-a18d-4f66-9d00-82be1153f6d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_BenchmarkAchievementAxis_0076039f-5ae6-4499-8627-287db57753cc" xlink:href="vrna-20221231.xsd#vrna_BenchmarkAchievementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostTable_2021eba8-a2fd-452b-8ead-a2dac7e6ece7" xlink:to="loc_vrna_BenchmarkAchievementAxis_0076039f-5ae6-4499-8627-287db57753cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_BenchmarkAchievementDomain_606b9b8b-14aa-474a-b4a7-a2bee0f73bb2" xlink:href="vrna-20221231.xsd#vrna_BenchmarkAchievementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrna_BenchmarkAchievementAxis_0076039f-5ae6-4499-8627-287db57753cc" xlink:to="loc_vrna_BenchmarkAchievementDomain_606b9b8b-14aa-474a-b4a7-a2bee0f73bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_FirstCommercialSaleMember_54532a21-635f-4ee7-b9f7-93bbcb86bdf3" xlink:href="vrna-20221231.xsd#vrna_FirstCommercialSaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vrna_BenchmarkAchievementDomain_606b9b8b-14aa-474a-b4a7-a2bee0f73bb2" xlink:to="loc_vrna_FirstCommercialSaleMember_54532a21-635f-4ee7-b9f7-93bbcb86bdf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a84fb3c0-e310-4889-ab2a-33419b4ce1bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostTable_2021eba8-a2fd-452b-8ead-a2dac7e6ece7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a84fb3c0-e310-4889-ab2a-33419b4ce1bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_56fbdcb8-8b4b-4f0f-968f-1467568525fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a84fb3c0-e310-4889-ab2a-33419b4ce1bc" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_56fbdcb8-8b4b-4f0f-968f-1467568525fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d7fbf651-012d-417d-934d-1e31f58444a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_56fbdcb8-8b4b-4f0f-968f-1467568525fe" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d7fbf651-012d-417d-934d-1e31f58444a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostLineItems_e56b8a70-fa70-4940-97fb-4e4d6818c5e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostTable_2021eba8-a2fd-452b-8ead-a2dac7e6ece7" xlink:to="loc_us-gaap_CapitalizedContractCostLineItems_e56b8a70-fa70-4940-97fb-4e4d6818c5e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SublicensePayment_c3be259b-490c-4cf1-867d-e50778cb264c" xlink:href="vrna-20221231.xsd#vrna_SublicensePayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_e56b8a70-fa70-4940-97fb-4e4d6818c5e2" xlink:to="loc_vrna_SublicensePayment_c3be259b-490c-4cf1-867d-e50778cb264c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SublicensePaymentEquityIssuanceThresholdTradingDays_7c0128ed-6ffe-4cad-9392-5549954811f8" xlink:href="vrna-20221231.xsd#vrna_SublicensePaymentEquityIssuanceThresholdTradingDays"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_e56b8a70-fa70-4940-97fb-4e4d6818c5e2" xlink:to="loc_vrna_SublicensePaymentEquityIssuanceThresholdTradingDays_7c0128ed-6ffe-4cad-9392-5549954811f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_a9fb0e81-d20d-4c25-a2de-ed9c37eb0664" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_e56b8a70-fa70-4940-97fb-4e4d6818c5e2" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_a9fb0e81-d20d-4c25-a2de-ed9c37eb0664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_1926118a-76dc-40c1-b1f8-acf2233d55aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_e56b8a70-fa70-4940-97fb-4e4d6818c5e2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_1926118a-76dc-40c1-b1f8-acf2233d55aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_EquityInterestReceivable_0406d368-a6b3-4e86-9f0c-0ac25785ddca" xlink:href="vrna-20221231.xsd#vrna_EquityInterestReceivable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_e56b8a70-fa70-4940-97fb-4e4d6818c5e2" xlink:to="loc_vrna_EquityInterestReceivable_0406d368-a6b3-4e86-9f0c-0ac25785ddca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ContractWithCustomerFutureEligibleMilestonePayments_e02a5870-2c8a-49a6-8e30-d8eb4c158a5f" xlink:href="vrna-20221231.xsd#vrna_ContractWithCustomerFutureEligibleMilestonePayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_e56b8a70-fa70-4940-97fb-4e4d6818c5e2" xlink:to="loc_vrna_ContractWithCustomerFutureEligibleMilestonePayments_e02a5870-2c8a-49a6-8e30-d8eb4c158a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_416588e6-141d-49bc-b8b0-2ece21b28add" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_e56b8a70-fa70-4940-97fb-4e4d6818c5e2" xlink:to="loc_us-gaap_ContractWithCustomerLiability_416588e6-141d-49bc-b8b0-2ece21b28add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNet_d3b2ae1d-d635-476b-b5b4-262c602161a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_e56b8a70-fa70-4940-97fb-4e4d6818c5e2" xlink:to="loc_us-gaap_CapitalizedContractCostNet_d3b2ae1d-d635-476b-b5b4-262c602161a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_c1ba25d4-65b4-4806-a2a8-97f368f1db4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_e56b8a70-fa70-4940-97fb-4e4d6818c5e2" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_c1ba25d4-65b4-4806-a2a8-97f368f1db4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/BenefitplansDetails" xlink:type="simple" xlink:href="vrna-20221231.xsd#BenefitplansDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/BenefitplansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_cc9cdf1a-da4f-4a98-b156-6822b5961e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_a9ac3674-bb16-420a-961b-e4f75baea715" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_cc9cdf1a-da4f-4a98-b156-6822b5961e3e" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_a9ac3674-bb16-420a-961b-e4f75baea715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/TaxationLossBeforeTaxDetails" xlink:type="simple" xlink:href="vrna-20221231.xsd#TaxationLossBeforeTaxDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/TaxationLossBeforeTaxDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_73c6df82-c595-4162-94b7-db9cd180873a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_0126d850-4770-439a-872c-adc575984dad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_73c6df82-c595-4162-94b7-db9cd180873a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_0126d850-4770-439a-872c-adc575984dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e511cb3e-5fd5-4a0b-b450-97cd4040d629" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_73c6df82-c595-4162-94b7-db9cd180873a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e511cb3e-5fd5-4a0b-b450-97cd4040d629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e6b0820b-819d-44a7-b3cf-89462ddd70f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_73c6df82-c595-4162-94b7-db9cd180873a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e6b0820b-819d-44a7-b3cf-89462ddd70f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/TaxationTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="vrna-20221231.xsd#TaxationTaxExpenseBenefitDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/TaxationTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0d8861c3-af12-4e89-a338-a20a786b4a21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_0b8988a7-1be1-4455-9c3a-c4d0eb6bef13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0d8861c3-af12-4e89-a338-a20a786b4a21" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_0b8988a7-1be1-4455-9c3a-c4d0eb6bef13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_8aeed0fc-405e-42e2-b208-2c39c974404f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0d8861c3-af12-4e89-a338-a20a786b4a21" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_8aeed0fc-405e-42e2-b208-2c39c974404f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e387eb87-da85-4794-b8e8-9908c02b4ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0d8861c3-af12-4e89-a338-a20a786b4a21" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e387eb87-da85-4794-b8e8-9908c02b4ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_de794696-a99f-4919-806b-769a36b60685" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0d8861c3-af12-4e89-a338-a20a786b4a21" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_de794696-a99f-4919-806b-769a36b60685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_7e36c90e-c50a-4a18-8a5b-b9941ed1a094" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0d8861c3-af12-4e89-a338-a20a786b4a21" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_7e36c90e-c50a-4a18-8a5b-b9941ed1a094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_66874a43-c7ed-48ed-817b-413b66aa2ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0d8861c3-af12-4e89-a338-a20a786b4a21" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_66874a43-c7ed-48ed-817b-413b66aa2ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1214acb2-7f76-4710-a611-9dd0226a48c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0d8861c3-af12-4e89-a338-a20a786b4a21" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1214acb2-7f76-4710-a611-9dd0226a48c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/TaxationReconciliationofStatutoryRateDetails" xlink:type="simple" xlink:href="vrna-20221231.xsd#TaxationReconciliationofStatutoryRateDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/TaxationReconciliationofStatutoryRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8cd12fe7-1bbe-47f9-9cee-0920244d5faa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_778e82b3-5a8e-42aa-a466-c1905ba0ca00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8cd12fe7-1bbe-47f9-9cee-0920244d5faa" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_778e82b3-5a8e-42aa-a466-c1905ba0ca00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_2a5d1ead-b97f-48a1-90dc-1f94c8ea092b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8cd12fe7-1bbe-47f9-9cee-0920244d5faa" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_2a5d1ead-b97f-48a1-90dc-1f94c8ea092b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_731170a8-d5a1-4660-a22f-8b3ac25379b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8cd12fe7-1bbe-47f9-9cee-0920244d5faa" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_731170a8-d5a1-4660-a22f-8b3ac25379b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_0d7c4a2a-be4c-4f23-9e0a-db0ad5c0b980" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8cd12fe7-1bbe-47f9-9cee-0920244d5faa" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_0d7c4a2a-be4c-4f23-9e0a-db0ad5c0b980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_407b17f3-63f3-4bf0-8532-27318aed6a32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8cd12fe7-1bbe-47f9-9cee-0920244d5faa" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_407b17f3-63f3-4bf0-8532-27318aed6a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_EffectiveIncomeTaxRateReconciliationCapitalAllowancesPercent_a11ca945-9edb-4080-8995-8bcf4d2abd76" xlink:href="vrna-20221231.xsd#vrna_EffectiveIncomeTaxRateReconciliationCapitalAllowancesPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8cd12fe7-1bbe-47f9-9cee-0920244d5faa" xlink:to="loc_vrna_EffectiveIncomeTaxRateReconciliationCapitalAllowancesPercent_a11ca945-9edb-4080-8995-8bcf4d2abd76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_586714b1-07d9-449d-a2ff-56e59fd46d11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8cd12fe7-1bbe-47f9-9cee-0920244d5faa" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_586714b1-07d9-449d-a2ff-56e59fd46d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="vrna-20221231.xsd#TaxationDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_76577c71-cad3-4c65-be22-2fcb963ac181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_cf6c5d4d-8ae5-470e-8c4d-940f473330c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_76577c71-cad3-4c65-be22-2fcb963ac181" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_cf6c5d4d-8ae5-470e-8c4d-940f473330c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_DeferredTaxLiabilitiesContingentLiability_d7c0bf69-080e-4ef5-9bf7-8a530c3b9dce" xlink:href="vrna-20221231.xsd#vrna_DeferredTaxLiabilitiesContingentLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_cf6c5d4d-8ae5-470e-8c4d-940f473330c5" xlink:to="loc_vrna_DeferredTaxLiabilitiesContingentLiability_d7c0bf69-080e-4ef5-9bf7-8a530c3b9dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_da52d451-bc5b-419e-88f3-a25b3e59d56f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_cf6c5d4d-8ae5-470e-8c4d-940f473330c5" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_da52d451-bc5b-419e-88f3-a25b3e59d56f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_da0b4bff-c82b-43df-8635-a5c607e5ac6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_76577c71-cad3-4c65-be22-2fcb963ac181" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_da0b4bff-c82b-43df-8635-a5c607e5ac6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_6eaaa49f-bab3-4778-b000-2995ff1b9bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_da0b4bff-c82b-43df-8635-a5c607e5ac6d" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_6eaaa49f-bab3-4778-b000-2995ff1b9bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_6ae6215e-7adc-46c8-978e-73caf14f9c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_da0b4bff-c82b-43df-8635-a5c607e5ac6d" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_6ae6215e-7adc-46c8-978e-73caf14f9c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_f6adb8a3-0bfc-4410-ad24-bbfce6d1d503" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_da0b4bff-c82b-43df-8635-a5c607e5ac6d" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_f6adb8a3-0bfc-4410-ad24-bbfce6d1d503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_7639e9cf-fecb-44b2-9563-699b7d403c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_da0b4bff-c82b-43df-8635-a5c607e5ac6d" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_7639e9cf-fecb-44b2-9563-699b7d403c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_06d995aa-1602-4316-8c0e-484f78b28847" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_da0b4bff-c82b-43df-8635-a5c607e5ac6d" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_06d995aa-1602-4316-8c0e-484f78b28847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_647cc15c-c65b-4d3f-8563-8a13317e72d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_76577c71-cad3-4c65-be22-2fcb963ac181" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_647cc15c-c65b-4d3f-8563-8a13317e72d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_70dfa276-d177-4c86-a6cf-8c78d9ac3c65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_76577c71-cad3-4c65-be22-2fcb963ac181" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_70dfa276-d177-4c86-a6cf-8c78d9ac3c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_8363834e-060e-4333-9c9e-02ba7755deda" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_76577c71-cad3-4c65-be22-2fcb963ac181" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_8363834e-060e-4333-9c9e-02ba7755deda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_412a661a-a422-4b1d-bdbe-4c4a83690576" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_8363834e-060e-4333-9c9e-02ba7755deda" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_412a661a-a422-4b1d-bdbe-4c4a83690576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_8ffd0e39-0ccb-4e2f-9ef5-5249047beba4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_412a661a-a422-4b1d-bdbe-4c4a83690576" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_8ffd0e39-0ccb-4e2f-9ef5-5249047beba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_0c003351-917d-4834-8f6a-c7454d7d5251" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8ffd0e39-0ccb-4e2f-9ef5-5249047beba4" xlink:to="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_0c003351-917d-4834-8f6a-c7454d7d5251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_d6609f2c-f073-49a8-b55d-f697fb863055" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_8363834e-060e-4333-9c9e-02ba7755deda" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_d6609f2c-f073-49a8-b55d-f697fb863055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_59f5342f-c639-468b-99e4-b5c6fd0b10f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_d6609f2c-f073-49a8-b55d-f697fb863055" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_59f5342f-c639-468b-99e4-b5c6fd0b10f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_1234ac4a-efe1-48fc-91ec-61926e157832" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_59f5342f-c639-468b-99e4-b5c6fd0b10f7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_1234ac4a-efe1-48fc-91ec-61926e157832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates_370b238d-a930-4b37-b018-6064b53fd06e" xlink:href="vrna-20221231.xsd#vrna_SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_59f5342f-c639-468b-99e4-b5c6fd0b10f7" xlink:to="loc_vrna_SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates_370b238d-a930-4b37-b018-6064b53fd06e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance_84434cb6-5210-4be7-878c-cdeb1a028ebd" xlink:href="vrna-20221231.xsd#vrna_SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_59f5342f-c639-468b-99e4-b5c6fd0b10f7" xlink:to="loc_vrna_SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance_84434cb6-5210-4be7-878c-cdeb1a028ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_c796a02c-d516-4e7c-9163-f81ee1d65875" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_59f5342f-c639-468b-99e4-b5c6fd0b10f7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_c796a02c-d516-4e7c-9163-f81ee1d65875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/TaxationNarrativeDetails" xlink:type="simple" xlink:href="vrna-20221231.xsd#TaxationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/TaxationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_896e0dd2-7cdf-4410-bddb-3f6435b0ce17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_b2a574ce-e392-42d8-bd0a-67684e22ca66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_896e0dd2-7cdf-4410-bddb-3f6435b0ce17" xlink:to="loc_us-gaap_OperatingLossCarryforwards_b2a574ce-e392-42d8-bd0a-67684e22ca66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_0d0153ec-57fa-4466-933d-510d62a3afbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_896e0dd2-7cdf-4410-bddb-3f6435b0ce17" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_0d0153ec-57fa-4466-933d-510d62a3afbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationInterestAccrued_fc9884d1-6141-49ca-8c98-6e3d795b32f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationInterestAccrued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_896e0dd2-7cdf-4410-bddb-3f6435b0ce17" xlink:to="loc_us-gaap_IncomeTaxExaminationInterestAccrued_fc9884d1-6141-49ca-8c98-6e3d795b32f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAccrued_ee800101-d009-4b24-a967-c376c0f5f900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAccrued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_896e0dd2-7cdf-4410-bddb-3f6435b0ce17" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAccrued_ee800101-d009-4b24-a967-c376c0f5f900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="vrna-20221231.xsd#SharebasedcompensationShareBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cf0fbc14-1d2e-4247-af52-6a2adb384f49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8f0cadc1-bdfb-4a5d-a1b4-c17faa3184e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cf0fbc14-1d2e-4247-af52-6a2adb384f49" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8f0cadc1-bdfb-4a5d-a1b4-c17faa3184e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ff0e9d7e-d99b-49c3-abd4-1e4c7bed2e51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8f0cadc1-bdfb-4a5d-a1b4-c17faa3184e9" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ff0e9d7e-d99b-49c3-abd4-1e4c7bed2e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_337f27a7-43bd-46e9-99da-fbdbbe3875f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ff0e9d7e-d99b-49c3-abd4-1e4c7bed2e51" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_337f27a7-43bd-46e9-99da-fbdbbe3875f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ddda2d04-bee1-4349-a709-75ba2573b9ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_337f27a7-43bd-46e9-99da-fbdbbe3875f3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ddda2d04-bee1-4349-a709-75ba2573b9ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c8c1e5ef-03dc-4903-8f08-7ab0eb12e1db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_337f27a7-43bd-46e9-99da-fbdbbe3875f3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c8c1e5ef-03dc-4903-8f08-7ab0eb12e1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e82eb099-9fa4-40df-99aa-e2518d050785" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8f0cadc1-bdfb-4a5d-a1b4-c17faa3184e9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e82eb099-9fa4-40df-99aa-e2518d050785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_4205f85a-6927-426b-8bea-2ada805fc367" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e82eb099-9fa4-40df-99aa-e2518d050785" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_4205f85a-6927-426b-8bea-2ada805fc367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/SharebasedcompensationNarrativeDetails" xlink:type="simple" xlink:href="vrna-20221231.xsd#SharebasedcompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/SharebasedcompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ce6aed61-3489-4afa-8b30-6afd86ac2f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1caf82b5-0e93-456d-b9bd-d0ff90c278a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ce6aed61-3489-4afa-8b30-6afd86ac2f6d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1caf82b5-0e93-456d-b9bd-d0ff90c278a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0e2ab3bc-3e6f-4863-b101-5cdac4416e70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1caf82b5-0e93-456d-b9bd-d0ff90c278a8" xlink:to="loc_us-gaap_AwardTypeAxis_0e2ab3bc-3e6f-4863-b101-5cdac4416e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9c5949a7-1d3c-4a6a-84f5-5a03ffb3b87c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0e2ab3bc-3e6f-4863-b101-5cdac4416e70" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9c5949a7-1d3c-4a6a-84f5-5a03ffb3b87c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_24ca378e-7bea-4699-a8ae-c6f5e10c28ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9c5949a7-1d3c-4a6a-84f5-5a03ffb3b87c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_24ca378e-7bea-4699-a8ae-c6f5e10c28ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6567004c-fc1a-4198-b87d-ed06e412ba60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9c5949a7-1d3c-4a6a-84f5-5a03ffb3b87c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6567004c-fc1a-4198-b87d-ed06e412ba60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_2a8ad870-4d32-420f-8d6e-40269c6a3010" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1caf82b5-0e93-456d-b9bd-d0ff90c278a8" xlink:to="loc_us-gaap_PlanNameAxis_2a8ad870-4d32-420f-8d6e-40269c6a3010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0fbcff94-41a9-4f88-a163-7e0ec8399083" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_2a8ad870-4d32-420f-8d6e-40269c6a3010" xlink:to="loc_us-gaap_PlanNameDomain_0fbcff94-41a9-4f88-a163-7e0ec8399083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_EMIOptionPlanMember_e7c4b1f8-b5da-4321-a1a6-904a6dd5151c" xlink:href="vrna-20221231.xsd#vrna_EMIOptionPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_0fbcff94-41a9-4f88-a163-7e0ec8399083" xlink:to="loc_vrna_EMIOptionPlanMember_e7c4b1f8-b5da-4321-a1a6-904a6dd5151c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_PreIPOOptionPlanMember_2bdc636c-f4c6-42e8-8216-bbb8a13aa583" xlink:href="vrna-20221231.xsd#vrna_PreIPOOptionPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_0fbcff94-41a9-4f88-a163-7e0ec8399083" xlink:to="loc_vrna_PreIPOOptionPlanMember_2bdc636c-f4c6-42e8-8216-bbb8a13aa583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_A2017IncentivePlanMember_4f549677-3d81-45be-b035-bd0fd1b59c7a" xlink:href="vrna-20221231.xsd#vrna_A2017IncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_0fbcff94-41a9-4f88-a163-7e0ec8399083" xlink:to="loc_vrna_A2017IncentivePlanMember_4f549677-3d81-45be-b035-bd0fd1b59c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5f0eae50-0aea-4259-ac1b-73b65cf258d9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1caf82b5-0e93-456d-b9bd-d0ff90c278a8" xlink:to="loc_srt_RangeAxis_5f0eae50-0aea-4259-ac1b-73b65cf258d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_66a219eb-90c4-48bb-8399-ee198eb7e49e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5f0eae50-0aea-4259-ac1b-73b65cf258d9" xlink:to="loc_srt_RangeMember_66a219eb-90c4-48bb-8399-ee198eb7e49e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5cabc3e4-36c2-43ab-b7bb-f67371702dda" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_66a219eb-90c4-48bb-8399-ee198eb7e49e" xlink:to="loc_srt_MinimumMember_5cabc3e4-36c2-43ab-b7bb-f67371702dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b9320f53-93c2-4c80-9e8b-e253d8fac6e7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_66a219eb-90c4-48bb-8399-ee198eb7e49e" xlink:to="loc_srt_MaximumMember_b9320f53-93c2-4c80-9e8b-e253d8fac6e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6af08090-f70f-49df-a078-8ddd87a4a2f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1caf82b5-0e93-456d-b9bd-d0ff90c278a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6af08090-f70f-49df-a078-8ddd87a4a2f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5ed0907d-d5d4-41c3-8f1a-3492d18ccc2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6af08090-f70f-49df-a078-8ddd87a4a2f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5ed0907d-d5d4-41c3-8f1a-3492d18ccc2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_73227ce4-1b9e-4fa3-85ae-a4edc034daa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6af08090-f70f-49df-a078-8ddd87a4a2f1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_73227ce4-1b9e-4fa3-85ae-a4edc034daa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_59f3d3b2-416c-4cb1-95ad-ca65edf057f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6af08090-f70f-49df-a078-8ddd87a4a2f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_59f3d3b2-416c-4cb1-95ad-ca65edf057f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized_461e02d6-6b8f-4f9d-b34c-69e1f8f805ba" xlink:href="vrna-20221231.xsd#vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6af08090-f70f-49df-a078-8ddd87a4a2f1" xlink:to="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized_461e02d6-6b8f-4f9d-b34c-69e1f8f805ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0d02ff68-12ec-45eb-a29a-94218e6b6b00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6af08090-f70f-49df-a078-8ddd87a4a2f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0d02ff68-12ec-45eb-a29a-94218e6b6b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_ef74e0ac-d175-4021-a2de-4f08e41dfe02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6af08090-f70f-49df-a078-8ddd87a4a2f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_ef74e0ac-d175-4021-a2de-4f08e41dfe02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired_433d661b-8972-4487-b67d-977bb09b7b78" xlink:href="vrna-20221231.xsd#vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6af08090-f70f-49df-a078-8ddd87a4a2f1" xlink:to="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired_433d661b-8972-4487-b67d-977bb09b7b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod_f37d8765-4d8e-4260-aa36-73d9617409a2" xlink:href="vrna-20221231.xsd#vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6af08090-f70f-49df-a078-8ddd87a4a2f1" xlink:to="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod_f37d8765-4d8e-4260-aa36-73d9617409a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingDepositoryReceiptRatio_8771f9a4-c2ad-4bfe-91c2-1ed376772c23" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityListingDepositoryReceiptRatio"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6af08090-f70f-49df-a078-8ddd87a4a2f1" xlink:to="loc_dei_EntityListingDepositoryReceiptRatio_8771f9a4-c2ad-4bfe-91c2-1ed376772c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue_01d47faf-6de5-48f3-a443-a21ccceacdf6" xlink:href="vrna-20221231.xsd#vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6af08090-f70f-49df-a078-8ddd87a4a2f1" xlink:to="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue_01d47faf-6de5-48f3-a443-a21ccceacdf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_e45f2d27-9eba-49bb-946b-5334c134c237" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6af08090-f70f-49df-a078-8ddd87a4a2f1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_e45f2d27-9eba-49bb-946b-5334c134c237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_2ad5f9ff-c358-4cfd-8bb3-8e552242bef3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6af08090-f70f-49df-a078-8ddd87a4a2f1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_2ad5f9ff-c358-4cfd-8bb3-8e552242bef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1e93da97-f8b1-47a0-9282-58852dc2b879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6af08090-f70f-49df-a078-8ddd87a4a2f1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1e93da97-f8b1-47a0-9282-58852dc2b879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails" xlink:type="simple" xlink:href="vrna-20221231.xsd#SharebasedcompensationShareOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a29eba8b-2b91-4ada-9a47-5e571f4b399f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingDepositoryReceiptRatio_170e627b-a3b6-4379-b8f4-96eb7b84ed4c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityListingDepositoryReceiptRatio"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a29eba8b-2b91-4ada-9a47-5e571f4b399f" xlink:to="loc_dei_EntityListingDepositoryReceiptRatio_170e627b-a3b6-4379-b8f4-96eb7b84ed4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_976821aa-6629-4a7b-81b6-0a72dec62ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a29eba8b-2b91-4ada-9a47-5e571f4b399f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_976821aa-6629-4a7b-81b6-0a72dec62ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_25fe9eeb-7192-4cce-868e-c2516b4939b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_976821aa-6629-4a7b-81b6-0a72dec62ecc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_25fe9eeb-7192-4cce-868e-c2516b4939b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3dcf40b5-673b-4483-90c5-bb6fc1fbc9e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_976821aa-6629-4a7b-81b6-0a72dec62ecc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3dcf40b5-673b-4483-90c5-bb6fc1fbc9e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c6ef047c-ed57-4432-9d61-bf92660979a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_976821aa-6629-4a7b-81b6-0a72dec62ecc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c6ef047c-ed57-4432-9d61-bf92660979a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b322f863-47cb-4980-8bb9-d5a79ac806f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_976821aa-6629-4a7b-81b6-0a72dec62ecc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b322f863-47cb-4980-8bb9-d5a79ac806f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_368f7628-afa5-4e7d-8634-0dedbad04e51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_976821aa-6629-4a7b-81b6-0a72dec62ecc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_368f7628-afa5-4e7d-8634-0dedbad04e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c5001e3b-b941-41f6-8567-8e2ba9fb3c08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a29eba8b-2b91-4ada-9a47-5e571f4b399f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c5001e3b-b941-41f6-8567-8e2ba9fb3c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a1c1a7ab-5dcc-40c1-9ed3-c796143d63fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a29eba8b-2b91-4ada-9a47-5e571f4b399f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a1c1a7ab-5dcc-40c1-9ed3-c796143d63fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c8d3b55d-2bec-46fb-8008-57785a4a2bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a1c1a7ab-5dcc-40c1-9ed3-c796143d63fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c8d3b55d-2bec-46fb-8008-57785a4a2bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1fe394db-a2a7-4ae1-99f3-6ded97080394" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a1c1a7ab-5dcc-40c1-9ed3-c796143d63fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1fe394db-a2a7-4ae1-99f3-6ded97080394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_35e07147-683d-4539-8abe-1e2b5f6235ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a1c1a7ab-5dcc-40c1-9ed3-c796143d63fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_35e07147-683d-4539-8abe-1e2b5f6235ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c8a24d31-ca75-439e-8c5b-70b28ad23e6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a1c1a7ab-5dcc-40c1-9ed3-c796143d63fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c8a24d31-ca75-439e-8c5b-70b28ad23e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_548a4f04-1234-453c-8482-6a5c74b3bfaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a1c1a7ab-5dcc-40c1-9ed3-c796143d63fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_548a4f04-1234-453c-8482-6a5c74b3bfaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_bc4d021d-c31e-4375-9e40-3c98eab540b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a29eba8b-2b91-4ada-9a47-5e571f4b399f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_bc4d021d-c31e-4375-9e40-3c98eab540b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_998778d8-6172-4995-8436-6053823286dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a29eba8b-2b91-4ada-9a47-5e571f4b399f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_998778d8-6172-4995-8436-6053823286dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d69b564b-7759-4e9b-8eb7-6a377012b353" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_998778d8-6172-4995-8436-6053823286dc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d69b564b-7759-4e9b-8eb7-6a377012b353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_e76fcdd7-a42f-47fa-927a-8a9706fda06f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_998778d8-6172-4995-8436-6053823286dc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_e76fcdd7-a42f-47fa-927a-8a9706fda06f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_70c8be00-2a7a-441f-bf3b-d14360c4a404" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_998778d8-6172-4995-8436-6053823286dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_70c8be00-2a7a-441f-bf3b-d14360c4a404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f729f972-7dfa-4b7c-ad2d-5b1ab046c1ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_998778d8-6172-4995-8436-6053823286dc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f729f972-7dfa-4b7c-ad2d-5b1ab046c1ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c9a709af-11c6-4c1c-b26a-332a83dc12d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a29eba8b-2b91-4ada-9a47-5e571f4b399f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c9a709af-11c6-4c1c-b26a-332a83dc12d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_c6c3c3b7-9dcd-430c-aa8a-c7427b76051d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a29eba8b-2b91-4ada-9a47-5e571f4b399f" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_c6c3c3b7-9dcd-430c-aa8a-c7427b76051d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/SharebasedcompensationWeightedAverageAssumptionsDetails" xlink:type="simple" xlink:href="vrna-20221231.xsd#SharebasedcompensationWeightedAverageAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/SharebasedcompensationWeightedAverageAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dce99c16-b76d-4e8a-b760-29fed300069c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9b21257f-65cc-4d1f-a864-9f7d3bfe6c08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dce99c16-b76d-4e8a-b760-29fed300069c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9b21257f-65cc-4d1f-a864-9f7d3bfe6c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_486e41c4-2c58-408a-9149-c17cde37d7b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9b21257f-65cc-4d1f-a864-9f7d3bfe6c08" xlink:to="loc_us-gaap_AwardTypeAxis_486e41c4-2c58-408a-9149-c17cde37d7b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c3248f81-514a-4444-b1d6-8298134de4c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_486e41c4-2c58-408a-9149-c17cde37d7b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c3248f81-514a-4444-b1d6-8298134de4c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5ae01c83-b405-4df1-b2bc-16bdc9b6d550" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c3248f81-514a-4444-b1d6-8298134de4c2" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5ae01c83-b405-4df1-b2bc-16bdc9b6d550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_55c38c54-54c6-4cc0-867e-8b9c0a0f80f3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9b21257f-65cc-4d1f-a864-9f7d3bfe6c08" xlink:to="loc_srt_RangeAxis_55c38c54-54c6-4cc0-867e-8b9c0a0f80f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_34e69f59-5cbf-46fb-8279-8c3938d5638e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_55c38c54-54c6-4cc0-867e-8b9c0a0f80f3" xlink:to="loc_srt_RangeMember_34e69f59-5cbf-46fb-8279-8c3938d5638e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8700f913-ffc8-4964-a5e3-05d67b140b1f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_34e69f59-5cbf-46fb-8279-8c3938d5638e" xlink:to="loc_srt_MinimumMember_8700f913-ffc8-4964-a5e3-05d67b140b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_76e38050-9c87-4d2c-8860-3f087692e7b4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_34e69f59-5cbf-46fb-8279-8c3938d5638e" xlink:to="loc_srt_MaximumMember_76e38050-9c87-4d2c-8860-3f087692e7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f179693b-fd4a-4e33-b9e0-608991c395ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9b21257f-65cc-4d1f-a864-9f7d3bfe6c08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f179693b-fd4a-4e33-b9e0-608991c395ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_18b3599f-fb35-407d-af9a-4c36b4eaf00b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f179693b-fd4a-4e33-b9e0-608991c395ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_18b3599f-fb35-407d-af9a-4c36b4eaf00b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_57daec93-35ed-4128-844d-fb32c48c9891" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f179693b-fd4a-4e33-b9e0-608991c395ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_57daec93-35ed-4128-844d-fb32c48c9891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5ca5ac7c-b200-470c-8b12-5a487757997b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f179693b-fd4a-4e33-b9e0-608991c395ef" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5ca5ac7c-b200-470c-8b12-5a487757997b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_38fa007b-c377-4405-9190-d4d12493e67b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f179693b-fd4a-4e33-b9e0-608991c395ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_38fa007b-c377-4405-9190-d4d12493e67b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_b188b1cc-3976-414a-bf50-de86fd2d7a40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f179693b-fd4a-4e33-b9e0-608991c395ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_b188b1cc-3976-414a-bf50-de86fd2d7a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_85246846-33ee-4f53-b825-76e780c874b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f179693b-fd4a-4e33-b9e0-608991c395ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_85246846-33ee-4f53-b825-76e780c874b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_39df730e-89f7-41bd-a60d-527247af05b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f179693b-fd4a-4e33-b9e0-608991c395ef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_39df730e-89f7-41bd-a60d-527247af05b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails" xlink:type="simple" xlink:href="vrna-20221231.xsd#SharebasedcompensationRSUActivityDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cc88f498-ecac-41e7-8d19-5206fe53d56e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a0abaa2-ff81-4809-af2e-3e3de7308260" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cc88f498-ecac-41e7-8d19-5206fe53d56e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a0abaa2-ff81-4809-af2e-3e3de7308260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_07f5baf7-d7ed-473d-9475-8c376c9375b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a0abaa2-ff81-4809-af2e-3e3de7308260" xlink:to="loc_us-gaap_AwardTypeAxis_07f5baf7-d7ed-473d-9475-8c376c9375b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_82764404-afc7-47a1-ba1c-fc9e927dac35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_07f5baf7-d7ed-473d-9475-8c376c9375b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_82764404-afc7-47a1-ba1c-fc9e927dac35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5e02f3ec-55ef-4c9c-a134-366aca639c78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_82764404-afc7-47a1-ba1c-fc9e927dac35" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5e02f3ec-55ef-4c9c-a134-366aca639c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_RestrictedStockUnitTimeBasedVestingMember_b76c5e20-8507-4fdf-8120-be8c5632c65e" xlink:href="vrna-20221231.xsd#vrna_RestrictedStockUnitTimeBasedVestingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_5e02f3ec-55ef-4c9c-a134-366aca639c78" xlink:to="loc_vrna_RestrictedStockUnitTimeBasedVestingMember_b76c5e20-8507-4fdf-8120-be8c5632c65e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_RestrictedStockUnitMilestoneBasedVestingMember_eeee5011-1ed4-4145-bc42-fc7f8e52a0a3" xlink:href="vrna-20221231.xsd#vrna_RestrictedStockUnitMilestoneBasedVestingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_5e02f3ec-55ef-4c9c-a134-366aca639c78" xlink:to="loc_vrna_RestrictedStockUnitMilestoneBasedVestingMember_eeee5011-1ed4-4145-bc42-fc7f8e52a0a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13e25830-f5dd-47d1-afb5-a27735a553cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a0abaa2-ff81-4809-af2e-3e3de7308260" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13e25830-f5dd-47d1-afb5-a27735a553cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_3a6090cb-12bc-460f-a9b4-17ff8d62e799" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13e25830-f5dd-47d1-afb5-a27735a553cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_3a6090cb-12bc-460f-a9b4-17ff8d62e799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_41d24fea-6705-41f7-8e17-a96229adf4d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_3a6090cb-12bc-460f-a9b4-17ff8d62e799" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_41d24fea-6705-41f7-8e17-a96229adf4d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4b2e08fe-bd54-4832-b942-39958bd6a058" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_3a6090cb-12bc-460f-a9b4-17ff8d62e799" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4b2e08fe-bd54-4832-b942-39958bd6a058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_624fee9e-87d2-4902-aff2-32e70aeef93f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_3a6090cb-12bc-460f-a9b4-17ff8d62e799" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_624fee9e-87d2-4902-aff2-32e70aeef93f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_483bcced-abdd-494c-aa7c-32457fec8181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_3a6090cb-12bc-460f-a9b4-17ff8d62e799" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_483bcced-abdd-494c-aa7c-32457fec8181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_29c7f654-bb49-4740-b04b-61cb973cc9c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_3a6090cb-12bc-460f-a9b4-17ff8d62e799" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_29c7f654-bb49-4740-b04b-61cb973cc9c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_90f353f1-e074-4520-a908-08de45648fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13e25830-f5dd-47d1-afb5-a27735a553cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_90f353f1-e074-4520-a908-08de45648fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bb0cab01-6125-4efe-a856-d7f608a461c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_90f353f1-e074-4520-a908-08de45648fb0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bb0cab01-6125-4efe-a856-d7f608a461c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d8276f0a-cba3-43de-9e7f-3ed73eb1859d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_90f353f1-e074-4520-a908-08de45648fb0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d8276f0a-cba3-43de-9e7f-3ed73eb1859d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_adf28524-bc51-41f4-809d-493d91bd35bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_90f353f1-e074-4520-a908-08de45648fb0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_adf28524-bc51-41f4-809d-493d91bd35bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_6724e17d-ceb3-4bb6-a452-56f75f8488db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_90f353f1-e074-4520-a908-08de45648fb0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_6724e17d-ceb3-4bb6-a452-56f75f8488db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a78e887e-2f99-4c8a-8878-bf1ae570d43b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_90f353f1-e074-4520-a908-08de45648fb0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a78e887e-2f99-4c8a-8878-bf1ae570d43b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_a1180290-4a85-45b8-bb91-3654a4441503" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13e25830-f5dd-47d1-afb5-a27735a553cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_a1180290-4a85-45b8-bb91-3654a4441503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3094e0c4-68a9-45bc-adb1-cdb6041740c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13e25830-f5dd-47d1-afb5-a27735a553cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3094e0c4-68a9-45bc-adb1-cdb6041740c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod_46b79d3d-0920-4cca-9fee-4d1743b929d5" xlink:href="vrna-20221231.xsd#vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13e25830-f5dd-47d1-afb5-a27735a553cf" xlink:to="loc_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod_46b79d3d-0920-4cca-9fee-4d1743b929d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/NetlosspershareComputationDetails" xlink:type="simple" xlink:href="vrna-20221231.xsd#NetlosspershareComputationDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/NetlosspershareComputationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_788057c4-c971-4bf8-9a84-9ef190a751cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingDepositoryReceiptRatio_67932bf0-0164-47e1-8ec7-860ecc1afeb7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityListingDepositoryReceiptRatio"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_788057c4-c971-4bf8-9a84-9ef190a751cf" xlink:to="loc_dei_EntityListingDepositoryReceiptRatio_67932bf0-0164-47e1-8ec7-860ecc1afeb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_28e35e6d-f3b4-4ce5-9925-927e1e081782" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_788057c4-c971-4bf8-9a84-9ef190a751cf" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_28e35e6d-f3b4-4ce5-9925-927e1e081782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c980f7aa-6962-4921-a2b4-8fa34c436fad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_28e35e6d-f3b4-4ce5-9925-927e1e081782" xlink:to="loc_us-gaap_NetIncomeLoss_c980f7aa-6962-4921-a2b4-8fa34c436fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_a53b9550-852c-45cf-890f-c271e5537d70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_28e35e6d-f3b4-4ce5-9925-927e1e081782" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_a53b9550-852c-45cf-890f-c271e5537d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_fad582c0-cb82-40ac-9843-979a0f943671" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_28e35e6d-f3b4-4ce5-9925-927e1e081782" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_fad582c0-cb82-40ac-9843-979a0f943671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_0f1e7429-3a6e-46e6-923c-aaaed0eea290" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_788057c4-c971-4bf8-9a84-9ef190a751cf" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_0f1e7429-3a6e-46e6-923c-aaaed0eea290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f321c7e1-28e1-486f-881a-a53b19da02b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_0f1e7429-3a6e-46e6-923c-aaaed0eea290" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f321c7e1-28e1-486f-881a-a53b19da02b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5637eabe-0dc6-485b-a131-d82f3a9c96a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_0f1e7429-3a6e-46e6-923c-aaaed0eea290" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5637eabe-0dc6-485b-a131-d82f3a9c96a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_9b37edd7-3ce6-4889-8bfb-fbf373ca39a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_0f1e7429-3a6e-46e6-923c-aaaed0eea290" xlink:to="loc_us-gaap_EarningsPerShareDiluted_9b37edd7-3ce6-4889-8bfb-fbf373ca39a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_475937e8-e0ca-45a5-a9c0-06393bf89f05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_0f1e7429-3a6e-46e6-923c-aaaed0eea290" xlink:to="loc_us-gaap_EarningsPerShareBasic_475937e8-e0ca-45a5-a9c0-06393bf89f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8947d204-319c-4ca6-9370-b3689ff3f17b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_788057c4-c971-4bf8-9a84-9ef190a751cf" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8947d204-319c-4ca6-9370-b3689ff3f17b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://veronapharma.com/role/CommitmentsandcontingenciesDetails" xlink:type="simple" xlink:href="vrna-20221231.xsd#CommitmentsandcontingenciesDetails"/>
  <link:presentationLink xlink:role="http://veronapharma.com/role/CommitmentsandcontingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5e608904-17a2-4976-ace2-dc466393e975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_db09f9a7-f51d-4654-987a-a2e8b1cdbdf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5e608904-17a2-4976-ace2-dc466393e975" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_db09f9a7-f51d-4654-987a-a2e8b1cdbdf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_1ad1dbaa-eed8-496c-84e4-8657547dc498" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5e608904-17a2-4976-ace2-dc466393e975" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_1ad1dbaa-eed8-496c-84e4-8657547dc498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>vrna-20221231_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vrna-20221231_g1.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1"F17AI9@  34T *@    @ ! $[  (
M   1   (2H=I  0    !   (7)R=  $    B   0?.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %9I8W1O<FEA
M(%-T97=A<G0    !ZAP !P  " P   AN     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                          !6 &D 8P!T &\ <@!I &$ ( !3 '0 90!W
M &$ <@!T    _^$*:6AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X
M<&%C:V5T(&)E9VEN/2?ON[\G(&ED/2=7-4TP37!#96AI2'IR95-Z3E1C>FMC
M.60G/SX-"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B/CQR
M9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R
M,BUR9&8M<WEN=&%X+6YS(R(^/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70]
M(G5U:60Z9F%F-6)D9#4M8F$S9"TQ,61A+6%D,S$M9#,S9#<U,3@R9C%B(B!X
M;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B+SX\
M<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB=75I9#IF868U8F1D-2UB83-D
M+3$Q9&$M860S,2UD,S-D-S4Q.#)F,6(B('AM;&YS.F1C/2)H='1P.B\O<'5R
M;"YO<F<O9&,O96QE;65N=',O,2XQ+R(^/&1C.F-R96%T;W(^/')D9CI397$@
M>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS
M>6YT87@M;G,C(CX\<F1F.FQI/E9I8W1O<FEA(%-T97=A<G0\+W)D9CIL:3X\
M+W)D9CI397$^#0H)"0D\+V1C.F-R96%T;W(^/"]R9&8Z1&5S8W)I<'1I;VX^
M/"]R9&8Z4D1&/CPO>#IX;7!M971A/@T*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" \/WAP86-K970@96YD/2=W)S\^_]L 0P '!04&!00'!@4&" <'" H1"PH)
M"0H5#Q ,$1@5&AD8%1@7&QXG(1L=)1T7&"(N(B4H*2LL*QH@+S,O*C(G*BLJ
M_]L 0P$'" @*"0H4"PL4*AP8'"HJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ_\  $0@"9@1_ P$B  (1 0,1 ?_$
M !\   $% 0$! 0$!           ! @,$!08'" D*"__$ +40  (! P,"! ,%
M!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A""-"L<$54M'P)#-B<H()
M"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T
M=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%
MQL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$!
M 0$! 0$        ! @,$!08'" D*"__$ +41  (! @0$ P0'!00$  $"=P !
M @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:
M)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#
MA(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3
MU-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P# 0 "$0,1 #\ ^D:*** "
MBO*?V@O&/B+P1X)T_4O"U_\ 89I=16WED\F.3<IC=L8=2.J=:\Q\/>(?VB?%
M6@V^LZ#<_:]/N=WE3>7IZ;MK%#\K $?,I'([4 ?4E%>-_"NY^,<GC*1/B0LH
MT@6K[=T5JH\W<NWF(;NF[VKV2@ HHHH **** "BO _VF?#OB[7QHB^'K&_U'
M35$@GM[)&DQ*2NUG1>2,#@]!STSSZA\+M,UK1_ACHEAXH=WU2& B;>^YE!=B
MB$^JH57\* .LHKY":+7?V@OC%J6ERZT]CIMJ)I84*EXX($<(N(\J"Q++DY!Y
M/H!7TM\._!@\ ^";3P^+YM0:W:1FN3'Y>\LY(^7<V, @=3T_"@#IZ*** "BB
MB@ HHKROXV_%C4OAA'HPTK3[6\?4O/W&Y+83R_+Q@*1G/F>O:@#U2BJ6BW<]
M_H&GW=XJ)<7%M'+*L>=H=E!(&<\9-7: "BBOEGXO>"_B-KOQO:?1[+4I[=GB
M_LV\AW>3;+L7)WCB/#;B<X/?F@#ZFHID0=84$K;Y H#,!C)[FGT %%%% !11
M10 4444 %%<)\9_$.L>%?A7J6L^';G[+>VSP[9O+1]JM*JGAP1_%CIWKRKX(
M?'/6]=\9MH/CG4UNQJ"A;&8P1Q>7*,_)\BC.X'OW4 =: /I"BN<^(.IWNB_#
MG7M3TJ<VUY9V,LT,H16VLJY!PP(/3N*X/]GKQQXB\<^']8NO%.H_;IK>Z2.(
M^1''M4ID\(HSSZT >OT444 %%%% !1110 4444 %%?+/[5GG0>,M&ECF=$GT
MXQLBN0&VR,>1T_CKZ*\$HL?P_P##R1J%5=+M@H'8>4M &Y1110 4444 %%%%
M !1110 445\H>-KS7?C%\>KCP5;ZJ]CI=K<RVJ)R8X_)!\R1DR-[%E;'U Z<
MT ?5]%>.'X7ZWX#^ OB'P[X3U2;4]7NG\^*:./R'VDQAXT&YL'8K]#R6K'_9
MG\+>+- BUNX\16E[IUA<>6(;6]5HV:0$[G"-R."!G SQUQP >]T5\>^"UD7]
MJY+.XE:5+;6[U$5F+!=OFXQGZ"OL*@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHK \=V^KW?@#6[?PVSKJDEG(ML8WVMOQT4]CV!]<=* -^BOG;]FOPEXR
MT/Q#K-]X@LK_ $[3)K?88+U&C,UP74APK<G"A@6[[AU[?1- !17FO[08/_"C
MM=D5V1HS;D%3C.9XU(/MAC7)?LH*H\!:RX W'4\$^H$2?XF@#W>BOE?P3X+^
M)"?M"+J>J6FI0K%>O)>:A-N$,L.3E5<\.", *.F1P,<?5% !1110 4444 %%
M<M;_ !+\(7?C'_A%K76X9M9W,GV:.-V&Y02R[PNS( .1G/%=30 45\?_ !IB
M=OVC9;5II?L]S<63&,,0HRD:G Z=L_4U]@4 %%%% !1110 45X[\8_C%K/P\
M\2:=H^AZ;8W4E];B4279<A6+LH&%(XX!ZU[%0 45\A?!)9A^T8D#R23+:M>H
MI8D[0%<?AVKZ]H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** /$OVJ_\ DEFF_P#8:B_]$3UQOPH^/GAC
MP+\.K'0-8L=8GNK9Y69[:&)H\-(S#!:0'OZ5V7[5?_)+--_[#47_ *(GI?@)
MX,\+ZQ\']-O=7\-Z1?W3RSAI[JPBE=@)6 RS*2<#B@#NOAS\2]+^)>GWUYHU
MI=VT5G,(F%V%#-D9!PK'M[UX1\5_'GC7PO\ 'B6RTG6;R2TCN+::VT_SF6*4
M%48QL!C*EMP//0U]+Z-X<T7P['-'H.E6>FQSOOD2TA6)6;IG"@"OEKX\S+;_
M +1%E,X)6-+-R!UP&S0!T'B3PC\>KK2;CQ%?>)6MVAC,[:;I^H/"Z*!D@)&
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M6_"'Q]\164NM7&OC37VF1-)L;][>11_= C&TG_><GWKF/VJ_^2IZ;_V!8O\
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M=/\ #CX&0?#WQ?+KZ>()]2FEMWA9);<)G<RDL6W')^7]: /(F\:?$^[^/_\
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M[T ;WC;P)\7O#WPYU.;Q+XF35M&D6,WMM)?R7#H!(A4CS%XPP7[IKNOV4?\
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MN;?;O<MC:BD<9Q^%7?!O[.]];>+;;Q'\0/$1UF[M9%E2%&>3S'7E2\C_ #$
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MHH \+^$'P4\3^ OB!/K^OWVE7$,UK+$5LY9&?>[*V<-&HQ\I[UVOQ<^%MO\
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M\,9](32-/LKI-1CF):Z#G:R%.FUAG[XKO/ NMWGB7P'HVM:G'#%=7]JD\B0
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M#AIXB<C;G^)26..X8XY ! /0_ _A#1O#?@.QTBPM('MWMD-PQ0-]I8J"SO\
MWLDG\.!Q7RUXNTN+X??M*QP^'#]GAAU&VG@CC.!&)-C-'_N_,PQ_=.*Z'PQ^
MT-XF\%>'K?PSKGA=KR]LXQ!;O/(\$BJ.%5T*$L0..,< =^:N?#/X:>*?'OQ*
M_P"$]\>VLEE;+<B["31&-KF1?N*J'D(N%Y/4  9R2 "+]K&)1XMT"4?>:Q=3
M]!)D?S-?0OA70M)L_!%A86NFVD5I-9Q^; L*A),H,[AC!SDYSUKYW_:PF9O&
MFAPD#:FGLX/?)D(/_H(KZ.\&?\B'H'_8-MO_ $4M 'R_\&+6+3/VFKBPL@8[
M>":^@1,]$7> /?H/RIGQAN9?%_[24&@:E.T=A%>6FG1@-@1QR;"[>F27)S[#
MTJ;X12K-^U-=RIG:]UJ##/H?,KK/V@OA'K&I:^/&?A&VENY61!>V]ODS*R#"
MRH!RWRA00.1@'G)P >^6&A:5IFC)I-AI]M!IZ)L%LL8V8]QW^IZUYU^T1%'#
M\#-2BA18XTDME1$& H$JX '85YII'[4'B'2;"/3/$7A47^J1*(S-Y[6[N>@+
M1[&Y]<8^@KI?BOK^J^(_V8(M7UJQ&FWE]<QM+:JK#8OG-L&&Y^ZJGZT 7?V7
M=,L4^&L^HK9P"]DU"6-KGRQYA4*F%W=<<GCW->9?M':3;:?\:; Z9&EI)?64
M$\CQH!^],LB;\=SA%_*O5/V7)ED^$MRJYS%JLR-GU\N,_P B*\R_:8NT7XT:
M6\GRK;:=;[CUX\Z5L_K0!V7[6&LW5KX>\/Z1"Y6WOIYII@#C=Y00*#ZC,A/U
M KM_@5X5TK0OA3I5U9V\376J6XN+NXP"TA;G:3Z*,#'L>Y-,^.?PVN?B)X/A
M&D;3JVFR--;([;1,I&'CR> 3A2">,KSC.1XKX+^,WBGX1Z.?"_B/PQ-<QV[M
M]FCN7:VDBR<E<E6#+DDCCOUQC !2_:'\.V7@_P"*EM=^'E6Q^V6R7OEP?)Y4
MP=@64#[N=H/'?-=/^TYXBO;O1_".GNVR&ZMC?3H.CR%5 _++?]]5E:3X+\8?
M';XBKXC\56,FF:*"H9WC*+Y*G(BB!Y8G)^;H"2?1:]/_ &@_AE>>,O#%CJ'A
MRV,^HZ1N46L?6:%L9"CNRE00.XW=\"@#I/@QX5TSP[\*]$>RMHA<:C8Q7=U/
ML&^5I5#X)[@!@ /05X1K-E'I_P"V-!;P01P1C6+5Q'$H51N2-LX'KG/U-2^
M/CWXB\%Z%!X3O_"\NKSVN8K53(\,R+V1EV,6QT'3C [5B#5M:OOVGM(U/Q7I
MATS4KK5;$O9@8\I6$:Q@Y[[=N??/ Z4 =U^UR.?")[_Z;_[0KT"]4+^R>H4
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M-<@&,*.26SQBKE>?_'#P_JWB;X3:GI^@1//=;HY3;I]Z9$<,5 [GC..^,=:
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M0'T#1()9IU0(R1_.C*(X]V"P^;G'  (XX%?55 !1110 4444 %%%% !1110
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MM%DO!J=M+:S-&ER $0,NS]YA@PXR.O8UW&M?\G%>&/\ L"W?_H2TGBC_ ).
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M2ZU*6VD&4N)(U C!'?:23CT)JY\:?#&CZS\*]9N+^QB>XTVRDGM)@N'A95R
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5L%#M<DC Y XH ^J:*^=/V=O%3>&;7Q9X3\0OY+Z(9;[:Q^X(_EG'/8%5/\
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MAMO.5P,]CUKO/!&H7OCO]FG&M>)I=&G7=!-K1DP\<<<P.2VY>J#823SG)SW
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M0 D]*Y_X&_\ )$_#?_7!_P#T:]>6?M;7EP/^$7LPQ%LWVF4KV9QY8!_ $_\
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M:L[^<X#;W&W9M^;A<[N@KUZ@#F?'\GBJ'PE+/X#2&76(94D2&8*5F0'YT^;
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M0_\ C%=)10!S?_">:1_SY^(/_"<U#_XQ1_PGFD?\^?B#_P )S4/_ (Q7244
M<W_PGFD?\^?B#_PG-0_^,4?\)YI'_/GX@_\ "<U#_P",5TE% '-_\)YI'_/G
MX@_\)S4/_C%'_">:1_SY^(/_  G-0_\ C%=)10!S?_">:1_SY^(/_"<U#_XQ
M1_PGFD?\^?B#_P )S4/_ (Q7244 <W_PGFD?\^?B#_PG-0_^,4?\)YI'_/GX
M@_\ "<U#_P",5TE% '-_\)YI'_/GX@_\)S4/_C%'_">:1_SY^(/_  G-0_\
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M%=)10!S?_">:1_SY^(/_  G-0_\ C%'_  GFD?\ /GX@_P#"<U#_ .,5TE%
M'-_\)YI'_/GX@_\ "<U#_P",4?\ ">:1_P ^?B#_ ,)S4/\ XQ7244 <W_PG
MFD?\^?B#_P )S4/_ (Q1_P )YI'_ #Y^(/\ PG-0_P#C%=)10!S?_">:1_SY
M^(/_  G-0_\ C%'_  GFD?\ /GX@_P#"<U#_ .,5TE% '-_\)YI'_/GX@_\
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M<U#_ .,5TE% '-_\)YI'_/GX@_\ "<U#_P",4?\ ">:1_P ^?B#_ ,)S4/\
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MZ<+>@#I**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MCU- '*^&]';3;=I;@8GE R/[H]*Z;2E+ZQ9J!G]\G'XBMJ+P5=%AY]U"@[[
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MH^8XR1UKF?$6I:W>?LKK>:]!'(3::7)%/%>/<SW69X26D#1KM<\<!GR2>?4
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M&LWJ,=;TFUL<QK)%)9W_ -JC<'/!)1"&''0%2",,>0*7CS_D7;7_ +#6E?\
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M8+6)G:1D@C"*68Y9L#N2<D]ZIZMX8T#7Y8Y-=T/3=3DB4K&]Y:1S% >H!8'
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M;K%/OA82!"N&Z@$J1\P![D"O6** //==TW7/$NF^#730;JQFTO7[6YNX+F>
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M5 8<YR!WW@K3[K2/ /A_3=0B\F[L],MH)X]P;8Z1*K#()!P0>0<5MT4 >?\
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M !1110 4444 %%%% '-^%_\ D8O&?_8:C_\ 3?9UTE<WX7_Y&+QG_P!AJ/\
M]-]G724 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!7.3)"S'YB>]5+GQQKUOX'\=6M]+!%XC\+1/MO+:'$<Z-%YD,PC?<%)'5?F
M(.#@X$F@ZH/#7CWQO)JNFZR([Z_AEMI+;1[JX291;HI(>.-EZ@CK5#4/#FM7
M?@?XC:[>Z;<0ZEXDMV6UTM0)9HX8HC'$&"9'F-RQ52V,@9SF@#M/#6EZH;;3
M]2OO%>K7XD@622UGALUB<LG_ $S@5P 3D88=!G(R#QWQ,\<:]9:L+7PC>+:V
M^D7%H-6N#"DGF/<2JB6Z[@<'86=B!D909&:V/!$?A*Q^P1Z1X7ETO5WM5BDN
M?^$8N+7G8"P:8PJN"5[MR<=\5RWBKP'XLTCX>-IUGJEGK+3:M!>7#0Z++]IG
ME:X5FE=A<,"!QGY1\JXR,9 ![114-HMREG$M_-%-<A0)9(8C&C-W(4LQ4>Q8
M_6IJ "BBB@ HHHH **** "BBB@"MJ4SV^DW<T+;9(X'=3C."%)%>2P^)/%.E
M?"?0?'4WB6YU*>=K5KO3+JVMA%<+,XC9(_+B1U<;PP.YA\IR#7K&JHTFC7J1
MJ7=K>0*JC))VG@5P?PS\!Z?;>!O#-UK5A?-J5I;1RBWU&ZN)$M9@/O+!(Q2-
MAV(4$=L4 6#<ZWK?Q7UW1(?$E_I=AI]C:S11V4%L26DW[B3+"Y/W1Z4NF^)]
M:LK[Q)X9UV>.YU+2; 7UGJ,<0C^TPLK ,Z?=#JZD''RGC '2JR7I\/\ QF\1
MZAJ.GZL;.\TZSC@GM-*N;I'9/,W#,4; $;AU]:=9:3J>L:SXH\6WEA<627NE
M#3],LYEQ.\2J[EW0<J69^$/S #D \  M?#^#7-;\(Z#X@U3Q=JT\MW:Q7,]K
MY%FL+EE!*_+;APOT;/O2_$"76O#_ (9USQ-%XNEL!8PF>ULQ:6_V=BH&V*0N
MC2,SO\N5=?O# !'.%\,+3PMH_A_PY'/X1N+'Q'%;1PS73>%[B.1)2NURT_D@
M#.2"Q;&"<G%:7B]_#>I2:C]N\':I/KUN#%:7<.B2M,SJ,Q/#=QJ50;B"&\Q=
MISG;@T =SHUS=7NA6%UJ-M]DNY[:.2>W.?W4C*"R<^A)'X5C?$75KW0OAOKV
MJ:5-Y%[:63RPR[%;8P'!PP(/XBJ6E:[>>%?#GA'2O%YN+S7-3,=D[P[9")1&
M69G.1D +RPSSS[U/\4+.YU#X6>(K2PMY;JYFL)$BAA0N[L1P HY)^E &%=ZI
MK_A?4O"$\OB"YUJVUV[2QNK.^@MU9#)&7$L30QH1M*$$-N!#=CS3]'D\0>)_
M%7BZW'BS4=-ATO4%MK2&TMK1D53"C?-YD+,W+'^*M[PYX+TC3!8:D;:ZFU&&
MV"1RZA>3W3V^Y0'$?G.WEYZ';C(X-<UX>U4>&/&/C9M5TS6@MYJBSVSVVC75
MPDR"!%RKQQLO4$=: (KWQUKUO\/_ !O%=R06_B3PNKH;JVB_=RAD#PS"-]VT
ME2,J=PR#@X.!U_A_2=32.SO[WQ5JVH*\(=[:XAM%C8LO_3.!6X)R,-VYS7"Z
MKX9UNY^'WQ$UF]TV>/5/$J%H-,C EECBCB$42D)D&0@9(4G&0,YS70^#4\)6
M<MI%H7AB32M5DMO*>Y_X1BXM!PN6#2M"JXRO=AD@=\4 8GQ%\<:]:Z_#:^$[
MQ;6STJ]M(=6G,"2>=)<2HJVZ[@<80L[$<C<@XR:]6KQ?Q-X#\6:-X#MM,LM4
ML]8+:S;W<[Q:++]HFE:X#M-(PN"" >3\H^48RN,CV.T6Y2SB6^EBFN0H$LD,
M1C1F[D*68J/8L?K0!+1110 4444 %<#J=YK6I?&1_#MIX@O=*TZ/0([[99PV
M[,TIN'0DM+$_&T#@8Z5WU><ZEX7;6?CM)=WD.J1:>OAN.-;JSNKBU0RBYD)0
MR1,N3M.=I/H<4 8NH>.O$D7PR\1.NHH-5T37TTA=3@@C_?IYT2ERC H'Q(0P
M P". .@W_%5_K_P\TZ/Q$^O7.NZ1;S1IJ5KJ%O LD<3N$\V)X8X\%2P)5@P(
MSRN,U'\2_#<6G_"*32/#&DR&*"ZM'2UL8&E<A;F-G;:H+,< L3R3R3FD\;3S
M?$701X4T'3M42#4)HQJ%_>Z?-9QVENKJ[$><BF1V"[55 >I+%1@D L:G>:UJ
M7QD?P[:>(+W2M.CT".^V6<-NS-*;AT)+2Q/QM X&.E=+-I&J'18[&W\27B3^
M:&EU&2W@>X9,D[5 01*>@R8VXSQDAAP?BC2]+D^-QO\ Q3X;GU;2CX=CABE_
ML274(UG%S(Q'R1OM;:<]N#[UU-W?>'E\(VUN?#-Y<Z#-)]G:R30I"L"C+ M:
ML@?9N4 80\D'IR "GX-UG5I/'/B;P]>ZD^M6.EBW:&_EAC22.1U)>!S&JHQ&
M W"@C=@YXKN*\Y\&V,D/Q#U.]\.:?=Z-X/\ [/2(VES;26<<EZ'W&2&WD"F-
M1&0&8*H9O4@FNN\)^);3QAX7M-=TZ&X@M;O>8TN4"OA79,D D8.W(YY!!H Y
M.WG\0>(OB3XPTF#Q3?Z5:Z2MF+2.UMK5U!EA+,6\R)F;YAG&1U/X8K>.O$&M
M> ?!UY!J TV\U7Q&-*N[JQBC=98@9T+QB574;C&IS@X/'2M*R\&1ZU\5/'4^
MMV^JQ6-RMBD#P7MS:17*^05<9C=1)@\'.<9QQDU9^)&FBQL/!HTC2IS9:7XB
MMIY(--LGE^SP)'*"PCB4D*,@<#N* )M5U/7? NNZ,]_J\VNZ)JU[%ITIO((D
MN+.:3<(Y%:%$4QDX4AER#@AN<5%83Z[XB^)7C'3!XHU'3;+2)+-+6"R@M2 )
M+=7;)EA=C\V3U[T:_P#:?B#K&A6.EZ?J%MI.G:C#J5_?7UG):;C$24AC255=
MBS8)8+M 'WLG%89TK08_BQXUN_&7A.?4H;J2R-C</X=FOT95ME5]CI$X'S<'
MGJ/:@#N_$^NR>$/"2RJ\FJ:FY2TL4F"A[RY?A VP*HR>6P   Q[5D?"C5M=U
M3P_JT7BG4AJ=_INM76GFY6!(@ZQ$+D*@ '.3Z\U-J/AK4-<U_1?$6A:G:V-O
MI]H\=I8:CH\K")WP#+L\V)D8(-@##@%O7C/^$VE^(--'B?\ MTQI%-K][*B?
M8)(&E+2 ^<I:1LQM_",'_>:@#T2N;\>?\B[:_P#8:TK_ -.%O725S?CS_D7;
M7_L-:5_Z<+>@#I**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH YOPO\ \C%XS_[#4?\ Z;[.NDKF_"__ ",7C/\ [#4?_IOLZZ2@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YOPO\
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M+0M#6+5,B83LZH7#;4..,@GT)_&@#T.BD!#*".A&12T %%%% !1110 4444
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M !7-^//^1=M?^PUI7_IPMZZ2N;\>?\B[:_\ 8:TK_P!.%O0!TE%%% !1110
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 <WX7_Y&+QG_P!AJ/\
M]-]G725S?A?_ )&+QG_V&H__ $WV==)0 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 45X=\0/CE<6>NQV'@A[>:&SES=7<B[TN2.L2?[/
MJXY)Z<#)].\$^-M,\<Z$+_36\N:/"75HY^>W?T/J#V;H1^( !T=%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <WX7_Y
M&+QG_P!AJ/\ ]-]G725S?A?_ )&+QG_V&H__ $WV==)0 4444 %%%% !7$?%
M3X<6_P 2/"HLO.6UU*U?SK&Z(.(WQRIQSM;H?3 /.,5V]% 'Q9)\&/BI+>'3
MY-$EVYP9OM$7ED>NX-R/;K[5V-K\&!\//#Z:YKB1ZEJWG(J*8MUO:Y!.[##Y
MSD8R1CGIWKZBJ.XMH+RW>"[ACGA<8>.5 RL/<'@T <EX26Z\1>%+.]U)$0W$
M;"0;?O@$KG'N!G\:Z+1]%L-!T\66E6X@@#%MH).2>I)/-78XTAB6*%%CC0!5
M11@*!T %.H **** "BBB@ HHHH **** "BBB@ HHHH **** "L_4]$L]4&9T
M*R@8$J<-_P#7K0HH XV?P5<AO]&NHG'_ $T!7^6:(?!5R6'VBZB1>^P%C^N*
M[*B@#.TS1+32ES I>4CF5^3_ /6K1HHH **** "BBB@ HHHH **** "BBB@#
MB/&?BW4K#7(= T+[/!=/:_:YKNX4OY<9<J B9&YB5.23A>.#FN1N[&ZU? \1
M:O?:O'U-O.ZI ?K%&JJP_P!X&O2_$?A33O$T41O/-M[NW)-O>VQ"S09Z[200
M0<<JP*GN.!6 OPN@S^^\3Z_,/0O;IG_OB$&@#GDC2.-8XT5$4855& /H*JVU
MY<:O<M:^&;)]5G0[7D1MEO"?]N8\#Z+N;VKM8?A?X84@WMO=:EZK?WTTT9^L
M9;8?^^:ZNVMH+.V2WM(8X((QM2*) JJ/0 <"@#A],^&D4[+<>,;L:J_46$:F
M.S3ZIUE_X&2IZA17=111P1)%"BQQH JH@P% Z #M3J* "BBB@ IDT$5Q$8[B
M))4/574,#^!I]% &-%X/\,P:E'J$'A[2H[V)MT=REE&LBGU# 9S6S110 5S?
MCS_D7;7_ +#6E?\ IPMZZ2N;\>?\B[:_]AK2O_3A;T =)1110 4444 %%%%
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M/IU&#7F/Q1_Y*MXB_P"OI?\ T4E>X? G_DE-I_U]7'_HUJ /1J*P/&WC#3_
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M9C^(![717D(\&Z5!\6?#7ARZ@6YT^P\*21FW8GRY]DT8_>)T=2?FVMD;@#U
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M!75:?I6G^+_BGXOC\56D&JQ:0;2WL+&]C$L5O&\0=I%C;Y=SOD;\9PF <9H
M](HKPP7=Q%X37PTU]<?V&_CC^PDD,K%C88W>1YF<[=X,/7[ORUV/C?X=Z2G@
M;5F\)Z7;:9J$*1WMJME'Y2>?;L9(R(UPNX\J6QN((&>!@ ]"K(\,^)+/Q7HY
MU+3HYXX1/+!MG4!MT;E&/!(QE3CGI7 Z%?V/Q5\?6VJO;17.BZ3HBYAF4.IN
M;Q 70@\';$-I!_O_ )XOA*TM?#?P)\2>(O#^F6EKK4"ZFD=[!:H)E19GP-P&
M=J[5(!X&T>E 'M]%>2:1X(UAF\-:IH>C^'])F@N(+F[U:UU266YU"W;!F60F
MV7S3(#N^9S\P!SWHU*P_X1#QK=ZUXPT*#5]/U#58Y+3Q!!-_I6F;FC2*!E.'
M$8;(_=L003N7YB* /6Z*** "BBB@ K(\5^);/P?X7O=>U..>6ULD#R);J&<@
ML%X!('4^HK7K@/CE_P D3\2?]<$_]&I0!TECKNI7LDB2^%=5L-L3.DEW-:;'
M8=$_=S.03ZXQ[UFR>,M0LIO"MKK&@_8;[7IY()K?[8LGV,K&S_>5<29V]L=:
MO16WB.&VO&US5=+O+?[,X6.STR2W<-C@EFGD!&,\8'4<\8/CUC96VI>"?@W9
MW\TD-O-<,CF.8Q,W[E_DW @X8_*0#R&([T ?0%%>53Z?9^'/B1KFD>'8(;#2
M[KPK+>75C:H$A2X638D@0<*S(6!P!G8/2LW0[&+PK^S6?$FB0#^WF\/[SJ3(
M'N "@(4/C.Q !M7H @],T >SU@:5XH_M/QMXA\/?8_*_L6.U?[1YN[SO/5VQ
MMQ\NW9ZG.>U<)XK\-:/X5\#Z5K_A:"*#7(KRR,.H0C]_J#2S(LBRO]Z4.KL2
M&)SU[5)IWA[1O$'QV\;IKMO%?)#:Z<T=E<X>%R8W!=HC\K%> "0=N\XZT =O
MXL\4?\(O%I#_ &/[5_:6K6VFX\W9Y?G-MW]#G'IQGU%;]>#!Y%\':%8+,\UC
MIGQ%AL=.9V+8MH[DA%#')(7E1[* . *Z'QZWAO68?%0M?"=YKNHZ?:NL^K*L
M1&G3"(LJQR32JR%!M<B$$ MGEB: /6*R-=\2V?A^ZTB"]CG=M6OEL8#$H(61
ME9@6R1A<*>F3TXKSR]TC7?%'@WP+XA_LRS\5Q6VDQSWFB:A.(UNYI88\3 N&
M0NN7QO'1FP036=XBB\*>+-)^&VI:;HT+V%QK:6B1WUNK2)"JS!H&W;OD#J1M
MR5X&.,4 >UT5Y?XW\*26.N6FLQ>&--\1>&=/TPVC:$^R/['^\WO<0QN/*8[!
MMV_*WR@ \D5WWAS4+'5?#&F7VDM*UC<6L<EN9F9GV%1C<6))..I)))[F@#2K
MF_'G_(NVO_8:TK_TX6]=)7-^//\ D7;7_L-:5_Z<+>@#I**** "BBB@ HHHH
M **** "BBB@ HHKBOB/\1[+P'I850EUJ]RI^R6>?P\Q\=$!_$G@=R #M:*XO
MX<?$>Q\>:60P2UU>V4?:[//X>8F>J$_B#P>Q/:4 %%%% !7R3\4?^2K>(O\
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MW<)"VT-AGCB9>A!ZT 9_PG\)2^$?!/D7UC'87]_=S7MW;1N&6%W;Y4!!((5
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MN+:4IJ=S&UQ& 0%F*R S<,P^?<?F/J:W[>WAM+:*WM8DA@A0)'%&H544# 4
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MM4LH[+4+&]DL;J.%B8S(@4DKDD@8<<9/0\UVM !1110 4444 %%%% !1110
M4444 <WX7_Y&+QG_ -AJ/_TWV==)7-^%_P#D8O&?_8:C_P#3?9UTE !1110
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M=:S]-\/^,O&/Q2T7Q5XPT.#PY9:#!*MO9K?)=23RR+M+%DX"]..O'?->L44
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M +#4?_IOLZZ2N;\+_P#(Q>,_^PU'_P"F^SKI* "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB*R_#/PQ\'>#I+A_#NA06KW41AF=W>9GC."4S(S':<#(Z' KJJ* .*TWX.^
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MYOPO_P C%XS_ .PU'_Z;[.NDKF_"_P#R,7C/_L-1_P#IOLZZ2@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YOPO_P C%XS_
M .PU'_Z;[.NDKF_"_P#R,7C/_L-1_P#IOLZZ2@ HHHH **** "BBB@ HHHH
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MVV@.FQPH(MN @VMP>!ECDG% %/X(_P#(^?%'_L89/_1LU9?QMU.X/Q(\,_\
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M\K.X9QM\MNGUKD?^&N?^I)_\JW_VFN)_:7_Y+)<?]>4'\C7DE 'Z$>#?$?\
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MYZU\[>(_^1JU7_K]F_\ 0S1X<_Y&K2O^OV'_ -#% 'Z(T444 %%%% !1110
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MI?\ Y+)<?]>4'\C7DE 'W9\&O^2-^&?^O(?S-=O7$?!K_DC?AG_KR'\S7;T
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M;1-,N+#6/$=Q<!1'J&I)<P8;)*"TMXCGT.Z)OTK9HHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG_OS%_\ '*^<J* /HW_AH3PI_P! _6?^_,7_ ,<H_P"&A/"G_0/UG_OS%_\
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M\-">%/\ H'ZS_P!^8O\ XY1_PT)X4_Z!^L_]^8O_ (Y7SE10!]&_\-">%/\
MH'ZS_P!^8O\ XY1_PT)X4_Z!^L_]^8O_ (Y7SE10!]&_\-">%/\ H'ZS_P!^
M8O\ XY1_PT)X4_Z!^L_]^8O_ (Y7SE10!]&_\-">%/\ H'ZS_P!^8O\ XY1_
MPT)X4_Z!^L_]^8O_ (Y7SE10!]&_\-">%/\ H'ZS_P!^8O\ XY1_PT)X4_Z!
M^L_]^8O_ (Y7SE10!]&_\-">%/\ H'ZS_P!^8O\ XY1_PT)X4_Z!^L_]^8O_
M (Y7SE10!]&_\-">%/\ H'ZS_P!^8O\ XY1_PT)X4_Z!^L_]^8O_ (Y7SE10
M!]&_\-">%/\ H'ZS_P!^8O\ XY1_PT)X4_Z!^L_]^8O_ (Y7SE10![OXE^+_
M ( \7:!<:/KNC:O<VEP,$&&(,A[,I\SAAV-'AKXO^ /".@6^CZ%HVKVUI;C
M AB+.>[,?,Y8]S7A%% 'T;_PT)X4_P"@?K/_ 'YB_P#CE'_#0GA3_H'ZS_WY
MB_\ CE?.5% 'T;_PT)X4_P"@?K/_ 'YB_P#CE'_#0GA3_H'ZS_WYB_\ CE?.
M5% 'T;_PT)X4_P"@?K/_ 'YB_P#CE'_#0GA3_H'ZS_WYB_\ CE?.5% 'T;_P
MT)X4_P"@?K/_ 'YB_P#CE'_#0GA3_H'ZS_WYB_\ CE?.5% 'T;_PT)X4_P"@
M?K/_ 'YB_P#CE'_#0GA3_H'ZS_WYB_\ CE?.5% 'T;_PT)X4_P"@?K/_ 'YB
M_P#CE'_#0GA3_H'ZS_WYB_\ CE?.5% 'T;_PT)X4_P"@?K/_ 'YB_P#CE'_#
M0GA3_H'ZS_WYB_\ CE?.5% 'T;_PT)X4_P"@?K/_ 'YB_P#CE'_#0GA3_H'Z
MS_WYB_\ CE?.5% 'T;_PT)X4_P"@?K/_ 'YB_P#CE'_#0GA3_H'ZS_WYB_\
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M^L_]^8O_ (Y1_P -">%/^@?K/_?F+_XY7SE10!]&_P##0GA3_H'ZS_WYB_\
MCE'_  T)X4_Z!^L_]^8O_CE?.5% 'T;_ ,-">%/^@?K/_?F+_P".4?\ #0GA
M3_H'ZS_WYB_^.5\Y44 ?1O\ PT)X4_Z!^L_]^8O_ (Y1_P -">%/^@?K/_?F
M+_XY7SE10!]&_P##0GA3_H'ZS_WYB_\ CE'_  T)X4_Z!^L_]^8O_CE?.5%
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M"G_0/UG_ +\Q?_'*/^&A/"G_ $#]9_[\Q?\ QROG*B@#Z-_X:$\*?] _6?\
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MHV[YS;D8+=SE2>>>0>]86AW<]Q#\7!//)*-DQ&]RW0S*.OL /H!0!XM1110
M4444 %%%% !1110 4444 %%%% 'T;^SW_P D_OO^PI)_Z*BKU2O*_P!GO_DG
M]]_V%)/_ $5%7JE 'QUXW_Y*!XA_["ES_P"C6K#K<\;_ /)0/$/_ &%+G_T:
MU8= !1110 4444 %%%% !1110 4444 %=9IWPP\8ZKI<6HV.B226LR"2-S+&
MA=3R"%9@2#]*Y.OI;PIX8T[3KWPWJ&GV4NJQ_8P/[<N-68"$E,")(<X(.<!<
M #ZB@#PC2/ WB37K:>?2=*EN$MYQ;R@,JLDG]TJ2#WY.,#O5^'X8^)QXJL-"
MU#3GLY[T[E<NCJ(P?G8$-@[1R5SGIZBO1XIFM? OQ0>"4PLNL7 5D;:1EP.O
MZ50U6\CC\#?#"ZO)U5(KU&>61ONHKKDD^@ _2@#'3X6W/ASXD:=I^M:;-K>D
M73R+#Y$D<+W6V$L< R@IM/JPSM]\5Y_K<$=KX@U"W@MWMHXKJ1$@D;<T0#$!
M203DCIG)^M>X2:!?V7[25CK4Z1BQU&23[-(LJDR;;,@G .1SQS7GVI:YX7L?
M$.N0:SX0_M:[_M.Y(N_[3E@X,C8&Q1CB@ U?PFEQX7\)KHGAV[M]2U0%6N9;
ME#'>,0"-H\P[?7D)^-9MU\,?&-EIMQ?W.A3);6V[S6\Q"0%)!.T-DC@\@8QS
MTYKU2)E&D?"@%ADS+@9_V!2Z+>3R?'?QG#)<.\/]EO\ (SDJ-OE8X]MS?F:
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M9 WR]=JDY;ZJ#GM53P_X"\3>*;1[K0M*DN8$;893(D:Y] 7(SU[5[G!=2O\
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M_DH'A[_L*6W_ *-6L.MSP1_R4#P]_P!A2V_]&K0!]BT444 >'_M'_P#,M_\
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MQ=EM9&AD2WB='C;:RMY,IR#V.: /(-9\ >)O#^GS7VK:88+:"5899!-&^QR
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MBHJ]4H **** /CKQO_R4#Q#_ -A2Y_\ 1K5AUN>-_P#DH'B'_L*7/_HUJPZ
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^C?V>_P#DG]]_
MV%)/_145>J5Y7^SW_P D_OO^PI)_Z*BKU2@#XZ\;_P#)0/$/_84N?_1K5AUN
M>-_^2@>(?^PI<_\ HUJPZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .K\5>-O^$B\/Z'HUM8
M?8+32(?+"^=YGG-@#>?E&#P?7[QKE*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "MSP1_R4#P]_P!A2V_]&K6'6YX(_P"2@>'O^PI;
M?^C5H ^Q:*** /#_ -H__F6_^WK_ -I5X=7N/[1__,M_]O7_ +2KPZ@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#I/ GBR/P7XC.KOIJ
MZA(L#QQ(TOE^6S8^?.T]LC'^UUK NKF6]O)KJY;?-/(TDC>K$Y)_,U%10 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!]&_L]_\D_OO^PI
M)_Z*BKU2O*_V>_\ DG]]_P!A23_T5%7JE !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
3 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>vrna-20221231_g10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vrna-20221231_g10.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#^17AI9@  34T *@    @ ! $[  (
M   1   (2H=I  0    !   (7)R=  $    B   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %9I8W1O<FEA
M(%-T97=A<G0    %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,U
M,   DI(  @    ,U,   ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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ML>>1D'!YXH Z:BO-O^%\>"D\93>&[J>ZM+FWEFAGN+F-8X(FB#%@S%L_P$#
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MC:JR' P.=WUH ]@HKR[3OVA_ .H6&H7CWMQ9Q6/EC;<Q /<%]V!&BDLV-O/
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M<ZXY?MGO0!]B45GVNM6=QX;@UN>1;2SEM5NF>X8*(D90V6/08!YKS'5?VFO
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM=L;R6ZQRK+NC5B"CLO3=COTKY_\4S:)X\^(]@/A-X?O=,FN"H,)55'F[O\
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M\JJZMM4GE>X!/#>U9/@']IBPT'P3::1XGTJ^N+W3X1!#-:["LRJ,)OW,"I
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ML=+L;6PM85BECAM8%C16$Z,2%4 #/.?J:\*?6I_@]^TEJFI:M9336S75PY1
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M7Y(GUW1-.U-X01&UY:1S% >H&X'%7[2TM["SBM;&WBMK:%0D4,*!$C4= %'
M'L*EHH ",C!Y%8-QX$\(W=R;B[\*Z+/.3DRRZ=$S$_4KFMZB@""SL;33[<0:
M?:PVL(Z1P1A%'X#BJ^JZ%I&NPK%K>EV6HQJ<JEW;I*H^@8&K]% &1)X3\/2Z
M.-)?0M-.FAPXL_LB>3N'0[,;?TJ[INEV&CV*66D6-M86J$E8+6%8D4DY.%4
M#)YJU10 R6*.>%HIXUDC<89'7(8>A!K!/@#P:9_./A+0C+G/F'38=V?7.VNA
MHH 9##%;PI#;QI%$@PJ(H55'H .E?.7QV^-.B:UX8O/!WA@SWES<3K%=SF)H
MUC$<@)1<X+,64#IC&>M?2%<IIGPQ\&:1KTVMV.@6PU*:9IVN92TK"1CDLN\G
M:<D],4 4/@WX0E\%?"_3=-O8O*OI@UU=H1RLC\[3[JNU3_NUU.K^']&U^.)-
M=TBPU-(23&M[;),$)ZD;@<5HT4 5[&PL]+L8[/3+2"SM8AB."WC$:(,YX48
MY-9]KX1\-V6K_P!JV7A[2K?4=S/]LBLHTFW,"&.\+G)!.3GG)K8HH HZKHNE
M:]:K:ZYIEGJ5NCB18KRW69%8 @, P(S@D9]S7,^/["RT+X,>)[31;&VL+9=*
MN0L%M"L<:[D;=A5  SDUVE4]6TJRUW1[K2]4A,]G=QF*>,.R;U/494@C\#0!
M\W_LL:5I^L6GB^UU>PM;^W)LB8;J%94)_?\ 9@17T9I6@Z/H4;1Z)I5CIJ.<
MLMG;)"&^H4"LOPC\/O#'@3[9_P (IIGV#[;L^T?Z1++OV;MOWV;&-[=,=:Z2
M@ K(U'PEX<UB\%WJWA_2[ZY&,37-E'(X_P"!,":UZ* &Q11PPI%"BQQHH5$0
M8"@= !V%9%YX.\,:C>_;-0\.:3=76<^?/8Q.^?\ >*YK9HH 9%%'!"L4$:QQ
MH,*B+@*/0 5EZIX1\-ZY=BZUOP_I6HW 0()KNRCE<*,D#<RDXY/'O6O10!')
M;P36KVTT,<D#H8VB90592,%2.A&.,5GZ3X8T#0)9)-"T/3=,DE4+(]G:1PEP
M.@)4#(K4HH R]6\,:!K\L<FNZ'INIR1*5C>\M(YB@/4 L#@5+=Z%I%_8Q65]
MI5E<VD*[(X)K='C1<8P%(P!@8Q5^B@#$L/!?A;2KD7&E^&M(LIUY$MO811L/
MQ50:VZ** "L6Z\&>%[W4#?7OAO2+B\8Y-Q+81/(3Z[BN:VJ* ,>Z\(^&[Z^B
MO+WP]I5S=0A5BGFLHW>,+RH5BN1CMCI6Q110!A7/@?PG>W7VJ\\,:-<7&<^;
M+I\3/^97-7KS0M(U#2UTV_TNRNK!<;;6:W1XACI\A&./I5^B@"GI>CZ9H=G]
MDT73K33K;<7\FT@6)-QZG:H SP.:N444 9.I^%/#NM3B?6=!TS4)1TDNK..5
MA^+ UH6EG;6%LMO8V\5M G"Q0H$5?H!Q4U% %#4]!TC6T":SI5EJ"J,!;NW2
M4#_OH&J^F>$O#FBS^?H_A_2]/E_YZ6ME'$WYJ!6O10!4U#2M/U:W\C5;"VO8
M<Y\NYA61?R8&LZQ\$^%=,N5N--\,Z/9SKRLMO811L/Q"YK<HH **** ,_5?#
M^C:]&B:YI-CJ21G*+>6R3!?IN!Q3?^$;T/\ L1M&_L;3_P"RVQNL?LJ>0<$$
M9CQMZ@'IU K2HH H:3H6DZ#;O!H>EV6FPR-O>.SMTA5FQC)"@ G '-3WUA9Z
MI8R6>IVD%Y:RC$D%Q&)$<9SRIR#R*L44 9^D^']&T".2/0M)L=,24AI%L[9(
M0Y'0D*!FH-2\)>&]9NQ=:OX?TN_N ,":ZLHY7'_ F!-:]% &->^#_#.I101Z
MCX=TF[2V4K L]C$XB!ZA05X'TJSJ7A_1M9LXK36-(L;^VA(,4-U;)*D9 P"J
ML"!QQQ6A10!0M]!TBTTG^R[32K*#3^?]$BMD6'DY/R 8Y//2LY/ /@Z*X^T1
M^$]#2;);S%TV$-GUSMS7044 (B+&BHBA548"@8 'I2T44 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '
M(_%37=0\,_"_6]7T6<6]]:PJT,I17V$NJYPP(/!/45@6_@[XG7%K%-_PMO;Y
MB!L?\(W;'&1G^]5[XY?\D3\2?]<$_P#1J5GV?_"[/L%OY7_" ^7Y2[=WVW.,
M<9]Z /1-*M[RTTBUM]4OO[0O(HE6>[\D1><X'+[%X7/H*MUS_C.W2Y\)SI?>
M(7\.VH*F[OX)%C98\_,JNWW">F[KZ5\]>*M:^%'A>Q.L?#'7+N+Q393Q2((Y
M;MEO1O4.DC2 H1M+'J,XQ[4 ?4M%>9?'071\*Z"-.N!;7A\167D3E=PBDW-M
M;'?!P<5M^%/A=H'A'5O[8LC>W.L2PF*[O[JZ>1[HD@EG!.W.1V Q0!3^$>I7
MVIZ+K[ZE>3W;P^(;V&)IY"Y2-7&U 3T SP.U=]7D/@#0(/%/PU\<:'=8$=]K
MNI0[C_ Q8;6_ X/X5T7@#QB)OA*NJZ^YCNM$AEMM4!.626WR'S[D*&_X%0!W
ME%<)\(=,N;?P3_;.J+MU+Q%<R:M= _P^:<HOT"!>.W-='XL@-SX6O8O[<?0$
M*J9-21E5H(PP+D,W"DJ"N[MG/:@#8HKY=\77WPAT32KK4/ GB6]A\7VF);>]
MBFNY6N9 1D.S QL",YZ#\.*]2^-5_)/^SSJ6H !)9(K*<#J QN(6H ]0HKRC
M4?@?I-UHEQJ&KZKJE]XJ6%I5UTW<B21RX)!1%.U4!X"XX'&>]6-/\?ZA;_LV
MQ^,KIA-J4>F$[W&0\P8QJY ]6P2* /3ZX#X4:G?:E_PFO]HWEQ=?9?%E];P>
M=(7\J)=FV-<]%&3@#@9K'TGX':)>Z-;:EK]]JEUXHFB6676DOY5FCD(S\@!V
MA03@ CI4GP'MKBSTCQC:WMVU[<P^++V.:Y90IF<+$&<@="2"<>] 'J=%4]7%
MZVB7PTH@7QMY!;%L8$NT[>O'7'6O#? WA3X?^(([2+7;S5+'X@1X-X]Y?S07
MHG'+;%8[67.<8!XZ\YH ]^HKSKXE$_\ "<?#L9X_MIN/^V+5H?&(X^#GB;'_
M #XM_,4 =K17FGC]-7E^#FF_V/\ ;C'BS.HC3C_I+6F!YOE]]V/3MGMFHOAS
MX6^&O]JQZW\.KZ1+B%&%S;Q7\K%]P(_?12$L"#ST'(H ZS_A+A_PM+_A#?L7
M/]C?VK]K\W_IMY7E[,?CG/MCO725X+=?";P3>?M$3:+<Z+OT^;PXVIR0_:YA
MNN3=["^X/G[IQC./:N^\7^'_  ]I'@FPTR^\03>&/#-B0DL4-R8VN$ ^6'S2
M2^.N0,EAQ0!WE8FMVOB*?7-$ET*_MK;3H9W;5(94RT\>WY50[3@AN>J_7M7@
MMMK?PWT#QYX6D^$6KW*7=WK$-EJ-BK71AG@E)1G8S#!*G;C![Y[9KU#XDDCQ
MU\.\''_$Y?\ ]$M0!Z+17D?Q-TN]USXO^#=*T_5KC2/M=E?)/<VN/-$0",RH
M3]TD#&[MFJ'B[P)I7PNDT;Q3X)>\L+I=5M[>^C:[DE2^BD?:P<.3SSU'\\$
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M_P#)T_4)T822V[*&57+ $LO(R0.WM7IM !1110 4444 %%%% !1110 4444
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M18(BY2-7.YSCHH[D\"N^HHH X'X1Z;?:9HNOIJ5G/:/-XAO9HEGC*%XV<;7
M/4''![UPWC31]0A^)]WX*L(V_LGQW-;WMPZG'D"$YNL8[NJ)S_M8KW>N2L?"
MM\?BIJ7BO59H)(!8QV&EPQLQ:*/.^5G!  8OC&">!S0!U<<:11K'&H5$ 55
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M5R5C56)+'CI77_$#3;Z^\9> YK*SGN(K75GDN)(HRRPIY3#<Q'"C/&37>T4
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M)X?_ ._Z?_)5 'MM%>)?\)1^T-_T(GA__O\ I_\ )5'_  E'[0W_ $(GA_\
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M[0W_ $(GA_\ [_I_\E4 >VT5XE_PE'[0W_0B>'_^_P"G_P E4?\ "4?M#?\
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M_P"_Z?\ R50![;17B7_"4?M#?]")X?\ ^_Z?_)5'_"4?M#?]")X?_P"_Z?\
MR50![;17B7_"4?M#?]")X?\ ^_Z?_)5'_"4?M#?]")X?_P"_Z?\ R50![;17
MB7_"4?M#?]")X?\ ^_Z?_)5'_"4?M#?]")X?_P"_Z?\ R50![;17B7_"4?M#
M?]")X?\ ^_Z?_)5'_"4?M#?]")X?_P"_Z?\ R50![;17B7_"4?M#?]")X?\
M^_Z?_)5'_"4?M#?]")X?_P"_Z?\ R50![;17B7_"4?M#?]")X?\ ^_Z?_)5'
M_"4?M#?]")X?_P"_Z?\ R50![;17B7_"4?M#?]")X?\ ^_Z?_)5'_"4?M#?]
M")X?_P"_Z?\ R50![;17B7_"4?M#?]")X?\ ^_Z?_)5'_"4?M#?]")X?_P"_
MZ?\ R50![;17B7_"4?M#?]")X?\ ^_Z?_)5'_"4?M#?]")X?_P"_Z?\ R50!
M[;17B7_"4?M#?]")X?\ ^_Z?_)5'_"4?M#?]")X?_P"_Z?\ R50![;17B7_"
M4?M#?]")X?\ ^_Z?_)5'_"4?M#?]")X?_P"_Z?\ R50![;17B7_"4?M#?]")
MX?\ ^_Z?_)5'_"4?M#?]")X?_P"_Z?\ R50![;17B7_"4?M#?]")X?\ ^_Z?
M_)5'_"4?M#?]")X?_P"_Z?\ R50![;17B7_"4?M#?]")X?\ ^_Z?_)5'_"4?
MM#?]")X?_P"_Z?\ R50![;17B7_"4?M#?]")X?\ ^_Z?_)5'_"4?M#?]")X?
M_P"_Z?\ R50![;17B7_"4?M#?]")X?\ ^_Z?_)5'_"4?M#?]")X?_P"_Z?\
MR50![;17B7_"4?M#?]")X?\ ^_Z?_)5'_"4?M#?]")X?_P"_Z?\ R50![;17
MB7_"4?M#?]")X?\ ^_Z?_)5'_"4?M#?]")X?_P"_Z?\ R50![;17B7_"4?M#
M?]")X?\ ^_Z?_)5'_"4?M#?]")X?_P"_Z?\ R50![;17B7_"4?M#?]")X?\
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MZL"\")O,HP,J%[D],=Z /6]*\6^'-=NGMM$\0:7J,Z(9&BM+V.5E0$ L0I)
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M6D:&<'!(<@?,#GO72^-?$\WPR\5>'O#_ ("\*Z1MU\S![>"W$!:8!5C;*8
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M!=0DVT'FDC^(AL[MV%SR@S6G\0/@+=WO@R5="\3^*-;U&T9)+*QU35$DA)!
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MY3=&EQ&\B9']Y%9,=#NP>#6E61XFM;2\TF&/4+O[)$NH64BR$9W2)=1/&G_
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M-CI4GAS]G\1> [;3-4\6^*;&2>V_TS3[/4E%HLCC+IY>TAADX/)SSSS7M5%
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M?]!7Q!_X$0?_ !FC_AE3P1_T%?$'_@1!_P#&:]MHH \2_P"&5/!'_05\0?\
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M ,9KVVB@#Q+_ (94\$?]!7Q!_P"!$'_QFC_AE3P1_P!!7Q!_X$0?_&:]MHH
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M  RIX(_Z"OB#_P "(/\ XS1_PRIX(_Z"OB#_ ,"(/_C->VT4 >)?\,J>"/\
MH*^(/_ B#_XS1_PRIX(_Z"OB#_P(@_\ C->VT4 >)?\ #*G@C_H*^(/_  (@
M_P#C-'_#*G@C_H*^(/\ P(@_^,U[;10!XE_PRIX(_P"@KX@_\"(/_C-'_#*G
M@C_H*^(/_ B#_P",U[;10!XE_P ,J>"/^@KX@_\  B#_ .,T?\,J>"/^@KX@
M_P# B#_XS7MM% 'B7_#*G@C_ *"OB#_P(@_^,T?\,J>"/^@KX@_\"(/_ (S7
MMM% 'B7_  RIX(_Z"OB#_P "(/\ XS1_PRIX(_Z"OB#_ ,"(/_C->VT4 >)?
M\,J>"/\ H*^(/_ B#_XS1_PRIX(_Z"OB#_P(@_\ C->VT4 >)?\ #*G@C_H*
M^(/_  (@_P#C-'_#*G@C_H*^(/\ P(@_^,U[;10!XE_PRIX(_P"@KX@_\"(/
M_C-'_#*G@C_H*^(/_ B#_P",U[;10!XE_P ,J>"/^@KX@_\  B#_ .,T?\,J
M>"/^@KX@_P# B#_XS7MM% 'B7_#*G@C_ *"OB#_P(@_^,T?\,J>"/^@KX@_\
M"(/_ (S7MM% 'B7_  RIX(_Z"OB#_P "(/\ XS1_PRIX(_Z"OB#_ ,"(/_C-
M>VT4 >)?\,J>"/\ H*^(/_ B#_XS1_PRIX(_Z"OB#_P(@_\ C->VT4 >)?\
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M(T$JN$D7[R'!X8=QU% %FBBB@ HJA/KFG6VO6FC3W&W4+V*2:"'8QWHF-QW
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M1^9]JD1VB;8H,:E0!M4C Z_4UT% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[I.M:0FJ/Y>GW>HV8BANF(R%5@Q()'0,%)[4 =M1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4R=I%MY&A4-($)13W..!
M3Z* /,_@O';2_ #2S(VZ.X@N6N'(W%F,LF\GU/4?A6A\$6D;X*^&S*6+?9F
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MCGD?VSX/\06WVC=Y?SV3[MN,_=N3C[PK*_X7KI'_ $+?B#_OFU_^/U!\;?\
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M[HH ^A/^&C?#/_0"\0?]^K;_ ./UK>'OC/8>*M0>QT'POX@N[B.(S,G^B)A
M0"<M< =6'YU\RUZI^SW_ ,E OO\ L%R?^C8J /7M3\=W>C:;+?ZEX*\00VT.
M-[^;8MC) ' N2>I%<_\ \+UTC_H6_$'_ 'S:_P#Q^ND^)O\ R3G4_P#ME_Z.
M2OGZ@#UW_A>ND?\ 0M^(/^^;7_X_1_PO72/^A;\0?]\VO_Q^O(J* /8K7XV:
M;>WD-K:^&/$#SSR+'&N+0;F8X R;C'4UTW_"4:O_ -")X@_[_P"G_P#R57AG
MA7_D<=&_Z_X/_1BU]+T <W_PE&K_ /0B>(/^_P#I_P#\E4?\)1J__0B>(/\
MO_I__P E5TE% '-_\)1J_P#T(GB#_O\ Z?\ _)5'_"4:O_T(GB#_ +_Z?_\
M)5=)10!S?_"4:O\ ]")X@_[_ .G_ /R51_PE&K_]")X@_P"_^G__ "57244
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M_P#T(GB#_O\ Z?\ _)5<;\$O^8W_ -N__M2O5J .;_X2C5_^A$\0?]_]/_\
MDJC_ (2C5_\ H1/$'_?_ $__ .2JZ2B@#F_^$HU?_H1/$'_?_3__ )*KHHW+
MQ([1M&S*"4;&5/H<$C/T)IU% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!\Y?M"?\E L?\ L%Q_^C9:\KKU3]H3_DH%C_V"X_\
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MUC)QMD>ZB2-_^ NRM_P&@#7HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "OG+]H3_DH%C_V"X_\ T;+7T;7SE^T)_P E L?^P7'_ .C9: /*Z***
M "O5/V>_^2@7W_8+D_\ 1L5>5UZI^SW_ ,E OO\ L%R?^C8J /8OB;_R3G4_
M^V7_ *.2OGZOH'XF_P#).=3_ .V7_HY*^?J "BBB@#5\*_\ (XZ-_P!?\'_H
MQ:^EZ^:/"O\ R..C?]?\'_HQ:^EZ "BBB@ HHHH **** "BBB@#XZ\;_ /)0
M/$/_ &%+G_T:U8=;GC?_ )*!XA_["ES_ .C6K#H **** /HW]GO_ ))_??\
M84D_]%14WXV_\P3_ +>/_:=._9[_ .2?WW_84D_]%14WXV_\P3_MX_\ := '
ME-%%% !75_#+_DHVF?\ ;7_T2]<I75_#+_DHVF?]M?\ T2] 'T#1110 4444
M %%%% !1110!A^-_^2?^(?\ L%W/_HIJ^.J^Q?&__)/_ !#_ -@NY_\ 135\
M=4 %%%% !7V+X(_Y)_X>_P"P7;?^BEKXZK[%\$?\D_\ #W_8+MO_ $4M 'C7
MQ-_Y*-J?_;+_ -$I7*5U?Q-_Y*-J?_;+_P!$I7*4 %%%% 'JWP2_YC?_ &[_
M /M2O5J\I^"7_,;_ .W?_P!J5ZM0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%>=3_ !/U.YM]2U3PUX1GU?0=-EDBFOQ>I$\WEG]XT,1!,BC!Y)7.
M.*[?1=7L]?T.RU;3)#):7L*S0L1@E6&1D=CZB@"]17"Z_P".M?M/'$OAOPQX
M336Y;>QCO)I9-46U"AW90 &0Y^[USWZ5U&@7NJW^D)/K^DII%ZS,&M$NA<!0
M#P=X !R.>G% &E1110 4444 %%%% 'SE^T)_R4"Q_P"P7'_Z-EKRNO5/VA/^
M2@6/_8+C_P#1LM>5T %%%% 'U3\&O^22:-_VW_\ 1\E<7\9?^1QM/^O!/_1D
ME=I\&O\ DDFC?]M__1\E<7\9?^1QM/\ KP3_ -&24 >?T444 %?2_A7_ )$[
M1O\ KP@_]%K7S17TOX5_Y$[1O^O"#_T6M &K1110 4444 %%%% !7E?[0G_)
M/['_ +"D?_HJ6O5*\K_:$_Y)_8_]A2/_ -%2T ?.5%%% !7N/[.'_,R?]NO_
M +5KPZO<?V</^9D_[=?_ &K0!M?&W_F"?]O'_M.O*:]6^-O_ #!/^WC_ -IU
MY30 4444 >U_!K_D3KO_ *_W_P#1<=>@UY]\&O\ D3KO_K_?_P!%QUZ#0 44
M44 %%%% !1110!A^-_\ DG_B'_L%W/\ Z*:OCJOL7QO_ ,D_\0_]@NY_]%-7
MQU0 4444 =Q\&O\ DK>C?]M__1$E>_?$W_DG.I_]LO\ T<E> _!K_DK>C?\
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M1110 4444 8?C?\ Y)_XA_[!=S_Z*:OCJOL7QO\ \D_\0_\ 8+N?_135\=4
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M_:M %CXK0:Y#_9/]O:CI][GSO*^Q6#VVS[F=VZ:3=GC&,8P>N>/.Z]6^-O\
MS!/^WC_VG7E- !1110!ZK\+[;Q'-X8N&T/5=+L[?[8P:.\TR2X<ML3)#+/&
M,8XP>AYYP.S^P^-_^AA\/_\ @AF_^3*PO@U_R)UW_P!?[_\ HN.O0: .;^P^
M-_\ H8?#_P#X(9O_ ),H^P^-_P#H8?#_ /X(9O\ Y,KI** .;^P^-_\ H8?#
M_P#X(9O_ ),H^P^-_P#H8?#_ /X(9O\ Y,KI** .;^P^-_\ H8?#_P#X(9O_
M ),H^P^-_P#H8?#_ /X(9O\ Y,KI** .#\76?C!?!.N->:[H<MN-.N#+'%HL
MR.Z^6V0K&Z8*2.A(./0]*^6J^Q?&_P#R3_Q#_P!@NY_]%-7QU0 4444 =?\
M"J.^E^)FE)I5Q;VUV?.\N6YMVFC7]R^<HKH3QD?>&#SST/MGCVT\4Q>"+]]5
MUG1[FT'E^9%;:3+#(W[Q<8=KEP.<'[IR...H\<^#7_)6]&_[;_\ HB2O?OB;
M_P DYU/_ +9?^CDH ^?J*** "NS^%\6JS>)[A=#O+.SN/L;%I+RT:X0KO3("
MK)&0<XYR>AXYR.,KT#X-?\CC=_\ 7@__ *,CH ](^P^-_P#H8?#_ /X(9O\
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MC?\ Z&'P_P#^"&;_ .3*/L/C?_H8?#__ ((9O_DRNDHH YO[#XW_ .AA\/\
M_@AF_P#DRC[#XW_Z&'P__P""&;_Y,KI** .;^P^-_P#H8?#_ /X(9O\ Y,H^
MP^-_^AA\/_\ @AF_^3*Z2B@#XV\7+.OC;7%O)(Y;@:C<"62*,HCMYC9*J2Q4
M$] 2<>IZUCUN>-_^2@>(?^PI<_\ HUJPZ "BBB@#W;X(6WB.;P3=MH>JZ79V
M_P#:+AH[S3)+ARWEQY(99XP!C'&#T//. _XK0:Y#_9/]O:CI][GSO*^Q6#VV
MS[F=VZ:3=GC&,8P>N>-3]GO_ ))_??\ 84D_]%14WXV_\P3_ +>/_:= 'E-%
M%% !71> H[Z7QO8)I5Q;VUV?,\N6YMVFC7]VV<HKH3QD?>&#SST/.UU?PR_Y
M*-IG_;7_ -$O0!Z[]A\;_P#0P^'_ /P0S?\ R91]A\;_ /0P^'__  0S?_)E
M=)10!S?V'QO_ -##X?\ _!#-_P#)E'V'QO\ ]##X?_\ !#-_\F5TE% '-_8?
M&_\ T,/A_P#\$,W_ ,F4?8?&_P#T,/A__P $,W_R97244 <W]A\;_P#0P^'_
M /P0S?\ R91]A\;_ /0P^'__  0S?_)E=)10!P?BZS\8+X)UQKS7=#EMQIUP
M98XM%F1W7RVR%8W3!21T)!QZ'I7RU7V+XW_Y)_XA_P"P7<_^BFKXZH ****
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M2?WW_84D_P#145-^-O\ S!/^WC_VG3OV>_\ DG]]_P!A23_T5%3?C;_S!/\
MMX_]IT >4T444 %=7\,O^2C:9_VU_P#1+URE=7\,O^2C:9_VU_\ 1+T ?0-%
M%% !1110 4444 %%%% &'XW_ .2?^(?^P7<_^BFKXZK[%\;_ /)/_$/_ &"[
MG_T4U?'5 !1110 5]B^"/^2?^'O^P7;?^BEKXZK[%\$?\D_\/?\ 8+MO_12T
M >-?$W_DHVI_]LO_ $2E<I75_$W_ )*-J?\ VR_]$I7*4 %%%% 'JWP2_P"8
MW_V[_P#M2O5J\I^"7_,;_P"W?_VI7JU !1110 4444 %%%% !1110 4444 %
M%%% !1110 45Y;K_ (I\;6?Q*\.V\D5MI6@7VJR6*P?++/>(JL?-8X(C4X!5
M1\WKZ5ZE0 45Y]?ZOXB\4_$75?#7AO5QH5EH5O ][>):I/-+-,I9$4294*%&
M2<$YXJY\//$FJZI-KNA^)9(;C5= O1;274$?EK<QLH:.0KT5B,Y XXH [6BB
MB@ HHHH **** /G+]H3_ )*!8_\ 8+C_ /1LM>5UZI^T)_R4"Q_[!<?_ *-E
MKRN@ HHHH ^J?@U_R231O^V__H^2N+^,O_(XVG_7@G_HR2NT^#7_ "231O\
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MP3_MX_\ := 'E-%%% !75_#+_DHVF?\ ;7_T2]<I75_#+_DHVF?]M?\ T2]
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M#WX@_P"_&G__ "+1_P (OJ__ $/?B#_OQI__ ,BUTE% '-_\(OJ__0]^(/\
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MFE.MFS&:S2%G8;T&T^;&ZXYSP,\#GKGC*] ^#7_(XW?_ %X/_P"C(Z /2/\
MA%]7_P"A[\0?]^-/_P#D6C_A%]7_ .A[\0?]^-/_ /D6NDHH YO_ (1?5_\
MH>_$'_?C3_\ Y%J>R\/:E:WD4\_C#6KR-&RUO/#9!)!Z$I;JV/H16[10 444
M4 %%%% !1110 4444 %%%% !1110 5D>)H+&XTF%-4N6MH!J%DZNHR3*MU$T
M2=#PT@1?^!=NM:]9'B:73X=)A;5K>2X@.H62HD9P1,;J(1-U'"R%&/L#P>A
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MC:[BM-6O-*==.=C-9I"SL/,C&T^;&ZXYSP,\#GKGSBO5/V>_^2@7W_8+D_\
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MFAEAL0D@$;$JVVV#8/0X(/H17RU7V+XW_P"2?^(?^P7<_P#HIJ^.J "BBB@
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MB@ HHHH **** "BBB@ HHHH P_&__)/_ !#_ -@NY_\ 135\=5]B^-_^2?\
MB'_L%W/_ **:OCJ@ HHHH *^Q?!'_)/_  ]_V"[;_P!%+7QU7V+X(_Y)_P"'
MO^P7;?\ HI: /&OB;_R4;4_^V7_HE*Y2NK^)O_)1M3_[9?\ HE*Y2@ HHHH
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M$25]4T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'_0F^'__  5P?_$T?\*Y\$?]";X?_P#!7!_\37244 <W_P *Y\$?]";X?_\
M!7!_\31_PKGP1_T)OA__ ,%<'_Q-=)10!S?_  KGP1_T)OA__P %<'_Q-'_"
MN?!'_0F^'_\ P5P?_$UTE% '-_\ "N?!'_0F^'__  5P?_$T?\*Y\$?]";X?
M_P#!7!_\37244 <W_P *Y\$?]";X?_\ !7!_\31_PKGP1_T)OA__ ,%<'_Q-
M=)10!S?_  KGP1_T)OA__P %<'_Q-'_"N?!'_0F^'_\ P5P?_$UTE% '-_\
M"N?!'_0F^'__  5P?_$T?\*Y\$?]";X?_P#!7!_\37244 ?&WBZV@L_&VN6M
MG#'!;PZC<1Q11(%2-1(P"J!P  , "L>MSQO_ ,E \0_]A2Y_]&M6'0 4444
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M5O1O^V__ *(DKZIH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKZG<K'8>7$#<SW<DF00Y^8GEB>>F1[5ZGI$%S;:)8P7\OG745O&D\O\ ?<*
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M'V16(4_9YCD9_P"NU2Z;^U)XQN=5M(+S3_#\5O),B2R>1,NQ2P!.3+@8'<T
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M//&10![%17#>)_BKX7TSPGJM]HOBCP_>:A;6DLMK;_VA%)YLBJ2J[5?)R<#
MYKP+_AJKQQ_T"O#_ /X#S_\ QZ@#ZVHKYJ\!_M*:]KOCC3M-\3Q>']-TJ=G%
MQ=;9(O+ 1B/G>4J.0!R.]>X_\+'\$?\ 0Y>'_P#P:0__ !5 '245\T>./VE?
M$&B>-M2T[PU#X?U'2[>0+;W6R27S%V@D[TE"GDD<#M6!_P -5>./^@5X?_\
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M^&_&D^G>#_\ A']6TM(HV2Z^>?<Q7+#?'*%X/M0!]%T5\D_\-5>./^@5X?\
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MT^]Q57P_XVT7Q'-]GLKD1WFZ<"TF91*RPRF)I H)^7<IP>] '04444 %%%%
M!1110 4444 %%%% !1110 4444 >">(O@9XEU?Q1JNI6U]I*PWEY-/&LDT@8
M*[E@#B,C.#ZUF_\ #/?BO_H(:-_W^E_^-U]&T4 ?.7_#/?BO_H(:-_W^E_\
MC='_  SWXK_Z"&C?]_I?_C=?1M% '%?"WP=J'@CPO<Z;JTUM--+>-.K6S,RA
M2B+CYE!SE3VKM:** "BBB@ HHHH **** "BBB@ HHHH **** ,/QO_R3_P 0
M_P#8+N?_ $4U?'5?:'B+3Y=7\+ZKIMLR+->6<T$;2$A0SH5!. 3C)]*\#_X9
M[\5_]!#1O^_TO_QN@#RNBO5/^&>_%?\ T$-&_P"_TO\ \;H_X9[\5_\ 00T;
M_O\ 2_\ QN@#RNOL7P1_R3_P]_V"[;_T4M>'?\,]^*_^@AHW_?Z7_P"-U[YX
M=T^72/"^E:;<LC36=G#!(T9)4LB!21D XR/2@#1HHHH **** "BBB@ HHHH
M**** ,_7]%MO$?AV_P!&OGE2VO[=[>5H2 ZJPP2"01GZ@UR][\)/#6H3^%)K
ML73OX5BCBLR9%_?+&%V"7Y?FP4!XV\D]CBNXHH Y:+X>:&NI^*+RX6:['BA8
MEO[>=P8\1H5 3 !'#$\DG.,8K'T'X.:+X>OX)K;6?$%Q;6N[[+I]UJ)>VMRR
ME<K'@=F/4FO0:* //)_@QH4W@71/"T>IZS;6VB7;7EG=V]PB7"R%G;._9C@N
M<$ $8'-:7A3X8Z+X5UB76%NM3U?5Y(_*.H:O=FXF5/[H.  /PS78T4 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !65XHLI]1\+W]I9P?:)YHBL<?VM[
M;)[?O4^9<=<CTQ6K10!X[\-?"'BW2_&%Y>:_<37UM#J,RL\LTMMAS @\]4QM
MN5;(3<^,;"PYKV*BB@ HHHH **** "BBB@ HHHH **** "BBB@ KRO\ :$_Y
M)_8_]A2/_P!%2UZI7E?[0G_)/['_ +"D?_HJ6@#YRHHHH *]Q_9P_P"9D_[=
M?_:M>'5[C^SA_P S)_VZ_P#M6@#W"BBB@ HHHH **** "BBB@ HHHH ****
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MFD?\^?B#_P )S4/_ (Q0!TE%<W_PGFD?\^?B#_PG-0_^,4?\)YI'_/GX@_\
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M *?_ /)5 '245S?_  E&K_\ 0B>(/^_^G_\ R51_PE&K_P#0B>(/^_\ I_\
M\E4 =)17-_\ "4:O_P!")X@_[_Z?_P#)5'_"4:O_ -")X@_[_P"G_P#R50!T
ME%<W_P )1J__ $(GB#_O_I__ ,E4?\)1J_\ T(GB#_O_ *?_ /)5 '245S?_
M  E&K_\ 0B>(/^_^G_\ R51_PE&K_P#0B>(/^_\ I_\ \E4 =)17-_\ "4:O
M_P!")X@_[_Z?_P#)5'_"4:O_ -")X@_[_P"G_P#R50!TE%<W_P )1J__ $(G
MB#_O_I__ ,E4?\)1J_\ T(GB#_O_ *?_ /)5 '245S?_  E&K_\ 0B>(/^_^
MG_\ R51_PE&K_P#0B>(/^_\ I_\ \E4 =)17-_\ "4:O_P!")X@_[_Z?_P#)
M5'_"4:O_ -")X@_[_P"G_P#R50!TE%<W_P )1J__ $(GB#_O_I__ ,E4?\)1
MJ_\ T(GB#_O_ *?_ /)5 '245S?_  E&K_\ 0B>(/^_^G_\ R51_PE&K_P#0
MB>(/^_\ I_\ \E4 =)17-_\ "4:O_P!")X@_[_Z?_P#)5'_"4:O_ -")X@_[
M_P"G_P#R50!TE%<W_P )1J__ $(GB#_O_I__ ,E4?\)1J_\ T(GB#_O_ *?_
M /)5 '245S?_  E&K_\ 0B>(/^_^G_\ R51_PE&K_P#0B>(/^_\ I_\ \E4
M=)17-_\ "4:O_P!")X@_[_Z?_P#)5'_"4:O_ -")X@_[_P"G_P#R50!TE%<W
M_P )1J__ $(GB#_O_I__ ,E4?\)1J_\ T(GB#_O_ *?_ /)5 '245S?_  E&
MK_\ 0B>(/^_^G_\ R51_PE&K_P#0B>(/^_\ I_\ \E4 =)17-_\ "4:O_P!"
M)X@_[_Z?_P#)5'_"4:O_ -")X@_[_P"G_P#R50!TE%<W_P )1J__ $(GB#_O
M_I__ ,E4?\)1J_\ T(GB#_O_ *?_ /)5 '245S?_  E&K_\ 0B>(/^_^G_\
MR51_PE&K_P#0B>(/^_\ I_\ \E4 =)17-_\ "4:O_P!")X@_[_Z?_P#)5'_"
M4:O_ -")X@_[_P"G_P#R50!TE%<W_P )1J__ $(GB#_O_I__ ,E4?\)1J_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5E>([3[;I<,7VY;';?V<OFNV VRYC?R^
MHY?;L [EN_2M6LCQ-'I\NDPKJ\TD-N-0LF1HADF8741A7H>#($4^Q/(Z@ UZ
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW]N\;_\ 0O>'_P#P?3__ "'1]N\;_P#0O>'_ /P?3_\ R'0!TE%<W]N\;_\
M0O>'_P#P?3__ "'1]N\;_P#0O>'_ /P?3_\ R'0!TE%<W]N\;_\ 0O>'_P#P
M?3__ "'1]N\;_P#0O>'_ /P?3_\ R'0!TE%<W]N\;_\ 0O>'_P#P?3__ "'1
M]N\;_P#0O>'_ /P?3_\ R'0!TE%<W]N\;_\ 0O>'_P#P?3__ "'1]N\;_P#0
MO>'_ /P?3_\ R'0!TE%<W]N\;_\ 0O>'_P#P?3__ "'1]N\;_P#0O>'_ /P?
M3_\ R'0!TE%<W]N\;_\ 0O>'_P#P?3__ "'1]N\;_P#0O>'_ /P?3_\ R'0!
MTE%<W]N\;_\ 0O>'_P#P?3__ "'1]N\;_P#0O>'_ /P?3_\ R'0!TE%<W]N\
M;_\ 0O>'_P#P?3__ "'1]N\;_P#0O>'_ /P?3_\ R'0!TE%<W]N\;_\ 0O>'
M_P#P?3__ "'1]N\;_P#0O>'_ /P?3_\ R'0!TE%<W]N\;_\ 0O>'_P#P?3__
M "'1]N\;_P#0O>'_ /P?3_\ R'0!TE%<W]N\;_\ 0O>'_P#P?3__ "'1]N\;
M_P#0O>'_ /P?3_\ R'0!TE%<W]N\;_\ 0O>'_P#P?3__ "'1]N\;_P#0O>'_
M /P?3_\ R'0!TE%<W]N\;_\ 0O>'_P#P?3__ "'1]N\;_P#0O>'_ /P?3_\
MR'0!TE%<W]N\;_\ 0O>'_P#P?3__ "'1]N\;_P#0O>'_ /P?3_\ R'0!TE%<
MW]N\;_\ 0O>'_P#P?3__ "'1]N\;_P#0O>'_ /P?3_\ R'0!TE%<W]N\;_\
M0O>'_P#P?3__ "'1]N\;_P#0O>'_ /P?3_\ R'0!TE%<W]N\;_\ 0O>'_P#P
M?3__ "'1]N\;_P#0O>'_ /P?3_\ R'0!TE%<W]N\;_\ 0O>'_P#P?3__ "'1
M]N\;_P#0O>'_ /P?3_\ R'0!TE%<W]N\;_\ 0O>'_P#P?3__ "'1]N\;_P#0
MO>'_ /P?3_\ R'0!TE%<W]N\;_\ 0O>'_P#P?3__ "'1]N\;_P#0O>'_ /P?
M3_\ R'0!TE%<W]N\;_\ 0O>'_P#P?3__ "'1]N\;_P#0O>'_ /P?3_\ R'0!
MTE%<W]N\;_\ 0O>'_P#P?3__ "'1]N\;_P#0O>'_ /P?3_\ R'0!TE%<W]N\
M;_\ 0O>'_P#P?3__ "'1]N\;_P#0O>'_ /P?3_\ R'0!TE%<W]N\;_\ 0O>'
M_P#P?3__ "'4]E=^+7O(EU#1-%@MBW[R2#6)974>H0VJ@GVW"@#=HHHH ***
M* "BBB@ HHHH **** "BBB@ K(\37%E;:3"^IVS7,)U"R144XQ*UU$L3_P#
M9"C?\!K7K,\075Q9Z;%+:68O)&OK2(QE"VU'N(T=\#^XK,^>VW)Z4 :=%%%
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M /@^G_\ D.C[=XW_ .A>\/\ _@^G_P#D.@#I**YO[=XW_P"A>\/_ /@^G_\
MD.C[=XW_ .A>\/\ _@^G_P#D.@#I**YO[=XW_P"A>\/_ /@^G_\ D.C[=XW_
M .A>\/\ _@^G_P#D.@#I**YO[=XW_P"A>\/_ /@^G_\ D.C[=XW_ .A>\/\
M_@^G_P#D.@#I**YO[=XW_P"A>\/_ /@^G_\ D.C[=XW_ .A>\/\ _@^G_P#D
M.@#I**YO[=XW_P"A>\/_ /@^G_\ D.C[=XW_ .A>\/\ _@^G_P#D.@#I**YO
M[=XW_P"A>\/_ /@^G_\ D.C[=XW_ .A>\/\ _@^G_P#D.@#I**YO[=XW_P"A
M>\/_ /@^G_\ D.C[=XW_ .A>\/\ _@^G_P#D.@#I**YO[=XW_P"A>\/_ /@^
MG_\ D.C[=XW_ .A>\/\ _@^G_P#D.@#I**YO[=XW_P"A>\/_ /@^G_\ D.C[
M=XW_ .A>\/\ _@^G_P#D.@#I**YO[=XW_P"A>\/_ /@^G_\ D.C[=XW_ .A>
M\/\ _@^G_P#D.@#I**YO[=XW_P"A>\/_ /@^G_\ D.C[=XW_ .A>\/\ _@^G
M_P#D.@#I**YO[=XW_P"A>\/_ /@^G_\ D.C[=XW_ .A>\/\ _@^G_P#D.@#I
M**YO[=XW_P"A>\/_ /@^G_\ D.C[=XW_ .A>\/\ _@^G_P#D.@#I**YO[=XW
M_P"A>\/_ /@^G_\ D.C[=XW_ .A>\/\ _@^G_P#D.@#I**YO[=XW_P"A>\/_
M /@^G_\ D.C[=XW_ .A>\/\ _@^G_P#D.@#I**YO[=XW_P"A>\/_ /@^G_\
MD.C[=XW_ .A>\/\ _@^G_P#D.@#I**YO[=XW_P"A>\/_ /@^G_\ D.C[=XW_
M .A>\/\ _@^G_P#D.@#I**YO[=XW_P"A>\/_ /@^G_\ D.C[=XW_ .A>\/\
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M** "BBB@ JGJFF6^KVB6UWN\M+B"Y&PX.^&5)4_#<BY]JN44 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!Y/\ %+XI:WX(\46VFZ3:V$T,MFL[-<QNS!B[KCY7 QA1VKBO^&A/%?\
MT#]&_P"_,O\ \<H_:$_Y*!8_]@N/_P!&RUY70!ZI_P -">*_^@?HW_?F7_XY
M7T;7P]7W#0!@>.?%'_"%^"=2\0FT^V_88P_V?S/+WY8+C=@XZ^AJKI.L^,[K
M5(8=7\(65A9L3YMS'K0G:,8.,)Y*YYP.HZUD_'+_ )(GXD_ZX)_Z-2MS0M*\
M5V6HF77_ !1::I:^60((=)%LP;C#;_-;WXQWH Z.BO$O"O@'0_%%GXZO-?CG
MO'3Q%J:6R-.X2U(<G?&H. ^3G=UX ^LEK9^(/'?P%\(7<2-J\D,B2ZAI\ET8
M6U*&,NAC,F>IPI^8X)'- 'J_B&[U6PT&YN?#^F+JNHQA?)LWG6$2DL ?G;@8
M!)]\8KGO&/B?7-/USPYH'ANVL5U/7#.QFO\ <\-ND**SY5""Q.X 8(KS_P 2
MW/AM_P!GGQE:>%](N-#:UE5;[3+E65[>8M%G@DC!4*1M.#UZDUM>/?!WA[6/
MC9X-_M/2;>Y_M*"_^U^8N?.\J*+R]W^[DXH ]3L_M7V&#^T/)^U^6OG^1GR]
M^/FVYYVYSC/.*FKP5[2;Q;XY\4IJG@B\\4V>E7@TZR@34HK>&RC1!]U'D4[V
MSNWXST /%6-<TKQ#;_!/2-*\3F[L;Q?$-M# [7*2W$,!N?W1,BE@752,'/84
M >Y5D:1XDL]9UC6=-M8YDFT>X2WN#(H"LS('!7!.1AAUQS7G>H>'=-\!_%KP
M2WAB*6S&L/=6NHKY[O\ :U6+>K2;B2S!N=W6F_#KP+X8M/B1XOFMM%M8Y-)U
M*%;%E7FW!MU)"_B2?QH ]=K+T*]U>]COCKFDKIC17DD5JJW*S>? ,;)3C[I;
MGY3R,5YE\-?!&DZMXD\3>(=6$]W=V7BN_P#L*-.ZQVI6;)95! W,2,DYR !Z
MYP]9./@5\4B.O_"2WW_I2E 'OM%>/>+_  MIW@+6O!.LZ";E=5N_$5MIM]>R
MW#O)>Q3!P_FDGYN5!'8=L<5GZV+KQ;\6O%%CJGA"Z\5V&BK;06MDM_%!%;>9
M%O:1D=UW,Q/#8. M 'N-%<3\*M.U_2?"]Y9>([.XLDBU&;^S;>YNDN)(K0A3
M&K2*S9P2PY.< 5VU !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MPWXPUK7_ (B:F+B^=?#=UIES<:;!%$BN$BF2$3A\;LN1(RY.,,IHO/AAK;^
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ML[V.^6:6Y,LTDJ2>9\[N#D%NHXXX&*W-3OXM*TF\U&X5VAM('GD6, L552Q
MSCG J/1-5@U[0-/U>S21+?4+6.ZB64 .JNH8!@"1G!YP30!3UCPM8ZWX@T36
M+N2=;C1)9);98V 1C(FP[P021CI@CFJ2>!;*#QK<>);'4M4LYKMD>[LX+@"V
MN61=JLZE2<XQT(SCFNGHH R/#WAJS\-1ZBEA)/(-1U&?49?.8';)*VY@N /E
MST!R?<UCW/PVT>[\)Z_X>DN;X6FO7TM]<NLB>8DDCAV"';@+E1C()QWKKZ*
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M"5=W 'S-T/<9[5ZE0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M698GPN,LLG1O]T 5VE% 'F7B#P'XML?B)?\ B[X>:CI,,^K6J6]];ZLDA4%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
C **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>vrna-20221231_g11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vrna-20221231_g11.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#^17AI9@  34T *@    @ ! $[  (
M   1   (2H=I  0    !   (7)R=  $    B   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %9I8W1O<FEA
M(%-T97=A<G0    %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,Y
M.0  DI(  @    ,Y.0  ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                            ,C R,SHP,CHQ-2 Q,3HS,3HU,@ R,#(S
M.C R.C$U(#$Q.C,Q.C4R    5@!I &, = !O '( :0!A "  4P!T &4 =P!A
M '( =    /_A"R-H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A
M8VME="!B96=I;CTG[[N_)R!I9#TG5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED
M)S\^#0H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(CX\<F1F
M.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M
M<F1F+7-Y;G1A>"UN<R,B/CQR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2)U
M=6ED.F9A9C5B9&0U+6)A,V0M,3%D82UA9#,Q+60S,V0W-3$X,F8Q8B(@>&UL
M;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(B\^/')D
M9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M8F$S9"TQ
M,61A+6%D,S$M9#,S9#<U,3@R9C%B(B!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"\B/CQX;7 Z0W)E871E1&%T93XR,#(S+3 R+3$U
M5#$Q.C,Q.C4R+CDY-#PO>&UP.D-R96%T941A=&4^/"]R9&8Z1&5S8W)I<'1I
M;VX^/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M
M8F$S9"TQ,61A+6%D,S$M9#,S9#<U,3@R9C%B(B!X;6QN<SID8STB:'1T<#HO
M+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B/CQD8SIC<F5A=&]R/CQR9&8Z
M4V5Q('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^/')D9CIL:3Y6:6-T;W)I82!3=&5W87)T/"]R9&8Z
M;&D^/"]R9&8Z4V5Q/@T*"0D)/"]D8SIC<F5A=&]R/CPO<F1F.D1E<V-R:7!T
M:6]N/CPO<F1F.E)$1CX\+W@Z>&UP;65T83X-"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/#]X<&%C:V5T(&5N9#TG=R<_/O_; $, !P4%!@4$!P8%!@@'!P@*
M$0L*"0D*%0\0#!$8%1H9&!48%QL>)R$;'24=%Q@B+B(E*"DK+"L:("\S+RHR
M)RHK*O_; $,!!P@("@D*% L+%"H<&!PJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*O_  !$( FH$>P,!(@ "$0$#
M$0'_Q  ?   !!0$! 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,#
M @0#!04$!    7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S
M8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H
M:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ
MPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 #
M 0$! 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  !
M G<  0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q
M%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X
M>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(
MR<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /I&
MBBB@ HHHH **Y#XK:YJ/AKX7:WJ^BW'V:^M8E:&78K[29%!X8$'@GJ*^?O"?
MC;X^>.+&>\\+:@+Z"WD\J5O)L(]K8!QAU!Z'KTH ^L**\)\"W'QW'C[38O&P
MD_L3>WVL^59[=NQL?-&,_>V]#7NU !1110 4444 %%> ?'4_%-_&VGQ>"5UD
M:48$,;:3O ,VX[O-*=/X?O?+C\:]C34;W0_A\NI^(]CW]AI8N+_80%:5(MTF
M".,9!H W**^//!?@C7_V@=:UG5]=\2M:BU=/F>$S@%]Q"(FY0J@+Z^G7FOK7
M1-+31/#^GZ7%(9$LK:.W$C=7V*%W'W.,T 7J*** "BBB@ HHKQ[P/\8]7\7_
M !BU+PF^F65M86)N<RJ7:5O*?8#G..<C/% 'L-%%% !17*?$U_$D?PYU9O!2
MNVL^6OD"(9DQO&_9_M;=V/TYQ7#_ +/J?$$:=JS^/VU3[,SQ_8UU8OYX;YM^
M _SA?N]>/3O0!['1110 4444 %%%% !17F?QV?QJG@6'_A %O3<-<@71TX$W
M BVG[NWYOO8SMY_#-6_@I'XPC^',?_"?M=&_-PY@^V$F<087:),\[MV_[W.,
M4 >@T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45\T_M;1
MNMUX6DW?)(ERI /4J8^O_??ZFO<?ALJK\*_"@4 #^QK0X [F%2: .EHHHH *
M*** "BBB@ HHHH **KW\!NM-N;<#)EA=  <=01UKY2_9=>2\^+-[+=2R2O%H
MTI5G8DC]]$._^\: /K6BOG/XJ_\ "X9OBZ(O"0UA-+!B^PM8[A;'Y06,I'R?
M>W9W]O:O7/B5XQN_ /PZNM?AM8;RZMS$GENQ5"S.JD\<XY- '845QGPH\8ZA
MX\\ V^OZM;VUM-<32JL=L&VA58J.I)SP:[.@ HHHH **** "BBB@ HKY3\<W
M6M_&'X]S^";;5FL=+M)I+9$R6C3RE)D<H"-[%E8#/L..:]Z^%_P]3X:^$GT5
M=1.I-)<O<-.8?*^\%&T+N; &WUZDT =E17._$*%[CX9^)8XB1(=*N2A5L$,(
MF(Y^N*\'_9/+7&N^)KB>1Y)1;VZ[G8DX+/\ X"@#Z:HKYQUK_A<DWQ\*V']K
MQZ0M^OD^7N%A]EW#[W\!.SKGYLYQVKUKXN>++CP7\,-5U?3V"WH58;9CCY'=
M@N[GKM!+8]J .THKY5^%/P;U#Q_;V'CK6_$T@/V[S/*DB:>2X6-_F#2%P5R0
MPZ'U]J^JJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MO'KCXQZO_P +^C\ 6NF60LQ<K%)<R%S(5\GS"1@@ _G7L- !1169XD;5$\+:
MHWA]5;51:2FS5L8,NT[.O'7'7B@#3HKP/X#+\46\6ZE+XW;61I/D,"NK[QF;
M<NWR@_.,;ON_+^E>^4 %%%>4_M(+*/@[<SP.\;P7<#[D<J1EMO;_ 'J /5J*
M\:_9>0+\)[F3)+S:K,[DG.3LC']!7LM !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!P'QR_Y(GXD_P"N"?\ HU*\"^"'QAT#X:Z'J=GKMGJ5Q)=W
M*RQFSBC8 !<<[G7FO??CE_R1/Q)_UP3_ -&I7E?[,GA?0-?\,:W+KNAZ;J<D
M5XBQO>6D<Q0;,X!8' H ]3^'?Q@T3XEZG?6>B6-_;?8HEE9[Q47<"<<!6;O7
MD?[0/C?Q7X2^*=K!I&NWMM8O9PW:VL4Q2,G>RD':02"8^1GN?6OH;2/"GA_P
M_<RW&@Z)I^F2S*$D:SMDBW@= =H%?,_[5S(?B%HZ@CS!I8+#O@RR8_D: -O7
M/"WQZ\1Z7+X@FU\:>#&9H]*T^_>WD5<9"@1C:3C^\Y-;'[.7Q/UWQ9=ZEX?\
M2WAOY;6W%S;7$F/-V[@K*Q_B&67!//)R>E>YZ=_R"[7_ *XI_P"@BOF']EY8
M6^*'B&2%5VBP<1E1@!3,G ]N!^5 %CQE\0/'/C[XPW7@?P9K(T."WN9;2,B8
MP&1HLAW:107Y*G 7MCC/-=;X \ ?%KPYX^TZ?Q1XJEU71 9#=*NIRS@_NVV@
MK* ?O;>E3_%#]GNV\8:Q/X@\,Z@-+U>9@\L<H)AF<?Q9'*-TR0"#Z9R:XCP!
M\0O'?@#XH67@7QU+-?6]U<16@6YD\UXC(0L<D<G4KDC@DC&1P10 []HOQIXL
M\-_$6+3]&\07^GV4^G1SB*VG,>"6="<KS_!ZUWGQ\\*>,-:T>34_#>O#3](T
M[3+A]1M/MDL1ND"EF7:BE7RH(PQQS[FO+/VJ_P#DJ>F_]@6+_P!'SU](_$@@
M?"OQ7DX_XDUV.?\ KB] 'R=\)O!'CKQ=9:HW@7Q+_8L4#QK<H;^>W\TL&V\1
MJ=V #U]:]^^+OQ/G^%O@[3K"R*7.OWD(CBDD^98PB@-*0>O)X!ZGGL17(?LE
M?\@CQ-_UWM__ $%ZY?\ :MMIU^(FD7+*WV>32ECC;L7660L/R=/S% %ZU\%_
M'G7M$C\2KXINH9)HO/BL#J4D,C@\C]VH$8)'8D>^*[;X!?%75/&\.H>'O%,O
MF:K8Q^;'<!0CRQ9VMN XW*Q7G'.X=QDY?A[X3>)_$GAZRU73/C7KLUE=PJZA
M!-P".5/^D<$=".Q%=9\,_@E!\./%=UKJ:]/J<MU:/;.DL 3[SHY;=N.3E/UH
M \.\)>/_ (J7?Q O-"T769M5U.X6:S07LN8H-K M,%)V!@$/)!X)X.:T/'6G
M_&?X<00>(-8\875S!+*$+VE_))'$Y!(#1,H7!P>BD4WX1LC_ +4]XT>"AN]0
M*D=,?O,5[%^T>4'P4U'?C<;BWV9'?S!T_#- $.GZIXG^+?[/]O<Z!J,>D>(;
ME@DES'.\"JT<N&(:,%EW*N< ?Q8Z5\Y^ _#'B_Q#\1M0TOPSKQT[6XEF:XOC
M>31&0*X#_O$!8Y8@\CGO7TG^SBJK\$],*@ M/<$^Y\UA_2O)?@1(D/[1NM1S
M,$>1+U%5N"6$H./KA2?PH ]"\5V7C+P#^S9<&\\132^(+&<2S7\%Q)(SK)/M
MQO<!C\KCJ!C'M7E?AOQA\7O'OA;^P?",FHW+VLKRWFI+=[)7W\JGFNPV 8.%
M4Y-?0'QR_P"2)^)/^N"?^C4KB/V4?^2?ZQ_V%#_Z*2@"(2^/O#'[,FLW^NZI
MJ<'B*"Z$D<ES+OEBB$L:%=QSD$;VSSG=]*O_ +/>N:]XK^'6ORZMK%Y>7INW
MAAN)YB[1?N5QMSTP3GZUUOQR_P"2)^)/^N"?^C4KB/V4?^2?ZQ_V%#_Z*2@#
MS#X=_$#XK>)=>N]'\.ZQ)?W]]!DRW\VY;1%;+2(&.T'Y@/ND],"KGC>/XQ_"
MNXM-8UGQ==745S+L62&^DGA#XSL:.0 <@'^''!IW[-C(_P ;;]H2#&UC<%2.
MF/,3%>H_M1F,?"6W\S;N.JP^7D?Q>7)T_#- '7^'_B);7?P:MO'.L[8HULFF
MN5AZ&1"495'NZX )[@5X=I>M_%SXX:I?W7AG5SH.E6\FU1'=/;QQ]PF^-2[M
MC!)Z<]@0*W;^SEF_8CMDLXR0D22R*G]T7>YC_4_G7&?!+P=JWC/1]0M]#^)&
MI>&9K6?>^G6GF8D5E&)?EE3))!4\<;1SR* -W0/B!X_^%/Q-L_#'Q%U%]2L+
MHQAWFE\[$;G:LR2'YL @Y!]#QG!KZAKP>?\ 9JNM3U"WOO$/Q!U+5KJ!EQ+<
MVY<X!R%!>5B!^->\4 >/_M(>(-=\,^!]-O\ P[J=QISR:@+>5[=]I8-&[ 9Z
M_P ':LS3=?\ $-Q^R(=?BUJ\&M)'-/\ ;GE+2G;=L"-QS_ "H].,=*F_:K_Y
M)9IO_8:B_P#1$]5/"C(O[%DYDP!_9M^.?4SRX_7% '$?#?6_B_\ $+0-0TGP
MYX@2*."X\ZYU2_N&,PWJ L2MAF5?D)^51R3D\UD:AXV^*7P>\;?V?KNNSZE(
MB+*8;RY>Z@N(VR 07^8#(/3:<BN__9*_Y!'B;_KO;_\ H+UR'[5?_)4]-_[
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MQ_X<M]"L/B#K$.KQ+Y[6%PD[3,/]7Y@9F4.?X.N>^*^L/AQ_R2SPI_V!;/\
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M#D C!XK6^-7P5\2?$CQK:ZOHEYI5O;P6"6I6[FD5RPDD8G"QL,?.._:O<Z*
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M?"W3_"_B06=Y)##+#<"'+PR(TCD#Y@"?E8 Y'7->0Z]^S#J-EK3:A\//$BV
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M)=/T?QOX+NO#?]J2F&RNA>QW<4DF,A&9 -I/8<T >B4R:58())7!*QJ6('7
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MGI7-V/P=TNWO[:YU/Q)XIUM;65)H;?4]6:2)&4@J=H"YP0.#0!!XI>*#X_\
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MIV#-OD8LW0 8R>.*+#PM8Z?XOU;Q'!).UYJL4,4Z.P,:B($+M&,@G/.2?PH
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MOJ4D\:65]#?1F!@I,D1RH.0?E]>_N* .%^(G@/3O#NA-XO\  >EVND:WH/\
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M 56LM.LM-69=.L[>T6>5IY1!$J"21OO.V!RQ[D\FK-% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M1W-M!>6LMK>0QSV\R&.6*5 R2*1@JP/!!!P0:DHH CM[>&TMHK>UB2&"% D<
M4:A510,!0!P !QBI*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HJ"]OK33+*6\U*ZAM+6$;I)YY!&B#U+'@5A?\
M"Q_!'_0Y>'__  :0?_%4 =)17-_\+'\$?]#EX?\ _!I!_P#%4?\ "Q_!'_0Y
M>'__  :0?_%4 =)17-_\+'\$?]#EX?\ _!I!_P#%4?\ "Q_!'_0Y>'__  :0
M?_%4 =)17-_\+'\$?]#EX?\ _!I!_P#%4?\ "Q_!'_0Y>'__  :0?_%4 =)1
M7-_\+'\$?]#EX?\ _!I!_P#%4?\ "Q_!'_0Y>'__  :0?_%4 =)17-_\+'\$
M?]#EX?\ _!I!_P#%4?\ "Q_!'_0Y>'__  :0?_%4 =)17-_\+'\$?]#EX?\
M_!I!_P#%4?\ "Q_!'_0Y>'__  :0?_%4 =)17-_\+'\$?]#EX?\ _!I!_P#%
M4?\ "Q_!'_0Y>'__  :0?_%4 =)17-_\+'\$?]#EX?\ _!I!_P#%4?\ "Q_!
M'_0Y>'__  :0?_%4 =)17-_\+'\$?]#EX?\ _!I!_P#%4?\ "Q_!'_0Y>'__
M  :0?_%4 =)17-_\+'\$?]#EX?\ _!I!_P#%4?\ "Q_!'_0Y>'__  :0?_%4
M =)17-_\+'\$?]#EX?\ _!I!_P#%4?\ "Q_!'_0Y>'__  :0?_%4 =)17-_\
M+'\$?]#EX?\ _!I!_P#%4?\ "Q_!'_0Y>'__  :0?_%4 =)17-_\+'\$?]#E
MX?\ _!I!_P#%4?\ "Q_!'_0Y>'__  :0?_%4 =)17-_\+'\$?]#EX?\ _!I!
M_P#%4?\ "Q_!'_0Y>'__  :0?_%4 =)17-_\+'\$?]#EX?\ _!I!_P#%4?\
M"Q_!'_0Y>'__  :0?_%4 =)17-_\+'\$?]#EX?\ _!I!_P#%4?\ "Q_!'_0Y
M>'__  :0?_%4 =)17-_\+'\$?]#EX?\ _!I!_P#%4?\ "Q_!'_0Y>'__  :0
M?_%4 =)17-_\+'\$?]#EX?\ _!I!_P#%4?\ "Q_!'_0Y>'__  :0?_%4 =)1
M7-_\+'\$?]#EX?\ _!I!_P#%4?\ "Q_!'_0Y>'__  :0?_%4 =)17-_\+'\$
M?]#EX?\ _!I!_P#%4?\ "Q_!'_0Y>'__  :0?_%4 =)17-_\+'\$?]#EX?\
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M110 445SC_$/P5%(T<GB_04=2596U.$$$=01NH Z.BN;_P"%C^"/^AR\/_\
M@T@_^*H_X6/X(_Z'+P__ .#2#_XJ@#I**YO_ (6/X(_Z'+P__P"#2#_XJC_A
M8_@C_H<O#_\ X-(/_BJ .DHKF_\ A8_@C_H<O#__ (-(/_BJ/^%C^"/^AR\/
M_P#@T@_^*H Z2BN;_P"%C^"/^AR\/_\ @T@_^*H_X6/X(_Z'+P__ .#2#_XJ
M@#I**YO_ (6/X(_Z'+P__P"#2#_XJC_A8_@C_H<O#_\ X-(/_BJ .DHKF_\
MA8_@C_H<O#__ (-(/_BJ/^%C^"/^AR\/_P#@T@_^*H Z2BN;_P"%C^"/^AR\
M/_\ @T@_^*H_X6/X(_Z'+P__ .#2#_XJ@#I**YO_ (6/X(_Z'+P__P"#2#_X
MJC_A8_@C_H<O#_\ X-(/_BJ .DHKF_\ A8_@C_H<O#__ (-(/_BJ/^%C^"/^
MAR\/_P#@T@_^*H Z2BN;_P"%C^"/^AR\/_\ @T@_^*H_X6/X(_Z'+P__ .#2
M#_XJ@#I**YO_ (6/X(_Z'+P__P"#2#_XJC_A8_@C_H<O#_\ X-(/_BJ .DHK
MF_\ A8_@C_H<O#__ (-(/_BJ/^%C^"/^AR\/_P#@T@_^*H Z2BN;_P"%C^"/
M^AR\/_\ @T@_^*H_X6/X(_Z'+P__ .#2#_XJ@#I**YO_ (6/X(_Z'+P__P"#
M2#_XJC_A8_@C_H<O#_\ X-(/_BJ .DHKF_\ A8_@C_H<O#__ (-(/_BJ/^%C
M^"/^AR\/_P#@T@_^*H Z2BN;_P"%C^"/^AR\/_\ @T@_^*H_X6/X(_Z'+P__
M .#2#_XJ@#I**YO_ (6/X(_Z'+P__P"#2#_XJC_A8_@C_H<O#_\ X-(/_BJ
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M@TN"^+;1:RWL:RD^FPG.?PH XW_AGSX8_P#0L_\ D_<__'*/^&?/AC_T+/\
MY/W/_P <I/B1XMUKP_\ $7X?Z7I-YY%GK%]+%?1^4C>:BF$ 98$K]]NA'6O2
MJ /-O^&?/AC_ -"S_P"3]S_\<H_X9\^&/_0L_P#D_<__ !RO2:* /-O^&?/A
MC_T+/_D_<_\ QRC_ (9\^&/_ $+/_D_<_P#QRO2:* /-O^&?/AC_ -"S_P"3
M]S_\<H_X9\^&/_0L_P#D_<__ !RO2:* /-O^&?/AC_T+/_D_<_\ QRC_ (9\
M^&/_ $+/_D_<_P#QRO2:* /-O^&?/AC_ -"S_P"3]S_\<H_X9\^&/_0L_P#D
M_<__ !RO2:* /-O^&?/AC_T+/_D_<_\ QRC_ (9\^&/_ $+/_D_<_P#QRO2:
M* /-O^&?/AC_ -"S_P"3]S_\<H_X9\^&/_0L_P#D_<__ !RO2:* /-O^&?/A
MC_T+/_D_<_\ QRC_ (9\^&/_ $+/_D_<_P#QRO2:* /-O^&?/AC_ -"S_P"3
M]S_\<KB?AMX>TOPK^U9XJT;0;;[+I]MHJ^5#YC/MW?97/S,23\S$\GO7O]>)
M>%_^3R?&?_8%C_\ 0+.@#VVBBB@ HHHH **** "LS5;6YN-2T66VO!;QVUZT
MMQ&7*_:$-O,@3 ^]AG1\'CY,]0*TZR-:MK.?5O#\EW=>1-;Z@\EK'C/GR?99
MU*>WR-(W_ * ->BBB@ HHHH **** "BBB@ HHHH *^9/V?\ X6^#O&_@&]U+
MQ/H_VZ[BU.2!)/M4T>$$43 81P.K-SC/-?3=>)?LJ?\ )+-2_P"PU+_Z(@H
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ML&O&\9Z9H$EK'92W"76DSR )(H!$;I)R<\\C@8H H_\ #/GPQ_Z%G_R?N?\
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M<KTFB@#S;_AGSX8_]"S_ .3]S_\ '*/^&?/AC_T+/_D_<_\ QRO2:* /-O\
MAGSX8_\ 0L_^3]S_ /'*/^&?/AC_ -"S_P"3]S_\<KTFB@#S;_AGSX8_]"S_
M .3]S_\ '*/^&?/AC_T+/_D_<_\ QRO2:* /-O\ AGSX8_\ 0L_^3]S_ /'*
M/^&?/AC_ -"S_P"3]S_\<KTFB@#S;_AGSX8_]"S_ .3]S_\ '*X!/!VA>"/V
MM/".F^&+'[#:2Z9+.\?G/)ES'=*3EV)Z*O&<<5]$5XEXH_Y/)\&?]@63_P!
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MI=WNZN$C'ER>X9-O/?!->^6?@_0]/\43>(K2QV:M/:K:27)F=BT2[<+@L1_
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M3_DEFI?]AJ7_ -$05[;7B7[*G_)+-2_[#4O_ *(@H ]MHHHH **** "BBB@
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MB#_OJ?\ ^1Z]MHH \2_X7EXW_P"B+^(/^^I__D>C_A>7C?\ Z(OX@_[ZG_\
MD>O;:* /$O\ A>7C?_HB_B#_ +ZG_P#D>C_A>7C?_HB_B#_OJ?\ ^1Z]MHH
M\2_X7EXW_P"B+^(/^^I__D>C_A>7C?\ Z(OX@_[ZG_\ D>O;:* /$O\ A>7C
M?_HB_B#_ +ZG_P#D>C_A>7C?_HB_B#_OJ?\ ^1Z]MHH \2_X7EXW_P"B+^(/
M^^I__D>C_A>7C?\ Z(OX@_[ZG_\ D>O;:* /$O\ A>7C?_HB_B#_ +ZG_P#D
M>C_A>7C?_HB_B#_OJ?\ ^1Z]MHH \2_X7EXW_P"B+^(/^^I__D>C_A>7C?\
MZ(OX@_[ZG_\ D>O;:* /$O\ A>7C?_HB_B#_ +ZG_P#D>C_A>7C?_HB_B#_O
MJ?\ ^1Z]MHH \2_X7EXW_P"B+^(/^^I__D>C_A>7C?\ Z(OX@_[ZG_\ D>O;
M:* /$O\ A>7C?_HB_B#_ +ZG_P#D>C_A>7C?_HB_B#_OJ?\ ^1Z]MHH \2_X
M7EXW_P"B+^(/^^I__D>C_A>7C?\ Z(OX@_[ZG_\ D>O;:* /$O\ A>7C?_HB
M_B#_ +ZG_P#D>C_A>7C?_HB_B#_OJ?\ ^1Z]MHH \2_X7EXW_P"B+^(/^^I_
M_D>C_A>7C?\ Z(OX@_[ZG_\ D>O;:* /$O\ A>7C?_HB_B#_ +ZG_P#D>C_A
M>7C?_HB_B#_OJ?\ ^1Z]MHH \2_X7EXW_P"B+^(/^^I__D>C_A>7C?\ Z(OX
M@_[ZG_\ D>O;:* /$O\ A>7C?_HB_B#_ +ZG_P#D>C_A>7C?_HB_B#_OJ?\
M^1Z]MHH \2_X7EXW_P"B+^(/^^I__D>C_A>7C?\ Z(OX@_[ZG_\ D>O;:* /
M$O\ A>7C?_HB_B#_ +ZG_P#D>C_A>7C?_HB_B#_OJ?\ ^1Z]MHH \2_X7EXW
M_P"B+^(/^^I__D>C_A>7C?\ Z(OX@_[ZG_\ D>O;:* /$O\ A>7C?_HB_B#_
M +ZG_P#D>C_A>7C?_HB_B#_OJ?\ ^1Z]MHH \2_X7EXW_P"B+^(/^^I__D>C
M_A>7C?\ Z(OX@_[ZG_\ D>O;:* /$O\ A>7C?_HB_B#_ +ZG_P#D>C_A>7C?
M_HB_B#_OJ?\ ^1Z]MHH \2_X7EXW_P"B+^(/^^I__D>C_A>7C?\ Z(OX@_[Z
MG_\ D>O;:* /$O\ A>7C?_HB_B#_ +ZG_P#D>C_A>7C?_HB_B#_OJ?\ ^1Z]
MMHH \2_X7EXW_P"B+^(/^^I__D>C_A>7C?\ Z(OX@_[ZG_\ D>O;:* /$O\
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M ,CU[;10!XE_PO+QO_T1?Q!_WU/_ /(]'_"\O&__ $1?Q!_WU/\ _(]>VT4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%9&M6EK<ZMX?EN;M;>6UU!Y;>,C_ (^'-K.A0?1'=_\ @%:]9&M'3QJWA_[>
MLAN#J#BQ*=!-]EGR6]O+\W\<4 :]%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\0?^$YJ'_P 8J.?XAZ';6\D]S!KL,,2%Y))/#U^JHH&223#@ #O0!U%%>?\
M_"\_A[_T&Y__  5W?_QJC_A>?P]_Z#<__@KN_P#XU0!Z!17G_P#PO/X>_P#0
M;G_\%=W_ /&JGLOC+X(U*\2UT_4;V[N),[(8-'O'=L#)PHBR> 3^% '<T5RM
MU\1M LK9KB]CUNW@3&Z67P_?HJY.!DF''4@5G_\ "YO _P#T$KW_ ,$]Y_\
M&J .ZHKA?^%S>!_^@E>_^">\_P#C5'_"YO __02O?_!/>?\ QJ@#NJ*Y"Q^*
M/AC4]_\ 9KZM=^7C?]GT*^DVYSC.(>,X/Y5;_P"$\TC_ )\_$'_A.:A_\8H
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M?@9X-\,:OX'O)]6\.:1?3+J+HLES8Q2,%\N,XRRDXR3Q[TWXP>#?#&F?V/\
MV;X<TFT\SS]_V>QBCW8\O&<+SC)_.@#W"BOD3^PM(_Z!=E_X#I_A1_86D?\
M0+LO_ =/\* /KNBOD3^PM(_Z!=E_X#I_A7N/P[\!^$+WP%IUQ>^%-$N)W\W=
M++IT+LV)7 R2N>@ H ]*HKF_^%<>"/\ H3?#_P#X*X/_ (FC_A7'@C_H3?#_
M /X*X/\ XF@#I**YO_A7'@C_ *$WP_\ ^"N#_P")H_X5QX(_Z$WP_P#^"N#_
M .)H Z2BN;_X5QX(_P"A-\/_ /@K@_\ B:/^%<>"/^A-\/\ _@K@_P#B: .D
MHKF_^%<>"/\ H3?#_P#X*X/_ (FO'/C[X4\.Z-_8']D:!I=AYOVGS/LMG'%O
MQY6,[0,XR?S- 'T/17PM_9]E_P ^D'_?I?\ "C^S[+_GT@_[]+_A0!]TT5\+
M?V?9?\^D'_?I?\*^D_A/X&\):E\+])NM0\+Z+=W$GG;YI]/B=VQ,X&6*Y/
M_"@#U:BOFGXB>&- LO'NHV]EH>FV\">5MBBM(T5<Q(3@ 8ZDFN:_L+2/^@79
M?^ Z?X4 ?7=%?(G]A:1_T"[+_P !T_PH_L+2/^@79?\ @.G^% 'UW17$>&OA
M]X,G\*:3-/X1T&262RA9W?3(2S$H"225Y-:?_"N/!'_0F^'_ /P5P?\ Q- '
M245S?_"N/!'_ $)OA_\ \%<'_P 31_PKCP1_T)OA_P#\%<'_ ,30!TE%<W_P
MKCP1_P!";X?_ /!7!_\ $T?\*X\$?]";X?\ _!7!_P#$T =)17-_\*X\$?\
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M)(I+V%71[5"K N 001R*^A/^%<>"/^A-\/\ _@K@_P#B: .DHKF_^%<>"/\
MH3?#_P#X*X/_ (FC_A7'@C_H3?#_ /X*X/\ XF@#I**YO_A7'@C_ *$WP_\
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MO[\1GZC5K(UJ/3WU;P^U_+)'<)J#M8J@XDF^RS@JW!X\LRGMR!SV(!KT444
M%%%% !1110 45B:?XQ\/ZMXDO- TS5(;K4[&/S+B&++",9QRP&W.3@C.1W%;
M= !1110 4444 %8?C?\ Y)_XA_[!=S_Z*:MRL/QO_P D_P#$/_8+N?\ T4U
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M^!UKUF:K=7-OJ6BQ6UF+B.YO6BN)"A;[.@MYG#Y'W<LB)D\?/CJ10!IT444
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M2D6\5A->26K(QV.-H$4SMGG/(QP>>F<;]G#_ )F3_MU_]JUU_P 9?^1.M/\
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MT:7ELDP0^H# X-9?_"N?!'_0F^'_ /P5P?\ Q-=)10!S?_"N?!'_ $)OA_\
M\%<'_P 31_PKGP1_T)OA_P#\%<'_ ,37244 >*?&_P )^'="\$VEUH>@:7IM
MP^HI&TMG91PNRF.0E25 .,@''L*\)KZ-_:$_Y)_8_P#84C_]%2U\Y4 %%%%
M'NWP0\)^'==\$W=UKF@:7J5PFHO&LMY91S.JB.,A06!.,DG'N:?\5O#FA^'_
M .R?[!T;3],\_P [S?L5JD/F;=F-VT#.,G&?4UJ?L]_\D_OO^PI)_P"BHJ;\
M;?\ F"?]O'_M.@#RFBBB@ KV;P%X*\+:OX(L+W5?#6CWUW+YGF7%S8122/B1
M@,LRDG  'T%>,U] _#+_ ))SIG_;7_T<] $__"N?!'_0F^'_ /P5P?\ Q-'_
M  KGP1_T)OA__P %<'_Q-=)10!S?_"N?!'_0F^'_ /P5P?\ Q-'_  KGP1_T
M)OA__P %<'_Q-=)10!S?_"N?!'_0F^'_ /P5P?\ Q-'_  KGP1_T)OA__P %
M<'_Q-=)10!S?_"N?!'_0F^'_ /P5P?\ Q->0?'CPYH?A_P#L'^P=&T_3//\
MM'F_8K5(?,V^5C=M SC)QGU-?0=>'_M'_P#,M_\ ;U_[2H \.HHHH *^COA5
MX*\+:O\ #/2KW5?#6CWUW+YWF7%S8122/B9P,LRDG  'T%?.-?5/P:_Y))HW
M_;?_ -'R4 >6^/=-L=(\;W]EI5G;V-I%Y?EV]M$L<:9C4G"J !DDGZFN=KJ_
MB;_R4;4_^V7_ *)2N4H **** /=_#W@'P?>>&-+NKSPIH<]Q-9PR2RRZ;"SR
M,4!+,2N223DDUH_\*Y\$?]";X?\ _!7!_P#$U?\ "O\ R)VC?]>$'_HM:U:
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M+Q;=;6^:5XRV#<@VTR>6!W(+A\?[!/:@#4HHHH **** "BBB@ HHHH ****
M"BBB@ K#\;_\D_\ $/\ V"[G_P!%-6Y6'XW_ .2?^(?^P7<_^BFH ^.J***
M"NX^#7_)6]&_[;_^B)*X>NX^#7_)6]&_[;_^B)* /?OB;_R3G4_^V7_HY*^?
MJ^@?B;_R3G4_^V7_ *.2OGZ@ HHHH ]6^"7_ #&_^W?_ -J5ZM7E/P2_YC?_
M &[_ /M2O5J "BBB@ HHHH **** .'^,O_))-9_[8?\ H^.OE:OJGXR_\DDU
MG_MA_P"CXZ^5J "BBB@#W']G#_F9/^W7_P!JUU_QE_Y$ZT_Z_P!/_1<E<A^S
MA_S,G_;K_P"U:Z_XR_\ (G6G_7^G_HN2@#Q2BBB@ KVOX-?\B==_]?[_ /HN
M.O%*]K^#7_(G7?\ U_O_ .BXZ /0:*** "BBB@ HHHH *\K_ &A/^2?V/_84
MC_\ 14M>J5Y7^T)_R3^Q_P"PI'_Z*EH ^<J*** "OHW]GO\ Y)_??]A23_T5
M%7SE7T;^SW_R3^^_["DG_HJ*@#'^,O\ R.-I_P!>"?\ HR2O/Z] ^,O_ ".-
MI_UX)_Z,DKS^@ HHHH ^@?AE_P DYTS_ +:_^CGKJZY3X9?\DYTS_MK_ .CG
MKJZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#RO]H3_ ))_8_\ 84C_ /14M?.5?1O[0G_)/['_ +"D?_HJ
M6OG*@ HHHH ^C?V>_P#DG]]_V%)/_145-^-O_,$_[>/_ &G3OV>_^2?WW_84
MD_\ 145-^-O_ #!/^WC_ -IT >4T444 %?0/PR_Y)SIG_;7_ -'/7S]7T#\,
MO^2<Z9_VU_\ 1ST =71110 4444 %%%% !7A_P"T?_S+?_;U_P"TJ]PKP_\
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M:O\ ]")X@_[_ .G_ /R51_PE&K_]")X@_P"_^G__ "50!E_&7_DDFL_]L/\
MT?'7RM7T=\5=>U&]^&>JV]SX3UC3XG\G=<W,MFT:8F0\B.=FYQCA3R>PYKYQ
MH **** /<?V</^9D_P"W7_VK77_&7_D3K3_K_3_T7)7GOP'U2[TW^WOL6A:A
MJ_F?9]WV*2W7RL>;C=YTJ=<\8ST.<<9ZSXH:S?:CX8MXKSPUJFE(MXK":\DM
M61CL<;0(IG;/.>1C@\],@'E5%%% !7M?P:_Y$Z[_ .O]_P#T7'7BE>J_"_6;
M[3O#%Q%9^&M4U5&O&8S6<EJJ*=B#:1+,C9XSP,<CGK@ ]7HKF_\ A*-7_P"A
M$\0?]_\ 3_\ Y*H_X2C5_P#H1/$'_?\ T_\ ^2J .DHKF_\ A*-7_P"A$\0?
M]_\ 3_\ Y*H_X2C5_P#H1/$'_?\ T_\ ^2J .DHKF_\ A*-7_P"A$\0?]_\
M3_\ Y*H_X2C5_P#H1/$'_?\ T_\ ^2J .DKRO]H3_DG]C_V%(_\ T5+78?\
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M'/;S7D,<L4J!DD4N 58'@@@X(->[_P#"N?!'_0F^'_\ P5P?_$T =)17-_\
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M#_T?'7RM7U3\9?\ DDFL_P#;#_T?'7RM0 4444 >X_LX?\S)_P!NO_M6NO\
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M)OKB!_*VRQ6SNK8B0'! QU!%<S_PBOB'_H ZG_X!R?X4 95%:O\ PBOB'_H
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MO[/?_)/[[_L*2?\ HJ*@#'^,O_(XVG_7@G_HR2O/Z] ^,O\ R.-I_P!>"?\
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M\)1J_P#T(GB#_O\ Z?\ _)5'_"4:O_T(GB#_ +_Z?_\ )5=)10!S?_"4:O\
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M_P#'JZCPRUWX5TV2QT[P3XGDBDF,Q,]SIQ;) ':Y''RBN]HH YO_ (2C5_\
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M ]F\!:]J-EX(L+>V\)ZQJ$2>9MN;:6S6-\R,>!).K<9QRHY'<<UT7_"4:O\
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MP/O?O'C;!X^3/4"@#2HHHH **** "BBB@ HHHH **** "BBB@ K#\;_\D_\
M$/\ V"[G_P!%-6Y65XILKC4O!^LV-E'YEQ<V$\,2;@-SM&P R>!R1UH ^,Z*
M[C_A37CW_H!?^3D'_P 71_PIKQ[_ - +_P G(/\ XN@#AZ[CX-?\E;T;_MO_
M .B)*/\ A37CW_H!?^3D'_Q==7\,_AGXM\/_ !$TS4]7TG[/9P>;YDOVF)]N
MZ)U'"L3U('2@#WZBBB@ HHHH **** "BBB@ HHHH **** .'^,O_ "236?\
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M_G_]&-0!E4444 :OA7_D<=&_Z_X/_1BU]+U\T>%?^1QT;_K_ (/_ $8M?2]
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MO2?A':_$_P )?VO_ ,)YI'B#7/M7D_9/^)K;7'D[?,W_ .MN!MSN7IUQST%
M'MM%<CJ7B+7KG2KN"S\$^((KB6%TBD^TV"[&*D Y%UD8/<5\[_\ "!_M#?\
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M&!V% 'U;17R7'X$_:$65&>[\0%0P)'_"1IR/^_\ 7TA_PE&K_P#0B>(/^_\
MI_\ \E4 =)17@_Q8TWXK^*]:L;CP-IOB#1;6&W,<\7]L6]OYC[B=V([@@\<9
M-<#_ ,('^T-_S^>(/_"C3_X_0!];45Y5\,)O'GACP@;#QGX<\0:QJ/VEY/M/
M]HVD_P A PNZ2Y#<8/'3FM#QYJ/C#7? ^HZ;X8\*>(--U6X5!;W7VZRB\LAU
M)^=+DL. 1P.] 'HM>5_M"?\ )/['_L*1_P#HJ6O'?^$#_:&_Y_/$'_A1I_\
M'ZS=<\,?%71[6*Y^(5QJDFF&79&MYJXND\TJV,()&P<!N<>O/- &-116%<:7
MJTEU*\5]MC9R57SG&!G@=* -VOHW]GO_ ))_??\ 84D_]%15\H_V1K/_ $$/
M_(S_ .%?2OP-UC4--\"W4%KX;U35E-^[-/9RVJH#Y48VGS9D;/&>F.1SUP +
M\9?^1QM/^O!/_1DE>?UJ?'6'Q!XC\4Z=-907GA]HK+8\%Y<H'D&]B&'D/(N.
MHY(/!X]?+_\ A%O%O_0=_P#)R7_"@#O**Q_#FGZEIUC+'J]W]KE:3<K^:SX7
M XRP]<U>U*">YTRXALY?*GDC*QR;BNT^N1R* /HOX9?\DYTS_MK_ .CGKJZ^
M/=)\$?'";2X9/#NH:Q+IIW>2]MKHBC/S'=A6E4CYL]0.?SKL?A]X<^-7A_QW
MI^I^*X?$&IZ3!YOVBT_MR&;S-T3*OR/.%.&*GD]L]: /I&BN;_X2C5_^A$\0
M?]_]/_\ DJO"/&7A;XXZSXRU/4/#P\06&F7$Q>VMO[>BB\I<#C:DY4?04 ?3
M=%?,6F?"?X[7]F)KKQI=:9(6(^SW6OW#.!ZYBWK@_6OHW0+2\L/#>F6>J7'V
MF^M[2**YGWE_-D5 &;<W)R03D\F@#0HHHH *R_$?B32?"6AS:QX@N_LEA"56
M27RW?!8A1PH)/)':M2O+OVC/^2(ZK_UVM_\ T<M '<V/BS0]2\)_\)-9:C%)
MHWDO.;O!"A$SN)!&1C:<@C/%4]%^(/A;Q!X9NO$.EZQ$^DV<C1W%U*CPK&P"
ML0?,"GHR_G7B&I17^G>(-6^#%DDB6VN:U'=6LJ<"+3Y 99U7TV[, 8Y^:L:^
MM/(^#?B)((&_LJS^(4AOHHE^46JJHQ@=MVS]* /=],^,'@/6(=0DTWQ#%,NG
M0/<W(\B52L2?>8 J"P&?X<U-KGQ5\&>&]/TJ^UK6?LUMJ]N+FR?[+,_FQD*=
MV%0E>&7AL'FN9\<>*_!.M_#;7;;P[J6E7MXNA7+6\=H59X8=HW#CF,?=^4X^
MG%<K'J5CI'BCX(7VJWEO8VD7A^7S+BYE6.-,V2@99B ,D@?4T >KV/Q%\-:S
MX6U#7?#^I1:I;V$+2RQPY$@PI(4HP# G&!D5<_MZ\C\4V&CW.E^4MW:23FY^
MT!E#ILW(J@9(^?[QV]. <\>/V]O;>-?C'XPF\!RPOI\GA[[/<75N!Y$U[O#1
M\CAC@#+#L&KUBXT;6K_Q7I>MK?V=I;6L+(;"6Q:27$FPR RK,%S\@P0I Y^]
M0!J:'JHUG3?M)A\B1)I;>6+?NV21R-&PSQD94D' R"#6A6-X6T^YL-*F.H((
M[FZO;BZ>,,#L$DK,BY'&0A4''&0:V: "BBLKQ!X:TSQ/9QVNLQSR0QR>8HAN
MI8#NP1UC92>">"<4 5/&WB7_ (17PM/?01?:+Z1EMK"V'6XN)#MC0?CR?8$]
MJ\\^#.AS>'/B3\0=+N[I[RZC72Y+FX<Y\V:2!Y)6^A=F(]L5T>K_  SN&OM"
ME\*ZZ-)AT0S/!!>6SWX,LG!D+/*"2 2!DG&3C%8W@'PYXOT_XS>,;[6=1$MI
M+]B\VX.E&%-2Q;L%\IMY">62 V-V3_=H ]9HHHH YO\ X6/X(_Z'+P__ .#2
M#_XJGQ?$'P9<3)#!XNT*661@J(FIPEF8G   ;DUYG_PRIX(_Z"OB#_P(@_\
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MNJ*/XF.!4/\ :%E_S]P?]_5_QI;RTCOK8P2E@I(.5//%9O\ PC%E_P ]9_\
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MT@GFYQ\N[8/E&.![F@#M;_4++2K&2]U.\@L[6( R3W$JQHF3@98D <D"L/\
MX6/X(_Z'+P__ .#2#_XJL[7OA%X(UW0[G3?^$=T[3?M  ^U:=8P0SQX8'Y'V
M''3'3H37#_\ #*G@C_H*^(/_  (@_P#C- 'JFF>,?#.M7@M-'\1:3J%R5+""
MUOHI7('4[58G%;.:\I\,_LZ>"/#6LKJ&+S5MJ,GV;51!/"<]ROE#D=C79?\
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M-=7\\;6BW)-W(C'<7=<?*B\845SU $,EY;1.4EN(D<=59P"*;_:%E_S]P?\
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M_84C_P#14M?.5?1O[0G_ "3^Q_["D?\ Z*EKYRH **** /HW]GO_ ))_??\
M84D_]%15ZI7E?[/?_)/[[_L*2?\ HJ*O5* "BBB@ HHHH **** "BBB@ HHH
MH *\/_:/_P"9;_[>O_:5>X5X?^T?_P RW_V]?^TJ /#J*** "OJGX-?\DDT;
M_MO_ .CY*^5J^J?@U_R231O^V_\ Z/DH [BBBB@ HHHH **** "BBB@ HHHH
M **** /G+]H3_DH%C_V"X_\ T;+7E=>J?M"?\E L?^P7'_Z-EKRN@ HHHH ^
MQ?!'_)/_  ]_V"[;_P!%+6Y6'X(_Y)_X>_[!=M_Z*6MR@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ K.U.WU"?4='DL)O+@@O&DO5W8\
MV'[/,H7W_>-$<?[.>U:-9&LV<%SJWA^6>]6V>UU!Y88F'-RQM9T\L<CD*[/W
MXC/'< &O1110 4444 %%%4M9U2#0]"O]6O0YM["VDN91&,L412QP.YP* +M%
M</H7Q,_M^[LHK?P9XKMH+W:4O+FQC6!589#LPD.%QWP:[B@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *Y_QCX.T_QOH\6FZM-<PPQ3B=6MF56+
M!67'S*1C#'M7044 >5_\,]^%/^@AK/\ W^B_^-T?\,]^%/\ H(:S_P!_HO\
MXW7JE% 'E?\ PSWX4_Z"&L_]_HO_ (W7:>#O!VG^"-'ETW29KF:&6<SLURRL
MP8JJX^50,84=JZ"B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_I__ ,E4?\)1J_\ T(GB#_O_ *?_ /)5=)10!S?_  E&K_\ 0B>(/^_^G_\
MR51_PE&K_P#0B>(/^_\ I_\ \E5TE% '-_\ "4:O_P!")X@_[_Z?_P#)5'_"
M4:O_ -")X@_[_P"G_P#R57244 <W_P )1J__ $(GB#_O_I__ ,E4?\)1J_\
MT(GB#_O_ *?_ /)5=)10!S?_  E&K_\ 0B>(/^_^G_\ R51_PE&K_P#0B>(/
M^_\ I_\ \E5TE% '-_\ "4:O_P!")X@_[_Z?_P#)5'_"4:O_ -")X@_[_P"G
M_P#R57244 <W_P )1J__ $(GB#_O_I__ ,E4?\)1J_\ T(GB#_O_ *?_ /)5
M=)10!S?_  E&K_\ 0B>(/^_^G_\ R51_PE&K_P#0B>(/^_\ I_\ \E5TE% '
M-_\ "4:O_P!")X@_[_Z?_P#)5'_"4:O_ -")X@_[_P"G_P#R57244 <W_P )
M1J__ $(GB#_O_I__ ,E4?\)1J_\ T(GB#_O_ *?_ /)5=)10!S?_  E&K_\
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M<^"/^A-\/_\ @K@_^)KI** .;_X5SX(_Z$WP_P#^"N#_ .)KR#X\>'-#\/\
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M\)1J_P#T(GB#_O\ Z?\ _)5'_"4:O_T(GB#_ +_Z?_\ )5 '245S?_"4:O\
M]")X@_[_ .G_ /R51_PE&K_]")X@_P"_^G__ "50!TE%<W_PE&K_ /0B>(/^
M_P#I_P#\E4?\)1J__0B>(/\ O_I__P E4 =)17-_\)1J_P#T(GB#_O\ Z?\
M_)5'_"4:O_T(GB#_ +_Z?_\ )5 '245S?_"4:O\ ]")X@_[_ .G_ /R51_PE
M&K_]")X@_P"_^G__ "50!TE%<W_PE&K_ /0B>(/^_P#I_P#\E4?\)1J__0B>
M(/\ O_I__P E4 =)17-_\)1J_P#T(GB#_O\ Z?\ _)5'_"4:O_T(GB#_ +_Z
M?_\ )5 '245S?_"4:O\ ]")X@_[_ .G_ /R51_PE&K_]")X@_P"_^G__ "50
M!TE%<W_PE&K_ /0B>(/^_P#I_P#\E4?\)1J__0B>(/\ O_I__P E4 =)17-_
M\)1J_P#T(GB#_O\ Z?\ _)5'_"4:O_T(GB#_ +_Z?_\ )5 '245S?_"4:O\
M]")X@_[_ .G_ /R51_PE&K_]")X@_P"_^G__ "50!TE%<W_PE&K_ /0B>(/^
M_P#I_P#\E4?\)1J__0B>(/\ O_I__P E4 =)17-_\)1J_P#T(GB#_O\ Z?\
M_)5'_"4:O_T(GB#_ +_Z?_\ )5 '245S?_"4:O\ ]")X@_[_ .G_ /R51_PE
M&K_]")X@_P"_^G__ "50!TE%<W_PE&K_ /0B>(/^_P#I_P#\E4?\)1J__0B>
M(/\ O_I__P E4 =)17-_\)1J_P#T(GB#_O\ Z?\ _)5'_"4:O_T(GB#_ +_Z
M?_\ )5 '245S?_"4:O\ ]")X@_[_ .G_ /R51_PE&K_]")X@_P"_^G__ "50
M!TE%<W_PE&K_ /0B>(/^_P#I_P#\E4?\)1J__0B>(/\ O_I__P E4 =)17-_
M\)1J_P#T(GB#_O\ Z?\ _)5'_"4:O_T(GB#_ +_Z?_\ )5 '245S?_"4:O\
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M]";X?_\ !7!_\31_PKGP1_T)OA__ ,%<'_Q- '29HS7-_P#"N?!'_0F^'_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **\3U;XS:I9>//[.CALFM8(KF)YDN
M0; N)8PDDMQLW1[ Q5U (#.@_BX]JC??$C_*=R@_*V1^![B@!U%%% !1110
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M:T:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P"2JZ2B@#F_^$HU?_H1/$'_ '_T_P#^2J/^$HU?_H1/$'_?_3__ )*KI**
M.;_X2C5_^A$\0?\ ?_3_ /Y*H_X2C5_^A$\0?]_]/_\ DJNDHH YO_A*-7_Z
M$3Q!_P!_]/\ _DJC_A*-7_Z$3Q!_W_T__P"2JZ2B@#F_^$HU?_H1/$'_ '_T
M_P#^2J/^$HU?_H1/$'_?_3__ )*KI** .;_X2C5_^A$\0?\ ?_3_ /Y*H_X2
MC5_^A$\0?]_]/_\ DJNDHH YO_A*-7_Z$3Q!_P!_]/\ _DJC_A*-7_Z$3Q!_
MW_T__P"2JZ2B@#F_^$HU?_H1/$'_ '_T_P#^2J/^$HU?_H1/$'_?_3__ )*K
MI** .;_X2C5_^A$\0?\ ?_3_ /Y*H_X2C5_^A$\0?]_]/_\ DJNDHH YO_A*
M-7_Z$3Q!_P!_]/\ _DJC_A*-7_Z$3Q!_W_T__P"2JZ2B@#F_^$HU?_H1/$'_
M '_T_P#^2J/^$HU?_H1/$'_?_3__ )*KI** .;_X2C5_^A$\0?\ ?_3_ /Y*
MH_X2C5_^A$\0?]_]/_\ DJNDHH YO_A*-7_Z$3Q!_P!_]/\ _DJC_A*-7_Z$
M3Q!_W_T__P"2JZ2B@#F_^$HU?_H1/$'_ '_T_P#^2J/^$HU?_H1/$'_?_3__
M )*KI** .;_X2C5_^A$\0?\ ?_3_ /Y*H_X2C5_^A$\0?]_]/_\ DJNDHH Y
MO_A*-7_Z$3Q!_P!_]/\ _DJC_A*-7_Z$3Q!_W_T__P"2JZ2B@#F_^$HU?_H1
M/$'_ '_T_P#^2J/^$HU?_H1/$'_?_3__ )*KI** .;_X2C5_^A$\0?\ ?_3_
M /Y*H_X2C5_^A$\0?]_]/_\ DJNDHH J:9>SW]F)KK3;K3)"Q'V>Z:)G ]<Q
M.ZX/UJW110 4444 %%%% !1110 4444 %%%% !1110 5E>(/#6F>)[..UUF.
M>2&.3S%$-U+ =V".L;*3P3P3BM6B@#E]5B'@/X=W_P#PBVFWE[+:PNUI:(TM
MW))*Q^7[Q9R-S GG@ ]A1\.?##^$O >G:;<L9+YD-Q?2,<M)<2'=(2>_S'&?
M0"NHHH **** ,_5M T?7XHXM=TFQU..)MT:7ELDP0^H# X-9?_"N/!'_ $)O
MA_\ \%<'_P 37244 <W_ ,*X\$?]";X?_P#!7!_\31_PKCP1_P!";X?_ /!7
M!_\ $UTE% '-_P#"N/!'_0F^'_\ P5P?_$T?\*X\$?\ 0F^'_P#P5P?_ !-=
M)10!S?\ PKCP1_T)OA__ ,%<'_Q-'_"N/!'_ $)OA_\ \%<'_P 37244 <W_
M ,*X\$?]";X?_P#!7!_\31_PKCP1_P!";X?_ /!7!_\ $UTE% '-_P#"N/!'
M_0F^'_\ P5P?_$T?\*X\$?\ 0F^'_P#P5P?_ !-=)10!S?\ PKCP1_T)OA__
M ,%<'_Q-'_"N/!'_ $)OA_\ \%<'_P 37244 <W_ ,*X\$?]";X?_P#!7!_\
M31_PKCP1_P!";X?_ /!7!_\ $UTE% '-_P#"N/!'_0F^'_\ P5P?_$T?\*X\
M$?\ 0F^'_P#P5P?_ !-=)10!S?\ PKCP1_T)OA__ ,%<'_Q-'_"N/!'_ $)O
MA_\ \%<'_P 37244 <W_ ,*X\$?]";X?_P#!7!_\31_PKCP1_P!";X?_ /!7
M!_\ $UTE% '-_P#"N/!'_0F^'_\ P5P?_$T?\*X\$?\ 0F^'_P#P5P?_ !-=
M)10!S?\ PKCP1_T)OA__ ,%<'_Q-'_"N/!'_ $)OA_\ \%<'_P 37244 <W_
M ,*X\$?]";X?_P#!7!_\31_PKCP1_P!";X?_ /!7!_\ $UTE% '-_P#"N/!'
M_0F^'_\ P5P?_$T?\*X\$?\ 0F^'_P#P5P?_ !-=)10!S?\ PKCP1_T)OA__
M ,%<'_Q-'_"N/!'_ $)OA_\ \%<'_P 37244 <W_ ,*X\$?]";X?_P#!7!_\
M31_PKCP1_P!";X?_ /!7!_\ $UTE% '-_P#"N/!'_0F^'_\ P5P?_$T?\*X\
M$?\ 0F^'_P#P5P?_ !-=)10!S?\ PKCP1_T)OA__ ,%<'_Q-'_"N/!'_ $)O
MA_\ \%<'_P 37244 <W_ ,*X\$?]";X?_P#!7!_\31_PKCP1_P!";X?_ /!7
M!_\ $UTE% '-_P#"N/!'_0F^'_\ P5P?_$T?\*X\$?\ 0F^'_P#P5P?_ !-=
M)10!S?\ PKCP1_T)OA__ ,%<'_Q-'_"N/!'_ $)OA_\ \%<'_P 37244 <W_
M ,*X\$?]";X?_P#!7!_\31_PKCP1_P!";X?_ /!7!_\ $UTE% '-_P#"N/!'
M_0F^'_\ P5P?_$T?\*X\$?\ 0F^'_P#P5P?_ !-=)10!S?\ PKCP1_T)OA__
M ,%<'_Q-'_"N/!'_ $)OA_\ \%<'_P 37244 <W_ ,*X\$?]";X?_P#!7!_\
M3711QI#$D4*+'&BA411@*!T '84ZB@ HHHH **** "BBB@ HHHH **** "L[
M4YKB/4-'6WL5N8Y;QEGE*Y-LGD2D2#T)8*G_ &T-:-% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC\41O+<Z3(D<PGBCP5B=@/,*M@A5#;CW !X/2MFXN([6UEN+AMD4*%W;!.%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%.N1G:]KIPS'"W(_>S'Y4&00>N#VKL#?M9: =0UA%MV@MO/NE0[A&0NYP#W
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M^1QUG_K_ )__ $8U95:OBK_D<=9_Z_Y__1C5E4 =7\,O^2C:9_VU_P#1+U]
MU\_?#+_DHVF?]M?_ $2]?0- '%?$_5]7TK2-$CT'46TVXU+7+33WN5A24I'*
MQ5L*X(S^':LVWU;Q-X4^)V@^&];UL>(+'Q!#<F*:6TC@FMI($#G/E@*RD''3
M.?U=\9K<WFC>&+9+B:U:;Q/I\8G@($D1+D;E)! 89R,@C/:MO0O &GZ-KIUN
MZU#4]:U41&&.\U2X$K0QGJJ*JJJY[X&3^)H Q_ /B6.S\%ZUJOBC5REO:ZU?
M1FYO9R1&@G*JH+'H.  /8"N@\/\ CWPWXHOY;'1=2\V[A3S&MYH)()-F<;PL
MBJ67/<9%>8V/B-O#'PGU6]BL[.YED\67,$3WZYM[9VNCMFD]%4C.1CG'-6],
MNKR;X^Z%'J/BG3-?N8]+N]W]GV@A%N#L(5B)'W9ZC.,8]Z .[U7XF^$-$U6;
M3M2UE([BW($^R&21(">@D=5*H?\ >(JWX@\<>'?"[VZ:UJ2Q2W2EX88HGGDD
M4=6"1JS;??&*X7X4ZYHFA^"M9L_$VHV-GJ-KJMX=66[D5&9VD)W,&QN#+C![
M]*S;EM3A^/7B-H/%6G>'FO=/LWTY[^Q6<7%N%(=8RTB;<2 D@9SG/&* .E^)
M/BR"_P#@5K6O^$=78KY"F"\LI61T/FJ#@C#*>H(X-;UE\2?".HZ]'HUEK<,M
M[,S+" CB.8KU$<I&QR/16->9>(M&ATWX%?$![3Q':>(I;^_\^XEL8!%''.S0
M[D"J[C/0GGO6K\0]7\.Z[X8\(6'A*ZL[B[EUJR;3(+4@O"$;+':.4"J"&R!C
MH: /0/$/CGPYX6N8K;6]1$-S,I=+>*&2>4K_ 'MD:LVWWQBM#0]?TOQ+I2:E
MH5[%>VCDJ)(ST(Z@@\@CT.#7GWA[4+'2/CGXW7Q#=06E[=Q6;V#W,@3S+81$
M,(R>P<'<!WYYQ5CX7/!>^+/'>JZ-\VB7NJ1_9)8_]5-(L0$[IV(+_P 0X/J<
M4 >DT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %9=[X;TC4=4M-1O+%)+JS>22)\D?,\?E,6 .'RGR_,#Q6I1
M0!GZOH6F:[I<VG:K:)/:S0M Z9*'8V-RAE(*@X'0CI5A+"TCM3;+;1>2V-R%
M00W3DYZG@<GTJQ10!G:3X?TO0Q-_9EHL)GGEN)&+,[%Y6WR'+$D MS@<>U:-
M%% 'SQHO@:W\;_&[XC6FH:MK&GVT<T(EATZZ\E;E6!^648.Y<#@>YKW?0="T
M[PSH=KH^BVRVUE:ILBC4DXYR22>22222>I-:%% 'SOJWB;X=^&]>U&[\!?$"
MX\-:H]PYN[)["YN;*>4'#;HS&<'.1N4\=J]EU&VG\5_"^ZMEEADN-7T9XQ)"
M&6-FEA(RN[D+EN,\XZUT=% 'RO)J\?B/X)Z'\+;"UO/^$L2^6&YLGM77[,JR
MNQD=B,;<$=\C\*]I\4Z]:^+U\9?#S38+L:Q;Z0Q+O&!"YECR@5LYZLH.0._I
M7?T4 ?+[:U#XN^%_@_X<:3;7A\2VFH0K?6DEJZ?8TC+[I')&,8(/7IG.*Z*+
MQ!8_"OXG?$0>*([J)?$'E7.END#R"[;$F8U*@C.Z3'.!P<GIGWZB@#PS0K^S
M^&G[-%MIWC.=M-O-3M+M+>%X)&8O('9$(53M.&&<XQFM[]GSQ1H^K?#+3]%T
M^\\W4-)@Q>0^4Z^5OD<K\Q !R!V)KU6B@#-UOP_I?B/3Y;+6;1;B"4!7 9D8
M@.K@;E(8#<BG /..:N&TMC#Y1MXO+W^9LV#&[=NW8]=W.?7FIJ* ,[1?#^E^
M'K%+/1[1;>%"Y +,[?.[2-\S$G!9V.,]Z\H_:(M#?-X(M1-/ )]=CB\ZW;;)
M'NP-RMV8=0?45[110!R'@_X::+X-U*[U2UGU#4]5O%"3ZCJESY\[J,?+NP..
M!V[#T%<[\79_AY!?:7)XVUF[T/6(D=]-O[%9O.B&>2#&K#&<<,/IWKU&B@#S
MOX2^*V\2VNJ1+XLM_%-O921K#=K826LRA@WRRJRA6/ P5Z\YKE-5UBQ^&G[1
M.M^(_%7VBVTG7=+C6WNT@>1#*@C4Q_*#@_NR?Q'K7M]% 'A_PZ\0)\,_A'?>
M)?%.GZA'!K.NRW4%M%"#,J2A50LI(_N$_0C&<TVYUVP^%WQ\\4:OXK^TV^F:
M[9PO97*6[R+)(BJ&C^4'YLAOPQG&:]RHH \;^%FIVGPT^#,>K^.I'T>#4=1E
MN$62"1W02?<!55)Y"$].A%4_V9/%&CS^!E\,Q7F[6+=YKJ6V\IQMB+J V[&T
M\L. <\U[A10!2U;1[#7--GL=5MEN+>XB>&122I*.NU@&&",@XX(J:SLK;3[9
M8+.%8HU  "]\ *,GJ3@ 9//%3T4 >#>,?#O_  D_[4EKIS:IJFDJV@!_M.EW
M'D38#/QNP?E/<5ZWX/\ !>C>!M$_LOP_ T<32&6625R\DSGJS-W/ ]JWJ* /
M#O'VK?#C2/'E_>6WC.]\)>,$"I=3VEK/-'+\JE1+'L*.,;3P1T%>F_#W7)?$
M?@/3M4N-2M=4DF\P&\M()(8Y@LK("$D 93A1D8QG..,5TE% 'S1;ZY:^ - ^
M)/@G6X+Q=8UBZNO[*A2V=_MBSQE$9"HQZ$]/3KD5Z?X-UV#P/I/@;P)K=M=C
M6-0L#M\N,&.%D7<RNV<@CIP#R*](HH ^8++6;?P/X \>?#O5K:]_X2#4=0N?
M[.M4MG<W:2HB*Z$#&,+N[<'CGBNH\0:9\.=%\+^&-%^+MA=K?V&B0I#<HESY
M6X@AHE:(X+@KG##H5]:]WHH \M_9^MM:MOAW,NL"\6S:^D.EQWW^M6UP-N1V
M&=V!]<<8KU*BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** .9NOAWX6O;R:ZNM+WSSR-)(WVB4;F8Y)P&QU-1?\*R\(_\ 0(_\F9?_
M (NNKHH Y_3/ OAS1M2BO]-T[R;F'.Q_/D;&00>"Q'0FN@HHH KW=A9WXA%_
M:07(@F6>(31A_+D4Y5UST8'H1R*L444 4DT;3([&>RCTZT6TN&9YH! HCE9C
MEBRXP23R2>M0Z?X9T+26A;2M$TZR,&_R3;6B1^7OQOV[0,;MJYQUP,]*TZ*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
;"BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>vrna-20221231_g12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vrna-20221231_g12.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#^17AI9@  34T *@    @ ! $[  (
M   1   (2H=I  0    !   (7)R=  $    B   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %9I8W1O<FEA
M(%-T97=A<G0    %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,T
M,@  DI(  @    ,T,@  ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MB@ HHHH **** "BO,H_C/;7'QD7X?VVB3O/Y[PR7C3@*NV,R$A<'/ ]17IM
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M!']D@<(ZG:Z[F0D] W)/WJ]FE\7VI^&3>+D;;;G2S?KZC]WO"\]\\8]:X/\
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M[<O_ &O6)XM8+^VE;EB /[3T\<GN8(: /9OA6_Q#M=,U>Z^+4JQLC(UL6:W
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M ,>GKSK_ !15&_9(\-%P,K9Z84SZ^2H_D373?LU?\D9MO^OR?_T*@#@_A_\
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M+O[J.X6>Z\E65I"$V\ (J],=ATKAOCM:2W_[1=A9VUT]G-<+9Q1W,>=T+,V
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M-O\ V;YFPD#/S>:,\Y/0=:\;^+GPC_X57_9'_$[_ +5_M+SO^73R/+\OR_\
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M*[M\>&(9<=\T =117FUO\<?#M_%9OI.EZ[JGVB-)9Q8V/G?80Y^7SRK84]\
MFNA\6?$'1O"%Q;V=VEY?ZG=*6@TS3;<SW,JCN$'0>Y(SVZ&@#J**Y#PK\2M'
M\4ZJ^E?9-3T;54C\T:?K%H;>9TSC<HR0P^AS4OBKXAZ/X4OHM.FAO]4U6:/S
M8]-TJU:XN"F<;MHX SW)&: .JHKE/!_Q%T?QE=W=C:0:AIVIV0#7&G:G;&">
M-3T;;D\?0\<>HKSFZ^*]];?'*;_BF_&<VGQ:&T/]DQ6!9WE%S_Q]+%OP8ROR
MB3KVH ]QHKG[KQII6F>#8_$NO"YT:T>-6,-_"4G1CT0QC)W_ .R,US=K\:-#
M>^@AU?1?$6@VURXC@O\ 5M-,%M(Q/'SY.,^IP* /1**Q?%/BG3_"&EPZAJPD
M^SRW45KNCV_(TC;0S%B %&<D]A6/X;^)NE^*]=^P:3I>M&V=7:#59K$QV=P%
MZ[)"<G\A0!V5%4M9U+^Q]&NM0^Q7E_\ 9T+_ &:QB\V:7V1<C)]J\<^&_P 5
MKZ2\U^WU'PYXRU/[3XCN1!*M@9DT^)B@6"0E_P!V4Y)0<+F@#U]]?TR/Q-'X
M?>YQJDMJ;M+?8W,0;:6W8V]3C&<^U:->1^,/$FE^%/C]I^J:Y<BWMD\-RH/E
M+-(YN!A%4<LQ[ 5T?A_XLZ+KOB&'1+K3=:T*_N5+6D6LV)M_M0')\LY.>/7%
M '<T5A>*O&.C^#K&*XUF:3?</Y=M;01&6:X?^ZB+R3^@[FL3P]\5]'UWQ%%H
M=WI>MZ!J5PK-;6^M6)MS<!1D[.2#@>N* .XHKF_%?CW0_!=YIL/B&9[6+4?.
MV7) \N+RH]YWG.>>@ !)) K T_XT>'[S6+.RO--UW2(;^01V5_J>GF"VN6/W
M0CD]^V0* /0Z**R?$>EZAK.E?8M,U>71VDD'G7,$8:7R^=RH3PK'CYL''I0!
M<AU73[C4I]/@OK:6]MU#36R3*9(@>A90<@'WJ/5]:T_0;'[9JURMO"76-206
M9W8X5%4 EF/90"37FG@7P_IWACXY^(]-TB%HH%T>U=B[EWD<NQ9V8\LQ/))K
M;^(S&P\2^#-<OL_V/INHRF^?:2L)D@=(Y6QT56/)Z#=S0!U.B^)M*\0/<QZ9
M<.T]H0+BWGMY()H<C*[HY%5P#@X)&#CBI=0UW3=*O]/LKZY$=UJ4IAM(0C,T
MK ;CPH. !R6. .YYKAM/U33[_P"+6J>+=.O(7\/V/A];:[U&-MT$DHF,G#CA
MMB9R1G[X':K?@6SN/$NL3_$#686B>]B\C1K60<VMEG(<CL\OWCZ#:/6@#OJ*
M*Q?%'BW2/!^FI>:W.R"60100Q1F26>0]$1!RQ_R: -JBN$T+XMZ-K'B&WT2]
MTK7= OKO/V2/6; VXN<#)V')SQZXK7\5^/=#\%WFFP^(9GM8M1\[9<D#RXO*
MCWG><YYZ  $DD"@#I**\\T_XT>'[S6+.RO--UW2(;^01V5_J>GF"VN6/W0CD
M]^V0*[+7M>TSPSHESJ^N7:6EC;+NDE?)QS@  <DDD  <DT 6[R[@T^QGO+M_
M+M[>-I97P3M51DG YZ"HM*U2SUO2+74],F\^SNXEF@EVE=Z,,@X(!''8BO+]
M>^,NA:CX5U6UO=*U[18KZPGCL[W5=.,-O<LT;;0CY/7MG%==\*O^21^%_P#L
M%P?^@"@#K:*HZUK6G^'=%N=6UFY2ULK5-\LK]A].I)/  Y)->;WWQ_T;3X89
M[GPEXP2VN'"6]PVEJD<Y/386D&[/84 >K45R]]X\LM+^'_\ PENJ:9JEE:CR
MP]G<VZQW,>^41#<C, .6!Z].?:J>B_%'2/$/B>/2='T[6+FWE:1(]86R/V%V
M12642YY^Z1G&">_- ':45P^O?%;1M&UJ?2+#3=:\17]K@74&AV)N3;D] YR
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M."1G( Y-=W0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[KSC'0T 9GC;Q5=Z5XBT?1?#>AV^K>([Z.9[9[F01QVL2XWNSXW8/ VKUQ[
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MU(S?8A.XCCMT11YDC/@D#!' Y//X];865OING6UC91B*VM8EAA0=%10 H_
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M:Q>W_@'QE=^&%U"8W%U:?8X[NW:4_>=4?&PGOC_"M[PEX8U;09;JYU[Q7?\
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M7R9&4$Q[F(.#VSBKGAGX6'0/'$?BJ\\17VL:BUG);74EXH)E+,I4K@XC5=I
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,EBCGA
M>&>-9(I%*NCKE6!X((/44^B@#S^?X%?#:XO3=2>%H!(3G;'/,B?]\*X7]*[?
M3M-LM(T^&PTJTAL[2%=L<$"!$0>P%6:* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"C
MK&BZ;X@TR73M;L8+ZSEQOAG0,IQT/L1Z]17'V7P.^'&GWXO+?PM;F56W 332
MRIG_ ''<K^E=]10 BJ%4*H  &  .E+110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!G/H&F2>)H_$#VV=4BM3:)<;VXB+;BNW.WJ,YQG
MWK1HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*^(/_ B#_P",U[;10!XE_P ,J>"/^@KX@_\  B#_ .,T?\,J>"/^@KX@_P#
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MX$0?_&:/^&5/!'_05\0?^!$'_P 9KVVB@#Q+_AE3P1_T%?$'_@1!_P#&:/\
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M1KB*>S:\OA*(UC(98@-F!'D#@ 'CJ* ,OPG_ ,G9>.O^P;;?^BK>O8ZYO3_
MVF:;\0M6\8P373:CJL"03QNZF)5144%1MR#A!U)[UTE !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %>)?LJ?\ )+-2_P"PU+_Z(@KVVO$OV5/^
M26:E_P!AJ7_T1!0![;1110 4444 %%%% !1110!D>&8;"#29DTFX>X@.H7KN
M[C!$K74K2KT'"R%U'L!R>IUZR/#,UA<:3,^E6S6T U"]1D<Y)E6ZE65NIX:0
M.P]F[=*UZ "BBB@ HHHH **** "BBB@#S;]H/_DA/B'_ +=O_2F*NE^''_)+
M/"G_ &!;/_T0E<U^T'_R0GQ#_P!NW_I3%72_#C_DEGA3_L"V?_HA* .DHHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "O _BO9ZC?_M'>"[71-4_L
MB^DL7$-[]G6?R3F4D[&X;(R.?6O?*XCQG\*]*\:^(K#7+G5M9TO4+"$PP3Z7
M=+"R@DG.2A(/S$<$<&@#&\<:7KND? ?Q7!XG\1_\)#=M [I=?84M=B84!-B$
M@X(8YZ_-CM7)^%HSX*?X>>+XOET[7=+MM&U4 <+(4!@E/XC:2>@'O7HMM\,+
M6/POK.A:AXE\2:O;:O&L4DFIWXGD@ S_ *LE,+G/.0<X%:4_@+1[KX=Q^"[C
M[1)ID=LELCEQYJA,;7#8QN!4'..HZ4 ?/-M_R97=_P#82'_I0E=!XO\ ^%F_
M\*!D_M7_ (1/^P/[,ML_9OM/VKROW>S[WR;ONY[=<5Z8GP<\/)\+Y/ BW6I?
MV9)-YS3>:GG[MX?KLVXR /N]/SK>UCP7IVM> 6\(W4MRFGM:QVOF1NHE"IMP
M<E2,_*.U 'B?CWQ''IG[,7@[1#="V?7+>U@DE()\N!%5I&P.2 =@('4$U2'C
MKP=I_P ??"FJ^!]36?3;BRCT>^06\D6Q1^[C)WJN1_J^G3RZ]DM?A3H5KK/A
MG43<ZA,WAFS^R6,,LJ&,C!'F. @)?D<@@?*..*O>/? &D?$70X=+UR2ZAC@N
M%N(YK1U216 (X+*PQACV]* /*=4\,VWC']H_QOH-[@1WOAA45R,^6^ZV*/\
M@P!_"L_2O$5SK_Q'^%T6K9&L:3+?Z;J*MU$T484D_P"\-K?4FO9]/\!Z9IWQ
M N_&,=S>2ZG=V*V,HED4QE%V?-@*#N/EKDYQUXJA-\*/#TOQ.B\=*]Y%J<9W
MF&.51 [^7Y>XKMSG;CH1D@'UH X3X$R1Q_$KXEVUYE=3;5"Y$GWVC\V7D>V2
M/^^EK7_:5_Y(S<_]?D'_ *%70^)OA)X?\2>(?[?CN=3T36"H5[_1[O[/+( ,
M?,<$= !G&<?2H;OX.Z!?>"+OPS>7^L3PWMREU<7LUYYMS)(N "7=2.@QC;0
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M&J_!'_0*\0?^ \'_ ,>H_P"&J_!'_0*\0?\ @/!_\>KVVB@#Q+_AJOP1_P!
MKQ!_X#P?_'J/^&J_!'_0*\0?^ \'_P >KVVB@#Q+_AJOP1_T"O$'_@/!_P#'
MJ/\ AJOP1_T"O$'_ (#P?_'J]MHH \2_X:K\$?\ 0*\0?^ \'_QZC_AJOP1_
MT"O$'_@/!_\ 'J]MHH \2_X:K\$?] KQ!_X#P?\ QZC_ (:K\$?] KQ!_P"
M\'_QZO;:* /$O^&J_!'_ $"O$'_@/!_\>H_X:K\$?] KQ!_X#P?_ !ZO;:*
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M?] KQ!_X#P?_ !ZO;:* /$O^&J_!'_0*\0?^ \'_ ,>H_P"&J_!'_0*\0?\
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MVFHZC%<0^:N&"O)<. <$C< PR 3UKWFB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% &1X9DT^729FTB&2&W&H7JNLIR3,+J43-U/!D#D>Q' Z#7K*\.78
MO=+FE6Q2Q"W]Y%Y2+@-LN9$\SH.7V[S[N>O6M6@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]O7?44 <#_PAWC__ **G>?\ @GMZ/^$.\?\ _14[S_P3V]=]10!P/_"'>/\
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M>?\ @GMZ/^$.\?\ _14[S_P3V]=]10!P/_"'>/\ _HJ=Y_X)[>C_ (0[Q_\
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MEW&KW-M'NBL;8$R3MD *, GOV!X!X-6=(N[B_P!%LKR]LVL+FXMXY9;1VW-
M[*"4)P,D$XZ#I0!PO_"!^/O^BK7G_@FMZ/\ A _'W_15KS_P36]>C44 ><_\
M('X^_P"BK7G_ ()K>C_A _'W_15KS_P36]>C44 ><_\ "!^/O^BK7G_@FMZ/
M^$#\??\ 15KS_P $UO7HU% 'G/\ P@?C[_HJUY_X)K>C_A _'W_15KS_ ,$U
MO7HU% 'G/_"!^/O^BK7G_@FMZ/\ A _'W_15KS_P36]>C44 ><_\('X^_P"B
MK7G_ ()K>C_A _'W_15KS_P36]>C44 ><_\ "!^/O^BK7G_@FMZ/^$#\??\
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MSGVKB?C!\0=*\2?L\OJ>A3N+?6KJ*S0RJ49"'WNK#GM&0<9]J /;Z*X#P/\
M$CP]JMV?#%M:ZGI<^F6"2HNJVGV;SK=0%\Q<D_+C!YQP<]CB@_Q\\)I<1R&T
MUK^R))_LZ:X; BQ9_02$Y['^&@#TZBBB@ HHHH **** ,CPS:VMGI,T5A=B[
MB;4+V5I ,;9'NI7D3_@+LR?\!K7K(\,MI[:3,=(21+?^T+T.)>OG"ZE\X_0R
M;R/;%:] %>[_ (/QJM5F[_@_&JU !1110 4444 %%%% !1110 4444 %%%%
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MK%@<GZ>E 'L-%0VEO]DLH+82RS"&-8_,F?<[X&,LW<GJ3ZU-0 4444 %%%%
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MZ25!95SN ^]7KU% 'S];^"/B'K>D^!/#VL>';72]$T&]ADO E[%*\WE_\M6
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MM]X_>SG/-=)7$_$+XL>'/AM]E37?M5Q<W0+);62*\@0<;V#,H"YXZ\G..AP
M<=\1_!NKZ]XUNKJV^&NEZVY@6*QUF;5!"(3LZS0$_O-K$XXZ 5Z%\//"G_"$
M^ -*\/M(LLMI$?.D0<-(S%WQ[;F./;%5?$7Q"7P\UD$\*>*-7%W;B<-I6F^>
ML0/\+G<,-[<UEZ#\9-,\2^&]5UG1_#GB2YCTR:."2VCL4>>5V."$17.=O!;.
M, CK0!Z'17G.B_&C3-8\:6?A9_#/B?3=3O%+HFHV*0A4 )WL#)D+\IYP:W?
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M#*=Q.,*3\P'%4K'XY>%[_6;*SBM-8CL]0N?LMGJTUB4L[B7. JR$Y//'3ZT
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MQ1W+C[TA!!"[GXX)(2@#6^!OB7Q%XO\  USK7BF]2[DGU"5;4QPK&JPJ%&
M 2-V[[V3ZT[X+:IJ.I:#XBBU6^N+Y]/\17=G#+<RM(_EKL(&6).!N-4/A9K,
M?A/X'$ZKHNK:/_PC]M(]R-3M3 9W.Z1C&"<L"6P"0.>,5<^ FCW.F?"NWO-0
M7;=ZU<RZG*,8_P!80%/XJJG\: /2J*** "BBB@"O=_P?C5:K-W_!^-5J "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *DM_]>OX_P JCJ2W_P!>OX_RH NT444
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M[[Q#J&AVMUYFHZ:L;74'EL/+#C<OS$;3D>A- '(?\([\4/\ H>],_P#!,O\
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MQ5_Z'[2__!*O_P 57HU% 'G/_"-_%7_H?M+_ /!*O_Q5'_"-_%7_ *'[2_\
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M3LXDFG@\MAL1ONG<1M.?8T <A_PCOQ0_Z'O3/_!,O_Q5'_"._%#_ *'O3/\
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MM0!S/_"._%#_ *'O3/\ P3+_ /%4?\([\4/^A[TS_P $R_\ Q5>A44 >>_\
M"._%#_H>],_\$R__ !5'_"._%#_H>],_\$R__%5WEW>6UA9RW5_<16UM"NZ2
M:9PB(/4L> *?%-'<0I-!(LL4BAD=&!5E(R"".HH X#_A'?BA_P!#WIG_ ()E
M_P#BJ/\ A'?BA_T/>F?^"9?_ (JO0J* //?^$=^*'_0]Z9_X)E_^*H_X1WXH
M?]#WIG_@F7_XJO0JCN)X[6VEN)VVQ1(7=L$X4#)/% ' _P#"._%#_H>],_\
M!,O_ ,51_P ([\4/^A[TS_P3+_\ %4S_ (7W\-?^AD_\D;G_ .-U>UGXQ^!/
M#^L7.E:OKOV>]M7V31?9)WVG&<95"#U[&@"I_P ([\4/^A[TS_P3+_\ %4?\
M([\4/^A[TS_P3+_\572>)/&_AWPA:VEQXBU);**\;9 QB=]YQD\*"0 #U/ I
MWB?QGH'@W3H+_P 2:@+.VGD$44@B>3<V"<812>@//2@#F?\ A'?BA_T/>F?^
M"9?_ (JC_A'?BA_T/>F?^"9?_BJZ7PKXTT#QK9SW7AF_^VPV\@CE;R9(]K8S
MC#J">*W: //?^$=^*'_0]Z9_X)E_^*H_X1WXH?\ 0]Z9_P""9?\ XJO0JYOQ
M1XN_X1[6/#^E6]E]MO-<O?LZ1^=Y?EQJ-TDO0YV@CCC.>HH P?\ A'?BA_T/
M>F?^"9?_ (JC_A'?BA_T/>F?^"9?_BJV+'XA:1J'BA-$AAO TUQ<6MO=M&OD
MSS0#,J*0V[*C/)4 X.":9>>/(F\)Z_KFA:=-J,6C&0 NXBCN_+&9/+<;B0N&
M&=N"5('K0!E?\([\4/\ H>],_P#!,O\ \51_PCOQ0_Z'O3/_  3+_P#%5VFB
MZM;Z[H5CJMD<V][ D\>>H# '!]^:O4 >>_\ "._%#_H>],_\$R__ !56H?#?
MQ4,0V^/M+ ]/[%7_ .*KN*NV_P#J%_'^= 'GO_"-_%7_ *'[2_\ P2K_ /%4
M?\(W\5?^A^TO_P $J_\ Q5>C44 ><_\ "-_%7_H?M+_\$J__ !5'_"-_%7_H
M?M+_ /!*O_Q5>B22)#$TDKJD:*69V. H'4D]A6#X>\=^&O%<VI1^'=6BU Z8
M5%TT*MM3=NVD,1A@=C<J3TH YG_A&_BK_P!#]I?_ ()5_P#BJ/\ A&_BK_T/
MVE_^"5?_ (JGVGQY^&U]>0VEKXCWSSR+'&OV&Y&YF. ,F/'4UJ^(?BIX)\*Z
MRNE:]X@M[6^.,PA'D,>>F\HI"<$'YL<<T 8__"-_%7_H?M+_ /!*O_Q5'_"-
M_%7_ *'[2_\ P2K_ /%5W.M:K;Z%H5]JUZ<6]C;O<28Z[44L<>_%<G'\5]!T
M[P1HWB'QG/#H#:O )X;0NUP^T\@C:FYOE*DG;QNQ0!2_X1OXJ_\ 0_:7_P""
M5?\ XJC_ (1OXJ_]#]I?_@E7_P"*K:O?BAX-T_PE:^)[G6XQH]W-Y$-U'%))
MNDPQVE54L#A&Z@=*O^$_&OA_QQI\U]X7O_MUO!+Y,C^3)'M? .,.H/0B@#EO
M^$;^*O\ T/VE_P#@E7_XJC_A&_BK_P!#]I?_ ()5_P#BJW?%/Q*\(>"KR&T\
M3:W#97$RADA\MY'VG(#$(I('!Y.!Q46I?$&SL=:\*PV\4=YI7B5WBAU**?Y8
MY-H:-=N.=_3.1@CI0!C_ /"-_%7_ *'[2_\ P2K_ /%4?\(W\5?^A^TO_P $
MJ_\ Q5>C44 ><_\ "-_%7_H?M+_\$J__ !5'_"-_%7_H?M+_ /!*O_Q5>C44
M ><_\(W\5?\ H?M+_P#!*O\ \51_PC?Q5_Z'[2__  2K_P#%5Z-10!YS_P (
MW\5?^A^TO_P2K_\ %4?\(W\5?^A^TO\ \$J__%5TWB7QYX8\(2V\7B/6(+*:
MY8+%"0SR/DX!V*"V,]\8]Z7Q7XY\-^"+:&?Q3JL5@DY(B5E9W?&,X1 6(&1D
MXXS0!S'_  C?Q5_Z'[2__!*O_P 51_PC?Q5_Z'[2_P#P2K_\56_<_$?PA:>$
MX?$UQKUJND7!VQ7(W'>W/RA0-Q;@Y7&1@\5=\+^,-!\9Z:U_X9U*._MT?RW9
M5961L9P58!A^(H Y/_A&_BK_ -#]I?\ X)5_^*H_X1OXJ_\ 0_:7_P""5?\
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MK/O,$B,592<#/3.<#@T <W_PC?Q5_P"A^TO_ ,$J_P#Q5'_"-_%7_H?M+_\
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M8VXDX^?@D<YX- 'S[XS\=^);Z+P;:_;KNVMK[0(KVXEM=7ATII[@Y#$SR#:
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M-Y6_SHI%VR1GD8R.C<XYX.: ///$OA.Q3Q2^D>'+J_9K:&ZO;_$B^7IEO/\
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MO_X4WX=\W=N^SMC=Z>8V/PQBNYJCHNE6^A:%8Z59#%O90)!'GJ0H R??BKU
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M6]E;)]V&VB6-%^BJ !0!Y9X7N;*S^+WQ<NM=V"VAAL9)_-3>/(%NY;*X.1M
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MZ),__A16O^%>C44 ><_\)K\2O^B3/_X45K_A1_PFOQ*_Z),__A16O^%>C44
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M/B'_ -%3E_\ !#;?XUZ%10!Y[_PAGQ#_ .BIR_\ @AMO\:/^$,^(?_14Y?\
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MGAW1[Z2VU*]EA\J5()KC[),UO#(^W:LDX0QH?F7AF&-PSUH YO\ X0CXC_\
M169?_"?MO\:/^$(^(_\ T5F7_P )^V_QKM!KEM_PE#:"Z2I=_8Q>1LP&R6/?
ML;:<YRIVYR!]]>N>-*@#SG_A"/B/_P!%9E_\)^V_QH_X0CXC_P#169?_  G[
M;_&O1J* /.?^$(^(_P#T5F7_ ,)^V_QH_P"$(^(__169?_"?MO\ &O1J* /.
M?^$(^(__ $5F7_PG[;_&C_A"/B/_ -%9E_\ "?MO\:]&HH \Y_X0CXC_ /16
M9?\ PG[;_&C_ (0CXC_]%9E_\)^V_P :]&HH \Y_X0CXC_\ 169?_"?MO\:/
M^$(^(_\ T5F7_P )^V_QKI+#QUHFJ7QM=/\ [2N&%P]L98](NS")%8JP,WE;
M  P()W8XZUJZQJUIH6B7NK:D_EVEE \\S 9(51DX'<\<#N: .&_X0CXC_P#1
M69?_  G[;_&C_A"/B/\ ]%9E_P#"?MO\:ZG6/&>A^'-.L;OQ'>KI9OBJPV]P
M,S,S8^78N22"P!QD#N<<UNT ><_\(1\1_P#HK,O_ (3]M_C1_P (1\1_^BLR
M_P#A/VW^-;U[\1- TY6?4%U>VB618C--H5ZL89F"J-YAV\L0 <\DBM:QURVO
M]:U/2HTECNM,:+S5D  =9%W(ZX)RIPR\X.4;CN0#B_\ A"/B/_T5F7_PG[;_
M !H_X0CXC_\ 169?_"?MO\:]&HH \Y_X0CXC_P#169?_  G[;_&C_A"/B/\
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M2&$<<?ZKR_?UYS6C67X=M'LM+FBDO5O2U]>2^:K;@H>YD<1Y]4#;,=MN*U*
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M&B21^6<\'D@@+P-HH D\ VUQ9^ =,%UJ!U6Z> 2277VUKH2L>>)6)R.V1QZ
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M5% 'GO\ PD'Q1_Z$?2O_  <#_P")J2'Q#\4Q*-O@?2B?3^V!_P#$UWU26_\
MKU_'^5 '#?\ "1?%;_H1-)_\'(_^)H_X2+XK?]")I/\ X.1_\37HU% 'G/\
MPD7Q6_Z$32?_  <C_P")H_X2+XK?]")I/_@Y'_Q->C44 ><_\)%\5O\ H1-)
M_P#!R/\ XFC_ (2+XK?]")I/_@Y'_P 37HU% 'G/_"1?%;_H1-)_\'(_^)H_
MX2+XK?\ 0B:3_P"#D?\ Q->C44 ><_\ "1?%;_H1-)_\'(_^)H_X2+XK?]")
MI/\ X.1_\37H,EW;PW$,$T\4<UP2(8V<!I"!D[1U.!R<=JEH \Y_X2+XK?\
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MD=-PYV]1T-7J //?^%=^)O\ HI>N?]^8?\*/^%=^)O\ HI>N?]^8?\*]"HH
M\]_X5WXF_P"BEZY_WYA_PH_X5WXF_P"BEZY_WYA_PK;UKQM;Z-?:Q$]JT\.C
M:4=1O)4?E22WEQ!<<E@CG)(Q@=<Y$,?C=[2QU8Z_IRVE_ICQ1_9+2X^T?:7E
M4&)(V*H2[,=F,#GOCF@#*_X5WXF_Z*7KG_?F'_"C_A7?B;_HI>N?]^8?\*Z6
M[\13Z9=:!!JMBD!U:0V\CQS[UM[CRRZIG:-P.UQNXY XYXW: //?^%=^)O\
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M $5#7O\ OQ#_ (5Z-10!YS_PK;Q1_P!%0U[_ +\0_P"%'_"MO%'_ $5#7O\
MOQ#_ (5Z-10!6TVUELM+M;6YNY+V:"%(Y+F4 /,P !<XXR>M6:** *]W_!^-
M5JLW?\'XUQ/Q(U#6[;PO]@\+6=S/JFJ2K9130QLRV@?AIG8?="C/)[D4 96E
M?%B#5_B:/"UMI4GV*1IXK?56FPEQ+"H,BJFWD Y&=W:NMO/%'A_3I)8]0US3
M;5X7$<BSW<:%'(R%()X)!!QZ5Y /ASXF\%>*? <R:M-XAT_3;YK5(K72%@^Q
M12KM>1V0L2#W9O<YYK,USP9>ZKX/\>>(;KPO<W?B#5=7-OIL4MDSRQ6X=%61
M 1E<KN^<8X4<XH ][CU?39;JYMHM0M7N+1%>YB6=2T*L,J7&<J".03U%12:L
MMSX?EU/P\L6LDPL]JEM<)LN6&<*),[1DC&>U>'>+-'U>P^*+^$O"^&D\1>';
M:RN;@-G[-'&VQY&'7'E(1[EACFO=='TJUT/1;/2]/3R[6SA6&)?]E1CGWH \
MZT3XH>,=;\17FD0?#C;+ILT45^W]N1$6^_D'[F'P 3A2?UJ?1/B9XI\2W<DG
MA_P";S2$OGM?[1.LQ1Y57VE_+9=W3G SZ9JKX$@UG2_!/C;Q%<Z;?1:KJ5_>
MWMM:/;NLS*%_=*$(W$DY X[BN0^%FEZ)X9M+2_G^''BQ?$VG6<TTE_+8S+'*
M^UAL0%\$D-L'R9[^IH ]"\?_ !8@\$:Q;:?%I4FIG:DM_*DWEI91.X1&8[3D
MDDX''2K_ (X\=WOA?6-$T?1- .O:IK#3>3;"\6WPL:AF)9@1T/?'0UY9K'PS
M\<:I\/-=UN]UIA>:X@U"]T*/24DE=E(:.$2D^8-H"@*!Q@C!YR[Q=;G7_'NC
MW?C/P1XFUG2(/#\*F"PL9BRW3X=MQ!3& 2",\$ 8H ]K\+ZEK>JZ6\_B7P__
M &!=B8HMK]M2ZW)@$/O0 #))&/;WK9K*\+VUG:>%=,@TO3KC3+-;9/)L[D$2
MP*1D(X))##/.23FM6@ KPI9-33X6M<W5A:#0M.\02WT]W#<EKM4COW=BD10*
M#D8SYA^7/!)Q7NM<NGPY\,KE3:74EN9S<FTEU&Y>V:0OO+&!I#&?F.[!7&>:
M .7\<>+]7M!KU[X:N]5F71(5>1;:UM19Q/L$A29ICYLA*D$F'&%91]X$G:-_
MJ_B?QCJ6F:?K$^B6VEV5M*OV:&&1[B2<.V7,J,-BA  % ));+= -+5_ 'AO7
M;B\EU.PDE^WJ%NXDNYHXKC PK/&KA&8 ##$9&U2""!BQJ?@W1-7NH[F[MYTG
M2#[-YMK>36[/%U\MS&ZEU]FR!D^IH \]U#6]1TSXK:YIEK<I82ZJ=-MGU=X=
MT5LWER8"J<CS'/"!OESU).%;N/'^K7WASX;ZOJ>FW!%[96N^.9T5LL,<D8QS
M]*MW7@[0+Z'5(;O3(I8M6AC@O(R6VR)&"$ &<+MSP5P0<'J!4'C3P[<>(/A[
MJ?A_39$2>YM?(A>ZD9@#Q@LWS,>G7DF@#)N-3U?PQXMTNVU;76U&TU.UNI)_
M.M8T6U>%%??&$ ;R\$C:[.WW?F)R3EZ%XIUMO&'AZ.>75Y]-UR*<A]1MK2*)
M]L?F(\"Q'S4& ?EER=K#/(S78:=X,T'2KM[BTL29&@-NHGGDF6*'_GE&KL1&
MG3Y$ 7  Q@"H--\ ^'-(U"SO;*RF%Q8*5M&FO9YA;J5*E$#N0JX)&T #IQP,
M ''6/B?Q'JFC^$4CU?[-/JVL7]I=7 MHV8Q1M<;0H(P& C7!P1D L&&0>J\'
MZEJ,FL>(]%U6]?4&TB\CCBNY(T222.2%)0&"*JY!8C(4<8K1MO"6B6::<EM9
M;%TRXEN;0>:Y\N27?O;D\Y\Q^#D#/&,"LWQ1X)M];TW4K.S6.W_MRY@;5IF=
MBTD484$(.0&*(J#H!DGDCD L?$'5;S0_AYKFIZ7-Y%Y:V;RPR;0VU@.#A@0?
MQ%9MI?:UI'CO1M-U'6'U2WUFQN)G22WCC6WEB,9_=[%!"$2$;79R,#YCR3U.
MK:59ZYI-SIFJ0^?9W49BFCW%=RGJ,J01^!ILNC6$^JV.I2P;KNPCDBMI-[#R
MUDV[QC.#G8O4'&.* .;\0,9_BQX0MI,^3%;W]TH/1I56.,?B%E?_ +ZKF]:T
M:Z\/ZI!9:?K.XQ17]Q;B*UQ)IMM,_F3S.^XAV'*1#:N6;)W!6([G7M"GU#6M
M"U6P>-+K2[IF;S20)()$*2KP#SC:P]T XZUH0Z18P7E]=1P SW^W[2[L7\P*
MNU5P2<*!GY1@9+'&220#B=*OX-4\%ZEX9N]&ATJ!="2XAABNC.K6TZ2*"S%5
MQ("C;NO)SN.372>!+R?4/AWX>O+LL9Y],MWD9NK,8URWX]?QJE>>![>S\*:M
MIGA119W6I6RVAGN;F67RH\%0%+%B BLY5!A03VR372V-G#IVGVUE:)L@MHEA
MB7^ZJ@ #\A0!/1110 4444 %%%% !1110 5);_Z]?Q_E4=26_P#KU_'^5 %V
MBBB@ HHHH *YSQYH<6O>$+ZVNKN\@MT@EDEBM9O*%POEL/+<CYBASD@$9Q@Y
M&0>CK,U[1Y=<TUK./5KW3$D!61[-82TBD$%3YL;@#GL ?>@#!\'Z7I^L?!OP
MO::Q EQ9G1[)Y(I2=CA84.''1EXY4Y![BLWX86<"ZSXIU+0(4M?"U[=0KI4$
M*[(7:-"LTT:#@([X (X;9GO6C)\.89O /_"(3>(M:;3A'' CAK=)4A10HARL
M(#(0 #N!)&03@D5MZ)H=SHP*2Z[J&I0A D<-S%;(D('3:(88^W&#D4 8,+G4
M/CC="7E-(T*,0*1]U[B9C(P^H@C'X&L.\\/Z1;?%7P]9>"K&&UU&P>2[UN\M
M_O\ V=T("7$G61Y'(8!RS?(S>]=7/HMY!\3;?7;./?:W>F/87I#*#$R/YD+X
M/7[\JG'JO;.*OA_X?OX:D8V'BO7'CENC=7,<ZV;FZ<D%O,?[/O.0,9W @8 (
MP, %GXB>&[KQ9X-FTJP2TDE>XMYO+O6*Q2+',DC(Q"MP0I'W3UK*\*II<6L:
MYX2N?!^E^'KMK6.:9-+V/!>V\FY VX1QG(82*59>.H)!K??PPY@OEA\0:U#+
M=WOVQ)EN%=K8X \N-71E\O /R,K#YB>N"*UOX<;P[!K&L6+WFNZ_=6^/.O)(
MQ)-Y:GRHEVA(XUR3T"@EB3D\T 5OA5>S7WPNT5KJ1I98(GM#(W5_)D:($^N0
M@.>]=?6)X-T$^%_!>E:,\GFRVENJS2#H\AY=A[%BQK;H **** "BBB@ HHHH
M **** "O-_$NAQ6_QH\%:O)=WES<7%W>1I'--F*W3[%)E8T& ,E023EB>^
M/2*Y76O!#ZUX@L]7?Q/K-I+82/+9Q6Z6FRW9HS&V-\#%LJS?>+=>,<4 .^)F
MJSZ)\+_$6H6C,D\5A*(G4<HS#:&'T)S^%<_<:'8W'Q \/>#M0M8KK0]-\/27
M"6,R;H994DBA5G0C:VU2V,]"V>M=GXCT-/$7A'4M#N)6VWUI);&4XR"RD!N!
MC(//2L>/PQ<ZYI6@:CJL]YH?B+3[;RWN+&2)F4L@65#N5XW1BH;E200",'-
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M.-%GNFF3<DIV,P *C 7@J %P,5I'P!H\FC:U87;75TVN%OMUW-(#-(#]T!@
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M)<6^@:'XNTN&SM1I$'B*&WCBN-RVEE'-'"S,Z(1F$.Q)CR%.X@X!->PT4 >
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M!=+?3HX\\_NMDI_#+%_RJ'PS96NG?%[Q+::?;0VMM#I.G+'#!&$1!NN. HX
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M*H+:^M+RV-Q:74,\"LRF6*0,H*DAAD<9!!!]"#0!PGVSXN_] GPG_P"!4_\
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M"I_\*/MGQ=_Z!/A/_P "I_\ "O0J* //?MGQ=_Z!/A/_ ,"I_P#"C[9\7?\
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M.?MOQC_Z!'A#_P "[C_"C[;\8_\ H$>$/_ NX_PKT:B@#SG[;\8_^@1X0_\
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M&4MKX)/B>YTIX;02JYBDEVR+:M(%\Y@5X(0[]GH,9SQ0!C?\*JN?^BA^-/\
MP9+_ /$4?\*JN?\ HH?C3_P9+_\ $5Z""& (.0>01WI: //?^%57/_10_&G_
M (,E_P#B*/\ A55S_P!%#\:?^#)?_B*]"HH \]_X55<_]%#\:?\ @R7_ .(H
M_P"%57/_ $4/QI_X,E_^(KT*B@#SW_A55S_T4/QI_P"#)?\ XBC_ (55<_\
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MIK?R+C3UAFC/F;O/AD4X<# QATD4CG[H.><4 <C_ ,*DNO\ HI'C?_P9K_\
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M90JW'AQ)+K:,;G6X*Q,WO@R 'T'MQK0>!?#]OX:?0!:W$VF,$"P7%]/-Y00
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M6.21(V \P(X?8W!^4E0"!C(R,\T +H*31>&]-CNO]>MI$LG&/F"#/ZUH444
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MIO\ T-?C#_P=/_A1_P *8TW_ *&OQA_X.G_PKT*XN(;2UEN;F18H84,DDC'
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M=>&]#OM,@TV^T73[FQML>1:S6J/%%@8&U",# )' [T >9MJ6J7.F6>GPZWJ
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MLY=MQ))8G<>N:T-6T>QURS2UU2#SX4FCG5=[+AXW#H<J0>&4''0]Z .3U2X
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MD':01C>W7/&E0!R&N?$WPYHOA:\UO[6)XK>\?3EC.8O,NU)!BW. !R#EC\H
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MIQ[>E '(?V-\5O\ H;-"_P#!8W_Q5']C?%;_ *&S0O\ P6-_\57H5% 'GO\
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M1:__ &!_97^C?:/[0U&&Q_UFWR_,S\_0YQCIQ]: .6_X4GX1_P"HM_X-)_\
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M1M(MK;Q!HEHM\EL+AKB"[A8%@4?:C9)1TY488 \B@"A_PHSP=ZZO_P"#6?\
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M+NYL/B)XSO+"/S;JW\.6\L*$9W.IN"HQWY KT*H5L[9+V2\2VA6ZE18Y)Q&
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M% !1110!XQI>L^(/#_A3Q7XRMY-)D6#6;N2^M;BTD^T7"13F/9YXD 0B-0J
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M@%RBBB@ HHHH **** *]W_!^-5JLW?\ !^-5J "BBB@ HHHH **** "BBB@
MK.UZTU._T6>VT+5%TF^?;Y=XULLXCPP)^1B <@$>V<UHT4 >>_\ ")?$G_HI
MT/\ X3T/_P 51_PB7Q)_Z*=#_P"$]#_\57H594WB;1X/%$'AV6]5=5N(3/%;
M;&RR?-SNQM!^5N"<G:>.* .2_P"$2^)/_13H?_">A_\ BJ/^$2^)/_13H?\
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M )(.-:TNH+ZR@N[219;>XC66*1>CJPR"/J#0!P?_  B7Q)_Z*=#_ .$]#_\
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MBI0_^$Y!_P#%UV-KXAL[O7WTB-9DN!9QWT;2)M66)V9<KWRI7# @$;E]:U:
M/.?^$/\ B=_T5*'_ ,)R#_XNC_A#_B=_T5*'_P )R#_XNO1J* /.?^$/^)W_
M $5*'_PG(/\ XNK.G>%?B);ZI:S:C\2(KRTCF1Y[8:##'YR!@63<&RN1D9'3
M-=[10 4444 9'AD:>-)F_L@R&W_M"]W^;U\[[5+YWX>9OQ[8K7K(\,WEM?:3
M-+96:V<:ZA>Q-&IR&=+J5'?IU=E9_P#@7>M>@#GO%G@+PUXX2U7Q3I@OUM"Q
M@!FDCV;L;ON,,YVCKZ5S7_"@?AG_ -"RO_@;<?\ QRO1J* /.?\ A0/PS_Z%
ME?\ P-N/_CE'_"@?AG_T+*_^!MQ_\<KT:B@#SG_A0/PS_P"A97_P-N/_ (Y1
M_P *!^&?_0LK_P"!MQ_\<KT:B@#SG_A0/PS_ .A97_P-N/\ XY1_PH'X9_\
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M_P#H65_\#;C_ ..4?\*!^&?_ $+*_P#@;<?_ !RO1J* /.?^% _#/_H65_\
M VX_^.4?\*!^&?\ T+*_^!MQ_P#'*]&HH \Y_P"% _#/_H65_P# VX_^.4?\
M*!^&?_0LK_X&W'_QRO1J* /.?^% _#/_ *%E?_ VX_\ CE'_  H'X9_]"RO_
M (&W'_QRO1J* /.?^% _#/\ Z%E?_ VX_P#CE'_"@?AG_P!"RO\ X&W'_P <
MKT:B@#SG_A0/PS_Z%E?_  -N/_CE'_"@?AG_ -"RO_@;<?\ QRO1J* /.?\
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M"RO_ (&W'_QRO1J* *VFZ=:Z1I5KING1>3:6D*PP1AB=B*,*,G)/ ZFK-%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@#S;_A7'C'_HJ.I?^"Z"C_A7'C'_ **CJ7_@N@KTFB@#S;_A7'C'_HJ.I?\
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M  6P?X5Z-10!YS_PK[QM_P!%4U/_ ,%L'^%'_"OO&W_15-3_ /!;!_A7HU%
M'G/_  K[QM_T534__!;!_A1_PK[QM_T534__  6P?X5Z-10!YS_PK[QM_P!%
M4U/_ ,%L'^%'_"OO&W_15-3_ /!;!_A7HU% 'G/_  K[QM_T534__!;!_A1_
MPK[QM_T534__  6P?X5Z-10!YS_PK[QM_P!%4U/_ ,%L'^%'_"OO&W_15-3_
M /!;!_A7HU% 'G/_  K[QM_T534__!;!_A1_PK[QM_T534__  6P?X5Z-10!
MYS_PK[QM_P!%4U/_ ,%L'^%'_"OO&W_15-3_ /!;!_A7HU% 'G/_  K[QM_T
M534__!;!_A1_PK[QM_T534__  6P?X5Z-10!YS_PK[QM_P!%4U/_ ,%L'^%'
M_"OO&W_15-3_ /!;!_A7HU% 'G/_  K[QM_T534__!;!_A1_PK[QM_T534__
M  6P?X5Z-10!YS_PK[QM_P!%4U/_ ,%L'^%'_"OO&W_15-3_ /!;!_A7HU%
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M%% !1110!E>&YK:?2YGLK)K*,7]XC1-_$ZW,JO)_P-@S_P# JU:** "BBB@
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MY]/5MZVDMJC1!LDY"$8SDDYQW--N?#.@WFEV^FWFB:=<6%J0;>UEM(VBA(!
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
@@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>vrna-20221231_g13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vrna-20221231_g13.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1"F17AI9@  34T *@    @ ! $[  (
M   1   (2H=I  0    !   (7)R=  $    B   0?.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %9I8W1O<FEA
M(%-T97=A<G0    !ZAP !P  " P   AN     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                          !6 &D 8P!T &\ <@!I &$ ( !3 '0 90!W
M &$ <@!T    _^$*:6AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X
M<&%C:V5T(&)E9VEN/2?ON[\G(&ED/2=7-4TP37!#96AI2'IR95-Z3E1C>FMC
M.60G/SX-"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B/CQR
M9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R
M,BUR9&8M<WEN=&%X+6YS(R(^/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70]
M(G5U:60Z9F%F-6)D9#4M8F$S9"TQ,61A+6%D,S$M9#,S9#<U,3@R9C%B(B!X
M;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B+SX\
M<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB=75I9#IF868U8F1D-2UB83-D
M+3$Q9&$M860S,2UD,S-D-S4Q.#)F,6(B('AM;&YS.F1C/2)H='1P.B\O<'5R
M;"YO<F<O9&,O96QE;65N=',O,2XQ+R(^/&1C.F-R96%T;W(^/')D9CI397$@
M>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS
M>6YT87@M;G,C(CX\<F1F.FQI/E9I8W1O<FEA(%-T97=A<G0\+W)D9CIL:3X\
M+W)D9CI397$^#0H)"0D\+V1C.F-R96%T;W(^/"]R9&8Z1&5S8W)I<'1I;VX^
M/"]R9&8Z4D1&/CPO>#IX;7!M971A/@T*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" \/WAP86-K970@96YD/2=W)S\^_]L 0P '!04&!00'!@4&" <'" H1"PH)
M"0H5#Q ,$1@5&AD8%1@7&QXG(1L=)1T7&"(N(B4H*2LL*QH@+S,O*C(G*BLJ
M_]L 0P$'" @*"0H4"PL4*AP8'"HJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ_\  $0@#'P7M P$B  (1 0,1 ?_$
M !\   $% 0$! 0$!           ! @,$!08'" D*"__$ +40  (! P,"! ,%
M!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A""-"L<$54M'P)#-B<H()
M"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T
M=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%
MQL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$!
M 0$! 0$        ! @,$!08'" D*"__$ +41  (! @0$ P0'!00$  $"=P !
M @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:
M)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#
MA(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3
MU-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P# 0 "$0,1 #\ ^D:*** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *\#^+_ ,=?$WP_\?2:'HUCI,]LMM'*'NX9
M&?+9SRLBC''I7OE?('[4( ^+D6!UTR'/O\\E %G_ (:K\;_] KP__P" \_\
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M_G0!]W5YA\;_ (E:Q\-=#TR\T*VL;B2[N6BD%Y&[  +GC:R\UZ?7A'[5R@^
MM&8@;AJ> <<@>4_^ H ZCX(?$K6/B5H>IWFNVUC;R6ERL48LXW4$%<\[F;FO
M3Z\)_91 _P"$!UDXY_M/K_VR2O<YYXK:WDGN'6.*)"[NQP%4#))_"@#Q/XS?
M'#6/ /B^TT+PS9Z?>2M;"6X^UQ2.59F(55VNO.!GO]X5D_"O]H77O&/Q!LM!
M\166E6]M>JZQR6D4BL) I902TC#!P1TZD5Y_X'\WXK?M*IJ\Z%K;[8VH.&_@
MABQY2G\1&I^M<QXTL+CX<?&F^6Q 1M-U);NT'0;"1+&/I@@'\: /NRO+/CC\
M3=<^&FG:1<Z#:6-Q]MEDCE-Y$[A=H4C&UUP3D]<]*]'T?5+?6]$LM4LFW6][
M EQ$?]EE##^=>&_M8_\ (I:!_P!?S_\ HN@"[\&OCQ?>/?$UQH?BBWT^TN9(
MO,L6LT=!(5R74[G;)Q@C&/NM7N-? MYI5_X2L_"WBS2)Y(DU"(W%M<+_ ,LY
MX92CK^!4'TPV.:^S_AOXZL_B%X+M=9M=L<_^JNX <F&8#YA]#U'L10!Y!JGQ
M^\66/Q?F\)Q66BM9KK L5E:WE\SRS*%!)\W&[!ZXQGMVKZ*KXQ\0VBG]JW[.
M&.)?$MOD^FZ9"?YU]4_$/Q6O@GP!JNOE0TEK#B%#T:5B%0?3<PS[9H Y+XI?
M'/1OAY,VF6L/]JZWM#&V1]J0 C@R-S@]]HYQUQD$^-#XS_&?Q46N?#5C<+;[
MCQI>C^>@]LLK_P ZYOX1^$F^*/Q5QX@DDNK= ]_J+LV#-\P^4G_:9AG';.*^
MUK:V@L[6.VM(8X((E"1Q1J%5%'0 #H* /$?@?XX^(GB3Q??Z9XZ\Q;>ULC+B
MYL!;RF0NH7HJ\8+=NPK8^.GQ5USX9?V%_8-KI]Q_:/VCS?ML;OM\OR\;=KK_
M 'SG.>U>MU\[_M:@?V3X8..1/< '_@,= '(_\-5^-_\ H%>'_P#P'G_^/4?\
M-5^-_P#H%>'_ /P'G_\ CU>K_LR3>;\'E3&/*OYTSGK]UO\ V:O5)(M.ENC'
M+':O.W5652QX].O2@!VG3RW6EVEQ<J$FEA1Y%4<!BH) _&K-  50%& . !VH
MH \4^,OQMUGX;>,;71]+TRQNX9[!+IGN=^X,9)%Q\I'&$'YUYL_[5?C4N?+T
MG057/ :"8D#Z^:*L?M7 ?\)]HQQR=,P3_P!M7KV[X);9?@KX=9HT&^V96POW
ML.R\^O H \C\._M7WHND3Q7X?MW@8X>;3G9&0>H1R=WTW"OHO1-:T_Q%HMKJ
MVC7*W5E=)OBE7N/0CL0>"#R"*^<?VI?"NAZ4^BZSIMM!9W]X\L4Z0H$$ZJ%(
M<@=QG&>^X9Z"N@^ ^LZAH/[.NO:O%;_:VTZZNKBV@D;:K(D,;$ CMG?^- 'O
MM%?./A?]J22[U2^?Q5IMG9Z=!9/+"EJ':::8,@1 2<<@MV'KD &LJS_:C\5Z
MEXC@M;+P[I1@N9EBBMV:0R$L0 /,W8ZG^Y0!]1T5F^(/$&F>%]#N-7UV[2TL
MK=<O(_?T '4D] !R:^=?$7[5^H-=NGA30+:.W4_)+J3,[./4HC +_P!]&@#Z
M<HKYK\+?M6S/>QP^,M#@2!VPUUII8>7[F-B<CZ-GV-?1>FZE9ZQIEOJ&F7,=
MU:7*"2&:,Y5U/>@"S17B_P 3/VB=-\%ZS-HF@V U?4;<[+B1I=D,#]TX!+,.
MX& .F<@BN+N/VA?B=IMNFI:MX*MK?2W;Y9I+"YB5@3P!(S[<^^* /IRBOD/7
M/$'B?]HSQ9;Z5H CTRVM;+S7L;B\Q%O##=)P,N?F4#Y3@#ZUZQJ.JZW\!O@7
MHL;6MKJ]Y;7!M[EO/?8OF-(X8$J"0/E7&!V]* /9**^<],_:E*^#[Z]UC3+6
M36?M(BL[&U+(ACV@EW9BW .>G7@>IJW\*OCYXH\=_$"UT'4-'TQ;:X61WFMA
M(C0JJ%LG<S \@#MUH ^@:*\/^+'Q_O/ /B^7P]I6B6]U+#%'(]Q<3-C+#.-@
M [8YW=Z\\7]JSQH)07TC03'GE1#,#CZ^;_2@#ZSHKS+X3?&C3_B89[&6S.FZ
MO;Q^:UOYF])4R 61L#H2,@],CK65\9?C-J_PSUZRT_3M'M+N.[M?/6>X=AAM
MY4KM&.@ .<_Q>W(![%17SA??M5B'PW8?8-%CNM:DAW7A<M';POD_*HR6;IGJ
M.O4]!CZ1^U?X@COD_M_0=-N+4D!A9>9$X'<C<S _3CZT ?4]%?//B_\ :ILK
M9EA\$Z2;UBH+76H91%) . BG)QT)R.1QD<UC>'OVKM5&H1IXJT*RDM&;#R:?
MOC>,>H5V8-],CZT ?3]%065Y!J-A;WME*LMM<Q++%(O1T89!'U!%3T %%>:_
M%?XS:9\,U@M%M3J6KW*>8EJ)-BQIG&]VP<9(. !S@]*\6?\ :L\9&;,>CZ$L
M6?NM#,6Q]?-_I0!]9T5PWPC\=7_Q#\$G6]4L(;&3[4\") Q*NJA?FYZ<EACG
MI7 Z?^TS'J?C.P\/6WA.17N[]+(RRWX786D";MOEG/7.,B@#W>BBO"M/_:73
M4?'-CX;C\*21O=:C'8/-)?@>66E$>[:(SG&<XR* /=:*\X^,OQ+U#X9:+I]]
MIVF07PNYVA<SNRB,A<KTZYP>_:O-[3]JL1^$VFO]%CGUYKAU2W@+1P)$ NUF
M8EB226&!Z=N,@'T?17RE;?M7>*DO UYH6CRVV>8XA+&^/]\NP_\ ':Z[7?VJ
MM'AT2V?P[HT]SJ4R9EBNFV1VS>A(Y<\=L#!'(/% 'O\ 17RKIW[5_B2.\!U?
M0=*N+;<,I:^9$^/]YF89_"OI#PQXGLO&'A.TU[0R6@NXBT:R<%6&04;'0A@0
M: -JBOFG2OVJ+^3Q-;0Z]HMI8:4'8731"2690%; 7D#.[:.1Z_A2US]J_6Y+
MUO\ A&] L(+4-A3?EY78>I",H!]N?J: /J.BOGOPI^U387%O<+XSTEK2:*(O
M%)I^76=A_!M8Y4GL22/4BN;U3]J_Q%)?$Z+H&EV]IGA;LR2R$?564#\C0!]4
M45Y'\(OCI;_$74)-&U2P73M66,RQB-RT4ZC&[&>589SCGC)SQ70_%OXD'X9>
M%K?5(M.74)KJZ%LD32F-5RC,6)P<XV@8XZ]>* .[HKY.N/VK?&#2YM=&T../
M^[)',Y_,2#^5=;X"_:>76-;MM+\8Z7!8BY<1I?6C-Y:.>!N1LD GODX[^M '
MT)17'_%'QG>> ? MQK]A8Q7S02QH\<KE0%9MN>/<C\Z\CT+]J5F\/ZQ>>(M,
MM1?0M$FG65H77SRP?>79B<!=J\@?Q <YX /HRBOG3X=_M#^*?&/Q#T[0;G1=
M+%O?3%<P"19(D"EF;)8AL*I/0=*O^*/VF;GPKXJU'0[[P3F:QN&A+?VKC> ?
ME8#R>C#!'UH ]\HJGI&I0:SHMEJ=H<P7MNEQ&?\ 9=0P_0UXMK'[2;6/CVZ\
M,:9X2_M"6*_-A%,-2V><X?9]WRCCYO<T >ZT444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'FO49/BCX$B?:WC#1"?]F^C8?F#0!U5%5-+U2QUK38=0TFZCN[.<$Q31'*N
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MT<$]_;R"X,:[?,*,N&..IPV,^@%>H_LU?\D9MO\ K\G_ /0J\]_:U=3K'AE
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<#N>PKZXTS3K;1])M--L4V6UG D$*YSA%4*!^0H \\^$GP=_X5;=:I-_;O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#I:*\?\ "GB7XQ^,/"]EKVF1^!HK6]0O&EPMXK@!BO(!(ZCU-=?X8_X67_;
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M\=7L^E>*K&VT_4F@%Y9&V1ECN8,E6(W,W((]>>>/E->N4 (JJBA4 55&  ,
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M'H.M=+/XSBN/A;?>,-(@?$.FSWD4%VA1@\:,2CCMAE(.#]#0!U%%>1>&M?\
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M?_\ !7!_\37F5QHNE:#^UKX=M=#TRSTVW?0I)&BL[=849B9P6(4 9P ,^PH
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M3\-_]<'_ /1KT =_7C#ZWI6@_M6:K=:YJ=GIMN_AM(UEO+A849C+$0H+$#.
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M?';P?:7/CGS]0NEN&LK[^R(5^Q+AB5\L'$F1QEJ]FTRQ\2>'?"6J-XA\3?\
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MGA!R$D5BK8/H<9'L17/_ &CXU72B6"R\$6*,,^1=2W4DB>Q9/E/X5G?LU?\
M)&;;_K\G_P#0J ,C3?B%\0-:^(?BSPIX?A@NI+;42D%_>1*MOIMN"0=VP NQ
M.-H.3P>V<7O$FL?$;X600>(=?\06OBS01.D>H0C3TM9;97. R%/O $@<GN..
M<BU\(O\ DHWQ._[#2_\ M2MGXZ*&^"7B,, 1Y,9Y'<2I0!V.HZW8:7X>N-;N
MYP+"WMFN7E'.8PN[(]21T'>O,M"N?B;\1M.'B+3_ !!:^#]*N27T^S&G)=RR
MQ=FD9SQGKQV[>J?$AI_^&5)&MRQD.DV.X]RI:'=_X[FO1O"0@'@K1!98%O\
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M R467.\^@SC/J*ZKX=^-K?Q_X,MM;@A^S2LS0W-L3DPS+]Y<_D1[$5U%>1?
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MU#5DND3U(CB&<^F>*Z*/PWJ=M\,[[0[O59]:U2XLKA&N[DA3++(K< =%4%L
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MI>,B]VBC0?>]-W%7O@OX4U3P9\.TT?7+?R+F.[G<+YBOE"WRME21R.<5W]%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA/6_!>J>)M-N+B:VTF/S+RV\K$\><X&TG!S@X.<<'G@UQG_#5?@C_H%>(/\
MP'@_^/4 >VT5D^%O$=IXN\+V.NZ;'/%:WL9DC2X4*X&2.0"1V[$T>)O$VE^$
M/#]QK6O3F"RM\;W5"YR2   .222!0!K45X[9_M/> KK45M9(]6M8V;'VJ>V7
MRQ[G:Y;'_ :]?@GBNK>.>VD26&5 \<B-E74C((/<$4 /HHHH **** "BBB@
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M0N$0(O".!]U0.!VKRCX]:3:Z-XI^&NF:5;F&SM9/(@C!9MJK)" N223QZG-
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M,0!\P5@Q;?N.<-G- 'MGAOXV:K?_  "UKQ?>64$NK:/*+8A5(CF9C&%D*@\
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M0!T/CGXI_$+3?C?K/A/PBHU &&**QLQ;HWE.T,<C2YQDXR_WFVC.3P*LZ_\
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M;^+5-*M-0MU=8KN!)T6088*RA@"/7!JS0 4444 %%%% !1110 4444 %%%%
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M [Y^J?!_BJQ\;>$[/Q!I45Q#:7F_RTN5"R#:[(<@$CJI[]* -NBBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBJ.M7
MUSINAWE[86$FI7-O"TD=G$P5IF SM!/<T 7J*\F_X6SXW_Z)#K/_ (%#_P"-
MT?\ "V?&_P#T2'6?_ H?_&Z /6:*\F_X6SXW_P"B0ZS_ .!0_P#C='_"V?&_
M_1(=9_\  H?_ !N@#UFBO)O^%L^-_P#HD.L_^!0_^-T?\+9\;_\ 1(=9_P#
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MO^%L^-_^B0ZS_P"!0_\ C='_  MGQO\ ]$AUG_P*'_QN@#UFBO)O^%L^-_\
MHD.L_P#@4/\ XW1_PMGQO_T2'6?_  *'_P ;H ]9HKR;_A;/C?\ Z)#K/_@4
M/_C='_"V?&__ $2'6?\ P*'_ ,;H ]9HKR;_ (6SXW_Z)#K/_@4/_C='_"V?
M&_\ T2'6?_ H?_&Z /6:*\F_X6SXW_Z)#K/_ (%#_P"-T?\ "V?&_P#T2'6?
M_ H?_&Z /6:*\F_X6SXW_P"B0ZS_ .!0_P#C='_"V?&__1(=9_\  H?_ !N@
M#UFBO)O^%L^-_P#HD.L_^!0_^-T?\+9\;_\ 1(=9_P# H?\ QN@#UFBO)O\
MA;/C?_HD.L_^!0_^-T?\+9\;_P#1(=9_\"A_\;H ]9HKR;_A;/C?_HD.L_\
M@4/_ (W1_P +9\;_ /1(=9_\"A_\;H ]9HKR;_A;/C?_ *)#K/\ X%#_ .-T
M?\+9\;_]$AUG_P "A_\ &Z /6:*\F_X6SXW_ .B0ZS_X%#_XW1_PMGQO_P!$
MAUG_ ,"A_P#&Z /6:*\F_P"%L^-_^B0ZS_X%#_XW1_PMGQO_ -$AUG_P*'_Q
MN@#UFBO)O^%L^-_^B0ZS_P"!0_\ C='_  MGQO\ ]$AUG_P*'_QN@#UFBO)O
M^%L^-_\ HD.L_P#@4/\ XW1_PMGQO_T2'6?_  *'_P ;H ]9HKR;_A;/C?\
MZ)#K/_@4/_C='_"V?&__ $2'6?\ P*'_ ,;H ]9HKR;_ (6SXW_Z)#K/_@4/
M_C='_"V?&_\ T2'6?_ H?_&Z /6:*\F_X6SXW_Z)#K/_ (%#_P"-T?\ "V?&
M_P#T2'6?_ H?_&Z /6:*\F_X6SXW_P"B0ZS_ .!0_P#C='_"V?&__1(=9_\
M H?_ !N@#UFBO)O^%L^-_P#HD.L_^!0_^-T?\+9\;_\ 1(=9_P# H?\ QN@#
MUFBO)O\ A;/C?_HD.L_^!0_^-T?\+9\;_P#1(=9_\"A_\;H ]9HKR;_A;/C?
M_HD.L_\ @4/_ (W1_P +9\;_ /1(=9_\"A_\;H ]9HKR;_A;/C?_ *)#K/\
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M_1(=9_\  H?_ !N@#UFBO)O^%L^-_P#HD.L_^!0_^-T?\+9\;_\ 1(=9_P#
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M='_"V?&__1(=9_\  H?_ !N@#UFBO)O^%L^-_P#HD.L_^!0_^-T?\+9\;_\
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M^B0ZS_X%#_XW1_PMGQO_ -$AUG_P*'_QN@#UFBO)O^%L^-_^B0ZS_P"!0_\
MC='_  MGQO\ ]$AUG_P*'_QN@#UFBO)O^%L^-_\ HD.L_P#@4/\ XW1_PMGQ
MO_T2'6?_  *'_P ;H ]9HKR;_A;/C?\ Z)#K/_@4/_C='_"V?&__ $2'6?\
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M=9_\"A_\;H ]9HKR;_A;/C?_ *)#K/\ X%#_ .-T?\+9\;_]$AUG_P "A_\
M&Z /6:*\F_X6SXW_ .B0ZS_X%#_XW1_PMGQO_P!$AUG_ ,"A_P#&Z /6:*\F
M_P"%L^-_^B0ZS_X%#_XW1_PMGQO_ -$AUG_P*'_QN@#UFBO)O^%L^-_^B0ZS
M_P"!0_\ C='_  MGQO\ ]$AUG_P*'_QN@#UFBO)O^%L^-_\ HD.L_P#@4/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MR2[AF91@,%8@J?<'U]: ,OX02I::KXBTK7;6YA\9"9+C5YYY%D6[!!$;QLH
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M^V\2>+?%,OB"_L8'@LE6R2UCA#XWL54G<Q QG/X=, %SXJ_\DC\4?]@N?_T
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MAE)!0'MP<=>O-;EU\,/#UQ\,T\$+')%IL48$4B-B5) =PES_ 'MV2>QR1TH
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M%_SU3_OH4>?%_P ]4_[Z%9'_  AGA?\ Z%O2/_ "+_XFC_A#/"__ $+>D?\
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M(9X7_P"A;TC_ , (O_B:/^$,\+_]"WI'_@!%_P#$T :_GQ?\]4_[Z%'GQ?\
M/5/^^A61_P (9X7_ .A;TC_P B_^)H_X0SPO_P!"WI'_ ( 1?_$T :_GQ?\
M/5/^^A1Y\7_/5/\ OH5D?\(9X7_Z%O2/_ "+_P")H_X0SPO_ -"WI'_@!%_\
M30!K^?%_SU3_ +Z%'GQ?\]4_[Z%9'_"&>%_^A;TC_P  (O\ XFC_ (0SPO\
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MPO\ ]"WI'_@!%_\ $T :_GQ?\]4_[Z%'GQ?\]4_[Z%9'_"&>%_\ H6](_P#
M"+_XFC_A#/"__0MZ1_X 1?\ Q- &OY\7_/5/^^A1Y\7_ #U3_OH5D?\ "&>%
M_P#H6](_\ (O_B:/^$,\+_\ 0MZ1_P" $7_Q- &OY\7_ #U3_OH4>?%_SU3_
M +Z%9'_"&>%_^A;TC_P B_\ B:/^$,\+_P#0MZ1_X 1?_$T :_GQ?\]4_P"^
MA1Y\7_/5/^^A61_PAGA?_H6](_\  "+_ .)H_P"$,\+_ /0MZ1_X 1?_ !-
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M_P# "+_XFC_A#/"__0MZ1_X 1?\ Q- &OY\7_/5/^^A1Y\7_ #U3_OH5D?\
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M -"WI'_@!%_\30!K^?%_SU3_ +Z%'GQ?\]4_[Z%9'_"&>%_^A;TC_P  (O\
MXFC_ (0SPO\ ]"WI'_@!%_\ $T :_GQ?\]4_[Z%'GQ?\]4_[Z%9'_"&>%_\
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MSPO_ -"WI'_@!%_\30!K^?%_SU3_ +Z%'GQ?\]4_[Z%9'_"&>%_^A;TC_P
M(O\ XFC_ (0SPO\ ]"WI'_@!%_\ $T :_GQ?\]4_[Z%'GQ?\]4_[Z%9'_"&>
M%_\ H6](_P# "+_XFC_A#/"__0MZ1_X 1?\ Q- &OY\7_/5/^^A1Y\7_ #U3
M_OH5D?\ "&>%_P#H6](_\ (O_B:/^$,\+_\ 0MZ1_P" $7_Q- &OY\7_ #U3
M_OH4>?%_SU3_ +Z%9'_"&>%_^A;TC_P B_\ B:/^$,\+_P#0MZ1_X 1?_$T
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MS+G'.,YKT:OG?2M&\7_$WXUZ+XOU;PA+X4T_20K/]I!$DQ1F8#YE5F))Q]T
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M)K!G0HNH3>;/:-@[E9B _/& PXP:K?&?4]4TGP/;7&A7CV=Z=5M$21790<R
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MAZS\3:AI&DC1(;FY2SDP[?O67$9.1&22,N!G"XH ]8IDTJP022N"5C4L0.N
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M!;+X'.,4 >M45XEIGQ*UVV_9ONO$*W2ZEJ\%PUA:WC(!YI,PC25@>,X;//7
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M<IH/@SQ!>>.8?%WCR]T^6^LK=[?3['3$?R+8/]]]S_,S$<=  *[ZB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .<G\)";
MXEVOB[[;@V^F/I_V7ROO;I ^_?GCIC&/QJYXD/B-=-3_ (1!-+>^\T;QJCR+
M%Y>#G!C!.[.WVQFM>B@#R_X?^%OB%X5U;41J7_",R:=J^KSZI>&WGN#-&TH&
M5C!0# *CK[UU\WP^\&7$\DUQX1T*661B[R/IL+,S$Y))*\DFNAHH \^^'/PQ
MM?"GPT'A_6;33I-0N8)[?4;NRCYN8W=R 7*AFPC@<CC'%8MKX%^).F^$V\%Z
M?KVA?V&(WMHM2EAE-[';MD;=@^3<%. <_P"->MT4 9OA[0[3PSX;L-%T[=]F
ML8%AC+G+, .I]R>3]:Q;?PK?0_%^\\5-+;FQGT>.Q6,,WFB192Y)&,;<'US[
M5UE% '&^'_!]_I7Q5\6^)KB:W:SUN.T6WC1F,B&*((V\$8'(XP3^%1^&?!>H
M:+XE\:ZA=3VSP^(+A);98V8L@"%3OR!@Y/;-=M10!Y'X)\+_ !6\#^#[+P[8
M+X.N+>S\S9+/<76]M\C.<XC ZL17K:;MB^9C=CYMO3-+10!YE\&A_9#^+?"D
MV%FT?6Y71._V>8!XF_$;JY;X96/CZ/PYJEQX.U/1GM;G5KQ3;:M'(/LKB4C?
M&R9W9ZE6&,CKUKV6+0=-@\17&NPVP34KF!;>:978>8BG*@KG:2,]<9QQG%&A
MZ!IGARQ>ST6V^S6\DSSLF]GR[G<QRQ)Y)Z=* ,GX?^#4\$>$TTI[MKZZDE>Y
MO+IUQY\SG+-CTZ#\*SM5^%VG/J+ZMX2OKGPKJSG<\^FX$,Y_Z:P'Y''/H#[U
MW%% '!^+/!>MR^-K+QEX)O;*WUB&U-C<V^HJY@NH"VX E/F4@\Y [#TY=X7\
M&:TOC2X\8^-[VQN=7:U%E:VVG*XM[2'=N(!?YF8GJ2!W[' [JB@#CK;PQKVM
M>'_$NC>/-2M[ZTU.>9++[(@1K>V8812=HRR]><\CJ:Y8^!OB3<^$5\%7NO:$
MNA>0+-]1BBE-Z]L %V;#\@8K\I.3Q[\UZU10!P'BCX;RSV_AJ[\%W<.F:MX6
M'EZ<;E2\+Q% C1R8YP5 Y'/7US3--\&^)M9\;Z=XE^(%YI9.CI(-/T_21(8D
MD<8:5WDP6.!P,8''X^A44 >;W/@SQ=X<\9:QK7P^O='>VUQUFO+#6!*%CF (
M,D;1@GGN#^?3&OX(\&7OA>UUC4-1O8=1\1:U.;F\N0A2+< 1'&HZA%!QZ\FN
MQHH \DN_#/Q6N_'.G^)W7P<MS8VLMJD0N+K8RN023^[SGBK_ ,9;F_;X0KH\
MXA&M:[-:Z<J6Y8QF=W4N$SR5PKXSCCK7IE9VH:!INJZGIVH:A;>=<Z7(TMHQ
M=@(W9=I;:#@G'3(..V* +=G:I8V%O:1?ZN")8U^BC _E7GGQ:^'.L>-#IU[X
M4O[;3M4MHY[2:6X9E62VFC*.ORJ<GT^I.<XKTFB@#F[S0=6TKP98:3X%O+2Q
MN-.2*.'[;"9(I8T7;L?'S#/!W#G(]ZP_#/@WQ$WQ$F\9^,I](CO18?8(;;2$
M?84+AB[NX#,W& ,8Q].?0** .*^,7_)'/$W_ %XM_,5R?_"&?$/Q%X%L_#%Y
MX@T@Z!=6\2S7XAD%^8, ^7M_U9./EW9Y'4=<^J:SH]CX@T:ZTK5X/M%E=H8Y
MHM[+O7TRI!'X&K-O!':VT5O NR*) B+G.% P!0!Q^M>"9[KQ-X(NM*>WAT_P
MV\HDCD9MY0PB- F 02,<Y(K$C\$>-/#OC+7]1\(7?A][37;G[3)-J<,IN+5B
M,$+LX=1U )'\\^GT4 >8Z=\)9I?A%JW@OQ#J$4LM]=SW"7L"GY2TF^-RO'.0
M"5''4 ]ZU-#L_BA'=6-OK^H^&VL;=E^T7-K%,UQ=*.Q#85">Y&?;%=U10!YL
M_@OQ?X7\6:QJOP_OM'DLM;G^U76G:NLJK%.1\SH\8)^8\D$5K:CX>\4:[\--
M=T;7M0TV?5M3AFBA:VB>*W@#(%5,G<Q .3N///3BNSHH \DN/ /Q'N/!R^"W
M\1:,VB/ MM)J#0R?;5@Q@Q!1\C<?+N)!(ZC-;GBCX;S7%MX9NO!M]'IFK>%E
M\O3WN4+Q21% C1R <X*@#(YZ^M=_10!YS#X,\6>)?%.D:M\0KW1TM=%F-S::
M?I"R,DD^/EDD>0 _+U  _&O1J** "BBB@ HHHH **** "BBB@ HHHH ****
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M\)OX:_Z#-M_WT:/^$W\-?]!FV_[Z- &]16#_ ,)OX:_Z#-M_WT:/^$W\-?\
M09MO^^C0!O45@_\ ";^&O^@S;?\ ?1H_X3?PU_T&;;_OHT ;U%8/_";^&O\
MH,VW_?1H_P"$W\-?]!FV_P"^C0!O45@_\)OX:_Z#-M_WT:/^$W\-?]!FV_[Z
M- &]16#_ ,)OX:_Z#-M_WT:/^$W\-?\ 09MO^^C0!O45@_\ ";^&O^@S;?\
M?1H_X3?PU_T&;;_OHT ;U%8/_";^&O\ H,VW_?1H_P"$W\-?]!FV_P"^C0!O
M45@_\)OX:_Z#-M_WT:/^$W\-?]!FV_[Z- &]16#_ ,)OX:_Z#-M_WT:/^$W\
M-?\ 09MO^^C0!O45@_\ ";^&O^@S;?\ ?1H_X3?PU_T&;;_OHT ;U%8/_";^
M&O\ H,VW_?1H_P"$W\-?]!FV_P"^C0!O45@_\)OX:_Z#-M_WT:/^$W\-?]!F
MV_[Z- &]16#_ ,)OX:_Z#-M_WT:/^$W\-?\ 09MO^^C0!O45@_\ ";^&O^@S
M;?\ ?1H_X3?PU_T&;;_OHT ;U%8/_";^&O\ H,VW_?1H_P"$W\-?]!FV_P"^
MC0!O45@_\)OX:_Z#-M_WT:/^$W\-?]!FV_[Z- &]16#_ ,)OX:_Z#-M_WT:/
M^$W\-?\ 09MO^^C0!O45@_\ ";^&O^@S;?\ ?1H_X3?PU_T&;;_OHT ;U%8/
M_";^&O\ H,VW_?1H_P"$W\-?]!FV_P"^C0!O45@_\)OX:_Z#-M_WT:/^$W\-
M?]!FV_[Z- &]16#_ ,)OX:_Z#-M_WT:/^$W\-?\ 09MO^^C0!O45@_\ ";^&
MO^@S;?\ ?1H_X3?PU_T&;;_OHT ;U%8/_";^&O\ H,VW_?1H_P"$W\-?]!FV
M_P"^C0!O45@_\)OX:_Z#-M_WT:/^$W\-?]!FV_[Z- &]16#_ ,)OX:_Z#-M_
MWT:/^$W\-?\ 09MO^^C0!O45@_\ ";^&O^@S;?\ ?1H_X3?PU_T&;;_OHT ;
MU%8/_";^&O\ H,VW_?1H_P"$W\-?]!FV_P"^C0!O45@_\)OX:_Z#-M_WT:/^
M$W\-?]!FV_[Z- &]16#_ ,)OX:_Z#-M_WT:/^$W\-?\ 09MO^^C0!O45@_\
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M\)OX:_Z#-M_WT:/^$W\-?]!FV_[Z- &]16#_ ,)OX:_Z#-M_WT:/^$W\-?\
M09MO^^C0!O45@_\ ";^&O^@S;?\ ?1H_X3?PU_T&;;_OHT ;U%8/_";^&O\
MH,VW_?1H_P"$W\-?]!FV_P"^C0!O45@_\)OX:_Z#-M_WT:/^$W\-?]!FV_[Z
M- &]16#_ ,)OX:_Z#-M_WT:/^$W\-?\ 09MO^^C0!O45@_\ ";^&O^@S;?\
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M  PULZ+&EZ7S."#DC=&G3'OUH [*BBB@ HHHH ***AO)&AL9Y4^\D;,,^H%
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M5^#-,UVZTXZ:]_#YPMC+YNQ"3M.[ SE<-T'6@#<HHHH **** "BBB@ HHHH
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MP>#R.] &I17/> -4O-;^'>@ZIJ<OG7EW8133R;0N]RH).  !SZ"NAH ****
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M^7GMNP,_D*YNZ^(^IZAK5_I_@3PG-XB7393!=WCWJ6D"RC[T:LP.]AQG XH
M[ZBN,\5:MXF/PHO-:TNU?1=<MK<W1LY?+GV^6VYXR1E6#*K $<\C&#71Z!K-
MOXA\.:?K%G_J+ZV2= >H#*#@^XSB@#0HHHH **** "BBN+^*?B#4_#?A6TO-
M&N?L\\FIVL#-Y:OF-Y &&&!'([]: .THHHH **** "BBN)^#OB'4_%7PGT;6
M=>N?M5_<^?YLWEJF[;/(@^50 /E4#@4 =M1110 4444 %%%% !1110 4444
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M9KOA1_%DOC#P_!9$G56RZI(0NW:Y+<\L,;B#M)'2@#@?A=\+$\=_"G6]3O\
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M/&WBCQ"+_P __A('MV^S^3M\CRD9?O;CNSNST&/>@#F/V??^28/_ -A.Z_\
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MYSLCC7(7)ZG)/YG( GQ>,@^#WB?RMV[^SY,[?3O^F:=I_P!F/P.M=WE_9?\
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M^5M\G"!=N<G=TSG H X3P59_$/X<^'U\)6_A.UUNSLY9?L6J+JD=NAC=V?\
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MF0QRQ2H&212,%6!X((."#1;V\-I:Q6UI#'!!"@CBBB4*J*!@* .  .,"I**
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M* ,'_A*3_P! '6O_  $_^RH_X2D_] '6O_ 3_P"RK>HH P?^$I/_ $ =:_\
M 3_[*C_A*3_T =:_\!/_ +*MZB@#!_X2D_\ 0!UK_P !/_LJ/^$I/_0!UK_P
M$_\ LJWJ* ,'_A*3_P! '6O_  $_^RH_X2D_] '6O_ 3_P"RK>HH P?^$I/_
M $ =:_\  3_[*C_A*3_T =:_\!/_ +*MZB@#!_X2D_\ 0!UK_P !/_LJ/^$I
M/_0!UK_P$_\ LJWJ* ,'_A*3_P! '6O_  $_^RH_X2D_] '6O_ 3_P"RK>HH
M P?^$I/_ $ =:_\  3_[*C_A*3_T =:_\!/_ +*MZB@#!_X2D_\ 0!UK_P !
M/_LJ/^$I/_0!UK_P$_\ LJWJ* ,'_A*3_P! '6O_  $_^RH_X2D_] '6O_ 3
M_P"RK>HH P?^$I/_ $ =:_\  3_[*C_A*3_T =:_\!/_ +*MZB@#!_X2D_\
M0!UK_P !/_LJ/^$I/_0!UK_P$_\ LJWJ* ,'_A*3_P! '6O_  $_^RH_X2D_
M] '6O_ 3_P"RK>HH P?^$I/_ $ =:_\  3_[*C_A*3_T =:_\!/_ +*MZB@#
M!_X2D_\ 0!UK_P !/_LJ/^$I/_0!UK_P$_\ LJWJ* ,'_A*3_P! '6O_  $_
M^RH_X2D_] '6O_ 3_P"RK>HH P?^$I/_ $ =:_\  3_[*C_A*3_T =:_\!/_
M +*MZB@#!_X2D_\ 0!UK_P !/_LJ/^$I/_0!UK_P$_\ LJWJ* ,'_A*3_P!
M'6O_  $_^RH_X2D_] '6O_ 3_P"RK>HH P?^$I/_ $ =:_\  3_[*C_A*3_T
M =:_\!/_ +*MZB@#!_X2D_\ 0!UK_P !/_LJ/^$I/_0!UK_P$_\ LJWJ* ,'
M_A*3_P! '6O_  $_^RH_X2D_] '6O_ 3_P"RK>HH P?^$I/_ $ =:_\  3_[
M*C_A*3_T =:_\!/_ +*MZB@#!_X2D_\ 0!UK_P !/_LJ/^$I/_0!UK_P$_\
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M* ,'_A*3_P! '6O_  $_^RH_X2D_] '6O_ 3_P"RK>HH P?^$I/_ $ =:_\
M 3_[*C_A*3_T =:_\!/_ +*MZB@#!_X2D_\ 0!UK_P !/_LJ/^$I/_0!UK_P
M$_\ LJWJ* ,'_A*3_P! '6O_  $_^RH_X2D_] '6O_ 3_P"RK>HH P?^$I/_
M $ =:_\  3_[*C_A*3_T =:_\!/_ +*MZB@#!_X2D_\ 0!UK_P !/_LJ/^$I
M/_0!UK_P$_\ LJWJ* ,'_A*3_P! '6O_  $_^RH_X2D_] '6O_ 3_P"RK>HH
M P?^$I/_ $ =:_\  3_[*C_A*3_T =:_\!/_ +*MZB@#!_X2D_\ 0!UK_P !
M/_LJ/^$I/_0!UK_P$_\ LJWJ* ,'_A*3_P! '6O_  $_^RH_X2D_] '6O_ 3
M_P"RK>HH P?^$I/_ $ =:_\  3_[*C_A*3_T =:_\!/_ +*MZB@#!_X2D_\
M0!UK_P !/_LJ/^$I/_0!UK_P$_\ LJWJ* ,'_A*3_P! '6O_  $_^RH_X2D_
M] '6O_ 3_P"RK>HH P?^$I/_ $ =:_\  3_[*C_A*3_T =:_\!/_ +*MZB@#
M!_X2D_\ 0!UK_P !/_LJ/^$I/_0!UK_P$_\ LJWJ* ,'_A*3_P! '6O_  $_
M^RH_X2D_] '6O_ 3_P"RK>HH P?^$I/_ $ =:_\  3_[*C_A*3_T =:_\!/_
M +*MZB@#!_X2D_\ 0!UK_P !/_LJ/^$I/_0!UK_P$_\ LJWJ* ,'_A*3_P!
M'6O_  $_^RH_X2D_] '6O_ 3_P"RK>HH P?^$I/_ $ =:_\  3_[*C_A*3_T
M =:_\!/_ +*MZB@#!_X2D_\ 0!UK_P !/_LJ/^$I/_0!UK_P$_\ LJWJ* ,'
M_A*3_P! '6O_  $_^RH_X2D_] '6O_ 3_P"RK>HH P?^$I/_ $ =:_\  3_[
M*C_A*3_T =:_\!/_ +*MZB@#!_X2D_\ 0!UK_P !/_LJ/^$I/_0!UK_P$_\
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M.,\CIW%:/[.=Y)=?!33$E)/V>:>)23GCS"P_]"Q^% 'J5%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7)^./B5X<^'UFLNNW+M<2*
M6BLK91)/(!U(7(  ]20/>F7WQ"BL=??2CX7\4SLDPB^U6^D.]N<X^82="O/6
MLSXO:/IT7PT\6:M'90#4)].\N2ZV#S&12,+NZX]J .\L[I+ZQ@NX@PCGC610
MPY 89&??FH=7U:QT+2+G5-6N4M;*U0R33.>%']3V ZD\5%X>_P"19TO_ *\X
MO_0!7 _'P[_ >GVC_-!>:W9P3QGI(A<DJ?;*C\J +MI\9]"ENK%=0TG7M(LM
M1D$=GJ6HV'E6T['[N'W$C/4%@..:]"KSOX\6T,WP1U\2*,11Q/'CC:PF3&/Y
M5V^C2R3Z#82W!+2R6T;.3U+%03^M %VBO.OACJE_J'BKQ]#?WMQ<Q6FN-%;I
M-*SB%,?=4$_*/8<5C^$M<U6Z\-_%:6YU*[EDL-7U*.T=YV)MT1#L5#GY0,<
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MXDM\MY6HR,K/(FXX#,O#,OW2>"<<\UR'CN0W/QR^&NG29\C??W) /5T@RI_
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MWOD@*/J:M^$/&^D>-;2YDTK[1#<64ODWEE>1&*>V?^ZZ=NAZ9'!]#7)?#?\
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M";0?"^EW5C%>Z;);O+)<.ZQL(X'C.TJI/5@1D#BK'Q7^&NK>.]'\.V>E75G
MVF72RSM<LX#*% .W:IR>.AQ]:],HH ^</B9I>IZU^U3HECH.JMI&HOI>ZWO%
M7=Y;*D[\CN#MVGV)X/2NO\#?"3Q+;?$;_A-OB/K]MK&JP1&.V6V4[%RI7=]U
M0,*6^4+C)SG->B7'@S0+KQG:^+)]/#:W:1&&&[\UQL0A@1M#;3P[#)&>:W*
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M <>U<%>>"/B-XB\.Q>%/$VMZ&FB82*ZO;&.7[9=1(1\I#?(A; R1G^8/J]%
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M)Y'4''\L>CT4 >=^&/AUJ-M8^,+3Q??VVHCQ-)NDEM4,> T6QQM(^7!SCD\
M$G-5O#_ASXH>'M)L_#UOK'AN72[(+!#J$D$QNA N J^7]S(48SN/X]:]-HH
M\\U?P5XFTKQY?^*_A_?Z8DNK11QZCI^JI((96C&%D5X\D,!D8QCD^O'0Z%9^
M*GTZ_P#^$NO-,EN+A=L$&G1.L4 P1RSG<Q.1S@=.E=%10!X_X>\!_$_PIX(A
M\,Z/K^@RVSPE&GN8Y?-L2V=XA*@"09)(W $$]P*V+_X16Y^%^B^&-'U%K.^T
M*>.\L-0*9VW*L6+E?0LS'';(ZXKTBB@#S#4/!?CGQO\ 8M.\?W^@P:);W"7%
MQ!I"2M)?%#D(YDP$7."0,UZ?110 4444 %%%% !1110 4444 %%%% !1110
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M5#;'.6+;2"#A5;J,9Q6)^SZWBB#P[JVF^*+;5X;:SN@-.?5[=XI6B(/&&[#
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MOE0SW&XINP3SOC3T/3-<E\#9(A\1OB-)<HDGB<7$A@2XP&8>9)O [XW[-W_
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MQ_:2_P!_!WG_ -#W9_#VI/VA!%)\4/AY'IX5M5^U?,(_]9M\Z+RO_'O,Q^-
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MDBNX;[3Q.[QEHHPRR@,3ALD<^@/J<@'LE4=;UFR\/:'>:OJLODV=G$997QG
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ML0%P 3@9/%.\%))X?U;XE>"K:XGN-(T>&.:P6:4R&W6:!F:,,><#C ]CW)-
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M\ 67B+Q9)=ZEK^KP_:GU/[4ZR6[,25$8!VJ%X&,8X].* /9J*X#X)Z[J&O\
MPOLYM8N6N[JVFFM6N7.6F6-R%8GN<8&><XS7?T %%%% !1110 4444 %%%%
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M;PKH?BK2["\T36/"OB]K=EEBNYY'BU0A/G8/N9),'+#H01Z#% 'M=%8OC/\
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M0S$-G.<U[C0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5GZ]H>G^)=!N]'UFW%Q97D>R6,G&1G((/8@@$'L0*T**
M /#(_P!G'4+"-['1?B3K5AHTA.^P56PP/4$K(JG/^Y2_#+PQXM^$_C)_#$NA
MPZKX>U:X+C6[=2'BPAVB4<X'&,' RQPQZ5[E10!XG!^S;:6FKW:V?B[5K7P[
M>2;Y]&MR4$@S]QG#89>W*9QW[UJV/P(T^+X1S>!K_6)KE7O3>QWL< C:.3@#
MY"S C P>><GI7J]% 'AH_9RO+B?3;G6?B!J6J7&G7$<D!NH&>-(E.3&JM*2N
M2%Y!P,=#V[C4/AJM]\9]+\?_ -JF,V%JUO\ 8?L^?,RDB[O,W<?ZS.-IZ>]=
MU10!PWA/X;+X6^(7B7Q0NJ&Z_MU]_P!F-OL\CYBQ^;<=W7T%8/A/X'MX.\>-
MK>D^+-032FG>=M'"%8W)#!0[!\,%W<97/ YKU>B@#YH^-/A73_%'[1'AO1[(
MM]KU**(:DJ< 1*S'=G^]Y:M^"K7TK'&D4:QQJ%1 %50. !VJE_86D_VU_;']
MEV7]J;=GV[[.GG[<8QYF-V,<8S5^@#SKXC_""R\?:I9ZS:ZO=Z'K=G'Y<5]:
MC/RY)&0"#D$G!##J>O&*O@3X*V_A7Q0?$VO^(+[Q-K:H4BNKP$",$8SAF9BV
M"1DMT)XKT^B@#A=$^&@T?XP:WXZ_M7SO[5M?L_V+[/M\K_5<[]QW?ZKIM'7V
MKMIXA/;20DX$B%21VR,5)10!X'I7[.'B'08'@T+XJ:GID,C[WCL[62)6;&,D
M+. 3@#FNYLOA8]M\4-,\9W&O274UEIJ64D,EO\T[",H93(7)!.<XP>>]>AT4
M <-X;^&P\/\ Q0\0>,?[5^T?VRFS[)]GV^3RI^_N.[[OH.M<YXG^!']H^+;S
MQ%X0\7:EX5O;]S)=BT!*R,>6(VNA&3R<D\DUZY10!R?P^\#?\()I%U:RZS>Z
MS=7EQ]HN+N\.69MH7CDG&%'4FN&_:8TJXF\ :?KMBN9M%U!)BV/NHWRY_P"^
M_+KV6H;NSMM0LY;2_MXKJVF4I+#,@='4]05/!'UH \]\5^"E^*VDZ!XAT/Q-
M?Z!<QVIEMKFR).4E",00&4Y&T="*J^"O@E!X=\51^)O$GB/4/$^LP*5@N+S(
M$>01G#,Q) )QEL#)XKTRSL[73[.*TT^VAM;:%=L<,$81$'H%' %34 >7^.?@
M;I7BSQ"?$6D:K>>'=<;E[NSY#MC 8J"I#>X89[^M4/"_P'ETKQK8^*/$OC34
M_$5_8',#7"$= < EW<D#<3@$5Z_10!P-I\+UM?C9>_$'^UBQN[<0_8/L^-A$
M21Y\S=S]S.-O?K4<'PK%A\99/'FDZRUHEU$4O=.%MN6X)7!._<-N2$;&T\K[
MUZ%10!Y%XI^ =KJ?BJX\1>$O$M_X5U"Z8O.UF"59B<L1M9&&3R1G&>U<AJ7P
M=\8> _$UAXV\/WI\<:C:DM=0Z@I$SG!&Y,N2>#QR2#R,]!]&44 4=$OI]3T#
M3[^\LY+"XNK6.:6TESO@9E#&-L@'*DX.0.G2N/\ 'WPO7QSXJ\-:RVK&Q_L*
M?SO)%OYGG_.C8W;AM^YC.#UKOJ* ,#QKX.TSQWX6N-"UGS!!,0ZR1$!XG4Y#
M*3D9_H37EEM^S:\\EI:^)/'>KZOHEFP,.F,K(J =%!,C!1CCY5!QTQ7N5% '
M!?$OX567Q#T33;**_DT>?2Y-UG/!%O$8P!MVY']U<8(QBL76_@>WB#P9HNF:
MCXNU*;6M'FDG@UN0%Y"TC!CE2^>-JX^?(VCFO5Z* /(/#GP(GT7QUI'BK4O&
M=_K5_8ES,U[$7,X*%5 8N2@&XGG=GVKIO#GPV7P_\4?$'C%=4,_]LQ[/LAM]
MOD\J2=^X[ON^@ZUW-% '+?$#P0GCSP_#IQU2[TJ:WN5NH+JT.'1U5E]N,.>A
M':N%T?\ 9_/]OV6I^-_&>J>*_L#B2V@NMP12"#@[I')&0#@8SCFO8Z* /+O'
MOP4A\6>+%\3Z%XAO?#6ME DMU:J6\S V@\,K [<+D-T XJ:+X*:;/\-[KPIK
M^L:AJSW5Y]O?49F_?+/M50RYW<87&"3U//->ET4 >'V?[.#3W-I%XK\<ZMKN
MDV3!H-.=61% Z+DR, ,<': <=,5VWBKX9Q^)?'GACQ)'J7V)= <$6BVVX3 ,
M& #;ALZ8Z&NZHH Y3XA_#W2OB/X=72]6>6!X9/.M[F'&^)\8SSP00>1_(X-<
M;X<^".J:9X@T_4-?^(>LZY;Z=.L]O92[UC#*<KG=(XQP.@%>NT4 >&>.$_X2
M[]J+PCHEN-\6@0C4+EE_Y9L#Y@!_[YA_[[KW.J4&C:7:ZK<:G;:;:0ZA<J%G
MNXX%664#& S@98<#J>PJ[0 4444 %%%% !1110 4444 %%%% !1110 4444
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M6R-]XJBD_,>03GH3[8Z]],L)+VWO'LK=KJU1DMYS$I>%6X8*V,J#@9 ZU:H
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M71-7D>%/6VG_ 'D3?C\U>F576PLTU"2_2T@6\DC$3W(C D= <A2W4@$GCWH
MQ/!'A/\ X0W0IM.^V_;/-O9[KS/*\O'F.6VXR>F<9SS6%X-^$UEX*^(&L^(M
M+OV-KJ41CCTXPX%MEP[;7W<KNS@;1C/>O0** //)_A_XQ,4UC:_$R_33)B5,
M<VGQ2W*(>JK<$@YQQD@D54\>:=8?#_X"W?AWP_"Q$\ TNSA)R\\MPVP\\98[
MV8_C7IU5[O3[._:!KZT@N3;2B> S1!_*D&0'7(^5AD\CGF@"IX:TA?#_ (5T
MO1XR"MA:16^1WV(%S^.,UA_$CP$OQ \/V]E'J+Z5>V=TEU:WT<7F-$P!!XW+
MG()[^A[5U]% '.6GA"/3?A[;>%M)U"YT\6UJD$5[;86567!\STR6!)'0Y(K%
MTOX>:L_BO3-=\8^+IM?ET@2?8(4L8[5(V==K.^TG><?0>U=[10!B^,_^1#U_
M_L&W/_HIJ\K\%_#?6]:^$^CV5KXYO[+0M4T^-KO3S:QRN ZY=(YCRBG)XP>I
M[&O:YH8KFWD@N(TEAE4I)'(H974C!!!Z@CM3;6UM[&TBM;*"*VMX4"10PH$2
M-1P %'  ]!0!RFM_#RSU'1O"NEZ;<?V?:>&]4M;^%/+\SS%@# 1YW#&=WWN?
MH<U4UOX>ZI-XUN/$WA/Q5+H-Y?0)!>HUBETDRI]T@,1M8#OS].N>[HH XKPM
M\-X= M?$=MJ>J3ZY%X@DWW)NXP';,>QP2#@YY/ & 0.V:S-(^&GB;0[2#2=.
M^(E]'H-NP$-J=/B-PD8.1'YYYQV^[^G%>D44 <-K_P .[NZ\72^*/"7B.?P[
MJUS"L%XPMDN8;E5^Z6C8CY@.,YZ#ZYV- \/:MI]A?)KWB6XUNZO!CS9+=(8X
M1@C"1IT'/.22<#FNAHH \GTOX-ZYH/A=?#VA_$&^M-,FB*7<)L4DW$\.869L
MP[AVRV"2172:E\+="O\ X=V/A&%I[.WTTI)974+8F@F0DB4'^\26)_WCTKM*
M* /.A\,M9UB\L?\ A.O&<_B#3]/G6XAL4L([1))%^Z92I)?'7' KT6BB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H[BWAN[:2WNHEEAE4H\
M;C(8'J"*DHH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
M0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#
M'_0!L/\ OP*/^$'\,?\ 0!L/^_ K>HH P?\ A!_#'_0!L/\ OP*/^$'\,?\
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MJ.E87C?XA:3X!_LO^V+>^G_M.Y^S0_9(@^UN.6RPXY[9/M0!U5%%% !1110
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MNWO[.*[LIX[BWF0/%+$P974C(((ZBJ7B#Q)H_A72FU+Q#J$-A:*=OF2GJ?0
M<L>#P 30!IT5SGAGX@>%_&$\T'A[5H[JX@&Z2!XWBD4>NQU5L<CG&.:SM5^+
MO@G1=9NM*U'5Y$O;-PD\<=A<2A&P#C<D9'0^M ':45G:'K^F^(]%BU;2)VFL
M9=VR62)XL[25/RN 1R#U%<W#\8O -QJRZ;%XDMC.\OE*YCD$+/Z"8KY9_P"^
MJ .UHK&\2>+]!\(6D=SXCU.&Q29BL2MEGE(ZA$4%FZCH#U%0^%_'/AOQG'.W
MAK58[UK<XFCV-')'R1\R. PZ'G':@#?HKG/#WBY=:\3>(="N+/['>Z)<(A7S
M=XFAD7='*.!C/.1SC'4UT= !1110 445S'CSQD/!&CV5\UB;W[5J$-D$$OE[
M?,)&[.#G&.G?U% '3T444 %%%5[K4;*QDMX[Z\M[9[J40P+-*J&9SR$4$_,W
M!X'- %BBL;Q+XJTOPG:V=QK,DB1WMY'90^7$7)E?.T$#H.#S6S0 4444 %%%
M8VO>*M,\.7>E6VJ22I)JUXME:B.(OND;H#CH/<T ;-%%% !1110 4457N=1L
MK.XMX+R\@@FNG\NWCEE56F;&=J@GYCCG H L4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%8/BOQMX>\$6,-YXIU)+"&>3RXB8W
MD9VQGA4!/3OC'3UH WJ*SM7\0:3H.C-JNLZA!96*@'SYFV@YZ =R3Z#FL?PW
M\2_"/BW4GT_0-9CN+Q%WFWDADA<KZA9%4L/IF@#J:*X_7?B5I.@ZE?6DMEJ5
MY'I:1OJ5U:0*\5BKC*F0E@?N_,0H8@<D5K^(?%6F^&O#IUF]>2:!BBP1VR[Y
M+EW(")&N1N9B>!^/ YH V:*9$YDA1VC:(LH)1\;E]C@D9'L36!XQ\6#PK:Z<
M(;,W]]J=_%8VEJ)?+WNYY8M@X55!)..WO0!T5%%% !113)98X(7FGD6.*-2S
MN[850.223T% #Z*XO3OB]X$U76(M,L?$4#W,TGEQ;HI$CE;.,+(RA&.?0G-=
MI0 45SGB;X@>%_!\\,'B'5H[6XG&Z.!(WED8>NQ%9L<'G&.*T/#_ (DT?Q5I
M2ZEX>U"&_M&.WS(CT/H0>5/(X(!H TZ*XJ;XQ> ;?5FTV7Q);"=)?*9Q'(85
M?T,P7RQ_WU72:SK^D^'M)?4];U"WLK),9FF?"DGH!ZD]@.30!HT5S'AGXC^$
M_&%])9>']82YNXEWM;R120R;>/F"R*I(Y'(]:D\3?$#POX/GA@\0ZM':W$XW
M1P)&\LC#UV(K-C@\XQQ0!T=%8NE^*=.\1^&Y=7\)W,&KQA&\I8Y-F^0#(1LC
M*$\=1D9Z4SP7XIM_&G@^PUZTB,"W<9+P,VXPR*2KH3@9PP(S@9ZXH W:***
M"BBB@ HKF+OQD+7XG:?X/^PES>:?)>_:_-QLVMMV[,<YQUR/I73T %%%% !1
M5==1LFU)].6\MS?)$)GM1*OFJA. Y7.0N>,]*SO^$JTO_A-/^$6\R3^U/L?V
MW9Y3;/*W;?O=,Y[4 ;-%%% !1110 45C1>*M,F\9S^%HY)3JD%F+UT,1V",L
M%SNZ9R1Q_@:V: "BBB@ HHHH **KIJ-E+J$MA'>0/>0HLDMLLJF2-6Z,5SD
MXX)JQ0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MSQ%H/BJUU92([W2)HY/L[X)"DQJO<8(*]\@\5H?$/X;^,O'6@^&?$,UKI?\
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M"A%4KS@L23SQ6WX:\.^(M8^)$GCCQA8P:0T%B;#3]+BN!.\:EMS22.ORDGH
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M\1C!AU;7YQ;N,?/#%\BMGTZ_E0!J?%KQ)J_A7P9#J/AYA]L_M&VB$9"XE5G
M*98$#=TSU&:J7^K^)/AUX"USQ/XSUJ'79HH8Y(;."S6WBMY6;;Y:N,LR%G09
M;D!<]\5?^*?A_4_$GA6TL]&MOM$\>IVL[+YBIB-) 6.6(' [=:TO'_A5?&W@
M/5?#S2B%KV(".0YPLBL'0G';<HS[4 >)WGQCO])TI-<A^)>EZW>J4DF\/KI!
MBB8$C<D<V-X(!."QYQ^%>C^*O%6NZKXUT7P=X-O8M)N+^P.IW>HS6XF>"#.U
M0D;<%BP(.>E)INN?%&WTV#2Y_ ]@]Y"BQ-J;:N@MGP -_E@&0>NW'X]J?XS\
M.^(;/XC:5XY\):?%J\]O8OIU[I\EPL#20EMZE';Y00Q).?0#Z ',Z=:>(K']
MI31[7Q1J5OJLD>B3_9[V* 0M+&7/^L0?*&!R/EX(Q78?#SQ)JNN^)/&MKJES
MY\.EZPUM:+Y:KY<8'W<@ GZG)K&TG0_&NJ?&;3?%WB/1[73;&/39K5;>&Z69
MK?)RHD;C<S$L?E!4 #G-+#I?C3P7X]\2W7A[PY;:[I>OSI=QR?;DMC:R[=K"
M0,,L">?E!/'J>  \/?$348/#_P 1M8UV7[9%X=UB\@M(A&J8BC^Y'E1SSQN.
M3S5KP[IWQ+U.RTO7[[Q?9P_:Q'<3:-_92"&.)L$QB3/F;@IZDGG\ZS/"7PXU
MV7P5X\T7Q:(;:Z\1:C<7"3V[!HV,B*=ZC)(4/GAL' K2\-ZE\3--TW3="O\
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M^5G'VK[*OE_7&_=_X[7>^,/B'X;\#:3#J'B&^\I+D?Z/$B%I)^ 3M7VR,DX
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M036U["8Y+:8#[LB9R/P/KSQ4'PZ\63>,?!\5_J$$=MJ4$TEI?V\>=L,\;;6
MR20.A )/!% '4T444 %%%% !17':OXOOK#XM>'_"T,-NUEJ=G<3S2,K>8K1C
M*A3G ''.0?PKL: "BBB@ HK-_P"$@TS_ (2G_A'/M7_$V^Q?;_L_EM_J-^S?
MNQM^]QC.?:H)=>GC\:0Z"-&OW@ELS<G4UC_T9&#%?*+?W^,X]"/P -FBBB@
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M1+6?3[J"ZB\M5\R"0.N0!D9'>O-=9*_$7XV:';Z.!+IG@V5[C4+]>4-PVW;
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MD\0*.P>/:Y*X 0[B< $X&.:B\/\ ASXH>'M)L_#UOK'AN72[(+!#J$D$QNA
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@!'19(V210Z,"&5AD$>AKGV\">'&\(P^%VTXMHT+AX
M[4SR?*1)Y@^;=NP&YQG&..G%=#10 4444 %%%% !1110 4444 %%%% !1110
M!G:=H.F:3?ZC>Z?:B*YU.837<I=F:5PH4=2<  8 & /3FM&BB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_@7'_C5G^R]/_P"?&V_[\K_A1_9>G_\ /C;?]^5_PH K?\)-H/\ T&]._P#
MN/\ QH_X2;0?^@WIW_@7'_C5G^R]/_Y\;;_ORO\ A1_9>G_\^-M_WY7_  H
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M\)-H/_0;T[_P+C_QH_X2;0?^@WIW_@7'_C5G^R]/_P"?&V_[\K_A1_9>G_\
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MU9_LO3_^?&V_[\K_ (4?V7I__/C;?]^5_P * *W_  DV@_\ 0;T[_P "X_\
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M_C5G^R]/_P"?&V_[\K_A1_9>G_\ /C;?]^5_PH K?\)-H/\ T&]._P# N/\
MQH_X2;0?^@WIW_@7'_C5G^R]/_Y\;;_ORO\ A1_9>G_\^-M_WY7_  H K?\
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M^!<?^-6?[+T__GQMO^_*_P"%']EZ?_SXVW_?E?\ "@"M_P )-H/_ $&]._\
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M_P!!O3O_  +C_P :/^$FT'_H-Z=_X%Q_XU9_LO3_ /GQMO\ ORO^%']EZ?\
M\^-M_P!^5_PH K?\)-H/_0;T[_P+C_QH_P"$FT'_ *#>G?\ @7'_ (U9_LO3
M_P#GQMO^_*_X4?V7I_\ SXVW_?E?\* *W_"3:#_T&]._\"X_\:/^$FT'_H-Z
M=_X%Q_XU9_LO3_\ GQMO^_*_X4?V7I__ #XVW_?E?\* *W_"3:#_ -!O3O\
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MVW_?E?\ "@"M_P )-H/_ $&]._\  N/_ !H_X2;0?^@WIW_@7'_C5G^R]/\
M^?&V_P"_*_X4?V7I_P#SXVW_ 'Y7_"@"M_PDV@_]!O3O_ N/_&C_ (2;0?\
MH-Z=_P"!<?\ C5G^R]/_ .?&V_[\K_A1_9>G_P#/C;?]^5_PH K?\)-H/_0;
MT[_P+C_QH_X2;0?^@WIW_@7'_C5G^R]/_P"?&V_[\K_A1_9>G_\ /C;?]^5_
MPH K?\)-H/\ T&]._P# N/\ QH_X2;0?^@WIW_@7'_C5G^R]/_Y\;;_ORO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !7BG_#5'@;SMG]G:]MW8\S[-%C'K_K<X_#->UU\=?"+Q?XA
MT7P?KNC>'_ MUXE34I-KSHCO#"2FW:ZA"#ZX+"@#ZM\+>*M'\9:%'J_AZ[%U
M:2,4)VE61AU5@>01D?F*V*^<]+B\1? G]G>_O+E$AUS4[]3#&<.+3>H +=06
M"HQQTR1GH:I^(- ^)W@GP#%\0'^(U]=SHL,UQITA=HD$K*H #,4;!< C8!UQ
M0!],45X)XX^(WB;Q&O@3P]X2NO[%O?%-I%=7-TO6(/@;5/4 $.<CDX7IS5"X
ME\<?!OXC^%K/5?&5WXGTG7[GR)([S<67YD5L;V8KCS%((89P010!Z%IOQ&U6
M]_:"U?P+);6:Z98V2SQS*K><S&.)N3NVX_>$8V]AS7I%>#:-*L'[97BJ5\[8
M])5CCT$%L:\W?XEZGXRGU'6=7^*-UX3GCE;^S](M;:X:-E !4,T7RXSQEMQX
M.1B@#[!KS?XV?$;5?AMX7L-2T2VL[B:YO1 PNT9E"[&;@*RG/RCO7FM_\:/$
MH_9PL]8$^S6[K46TUKY4 .U5+F0#IN( 7IUR>*YCXR^"O&7A/P3I;^*/&4WB
M"VN;L%[>XW,UO/Y;?==BQ*XW#^'MQ0!]<T45\M^-?B/>^(_B=KNDZA\0;KP/
MI&D3O:VWV.WGD>=T8HQ/DX/)!/)P!C ZT ?4E%> _"WQ!XC^)?P_\7>&I/$=
MU)>Z:Z+INNP.\$D@8N4)88;!,7.?FVN0:Y;PKX_\7_$2X\-?#T:K>:=>6=S(
M=4U2"\*S7$,?0"16R3C<#R<D*W/- 'U/17B?QENKBV\16T-U\5!X.TL6B[;6
MU266Z>3<V7*QD.5("C);L>.N<3X.?$G5HK;QO%J6NS^)M.T&R>]L[RX5A)*J
M!R?O_, P X8DB@#Z'HKYO\&Z#\4/B7X?;QK;?$2XTNXFGD^R:>F\6Y"L1A@&
MVJ,Y&"C\#)S2_%OXBZE+\4W\'OXQE\'Z3I]O&;G4+:WE>2:5D5^!%\^,, !D
M#ALD\4 ?1]%?/WP4\?:M?^)O$7A>;Q)+XGTZSL&N['5IHG20X*@@[_G_ .6G
M1LX*'!Q67\&;+X@?$/3;;6+KQ[?VNFZ/J(3R#(\LEX05DD61MP^7:X SN'L.
MX!Z=X(^(FJ>)OBEXN\-7MM9Q6>B2;+=X582/AROSDL0>G8"O1Z^7M#\.>)/%
M'QS\?Z?X9\2OX<C-T[7=U#&6E9?,.U5P01SDDA@>*ZSX2^)O%EOK_C+P/XBU
MO[==:-"\EIJ5XV_RR"5W.S9)7E&P<XP10![K6'XJ\9Z!X)T^&^\4:@+&VFE$
M,;F)Y-SX)QA%)Z \]*^6_$GBG5-!M6U&P^-MWK&NQ.I.G6D4_P!G;)^8JY/E
M,!UP5&16Y^T!'J6N?#_P;XPN]5E$.H65LLFEJ"(5F>)I6F'S8SAMO3.!U[4
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M>._!VL>)V9O#ZQ2V6N:BJNT,4T1<&4D@/LX)+$9R>@P!5_MS4/\ HOWA;_P
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MEO-*^A+,,=@?:HKKP9XW\97>F6_Q!OM"CT?3[I+N2VTA)2][(GW0YDP%7/)
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M"6DPK#+$CKV_ 8A^%ND?V+\0_BEI=O<75VL'V)(I+F0R2D>5*54MU. 0H[X
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MGY=PLOGP#&V0X^Z3SP>?:MFO$M"/_%J_C/\ ]AG7/_1(H ]MHKP"\^'6F?\
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MQ?[05M+9@Z *JE?,6520=H.,5K>!?@AI?A/Q$?$6KZK>>(M< ^2[O3Q&<8W
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\.M0/C&\\2>#O%$OAV\U*-(]03[%'=1W&P85@K$;6 [\_3DYG\#?#H>"M?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !17+^.?&8\%6VBS&P^VC5-7@TP@3>7Y7F!CYGW3NQM^[QG/45U%
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MK:^'7@<> O#<NG2:B^J7=Q=/=7-Z\7EF5VP/N[FQA54=>U %7XQ?\D<\3?\
M7BW\Q7(_$&QEU2/X86,5]<6#7-TL;7-JVV5%-MAMK=B1D9[9S7I/C'P[_P )
M;X-U/0?M7V3[? 8?/\O?Y>>^W(S^8K.U7P1_:=UX3F&H>5_PCDXFV^3N^T8C
MV8^\-OKGF@#B+OPIIWP[^,'@Q_"/G6,&MM<VNHVYGDD2YV1;E=MS'Y@><_\
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M.!VD$>] Y.T_O,XZ9 XKHO&'@)_$6M:=KVBZS-H.O:<C10WL4*S*\;=4DC;
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\5
ML_"$'CB;XH:-*_DSMK*2VEP.L$ZQ HX[\'@X[$U[56+H?A:RT#5=9U"SDN'F
MUFZ%U<"5@55@H7"X P,#OF@#R#POXMN/%?Q3\"#5T,.N:7;ZE8ZI W5)T106
M^C#!],DCM6]X5TC3/%GQD\<WOB:W@U.ZTJ:"SLK>[C$B6L!0G*JV0-QSS]?4
MUUW_  K;05^)B>.H1<0ZL(3$Z1NHAERI3>R[<[MN!P0.!Q4?B'X9Z3KWB+^W
M[;4-6T/5VB$,MYI%UY#SH.BN""&Q@=L\#T& #F?!%C;>'?CSXMT+0(EMM(>P
MM[R2TBXB@N#@?*HX7<ISC^@%=1\3O"=[XS\%R:9I<\$=REQ%<+%= F&XV-N\
MJ3'.T_T%7_"?@K2/!MO<KI8N)KF\D\R[O;R8RSW+]B[GKCT&!UXY-3^*/"]G
MXKTR*SO;B]M&@F%Q!<V-P89H9 "H96'LS#G(YH XKP/K.CV7BW4M,U/P;#X1
M\16^FBZN!:[&@N+56V^8K1@ @-ZKD=,G!KS[Q*=(U7X3ZK-X1^%!CT/[-)-!
MK<\L$4J[<_O@&)E;[OKDCZU['X<^'6D^'KZ\U"6[U+6M1O8/LTU[JUSY\IAS
MGRQ@ !<]@*P?^%&>'O[,GTHZSXB.CR*XCTLZB?L\!8'E%VYX)W ,6&>2#0!A
M?$.SMM1^&O@"^U"VAN;N;4=*CDGFC#.ZL,LI8C)!).1T-+\8;*X36_ GA;0+
M#2TT^_O;B22QNU:*SFDC56C601CD$LQVX.2!Q7H6J>!M,U?P[HVC7,UTMOH\
M]M/;O&ZAV: 83<2I!![X ]L58\6>#](\::2EAKD+LL4HF@FAD,<L$@Z.C#D&
M@#SW2OAYXNB^(NA^(9]/\'Z+#8>8ET-#,R/<Q.N-C*4"M@X(ST_"IM)\.Z)-
M^T'XEAFT?3Y(DTFUE6-K5"JN6;+ 8ZGN:ZG0OAU;:+K%OJ5SXB\1ZU/:AA -
M4U$RI'N4J3L4*"<$C+ GGZ4>(/AOINO>*8_$,>IZQI&HB 6\TNE7?D?:(@V0
MC\'(]Q@^_ P <O>W=O\ #WX[75]=N(-'\5::TTKGA4NK522?3F/)]R:T_@Q8
MSR^%+SQ1J*%+[Q1>R:DZL<E(B<1)GT" $?[U9/Q]TVV\1Z5X9\-!&;4=5UB.
M.V=#AHHPI$S^X"MR/<'M7JEI:PV-E!:6D8B@MXUBB1>BJHP!^0H X/XF>#]5
MU[5O#^MZ19V.L?V+),TNBZBVV&Z#J &!(*AUQP6&.<\8YYV;5=$O_@GX_@T7
MP\_ARZMH[E=2TUE $=P8@"5V_*055>1@'&<<Y/?^*/!%KXGN[:\_M75](O;9
M&C2ZTJ[,+E"02K @JPR.XJK9?#30['P;JWAV&6^>+6!)]NO9I_,N9V<;2Y=@
M1G'MCVZT >>>,FC;2_A/'<Z=-KEJL0GGT:"+S7N52U4^8$/#;,YP>N['>M;P
M'X=CO_BUJ/BVQ\(R>'-&_LY+:&"^LDMY9KG?DS+'UCPF5[9SGUJA\5+&PTG7
M/!%IJUQJ6D^'M+@E4Z[8*_VB!A&J+&9$!V!@ 2=O..V#1X)UA[GXH:9;>!/$
M_B#Q+X<-O.=7FU5GFA@(7]UY<KJ#N+]0,\?C@ G^%_@WP_KFL>/=3UO2K;4;
MC_A*=0M%^UQB58XPP8A5;(4DN<D<GCTJOX(O-"\/?!#Q5#XG66;P]I>KWEG]
MG!+,8?-55C&"#RSXZC[W)Q7J/AGPI8^%?[7_ +/EN)/[6U.;4Y_/93MEEQN"
MX PORC .3[FLV'X;:"GA36?#MRMQ>:?K-W+>7*SN-PDD8-\I4# #*".I&.IH
M \D\6K+')X1OK/X9CPC##KMF+?44FMTD*LV#&T<?SC<.H/ISUKT&]_Y.8TO_
M +%F;_TH%/7X,:-(UDVI:]XCU1]/N(I[1K_4!*(#&P8!5V[<'&"2"V,@$5U4
MOA:QE\<0>*FEN/MT%BU@L89?*\MGWDD8SNR/7&.U 'D6IZ#'\.VUJZ\;^$;/
MQ+X?O=1>\?78 IO;82.-HD5L-\I/#(W'XU[K&ZRQK)&<JP#*?4&O/Y_@SH5T
MQ@NM7\03:091*=%DU$FS)!R%VXW;<_P[L5Z"JA5"J  !@ #I0!XU=7&AZ_JV
MOQ^%/A7_ ,).#=RV^HZE/)!"))QPX1YCN.,\8P!VK-\*>&-4\=_LP^%[6QN8
M9+JTNS<B"^),%VD-S*!!)C)V8 X_V17=3_!_1)-6O[JUU77;"UU*8SWNF66H
M&*UG=OO$J!N&[OAAZ=*M1_"W18/!.G^&;2]U2T@TR>2XL[NVNO*N(7=G8X=0
M!C]XPP0>,9SUH Q/!MSIE]K6O^'V\*?\(7XG?3U%S]DV&.2([E26-DPK8+=P
M#VR<''.^&]/MOAW?>&]"\;^"[!9/MJ6NF>)M-"D37#9V>8,"168=<D@\\8%>
M@Z+\,]%TF/5C<W.I:Q=:O;FTO+W4[HRS/"01Y88 ;5P3T [>@JIIWPFTFSU>
MQO[_ %G7]:&FRB:QM=4U S0VT@^ZZK@$D=BQ.* .?\*Z1IGBSXR>.;WQ-;P:
MG=:5-!9V5O=QB1+6 H3E5;(&XYY^OJ:@\.01^$_C#XYTKPQ"MOIJ:1%?FTB'
M[J&ZV\;5'"[ASCO] *['Q#\,])U[Q%_;]MJ&K:'J[1"&6\TBZ\AYT'17!!#8
MP.V>!Z#&CX3\%:1X-M[E=+%Q-<WDGF7=[>3&6>Y?L7<]<>@P.O')H X3X2>"
M?"VO?"33[[5]*L=7N]5$D]]=W4"R2RRF1MV7/((/'![9K2ND6+]I/28XQA5\
M,2JH] )Q4_\ PIG189[A=+UOQ%I.GW4ADFTNPU(Q6S$G+87&Y0>X##TZ5TB^
M$-/7QC:>)%DN1=VFG'3HX]X,?E%@V3D;BV1US^% 'E]]/H>OKXB_X1+X5?V_
M;2W%PE]JT\L$'F39.]D:4[R 2<8QCL!6;>0Q:C^QE!=7\4=S<6U@!!-,@9XL
M7 4;2>1\H X["O0&^#FA?VA>2VVJ:[::??3&>ZTBVU QVDSL<ME0-V#W 8#M
MTK9L_A_HEI\.1X)D$]UI @: ^>X\PJ6+9W* ,@G(('84 <?\6%7PI\ ]5G\,
M6L.FRSPV\<LEG"(SM=T5B2H'4$C/O7/:K\*O&&J^&[:PTO1O &D-;M%+9ZCI
MSW"SPE6#!E?R\G..<YSG/7!KT[1OA_IVE^&;S0;_ %#5=>L+Q!$\>KW7G;8P
M,!%P%VCZ<Y[\"LBS^#VF6:Q6X\2>*)=,A8&/3'U5OLZ@=$P &V^Q;% &/XEL
MX?$7[1/A_1?$4,5WIUGH4E_#;2KF&2Y,A0DJ>&PJ@@'IUJHGA[1_#W[46F+H
M=E#9+=:)-/-# -J;]Y&X*.%R .F,XKOO%O@/2_&$]C=W<]]I^HZ>S&TU#3I_
M)GAW8W -@@@XZ$'OZFJ&A?"O0] \40>(H+O4[O58X9(I;F]NO.>YWX^9R1G(
M   7 'I0!T/B;1(O$GA74]%N,;+ZUD@R1]TLI ;\#@_A7A#/=_$OX<>#O TS
M/'?(EXNH -S$UG&T4>[UR[Q&OHNN2T#X;Z'X;\;:OXHTTW/VW5MQEB=U,49=
ME9RBA01N95)R3TH \\TO6V^)>J?#*PE_>"QM6UK5$;.5F@_<(2.W[X/UKI?#
M]O#=_'CQ];W4,<\,EAIZO'(H97!C;((/!%;WA3X;:'X.\0ZSK.DM=/<ZO)OD
M6>162 %V<I& H(4LQ."3T%:=AX6L=.\8:MXCAEN&O-6BABG1V4QJ(@0NT 9!
M.><D_A0!PGP4T32DT_7KQ=,LUNK?Q'?1PSBW7?&H8 *K8R!@D8'K5#X7>#?#
M^M:QX^U+6M*MM1N#XJU"U7[7&)52/<I.U6R 3N.2.2 !VKM-)^&VF:%XNN==
MTG4]8M4NKA[J?2X[O%G),X(9S'C)/.<9QD#C@5J^&?"ECX5_M?\ L^6XD_M;
M4YM3G\]E.V67&X+@#"_*, Y/N: .0^!<0L_!FJZ;$S&UT[7;VUMD8Y\N-7R%
MS]23^-9?QN.IW_B7P-H%A%97%OJ-[.\MMJ3.MK/)&B&-)=G)&68A><D#BO0_
M"_A6R\)VE];Z=+<2I>WTU](9V4D22'+ 8 ^7CCJ?>D\6>#](\::2EAKD+LL4
MHF@FAD,<L$@Z.C#D&@#SW2OAYXNB^(NA^(9]/\'Z+#8>8ET-#,R/<Q.N-C*4
M"M@X(ST_"D\*^%-%U[XT^/[[6]/AU"2SN;9(([I!)''O@&Y@AXW':!G&<"NP
MT+X=6VBZQ;ZE<^(O$>M3VH80#5-1,J1[E*D[%"@G!(RP)Y^E:FC^%;+1/$&N
M:Q:2W#W&MRQRW"R,I1#&FP;  "!CKDF@#SKP)X>62T^)WA'2+E]-M&U&6&T\
MOI:F6$9*@8P 2.!C@?C4'A""U\%^(O#&@>,/ ]CIVJ1AK?2]>TO:T5RXB*MO
M( =692<ALY)S[CT"+P#HZ)XC21[J6/Q'-YUXK2[=C;0O[LJ 5Z ]2<U0T?X6
MZ9I>O6FKWNLZ[KES8;OL2ZM?>>EL2,$J !SCC)R: ,CP3:6U]\3?B;;7MO%<
MP27MF'BF0.K?N,\@\&L'X9V\.C_L_P"K:[I-A;IJ]O!J;0W,<"^:2C2%5W 9
M(RJ\>PKU'1_"UCHGB#6]8M);A[C6Y8Y;E9&!12B; $  (&/4FF^%?">G^$?#
M@T33GFGM!)+)_I)5F/F.68'  QEB.G2@#Q#POX \3>)/A7:I;:#X$N8-5M#(
M=0O&N&O&=P<R/($)\P$]CP1BNA\?>'+D^%?AGX<\4W/VN?\ M>WL[V6"5AYH
M\IU;#G#<C@G@G)Z5T\7P:T>R,L.C:_XETC3I6+-IEAJ9CMQGDX&"R@Y[,*Z'
M4O!&EZE#X>ADDNHH_#US%<V:QRYW&-=JARP)88//()]: .&\7^&M&\,_$KX>
M7OAW3K;2YGOY;.3['$L0DB,1^5@!\W3C/J:=-X?T:Y_:?D@N-)L989?"9N9(
MY+9&5Y3>X,A!'+$?Q=:[_7/"UEK^K:+J%Y+<)+HUT;JW6)E"LQ4KAL@Y&#VQ
M69XI^'6F^*==M-:.I:MI&J6L)MQ>:5="&1XB2?+8E3E<DGMR: .2\3>'M,U_
M]HS0[/5K9;BT@\/O-]F;_5R%9_E#KT902#M/&5'I5WQ_96NG^+OAQ:V%M#:V
M\>M/LA@C"(N8F)P!P.23^-=@?"5B?&EKXG,UT;ZUT\Z>B-("AC+ABQR-Q;(Z
MY_"GZWX6LM?U;1=0O)+A)=&N3=6ZQ, K.5*X;()(P>V* //O^$9TGQ%^TAK3
MZW9QWR66DVLL,$XW1;R6 8H>&(&<9Z9-'A.TB\,?%+XD6/A^!;>TCL[2\ALX
MD C28Q.3M4=,D=!_A7H-KX6LK3QI?^)HY;@WM]:QVLD;,OEA4)((&,YYYY-)
M8>%;+3O&&K>)(9;AKS58H8IT=E,:B($+M&,@\\Y)_"@#PSP!X2\3>*?AK'>1
M:'X'U1-7\YY[[56G>\E<NP+.X0X8$<8/&!T->U?#[0]5\-> -)T;Q!=0W=_9
M0F*2:!F9"H8[ "P!.%VCD#I6$?@[H]O>7,FAZYXBT&VNI&EFL=+U$Q0,QZD*
M5)7/^R17;:5IEOHVDVVG67F>1;1B-#+(9&('<LQ))]S0!;HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6O\ P >C_A*X_P#H#:U_X /6]10!@_\ "5Q_] ;6O_ !Z/\ A*X_^@-K7_@
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M6O\ P >C_A*X_P#H#:U_X /6]10!@_\ "5Q_] ;6O_ !Z/\ A*X_^@-K7_@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *H7^B:?J>H:??7UOYMSIL
MK36C[V'ENRE"< X/RDCG-7Z* ,;Q#X1T+Q6;$^(-/2\;3YQ<6S,[*8W'?*D9
M' R#P<#(K-\0_##P=XIU1M2US18Y[UU"//'-)"TB@8 8QLNX8 '.>@KJZ* *
MFEZ58Z)ID.GZ3:16=G NV*&%=JJ/I5NBB@ K/&AZ</$C:^+?_B9M:"R,^]N8
M0Y<+MSM^\2<XS[UH44 9MEX=TK3]2U2_M+14N=69'O7+LPF*KM7()('R\8 %
M85E\*?!6GZE%>VFA1))#+YT,;32-#$_7<D)8QJ?<**Z^B@##\2>#=!\6_93K
M]C]I>S9FMY4FDADB+##8=&5L$=1G!K6-I ;$V9C!MS'Y1C)XV8QC\JFHH Y?
M1OAOX4T#5(]2TS2MMW""L,DUS+/Y((P=@D9@G''RXXXK(\>> 7OO!&JZ;X3M
M8UDU34DU#4+:2X9!??,ID3><^66"*.,#CMDUW]% 'C>C> [X>,-$OM"\$KX'
MAL;CS;ZY74DD-W%M(,'EQ,P8$D?,V,8KU32M#T[1&OFTRW\@ZA=O>W/SLWF3
M, &;DG&0HX&!QTK0HH YZW\">&[7PS8^'[?3=FEZ?<+<VUN)Y/W<BR&0-NW;
MC\Y)P21^%:)T/3CXD77S;_\ $S6T-D)][<0EPY7;G;]X YQGWK0HH S;7P]I
M5G=:I<06:B35G#WV]BZSD($Y5B0!M &  *Q]'^&?A'0-4AU#2M(6&XMRQ@W7
M$LB0%@03&C,53.3]T"NJHH XF?X/> [DW F\/1-'<%BT(GE$:ENK(@?:A]U
M-=/)H>G2^((-<DM\ZC;V[VT<V]OEC8AF7;G:<E1SC-7Z* ,ZUT#3+/7[[6[:
MVV:CJ"1QW,V]CYBQ@A!@G P">@&>]4=!\$>'O#&H75YH6G_8Y;K/F!9Y&3D[
MCM0L53)Y.T"M^B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
1BB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>vrna-20221231_g14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vrna-20221231_g14.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#^17AI9@  34T *@    @ ! $[  (
M   1   (2H=I  0    !   (7)R=  $    B   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %9I8W1O<FEA
M(%-T97=A<G0    %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,S
M-@  DI(  @    ,S-@  ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC;]WU/6O2/@[\<&\4ZOHO@R/PX+1+>Q\MKL7GF<118!V>6,9('?C-8?[7/\
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MC 'WF^GH3T&:X[X>_"OP1<?"O06O?#6GW<U]IL%S<7$\(>5GDC#MA_O 98X
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M3V002E[E[T,5\OK\FP=3Q]ZN!_9)_P"0IXH_ZXVW_H4E8OP-/_&2&H_]OO\
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MS@#&!\O3 KT#XF:SXM^*>B06/_"H=7TV[M91)'>O'(SJN""@S"F0<],]@>U
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MO"?VKO\ DG^C_P#84'_HIZ]VHH \S_9XE$GP-T-0"#&]RI]_](D/]:],HHH
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MO4FFZ78:/8I9:18VUA:H25@M85B123DX50 ,GFHM#_M?^Q;;_A)/L7]J;?\
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MU?XD^,?#UQ# EKH7V+[/)&K!W\Z$NV\DX."., <>M<N/B)XSUCQ?X@\,^%=
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[[H_X2[P_P#]!:V_[[K9HH QO^$N\/\ _06MO^^Z/^$N\/\ _06MO^^ZV:*
M,;_A+O#_ /T%K;_ONC_A+O#_ /T%K;_ONMFB@#&_X2[P_P#]!:V_[[H_X2[P
M_P#]!:V_[[K9HH QO^$N\/\ _06MO^^Z/^$N\/\ _06MO^^ZV:* ,;_A+O#_
M /T%K;_ONC_A+O#_ /T%K;_ONMFB@#&_X2[P_P#]!:V_[[H_X2[P_P#]!:V_
M[[K9HH QO^$N\/\ _06MO^^Z/^$N\/\ _06MO^^ZV:* ,;_A+O#_ /T%K;_O
MNC_A+O#_ /T%K;_ONMFB@#&_X2[P_P#]!:V_[[H_X2[P_P#]!:V_[[K9HH Q
MO^$N\/\ _06MO^^Z/^$N\/\ _06MO^^ZV:* ,;_A+O#_ /T%K;_ONC_A+O#_
M /T%K;_ONMFB@#&_X2[P_P#]!:V_[[H_X2[P_P#]!:V_[[K9HH QO^$N\/\
M_06MO^^Z/^$N\/\ _06MO^^ZV:* ,;_A+O#_ /T%K;_ONC_A+O#_ /T%K;_O
MNMFB@#&_X2[P_P#]!:V_[[H_X2[P_P#]!:V_[[K9HH QO^$N\/\ _06MO^^Z
M/^$N\/\ _06MO^^ZV:* ,;_A+O#_ /T%K;_ONC_A+O#_ /T%K;_ONMFB@#&_
MX2[P_P#]!:V_[[H_X2[P_P#]!:V_[[K9HH QO^$N\/\ _06MO^^Z/^$N\/\
M_06MO^^ZV:* ,;_A+O#_ /T%K;_ONC_A+O#_ /T%K;_ONMFB@#&_X2[P_P#]
M!:V_[[H_X2[P_P#]!:V_[[K9HH QO^$N\/\ _06MO^^Z/^$N\/\ _06MO^^Z
MV:* ,;_A+O#_ /T%K;_ONC_A+O#_ /T%K;_ONMFB@#&_X2[P_P#]!:V_[[H_
MX2[P_P#]!:V_[[K9HH QO^$N\/\ _06MO^^Z/^$N\/\ _06MO^^ZV:* ,;_A
M+O#_ /T%K;_ONC_A+O#_ /T%K;_ONMFB@#&_X2[P_P#]!:V_[[H_X2[P_P#]
M!:V_[[K9HH QO^$N\/\ _06MO^^Z/^$N\/\ _06MO^^ZV:* ,;_A+O#_ /T%
MK;_ONC_A+O#_ /T%K;_ONMFB@#&_X2[P_P#]!:V_[[H_X2[P_P#]!:V_[[K9
MHH QO^$N\/\ _06MO^^Z/^$N\/\ _06MO^^ZV:* ,;_A+O#_ /T%K;_ONC_A
M+O#_ /T%K;_ONMFB@#&_X2[P_P#]!:V_[[H_X2[P_P#]!:V_[[K9HH QO^$N
M\/\ _06MO^^Z/^$N\/\ _06MO^^ZV:* ,;_A+O#_ /T%K;_ONC_A+O#_ /T%
MK;_ONMFB@#&_X2[P_P#]!:V_[[H_X2[P_P#]!:V_[[K9HH QO^$N\/\ _06M
MO^^Z/^$N\/\ _06MO^^ZV:* ,;_A+O#_ /T%K;_ONC_A+O#_ /T%K;_ONMFB
M@#&_X2[P_P#]!:V_[[H_X2[P_P#]!:V_[[K9HH QO^$N\/\ _06MO^^Z/^$N
M\/\ _06MO^^ZV:* ,;_A+O#_ /T%K;_ONC_A+O#_ /T%K;_ONMFB@#&_X2[P
M_P#]!:V_[[H_X2[P_P#]!:V_[[K9HH QO^$N\/\ _06MO^^Z/^$N\/\ _06M
MO^^ZV:* *%AKNEZG.T.GWT-Q(J[RJ-D@9 S^HJ_110 4444 %%%% !1110 4
M444 %%%% !1110 453U?4%TG1+[4GC,JV=O).4!P6"*6QG\*\?M?C_J[>%8?
M%6H?#VYA\-O+Y;:A;ZI',4._9S'L4CYN,G SCGF@#VRBJVFZA;:MI=KJ-A*)
M;6[A6:&0?Q(PR#^1JS0 445S/Q&\2W?@_P"'FK:]IT4,US91!XTG!*$EU7D
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M".A/.#P< UT[>/;\_'*V\'0Q6CZ7/I/VX3A6,I?)QAMVW;@#MGWH [^BBB@
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M)IR>'E62."=HVFC4N/+9E(.T\9QUQ7M7AO0+7PMX:L=$T]YI+:QB$4;SL"Y
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M;E8*!P..0>II^A?!G0M#\86'B@:KKFHZM8B11<:C>B<S!T*8?*]%#'&,>^:
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M-1_\%\W_ ,30!MT5B?\ "6:?_P \-1_\%\W_ ,31_P )9I__ #PU'_P7S?\
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M_P"$HLO^?74__!=/_P#$T ;-%8W_  E%E_SZZG_X+I__ (FC_A*++_GUU/\
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M_GUU/_P73_\ Q- &S16-_P )19?\^NI_^"Z?_P")H_X2BR_Y]=3_ /!=/_\
M$T ;-%8W_"467_/KJ?\ X+I__B:/^$HLO^?74_\ P73_ /Q- &S16-_PE%E_
MSZZG_P""Z?\ ^)H_X2BR_P"?74__  73_P#Q- &S16-_PE%E_P ^NI_^"Z?_
M .)H_P"$HLO^?74__!=/_P#$T ;-%8W_  E%E_SZZG_X+I__ (FC_A*++_GU
MU/\ \%T__P 30!LT5C?\)19?\^NI_P#@NG_^)H_X2BR_Y]=3_P#!=/\ _$T
M;-%8W_"467_/KJ?_ (+I_P#XFC_A*++_ )]=3_\ !=/_ /$T ;-%8W_"467_
M #ZZG_X+I_\ XFC_ (2BR_Y]=3_\%T__ ,30!LT5C?\ "467_/KJ?_@NG_\
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M-_PE%E_SZZG_ ."Z?_XFC_A*++_GUU/_ ,%T_P#\30!LT5C?\)19?\^NI_\
M@NG_ /B:/^$HLO\ GUU/_P %T_\ \30!LT5C?\)19?\ /KJ?_@NG_P#B:/\
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MXUMM,\4CPS;Z7JFIZI]A2]6.UCC(:,NR9+NZJI!0D[B <@#).*P_$OQ.EM?
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M *&?6?\ P82__%4?\)OXK_Z&?6?_  82_P#Q5 'V+17QU_PF_BO_ *&?6?\
MP82__%4?\)OXK_Z&?6?_  82_P#Q5 'V+17QU_PF_BO_ *&?6?\ P82__%4?
M\)OXK_Z&?6?_  82_P#Q5 'V+17QU_PF_BO_ *&?6?\ P82__%4?\)OXK_Z&
M?6?_  82_P#Q5 'V+17QU_PF_BO_ *&?6?\ P82__%4?\)OXK_Z&?6?_  82
M_P#Q5 'V+17QU_PF_BO_ *&?6?\ P82__%4?\)OXK_Z&?6?_  82_P#Q5 'V
M+17QU_PF_BO_ *&?6?\ P82__%4?\)OXK_Z&?6?_  82_P#Q5 'V+17QU_PF
M_BO_ *&?6?\ P82__%4?\)OXK_Z&?6?_  82_P#Q5 'V+17QU_PF_BO_ *&?
M6?\ P82__%4?\)OXK_Z&?6?_  82_P#Q5 'V+17QU_PF_BO_ *&?6?\ P82_
M_%4?\)OXK_Z&?6?_  82_P#Q5 'V+17QU_PF_BO_ *&?6?\ P82__%4?\)OX
MK_Z&?6?_  82_P#Q5 'V+17QU_PF_BO_ *&?6?\ P82__%4?\)OXK_Z&?6?_
M  82_P#Q5 'V+17QU_PF_BO_ *&?6?\ P82__%4?\)OXK_Z&?6?_  82_P#Q
M5 'V+17QU_PF_BO_ *&?6?\ P82__%4?\)OXK_Z&?6?_  82_P#Q5 'V+17Q
MU_PF_BO_ *&?6?\ P82__%4?\)OXK_Z&?6?_  82_P#Q5 'V+17QU_PF_BO_
M *&?6?\ P82__%4?\)OXK_Z&?6?_  82_P#Q5 'V+17QU_PF_BO_ *&?6?\
MP82__%4?\)OXK_Z&?6?_  82_P#Q5 'V+17QU_PF_BO_ *&?6?\ P82__%4?
M\)OXK_Z&?6?_  82_P#Q5 'V+17QU_PF_BO_ *&?6?\ P82__%4?\)OXK_Z&
M?6?_  82_P#Q5 'V+17QU_PF_BO_ *&?6?\ P82__%4?\)OXK_Z&?6?_  82
M_P#Q5 'V+17QU_PF_BO_ *&?6?\ P82__%4?\)OXK_Z&?6?_  82_P#Q5 'V
M+17QU_PF_BO_ *&?6?\ P82__%4?\)OXK_Z&?6?_  82_P#Q5 'V+17QU_PF
M_BO_ *&?6?\ P82__%4?\)OXK_Z&?6?_  82_P#Q5 'V+17QU_PF_BO_ *&?
M6?\ P82__%4?\)OXK_Z&?6?_  82_P#Q5 'V+17QU_PF_BO_ *&?6?\ P82_
M_%4?\)OXK_Z&?6?_  82_P#Q5 'V+17QU_PF_BO_ *&?6?\ P82__%4?\)OX
MK_Z&?6?_  82_P#Q5 'V+17QU_PF_BO_ *&?6?\ P82__%4?\)OXK_Z&?6?_
M  82_P#Q5 'V+17QU_PF_BO_ *&?6?\ P82__%4?\)OXK_Z&?6?_  82_P#Q
M5 'V+17QU_PF_BO_ *&?6?\ P82__%4Z/QUXLCD5U\3:N2I! :^D8<>H)P?H
M: /L.BN!^&?Q,MO&MB+2]*6^LP)F6(<"8#^-/ZCM]*[Z@ HHHH **** "J$G
M^M?_ 'C5^J$G^M?_ 'C0 VBBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@"2W_UZ_C_*KM4K?_7K^/\ *KM '&:A
MX<O+WXO6VK2V@ETC^P9[&:1G7!=YD.PKG<<J#SC'O7->"?A_K^DPZX->VW#6
M-A)HN@$.N7L\LZNW)PS91><8$8^I]8HH \NB\/>*=/\  G@?3!:W[VUA;B+6
MM/TN_2WNG(APFV7S$&U7'S!9 3D=0"*QV\!^(Y?A[\0K"/2)XKG6[A)=/MKG
M45N)739&,/*[GYAM(.YB 00"PP3[310!RD>BZ@OQCN=<-O\ \2Y]!BLUGWKS
M,MQ(Y7;G=]U@<XQSUKD9/!'B%_AEXBTU;(?;YO$4NIVENTZ?OXA=K,H#9(4L
MJG ;')&<=:]9HH \Y\4^']2UW7M!\4)HNK8MH+BUN]+@U-;2\5792KK)%,$;
ME,E3+@A@>HQ5/7?!-Q??##Q9:Z%X>O+/5-91 (M0U7[5<W!0* 9'>5U7 !
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M *!-K_WQ0!LT5C?\(AX?_P"@3:_]\4?\(AX?_P"@3:_]\4 ;-%8W_"(>'_\
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MWLAZ^D;G^3?@:]OKX>KW+X2_%K=Y'AWQ3<?-PEG>R'KZ1N?Y-^!H ]OHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J
MA)_K7_WC5^J$G^M?_>- #:*** "BBB@ HHHH ***\ML6/B#]IC4I)B6A\-:2
MD,*]EEFPQ;Z[69?P'I0!ZE17S_\ "'QAX@A\4(_B35;N_P!+UZZN+.W>ZF:0
M6]U$=RJN>%#*V !C)'M75_#[QK'I/PZU[7?%VJ7$L%IK5S$)9G:5PNY0D:@Y
M/4X '3Z4 >JT5QWAGXEZ5XDUPZ.VFZQHVH-$9H;?5K,P-/&.K)R<BO*/@_\
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M\E L?^P7'_Z-EKRNO5/VA/\ DH%C_P!@N/\ ]&RUY70 4444 %%%% !1110
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M_"*>'_\ H"V/_@.O^%:]% &1_P (IX?_ .@+8_\ @.O^%'_"*>'_ /H"V/\
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M_P#@.O\ A6O10!D?\(IX?_Z MC_X#K_A1_PBGA__ * MC_X#K_A6O10!D?\
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M_A;/PT_Z%6Z_\ 8/_CE>$T4 >[?\+9^&G_0JW7_@#!_\<H_X6S\-/^A5NO\
MP!@_^.5X310![M_PMGX:?]"K=?\ @#!_\<H_X6S\-/\ H5;K_P  8/\ XY7A
M-% 'NW_"V?AI_P!"K=?^ ,'_ ,<H_P"%L_#3_H5;K_P!@_\ CE>$T4 >[?\
M"V?AI_T*MU_X P?_ !RC_A;/PT_Z%6Z_\ 8/_CE>$T4 >[?\+9^&G_0JW7_@
M#!_\<H_X6S\-/^A5NO\ P!@_^.5X310![M_PMGX:?]"K=?\ @#!_\<H_X6S\
M-/\ H5;K_P  8/\ XY7A-% 'NW_"V?AI_P!"K=?^ ,'_ ,<H_P"%L_#3_H5;
MK_P!@_\ CE>$T4 >[?\ "V?AI_T*MU_X P?_ !RC_A;/PT_Z%6Z_\ 8/_CE>
M$T4 >[?\+9^&G_0JW7_@#!_\<H_X6S\-/^A5NO\ P!@_^.5X310![M_PMGX:
M?]"K=?\ @#!_\<H_X6S\-/\ H5;K_P  8/\ XY7A-% 'NW_"V?AI_P!"K=?^
M ,'_ ,<H_P"%L_#3_H5;K_P!@_\ CE>$T4 >[?\ "V?AI_T*MU_X P?_ !RC
M_A;/PT_Z%6Z_\ 8/_CE>$T4 >[?\+9^&G_0JW7_@#!_\<H_X6S\-/^A5NO\
MP!@_^.5X310![M_PMGX:?]"K=?\ @#!_\<H_X6S\-/\ H5;K_P  8/\ XY7A
M-% 'NW_"V?AI_P!"K=?^ ,'_ ,<H_P"%L_#3_H5;K_P!@_\ CE>$T4 >[?\
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M ,!U_P */^$4\/\ _0%L?_ =?\*UZ* ,C_A%/#__ $!;'_P'7_"C_A%/#_\
MT!;'_P !U_PK7HH R/\ A%/#_P#T!;'_ ,!U_P */^$4\/\ _0%L?_ =?\*U
MZ* *-EHFEZ;,9M/T^VMI2NTO%$%)'7&1]!5ZBB@ HHHH *H2?ZU_]XU?JA)_
MK7_WC0 VBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@"2W_ ->OX_RJ[5*W_P!>OX_RJ[0 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %>@_#+XFW/@N]%EJ!>?19G_>1CEH
M"?XT_J._UKSZB@#[;L[RVU&RAN[&9)[>9 \<L9RK ]Q4U>7? _P_X@T;P[+/
MK$[Q6-WA[6QD'S)ZR?[.?[O?K7J- !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %4)/]:_^\:OU0D_UK_[QH ;1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
M);_Z]?Q_E5VJ5O\ Z]?Q_E5V@ HHHH **** "BBB@ HHHH **** *&C:'IWA
M^P:STBW\B!II)V!=G+2.Q9F+,2222>IK-;P+X>*7(BLYK=KF^?4))+6\FAD%
MPZ[7=71PR;AP0I /<5T-% &"?!/A\^')-#;3]UC),;APTTAE:8OO\TR[O,,F
M[G?NW>]6(_#.EQWNF7C13376E1RQVD\]U+*Z++C?EG8E\[5Y;)&.,5K44 8D
M_@_0KE-;2>QW+KX"ZD/.<>> FP=&^7Y1CY<?G5FX\/Z9=76EW$]MNETEBUDW
MF,/*)0H> ?F^4D<Y_.M*B@#'D\)Z'-<ZQ/-I\<KZY&D>HB1F99U1"B@J3@84
MD< 54T_P%X>TS5K35+>UN)+^S1H[>XNK^>X>)&7:4!D=OEQ_#T&20,UT=% !
M1110 4444 %%%% !1110 4444 %%%% 'SE^T)_R4"Q_[!<?_ *-EKRNO5/VA
M/^2@6/\ V"X__1LM>5T %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5[?\ "7X2[O(\1>*;?Y>'
ML[*0=?21Q_)?Q-'PE^$N[R/$7BFW^7A[.RD'7TD<?R7\37N5 !1110 4444
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M%1_97A7_ *$!/_!-%7:T4 <5_97A7_H0$_\ !-%1_97A7_H0$_\ !-%7:T4
M<5_97A7_ *$!/_!-%1_97A7_ *$!/_!-%7:T4 <5_97A7_H0$_\ !-%1_97A
M7_H0$_\ !-%7:T4 <5_97A7_ *$!/_!-%1_97A7_ *$!/_!-%7:T4 <5_97A
M7_H0$_\ !-%1_97A7_H0$_\ !-%7:T4 <5_97A7_ *$!/_!-%1_97A7_ *$!
M/_!-%7:T4 <5_97A7_H0$_\ !-%1_97A7_H0$_\ !-%7:T4 <5_97A7_ *$!
M/_!-%1_97A7_ *$!/_!-%7:T4 <5_97A7_H0$_\ !-%1_97A7_H0$_\ !-%7
M:T4 <5_97A7_ *$!/_!-%1_97A7_ *$!/_!-%7:T4 <5_97A7_H0$_\ !-%1
M_97A7_H0$_\ !-%7:T4 <5_97A7_ *$!/_!-%1_97A7_ *$!/_!-%7:T4 <5
M_97A7_H0$_\ !-%1_97A7_H0$_\ !-%7:T4 <5_97A7_ *$!/_!-%1_97A7_
M *$!/_!-%7:T4 <5_97A7_H0$_\ !-%1_97A7_H0$_\ !-%7:T4 <5_97A7_
M *$!/_!-%1_97A7_ *$!/_!-%7:T4 <5_97A7_H0$_\ !-%3DTWPO'(KQ^ @
MCJ059='B!!]179T4 8W_  D7_4&U;_P&_P#KT?\ "1?]0;5O_ ;_ .O6S10!
MC?\ "1?]0;5O_ ;_ .O1_P )%_U!M6_\!O\ Z];-% &-_P )%_U!M6_\!O\
MZ]'_  D7_4&U;_P&_P#KULT4 8W_  D7_4&U;_P&_P#KT?\ "1?]0;5O_ ;_
M .O6S10!C?\ "1?]0;5O_ ;_ .O1_P )%_U!M6_\!O\ Z];-% &-_P )%_U!
MM6_\!O\ Z]'_  D7_4&U;_P&_P#KULT4 8W_  D7_4&U;_P&_P#KT?\ "1?]
M0;5O_ ;_ .O6S10!C?\ "1?]0;5O_ ;_ .O1_P )%_U!M6_\!O\ Z];-% &-
M_P )%_U!M6_\!O\ Z]'_  D7_4&U;_P&_P#KULT4 8W_  D7_4&U;_P&_P#K
MT?\ "1?]0;5O_ ;_ .O6S10!C?\ "1?]0;5O_ ;_ .O1_P )%_U!M6_\!O\
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M 'J]%9VF>(-&UMY4T;5['4&A_P!8+2Y24I]=I.*A_P"$M\.9@'_"0:7FY<I
M/ML?[U@=I"\\D$8P.] &O17)>(/B9X:\,^*]/T#5KU(;F]#%I3+&L5J N1YQ
M9@4W=N.:V;CQ-H-H[I=:WIT+1^7O62[C4KYGW,Y/&[MZ]J -2BN0T3Q5?2^(
M/%<7B*71[/3-'EC%O-%>(76-@Q+3C>?+/ QN"]^N,UO6_B'1;O4O[.M=7L)[
M[;O^S1W*-)MQG.T'.,=Z -&BLW4/$>B:3=1VVJZQI]C/+_JXKFZ2-G^@8@FM
M('(R.10 4444 %%%% !1110!);_Z]?Q_E5VJ5O\ Z]?Q_E5V@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\^>F?]^I/_BZ/^%R^(?^?/3/^_4G_P 77G]% 'H'_"Y?$/\ SYZ9_P!^I/\
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MYSQ7,O\ #?57^'VO:*+NS6]O=<DU6T?<YCQ]I69$<[01G;@D XSD9QBO2J*
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MZW/J,'DL3MC=(U ;(&&RAX&1TYKIZ* "N4^)O_).=3_[9?\ HY*ZNN4^)O\
MR3G4_P#ME_Z.2@#Y^HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "NQ\">.Y_"]T+6\+3:7*WSIU,1_O+_4=ZXZM3P[X=OO$N
MJI9:>G/625ONQ+ZG_/- 'TG:W4%[:QW-I*LT,JAD=#D,*EK,\/:%;>'-%ATZ
MS+LD>2SN<EV/4^WTK3H **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *H2?ZU_]XU?JA)_K
M7_WC0 VBBB@ HHHH **** "BBN,D\8WT_P 8XO".G06[65OIIO=0G=6+J2=J
M(I! '52<@Y![8H [.BO.?AY\7K;QWX@O])?2VTR:!6DMB]P)/M**^QC]T;2#
MCCGK[5T/@?Q>/&FDWE\++[%]EOYK/9YOF;O+(&[.!C.>G;UH Z"ZM;>^M);6
M]@BN+>92DD,R!T=3U!!X(]JQ8O GA& 2"'PKHD8D0H^S3H1O4]0?EY' XK?K
MB_A1XRO_ !WX#AUO5H;:"Y>>2,I;*RIA3@<,2?UH ZTV5JVGFQ:VA-F8O)-N
M8QY9CQC9MZ;<<8Z8JK;^'M%M)+.2UTBP@>Q5DM&CMD4VZMG<$('R@Y.<8SFM
M&N4^)GBB]\%_#K4]?TR*":ZM/*\M+A6*'?*B'(!!Z,>] '06^E:?:7]S?6EA
M:P7=WC[1<1PJLDV.F]@,MCWJM'X8T"*WMK>+0]-2&SF\^VC6TC"P29SO08PK
M9[CFLJP\5:G=>*-.TI_#]P;*ZTM;V35E)\A)#_RRQMQGORV?;O74T 5-2TG3
MM9L_LFL6%K?VVX-Y-U"LJ9'0[6!&:MT44 %%<9X8\8WVI?$#Q1X7UB"WBETI
MXY;-X58>=;R#(+9)RPRH)&!D]!BNSH **** "BBB@ HHHH DM_\ 7K^/\JNU
M2M_]>OX_RJ[0 4444 %%%% !1110 4444 %%%% !7G^@I+X_U/6]0U6^U*#3
M]/U*?3K"SL;Z:T&(BJO*[0LK.S.&P&)"@# !)KT"N#TBPUOP/K.M0V>AW&N:
M1JE_+J5N]C- DMM))@R1NLTB#;NRRE2>I! XH 37'O8]>\.^!;+5[]([R*XN
M;R_:4?:C;Q8"Q+( ""2ZKO\ O[4SNW'=4>MQ3> _$/AV[TK4-2FT[5=2CTR^
MLKZ]EO%_>*_ERHTS,R$, "%(# C(X!J?7-)\076J^'O&%CID2ZIIJSQ76D_:
ME+36TN/E60@+YJ[4;&=N2PWD ,5O]-UCQKXBT.34='GT32-%O!J#K>30O/=3
MJK+&JB%W544MN)9LDX '>@#!6WCUGQ=\19-<U_6+"VTMX1;S6VK3V\=DIM59
MG"*XCX/S?,"">N<FJ@U;6_$5C\*TUZ[OK276/..HI:7,EFUQMMF92QB92,D!
ML# YZ8XKH=&\ VLWQ%\6:UXD\/V%TEU=VTNFW-U#%,VU(%5BN<LF&'?'3-6O
M'.F:M-XL\(:SI6E3ZG#I-U<27,-O+$D@5X&0$>:Z*>3ZT 5RUYX+^(NAZ7;:
MA?7NB>(//C-O?W#W+6<\<0=625R9"K!6!5F(!Y&,D5W]<5%I.K>)O'6EZ_K.
MFMI%AHB3?8[.>5)+B::5 C2/Y;,BJJ[@H#,222<<5VM !1110 4444 %%%%
M!1110 4444 %<I\3?^2<ZG_VR_\ 1R5U=<S\1+6XO? 6HV]E!+<3OY6V*)"[
M-B5"< <] 30!\\T5J_\ "*^(?^@#J?\ X!R?X4?\(KXA_P"@#J?_ (!R?X4
M95%:O_"*^(?^@#J?_@')_A1_PBOB'_H ZG_X!R?X4 95%:O_  BOB'_H ZG_
M . <G^%'_"*^(?\ H ZG_P" <G^% &516K_PBOB'_H ZG_X!R?X4?\(KXA_Z
M .I_^ <G^% &516K_P (KXA_Z .I_P#@')_A1_PBOB'_ * .I_\ @')_A0!E
M45J_\(KXA_Z .I_^ <G^%'_"*^(?^@#J?_@')_A0!E45J_\ "*^(?^@#J?\
MX!R?X4?\(KXA_P"@#J?_ (!R?X4 95%:O_"*^(?^@#J?_@')_A1_PBOB'_H
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 50D_P!:_P#O&K]4)/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !5"3_6O_O&K]<]>:W#;7LL+6>H2%&(+16<C*?H0.:
M-"BLG_A(8?\ GPU3_P  )/\ "C_A(8?^?#5/_ "3_"@#6HK)_P"$AA_Y\-4_
M\ )/\*/^$AA_Y\-4_P# "3_"@#6HK)_X2&'_ )\-4_\  "3_  H_X2&'_GPU
M3_P D_PH UJ*R?\ A(8?^?#5/_ "3_"C_A(8?^?#5/\ P D_PH UJ*R?^$AA
M_P"?#5/_   D_P */^$AA_Y\-4_\ )/\* -:BLG_ (2&'_GPU3_P D_PH_X2
M&'_GPU3_ , )/\* -:BLG_A(8?\ GPU3_P  )/\ "C_A(8?^?#5/_ "3_"@#
M6HK)_P"$AA_Y\-4_\ )/\*/^$AA_Y\-4_P# "3_"@#6HK)_X2&'_ )\-4_\
M "3_  H_X2&'_GPU3_P D_PH UJ*R?\ A(8?^?#5/_ "3_"C_A(8?^?#5/\
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 26_P#KU_'^57:I6_\
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M4/WB,Y&,GBFK\0=&?P?#X@5;HQSS?98[+RO]):YWE/L^S./,W@KUV\9SMYH
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MO_0#0 ?\)#HO_07L/_ E/\:/^$AT7_H+V'_@2G^->#T4 >\?\)#HO_07L/\
MP)3_ !H_X2'1?^@O8?\ @2G^->#T4 >\?\)#HO\ T%[#_P "4_QH_P"$AT7_
M *"]A_X$I_C7@]% 'O'_  D.B_\ 07L/_ E/\:/^$AT7_H+V'_@2G^->#T4
M>\?\)#HO_07L/_ E/\:/^$AT7_H+V'_@2G^->#T4 >\?\)#HO_07L/\ P)3_
M !H_X2'1?^@O8?\ @2G^->#T4 >\?\)#HO\ T%[#_P "4_QH_P"$AT7_ *"]
MA_X$I_C7@]% 'O'_  D.B_\ 07L/_ E/\:/^$AT7_H+V'_@2G^->#T4 >\?\
M)#HO_07L/_ E/\:/^$AT7_H+V'_@2G^->#T4 >\?\)#HO_07L/\ P)3_ !H_
MX2'1?^@O8?\ @2G^->#T4 >\?\)#HO\ T%[#_P "4_QH_P"$AT7_ *"]A_X$
MI_C7@]% 'O'_  D.B_\ 07L/_ E/\:/^$AT7_H+V'_@2G^->#T4 >\?\)#HO
M_07L/_ E/\:/^$AT7_H+V'_@2G^->#T4 >\?\)#HO_07L/\ P)3_ !H_X2'1
M?^@O8?\ @2G^->#T4 >\?\)#HO\ T%[#_P "4_QH_P"$AT7_ *"]A_X$I_C7
M@]% 'O'_  D.B_\ 07L/_ E/\:/^$AT7_H+V'_@2G^->#T4 >\?\)#HO_07L
M/_ E/\:/^$AT7_H+V'_@2G^->#T4 >\?\)#HO_07L/\ P)3_ !H_X2'1?^@O
M8?\ @2G^->#T4 >\?\)#HO\ T%[#_P "4_QH_P"$AT7_ *"]A_X$I_C7@]%
M'O'_  D.B_\ 07L/_ E/\:/^$AT7_H+V'_@2G^->#T4 >\?\)#HO_07L/_ E
M/\:/^$AT7_H+V'_@2G^->#T4 >\?\)#HO_07L/\ P)3_ !H_X2'1?^@O8?\
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MD_UK_P"\:OU0D_UK_P"\: &T444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/_\ 0&L?^_"_X4?\(EX?_P"@-8_]^%_PH UMZ_WA^=&]?[P_.LG_ (1+P_\
M] :Q_P"_"_X4?\(EX?\ ^@-8_P#?A?\ "@#6WK_>'YT;U_O#\ZR?^$2\/_\
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M]_4_^(H_X5CH?_/Y??\ ?U/_ (BHO[1^'7_/"Q_\ 7_^(H_M'X=?\\+'_P
M7_\ B* )?^%8Z'_S^7W_ ']3_P"(H_X5CH?_ #^7W_?U/_B*B_M'X=?\\+'_
M , 7_P#B*/[1^'7_ #PL?_ %_P#XB@"7_A6.A_\ /Y??]_4_^(H_X5CH?_/Y
M??\ ?U/_ (BHO[1^'7_/"Q_\ 7_^(H_M'X=?\\+'_P  7_\ B* )?^%8Z'_S
M^7W_ ']3_P"(H_X5CH?_ #^7W_?U/_B*B_M'X=?\\+'_ , 7_P#B*/[1^'7_
M #PL?_ %_P#XB@"7_A6.A_\ /Y??]_4_^(H_X5CH?_/Y??\ ?U/_ (BHO[1^
M'7_/"Q_\ 7_^(H_M'X=?\\+'_P  7_\ B* )?^%8Z'_S^7W_ ']3_P"(H_X5
MCH?_ #^7W_?U/_B*B_M'X=?\\+'_ , 7_P#B*/[1^'7_ #PL?_ %_P#XB@"7
M_A6.A_\ /Y??]_4_^(H_X5CH?_/Y??\ ?U/_ (BHO[1^'7_/"Q_\ 7_^(H_M
M'X=?\\+'_P  7_\ B* )?^%8Z'_S^7W_ ']3_P"(H_X5CH?_ #^7W_?U/_B*
MB_M'X=?\\+'_ , 7_P#B*/[1^'7_ #PL?_ %_P#XB@"7_A6.A_\ /Y??]_4_
M^(H_X5CH?_/Y??\ ?U/_ (BHO[1^'7_/"Q_\ 7_^(H_M'X=?\\+'_P  7_\
MB* )?^%8Z'_S^7W_ ']3_P"(H_X5CH?_ #^7W_?U/_B*B_M'X=?\\+'_ , 7
M_P#B*/[1^'7_ #PL?_ %_P#XB@"7_A6.A_\ /Y??]_4_^(H_X5CH?_/Y??\
M?U/_ (BHO[1^'7_/"Q_\ 7_^(H_M'X=?\\+'_P  7_\ B* )?^%8Z'_S^7W_
M ']3_P"(H_X5CH?_ #^7W_?U/_B*B_M'X=?\\+'_ , 7_P#B*/[1^'7_ #PL
M?_ %_P#XB@"7_A6.A_\ /Y??]_4_^(H_X5CH?_/Y??\ ?U/_ (BHO[1^'7_/
M"Q_\ 7_^(H_M'X=?\\+'_P  7_\ B* )?^%8Z'_S^7W_ ']3_P"(H_X5CH?_
M #^7W_?U/_B*B_M'X=?\\+'_ , 7_P#B*/[1^'7_ #PL?_ %_P#XB@"7_A6.
MA_\ /Y??]_4_^(H_X5CH?_/Y??\ ?U/_ (BHO[1^'7_/"Q_\ 7_^(H_M'X=?
M\\+'_P  7_\ B* )?^%8Z'_S^7W_ ']3_P"(H_X5CH?_ #^7W_?U/_B*B_M'
MX=?\\+'_ , 7_P#B*/[1^'7_ #PL?_ %_P#XB@"7_A6.A_\ /Y??]_4_^(H_
MX5CH?_/Y??\ ?U/_ (BHO[1^'7_/"Q_\ 7_^(H_M'X=?\\+'_P  7_\ B* )
M?^%8Z'_S^7W_ ']3_P"(H_X5CH?_ #^7W_?U/_B*B_M'X=?\\+'_ , 7_P#B
M*/[1^'7_ #PL?_ %_P#XB@"7_A6.A_\ /Y??]_4_^(H_X5CH?_/Y??\ ?U/_
M (BHO[1^'7_/"Q_\ 7_^(H_M'X=?\\+'_P  7_\ B* )?^%8Z'_S^7W_ ']3
M_P"(H_X5CH?_ #^7W_?U/_B*B_M'X=?\\+'_ , 7_P#B*/[1^'7_ #PL?_ %
M_P#XB@"7_A6.A_\ /Y??]_4_^(H_X5CH?_/Y??\ ?U/_ (BHO[1^'7_/"Q_\
M 7_^(H_M'X=?\\+'_P  7_\ B* )?^%8Z'_S^7W_ ']3_P"(H_X5CH?_ #^7
MW_?U/_B*B_M'X=?\\+'_ , 7_P#B*/[1^'7_ #PL?_ %_P#XB@"7_A6.A_\
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M_"@#6WK_ 'A^=&]?[P_.LG_A$O#_ /T!K'_OPO\ A1_PB7A__H#6/_?A?\*
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M 4444 26_P#KU_'^57:I6_\ KU_'^57: "BBB@ HHHH **** "BBB@ HHHH
M\/\ '&J:#XG\8^,M/UC7=.T[^R]%&G6"7=Y'"6NI")VD4,0>&C@4D>AKIO\
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M4<D5J;MX0BI(NU@5CC0'H#N^\<#)( % '5T444 %%%% !1110 4444 %%%%
M!7.^/O\ D1[_ /[9_P#HQ:Z*N=\??\B/?_\ ;/\ ]&+0!XQ1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !6IX<NM3M-<@;10SW+':(QTD'<-[?RZU2L[.XU"\CM;.)I9I#A
M57O7L7A3PI;^'+/<VV6]D'[V7'3_ &5]OYT ;T9<QJ95"N0-RJ<@'N,]Z=11
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M57:I6_\ KU_'^57: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *YWQ]_R(]_\ ]L__ $8M=%5+5]+A
MUK2IK"Z:1(IMNYHR PPP;C(/<4 >!T5ZM_PJ_1?^?J__ ._B?_$4?\*OT7_G
MZO\ _OXG_P 10!Y317JW_"K]%_Y^K_\ [^)_\11_PJ_1?^?J_P#^_B?_ !%
M'E-%>K?\*OT7_GZO_P#OXG_Q%'_"K]%_Y^K_ /[^)_\ $4 >4T5ZM_PJ_1?^
M?J__ ._B?_$4?\*OT7_GZO\ _OXG_P 10!Y317JW_"K]%_Y^K_\ [^)_\11_
MPJ_1?^?J_P#^_B?_ !% 'E-%>K?\*OT7_GZO_P#OXG_Q%'_"K]%_Y^K_ /[^
M)_\ $4 >4T5ZM_PJ_1?^?J__ ._B?_$4?\*OT7_GZO\ _OXG_P 10!Y317JW
M_"K]%_Y^K_\ [^)_\11_PJ_1?^?J_P#^_B?_ !% 'E-%>K?\*OT7_GZO_P#O
MXG_Q%'_"K]%_Y^K_ /[^)_\ $4 >4T5ZM_PJ_1?^?J__ ._B?_$4?\*OT7_G
MZO\ _OXG_P 10!Y317JW_"K]%_Y^K_\ [^)_\11_PJ_1?^?J_P#^_B?_ !%
M'E-%>K?\*OT7_GZO_P#OXG_Q%'_"K]%_Y^K_ /[^)_\ $4 >4T5ZM_PJ_1?^
M?J__ ._B?_$4?\*OT7_GZO\ _OXG_P 10!Y317JW_"K]%_Y^K_\ [^)_\11_
MPJ_1?^?J_P#^_B?_ !% 'E-%>K?\*OT7_GZO_P#OXG_Q%'_"K]%_Y^K_ /[^
M)_\ $4 >4T5ZM_PJ_1?^?J__ ._B?_$4?\*OT7_GZO\ _OXG_P 10!Y317JW
M_"K]%_Y^K_\ [^)_\11_PJ_1?^?J_P#^_B?_ !% 'E-%>K?\*OT7_GZO_P#O
MXG_Q%'_"K]%_Y^K_ /[^)_\ $4 >4T5ZM_PJ_1?^?J__ ._B?_$4?\*OT7_G
MZO\ _OXG_P 10!Y317JW_"K]%_Y^K_\ [^)_\11_PJ_1?^?J_P#^_B?_ !%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %4)/]:_\ O&K]4)/]:_\
MO&@!M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% #9+2"_0VUW&)87^\A[XY'ZBH?\ A$="_P"@='_WTW^-7+?_
M %Z_C_*KM &-_P (CH7_ $#H_P#OIO\ &C_A$="_Z!T?_?3?XULT4 8W_"(Z
M%_T#H_\ OIO\:/\ A$="_P"@='_WTW^-;-% &-_PB.A?] Z/_OIO\:/^$1T+
M_H'1_P#?3?XULT4 8W_"(Z%_T#H_^^F_QH_X1'0O^@='_P!]-_C6S10!C?\
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M/^$C\$?] 2[_ .^1_P#'*X*B@#O?^$C\$?\ 0$N_^^1_\<H_X2/P1_T!+O\
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M/^$C\$?] 2[_ .^1_P#'*X*B@#O?^$C\$?\ 0$N_^^1_\<H_X2/P1_T!+O\
M[Y'_ ,<K@J* .]_X2/P1_P! 2[_[Y'_QRC_A(_!'_0$N_P#OD?\ QRN"HH [
MW_A(_!'_ $!+O_OD?_'*/^$C\$?] 2[_ .^1_P#'*X*B@#O?^$C\$?\ 0$N_
M^^1_\<H_X2/P1_T!+O\ [Y'_ ,<K@J* .]_X2/P1_P! 2[_[Y'_QRC_A(_!'
M_0$N_P#OD?\ QRN"HH [W_A(_!'_ $!+O_OD?_'*/^$C\$?] 2[_ .^1_P#'
M*X*B@#O?^$C\$?\ 0$N_^^1_\<H_X2/P1_T!+O\ [Y'_ ,<K@J* .]_X2/P1
M_P! 2[_[Y'_QRC_A(_!'_0$N_P#OD?\ QRN"HH [W_A(_!'_ $!+O_OD?_'*
M/^$C\$?] 2[_ .^1_P#'*X*B@#O?^$C\$?\ 0$N_^^1_\<H_X2/P1_T!+O\
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M:PS17D;)),>D2L#@N>RCFI['6M/U'4=0L+*X\RYTV18KM-C#RV9 ZC)&#\K
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M/_(L:I_UYS?^@&@#P>BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4#GI0.>E>F^"?!/V3R]4UB
M/]_]Z&!A_J_]IO?V[?7H '@GP3]D\O5-8C_?_>A@8?ZO_:;W]NWUZ=Y110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 50D_UK_[QJ_65<^&M+O+E[BXAE:20Y8BYE7] V!0!
M)15;_A$=&_Y]YO\ P+E_^*H_X1'1O^?>;_P+E_\ BJ +-%5O^$1T;_GWF_\
M N7_ .*H_P"$1T;_ )]YO_ N7_XJ@"S15;_A$=&_Y]YO_ N7_P"*H_X1'1O^
M?>;_ ,"Y?_BJ +-%5O\ A$=&_P"?>;_P+E_^*H_X1'1O^?>;_P "Y?\ XJ@"
MS15;_A$=&_Y]YO\ P+E_^*H_X1'1O^?>;_P+E_\ BJ +-%5O^$1T;_GWF_\
M N7_ .*H_P"$1T;_ )]YO_ N7_XJ@"S15;_A$=&_Y]YO_ N7_P"*H_X1'1O^
M?>;_ ,"Y?_BJ +-%5O\ A$=&_P"?>;_P+E_^*H_X1'1O^?>;_P "Y?\ XJ@"
MS15;_A$=&_Y]YO\ P+E_^*H_X1'1O^?>;_P+E_\ BJ +-%5O^$1T;_GWF_\
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MT#?_ "/)_P#%59_X1/2/^>,__@9-_P#%4?\ ")Z1_P \9_\ P,F_^*H K?\
M" ^&O^@;_P"1Y/\ XJC_ (0'PU_T#?\ R/)_\55G_A$](_YXS_\ @9-_\51_
MPB>D?\\9_P#P,F_^*H K?\(#X:_Z!O\ Y'D_^*H_X0'PU_T#?_(\G_Q56?\
MA$](_P">,_\ X&3?_%4?\(GI'_/&?_P,F_\ BJ *W_" ^&O^@;_Y'D_^*H_X
M0'PU_P! W_R/)_\ %59_X1/2/^>,_P#X&3?_ !5'_")Z1_SQG_\  R;_ .*H
M K?\(#X:_P"@;_Y'D_\ BJ/^$!\-?] W_P CR?\ Q56?^$3TC_GC/_X&3?\
MQ5'_  B>D?\ /&?_ ,#)O_BJ *W_  @/AK_H&_\ D>3_ .*H_P"$!\-?] W_
M ,CR?_%59_X1/2/^>,__ (&3?_%4?\(GI'_/&?\ \#)O_BJ *W_" ^&O^@;_
M .1Y/_BJ/^$!\-?] W_R/)_\55G_ (1/2/\ GC/_ .!DW_Q5'_")Z1_SQG_\
M#)O_ (J@"M_P@/AK_H&_^1Y/_BJ/^$!\-?\ 0-_\CR?_ !56?^$3TC_GC/\
M^!DW_P 51_PB>D?\\9__  ,F_P#BJ *W_" ^&O\ H&_^1Y/_ (JC_A ?#7_0
M-_\ (\G_ ,55G_A$](_YXS_^!DW_ ,51_P (GI'_ #QG_P# R;_XJ@"M_P (
M#X:_Z!O_ )'D_P#BJ/\ A ?#7_0-_P#(\G_Q56?^$3TC_GC/_P"!DW_Q5'_"
M)Z1_SQG_ / R;_XJ@"M_P@/AK_H&_P#D>3_XJC_A ?#7_0-_\CR?_%59_P"$
M3TC_ )XS_P#@9-_\51_PB>D?\\9__ R;_P"*H K?\(#X:_Z!O_D>3_XJC_A
M?#7_ $#?_(\G_P 55G_A$](_YXS_ /@9-_\ %4?\(GI'_/&?_P #)O\ XJ@"
MM_P@/AK_ *!O_D>3_P"*H_X0'PU_T#?_ "/)_P#%59_X1/2/^>,__@9-_P#%
M4?\ ")Z1_P \9_\ P,F_^*H K?\ " ^&O^@;_P"1Y/\ XJC_ (0'PU_T#?\
MR/)_\55G_A$](_YXS_\ @9-_\51_PB>D?\\9_P#P,F_^*H K?\(#X:_Z!O\
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MXS_^!DW_ ,50!LT5C?\ ")Z1_P \9_\ P,F_^*H_X1/2/^>,_P#X&3?_ !5
M&S16-_PB>D?\\9__  ,F_P#BJ/\ A$](_P">,_\ X&3?_%4 ;-%8W_")Z1_S
MQG_\#)O_ (JC_A$](_YXS_\ @9-_\50!LT5C?\(GI'_/&?\ \#)O_BJ/^$3T
MC_GC/_X&3?\ Q5 &S16-_P (GI'_ #QG_P# R;_XJC_A$](_YXS_ /@9-_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
G%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>vrna-20221231_g2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vrna-20221231_g2.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#^17AI9@  34T *@    @ ! $[  (
M   1   (2H=I  0    !   (7)R=  $    B   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %9I8W1O<FEA
M(%-T97=A<G0    %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,W
M-P  DI(  @    ,W-P  ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M_@SXK6?BK2E\N+476[C8#A+F(C=^?R-[ECZ4 ?4?B+Q'I7A30Y]8\078M+"
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MY4 &!@$G (KYI^.UK')^T7:QD$"X^Q[\'U(7^0%>B?M76JO\/='NR!NBU01
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M\M$8@Y+JW&[=\H ]<\UV_P 6/!]GX*_9CDT"SE>>*PGB9)7 5G9I\DD#_?-
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M&6X'F"4NF3Z9VYKS+X-_$D_"3Q+JFB^+;.YAL[EPMPH3]Y:S)D9V]P0<''/
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M?M<Q_>N26;:7V\ECQC'M6YXE\,:1XOT5])\16GVNQD=7:+S7CR5.1RA!Z^]
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MH! !9F)_B;H>]0>%/A;X.\$:K)J7AC1_L-W+"8'D^U3290LK$8=R.JKSC/%
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M_=^57"\?2M/Q9X*\/^.-/AL?%%A]NMX)?.C3SI(]KX(SE&!Z$T <;^SK(S_
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M(5?['*9/'S!]O\Z[5_@I\.Y-(_LT^%K46_F+(2LDBR%@"!F0-O(Y/&<5L1^
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M))N? &<NQ/0"@#=KYR_:WF*VOA2#'#O=N3Z8$0_]FKZ-KF_%WP^\,>._L?\
MPE>F?;_L6_[/_I$L6S?MW?<9<YV+USTH J_"E@WPC\+E2"/[,A''^X*\ TZ1
M)/VT79&R!J<RY]Q P/ZBOJ#1M'L?#^C6NE:1!]GLK1!'#%O9MB^F6))_$USL
M?PJ\&0^,#XICT;&M&X:Y-U]JF/[PYRVW?M[GC&* /"OVH=6OF\>Z-I&H/<)H
M26R7'EQ<"1S(P=AV+!0 ,],^]6?$_BKX&VOPXU&P\*:=:3:G/9M%;,VF.TT<
MA7"L995X()SD-FOH+Q+X2T'QAIZV7B72X-0@4[D$@(9#W*L,,OX$5SUA\%/A
MWID<R6OA:U(FC:-C-)),P5A@[2[$J<'J,$=J /-?V4[J&#PEXE,IVB&YCED)
M'1?+/_Q)J]XB^)'P-^(&GA_%+XN-F$>2QF6XC]A)&I_+<17IWACX;^%/!L%_
M#X<TK[)%J**ETAN)91* & &'8X^\W3UK#F^ GPTGG,K^%XPQ.<)=SHO_ 'R'
M _2@#P+X(#[+^T)'!X-N;JZT7,ZR2RIM+VVP[2X[?-LQTYQP,XJ#XKZ!<_#S
MXX2Z[>Z7#J6EWU\VH11W40>&Y#MNEB8$$9!9AWQE37UAX=\):!X3M6M_#FDV
MNG1O]\PQX9_]YNK?B:MZMH^FZ[I[V.M6-O?VC\M#<1AU)['![^] 'B^E_$WX
M"R6:7;Z-I.FW.W)@?0 9%..1N2,K[=:]&^'/B7PKXITB]O?!%@MI8Q71@D=+
M1;<2R!5;( Y/##D@5E'X!_#,W'G'PO'NSG NY]O_ 'SYF/TKLM"\.Z1X8TW[
M!X?TZ#3[7>7,4";0S$ %CZG  R?04 :5?/'Q6^/@;4KKPCX1NETYEE>UO=9N
M5<K"1E6$816;J"-X!]A_%7T/7GM[\"/AQJ%_<7MYX=\VXN96EE<WUR-SL<DX
M$F.IH \W^&GB_P"#GPPTQOLOB*34]6N1BZO_ .SIU;']Q04^5<]LDD]>V.@_
M:;O(9O@W92H6V76I0&/*XSF.1N1VX%=#_P ,^?#'_H6?_)^Y_P#CE=9XG\%>
M'_&.BP:3XDL/MEC;RK-%%YTD>UU4J#E&!/#$<GO0!X=\$OC+X-\*?#2#1/$F
MHR6-Y:S2L%^S22"168L""BGUQSCI7!>,M5NOCS\:+:W\.6TPM-B6L!=>8X%8
MEYG'0#+,?IM'7BOH^X^"7P[NM,M;";PQ;F"T4K$5FE60 L6(,@;>W+$\D]:W
M_#/@KPYX-MWA\,Z1;Z>),>8T8)=\=-SL2Q_$T ;%M;QVEI#;0C$<*+&@)Z #
M K.\5Z<^L>#-:TR)=SWFGSVZJ#U+QLH'ZUK44 ?(/[/GQ'T/X>ZMKEMXJEDL
MX-02';/Y+.(WB+_*RJ"W/F'MVKTS]HC6M/U[X%V&J:5<B>SO=0A>WD*E/,&R
M3LP!['@CM7>:[\'? /B357U+5_#=O)=R-NDDBEDA\QNY81LH8^Y&:T=8^'GA
M;7_"]EX<U725ETFQ=7MK9)I(Q&55E7E&!/#,.3WH Y+]G)@?@EI8!!(GN ?;
M]ZU+^T9_R1'5?^NUO_Z.6N[\->%]'\'Z*ND^';/['9([.L7FO)AFY)RY)_6E
M\2>&=)\7:))I'B&U-W8RLK/#YKQ[BIR.4(/4>M 'C/P"U&ZM/V>/$-SI,327
M]E/>- FW.^40(Z@#OR0*\K^$FL_#[^V]6U+XM,UW>3,KV\MW%)/&S$L9"P0$
MEB=OW@17UIX4\':%X(TJ33?#%C]AM)9C.\?G/)ERJJ3EV)Z*O&<<5@ZK\%OA
M[K6JOJ.H>&;=KF1][M%+)"K-G))5&"DD]>.: /EKXK>(?!NL?$.PO/ EE!::
M3;6T4<HM[(6ZR2+([,P0 9^4J,D \>U>]_M0?\DBC_["4/\ Z"]=/J'P2^'6
MIQVZ7/A>V5;="D8MY9(."<_-L8;C[MDUO^)?!>@>,-$ATCQ'8F\L8)%ECB\^
M1,,JE0=R,">&/4T >:_ /5;;0OV?9=6ORPMK&2[N)=HRVU/F.!W.!P*R/%OC
M;X#^/K-Y]?N#'?LF!<16,\=ROI\ZH5;'HQ(KUW2/ GAO0O"T_AS3-,6/2+@N
M9;625Y5?< &R78G!QTS7-GX!?#,S^:?#";LYP+RXV_\ ?/F8_2@#Q7]F1KR+
MXJ:I#I$L\VC?9)/.=TVA@''E,PZ!CSQ[M[U]7UFZ%X=T?PS8?8O#^FVVGV^<
ME+>,+N/J3U)]SS6E0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5YSXA^!G@_Q5XVN/$VNI?7-S<^7YMM]HV0
MML0(.% ;HHS\U>C44 06-C:Z;8PV6GV\=M:P($BAB4*J*.@ '2IZ** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "J.LZ-IWB#29],UJSBO;*<8DAE&0W<?0@\@CD5>HH
M \:O?V7? 5U<&2"?6;)2>(H+I"H_[[1C^M;_ (7^!'@3PK>17EMILE_=PD-'
M-?R^:5([A<!<^^WBO1J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** ,GQ7JTV@^#-:U>U1))]/T^>ZC20':S1QLP!Q@XR*A\%:U<>
M)/ VC:S>I%'<7]G'/*D((0,R@D $DX^I-5_B/_R2SQ7_ -@6\_\ 1#USGATX
M_9HM2/\ H66_])S0!Z/17A_P]^$.F^+/AOHNH>.KV]U>66RC^PQ)<O%%81;?
MD$:J0"V,$L0>?7J:_P /_!E]X\MM6TOQYKU[JVA^&M4GTBWL%F:+[0T1_P!9
M,ZD,^ RA1GC!_$ ]XHKROX>V+^"_BGX@\$V5U<3:(+&'4M/@GD,GV0%BCHK$
MYVYZ#V]<DYVJ>';OQ7\>M?TK^U[G3M+;2[22^2S;9+<J"X6,/_"I+$MCDXQW
MH ]EHKQ?Q)X-T_X17VB^)O IN;&W?4X;34[!KJ22*[BE.TL0Y/S@XP??VJ]\
M8['4-3\:^ +#1]0;3;JYO+J,7:#YH5,(#LO^ULW8/KB@#UJBO.V\+>'/@_X6
MU_Q+H-M<&YCL6><SW4DIN9%R59MQ."6(R1CKTK)T+X-Z-XGT&TUGXBR7FNZY
M?Q+<RRR7LJ);LXW;(E1@ JY []/3B@#UJBO*O!]E/IGBWQ-\,=7O;C5M%;3E
MNK%[N3?+';RYCDA9CU /3V_*M'X+7MQ'X/N?#.IL6U#PQ>R:;*6&"\:G,3@?
MW2A '^[0!Z)17E7@K4TDB\<_$^[W2VT[RK9<_P#+G:*P!7TW,&)]Z\XT[Q#\
M(_$]A'JWQ2\2W6JZ_=#S98BEZD5B3R(HEC4* O3.3D@GO0!].45Y'\$_%%IJ
M.J>(] T36;K7-!TUH9=-O+L/YJ)(IW0DN Q"LO&1T_"L'P-\/X_&^O>.&\2:
MA=3:!!XJOT32(9FB26;<-TDC*0S#:4 &>,'UY />J*\&L/!.HVOQ0U+X=:7X
MCO[+P@;./5'M4F)F5"=AMTE/*H6Y//0 =R3JOX4LOA7\4O"C>#VN+/2==EEL
M;_3VN'EC9PFY)!O)(;(Y.>@XZG(![)17D?QC\9Z?IWB'1?"^MZ_<:!I%Y%)=
M:C=6B.9I44[4A4HI*ACNR<=%QWKSK6M?^$GAK3GUCX5>(;O3?$5JRRQ1J+UH
M[W##='*)1M(89[CF@#ZAHKR3XUR7VJ>%/!#Z1.+"_O/$M@;:5UW""1TDVL1W
MP2#CVJ#Q3\&=(TOPAJ.O:=J.JMXKL+5[M-;EOI#-+)&I?##.T*<8P!P.] 'J
M/B+5QX?\+ZKK+0^>-.LYKHQ!MOF>6A;;G!QG&,XJ+PKK@\3>$M+UL6_V;^T+
M6.X\G?O\O<H.W=@9QZX%<!XOL-,^(G[/J^(/$-D)[R#09-2@(D=!%<?9BVX!
M2 1N'0Y'M1\&_AOX4TSPKX=\56.E>5K4^G(\EU]IE.XNGS'86V\Y]* /5:*\
M%&E>%?$_Q,\2:=\7IYEU5=08:+;W=Y);P?8\ 1-"595+GG/)Y[9S7M6@Z-#X
M>T.VTJTGN9X+52L;W4OF2;<D@%CUQG ]@* &^(H-7N?#=_#X;NH;/5GA86D\
MZ[DCD[$C!X_ _0U-I$=_#HEC%K,\=QJ*6\:W4T2X224*-[*,# +9(X%<]\5.
M/A)XI_[!<_\ Z :Y3Q^3_P ,L2G//]BVG_M*@#UBBO*+3X(Z5KVA17GC34M0
MU;Q#/"'&I"Z>/[(Q4<0HI"A1VR#GVZ5O?![6M1UKX;VIUN=KF_LIYK&:=CDR
MF*0J&)[G &3W.30!W-<!\#M3OM8^#.AWVK7EQ?7<OVCS+BXD,COBXD RQY.
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M<616#%<\@=O?K7G_ .S_ /#?PIJ'@71?%EWI7F:W%<RNEU]IE&"DC!3L#;>
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M A=H  .0=QR>]:5D3_PTOJ@SQ_PC,/\ Z4&@#T>BO//&?@OPOJVK7&H_$CQ
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MJB@#DOBIS\)/%/\ V"Y__0#7*>/P?^&6)1CG^Q;3_P!I5ZQ10!7T_C3+7/\
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MU'2+:)E^S:DUL\MM<J5!R&0$@@DC&.W6N^HH \A;78_BI\2/"]WX4LKF31=
MGDN[C6+BW:&.0LFU8HMP!8DXST[5Z]110!Y9\7)5T/QAX%\77L-PVEZ->7*7
MLL,1D\A98P [  G *]?ZD5>\6^*=+\8_ SQ3JF@2RSV1L+F-)9('B\S"<E0P
M!QSUQV->BT4 8O@T8\!Z #_T#;?_ -%+7)60/_#2^J'''_",P_\ I0:]'HH
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M .?XK^).G_$GPW<^%/AK'<ZS>ZLOV::Z-I)%;V4;??>1G4?PYP!W(^A]BHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BD9@JEF(  R2>U5=,U;3M:LQ=Z-J%KJ%L6*B>TF65"1U&Y21F@"W1110 4
M444 %%%% !1110 4444 %%%% !15.WUC3+O4KC3K74;2>]M0#<6T<ZM)"#TW
M*#E?QJ*+Q%HD^LOI$&L6$FIH"7LDND,RXZY0'<,?2@#1HHHH **** "BFR2)
M#$TDKJD:*69V. H'4D]A5?3=4L-8L4O=(OK:_M7)"SVLRRHQ!P<,I(.#Q0!:
MHHHH **** "BBB@ HHHH **** "BBJFI:KI^C637FL7]M86JD!I[J98D!/ !
M9B!S0!;HI$=9(U>-@Z, 593D$>HI: "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "L:UU.XE\<ZII;E?LUMIMG<QC;SOEEN5;GTQ"GZ^M;
M-<W8_P#)4]=_[ NF_P#H^^H Z2BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HJGINL:9K,,DNCZC:7\<4ABD>UG64(XZJ2I.#R.*N
M4 %%%% !1110 4444 %%%% !1110 4453AUC3+C59],M]1M)=0MU#S6B3JTL
M2G&"R Y Y')'<4 7**S5\1:(^M?V.FL:>VJ<_P"@BZ0S\#)_=YW=.>E:5 !1
M110 444CNL:,[L%51DL3@ >M "T54TW5=.UFS%WH]_:W]L6*B:UF65"1U&Y2
M1D5;H **** "BBB@ HHHH **IZ9K&F:U!)-H^HVFH11R&)Y+6=955QU4E2<'
MD<>]7* "BBB@ HHHH ***IWVL:9ID]K#J6HVEG+>2>5;1W$ZQM._'RH"?F/(
MX'J* +E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% 'RKI%QX4U+Q]X@L_CI+J%OKQO6%E<
M3SRQ0VZ9. A4X4=P3\N,<^O5?%SQ'XG\,:KX$TSPS_:$NFQR0I;WJ:L VL$>
M6/+DQCJ,9=LJ=Y.*N>/_ !!>>.O"=WH-_P#";Q =>D0QVTTEHCP6TG9UN0>W
M7@ 'H>#6;XM\ >)M"^'/PX5+"YUJY\-WHFOH+%/-E"LXDVJH^\%QLR/0=J .
M_P!8^*6H^';WP78:_P"%C97_ (GO'M9;<:@LGV(B5$5MRJ1)D2*V!C'2M'5/
MB*--^,FC> _[+\PZI9-=_;OM&/*P)CM\O;S_ *GKN'WO:N&^*=MKGB=/ /CC
M2/#&K/'HNHM<W.E20;;U4\V,C]V">HA/')&X9[XKPQ^(_$_[2OA;Q9<>$]5T
MG2([*:WCDNX<,JB*8[I0N1$2TN I.3@>M &[=_&6XU2]UV#PUX/O]9T72-\-
M]JD%PBE2 03'$1F0#!/!SCG'2N!^%GQ#;X;_  .LM3FTAM0L;C7I+:YE2?8;
M8%$(;&T[N W''( SS6KX(C\6_#5?%'A1?!>J:M<7][)-IU] H^R.&&T&24G"
M# ![GD@@59^&_P /=0U7]F_6O"^NZ;<:?>W5S.\$5W"8V5P$,;88 XW+U[C-
M 'HGB?XCQZ%XW\,>&;#3O[3N=>?)9+C9]GAR/WN-IW#&\XX^X>:Z?6])37-%
MN--FN;JUCN%"O+9RF*4#() 8<C.,'V)KY]_9VM-2\5>,;GQ/KV7&@:;#H]GN
M7[I QU]0H.?^NE>Y>.-;U+P[X,U#4M#TJXU;48D M[2WB:1G=B%!*KR0,Y..
MP- '@OBWP[8> OCYX0L/AO+=VU[>21'4+6.Y>7<ADY+EB3RF\D$X &<#K71-
MI<'Q7^/WB31_%;3W&@^'[98[?3DG>)&D.WYVVD9.2YZC^'TK%^&&HS>%=0O?
M$7BSP+XZU?Q5J4C&>]&ADI"I/W4)8'GC)P.    .>DN;;7/AK\;]>\31^&]6
MU[0]?MUP=(M_/EBF&WAESD#(;G@88=<8H S_ (9LR0_$7P)K>L:@NBZ%<$PW
M<4[>=!;AGW*& ) VQC( [MCK7*63>$Y_C5X6B^"-]/;9EWZK+-<2I'<(&4LN
M)B&=BN_*@<Y&.A(] ^'ND>*/#-MXN\=ZCX:N)]3UZ^6:+1DE5)HX [$GG@L
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MF:8=5O/$4H$<8G\KR(CM_>'Y6R/F)QQ]T\\5YU<?#:?PM^RMKUAK;*NJ7/\
MQ,[K+@^7(KH0F[H3M0 ^Y.,U8^ _A[5?$E[;_$'Q6,M;6$>F:/&1C$4:;'E_
M'YA[EG[8H ]WHHHH **** "BBB@ HHHH **** "BBB@ KF['_DJ>N_\ 8%TW
M_P!'WU=)7-V/_)4]=_[ NF_^C[Z@#I**** "BBB@ HHHH **** "BBB@ HHH
MH **** "OEB"Y\+WOQ0\26?QU;4(M1-X1IDTLTL<%O%N8+LV$;1C;ACE<#)Y
MR3]3UXEX^\1W7B_PUJ'A_4_A/X@FUB2.2*SG-HLMO!(00LJW /&#@\#GH>M
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MOP5X6N?$VJV,8>^5+M+>*V/=#(P(+#ICUXZ@XATSXV:?J/PY\0>)7TF>TN]
M8QW>FSR@,)<X50^.A;C.W((/'KQOA"Y\3?"W7O&-M=^!]<UJ\U:_:YL[RP@\
MV";E]OF2?P#YL]R,G@5R_B_PMK'@KX&SVFM;7\1>,M<CDN;>-@=@Y<)GH3O
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YNQ
M_P"2IZ[_ -@73?\ T??5TE<W8_\ )4]=_P"P+IO_ */OJ .DHHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@WQ3,V][A$;YNN-K$;>GMFD\>:BL/@#X-7#2Q37L AFCMKN18[>546+/FNQ
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M %%%% !1110 4444 %%%% !7-V/_ "5/7?\ L"Z;_P"C[ZNDKF['_DJ>N_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M X')Q63J'Q&T&PT&ZU0F\D6SGA@GM3:O!<1F5PB%HI@C!26SDC! .,XH O\
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M;P233-MCC4NQQG  R:Y[2/'NAZ]]E.E#59XKO!AN/[%O$A<'H?-:((![DXH
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M83LSDE23FN@\5:?>6OQ%\)^(["VFN(D>;3+Y88RY2*8 I(0 <*LB+D] &R<
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MU$'PPLD71(KK7M;O;?09XI].MYYH@D)C&%!V1J7&.,N68#H1DYSO$WA8:_\
M'+PO>_8;A8=)LI;JYN_+/DRD.!!%NQ@NK[GQG('..0: .XT*PETKP_86%S=3
M7D]M;I%+<SR&1YG"@,[,>22<G\:XCQ]./%WB72_ VDKYT\%W!J6JW"_=L((V
MWJ&/:20@!5ZXRQ&.:]&(RI ./<=JXC1?AJ_AZ.Y72/&/B"$W<[7-Q(R64CS2
M-U9G>V+$_4\=J ,'Q3)K?_"W)9_AOY%UKD&E+#JMOJ*_Z&D1+O"=X8.)2V0%
M ((;)*XR=CX026S>%+Y<72:LNJ7#:TEU&J,M\Q#2X"DKL^8;2I((QWS6Q?\
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MN=^(/PSO?$WBS1M=T&\M[22*XMQJD4Y8+<PQ2B1", _O%(8#.,AL9 %>DT4
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MP@)]<#OP*GH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1R>PHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB.-@2&9CG+GOZ5Z)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %<W8_\E3UW_L"Z;_Z/OJZ2N;L?^2IZ[_V!=-_]'WU '24444
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ME:E</I3"?XX>(9;1@T$&CV<%R5.0)_,F8*?]H(P./1AZBNXH **** "BBB@
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MKFNUKRX/>^*-/\%Z)'HVIV=UI5[;7>IO=V3PPVPME.561E"REGVJOEEL@D\
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MBBB@ HHHH [/X8_\C-<?]>;?^AI7J=>6?#'_ )&:X_Z\V_\ 0TKU.@ HHHH
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M/1M3L[K2KVVN]3>[LGAAMA;*<JLC*%E+/M5?++9!)X KU&BB@ HHHH ****
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M $6M<[0 4444 =%X#_Y':P_[:?\ HMJ]DKQOP'_R.UA_VT_]%M7LE !1110
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M*** .\\-_P#(OVW_  +_ -#-:E9?AO\ Y%^V_P"!?^AFM2@ HHHH \2\4?\
M)Y/@S_L"R?\ H%Y7MM59-+L)=3BU&6QMGOH5V1W30J947G@/C('S-QGN?6K5
M !7/>//^1)O_ /MG_P"C%KH:Y[QY_P B3?\ _;/_ -&+0!XU1110 4444 =G
M\,?^1FN/^O-O_0TKU.O+/AC_ ,C-<?\ 7FW_ *&E>IT %%%% 'G'P0\!:M\.
M_!-YI.O26KW$VHO<J;60NNPQQJ,D@<Y0_I7H]8WA?Q=H?C32Y-1\,WZWUI%,
M8'D$;IAPJL1A@#T9?SK9H **** /FCQ5_P CCK/_ %_S_P#HQJRJU?%7_(XZ
MS_U_S_\ HQJRJ "BBB@ KZ7\*_\ (G:-_P!>$'_HM:^:*^E_"O\ R)VC?]>$
M'_HM: -6BBB@ HHHH **** "BBB@ HHHH **** "N;L?^2IZ[_V!=-_]'WU=
M)7-V/_)4]=_[ NF_^C[Z@#I**** "BBB@ HHHH **** "BBB@ HK@O'OB.YT
M/7].34=9N/#OAZ6WE:75;:WCD)N05V0L9(Y%12NX@E?F(P#V.;I?B;Q-J]KX
M5T6XO)+"\UA;NYDU);:,3M:0L/*<1L&1))5>,G*D#+84'& #T^BN3\':KJ,F
MM>(O#VLWC:A/HUS'Y5Z\2QO-#-&)$WA %W*=RY4 $ <9SGK* "BBB@ HHHH
M**** "O+H_&OC%OC"VA-I?\ Q)P2OF^01^[\P@2[?O\ /W=^=G&<<UZC10 4
M444 %%%% !1110 4444 %%%% !1110!Y?1110 4444 =EX0_Y!$O_7<_^@K6
M]6#X0_Y!$O\ UW/_ *"M;U !1110 4444 %%%% !1110!XWX\_Y':_\ ^V?_
M *+6N=KHO'G_ ".U_P#]L_\ T6M<[0 4444 =%X#_P"1VL/^VG_HMJ]DKQOP
M'_R.UA_VT_\ 1;5[)0 4444 %%%% 'E/B#PKK=W^T_X7\2V^GR2:/9Z6\,]V
M&7;&Y6Y !&<_\M$[=Z]6JI)JVG0ZI%IDM_:I?S)OBM&F42R+SR$SDCY6Y ['
MTJW0 4444 >4_&W_ )@G_;Q_[3KRFO5OC;_S!/\ MX_]IUY30 4444 %?5E?
M*=?5E !1110!EZ!XDT;Q38/>^'M1@U"VCE,+2P-D!P 2OUPP/XUJ5XE^RI_R
M2S4O^PU+_P"B(*]MH **** "BBB@ HHHH **QO$L'B.>RB7PG>Z?9W(DS*]_
M TJE,'@!6&#G'-<I)%\387*2^*/":,.JM8R@_P#HR@#M=$UJR\0Z-!JFENTE
MK/N\MF4J3M8J>#[@U?KGO >A2>&O ^G:3/=PWDMNK[YX1A'+.S<#_@6*M>)?
M$^F^$])-_JK2D,VR&"WB,LUQ)@D(B#DL0#[#!)( )H UZ*YT^-M+'@JP\3%+
MG[-J,4+VEL(P9YGE \N)5!QO)('7 ZD@ FG:5XPM;^]O[&_LKS1;[3X5N9[;
M4/+!\ALXE#1NZ%<JP.&R"IR!QD Z"BN3T_X@V5]>::DNE:I96>KL4TW4+J*-
M8;L[2R@!7+H70%E\Q$R!Z\5UE !1110 4444 07O_'A<?]<F_E7(5U][_P >
M%Q_UR;^5<A0 4444 %7M'_Y"T/\ P+_T$U1J]H__ "%H?^!?^@F@#J**** "
MBBB@ HHHH *X/Q)_R,%S_P !_P#0!7>5P?B3_D8+G_@/_H H RZ*** "BBB@
M#O/#?_(OVW_ O_0S6I67X;_Y%^V_X%_Z&:U* "BBB@#RCQ!XIUJT_:@\+^'+
M?4)(]'O-+>:>T &V1PMR0QXS_ G?M7J]>::YX'UF_P#VBO#GC&W2$Z1I^FO;
M3L9 '#E;@#"]Q^]7]:]+H *Y[QY_R)-__P!L_P#T8M=#7/>//^1)O_\ MG_Z
M,6@#QJBBB@ HHHH [/X8_P#(S7'_ %YM_P"AI7J=>6?#'_D9KC_KS;_T-*]3
MH **** /$OV5/^26:E_V&I?_ $1!7MM8GA3P=H7@C2I--\,6/V&TEF,[Q^<\
MF7*JI.78GHJ\9QQ6W0 4444 ?-'BK_D<=9_Z_P"?_P!&-656KXJ_Y''6?^O^
M?_T8U95 !1110 5]+^%?^1.T;_KP@_\ 1:U\T5]+^%?^1.T;_KP@_P#1:T :
MM%%% !1110 4444 %%%% !1110 4444 %<W8_P#)4]=_[ NF_P#H^^KI*YNQ
M_P"2IZ[_ -@73?\ T??4 =)1110 4444 %%%% !575-0CTG1[S49U9XK.!YW
M5/O$(I8@9[\5#K>D_P!MZ:UG_:%]I^6#>?83>5*,=MV#Q7DVI3>"2]YIMY\0
M/&MTJE[:X6!KFXC)Y5TW) 5/<'!H ]BLKI+ZPM[N,,J3Q+*H;J PR,_G4]5]
M/CABTNUCM-WD)"BQ;P0VT*,9!YSBK% ''ZYX>UAO'EKXETFWTW4Q#I[V2V>H
MW#P"W8ON,L;K')RRG8PVC(5>>H.)I?PZU?P_#H^HZ2VFMJ6GW=Y-_9Y=XK1(
M;I@SV\3A6**A"E3LP<'Y5W<>ET4 <WX4\/WNFW^LZQK3VYU/6KE)98K4EHH(
MXT$<<89@"Y"C)8A<ECP,5TE%% !1110 4444 %5=0O?L-NLOE^9EMN-V.Q_P
MJU67K_\ QX)_UU'\C0!!_P )%_TZ_P#D3_ZU'_"1?].O_D3_ .M6)10!M_\
M"1?].O\ Y$_^M1_PD7_3K_Y$_P#K5B44 =G!)YUO'+C&]0V,],BGU!9?\>%O
M_P!<E_E4] !1110 4444 %%%% !1110!Y?1110 4444 =EX0_P"01+_UW/\
MZ"M;U8/A#_D$2_\ 7<_^@K6]0 4444 %%%% !1110 4444 >-^//^1VO_P#M
MG_Z+6N=KHO'G_([7_P#VS_\ 1:USM !1110!T7@/_D=K#_MI_P"BVKV2O&_
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MQ1O=3K$'<H<*"Q&3P>/:KFCS:C<:1;RZW:0V=\RDS00S>:B')P V!GC':KM
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M61@>54@[ACC)WJ "BBB@ HHHH *R]?\ ^/!/^NH_D:U*R]?_ ./!/^NH_D:
M.=HHHH **** .OLO^/"W_P"N2_RJ>H++_CPM_P#KDO\ *IZ "BBB@ HHHH *
M*** "BBB@#R^BBB@ HHHH [+PA_R")?^NY_]!6MZL'PA_P @B7_KN?\ T%:W
MJ "BBB@ HHHH **** "BBB@#QOQY_P CM?\ _;/_ -%K7.UT7CS_ )':_P#^
MV?\ Z+6N=H **** .B\!_P#([6'_ &T_]%M7LE>-^ _^1VL/^VG_ *+:O9*
M"BBB@ HHHH XG5/B+_9OQDT;P%_9?F_VI9-=_;OM&/*P)CM\O;S_ *GKN'WO
M;GMJ\4\3HY_;&\&N%8J-&D!;' ^2[KVN@ HHHH \I^-O_,$_[>/_ &G7E->K
M?&W_ )@G_;Q_[3KRF@ HHHH *^K*^4Z^K* "BBB@#QW]F;2M1T?X::A;ZO87
M5A,VKR.L=U"T3%?)A&0& .,@\^QKV*BB@ HHHH **** "BBB@ HHHH ****
M*FJ:K9:)I<^HZK<I;6ENNZ25^@'0  <DDD  <DD 9)K/T[QCHFIRW<4-U+;3
M6<(GGAO[66SDCBY_>%9E4[.#\V,<=:R?BG+:)X$E@O8))OM5U;6\!2<0>5.T
MR>5(9"K! K[6)*L.,$'.*\V\9VNN6-OXKTWQ%?#7=;N/"YE@OK51 (K6)T$J
M- ,A6=B[;\G=@@!0H6@#US2/&NA:W?QV=A=3>?-$9X%N+.:W%Q&,9>(R(HD7
MD'*$C!!Z&MZN"\2W-OJ'CCX??V1+'*6N)[M#"P(^R_97!?C^ ED&>F2*[V@
MHHHH **** (+W_CPN/\ KDW\JY"NOO?^/"X_ZY-_*N0H **** "KVC_\A:'_
M (%_Z":HU>T?_D+0_P# O_030!U%%%% !1110 4444 %<'XD_P"1@N?^ _\
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M>%Q_UR;^5<A77WO_ !X7'_7)OY5R% !1110 5>T?_D+0_P# O_035&KVC_\
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MC7?USUYXXT6P\>V'@ZXEE&KZA;FX@01$H4 <G+=!_JFKH: "BBB@#RGXV_\
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MPEKEY^TYX8\3VU@SZ-9:6\%Q=AU C<K<@#&=Q_UB=!WKU2@ HHHH \I^-O\
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MQCH7C?2I-2\,7WVZTBF,#R>2\>'"JQ&'4'HR\XQS6W7B7[*G_)+-2_[#4O\
MZ(@KVV@ HHHH ^:/%7_(XZS_ -?\_P#Z,:LJM7Q5_P CCK/_ %_S_P#HQJRJ
M "BBB@ KZ7\*_P#(G:-_UX0?^BUKYHKZ7\*_\B=HW_7A!_Z+6@#5HHHH ***
M* "BBB@ HHHH **** "BBB@ KF['_DJ>N_\ 8%TW_P!'WU=)7-V/_)4]=_[
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M444 %%%% '7V7_'A;_\ 7)?Y5/4%E_QX6_\ UR7^53T %%%% !1110 4444
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M)V%)+F",$-<E3@@,KD)G!V*#T(KUSQ!X?TWQ1HD^D:Y US8W&/-B69X]^""
M2A!QD#C-5K#PEI6GK.J&_NHKB$P2P:AJ=S>1,AZCRYI&7GITZ9'0F@#G?$UM
M;6'C?X>C28HXBES/:QB%1@6WV5R5&/X1M0^G KO:P=%\%:%X?NDN=-M9O.BA
M%O"]S>37)@B_N1^:[>6O X7 .!Z"MZ@ HHHH **** (+W_CPN/\ KDW\JY"N
MOO?^/"X_ZY-_*N0H **** "KVC_\A:'_ (%_Z":HU>T?_D+0_P# O_030!U%
M%%% !1110 4444 %<'XD_P"1@N?^ _\ H KO*X/Q)_R,%S_P'_T 4 9=%%%
M!1110!WGAO\ Y%^V_P"!?^AFM2LOPW_R+]M_P+_T,UJ4 %%%% 'FNM^!M9O_
M -HGP[XRMU@_LG3M.>VG+28DWE;@#"]Q^]7]:]*K(N/%6B6GBJT\-7&H1QZQ
M>1&:"T*MND0!B2#C'_+-^_:M>@ KGO'G_(DW_P#VS_\ 1BUT-<]X\_Y$F_\
M^V?_ *,6@#QJBBB@ HHHH [/X8_\C-<?]>;?^AI7J=>6?#'_ )&:X_Z\V_\
M0TKU.@ HHHH QO"_A'0_!>ER:=X9L%L;268SO&)'?+E54G+$GHJ_E6S7G'P0
M\>ZM\1/!-YJVO1VJ7$.HO;*+6,HNP1QL,@D\Y<_I7H] !1110!\T>*O^1QUG
M_K_G_P#1C5E5J^*O^1QUG_K_ )__ $8U95 !1110 5]+^%?^1.T;_KP@_P#1
M:U\T5]+^%?\ D3M&_P"O"#_T6M &K1110 4444 %%%% !1110 4444 %%%%
M!7-V/_)4]=_[ NF_^C[ZNDKF['_DJ>N_]@73?_1]]0!TE%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %9>O_P#'@G_74?R-:E9>O_\ '@G_
M %U'\C0!SM%%% !1110!U]E_QX6__7)?Y5/4%E_QX6__ %R7^53T %%%% !1
M110 4444 %%%% 'E]%%% !1110!V7A#_ )!$O_7<_P#H*UO5@^$/^01+_P!=
MS_Z"M;U !1110 4444 %%%% !1110!XWX\_Y':__ .V?_HM:YVNB\>?\CM?_
M /;/_P!%K7.T %%%% '1> _^1VL/^VG_ *+:O9*\;\!_\CM8?]M/_1;5[)0
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M17&X ^F0/>IMUQ_SRB_[^G_XF@"6BHMUQ_SRB_[^G_XFC=<?\\HO^_I_^)H
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MD$<KL) 2/+8<8/J*U** .1^P7?\ S[2_]\&C[!=_\^TO_?!KKJ* .1^P7?\
MS[2_]\&C[!=_\^TO_?!KKJ* *MK,L=G"CI*&6-01Y3<''TJ7[2G]V7_OTW^%
M2T4 1?:4_NR_]^F_PH^TI_=E_P"_3?X5+10!%]I3^[+_ -^F_P */M*?W9?^
M_3?X5+10!%]I3^[+_P!^F_PH^TI_=E_[]-_A4M% $7VE/[LO_?IO\*/M*?W9
M?^_3?X5+10!Y]_8FI?\ /G+^5']B:E_SYR_E7H-% 'GW]B:E_P ^<OY4?V)J
M7_/G+^5>@T4 8?AR*6PTZ2*[AEC<RE@/+)XP/0>U:_VE/[LO_?IO\*EHH B^
MTI_=E_[]-_A1]I3^[+_WZ;_"I:* (OM*?W9?^_3?X4?:4_NR_P#?IO\ "I:*
M (OM*?W9?^_3?X4?:4_NR_\ ?IO\*EHH B^TI_=E_P"_3?X4?:4_NR_]^F_P
MJ6B@#R_Q;X;UC4_%%W=V-A++!)LVOPN<(H/!YZ@UB_\ "&>(/^@9+_WTO^->
MU44 >*_\(9X@_P"@9+_WTO\ C1_PAGB#_H&2_P#?2_XU[510!Y?X2\-ZQIGB
MBTN[ZPEB@CW[GX;&48#@<]2*]+^TI_=E_P"_3?X5+10!%]I3^[+_ -^F_P *
M/M*?W9?^_3?X5+10!%]I3^[+_P!^F_PH^TI_=E_[]-_A4M% 'B7B8._[7_@^
MY6&8PIH\BL_E-@'9=^WN*]H^TI_=E_[]-_A4M% $7VE/[LO_ 'Z;_"C[2G]V
M7_OTW^%2T4 ><_%+0=4\1_V5_8UE+<_9_.\SC9MW;,?>QG[IKS[_ (5WXK_Z
M \O_ '\3_P"*KZ'HH ^>/^%=^*_^@/+_ -_$_P#BJ/\ A7?BO_H#R_\ ?Q/_
M (JOH>B@#YX_X5WXK_Z \O\ W\3_ .*KZ"^TI_=E_P"_3?X5+10!%]I3^[+_
M -^F_P */M*?W9?^_3?X5+10!%]I3^[+_P!^F_PI5G1F  DR?6-A_2O%OV5/
M^26:E_V&I?\ T1!7MM !1110 4444 %%%% !1110 4444 %0WEI!?V,]G>1+
M-;W$;12QMT=&&"#]0:FHH Y;2O 5IIU]IT]SJNJ:HFDJRZ=;WTD9CM,KMR-B
M*78+\H:0N0"<'))/4T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% 'GNL?$'4M.^/6@>!H;:U;3]3T][J6=
ME;SE8+.<*=V,?N5Z@]37H5>0>(]%U6?]K#PGJ\&F7DFF6^DR1S7J6[&&-MMU
M\K.!M!^9>"?XAZUZ_0 4444 %%%% !1110 4444 %%%% 'B7[*G_ "2S4O\
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MGD'$S]O84 <=^RI_R2S4O^PU+_Z(@KVVJUAIMCI<#0:996]G$S;S';Q+&I;
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MB@ KF['_ )*GKO\ V!=-_P#1]]725S=C_P E3UW_ + NF_\ H^^H Z2BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5OX=MDU,2F82AGVJ^<[A'NV YYR%ZT[7_A7X*\4:XNL:[H%O=WXQF8NZ;\8
MWJK /P /F!XXH \D^(VCVE]^R]HVOZE;M/J\&EV,45S,S%D5F3) )P"1U;&2
M.^*^@=._Y!=K_P!<4_\ 017.^*?AGX0\:36LGB71UNVLXS%!MN)8A&GH!&RB
MM;PYX:TGPEH<6D>'[3[)8PLS)%YCR8+$D\L2>I/>@#4HHHH **** "N;L?\
MDJ>N_P#8%TW_ -'WU=)7-V/_ "5/7?\ L"Z;_P"C[Z@#I**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC9678D@)5@2,,#M/()QCG% &A15+2M6L]<T>WU32I3<6=U'YD,FQDWJ>A 8
M\^]<QX2\5>(-8\9ZYI/B#2K72X[.WMKBV@CE\V95E,@(E<'86_=YPO SC<W6
M@#M**Q/$UZ;(Z/C6?[*$VIPPD?9?/^U[@W[C_8W?W^V/>J=Y\1O"]A>7MM<Z
MC()-/E$-Z8[.:1+0D @RNJ%8U(;AV(4X;!^5L '3T57OKDVVF7-S#M9HX6D7
M/()"DC\*\^T#QKXEDC\&7FLR:3=V_BE!BVLK22":V8P&;<"TKB10%(;A<9!]
MJ /2:*P;KQKH5GJ@L;BZF5S.MN9A9S-;K*QP(VG">6K9(&"P.2!UJ2X\7Z+;
M:\='EN93>*\<<FRUE>*%Y,>6DDJJ4C9LKA68$[EX^89 -JBN>U+QUX>TF^EM
M;Z]D0V[(ES,EI-)!;,V,"694,<1Y!.]A@$$X!!K)U'7M0C\;>)--.J?8+&S\
M/1WD4WV=9?LLK-.&EVXR^ BG:3@[>G- ';T5RZ^-M%TRTTFUU'59;V^O;!+F
M'R+"5Y;Q,+F18HT)R<[BH&0,G& 2+R^+]"?PW!KJ7X?3[A@D+I&[/*Y8KY:Q
M@;R^X%=@7=D$8R* -JBLS1O$.FZ^MQ_9LTADM7$=Q!/;R030L5##?'(JNN00
M1D<CD5F2^(+72O$'B&;4]?W6>FV$-U-8_8R/L28D+2>8 3)OVGY1DC9[T =-
M16%I/C70=;U);'3;R22>2(SP^9;2Q)<1@@%XG=0LJ\CE"1R#5/QKKNK:3<>'
M[/0WLXI]6U(6;S7EN\RQKY4CY"JZ$G* ?>[T =317%^(]8\3^'M)TJ,WNDW.
MHZEK$-B+C^SI4ABCD!Y\KSR2P(Z[P.>G>G>)-9\2^$/"-QK5_<:9J8L[B*2Y
M6VT^2#%IN E*@S/EU4E@<XPI&#0!V5%<YKGB&YM?$OAW1M(6"6;4YI);AI 6
M$=I&F7<8(Y+-&H)R/FZ&NCH **YF]UF\E^)>F:!92^5;Q6$VH7WR@^8NX111
MY(R/F+MD8/[L#."08C\3O""R,)-7\N*.X:VEN9+:5;>&56*F.28IY<;94\,P
M)!4C(920#JZ*YV#QII>IZ;JDFC32-=:?;&=H+NUEMV *DHVR158H=IPPX.#S
M4N@:A>^)/AYIFI&5+._U/2HI_,A3*PRR1!LJK9X#-D YZ<YH W:*P/ VO2^)
MO!.F:K=H$NI8BERJ]!-&QCD ]MZ-4<WC_P -V^H2VDM_(/(N!:S7(M)C:Q39
M \MK@)Y2MDA2"P()P>>* .CHKGM4\=>']&U2XTV]NYVOK:%;B6VMK*>XD2)L
MXDVQHQV#:06Z*2H)&Y<[5E>VVHV,%[83)<6UQ&LL4L9RKJPR"#Z$4 3T5YQI
M?B;QOJGA2]\1V7]B726MS=*FD_9)8I)T@F="HN/.8!RJ9!,9&2 <#D=+%XZT
M271-,U.-[J6/5+<7-O!;64MS,8R 2QCB5V &X G& 2!GD4 =%16-:>+=#OYM
M*BM+]96UB![BQPC8F1 "^#C (W#*G#=>.#5S3M8L=6DO4T^?SC8W+6MP0C )
M*H!*Y(P<;ADC(SQU!H NT444 %%%% !1110 4444 %<W8_\ )4]=_P"P+IO_
M */OJZ2L*TL;F/XA:O?O$1:SZ78PQR]F=);LNOX"1#_P*@#=HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **BNI6@LYI4 +1QLP!Z9 S7G&B>.?$HTKP?
MK.NG2KJQ\32Q6Q@LK22"6UDEC+H=S2N)%&Q@1A3R#V(H ],HKG$\9Z+J=QJ&
MG:5J$QN[3SH9YH[&62.TDCR&WMLV @@D D;NV<BJEEXXT73=!T!=5UR34KO4
M[$3VT\6GR"34 H3<Z0QJ2"=X;8!D#)QA20 ==17*P?$OPG<M#Y&J,ZRRK"9!
M:S;()&;:L<S[-L+EN-LA4]..15W6/&>B:#<21:E<3J85#SR0V<TT=NIZ&5XT
M98QCGYR..>G- &[16'JWC+0]%U&WT^^NY#>74)GM[:VM9;B29 0"46-6+8SG
M YP">@)I3XQT)=$U+5VO]MEI<TD%Y(T3@PR1G#*5*[B>1C .<C&<B@#;HJM>
MZC9Z;ILNH:C<1VMI#'YDLTQV*B^ISTK-T[QAHVIS7,$$UQ#<6L/VB6WO+*:U
ME$62-X25%9ER",@$9XZT ;=%<UI'Q!\,Z[=64.EZA)+_ &@A:SE:TFCBN,+N
M94E9 C,!G*@[E*L" 5(&-\0/B-I^B>%_$*:5J,D6K6%M(J3K9R200W'E[E1I
M2AB#\KA&;)) QD@$ [ZBN=N/&NC:7/;:?J5W*VIRVD=R+2WM)9YI$;(W*D:L
M6&5;.!QU.!BII/&>@1^';37/[05["]98[5HHWDDG=C@1I$H+L^0<H%W#:V0,
M' !N45R>K>+M-O\ P7K=YI6O/H\FGQD7%U-I[F:P. P9[:10_3D KR#D9JWJ
M/CC0='U'^S+V\FDU!;=+DV]M933R&)MP$FR-&.W*')Z+QG&1D Z&BN.UWXDZ
M7I'_  CLMK!<ZG::[,%BN+2WFE58S&SAQLC;>WR@;.&P2>BFNEN]6L[#0Y]8
MO9'@LK>V:ZF>2)PR1JNYB4QN! !^7&>V,T 7**Y1?B9X3:1$&I2;IDWVP^Q3
M_P"F#('^C_)^_P"HXCW5H1>,="F\.OKB7X%@DC1,S1.L@E#;#%Y1&_S-WRA-
MNXG  Y% &W17*7WQ#T>W\,ZUJUFMW<RZ/"9)[&2RGAG4E"R;HVCWJC8_UA7:
M,,<_*<2V?CW1IO#5AK-\;K3X;V:&V1;FRG0F:4#:JAD!9<M@.!M/KUH Z:BJ
M6L:Q8:!I,VIZQ<K:V4&WS9G!(3+!03CMDCGM5+2/%VBZYJ+V&G7,IN4A^T+'
M-:RP^;%G'F1F15$B9Q\R9'(YY&0#:HKA?!GC<2?#/PYJGB6ZGNM1U*U\QEM;
M)YI92/O,(H4)VC(R0N!D9ZC.^WC'05\.0:Y]OW6%RXB@9(7:260L5\M8@N\O
MN!&P+N!!!'!H VZ*PCXST-='&I/<S)$UQ]E6%[.9;AINOEB IYI?'S;=N=OS
M=.:P?&'CJ%/AOJFM^&M0,$]C<00RM/;F*2W)GC5UDCE4%#L8_>4<$$=C0!W=
M%8ND>+=&US4);'3[B4W,<0G\J>UE@,D1) DC\Q5\Q,C&Y,CD<\C-:Q\?^&]1
MO;>VM+^1OM4K0VUP]I,EO<N,_+%.R".0_*<;6.<'&: .CHJGJVKV.A:7-J&J
MW"V]K"!N<@DDDX"@#)9B2 % ))( !)K-'C70AI%SJ4UU+;06L@BE2ZM)H)@[
M8VJ(702$MD;0%);/&: -2/3+"'4IM1ALK>.]G14FN5B422*.@9L9('8&K58=
MGXRT.^MM0FBN9HO[-C,UW#=6DUO-#'M+;S%(JOM(!P0,'! R0:J?\+%\+C1&
MUF34GBTM9(HQ?2VDR0N9#A2KL@5AG@L"0O\ $10!T]%8<_C'1[:PMKJ=KZ/[
M6[)!;-IMQ]IE*_>Q;^7YI ').W &#T-'_"9:#_PC_P#;7]H#[%YOD9\I_,\W
M=M\KRL;_ #-W&S;NSQB@#<HKBM<^)^E:39Z?<6UIJ%X+K4H["6/[!<I);EMI
M)=#$6#;75E0@%P1MS6U>>+](L$M?/:\,UW%YT5K#IUQ+<>6, NT*(9$ ) )9
M1@D \G% &W16'/XST"#0[+5OM_GV>H,$M#;0O/).QR=J1HI=B,'( R,'.,&L
MGP5XJD\3>)_%B179N-/L;N"*T1H?+:'-NAD1@5#!A(7!#\J01QC% '94444
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M66>S;RC$92S.$G8X_>#&T,>O KN+B]M;22".ZN88'N9/*@620*97P3M4'J<
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M)9G"M(#RP+X^=@&(P3J>"M.UF'Q-XKU;6]-_L]=6NX)K:+STE;RTMTC^;:2
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
=10 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>vrna-20221231_g3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vrna-20221231_g3.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#^17AI9@  34T *@    @ ! $[  (
M   1   (2H=I  0    !   (7)R=  $    B   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %9I8W1O<FEA
M(%-T97=A<G0    %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,X
M-@  DI(  @    ,X-@  ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M"BLH7;(N 1OX.?NT >PT5R7PQ\8OX\^'NG:]<)#'=3!TN(X00J2*Q4@ DD#
M!ZGK7GOA/XR^)O%OQNNO"EA9:6VBVUS<![H0R>;Y$1(#9\S&2=HSM_BZ4 >W
MT5Y7\4_CII/P\NO[)LK;^U=;*AFMU?;';@]-[<\D<A1SCKC(SYU+^T9\0M"E
MANO%/@B&VT^9OW>^UN+8N.N%D<D$X]J /IFN'N/BWX;M_B/'X( O9=7>983Y
M< \M&*;^6)'&#V!ING_$F'Q7\+=0\3^";=KR_M[>0II\D3.ZW"KD1LBG+9X^
MZ>0>*^55\7>+V^-O_"2KH(/BCSRW]EBSF^^(MA7RMWF?=YQGWZ4 ?<E%><_#
MOQIXMU;P/K.N>/-!.E7-B\C16HM);?S(TB#9"R$L<G(ST_*O-IOCG\6KQ3<:
M/\.66UY.Z33;N88QG[RE1^E 'T?7@_[07Q,\6> ]=TJV\,ZC':07EH[.&MDD
M(<-C(+ ]B./:IOA=^T'<>+/%D7AGQ7I,.GW\Y9(9K?<J>8H)*,C$E3P>YYXQ
M7+_M;?\ (4\+_P#7&Y_]"CH ^@_"=U=WW@O1+O4IO/O+C3X);B4*%\R1HU+-
M@  9))P!BK6M:C_9&@:AJ0B\XV=M)<>5NV[]BEL9P<9QC.#5+P9_R(>@?]@V
MV_\ 12T>,_\ D0]?_P"P;<_^BFH \'_X:Y_ZDG_RK?\ VFM70_VKM$O+Q8M?
M\/76F1,V//@N!<A!ZL-JG'T!/L:YO]DQO^*B\1)M4YM86R1R,.P_K6S^U7I^
M@PZ)I%VD5M%KLEV1E% DD@V-N+8Y(#;,$],GU- ':?&OQ]JOAGX:Z;XC\$W\
M)6ZO8D\\1I*CPO&[ C(/=5Y]ZUO@KXCUCQ9\+[+6/$5Y]LO9YI@TGE)'A5<J
M!A !V]*\5\20W<'[&OAQ;[=N;4 \8;J(R\Q3\,$$>Q%1?#OXN>(?#_PUL?#W
M@?PC=:Y?VK3/<W'V>26.+=(S*-L?)X())(H ^K:*\ ^'7[1E_KGC*V\-^,]'
MM[&XNYOLT<UL'C\N8G"HZ.21DX7KP>WIW?Q8^(>L^!8M+A\-^'WUN^U$RD1J
MKOY:QA,G:@)/+CN* /1**^9+_P#: ^*FA;;GQ!X'M[&RW8W7.G74&?0;V?&?
MPKVOX<?$6P^(?@W^W+>(V30NT5W!(^[R74!C\W&5P00<#]* .PHKYUU3]H[Q
M-K6N7%G\,O"1U2WMR?WLEM-</(N<;]D9&P'MDG\.E=I\(_B/XP\9ZUJ6G>,?
M#T6D/8P+)D6\L#,S,0!LD)XP#W[4 >K45Y#\4OCQ:^"-870/#]@-8ULD"6,L
M1' 6'RJ<<LQR/E&.O7/%<2G[1OCGP_?VY\=^"EM+.<_+MM9[60KW*^:2&^G'
MU% 'TI15'1-9LO$.AV>KZ5+YUG>1+-$^,$@CN.Q'0CL:;X@?4HO#6I/H$2S:
MHMI*;*-BH#3;#L!W$#&['4B@#0HKYDU;6?VD-%LYM2U".1;6$&200P6,VU1R
M>$!;&*] ^!GQ<OOB/:W]CKMM%'J6GJCF:!2J3(Q(SM[$$#V.>U 'K=%%>*?&
M;XU:[\-O%5KI6EZ58W,5Q9K<B>YWGDNRE<*1TVY_&@#VNBOF_5OVA?'UQ;OJ
MWAKP(T>A+EA>7EG/,I0?Q%T*HOZX]:[SX1_&ZS^),TNF7UFNFZS"GF")'W1S
MH.K(3R",\J<^N3S@ ]4HKP?Q3^T%J'A/XMW'AO5M-M(=(L[A5GN0DCS&)D#@
MJ,@9(9>QK+\+_M'^(O%GQ+T[1;#0]/BTV_NUA <NTZ1D_,Y8-M)"Y.-O;K0!
M]&45YK\4_C1H_P -52R$!U+69DWI9H^U8U/1I&YP#V !)]AS7E\W[1?Q%TI8
MM1USP1!!I$Q_=.]I<0>8#TVRL2IX]%H ^FJ*Y+X=_$72/B1X>.HZ1NAFA8)=
M6DAR\#GH#Z@XX/?V(('G7B3X_:G=>-9/"OPS\/+K5]'(T1GG8E'=<[MJ@CY1
MC[Q8#\.: /<J*^:_%WQM^)GA.QN=+\9^%;32KN_MI$L[RS<KY;8QO4[Y%8J2
M#@$8R/QZ#X:^"+SX;>!=;\=V^L1>(+N_TD7L<(C8(VU3*?G)+,3TZ T >Z45
M\T6'[5=W_8&I3:GH]HVIB2-;"W@#K&5(;>\C$GIA>!@G/U([7X1_&#7?'.@^
M(]3U_3+&*+1H1(K6:NOFG:[%<,S= @_/I0![%17SA-\<_BU>*;C1_ARRVO)W
M2:;=S#&,_>4J/TK=^%W[0=QXL\61>&?%>DPZ??SEDAFM]RIYB@DHR,25/![G
MGC% 'N5%>(?%;XY:S\//'T.AP:59363117#3R[VD,;'#8 8#(VMC\*P?$/[0
MWCA87U7PYX%D@T <I?:E9SNKKV8NA5%SZ9/U- 'T;17SWIG[3MYJ^BK;:7X.
MNK_Q*S$+;6I:2$KC[_R@O_P''_ JS+#]IOQ/I'B-;+QYX7@M(=X$T<4,MO/"
MI_BVR,=W'..,^M 'TO13(98[B!)H7#QR*&1AT8$9!I] !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>.?M0?\
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MQS72QN <9!CP?YUB:MXK^./CCPI?Z/<>#/LMK);.MS(=.DAEE0+DA1*W+'&
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MHIPTEQI=W O_ 'TSX':O2O!WQ03XH_#/Q!<6&GO;:M9VLL<EFA\W<S1MY93
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MASD L!DU)^T]X=U_Q!K/A\:%H6I:E';V\WF26=I),%+,O!V@X^[0![AX-.?
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MC5[#QKX8U!;:]:/?-%&-RLFX J3A74[ST:OK>B@#Y[\5?')OB%X7O_#OP_\
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M.[@O[&"\LY5FM[B-98I%Z.C#((^H-5-,U_3-8O=1M--N?/FTR?[/=@(P$<F
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MZHP9L-^!YJ+P/J?C30O ^G66B_!^*:TEM8W>X_M^V4WA903(X*YRV<X/3.*
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M L*(Y<;E" <^YZUM_!C7Q_PD'BCPV^F:II$7VHZKIUGJML8)E@F/SJ$Y^59
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M]3S?A'>1[F3==VB[D.",SIR#ZU+!\(/(N(YO^%A^/)/+<-LDUO*M@YP1LY%
M"_&2UATWX"ZY9V*F*"WLXH8D#$[4#HH&3R>..:I_"V\N/#&JW7P]U>5G%K"+
M[1)I#DS6;]4SW,;';].@P*T?CE_R1/Q)_P!<$_\ 1J5%\0M O;KPOI/B;P['
MNU_PV%O+50.9X]H\V \$D.F>!W ]: &7I_XR7TL?]2S-_P"E I=:/_&1/AC_
M + UY_Z$M9>E:]9>*/CIX=UO2WWVM[X3EE3GE?WXRI]P<@^X-,^('A__ (27
MXX^&M/\ [6U32,Z3=/\ :=*N?(F&&7C=@\'N* /7:\W_ &?3GX$^'L_]//\
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M) 5*$X!(X7!P#UK0\ ^&9_"?@VUTV_FCN-0+27%[/'DK+/(Y=V!(!(R<#('
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M8N&P. 3Z#H.*]2HH YK2--\6Q^%-0M];U^UFUNY\PVMW;686*S)0! $/WPK
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M4ZEX%T^7Q#HS?8X].\V/5Y=3$\MXP/&Y-NY21DY)/3WJOX,^,6K>.TT^;0?
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M>&FG:)=1CNXQ-(JL59TMR-S*"/7/7B@#TFBBN,UKQ=XH@UJZL/#7@2[U9+3
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M*/\ :( +?C5G3]-L=(L(['2K.WL;2+/EV]M$L<:9))PJ@ 9))^IH \Y^&/\
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M_P !QWK*^!>H)XK\9?$C4-/7[-_:RI,@Z>6TAE/Z$]:^AHK>&"V2W@B2."-
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MGS'K):6<<3'\5 - 'F&GZUIW@K]HOQ<?%5]#IT6N6EK/8W5VXCC=8T",N\\
M@@CD_P /TJKX?\1Z;XH_:HEOM$F-S9IX?:%+@*0DQ68;F0_Q+G*Y'&5->P:K
MH6D:]"D.N:59:E%&=R)>6Z3*I]0&!Q3H=%TNVO(KNWTVSBN88/L\4T<"JZ19
MSY88#(7/.T<9H C\0_\ (LZI_P!><O\ Z :\+^#GA*W\;_LUZKH-SM4W-],8
M9"/]7*%0HWX,!GVR*^@Y(TEC:.55='!5E89# ]015;3-)T[1;(6>CV%KI]J&
M+""UA6) 3U.U0!F@#Y:^'.N7>L?M!>"+;5HFBU/1M.GTN\#]3)#'= 9]3L*
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MNZF.Z2>?3XG=SZEBN36C9Z/ING:8--T_3K2UL0& M8(%2( G)^0#'))SQWH
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MSUH \'\1Z?<7/[-'@*_C>YCM-+N[:ZO)+7_60Q#>IE7KRI88.#C.:WM6\,^
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MLUY.D$;26\(4,[!03B4G&3Z5["[B.-G/102<4ZB@#Q+_ (:K\$?] KQ!_P"
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MC']*[7Q7XEL_!_A:]U[4XYY;6R4-(ENH9R"P7@$@=2.XK8HH \2_X:K\$?\
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M?$W_ ))SJ?\ VR_]')7S]0!]645\IT4 ?5E%?*=% 'U917RG10!]645\IT4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH Q/"G@[0O!&E2:;X8L?L-I+,9WC\YY,N552<NQ/1
M5XSCBMNO-O@9XZUCX@^![S5?$'V<W,.HO;+Y$>Q=@CC8<9/.7->DT %%%% '
M._$*1X?ACXHEA=HY$T>[974X*D0O@@]C7._ 2YGN_@CH$]W-)/*WVC=)*Y9C
MBYE')/M79>(](_X2#PKJNC>?]G_M&RFM/.V;_+\Q"F[;D9QG.,BLWX?>$?\
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M^1QT;_K_ (/_ $8M:GBS4-$DU+5;>VT.2&]^U2#[6;UF&X2?,=FW'.#QGC-
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M%]?V%Y>VD'F6]BJM</N4; V0."<GH>F:??Z)J&EV5E=WUOY4%\ADMWWJ=Z@
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M2DO=/?CI)$WWHF]#_GFM6LGPYX<L?#&E+96"<]996'S2MZG_  [5K4 %%%%
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M#&8Q*^-NU0W(^7(S]* -'1_$6HW?Q;>"YNYI+2>ZEMVMF8F/R_F 7;TXP/\
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M[3Q?&D7A2[^S@!)/$=TSX]1D+^E9GC#!T+PNS@"8Z=ACCDH&.W^M '*4444
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MX4?\(KX>_P"@#IG_ (!Q_P"% 'S117TO_P (KX>_Z .F?^ <?^%'_"*^'O\
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M_P" <?\ A0!\T45]+_\ "*^'O^@#IG_@''_A1_PBOA[_ * .F?\ @''_ (4
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MY_R0GP]_V\_^E,M>CNB2QM'(JNC JRL,@@]B*2&"*VA6*WB2*->B(H4#OT%
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M<XSM8EAEL<[5R?:G:O\ $;P_H_AG2_$$\TLVF:G.D,,\$>[!968%AP<?(00
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M>U_&7_D3K3_K_3_T7)7BE !1110 4444 %%%% !1110 4444 %%%% !1110
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M%;479AV-Q$6*!MV,?>!&,Y]J\XE^)>OV.@V_BC4$T#^QY/+DETZ"X=KV&%R
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M!?1ZALUG2D-S$Y99"&P2">3R".>:V);.VO/CY,EY;Q3JOAF,A94# '[4_/-
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M-MW?Z4>,G@?6O//#GB*/4/!7A_0-=UO3[#0[::&62<VMR)6"2;A$9#&(1\P
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MO$'_ (#P?_'J]MHH \2_X:K\$?\ 0*\0?^ \'_QZC_AJOP1_T"O$'_@/!_\
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M'_\ P?3_ /R'1]N\;_\ 0O>'_P#P?3__ "'0!TE%<W]N\;_]"]X?_P#!]/\
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M'_\ P?3_ /R'0 ZBF_;O&_\ T+WA_P#\'T__ ,AT?;O&_P#T+WA__P 'T_\
M\AT 8FG>$K#3/"UWH,$MPUK=&<N[LI<><6+8( '&XXX_.KVAZ1;Z!H-EI-FT
MCV]E L$;2D%BJC )( &?P%7?MWC?_H7O#_\ X/I__D.C[=XW_P"A>\/_ /@^
MG_\ D.@!U<-=_#".]UJWU:;Q;XD^V6H<6\@N(/W0?[P7]ST-=O\ ;O&__0O>
M'_\ P?3_ /R'1]N\;_\ 0O>'_P#P?3__ "'0!S^N>#++7FT^>:]O[74-.4K;
MZC:3".< @!@3@J0<<@C%2:%X/TS0;>^5#<7T^I'-[=7TGFRW/&T!C@# !(
M &3Q6Y]N\;_]"]X?_P#!]/\ _(='V[QO_P!"]X?_ /!]/_\ (= '%6WPKT:!
M;>VDU'5[G2K642P:3<7>ZVC(.5&-NXJ#T5F(KMZ;]N\;_P#0O>'_ /P?3_\
MR'1]N\;_ /0O>'__  ?3_P#R'0 ZBF_;O&__ $+WA_\ \'T__P AT?;O&_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% $%I>VM_$9;&YAN8PVTO#(' /ID=^14]>)?LJ
M?\DLU+_L-2_^B(*]MH **** .;^(_P#R2SQ7_P!@6\_]$/7-?L^?\D)\/?\
M;S_Z4RUZ+<6\-W;2V]U%'-!,ACDBD4,KJ1@J0>"".,5'8V%GI=E'9Z9:06=K
M'G9!;QB-%R23A1@#))/XT 6*\Y\9?%*/2;B33] 2.XN4)62=^4C/H!W/Z?6M
MKXD>()- \)2&U<I=7;"")@>5R,LP_ ?F17S_ $ ;UWXX\37DI>76KM">T,AB
M _!<56_X2KQ#_P!!W4__  ,D_P :RJ* -7_A*O$/_0=U/_P,D_QH_P"$J\0_
M]!W4_P#P,D_QK*HH U?^$J\0_P#0=U/_ ,#)/\:/^$J\0_\ 0=U/_P #)/\
M&LJB@#5_X2KQ#_T'=3_\#)/\:/\ A*O$/_0=U/\ \#)/\:RJ* -7_A*O$/\
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M1\26"MKBV&E>&[K39 6V0DR2/.N2 X5N>QZ<4 4O^$J\0_\ 0=U/_P #)/\
M&C_A*O$/_0=U/_P,D_QJE>:=>Z=((]0L[BU=AD+/$R$CUP15@^']9"RDZ3?
M0<2G[,_[OC/S<<<<\T 2_P#"5>(?^@[J?_@9)_C1_P )5XA_Z#NI_P#@9)_C
M5K0_"-]KFC:A?V\=QBU0&)$MV?[0V<%5([CKQFLU-%U2622./3;QWBD$<BK
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M +\)_P#(M'_"+_M#?]#WX?\ ^_"?_(M>VT4 >)?\(O\ M#?]#WX?_P"_"?\
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M"WUC3[K3YVU>218KJ!HF*F&$;@& .,@C/L:]AID4\4ZEH)4E4'!*,",_A3Z
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M&ZM-+N9X9  2CK$S*>>." :PO@SKNI>)?A'HNK:Y=-=WUQY_FS,H!;;/(HX
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M?MO!_P 1;*W$%FM[;PCI'%J**H_ 28JB_P -?&,DC/)I9=V)+,UU$23ZGYZ
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M12S' Y/ / JMX<\1:9XKT"VUK0K@W%A=;O*E,;)NVL4/# $<J1TH \\^-O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!N\N"%<*F6+' ]R2?QH \U^-O_,$_P"WC_VG7E->K?&W_F"?]O'_ +3KRF@
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MOMN(IC\O\+'M5"B@#HJ*S=/NVW"&3)'\)]*TJ "BBB@ HHHH **** "BBB@
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M(_Z'+P__ .#2#_XJ@#I**YO_ (6/X(_Z'+P__P"#2#_XJC_A8_@C_H<O#_\
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MY\,?^A9_\G[G_P".5Z310!YM_P ,^?#'_H6?_)^Y_P#CE'_#/GPQ_P"A9_\
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M_P \_P#QXT?8+;_GG_X\:L44 116T4!)B3:3WSFI:** "BBB@ HHHH ****
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MBKK$+*1%!#$$YW(W]T=,5RVE_LR>#=)UBSU&VU/76FLYTGC62XA*ED8, <1
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MK"!8(FF(+E5& 20 ,_0"O//%W[/GA7QIXJO?$&J:AK$5W>%3(EM-$L8VH$&
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MH$0./H17K5% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)X?_ ._Z?_)5>VT4 >)?\)1^T-_T(GA__O\ I_\ )5'_  E'[0W_ $(GA_\
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M[0W_ $(GA_\ [_I_\E5[;10!XE_PE'[0W_0B>'_^_P"G_P E4?\ "4?M#?\
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M?_[_ *?_ "51_P )1^T-_P!")X?_ ._Z?_)5>VT4 >)?\)1^T-_T(GA__O\
MI_\ )5'_  E'[0W_ $(GA_\ [_I_\E5[;10!XE_PE'[0W_0B>'_^_P"G_P E
M4?\ "4?M#?\ 0B>'_P#O^G_R57MM% 'B7_"4?M#?]")X?_[_ *?_ "53O"WQ
M0^(@^+ND^#/'^@:3IIU*WDG'V4EG"*DC*VX2NO)B88ZU[77B7BC_ )/)\&?]
M@63_ - O* /;:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@#Q+]JO_DEFF_\ 8:B_]$3U[;7B7[5?_)+--_[#47_HB>O;
M: /E#X>^(-0B^&WC3PQHWA76M9O-8NKF".XM+;=;0^9&$/F29^4@?-C'IR,U
MV5Q8GX;_  J\*>&->\2ZUIFH3-,TFG^'(UDN[IW?<(XW_AV[L9'WB>*](^&7
MP['PYTO4K,:G_:/VZ^:[W_9_*V94#;C<V>G7CZ4SQ]\.'\8:MH^M:3KDNA:U
MH[L;:\2W6=<-C(9&(!Z>N.3D&@#R?P;JNLZ_>^._!M]K/BR#38--%W;-K#^5
MJ=N1M8JS<D!MV".A7& ,U9^"&C2V'P3UCQ-;:WJZS&ROHH[+[7_HL+ ;A*D8
M'RR97[V>YKT'P;\*)O#/C+5O$6J>);C7+K5[3[/<FXMQ&Q;(RP(; &% "XX'
M>H?"'PDOO".CZOH4/BV>[T*^MKB&VL9+% ;9Y<#S#(#ER ,8^4<G@4 >;3_$
M?Q)IG[//@O[-J6H3:MKM[/;S7RYN+HQK<2 A-QR7(*JO/; QU&W\/]6\667Q
M0T^RL[7Q]=>&[V%UO7\6VC;K>0*S*Z2= "0!@XZGKQCK!\$]/F^%&D^#;W59
MVN-(F>XM-4MX_*DCE:1WR%R>/GQC/8'@XQL^&O!WBC3=8AOO$WCV]UU+=66*
MU2RCM(CE<9D"9,A'49/7F@#R/PW!XK\8>$?&NIS^.M=LET*\O#90VMR5RZ+O
MQ(_WF3& $! '-8/Q!O;_ ,8?!;P#XHUC4[UKVXO#92Q)+MA8I)*OG;,?ZW"#
MYO<\5[EX5^& \,>&/$^C_P!K&Z&OW%Q-YOV;9Y'FIMQC<=V.N<C/M65<?!*W
MN_@YI?@:;6Y!+I=RUU;ZC';@8D+R-DQ[CD8E(QN[ Y[4 =]X<T/_ (1W0XM-
M_M34M5\MF/VK4[CSIWR2<,^!D#.!QTKR"VA\1>,?C?XW\.#Q?J^E:1:B"799
M3E9$/E@!8V.?+4EB6VCYL"O7_#>G:GI6APVNNZRVMWREC)>M;K!YF22!L7@8
M&!^%>'V'AS5=>_:+\>-H'B.Z\/7UO'!MN8H%F1U:- 5>-N&Z CD8(S0!FV/Q
M7\3^&_A+XMMKG47U#5]%U9=-M=1N%WMM8L-S9SDCRW()S]X9SBM/QO!XI^$_
MAW0_&-MXVUK5Y9+F&/4;'4+GS+>;>A8^6A'R#Y2.YYSD8KN=,^".@6?PVO\
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M@80#S#COE1SR1747_P #],D^$K>!])U*2S62Y6ZFOY81,\T@(RS*&7J !UX
M'6MSQ?\ #L>*M4\)7G]IFT_X1N^2[">1O^T;2AVYW#;]SKSUZ4 7[7POJEO\
M1[WQ'+XFO9M-N;588]$8'R(& 7YQ\V,G:3]T'YCSVKIJYFU\+ZI;_$>]\1R^
M)KV;3;FU6&/1&!\B!@%^<?-C)VD_=!^8\]JZ:@ HHHH **** "BBB@ HHHH
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MD_(".><<<USFI^,M6T._TQ]:\/PVVE:E?QV"3KJ >XA>3(0R1!-@!; .V1L
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MDCPIY>'"J"<.T?(8#( 8@'HU07E]::=;_:-0NH;6'<J>9/($7<Q"J,GC))
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M2V%)VCU6B@#D=3T[Q7XC\(:[I.K6^CV,E]I<UI!]FNY9PTLD;+N9FC38HR.
MKGGKQ@Y.G>%=0\!-)?Z3<V\6DRZ>TNL6HW,8[J.+_CYMUQAF;'S*=N[ /6O1
M** /!O#>ER>"_"/@_P 3&?3M9AGEMH+:S<W1E#W)"EX=]S)$LV6+-MB7/[P
M@&O5?#OAV[TCQ7XIU.YDA:'6+N&>!8V)952!(SNR  <J>A/%7;+PCX;TW4SJ
M6G>']*M+XEB;J"RC27+?>^<+GG)SSS6O0!YM;>"_%FD^#+WP5I,^DMI,QFAM
MM4GED^T6UO*Q+*8-A61UWN ?,4'Y20.0=*]\'7^E:WX=U3PFMI<'1].?2VM=
M0N&A$D!";6$J(Y#*8QP5((8],<]O10!Y=-\./$5WX&\9:7>WVFR:CXAU$7D4
MD>](D&(<J1@D8\L@=<\'N0.JUWPU>:I\0/"FN6\D"VVC?;/M".Q#MYT01=H
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M1B74PK(&W#&!G>,8)[]*X;6?#U]X3_9W?PG=S6\NJ7\[V$'D%F21[J[8J!D
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M#C([@4 >5VNKWNE> _%R:5.UK=ZCXYN=/CN4.&@$URJ,X]PI.#V.#VKTW3_
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M,I!3C /.:M^/O#=]XGTBQM]/:WE6VOXKJXL+R1HX+^)<YAD958[<D-@JP)4
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M %7"AI%+%3P,C-B^\?/_ &QH.G^']*_M0Z]I\E]:3&X$,:JOED%SM)"E9,Y
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M7$-[;[+50X0DX#@@@$$J>H)!!/H$_BRVTV33=*L++4M:U&>S6Y6VMS$9E@
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M:$3P>(Y[TVKL#L?YIFV'<.HP3@CUK,F\<WUW\ X=8MF9==O($TU%SM87S/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MSD9H YNS\3^&_#OAF#5]-U:]UG1;Z^AMUN/MIO!:-)A,M)(Q<+N(W EBI;@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MSUP#D9!E\5Z'J ^)G@* ^*=6,CF^47!BM-Z$0$E@/(VY(.TY4C & #DGL?\
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M4 %>)>*/^3R?!G_8%D_] O*]MKQ+Q1_R>3X,_P"P+)_Z!>4 >VT444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'E_Q^\&:
MYXX^']IIWAFT6\O(-2CN&B,J1Y01R*2"Y ZN.]87_"4?M#?]")X?_P"_Z?\
MR57MM% 'B7_"4?M#?]")X?\ ^_Z?_)5'_"4?M#?]")X?_P"_Z?\ R57MM% '
MB7_"4?M#?]")X?\ ^_Z?_)5'_"4?M#?]")X?_P"_Z?\ R57MM% 'B7_"4?M#
M?]")X?\ ^_Z?_)5'_"4?M#?]")X?_P"_Z?\ R57MM% 'B7_"4?M#?]")X?\
M^_Z?_)5'_"4?M#?]")X?_P"_Z?\ R57MM% 'B7_"4?M#?]")X?\ ^_Z?_)5'
M_"4?M#?]")X?_P"_Z?\ R57MM% 'B7_"4?M#?]")X?\ ^_Z?_)5'_"4?M#?]
M")X?_P"_Z?\ R57MM% 'B7_"4?M#?]")X?\ ^_Z?_)5'_"4?M#?]")X?_P"_
MZ?\ R57MM% 'B7_"4?M#?]")X?\ ^_Z?_)5'_"4?M#?]")X?_P"_Z?\ R57M
MM% 'B7_"4?M#?]")X?\ ^_Z?_)5'_"4?M#?]")X?_P"_Z?\ R57MM% 'B7_"
M4?M#?]")X?\ ^_Z?_)5'_"4?M#?]")X?_P"_Z?\ R57MM% 'B7_"4?M#?]")
MX?\ ^_Z?_)5'_"4?M#?]")X?_P"_Z?\ R57MM% 'B7_"4?M#?]")X?\ ^_Z?
M_)5'_"4?M#?]")X?_P"_Z?\ R57MM% 'B7_"4?M#?]")X?\ ^_Z?_)5'_"4?
MM#?]")X?_P"_Z?\ R57MM% 'B7_"4?M#?]")X?\ ^_Z?_)5'_"4?M#?]")X?
M_P"_Z?\ R57MM% 'B7_"4?M#?]")X?\ ^_Z?_)5'_"4?M#?]")X?_P"_Z?\
MR57MM% 'B7_"4?M#?]")X?\ ^_Z?_)5'_"4?M#?]")X?_P"_Z?\ R57MM% '
MB7_"4?M#?]")X?\ ^_Z?_)5'_"4?M#?]")X?_P"_Z?\ R57MM% 'B7_"4?M#
M?]")X?\ ^_Z?_)5'_"4?M#?]")X?_P"_Z?\ R57MM% 'B7_"4?M#?]")X?\
M^_Z?_)5'_"4?M#?]")X?_P"_Z?\ R57MM% 'B7_"4?M#?]")X?\ ^_Z?_)5'
M_"4?M#?]")X?_P"_Z?\ R57MM% 'B7_"4?M#?]")X?\ ^_Z?_)5'_"4?M#?]
M")X?_P"_Z?\ R57MM% 'B7_"4?M#?]")X?\ ^_Z?_)5'_"4?M#?]")X?_P"_
MZ?\ R57MM% 'B7_"4?M#?]")X?\ ^_Z?_)5'_"4?M#?]")X?_P"_Z?\ R57M
MM% 'B7_"4?M#?]")X?\ ^_Z?_)5'_"4?M#?]")X?_P"_Z?\ R57MM% 'B7_"
M4?M#?]")X?\ ^_Z?_)5'_"4?M#?]")X?_P"_Z?\ R57MM% 'B7_"4?M#?]")
MX?\ ^_Z?_)5'_"4?M#?]")X?_P"_Z?\ R57MM% 'B7_"4?M#?]")X?\ ^_Z?
M_)5'_"4?M#?]")X?_P"_Z?\ R57MM% 'B7_"4?M#?]")X?\ ^_Z?_)5'_"4?
MM#?]")X?_P"_Z?\ R57MM% 'B7_"4?M#?]")X?\ ^_Z?_)5'_"4?M#?]")X?
M_P"_Z?\ R57MM% 'B7_"4?M#?]")X?\ ^_Z?_)5'_"4?M#?]")X?_P"_Z?\
MR57MM% 'B7_"4?M#?]")X?\ ^_Z?_)5'_"4?M#?]")X?_P"_Z?\ R57MM% '
MB7_"4?M#?]")X?\ ^_Z?_)5'_"4?M#?]")X?_P"_Z?\ R57MM% 'B7_"4?M#
M?]")X?\ ^_Z?_)5'_"4?M#?]")X?_P"_Z?\ R57MM% 'B7_"4?M#?]")X?\
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5110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>vrna-20221231_g4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vrna-20221231_g4.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#^17AI9@  34T *@    @ ! $[  (
M   1   (2H=I  0    !   (7)R=  $    B   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %9I8W1O<FEA
M(%-T97=A<G0    %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,S
M-P  DI(  @    ,S-P  ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MBBB@ HHHH **** "BBB@ HHKG&^(G@I'*/XPT!64X*G4X00?^^J .CHKF_\
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M-P^$/V?=:T"VF:>.QT"\C$K+M+_N7)..V237?5S?Q'_Y)9XK_P"P+>?^B'H
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M$CPPWB%O$$"Z6)VMQ.R.-\@ )55*[F.#G@&O,(Y)=?\ V*"]^_FR1V3!6;/
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M7/9+"XX_-!5'XXZU;:U^SK?:GI;F2SU 6LD3LI4LAF1@<'D=!6E_PSY\,?\
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M<?:IGY?.[Y6<KSD]JZ^@#XL^&.N^"[GQKJVK?&)Y+N>;$D4ES%)*AEW'?O1
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MR6,+,R1>8\F"Q)/+$GJ3WK0N+>.ZM9;>X7?%,A1UR1E2,$9'M0!\<?L_^/\
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MB!'^U31[4#%L81P.K'G&: /._P!I68Q?!324 SYNH6Z'V_<R-_[+70?LY_\
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M@LWF2>;P<C$N[>![ \]Z /.M#F2+]B.5G/'V2Y3CU-VX'\Q3_P!D[_D4M?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MKP.EA>3VR77B&&&=8I"HFC*/E& ^\/8U4^,L:Q^'_#$4*!57Q+IZHBC  WG
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MF&(2F>W=-KE4(P[+A6"^WM7-#QK\#95,=GX7T^[O@.=/@\,9GSZ8,0&?Q[T
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MN?A;J=K?K>I!<7%VFCIJ1/VA+-AB$29YSUZ]L=L4 9?P4\#_ &;PCX;\1_\
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M%'.>/?MD @\5^*H_$'Q!U/PQ=^.8?!ND:/'$+B2*\BMKJ]FD7=A'<_*JKC)
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M*K-&\<#WOF<M K\A=F<X Y_"O7Z "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXTTC0AX9OIH-1U*'3SJ,[B"$/(5YC!!,F W/09&,T >@T444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %4+F1UN&"NP'' /M5^LZZ_X
M^7_#^5 #/.D_YZ-_WT:/.D_YZ-_WT:910 _SI/\ GHW_ 'T:/.D_YZ-_WT:9
M10 _SI/^>C?]]&CSI/\ GHW_ 'T:910 _P Z3_GHW_?1H\Z3_GHW_?1IE% #
M_.D_YZ-_WT:/.D_YZ-_WT:910 _SI/\ GHW_ 'T:/.D_YZ-_WT:910 _SI/^
M>C?]]&CSI/\ GHW_ 'T:910 _P Z3_GHW_?1H\Z3_GHW_?1IE% #_.D_YZ-_
MWT:/.D_YZ-_WT:910 _SI/\ GHW_ 'T:/.D_YZ-_WT:910 _SI/^>C?]]&CS
MI/\ GHW_ 'T:Q/%GB >%O"]YK#6QNA;!/W(?9NW.J]<''WO2L_PYXC\0:U-
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MQ'9ZA/KGA2XTQ;2QEO$;[2LJ2A #L+*/E8YZ'T/I0!V/G2?\]&_[Z-'G2?\
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MYZ-_WT:910!H6;,T)+$D[NYHI++_ %)_WOZ44 6*J77^M'^[5NJEU_K1_NT
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MIW!Y8H8_D((^Z:X/XV>(=%7QAX#MVU>P$^G^([>6]B-RFZV0,AW2#.4&.<G
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M ,$,?_Q5'_"+?%/_ **-8?\ @AC_ /BJ]&HH \Y_X1;XI_\ 11K#_P $,?\
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M ,$,?_Q5>C44 ><_\(M\4_\ HHUA_P""&/\ ^*H_X1;XI_\ 11K#_P $,?\
M\57HU% 'G/\ PBWQ3_Z*-8?^"&/_ .*H_P"$6^*?_11K#_P0Q_\ Q5>C44 >
M<_\ "+?%/_HHUA_X(8__ (JC_A%OBG_T4:P_\$,?_P 57HU% 'G/_"+?%/\
MZ*-8?^"&/_XJC_A%OBG_ -%&L/\ P0Q__%5Z-10!YS_PBWQ3_P"BC6'_ ((8
M_P#XJC_A%OBG_P!%&L/_  0Q_P#Q5>C44 ><_P#"+?%/_HHUA_X(8_\ XJC_
M (1;XI_]%&L/_!#'_P#%5Z-10!YS_P (M\4_^BC6'_@AC_\ BJ/^$6^*?_11
MK#_P0Q__ !5>C44 ><_\(M\4_P#HHUA_X(8__BJ/^$6^*?\ T4:P_P#!#'_\
M57HU17-S#9VDUU=2+%! C22.W15 R2?H!0!Y]_PBWQ3_ .BC6'_@AC_^*H_X
M1;XI_P#11K#_ ,$,?_Q57-&^-7P]U_58=-TOQ)%)=W#!(DEMYH0['@ ,Z 9/
M89YK9L_&NFWWQ O_  A;Q7+7^GVJ75Q+L7R5#;<)G=G=A@<8QCO0!S7_  BW
MQ3_Z*-8?^"&/_P"*H_X1;XI_]%&L/_!#'_\ %5Z-10!YS_PBWQ3_ .BC6'_@
MAC_^*H_X1;XI_P#11K#_ ,$,?_Q5>C5SWBKQIIWA&XT>#48;J>76+Y+&V2V1
M6(=NA;+#"CC)&3STH YK_A%OBG_T4:P_\$,?_P 51_PBWQ3_ .BC6'_@AC_^
M*KT:B@#SG_A%OBG_ -%&L/\ P0Q__%4?\(M\4_\ HHUA_P""&/\ ^*KT:B@#
MSG_A%OBG_P!%&L/_  0Q_P#Q5'_"+?%/_HHUA_X(8_\ XJO1J* /.?\ A%OB
MG_T4:P_\$,?_ ,51_P (M\4_^BC6'_@AC_\ BJ]&HH \Y_X1;XI_]%&L/_!#
M'_\ %4?\(M\4_P#HHUA_X(8__BJ]&HH \Y_X1;XI_P#11K#_ ,$,?_Q54KCP
MS\3A.P?XA6)/'/\ 8<?I_O5ZG6==?\?+_A_*@#SG_A&?B9_T4&R_\$D?_P 5
M1_PC/Q,_Z*#9?^"2/_XJO0** //_ /A&?B9_T4&R_P#!)'_\51_PC/Q,_P"B
M@V7_ ()(_P#XJO0** //_P#A&?B9_P!%!LO_  21_P#Q5'_",_$S_HH-E_X)
M(_\ XJO0** //_\ A&?B9_T4&R_\$D?_ ,51_P (S\3/^B@V7_@DC_\ BJ[+
M6-:T_0--?4-7N!;VL9 :0JS8).!PH)K,T/QYX;\2:@;'1=1^TW 0R%/(D3Y1
MC)RR@=Q0!@?\(S\3/^B@V7_@DC_^*H_X1GXF?]%!LO\ P21__%5Z!10!Y_\
M\(S\3/\ HH-E_P""2/\ ^*H_X1GXF?\ 10;+_P $D?\ \577CQ!I;:]-HPNU
M^WP0?:)8MK?)'Q\Q;&T=1QG/-4/#?C*Q\4W%PNEVM\+>'.V[F@VPS8.#L;//
MT(% '/\ _",_$S_HH-E_X)(__BJ/^$9^)G_10;+_ ,$D?_Q5>@44 >?_ /",
M_$S_ **#9?\ @DC_ /BJ/^$9^)G_ $4&R_\ !)'_ /%5Z!10!Y__ ,(S\3/^
MB@V7_@DC_P#BJ/\ A&?B9_T4&R_\$D?_ ,578:/KVFZ_;S3Z1<BYB@F:"1PC
M* X )'(&>HY''-:% 'G_ /PC/Q,_Z*#9?^"2/_XJC_A&?B9_T4&R_P#!)'_\
M57H%% 'G_P#PC/Q,_P"B@V7_ ()(_P#XJC_A&?B9_P!%!LO_  21_P#Q5>@4
M4 >?_P#",_$S_HH-E_X)(_\ XJC_ (1GXF?]%!LO_!)'_P#%5Z!10!Y__P (
MS\3/^B@V7_@DC_\ BJ/^$9^)G_10;+_P21__ !5>@44 >?\ _",_$S_HH-E_
MX)(__BJ/^$9^)G_10;+_ ,$D?_Q5>@44 >?_ /",_$S_ **#9?\ @DC_ /BJ
M/^$9^)G_ $4&R_\ !)'_ /%5Z!10!Y__ ,(S\3/^B@V7_@DC_P#BJ/\ A&?B
M9_T4&R_\$D?_ ,57H%% 'G__  C/Q,_Z*#9?^"2/_P"*H_X1GXF?]%!LO_!)
M'_\ %5Z!10!Y_P#\(S\3/^B@V7_@DC_^*H_X1GXF?]%!LO\ P21__%5Z!10!
MY_\ \(S\3/\ HH-E_P""2/\ ^*H_X1GXF?\ 10;+_P $D?\ \571:]XW\/>&
M;R.UUS41;3R1^8J>3(Y*Y(S\JG'(/Y5%>^/-!M/"<GB*&Y:]L$<1_P"C+ERQ
M(&W#8P><\XXH PO^$9^)G_10;+_P21__ !5'_",_$S_HH-E_X)(__BJ[V&43
MV\<H5E$BA@K#D9&<'WI] 'G_ /PC/Q,_Z*#9?^"2/_XJC_A&?B9_T4&R_P#!
M)'_\57H%!.!D\"@#S_\ X1GXF?\ 10;+_P $D?\ \51_PC/Q,_Z*#9?^"2/_
M .*KJ?#/B6S\5Z2=1TZ.>. 2M$//4 L5[C!/'-:] 'G_ /PC/Q,_Z*#9?^"2
M/_XJC_A&?B9_T4&R_P#!)'_\57H%% 'G_P#PC/Q,_P"B@V7_ ()(_P#XJC_A
M&?B9_P!%!LO_  21_P#Q5>@44 >?_P#",_$S_HH-E_X)(_\ XJC_ (1GXF?]
M%!LO_!)'_P#%5Z!10!Y__P (S\3/^B@V7_@DC_\ BJ/^$9^)G_10;+_P21__
M !5>@44 >?\ _",_$S_HH-E_X)(__BJ/^$9^)G_10;+_ ,$D?_Q5>@44 0>#
M[+6;#0VA\1ZO'JUYYS-]HBM1  N!A=H)]^?>BM:R_P!2?][^E% %BJEU_K1_
MNU;JI=?ZT?[M $-%%% !1110 4444 %%%% !1110 4444 %%>5:EXB\3:EXD
M\5-I7B*+2-,T%%PLEI%()'VG*EF&1EE;U[#%;N@?$&UA\ Z9K/C*ZBL9[O<!
MA"3+M8C<$4$\@ ],<^XH [BBN>M/'GAJ_L[ZZL]46:WT^)9;F18GVQJPR.=O
M)X/ R>,8HM/'GAF]@O)[;5H6BL462XD*LJQANG)')XQ@<YXH Z&BN:TOXA>%
MM:OK>RTO55N+FY9EBB6&0,2HR<Y7@8YR<#@^E1W'Q+\(6DS17&M1(ZS- R^6
MY(=3@_P],_Q=#ZT =316#8>-O#FJ:XVCZ?JL-Q?+G]V@8AL#)PV-I_ FHM4^
M('A;1=3.GZEK$,-TIPT81WV'T8J"%_$T ='17$^)/BCHGAS7K+3976;SCNN9
ME+8MD*AE;A3OR#T%:FK>/_#&AS10ZIJT<$LJ*ZQ^6[,%(R"P4$KQZXH Z*BL
M34/&/A_2[:RN+_5(8H;]&>VDP6615&200#V(Z^N.M:&EZI9ZSID.H:;+YUK.
M-T<FTKN&<=" >U %NBBB@ HHHH **** "BBB@ HHHH ='_K4_P!X5?JA'_K4
M_P!X5?H **** "BBB@ HHHH \2^,PU;7/BQX#\/>&_L;:C;/+JBI?E_(RF&0
MR;/FQ^Z<<>N*U_B!XL\;^$OA?;2WDNF)XJO]3BL[;^RHV:$[FR !,#DE5()(
MXW<>M;7BKX3Z=XJ\7)XE?7_$&DZC';"U1]*O%@VQ@DXSL+<ECGFK$GPQTZYM
M?#L.I:QK6I'P_>F^@FO;M9I)Y=VX>:Q7+!>@ V\4 <UX5\0>-K;XVS>%?$NL
M6FJV[Z1_:$L=O9K"EFY<+L1OO,.1RQYST%9?@'QQXQUKXC&P\4:W#I5RCS/<
M>&KO2_*V0 ';)#<=9#G'4@8#$9Q7H,OPXT6Y\1>(M9NI+R:?Q#9K972-,%2.
M((%Q'M 9<@ G)/-9^B_"/1M&O;F_DU77-4U":T>RCO=3O?/EMHF!!6,E<+UX
MR#^IH \>UK7-7U7]GO7O$L-]!9R:YKLD?EV^FPH]Y;L?+6%F5021\S;SECMQ
MGDUM:MXG\7^ (='^'&AWM_JVH6MBMQ<W^F:&ES-:0#"1Q) &"MC R[DYW#N:
MTM9\'SR:EX1^&OAO1=8_L'P_J<>H7NJWT0$$J#,FU9!@.Q,CJ< 8/8X)KN_%
M7PMTGQ3XBBUY=4UK1-52#[.UWH][]G>2/.=K'!XY[8[>@H X#4/''Q'\/_!.
M^U#7PUMK\^I1V>D32VD23RHS [GA&Y%8@.,?_6)V-"\0>.[3XU0>%_$.LV=_
M#>:.VH306]FJ)8-N*A5;[SX( RQY#=!77:C\-],U73- L=1U'5KJ/0KY;Z%[
MBZ\V2XD5B1YKN"6')&!CC@8J]:>"].M/B!?^,%EN9-2O;1;-D=U,<<:E3A %
MR,E03DF@#QCX8_\ "16D?C;XB7OBHW-K!/<I=1'3XE_M+[-"WE2;A_JP-W"K
MW&,FM6Q\1^/K7X*WOCGQ3XAM7BET=Q;6 T^+)DD8+%,[XP2=WW NW!&03FNO
MTWX+:#I/AO6M!LM4UQ=.U="C0->!EME+981*5PN> 2020.M;6O\ P]TGQ%\/
MH/!MU/>0:9#%!"IMW19"D6-H)*D?PC/'Y4 >;P:YXPMM8\"^"O"-S8:=<W&@
M_;]4/V")88MX^_Y:* "K!L*NT$L,\4W1?BUX@T7X7>*=7U^>+7+W2]9?2M.N
M! L/VM\@#*)Q@9W8')'&>]>HVG@C3+/QY=>+8I;DW]Q8K8"-F4Q11*0?D&W(
M.5!Y)K%A^#OAB/X=R>#9C>W-A)<&Z,\LR^?YI.=^Y5 R.G3IUS0!R7PY\0_%
M+5_&UM_;4.I/H<D;M?#5M%CT[[,VT[1#AB\GS8&3V[#K7M5<OX2\#IX2FFD7
MQ'XBUEI4" :QJ+7"QC.?E7  /OC-=10 4444 %%%% !1110 4444 %%%% !1
M110 4444 %<)\:M7_L7X-^(K@'#36OV50#U\UA&?T8G\*[NN=\;>"M.\>Z#'
MI&LS745HMPEPPM753(5SA6RI^7GZ\#F@#R/0? 7B[Q7I7@C2-=\.VWA[1/#;
M17+SM>I//>, #\JH/W88\D'IGJ<"J5IXTG\//\3?'EC MU>WFMQZ-IOF?<+1
M@J"?;:5/X <9KZ+ P,#@5Y^/@SX:_P"%>R^$))]1DLY+PWINFF07 F)^^&"!
M<]ON]* .2@UOXA:)\5O#'A36_%]IJ8OHVO\ 4!#I\41@C1&)C)Q]PE2 V%;C
MM5SPEKWQ!^),DOBC0-=L-)T&+4##:Z9+9"0W<",-S22'YD8@G '<=AS74>&_
MA+H/AGQ4?$4%WJE_J+69M))=1NA.9 6!+L2N2V %ZXQQBH?#?P<T#PKK$=YI
M>H:T;6&<W$&ERWQ:SBD(QN$>!DCL23VH \QO?BG\1O&&JWESX!M=5BL(KEH=
M/6VT2.XMKM58 M+<R,-A/)PHX&!GO6QX]3Q)XG^+G@+1+*2TL]:T_3FU.[=D
M,L-M(^%9PN?FVLGR@GJ1G@UV.F?!C1]$U4W.B:_XFTVT-Q]H.F6FJ-':ELY(
MV 9P<8QGI5CQ'\)-(\2>*+CQ%+J^N:?JDT*0)<:=>B!H(U!!5,+T;/.[/MB@
M#@K/XN>)?#W@GQ<^L3P:_J&CZP-*T^]$"PI<R,2/F5, !0N>.N0,]ZU8M=\?
M^$?B?X4T3Q)XDL]?B\0B7S[2*P2$V>Q<Y1EY89/5NH4\#K772_"3PI+X _X0
M\6LT>G>:+CS$E(F,W_/4OW;MR,8XQC%.\*_"[1/"VMMK7VS5-9U8Q>2M_K%W
M]HECC_NJ<  =NF<<=S0!VE%%% !1110 4444 %%%% !6==?\?+_A_*M&LZZ_
MX^7_  _E0!#1110 4444 %%%% 'G'QC,U]INB:%:;3<:EJ*JH<D*<#'..V74
MGZ5HZSK/B;P[X!U?4==?2HKR% MF=.5RJEB%!(DZD$YQC'%:7B?P39^*;^RO
M+J_U&SGL0WD/93+&5)QDY*DYX'2H+CX?V=[X=?1]1UC6;Z![A9VENKH22?*.
M$R5P%[XQU[T <WI^O>,;3Q?X8M-7U""X75X&DFLDME7R5"YW%QR6ZD]!D$8I
M9/%'B1_B.^EW6IQZ1']L$=I97%CNCO(0V"PEZAB.0.F3C(KM;CPO8W7BN#7Y
MI)S<P6IM8XPP$:J<Y.,9S\Q&<UEZ7\.-)TS5+6]-WJ5[]B)-I!>71DBML_W%
MQQ^M '&ZIJ]]>6'C[5K>[@M5M)ELHIDLXR[H"49"^-Q#$K@DG':HX=6USP-X
M.T/1-/GEO[_5(_/AB@L0[V46-[!4!_>-EF.2>QJ[XF\,2V^FCP7X=L-4N4U&
M^6]O-1G0&% 3\PW@ 9&U3C'YUVGB'P5IOB*2RFEFO+&YL05M[FQF\N1 >P.#
MZ4 <C8>)?&&G>$?$6IZ_YPAMX =/N+RS2WF,C<#,2D@ $CK^O.&67B#QE::[
MX235M2@F76ES+8K;*NQ JG>6 SN().!@ @BNLN_ MG?^%9-!OM4U:Z@EE$KS
MSW7F3,1C W," O . *O3>%["?Q18:ZS3"XT^!H((@P\M0003C&<X8CK0!P?A
M*QUC4OB7X@U:3Q!B/3[A;28_9$_TB-228_\ 8"[0,C)-2>'/$/BK5/#U]XIO
M-7AATJT:YDCMOLJ%YT56V@MCY0#@#N<'/:NIT_P#INF:AJ=U9WFH(-2$GF0?
M:/W4;/U=5Q][T)SBK$?@S3XO Y\*Q3726)C,9D#+YN"^X\[<<DGM0!P=MKVN
MZ?X3\'VFB-:Q:IK=Q)++MM8XXW3/\2JH &&4D@9.WK6CI'C'6=(O/%J>(;U-
M5M]#C1DF2!8<NPX0!>Q/'.3Q75Q>#=.BU?1]062X,FCVOV6UC++LV[=N2-N2
MV#V(^E,A\#:3';:Y!*9[A-<F:6Z\UQD$DD!< 8 )XZT </X?\2_$#6=:T^=(
M+O[)<2*UQ#<:8L%M'"<'<DQ.Y^.G]:];KFO#_@F#P[=1R6^M:U<Q1(4CM;J]
M+PH,8P$  X[>E=+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '
MDDU]K%S\9=;OO#^B+J[6%JEF/,N5B6$L =QSUY#C ]ZS]3\*SZ'H'A_PW>O&
M]YKFM"YNEB^XJ@ %1[ ,#]:]2T/PQ9Z!>ZI=VDL\LVJ7!N)VF8'#9)PN , 9
M/'-+?^&;+4O$NFZW<R3_ &C35<0QJP\L[A@DC&<_B.@H X:]\6>(]4D\1:MI
M&JVVF:3H+M$D4MLLANW7J"3RN3@#'J!3;;Q=XEN]'\+Z1:WL1UW7$DN);R:%
M<0P@L00@ !.T'J.WO6W>?";0;V:_9KO4XXKZ4S/;QW($2R$YW!2IYZ]<XSQ5
M_5OA_I6JC3&%Q?6,^EPB"VN;*?RY%0# &<'],=30!S_B/Q)XF\(Z7:Z7/=)K
M&LZA<N+>XMK3+B!0N3Y(P"^2<#.,=^*K6&O^+;?PMXDO/$8N6L8;-OL<][9I
M:SM(1@#RU)P,G^7O747_ ,.](OM-TZU^T7]O+IK.UO>07&V<%CN8ER#DD\YJ
M6;P/:7/A>XT*]U75KN"YD5Y)KF[\R4[2"%!88 RO0#UH \\T*X\3^#=&\(*M
M];M::I<J@TM;==Q20[MYD^]N^;Z#CKTK<N/$7B7Q'<>(+O0M7M]&TS0V>-2]
MLLK7#("6W%ONCCJ/4<5T6C_#S2-'U:'4%GO[V2V4I:)>W'FI:@]HQCC\<U4N
M_A7H=W>W4OVO5(;>\E\ZXLH;K;!*V<Y*XSU]^.U &MX&UF[\0>"M.U3445+F
M=&W[1@'#LH./< '\:WZBM;6"RM(K6TB6&"% D<:# 51T J6@ HHHH **** "
MBBB@ HHHH OV7^I/^]_2BBR_U)_WOZ44 6*J77^M'^[5NJEU_K1_NT 0T444
M %%%% !1110 4444 %%%% !2$X4D]O09I:* /*? GP]T_6K2]UKQCHLQU&ZU
M"69([OS(RJ$@\ID9R2W4&K/B*WO]*^*VGZG%X=O-4T^VT[R+*.SA!2&7)Q[)
MQW/;&.E>FT4 >(+HNO?\*R\1RMH]U'JFNZJ UM';/N2,,&SMQD+G<,XQ@^]=
M/\1?#LUOX.T73]%TR:\L;*[A-U:VD6YY(E!_A')Y)_$Y/K7I%% 'ENEIJNI_
M$VZ\1W/AV[TZUT[266SADMR&D..%XXW$%N!D@8%89\):BGP@M;0:3=-JVLZF
MK7F+9O,B3>V"_&54;0>>/FKVZB@#SW^PIU^+FG_V?IK6VFZ/I#);RF%A$9&R
MNT-C!.'Z=>#7%>&O"S.S:;XJTGQB]Q=79-TEO@6,I+<.S9&?4G/N*]WHH \X
MO;:]L?C/IDZZ+>S:9!IZVEK+;0[HH2QP6=NB@*3[\#CFN3BT"Z7Q!K2^)M+\
M8337UY(6_L@#[+<1$\!R<#U[XQ@<5[G10!YU>>&4F^)_AZRBTN7^Q-%T]GC9
MHF,(DR0%W'@L,*>N:]$ "C"@ >@I:* "BBB@ HHHH **** "BBB@ HHHH ='
M_K4_WA5^J$?^M3_>%7Z "BBB@ HHHH **** "BBB@ HHKSWXB>/M9\->*O#.
M@>&-,MM3O]:><-#.Q7:J*,-N!X&223@\(W&<4 >A45Y7X6^)'B+4M-\:6_B+
M_A'M-U+PY.+:.^>:2.P:5MP4.SG< & !/!.X  &J^@>.?&>I>(;&UN/%/PNN
MK>29?/AT[4)I+AHAR_EJ6P6V@D9X]>* /4=2U73M&LFO-8O[6PM5(4SW4RQ(
M">@W,0*IWGBWPYIUE:WFH>(-+M;6]7?:SSWL:).O!RC$X8<CIZBOFWXL>,M.
M^(7A_5M8;6+06-C(MKH>DBZ433R%P)+N2('<!LW!01T.>._L/B4>#/"OP=T[
M4=?TS2M<L](TZ*+3O/ACN%F8QJ%$;$'A]JDD=AGG% '9Z5XJ\/:]-)#H>NZ9
MJ4L2[Y$L[R.9D7IDA2<#WIUAXET+5;Z6RTO6M.O;J'_6P6]TDCI]54DC\:\)
ML/ASX@T?X!>(-2TJP*>*/$FR>:UL8A&8;8R ^3&@QM^0L2HYYV]A57PRFGW'
MQP\"V7AOP??>%WTZQFDO1>VJV\TZ>6R[W .YAN!&YN3N]* /I.BBB@ HHHH
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M PH8C=R1T]:T*^5+Z:Q\7?$WP3J^O:YIMUJFKZD+BXAM[Y)(M,MHRK0VN0V
MS$MG."6.!SG/U70 4444 %%%% !1110 4444 %9UU_Q\O^'\JT:SKK_CY?\
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MM4;*&!-9\#Z9:>'+S2=2ANDDNKBZ@$3W&TJ9"#]YEX)Y[<4 >\T444 %%%%
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M1J*\Y_X65XF_Z)?X@_[^P_XT?\+*\3?]$O\ $'_?V'_&@#T:BO.?^%E>)O\
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M&,(B#A%XS@>WH*RO^%E>)O\ HE_B#_O[#_C1_P +*\3?]$O\0?\ ?V'_ !H
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M+_&C_A8GB/\ Z)MKO_?V+_&@#T"BO/\ _A8GB/\ Z)MKO_?V+_&C_A8GB/\
MZ)MKO_?V+_&@#T"BO/\ _A8GB/\ Z)MKO_?V+_&C_A8GB/\ Z)MKO_?V+_&@
M#T"BO/\ _A8GB/\ Z)MKO_?V+_&C_A8GB/\ Z)MKO_?V+_&@#T"L#7/"YUOQ
M%HFI27GEQ:3*TOV?RL^:QQ@[L\8QZ&N>_P"%B>(_^B;:[_W]B_QH_P"%B>(_
M^B;:[_W]B_QH W-/\&P6_B+7=4U"9-0&L;%:": ;8T48VG).[MV'2K\'A7P_
M:W$<]KH6F0S1L&22.SC5E(Z$$#(-<I_PL3Q'_P!$VUW_ +^Q?XT?\+$\1_\
M1-M=_P"_L7^- &CXH^&^C>(-,^S65I8Z7*TRR/<P6*;V49RN1@C/KFK6J^&M
M4D:"/PSK_P#8%G%%Y1M8+&.1#R3D9QM//:L3_A8GB/\ Z)MKO_?V+_&C_A8G
MB/\ Z)MKO_?V+_&@#6L_!3:/X;?3_#^K36-]+/\ :)M1>)9I)G[E@>"#Z?XF
MG:#X,;3M;DUO6M5FUG5FC\I+B6,1K$G<(@X&?\]36/\ \+$\1_\ 1-M=_P"_
ML7^-'_"Q/$?_ $3;7?\ O[%_C0!Z!17G_P#PL3Q'_P!$VUW_ +^Q?XT?\+$\
M1_\ 1-M=_P"_L7^- 'H%%>?_ /"Q/$?_ $3;7?\ O[%_C1_PL3Q'_P!$VUW_
M +^Q?XT >@45Y_\ \+$\1_\ 1-M=_P"_L7^-'_"Q/$?_ $3;7?\ O[%_C0!Z
M!17G_P#PL3Q'_P!$VUW_ +^Q?XT?\+$\1_\ 1-M=_P"_L7^- 'H%%>?_ /"Q
M/$?_ $3;7?\ O[%_C1_PL3Q'_P!$VUW_ +^Q?XT >@45Y_\ \+$\1_\ 1-M=
M_P"_L7^-'_"Q/$?_ $3;7?\ O[%_C0!Z!17G_P#PL3Q'_P!$VUW_ +^Q?XT?
M\+$\1_\ 1-M=_P"_L7^- 'H%%>?_ /"Q/$?_ $3;7?\ O[%_C1_PL3Q'_P!$
MVUW_ +^Q?XT >@45Y_\ \+$\1_\ 1-M=_P"_L7^-'_"Q/$?_ $3;7?\ O[%_
MC0!Z!17G_P#PL3Q'_P!$VUW_ +^Q?XT?\+$\1_\ 1-M=_P"_L7^- 'H%<,GP
MX=/ -]X;&L'S+^Z-S/>"V^\2RDC;O_V0,YJ#_A8GB/\ Z)MKO_?V+_&C_A8G
MB/\ Z)MKO_?V+_&@#JG\+:'/% M[I%C>/!"L*R7%JCMM48 R0>*RO$W@:/5_
M#O\ 8^A7,7A^VDE\R=;2U4+,,8VD*5]OR%97_"Q/$?\ T3;7?^_L7^-'_"Q/
M$?\ T3;7?^_L7^- &IX;\*:WH4/V6?Q.MS9);M%#;Q:;% (V/1\J221S]2>:
MK)X!OK^^M9/%GB6?6[:S<20VIMD@0L.A?:3OQ[U4_P"%B>(_^B;:[_W]B_QH
M_P"%B>(_^B;:[_W]B_QH M^,/ VK^++DJWB?[+IRRI-#9_V>C^6ZKC)?<"W)
M)P>.?:NJTNWN[33(8-2OOM]T@(DN?*$7F'/7:.!Z?A7%?\+$\1_]$VUW_O[%
M_C1_PL3Q'_T3;7?^_L7^- 'H%%>?_P#"Q/$?_1-M=_[^Q?XT?\+$\1_]$VUW
M_O[%_C0!Z!17G_\ PL3Q'_T3;7?^_L7^-'_"Q/$?_1-M=_[^Q?XT >@45Y__
M ,+$\1_]$VUW_O[%_C1_PL3Q'_T3;7?^_L7^- 'H%%>?_P#"Q/$?_1-M=_[^
MQ?XT?\+$\1_]$VUW_O[%_C0!Z!17G_\ PL3Q'_T3;7?^_L7^-'_"Q/$?_1-M
M=_[^Q?XT >GV7^I/^]_2BLGP?J]YK6AM=:AHUUHTWG,GV:Z92^ !\WRD\'^E
M% &]52Z_UH_W:MU4NO\ 6C_=H AHK!\;^(#X7\$ZIJ\8#3V\!^SIC.^9OEC7
M'?+E1BN0^'5F?!7BZ_\ !EQ(6%Q86VJ6Y9L[WV"&X.?4R('_ .!$T >FT5Y]
MJOQ(U.VTRYU?3/#]K=:1#J0TU9[C4FAE=_-$)?RQ"^$$A(^]N(&=O:M>Y\5:
MI/KUWH_AW1K:_NM-A1]0>YOS;Q122+N2)&$3EV*Y)R% !7G)P #JJ*R_#6OV
MWBCP[:ZQ8I)'%<!OW<H :-E8HRG'&0RD<>E1>+O$'_"*^$-2US[-]K^PPF7R
M/,V;\=MV#C\C0!LT5Q%SXYUJSUO3--N?"V)=;24Z:%U!20R ,1<?)B+"G<2A
MEZ$ ,< S6_Q"@M](\17/B*R^P7'AV39>0V\WVA7W*&C,;%5+;@P !"\\'UH
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MHKR/XQR/XHT?7]#@=AIVA:7+J&I,AQON/+9K>#/MCS2/:/LU>E^'O^19TO\
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M]/GC9O\ @7UKNJ "BBB@ HHHH **** "LZZ_X^7_  _E6C6==?\ 'R_X?RH
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MPE>@_P#05MO^^Z ,&#P[XBUSQ+H>J>+ETNU70P\D4.G7$DWVFX="A=B\:;%
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M&X?@V10!LT444 %%%% !1110 4444 %%%% #H_\ 6I_O"K]4(_\ 6I_O"K]
M!1110 4444 %%%% !1163J^EZEJ5Q%]BU^ZTFW1#O6SMX6DD;(P2TJ. H&>
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M<VU.6(&<+E<GN*Y;X=^([^Y^%YUCQ3?F^N;22\%Q="%(RZPS2+G8H 'RITH
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M^%>3ZWX]U6.'Q1<'Q1_96N:3J+6VG>'/L\#?;%!4P@HR&:0S YS&P #<="2
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MC&Z68J>#@84 ]6=?>I?#K:GXG^'?A^]FUN\L;VYLH;B>YM(H-TK-&"<B2-E
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M! (SQP:32]-MM'TFTTVPC\NVM(5AB7T51@?RH M4444 %%%% !1110 4444
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M:J'C7Q%<>'M(M3IT<4NHZC?06%FDP)3S)&Y+ $'"H';@C[O:@"W_ ,(KHO\
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M3F421JQ42 E$.&P2 5!QCUH M_\ "*Z+_P ^*_\ ?QO\:/\ A%=%_P"?%?\
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M'K@51UWQ5<V7B6Q\.Z%IT>I:M=P27;I/=?9X;>W0A2[N$=LEV50%4YYR0!R
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M+[4_%=O8Z=#9QM*S6MX]P-BC))+11D'V .: '_\ ",:/_P ^2_\ ?;?XT?\
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M*S?'GQ 3P7]CC@TYM3N9W5I8EF\L6\!D6/S6.T_QR(H&.<GG@T ;G_",:/\
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M"L--N-.L=%TZVL;G/GVL-HB12Y&#N4##<<<T <MX3T"^T7QO=NMGH>B:=<6
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M#@8 NZR<?';PQYIPITB^$6<<OOAS^E=K:6=MI]G%:6%O%:VT*A(H84"(BCH
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M58Z:LI!D%G;)$'(Z9V@9ZFD?P_HTFFSZ<^D6+6-Q(99K4VR&*5RP8LR8P3D
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MFL_4/!_AK5KU[S5/#NDWMU)@//<V,<CM@8&6923@ "@#G_BUG_A#[7RL^?\
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MN40)>P!@IDCVL2!\RG#A6PZG'7%JS\1KJ^C:C?Z'9RW8M6ECMC(PCCO70?\
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MVMQ(^FPW-]$MK(T*R31E\B(XRPW$#('/.!T[5R7C+_B>^+?#OA5?FA:8ZKJ
M':& CRU(]&E*?]\&NUH YKPWX\TCQ7K%]8:.EVXLXHIOM,L!CBG23.&CW89A
ME2,X .."1S6]?WL&FZ;<WUXXCM[6)II7/\**"2?R%<CI'_):O$G_ &"K'_T*
M:E^,$CQ?"+Q"8V*EK8(S 9PK.H;]": +R^-(X?#.C:C?:=<+?:SL%II=LRR3
M2,R[]N6VJ,("S%BH&#STS>T+Q+;Z[/>VHM;JPO[!U6ZLKM5$D8891LHS*58
MX(8C@]Q7/Z\JV_Q<\$H4VP"UU".' ^4/LC./KL5OP!]Z=IBB3XWZ]+#RD.C6
MD4Q':0R2L ??;B@#I-7U>73&@CMM(U#5)IMQ$=DB (JXR6>1T0=0 "V3S@$
MD9/_  F\5UX+U37=)T^XN)]+,J7.G3D131R1<R1G&X;@O(QD'(P>:TO$WB2R
M\*Z')J6H;W 81P6\*[I;F5CA(HUZLS'H/J3P":R_!7AZZTOP[?2:^(UU'6KJ
M6_OXXR"D+2 #RP>X555<]R"><T ='8WD.HZ?;WMHV^"YB6:)O[RL 0?R-3UQ
M?P>GEN/A!X=><DL+78,_W59E7] *[2@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH ***H:^LK>&]36V#&8VDHC"CDML.,?C0!@1_$?39%MKO^S]171KN
MZ%K#K)CC^S,Y)53]_P P(7&T.4"Y(YP<UUU>1:P8;C]E6RAM\,TVDV4$2CJT
MQ,:@#WWUZW+*D,+RS,$CC4LS,>% Y)H R$\0B;QM+X>M[?S/LUBMW<W&_B(N
MY6./;CDD*YZC  X.>$UGQ-!I&HVFFPV5WJ>I7BO)%9V03>(TQND9I&5%4$J.
M6!). #SC'^&T3WVDW_BBY4B?Q%=M>(&'S);#Y(%_[]J&^KFHX6V_'J[64$%_
M#D1A)'!47#[\?BR9^H]J .B\/^(+3Q'827-FDT+P3-;W%M<(%EMY5QN1P"1G
MD'@D$$$$@UJ5Q/@90_C'QU<0\V[ZM'&K#H72WC#_ )'K7;4 %%%% !1110 4
M444 %%%% !1110!?LO\ 4G_>_I119?ZD_P"]_2B@"Q52Z_UH_P!VK=8VK6^I
M2WBM9:A#;Q[ -CVWF'.3SG<* (-6T33]<AMXM4M_/2VN8[J(;V7;+&<HWRD9
MP>QX]:8_A[2I?$T7B"2S1M5AMC:I<Y.5B+;BN,XZYYQGD^IJ/[%KG_08MO\
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MV4?8M<_Z#%M_X __ &R@"OIO@K0])N(9;*WN%6W):""2^GE@@//,<+N43 )
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MI-;&JZ59:WIDVGZI!Y]M-C>FXJ<@AE(92"K @$$$$$ @Y%5/L6O?]!JV_P#
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M"87%D&%O<6MU+;31AAAE$D3*VTCJ,X.!Z5B>+/"CCX:S>%/!]A'!'>[+-]K
M"&&1@)I6+'+MM+$GEF8Y.3FMS[%KW_0:MO\ P _^V4?8M>_Z#5M_X ?_ &R@
M#3@@CMK>."!=D42!$4=@!@"I*R/L6O?]!JV_\ /_ +91]BU[_H-6W_@!_P#;
M* ->BLC[%KW_ $&K;_P _P#ME'V+7O\ H-6W_@!_]LH UZ*R/L6O?]!JV_\
M #_[91]BU[_H-6W_ ( ?_;* ->BLC[%KW_0:MO\ P _^V4?8M>_Z#5M_X ?_
M &R@#7HK(^Q:]_T&K;_P _\ ME'V+7O^@U;?^ '_ -LH UZ*R/L6O?\ 0:MO
M_ #_ .V4?8M>_P"@U;?^ '_VR@#7HK(^Q:]_T&K;_P  /_ME'V+7O^@U;?\
M@!_]LH UZ*R/L6O?]!JV_P# #_[91]BU[_H-6W_@!_\ ;* ->LW6_#VF>(K6
M*#5K=I1!*)H9(Y7ADAD'1DD0AD/;((X)'0U%]BU[_H-6W_@!_P#;*/L6O?\
M0:MO_ #_ .V4 3:+H&F^'[62#2H&C$TAEFDEE>:69SU9Y')=ST&6)P !T K,
ML_#MW_PL?4?$FHR0O%]BBL=-CC8EHH\EYF8$ !F?:.">$'K@7?L6O?\ 0:MO
M_ #_ .V4?8M>_P"@U;?^ '_VR@#7KF[/X?\ AJPOHKJVT]U\BX:Z@MVNIFMH
M)CDF2. N8D;+-@JH(R<8S5W[%KW_ $&K;_P _P#ME'V+7O\ H-6W_@!_]LH
MUZ*R/L6O?]!JV_\  #_[91]BU[_H-6W_ ( ?_;* ->BLC[%KW_0:MO\ P _^
MV4?8M>_Z#5M_X ?_ &R@#7HK(^Q:]_T&K;_P _\ ME'V+7O^@U;?^ '_ -LH
M UZ*R/L6O?\ 0:MO_ #_ .V4?8M>_P"@U;?^ '_VR@#7HK(^Q:]_T&K;_P
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M:JY5EFM96\P @<@J79><?=R.,5L_8];_ .@Q;_\ @#_]G1]CUO\ Z#%O_P"
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MMM%O]*CM&:UU)76\,L\DDMP'7:V^5F+L=O&2V0, 8P*D^QZW_P!!BW_\ ?\
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M!_\ LZ/L>M_]!BW_ / '_P"SH U:*ROL>M_]!BW_ / '_P"SH^QZW_T&+?\
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MMT).T$L68G)9F.2S$\EB22>2:N5E?8];_P"@Q;_^ /\ ]G1]CUO_ *#%O_X
M_P#V= &K165]CUO_ *#%O_X _P#V='V/6_\ H,6__@#_ /9T :M%97V/6_\
MH,6__@#_ /9T?8];_P"@Q;_^ /\ ]G0!JT5E?8];_P"@Q;_^ /\ ]G1]CUO_
M *#%O_X _P#V= &K165]CUO_ *#%O_X _P#V='V/6_\ H,6__@#_ /9T :M%
M97V/6_\ H,6__@#_ /9T?8];_P"@Q;_^ /\ ]G0!TEE_J3_O?THJ#1H[F*Q*
MWLZ7$F\_.D7EC'';)HH OU4NO]:/]VK=5+K_ %H_W: ,G6-<L-"MXIM2ED43
M2"**.&!YI)7()VK&@+,< G@' !/05"_BG1D\-Q:^;Y6TV94:*9$9C)N("J$
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MB_(O4EO*UM\>KVVBXCO?#L-Q*/5X[AT4_DY% ';T444 %%%% !1110 4444
M7[+_ %)_WOZ4467^I/\ O?THH L54NO]:/\ =JW6/J]U?P7:K9Z<+I"@)<SA
M,')XP1_G- %?6])CUW1KC3+BXN+>"Y79*ULX5V3/S)D@X##*DCG!."#S5#6/
M"5KJG]G/:7=WI%QIJ/%:W&GF-6CB=0K1X=&7:0JGID%%P15C^T-8_P"@(/\
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MOK"Z,MWXCU/4T*%1#=QVJH#D?-^ZA1L\>N.>E']H:Q_T!!_X&+_A1_:&L?\
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M_:.M?] )?_ Q?\*/[1UK_H!+_P"!B_X4 :]%9']HZU_T E_\#%_PH_M'6O\
MH!+_ .!B_P"% &O161_:.M?] )?_  ,7_"C^T=:_Z 2_^!B_X4 :]<I>^ X]
M4CEM-6\0ZU?:3-*TDFES2P^4X+%O++B,3% 3T,G0 '(XK4_M'6O^@$O_ (&+
M_A1_:.M?] )?_ Q?\* ,WQ#X%A\0:]IFK?VSJ6GS:6A%K%:BW:*-CP7V2Q.-
M^. >P'&.<V;KPM<WWAVXTJ\\4ZX[S2K(+^&2&WN8@I4[%:*)0%.WG*DD,1GT
ML_VCK7_0"7_P,7_"C^T=:_Z 2_\ @8O^% #-8T"[U:=C%XEU?3;=X_+>VLOL
MZJPYR=[1-(I(/57&,9&#S5[2=*L=#TFVTS2;=;:SM8Q'%$N3M ]SR2>I)R22
M222:J?VCK7_0"7_P,7_"C^T=:_Z 2_\ @8O^% &+IVFW6D?%[6KA;>9[#7K"
M"X,ZH2D=Q!F-D)Z LC1D9Z[#Z4Z;P#+-XHCU]O%NNB^BA>WC(2SVI$SAC'C[
M/R,J.3EN.M;']HZU_P! )?\ P,7_  H_M'6O^@$O_@8O^% %+5/!D5]KLVL:
M=K&IZ)?7-N+:ZDT]HL7**24WK+&XW+E@& # ,1GIB0>#;&WT71]*TF[U#2K3
M2;J.YC2QN2AGVDDQRDY+HY8E@?O'O5G^T=:_Z 2_^!B_X4?VCK7_ $ E_P#
MQ?\ "@"EJG@^74IKT)XHUVRM+[_7V=O-"4Y4*P1GC:2,$#HCJ 22,$DUC^,/
M#JRZ-X9\'Z)ILBZ8=0M_.\M"8[:UM_WA#,<\L411GDEB><5TO]HZU_T E_\
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M/^@*O_@6O^%'V_6/^@*O_@6O^% &K165]OUC_H"K_P"!:_X4?;]8_P"@*O\
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MF,&&,D$JBQHB#) ).W<>F< "K'V_6/\ H"K_ .!:_P"%'V_6/^@*O_@6O^%
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M#4+*8RNUK>K;E-\CEG;Y(E8Y)/!)')XZ8O?;]8_Z J_^!:_X4?;]8_Z J_\
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MOM^L?] 5?_ M?\*/M^L?] 5?_ M?\* -6BLK[?K'_0%7_P "U_PH^WZQ_P!
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MC'#OAW?:-K7Q/6Y\(Z-_PBEI;Z.#>:=+"EM)J!=E,<BPJ?F1 3^^[EP!D'-
M'LE%>1_$3P3X3N+S0/">C^%]'M;W6[T&>>VT^*-X;2'YYF#JN5)^5 >/O]:]
M1U&Z32]'NKL(-EI;O+L P,*I./TH EM[RVN_-^RW$4_DR&*7RW#>6XZJV.A&
M1P>>:FKQQ[.[B_9ELKF.[A22[BAU/4#<7(M1>+-,)IHC*2 OF!RF2<$';T-1
M>#=8TN3Q?K^M>$M)_P"$:L-.T3_2=$G@6UEN9O\ 6I,;=3PJH=OF?Q;\ X&:
M /:**\/U'1;;2O@-8>/+>)#XL@MK;63K##_2)9'*LZ/(.60H[)L/R[<#' KV
MJ]CGEL+B.TE$,[Q,L4A&0C$<''L: )J@@O;6ZFGBMKF&:2V?RYTCD#&)L!MK
M ?=."#@]B*^??"EYIE]JG@W3=/T^/2O$D-^9K[Q&9(VCU=8O^/A8[E6)NFE+
MC*\E<G/W:]/A==+^/-S;Q*5CUS0UN)<'@S6\NP-CW20#/^R* .ZHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BJ.KZ)IVOV:V>LVB7EJ)%D:WER
M8Y".@=.C@'G:P(R <9 (XCX>VMM!XY\9Q^&HUMO#D4T$$4,"A8%O%0B?RE'"
MX_=AL#!8>U 'HM%>9>%-"BT#XWZS;QWE[?22Z%;3375].9997,\HR3P%&  %
M4!0!P!5"XO(?$/Q \4R:YX4O_%5IHLD=G:V4<,,L%LOE+(\FR:15>5V8C*AF
M"J!P&&X ]<J%;RV>^DLTN(6NHXUD> ."ZHQ(5BO4 E6 /?!]*H>&-0TC5?"^
MGWOAH1+I4T"FU2&/RU1.FT+@;<8QCMBN5\!V]OXAG\:ZCJD$=TFH:U-8M%-&
M&1K>W40HA4C!'#G'^T?>@#OZ*\GO_"7AJ\^,>A:1H?AW2[&/0X_[8OY[.QCB
M;?DI;Q[U /WMS[>AV"JAU"TUSQ%XMU7Q-X0O_%5MH][+9V\"V\$T%G#%&I8I
M'-(NZ1VW$[ S8"CC@4 >QT51T.\TW4- L+O03$=,FMT>T\E-B"(J-H"X&T 8
M&,#'3 KS_P 1:#%9?&_P5JKWM]=W-Y>7P N9RT=NGV)OW<48PJK\N2<;B>I-
M 'I'VVU^W_8?M,/VORO.^S^8/,\O.-^WKMSQGIFIJX7QU(ND^./ ^M*N'DU)
M])D*_P 4=Q$Q /J \2'VQ[UW5 !1110 4444 %%%% !6==?\?+_A_*M&LZZ_
MX^7_  _E0!#1110 4444 %%%% !116+XGL]%N=/CD\1Z=)J-K!)N%NMI+=J6
M(P"845M^,]2IQUXH VJ*\Z^&MI;7FG^*;:V#VNC7&I2QVNFK*8I+-"H#C8I#
M0;FW,$^4KG.!FF_V1I>D?&+0K+P?8V^G&*RN)=8BL81%&T! 6'S N 6\S)&>
M<!NU 'H]%>;?%+P_H-EX5OM1M]/C'B.]N(TTV\09NVO&8>4L<I.X8V_=! "J
M>,5Z- )%MXQ.P:4* [*, MCDT -CN[>:XFMX9XI)K?:)HU<%H\C(W#J,CD9J
M6O);+7KO2_@IXE\8V9QJ&I7EW<HY7)C)F,$?U"JBX^E:_AX>&M"U_2;2Y\*7
M6G:I>K(+36M1MH'FO)0N7W3*[R+(ZEFQ)M)^8=1B@#T.BO&_'[OXHU.#5@[?
MV5H>MV=E9 'Y9[DW"">7CJ%&(QU&?,]J]DH *A2\MI+R6TCN(GN855Y85<%T
M5L[25Z@'!P>^#7DWA[3=*\&6D<WCGP2L4[:K*PUZ2VM9TC,DS-"S.KM*HR54
M,5 !(Y%=3KSKI?Q?\+7<:X.JVMWILY'<(!-'^15Q_P #- ';4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !117F^JZ''I_QL\+7YO+V[N+[^T&8W
M,Y984$*;8XT&%11ST&23DDT >D45YMXCDT0_%1XOB UD-'&E(^F+JNT6C2^8
M1,1O^0R@&/\ V@IXXS7-Z;J;W_@RQ\-6UW</I4WBU]&21G8/)8)NE$>X_-@J
M!'[KD=* /;:BNKNWL;62YO;B*VMXQEY9G"(@]23P*X6'3K3PI\7-+LO#]K!I
M]AK&FW!N;2V01Q&2%HRL@1< -ARN1U'7H*M_$)S>:AX5T,_ZG4=9C>=<9#QP
M*TVT^Q9$_*@#M**\TUZZ&M_%*YTG4=#O-?T_2=/BECTV%8C"\LK-F642ND;%
M0@558DC<Q X)$6MV5CXO\ :*O@WP\LEA9:Y#+>Z,L,-N8UBD8SQ-&[*F[.05
MS@D]2#F@#U"BN3\'77AU-0U/2]'\.+X;U&W\M[JR:TA@>1"#LD!B)21?O#(8
MX((..^GXFL]&NM.23Q%I\FHVL$@86ZVLMTK,00"T**V_&>ZD \\$9H U;FY@
MLK66YO)H[>WA0O)+*X544#)))X 'K3T=9$5XV#*PRK*<@CUKSOX:VMI=Q^*X
M+:%8-$GU!XK;2),(ULFP+(&AZPAVW,$(4X.<#-:GPJNY+CX=6%O.S-+ISRV#
M,QSD0R-&IS_NJM '8T444 %%%% !1110 4444 7[+_4G_>_I119?ZD_[W]**
M +%5+K_6C_=JW6-JVL6EA>"&X^T;]@;]W:RR#&3W52* (-;35)=&N(] DMX=
M0D79%-<Y*19."^ #N*C)"]"0 2 <UR]QX+N]&FT&[\(+:S3Z3#<P/%J-PZ"X
M\\*SRM(JN3)OC#'CYMS<C KH?^$ETW_I\_\  "?_ .(H_P"$ETW_ *?/_ "?
M_P"(H /"VB?\(WX2TO1?.\\V%K' 9<8WE5 )QV!/;M7*P?#NX?Q/KC:A-;2:
M#?)=M;6Z[C(DETL0F+ C&,QN1@_\M&KJO^$ETW_I\_\  "?_ .(H_P"$ETW_
M *?/_ "?_P"(H YKP]X+UBR\$Z[::W=6EQKNL0M'+<1,QC.+=88^2H.,+N/'
M!9L9I9O"&LVMGX)N---C<7_AN P307$SQ13AK?RF*R!&(P0",IR/2ND_X273
M?^GS_P  )_\ XBC_ (273?\ I\_\ )__ (B@"E8Z!>P?$/4/$$[0"WN]-M[5
M8T<EU='D9LY4#;\XP>OL*3P+X=N_#&@SV5_)#)+)?W-R#"Q*[9)6=1R!S@\U
M>_X273?^GS_P G_^(H_X273?^GS_ , )_P#XB@#'E\/:SHWB_4=<\,?8;J'5
MUC-[87T[P!98UVK+'(J/U4 %2O.,Y[4FL:!KNOQ^'IK]].AGT[6X]0FBA=RJ
MPK'(NQ7(R[Y<')5 ?08YV?\ A)=-_P"GS_P G_\ B*/^$ETW_I\_\ )__B*
M,FX\*WLOQ U37%EMQ:WFB+I\:%FWB02.V2,8VX8<YS[55'@.>[^#]CX0O+U+
M>\MK6W074 +JDT15E8 X+#<HX../2N@_X273?^GS_P  )_\ XBC_ (273?\
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M_P!\4 ;,?^M3_>%7ZYJ/Q-IOF+_Q^=1_RX3_ /Q%7O\ A*-,_P"GS_P7S_\
MQ% &O161_P )1IG_ $^?^"^?_P"(H_X2C3/^GS_P7S__ !% &O161_PE&F?]
M/G_@OG_^(H_X2C3/^GS_ ,%\_P#\10!KT5D?\)1IG_3Y_P""^?\ ^(H_X2C3
M/^GS_P %\_\ \10!KUC:M+XF@OXVT*STF]M&BQ)'>7<EM(DF>H=8Y RD=MJD
M$9R<X#O^$HTS_I\_\%\__P 11_PE&F?]/G_@OG_^(H XR7X9:C/X%U*S>^LQ
MK6H:P-=D'E$VAN R,(2/O&+]VJEB,GEL?PUK1^'-<UGQYI'B+Q#!ING+HL,Z
M6\-A=/<M<-,NUM[O%'M50 0 #DG.1C!W?^$HTS_I\_\ !?/_ /$4?\)1IG_3
MY_X+Y_\ XB@#,TWPQ>+\2M7\4ZM+!()+6*QTR.)F)A@'SR%\@#<TG/'8#FNA
MU.S&HZ3=V3':+F!X2?3<I']:H_\ "4:9_P!/G_@OG_\ B*/^$HTS_I\_\%\_
M_P 10!P&A:'>^+?@MX6MK26"'4_#]S"3;W0)B>:S9HC#)C) )7J <<$ UOKX
M3U37O&D>O>*8-/LH[;39K".TL+E[@SB8C>SR-''@ # 4*>23N[5M6^N:':>;
M]EMYX/.D,LOEZ9,OF.>K-B/DG Y//%3?\)1IG_3Y_P""^?\ ^(H XN/P)XDG
M\'6/@?49M,.@VLL4<E_'-(;FXM8G#)$82@5&.U5+"0C&2%YP.KU?2]:US^V]
M)NI[*WT2_P!.:VMYH _VJ.5U979L_+@ @C'.>M6?^$HTS_I\_P#!?/\ _$4?
M\)1IG_3Y_P""^?\ ^(H XU_!7B35?#N@>&]7AT6ST_1[BVE-[93R22RK;_="
M0F)5B+8&3O;:"P .:O0H-4^/5Q<1'=%H>AK;RD=IKB7>%_[XC!_X$*Z3_A*-
M,_Z?/_!?/_\ $5!!K>A6LT\MM;30R7+^9.\>F3*96P%W,1'\QP ,GL!0!O45
MD?\ "4:9_P!/G_@OG_\ B*/^$HTS_I\_\%\__P 10!KT5D?\)1IG_3Y_X+Y_
M_B*/^$HTS_I\_P#!?/\ _$4 :]%9'_"4:9_T^?\ @OG_ /B*/^$HTS_I\_\
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M1[D2PM%R!;L$(W9ZMTQ[UTG_  E&F?\ 3Y_X+Y__ (BC_A*-,_Z?/_!?/_\
M$4 <SXU1]7\9>!-&<*MPFH-JTZ1L6$:P0L,[L#C?*J@D#.:[VL'^V]"^W_;O
MLT_VORO)^T?V9-YGEYSLW>7G;GG'3-3_ /"4:9_T^?\ @OG_ /B* ->BLC_A
M*-,_Z?/_  7S_P#Q%'_"4:9_T^?^"^?_ .(H UZ*R/\ A*-,_P"GS_P7S_\
MQ%'_  E&F?\ 3Y_X+Y__ (B@#7HK(_X2C3/^GS_P7S__ !%'_"4:9_T^?^"^
M?_XB@#7K.NO^/E_P_E4/_"4:9_T^?^"^?_XBL^Y\2Z<;AB/MG;_EPG]/]R@#
M0HK*_P"$DT[_ *>__ &?_P"(H_X233O^GO\ \ 9__B* -6BLK_A)-._Z>_\
MP!G_ /B*/^$DT[_I[_\  &?_ .(H U:*RO\ A)-._P"GO_P!G_\ B*/^$DT[
M_I[_ / &?_XB@#5K-U=]<B:W?0(-/N0"PGAO9GAR,?*5D57Q@]04.<]1CEG_
M  DFG?\ 3W_X S__ !%'_"2:=_T]_P#@#/\ _$4 8FD>'M=T^Y\2:^_]F_V]
MK*QB*V5W-K!Y*,L0:3:'?[V6.T>@'&:K>"=!\2^&XRFI:?I5U=7LWG:IJO\
M:LCSW#G^((;90% X5-P"CCU)Z3_A)-._Z>__  !G_P#B*/\ A)-._P"GO_P!
MG_\ B* .6DT'Q9)X\G\07EAHNII;[HM(CEU.6$6<1X9MHMV'FN,9;/ ^4<=>
MZMVF:UB:[CCBG* RI$Y=5;'(#$ L,]R!GT'2L[_A)-._Z>__  !G_P#B*/\
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MR7?:"?O=:77D&J?&#PK9Q')TJUN]1N!_=#J(8_S+/Q_LGTKH?^$DT[_I[_\
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M9IK:=J.I7E_-?:D+AY+>*1Y2S-Y; .4P=H&5.0#T)XVO^$DT[_I[_P# &?\
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M$WH'7<C91F4JP!P0QY4CC%8GBN0ZC\0O".@L?]'$LVJ7"_WO(4"(?A)(K?\
M !0!VM%>2W7B-K+QA/<7FMW,&H6NO-'/8O=,(DTP0;C(8,[1'CYO-VYW<;NU
M=-X/UQ-<UZ^O;[5HX[V>,?9="^U 26EJ#E9)(0<B1PRL21E0RKZY .THKB?
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MC.55@ " 17H>]?[P_.C>O]X?G0!C^#M(N= \$Z-I-](LMS9644$K*<KN5 "
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ML+W1[^;XJZ3K$<&;"WTNYMY9MZ_+(\D948SDY"GD#'%=/O7^\/SHWK_>'YT
M>8-X&URZ\-^*[98HK>[N?$YU>P6:0%+A$,++N*YVAC&PY&1QD5M7%IK7BSQ-
MX?N;S1)]$LM'G:\E-Y/#(\TAC9%2,1.XVC<26;'; ZX[7>O]X?G1O7^\/SH
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MA^=&]?[P_.@#CO!?AG^Q+_5]:N=.M-%2]$<<&G6X15L[>,,1N*?+O9G=FVY
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MEE \"[/,\LH\;.Y!SR"&P1V&* -C_A&- _Z >F_^ D?^%'_",:!_T ]-_P#
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MMK:W37]J+>\9%M93,NR<N,H$.<,6[8Z]J *W_",:!_T ]-_\!(_\*/\ A&-
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M>,M6UCPYX1LM9:Z@$EA<V[ZHL46(YX68)*%#9*@;MXYS\O4]" ;/_",:!_T
M]-_\!(_\*/\ A&- _P"@'IO_ ("1_P"%:E% &7_PC&@?] /3?_ 2/_"C_A&-
M _Z >F_^ D?^%:E% &;'X7T#S%_XD>F]1_RZ1_X5>_X17P]_T =,_P# ./\
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M?:[ LA9?+7J<'C)],)PI(&?8=Z ,K_A%?#W_ $ =,_\  ./_  H_X17P]_T
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M.J:H/#,VFZ?INFW367VF^M)+I[J9,>85598PBJWRY);<0>F.0#=_X17P]_T
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M.(;73I(75B 1\[3N"!SQM_$4 3_\(QH/_0$T[_P$C_PH_P"$8T'_ * FG?\
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M$:EMH4*B9.U%50 "6/J36Y0!Y@J)XE\6>,K_ ,+[;G3+W0$LY+JWP8KN\ E
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MBVAC4X0<G.69V)X^\!CB@#<HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$OB7P#IE_=[OMJQ^1>*XPRSQG9(".QW*3^-=/0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 .C_UJ?[PJ_5"/_6I_O"K] !1110
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MS-'(==L+&R<$>6+.]>Y##ODM%'C\C7 >-=&M+;QY\.;(R7-CI,:WFGJ]M<-
M58PQ^5'YBX9=PB8#:03TSR:N^%-1.D>,O&.GRZO--X=TI;>5;C4;QIA:2LC&
M6,S2,6( ",0S';GMF@#?\0>*+C3=?TW0='T^._U74(Y9E2XN3;PQ11@;F9PC
MMDEE  4YYS@"LA_'6J7?@GQ+?:=I4,.N>'9Y(KFREE,T4ACPYV. I8-$?E)
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M3!IHX(H+?6I3)-([!510;4#))[D=ZUCKUY;?$&'0KV&%;2]TYKFTE3.[S8W
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MF%4>1VR1\HW':I/. M:'B"*6#P+J<41S+'ILJJ5[L(B!C\:R_"$MM_PJGPQ
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M"MIUA;Z5I=KI]DFRVM(4@B7^ZBJ% _("K-%% !1110 4444 %%%% !6==?\
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M(%B5FP!DA0 3@#GVJ*#PYHEKJSZK;:-I\.HR%B]Y':HLS$]27 R<]^:S-/\
M%%ZOBJ/0/$6F0:?=W-LUS9R6MX;B*<(0)%RT:,&7<IQM((/7BNEH J-I.G/<
M7-P]A:M-=QB*XD,*EID P%<XRPP3P>.:ATKP[HNA&4Z'H]AIIFQYIL[5(=^,
MXSM SC)Z^M:-% '/Z7H%U!XVUK7]1DA=KJ.&ULDC))AMXP6()('+2.Y(&1@+
MSUKH*** "BBB@ HHHH **** "BBB@"_9?ZD_[W]**++_ %)_WOZ44 6*J77^
MM'^[5NJEU_K1_NT 0T444 %%%% !1110!PEU_P G Z=_V+D__I1'57XA7UQ?
M>-/"^@6.G7&IK!.=8OK>U:)9!'#Q%_K'5<&5A_$/N=Z[+5?#6A:[)')K>BZ=
MJ3Q K&UY:)*4![ L#BGZ=H&CZ.P.D:38V!$?E VMLD7R;BVWY0.-S,<>I)[T
M >?^#+^ZT[X@^+=#O]-N=*BU-?[9L;>Z,98[ALG.8W=?O@' .>22.:Y'PWJ<
M?@+P7X*\<3([:?+IDNF:D(U)/WGD@; _VU9,GIOKW:6PLYKV*\FM()+F%&2.
M=XP716QN4-U .!D=\5#_ &'I/]DII?\ 9EG_ &?'M*6GV=/*7!W#"8P,$9''
M7F@#RW2='N]'\:_#@:M_R%;R+5KW4#CDSRI&[#_@.0H]E%5W2]\9CQY=1>'-
M0U.WU@-I>GW5O):B)([<,JM^\E1O]:6;H>@Q7L,MC:3WMO>3VL,EU;!A!.\8
M+Q!@ VUCRN0!G'7%%E8VFF64=GIMK#:6L0Q'!!&(T09SPHX')H Y_P"'7B"7
MQ+X!TR_N]WVU8_(O%<899XSLD!'8[E)_&J%K_P 5%\7[JY/S6?ABU%M%Z&[G
M :0CW6,(O_ S77VMC:6(E%C:PVPGE:>40QA/,D8Y9VQU8]R>367X4\.?\(UI
M,MO+=?;;JZNIKRZNO+V>=+(Y8G;DX &% R>%% '/_&K_ )(_K?\ VP_]*(Z1
M)4TKX[7/V\B)=9T>)+&1S@2/#(YDB4]VPZMCTKM;VQM-2LWM-1M8;NVDQOAG
MC#HV#D94\'D _A4>I:7I^L69M-7L;:_MB0QANH5E0D=#M8$4 9OB*W\.^(=.
MN= UZXM98YVCBDMVN LBR-\T8'.0QVY7N<5SOA.;6-%^(5[X1N=:GU_3;?38
M[R*ZNPK7-HQ?8(977&\L 7!(S@>G)ZR/PUH46C2:1%HNG)ILAW/9+:((7.0<
ME,;3R >G85-I>C:9H=JUMHNFVFG0,YD:*T@6)2Q !8A0!G  S["@"[1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 .C_UJ?[PJ_5"/_6I_O"K] !1
M110 4444 %%%% !1110 5Y_XB36I/B"NH7'AK4-2TK2K(C3FLYK7:UQ(")97
M$LR,-J81>#]Z0]Q7H%! 92&&0>"#WH X+X)W,L_P@T%9;*>V$5JJ(\K1D3#^
M^NUB0.WS!3QTJ/P^K2?%?XBQ D3/!IXCR0/E\AP,=_O%J[JSLK73K.*TT^VA
MM;:%=L<,$81$'H%' %8A\/7$'Q'7Q%9R1"WNM.-G?1,2&9D?="Z\8.-T@.<<
M$=: /.(;V ?LGM8D#[8+!M)-MQO^UE_*\K;_ ']YZ?CTYKU :K::3IYL#<0S
MZE8Z=]H:PCE7SF15QN"=<%A@'&,U*/#&@C7/[:&B:<-5SG[?]DC\_.W;GS,;
MON\=>G%6QIMB-4.I"SMQ?M#Y!NA$OFF/.=F_&=N><9QF@#P.UTDZ+X-\/_$2
MTO(;JWEU"&\A\+H\C6,3W#JFVW0L2)T+NV?F4-NVHN*](U[=_P +U\(^3G/]
MF:AYV/[F8L9]MWZUTUMX2\-V>L'5K3P_I<&I%V<WD5E&LVYLAFW@;LG)R<\Y
M-4[;P]='XC7WB._DA:%;&.QT^),ED7<7E9LC@LVT  GA!ZXH Z.BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#$\1:#H?B*;3[76RQ
MN()6N;(17LEM*KJNTNAC96X#\XZ9KG_ MU<P^-/%FAPW]WJ.CZ;);_9IKN=I
MWAE=6:6#S6)9POR'#$E=V":ZS5M"TG7K=(-<TNRU*&-MZ1WENDRJV,9 8$ X
M)YJ>PT^RTJQCLM+LX+*TBR(X+:)8XTR<G"J !R2?QH XS63CX[>&/-.%.D7P
MBSCE]\.?TI?BC_JO"7_8T6'_ *$U;'B3P]<:IK?A[5].DBCO-'O2Y\TD![>1
M#',G /."&';*#IU%C4O!GA?6;YKS5_#>D7]TX :>ZL8I78 8&692>!0!HW.H
MV5G<VUO=WEO!/=L4MXI955IF R0@)RQQS@5XEJ>@'Q@/&_B:'5(]#73[V2";
M3%D<6]\MM@DWR[P&\P+@;=N$/)?.*]GCT'2(H[%(M*L433R39*ML@%L2,'R^
M/DXXXQ5>^\)>'-3U(:CJ6@:7=WR[2+JXLHY)1M^[\Y&>.WI0!P7BW5)=;\ _
M#_5!9FQN;S7-*FCME!_=,QR5' X"[OPKU2N<UWP]=ZWXN\/7<DD(TK2));N2
M%B2\MP4\N(XQ@*H>1LYSG;QUKHZ "BBB@ HHHH **** "BBB@ K.NO\ CY?\
M/Y5HUG77_'R_X?RH AHHHH **** "BBB@ HHHH *S/$W_(I:O_UXS?\ HLUI
MU0U70M(UV../6]*LM12(EHUN[=)0A/4@,#B@#-^'W_),O#'_ &![3_T2M9*G
M_B_T@<_\RPAC''_/TV_W_N?I74:5H6D:%')'HFE66G)*0TBVEND0<CH2% S6
M?JN@3W'C+1->L'B5[-9K:[20D>;;R+GY2 ?F61$(!P,%N>E ')>%M2MM&^&O
MBM-4=(9-+O=1^UH[<C<[NN1WW*RX]<\5T?@4Q:+X)\,:+J5Q#;ZFVFQ;;220
M+*Q6,%P%SD[<\XZ5KW7AS0[[5(M3O=&T^XOX2IBNYK5'E0J<J0Y&1@\C!XJU
M+I]G-?P7TUI!)=VZLL-P\0,D0;[P5L9 /?'6@#B=:F/Q!\0GPWIQ)T/2KM'U
MJ['W9I8R'6S4]SD*7(^Z !U-3>/,_P#"6^!?)SYW]L-C'79]GDW_ (8ZULR>
M O!\TKRS>%-$DD=BS.VG0DL3U).WDTRY\.SW7CK2]4<VZ:9I-E*EK @(<3R8
M4MC& HC&T8.?G/0#D Z*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *XCXHO]ETWP_J,V%L[#Q!9SW<K'"Q1;BI=CZ NIKMZ
M9/!%=6\EO<Q)-#*A22.10RNI&""#P01VH XS6]M]\9?"T%OAY--LKVYN<?\
M+)) D:9]-S!L?[IKMJHZ7H>DZ'%)%HFEV6G1R-N=+2W2(,?4A0,FKU !1110
M 4444 %%%% !1110 4444 %%%% %^R_U)_WOZ4467^I/^]_2B@"Q52Z_UH_W
M:MU4NO\ 6C_=H AHHHH **** "BBB@#)D\1VD?C"#PVT<WVR:R>]5PH\L(KA
M""<YW98=L>]3ZYK%MX?T.[U6^#M!:QEV2, NYZ!5!(!8G '(Y(KD[K_DX'3O
M^Q<G_P#2B.JWQ,U6-M=\+>'Y([J6&XOAJ%Z+6UDN&$%OAP"D:LV&D,8SC'%
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MIXOM['68M(T_3K[6=1DM_M36]AY7[J'. [/*Z( 2" -V3@X& :\=N]/U._\
M!>N>)]&F9/ LVH37]UX=DG7?>11R-Y[+,$W0J[1Y\D9!^;YEW8KTE=)U9?%B
M>,?"4.GW=MJNE0P365_.]J8]IWQNKI')_"[ I@= <]J .E\.>(;#Q3H,&K:6
M9/)FRK1S(4DA=25>-U/W65@01[<9&#4,GB-?^$XA\-V]MYLGV%KVYF\S @3>
M$C&,<ECO[C 0]:YGX/K<OX?UV\NGB=;[Q#?3Q/ #Y;#S-I*9Y*[U?FI?"Q,G
MQC\>O)R\4>FQ1Y'W4\EVX/H69ORH T;+XB:'J7C;_A&=/^U7%SY<S&Z6 BVW
M1,%DC$AQN8%AG:"!G!(/%6M4\716&O#1;#2[_6-2%N+J6"Q\H>1$6VJS-+(B
M\D'"@D\$XQS6-K/_ "7/PQ_V"+__ -#AK#\1V.L>(/BKJ2^ -2_L'5]+TR*'
M4;^8++%<"3>\,7D%3D@C/FY!4$C:W2@#T'PWXAL/%6@6VKZ49/L\X(V3(4DB
M=259'4]&5@01[<9'-5=7\5P:;K$>D6>GWNKZH\7GM9V(CW119(\QVD=$4$C
M!;)/0'!QD?":XM'\!16=G9/92:;<SV5W&\WG%[B-R))/,P-^YLMG Z].*P]+
MT[4=2^,/CZ.TU^[T=D^P%?LL$#O(AM_ER94<;0WF< #DGF@#KM6\5R:/%H<]
M]I$]O!J=\EE/YTJ>99M("(RP0LK N%4X;C<#STKHZ\8\2^(]1\0?LQW^L:D4
M_M&WD4+<0IM662"\54E4=MQ0' XR2!7L] !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %8'C3QEIO@7PZ^KZNEQ-&K!4@M4#RRG!)VJ2 =JAG.2
M,*I-;]>,_$+4EOIO&5SK-AJT46F:+=V&DK_9-R\+O) ?-N?-6,QJ#D1@EAA5
M<D@-0!Z!K'CBSTG3=#NET^_OGUR5(K.VMA$)"SQF0;B[JHX!_BZUKZ3J-UJ,
M#O>:->Z2RM@1WCP,SC'4>5(XQ]2#[5R=AH%GXW\$^%+E;W5--ETI8;BWFB@$
M,@D6+9RD\1!7#'!VX/!!(JQX/UC53XP\2>&=6OSJHTC[/+!?/$D<A696;RY
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MKA1Y817"$$YSNRP[8]ZGUS6+;P_H=WJM\':"UC+LD8!=ST"J"0"Q. .1R10
MDVAZ=<:[!K,UL&U"W@>WCFW,,1N064@'!&0#R#CM6+9_#;PQ8VUO:PVEV]G;
M,&BLKC4KF:W4@Y'[EY"AP>1E>#SUK6T#Q!9^(_#\.KV0DC@E#928 /&RL596
M )&05(.">E<YIOQ0L+_3M+U.?1=7L-*U69(+;4+E8#%O<D('$<K.@+#;N*@
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M%"@_I5ZH[>XBN[6*XMW$D,R"2-QT92,@_E4E !1110 4444 %%%% !6==?\
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M339C$\JRL$D@A=PK2$#<#MSDC/0'FNLH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH PM5\&:+K6MQ:O>QWBZA%#Y$<]MJ%Q;LL><E1Y;J
M.3U]>/04^3PEI,VDC3K@7T\*SBXCDFU&X>:*0<!DF9S(G''RL."?4YJ>'O'>
ME^)M>U;2M+BNF?2R \[HHBG^9DS&V[Y@&1ES@#(JIK'C^;0--:_U;PAKT%NK
MI'N#V3EF9@JJ%6X)))(& #0!MZ/X:TK0I[B?3X)#<W./.N;FXDN)G & IDD9
MFVCLN<#GCDUG>.=%N]5T[3[O28?/U#2=1@OH(MP7S0IVR)N. ,QL^,\9Q73
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M"Y/_ (W1YOB'_GSTS_P+D_\ C=7-0U.QTBR:\U:]M[&U0@-/<RK&BDG RS$
M9-0Z5K^CZ\DK:'JUCJ2PD"0V=RDP0GIG:3CH: (?-\0_\^>F?^!<G_QNCS?$
M/_/GIG_@7)_\;IZ^)-#?6O['36=/;5,D?81=(9\A=Q'EYW=.>G3FKUU=6]C:
M2W5[/%;V\*EY)IG"(BCJ23P![T 9WF^(?^?/3/\ P+D_^-T>;XA_Y\],_P#
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M3P1320-(%(7?&Q5P"0,@,",CCCK0!5\WQ'_SYZ7_ .!<G_QNCS?$?_/GI?\
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M0_\ /IIG_@5)_P#&Z/-\0_\ /IIG_@5)_P#&ZU:* ,KS?$/_ #Z:9_X%2?\
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M=QO*I7[P* Y&._'%6=2U73]&M/M6KW]K86^X+YUU,L29/0;F(&: *OF^(?\
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MNCS?$/\ SZ:9_P"!4G_QNM6B@#*\WQ#_ ,^FF?\ @5)_\;H\WQ#_ ,^FF?\
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M!54  DDL0, 4FIZOINBVHN=9U"UT^W9P@ENYUB0L02!EB!G@\>U %;S?$/\
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MJ (:*** "BBB@ HHHH *;(@DC9&+ ,""58J>?0CD?44ZFR!S&PB95?!VLRY
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MBPU.TL+6]@>"X,UBT[D,,90B5 I'/4-0!;BCB?PO:/+8?V@88(IH[<*A9I$
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M@7J?_@,?\:UJ* ,G^WA_T"]3_P# 8_XT?V\/^@7J?_@,?\:UJ* ,G^WA_P!
MO4__  &/^-']O#_H%ZG_ . Q_P :UJ* ,N/7AYB_\2O4^H_Y=C_C5[_A(!_T
M"=4_\!3_ (U8C_UJ?[PJ_0!D?\) /^@3JG_@*?\ &C_A(!_T"=4_\!3_ (UK
MT4 9'_"0#_H$ZI_X"G_&C_A(!_T"=4_\!3_C6O10!D?\) /^@3JG_@*?\:/^
M$@'_ $"=4_\  4_XUKT4 9'_  D _P"@3JG_ ("G_&C_ (2 ?] G5/\ P%/^
M-:]% &1_PD _Z!.J?^ I_P :/^$@'_0)U3_P%/\ C6O10!D?\) /^@3JG_@*
M?\:/^$@'_0)U3_P%/^-:]% &1_PD _Z!.J?^ I_QH_X2 ?\ 0)U3_P !3_C6
MO10!D?\ "0#_ *!.J?\ @*?\:/\ A(!_T"=4_P# 4_XUKT4 9'_"0#_H$ZI_
MX"G_ !H_X2 ?] G5/_ 4_P"-:]% &1_PD _Z!.J?^ I_QH_X2 ?] G5/_ 4_
MXUKT4 9'_"0#_H$ZI_X"G_&C_A(!_P! G5/_  %/^-:]% &1_P ) /\ H$ZI
M_P" I_QH_P"$@'_0)U3_ ,!3_C6O10!D?\) /^@3JG_@*?\ &C_A(!_T"=4_
M\!3_ (UKT4 9'_"0#_H$ZI_X"G_&C_A(!_T"=4_\!3_C6O10!D?\) /^@3JG
M_@*?\:/^$@'_ $"=4_\  4_XUKT4 9'_  D _P"@3JG_ ("G_&C_ (2 ?] G
M5/\ P%/^-:]% &1_PD _Z!.J?^ I_P :/^$@'_0)U3_P%/\ C6O10!D?\) /
M^@3JG_@*?\:/^$@'_0)U3_P%/^-:]% &1_PD _Z!.J?^ I_QH_X2 ?\ 0)U3
M_P !3_C6O10!D?\ "0#_ *!.J?\ @*?\:/\ A(!_T"=4_P# 4_XUKT4 9'_"
M0#_H$ZI_X"G_ !H_X2 ?] G5/_ 4_P"-:]% &1_PD _Z!.J?^ I_QH_X2 ?]
M G5/_ 4_XUKT4 9'_"0#_H$ZI_X"G_&C_A(!_P! G5/_  %/^-:]% &1_P )
M /\ H$ZI_P" I_QH_P"$@'_0)U3_ ,!3_C6O10!D?\) /^@3JG_@*?\ &C_A
M(!_T"=4_\!3_ (UKT4 9'_"0#_H$ZI_X"G_&C_A(!_T"=4_\!3_C6O10!D?\
M) /^@3JG_@*?\:S[G7@;AO\ B5ZGV_Y=CZ?6NGK.NO\ CY?\/Y4 8G]O#_H%
MZG_X#'_&C^WA_P! O4__  &/^-:M% &5_;P_Z!>I_P#@,?\ &C^WA_T"]3_\
M!C_C6K10!E?V\/\ H%ZG_P" Q_QH_MX?] O4_P#P&/\ C6K10!E?V\/^@7J?
M_@,?\:/[>'_0+U/_ ,!C_C6K10!E?V\/^@7J?_@,?\:/[>'_ $"]3_\  8_X
MUJT4 97]O#_H%ZG_ . Q_P :/[>'_0+U/_P&/^-:M% &5_;P_P"@7J?_ (#'
M_&C^WA_T"]3_ / 8_P"-:M% &5_;P_Z!>I_^ Q_QH_MX?] O4_\ P&/^-:M%
M &5_;P_Z!>I_^ Q_QH_MX?\ 0+U/_P !C_C6K10!E?V\/^@7J?\ X#'_ !H_
MMX?] O4__ 8_XUJT4 97]O#_ *!>I_\ @,?\:/[>'_0+U/\ \!C_ (UJT4 9
M7]O#_H%ZG_X#'_&C^WA_T"]3_P# 8_XUJT4 97]O#_H%ZG_X#'_&C^WA_P!
MO4__  &/^-:M% &5_;P_Z!>I_P#@,?\ &C^WA_T"]3_\!C_C6K10!E?V\/\
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M^QVW_/O%_P!\"@"I_P )#HO_ $%[#_P)3_&C_A(=%_Z"]A_X$I_C5O[';?\
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M\"@"I_PD.B_]!>P_\"4_QH_X2'1?^@O8?^!*?XU;^QVW_/O%_P!\"C[';?\
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M2'1?^@O8?^!*?XU;^QVW_/O%_P!\"C[';?\ /O%_WP* *G_"0Z+_ -!>P_\
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M .@K8_\ @2G^-']OZ/\ ]!6Q_P# E/\ &N@^QVW_ #[Q?]\"C[';?\^\7_?
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M@K8_^!*?XT?V_H__ $%;'_P)3_&N@^QVW_/O%_WP*/L=M_S[Q?\ ? H Y_\
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ML=M_S[Q?]\"C[';?\^\7_? H Y_^W]'_ .@K8_\ @2G^-']OZ/\ ]!6Q_P#
ME/\ &N@^QVW_ #[Q?]\"C[';?\^\7_? H Y_^W]'_P"@K8_^!*?XT?V_H_\
MT%;'_P "4_QKH/L=M_S[Q?\ ? H^QVW_ #[Q?]\"@#G_ .W]'_Z"MC_X$I_C
M1_;^C_\ 05L?_ E/\:Z#[';?\^\7_? H^QVW_/O%_P!\"@#D],N?#6C6C6NF
M7]C! TTDWEB[! :1R[8!;@%F)P.!G@"KG]OZ/_T%;'_P)3_&N@^QVW_/O%_W
MP*/L=M_S[Q?]\"@#G_[?T?\ Z"MC_P"!*?XT?V_H_P#T%;'_ ,"4_P :Z#['
M;?\ /O%_WP*/L=M_S[Q?]\"@#G_[?T?_ *"MC_X$I_C5*PN/#.F7%[/97UC'
M+?S_ &BY<W88R/M"YR6.!A0 !P.PKK?L=M_S[Q?]\"C[';?\^\7_ 'P* .?_
M +?T?_H*V/\ X$I_C1_;^C_]!6Q_\"4_QKH/L=M_S[Q?]\"C[';?\^\7_? H
M Y_^W]'_ .@K8_\ @2G^-']OZ/\ ]!6Q_P# E/\ &N@^QVW_ #[Q?]\"C[';
M?\^\7_? H Y_^W]'_P"@K8_^!*?XT?V_H_\ T%;'_P "4_QKH/L=M_S[Q?\
M? H^QVW_ #[Q?]\"@#G_ .W]'_Z"MC_X$I_C1_;^C_\ 05L?_ E/\:Z#[';?
M\^\7_? H^QVW_/O%_P!\"@"OI-U;WEFTMI/%/'O(WQ.&&<#C(HJZB+&H6-0J
(CH%&!10!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>vrna-20221231_g5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vrna-20221231_g5.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#^17AI9@  34T *@    @ ! $[  (
M   1   (2H=I  0    !   (7)R=  $    B   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %9I8W1O<FEA
M(%-T97=A<G0    %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,X
M-P  DI(  @    ,X-P  ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4H&!(E\P![9G4U].:981:5I-GIUNSM#:0)!&TA!8JBA03C'.!7"^$/@KX?\
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M:1/=3VL4CR*UVZL^6.2,JJC&?:N8\;? KP=XZUE]6U!+RQOI<>=-82JGG8&
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MX4_9]\#>$]4CU&*WN]3NH6#PMJ,JR"-AT(55521VR#CK7IS*&4JP!!&"".M
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M0Y+F6W:=IVDNG5G9V !R551T4#IVK<U/3X-6TF[TZ\!:WO('@E ZE'4J?T-
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MRH2,DL>21C/2J'QMT7X<Z+_8T7PWN;.:7]]]N-M>O<[A\GEDL691_'TQUKZ
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M&X8Z&K.N_$:]BU^YT/P5X7NO%&HV6/MACN$MK>W)&0C2OQOQSM H [JBN/\
M"/CTZ_JUSH6N:-<^'M?MHA.^GW,BR"2(G'F1R+PZ@\$CO6?J_P 1]8/B*_TC
MP3X,NO$CZ6RQWTYO([2*)R-VQ6<'>P!&0/6@#T"BLSP[JUQK>@6^H7NEW6D7
M$N\265V!YD3*Y4YQP0=N0>X(/>M.@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M()+NW5DAN&B!DC5OO!6QD X&<=<58HHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$\/_ /?]/_DJO;:* /$O^$H_:&_Z$3P__P!_T_\ DJC_ (2C]H;_ *$3P_\
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M_#'_ *&;_P D+G_XW1_PT'\,?^AF_P#)"Y_^-UTO_"N/!'_0F^'_ /P5P?\
MQ-'_  KCP1_T)OA__P %<'_Q- '-?\-!_#'_ *&;_P D+G_XW1_PT'\,?^AF
M_P#)"Y_^-UTO_"N/!'_0F^'_ /P5P?\ Q-'_  KCP1_T)OA__P %<'_Q- '-
M?\-!_#'_ *&;_P D+G_XW1_PT'\,?^AF_P#)"Y_^-UTO_"N/!'_0F^'_ /P5
MP?\ Q-'_  KCP1_T)OA__P %<'_Q- '-?\-!_#'_ *&;_P D+G_XW1_PT'\,
M?^AF_P#)"Y_^-UTO_"N/!'_0F^'_ /P5P?\ Q-'_  KCP1_T)OA__P %<'_Q
M- '-?\-!_#'_ *&;_P D+G_XW1_PT'\,?^AF_P#)"Y_^-UTO_"N/!'_0F^'_
M /P5P?\ Q-'_  KCP1_T)OA__P %<'_Q- '-?\-!_#'_ *&;_P D+G_XW1_P
MT'\,?^AF_P#)"Y_^-UTO_"N/!'_0F^'_ /P5P?\ Q-'_  KCP1_T)OA__P %
M<'_Q- '-?\-!_#'_ *&;_P D+G_XW1_PT'\,?^AF_P#)"Y_^-UTO_"N/!'_0
MF^'_ /P5P?\ Q-'_  KCP1_T)OA__P %<'_Q- '-?\-!_#'_ *&;_P D+G_X
MW1_PT'\,?^AF_P#)"Y_^-UTO_"N/!'_0F^'_ /P5P?\ Q-'_  KCP1_T)OA_
M_P %<'_Q- '-?\-!_#'_ *&;_P D+G_XW1_PT'\,?^AF_P#)"Y_^-UTO_"N/
M!'_0F^'_ /P5P?\ Q-'_  KCP1_T)OA__P %<'_Q- '-?\-!_#'_ *&;_P D
M+G_XW1_PT'\,?^AF_P#)"Y_^-UTO_"N/!'_0F^'_ /P5P?\ Q-'_  KCP1_T
M)OA__P %<'_Q- '-?\-!_#'_ *&;_P D+G_XW1_PT'\,?^AF_P#)"Y_^-UTO
M_"N/!'_0F^'_ /P5P?\ Q-'_  KCP1_T)OA__P %<'_Q- '-?\-!_#'_ *&;
M_P D+G_XW1_PT'\,?^AF_P#)"Y_^-UTO_"N/!'_0F^'_ /P5P?\ Q-'_  KC
MP1_T)OA__P %<'_Q- '-?\-!_#'_ *&;_P D+G_XW1_PT'\,?^AF_P#)"Y_^
M-UTO_"N/!'_0F^'_ /P5P?\ Q-'_  KCP1_T)OA__P %<'_Q- '-?\-!_#'_
M *&;_P D+G_XW1_PT'\,?^AF_P#)"Y_^-UTO_"N/!'_0F^'_ /P5P?\ Q-'_
M  KCP1_T)OA__P %<'_Q- '-?\-!_#'_ *&;_P D+G_XW1_PT'\,?^AF_P#)
M"Y_^-UTO_"N/!'_0F^'_ /P5P?\ Q-'_  KCP1_T)OA__P %<'_Q- '-?\-!
M_#'_ *&;_P D+G_XW1_PT'\,?^AF_P#)"Y_^-UTO_"N/!'_0F^'_ /P5P?\
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M_P"#[70],L]-MWTF61HK.W6%&8QW8+$* ,X &?85[W0 4444 %%%% !1110
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M44 %%%% !1110!XE\#?^2I_%G_L-#_T?=5[;7B7P-_Y*G\6?^PT/_1]U7MM
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MOB#_ ,"(/_C-'_#*G@C_ *"OB#_P(@_^,T >VT5XE_PRIX(_Z"OB#_P(@_\
MC-'_  RIX(_Z"OB#_P "(/\ XS0![;17B7_#*G@C_H*^(/\ P(@_^,T?\,J>
M"/\ H*^(/_ B#_XS0![;17B7_#*G@C_H*^(/_ B#_P",T?\ #*G@C_H*^(/_
M  (@_P#C- 'MM%>)?\,J>"/^@KX@_P# B#_XS1_PRIX(_P"@KX@_\"(/_C-
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M"OP;86NE6]KH^V+1[LWMBINIF\B8E26&7.>5!P<CCI7 _P#"4?M#?]")X?\
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M>&=2\/0:*D6DZI.+B[M4FD57<%6!!#94 HO"D#CI7GW_  E'[0W_ $(GA_\
M[_I_\E4?\)1^T-_T(GA__O\ I_\ )5 'L]G:0:?8P6=HGEV]O&L429)VJHP!
MD\]!4U>)?\)1^T-_T(GA_P#[_I_\E4?\)1^T-_T(GA__ +_I_P#)5 'MM%>)
M?\)1^T-_T(GA_P#[_I_\E4?\)1^T-_T(GA__ +_I_P#)5 'MM%>)?\)1^T-_
MT(GA_P#[_I_\E4?\)1^T-_T(GA__ +_I_P#)5 'MM%>)?\)1^T-_T(GA_P#[
M_I_\E4?\)1^T-_T(GA__ +_I_P#)5 'MM%>)?\)1^T-_T(GA_P#[_I_\E4?\
M)1^T-_T(GA__ +_I_P#)5 'MM%>)?\)1^T-_T(GA_P#[_I_\E4?\)1^T-_T(
MGA__ +_I_P#)5 'MM%>)?\)1^T-_T(GA_P#[_I_\E4?\)1^T-_T(GA__ +_I
M_P#)5 'MM%>)?\)1^T-_T(GA_P#[_I_\E4?\)1^T-_T(GA__ +_I_P#)5 'M
MM%>)?\)1^T-_T(GA_P#[_I_\E4?\)1^T-_T(GA__ +_I_P#)5 !XH_Y/)\&?
M]@63_P! O*]MKP;PWX;^)^O_ !VT+QCX[\.V.EP:=:2VS/:7$97:8Y@ORB5V
M+;I?I@?G[S0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !61>0V#>+]
M*FGN'2_2UNEMX0/ED0F+S"3CJ"$QR.IZ]M>LB]FL%\7:3%/;N]\]O<FWF#?+
M&@,6\$9YSE.QZ=J ->BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHKQ;Q]XR\>6/Q-\-VFG^%+A;9;VY6UBCUN-$UA1'_&N,1A1\V'S^
M= 'KNIZQIFB6HN=9U&TT^ L%$MW.L2DGH,L0,U/=75O8VDMU>SQ6]O"I>2:9
MPB(HZDD\ >]>&_M Z7%J/PCC\2ZUHJV&OC[/ T37/G_95+DE%8?)G)Y90">
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MX+$A@@!V#HN. * /3Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*/47-Y>R0M(421/+ 6%^#YF=V>V,=Z[(9VC=P>^#110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !69>VES+XBTNZBNQ%!"DZRV^\CSBP7:<=#C!Z],UIUD:A;
MV4GBC1I[BZ,=W$LXMX<?ZT%5W?D /SH UZ*** "BBB@ HHHH **** "BN=\#
MR/+X?N6E=G8:QJB@L<G OYP!]  !^%=%0 4444 %%%% !1110 50UC6[#0K1
M;C4I_+#N(XHU4O),YZ(B#EF/H!6=J_B9H;\Z1H%K_:>L;06C#;8;4$</._\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT))YKWFB@#-\.:4="\+:5I#R^>VGV4-J9<??*(%W?CC-:5%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !61J,FGIXFT9+J&1[U_
M/^R2*?E3" ONY[C&.#^%:]96HW8@\0Z/ ;%)C<-,HN"O-OB//!QQNQCJ* -6
MBBB@ HHHH **** "BBB@#F_ ?_(NW7_8:U7_ -.%Q725S?@/_D7;K_L-:K_Z
M<+BNDH **** "BHKN[@L;.6ZO)D@@A0O))(V%51U)->&:C\?KA/&D<FFVPD\
M/Q$QO$R@2SC/^L!/W2.R^G7KP >ZRS1V\+S3R+%%&I9W=@%4#J23T%<JVI:E
MXPW0^'Y'T_16RKZOTEN/46ZD<#_IJW']T'[PTXFT+QQX?MK@+%J6FRLLRH^2
MI93P'7O@]5;N.G%;0&!@4 4=(T:PT*P%GI=NL$0)9N2S2,>KLQY9CW8DDU>H
MHH **** "J.IZ)I6M"$:QIEGJ MW\R'[5;I+Y;?WEW X/N*O44 9NH>'-$U:
M\AN]5T?3[VY@_P!5-<VJ2/'W^5F!(_"J7CGPO_PFG@G4O#QN_L7VZ,)]H\OS
M-F&#9VY&>GJ*WZ* ,?1O"^D:)&&M--LH[MX5BN+J*U1)+C  RY R<X[DTZ3P
MIX=ET>'29= TM].@8O#9M9QF&-B2253&T'))R!W-:U% &:GAS0X].N-/CT;3
MTLKIS)/;+:H(Y6( +,N,,<*.3Z#TH'AS0UT8Z0NC:>-,/6R%JGD_]\8V_I6E
M10!CV_A#PW9V+6=IX>TJ"U>59F@BLHU1I%^ZY4+C<,<'J*LZ=H6D:0T[:3I5
ME8M<-NF-M;I&93ZMM R?K5^B@#,L/#6A:5?2WNEZ+IUE=3?ZR>WM$CD?ZLH!
M-:=%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5G7TFI)K>F+9QAK)S*+QL#Y1LRGO][CBM&LV_M;V;6]*GM;D1
M6UN\IN8BY'F@QD*,#@X;!YZ4 :5%%% !5#6=6CT33)+V6VNKH)TBM(3([''3
MT4<?>8JH[D"K]9GB.:ZBT&Z6QTVYU*:6-HE@MGB5OF!&<R.BX'US[&@"A=^,
M[6W\,:3K4&GWUXFKF!;6VA$8E)F7<H.]U0<=?FI][XK&G:3:W5_HVI0WEY<B
MVMM+S ]Q-(<G *R&,#:K,27  4YQTK!T^SNC\--$TO7_  )+JALXH+6YTZY>
MSD;,<('G(&D,;#<,<LK8)..QSK'PIK6CZ=I6I6>DM_Q+]=GU"'0HKB/=;VLT
M4D7E1DL(PRF0R; P0995)P,@'<Z!X@M_$%K</#!<6EQ:7#6UU:7042P2  [6
MVLRG*LK JQ!##FM6N:\'Z9>VUQKNK:I:M93ZS?\ VE;1W1F@C6*.)0Q0E=Q$
M>XX)'S 9.#72T <WX#_Y%VZ_[#6J_P#IPN*Z2N;\!_\ (NW7_8:U7_TX7%=)
M0 4444 4M9TJQUO1[G3M6B6:SN$VRHQQQUSGL00"#V(KYATGX9:OXCUN-=#@
ME.B7,\H@U*9?E$2.5W-C^+T'<].AQ[Y\2]5GLO"AT[33_P 3'695T^U Z@R<
M,WL N>>W%=%HVE0:'HEGI=F,0VD*Q+QUP.I]SU_&@#SS1M/\1?"FR:S@TU-?
MT#S&E>:QCV7<1/5F3.). !P<X'8#%=SX?\5:-XHM3/HM]'/M_P!9%]V2,^C(
M>1_*M>N7\0^ -)UVZ&H0>;I6KIRFHV+>7+G_ &L<,/KS[T =117GX\1>*O!G
M[OQA8G6=+7@:OIT?SH/66+M[D<?6NQT?7-,\06*WFC7L-Y ?XHFSM/H1U!]C
M0!?HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M);>+_"]GKMA;75M;7BEXH[M%63:&(!(4D8.,CGH10!L444C,%4LQ  &23VH
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M !1110 4444 <WX#_P"1=NO^PUJO_IPN*Z2N;\!_\B[=?]AK5?\ TX7%=)0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,Y,KR-)(V,L6<DD\>M2:MX<TK7;S3;K5;7SYM+N!=6C>8R^5(/XOE(S]#D4
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M-/B+)I7C71=.DL_$NN^';R&*"]6!(A-')NW_ " JI=-GW<]3CGOSFN7UC/\
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MB.+7;Z4:5;R3Z;&AQJ6<12R9QMC[N ,Y<?+V!/.-FFQQI%&L<2*B( JJHP%
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M]X4U_1K/2K>'2OM\422F:=3YB* [@[.C$D*#CCYC7H\<4<,82%%C10 %48
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MDGM;K<& DCMV!>*4@C+ C\!Q7M- !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5FZE;ZA-JFD2V,WEV\%R[7B;L>9&89% QW_>%#
M^%:59&KV<%QK&@SS7JVTEM>N\,3#FY8VTRE!R.0K%^_"'CN #7HHHH ****
M"BBB@ HHHH YOP'_ ,B[=?\ 8:U7_P!.%Q725S?@/_D7;K_L-:K_ .G"XKI*
M /D_XH:=XCL?&ES)XJD-Q+.2UO<*"(I(P> @_A S]WJ#ZYR?5/@-IWB.TT.>
MXU&0QZ+.-UG;R@[RV>9%_NH>>.YY&.^]\2K6#5]8\(:-<PI-'<ZKYSHRYW)&
MA+#Z$'FN]50BA4 55&  , "@!:*** "BBB@ HHHH **** "BBB@#+\0>'=,\
M3Z6UAK%L)HCRC#AXF[,K=017(6FO:M\/KB/3?&<KWVBNXCL]< R8_1)QV/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW-]$.'']R1?XE/3GI^E0>&/&KW=^= \56ZZ5X@B'^J)_=70_OQ-W!].H_ X
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M-*^$'@+1-8M-4TSPY;P7EF ()/,D;81T;#,06_VB"?>NTHH XW5/A'X$UKQ
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MYP!ACQQ\QQWJY\7-!\2ZKXFGMK3PQ/+#+I4<=M=VGA^*]>=_+.Y))G.;?!R
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M;M;C3+@2;_WNDS>;;-AR/D;OTP??-:U !1110 4444 <WXH_Y&+P9_V&I/\
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MNX/IU'X''7T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MGG5+^VM!COND#?\ LM '0^$[+^S?!NCV>,&"RA1OJ$&?US6O0    , = **
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S(_#>CQ:Y<ZQ'IT
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M!@BJ6Q@CDCC-;>B:YIGB/2(-4T.\BO;*<$QS1'@X."/4$'@@\BO ;:::'3?
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M03O&T;?B%-?1M5H]2L9M2FT^&]MY+VW57FMEE4R1JWW2RYR >Q/6@#RKP_X
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M#&T]15O1M8L?$&C6VJZ3,9[*[3S(93&R;U]=K $?B* +U%%% !1110 4444
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MVE?VC;-.7U")+<J<>7*0VUCR.!SZ]: ->J>K:I;:+I%SJ5]O\BV0NXC0NQ]
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MO2_A;9M\1O%GB#Q/INCZM;:M);/8+<6XGD@\M"KY#IA<G;]TG..>E9U]X/\
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MVE%<!_PE_B3PI^[\<Z/]ILE_YC&E*70#UDCZK[GIZ5V&D:WIFO60N]&OH;R
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M7#MTC^TJK_\ ?#$-^E=&0&4JP!!&"#WKFM7^&_@S7=QU3PQIDSMUD%LJ.?\
M@:X;]: -V_U.PTK3Y+_5+VWLK./&^XN95CC7) &68@#)('U(K(MO'W@^\NHK
M6S\6:'/<3.(XHHM2A9Y&)P%4!LDDG  KQ_XQ?";P[X4^%&LZGX=FU2P6'R/]
M!2_D>VDW3QKAD8G.,Y'/! -?._@LWJ^/O#YTE87OQJ=L;5;@D1F7S5V!L<[=
MV,XYQ0!^A%%>:?\ "R/%NA<>,_AUJ2QKUO-$E6]C(_O;!AE'UK6T7XP>!==E
M$%OX@M[6YSAK>_S;2*WIB0#)^F: .UHIL<B2QK)$ZNC#*LIR"/K3J "BBB@
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MR2LQSZ[?RKOJ "BBB@ HHHH YOP'_P B[=?]AK5?_3A<5TE<WX#_ .1=NO\
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MW0+65IH[&$1^:PP7;JS8[98DX[5M4 %%%% !63K7A;0?$<1CU[1K'4!C -Q
MKLOT)&1^%:U% 'FTGP2T6PD:;P;K&M^%I2=VW3KYC"3_ +4;Y!'MD4W[!\7O
M#W_'IJVA^+;=?X+V V=P1Z I\F?<UZ710!YI_P +=O-&^7QSX&UW1,??N;>,
M7MLOUDC_ ,*Z30/B1X.\3[1HGB.PN)&^["TOERG_ ( ^&_2NGKF]?^'?A#Q/
MN.N>';"ZD;K-Y024_P# UPWZT =)17FG_"GY]'^;P+XUU[0,?<MI)A>6R_\
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M%K[M!X=M_P"R%B/D:U<:7'I]VY_N^6O+@_WMD0]C7I-<S9>&_"WA:\:_M_\
M19HHVW--?2OM7'/RNY'3VKHH[B.:U6XB;?$Z!U903N4C(('?B@"2BN/U][SQ
MGX=5/"[7MK+#>Q/,EY]LTEIHU.702>6) ".,J"*YG2KU]<\2:=X5G.JZ7!:/
MJ!U"&/6KF5YIH?L^P+=%A*T>RY#XRO. 1P00#U:N)^*OQ%_X5EX5MM9_LO\
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MTY'KC!KKO#WCCPQXK0'P]KEE?,1GRHY0)!]4.&'XB@#>HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P"1=NO^PUJO_IPN*Z2N;\!_\B[=?]AK5?\ TX7%=)0 4444 %%%% !1110
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M5(%U!YS&NXAL*S=\9SCO7>5FV/AS1-,N1<:;HVGVDX!42V]JD;8/49 S6E0
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M&<\#ZDG\:M444 %%%% !1110 54U+2M/UBT-KJUC;7UNW6*YA613^# BK=%
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M._#'Q/!C[QL$2\ _%2* /2:*\W7X\>"H6":Q)J>C.3C;J&FS(0?^ J:W-/\
MBGX$U/'V3Q9I.3T66Z6)C^#X- '645!:7]I?Q^98W4%RG]Z&0./S%3T %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <WXH_P"1B\&?]AJ3
M_P!-]Y725S?BC_D8O!G_ &&I/_3?>5TE !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %9/B:TCOM!D@FODL%,T+?:)#@ K*C =1]X@+
MU[]^E:U9'BE-/D\.S+K,LD5F9(M[Q#Y@?-7;V/\ %M[4 :]%%% !1110 444
M4 %%%% '-^ _^1=NO^PUJO\ Z<+BNDKF_ ?_ "+MU_V&M5_].%Q724 %%%%
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MX@'_ &VL/_DF@#I**YO_ (2K5._@?Q /^VEC_P#)-'_"5ZCW\%>(!_P*S_\
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M5_\ H1/$'_?_ $__ .2J/^$HU?\ Z$3Q!_W_ -/_ /DJ@#I**YO_ (2C5_\
MH1/$'_?_ $__ .2J/^$HU?\ Z$3Q!_W_ -/_ /DJ@#I**YO_ (2C5_\ H1/$
M'_?_ $__ .2J/^$HU?\ Z$3Q!_W_ -/_ /DJ@#I**YO_ (2C5_\ H1/$'_?_
M $__ .2J/^$HU?\ Z$3Q!_W_ -/_ /DJ@#I**YO_ (2C5_\ H1/$'_?_ $__
M .2J/^$HU?\ Z$3Q!_W_ -/_ /DJ@#I**YO_ (2C5_\ H1/$'_?_ $__ .2J
M/^$HU?\ Z$3Q!_W_ -/_ /DJ@#I**YO_ (2C5_\ H1/$'_?_ $__ .2J/^$H
MU?\ Z$3Q!_W_ -/_ /DJ@#I**YO_ (2C5_\ H1/$'_?_ $__ .2J/^$HU?\
MZ$3Q!_W_ -/_ /DJ@#I**YO_ (2C5_\ H1/$'_?_ $__ .2J/^$HU?\ Z$3Q
M!_W_ -/_ /DJ@#I**YO_ (2C5_\ H1/$'_?_ $__ .2J/^$HU?\ Z$3Q!_W_
M -/_ /DJ@#I**YO_ (2C5_\ H1/$'_?_ $__ .2J/^$HU?\ Z$3Q!_W_ -/_
M /DJ@#I**YO_ (2C5_\ H1/$'_?_ $__ .2J/^$HU?\ Z$3Q!_W_ -/_ /DJ
M@#I**YO_ (2C5_\ H1/$'_?_ $__ .2J/^$HU?\ Z$3Q!_W_ -/_ /DJ@#I*
M*YO_ (2C5_\ H1/$'_?_ $__ .2J/^$HU?\ Z$3Q!_W_ -/_ /DJ@#I**YO_
M (2C5_\ H1/$'_?_ $__ .2J/^$HU?\ Z$3Q!_W_ -/_ /DJ@#I**YO_ (2C
M5_\ H1/$'_?_ $__ .2J/^$HU?\ Z$3Q!_W_ -/_ /DJ@#I**YO_ (2C5_\
MH1/$'_?_ $__ .2J/^$HU?\ Z$3Q!_W_ -/_ /DJ@#I**YO_ (2C5_\ H1/$
M'_?_ $__ .2J/^$HU?\ Z$3Q!_W_ -/_ /DJ@#I**YO_ (2C5_\ H1/$'_?_
M $__ .2J/^$HU?\ Z$3Q!_W_ -/_ /DJ@#I**YO_ (2C5_\ H1/$'_?_ $__
M .2J/^$HU?\ Z$3Q!_W_ -/_ /DJ@#I**YO_ (2C5_\ H1/$'_?_ $__ .2J
M/^$HU?\ Z$3Q!_W_ -/_ /DJ@#I**YO_ (2C5_\ H1/$'_?_ $__ .2J/^$H
MU?\ Z$3Q!_W_ -/_ /DJ@#I**YO_ (2C5_\ H1/$'_?_ $__ .2J/^$HU?\
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M %%%947B?1Y_$C:!!?)+J2Q/*T,:LP4*5# N!M##S$)4G=AU.,$&@#5HHHH
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M9N)+:R* RRQC+( P(.,'OCM6O61XKGL;;PK?S:M;-=6219FA4X++D9QR/YT
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M#HGC"R\>Z)?:AI.G74LVHW,]U?0:A,X6-HBBJ0;<"-43 5=Q#-G)!8M7JM%
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ML(!"X8D ]2M9UOXA\276D:;?W-KX>TB*]N;39Y^IR3>9%*?F1<Q1XF(("#+
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M!HT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB)-,2265,[5YZ ;FX&.23U-6Z** "BBB@ HHHH **** "BBB@ HHHH ****
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EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>vrna-20221231_g6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vrna-20221231_g6.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#^17AI9@  34T *@    @ ! $[  (
M   1   (2H=I  0    !   (7)R=  $    B   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %9I8W1O<FEA
M(%-T97=A<G0    %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,Q
M.0  DI(  @    ,Q.0  ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                            ,C R,SHP,CHQ-2 Q,3HR-3HR-0 R,#(S
M.C R.C$U(#$Q.C(U.C(U    5@!I &, = !O '( :0!A "  4P!T &4 =P!A
M '( =    /_A"R-H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A
M8VME="!B96=I;CTG[[N_)R!I9#TG5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED
M)S\^#0H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(CX\<F1F
M.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M
M<F1F+7-Y;G1A>"UN<R,B/CQR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2)U
M=6ED.F9A9C5B9&0U+6)A,V0M,3%D82UA9#,Q+60S,V0W-3$X,F8Q8B(@>&UL
M;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(B\^/')D
M9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M8F$S9"TQ
M,61A+6%D,S$M9#,S9#<U,3@R9C%B(B!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"\B/CQX;7 Z0W)E871E1&%T93XR,#(S+3 R+3$U
M5#$Q.C(U.C(U+C$Y,3PO>&UP.D-R96%T941A=&4^/"]R9&8Z1&5S8W)I<'1I
M;VX^/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M
M8F$S9"TQ,61A+6%D,S$M9#,S9#<U,3@R9C%B(B!X;6QN<SID8STB:'1T<#HO
M+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B/CQD8SIC<F5A=&]R/CQR9&8Z
M4V5Q('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^/')D9CIL:3Y6:6-T;W)I82!3=&5W87)T/"]R9&8Z
M;&D^/"]R9&8Z4V5Q/@T*"0D)/"]D8SIC<F5A=&]R/CPO<F1F.D1E<V-R:7!T
M:6]N/CPO<F1F.E)$1CX\+W@Z>&UP;65T83X-"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/#]X<&%C:V5T(&5N9#TG=R<_/O_; $, !P4%!@4$!P8%!@@'!P@*
M$0L*"0D*%0\0#!$8%1H9&!48%QL>)R$;'24=%Q@B+B(E*"DK+"L:("\S+RHR
M)RHK*O_; $,!!P@("@D*% L+%"H<&!PJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*O_  !$( E$$JP,!(@ "$0$#
M$0'_Q  ?   !!0$! 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,#
M @0#!04$!    7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S
M8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H
M:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ
MPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 #
M 0$! 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  !
M G<  0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q
M%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X
M>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(
MR<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /I&
MBBB@ HHHH *YV7XA>"X)GBF\7Z#')&Q5T?4X05(X((W<&NBKXE\%^#]-\=_&
M^]T'69;J&VGN+M]]HZJX*EF'+*PQQZ4 ?6W_  L?P1_T.7A__P &D'_Q5=%'
M(DT2R1.KQNH974Y# ]"#W%>(2_LI^#CCR-8UQ/7?+"V?RC%>GZYXGT#X>>';
M.7Q%?26MD@2U2<V\DN6"\ ^6IQD*>N* .BHK$\*^,=!\;:7)J/AB_%]:QRF%
MW$3QE7 !(PX!Z,.W>LRS^*?@[4/%[>%['5S<:RDSP-;1VDQPZ9W#?LVX&#DY
MQQUH ZZBN<\3?$'PKX.F2'Q+K=M83R1^8L+DM(4R1NVJ"<9!&<=C6%8?'3X;
M:C=I;6_BB!9'. ;B":%?Q9T"C\30!Z!12(ZR(KHP96&0P.01ZUS7B;XC>$?!
MTOE>(]=M;.? ;R,F27!Z'8@+8_"@#IJ*YCPI\1_"?C>XF@\+ZPE]- GF21^3
M)&RKG&<.HXR:T/$7BS0?"=FMUXCU6VTZ)SA/.?#.>^U>K?@* ->BN)T/XQ^
M/$6H1V6E>);=[F1@L<<T<D!=CT \Q5R?85T7B'Q-H_A33!J'B&_CL+0N(Q+(
M"06() X!YP#0!J5SGCCQQI7P_P!!35]=2Y:U>=8/]&C#L&8,02"1Q\I_2J=Q
M\5_!%KX:@U^X\001Z;<R/'!*8Y-TK(VUMJ;=YP>X&*\_^./B+1O&GP!N-7\.
M7:7]G'?0CSE1EV,&P>& (/S#MWH ]+\">.=,^(7AUM9T2&ZAMEG:#;=(JN64
M DX5F&/F'>NDKP/X'^-O"W@CX+VLOB76+?3VN+V=UC8EY'P0,A%!8C@#(&*]
M8\+?$/PGXT9T\,ZW;WLL8W-#AHY /78X#8]\8H Z2BLKQ!XFT7PKIXOO$6I6
M^GV[-L5YFQN;&< =2< \"N/'Q]^&9G\D>)TW9QDV=QM_[Z\O'XYH ]%HK,7Q
M)H[^&I?$$.HP3Z3# ]P]W WF((T!9C\N2< '@<\5\J:Y\0]%U+]I:W\1?VW/
M+X8AN[>5)2LNQ D*9(C(W#YU/\//7WH ^O))$BC:25E1$!9F8X"@=237,^&O
MB3X1\7ZI<:=X<UN"^N[=2SQ*CJ2H."5W !AR.5SUJK:>-?!_Q!\&Z\^GZJ9M
M(AMI8;^Y\J2'RD:,[C\Z@\+DYQ7FOP-\#>"-(\:W]_X;\8MXCOK>!E6..T:%
M((V;&2QR'/&.".YQ0![Y15#6=<TOP]IS7^N:A;V%JIP9;B0(N?09ZGV'-<A9
M?''X<:A>_9;?Q3;+)G&9XI84S_ONH7]: .^HJ-KB%;4W/F*8 GF>8#D;<9SQ
MU&*Y;2OBEX)UJ6\33?$5I*+&$SW,C;DCCCR!N+L O4CO0!UM%<#!\<?AQ<:B
M+*/Q3;"8G:&>*5(\_P#70J$_6N]1UDC5XV#HP!5E.01ZB@!:*AN[N"PLI[N[
MD$5O;QM++(W1%49)_ "N8TWXI>"M7MM1N+#Q#;26^F(LEW,P9$B5B0OS, #D
M@C R>GJ* .MHKE_"GQ(\)^-[J>V\+ZPE]-;KOEC$,D95<@9^=1D9(Y%9-]\<
MOAOITQCN/%5L[ XS;Q2SC\T4B@#OJ*YGPO\ $;PEXSE:+PUKEO>S*NXP8:.3
M'KL<!L>^*\M_:3\>:7!X7D\+Z?JTL.NI=0RS6\2R(?**,>7 VD<KQG\* />*
M*\0^"?Q0\'67@7PYX5EU=SKDCO$;8V\Q)EDF=N7V[?XLYS7LNI:I8Z-I\M]J
MUY!96D(S)-/($5?Q- %JBO/XOCI\-IK[[*GBFW$F<;G@E5/^^R@7]:[V">*Z
MMXY[:5)H95#I)&P974\@@C@B@!]%-ED2&%Y9#M1%+,?0#K7*Z5\4?!6MRWJ:
M9X@M9_L$!N;E\,L<48(!8NP"XR1WH ZRBN4\,_$[P=XQU273?#>M1WMW$I=H
MA#(AV@X)!90".1R/6KOB;QQX:\&Q(_B;6;;3S("R1R,6D<#J0B@L1]!0!O45
MQ_ASXK^!_%E\MEH/B&WN+ISA()$>%W/HHD52WX5V!.!D\"@ KS?5/CAX;TKX
MB)X+FL=5EU-[N*T#Q11^4'D*A?F,@./F!Z5>U3XT_#S1]2:POO$]M]H5MK"&
M.295.<8+(I4?B:^=_$]]8:G^UMI][H]S#=6=QK.ER1S0OO5\B D@_7/TZ4 ?
M85%<IXK^)WA#P1?QV7B?65L;F6(3)%Y$LA*$L WR*>,JP_"NECNX9;%;M'S
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MOBSXN2>'-::=;*#SS(D$FTOY9X4MCIGKCGZ5[%^R_P"";[1=#U'Q)JD+V_\
M:HCCM(W&"T2Y)DQZ,2,>RYZ$5P'P#F-Q^T)=S$8,D=VY [9;- &[\>?@WX7\
M(>"8-=\*6<EE)#<I#<1FX>19$8'YOG)((8#IQR>*]6^ 5Y<7OP1T![LLS1K-
M$C,<Y1)G5?R "_A6-^TW,8O@\R 9\W4($/M]YOZ5K?L^'/P)\/\ M]I_]*9:
M /0K^U6^TZYM) "L\31,#T(8$?UKXB^#W@0?$?QA-H-UJ4]E8);&\N1 ?FE"
M,JJ #QG,G4@X&?6ON&65887E?[J*6./05\F?LJ?\E3U+_L"R_P#H^"@#W3X>
M_!W1OAQ>:M-I%_>W"ZC"D0^TE"\07=G#*!G.X=N-M<9K'PY^ W@[-IXDE@2Z
M51E9M2F:8>Y2-N/^^:]:\:WU]IG@37+[2%9[ZWL)I;<*NX[PA(('?!YQWKY0
M^#VL?#6"XU6]^*G^DZA)('@DO();B-@<[B0H;+$]2P^G>@#,M9]!T3X_:1/\
M.;^6?21J5M]GDD5U(#E5D0[P&(^9EY'0]^M>K_M2>$]$MO#=MXI@LMNLW6HP
MVLUUYKG=&(9/EV$[1]Q>0,\5Y=KVK>&=9^/VDWO@FVCM=(;4+)4CBM1;H&#H
M&(08P"1G) ->Z_M/:=/??"-)X%++8ZE#<2X&<(5>//YR+0!6^"7PO\'S^!O#
M?BR71PVM@&<71N9?OK(P!V;]O  [5YM^T%XLD\0_%F+PM?7[V&A:9)#',^UF
M56<!GF*C)8JKX QV..M=W\#_ (P>$[/P'HGA;5KY[35XY3:10_9I7$Q>4[,,
MJD#.X#DCGVK@/V@?#5]X7^+D?BQK-+S3=0EAN$$T8>)I(PH:*0'@@[<X/4,1
MS@T 3>)K'X MX*NX/#>K7*:W%;DVUP8[LM-*!E0X9-@#'@X QFN\_96UR\OO
M!>K:5=2&2#3KI3;[CG8L@)*CVRI/_ C4>B_$_P"!-S81W=WH&DZ3=A<M;OH2
MNRMW :.,@_7(_"O2/ASXG\)>*;&_N? ]@EK:03B&61+-;=97VYX P3@'N!UH
M [(@,I##(/!![U\-^ ? ?_"7_%*Z\*#4)+"SWS+<O"22\4;YV@'@_,JGGIC/
M.*^Y*^2?@/*L_P"T3?2Q_=D6\9<^A;- 'LWA#X2>'_A%>:MXETR\OKM$TYU>
M.[*,RJOSMAE5>NP<8KYS\,ZQX9\;?$6_U[XQ:U+#;.#(L*),WFL3A8P8U)1%
M'T[<]:^T=6L%U71;W3Y&*I=V\D#,.P92N?UKXO\ !]S8?"SXE7FF?$CPW;:E
M:J#;SQW%JDYB.05FC#CD$>F,@^V* '_%*/X96\FG7WPGU&=+A)/W]N%N (\<
MK(KR@$'([$]L8Q7K'Q:^(^I1?L^^''20QZCXFM8EN94X^3RPTN/3<2!CT8UH
M_P#"SO@-96IDM-/THLPR88- *L?8YC _6J/[0FA-XD^$6@^(?#UFT5E8*MP;
M58@IAMY8U.=JY VX4$#@9)Z"@#/^#'P(\-:YX$MO$'C"UDOYM1R\-OY[Q)#&
M&*C[A!).,]<8(XZUPFL^%+#P7^U'H^C:,C1V$>L:=) CN790S1,02?\ :+?A
MBN_^#GQW\+Z+X M-"\77<FGW.F@QQ2BW>1)H\DK]P$@C..1V!SS7 :[XMTSQ
MA^TYHNNZ09?[/DU73U229-A8(\:EL=AD'K0!M_M7*!X^T9L#<=,P3CDCS7_Q
MKZ<_YEC_ +<__9*^</VL=-G3Q%H&I[&-O):R6^_' 97W8SZD/^AKMM._:)\#
M-X!M_P"T;ZXCU060CFLEM)&;S F#AL;,$]/FZ'G% 'F?[*G_ "5/4O\ L"R_
M^CX*9XOO;[XS_M#1^%Y+R2WTRWO);.!1T2.(,97 /&]A&Q!/^R#TIW[*SJOQ
M5U ,0"VC2A?<^="?Y U0\7P:K\&_V@CXB-H9[:2]EO;5FX6>&7<'0-V8!V7V
M.#C!&0#WF#]GOX=VIM9+;2;B.YMI$D6X%Y*69E(/(+%><=@*\\_:G\9WMM-I
MOA&SF>&WG@^VW@4D><"Y5%/L"C$CUV^E=W%^TA\.9--6Y?4[J*8KDVC64AD!
M],@%/_'J\[_:=\,7>J+HOCC3X9);%K-;:XXYA!8O&S = ?,89[$#U% &9IFF
M_L]0^$X[/5-<N;C56A_>WZ0WBLLA')5-FS /0$'WS5O]E?6KF#QEKOAV*X,V
MG26C7B]0-Z2(@8 ]-ROS_NKZ5I^"?B;\&KOP]:CQ9X:T72M4AC59V.AI*DK@
M8WJ4C8\]<'&/?K7I?P^\:> /%&OWEMX$TZ%)[:WWS74.GK;J4+ ;<X#')&<8
MQQ0!\[Z;!<?'KX\2?VA<RQZ?(SR?+]Z&TC^ZBYZ$Y SZL3[5Z'\9?@MX,\+?
M"R_UOP[ILEI>V+0_O#=2/O#2JAR&)'\7;%>9^%=2N/@;\;I4UVVE>WMVDM9R
MJ_-) _W94]>BM^8KT[XR_&GP5XI^%VHZ%X>U":^O;XP[56UD18PDJ2$L7 [(
M1QGDB@#H_P!E_P#Y)%)_V$IO_04KV.O&OV7G5OA',%8$IJDP8#L=D9_D17LM
M 'R/\(8E@_:ENHH_NQW6H*N?0>8*J_M%Z>J_'/Y?W9O;>V=G7KG[F?K\GZ5>
M^$__ "=9??\ 7YJ/_M2HOVB93)\=[12,>7;6JCW^=C_6@#U36?V;_ T7@V\A
MTVTNDU.*V=H;Y[IV<R!21N7.S!/7"C\*XW]DN[N/MOB:SRQMO+@EQGA7RXZ>
MI'_H(KZ*UJ4P:#J$H&3';2, >^%)KYR_9*/_ !-/$_\ UQM__0I* /IJOD7X
MQZ5#KW[3\&D73ND&H7-A:R-'C<JN$4D9[X-?75?'OQ>UD:1^U')J=SGRM,O;
M"<[%R=J1PN>.YZT >L^+OV</!DG@Z\'ANRFL=5@@:2"X-U(XD=1D*X8E<'&,
M@#&?PKBOV5_%=W%JFL^'+B1WL%M#J$8)R(65U5\#_:#@_P# :[/QI^T=X.C\
M'WJ^&+V;4-5N(&C@B^RR1K$S#&YRX P,YP,YZ>]<Q^RYX)N1#J_BF^C>*VN[
M<Z?:GH9%+ R,/8%5 /J&]* .-\*6=S\?_C9/+XDNYEL8XGNF@1L&.W5U584_
MN\NN2/\ :/4YKN/C+\!O#6B> [G7_!]M)83Z:!)/"T[R+/'D GYR2&&<\'&
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M3&1Y7VD@D;G8D#@=/2M/Q!X5T+Q79K:^(]*M=1B4DH)XP2A/=6ZJ?<$5K44
M>>0? 7X:6\XFC\+Q%LYQ)=3NO_?+.1^E=/JO@SP_K7A4>&M0TR)M' 0+9Q,T
M*J$(*@;"",$#H:W** ,3PIX.T+P1I4FF^&+'[#:2S&=X_.>3+E54G+L3T5>,
MXXJ7Q+X7T?QAHK:3XBL_MED[J[1>:\>67D'*$']:UJ* .#E^"7PZGTF#3I/#
M%N;>W),9$THD&2209 V\C)/!) K?\,>"?#?@VW>'PSI%OIXD #N@+2.!T#.Q
M+'\36[10!F:_X<T?Q3I;:=XAT^"_M6.[RYESM/J#U!]Q@URVF_!+X=:5*9+3
MPM:LQ!'^D223XR,<"1FP?<5WE% ',>$OASX5\"SW,OA72S8/=*JS'[3+)O"D
MD<.Q ZGI5CQ3X%\->-88XO$^D07_ ).?+=BR.@/4!U(8#VS6_10!S7A_X>>%
MO"VCWVEZ#I2V=G?J5N46:1FE!!'+LQ;HQZ'C-1^$_AKX3\#7=Q<^%M*^PRW*
M".5OM,LFY0<@8=R.M=310!EZ_P"&=%\46(L_$.F6VHP Y59XPVP^JGJI]QBN
M9TKX+?#S1KY;NQ\+VOG*VY3<223A3ZA9&8#\J[JB@  P,#@5Q_ASX4^#/"6N
M?VQX?T<VM^59#,;N:0D-][AW(Y^E=A10!B>*O!^A^-M)CTWQ/9?;;2.83K'Y
MTD>' (!RC GACQG%3^'/#6D^$M#BTCP_:?9+&%F9(O,>3!8DGEB3U)[UJ44
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M]X?M;6X PL[;I9%]<.Y)'X&NJHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK;0P1QP*NU8D0!0/3'3% 'FGPMUG2M _9WT/4?$%Q';Z=' 4FDE4LH#SL@!
M!X)8#TYYXKE]>OO"GA>[TV]^$'B.$:I>7\,9T'3+S[1;7BNP#AH02(B%R=PV
MXY[FO;8=*TZVTM=-M["UBL%78MJD*K$%]-@&,>V*JZ;X5\/:-=-<Z/H.F6$[
M_>EM;..)C]2H!H X/XEW]KH?Q7^&^MZM.EKIMM-J$$UU*P5(VE@54W$\ $@\
M^QJO\8$TOQO\-[+4],*:]I&DZS#=WT=A)O\ /@CW),J,I_NN3D'@ \UZAJ&F
MV.KV;V>JV5O?6S_>@N8ED1OJK @T6&G66E626>EV=O96L?W(+>)8T7Z*H %
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MU-<VUI!#<7"HLTL<05I @(0,0,D $@9Z9H X'X:_\CS\1/\ L-)_Z*6DO?\
MDYC2_P#L69O_ $H%=_;:?9V4UQ+9VD%O)=2>9.\405IGQC<Q ^8X &30VGV3
M:DNHM:0&]2(PK<F)?,6,G)0-C.W/..E 'EUAK^G> OC;XKMO%-U%IMKXA2VO
M=/O;EMD+^7'Y<B%SP"#ZGI]1FGXL\:Z+XI^)O@>T\.W)U**QU<FXO;==UNKM
M$VV,2=&; )P,\"O6=3T?3-;M?LVLZ=::A!G/E7<"RKGUPP(J.'0-'MX;6&WT
MFQBBLY/-M42V15@?!&Y !\IP2,CUH T*\MU/7;3P+\=+F^\22+9:3X@TN&*W
MOY>(DGA9LQLW1<JV<GCI7J55[_3K+5+1K74[.WO+=_O0W$2R(WU4@B@# T_X
MB^%]8\41:#H>J0ZK>20M,S6+":*)%QRTBG:,YP!DGZ5@?#7_ )'GXB?]AI/_
M $4M=QI>AZ3H<!@T32[/3HF.3':6Z1*3ZX4"IK;3[.RFN);.T@MY+J3S)WBB
M"M,^,;F('S'  R: //O@W_S/O_8YZC_[3IWP'_Y)3;?]?MW_ .CWKO[/3[+3
M_/\ L%G!:_:)FGF\B)4\V5OO.V!RQ[D\FBPT^RTNT6UTRS@L[=266&WB6- 2
M22=H ')))]S0!Y]X)_Y+M\3_ /N$_P#I,U-^'T7G^+OB5"#M,FK!<^F80*]#
MAT^RMKZYO;>S@BNKO9]HGCB57FVC"[V RV!P,]!1;:?9V4UQ+9VD%O)=2>9.
M\405IGQC<Q ^8X &30!Y7\*O'F@>'_ \'A?Q9JEGH>LZ"7M+JVOIEAW;6.UT
M+8W J0>/\";'CKXA#5_A!J6N^"[R\AM8[U+274HH2K)#O42S1<9( 8@-C/4C
MIFO0-3\,:!K5PD^LZ'INH31_<DN[2.5E^A8$BM!;>%+;[.D,:P;=GE!0%V^F
M.F/:@#YM\>:'\%[/P3?7&DWBZ[X@FM7-I-%J<UU.9 I/F2*K[5"@%CN   /'
M:N]\?_\ )J\O_8%L_P#VE7H-KX1\-V*W(L?#VE6PNT:.X$-E&GG*W#*^%^8'
MN#UJ[<:5I]YI9TR[L+6>P*",VDL*M$5&,+L(Q@8'&.U 'G?Q?_Y)EH__ &%-
M/_\ 1BUT/Q0\/3^(_A]J$&GY74;4+>V#K]Y9XCO3'N<;?^!5TMYIUEJ$"07]
MG;W44;K(D<T2NJLIRK $<$'D'M4.NZA-I/A^_P!0M;2:]GMK=Y8K:",N\SA2
M50*.22<"@#S7P'K<?Q0^(,?BZ-2-/T32X[:W0KPMY<*'GP?55VH?K7K-<;\*
M?#$GA3X=:?:7D0BU"Y!O+U=H4B:4[F! _NC"_P# :[*@#SB]_P"3F-+_ .Q9
MF_\ 2@4OQ*_Y'GX=_P#8:?\ ]%-7?'3[)M2746LX#?+$85NC$OFB,G)0/C.W
M/..F:+G3[.]FMY;RT@N)+63S('EB#-"^,;E)'RG!(R* //OV@_\ DA/B'_MV
M_P#2F*JGQVT2TU#1M!U/6;&6_P!%TO4EDU2"$L&%NRE6?Y2&PIP3CM7IE_I]
MEJMC)9:I9P7MK+CS(+B)9$?!!&58$'! /U%6" RD,,@\$'O0!X2WA+]G-+ 7
M9N='\HKNVC6YS)_W[$N[/MBNA^)%[%X;^$N@Q>%;JXTKP_->6=M<7EJ7$EII
M[@[G5FRP.-HR>?F]:[J/P5X5AOC>1>&='2Z)R9UL(@^?7=MS6Q-!%<6[P3Q)
M+"Z[6C=058>A!ZB@#YC^)VA_!W3_  3>/X8FCU?Q'-&&MYK749KN08(+228<
MHH"@YW#\*]0^+_\ R3+1_P#L*:?_ .C%KM[;PAX:L[6YMK/P]I4$%VNVXBBL
MHU68>C@+AA]:OW>FV.H6Z07]G;W,,;K(D<T2NJLIRK $8!!Z'M0!G>,_^1#U
M_P#[!MS_ .BFKS__ )M(_P"Y8_\ :->KS0QW$$D-Q&DL4BE'C=0RLI&""#U!
M%5_[*TXZ1_97V"U_L[RO)^Q^2OD^7C&S9C&W'&,8H \Q\?\ _)J\O_8%L_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 45G^(-630/#.IZQ)$TR:?9RW31J<%Q&A8@'MG
M&*\9T_\ :$\5:O81WVE?"36+ZTESY=Q;3RR1O@D'#+;D'!!'U% 'NU%>)?\
M"\O&_P#T1?Q!_P!]3_\ R/1_PO+QO_T1?Q!_WU/_ /(] 'MM%>)?\+R\;_\
M1%_$'_?4_P#\CT?\+R\;_P#1%_$'_?4__P CT >VT5XE_P +R\;_ /1%_$'_
M 'U/_P#(]'_"\O&__1%_$'_?4_\ \CT >VT5XE_PO+QO_P!$7\0?]]3_ /R/
M1_PO+QO_ -$7\0?]]3__ "/0![;17B7_  O+QO\ ]$7\0?\ ?4__ ,CT?\+R
M\;_]$7\0?]]3_P#R/0![;17B7_"\O&__ $1?Q!_WU/\ _(]'_"\O&_\ T1?Q
M!_WU/_\ (] 'MM%>)?\ "\O&_P#T1?Q!_P!]3_\ R/1_PO+QO_T1?Q!_WU/_
M /(] 'MM%>)?\+R\;_\ 1%_$'_?4_P#\CT?\+R\;_P#1%_$'_?4__P CT >V
MT5XE_P +R\;_ /1%_$'_ 'U/_P#(]'_"\O&__1%_$'_?4_\ \CT >VT5XE_P
MO+QO_P!$7\0?]]3_ /R/1_PO+QO_ -$7\0?]]3__ "/0![;17B7_  O+QO\
M]$7\0?\ ?4__ ,CT?\+R\;_]$7\0?]]3_P#R/0![;17B7_"\O&__ $1?Q!_W
MU/\ _(]'_"\O&_\ T1?Q!_WU/_\ (] 'MM%>)?\ "\O&_P#T1?Q!_P!]3_\
MR/1_PO+QO_T1?Q!_WU/_ /(] 'MM%>)?\+R\;_\ 1%_$'_?4_P#\CT?\+R\;
M_P#1%_$'_?4__P CT >VT5XE_P +R\;_ /1%_$'_ 'U/_P#(]'_"\O&__1%_
M$'_?4_\ \CT >VT5XE_PO+QO_P!$7\0?]]3_ /R/1_PO+QO_ -$7\0?]]3__
M "/0![;17B7_  O+QO\ ]$7\0?\ ?4__ ,CT?\+R\;_]$7\0?]]3_P#R/0![
M;17B7_"\O&__ $1?Q!_WU/\ _(]'_"\O&_\ T1?Q!_WU/_\ (] 'MM%>)?\
M"\O&_P#T1?Q!_P!]3_\ R/1_PO+QO_T1?Q!_WU/_ /(] 'MM%>)?\+R\;_\
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M?\+R\;_]$7\0?]]3_P#R/0![;17B7_"\O&__ $1?Q!_WU/\ _(]'_"\O&_\
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M* "BBO#/VGFMO['\*KJ)/V(ZKFX'/W-OS=.>F>G- 'N=%>1_#:T^$QN-8O\
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M#)#P?<=* /=:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#F_B/\
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M"GB&3]F3P1I4>A:DVHVNN>;/9BT?S8D\RY.YDQE1AEY(_B'K7TK110 4444
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ME7 -=5=>&=>;P[\%XUT74#)INH1/?(+5\VJB6,DR#'R# /7'2OH2B@ HHHH
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M_P#Y(H_X4;XW_P"BT>(/^^9__DBO;:* /$O^%&^-_P#HM'B#_OF?_P"2*/\
MA1OC?_HM'B#_ +YG_P#DBO;:* /$O^%&^-_^BT>(/^^9_P#Y(H_X4;XW_P"B
MT>(/^^9__DBO;:* /$O^%&^-_P#HM'B#_OF?_P"2*/\ A1OC?_HM'B#_ +YG
M_P#DBO;:* /$O^%&^-_^BT>(/^^9_P#Y(H_X4;XW_P"BT>(/^^9__DBO;:*
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M?\*-\;_]%H\0?]\S_P#R17MM% 'B7_"C?&__ $6CQ!_WS/\ _)%'_"C?&_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *RO$5V;+2X95LEO2U_9Q>4R
M[@N^YC3S.AY3=O![%<\=:U:SM=?4DT^(Z*H>Y^V6H<''^I-Q&)CSQQ%YA]?3
MG% &C1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MSH\Q_P"^WYTVB@!WF/\ WV_.CS'_ +[?G3:* '>8_P#?;\Z/,?\ OM^=-HH
M=YC_ -]OSH\Q_P"^WYTVB@!WF/\ WV_.CS'_ +[?G3:* '>8_P#?;\Z/,?\
MOM^=-HH =YC_ -]OSH\Q_P"^WYTVB@!WF/\ WV_.K]9U:- !112,P52S$  9
M)/:@!:*\4@^(WBC4/B?H.HV]TD/@?5]1FTVT@,";KG9&0)]Y7< TA.W!'"=.
M3GJO$OQET#PQKVJZ//I^LW][I,,<]REA:"4+&R;RY.X!552"Q;'WAC/. #T&
MBN"U/XP^'=.;1TCM=5U";6K#[=906-IYLDB<878#G<>>V/E.2*?9_%SP_?\
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M<\9H ^JZ*^5?">G^&M<\9?#ZV\.#4[N]N9?M^NZA<M,([J:%1(5PYVL5<$9
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M);IX['P\C:E<3W#R-=7#R  ON) .W! & ,<4 >V4444 %%%% !1110 4444
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MV;2=H'K@#/>@#S_]G[1=:LO ZZOJVM_:H=9+7JV'V5$\F1W8F0R#YG+@*<'
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M(>0Q;7(^4A^0W(->AUS?@_P)I'@J&Z_LUKJZN[UP]W?WTQFN+E@, NYZXYX
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M0H(!8XRPQC&:3P7\//&2>*=;O]?M+Z&/4?#L^GQRZGJ\=](LK.FU2R 87 )
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M;ILC4 8PJ]A[5:HH **** "BBB@ KF?B1JYT+X9^(=11MLD-A*(R>SLI5?\
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M8W4J6Q$]Q&LK?\!C+MGMC- &C1110!7N_P"#\:K59N_X/QJM0 4444 %%%%
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M0,E*[7_A:&N?]$R\4?\ ?$?_ ,51_P +0US_ *)EXH_[XC_^*H ]%50JA5
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MCJ^G36GAJVO+F]DC5HP99 <%4Q@(BA?F+9.WD<FI/^%H:Y_T3+Q1_P!\1_\
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M5%4?+MRV2#WVO!E_JEUXF\2V=YK;ZM8:7-#:6\DD$2/YNPR2[FC50Q'F(O
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M/9V'Q=CC8:E-?WVBM)?7,^D74'G73W&YW(DC&V, !5)PH"JN<C%>R4 %%%%
M!1110 4444 %%%% !6?JVOZ/H$,<NNZM8Z9'*VV-[RY2$.>N 6(R:T*X?2U$
M_P ;_$9O%#/;Z/91VNX?=B=YC)CV+*N?7:/04 =K%+'/"DT$BR12*&1T;*L#
MR"".HK'C\:^%IM4&FQ>)='DOS+Y(M5OXC*9,XV;-V=V>,8S6'\)!L\"O!&,6
MEOJ=_#: #@0K=2!0/8<@>@&.U9DL>N_"^QAE2]T[5-&NM;_?VQLWAN46[G/*
M2>:RN5>1?E*#*@\@T =9>>.O".G7DMIJ'BG1;6YA;;)#/J,2.A]"I;(-;<,T
M5S;QSV\B2PRJ'CDC8,KJ1D$$=01WKB_B1/)J<.F^#+*0I<>(IS%<%#AH[)!N
MN&_%<1_]M*[2*)((4BA0)'&H5%48"@< 4 /HHHH **** "BBB@ HHHH **Y;
MQ[\0M$^'.BQ:EKYG=9I?*B@MD#22'&3@$@8 ZDGT]:/ ?Q"TCXA^')]:T:.Z
MMK6WN&MY!>HJ,K*JL3\K,,8<<YH ZFBO(]7_ &EO .E:F;.%]1U(*VUKBRMU
M,0.<=7921[@$>E=UI/CWPYK7@V7Q38:BC:3 CO/,RE3%L&6#*1D$>G?(QG(H
M Z*BO.="^-WAK7-=T_3/L6L:<-4)73KO4+/RH+T@XQ&^XYYP.0.2!U.*Z3QM
MXXTCP%H:ZGK9F<22K#!;VR!YIW/\**2,^O4?RH Z*BH;2<W5E!<-!+;F6-7,
M,P >/(SM8 D9'0X)YJ:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S
MJT:SJ ,+4O!VCZKK)U:Y%]'?- MN9K34KFV)C4E@I$4B@@%B?QJ[;:'86NH0
MWT<<C74-I]C2::>25_*W!L$LQR20"6.2<#)-:%% & ?!.A"QM[6"WN+9+9Y7
MBDM;Z>"4>:^^0>8CAR&;!()()"\<##;KP\FEV]O<>$])L!J%G:M96BW%P\$,
M,+$$@!5?NBG[N3CJ*Z&B@#F--\"Z;!X%TOPWJ@:]2P$<@G5VA<3J=QE1T(9#
MN).0<X)&<$U=A\):/#:Q0?9YI5BO$O@UQ=RS.TZ@!79W8LV J@!B0-HXX%1:
MOKMU#XHTG0=)2&2YNMUS=O*I86]JA 9L CYF8A%[9R<';@W$\2Z%+J,.GQ:U
MISWMPI:&V6Z0R2 9R57.2/E;I_=/I0 2^'=*GN=3GGLUDDU6W6VO2[,PEB4,
M F"< 8=NF,YYJ&T\)Z/9)IJQ032?V6[269N+N68PED*'!=B2-I( .0.V*V:*
M ,J\\,Z3J#:HUW:F1M6MEM+T^:X,L0# )P?E&';[N.M3/HNGR:G8Z@]N#<Z?
M$\5J^]@(E<*& 7..0JC)&>/<UF>,O%\'A'1WN3;M>W9BDEAM$?:72-=TCLV#
MM15Y9L'J  2R@R#5=?NM#TV_TW1]/,EU;+-<PWNI/#]G9E!V@K"^_&2"3MZ=
M.>  T[P5H6DWR76GVT\/E2O-%!]MF-O$[[MS) 7\M"=[?=48W''6KNK:%8:T
M(?MRSK)"3Y<UM<RV\J ]0)(V5MIP,KG!P,C@5@>'O%6O^)O#LFIZ=H6F@_:W
MA@\S59!#<Q+D&9'%N3@L, %1D9.>F:(\=:Y/HWBZX32-/B?P]!)LN(KY[F&>
MX1"[Q<QQGY< ,>Q..QP ==HVA:;X>L6M-'M5MXGD::0[BSRR-]YW=B6=CQEF
M))P.:@N/"VCW6GZM8SVA:WUAVDOE\YP9F*JA^8'(^55& 0.*T;*Y6]L+>Z08
M6>)9 #V!&?ZU-0!1DT>R?58-3$(%[:V[V\$FYML:.5+#:#CDHOOQUKAM'^'$
M\.N:1/>V.G6-KI$S7$:6M_<70DD*L (XY0%M8\L7*(6!*Q@GY :]'HH *NV_
M^H7\?YU2J[;_ .H7\?YT 2445SMWXE>+QU'HD0A6VM]-?4-0FD!)C7=LB5<'
M R5D)SGA/>@#HJ*X:T^(5[);:/JU[H2VV@:U/'#:7?VS=.GFG$+RP[ JJ_R]
M)&(W+D=<=9K&IC2-+EO?L=Y?&/ 6WLH3++(20 %'3J>I( ')( S0!!K7AO2_
M$'V9M3@D,MHYDM[BWN)+>:$E2K;9(V5UR"00#@CK5;_A"O#_ /9%IIG]G#[)
M:7:7T2^:^XSJVX2,^[<[;N26)SWS57PKXIU#Q7X)&LV^CPVFH&6:'[!<7OR*
M\<K1D-*J'^Z3D*?QZU7LO%>N'QU:^&M5T33HGFLY+R6:RU22X^SQJP52RM!'
M]]B0,'^%O2@"S-\/M FUJ^U95U*WOM096NI;36+NW\XJNU<B.51P. ,<"K.J
M>#-%UBXM[B]ANA<V]N;9+FWOYX)FB)!*/)&ZLZY4'#$\\]2:W&944LY"JHR2
M3@ 5PL'Q&NI-/TW79M"6+PUJ=U';P7OVS-PBR-LCE>#8%5&;;TD+ .I(Z@ '
M:6-C:Z;8PV6GV\=M:P($BAB4*J*.@ '2IZCN)XK6VEN+F18H8D+R2.<*B@9)
M)[ "N'T;XI6U]I?B35-4TR;3;'0T2<,[[I)X7C\Q&V8&QF4KA23]X D4 =Y1
M7)V7B[5(M>TO3O$NA1:8-81_L<D-]YY614WF*4&--C[03\I<94C/3-WP;K\_
MB#0GEU!(H]1L[J:QO4A!"":)RI*@DD*P 8<GAAR: -^BBB@ HK'\6Z^OA?PE
MJ.LM'YS6D):*+_GK(?E1/^!,5'XUFW/B;5HM6M/#^GZ=9ZCKBV*7E\9+EK6V
MA4DKPP21LLZMM7!X4DMTR =52.BR1LDBAT8$,K#((]#6/X5\1)XGT%;\6TEG
M.DLEM=6LC!FMYXW*2)D<'#*<'N,' Z5D:_\ $!-'\8Z9H%KIS7INKF*VN[D3
M;%M&E#&,8P=S$(QV\8 !)^84 :&D^!?#VB7\%YI]E(LMLKI:B:ZFF2U5_O"%
M'8K$"!CY O''3BE;P/X>;19M).GXLYKQKYE$\@=;@OO,B.&W(V[D%2,=L5FW
M_C74C=ZR/#NA1ZG:Z$WEWLLM[Y#O($$C1PKY;!V567.YD&6 !ZD=-I.IVVM:
M-9ZI8,7MKV!)X6(P2CJ&&??!H @T;P_IN@13+ID+JUP_F3S33//+,V, O)(6
M=L  #).  !Q4MMH]C::O?:I;P;+R_6-;F7>Q\P1@A."<# 8] ,YYK!^('C:7
MP1H$NH6VAWFL21Q/,R0_NXHT3&YI)2"%X/  +,>@ZD=3$_F0H^,;E!QZ4 .H
MKA+SXC74.F:CKUIH2W/AS3+EX+B[^V;;AEC?9++'#L(9%.[K(I.QL#IFY?>,
MM2EU'5K;PMHD.K)HR*;N26^\C?(T8D$4.(W#MM*YW%%!91GK@ Z^BN2M?&Z7
MNL>&'M51M'\26<DEM*RD2I,JB0(W..4W\=BG4YKK: "BBB@ HHHH YKQ\GA^
M'PK+JWBS3/[3L=&;[>(-@<[U4J"%)"L<.>&XY]J^:?BK\1]$^+^H:'I'A^R7
M25MY"&U#5GC@"!@!M)4MA!C/7\*^E/&_Q T3X?6EE=>(S<I;WDY@66&'S C;
M2V6QSC [ FOG[X^?$'P9X_TO2K+P@&U/5UNPWVJ.S=&$94J8OF4,Q9BAP ?N
MT ;O[2UY)H7PZ\)>&+>X:2"7[\@./-$$:*,^Q,@./4#TJ2T^.&G>$M&L-/D^
M&.I:=X5=1%!=3J%\]0/O;&0*['&3\YSUS6)\8/!>MVOP&\#W.HQ2R7.B1&&\
M7&3 LH4@-CLNQ4SZXJQ\6OB_X?\ B%\,=/T+P^+F[UN_N(&DM!;L&@<=5SC#
M$L< +G.?PH [+QU'?'XB^"/B5X>TB[\0:);V;))#IL/FS!)$;:ZIG)XDS[%>
M<5RFGZ]K7@2;Q=XIDTBYL]:\9WZPZ!H]TG^D,=SGS)(^P'F+P>IXZ'->P>&C
M#\.?@[II\33"W32=.0W9SG:V,E!ZG)V@#J<5YSX?T;7?&FF>)/BGJ\$B:G/I
MES%X8LAR;6/RVV.O^TQ/![Y8_P 0P =?\*=)\.^#+%](E\0:;?>+;]S<:KMO
M$>>2;DE=N=V%R1]23WKTJOCB?_A'&^"_@K_A$_L1\<'6AO\ )V_;,[I<;L?-
MMW>5C/MCO7V/0 4444 %%%% !7DEQ-J&M^!?%GC :SJ5IJ6F7%\VG+;WKQP0
M):.VQ&A#>7)N\L[C(K$[SV QZW7#7GP]O9;76-)LM>6UT#6KB2>[M?L6Z=/-
M.9DBFWA55_FZQL1O;!Z8 +'B_P 57FF_"*[\1Z=MAO7L(Y82P#")Y=H#8/!V
ME\\\<<U0FM9O!OCGPK;66J:I=V^L-/9WL=_?27(D9(6D651(QV-E""$VKANG
M K<U/PDVLV>K:5J.HNVA7UDEI!80P*C6A (,BR<DG[I (P"HZYJM8>$=6EUG
M3]3\4:_%J4^EPO'9?9+#[,%D=-CS/NDDW.5X&-JC+?*<\ '*^#6E\.2:#;^.
MK/Q1:ZS=2- M]>:S)<V<\YW;4V)<NH)7IN0#*\<@55GN]2U+X8:]X\76-1@U
M:TN+R>S2.\=;>&.WF9$B, ;RW!$9W%E+'>>?NX[/_A$M9U34=*F\5:_;W]MI
M,XNH8++3C:F:=5*H\K&5]P&6.U0@W$'H,51N/AS=R:?J6A0ZZL7AK4KJ2XGL
MOL>;A5D;?)"D^\!49BQYC+ ,0&Z$ &9\2+V*#0;K5K:\\21:Q-91R:?]DEN(
M[.U8_=,CKMMPH8[G,Q/RY[;17H^GR/+IEK)--%/(T*,TL)RDA*C+*>X/45S^
MO>'O$&J1W]C8^(+2TTJ^B\EH)=+\V6!"@1EC<2*H!&2-Z/@L>HPHW-(TRWT3
M1+'2K'<+:QMX[:'><ML10JY/<X H N4444 %97B.T^VZ7#%]N6QVW]G+YKM@
M-LN8W\OJ.7V[ .Y;OTK5K(\31Z?+I,*ZO-)#;C4+)D:(9)F%U$85Z'@R!%/L
M3R.H ->BBB@"O=_P?C5"\M(;^QGL[I2\%Q&T4BABI*L,$9&".#U'-7[O^#\:
MK4 86E>#M)T5473VU)8DA\A(9=6NI8T3&,!'D*C X&!QVQ4\?A?1XK+2+1+,
M"WT5E>PC\Q\0LJ&-3U^8A6(^;/7/7FM:B@#%LO".BZ?JJZC;6TOGQ[_)$MU+
M)';[_O>5&S%(L]/D XR.AQ61;>#YHO$FB^5;VEGH7A]96L8H[F2:6:21-FYP
MRC;M#2?Q.26!R*[&D=UCC9Y&"HHRS,< #UH PIO!>AS:M+J)MITFGE6>9(;V
M:.&:1<89X5<1N?E&=RG.!G-6I?#>E30:O%);$IK6?M_[UP9LQB/KG*_(H'RX
MK-\.>*O[3T4ZUJTMII^GWL[_ -F"5O+9X%4D.Q8X)94>3  PG7.":V]-U;3M
M9L_M>CW]K?VVXKYUK,LJ9'4;E)&: *4OA72)=2T^_P#L\D5UIT7D6\EO<RQ8
MBRI\M@C .F44[6R..E2Q^'-*AT>_TN*U*6FH/.]T@E?,C3$F0[L[@26/0C';
M&!6G10!0M]#TZTU&.^M[8)<1VBV2.';"PJ<A ,X'/?&3@<\"J#^"= ?1[72Q
M9/';6<S3VQBN98Y89&9F9EE5@X)+MD[N<FLZP\>QZGXY;1;&P+Z<EG+<G5FF
M"HQC<(P5<?,NYL;\C)5\ @9-:#XA7<T.DZJ^A"/0-7O8K2UNFN_](_>_+%*T
M&S 1FP/]86 8$KU  .LTO2K31[$6MBL@CW,Y::9YI'8G)+.Y+,?<D\ #H!65
M)X%\/S7J7,]G+*(YO/2UDNYFM5DY^86Y?R@<DG[O4YZ\UCZQ\0[NP@US4+#1
MH;G2=!F^SWEQ/?>3*\@"EUBC\M@V Z@;F3<3@>IVQKL__">0Z(T2"VN-*:]C
M8J1(KI*J,#SC&)$XQD$'KV -+5-*L]9L39ZE#YUN9(Y"F]E!9'#KG!&0&4''
M0XYI%TBR37)-86'_ $^2W6V:8NQ_=*Q8*!G Y8G@9/?H*NT4 <;K?@M!I>CV
M6@:9:RP:6[F%)=3N;.:$LI&Y+F+<_1F#*0=VX'(V\Z'@GPQ_PBVAS6\@MQ<W
MEU)>7"VRD1([X^1<\D*JJNXX+;<D#.!T5% !6C6=6C0 4456U+4+?2=)N]1O
M7V6UG \\S?W412S'\@: +-%<5:^,]6DT[P[:_P!E6]QXAUJS:^-J9V@@M8@%
M8EWVNV1O1.%.6/89QL^%O$9\0V]\EU9_8-0TV[:SO+;S?,5' # J^!N1E96!
M(!YY (- &Y7.VG@+PY8ZE'>VU@RO#.UQ# US*UO!*V29(X"QC1OF;E5!Y/J:
MJ:MXYDTWQUI7AZ/0KR2"^N/L\FI2GRH4<Q-*%CR,RG"')&%7IG.0)-6\5:C'
MXJET#P]I5K?7=M8K>W+WM\;5%1V945"(Y"Q)1LY"@?+R<X !/J'@'PWJFFZM
M87NGM):ZQ<BZOXUN94\^0;<$E6! ^1>!@<=*NZ3X<LM%N'FLY]3D9UVD7FJW
M-TH&<\++(P!]P,T>%]?A\4^%[#6[6)X8KV(2+'(02O8C(X/(ZCKUJKXA\23:
M7J6G:3I=BE_JVI>8T$,L_DQ)'& 7=W"L5 W*!A6)+ =,D &E_8]C_;W]M>1_
MQ,/LWV3SM[?ZK=OV[<X^]SG&:NU@^&/$CZZ=2M;ZR_L_4]*NC;7ELLWFH"5#
MHZ/A2R,C*02JGJ".*H>+/%FL^%[34-5_X1Z&YT;355YYVU )/(G!=HHA&P8*
M"1AW0DJ>,8) .MHKG];UG7K6'S_#^A6VHP+:FX>2ZU#[-N/)$: 1N2V!SNVJ
M,KR><9D?CU;NP\(ZU9P!='\03"WD\Y?WL,DB$Q=#C&]2AZ\LI!XY .SHHHH
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M,[N& [-TQ6S10!P7PGNC'X7FL+FQU*TN8[V\N&2\TV>W!22YD="&D0!B58'
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M3R0^;Y;(_EH"[#,9!V@XR.V:ZK^R[/\ MDZMY -\;<6PF+$D1[MVT#.!D\G
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M(\1_^"B6K4/QJT!8@#H_B3\-'EH ])HKSG_A=F@?] ?Q+_X)Y:/^%V:!_P!
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M9H'_ $!_$O\ X)Y: /1J*\Y_X79H'_0'\2_^">6C_A=F@?\ 0'\2_P#@GEH
M]&HKSG_A=F@?] ?Q+_X)Y:/^%V:!_P! ?Q+_ .">6@#T:BO.?^%V:!_T!_$O
M_@GEH_X79H'_ $!_$O\ X)Y: /1J*\Y_X79H'_0'\2_^">6C_A=F@?\ 0'\2
M_P#@GEH ]&HKSG_A=F@?] ?Q+_X)Y:/^%V:!_P! ?Q+_ .">6@#T:BO.?^%V
M:!_T!_$O_@GEH_X79H'_ $!_$O\ X)Y: /1J*\Y_X79H'_0'\2_^">6C_A=F
M@?\ 0'\2_P#@GEH ]&HKSG_A=F@?] ?Q+_X)Y:/^%V:!_P! ?Q+_ .">6@#T
M:BO.?^%V:!_T!_$O_@GEH_X79H'_ $!_$O\ X)Y: /1J*\Y_X79H'_0'\2_^
M">6C_A=F@?\ 0'\2_P#@GEH ]&HKSG_A=F@?] ?Q+_X)Y:/^%V:!_P! ?Q+_
M .">6@#T:BO.?^%V:!_T!_$O_@GEH_X79H'_ $!_$O\ X)Y: /1J*\Y_X79H
M'_0'\2_^">6C_A=F@?\ 0'\2_P#@GEH ]&HKSG_A=F@?] ?Q+_X)Y:/^%V:!
M_P! ?Q+_ .">6@#T:BO/[3XQZ%>WT%K'I'B-7GD6-2^D2@ DXYXZ<UZ!0 5G
M:Z-3.G1?V(<7/VRUWYV_ZC[1'Y_WN/\ 5>9[^G.*T:R_$-I+>:9%%!>+9,M]
M:2F5G*[E2YC=H\C^^%*8[[L=Z -2BBB@"O=_P?C5:L3QIXWT_P )36D>H66J
M7)N%9E-C8O,!C'4@8!YZ5S'_  N;0?\ H$>(_P#P42T >A45Y[_PN;0?^@1X
MC_\ !1+1_P +FT'_ *!'B/\ \%$M 'H5%>>_\+FT'_H$>(__  42T?\ "YM!
M_P"@1XC_ /!1+0!Z%17GO_"YM!_Z!'B/_P %$M'_  N;0?\ H$>(_P#P42T
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MH ]&HKSG_A=F@?\ 0'\2_P#@GEH_X79H'_0'\2_^">6@#T:BO.?^%V:!_P!
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5D>)H;"XTF%-5N&MH!J%DZN@R3*MU$T2]#PT@13[-VZUKUD>)I=/ATF%
MM6MY+B ZA9*B1G!$QNHA$W4<+(48^P/!Z$ UZ*** *]W_!^-5JLW?\'XU6H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K1K.K1H **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *SJT:SJ "BBB@ HHHH **YSX@ZHVC?#O7;Z+/G)92)" ,
MDRN-B#'?YF7BN(T?1].TS7M!U'PQH<ND6&A:?.VLZA)ISV!NU\D!8BKJK2G<
MOF%B"!M'.30!ZI;7=M>([6EQ%.L<C1.8G#!74X93CH0001U!J:O,/!>HZPFA
M>'_#^B"UM]0NM..MZA=7T+S)"L\C.JA%="SL[-U8!0AZ\5:TCQYKFJ:780I;
MZ<=5U74[FTM)(U<VZ06Y*RSL-V7&4;"@KG<HR.6H ]%J&ZN[:QMS/>W$5O"I
M"F29PB@D@ 9/')( ]R*XK6_%VMZ#/9:)<BUN-7O#)-]KLM-NKB.*V0I^\:VC
M+2;B7V ;]O\ $6'W*Q->U;Q'K>@:#I]_IT*:A?>(D6W5XGMUN;> F=9FB9F>
M(?NP2A); [9P #U:BO/G\=:OI5QK6EZE#9:CJ=I>6EI8O:QO;1W$ERF55U9I
M"FW!8MN.5Q@9ZZFF:WKMMX\'AS7I-/O1/IIOHKFQM7M_**R!&1U:23(.Y2&!
M'0C'< '6T444 %%%% !5VW_U"_C_ #JE5VW_ -0OX_SH DHHHH **** "BN#
M\26\&O?%?1= UB&.[TE-*NKYK.==\,\PDBC4NA^5]H=B > 3GJ!4GPZ46&I^
M+=#M1LT[3-7VV<0)VP))!'(8U'90S,0!P-V!QB@#N**\(^*7BG1?$+ZDEQKM
MA!%X?U"UM[6P>\199KD747GSF/.[;&FY!D?\]3TP:ZKXL:=9ZQX;TWQ#!J=Q
M<P0WM@;2*"Y_T5]]W%^^PO\ K&*G )) !R "2: /3:*** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "LOQ%=O9:7#+'9+>EKZSB\
MIEW!0]S&ADQZH&WY[;<UJ5G:ZVI)IT1T5=US]LM0X.W_ %!N(Q,>>/\ 5>9[
M^G.* -&BBB@"O=_P?C5:K-W_  ?C5:@ HHHH **** "H;B[M[3R_M5Q%!YL@
MBC\QPN]ST49ZD]A7G'BNXT34/BLEOXATB;6;/2='+"WCTF2^59YY1C*HC!6V
M0<%L#YNO6L[2K*ZT>7PCI6NH;5+2XU#7'L_,W_8K>,,L,61D87SUX!P-N!TH
M ]>HKSEO&'BO['X<U/RM)CMO$5]##!820R>?;PR?/O9P^';RE8E0JA2PY.WY
MMC2M<U_Q)<3ZCHO]FQ:-#>/:QQW,4AENUCD*2RK(K8C&0VU=C9V\D;OE .NJ
M&.[MI;J:VBN(GN( K2Q*X+QAL[2PZC.#C/7!KSJP^(.O>(+JVN?#NG>=97%[
MY45M+I5R/,M@Q#3F\)6%<J"P4!\_*,EC@9W]O:]IB^//&&G?V>+&TU!EV743
MN]VMNBQ%$*NHC *MAB'R6/R@+\P!ZY17'2^(-=UG5-4MO#+:?8P:.HCN9]1M
MWG\VX*"3RU5)$V!59<L2V2V /ER=CPCKK>)O!^EZU);_ &9[ZV29H<YV$CL>
MX]/:@#9HHHH **** "M&LZM&@ HHHH **** "BH+V=K;3[B>-=SQ1,ZJ>Y S
MBO&1IUK8_"#PUXV@A4^)I+FPNYM4Q_I%RTTR)(CR ;F0K(R[#\H   X% 'MM
M%<YX[\51>$/"\E^TEO'<S2):V?VJ41Q&9SA2[GA4'+,?[JG'.!7"?# >'G\3
M^--#LO$%OJ_VP6[/<07P,MX6MP)YE:-LCYV.2I^4D $8% 'KU%>9^'-(TR+X
MQ74G@BQM]/TC3-/-EJIL8Q%!/=EPR1[5PK21J6+-U7>%)YQ7IE !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5G5HUG4 %%%
M% !1110!F:_H-MXCTV.QOI)D@6YAN&6(@>88I!(JMD'*EE&1U]Q4NMZ5%KN@
MWVDW,TT,-] \$DD# .JL,'!((!P?2JFK^(/[.UK2=)M;;[7>ZE(QV>9L$,"
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M15+2M*M]'M#;6DEW(A<N3=WLUT^2 /ORLS8XZ9Q^=7: "BBB@ HHHH ****
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5D>)GT^/283J\4DMO\
MVA9!%B/(F-U$(3U' D*$^P/7I6O65XDNULM+AEDL4O@U_9Q>4XR%+W,2"3H>
M4+;Q[H.1UH U:*** *]W_!^-5JLW?\'XU6H **** "N:^(U]/IOPUU^YLVVS
MK8R+&^<;&8;0WX9S^%=+5#7-'M?$&@WVD:AO^S7T#P2&,X8!AC(/J.HH XO6
M]!M;KQ)X+\(1J_\ 9VFV\UY-'&Q0-'%&($4X_A8S$$="-P/!-7/AA:6]O8^(
M)=.BCM]/FURY%I!"NV.../;$=JC@ M&YXXYKM8T,<2H69RH W-U;W-.H X34
MO#NO7FJ7%PNF(5DD)4IXTU*W!'8^7'%M3CL.![UT/B#Q%I7@GPM)J>M3O%:6
MJ*@RYDDD;HJ L<LQ/<GU)( )K:HH \W\/7FC>(+K4?%'B#Q#H[7GV$P?9K/4
MHI8](M6/(9P<&1CC<_3("KP,G)T?3KG5KKPOX<TCQ'8Z]H&A3Q7,UW86>%C6
M!?W,;S>:Z/(6V':H4@*6.,J#Z]10!YT?%?A[6_C%I,-IK^F7"6.FS&(17<;>
M9<32*@12#RP6-OE'(W#UK4M&.I_&2]N(>8-&TA;.1AT\Z>02E?J$BC/_  .N
MQK,T'0;;P]8RV]M)-.\]Q)<W%Q<$&2:5SEF8@ >@     ':@#3HHHH ****
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MI^.I_"%I)X@NM.UV[T_Q@R*$M;#4IX[BXN5C40*+0/MES\B_<(()YZFO4Z*
M.!\:ZEJDG@G2/#I;R?$/B81Z>YCQF$-'NN90/1$#].A*TOQ L8-.\,^%M,TR
M-81!KNF06:#H@25>/H$5OP!KO:S;_0[74M8TS4+II6?2WDE@B!'EF1TV;V&,
MDA2P'/&X]>, &E1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !6=6C6=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5VW
M_P!0OX_SJE5VW_U"_C_.@"2BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YQ_PH[PO_S^
MZ]_X-I?\:]'HH \X_P"%'>%_^?W7O_!M+_C1_P *.\+_ //[KW_@VE_QKT>B
M@#SC_A1WA?\ Y_=>_P#!M+_C1_PH[PO_ ,_NO?\ @VE_QKT>B@#SC_A1WA?_
M )_=>_\ !M+_ (T?\*.\+_\ /[KW_@VE_P :]'HH \X_X4=X7_Y_=>_\&TO^
M-'_"CO"__/[KW_@VE_QKT>B@#SC_ (4=X7_Y_=>_\&TO^-'_  H[PO\ \_NO
M?^#:7_&O1Z* /./^%'>%_P#G]U[_ ,&TO^-'_"CO"_\ S^Z]_P"#:7_&O1Z*
M /./^%'>%_\ G]U[_P &TO\ C1_PH[PO_P _NO?^#:7_ !KT>B@#SC_A1WA?
M_G]U[_P;2_XT?\*.\+_\_NO?^#:7_&O1Z* /./\ A1WA?_G]U[_P;2_XTO\
MPH_PP.E]K_\ X-YO\:]&HH \Y_X4AX8_Y_\ 7_\ P;S?XT?\*0\,?\_^O_\
M@WF_QKT:B@#SG_A2'AC_ )_]?_\ !O-_C1_PI#PQ_P _^O\ _@WF_P :]&HH
M \Y_X4AX8_Y_]?\ _!O-_C1_PI#PQ_S_ .O_ /@WF_QKT:B@#SG_ (4AX8_Y
M_P#7_P#P;S?XT?\ "D/#'_/_ *__ .#>;_&O1J* /.?^%(>&/^?_ %__ ,&\
MW^-'_"D/#'_/_K__ (-YO\:]&HH \Y_X4AX8_P"?_7__  ;S?XT?\*0\,?\
M/_K_ /X-YO\ &O1J* /.?^%(>&/^?_7_ /P;S?XT?\*0\,?\_P#K_P#X-YO\
M:]&HH \Y_P"%(>&/^?\ U_\ \&\W^-'_  I#PQ_S_P"O_P#@WF_QKT:B@#SG
M_A2'AC_G_P!?_P#!O-_C1_PI#PQ_S_Z__P"#>;_&O1J* /.?^%(>&/\ G_U_
M_P &\W^-'_"D/#'_ #_Z_P#^#>;_ !KT:B@#SG_A2'AC_G_U_P#\&\W^-'_"
MD/#'_/\ Z_\ ^#>;_&O1J* /.?\ A2'AC_G_ -?_ /!O-_C1_P *0\,?\_\
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M'_"D/#'_ #_Z_P#^#>;_ !KT:B@#SG_A2'AC_G_U_P#\&\W^-'_"D/#'_/\
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M.\+_ //[KW_@VE_QH_X4=X7_ .?W7O\ P;2_XUZ/10!YQ_PH[PO_ ,_NO?\
M@VE_QH_X4=X7_P"?W7O_  ;2_P"->CT4 ><?\*.\+_\ /[KW_@VE_P :/^%'
M>%_^?W7O_!M+_C7H]% 'G'_"CO"__/[KW_@VE_QH_P"%'>%_^?W7O_!M+_C7
MH]% 'G'_  H[PO\ \_NO?^#:7_&C_A1WA?\ Y_=>_P#!M+_C7H]% 'G'_"CO
M"_\ S^Z]_P"#:7_&C_A1WA?_ )_=>_\ !M+_ (UZ/10!YQ_PH[PO_P _NO?^
M#:7_ !H_X4=X7_Y_=>_\&TO^->CT4 ><?\*.\+_\_NO?^#:7_&E_X4AX8_Y_
M]?\ _!O-_C7HU% 'G/\ PI#PQ_S_ .O_ /@WF_QH_P"%(>&/^?\ U_\ \&\W
M^->C44 ><_\ "D/#'_/_ *__ .#>;_&C_A2'AC_G_P!?_P#!O-_C7HU% 'G/
M_"D/#'_/_K__ (-YO\:/^%(>&/\ G_U__P &\W^->C44 ><_\*0\,?\ /_K_
M /X-YO\ &C_A2'AC_G_U_P#\&\W^->C44 ><_P#"D/#'_/\ Z_\ ^#>;_&C_
M (4AX8_Y_P#7_P#P;S?XUZ-10!YS_P *0\,?\_\ K_\ X-YO\:/^%(>&/^?_
M %__ ,&\W^->C44 ><_\*0\,?\_^O_\ @WF_QH_X4AX8_P"?_7__  ;S?XUZ
M-10!YS_PI#PQ_P _^O\ _@WF_P :/^%(>&/^?_7_ /P;S?XUZ-10!YS_ ,*0
M\,?\_P#K_P#X-YO\:/\ A2'AC_G_ -?_ /!O-_C7HU% 'G/_  I#PQ_S_P"O
M_P#@WF_QH_X4AX8_Y_\ 7_\ P;S?XUZ-10!YS_PI#PQ_S_Z__P"#>;_&C_A2
M'AC_ )_]?_\ !O-_C7HU% 'G/_"D/#'_ #_Z_P#^#>;_ !H_X4AX8_Y_]?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO+QO_P!$7\0?]]3_ /R/7MM% 'B7_"\O&_\ T1?Q!_WU/_\ (]'_  O+QO\
M]$7\0?\ ?4__ ,CU[;10!XE_PO+QO_T1?Q!_WU/_ /(]'_"\O&__ $1?Q!_W
MU/\ _(]>VT4 >)?\+R\;_P#1%_$'_?4__P CT?\ "\O&_P#T1?Q!_P!]3_\
MR/7MM% 'B7_"\O&__1%_$'_?4_\ \CT?\+R\;_\ 1%_$'_?4_P#\CU[;10!X
ME_PO+QO_ -$7\0?]]3__ "/1_P +R\;_ /1%_$'_ 'U/_P#(]>VT4 >)?\+R
M\;_]$7\0?]]3_P#R/1_PO+QO_P!$7\0?]]3_ /R/7MM% 'B7_"\O&_\ T1?Q
M!_WU/_\ (]'_  O+QO\ ]$7\0?\ ?4__ ,CU[;10!XE_PO+QO_T1?Q!_WU/_
M /(]'_"\O&__ $1?Q!_WU/\ _(]>VT4 >)?\+R\;_P#1%_$'_?4__P CT?\
M"\O&_P#T1?Q!_P!]3_\ R/7KFK^(-&T".)]=U>PTQ)B1&U[<I"'(Z@;B,TW2
M/$NA>(&E70=:T[4S" 9197:3>7G.,[2<9P>OI0!Y+_PO+QO_ -$7\0?]]3__
M "/1_P +R\;_ /1%_$'_ 'U/_P#(]>VT4 >)?\+R\;_]$7\0?]]3_P#R/1_P
MO+QO_P!$7\0?]]3_ /R/7MM% 'B7_"\O&_\ T1?Q!_WU/_\ (]'_  O+QO\
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M9?#Z7.=4AMENWM]C<1%MH;=C;U&,9S[5HT >)?\ "\O&_P#T1?Q!_P!]3_\
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M_P#D>O;:* /$O^%Y>-_^B+^(/^^I_P#Y'H_X7EXW_P"B+^(/^^I__D>O;:*
M/$O^%Y>-_P#HB_B#_OJ?_P"1Z/\ A>7C?_HB_B#_ +ZG_P#D>O;:* /$O^%Y
M>-_^B+^(/^^I_P#Y'H_X7EXW_P"B+^(/^^I__D>O;:* /$O^%Y>-_P#HB_B#
M_OJ?_P"1Z/\ A>7C?_HB_B#_ +ZG_P#D>O;:* /$O^%Y>-_^B+^(/^^I_P#Y
M'H_X7EXW_P"B+^(/^^I__D>O;:* /$O^%Y>-_P#HB_B#_OJ?_P"1Z/\ A>7C
M?_HB_B#_ +ZG_P#D>O;:* /$O^%Y>-_^B+^(/^^I_P#Y'H_X7EXW_P"B+^(/
M^^I__D>O;:J0ZMIUSJ<^G6^H6LM];*&GM4F5I8@>A9 <@'W% 'CO_"\O&_\
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MO+QO_P!$7\0?]]3_ /R/7MM% 'B7_"\O&_\ T1?Q!_WU/_\ (]'_  O+QO\
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M7\0?]]3_ /R/7MM% 'B7_"\O&_\ T1?Q!_WU/_\ (]'_  O+QO\ ]$7\0?\
M?4__ ,CU[;10!XE_PO+QO_T1?Q!_WU/_ /(]'_"\O&__ $1?Q!_WU/\ _(]>
MVT4 >)?\+R\;_P#1%_$'_?4__P CT?\ "\O&_P#T1?Q!_P!]3_\ R/7MM% '
MB7_"\O&__1%_$'_?4_\ \CT?\+R\;_\ 1%_$'_?4_P#\CU[;10!XE_PO+QO_
M -$7\0?]]3__ "/1_P +R\;_ /1%_$'_ 'U/_P#(]>VT4 >)?\+R\;_]$7\0
M?]]3_P#R/1_PO+QO_P!$7\0?]]3_ /R/7MM% 'B7_"\O&_\ T1?Q!_WU/_\
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MMM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P 0^,-5;Q3IOA?P?;V;ZI>63:C-/J&XQ6ML&"ABB$,Q9C@ $8Q4&M^,]?\
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MD#KGBNF\4>/KFVUW2M \,G35U#4+,W[76JRE(+:WR &*J079B<  CH>:R_\
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M%&<OQCY%/&>I''6JMK\.O%BZ+XY\3ZK#!<>+_$UD]I!9VLP"VT3*%""1B!D
M+SG^ <DF@"3P%\4?'/C'06\1W&B:3::%8M,][+F7S9T16;; N2,C !9C@D\
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M5HKB0>;]F= 9 VP9+%_W3!<D DJ3CD5D?"K7=5^&'P1D\0^)%T]]"F#3V%O
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M$C4O$L?@S3?&-EK%O"LUM<F 36LL2[ R><-I5EVY (.1[#-C4_ U[KWPPO\
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MMM>)?'+_ )*G\)O^PT?_ $?:T >VT444 %%%% !1110 4444 %%%% !1110
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M,UKY1+[P.JJ0IYZ9JS\/]-L8OB)X\>*RMT:#4X!$5B4&,&V3(7CCJ>E &_\
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MR1W<G&>37IGB33K"?X[^%?M-G;R>=IM\7\R)3YA'E8SD<D"@#MKKQ%HECO\
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M7A_3-.US4]8L[7R[_5O*^VS;V/F^4NU."<#"G' &>]>1_P#"+_M#?]#WX?\
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M?X=\;*2OL3BO,O\ A%_VAO\ H>_#_P#WX3_Y%H_X1?\ :&_Z'OP__P!^$_\
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M<RNT<I# L69B6X9OO$CFO,/^$7_:&_Z'OP__ -^$_P#D6C_A%_VAO^A[\/\
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M$'((9""#DDYSG)KR_P#X1?\ :&_Z'OP__P!^$_\ D6C_ (1?]H;_ *'OP_\
M]^$_^1: ._D\!Z3HGA#7[+PMIHCN]2LI8V9YFDDG<QLJ!I)&)/)XR<#-9?A'
MX3^'++0?#USJ^@0IK-E96QG0RL8UN4B56<QJWELX(/SX)[YKE/\ A%_VAO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
:*** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>vrna-20221231_g7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vrna-20221231_g7.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#^17AI9@  34T *@    @ ! $[  (
M   1   (2H=I  0    !   (7)R=  $    B   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %9I8W1O<FEA
M(%-T97=A<G0    %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,S
M,0  DI(  @    ,S,0  ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M?#7C'P]XPM7N/#6K6^H)&<.(FPZ>FY3AA^(K/\0?$[P;X5UJ+2=?UZWL[Z4
MB)E=MH/0N5!"#W8CUH ZJB@$,H*G(/(([TV66.&%Y9G6.-%+.[G 4#J2>PH
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ML&H11D!_+)#(3TW*<,OXBMJ@ HKF-;^(_A+PYK4>D:UK45MJ$A0+;>6[N2Q
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M#DY !QVQ7G'[5_AZY=]#\0PQ,]M&CV<[@?ZLYW)GV.7_ "]ZZ7PQ^T=X-A\
MV3:U=7,>L6MHL<UFMN[--(JXRK@;<,1GDC&>: //?V;;J]T'XP:KX==R8I;>
M:*=.@,D+\-CU'S#_ ($:^C?%MEX3M]-G\0>+M*TVYBTZ(RFXN[2.5XP.0%+
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M<,&F2;O,MFS(K[AAMV\DMD#O7,K\"OALM\;L>%K?S"V[:9YC'G_<W[<>V*]
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MW'VBXCU.ZMU?RU3Y$D(484 <#C-=I7G/P0_Y$:^_[#5[_P"C374^-]1U/2/
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M^5+HEE((]/C?G"^1CYE'3).3UIVG_%"YB^ TWC/5+96U.RB>">W P&NED\D
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M[6)II7/144$D_D*\AT'5O$&K_M$64OBCPS_PCMPGAZ98X/M\=WYB><IW;D
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M>^/:HKZY-EI]Q=+!+<&")I!#"NYY, G:H[DXP!ZU3U?Q+H7A]HEU[6M.TPS
MF(7MVD/F8QG&XC.,CIZU)I.NZ3KUN\^AZI9:E#&VQY+.X295;&<$J2 <$<4
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MKZ%HH \=\*@C]D&X!&#_ ,(]?\'_ '9J[[X<@K\+?"H88(T:S!![?N4KI**
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% &=1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 .C_ -:G^\*OU0C_
M -:G^\*OT %%%% !1110 445S?C_ ,8VO@/P5?:[=[6:%-MO$3_KIFX1/SY/
MH 3VH Z2BOFWX7ZQXVT;XVZ7I7CC6]0N6UW2WO%L[FY=HXBX:10$)PI C(P
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M7\N 75PL?FM_=7<1N/(X%<SXU^*OA;P'I=I>ZO=O.;U!):V]HHDDF3&=P!(
M7GJ2!7CNK^-M)^,7QL^'UOH(N#9V,C74T=Q'L9'5O,92 2/NPKR"1\U 'TK1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9XF\6K8-9V\%F%@BDCVN-^Q4=AZLBL?^!=<5[KJ'A[1=7NX;K5='L+ZXM_\
M4S7-JDCQ\Y^4L"1SZ5+9Z1ING75U<Z?I]K:SWC![F6"!4:=AG!<@98\GD^IH
M N4444 %%%% !1110 4444 %%>9_M!ZR='^#&JJC[);YH[1#G&=S@L/^^%:O
MFR[T7P9'X:T9O .N:YJ7C6<1>;:6\+!(I"N9 I\M6X.0"&;^M 'V_17E6O\
MQ3E^'/AWP[HFJV5SXB\8W5E%YEC:GYW?;AF9@#U8,!@$G!.!5;PS\=IO$/CC
M3_"\W@S4=-OYDE>\2ZEVM;;(RXPA0%\XQSMY(ZT >O45\O:-\7O'&J_&2^U*
MT\+:Y>6\42VC^'H[F7R[-_E7?+^[(!R&.2@QGKQSZ1XI^.T6F>);O0O!_A?4
M?%E[8$B[-EN"0L#@C*HY.",$X SWH ]9HKD/AK\1+#XE>&7U;3[6:S>&8P3V
M\I#;' #<,.HPPYX[\5YE^U'JL']G^&-!NKDV]O>7S7%S( 3Y<: +N(&2?]8Q
M_P" T >^45\>66A:,GQ*\/V_P)UK7-1E,P>_N9T*1PJ&7!)V)E<;]P88/ &<
MXKW+QM\:XO#GBL^&?#7AR^\4ZQ"@>YM[(D>2, X^5&)(!!.!@9ZYXH ]1HKR
M'P[\=IO%$^OQ:5X,U!WT;3S<F%I?WTL^57R/+"$CDMSR<*?E[5QOP9^)GC#7
M_'VISW&C:OJVEZU?!5G:YD:UTA07<H,H5^ZRC&5S@>M 'T%!K>E76K3Z7;:G
M9S:A;KNFM([A6EB''+(#D#D=1W%7J\9\ >+O!<DOC7Q\N@IH:VMRT-UJ;7;S
MF[&=WRJ1A"QV?*O4D>U9\W[3#Q1)J8\ ZO\ \(\\FQ=4:3:K<XX&S83QTWT
M>[453TG5+76]&L]4TZ3S+2\A2>%R,$JPR..W6KE !1110 445C^+M7&@>"]9
MU8G!LK&:9<=2RH2!^)P* -BBOB[X>^&?A7K^DVJ^,_%.K6GB"[N3&MI:1L5Y
M;:F6\AQDGG.[OVKZ 7Q?8?"SQ7X7^'!TN1=(N;81VVKSW8SORPPR; ,EL9.1
M]\<=J /4:*\STGXTV&IQ^(M7?3FMO"FB?(-9>?)NY<@!(XMO.2>#N[KQSQRD
MO[2\MMILFIW?P_U>#390?L%[)(1%<MV!8IM7_@)>@#W>BO-?$OQGT_POX3T&
M_O=*N)]8UVVCGMM'MWWN-Z@X9L=,D+]W)/0<'$'A_P"-D-SHNN7_ (R\-ZAX
M6_L5(GEBN@S-)YA8(JAE0[B5Z8_'@T >HT5X:G[2GD7%I=:QX&U;3M O'"PZ
MI*QPX/<*4"MQSPYX]:Z/Q]\:[3P)XXMO#DFBW&I27%F)PUM)\YD8LJ1*FT[B
M2HYR, ]SQ0!VOBGQ=H?@K25U/Q/?BQM'E$*R&-WW.02% 0$]%)Z=JV(I%FA2
M6,Y1U#*<8R#7S%\:O&LOB;1/ R^(M#NM%%S>37-YITI+RI''((QP54Y8;\ @
M?KFO1_"'QR'B'Q]#X5UKPIJ'AZYNT9[1KQCNE 4L-R%%*Y"G!R1D8H ]8HKR
M'7_CW':>*+S1_"?A/4O% TUBM_<V6[;#@X; 5&R 01D[1D<'O4-E\?9M8\%>
M)/$>C^$+N>WT::..)3/EI5;<7=PJ'RPB@,?O=>HZT >R51T_6]*U::YBTK4[
M.]DM'V7"6UPLAA;GY7"D[3P>#Z&O!O@7\1/%/]C7Y\3:9K&IZ=LN-1;7[VXD
M:)$C0 Q)N4J?F5N W&3QP:WO /C3P3X5^%-]XYB\/?\ ".6^H7C*UO'=/=27
M<BDA0K/COO\ E& ,,?6@#VFBO#(OVE/LUW9S>(? VJZ3HMZP\C4I')#J?X@I
MC4,,<_*QX]:Z;QS\:M/\$>-+/0)M+GU#[59?:1):R9<LQ81QK'M^8L5'<8!S
MS0!Z;17F/P[^,O\ PF_BZ^\-:GX:O/#^IVL)F$-S(6)4%00P**5;YP<8/'>O
M3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH SJ*** "BBB@ HHHH **** "BBB
M@ KGY/'W@Z&5XIO%FAQR(Q5T;4H05(Z@C=P:Z"OG+]H'X=>%O"_@^#6M"TO[
M+J%WJJI--]HE?>K1RNPVLQ RR@\#M0![QI?BGP_KERUOHNNZ;J,Z)YC16EY'
M*RKD#<0I)QD@9]Q6K7A?B"WT3X(^"M)\7>#M"MEU/4&@LKF2XFGE!B>,ROA3
M)@',2UN6?Q2\4:;X;UCQ1XW\,1Z7HT<,<NEQ))^_G9VPJ/EC@\@Y*K@9.#0!
MZQ17@[_&;XA:+96?B+Q3X,M(?#%XR;)8'/G!7&5/+GMSRJ@^U=GXT\7>/(-7
MMK+X>>%(=5AEM$N3?W;[8?F)^499!G !^]GYAQZ@'HM%>,Z%\4O&/B7P_P"*
MM*7P]9Q>+=%50+<28ADR^V3.7X*@,1\Y!X_'F?V;;_Q@MO\ 8[+2[27PK)?S
M->W[N/.BF\A<*HW@D9$?\!^\>?0 ^C**^>]'^.'Q$\2^'+N\\.^$+&Z?3R\E
MY<X?R4CQD*JF0%G !)PQ/3Y:E3XZ>.=;\+2:WX9\&6S6>G)NU.[G=GC!')$8
M#*<!<$_>QGD=R >_T5Y7J?QLM[/X4Z/XIMM,:?4-8<P6VGA_^6JL5?)QDJ"O
M'&3E>F<C-TSXK>-]$\6:1I?Q,\+6NFVVM2B&UN+1_N,2 -WSN#RRY'RD9SB@
M#V:BO&=:^+OBZ'XG:UX/\->&K;5[FWV"SP638-BL[RL6QMRP ^[UZ^K-!^*G
MC+Q'H?BG1V\/V</B_1T4I:[BD4BEPLF0S\%5R0=^#D?B >TT5\Y_LVW_ (P6
MW^QV6EVDOA62_F:]OW<>=%-Y"X51O!(R(_X#]X\^GT90 4444 %%%% !1110
M 4444 .C_P!:G^\*OU0C_P!:G^\*OT %%%% !1110 445PGQKUDZ'\&_$%PC
M%9)K<6J;3@DRL(S^C$_A0!W=%?(GP_\  7PC\5VFD:=?>*M9_P"$EODQ+9VT
M95%DP25#- 1P!UW$<=:]Z^&WQ$LO$ECKEG_9W]D0^&)?LC![CS,Q(& <_*NW
MB,\<].M 'H-%>4:-\>-,N_A[J'C#6]+ETNP@O#9V<8G$LEZX7=A1M7!Y]P,'
MGBL_2/VA'G\3:7IOB+P3JFA6NK2K%97D[$B4L0 =K(N5RRY*DXS0![/17D_B
M7X[6WA_Q]JGA6W\/7FJWEG&@MULG+R74S*K>6$"G "L<MDGC&*AT#X[MK_@_
MQ'J<'A&^&K:!Y?G:2DI=Y [E#A@F1MPQ;*\ 4 >O45\\? ;X@^,-:\074.J:
M1J^J:?JUW)+_ &M/<2M;6 56;RTW*5ZX& PZCCBO3?C3K/\ 8?P<\0W*L5DF
MMOLJ8."3*PCX_!B?PH [JBOAQM(\"IX#L+CP[KFM7GCJ;R\6%M"WEHY;Y@#Y
M8/"YP59LGV/'T7<_$6;X6_##PU;^,([G5?$]W;K&EC&V9I7XX9N>1E5)Y)/3
M/- 'K%%>,Z7\?KR^\6:-X;O_  )J6E:KJ-TL4L-Y,8_)B8C]X-T89^-QQA?N
M]:X6[^+WC2]^-[7>F^&-?G@TN!X9/#D$\P#CYE$TJ+&0/]8IY4X^7GH: /J"
MBO+?%_QLB\/:\OA[0O#E_P"(]>2(27-E8DD6^0#M+*K$D9'1<=/I6Q\,?BA:
M_$FSU#9IEQI6H:9(L=Y:3MN\LMNQAL#/*,"" 01TH [JBBB@ HHHH **** "
MBBB@#PK]HTMK>K>"/"$6YCJ>I;Y%'896,'\I'_*LOXF:18?#GXX>!==\-6,.
ME6U],+>YBLHA%&X$BJ_RJ,9*2_C@5]$T4 ?-OB7Q(? '[4FHZ_XFT:^O[>YL
MEBTK[)&'8DQQKE-Q&>DBG!SEC^.A\'[G4O&/Q^\5^*=<L6L9[6U6W%J_)MBQ
M4*I_V@L;9]R>E?05% 'S;\"/$[6OQ"\5:1?:5J">(M:O99Y)&C'EVP02/^\)
M.0=S8Z')(KSSPK?Z;X6.H:5XP?Q[8ZY-<GS;'1[I88KD8X\Q3ABV=W(R"#Q7
MVK10!ROPUT33=#\ Z='I&B/H<=Q&+B2SE8M*KL,_O&8 EL8SGIC'05Y;XJLX
M/&W[6FDZ->V\5YI^CZ=ONK>:,.A)1GY4\')DB%>^44 ?/OA2TB\"?M9ZEH&E
MQ_9-*UFS,D-K$,1@^6)<A>@PR2 >@.*Y_P &^,[GX>_%#QO::GX9U+5/$VK7
MI-E';IG?^\<X)/(1MRG< W 'I7U%10!\Y?!C^U+KX<_$CQBD#3ZMJCW!C$0R
M7E6-Y/D'?YI>W7&.U,^"GC>ST?X+^(M/M+*\BOM(M+J_N;IXP(6E(Q&BG.=V
M O! Z5](44 ?* \*:N?V0K5]'M9I7O-7.H7D4:$LT W1@X')&4C;Z<]*NZW\
M09?B?\/=+^'7@#PS?+.RV\%X\L:K# L6T\,I.%W*"6;' Z9-?45% &7X9T5/
M#GA72]%C?S%T^TBM]Y_C*J 6_$C-:E%% !1110 5Y9^T;JYTOX,W\2MM?4+B
M&U4_\"WD?BL9%>IT4 ?-GPQ^(/PMQX7\/Q>"I)M?)M[<W[:5;,?M' ,OF;]^
M V6W8R .E-^)#7_QU\27UCX3BC;1O"EM.YORF?M5P5_U:'T)0 8]"QS\HKZ5
MHH ^3=8O[CQ'^R3I$6AV8"Z1J8AU1+=.@57(D8#L=\9)_O&I/B-X_D^)/A_P
MOX9\,Z!>Z5H<]Y#;QS7**OFR !%CC )!50W7_=X'?ZNHH ^;OB!JL?P\_:.T
M[Q-XATB[N="MM/2"R>WC#!,1LN%W$*2&+<9&,@^E2_&37=1^(GPBTS6K+0-4
MM=*BU<M- ZXF:%4(64@ A026&>0#CGFOHRB@#YG\ 2^#O''C+2+&VL?&WB6*
MV<N9O$5Z)+6QV(6!VID'D  ' .?PKI?!\*>*/VJ_%NLS()H-$MQ:0%ESY4H"
MQ\>_RR_G7N=% 'S3\2/%%M8?M,P:SJ>EWFJ:5X6M(EN4M8@_DLR,ZN0<#AI5
M.21RHYXK3\*G5OBS\9)/B#::9/I^DZ3I[V^F-=C:9Y"KA>1P<-(S'!('RC)K
MZ#HH ^3/AI\1;KX?^!_$7A^S\,ZC-XJ$TUS-*T8$<"+&,O*2=R[-K'&,'/49
MK;\,Z9?:3^QQK=UI]K++<ZM)),P126\HRI$QQUP$1C]"3TKZ8HH ^;K#QS8M
M^R3JEII5G>6WV"TCTZ26= $GEF?$OED$Y #,><=:R?'_ (8U/2?@C\-GCTZ:
M[TRQ#7>I0(A.&EVR#< .!\TBY/3..]?4]% 'S1XL\3W/[0M[HGAGP=HE_::/
M;W(N+Z^NXU418!7@J2O"LV!G))' Q70^#+.'Q)^U/XIU5XQ);:!;+:6V1GRI
M %CX)_W9?SKW:B@#PWX-J=>^-?Q$\4,F$2X^PPN?XEWG_P!EA0GZBO<J** "
MBBB@ HHHH **** "BBB@!LDB0Q-)*ZI&BEF=C@*!U)/85@0?$#P;<SI#;>+=
M"FE<X6./4H69C[ -S6-\:=8_L3X.>(KA3AYK;[*N.I,K",_HQ/X5\Q72?# ?
M!^RMM.AN+_QW.%#-#]H&QVDS@AOW9PIV@*"20/K0!]K@Y&1R**\\\"^(-)\'
M> -$T/QGXFTNQUFULT%Q;7NH11RQ9&Y596;/"D#\*CE^)%_%\>[+P28;-M*O
MM/\ M,%PH8RNVQF^]NV[<(W\.?>@#T>BO)1\8[@?$7Q9:R0V@\*>%[0O=7BH
MQG><87RU.[;DON4#'\/6N6E^-_Q(3PW/XP'@>R3PJ01!/),1(I)VHS?/EEW$
M#A #V/>@#VCQAXKT_P $^%;O7]8$S6EKMW) H:1RS!0%!(!.6'?UJWH.LP>(
M?#MAK-I%-#;W]NEQ$DZA7".,C(!(S@]B:\ ^+/BK5_%/P$\)#48;>'5?$E\C
MF&V#+&4&_9@$D\[HCR3WKT >-=0TCXS:#\-M%M;232X=,5[N>1&\V/;&^T+A
ML 86/J#]Z@#T^BO-8OB5?W'QVU#P=%%9+HVE:>;J\NG5O,1MBL?FW;0H\Q<Y
M7L>:XS4?CEXVU:TU+7? ?A.TE\,::S>9J&I/M,BJ,DJ/,3G'\(W'IWXH ]]H
MKF/AUXP/COP'I_B%[,V3W0</#NW ,CE20>X)7(KIZ "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#.HHHH **** "BBB@ HHHH **** "O)OVC-%U37?A
MU8VVB:==ZC.FJQR-%:0-*X7RI1NPH)QD@9]Z]9HH \9^.6@:QJWP;T*QTK2[
MR^N[>[MVE@MH&D= ()%)*J"< D#\:ZGXH>$+_P 8?">?2-, ^WJD4L43D+O9
M,$ID]"1D<]\5WM% 'R;9>%;AK&+2S\#[R75T01M?SWUXEN[C@N1E5Y//#@>E
M=C\5]#\0K\1+:2X\*ZIXI\)I:)#;:;8W,L<:.!@[O+!((/<CD$<\5] T4 >"
M? SPGJ^C^,?%']J>'+K0;2[MD$$3J[1HK$D(LC9WD C/)(/7!IWP-'B_P9J4
MW@O5O"%Y'9S7LMS+J[!EBCQ$  #MVN"8U (;^+I7O-% 'B/P,\/:SHWPM\2V
M6K:5>V-U-/+Y4-S T;2?N5 *@CD9XR*3X;>']9L?V;O$VF7VDWUMJ$\-^(K2
M:W=)9"T&%PA&3D\#CFO;Z* /F:Y^&7B36/@#X<2#2)SJ6DWEQ-+IERABDDB>
M0YX.#G@''!()QSBI/"'AN*_\7:0MM\%[K1?(NXY+B_O;Z[*1*K EE5RH)&.!
MEOH:^E:* /'_  GH6K6O[3WBO5;G3+N+3KC3]D-X\#"&1LV_"OC!/RMP#V/I
M3?!?A[5(OC[XXO;W3;RWT^\MRD-W) RQRY*?=8C#< ]/2O8J* /!O@:/%_@S
M4IO!>K>$+R.SFO9;F75V#+%'B(  ';M<$QJ 0W\72O>:** "BBB@ HHHH **
M** "BBB@!T?^M3_>%7ZH1_ZU/]X5?H **** "BBB@ KPC]JS5OLW@G1M)#%?
MMM^96QU*Q(01^<BG\!7N]% 'B'PU^(7PNU[QAIVD>$O!4ECJGEOY5\VE6T9C
M"QDEFD1RPR 1GN6]Z\SU:77=-^*/CWP)X7MF>Z\67ZQ[AP(HF9I&/^[MD()[
M+FOKNB@#YH^-G@S_ (1+PQX#L+>VOYO#FC&1;^:PPL@=BA:3)!"LV'()X!R*
MTOA:?"GC3QY:W=II_B_7CIT;SQZKXGO/-2V<$ ! N5+$\C)XVYZCCZ%HH \'
M^!P@U7QE\0/'EVN]9+UXK:8KDK$&9V _X"(ORKG_ (:Q:C-\"OB1XGM;61[_
M %N2=52($L5V'<P]<>=)_P!\FOIBB@#QO]FOQ'8ZA\.TT*QL;V*72<FZN9D
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MF("G'\("NS#OQ0!Z[!XO\-7.I?V=;>(=*FOLX^RQWL;2Y]-@;-6QK6EG63I
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MB-1)G[YQ]P]3S6QJ'QV^($VBS>*]$\'6,/A2*3:MQ?R_O91NVY&)%SSQ\JL
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M8&-NC)@["^-N?W"<?[0K)UE?'/A3]HW7/$>E^#+SQ FHVHMK*1,K"@*188N
M0N/+((8KG).:^B** /G?P#X%\8:E;_%"\\1V<MMKFL0265O+-&T:3.PDW^66
MZQYV ,.,?2N)\-^%=1TRUATN\^!]WJFN1,RG4KNYN$MY#G(++_JC@$#(8 XK
MZ^HH K:;:K8Z7:VL<$%NL,2H(;=-D:8'15[ =A5FBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH SJ*** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!T?^M3_>
M%7ZH1_ZU/]X5?H *P['QGH.I>+;[PS8W_FZOI\?FW-N(7'EK\O\ &5VG[Z\
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M#.'_ .*H Z*BN=_X6%X,_P"ANT'_ ,&</_Q5'_"PO!G_ $-V@_\ @SA_^*H
MZ*BN=_X6%X,_Z&[0?_!G#_\ %4?\+"\&?]#=H/\ X,X?_BJ .BHKG?\ A87@
MS_H;M!_\&</_ ,51_P +"\&?]#=H/_@SA_\ BJ .BHKG?^%A>#/^ANT'_P &
M</\ \51_PL+P9_T-V@_^#.'_ .*H Z*BN=_X6%X,_P"ANT'_ ,&</_Q5'_"P
MO!G_ $-V@_\ @SA_^*H Z*BN=_X6%X,_Z&[0?_!G#_\ %4?\+"\&?]#=H/\
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M#.'_ .*H Z*BN=_X6%X,_P"ANT'_ ,&</_Q5'_"PO!G_ $-V@_\ @SA_^*H
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M.QBL(+U3<V-G*@2UC#)ND?+G>S#=@*6QM[9Y]F_X6-X(_P"AQ\/_ /@TA_\
MBJ/^%C>"/^AQ\/\ _@TA_P#BJ ./A\&:]>_M+S^+=2L!'HMCIWD6%R9D8R.4
M .$!++S)+U Z>]9MGH>J>&?C!XW^)/BVV6UTJ&Q*6,KSH1*JA ,!22I(C P0
M"2_<UZ%_PL;P1_T./A__ ,&D/_Q597B'Q#\,O%>G)8:_XF\/WEHDR3^0=8C5
M69>5W!9!N'^RV0>,CB@ ^$GBOQ%XU\$_VYXITZVL'N)V^R);HZ"2  8<AF)Y
M.[![@ XKB_VA8_.USX?12Y^SR:T%D'\/+1CG\,_K7I"?$/P-'&J1^+_#R(H
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MT./A_P#\&D/_ ,51_P +&\$?]#CX?_\ !I#_ /%4 =)17-_\+&\$?]#CX?\
M_!I#_P#%4?\ "QO!'_0X^'__  :0_P#Q5 '245S?_"QO!'_0X^'_ /P:0_\
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MT./A_P#\&D/_ ,51_P +&\$?]#CX?_\ !I#_ /%4 =)17-_\+&\$?]#CX?\
M_!I#_P#%4?\ "QO!'_0X^'__  :0_P#Q5 '245S?_"QO!'_0X^'_ /P:0_\
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MT./A_P#\&D/_ ,51_P +&\$?]#CX?_\ !I#_ /%4 =)17-_\+&\$?]#CX?\
M_!I#_P#%4?\ "QO!'_0X^'__  :0_P#Q5 '245S?_"QO!'_0X^'_ /P:0_\
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M:Z"B@#G_ /A ?!W_ $*>A_\ @MA_^)H_X0'P=_T*>A_^"V'_ .)KH** .?\
M^$!\'?\ 0IZ'_P""V'_XFC_A ?!W_0IZ'_X+8?\ XFN@HH Y_P#X0'P=_P!"
MGH?_ (+8?_B:/^$!\'?]"GH?_@MA_P#B:Z"B@#G_ /A ?!W_ $*>A_\ @MA_
M^)H_X0'P=_T*>A_^"V'_ .)KH** .?\ ^$!\'?\ 0IZ'_P""V'_XFC_A ?!W
M_0IZ'_X+8?\ XFN@HH Y_P#X0'P=_P!"GH?_ (+8?_B:/^$!\'?]"GH?_@MA
M_P#B:Z"B@#G_ /A ?!W_ $*>A_\ @MA_^)H_X0'P=_T*>A_^"V'_ .)KH**
M,&/P!X.,BY\)Z'U'_,-A_P#B:N_\*]\&?]"CH/\ X+(?_B:TX_\ 6I_O"K]
M'._\*]\&?]"CH/\ X+(?_B:/^%>^#/\ H4=!_P#!9#_\37144 <[_P *]\&?
M]"CH/_@LA_\ B:/^%>^#/^A1T'_P60__ !-=%10!SO\ PKWP9_T*.@_^"R'_
M .)H_P"%>^#/^A1T'_P60_\ Q-=%10!SO_"O?!G_ $*.@_\ @LA_^)H_X5[X
M,_Z%'0?_  60_P#Q-=%10!SO_"O?!G_0HZ#_ ."R'_XFC_A7O@S_ *%'0?\
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M_P 37144 <[_ ,*]\&?]"CH/_@LA_P#B:/\ A7O@S_H4=!_\%D/_ ,37144
M<[_PKWP9_P!"CH/_ (+(?_B:/^%>^#/^A1T'_P %D/\ \37144 <[_PKWP9_
MT*.@_P#@LA_^)H_X5[X,_P"A1T'_ ,%D/_Q-=%10!SO_  KWP9_T*.@_^"R'
M_P")H_X5[X,_Z%'0?_!9#_\ $UT5% '._P#"O?!G_0HZ#_X+(?\ XFC_ (5[
MX,_Z%'0?_!9#_P#$UT5% '._\*]\&?\ 0HZ#_P""R'_XFC_A7O@S_H4=!_\
M!9#_ /$UT5% '._\*]\&?]"CH/\ X+(?_B:/^%>^#/\ H4=!_P#!9#_\3714
M4 <[_P *]\&?]"CH/_@LA_\ B:/^%>^#/^A1T'_P60__ !-=%10!SO\ PKWP
M9_T*.@_^"R'_ .)H_P"%>^#/^A1T'_P60_\ Q-=%10!SO_"O?!G_ $*.@_\
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M6FN:-?3:;_:=K K(SKP)1&WRD@YXZ'CUK0\>>.+C2[B'PQX2@&H>*]20_9X
M?DM$Z&XF/\*KU /4\5I^ O!MMX&\+1Z7#,UU<22-<7EVX^:YG?[[G\@![ 4
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M;0^[)).<?+@[3S0!U]%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M] !1110 4444 %%%5[K4+.Q:!;V[@MFN91# )I0AED/1%R>6.#P.: +%%%%
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MHV\MKX5T>3S-%M9EP]]-_P _3J>BCC8.O?UR >K4444 %%%% !1110 4444
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MM9I=GS;?S;M8)-T9!W1DGJ,C\Z .$\9:-KO@#P]9^)XO&VMW^IPW<"74-U<
MVMR'<*RK#C"#GC'(&?K7H7B3P>GB2ZAF?7M>TSR4*"/2]0:W5N<Y8#J:\I_X
M1C3?%?CO1-)T+Q+K?B:RTFY6]U*_O-0^T6\(3E(5V@(SN<9/) '7K7<?$[Q#
M?%;3P9X7DQK^O93S%/\ QYVW_+28XZ<9 Z<YQR* .<\ :?=ZA\3;_4M*\3>(
M+SPMHH:UW:CJ<D\=[<X(<@'@H@/7U (/I!X&LK7Q]IKZOJ/CW7K>^U&\N)8M
M/L]<,/E1>:P11$#E> .W0BO1[2V\.?#KP7:6$\]OI^E6RK;^;<$*KLW4N>F6
M)))/'->7?%*R^'USX872_!6G:+/XGO)XETU-$2)9E?>"7+1=%"AN6X_F #N?
MB/I,5I\#]<T][FXN4M].;$UY*999"GS LQY)R!S74^&[J2^\*Z3=S',D]E#(
MY]2R G^=<-\8;BZA^%<&@))YNJZW-;:9$0<EW9E+GZ$*?SKT2QM$L-/M[.'_
M %=O$L2\8X4 #^5 $]%%% !1110 4444 %%%% !1110 Z/\ UJ?[PJ_5"/\
MUJ?[PJ_0 4444 %%%% !7FU\Y\0?M$Z=8R*6M/#>D/>@'I]IF;RQD>R9(]\U
MZ37F.@#R/VEO%B2_*USH]I-$/[R+A2?SXH AE.J_$?XF^(-'37]2T70?#@AA
M*Z5/Y$UU<2*6):09(5<$8&,\>]6?A[J>L:3\0/$?@77-4N-7BT^*&\TZ\NSN
MG:!Q\RNW\1!(&>IY]@,[POJ]AX/^-7CG3O$=W#IQU:2WO[":ZD$:7"!"'"L>
M,J3C&<G!]*E\&7]KX@^,GC#QAI\JR:':6,.GQWJG,<[K\\A4]PN,9'!R".M
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M20RQLS)',RI'\J@GG:#TZ$'I6KXQ\-^,-<\=:+XA\-2:#=Z9IMJ7M;;4YIE
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M)%'D7<?R%=N<X=3NR >1SCBNBO\ PMX?U6_6^U30M-O;M,;;BXLXY)%QTPS
MFM6B@"K?Z98:I8M9:G96]Y:/C=;W$2R1M@Y&5((X(!JRJA5"J  !@ #I2T4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M *&?Q=_X.I/\*/\ A2^E?]#/XN_\'4G^%>C44 ><_P#"E]*_Z&?Q=_X.I/\
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M4 =C15>PFN+G3;:>]M39W,L*/-;&0.87(!9-R\-@Y&1P<58H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHKDM>\2>+=.UB6VT7P'/K%FH4I>
M)JMO ')&2-CG<,'CGTH ZVBN.UCQ1XQL=5EM]*^'T^IVJA2ETNKVT0<E02-K
M'(P25YZXSWKL: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** ,ZBBB@ HHHH **** "BBB@ HHHH ***BN;A+2TFN)LB.%&D?'H!DT
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M([T*0LWE'Y7=#N&&XW+G ]>*ZK3;U-2TJTOHQA+F%)E'LR@C^=<-\5->LO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH SJ*** "BBB@ HHHH **** "BBB@ JCK=L
M][X?U&UBW>9/:RQKM.#DH0,'UYJ]10!YO\/K$^)/V>-/TRTNS:->:7)9_: F
M\Q$EHV.,C)!SW%;>I>!A=_"G_A"K+4#:*+&.R%X8=YPH4,VS</O 'OWKIK*Q
MM-.MA;:?:PVD 9F$4$8106)).!QDDDGW-3T 06-I'I^G6UG ,16\2Q(/]E0
M/Y5/110 5S_B70]:U62VG\/^)I]#G@#*0+9+B*4''WD;&2,<$$8R:Z"B@#B]
M$^'TEOXDB\1>*M=N/$6KVZ-':R2PI!#:ANICB7@,1QDDG'YU03X;:UHVKZE<
M>"_&4NBV>IW3W=Q9S:='=*LSXW,C,1MZ=.>WI7H=% '.^$/!UMX3M[MEN[C4
M-0U";S[Z_NB#).^,#IP% X"CI3?$'A'_ (2#Q5X<U:6^,4&AS2SFU$6[SW9
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** /-+GXC:E;W<T*_#OQ;*(W9!(EFA5\'&0=_0U%_PLS5/^B;^+_\
MP"3_ .+KU"B@#R__ (69JG_1-_%__@$G_P 71_PLS5/^B;^+_P#P"3_XNO4*
M* /+_P#A9FJ?]$W\7_\ @$G_ ,71_P +,U3_ *)OXO\ _ )/_BZ]0HH \O\
M^%F:I_T3?Q?_ . 2?_%T?\+,U3_HF_B__P  D_\ BZ]0HH \O_X69JG_ $3?
MQ?\ ^ 2?_%T?\+,U3_HF_B__ , D_P#BZ]0HH \O_P"%F:I_T3?Q?_X!)_\
M%T?\+,U3_HF_B_\ \ D_^+KU"B@#R_\ X69JG_1-_%__ (!)_P#%T?\ "S-4
M_P"B;^+_ /P"3_XNO4** /+_ /A9FJ?]$W\7_P#@$G_Q='_"S-4_Z)OXO_\
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MB;^+_P#P"3_XNO4** /+_P#A9FJ?]$W\7_\ @$G_ ,71_P +,U3_ *)OXO\
M_ )/_BZ]0HH \O\ ^%F:I_T3?Q?_ . 2?_%T?\+,U3_HF_B__P  D_\ BZ]0
MHH \O_X69JG_ $3?Q?\ ^ 2?_%T?\+,U3_HF_B__ , D_P#BZ]0HH \P7XFZ
MFK@_\*W\7\'/_'DG_P 75G_A:VH_]$U\8_\ @$G_ ,77HU% 'G/_  M;4?\
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M4?\ HFOC'_P"3_XNC_A:VH_]$U\8_P#@$G_Q=>C44 ><_P#"UM1_Z)KXQ_\
M )/_ (NC_A:VH_\ 1-?&/_@$G_Q=>C44 ><_\+6U'_HFOC'_ , D_P#BZ/\
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M 2?_ !=>C44 ><_\+6U'_HFOC'_P"3_XNC_A:VH_]$U\8_\ @$G_ ,77HU%
M'G/_  M;4?\ HFOC'_P"3_XNC_A:VH_]$U\8_P#@$G_Q=>C44 ><_P#"UM1_
MZ)KXQ_\  )/_ (NC_A:VH_\ 1-?&/_@$G_Q=>C44 ><_\+6U'_HFOC'_ , D
M_P#BZ/\ A:VH_P#1-?&/_@$G_P 77HU% 'G/_"UM1_Z)KXQ_\ D_^+H_X6MJ
M/_1-?&/_ (!)_P#%UZ-10!YS_P +6U'_ *)KXQ_\ D_^+H_X6MJ/_1-?&/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
,@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>vrna-20221231_g8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vrna-20221231_g8.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#^17AI9@  34T *@    @ ! $[  (
M   1   (2H=I  0    !   (7)R=  $    B   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %9I8W1O<FEA
M(%-T97=A<G0    %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,W
M-@  DI(  @    ,W-@  ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(K;H **** "BBB@ HHHH ***HV6MZ5J5U);:=J=G=SQ+NDB@N$=D'3) .0*
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M8_A5[P9\;?"7CKQ/)H6BM>I=!6>)KF (DX7KL(8GISA@.* /0Z*** "BBB@
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M*/"G_"L]/U76-'LM6OM4C,TDE[ LHC4D[50,"%P .1R3GGI0!W'@CXK>$_B
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M?*OP?^)&B?#_ ,<:MK>M6E]/%>6[PQ"TC1G7=(K\AG48POJ:^@_@OIUCXD^
M/AV#Q#8VNJ0J)L17D"RH-D\JK\K CA1@5XK^S-H6D:]XTU:#7=+LM2ACT_>D
M=Y;I,JMYBC(# X.#UH ]G\;^)_!?C#X(PZWXK@U&'0M1D7RO)0?:(G#,%;@D
M _*>N1S@U/\  JS\'0^";FX\!P:@+66[9)I]2V^=,ZJ.3MXV@-@# [\=S2_:
M!TZRL/@-?6MA:0VMO;S6_DPP1A$C_>J,!1P.IKF_@EK,OAW]FK7M8MU#36,M
MW/&#T+K$I7/MG% 'HWC;XO\ A#P%<?9=:OVEOMNXV5FGF2J.HW<@+G_:(K#\
M._M%^ O$.H)9O<7FDRR-M0ZC"J(Q_P!Y68#\2*\@_9Y\&:;\0/%FNZYXN3^U
M6L?+<Q7/SK-+,7)=P?O8V'@\9;VKI?VC?AAX>TGPG!XF\/:=;:7/!.D$\-K&
M(XY4;.#M' 8''(QD$YZ"@#W/Q;XLTWP7X;FUS6C-]BA95<P1[VRQP./J0/QK
MB4_:'\ GPY_:\E[<1!IFA2S:(&X<J =VQ6.%YX+$5P>CZI=>)_V-=7CU&0S2
M:>K0+(_)*Q2)(GY# 'T%4/V9_!'AOQ%I.L:EK^CVNI7%O<)#%]K3S$12N3\A
M^4G/<B@#TKPK^T+X(\5ZS#ID3WVFW-PXCA_M"%461CT4,K, 3T&<5ZE7Q_\
MM&>$=*\'^.]-N?#=I%IT-[:^:T-N-BI*CD;E X7C;P.X-?7T6\PIYVT2;1OV
M],]\4 0:EJ5GH^FSZAJES':VENA>6:5L*BCN:\CO/VHO =M=-%!;ZS>(#Q/!
M:H$;Z!Y%;]*WOCQX;U?Q1\*;RRT"-Y[F.:.=K>/[TZ*>5 [GD-COM]:\(^&7
MCWX>Z#HZ>'OB#X(M7N8I'634Y+))Y#EB<2*PWKM^[\N>@X% 'T5'XR\,^,_A
M5J6ORQ74GA^2UG6Z22$JYC4$28 /IGD'M7 _ 6Q^&QU_6+GP%'K$]Y!"JR7.
MJ;,)&['Y(PN.Z9R1GISU%=U-:^&A\$M6A\'K;G0IM+O&@%NQ*$.CEL9.1\Q;
MCMTXQBO'?V2?^0IXH_ZXVW_H4E 'KOC7XS>#? EZUCJU])<7Z@%[2SC\R1,C
M(W'(53[$@\URJ_M0>";C3[QX(=2M[J*!WMXKRW4+,X4E4RC-C)P,G%>.^!K[
M3=!_:(O)_B8BQR+=7&^6[7*17!8E7;/\/7!Z<J>G-=5^TOXD\':]9:0F@7VG
MZEK"3$R7%BZRXAVXVLZ\'YMN!DXP>G< [CX9^*?B0UMJ_BCXF1O#X=33VO+:
M-((590,.2J+^\P$S][]36MIO[0_@#4+#4+M[ZXLHK$QC%U$ ]P7W8$:*2S8V
M\\ #(SUK5\$Z1?V_P(T_2M;#"Z.D-'(DO5%9&VJ1[*0,>U?._P"SCX3T3Q7X
MZOX_$6GQ:A%:67G1139*;]ZKDKT;@G@Y% 'LNF_M-> =0U-;27^T[!&;:+FZ
MME$7U)5V('N17:?$6?PXWPUU27Q9YD^A21)Y[6P+L59U",N/1BIS[9KQ#]IG
MP'X?T#1]'UG0-*M-,DDN6MIDM(A$D@*;E.U1C(VGD>O>NUU#?<?L?+]KP[#0
M(B.3T4+M_0"@"O\ !J?X>>'_  AXF\0>#(=8EAT^(R7USJ(0S.B(TFU N!@#
M/89..37BGQ*^(^C^.?BQIOB&.TNVTBT6WCDMKJ-/,:-)"SKM#%3G<>]>J_LK
MVT%YX(\26MY#'/;S7:QRQ2H&213'@JP/!!!P0:XCXK:%I&G?M':/IFGZ596M
MA)+8A[2"W1(F#2 -E ,'(Z\<T >[>#OBOX9^(VB:^;#3K^*PTJU4W<=U"@,D
M;K)E55&;/RQGTZBN&^"%C\+I/'E]-X%BUJ?4(+9I%EU+9Y<$98*1'C!R=V,L
M"<9YYY]A3PUH>B:+J,6BZ-8:;'<0,)EL[9(1)A2!NV@9ZG\Z^;_V4/\ D?-:
M_P"P;_[52@#Z.\6>-O#_ ('TU;WQ+J,=G&Y(B3!:24CLJ#D]N>@SS7G5I^T[
MX'O-4BLH[/6@99!&DK6L>TDG X$A;OZ5Y%?AOBY^T]_9.N2R+8+?36J1!L;8
M+<.VT8Z%O+.3V+&OI5/A=X&BC@6+PGI,9MV5XY$M560%3D'>!N/([F@!?'7Q
M&\/_  [L[:X\1S3)]K9E@C@A+LY4 GV'4=2.M<!%^U-X%DN!&UCKD:$X\U[:
M+:/?B0G]*[OQ_:>!EL;;5_B)#8/;V.]8'OE+@%]NX*G.XG8.,$\<5X#\1_'G
MP;UGPM?:=X;\+^5J3)_HE[9Z;%;*C@@@D@JQ4\C&T_3I0!](V/C#1=5\'R>)
MM*N_MFEQP/.9(5);" EAM/(88/!YKBM-_:'\ :C;:A</?7%E%8JA)NH@K3EB
MP"QH"68_+SQQD>^.._9<5[WX>>)+!WS"UWA4;H"\0!/XX'Y5YG^SMX6T;Q9\
M2;FU\16$=_;VNG27,<,N=GF"2-02/XAAVX/% 'MMC^TYX!O-26UE&JV<;-M^
MU7%LOECW.URP'_ :[3QS\1]%\ ^%[77]32YO+&[G2&$V"I(6+HSJWS,HVX0\
MY[BO&?VE_ /AW0O"VEZYH.D6>F3F^%I*MG$(ED5HW8950!D>7UZ\UZ/\/]*L
MM>_9_P! A\0Z?9ZBD5AYD<=U"LJH5#*C ,#A@IQGW- 'SM\$/B1HGPUUS4[[
M7K2^N!=6RPQ?8XT9EPV3G<Z\<"O=/B]KEKXM_9DO]>M(98H+N.VGA2; =0;F
M,<X)&<9[UY9^S'H&CZ_XBUV/7=)L=3CBM8VC2\MDF"$N<D!@<&O9/CQ:6UA^
MS[KEI8V\5M;0K:I%#"@1$47,6 %' 'L* .0_9TUF+P]\"O$&L7-O<7,-CJ<\
M\D5LH:0JL$); ) .!D]>U=]\/?C+X<^).K76G:';:C;W%M!Y["]CC7<NX*<;
M7;H2/SKD/V6(TF^$^J1RJ'1]8F5E89!!@AR*\W\)V;_";]J*/2')2QN+DVD;
M-_'!./W7/LQ3)]5- 'O/Q"^,7A[X:ZC:66NVNHW$UW$9D^Q1QOM4''.YUQS_
M "KM[&Z%]I]O=K')$L\2RB.4 ,@89P0"1D9YYKYD\56/_"T?VL(M)V>;I^E&
M.&X)Y'E0_/(#]9&9/Q%?45 $%]?6NFV,U[J%Q';6L"%Y9I6"JBCJ23TKR6\_
M:=\ 6NI&VB&JW<8;'VJ"U7R_K\S*V/\ @-<_^U9XDNK/0=%\/VS,D&H223W)
M!QO$>T*ON,L3]56NA^$'PC\*6OPVTJ_UC1+'5;_5+5+N6:]@6;:) &55# A0
M%(Z<YS0!X[HFJZ?KO[6-KJFC2K-97>J^;%(JE=P*=<'!!SGK7U?XA\1Z3X5T
M6;5M?O8[*RA^](^3D]E '+$^@YKY8L]'LM _:^@TW2X$M[2'4U,448PJ!HMV
M /3YJE_:7\13:A\4K;0[R69-+TR&(F.+!):3YG< G!;:0!GT]S0!ZA_PU#X"
M^W>1Y&L>7NQ]I^RIY>/7&_=C_@->J:#X@TOQ/HL&JZ%>1WEE.,I+&>_<$=01
MW!Y%?,M]X_\ @E>>$Y-"T_P+J*3- 8H+E;&#[0'QA6,HE+DYY[Y]*W_V49=1
M@7Q)IUTDT=J#!/&DB%0'.]6(SZ@+G_=% '*_"1%B_:HO$085;O4 H] /,KWS
MQW\8/"OP\U&+3]>DNGO)81.L%M!O.PDJ#DD+U4\9SQ7@OPG_ .3K+[_K\U'_
M -J5[G\0C\,M#O$USX@VNF2WDD8BB^UP?:))%4G 6/!X!;KC'/)H YRP_:A\
M!7EVD,\&L6*,>9KBU0HOUV.S?I7?^)_'>E>%_!)\5R1W&I:7B-Q)IX20E'("
MN-S*"N2._>OEWXM>,?AAXDT6*#P/X<?3=3BN WVF&RCMHGCP0RD*V2<[2,K^
M/6O:_@GI\7B;]G.TTC52TMM<QW5JV>H0RN./IGCTXH ZKX=_%#0_B9:WTV@P
MWL'V%T26.\1%;Y@2"-K-Q\I_*LSQ7\;/#OA'QM'X6OK'5+K4)/*"FTBB9,R?
M=&6D!SR.W>O&?@!/=>"/C?JOA#5#M>Y26U88P&EA)96'L5#X_P!X59\ V/\
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M@Z-I^F>?M\W[%:I#YFW.-VT#.,G&?4U;O+&TU&V-OJ%K#=0,<F*>,.I_ \4
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M)6.:SDFC60 F-U!RK=LAE(_"O/\ PAI_Q2\3^"]-\10_$N))+V 3K9S:#;[
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHKD_%?Q/\'^"-1AL/%&L+8W4T7G)%]GEE)3)&[Y%..01SZ&@#K**\
MV_X:#^&/_0S?^2%S_P#&Z/\ AH/X8_\ 0S?^2%S_ /&Z /2:*\V_X:#^&/\
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M\D+G_P"-T >DT5YM_P -!_#'_H9O_)"Y_P#C='_#0?PQ_P"AF_\ )"Y_^-T
M>DT5YM_PT'\,?^AF_P#)"Y_^-T?\-!_#'_H9O_)"Y_\ C= 'I-%>;?\ #0?P
MQ_Z&;_R0N?\ XW1_PT'\,?\ H9O_ "0N?_C= 'I-%>;?\-!_#'_H9O\ R0N?
M_C='_#0?PQ_Z&;_R0N?_ (W0!Z317FW_  T'\,?^AF_\D+G_ .-T?\-!_#'_
M *&;_P D+G_XW0!Z317FW_#0?PQ_Z&;_ ,D+G_XW1_PT'\,?^AF_\D+G_P"-
MT >DT5YM_P -!_#'_H9O_)"Y_P#C='_#0?PQ_P"AF_\ )"Y_^-T >DT5YM_P
MT'\,?^AF_P#)"Y_^-T?\-!_#'_H9O_)"Y_\ C= 'I-%>;?\ #0?PQ_Z&;_R0
MN?\ XW1_PT'\,?\ H9O_ "0N?_C= 'I-%>;?\-!_#'_H9O\ R0N?_C='_#0?
MPQ_Z&;_R0N?_ (W0!Z317FW_  T'\,?^AF_\D+G_ .-T?\-!_#'_ *&;_P D
M+G_XW0!Z317FW_#0?PQ_Z&;_ ,D+G_XW1_PT'\,?^AF_\D+G_P"-T >DT5YM
M_P -!_#'_H9O_)"Y_P#C='_#0?PQ_P"AF_\ )"Y_^-T >DT5YM_PT'\,?^AF
M_P#)"Y_^-T?\-!_#'_H9O_)"Y_\ C= 'I-%>;?\ #0?PQ_Z&;_R0N?\ XW1_
MPT'\,?\ H9O_ "0N?_C= 'I-%>;?\-!_#'_H9O\ R0N?_C='_#0?PQ_Z&;_R
M0N?_ (W0!Z317FW_  T'\,?^AF_\D+G_ .-T?\-!_#'_ *&;_P D+G_XW0!Z
M317FW_#0?PQ_Z&;_ ,D+G_XW1_PT'\,?^AF_\D+G_P"-T >DT5YM_P -!_#'
M_H9O_)"Y_P#C='_#0?PQ_P"AF_\ )"Y_^-T >DT5YM_PT'\,?^AF_P#)"Y_^
M-T?\-!_#'_H9O_)"Y_\ C= 'I-%>;?\ #0?PQ_Z&;_R0N?\ XW1_PT'\,?\
MH9O_ "0N?_C= 'I-%>;?\-!_#'_H9O\ R0N?_C='_#0?PQ_Z&;_R0N?_ (W0
M!Z317FW_  T'\,?^AF_\D+G_ .-T?\-!_#'_ *&;_P D+G_XW0!Z314%C>VV
MIZ=;7]A*LUK=1+-#*O1T8 JP^H(-% $]%%% !7A/CC3;'5_VNO"-CJMG;WUI
M+HK^9;W,2R1OA;LC*L"#@@'ZBO=J\2\4?\GD^#/^P+)_Z!>4 >D_\*X\$?\
M0F^'_P#P5P?_ !-'_"N/!'_0F^'_ /P5P?\ Q-=)10!S?_"N/!'_ $)OA_\
M\%<'_P 31_PKCP1_T)OA_P#\%<'_ ,37244 <W_PKCP1_P!";X?_ /!7!_\
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MKCP1_P!";X?_ /!7!_\ $T?\*X\$?]";X?\ _!7!_P#$UTE% '-_\*X\$?\
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M?A6R\/PS-IR7CG51,VUL99=T;=N@^7\:]"\*?\)5_94G_"<?V/\ VAYQ\O\
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MBC_D\GP9_P!@63_T"\H ])_X5QX(_P"A-\/_ /@K@_\ B:/^%<>"/^A-\/\
M_@K@_P#B:Z2B@#F_^%<>"/\ H3?#_P#X*X/_ (FC_A7'@C_H3?#_ /X*X/\
MXFNDHH YO_A7'@C_ *$WP_\ ^"N#_P")H_X5QX(_Z$WP_P#^"N#_ .)KI**
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MZ$WP_P#^"N#_ .)KI** .;_X5QX(_P"A-\/_ /@K@_\ B:/^%<>"/^A-\/\
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M(_Z$WP__ ."N#_XFNDHH YO_ (5QX(_Z$WP__P""N#_XFC_A7'@C_H3?#_\
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M **** "BBB@ HHHH **** "BBB@ KF_B/_R2SQ7_ -@6\_\ 1#UTE<W\1_\
MDEGBO_L"WG_HAZ .:_9\_P"2$^'O^WG_ -*9:])KS;]GS_DA/A[_ +>?_2F6
MO2: "BBB@ HHHH *SM3;4QJ&CC35!MFO&&H$[>(/L\N#SS_K?*Z<\^F:T:S-
M5M;FXU+19;:\%O';7K2W$9<K]H0V\R!,#[V&='P>/DSU H TZ*** "BBB@ H
MHHH *\2\4?\ )Y/@S_L"R?\ H%Y7MM>)>*/^3R?!G_8%D_\ 0+R@#VVBBB@
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M:-MK@')4X!P?0X(/XB@#Q3_A*/VAO^A$\/\ _?\ 3_Y*H_X2C]H;_H1/#_\
MW_3_ .2J]D_M*Q_M'^S_ +9;_;=F_P"S>:OF;?[VW.<>]%KJ5C?23QV-Y;W+
MV[;)EAE5S$WHP!X/'0T >-_\)1^T-_T(GA__ +_I_P#)5'_"4?M#?]")X?\
M^_Z?_)5>VT4 >)?\)1^T-_T(GA__ +_I_P#)5'_"4?M#?]")X?\ ^_Z?_)5>
MVT4 >)?\)1^T-_T(GA__ +_I_P#)5'_"4?M#?]")X?\ ^_Z?_)5>VT4 >)?\
M)1^T-_T(GA__ +_I_P#)5'_"4?M#?]")X?\ ^_Z?_)5>VT4 >)?\)1^T-_T(
MGA__ +_I_P#)5'_"4?M#?]")X?\ ^_Z?_)5>VT4 >)?\)1^T-_T(GA__ +_I
M_P#)5'_"4?M#?]")X?\ ^_Z?_)5>VT4 >)?\)1^T-_T(GA__ +_I_P#)5'_"
M4?M#?]")X?\ ^_Z?_)5>VT4 >)?\)1^T-_T(GA__ +_I_P#)5'_"4?M#?]")
MX?\ ^_Z?_)5>VT4 >)?\)1^T-_T(GA__ +_I_P#)5'_"4?M#?]")X?\ ^_Z?
M_)5>VT4 >)?\)1^T-_T(GA__ +_I_P#)5'_"4?M#?]")X?\ ^_Z?_)5>VT4
M>)?\)1^T-_T(GA__ +_I_P#)5'_"4?M#?]")X?\ ^_Z?_)5>VT4 >)?\)1^T
M-_T(GA__ +_I_P#)5'_"4?M#?]")X?\ ^_Z?_)5>VT4 >)?\)1^T-_T(GA__
M +_I_P#)5'_"4?M#?]")X?\ ^_Z?_)5>VT4 >)?\)1^T-_T(GA__ +_I_P#)
M5'_"4?M#?]")X?\ ^_Z?_)5>VT4 >)?\)1^T-_T(GA__ +_I_P#)5'_"4?M#
M?]")X?\ ^_Z?_)5>VT4 >)?\)1^T-_T(GA__ +_I_P#)5'_"4?M#?]")X?\
M^_Z?_)5>VT4 >)?\)1^T-_T(GA__ +_I_P#)5'_"4?M#?]")X?\ ^_Z?_)5>
MVT4 >)?\)1^T-_T(GA__ +_I_P#)5'_"4?M#?]")X?\ ^_Z?_)5>VT4 >)?\
M)1^T-_T(GA__ +_I_P#)5'_"4?M#?]")X?\ ^_Z?_)5>VT4 >)?\)1^T-_T(
MGA__ +_I_P#)5'_"4?M#?]")X?\ ^_Z?_)5>VT4 >)?\)1^T-_T(GA__ +_I
M_P#)5'_"4?M#?]")X?\ ^_Z?_)5>VT4 >)?\)1^T-_T(GA__ +_I_P#)5'_"
M4?M#?]")X?\ ^_Z?_)5>VT4 >)?\)1^T-_T(GA__ +_I_P#)5'_"4?M#?]")
MX?\ ^_Z?_)5>VT4 >)?\)1^T-_T(GA__ +_I_P#)5'_"4?M#?]")X?\ ^_Z?
M_)5>VT4 >)?\)1^T-_T(GA__ +_I_P#)58GC%/CQXW\)WGA[5?!.CPVEYL\Q
M[:YC60;'5Q@M<D=5';I7T110!C>#=-N=&\"Z#I=\JK=66FV]O,JMD!TB56 /
M?D&BMFB@ HHHH **** "BBB@ HHHH **Y[0-^FIK'VQKIH_[4;RFFW2,598P
M,=]NXGIP/PKF)(K_ .W71TN.Y77M][]J<JX4Q%)/(P3\I&?*VXY_6@#TBBN3
M\'+ M[>'2(YX],\B'"S(Z_O_ )M^ _.<;<GU_&O/;CXWZ[MN+BUTO1OLL27$
MA,EU*&C$;, CX3&]@N0 : /;J*\H\-?$7QKXFO(X+71-$BCD!V7!OFDC9@JL
M5RF>0&'\JZ6[O_B!9VKSMI^@2*F"RQSSDXSR<;>W6@#LJ*\GE^)7BU+>[GBT
MW1)XK579GBDN6#%3C:"(\9/4<_7%:-KXM\<7GV?R;'PV//+C]Y=7"&-D4,RL
M#'D'!^E 'H]%><1^+/'3,IFT[PY;02?ZFYGNYTCE[\$IZ<C.,UJ)>?$>1 \>
MG^%V5AD,M[.01_W[H [.BN#U'6?B)IEJD\^E^&V5IHX0$O)\Y=P@/^KZ985:
M^T_$G_H&^&?_  -G_P#C= '945QOVGXD_P#0-\,_^!L__P ;H^T_$G_H&^&?
M_ V?_P"-T =E17#3:I\28;RVM_['\.O]H+#S%NYRL>T9^8^7QGH*G^T_$G_H
M&^&?_ V?_P"-T =E17&_:?B3_P! WPS_ .!L_P#\;H^T_$G_ *!OAG_P-G_^
M-T =E17!KK/Q$?6)=.&E^&_-B@2<M]LGVE69E _U?7Y#^E6OM/Q)_P"@;X9_
M\#9__C= '945QOVGXD_] WPS_P"!L_\ \;H^T_$G_H&^&?\ P-G_ /C= '94
M5PUMJ?Q)N7N%_L?P[%Y$IBS)=S@/P#N7]WR.<9]C4_VGXD_] WPS_P"!L_\
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M;8BVG?S!QP3LV=N)#]#JUG:G+J,>H:.NGQA[>2\9;XD#Y(?L\I!_[^B(<>M
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M^QNO/_0(JD\4?"#0/$_B$:XMYJFCZGN5VNM*N1"[,!@-RIP<'&1@F@#C-/\
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M\1?^BAV/_A.I_P#'J[D'(R.110!PW_"-?$7_ **'8_\ A.I_\>H_X1KXB_\
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MM)\T=,XZ"KG_  C7Q%_Z*'8_^$ZG_P >KN:* .&_X1KXB_\ 10['_P )U/\
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MO]:ZN[_X\I_^N;?RKE/A'_R2+PW_ ->*_P!: .QHHHH **** "BBB@ HHHH
M*S=4M;VXU'1I+*Y$,-M>M+=H7*^?$;>9 @ 'S?O'C;!P/DSU K2K(UJTM;G5
MO#\MS=K;RVNH/+;QD?\ 'PYM9T*#Z([O_P  H UZ*** "BBB@ HHHH ****
M"BBB@ HHHH **** //OA/_K_ !W_ -C=>?\ H$5>@UY]\)_]?X[_ .QNO/\
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M %KJ[O\ X\I_^N;?RKE/A'_R2+PW_P!>*_UH [&BBB@ HHHH **** "BBB@
MK(UHZ>-6\/\ V]9#<'4'%B4Z";[+/DM[>7YOXXK7K(UF\AM=6\/Q36*7+W>H
M/#%*W6V86L[^8.#R51D[<2'GL0#7HHHH **** "BBB@ HHHH **** "BBB@
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M,ZS1:L6:,A"0P'D\D=<5R/@OQ3:ZEXIT>VL=;EEO!?/!=6RZ^VH)/#]B:7S
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MW2OLM_+)$)=WVZ.->6VA1GJQ/:MK1M5&K:0E])";4EG1XW<'848J>1P>1UH
MT**9'-%+GRI$?'7:P.*?0 4444 %5KS3K/4$VWMM%-@8!=02OT/4?A5FB@#R
M2_\ !5]H6O*5@N-6TF652J(C331YDWMM.X"-LXRW<>AKN=,U?4X-+MXK[0M3
MDN$0"1@83D_7S.?K7144 <3>^+KE=2G6Y\_1HX"1&MU'$4E8)O\ G.XD @$#
M;Z=3TKH+7Q+I-Q9PS2:A:Q-)&KM&TZY0D9P>>U7+K2["]N(I[RRMYY83F-Y8
MPQ3Z$]*?]BM?^?:'_OV* *W_  D&C_\ 04L_^_Z_XT?\)!H__04L_P#O^O\
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M#C4O=8TS3I(4U#4;6U>X.(5GF5#(?]G)YZC\Z +E%%% !1110 4444 %%%%
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M:VKR<< MA0<#)H Z>BJNFZE;:M8)>63,T3,R_.A5@58J00>00015J@ HHHH
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MC_Y)%X;_ .O%?ZUU=W_QY3_]<V_E7*?"/_DD7AO_ *\5_K0!V-%%% !1110
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M@@'%5=0T+Q/H^O?:M+:X\16UV4CN(+IK2)3$$92CGR@0H8JPV?[65SR?0:*
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M 4444 %<'\5O^//PI_V-6F_^CJ[RN#^*W_'GX4_[&K3?_1U '>4444 %%%%
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M6$MK=-;2;;C=&2 I!#,%[-Z5J6]U;W:%[6>*=0<%HW# '\* ):*** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!4<T$-S$8KB))8SU210P/X&I** .>B\!^&('=K?1X(#(VYO)+(">O0$5Q<7A
M5M$\4/I0UBPM+":(7)$L;AV47/F;06EQN[;L=.U>JU5N]+L-096O[&VNB@PI
MFA5]OTR* &?VUI?_ $$K/_O^O^-']M:7_P!!*S_[_K_C47_"-Z'_ - ;3_\
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M-6F_^CJ .\HHHH **** "BBB@ HHHH *HZS:S7NBW5M:LZS2IM1HYC$P/J'
M)'Y5>JEJ^IQZ1I<EY*A<(54*"!DLP4<G@#+#GM0!C>"?"LOA:QN8KB2UEEN)
M?,9X(-K'_??^,^^!735BZ#XDBUZ>YCCMGA$(62-F8'S8V+!6XZ9*'@]L'O6U
M0 4444 !Z5QGPF_Y)O8_]=KC_P!'O79GI7&?";_DF]C_ -=KC_T>] '9T444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=0:9")(&92 ZD*,,,Y'N*P? 7@^:P\3ZHYN[*.TTG5Y/+L['3A;1F22S@!8
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M[7'_ */>NS/2N,^$W_)-['_KM<?^CWH [.BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@"&[_X\I_\ KFW\JY3X1_\ )(O#?_7B
MO]:ZN[_X\I_^N;?RKE/A'_R2+PW_ ->*_P!: .QHHHH **** "BBB@ HHHH
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M#!!]B#7/CX>^%QTTS_R8E_\ BJ .EK.UO7;/0+6&:^$[^?,((H[>!IGD<@G
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M<I\(_P#DD7AO_KQ7^M=7=_\ 'E/_ -<V_E7*?"/_ ))%X;_Z\5_K0!V-%%%
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M._\ L;KS_P! BKT&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7MH;=;?S%8DINRWR\8^; [\5@_"*UOE\%VL\FH^9:-)<!+7R%&P^>_._J?\
MZ] '?T444 %%%% !17-SC4=3\57MG!JTUC!:P0LJ0QH=Q;=DDL#Z"I_[!U3_
M *&:^_[\Q?\ Q- &[16%_8.J?]#-??\ ?F+_ .)H_L'5/^AFOO\ OS%_\30!
MNT5A?V#JG_0S7W_?F+_XFC^P=4_Z&:^_[\Q?_$T ;M%87]@ZI_T,U]_WYB_^
M)H_L'5/^AFOO^_,7_P 30!NT5A?V#JG_ $,U]_WYB_\ B:/[!U3_ *&:^_[\
MQ?\ Q- &[16%_8.J?]#-??\ ?F+_ .)H_L'5/^AFOO\ OS%_\30!NT5A?V#J
MG_0S7W_?F+_XFD\/2WJZEK%C?7KWHM)HQ%)(BJP#1*Q!V@#J30!O4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M 0W?_'E/_P!<V_E7*?"/_DD7AO\ Z\5_K70:Y;7MSISC3]0^PLH8LWDK)N&#
MQ@]*Y[X1_P#)(?#7_7BG]: .RHHHH **** "BBB@ HHHH *R-:M[*;5O#\EY
M=&":#4'DM$ SY\OV6=2GM\C2-_P"M>LC6I-/35O#ZW\,DEQ)J#K8LAXBF^RS
MDLW(X\L2CORPX[@ UZ*** "BBB@ HHHH **** ,?Q5+J$/A^5]*60R^9%YC0
M1B26.+S%\QXU(.YPFX@8/('!/!I>#[B]F^W!Y-1GTQ&3['/JENT%PYP?,!5E
M5MH.,%E!.6Z@ UOW=Y;:?:275_<16UO$-TDTSA$0>I8\"JVDZ]H^OPR2Z%JM
MCJ<<3;9'L[E)@AZX)4G!H NR2)#$\LK!412S,>P'4US^@>+/[;NXH)M-GL/M
M=I]NLC*ZMY\&5&X@'Y6&],J?[P]\=!+&DT+Q2J&1U*LI[@]17,:1X/NM+*.=
M9:>:TL?[/T^1K=1]GARI.X9_>,?+3)X'R]!S0!"WQ#LT\='PTUMB59O)9C<1
M^8/W7F^9Y.=_E8XW],U<\/\ B\:Y=6\4FG3V*WUF;ZP>5U;[1 "@+$ Y0CS(
MR5//SCWQ5;P+O\0?;&U!6LC?G4#;FV7S3*4*X\[.=F#C;MSCC.*L>'O"+:)=
M6TMQJ3WRZ?9FPT]6B"&" E"0Q!.]CY48+<?=Z<F@##^$_P#K_'?_ &-UY_Z!
M%7H->7_"_0]+NM?\::K<6,$E_;^++Q(KADRZ#9'P#_P(_G7J% !1110 4V26
M.&,O,ZQH.K,<"G5ROCJUM[Y?#]M>P17$$FLQ!XI4#JX\N3@@\&@#H?[2L?\
MG\M_^_J_XT?VE8_\_EO_ -_5_P :S?\ A"O"O_0M:/\ ^ $7_P 31_PA7A7_
M *%K1_\ P B_^)H TO[2L?\ G\M_^_J_XT?VE8_\_EO_ -_5_P :S?\ A"O"
MO_0M:/\ ^ $7_P 31_PA7A7_ *%K1_\ P B_^)H TO[2L?\ G\M_^_J_XT?V
ME8_\_EO_ -_5_P :S?\ A"O"O_0M:/\ ^ $7_P 31_PA7A7_ *%K1_\ P B_
M^)H TO[2L?\ G\M_^_J_XT?VE8_\_EO_ -_5_P :S?\ A"O"O_0M:/\ ^ $7
M_P 31_PA7A7_ *%K1_\ P B_^)H TO[2L?\ G\M_^_J_XT?VE8_\_EO_ -_5
M_P :S?\ A"O"O_0M:/\ ^ $7_P 31_PA7A7_ *%K1_\ P B_^)H TO[2L?\
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M>VGT:ZLIKZ.U=HO-)DSC8K#.['\)^Z?9C0!'X4"FUG>.TO[=&88-Y>K<[O\
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M2'Z'5K.U.34DU#1UTZ,-;R7C+?D@?)#]GE(//_341#CU],T :-%%% !1110
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M&X_\#)O_ (JMVB@#"_X0S1?^>-Q_X&3?_%4?\(9HO_/&X_\  R;_ .*K=HH
MPO\ A#-%_P">-Q_X&3?_ !5'_"&:+_SQN/\ P,F_^*K=HH PO^$,T7_GC<?^
M!DW_ ,55_2]%L-&29=.A,?GN'D9G9V<@  DL2>@ J]10 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 0W?_'E
M/_US;^5<I\(_^21>&_\ KQ7^M=!KEI=W>G.MEJ,E@RJQ9HXD?>,'C#@USWPC
M_P"20^&O^O%/ZT =E1110 4444 %%%% !1110 5D:TVGC5O#XOTD:X;4'%B4
MZ+-]EGR6]O+\T?4BM>LG6;R&VU70(IK%+E[K4'BBE;K:L+6=_,'!Y*HR=N)#
MSV(!K4444 %%%% !1110 4444 87BN6\DT:XMM%@AU"_7RI)-.=H_P#2(#(
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MB0L]K,LJ$C@@,I(XJW65X9T7_A'O#5EIC2F>6%"9YCUFF8EY)#[L[,WXUJT
M%%%<[XX75)_#OV/2+"ZO1>3+!=BSDB29+<@^84,CH-Q V [LC?N&<4 :*^(=
M%;16UA=7L#I:YW7PN4\@8;:<R9V_>XZ]>*8_B;08M$369-;TY-+D.$OFNXQ
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M,IE?R@=RQKY0"\#=EFQM"E@#T6HKJZM[&TENKV>.WMX4+RS2N$2-0,EBQX
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M 5(4Y/RA:ZJ@ HHK)\3KHI\/W#>*$BDTR,JTT<RETD.X;5*#_6$M@!,'<2
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MX<TS2]"^)%WI_ABVMK/37T>">>WLP%C$AE=8WVCC<R!OFZL%&<X% '<T444
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M<D8&[&\.^/KC4#X:LF@MUDU73+>],VIZ@L4L_F!BRPJD(69T"Y8 1X#*<8/
M!O1>!]#BTR[TWR[V6QNX?(DMI]2N98UC_NHK2$1CM\F...E=#7 _#+Q5<:]I
MYLDWWRV$DZ7U_-<$E)C,Q2$ @EB(R"3D!05 R<A>^H \[^%D4<Y\?0SQK)%)
MXLO5='7*L#'$""#U%;EI\./"NG>)(-<TO1;&PN[>W>&(6MG#&JEB#Y@ 3.\
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MO&ZE61AD,#U!'<5RL?PQ\'P:]#JUIH&GVLL5M+;"*VM(HT(D*Y?Y5!W@*5#
MC =AWKK*YRP\8QWFL1Z;<:+JNGS7$$EQ9F\CC072(5#;0')0_.IVR!#STX.
M"'1_ EOI-[ILTNL:IJ4>DQ-%I]O>/%LM@5V9!2-6<A,J"[-P3W.:ET/PA)HN
MN7FJ-XCU;4);W:;B.[2V"2%5"J?W<*$$ 8X('J#3;3QE)-XEL]$OO#>KZ;<W
MD4LT;W+VKH$CQN8^5.[ 991G'5A4GA3Q:WBRSM[ZWT#5+&PNK<7$%W>-;[)%
M., +',[@D'/*@<'G. 0#HJ*** "BBB@"IJ6E:?K-DUGK%A;7]JQ!:"ZA65"1
MR"58$<5S]A\,?!VGOJ7E^'M-EAU*=9I+>6RA:./:BJ%1=G"_+NQS\S,>]=%J
M-[_9VGS70M;B[:,?+!:IODD). J@D#DGJ2 .I( )KGG\?6<.BZK?7>E:E;7&
MDS1PW.GR+%YX:39LVD2&,@[UYWXZYP10 EA\.M$T6WU)/#@DT2;4+I;EKC3H
MXHGB*[<1J-A4Q_*?D8,/G;UK4T+P]#H;7DWVRZU"\OI!+<W=VR;Y2JA5&$54
M4!0  JCU.22:;'KFH/I4MVWA;5HYTD"+9-+:>;(./F!$Y3 ]V!XZ5'X=\4+X
MAN]3M3I-_ILVF2I#.MVT+?.R!]H,4CC(4J2"1C<* -VBBB@ HHHH S-7\-:%
MK[1-KVBZ=J;0@B(WMHDQ0'KC<#C.!T]*YP?"W2K?0=$TC2M1O],MM&?S8Q;)
M;D7,N !+,KQ,CN,;@=HPWS=0".DUC5IM+2#[+I&H:M-,Q BLEC!0 9+,TCH@
M'08+9.> <'&<OC*.[T'3M4T;1=6U9+^)I5AMH41XE7&X.97158$XV[B2<X!
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M_P#QNC_A"]:_Z'S7/^^+?_XW0!U=O;P65I%;6D,=O;P((XHHE")&BC 4 <
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MUQ__  A>M?\ 0^:Y_P!\6_\ \;J&[\ :G?6<UK=>.-;DAF0I(NR 94]1_JZ
M.VHKCQX*UD#CQYKG_?$'_P ;H_X0O6O^A\US_OBW_P#C= '721I-$T<J*\;J
M59&&0P/4$=Q6+8^'/"WABZ6YTO1-)TFXN,6XEM;..%WW$'9E0"02H./85E_\
M(7K7_0^:Y_WQ;_\ QNH;GX?ZE=^5]I\<:V_DRK-'\D'RN.A_U?O0!U%UHFE7
MT%W#?:99W,5Z5:ZCFMT=;@J %+@CYL!5QG.,#TJ33M,L-'L4LM)LK>QM(\E(
M+:)8XUR<G"J !DDFN9_X0O6O^A\US_OBW_\ C='_  A>M?\ 0^:Y_P!\6_\
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MKZ?:& :MX4N,RRR[[BVNG;YY&?;GS.@W;0.P ':K7D_%C_G^\&_^ =U_\=H
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M'@ES@<*#O7Q?+JQ\4>';VS\-:A>6FD7,EW<3Q3VB+M>UEBVCS)E.0T@)R ,
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M#6HVMAJ%I:VT=U+-:E5,!N"694F+8;S%"X4G/4+UKM:X;R?BQ_S_ '@W_P
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MR)H%O)(""T\D,XCD4#D!<]<G@XYQGUKJ8'DDMXWGB\F1E!>/<&V'N,CK4E%
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M_P )!HW_ $%K'_P)3_&@#0HK/_X2#1O^@M8_^!*?XT?\)!HW_06L?_ E/\:
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M;38[M(VB+%D>-CDHRL589'7D'FLT3>&!=?:/[0L?-^T?:=WVM?\ 6;-F>O\
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MX+XO_B:W** ,/_A"/"G_ $+&C?\ @OB_^)H_X0CPI_T+&C?^"^+_ .)K<HH
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M5U_Q#;RSK(+T1*L2Q+())=L("<N%*J#C&06/% '9_P#"">$?^A6T7_P71?\
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M/+41N!MX!;K]":WQ9\37?A7P!->:9>QV%]/<P6MO<RA"L1>0!F.\%<!-QY%
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MH>GZIH*Z=#XALY;S3I%O/-EV(%8":/8HC)1@<!GP>* -W_A!/"/_ $*VB_\
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M  .7_P"(H_X0J?\ Z'#Q/_X'+_\ $5U-% '+?\(5/_T.'B?_ ,#E_P#B*/\
MA"I_^AP\3_\ @<O_ ,174T4 <M_PA4__ $.'B?\ \#E_^(H_X0J?_H</$_\
MX'+_ /$5U-% '+?\(5/_ -#AXG_\#E_^(H_X0J?_ *'#Q/\ ^!R__$5U-% '
M+?\ "%3_ /0X>)__  .7_P"(H_X0J?\ Z'#Q/_X'+_\ $5U-% '+?\(5/_T.
M'B?_ ,#E_P#B*/\ A"I_^AP\3_\ @<O_ ,174T4 <M_PA4__ $.'B?\ \#E_
M^(H_X0J?_H</$_\ X'+_ /$5U-% '+?\(5/_ -#AXG_\#E_^(H_X0J?_ *'#
MQ/\ ^!R__$5U-% 'G^@^&[[4/%OB+3[CQAXE\C3VMA#MOES\\6YL_)ZUT?\
MP@+_ /0X>*?_  /7_P"(J+PG_P E"\9?[]E_Z(KLZ .1_P"$!?\ Z'#Q3_X'
MK_\ $4?\("__ $.'BG_P/7_XBNNHH Y'_A 7_P"AP\4_^!Z__$4?\("__0X>
M*?\ P/7_ .(KKJ* .1_X0%_^AP\4_P#@>O\ \11_P@+_ /0X>*?_  /7_P"(
MKJYIH[>"2:9@D<:EW8]% &2:XGPWX]U+5_"<?BS6='L='\/-:R7;S-J,DUQ'
M$N2&,0@ .0,X#DX(QD\4 6_^$!?_ *'#Q3_X'K_\11_P@+_]#AXI_P# ]?\
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MLQLRKN=B0,G&T9]*U;SX?IJGA&\\-ZQXBUF_L+N.*+]Y]F1XD1@V%:.%?O8
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M SD $ AD7P]1?!]SX8NO$>M7>ES6(L$CE^S*T,04+\K)"I)VC&6W?GS77T4
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M'_A8EM_T+?BG_P $LW^%'_"Q+;_H6_%/_@EF_P * .NHKD?^%B6W_0M^*?\
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M5 Z&7SUR,Y(^48!QSU,W_"Q+;_H6_%/_ ()9O\*/^%B6W_0M^*?_  2S?X4
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M_P"A;\4_^"6;_"C_ (6);?\ 0M^*?_!+-_A0!UU%<C_PL2V_Z%OQ3_X)9O\
M"C_A8EM_T+?BG_P2S?X4 ==17(_\+$MO^A;\4_\ @EF_PH_X6);?]"WXI_\
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M !H_X2;0?^@WIW_@7'_C0!IT5F?\)-H/_0;T[_P+C_QH_P"$FT'_ *#>G?\
M@7'_ (T :=%9G_"3:#_T&]._\"X_\:/^$FT'_H-Z=_X%Q_XT :=%9G_"3:#_
M -!O3O\ P+C_ ,:/^$FT'_H-Z=_X%Q_XT :=%9G_  DV@_\ 0;T[_P "X_\
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M1Z9X'U?1-*T2_M?#TWA'1KFZL[S5"&BOFEC9&1(N"\I8;MRMD$D;'!P/9?\
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M_P : -2BLO\ X2C0/^@YIO\ X%Q_XT?\)1H'_0<TW_P+C_QH U**R_\ A*-
M_P"@YIO_ (%Q_P"-'_"4:!_T'--_\"X_\: -2BLO_A*- _Z#FF_^!<?^-'_"
M4:!_T'--_P# N/\ QH U*Y'XK_\ )(O%'_8,F_\ 036U_P )1H'_ $'--_\
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M"]I7_@%'_P#$UL44 8__  B'AK_H7M*_\ H__B:/^$0\-?\ 0O:5_P" 4?\
M\36%)XYAT[Q9XABU(ZC)8:<D$:+:Z5/.D;B,RR,9(XV )62/AFXV]!DDU],\
M::PVB:;"EA#J.KOI*:MJ'VBY%M';QODJN5C;+\, -H&$)+#C(!TO_"(>&O\
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M_P!"]I7_ (!1_P#Q-<M/XOURSN?&M_=6L#:1HJF&W$-U^]:58A(-H,."6\U
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MELXWCA_W%(POX5;TW2M/T:R6ST>PMK"U4DK!:PK$@)Y)"J .:YS_ (5W;?\
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MT<<YC!D16(+*&Z@$J,CO@>E<Q_PKNV_Z&/Q3_P"#N?\ QH_X5W;?]#'XI_\
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M4-1N(M-N9KBQLYI4\FV,OF;@ J L/WAP7+,N!@CG)]F^(?\ T%/#/_@LN/\
MX_1]F^(?_04\,_\ @LN/_C] %F3P59/X4L=#CO+V(6$L<]O>HR&=94?>)/F4
MH23G(*X.X\5;\/>&[7PY'>_9KBZNIK^Y^U7-Q=R!Y))-BH3D  #" [0 !D@
M# &7]F^(?_04\,_^"RX_^/T?9OB'_P!!3PS_ ."RX_\ C] %L>#-/%C';&>Z
M8QZL=6$Q==YF,ID(SMQMY*8QG;QGO55OA]ISZI]J>_U%K<:D-42P\Q! ESN#
M%\!-S989PS$ G( I/LWQ#_Z"GAG_ ,%EQ_\ 'Z/LWQ#_ .@IX9_\%EQ_\?H
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M>YUW6+^\DL&T^&^GEB6:UA;KY9CC4!B0IW$%LHO/%.U+P4-5@-K<^(M;%A+
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M+>%O_!7<?_)%'V;XC_\ 06\+?^"NX_\ DB@#KJ*Y'[-\1_\ H+>%O_!7<?\
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MH.&Z$X4@';45D>%]<?Q%H$>HRVHM)#+-"\2R^8H:*5HR5; RI*$@D#CM6O0
M4444 %%%% '.^$_^2A>,O]^R_P#1%=G7&>$_^2A>,O\ ?LO_ $179T %%%%
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MC_L&3?\ H)KKJY'XK_\ )(O%'_8,F_\ 030!UU%%% !1110 4444 %</HO\
MR4GQE_UTL_\ TG%=Q7EW_"5Z9H'Q0\7Q:BM\6D>S*_9M.N+@<6XZF-& Z]Z
M/0**Y/\ X65X>_NZQ_X(KW_XU1_PLKP]_=UC_P $5[_\:H ZRBN3_P"%E>'O
M[NL?^"*]_P#C5'_"RO#W]W6/_!%>_P#QJ@#K*A-I;->K>&WB-TD9B6<H-ZH2
M"5#=<$J#CID#TKF?^%E>'O[NL?\ @BO?_C5'_"RO#W]W6/\ P17O_P :H Z"
M/1],B(,6G6B8CDC&V!1A)&W2+TZ,P!([GDU%9^'M%TZVBM]/TBPM8(9O/BB@
MMD18Y,8W@ 8#8)&1S@UB?\+*\/?W=8_\$5[_ /&J/^%E>'O[NL?^"*]_^-4
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M_N:U_P""&^_^,T ==17(_P#"SO#G]S6O_!#??_&:/^%G>'/[FM?^"&^_^,T
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M/MEM_P _$7_?8H \Y^'WA[Q*_CS5_%OBG1H- :ZL8+&+3X+I)]WE]9"4X X
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MHHH **** "BBB@ HHKF/B/<S6?PYUF>WF>!EM\-+&Q5HT+ .P8<C"ECD=.M
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MDUT?_KDW_H;4 2_\*V\$?]"CHG_@!%_\31_PK;P1_P!"CHG_ ( 1?_$UTU%
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M6/E6\4<BW6FZ@+V$EBV8F<(JB10H)52PPP.>1D E_P"%;>"/^A1T3_P B_\
MB:/^%;>"/^A1T3_P B_^)KIJ* .9_P"%;>"/^A1T3_P B_\ B:/^%;>"/^A1
MT3_P B_^)KIJ* .9_P"%;>"/^A1T3_P B_\ B:/^%;>"/^A1T3_P B_^)KIJ
M* .9_P"%;>"/^A1T3_P B_\ B:/^%;>"/^A1T3_P B_^)KIJ* /._#/P_P#!
M]QXY\5V]QX7TB6"W:T\F-[*,K'NARVT8XR>376_\*R\"_P#0G:'_ ."^+_XF
MJGA/_DH7C+_?LO\ T179T <O_P *R\"_]"=H?_@OB_\ B:/^%9>!?^A.T/\
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MT//BC_O[:_\ QB@#H:*Y[_A7]U_T//BC_O[:_P#QBC_A7]U_T//BC_O[:_\
MQB@"'5_^2G>#_P#=OO\ T4M=Q7"R_# SZC:WTOC3Q.US9[_(D\ZVRF\8;_EA
MW JY_P (+??]#YXI_P"_MK_\8H ZZBN1_P"$%OO^A\\4_P#?VU_^,4?\(+??
M]#YXI_[^VO\ \8H ZZBN1_X06^_Z'SQ3_P!_;7_XQ1_P@M]_T/GBG_O[:_\
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M_MK_ /&*/^$%OO\ H?/%/_?VU_\ C% '745R/_""WW_0^>*?^_MK_P#&*/\
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MQ_\ &Z .EHKFO*^(O_/KX7_\"[C_ .-T>5\1?^?7PO\ ^!=Q_P#&Z '^$_\
MDH7C+_?LO_1%=G7G.EZ+\1-,U_5]32'PP[:F82R&ZN,)Y:;>/W?>MCS?B/\
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MHTGP#;:5=:;(VLZK?0Z1&T>FVUT\)CM,IY8*E8U9R$)4;V;ACU/-,\WXC_\
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3 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>vrna-20221231_g9.jpg
<TEXT>
begin 644 vrna-20221231_g9.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#^17AI9@  34T *@    @ ! $[  (
M   1   (2H=I  0    !   (7)R=  $    B   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %9I8W1O<FEA
M(%-T97=A<G0    %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,X
M,@  DI(  @    ,X,@  ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MWP)J>KZSX#TC4/$EK]DU.XMP]Q%LV8/8[3TR,'';- '04444 %%%% !1110
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M7Q!J6GVEQIL4_E6MT\8W>9(I/RD8/R5]-V@D6R@$V?,$:A]QR<XYH FHHHH
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M_P -<UX>\<)X,T^[\)?#KP==^)+3PPNW5K]+E( 9>?,95()D;*MP.>,#@ T
M>WU@>.]2U#1O &MZIHS(E[8V4ES$9%#+\B[CD'KP#3O!OB_3/'/A>VUW16?[
M//D-'(,/$XX9&'J#^!ZT[QH W@'Q &&0=,N00>_[IJ /FC1/VAO'^H:+=Z98
MVTFK^(;F8&UD@LE<01!?FVQHN6;.#SD"O0OAWXR^(U[\./&NJ>*WD&I:3 YL
M4NK!87$B1-(P9 JY'W ./6N3_9*C0ZQXFD**76"W4-CD L^1GWP/R%?07C/_
M )$/7_\ L&W/_HIJ /*OV?\ XE>)OB!JFO+XFO(YX[2*%H8XX$C"%F?/09/0
M=3VKG_$?QE\?^+OB!>^%_A3:1QBS>1!(4C:64(=K.3+\BKGH,9Z<\X%3]DG_
M )"GBC_KC;?^A25>\=_ CQ/I'BRZ\6?"W462::5IVM$F\F:-F.6"-]UE)_A)
M'IS0!TGPSO\ XS?\)S'8_$:%AI9@DD:4V]N1N &U0\/ .3GGT->=_$<8_; T
M?WU/2_\ T**NJ^$_QO\ $5[XTC\%_$&T_P!/D=H8[DP^5*DJ@G9(@P.<<$ <
MXZYR.'^,=A/JO[3\&GV=X]A<7=Q8017<>=T#,$4.,$'*DYX(Z=10!W_Q;^,6
MNIXOM/!OPME>35TFVW4L,"39?&!"H=2..K-VQU&&KU[P;8^(+#PO;1^,-6&J
MZNPWW$RPQQJA/_+-0B@$#U(R>3Z ?*G@?7;_ .!?Q?NM/\56D;PR,(+R?R]S
MB,G*S1-UVG()'<<$9 Q]BPS17-O'/;R++%*H='0Y5E(R"#W!% #+T7!L+@61
M"W)B;RB1D!\<?KBOE#P]^TAXW=M0AN85U;4+J-8]-MX;50L4A;EBJC>_R]!G
MM7UK7R1^SE%&?CG?913Y=G<E./NGS%&1Z<$C\: /2O@EXM^)&O>*M6M?B#]H
MAM;6T$JQ7>G+:NKLPVX^125VA^N>W-<_XD^.7C#Q=XRE\.?!ZQ65(MP%WY2R
M/+C@R#?\B)GH6Z\=,XKV_P =M<+\.?$C6187 TJZ,13[V_R6QCWSBODKX(6G
MC>_UG5+;X=Z_INCWI@1YQ?(K&:,,1\N8GZ$C/3J.O8 [9/C'\4?AOXDL[7XI
M6 N;.X.6W0Q*Y3.&,;Q?(2,@X.>PXSFO;/'_ ,1],\#>!/\ A(WQ>"X"BQB1
ML?:7<;EY[#')/H*\G\3_  8^+/CN"WB\9>+M$NUM6+0*D17:2.3E84]!ZUSO
M[1FGW>@^%_A[H-S,)!I^FM YCSL>2-(4+#/TXSZ^] %C0_B%\=_'CRZMX3MH
MSI\;D&..VMTA)'50TWS-^#9KE_"=[JVH_M0:?=>([-;'59-3_P!*MU&!&X0@
M@<GCC/4]:^F_A*EFGPA\+C3MOD_V=$6V=/,*YD_'?NS[UX'>*%_;24* !_:<
M9P!W,"DT ='\??BGXS\$>/+72_#>K)96DVGQW.T6L4C;B\BGEU/]P5[WJD\U
MEX?O)XY,SP6KNKE1RRH3G'3J.E?*_P"U6/\ BZ6FGM_8T7_H^:OJ+6IDN/".
MH31-NCDL9'4^H,9(H \4_9_^)_BWQUXPU6T\3ZH+NVALO.BB6VBC"-YBC.54
M$\$]2:T_BS\=KCPOX@'A7P591ZCK65261U,BQ.V-L:HO+OS]!D#!.0//_P!E
M#_D?-:_[!O\ [52LGX8W$(_:E:37'7SGU&]4-/\ \]SY@7\<\#WQ[4 =SI&I
M?M$)K>FS:O;M_9MQ=1),OV>T;RXV< DJGSJ ">3T[UF?M-2^.$NI%NSCP7)/
M MMQ!S<>6Q/3][V?KQ^E?3E>)?M5_P#)+--_[#47_HB>@#DO@VGQA>#PR+1M
MO@H3 DYM!^Y#G>/^>O7=[_A6G\8OBSXS\(_%&/0=%OH;6PEC@D0_94=\/PW+
M ]P>U>C_  +8-\$O#A4@CR9!P>XE>O"_VCO^2Y:;_P!>=M_Z->@#Z,^(/CW3
M/AWX6DUC50TK%O+MK9#AIY",A0>PXR3V [G /A-G\0_CIX_@EUCP;IZ6NF([
M*H@@@VMCL#/DN1WV]\_2K'[6TDWVKPM&2WDE+E@/X2V8\_CC'YU[5\*VM6^$
MGA8V!0Q?V7 &V=/," 2?COW9]\T >5_"S]H#4M4\4Q^%OB!:QV][-+]GANDC
M,1$V<>7(AZ$GC(QS@8[TGQU^*OC'P%XZL]/T*[AAT^>S2YP;=&8G>RLNY@?[
MH[=Z\^^-D4+?M&[-%"FZ>6T$@BZ^>=N/QQMK=_:Q5!XLT!@!O-DX)[XW\?S-
M &MK'CCX[^(+!]=\->'WT;1MGFQ(D,,DS1XSDK+EVR.?E09XQ[])\!OC'JOC
M^\O=#\2QPO?VMO\ :8KF%-GFH&"L&4< @LO(QG/3CGUKP]_R+.E_]><7_H K
MYH_9VMH4^/7B%(E C@LKKR@IX ^T1*/T- 'U17S]\>_BMXQ\">,[73/#MY#;
M6EQ8)<!VME=@Y=U(RP(_A!Z=Z^@:^4_VK_\ D?-%_P"P;_[5>@#U'XW^.O$O
M@CP+HVK>';F**2YG6"X>6!7R6C+@@'@?<;MWKA=)^)GQH\<^&;4^#-$7]Q'L
MN=5=(0;F0=2OF;8Q_NJ#SW[5T_[22HWP1TXN!N6^MBF?7RG'\B:W?V<_^2(Z
M5_UVN/\ T<U 'G_PT^-OC-?B1;^$/B#&L\EQ<&U9WMUAFMY?X<A %()P.G<'
M/K](U\K^-[:!OVR=- 4?-J&GR/@_QA(R#^@KZHH \(_:5E\<1:)(VCG'A(VB
M+J9Q!_K#, H^;]YU*?=X_6O./A,GQAD\.1IX!;;X?:](F;-H,/\ +O\ ]9\_
M3'3\*]U_:#_Y(3XA_P"W;_TIBK$_9>8'X1R@$$KJ<P.#T.R.@"A\?_B=XK\
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MLLC>8'8'!;(QC;QC^=7?V5/^26:E_P!AJ7_T1!7%?M9?\C-X>_Z\Y?\ T,4
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M/^,[;Q]\))]?M8&MO/LYTE@8Y\N158,,]QW!]"*\:_9*8?VKXG7(R8+<@?\
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M$8T!G\O[?]LD$6?O^5L^?'MGR_TJC>Q2K^PW$+Y2)0B-'OZ[3?C:1_P C\*
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MR@&OJ.B@#PWX6? :[T/Q(/%GCV^74-85S-#"DAD"2'K([G[S>@Z \Y)QC/\
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MU6SU&%9[=6DL[A95!\Y>"5)KU^@ HJMJ&HV6DV,E[JMY;V5K'C?/<RK'&F2
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MG!([$]* /1:**\X^$NJZAJ>H^.UU&^N+M;7Q/=P6XGE9Q#&I&$7)^51V XH
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M]=MOB[XXT77?$%YK0L8;%E><[45Y(M[E(Q\J#+8P.P&23S7JU !116/%XO\
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M)'';%QM+R.Z@ +G/?G\ZZ&?P3)IOP(NO!]C_ *3<QZ++;(4X$LQC;I[%S^M
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M^'NIW'A7P_IFF:S8H+VSN+&RCBE#Q$/@%5!Y"D8]2* &_M&?\D1U7_KM;_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-=BL;,JEV
M)"@C)]N:=10!PWPO\-ZII&GZKK'BF 0:_KU\]W=Q>8LGDH#MBB#*2"%7IR?O
M5W-%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7D.@Z
M;\0?AE!>:1H?A6Q\5:7)>2W-O<1:BEG. YS^]$@PQ'3(]J]>HH \QM- \9>,
M_&^AZ]XRTVQT#3]#>2>VL(+D7,\LKKM^>0 *%'!XZX^A'IU%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:MG=;RJ#&%3+.3P% [G/&*QT\?:/!J7V#6HFTF=@&07(&"#TR1PI]C0!A?\
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M-F..[@>%V0#(##!(_.I;2SBL[*"V0;EAC6,$@9( Q0!Y[_POOP1_SVU'_P
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MO?\ X[1_PK+0/^?C7?\ P?WO_P =H ZZBN1_X5EH'_/QKO\ X/[W_P".T?\
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MO_W0BBC5#"L8]@&KR/6-*U'P;>Z!Y/AZ2SU#3;:^D:6ZFA>*Y&>&4,_8,#C
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M1XQG_L>U_M#2=2:X\L;V$!Y/K^5;(\*Z(-3_ +0&GQBYW;MV3C/KMSC]*UZ
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MIO2%>"/*!)8J".O;\:TM5U#Q-J^F(-)NH-2?3F>9M3A0HX0G[F,#DKP0!VH
M]6CU6PENS:QWMN]P.#$L@+?E5NO'/$6J/I&BI!_84"^=Y?V35=-0.P)/S?-G
M=O\ YU#IOB.[BM$U/2M5^P2B5()K'4-TC7#$X9^3P.X Q0![317%Z-XVU/6+
M$WUKH8ELX7,<S)<#S,KU*ICD>G-=;9WD&H6<5U:2"2&5=R,.XH GHK#U+Q=I
M6EW+PSR2.8>9VB3<L ]7/05J6.H6FI6RW&GW,5S"P!#QL&% %BBBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#RW]H+_DGMC_V&+7_T(UZE7EO[07_)
M/;'_ +#%K_Z$:]2H **** "BBB@ HHHH *X[XB_ZGPW_ -C!:_\ LU=C7'?$
M7_4^&_\ L8+7_P!FH Z"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KF]
M._Y+-J'_ & +;_THGKI*YO3O^2S:A_V +;_THGH [6BBB@#'\3^+-$\&:/\
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M1S3+9ZA(O-O*<;CWV'HP^E '744 YZ44 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'E
MO[07_)/;'_L,6O\ Z$:]2KRS]H+_ ))[9?\ 88M?_0C7J= !1110 4444 %%
M%% !7'?$7_4^&_\ L8+7_P!FKL:X[XB_ZGPW_P!C!:_^S4 =!1110 4444 %
M%%% !1110 4444 %%%% !1110 5S>G?\EFU#_L 6W_I1/725S>G?\EFU#_L
M6W_I1/0!VM%%% 'DVM>"/$&N?M):/XDN+(+X>TBSVI<&9/GDVN0 F[<#OD'.
M,?+7J\K.D+M&GF.JDJ@.-Q],GI3J* / _"GPB\3/\%O%^D:Y&FG^(-?N_/ ,
MRL"$*.H9D+ !F#CO@&L#4? WQJUKX6P^%;O3K&VL-.6.**T@GB$UZ%8;=[^9
ML"J.>H)('!ZCZ;HH \(\;_"WQ=9R>!]8\"Q6U[?>&;&*U:TGD50S)@[OF(!!
M);/S ],>VOJ?A;XC_$+X6:_IGC3^S--U*\:%["SMC^[C\M@[!V!;EB,?>(&
M:]@HH ^>O!G@_P")^GWVF6,G@OPCH<%H\23ZS':VYN98U(W-N5FRY /.T<GM
M6EX_\&_$2_\ C8GC#PIIEG+'HUDD=B;R=-ERQ#;T"[@0?WK\MM'R]>E>YT4
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M444 %<-\5+,7^EZ!;-// )->M5\RWE,;KG?R&'0UW-<=\1?]3X;_ .Q@M?\
MV:@"G_P@$/\ T,GB;_P;R4?\(!#_ -#)XF_\&\E=910!R?\ P@$/_0R>)O\
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M (.):/\ A7D'_0S>*?\ P<2UUU% '(_\*\@_Z&;Q3_X.):/^%>0?]#-XI_\
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M"JI;I-A $E!WF1=XZY&?U[KXI^&+_P 7?#^[TS1S&;WS(IH8Y6PDA1PVTGW
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MV95]2ETN06D1C4.HW*ZC)^7 ((_&NWOK&VU*QEM+V(2P2KM93_G@^]<_X?\
MA_HOAV\-S:?:9Y [21_:9VD$;-U*@]_?K0!U%%%% !1110 4444 9WB'_D6=
M3_Z])?\ T$UR7P1_Y(]H?_7-O_0S76^(?^19U/\ Z])?_037)?!'_DCVA_\
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MW,D'E\HX55R&!!'W17":W\/)O!VJ#69WUS7/-BG>6:S=R8F$85-WS XXZYH
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M4J "BBB@ HHHH **** "N.^(O^I\-_\ 8P6O_LU=C7'?$7_4^&_^Q@M?_9J
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M[U>QLIK6*XN$5[J7R81G.YL$X_(&N7\>>$-!U2S?4]7M[^9XI(G(L5>21MC
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MG_Q-=910!R?_  L_P=_T&D_[\R?_ !-'_"S_  =_T&D_[\R?_$UUE% ')_\
M"S_!W_0:3_OS)_\ $T?\+/\ !W_0:3_OS)_\37644 <G_P +/\'?]!I/^_,G
M_P 31_PL_P '?]!I/^_,G_Q-=910!R?_  L_P=_T&D_[\R?_ !-8-A\1?"L?
MQ6O;Y]706SZ+!"LGDR<N)YB1C;GHP_.O2JYO3O\ DLVH?]@"V_\ 2B>@"?\
MX6IX+_Z#B?\ ?B7_ .)H_P"%J>"_^@XG_?B7_P")KKJ* .1_X6IX+_Z#B?\
M?B7_ .)H_P"%J>"_^@XG_?B7_P")KKJ* .1_X6IX+_Z#B?\ ?B7_ .)H_P"%
MJ>"_^@XG_?B7_P")KKJ* .1_X6IX+_Z#B?\ ?B7_ .)H_P"%J>"_^@XG_?B7
M_P")KKJ* .1_X6IX+_Z#B?\ ?B7_ .)H_P"%J>"_^@XG_?B7_P")KKJ* .1_
MX6IX+_Z#B?\ ?B7_ .)H_P"%J>"_^@XG_?B7_P")KKJ* .1_X6IX+_Z#B?\
M?B7_ .)H_P"%J>"_^@XG_?B7_P")KKJ* .1_X6IX+_Z#B?\ ?B7_ .)H_P"%
MJ>"_^@XG_?B7_P")KKJ* .1_X6IX+_Z#B?\ ?B7_ .)H_P"%J>"_^@XG_?B7
M_P")KKJ* .1_X6IX+_Z#B?\ ?B7_ .)H_P"%J>"_^@XG_?B7_P")KKJ* .1_
MX6IX+_Z#B?\ ?B7_ .)H_P"%J>"_^@XG_?B7_P")KKJ* .1_X6IX+_Z#B?\
M?B7_ .)H_P"%J>"_^@XG_?B7_P")KKJ* .1_X6IX+_Z#B?\ ?B7_ .)H_P"%
MJ>"_^@XG_?B7_P")KKJ* .1_X6IX+_Z#B?\ ?B7_ .)H_P"%J>"_^@XG_?B7
M_P")KKJ* .1_X6IX+_Z#B?\ ?B7_ .)K%\9?$OPC>>!=>MK;64>:;3;B.-/)
MD&YC$P Y7U->D5@^._\ DG/B3_L%77_HIJ +OA\Y\,Z61R#9Q?\ H K1K/\
M#_\ R+6F?]>D7_H K0H **** *FIV4FH:?);17<UFTF!YT.-ZC/.,_E6/I?@
M30=+U)-16V>ZU"/E+N\E::1?HS$X_"MZZNX+&UDN;R9(((EW/)(V%4>I-4U\
M0:0^K)IBZC;F^DC$BV_F#>RD9!Q]* -&BBB@ HHHH **** ,[Q#_ ,BSJ?\
MUZ2_^@FN2^"/_)'M#_ZYM_Z&:ZWQ#_R+.I_]>DO_ *":Y+X(_P#)'M#_ .N;
M?^AF@#OJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT$0337*&(-+YH; SU.,GBKVA^,/%7B:!+C2;CPJBS,WE6\LTQE"@GJ!WX[4
M>D45RNA^,=_@Z;6O$YMK(VTS0SM 6,>0P48SSR2*0_$GPTN/,NY(P6"[G@8
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M5;.0 #H!L-<I\$?^2/:'_P!<V_\ 0S0!WU%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#RW]H+_DGMC_V&+7_T(UZE7EO[07_)/;'_ +#%K_Z$:]2H **** "BBB@
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ML8[<2?*5'F."6?&<]LD FFVW@74=/^(6H>(=*\226MEJDL4M]IQLT?S3&NT
M2DY4$=<#/OTQVE% '+Z3X)@L==\4ZE>W/VX^(W02QM%M$<21E!'G)W<$\\?2
MN:M/A/K-GHO_  CD7CR_7PS\R?8ELXQ/Y1)S']HZXY/\/MTXKTVB@#DM7^']
MEJ$/A>SLIA8Z;X=O8[N.T6+>)3&I"#)/&"2<\YJUKWA+^W?%WAS69;TQPZ')
M-+]E$6?/=T"J2V?EVXST.<]JZ.B@ KF]._Y+-J'_ & +;_THGKI*YO3O^2S:
MA_V +;_THGH [6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *P?'?_).?$G_ &"KK_T4U;U8/CO_ ))S
MXD_[!5U_Z*:@"]X?_P"1:TS_ *](O_0!6A6?X?\ ^1:TS_KTB_\ 0!6A0 44
M44 <S\0;*YU#P=<6]K')(K2Q&=8B0YA#@R;<<YVYZ5Q]E:>&9_%>A2^ Y6N;
MFVN"+PQRNZQ0[#D29. <X]Z[_P 3:W_8&BM>)%YLKRQP0H3A3)(P5<GL,D9K
M$AO]<\.ZM81Z]+9W<&J3^0#;1>6T$A4L/]Y>",GGI0!V5%%% !1110 4444
M9WB'_D6=3_Z])?\ T$UR7P1_Y(]H?_7-O_0S76^(?^19U/\ Z])?_037)?!'
M_DCVA_\ 7-O_ $,T =]1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M53X&_P"A9L?^^3_C7744 <C_ ,*I\#?]"S8_]\G_ !H_X53X&_Z%FQ_[Y/\
MC7744 <C_P *I\#?]"S8_P#?)_QH_P"%4^!O^A9L?^^3_C7744 <C_PJGP-_
MT+-C_P!\G_&C_A5/@;_H6;'_ +Y/^-==10!R/_"J? W_ $+-C_WR?\:/^%4^
M!O\ H6;'_OD_XUUU% '(_P#"J? W_0LV/_?)_P :Q?&7PR\&6?@77KJU\.V<
M4\&FW$D;JIRK")B".>Q%>D5@^._^2<^)/^P5=?\ HIJ +OAX!?#&EJH  LX0
M .WR"M&L_P /_P#(M:9_UZ1?^@"M"@ HHHH SM>T.T\1:--IFH^:+>;&XQ.4
M88.1@CITKFY/A;HLT]O--?ZS));<PEM0<[#C&1[XKI#K^F":YB:[17M94AF#
M9&UWX4?C6C0!5TW3TTO3XK.&6:9(A@//(7<_4GK5JBB@ HHHH **** ,[Q#_
M ,BSJ?\ UZ2_^@FN2^"/_)'M#_ZYM_Z&:ZWQ#_R+.I_]>DO_ *":Y+X(_P#)
M'M#_ .N;?^AF@#OJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#RW]H+_ ))[8_\ 88M?_0C7J5>6_M!?\D]L?^PQ
M:_\ H1KU*@ HHHH **** "BBB@ KCOB+_J?#?_8P6O\ [-78UQWQ%_U/AO\
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M/^P5=?\ HIJ +WA__D6M,_Z](O\ T 5H5G^'_P#D6M,_Z](O_0!6A0 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M);:Q^V)<RW-PXVAV*?*JJ.0,YS]> "+X(1QWMCXJURX17U#4/$%TL\Q')1"
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MB@ K!\=_\DY\2?\ 8*NO_135O5@^._\ DG/B3_L%77_HIJ +WA__ )%K3/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *.O6BB@#QSX[>'M&T
M_P %6EY8:18VUR^L6VZ>&V1'.6.?F SS7L=>6_M!?\D]L?\ L,6O_H1KU*@
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M$/\ R+.I_P#7I+_Z":Y+X(_\D>T/_KFW_H9H [ZBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \M_:"_Y)[8_]ABU
M_P#0C7J5>6_M!?\ )/;'_L,6O_H1KU*@ HHHH **** "BBB@ KCOB+_J?#?_
M &,%K_[-78UB>*O#,?BG3[:V?4+O3I+6Z2[AGM/+WJZ9Q]]6!'/IV% %JBN>
M_P"$&U?_ *'_ ,0?]^;/_P",4?\ "#:O_P!#_P"(/^_-G_\ &* .AHKGO^$&
MU?\ Z'_Q!_WYL_\ XQ1_P@VK_P#0_P#B#_OS9_\ QB@#H:*Y[_A!M7_Z'_Q!
M_P!^;/\ ^,4?\(-J_P#T/_B#_OS9_P#QB@#H:*Y[_A!M7_Z'_P 0?]^;/_XQ
M1_P@VK_]#_X@_P"_-G_\8H Z&BN>_P"$&U?_ *'_ ,0?]^;/_P",4?\ "#:O
M_P!#_P"(/^_-G_\ &* .AHKGO^$&U?\ Z'_Q!_WYL_\ XQ1_P@VK_P#0_P#B
M#_OS9_\ QB@#H:*Y[_A!M7_Z'_Q!_P!^;/\ ^,4?\(-J_P#T/_B#_OS9_P#Q
MB@#H:YO3O^2S:A_V +;_ -*)Z?\ \(-J_P#T/_B#_OS9_P#QBJT?PVOHM8DU
M2/QUKXO9(%MFE\JTYC5F8+CR,=6)Z9YH [NBN1_X0W7/^B@^(/\ OS9?_&*/
M^$-US_HH/B#_ +\V7_QB@#KJ*Y'_ (0W7/\ HH/B#_OS9?\ QBC_ (0W7/\
MHH/B#_OS9?\ QB@#KJ*Y'_A#=<_Z*#X@_P"_-E_\8H_X0W7/^B@^(/\ OS9?
M_&* .NHKD?\ A#=<_P"B@^(/^_-E_P#&*/\ A#=<_P"B@^(/^_-E_P#&* .N
MHKD?^$-US_HH/B#_ +\V7_QBC_A#=<_Z*#X@_P"_-E_\8H ZZBN1_P"$-US_
M **#X@_[\V7_ ,8H_P"$-US_ **#X@_[\V7_ ,8H ZZBN1_X0W7/^B@^(/\
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M?_Y%K3/^O2+_ - %:%06-HMAI]M9QN\B6\2Q*[XW,% &3@ 9X[ 5/0 4444
M</XT\8Z;X7WP/HD]Y)<3P+,5M&,;AV R6 P6 /3UHL=8M;O6[&+PYX:DC/G'
M[5<7%D8!#'M/() R<X&!6YXPU9]%\//<PQ)),\T4$7F#*H[N%5V]@3G\*CUC
M6+S1]4T*)S'/%?S?99D"X;?L+;U]OE/'O[4 =!1110 4444 %%%% &=XA_Y%
MG4_^O27_ -!-<E\$?^2/:'_US;_T,UUOB'_D6=3_ .O27_T$UR7P1_Y(]H?_
M %S;_P!#- '?4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!-<E\$?^2/:'_P!<V_\ 0S76^(?^19U/_KTE_P#037)?!'_DCVA_]<V_]#-
M'?4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% 'EO[07_)/;'_ +#%K_Z$:]2KRW]H+_DGMC_V&+7_ -"->I4 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 445YY)\:?#PNKF"VTS7[T
M6TS0/+::8\D>]3A@&'7!H ]#HKSO_A=&C?\ 0 \4?^">2C_A=&C?] #Q1_X)
MY* /1**\[_X71HW_ $ /%'_@GDH_X71HW_0 \4?^">2@#T2BO._^%T:-_P!
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M]/99&SU81G->?_!C0]7E^'FA7L7BB\BL]K-]@%M"4QO/R[BN['XT >MT444
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M'J* -BBJFFZKI^LV2WFCW]M?VK$A9[6994)'! 921Q5N@ HHHH **"0JDL<
M<DGM69I'B70M?:5=!UK3M3:$ RBRNTF* ],[2<9P>OI0!IT53O\ 5]-THVXU
M34+6R-S*(8!<3+'YKGHB[B-S'T'-5-5\6^&]"NQ:ZWX@TO3KAD#B&[O8XG*D
MD!MK$'&0>?:@#7HJCI.N:3KUL]QH>IV>I0(^QY;.X295; .TE20#@@X]ZO4
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MD-I8Z1X?T&4:Q:7SVVF(5B$<,J,07$:^8Y"M@[% R%[;CZ!0!G>(?^19U/\
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M+:CX4U$>,9/$GAS5X+"ZN;-;2[@O;(W,,JHQ:-P%DC96&YA]X@@],C- &/\
M"6STV[\ HY:"[D;4I[N>V: J-.NC(7:!4<!D,9.!D _Q#@BCP@8];^*GBCQ)
MI*XTKR(--\]<;;VXB+%Y%(^\$#"/=[$#I4TWP[OD\$ZIHVE>(WLM0UF]>\U'
M4OLN[S'D $BH@=?+4A5488D#/))W5M>&=$UC0H(+&>]T=M+MH?*AM;#2I+8I
MC&/F:XD&.O;)SG/J <IHWA[2O#OQ[:#1[-;<7'AV6XG?<SR32O>!F=W8EG8D
M]6)XP.@ KTRN)7PCXG_X3I/$S^(M),RV1L# -&E"F$RB0\_:<[\C&>GM7;4
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MMVY[XQCVK,U*]UW0;CPE%-KDU[)JVKK%>%[>%$V&WE<QQA4RJ;D!&2S]BQH
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MRTE_!2>%]=N+,^1,]E;(;P*!YBI+ S@D8#%6(."#B@#T.BO$OB+(_BO5;?6
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M\=:QH;+;V]K?W3:9I[,"VF@[5"-'G]T0Y9_*.-N>0,D5N>&U\,>'M;T2VO\
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M_00'Y&@"I:_\EQF_Z\G_ *5Z'7EOA?6;3Q)\7+G4=)+36B6K(9<<9XXKU*@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /*HYK.+X8^(;75'C_M
M+[7<">-B/,9C*3'QU^[LQ7HVF7 %G:VEU*IOA;(\L1/S=,$X^M-G\/Z3<ZJF
MISZ=;R7L?W9V0;A^-7/LL O#=^4GV@IY9EQ\VW.<9],T <KY<?B'Q^-B+]AT
M$9)"\27+C]0JG\#7/K/9P^#/&UOJCQB]:[O-T<A'F.K9\K Z\C&*]*@MH+57
M%O$L8=R[;1C<QY)/O5.Z\/Z3>ZE%J%WIUO-=PXV3.@++CIS0!6M;.XN_ \=G
M*=MQ-8>62W8E,<UY;X)O?B/X*\+VV@KX$%Y':,RB<7JKO!8G.*]LK+U3Q-HV
MBW,=OJFI6]K+)RJ2. <>I]![T <5_P )O\0?^B<R?^!T?^-'_";_ !!_Z)S)
M_P"!T?\ C7I".LB*Z,&5AD$'((I: /-O^$W^(/\ T3F3_P #H_\ &C_A-_B#
M_P!$YD_\#H_\:])HH \U;QM\02I'_"NI!D8S]NCX_6J&A>*/B3I>AVME>^!9
M[V>%-KW#WZ9D.>IYKUFB@#S;_A-_B#_T3F3_ ,#H_P#&C_A-_B#_ -$YD_\
M Z/_ !KTFB@#S;_A-_B#_P!$YD_\#H_\:/\ A-_B#_T3F3_P.C_QKTFB@#S*
M?QG\09[:6+_A74@\Q"N?MT?&1CUJCX<\0_$+0?#6GZ4?A]),;.!8O,%Z@W8'
M7K7K=06=]:W\3R64\<Z)(T3-&V0&4X8?4&@#SW_A-_B#_P!$YD_\#H_\:/\
MA-_B#_T3F3_P.C_QKTFB@#S;_A-_B#_T3F3_ ,#H_P#&C_A-_B#_ -$YD_\
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M@_\ 1.9/_ Z/_&C_ (3?X@_]$YD_\#H_\:])HH \V_X3?X@_]$YD_P# Z/\
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MM^OMUH XS_A-_B#_ -$YD_\  Z/_ !H_X3?X@_\ 1.9/_ Z/_&O2:* /-O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5751*ZAAD!@%P1[\GGWK>H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763455785488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 03, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Verona Pharma plc<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">X0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1489389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3 More London Riverside<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">London<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">SE1 2RE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">GB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CountryRegion', window );">Country Region</a></td>
<td class="text">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">283 4200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary shares, nominal value &#163;0.05 per share*<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VRNA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 212.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">631,904,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of the registrant&#8217;s definitive proxy statement that the registrant intends to file with the Securities and Exchange Commission pursuant to Regulation 14A in connection with the registrant&#8217;s 2023 Annual Meeting of Shareholders are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001657312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CountryRegion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Region code of country</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CountryRegion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763455462768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">PricewaterhouseCoopers LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">876<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Reading, United Kingdom<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763456423728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 227,827<span></span>
</td>
<td class="nump">$ 148,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">2,499<span></span>
</td>
<td class="nump">4,037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_TaxCreditAndIncomeTaxesReceivableCurrent', window );">Tax incentive receivables</a></td>
<td class="nump">9,282<span></span>
</td>
<td class="nump">15,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">3,388<span></span>
</td>
<td class="nump">2,063<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">242,996<span></span>
</td>
<td class="nump">170,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Furniture and equipment, net</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">545<span></span>
</td>
<td class="nump">545<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetNoncurrent', window );">Equity interest</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">854<span></span>
</td>
<td class="nump">899<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets:</a></td>
<td class="nump">16,472<span></span>
</td>
<td class="nump">16,524<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">259,468<span></span>
</td>
<td class="nump">186,587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,910<span></span>
</td>
<td class="nump">10,044<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">13,752<span></span>
</td>
<td class="nump">22,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="nump">675<span></span>
</td>
<td class="nump">648<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Taxes payable</a></td>
<td class="nump">283<span></span>
</td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">1,409<span></span>
</td>
<td class="nump">327<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">19,029<span></span>
</td>
<td class="nump">33,422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Term loan</a></td>
<td class="nump">9,768<span></span>
</td>
<td class="nump">4,874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liabilities</a></td>
<td class="nump">205<span></span>
</td>
<td class="nump">286<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">9,973<span></span>
</td>
<td class="nump">5,160<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">29,002<span></span>
</td>
<td class="nump">38,582<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary &#163;0.05 par value shares: 631,338,246 and 489,177,550 issued, and 606,301,054 and 480,082,966 outstanding, at December 31, 2022 and 2021, respectively</a></td>
<td class="nump">40,526<span></span>
</td>
<td class="nump">31,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">529,187<span></span>
</td>
<td class="nump">385,070<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Ordinary shares held in treasury</a></td>
<td class="num">(1,549)<span></span>
</td>
<td class="num">(603)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(4,601)<span></span>
</td>
<td class="num">(4,601)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(333,097)<span></span>
</td>
<td class="num">(263,716)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">230,466<span></span>
</td>
<td class="nump">148,005<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 259,468<span></span>
</td>
<td class="nump">$ 186,587<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_TaxCreditAndIncomeTaxesReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Credit And Income Taxes Receivable, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_TaxCreditAndIncomeTaxesReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763455715872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>&#163; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>&#163; / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in pounds sterling per share) | (per share)</a></td>
<td class="nump">&#163; 0.05<span></span>
</td>
<td class="nump">&#163; 0.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">631,338,246<span></span>
</td>
<td class="nump">489,177,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">606,301,054<span></span>
</td>
<td class="nump">480,082,966<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763456126256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 458<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of sales</a></td>
<td class="num">(346)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">112<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">49,283<span></span>
</td>
<td class="nump">79,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">26,579<span></span>
</td>
<td class="nump">33,907<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">75,862<span></span>
</td>
<td class="nump">113,313<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(75,750)<span></span>
</td>
<td class="num">(73,313)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income/(expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_GainLossFromResearchAndDevelopmentTaxCredit', window );">Research and development tax credit</a></td>
<td class="nump">9,634<span></span>
</td>
<td class="nump">15,630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="num">(815)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Interest income</a></td>
<td class="nump">2,821<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(521)<span></span>
</td>
<td class="num">(340)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_UnrealizedGainLossOnWarrants', window );">Fair value movement on warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange (loss)/gain</a></td>
<td class="num">(3,817)<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">7,302<span></span>
</td>
<td class="nump">17,726<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(68,448)<span></span>
</td>
<td class="num">(55,587)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (expense)/income</a></td>
<td class="num">(253)<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (68,701)<span></span>
</td>
<td class="num">$ (55,569)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per ordinary share, basic (in dollars per share)</a></td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Loss per ordinary share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_GainLossFromResearchAndDevelopmentTaxCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) From Research And Development Tax Credit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_GainLossFromResearchAndDevelopmentTaxCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_UnrealizedGainLossOnWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrealized Gain (Loss) On Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_UnrealizedGainLossOnWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763453951856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>At-The-Market Sales Agreement</div></th>
<th class="th"><div>Public Stock Offering</div></th>
<th class="th"><div>Ordinary shares</div></th>
<th class="th">
<div>Ordinary shares </div>
<div>At-The-Market Sales Agreement</div>
</th>
<th class="th">
<div>Ordinary shares </div>
<div>Public Stock Offering</div>
</th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th">
<div>Additional paid-in capital </div>
<div>At-The-Market Sales Agreement</div>
</th>
<th class="th">
<div>Additional paid-in capital </div>
<div>Public Stock Offering</div>
</th>
<th class="th"><div>Ordinary shares held in treasury</div></th>
<th class="th"><div>Accumulated other comprehensive loss</div></th>
<th class="th"><div>Accumulated deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">488,304,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 184,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 366,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,700)<span></span>
</td>
<td class="num">$ (4,601)<span></span>
</td>
<td class="num">$ (207,050)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(55,569)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55,569)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">873,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted share units vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,097)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">25,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Common shares withheld for taxes on vested stock awards</a></td>
<td class="num">(6,850)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,850)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation', window );">Equity settled share-based compensation reclassified as cash-settled</a></td>
<td class="num">$ (588)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(588)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">480,082,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">489,177,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 148,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">385,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(603)<span></span>
</td>
<td class="num">(4,601)<span></span>
</td>
<td class="num">(263,716)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(68,701)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(68,701)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,696<span></span>
</td>
<td class="nump">114,080,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67<span></span>
</td>
<td class="nump">$ 140,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 6,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
<td class="nump">$ 133,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Issuance of ordinary shares to treasury (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Issuance of ordinary shares to treasury</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,748)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted share units vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(680)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Share options exercised</a></td>
<td class="nump">1,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">14,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Common shares withheld for taxes on vested stock awards</a></td>
<td class="num">(4,723)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,723)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation', window );">Equity settled share-based compensation reclassified as cash-settled</a></td>
<td class="nump">$ 128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">606,301,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">631,338,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 230,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 529,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,549)<span></span>
</td>
<td class="num">$ (4,601)<span></span>
</td>
<td class="num">$ (333,097)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Reclassification from Share-based Compensation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763453830816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (68,701)<span></span>
</td>
<td class="num">$ (55,569)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange loss/(gain)</a></td>
<td class="nump">3,817<span></span>
</td>
<td class="num">(176)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issue costs</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Accretion of redemption premium on debt</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">815<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,246)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">14,121<span></span>
</td>
<td class="nump">25,425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">636<span></span>
</td>
<td class="nump">629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_IncreaseDecreaseInEquityInterestReceivable', window );">Equity interest recognized as revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(15,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">1,538<span></span>
</td>
<td class="nump">501<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent', window );">Tax incentive receivables</a></td>
<td class="nump">3,964<span></span>
</td>
<td class="num">(6,924)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="num">(1,325)<span></span>
</td>
<td class="num">(343)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Right-of-use assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(440)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(7,146)<span></span>
</td>
<td class="nump">9,866<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(8,504)<span></span>
</td>
<td class="nump">11,389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(597)<span></span>
</td>
<td class="num">(373)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedTaxesPayable', window );">Taxes payable</a></td>
<td class="nump">136<span></span>
</td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="nump">1,196<span></span>
</td>
<td class="num">(379)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(59,862)<span></span>
</td>
<td class="num">(33,254)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of furniture and equipment</a></td>
<td class="num">(29)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(29)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of ordinary shares</a></td>
<td class="nump">149,797<span></span>
</td>
<td class="nump">733<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of offering costs in connection with the issuance of ordinary shares</a></td>
<td class="num">(9,533)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of Oxford Term Loan</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Oxford Term Loan issuance costs</a></td>
<td class="num">(245)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of SVB Term Loan</a></td>
<td class="num">(5,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfLoanCosts', window );">SVB Term Loan repayment costs</a></td>
<td class="num">(850)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments of withholding taxes from share-based awards</a></td>
<td class="num">(4,723)<span></span>
</td>
<td class="num">(6,850)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of share options</a></td>
<td class="nump">1,372<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by/(used in) financing activities</a></td>
<td class="nump">140,818<span></span>
</td>
<td class="num">(6,117)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(1,480)<span></span>
</td>
<td class="num">(223)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="nump">79,447<span></span>
</td>
<td class="num">(39,606)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of the year</a></td>
<td class="nump">148,380<span></span>
</td>
<td class="nump">187,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of the year</a></td>
<td class="nump">227,827<span></span>
</td>
<td class="nump">148,380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">$ 348<span></span>
</td>
<td class="nump">$ 215<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period of all taxes owed but not paid, including income, property and other taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfLoanCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan origination associated cost which is usually collected through escrow.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfLoanCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_IncreaseDecreaseInEquityInterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Equity Interest Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_IncreaseDecreaseInEquityInterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Tax And Tax Credit Receivables, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763455689840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and description of business operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_OrganizationAndBusinessDescriptionTextBlock', window );">Organization and description of business operations</a></td>
<td class="text">Organization and description of business operations <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Verona Pharma plc (the "Company") is incorporated and domiciled in the United Kingdom. Verona Pharma plc has one wholly-owned subsidiary, Verona Pharma, Inc., a Delaware corporation. Rhinopharma Limited (&#8220;Rhinopharma&#8221;), a Canadian company that was previously a non-operating, wholly-owned subsidiary, was dissolved in June 2021. The address of the registered office is 1 Central Square, Cardiff, CF10 1FS, United Kingdom.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company is a clinical-stage biopharmaceutical group focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. The Company&#8217;s American Depositary Shares (&#8220;ADSs&#8221;) are listed on the Nasdaq Global Market (&#8220;Nasdaq&#8221;) and trade under the symbol &#8220;VRNA&#8221;. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Liquidity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company has incurred recurring losses and negative cashflows from operations since inception, and has an accumulated deficit of $333.1&#160;million as of December 31, 2022. The Company expects to incur additional losses and negative cash flows from operations until its products potentially gain regulatory approval and reach commercial profitability, if at all.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company expects that its cash and cash equivalents as of December 31, 2022, will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months from the date of issuance.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In August 2022, the Company completed an upsized public offering of 14,260,000 ADSs, each representing eight ordinary shares of the Company, nominal value &#163;0.05 per share, at a price to the public of $10.50 per ADS, which includes the exercise in full by the underwriters of their option to purchase an additional 1,860,000 ADSs. The aggregate net proceeds from the offering were $140.2&#160;million after deducting underwriting discounts and commissions and estimated offering expenses payable.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In October 2022, the Company entered into a term loan of up to $150.0&#160;million (the &#8220;Oxford Term Loan&#8221;) with Oxford Finance Luxembourg S.&#192; R.L. (&#8220;Oxford&#8221;). This Oxford Term Loan replaced the Company&#8217;s existing $30.0&#160;million facility with Silicon Valley Bank. See Note 7 for further details.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In March, 2021, the Company entered into an open market sale agreement with respect to an at-the-market offering program (the &#8220;ATM Program&#8221;) under which the Company may issue and sell its ordinary shares in the form of ADSs, with an aggregate offering price of up to $100.0&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">During the year ended December 31, 2021, the Company sold 873,104 ordinary shares (equivalent to 109,138 ADSs) under the ATM Program, at an average price of approximately $0.86 per share (equivalent to $6.91 per ADS), raising aggregate net proceeds of $0.7&#160;million after deducting issuance costs. As of December 31, 2021, there remained $99.3&#160;million of ordinary shares, in the form of ADSs, available for sale under the ATM Program.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">During the year ended December 31, 2022, the Company sold 80,696 ordinary shares (equivalent to 10,087 ADSs) under the ATM Program, at an average price of approximately $0.86 per share (equivalent to $6.86 per ADS), raising aggregate net proceeds of $0.1&#160;million after deducting issuance costs. As of December 31, 2022, there remained $99.2&#160;million of ordinary shares, in the form of ADSs, available for sale under the ATM Program.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Additionally, between January 1, 2023 and March 3, 2023, the Company sold 20,321,384 ordinary shares (equivalent to 2,540,173 ADSs) under the ATM Program, at an average price of approximately $2.88 per share (equivalent to $23.08 per ADS), raising aggregate net proceeds of $56.9 million after deducting issuance costs. As of March&#160;3, 2023, there remained $40.6 million&#160;of ordinary shares, in the form of ADSs, available for sale under the ATM Program.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company&#8217;s commercial revenue, if any, will be derived from sales of products that we do not expect to be commercially available within the next year, if ever. Additionally, we may enter into out-licensing transactions from time to time but there can be no assurance that the company can secure such transactions in the future. Accordingly, we may need to obtain substantial additional funds to achieve our business objectives including to further advance clinical and regulatory activities, to fund prelaunch and launch related costs and to create an effective sales and marketing organization to commercialize ensifentrine. Any such additional funding will need to be obtained through public or private financings, debt financing, collaboration or licensing agreements and other arrangements. However, there is no guarantee that we will be successful in securing additional capital on acceptable terms, or at all.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_OrganizationAndBusinessDescriptionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization And Business Description</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_OrganizationAndBusinessDescriptionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763458639232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting policies</a></td>
<td class="text">Basis of Presentation and Summary of Significant Accounting policies<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Basis of presentation and consolidation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The consolidated financial statements include the accounts of Verona Pharma plc and its wholly-owned subsidiaries Verona Pharma, Inc. and Rhinopharma through to its dissolution in June 2021. All inter-company balances and transactions have been eliminated. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") and the following accounting policies have been consistently applied.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">At the end of the second quarter of 2020, the Company determined that it no longer qualified as a Foreign Private Issuer under SEC rules. As a result, beginning January 1, 2021, the Company was required to report with the SEC on domestic forms and comply with domestic company rules in the United States. The transition to U.S. GAAP was made retrospectively for all periods from the Company&#8217;s inception.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Use of estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual and prepayment of research and development expenses and the fair value of share-based compensation. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from the Company&#8217;s estimates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Business combinations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company applies the acquisition method to account for business combinations. The consideration transferred for the acquisition of a subsidiary is the fair value of the assets transferred, the liabilities incurred to the former owners of the acquiree and the equity interests issued by the Company. The consideration transferred includes the fair value of any asset or liability resulting from a contingent consideration arrangement. The excess of the cost of acquisition over the fair value of the Company's share of the identifiable net assets acquired is recorded as goodwill. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Identifiable ass</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">ets acquired and liabilities and contingent liabilities assumed in a business combination are measured initially at their fair values at the acquisition date. Acquisition-related costs are expensed as incurred and included in administrative expenses.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Cash and cash equivalents</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company considers all highly liquid investments purchased with original maturities of ninety days or less at acquisition to be cash equivalents. Cash and cash equivalents includes deposits held at call with banks, and in money market funds investing in U.S. and U.K. government debt and liquid securities from highly rated institutions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Equity interest</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As part of the Nuance Agreement, the Company received an equity interest in Nuance Biotech, the parent company of Nuance Pharma (see Note 8). As Nuance Biotech&#8217;s securities are not publicly traded the equity interest&#8217;s fair value is not readily determinable. The Company therefore follows guidance from ASC 321-10-35-2 and uses the fair value measurement alternative and measures the securities at cost, which is deemed to be the value indicated by the last observable transaction in Nuance Biotech's stock, subject to impairment. The valuation will be adjusted for any observable price changes in orderly transactions for an identical or similar investment in Nuance Biotech, or if there is an indicator of impairment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Furniture and equipment, net</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Furniture and equipment comprise office furniture and computer equipment and are stated at cost less accumulated depreciation, which is calculated on a straight-line basis over the expected useful economic lives, generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzQ1MDg_ff010e70-9a6d-4e4c-a482-a7e0d106f1e3">two</span> to five years.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Goodwill</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Goodwill consists of goodwill related to the acquisition of Rhinopharma. Goodwill is not amortized but periodically tested for impairment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Impairment of long-lived assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company reviews long-lived assets for impairment annually or whenever events or changes in circumstances indicate that the carrying amount of assets may not be fully recoverable. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Revenue recognition</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company&#8217;s revenue consists of revenue from the Company&#8217;s strategic agreements for the development and commercialization of ensifentrine. The terms of the agreements typically include non-refundable upfront fees, payments based upon achievement of milestones and eventually revenue from the commercialized product. These agreements usually have both fixed and variable consideration. Non-refundable upfront fees are considered fixed, while milestone payments and revenue from the commercialized product are identified as variable consideration.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under agreements within the scope of ASC Topic 606, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic 606. The Company&#8217;s performance obligations include intellectual property rights, (which include the license, patents and developmental and regulatory data) and manufacturing and supply. Management are required to judge when performance obligations are satisfied and consequently when revenue is recognized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company allocates the total transaction price to each performance obligation based on the estimated relative standalone selling prices of the promised goods or service underlying each performance obligation. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied. If the right to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the right when the right is transferred to the customer, and the customer can use and benefit from the right.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">At the inception of the arrangement, the Company evaluates whether the development milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company, such as approvals from regulators, are not considered probable of being achieved until those approvals are received.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Research and development costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Research and development (&#8220;R&amp;D&#8221;) costs are expensed as incurred. Research and development expenses include salaries, share-based compensation and benefits of employees, and other costs related to the Company&#8217;s R&amp;D activities, including contracts with clinical research organizations and contract manufacturers. The Company is required to estimate its expenses resulting from its obligations under contracts with vendors and consultants and clinical site agreements in connection with its R&amp;D efforts. The financial terms of these contracts are subject to negotiations which vary contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts. The Company&#8217;s objective is to reflect the appropriate clinical trial expenses in its consolidated financial statements by matching those expenses with the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of the trials and other development activities. Judgment is applied in determining assumptions related to patient progression and the timing of various aspects of the trial used to measure progress. The Company determines prepaid and accrual estimates through discussions with applicable personnel and outside service providers as to the progress of clinical trials, or other services completed. During the course of a clinical trial, the Company adjusts its </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">rate of clinical trial expense recognition if actual results differ from its estimates. The Company makes estimates of its prepaid and accrued expenses as of each balance sheet date in its consolidated financial statements based on facts and circumstances known at that time. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in the Company reporting amounts that are too high or too low for any particular period. The Company&#8217;s clinical trial prepaid and accrual expense is dependent upon the timely and accurate reporting of study recruitment from contract research organizations and activities carried out by other third-party vendors as well as the timely processing of any change orders from the contract research organizations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Share-based compensation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company has a share-based compensation plan under which various types of equity-based awards may be granted, including stock options and restricted stock units (RSUs). The fair value of share options and RSUs, which are subject to milestone or service conditions with graded vesting, are recognized as compensation expense on a straight-line basis using the graded-vesting method; f</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">orfeitures are recognized as they occur.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company uses the fair-value based method to determine compensation for all arrangements under which employees receive shares. The fair value of each option and RSU is estimated on the date of grant using the Black-Scholes valuation model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate. Expected volatility is based on the historical volatility of the Company&#8217;s ordinary shares over the expected term of the options. The expected term of options granted is derived using the simplified method, which computes the expected term as the average of the sum of the vesting term plus the contract term. Historically the risk-free rate has been based on the appropriate U.K. government debt yield. After delisting its Ordinary shares from AIM on October 30, 2020, the Company used U.S. government debt yields.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Details of the assumptions used are set out in Note 9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">to the consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Other income - United Kingdom R&amp;D tax credits </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Other income relates to R&amp;D tax credits receivable in the UK. As a company that carries out extensive research and development activities, Verona is subject to the UK R&amp;D Small and Medium Enterprise (&#8220;SME&#8221;) Program. Qualifying expenditures largely comprise employment costs for research staff, consumables, a proportion of relevant, permitted sub-contract costs and certain internal overhead costs incurred as part of research projects for which it does not receive income. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Tax credits related to the SME Program are received as cash and are recorded as other income, as they are akin to grant income, in the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Income taxes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company accounts for income taxes in accordance with ASC 740, &#8220;Income Taxes&#8221; (&#8220;ASC 740&#8221;). ASC 740 prescribes the use of the liability method, whereby deferred tax assets and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. ASC 740 establishes a single model to address accounting for uncertain tax positions. ASC 740 clarified the accounting for income taxes by prescribing the minimum recognition threshold a tax position is required to meet before being recognized in the financial statements. The Company has no uncertain tax positions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Comprehensive loss</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company accounts for comprehensive loss in accordance with ASC 220, &#8220;Income Statement - Reporting Comprehensive Income&#8221;. Comprehensive income represents all changes in stockholders&#8217; equity during the period except those resulting from investments by, or distributions to, stockholders.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Segment Reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company has one operating and reportable segment, pharmaceutical development. The Company&#8217;s long-lived assets are held in the United Kingdom.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Foreign Currencies</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Reporting and functional currencies</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The consolidated financial statements are reported in U.S. dollars, which is also the functional currency of our subsidiary. Transactions in foreign currencies are remeasured into our functional currency at the rate of exchange prevailing at the date of the transaction. Any monetary assets and liabilities arising from these transactions are remeasured into our functional currency at exchange rates prevailing at the balance sheet date or on settlement. Resulting gains and losses are recorded in foreign exchange loss in our consolidated statements of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Treasury shares</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the year ended December 31, 2020, the Company incorporated a trust to facilitate the acquisition of shares, by or for the benefit of employees and former employees. In the year ended December 31, 2022, the Company issued 28.0&#160;million ordinary shares (equivalent to 3.5&#160;million ADSs) to cover expected shares issued upon the vesting of share awards to employees. The Company issued no ordinary shares in the year ended December 31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company has the indirect ability to control the trust as trustees are required to act in accordance with the trust deed and because the Company controls the issuance of shares to cover awards. As a consequence, the trust is consolidated into the Company&#8217;s consolidated financial statements. The shares that were issued to the trust that have not been issued to employees to satisfy vesting of share awards are included in the Consolidated Balance Sheets as treasury shares.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Fair value of financial instruments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">US GAAP defines fair value and requires companies to establish a framework for measuring fair value and disclosure about fair value measurements using a three-tier approach. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our financial instruments include cash equivalents, an equity interest, other assets, accounts payable and accrued expenses and other liabilities. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgement and therefore cannot be determined with precision. The equity interest is held at cost subject to impairment, following </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">guidance from ASC 321-10-35-2</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. The carrying amounts of the other instruments are considered to be representative of their fair values because of their short-term nature.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Concentration of credit risk</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Financial instruments that potentially subject the Company to concentration of credit risk consist of principally cash and cash equivalents, bank deposits and certain receivables. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company holds cash and cash equivalents with highly rated financial institutions and in highly rated money market funds and the Company has not experienced any significant credit losses in these accounts and does not believe the Company is exposed to any significant credit risk on these instruments.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Lease accounting </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The company accounts for leases in accordance with ASU No. 2016-02, &#8220;Leases&#8221; (Topic 842) (&#8220;ASC 842&#8221;). The standard requires lessees to recognize almost all leases on the balance sheet as right-of-use (&#8220;ROU&#8221;) assets and lease liabilities, and requires leases to be classified as either operating or finance type leases. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Under ASC 842, the Company determines if an arrangement is a lease at inception. ROU ass</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">ets and liabilities are recognized at the commencement date based on the present value of remaining lease payments. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As the Company's leases do not provide an implicit rate, the Company determines the incremental borrowing rate in calculating the present value of lease payments. The ROU assets also include any lease payments made prior to commencement and are recorded net of any lease incentives received. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company&#8217;s lease terms may include options to extend or terminate the lease. When it is reasonably certain the Company will exercise such options the lease will be recognized as a liability and a corresponding ROU asset also recognized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Operating leases are included in Right-of-use assets and in Current and non-current operating lease liabilities on the Company's Consolidated Balance Sheets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Recently issued accounting pronouncements, not yet adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326)-Measurement of Credit Losses on Financial Instruments. This guidance replaces the current incurred loss impairment methodology. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Under the new guidance, on initial recognition and at each reporting period, an entity is required to recognize an allowance that reflects its current estimate of credit losses expected to be incurred over the life of the financial instrument based on historical experience, current conditions and reasonable and supportable forecasts. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates (&#8220;ASU 2019-10&#8221;). The purpose of this amendment is to create a two tier rollout of major updates, staggering the effective dates between larger public companies and all other entities. This granted certain classes of companies, including Smaller Reporting Companies (&#8220;SRCs&#8221;), additional time to implement major FASB standards, including ASU 2016-13. Larger public companies will have an effective date for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. All other entities are permitted to defer adoption of ASU 2016-13, and its related amendments, until fiscal periods beginning after December 15, 2022. Under the current SEC definitions, we meet the definition of an SRC as of the ASU 2019-10 issuance date and are deferring adoption for ASU 2016-13. The guidance requires a modified retrospective transition approach through a cumulative-effect adjustment to retained earnings as of the beginning of the period of adoption. We are currently evaluating the impact of the adoption of ASU 2016-13 on our consolidated financial statements, but do not believe the adoption of this standard will have a material impact on our consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Other accounting standards that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company&#8217;s financial statements upon adoption.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763457126000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_PrepaidExpenseDisclosureTextBlock', window );">Prepaid expenses</a></td>
<td class="text">Prepaid expenses <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Prepaid expenses consisted of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial and other development costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,169&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,027&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total prepaid expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,499&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,037&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_PrepaidExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expense, Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_PrepaidExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763457319408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Property leases</a></td>
<td class="text">Property leases<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The right-of-use assets (&#8220;ROU&#8221;) relate to rented office space in London, North Carolina and Georgia with leases ending in 2023, 2024 and 2025, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the year ended December 31, 2022, the Company entered into a lease arrangement in Georgia for office space and extended its existing London lease and recognized lease liability and corresponding ROU asset of $0.7&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the year ended December 31, 2021, the Company extended its existing London lease. As a consequence it modified its accounting for the lease and recorded $0.6&#160;million lease liability and corresponding ROU asset.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">To calculate lease liabilities the Company used a weighted average discount rate of 4% and 8% for the years ended December 31, 2022 and December 31, 2021, respectively. The weighted average remaining lease term as of December 31, 2022 and December 31, 2021 was 1.5 and 1.8 years, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Minimum annual payments over the remaining lease periods as of December 31, 2022 are as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.926%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum future lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">880&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The total operating lease expense included in selling, general and administrative costs was $0.6&#160;million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763457319408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued expenses</a></td>
<td class="text">Accrued expenses<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial and other development costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,314&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,336&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees, listing and general corporate costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">People related costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,752&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,256&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763457404880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_WarrantAndRightsDisclosureTextBlock', window );">Warrants</a></td>
<td class="text">Warrants<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">On May 2, 2022 all remaining warrants expired. No warrants were exercised or forfeited in the years ended December 31, 2022 and 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In 2016, the Company issued 31,115,926 units to new and existing investors at the placing price of &#163;1.4365 per unit. Each unit comprised one ordinary share and one warrant. The warrant holders could subscribe for 0.4 of an ordinary share at a per share exercise price of &#163;1.7238 until May 2, 2022. The warrant holders could opt for a cashless exercise of their warrants, whereby the warrant holders could choose to exchange the warrants held for a reduced number of warrants exercisable at nil consideration. The reduced number of warrants was calculated based on a formula considering the share price and the exercise price of the warrants.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">If, after a transaction, should the warrants be exercisable for unlisted securities, the warrant holders were able to demand a cash payment instead of the delivery of the underlying securities. Accordingly, the warrants were accounted for as a liability under ASC 480 &#8220;Distinguishing Liabilities from Equity&#8221;. The warrants were measured at fair value, classified as Level 3 in the fair value hierarchy, with movements recorded in other income/(expense) in the Consolidated Statements of Operations and Comprehensive Loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">At December 31, 2021, 31,003,155 warrants remained outstanding and entitled the investors to subscribe for, in aggregate, a maximum of 12,401,262 ordinary shares.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The warrants had no intrinsic value as at December 31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">There have been no changes in valuation techniques or transfers between fair value measurement levels during the years ended December 31, 2022 and 2021. There has been no change in fair value between December 31, 2021, and May 2, 2022 (expiration). The warrants were valued using the Black-Scholes model and the table below presents the assumptions used:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price in pounds sterling</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#163;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7238&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term to exercise</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.33</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annualized volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Calculated value of the warrants, in thousands of U.S. dollars</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows the movement of the value of the warrants (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">At January 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,246)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">At December 31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_WarrantAndRightsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant And Rights Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_WarrantAndRightsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763457772160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term loan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Term loan</a></td>
<td class="text">Term loan<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In November 2020, the Company entered into a term loan facility of up to $30.0&#160;million (the &#8220;SVB Term Loan&#8221;), consisting of advances of $5.0&#160;million funded at closing and $10.0&#160;million and $15.0&#160;million&#160;contingent upon achievement of certain clinical development milestones and other specified conditions. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The SVB Term Loan was categorized within Level 3 of the fair value hierarchy and the carrying amount of the debt approximated its fair value based on prevailing interest rates as of December 31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">On October 14, 2022 (the &#8220;Effective Date&#8221;), the Company entered into a loan and security agreement (the &#8220;Loan Agreement&#8221;) with Oxford Finance Luxembourg S.&#192; R.L. (&#8220;Oxford&#8221;) for an aggregate amount of up to $150.0&#160;million (the &#8220;Oxford Term Loan&#8221;). The Oxford Term Loan provides for an initial term loan advance in an aggregate amount of $10.0&#160;million funded on the Effective Date (the &#8220;Oxford Term A Loan&#8221;), and up to four additional term loan advances in an aggregate amount of $140.0&#160;million, which are available as described below and subject to terms of the Loan Agreement. The proceeds from the Oxford Term Loan will be used for general corporate and working capital purposes, and a portion of the proceeds of the Oxford Term A Loan have been used to repay in full the existing outstanding indebtedness owed to SVB.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The four additional term loan advances under the Oxford Term Loan consist of: a $10.0&#160;million term loan advance (the &#8220;Oxford Term B Loan&#8221;) which is available at the option of the Company from the Effective Date up to and including March 31, 2023; a $20.0&#160;million term loan advance (the &#8220;Oxford Term C Loan&#8221;) available during the period commencing on the later of January 1, 2024 and the date on which the Company receives positive ENHANCE-1 data in the Phase 3 clinical trial for ensifentrine sufficient to support the submission of a New Drug Application (&#8220;NDA&#8221;) with the United States Food and Drug Administration (the &#8220;FDA&#8221;) for ensifentrine through and including March 29, 2024; a $60.0&#160;million term loan advance (the &#8220;Oxford Term D Loan&#8221;) available during the period commencing on the later of October 1, 2024 and the date on which the Company receives final approval from the FDA for the Company&#8217;s NDA for ensifentrine up to and including December 31, 2024; and a $50.0&#160;million term loan advance (the &#8220;Oxford Term E Loan&#8221;) available during the interest-only period at the Company&#8217;s request and at Oxford&#8217;s sole discretion.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Each advance under the Oxford Term Loan accrues interest at a floating per annum rate equal to (a) the greater of (i) the 1-Month CME Term SOFR reference rate on the last business day of the month that immediately precedes the month in which the interest will accrue and (ii) 2.38%, plus (b) 5.50% (the &#8220;Basic Rate&#8221;). In no event shall the Basic Rate (x) for the Oxford Term A Loan be less than 7.88% and (y) for each other advance be less than the Basic Rate on the business day immediately prior to the funding date of such term advance. The Basic Rate for the Term A Loan for the period from the Effective Date through and including October 31, 2022 shall be 8.54205% and the Basic Rate for each Term Loan shall not increase by more than 2.00% above the applicable Basic Rate as of the funding date of each such term loan. The Oxford Term Loan provides for interest-only payments on a monthly basis until the payment date immediately preceding December 1, 2025, if the Oxford Term D Loan is not made, and December 1, 2026, if the Oxford Term D Loan is made. Thereafter, amortization payments will be payable monthly in equal installments of principal plus accrued interest. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Upon repayment, whether at maturity, upon acceleration or by prepayment or otherwise, the Company shall make a final payment to the lenders in an amount ranging from 1.30% to 3.00% of the aggregate principal balance, depending on the advances received under the Oxford Term Loan. The Company may prepay the Oxford Term Loan in full, or in part, in accordance with the terms of the Loan Agreement, which is subject to a prepayment fee of up to 2.00%, depending on the timing of the prepayment. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Oxford Term Loan is secured by a lien on substantially all of the assets of the Company, other than intellectual property, but including any rights to payments and proceeds from the sale, licensing or disposition of intellectual property. The Company has also granted Oxford a negative pledge with respect to its intellectual property. The Loan Agreement contains customary covenants and representations, including but not limited to financial reporting obligations and limitations on dividends, dispositions, indebtedness, collateral, investments, distributions, transfers, mergers or acquisitions, taxes, corporate changes, deposit accounts, transactions with affiliates and subsidiaries. The Loan Agreement also contains other customary provisions, such as expense reimbursement, non-disclosure obligations as well as indemnification rights for the benefit of Oxford.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763458723248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Significant agreements</a></td>
<td class="text">Significant agreements<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Ligand agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In 2006 the Company acquired Rhinopharma and assumed contingent liabilities owed to Ligand UK Development Limited (&#8220;Ligand&#8221;) (formerly Vernalis Development Limited). The Company refers to the assignment and license agreement as the Ligand Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Ligand assigned to the Company all of its rights to certain patents and patent applications relating to ensifentrine and related compounds (the "Ligand Patents") and an exclusive, worldwide, royalty-bearing license under certain Ligand know-how to develop, manufacture and commercialize products (the "Ligand Licensed Products") developed using Ligand Patents, Ligand know-how and the physical stock of certain compounds.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company is obligated to pay a milestone payment on obtaining the first approval of any regulatory authority for the commercialization of a Ligand Licensed Product, low single digit royalties based on the future sales performance of all Ligand Licensed Products and a portion equal to a mid-twenty percent of any consideration received from any sub-licensees for the Ligand Patents and for Ligand know-how. Royalties payable are based on the future sales performance so the amount payable is unlimited.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">At the time each contingency is resolved, the Company will record the contingent consideration payment (or payable) in connection with the Ligand Agreement as an expense and will classify it within R&amp;D expenses.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In March 2022, the Company entered into an Amendment Agreement (the &#8220;Amendment&#8221;) with Ligand whereby the Ligand Agreement was amended to clarify certain ambiguous terms in the Ligand Agreement. Pursuant to the Amendment:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">the Company agreed to pay to Ligand (i) $2.0&#160;million within five business days of the date of the Amendment and (ii) $15.0&#160;million upon the first commercial sale of ensifentrine by the Company or a sub-licensee, which amount is payable in cash or, at the Company's discretion, by the issuance of Company equity of equivalent value, as determined based on the volume-weighted average price of the Company's American Depositary Shares on the Nasdaq Global Market over the ten (10) trading days including and prior to such milestone event;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">the Ligand Agreement shall expire on March 24, 2042 unless terminated earlier by either party in accordance with its terms;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">upon termination of the Ligand Agreement, any Sub-licensee (as defined in the Amendment) shall have the right to enter into a direct license agreement with Ligand for the portion of the Program IP (as defined in the Amendment) that was sub-licensed by such Sub-licensee;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">the milestone payment may be paid in cash or, at the Company&#8217;s discretion, by issuing to Ligand shares in the Company of equivalent value; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt">each party&#8217;s right to terminate the Ligand Agreement is conditioned upon such party obtaining a final judgment of the English High Court declaring that the other party is in material breach of its obligations under the Ligand Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company accounted for the $2.0&#160;million payment at execution of the Amendment as selling, general and administrative expense in the consolidated statements of operations as the payment is related to a contract modification.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Nuance agreement </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company entered into a collaboration and license agreement (the &#8220;Nuance Agreement&#8221;) with Nuance Pharma Limited (&#8220;Nuance Pharma&#8221;) effective June 9, 2021 (the &#8220;Effective Date&#8221;), under which the Company granted Nuance Pharma the exclusive rights to develop and commercialize ensifentrine in Greater China (China, Taiwan, Hong Kong and Macau). In return, the Company received an unconditional right to consideration aggregating $40.0&#160;million consisting of $25.0&#160;million in cash and an equity interest, valued at $15.0&#160;million as of the Effective Date, in Nuance Biotech, the parent company of Nuance Pharma. The Company is eligible to receive future milestone payments of up to $179.0&#160;million triggered upon achievement of certain clinical, regulatory, and commercial milestones, as well as tiered double-digit royalties as a percentage of net sales of the products in Greater China. The Company will recognize these milestones when it is probable that a significant revenue reversal would not occur.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As of December 31, 2022, the $25.0&#160;million cash payment and $15.0&#160;million equity interest had been received and the holding in Nuance Biotech was recorded as Equity interest on the Consolidated Balance Sheet. The Equity </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">interest is recorded at cost as the Company has elected to use the measurement alternative for equity investments without readily determinable fair values. The Company will evaluate this investment for indicators of impairment quarterly. The Company did not identify events or changes in circumstances that may have a significant effect on the fair value of the investment during the year ended December 31, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Under the terms of the Nuance Agreement, at any time until three months prior to the expected submission of the first New Drug Application in Greater China, if (i) a third party is interested in partnering with the Company, either globally or in territory covering at least the United States or Europe, for the development and/or commercialization of ensifentrine or (ii) the Company undergoes a change of control, the Company will have an exclusive option right to buy back the license granted to Nuance Pharma and all related assets. The price is agreed to be equal to the aggregate of (i) all prior amounts paid by Nuance Pharma to the Company in cash under the agreement and (ii) all development and regulatory costs incurred and paid by Nuance Pharma in connection with the development and commercialization of ensifentrine under the Nuance Agreement multiplied by a single-digit factor range dependent upon achievement of certain milestones, subject to a specified maximum amount.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Nuance Agreement will continue on a jurisdiction-by-jurisdiction and product-by-product basis until the expiration of royalty payment obligations with respect to such product in such jurisdiction unless earlier terminated by the parties. Either party may terminate the Nuance Agreement for an uncured material breach or bankruptcy of the other party. Nuance Pharma may also terminate the Nuance Agreement at will upon 90 days' prior written notice. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company reviewed the buy-back option and determined that because it is conditional on a third party the Company does not have the practical ability to exercise it and, accordingly, the contract is accounted for under ASC 606.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The transaction price at the Effective Date of the Nuance Agreement was $40.0&#160;million consisting of the $25.0&#160;million upfront cash payment and $15.0&#160;million equity interest. Developmental and regulatory milestones, and the manufacture and supply of ensifentrine drug product, were not included in the transaction price as management determined that it is not probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Commercial milestones and sales royalties were also excluded and will be recognized when the milestones are achieved or the sales occur in Greater China.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The performance obligations in the Nuance Agreement include the grant of the license (including the right to commercialize ensifentrine until the end of the term, the sharing of certain know how, and the sharing of certain clinical and regulatory data), and manufacture and supply of ensifentrine drug product. The Company has determined that the manufacturing and supply was not at a discount.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company has determined that the license and the know how shared with Nuance Pharma constitutes functional intellectual property and that revenue relating to this should be recognized at a point in time. Consequently, the Company determined that it fulfilled its obligations to Nuance Pharma after it delivered the know how that will allow Nuance Pharma to file an investigational new drug application in Greater China. This know how was delivered in the year ended December 31, 2021, and the $40.0&#160;million revenue was therefore recognized as revenue in this period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">On the Effective Date, $4.0&#160;million of costs of obtaining the contract were recorded as a contract asset. As of December 31, 2021, the entire cost had been recognized in the Consolidated Statements of Operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">On April 13, 2022, the Company formalized the Agreement for the Manufacture and Supply of ensifentrine (&#8220;Nuance Supply Agreement&#8221;) with Nuance Pharma. The Company determined that the manufacturing and supply of ensifentrine to Nuance represents a distinct and separate performance obligation, for which consideration to be received is variable based on the quantities to be ordered by Nuance. Revenue earned with the manufacture and supply of the licensed product is, and will be, recognized as the supply is delivered to Nuance. The Company has determined it is acting as principal in relation to the manufacture and supply under the Agreement. In its capacity as principal, the Company will recognize the associated revenue on a gross basis. As of December 31, 2022, the Company has recognized $0.5&#160;million in relation to the clinical supply of ensifentrine to Nuance Pharma.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763458749184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Benefit plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanTextBlock', window );">Benefits plans</a></td>
<td class="text">Benefit plansThe Company maintains a 401(k) defined contribution retirement plan in the U.S. and a defined contribution plan in the U.K. for its employees and executive directors. The assets of the plans are held separately from those of the Company in independently administered funds.<span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The retirement plan cost charge represents the contributions payable by the Company to the plans during the year. Defined contribution costs during the years ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">December 31, 2022</span> and 2021 amounted to $319 thousand and $274 thousand, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -URI https://asc.fasb.org/subtopic&amp;trid=2235116<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763457126000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Taxation</a></td>
<td class="text">Taxation<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Verona Pharma plc operates in the United Kingdom and Verona Pharma, Inc. in the United States and they are subject to income taxes in those countries. U.K. corporation tax is charged at 19% and the U.S. Federal Income tax rate is 21%.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The components of (profit)/loss before income taxes are as follows (in thousands): </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,868)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,850)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,448&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,587&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The components of income tax expense are as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current tax expense/(credit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total deferred tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total income tax expense/(credit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">A reconciliation of the U.K. statutory income tax rate to our effective income tax rate is as follows (in percentages):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.K. tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development incentive</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share options exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred tax valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other differences</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effective income tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Components of the Company&#8217;s deferred tax assets and liabilities are as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,565)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,903)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,565)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,903)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,931&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D asset</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Future exercisable shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(516)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,041&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,155&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,476)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,252)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets, net of valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Movements in the deferred tax valuation allowance </span></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation allowance at January 1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase/(decrease) in valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,422)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation allowance at December 31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,476&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,252&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">These relate to the difference in the tax base of the IP R&amp;D asset and assumed contingent liability and the financial reporting base, which is nil under U.S. GAAP.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Management has reviewed cumulative tax losses and projections of future taxable losses and determined that it is not more likely than not that they will be realized. Accordingly, valuation allowances have been provided over deferred tax assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">At December 31, 2022 and December 31, 2021, the Company had U.K. net operating losses (&#8220;NOLs&#8221;) of $155.6&#160;million and $104.3&#160;million, respectively. The NOLs can be carried forward indefinitely to be offset against future taxable profits, but this is restricted to an annual &#163;5&#160;million allowance after which there will be a 50% restriction in the profits that can be covered by losses brought forward.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company files separate income tax returns in the U.K. and the U.S. All necessary income tax filings have been completed for all years up to and including December 31, 2021, and there are no ongoing tax examinations in any jurisdiction. No interest or penalties were recognized in the consolidated statements of operations or consolidated balance sheets. As of December 31, 2022, the Company has no uncertain tax positions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763457196096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share based compensation</a></td>
<td class="text">Share-based compensation<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company operates various share based incentive plans for its staff and issues ordinary shares or ADSs when share-based awards are exercised.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company records share-based compensation expense related to share options and RSUs granted to employees and directors. The expense is included in research and development and selling, general and administrative costs, based on the nature of individual employees&#8217; functions, and represents the relevant year's allocation of the expense. The costs of share-based compensation to employees are recognized in the consolidated statements of operations and comprehensive loss, together with a corresponding increase in equity over the vesting period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Options are issued with an exercise price of the closing market price on the day before the grant and generally vest over a period of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzgyMg_06949a37-1fa3-4277-8388-a28ff5d09dc6">one</span> to four years and the contractual life of all options is ten years. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows the allocation of share-based compensation between research and development and selling, general and administrative costs (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,420&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,654&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,771&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,121&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,425&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">EMI Option Plan and Pre-IPO Option Plan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The EMI Option Plan and the Pre-IPO Option Plan were adopted by our board of directors on September 18, 2006, and July 24, 2012, respectively. The total number of shares that may be issued under these plans is the current number of outstanding options over 114,000 ordinary shares, or 14,250 ADSs, for the EMI Option Plan and 1,860,000 ordinary shares, or 232,500 ADSs, for the Pre-IPO Option Plan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">No further awards have been granted under either plan since the 2017 Incentive Plan was adopted, and no further awards will be granted under them.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">2017 Incentive Plan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The 2017 Incentive Plan was adopted by our board of directors and became effective on April 26, 2017, in order to grant share based compensation to certain of the Company&#8217;s directors and employees. It provides for the grant of stock options, RSUs, and other share-based awards to Company&#8217;s directors, officers, employees and non-employee directors.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the year ended December 31, 2019, the Company modified the terms of all RSUs issued prior to January 1, 2019 to include a market based condition, which was also included in the terms of RSUs issued during 2019. The Company's stock price must be maintained above the equivalent of &#163;2 per ordinary share for thirty days for the RSUs to vest, in addition to the existing service condition. The RSUs vest five years after the date of grant irrespective of whether the &#163;2 market condition was met. This modification did not result in an increase in the fair value of the RSUs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Share option activity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The number of options, the weighted average grant date fair value per stock option, and the weighted average exercise price are all shown below on a per ordinary shares basis. The Company&#8217;s ADSs that are listed on the Nasdaq Global Market each represent eight ordinary shares.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows share option activity and includes the options outstanding from all three plans :</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.335%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.244%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of share options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average exercise price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average remaining contractual term (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate intrinsic value (thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at January 1, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,125,672&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,696,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,126,472)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December 31, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,695,200&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.38&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,024,000&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.90&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(620,016)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,822,688)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December 31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,276,496&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.22&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,412&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercisable at December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,382,256&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.48&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,543&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline"> (1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The exercise prices relate to the equivalent price for an ordinary share, calculated as one eighth of the ADS price.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following summarizes the aggregate intrinsic value and cash receipts related to stock option exercise activity for the years ended December 31:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.938%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.241%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">($ in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate intrinsic value of stock options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,413&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash receipts from stock options exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Determining the fair value of share options and RSUs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The total fair values of the options and RSUs were estimated using the Black-Scholes option-pricing model for equity-settled compensation, amounted to $19.6&#160;million for instruments granted in the year ended December 31, 2022 and $3.1&#160;million for instruments granted in the year ended December 31, 2021. The cost is amortized over the vesting period of the options and RSUs on a straight-line basis using the graded-vesting method. The following assumptions were used for the Black-Scholes valuation of share options granted in 2022 and 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Expected volatility</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Volatility is calculated using historical weekly averages of the Company's share price over a period that is in line with the expected life of the options and RSUs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Fair value of ordinary shares.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The fair value of ordinary shares has been based on the share price of the Company&#8217;s shares on AIM on the evening before the date of grant up until October 20, 2020 when the company delisted from AIM. Post this the fair value has been based on the ADS&#8217;s traded on Nasdaq on the evening before the date of grant.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Risk-free interest rate</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The risk-free interest rate has been based on U.K. Government debt yield for the relevant term at the time of grant up until October 20, 2020 when the company delisted from AIM. After this appropriate U.S Treasury yield rates were used.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Expected term.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As the Company does not have sufficient history to estimate its expected term, the Company applied the simplified method of estimating the expected term of the options, as described in the SEC&#8217;s Staff Accounting Bulletins 107 and </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">110. The expected term, calculated under the simplified method, is applied to all stock options which have similar contractual terms. Using this method, the expected term is determined using the average of the vesting period and the contractual life of the stock options granted</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Expected dividend</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">There are no expected dividends.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">A summary of the weighted-average assumptions applicable to the share options granted in the applicable years is as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.09% - 4.20%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.79% -1.32%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected lives, years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5-7</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5-7</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.50% - 84.27%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.35% - 87.68%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant date fair value (per share)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.34 - $1.33</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.62 - $0.78</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Restricted stock units activity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows RSU activity:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.957%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average grant date fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average remaining contractual term (years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at January 1, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,992,360&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,030,928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,002,584)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,673,352)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December 31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,347,352&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,877,864&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.07&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,006,264)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,676,608)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,542,344&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.01&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.476%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.243%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of RSUs outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average remaining vesting Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Period in which the target must be achieved</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs subject to time based vesting</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,028,680&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs subject to milestone based vesting</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">513,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 - 2024</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The intrinsic and fair value of RSUs that vested in the years ended December 31, 2022 and 2021, was $14.3&#160;million and $20.2&#160;million, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As of December 31, 2022, total compensation cost related to share options and RSUs granted but not yet recognized was $20.5&#160;million. This cost will be amortized to expense over a weighted average remaining period of 1.0 years and will be adjusted for subsequent forfeitures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763457332656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net loss per share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net loss per share</a></td>
<td class="text">Net loss per share <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Net loss per share is calculated on an ordinary share basis. The Company&#8217;s ADSs that are listed on the Nasdaq Global Market each represent eight ordinary shares. The following table shows the computation of basic and diluted earnings per share for 2022 and 2021 (net loss in thousands, loss per share in dollars):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68,701)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,569)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss available to ordinary shareholders - basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68,701)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,569)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding - basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529,071,526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473,188,457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss per share - basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.13)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.12)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">During the years ended December 31, 2022 and 2021, outstanding share options, RSUs and warrants of 53,818,840 and 63,443,814, respectively, were not included in the computation of diluted earnings per ordinary share, because to do so would be antidilutive.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763460968048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and contingencies</a></td>
<td class="text">Commitments and contingenciesManagement is currently negotiating a matter with a supplier that has an estimated exposure of approximately $1.5&#160;million. Management does not currently consider it probable that a payment will be made and therefore no accrual is recorded at December 31, 2022. This matter is expected to be resolved within the next 12 months.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763457190240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party transactions and other shareholder matters<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related party transactions and other shareholder matters</a></td>
<td class="text">Related party transactions and other shareholder mattersIn the years ended December 31, 2022 and 2021 there were no related party transactions.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763455891488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of presentation and consolidation</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Basis of presentation and consolidation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The consolidated financial statements include the accounts of Verona Pharma plc and its wholly-owned subsidiaries Verona Pharma, Inc. and Rhinopharma through to its dissolution in June 2021. All inter-company balances and transactions have been eliminated. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") and the following accounting policies have been consistently applied.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">At the end of the second quarter of 2020, the Company determined that it no longer qualified as a Foreign Private Issuer under SEC rules. As a result, beginning January 1, 2021, the Company was required to report with the SEC on domestic forms and comply with domestic company rules in the United States. The transition to U.S. GAAP was made retrospectively for all periods from the Company&#8217;s inception.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Use of estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual and prepayment of research and development expenses and the fair value of share-based compensation. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from the Company&#8217;s estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business combinations</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Business combinations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company applies the acquisition method to account for business combinations. The consideration transferred for the acquisition of a subsidiary is the fair value of the assets transferred, the liabilities incurred to the former owners of the acquiree and the equity interests issued by the Company. The consideration transferred includes the fair value of any asset or liability resulting from a contingent consideration arrangement. The excess of the cost of acquisition over the fair value of the Company's share of the identifiable net assets acquired is recorded as goodwill. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Identifiable ass</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">ets acquired and liabilities and contingent liabilities assumed in a business combination are measured initially at their fair values at the acquisition date. Acquisition-related costs are expensed as incurred and included in administrative expenses.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Cash and cash equivalents</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company considers all highly liquid investments purchased with original maturities of ninety days or less at acquisition to be cash equivalents. Cash and cash equivalents includes deposits held at call with banks, and in money market funds investing in U.S. and U.K. government debt and liquid securities from highly rated institutions.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Short term investments</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Equity interest</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As part of the Nuance Agreement, the Company received an equity interest in Nuance Biotech, the parent company of Nuance Pharma (see Note 8). As Nuance Biotech&#8217;s securities are not publicly traded the equity interest&#8217;s fair value is not readily determinable. The Company therefore follows guidance from ASC 321-10-35-2 and uses the fair value measurement alternative and measures the securities at cost, which is deemed to be the value indicated by the last observable transaction in Nuance Biotech's stock, subject to impairment. The valuation will be adjusted for any observable price changes in orderly transactions for an identical or similar investment in Nuance Biotech, or if there is an indicator of impairment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Furniture and equipment, net</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Furniture and equipment, net</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Furniture and equipment comprise office furniture and computer equipment and are stated at cost less accumulated depreciation, which is calculated on a straight-line basis over the expected useful economic lives, generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzQ1MDg_ff010e70-9a6d-4e4c-a482-a7e0d106f1e3">two</span> to five years.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Goodwill</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Goodwill consists of goodwill related to the acquisition of Rhinopharma. Goodwill is not amortized but periodically tested for impairment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text">Impairment of long-lived assetsThe Company reviews long-lived assets for impairment annually or whenever events or changes in circumstances indicate that the carrying amount of assets may not be fully recoverable.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Revenue recognition</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company&#8217;s revenue consists of revenue from the Company&#8217;s strategic agreements for the development and commercialization of ensifentrine. The terms of the agreements typically include non-refundable upfront fees, payments based upon achievement of milestones and eventually revenue from the commercialized product. These agreements usually have both fixed and variable consideration. Non-refundable upfront fees are considered fixed, while milestone payments and revenue from the commercialized product are identified as variable consideration.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under agreements within the scope of ASC Topic 606, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic 606. The Company&#8217;s performance obligations include intellectual property rights, (which include the license, patents and developmental and regulatory data) and manufacturing and supply. Management are required to judge when performance obligations are satisfied and consequently when revenue is recognized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company allocates the total transaction price to each performance obligation based on the estimated relative standalone selling prices of the promised goods or service underlying each performance obligation. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied. If the right to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the right when the right is transferred to the customer, and the customer can use and benefit from the right.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">At the inception of the arrangement, the Company evaluates whether the development milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company, such as approvals from regulators, are not considered probable of being achieved until those approvals are received.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development costs</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Research and development costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Research and development (&#8220;R&amp;D&#8221;) costs are expensed as incurred. Research and development expenses include salaries, share-based compensation and benefits of employees, and other costs related to the Company&#8217;s R&amp;D activities, including contracts with clinical research organizations and contract manufacturers. The Company is required to estimate its expenses resulting from its obligations under contracts with vendors and consultants and clinical site agreements in connection with its R&amp;D efforts. The financial terms of these contracts are subject to negotiations which vary contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts. The Company&#8217;s objective is to reflect the appropriate clinical trial expenses in its consolidated financial statements by matching those expenses with the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of the trials and other development activities. Judgment is applied in determining assumptions related to patient progression and the timing of various aspects of the trial used to measure progress. The Company determines prepaid and accrual estimates through discussions with applicable personnel and outside service providers as to the progress of clinical trials, or other services completed. During the course of a clinical trial, the Company adjusts its </span></div>rate of clinical trial expense recognition if actual results differ from its estimates. The Company makes estimates of its prepaid and accrued expenses as of each balance sheet date in its consolidated financial statements based on facts and circumstances known at that time. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in the Company reporting amounts that are too high or too low for any particular period. The Company&#8217;s clinical trial prepaid and accrual expense is dependent upon the timely and accurate reporting of study recruitment from contract research organizations and activities carried out by other third-party vendors as well as the timely processing of any change orders from the contract research organizations.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based compensation</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Share-based compensation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company has a share-based compensation plan under which various types of equity-based awards may be granted, including stock options and restricted stock units (RSUs). The fair value of share options and RSUs, which are subject to milestone or service conditions with graded vesting, are recognized as compensation expense on a straight-line basis using the graded-vesting method; f</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">orfeitures are recognized as they occur.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company uses the fair-value based method to determine compensation for all arrangements under which employees receive shares. The fair value of each option and RSU is estimated on the date of grant using the Black-Scholes valuation model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate. Expected volatility is based on the historical volatility of the Company&#8217;s ordinary shares over the expected term of the options. The expected term of options granted is derived using the simplified method, which computes the expected term as the average of the sum of the vesting term plus the contract term. Historically the risk-free rate has been based on the appropriate U.K. government debt yield. After delisting its Ordinary shares from AIM on October 30, 2020, the Company used U.S. government debt yields.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_GovernmentTaxCreditsPolicyPolicyTextBlock', window );">Other income - U.K. R&amp;D tax credits</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Other income - United Kingdom R&amp;D tax credits </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Other income relates to R&amp;D tax credits receivable in the UK. As a company that carries out extensive research and development activities, Verona is subject to the UK R&amp;D Small and Medium Enterprise (&#8220;SME&#8221;) Program. Qualifying expenditures largely comprise employment costs for research staff, consumables, a proportion of relevant, permitted sub-contract costs and certain internal overhead costs incurred as part of research projects for which it does not receive income. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Tax credits related to the SME Program are received as cash and are recorded as other income, as they are akin to grant income, in the consolidated statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Income taxes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company accounts for income taxes in accordance with ASC 740, &#8220;Income Taxes&#8221; (&#8220;ASC 740&#8221;). ASC 740 prescribes the use of the liability method, whereby deferred tax assets and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. ASC 740 establishes a single model to address accounting for uncertain tax positions. ASC 740 clarified the accounting for income taxes by prescribing the minimum recognition threshold a tax position is required to meet before being recognized in the financial statements. The Company has no uncertain tax positions.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive loss</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Comprehensive loss</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company accounts for comprehensive loss in accordance with ASC 220, &#8220;Income Statement - Reporting Comprehensive Income&#8221;. Comprehensive income represents all changes in stockholders&#8217; equity during the period except those resulting from investments by, or distributions to, stockholders.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Segment Reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company has one operating and reportable segment, pharmaceutical development. The Company&#8217;s long-lived assets are held in the United Kingdom.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currencies</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Foreign Currencies</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Reporting and functional currencies</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The consolidated financial statements are reported in U.S. dollars, which is also the functional currency of our subsidiary. Transactions in foreign currencies are remeasured into our functional currency at the rate of exchange prevailing at the date of the transaction. Any monetary assets and liabilities arising from these transactions are remeasured into our functional currency at exchange rates prevailing at the balance sheet date or on settlement. Resulting gains and losses are recorded in foreign exchange loss in our consolidated statements of operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Treasury shares</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Treasury shares</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In the year ended December 31, 2020, the Company incorporated a trust to facilitate the acquisition of shares, by or for the benefit of employees and former employees. In the year ended December 31, 2022, the Company issued 28.0&#160;million ordinary shares (equivalent to 3.5&#160;million ADSs) to cover expected shares issued upon the vesting of share awards to employees. The Company issued no ordinary shares in the year ended December 31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company has the indirect ability to control the trust as trustees are required to act in accordance with the trust deed and because the Company controls the issuance of shares to cover awards. As a consequence, the trust is consolidated into the Company&#8217;s consolidated financial statements. The shares that were issued to the trust that have not been issued to employees to satisfy vesting of share awards are included in the Consolidated Balance Sheets as treasury shares.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair value of financial instruments</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Fair value of financial instruments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">US GAAP defines fair value and requires companies to establish a framework for measuring fair value and disclosure about fair value measurements using a three-tier approach. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Our financial instruments include cash equivalents, an equity interest, other assets, accounts payable and accrued expenses and other liabilities. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgement and therefore cannot be determined with precision. The equity interest is held at cost subject to impairment, following </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">guidance from ASC 321-10-35-2</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">. The carrying amounts of the other instruments are considered to be representative of their fair values because of their short-term nature.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of credit risk</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Concentration of credit risk</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Financial instruments that potentially subject the Company to concentration of credit risk consist of principally cash and cash equivalents, bank deposits and certain receivables. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company holds cash and cash equivalents with highly rated financial institutions and in highly rated money market funds and the Company has not experienced any significant credit losses in these accounts and does not believe the Company is exposed to any significant credit risk on these instruments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Lease accounting</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Lease accounting </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The company accounts for leases in accordance with ASU No. 2016-02, &#8220;Leases&#8221; (Topic 842) (&#8220;ASC 842&#8221;). The standard requires lessees to recognize almost all leases on the balance sheet as right-of-use (&#8220;ROU&#8221;) assets and lease liabilities, and requires leases to be classified as either operating or finance type leases. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Under ASC 842, the Company determines if an arrangement is a lease at inception. ROU ass</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">ets and liabilities are recognized at the commencement date based on the present value of remaining lease payments. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As the Company's leases do not provide an implicit rate, the Company determines the incremental borrowing rate in calculating the present value of lease payments. The ROU assets also include any lease payments made prior to commencement and are recorded net of any lease incentives received. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company&#8217;s lease terms may include options to extend or terminate the lease. When it is reasonably certain the Company will exercise such options the lease will be recognized as a liability and a corresponding ROU asset also recognized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Operating leases are included in Right-of-use assets and in Current and non-current operating lease liabilities on the Company's Consolidated Balance Sheets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently issued accounting pronouncements, not yet adopted</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Recently issued accounting pronouncements, not yet adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326)-Measurement of Credit Losses on Financial Instruments. This guidance replaces the current incurred loss impairment methodology. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Under the new guidance, on initial recognition and at each reporting period, an entity is required to recognize an allowance that reflects its current estimate of credit losses expected to be incurred over the life of the financial instrument based on historical experience, current conditions and reasonable and supportable forecasts. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates (&#8220;ASU 2019-10&#8221;). The purpose of this amendment is to create a two tier rollout of major updates, staggering the effective dates between larger public companies and all other entities. This granted certain classes of companies, including Smaller Reporting Companies (&#8220;SRCs&#8221;), additional time to implement major FASB standards, including ASU 2016-13. Larger public companies will have an effective date for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. All other entities are permitted to defer adoption of ASU 2016-13, and its related amendments, until fiscal periods beginning after December 15, 2022. Under the current SEC definitions, we meet the definition of an SRC as of the ASU 2019-10 issuance date and are deferring adoption for ASU 2016-13. The guidance requires a modified retrospective transition approach through a cumulative-effect adjustment to retained earnings as of the beginning of the period of adoption. We are currently evaluating the impact of the adoption of ASU 2016-13 on our consolidated financial statements, but do not believe the adoption of this standard will have a material impact on our consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Other accounting standards that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company&#8217;s financial statements upon adoption.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144439<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21459-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_GovernmentTaxCreditsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Government Tax Credits, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_GovernmentTaxCreditsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763457184080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Summary of Prepaid Expenses</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Prepaid expenses consisted of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial and other development costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,169&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,027&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total prepaid expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,499&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,037&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763461018224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Minimum Annual Operating Lease Payments</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Minimum annual payments over the remaining lease periods as of December 31, 2022 are as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.926%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum future lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">880&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763457300496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial and other development costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,314&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,336&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees, listing and general corporate costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">People related costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,752&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,256&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763457297712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Valuation Assumptions of Warrants</a></td>
<td class="text">The warrants were valued using the Black-Scholes model and the table below presents the assumptions used:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price in pounds sterling</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#163;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7238&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term to exercise</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.33</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annualized volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Calculated value of the warrants, in thousands of U.S. dollars</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Movement of the Value of the Warrants</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows the movement of the value of the warrants (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">At January 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,246)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">At December 31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763455784992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Components of loss before income taxes</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The components of (profit)/loss before income taxes are as follows (in thousands): </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,868)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,850)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,448&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,587&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Components of income tax expense</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The components of income tax expense are as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current tax expense/(credit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total deferred tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total income tax expense/(credit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of the U.K. statutory income tax rate</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">A reconciliation of the U.K. statutory income tax rate to our effective income tax rate is as follows (in percentages):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.K. tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development incentive</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share options exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred tax valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other differences</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effective income tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Deferred tax assets and liabilities</a></td>
<td class="text">omponents of the Company&#8217;s deferred tax assets and liabilities are as follows (in thousands):<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,565)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,903)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,565)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,903)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,931&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D asset</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Future exercisable shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(516)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,041&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,155&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,476)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,252)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets, net of valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Movements in the deferred tax valuation allowance </span></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation allowance at January 1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase/(decrease) in valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,422)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation allowance at December 31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,476&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,252&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">These relate to the difference in the tax base of the IP R&amp;D asset and assumed contingent liability and the financial reporting base, which is nil under U.S. GAAP.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763455723104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Allocation of Share Based Compensation Expense</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows the allocation of share-based compensation between research and development and selling, general and administrative costs (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,420&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,654&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,771&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,121&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,425&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share Option Activity</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows share option activity and includes the options outstanding from all three plans :</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.335%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.244%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of share options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average exercise price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average remaining contractual term (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate intrinsic value (thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at January 1, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,125,672&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,696,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,126,472)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December 31, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,695,200&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.38&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,024,000&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.90&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(620,016)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,822,688)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December 31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,276,496&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.22&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,412&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercisable at December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,382,256&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.48&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,543&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline"> (1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The exercise prices relate to the equivalent price for an ordinary share, calculated as one eighth of the ADS price.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following summarizes the aggregate intrinsic value and cash receipts related to stock option exercise activity for the years ended December 31:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.938%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.241%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">($ in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate intrinsic value of stock options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,413&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash receipts from stock options exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted-Average Assumptions</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">A summary of the weighted-average assumptions applicable to the share options granted in the applicable years is as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.09% - 4.20%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.79% -1.32%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected lives, years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5-7</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5-7</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.50% - 84.27%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.35% - 87.68%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant date fair value (per share)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.34 - $1.33</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.62 - $0.78</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Restricted Stock Unit Activity</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The following table shows RSU activity:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.957%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average grant date fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average remaining contractual term (years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at January 1, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,992,360&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,030,928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,002,584)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,673,352)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December 31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,347,352&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,877,864&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.07&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,006,264)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,676,608)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding at December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,542,344&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.01&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.476%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.243%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of RSUs outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average remaining vesting Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Period in which the target must be achieved</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs subject to time based vesting</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,028,680&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs subject to milestone based vesting</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">513,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 - 2024</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763460968048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net loss per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of Basic and Diluted Earning Per Share</a></td>
<td class="text">The following table shows the computation of basic and diluted earnings per share for 2022 and 2021 (net loss in thousands, loss per share in dollars):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68,701)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,569)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss available to ordinary shareholders - basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68,701)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,569)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding - basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529,071,526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473,188,457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss per share - basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.13)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.12)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763451002464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and description of business operations (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 15, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 03, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>subsidiary </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>&#163; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>Rate</div>
</th>
<th class="th">
<div>Oct. 14, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>&#163; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_NumberOfWhollyOwnedSubsidiaries', window );">Number of wholly owned subsidiaries | subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 333,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 263,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in sale (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,696<span></span>
</td>
<td class="nump">873,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingDepositoryReceiptRatio', window );">Number of ordinary shares per ADS</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in pounds sterling per share) | (per share)</a></td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in sale (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,321,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vrna_TermLoanFacilityMember', window );">Term Loan Facility | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Oxford Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vrna_PublicStockOfferingMember', window );">Public Stock Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received from sale of stock</a></td>
<td class="nump">$ 140,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=vrna_AmericanDepositorySharesMember', window );">American Depository Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_SaleOfStockMaximumAggregateOfferingPrice', window );">Maximum aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in sale (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,087<span></span>
</td>
<td class="nump">109,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_CommonStockSharesAvailableForSaleValue', window );">Remaining ordinary shares available for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=vrna_AmericanDepositorySharesMember', window );">American Depository Shares | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in sale (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,540,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_CommonStockSharesAvailableForSaleValue', window );">Remaining ordinary shares available for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=vrna_AmericanDepositorySharesMember', window );">American Depository Shares | Public Stock Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in sale (in shares) | shares</a></td>
<td class="nump">14,260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 10.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=vrna_AmericanDepositorySharesMember', window );">American Depository Shares | Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in sale (in shares) | shares</a></td>
<td class="nump">1,860,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingDepositoryReceiptRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingDepositoryReceiptRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_CommonStockSharesAvailableForSaleValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Shares Available For Sale, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_CommonStockSharesAvailableForSaleValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_NumberOfWhollyOwnedSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Wholly Owned Subsidiaries</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_NumberOfWhollyOwnedSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_SaleOfStockMaximumAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Aggregate Offering Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_SaleOfStockMaximumAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vrna_TermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vrna_TermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vrna_OxfordTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vrna_OxfordTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vrna_PublicStockOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vrna_PublicStockOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=vrna_AmericanDepositorySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=vrna_AmericanDepositorySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763455299520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting policies (Details)<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>segment </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_StockIssuedDuringPeriodSharesHeldInTreasury', window );">Issuance of ordinary shares to treasury (in shares) | shares</a></td>
<td class="nump">28.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares', window );">Issuance of ordinary shares to treasury as ADS equivalent (in shares) | shares</a></td>
<td class="nump">3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Furniture and equipment, useful life</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Furniture and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_StockIssuedDuringPeriodSharesHeldInTreasury">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Held In Treasury</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_StockIssuedDuringPeriodSharesHeldInTreasury</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Held In Treasury (American Depository Shares)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763454024544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_PrepaidResearchAndDevelopmentFeesCurrent', window );">Clinical trial and other development costs</a></td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">$ 2,169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Insurance</a></td>
<td class="nump">2,027<span></span>
</td>
<td class="nump">1,555<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other</a></td>
<td class="nump">434<span></span>
</td>
<td class="nump">313<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Total prepaid expenses</a></td>
<td class="nump">$ 2,499<span></span>
</td>
<td class="nump">$ 4,037<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_PrepaidResearchAndDevelopmentFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Research And Development Fees, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_PrepaidResearchAndDevelopmentFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763456472512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property leases - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Discount rate (in percent)</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Weighted average remaining lease term</a></td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=vrna_LondonMember', window );">London | Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets recognized with associated liability</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=vrna_LondonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=vrna_LondonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763456516352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property leases - Maturity (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">215<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum future lease payments</a></td>
<td class="nump">907<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 880<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763461791280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_AccruedResearchAndDevelopmentFeesCurrent', window );">Clinical trial and other development costs</a></td>
<td class="nump">$ 12,314<span></span>
</td>
<td class="nump">$ 21,336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent', window );">Professional fees, listing and general corporate costs</a></td>
<td class="nump">1,364<span></span>
</td>
<td class="nump">919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">People related costs</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 13,752<span></span>
</td>
<td class="nump">$ 22,256<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Professional Fees, Listing, And General Corporate Costs, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_AccruedResearchAndDevelopmentFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Research And Development Fees, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_AccruedResearchAndDevelopmentFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763453764032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>&#163; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>&#163; / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_ClassOfWarrantOrRightNumberOfExercisedOrForfeited', window );">Number of warrants exercised and forfeited</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Stock warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,401,262<span></span>
</td>
<td class="nump">31,115,926<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights', window );">Issue price of warrants (in pounds sterling per share) | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 1.4365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares called by each warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of stock warrant (in pound sterling per share) | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 1.7238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 1.7238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of outstanding warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,003,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_ClassOfWarrantOrRightIntrinsicValue', window );">Intrinsic value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_ClassOfWarrantOrRightIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_ClassOfWarrantOrRightIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Issue Price of Warrants or Rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_ClassOfWarrantOrRightNumberOfExercisedOrForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Number Of Exercised Or Forfeited</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_ClassOfWarrantOrRightNumberOfExercisedOrForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763453992208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrants - Fair Value Assumptions (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>&#163; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>&#163; / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Stock warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,401,262<span></span>
</td>
<td class="nump">31,115,926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of stock warrant (in pound sterling per share) | &#163; / shares</a></td>
<td class="nump">&#163; 1.7238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 1.7238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected term to exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_WarrantLiabilityCurrent', window );">Calculated value of the warrants, in thousands of U.S. dollars | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=vrna_MeasurementInputAnnualizedVolatilityMember', window );">Annualized volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_WarrantLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Liability, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_WarrantLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=vrna_MeasurementInputAnnualizedVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=vrna_MeasurementInputAnnualizedVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763455296576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants - Movement in Value (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Warrant Activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">At January 1</a></td>
<td class="nump">$ 2,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustment', window );">Fair value adjustment</a></td>
<td class="num">(2,246)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">At December 31</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Fair Value Adjustment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763453188256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term loan (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 14, 2022 </div>
<div>USD ($) </div>
<div>loanAdvance</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of Oxford Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vrna_TermLoanFacilityMember', window );">Term Loan Facility | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of Oxford Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vrna_TermBLoanMember', window );">Term B Loan | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vrna_TermCLoanMember', window );">Term C Loan | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vrna_OxfordTermLoanMember', window );">Oxford Term Loan | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_LineOfCreditFacilityNumberOfLoanAdvances', window );">Line of Credit Facility, Number of Loan Advances | loanAdvance</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_DebtInstrumentPrepaymentFeePercentage', window );">Debt Instrument, Prepayment Fee, Percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vrna_OxfordTermLoanMember', window );">Oxford Term Loan | Line of Credit | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Debt Instrument, Interest Rate, Increase (Decrease)</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vrna_OxfordTermLoanMember', window );">Oxford Term Loan | Line of Credit | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_DebtInstrumentFinalPaymentPercentageOfPrincipalAmount', window );">Debt Instrument, Final Payment, Percentage of Principal Amount</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vrna_OxfordTermLoanMember', window );">Oxford Term Loan | Line of Credit | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_DebtInstrumentFinalPaymentPercentageOfPrincipalAmount', window );">Debt Instrument, Final Payment, Percentage of Principal Amount</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vrna_OxfordTermALoanMember', window );">Oxford Term A Loan | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vrna_OxfordTermALoanMember', window );">Oxford Term A Loan | Line of Credit | Debt Instrument Interest Rate, Period One | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vrna_OxfordTermALoanMember', window );">Oxford Term A Loan | Line of Credit | Debt Instrument Interest Rate, Period One | Minimum | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">2.38%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vrna_OxfordTermALoanMember', window );">Oxford Term A Loan | Line of Credit | Debt Instrument Interest Rate, Period One | Maximum | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">7.88%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vrna_OxfordTermALoanMember', window );">Oxford Term A Loan | Line of Credit | Debt Instrument Interest Rate, Period Two | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">8.54205%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vrna_OxfordTermBCDELoanMember', window );">Oxford Term B, C, D, E Loan | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vrna_OxfordTermBLoanMember', window );">Oxford Term B Loan | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vrna_OxfordTermCLoanMember', window );">Oxford Term C Loan | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vrna_OxfordTermDLoanMember', window );">Oxford Term D Loan | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vrna_OxfordTermELoanMember', window );">Oxford Term E Loan | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incremental percentage increase (decrease) in the stated rate on a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_DebtInstrumentFinalPaymentPercentageOfPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Final Payment, Percentage of Principal Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_DebtInstrumentFinalPaymentPercentageOfPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_DebtInstrumentPrepaymentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Fee, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_DebtInstrumentPrepaymentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_LineOfCreditFacilityNumberOfLoanAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Number of Loan Advances</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_LineOfCreditFacilityNumberOfLoanAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vrna_TermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vrna_TermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vrna_TermBLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vrna_TermBLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vrna_TermCLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vrna_TermCLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vrna_OxfordTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vrna_OxfordTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vrna_OxfordTermALoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vrna_OxfordTermALoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_InterestRatePeriodAxis=vrna_DebtInstrumentInterestRatePeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_InterestRatePeriodAxis=vrna_DebtInstrumentInterestRatePeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_InterestRatePeriodAxis=vrna_DebtInstrumentInterestRatePeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_InterestRatePeriodAxis=vrna_DebtInstrumentInterestRatePeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vrna_OxfordTermBCDELoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vrna_OxfordTermBCDELoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vrna_OxfordTermBLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vrna_OxfordTermBLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vrna_OxfordTermCLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vrna_OxfordTermCLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vrna_OxfordTermDLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vrna_OxfordTermDLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vrna_OxfordTermELoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vrna_OxfordTermELoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763456039312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant agreements (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>tradingDay</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 09, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vrna_LigandUKDevelopmentLimitedMember', window );">Ligand UK Development Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostLineItems', window );"><strong>Capitalized Contract Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_SublicensePayment', window );">Sublicense Payment</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_SublicensePaymentEquityIssuanceThresholdTradingDays', window );">Sublicense Payment, Equity Issuance, Threshold Trading Days | tradingDay</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vrna_LigandUKDevelopmentLimitedMember', window );">Ligand UK Development Limited | Selling, General and Administrative Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostLineItems', window );"><strong>Capitalized Contract Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_SublicensePayment', window );">Sublicense Payment</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vrna_LigandUKDevelopmentLimitedMember', window );">Ligand UK Development Limited | First Commercial Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostLineItems', window );"><strong>Capitalized Contract Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_SublicensePayment', window );">Sublicense Payment</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vrna_NuanceShanghaiPharmaCoLtdMember', window );">Nuance (Shanghai) Pharma Co Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostLineItems', window );"><strong>Capitalized Contract Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_EquityInterestReceivable', window );">Equity interest receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_ContractWithCustomerFutureEligibleMilestonePayments', window );">Future eligible milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Capitalized Contract Cost, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Contract with Customer, Liability, Revenue Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_ContractWithCustomerFutureEligibleMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Future Eligible Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_ContractWithCustomerFutureEligibleMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_EquityInterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Interest Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_EquityInterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_SublicensePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sublicense Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_SublicensePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_SublicensePaymentEquityIssuanceThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sublicense Payment, Equity Issuance, Threshold Trading Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_SublicensePaymentEquityIssuanceThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vrna_LigandUKDevelopmentLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vrna_LigandUKDevelopmentLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_BenchmarkAchievementAxis=vrna_FirstCommercialSaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_BenchmarkAchievementAxis=vrna_FirstCommercialSaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vrna_NuanceShanghaiPharmaCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vrna_NuanceShanghaiPharmaCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763457176160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Benefit plans (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Contribution cost</a></td>
<td class="nump">$ 319<span></span>
</td>
<td class="nump">$ 274<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763455784960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxation - Loss Before Tax (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">United States</a></td>
<td class="num">$ (3,868)<span></span>
</td>
<td class="num">$ (4,850)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United Kingdom</a></td>
<td class="nump">72,316<span></span>
</td>
<td class="nump">60,437<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Total</a></td>
<td class="nump">$ 68,448<span></span>
</td>
<td class="nump">$ 55,587<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763456081152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxation - Tax Expense (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">United States</a></td>
<td class="nump">$ 253<span></span>
</td>
<td class="num">$ (18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit', window );">United Kingdom</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax expense/(credit)</a></td>
<td class="nump">253<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">United States</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit', window );">United Kingdom</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense/(credit)</a></td>
<td class="nump">$ 253<span></span>
</td>
<td class="num">$ (18)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763454003360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxation - Reconciliation of Statutory Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.K. tax rate</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Non-deductible expenses</a></td>
<td class="num">(1.80%)<span></span>
</td>
<td class="num">(7.50%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development incentive</a></td>
<td class="num">(8.00%)<span></span>
</td>
<td class="num">(10.90%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Share options exercised</a></td>
<td class="nump">2.10%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in deferred tax valuation allowance</a></td>
<td class="num">(11.60%)<span></span>
</td>
<td class="num">(3.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_EffectiveIncomeTaxRateReconciliationCapitalAllowancesPercent', window );">Other differences</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="num">(0.40%)<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_EffectiveIncomeTaxRateReconciliationCapitalAllowancesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Capital Allowances, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_EffectiveIncomeTaxRateReconciliationCapitalAllowancesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763455992192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxation - Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_DeferredTaxLiabilitiesContingentLiability', window );">Contingent liability</a></td>
<td class="num">$ (34,565)<span></span>
</td>
<td class="num">$ (8,903)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(34,565)<span></span>
</td>
<td class="num">(8,903)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">38,893<span></span>
</td>
<td class="nump">26,931<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">IPR&amp;D asset</a></td>
<td class="nump">32,700<span></span>
</td>
<td class="nump">7,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Future exercisable shares</a></td>
<td class="nump">11,964<span></span>
</td>
<td class="nump">4,228<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="num">(516)<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">83,041<span></span>
</td>
<td class="nump">39,155<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(48,476)<span></span>
</td>
<td class="num">(30,252)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net of valuation allowance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember', window );">SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>Valuation Allowance [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Valuation allowance at January 1</a></td>
<td class="nump">30,252<span></span>
</td>
<td class="nump">30,321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates', window );">Change in tax rates</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance', window );">Increase/(decrease) in valuation allowance</a></td>
<td class="nump">18,224<span></span>
</td>
<td class="num">(7,422)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Valuation allowance at December 31</a></td>
<td class="nump">$ 48,476<span></span>
</td>
<td class="nump">$ 30,252<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_DeferredTaxLiabilitiesContingentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Contingent Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_DeferredTaxLiabilitiesContingentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>SEC Schedule 12-09, Valuation Allowances and Reserves, Change In Tax Rates</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>SEC Schedule 12-09, Valuation Allowances and Reserves, Increase In Valuation Allowance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763456422176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxation - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">$ 155,600,000<span></span>
</td>
<td class="nump">$ 104,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Interest and penalties recognized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationInterestAccrued', window );">Interest accrued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAccrued', window );">Penalties accrued</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763453144128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based compensation - Share-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">$ 14,121<span></span>
</td>
<td class="nump">$ 25,425<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">5,420<span></span>
</td>
<td class="nump">9,654<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">$ 8,701<span></span>
</td>
<td class="nump">$ 15,771<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763453329248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based compensation - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">69 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Rate </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>&#163; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Rate </div>
<div>shares</div>
</th>
<th class="th"><div>Aug. 15, 2022</div></th>
<th class="th">
<div>Jul. 24, 2012 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 18, 2006 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number granted (in shares)</a></td>
<td class="nump">9,024,000<span></span>
</td>
<td class="nump">1,696,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingDepositoryReceiptRatio', window );">Number of ordinary shares per ADS</a></td>
<td class="nump">800.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800.00%<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue', window );">Fair value for instruments granted during period | $</a></td>
<td class="nump">$ 19.6<span></span>
</td>
<td class="nump">$ 3.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Cost related to share options and RSUs granted but not yet recognized | $</a></td>
<td class="nump">$ 20.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected period for recognition</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vrna_EMIOptionPlanMember', window );">EMI Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vrna_PreIPOOptionPlanMember', window );">Pre-IPO Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Contract life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share Options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share Options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share Options | EMI Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized', window );">Number of American Depository Shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Further awards to be granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share Options | Pre-IPO Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,860,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized', window );">Number of American Depository Shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Further awards to be granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Intrinsic and fair value, vested | $</a></td>
<td class="nump">$ 14.3<span></span>
</td>
<td class="nump">$ 20.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units | 2017 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired', window );">Minimum stock price required to vest (in pound sterling per share) | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod', window );">Period to maintain minimum stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingDepositoryReceiptRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingDepositoryReceiptRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Award Vesting Rights, Minimum Stock Price Required</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Award Vesting Rights, Minimum Stock Price Required, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period, Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Number of American Depositary Shares Authorized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vrna_EMIOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vrna_EMIOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vrna_PreIPOOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vrna_PreIPOOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vrna_A2017IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vrna_A2017IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763453750144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based compensation - Share Option Activity (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>Rate </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Aug. 15, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingDepositoryReceiptRatio', window );">Number of ordinary shares per ADS</a></td>
<td class="nump">800.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of share options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance outstanding | shares</a></td>
<td class="nump">12,695,200<span></span>
</td>
<td class="nump">13,125,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted | shares</a></td>
<td class="nump">9,024,000<span></span>
</td>
<td class="nump">1,696,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited | shares</a></td>
<td class="num">(620,016)<span></span>
</td>
<td class="num">(2,126,472)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised | shares</a></td>
<td class="num">(1,822,688)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance outstanding | shares</a></td>
<td class="nump">19,276,496<span></span>
</td>
<td class="nump">12,695,200<span></span>
</td>
<td class="nump">13,125,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable | shares</a></td>
<td class="nump">10,382,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Beginning Balance, Weighted average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.38<span></span>
</td>
<td class="nump">$ 1.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, Weight average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">0.90<span></span>
</td>
<td class="nump">0.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited, Weight average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">1.04<span></span>
</td>
<td class="nump">1.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, Weight average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Ending Balance, Weighted average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">1.22<span></span>
</td>
<td class="nump">$ 1.38<span></span>
</td>
<td class="nump">$ 1.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, Weight average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock option activity, additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Weighted average remaining contractual term (years)</a></td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, Aggregate intrinsic value (in dollars) | $</a></td>
<td class="nump">$ 18,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, Aggregate intrinsic value (in dollars) | $</a></td>
<td class="nump">$ 39,412<span></span>
</td>
<td class="nump">$ 950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, Weighted average remaining contractual term (years)</a></td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of stock options exercised | $</a></td>
<td class="nump">$ 2,413<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of share options | $</a></td>
<td class="nump">$ 1,372<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingDepositoryReceiptRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingDepositoryReceiptRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763455687904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based compensation - Weighted-Average Assumptions (Details) - Share Options - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">2.09%<span></span>
</td>
<td class="nump">0.79%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">1.32%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">82.50%<span></span>
</td>
<td class="nump">85.35%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">84.27%<span></span>
</td>
<td class="nump">87.68%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected lives, years</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 0.34<span></span>
</td>
<td class="nump">$ 0.62<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected lives, years</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 1.33<span></span>
</td>
<td class="nump">$ 0.78<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763453897968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based compensation - RSU Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average grant date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 0.97<span></span>
</td>
<td class="nump">$ 0.98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">1.07<span></span>
</td>
<td class="nump">0.73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">1.03<span></span>
</td>
<td class="nump">1.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">0.96<span></span>
</td>
<td class="nump">0.97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">$ 1.01<span></span>
</td>
<td class="nump">$ 0.97<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>RSU Activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning balance</a></td>
<td class="nump">38,347,352<span></span>
</td>
<td class="nump">61,992,360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted</a></td>
<td class="nump">12,877,864<span></span>
</td>
<td class="nump">3,030,928<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited</a></td>
<td class="num">(1,006,264)<span></span>
</td>
<td class="num">(2,002,584)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested</a></td>
<td class="num">(15,676,608)<span></span>
</td>
<td class="num">(24,673,352)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending balance</a></td>
<td class="nump">34,542,344<span></span>
</td>
<td class="nump">38,347,352<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average grant date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Outstanding, Weighted average remaining contractual term</a></td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of RSUs outstanding</a></td>
<td class="nump">34,542,344<span></span>
</td>
<td class="nump">38,347,352<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vrna_RestrictedStockUnitTimeBasedVestingMember', window );">Time-Based Vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>RSU Activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending balance</a></td>
<td class="nump">34,028,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average grant date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of RSUs outstanding</a></td>
<td class="nump">34,028,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod', window );">Weighted average remaining vesting Period</a></td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vrna_RestrictedStockUnitMilestoneBasedVestingMember', window );">Milestone-Based Vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>RSU Activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending balance</a></td>
<td class="nump">513,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average grant date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of RSUs outstanding</a></td>
<td class="nump">513,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod', window );">Weighted average remaining vesting Period</a></td>
<td class="text">0 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Vesting Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vrna_RestrictedStockUnitTimeBasedVestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vrna_RestrictedStockUnitTimeBasedVestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vrna_RestrictedStockUnitMilestoneBasedVestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vrna_RestrictedStockUnitMilestoneBasedVestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763456084336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net loss per share - Computation (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>Rate </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Aug. 15, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingDepositoryReceiptRatio', window );">Number of ordinary shares per ADS</a></td>
<td class="nump">800.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss | $</a></td>
<td class="num">$ (68,701)<span></span>
</td>
<td class="num">$ (55,569)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss available to ordinary shareholders - basic | $</a></td>
<td class="num">(68,701)<span></span>
</td>
<td class="num">(55,569)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss available to ordinary shareholders - diluted | $</a></td>
<td class="num">$ (68,701)<span></span>
</td>
<td class="num">$ (55,569)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding - basic (in shares) | shares</a></td>
<td class="nump">529,071,526<span></span>
</td>
<td class="nump">473,188,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding - diluted (in shares) | shares</a></td>
<td class="nump">529,071,526<span></span>
</td>
<td class="nump">473,188,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Loss per ordinary share, diluted (in dollars per share) | $ / shares</a></td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per ordinary share, basic (in dollars per share) | $ / shares</a></td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of loss per share (in shares) | shares</a></td>
<td class="nump">53,818,840<span></span>
</td>
<td class="nump">63,443,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingDepositoryReceiptRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingDepositoryReceiptRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139763455705472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and contingencies (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss Contingency, Estimate of Possible Loss</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss Contingency Accrual</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14615-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12021-110248<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>vrna-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:vrna="http://veronapharma.com/20221231"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="vrna-20221231.xsd" xlink:type="simple"/>
    <context id="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id8686e244a6e42d3a8ac63e71fe128c3_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iaade0201ae634843939c414628a28829_I20230303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <instant>2023-03-03</instant>
        </period>
    </context>
    <context id="i46f03490e9ee4cdfbbb33910795928d1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id40f0f069eba45cba259ca5e4029e3c6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i914d9cdf65d04c2f90fe005e7472a193_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i628f4c337d8a4907b099660435d9a654_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib7f0ec0ed1784d75a7a6870bf8e210e8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9bcd9fdf0b49455fbda9ed3d6b4ffe6a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9f35aecd3e8247dab76bb02c4f16b0fc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if80b5e08771841e98a3888a3388c32e2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if823f7d8c92d4955b417d2877d92cf1e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i380ad8bec02d4cef80ab1e2a0293509c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrna:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i375548ad8ff84bd0982f3bccb9de8503_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrna:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i442b161bf35c4276ac36992d05e23115_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrna:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2541a30ef7e84fc1925bf03d916e97a2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic8a8c7eae65b43e9a11fdf51f5b2d5d8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib56e759a9ec24aa88f41a41be62db95d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia773a9ee14f34d1a8dc7c9d57c7401e1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9ece18e799b840598f8450de9ee4fb80_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie8f5a4cc91e843d384ab12b09f91edb8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i609c9125fe4c4df8b724395ec47768f6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2df52cddbf6047d99bc4c33dc209f75a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i079c0a66af1a4b4f8579073c30a06c55_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrna:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibab55600f3bc40aa902c283296c411ce_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrna:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5d11dce15ffe46c5a3f318667309b215_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrna:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2af5163aa9d84dad89a011496414bdd2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrna:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i111533997c354eed8392ec995f25323f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrna:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i979239b8c81f4ce297052fdb5fcfb029_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrna:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie6d783db1d43419d8f15b7dc0a5bcb2d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1aae0c0ff8a846889a7cab3fe123941d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie9ea6a1e50f743c7b2706c4f275812bf_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i91456de939c649aabb7986b2e37d0859_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i25dfa9d20fe64551adbf52bf5cde91b6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ica49ccad51694417b0ecd16ca773ee2b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i79d67ed1de10489aa0bb85ba9c0ec74a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9383bef872e64838b59e60f52963eea3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie238e662ca594fb8b2c61e9a8e7cc2b7_D20220815-20220815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vrna:AmericanDepositorySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrna:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-15</startDate>
            <endDate>2022-08-15</endDate>
        </period>
    </context>
    <context id="ice1cf713bbb6461a9be47f13e6cb343f_I20220815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <instant>2022-08-15</instant>
        </period>
    </context>
    <context id="ieb1aa532b71f489d849b821859d2f380_I20220815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vrna:AmericanDepositorySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrna:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-15</instant>
        </period>
    </context>
    <context id="i184e0ab9d5a54b338f38f20780281582_D20220815-20220815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vrna:AmericanDepositorySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-15</startDate>
            <endDate>2022-08-15</endDate>
        </period>
    </context>
    <context id="i7bd8f835b5424f209ef20622393563fe_D20220815-20220815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vrna:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-15</startDate>
            <endDate>2022-08-15</endDate>
        </period>
    </context>
    <context id="ia867c724f1754d6b8ce8489a52865172_I20221014">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:OxfordTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-14</instant>
        </period>
    </context>
    <context id="ib6f1e5c7e48647c0920bd6e598622618_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="ic5b573c06bda4d9abf4c5788689f8267_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vrna:AmericanDepositorySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i527c9fac13d64a47b9bf9214236f60e2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vrna:AmericanDepositorySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6695925fbed543f894ece49ef4cdea3a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vrna:AmericanDepositorySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i51dfe19fdb8b4c94be7f8c486773856a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vrna:AmericanDepositorySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic554433105b34f27be03700dabfb47f7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vrna:AmericanDepositorySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8aef53e83ae8405d96c0bb866c6a4b44_D20230101-20230303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-03</endDate>
        </period>
    </context>
    <context id="i7a0e931dedec4d268138428467b28255_D20230101-20230303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vrna:AmericanDepositorySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-03</endDate>
        </period>
    </context>
    <context id="i947febb528b2492baff336d20285fda1_I20230303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-03</instant>
        </period>
    </context>
    <context id="icff757a8f7aa4258a984848491ccbe0b_I20230303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vrna:AmericanDepositorySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-03</instant>
        </period>
    </context>
    <context id="icf154344047d460588bc54417f0e3d9b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i12dbdc5aaf3b4090a92274f569107ad3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1ffe1b3cbbcb48709153748921695a17_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i562a8171ec384150b25fc8dac4d3d04a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vrna:LondonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id194ff6c8cf4476bad35353399857ce0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vrna:LondonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie824d87e23bd49a6b8466e65062ab474_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="ia8b9d9c7ed4d45b39aee6fc8c9e89a1e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia06c5918648040c2b8e5e55554c67cb2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vrna:MeasurementInputAnnualizedVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibc128abfb89243b6bb31d0ca13db2070_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i30e7bb276e12407b8476499428f6f60a_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="i90f55e89f14448548416cbd47cfb6cf9_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:TermBLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="ie69772c787fa46e283c35e0159c9ed3b_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:TermCLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="i10a520855ec54e2da16ba70468d0a51b_I20221014">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:OxfordTermALoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-14</instant>
        </period>
    </context>
    <context id="i3541a8c38127458ba1aae3fdc52c63d5_I20221014">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:OxfordTermBCDELoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-14</instant>
        </period>
    </context>
    <context id="ic244fa4c95204e0e8dcfaefb2e6b8237_I20221014">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:OxfordTermBLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-14</instant>
        </period>
    </context>
    <context id="i22eac3eaf4ba4678a0eb3d0971d09767_I20221014">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:OxfordTermCLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-14</instant>
        </period>
    </context>
    <context id="i48aaa74363db4fc7b8d8426a1eff5049_I20221014">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:OxfordTermDLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-14</instant>
        </period>
    </context>
    <context id="id04385f9e7774756bbf90a20930f80ec_I20221014">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:OxfordTermELoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-14</instant>
        </period>
    </context>
    <context id="ibbe1ef2d7eb14330b2e19597ed9f08da_D20221014-20221014">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:OxfordTermALoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="vrna:InterestRatePeriodAxis">vrna:DebtInstrumentInterestRatePeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-14</startDate>
            <endDate>2022-10-14</endDate>
        </period>
    </context>
    <context id="ic419bc3e647a4ca9a2757dc9edc5107d_D20221014-20221014">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:OxfordTermALoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="vrna:InterestRatePeriodAxis">vrna:DebtInstrumentInterestRatePeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-14</startDate>
            <endDate>2022-10-14</endDate>
        </period>
    </context>
    <context id="i428494c244664464882b178b3d34c37f_D20221014-20221014">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:OxfordTermALoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="vrna:InterestRatePeriodAxis">vrna:DebtInstrumentInterestRatePeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-14</startDate>
            <endDate>2022-10-14</endDate>
        </period>
    </context>
    <context id="i3d4b040098df4fc3a356ffafd5e4b830_D20221014-20221014">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:OxfordTermALoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="vrna:InterestRatePeriodAxis">vrna:DebtInstrumentInterestRatePeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-14</startDate>
            <endDate>2022-10-14</endDate>
        </period>
    </context>
    <context id="i77e399a94d574a9c9520217f5ebd6515_D20221014-20221014">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:OxfordTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-14</startDate>
            <endDate>2022-10-14</endDate>
        </period>
    </context>
    <context id="i7ad954ea881e4224a373e39507e05382_D20221014-20221014">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:OxfordTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-14</startDate>
            <endDate>2022-10-14</endDate>
        </period>
    </context>
    <context id="ife6bb65a13724831ab4e8d78c473f147_D20221014-20221014">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:OxfordTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-14</startDate>
            <endDate>2022-10-14</endDate>
        </period>
    </context>
    <context id="i7d76374535984c8fbfde48cfb17a2b35_D20221014-20221014">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrna:OxfordTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-14</startDate>
            <endDate>2022-10-14</endDate>
        </period>
    </context>
    <context id="i2014cf02dad94153af60f28551c0469c_D20220301-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrna:LigandUKDevelopmentLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifa2a4633d09c407a94ff8f3507d2318d_D20220301-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrna:LigandUKDevelopmentLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="vrna:BenchmarkAchievementAxis">vrna:FirstCommercialSaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia63bdd4aff86454a9544c5c56ab3a539_D20220301-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrna:LigandUKDevelopmentLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i44405a18d6cc405cab4ed043524c8fde_I20210609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrna:NuanceShanghaiPharmaCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-09</instant>
        </period>
    </context>
    <context id="i2ed4c5f1e427439596625fc8558417f6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrna:NuanceShanghaiPharmaCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib45dfb15713741578ce57657f76c641a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrna:NuanceShanghaiPharmaCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idbecaaa2e50f422788c7776146b6f738_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vrna:NuanceShanghaiPharmaCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie22e6682054147c4961ab22e3d0b6106_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic9abfa929c414b3a8a9f9e7a5436d4f3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6ef7ac44600e4b82bd5f7115b1d6d54d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i01712b818a734e4a92734201de78b797_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7233af3af0bd4811889a59bfd4f27031_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i119cc232d51e4fbb9e1d846ac2bd0d41_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i26d09ecdd3a64d1a8904a12f454da71e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2a6b7ded42314692aa873d8195ffbd32_I20060918">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrna:EMIOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2006-09-18</instant>
        </period>
    </context>
    <context id="i20dbfdab854c46fdaca99b937c1a2004_I20120724">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrna:PreIPOOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-07-24</instant>
        </period>
    </context>
    <context id="i7ce1126e308447edb0ce8f68eda07d48_D20170401-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrna:PreIPOOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-04-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4854c977bffc4921b1f1611822527f5d_D20170401-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrna:EMIOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-04-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icd6f70b91dd0435991ce621ce894613c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrna:EMIOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5476c2b57bb84c3c9a60aba57bb6d479_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrna:PreIPOOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2fd6a66dcd33401c900f14a24e099e1b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrna:A2017IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic23d87e5f60a4b6cbb480b4fd31b6c15_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i28bc6028d27549bdbe82ed5d76e8a4d3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i47d19bc9bec84458b044241464c4ca53_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i659b636bd9904c8884a0708f012c5d76_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0887a875bbe3456c88ad04cb88647ce3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic01569d19cb64fe9a0f5cf16691732dd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6b874456201746c6bb2d1caa6f13eeed_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0cb073618a12467ebf16ed58054c7606_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0b5ab64a3a124f8683b6125306368d23_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i00a363abd6ea427e834a199f24664952_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vrna:RestrictedStockUnitTimeBasedVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1754f1ba19694c9bb318a7a84afebbe8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vrna:RestrictedStockUnitTimeBasedVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i280f6b8ea0fa434cb722279e0e05373e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vrna:RestrictedStockUnitMilestoneBasedVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4f452df8cc584b6c9688098f4a50632f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vrna:RestrictedStockUnitMilestoneBasedVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id9240e12e8374554928914a1dfb017fb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6c61487d635a4696b64cde5303229764_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0a63b0b903ee4acab0480335043b47f5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i709ea29e7e7249da99a23ab89c643290_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic1b945830df8444a9ed8c6acd123c8b9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001657312</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="gbpPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:GBP</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="subsidiary">
        <measure>vrna:subsidiary</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>vrna:segment</measure>
    </unit>
    <unit id="loanadvance">
        <measure>vrna:loanAdvance</measure>
    </unit>
    <unit id="tradingday">
        <measure>vrna:tradingDay</measure>
    </unit>
    <unit id="rate">
        <measure>utr:Rate</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl80L2ZyYWc6MzA1MTAyYzY2OTAxNDAyM2EzYzczNjNjNjgxMzFlMmEvdGFibGU6N2U4YTZkNzQyZTQ1NDk4NTkyY2ZjZGQ0MTkwM2FkZTAvdGFibGVyYW5nZTo3ZThhNmQ3NDJlNDU0OTg1OTJjZmNkZDQxOTAzYWRlMF8zLTEtMS0xLTU5MTI3_eb8d78c5-84fb-4fc6-a805-ef769838fbe1">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl80L2ZyYWc6MzA1MTAyYzY2OTAxNDAyM2EzYzczNjNjNjgxMzFlMmEvdGFibGU6N2U4YTZkNzQyZTQ1NDk4NTkyY2ZjZGQ0MTkwM2FkZTAvdGFibGVyYW5nZTo3ZThhNmQ3NDJlNDU0OTg1OTJjZmNkZDQxOTAzYWRlMF80LTEtMS0xLTU5MTI3_a70ddbae-cc59-48d9-a04a-e072b80b486c">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl80L2ZyYWc6MzA1MTAyYzY2OTAxNDAyM2EzYzczNjNjNjgxMzFlMmEvdGFibGU6N2U4YTZkNzQyZTQ1NDk4NTkyY2ZjZGQ0MTkwM2FkZTAvdGFibGVyYW5nZTo3ZThhNmQ3NDJlNDU0OTg1OTJjZmNkZDQxOTAzYWRlMF81LTEtMS0xLTU5MTI3_e291100e-79c0-4cef-94e0-25814e56ab5c">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl80L2ZyYWc6MzA1MTAyYzY2OTAxNDAyM2EzYzczNjNjNjgxMzFlMmEvdGFibGU6N2U4YTZkNzQyZTQ1NDk4NTkyY2ZjZGQ0MTkwM2FkZTAvdGFibGVyYW5nZTo3ZThhNmQ3NDJlNDU0OTg1OTJjZmNkZDQxOTAzYWRlMF82LTEtMS0xLTU5MTI3_d8c9ed14-4f05-49b0-b8c8-c014a9f043f9">0001657312</dei:EntityCentralIndexKey>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="icf154344047d460588bc54417f0e3d9b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzQ1MDg_ff010e70-9a6d-4e4c-a482-a7e0d106f1e3">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ie22e6682054147c4961ab22e3d0b6106_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzgyMg_06949a37-1fa3-4277-8388-a28ff5d09dc6">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGV4dHJlZ2lvbjpiM2ZiNDFlMGQ5OTU0ZjVkODkwZWYzNDdjYTRmMzRiOV80MDQz_ff200151-8460-4932-8d09-2c8629af66e0">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGV4dHJlZ2lvbjpiM2ZiNDFlMGQ5OTU0ZjVkODkwZWYzNDdjYTRmMzRiOV80MDM2_dd8a964b-1705-49a7-b715-a78291b70152">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGV4dHJlZ2lvbjpiM2ZiNDFlMGQ5OTU0ZjVkODkwZWYzNDdjYTRmMzRiOV8yMDQ_fe7f2e2d-4eae-418e-b56e-79cc516e28df">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGV4dHJlZ2lvbjpiM2ZiNDFlMGQ5OTU0ZjVkODkwZWYzNDdjYTRmMzRiOV8yMDQ_20368bcd-00cc-459b-a92d-118a6fc04597">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGV4dHJlZ2lvbjpiM2ZiNDFlMGQ5OTU0ZjVkODkwZWYzNDdjYTRmMzRiOV80MDQ1_989b70a8-3da4-4e10-b90e-f10cd51e7af2">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGV4dHJlZ2lvbjpiM2ZiNDFlMGQ5OTU0ZjVkODkwZWYzNDdjYTRmMzRiOV80MDQ4_0db8e31b-8fc0-44e3-a7f6-176573ac5ec8">001-38067</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGV4dHJlZ2lvbjpiM2ZiNDFlMGQ5OTU0ZjVkODkwZWYzNDdjYTRmMzRiOV80MDUy_4ef3e30f-e260-4b73-879a-34d648f9d12a">Verona Pharma plc</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGFibGU6NTk1ODYxMTFjNTY5NDhiMDk2YWQ4MTJjOTI4OTYxZWMvdGFibGVyYW5nZTo1OTU4NjExMWM1Njk0OGIwOTZhZDgxMmM5Mjg5NjFlY18wLTAtMS0xLTU5MTI3_362f94fb-a56a-4c5f-b273-c5b7042d85d9">X0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGFibGU6NTk1ODYxMTFjNTY5NDhiMDk2YWQ4MTJjOTI4OTYxZWMvdGFibGVyYW5nZTo1OTU4NjExMWM1Njk0OGIwOTZhZDgxMmM5Mjg5NjFlY18wLTMtMS0xLTU5MTI3_73a8aae0-006b-4498-8d7f-1dbf5c34efd3">98-1489389</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGFibGU6NTk1ODYxMTFjNTY5NDhiMDk2YWQ4MTJjOTI4OTYxZWMvdGFibGVyYW5nZTo1OTU4NjExMWM1Njk0OGIwOTZhZDgxMmM5Mjg5NjFlY18zLTAtMS0xLTU5MTI3L3RleHRyZWdpb246ZGI2MDYyYTZhNWIwNDBmNjkzNDg5Yzc0MzEzNmVmMGNfNQ_e7dd8cd6-65ab-4e53-952c-30d442a3e1ca">3 More London Riverside</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGFibGU6NTk1ODYxMTFjNTY5NDhiMDk2YWQ4MTJjOTI4OTYxZWMvdGFibGVyYW5nZTo1OTU4NjExMWM1Njk0OGIwOTZhZDgxMmM5Mjg5NjFlY18zLTAtMS0xLTU5MTI3L3RleHRyZWdpb246ZGI2MDYyYTZhNWIwNDBmNjkzNDg5Yzc0MzEzNmVmMGNfOA_a8bce48f-6663-403e-b436-e2618f55040d">London</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGFibGU6NTk1ODYxMTFjNTY5NDhiMDk2YWQ4MTJjOTI4OTYxZWMvdGFibGVyYW5nZTo1OTU4NjExMWM1Njk0OGIwOTZhZDgxMmM5Mjg5NjFlY18zLTAtMS0xLTU5MTI3L3RleHRyZWdpb246ZGI2MDYyYTZhNWIwNDBmNjkzNDg5Yzc0MzEzNmVmMGNfMTE_a775d6e6-f394-41e2-a847-c613ed5a13a9">SE1 2RE</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGFibGU6NTk1ODYxMTFjNTY5NDhiMDk2YWQ4MTJjOTI4OTYxZWMvdGFibGVyYW5nZTo1OTU4NjExMWM1Njk0OGIwOTZhZDgxMmM5Mjg5NjFlY18zLTAtMS0xLTU5MTI3L3RleHRyZWdpb246ZGI2MDYyYTZhNWIwNDBmNjkzNDg5Yzc0MzEzNmVmMGNfMTQ_e7095e92-fcf7-4a2f-a3d6-36b6c4a366ea">GB</dei:EntityAddressCountry>
    <dei:CountryRegion
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGV4dHJlZ2lvbjpiM2ZiNDFlMGQ5OTU0ZjVkODkwZWYzNDdjYTRmMzRiOV80MDM3_be4e8ae5-f053-462f-8538-1757a783ec0e">44</dei:CountryRegion>
    <dei:CityAreaCode
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGV4dHJlZ2lvbjpiM2ZiNDFlMGQ5OTU0ZjVkODkwZWYzNDdjYTRmMzRiOV80MDQ5_1f0a5415-10a1-4a0e-8c73-a766f8d4913b">203</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGV4dHJlZ2lvbjpiM2ZiNDFlMGQ5OTU0ZjVkODkwZWYzNDdjYTRmMzRiOV80MDUw_dd0776b9-4b4b-4a62-b737-ccf7c31cb3b1">283 4200</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGFibGU6YjFiMWEyZGEyY2FlNDkxNDljMTIzNjRjYmEzYzEwOWIvdGFibGVyYW5nZTpiMWIxYTJkYTJjYWU0OTE0OWMxMjM2NGNiYTNjMTA5Yl8xLTAtMS0xLTU5MTI3_21b9034d-2b40-4e9c-926a-93fc71e2ca0d">Ordinary shares, nominal value &#xa3;0.05 per share*</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGFibGU6YjFiMWEyZGEyY2FlNDkxNDljMTIzNjRjYmEzYzEwOWIvdGFibGVyYW5nZTpiMWIxYTJkYTJjYWU0OTE0OWMxMjM2NGNiYTNjMTA5Yl8xLTEtMS0xLTU5MTI3_a293c042-5737-4a10-9062-88b3f8676aee">VRNA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGFibGU6YjFiMWEyZGEyY2FlNDkxNDljMTIzNjRjYmEzYzEwOWIvdGFibGVyYW5nZTpiMWIxYTJkYTJjYWU0OTE0OWMxMjM2NGNiYTNjMTA5Yl8xLTItMS0xLTU5MTI3L3RleHRyZWdpb246MmFmZTQ3ODM0NmI5NGM5NDkzMWY2MGFjNjk4OGQ4ZGVfMzM_71837bdc-8e3d-45f1-9702-77f630186aca">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGV4dHJlZ2lvbjpiM2ZiNDFlMGQ5OTU0ZjVkODkwZWYzNDdjYTRmMzRiOV8yNDczOTAxMTYyOTUzNw_dfb163f9-1b8f-407b-99bf-c5fc8cd03752">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGV4dHJlZ2lvbjpiM2ZiNDFlMGQ5OTU0ZjVkODkwZWYzNDdjYTRmMzRiOV80MDM4_862c8b01-ba3d-4d9a-b092-11e65d373ea0">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGV4dHJlZ2lvbjpiM2ZiNDFlMGQ5OTU0ZjVkODkwZWYzNDdjYTRmMzRiOV80MDQ2_ce655380-bb6d-448d-84a2-74339959f98b">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGV4dHJlZ2lvbjpiM2ZiNDFlMGQ5OTU0ZjVkODkwZWYzNDdjYTRmMzRiOV80MDQ3_0ea40d34-4251-47c6-887f-d16882b7be4b">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGFibGU6MDhmMjNiNzQ5NjI1NGJjYTg4MjA2MmMzNjllOGNkZTcvdGFibGVyYW5nZTowOGYyM2I3NDk2MjU0YmNhODgyMDYyYzM2OWU4Y2RlN18xLTAtMS0xLTU5MTI3_bc8f5fd2-4297-4d02-bc97-844b713a379a">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGFibGU6MDhmMjNiNzQ5NjI1NGJjYTg4MjA2MmMzNjllOGNkZTcvdGFibGVyYW5nZTowOGYyM2I3NDk2MjU0YmNhODgyMDYyYzM2OWU4Y2RlN18xLTQtMS0xLTU5MTI3_5642daba-1025-4bb6-89a5-86d4f87c301c">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGFibGU6MDhmMjNiNzQ5NjI1NGJjYTg4MjA2MmMzNjllOGNkZTcvdGFibGVyYW5nZTowOGYyM2I3NDk2MjU0YmNhODgyMDYyYzM2OWU4Y2RlN18yLTQtMS0xLTU5MTI3_34c69152-34bf-46d0-a2fb-1dad2b6cb0e9">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGV4dHJlZ2lvbjpiM2ZiNDFlMGQ5OTU0ZjVkODkwZWYzNDdjYTRmMzRiOV80MDQw_304291f8-9fd8-48ef-b0f6-dcea7e87b311">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGV4dHJlZ2lvbjpiM2ZiNDFlMGQ5OTU0ZjVkODkwZWYzNDdjYTRmMzRiOV8yNDczOTAxMTYyOTYxNw_109f2697-fa65-46fc-b796-6b78db4dc297">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="id8686e244a6e42d3a8ac63e71fe128c3_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGV4dHJlZ2lvbjpiM2ZiNDFlMGQ5OTU0ZjVkODkwZWYzNDdjYTRmMzRiOV8zMDQ3_7c4915fc-7de9-48b5-af8c-1ed06c7a6699"
      unitRef="usd">212100000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="iaade0201ae634843939c414628a28829_I20230303"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGV4dHJlZ2lvbjpiM2ZiNDFlMGQ5OTU0ZjVkODkwZWYzNDdjYTRmMzRiOV8zNDU1_4a049a84-c1eb-4260-89c7-ae4ce171f594"
      unitRef="shares">631904598</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xL2ZyYWc6YjNmYjQxZTBkOTk1NGY1ZDg5MGVmMzQ3Y2E0ZjM0YjkvdGV4dHJlZ2lvbjpiM2ZiNDFlMGQ5OTU0ZjVkODkwZWYzNDdjYTRmMzRiOV80MDQy_ab7a42a5-b730-430a-ba32-1898100066c9">Portions of the registrant&#x2019;s definitive proxy statement that the registrant intends to file with the Securities and Exchange Commission pursuant to Regulation 14A in connection with the registrant&#x2019;s 2023 Annual Meeting of Shareholders are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl84OC9mcmFnOjU1YThmNGRlNDEyODRiYmRhNDY2MGUwNjE1MDhhOTRhL3RhYmxlOjM0OWY3NGEzZGU1OTRhY2JhY2I3ZDg2ZTIyMjBiNjA2L3RhYmxlcmFuZ2U6MzQ5Zjc0YTNkZTU5NGFjYmFjYjdkODZlMjIyMGI2MDZfMC0wLTEtMS01OTEyNy90ZXh0cmVnaW9uOjI3Zjg4MzA0MzhiMDRkOTZhNWUyMDNmNWQ5YzRlYTAxXzcx_ec816228-267b-45c5-ab87-2e81b16e128d">876</dei:AuditorFirmId>
    <dei:AuditorFirmId
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl85Ny9mcmFnOmE5NWMyMmJhMDAyNDQ4Y2E4YzI2MGM5ZjgwY2YwNmVjL3RhYmxlOmEyODViNjkwZjg0NDQ4MzU4MjMwYjlmMjkyYzQ2ZmQyL3RhYmxlcmFuZ2U6YTI4NWI2OTBmODQ0NDgzNTgyMzBiOWYyOTJjNDZmZDJfMC0wLTEtMS01OTEyNy90ZXh0cmVnaW9uOjAwYTYyZjcxZDdmYjQ4NWFiNzZhMDk1ODFlZTI1NDRhXzcx_ec816228-267b-45c5-ab87-2e81b16e128d">876</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDAvZnJhZzo1MGJhNWMxMmQ0Mjk0MWRjYjg5YzEzNjM1MmViYzYyYS90ZXh0cmVnaW9uOjUwYmE1YzEyZDQyOTQxZGNiODljMTM2MzUyZWJjNjJhXzMxMTg_2e18f9f5-32e7-45ae-b9f0-f6b4fc541fbf">PricewaterhouseCoopers LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDAvZnJhZzo1MGJhNWMxMmQ0Mjk0MWRjYjg5YzEzNjM1MmViYzYyYS90ZXh0cmVnaW9uOjUwYmE1YzEyZDQyOTQxZGNiODljMTM2MzUyZWJjNjJhXzMxMTc_257a4e38-beb0-48a5-bdf8-72cc2ea6e519">Reading, United Kingdom</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzQtMi0xLTEtNTkxMjc_765e1a0c-41cf-49d3-bd98-75707fd75822"
      unitRef="usd">227827000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzQtNC0xLTEtNTkxMjc_dd6decb0-24f7-446a-9b47-62be528accb1"
      unitRef="usd">148380000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzctMi0xLTEtNTkxMjc_f34e5d9d-a60c-4baf-a672-e1ad8c0b13d3"
      unitRef="usd">2499000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzctNC0xLTEtNTkxMjc_cc43a569-8bba-4ca2-88f2-ab46313c9472"
      unitRef="usd">4037000</us-gaap:PrepaidExpenseCurrent>
    <vrna:TaxCreditAndIncomeTaxesReceivableCurrent
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzgtMi0xLTEtNTkxMjc_81bb735b-138d-485f-b274-ca86357817d7"
      unitRef="usd">9282000</vrna:TaxCreditAndIncomeTaxesReceivableCurrent>
    <vrna:TaxCreditAndIncomeTaxesReceivableCurrent
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzgtNC0xLTEtNTkxMjc_ee3fdd81-e4bf-4273-8cdd-6b37e683898e"
      unitRef="usd">15583000</vrna:TaxCreditAndIncomeTaxesReceivableCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzExLTItMS0xLTU5MTI3_92807c6c-26f5-4f7b-9c41-fa0808e3fc85"
      unitRef="usd">3388000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzExLTQtMS0xLTU5MTI3_84894ffe-a4a4-4abc-a36a-2d099df4ad8c"
      unitRef="usd">2063000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzEyLTItMS0xLTU5MTI3_96252286-c91f-43d5-80ef-a28477698b5a"
      unitRef="usd">242996000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzEyLTQtMS0xLTU5MTI3_e2b418b3-3d37-4584-be86-2edc6a9d1bf1"
      unitRef="usd">170063000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzE1LTItMS0xLTU5MTI3_79d430d9-a66d-43c0-b0b2-eaa57bc96b36"
      unitRef="usd">73000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzE1LTQtMS0xLTU5MTI3_332da618-610f-40bf-8c5d-cc2c6f338a5b"
      unitRef="usd">80000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzE2LTItMS0xLTU5MTI3_1b55113e-5a16-457b-ab92-ab5942301666"
      unitRef="usd">545000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzE2LTQtMS0xLTU5MTI3_a6eed54f-5f47-4746-8bea-fe076d400285"
      unitRef="usd">545000</us-gaap:Goodwill>
    <us-gaap:ContractWithCustomerAssetNetNoncurrent
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzE3LTItMS0xLTU5MTI3_f6670fd5-5268-4dac-a0bf-25ae3bbbe515"
      unitRef="usd">15000000</us-gaap:ContractWithCustomerAssetNetNoncurrent>
    <us-gaap:ContractWithCustomerAssetNetNoncurrent
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzE3LTQtMS0xLTU5MTI3_c45df30c-d938-4402-90bb-378e1e53a333"
      unitRef="usd">15000000</us-gaap:ContractWithCustomerAssetNetNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzE4LTItMS0xLTU5MTI3_d2574b62-872e-42ae-ad1e-75205673af8d"
      unitRef="usd">854000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzE4LTQtMS0xLTU5MTI3_0b84cc12-71b2-4e30-852f-10dd954a8ac8"
      unitRef="usd">899000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:AssetsNoncurrent
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzE5LTItMS0xLTU5MTI3_fcfee9df-2b16-4f5c-8bd0-84646e598af0"
      unitRef="usd">16472000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzE5LTQtMS0xLTU5MTI3_90e0271b-33de-4e9a-802b-5f104056c2b8"
      unitRef="usd">16524000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzIwLTItMS0xLTU5MTI3_e0e4301a-9a12-494c-a998-f20caf7e1786"
      unitRef="usd">259468000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzIwLTQtMS0xLTU5MTI3_7d1a1732-de3c-42c7-8c3a-a678de918842"
      unitRef="usd">186587000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzI0LTItMS0xLTU5MTI3_b67e607c-2a33-41c8-8892-dfd84b246ca9"
      unitRef="usd">2910000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzI0LTQtMS0xLTU5MTI3_e684063f-ead5-4083-8174-147ad653631c"
      unitRef="usd">10044000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzI1LTItMS0xLTU5MTI3_dbb52186-36fb-451e-9f7e-228e91064190"
      unitRef="usd">13752000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzI1LTQtMS0xLTU5MTI3_3f20433c-d5f1-4e02-9372-93dbbc353c2d"
      unitRef="usd">22256000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzI3LTItMS0xLTU5MTI3_057b8d39-625e-4553-a3e8-bc6fe4b9c538"
      unitRef="usd">675000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzI3LTQtMS0xLTU5MTI3_43f86712-74bc-4169-ae36-8b91012664f5"
      unitRef="usd">648000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzI5LTItMS0xLTU5MTI3_867138c8-3533-44e4-8fda-bab374840ddc"
      unitRef="usd">283000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzI5LTQtMS0xLTU5MTI3_3d8bb306-da18-42e7-a3a3-1eca2ca067a5"
      unitRef="usd">147000</us-gaap:TaxesPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzMwLTItMS0xLTU5MTI3_99019260-54ef-4348-99c6-cb075803487e"
      unitRef="usd">1409000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzMwLTQtMS0xLTU5MTI3_f7258857-3599-42d3-bfb7-cd48cbe6c23f"
      unitRef="usd">327000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzMxLTItMS0xLTU5MTI3_315c4f75-9a64-4490-b9df-2ddeaa5fdd0f"
      unitRef="usd">19029000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzMxLTQtMS0xLTU5MTI3_2d15fb4c-b6f1-48e9-868b-92baa1eb584b"
      unitRef="usd">33422000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzM1LTItMS0xLTU5MTI3_03db1c67-f742-4284-85e8-4863d50461a2"
      unitRef="usd">9768000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzM1LTQtMS0xLTU5MTI3_800bcaac-ad8a-4bbb-8862-afeede87d2cf"
      unitRef="usd">4874000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzM2LTItMS0xLTU5MTI3_c1104ed7-8df1-40f3-9ce3-dddc7d03fb94"
      unitRef="usd">205000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzM2LTQtMS0xLTU5MTI3_7bdeab6a-7f08-41b7-81ac-007cf88ea229"
      unitRef="usd">286000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzM3LTItMS0xLTU5MTI3_d71ec89a-835c-4679-82ee-487b2091ce0f"
      unitRef="usd">9973000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzM3LTQtMS0xLTU5MTI3_b6ca69b6-9c98-4b09-b5a2-36cc71064e08"
      unitRef="usd">5160000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzM4LTItMS0xLTU5MTI3_e6bbd066-1b10-4e28-b101-911951d4cbb5"
      unitRef="usd">29002000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzM4LTQtMS0xLTU5MTI3_8df090bd-852b-4f21-acfd-589d0237ef34"
      unitRef="usd">38582000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzQwLTItMS0xLTU5MTI3_f163d427-f9d1-4247-abff-ae56786cc294"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzQwLTQtMS0xLTU5MTI3_c057b8e2-811b-4e2c-8ef5-6e351e89aa32"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzQzLTAtMS0xLTU5MTI3L3RleHRyZWdpb246NDEwM2EyZDI2NDVhNGQwMGE0MjY2YWU0Nzc0ODllM2RfMTM_249dbafe-c5df-4a7a-9e26-613b18a3fdbe"
      unitRef="gbpPerShare">0.05</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzQzLTAtMS0xLTU5MTI3L3RleHRyZWdpb246NDEwM2EyZDI2NDVhNGQwMGE0MjY2YWU0Nzc0ODllM2RfMTM_af5c73c5-146a-4d84-94bc-288da41cabdb"
      unitRef="gbpPerShare">0.05</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzQzLTAtMS0xLTU5MTI3L3RleHRyZWdpb246NDEwM2EyZDI2NDVhNGQwMGE0MjY2YWU0Nzc0ODllM2RfMzQ_feaa870e-9f48-42fe-bc1d-6b9afa757316"
      unitRef="shares">631338246</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzQzLTAtMS0xLTU5MTI3L3RleHRyZWdpb246NDEwM2EyZDI2NDVhNGQwMGE0MjY2YWU0Nzc0ODllM2RfNDE_1e7c495d-85ae-4f28-a284-299875e04548"
      unitRef="shares">489177550</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzQzLTAtMS0xLTU5MTI3L3RleHRyZWdpb246NDEwM2EyZDI2NDVhNGQwMGE0MjY2YWU0Nzc0ODllM2RfNTY_12a5fe37-0d73-4ccd-9f96-94dd49ae47a2"
      unitRef="shares">606301054</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzQzLTAtMS0xLTU5MTI3L3RleHRyZWdpb246NDEwM2EyZDI2NDVhNGQwMGE0MjY2YWU0Nzc0ODllM2RfNjM_2aabeb57-be9c-41fc-9cca-1ed11fa76422"
      unitRef="shares">480082966</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzQzLTItMS0xLTU5MTI3_34553d7e-02da-464d-aece-42d718e361c8"
      unitRef="usd">40526000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzQzLTQtMS0xLTU5MTI3_13ef434f-e993-4ba1-b714-b5d828e44c5a"
      unitRef="usd">31855000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzQ0LTItMS0xLTU5MTI3_fc76a5d8-8568-47bf-b874-79cd994ee312"
      unitRef="usd">529187000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzQ0LTQtMS0xLTU5MTI3_6ba4ca40-3a10-4a8d-960b-741ec1a73aec"
      unitRef="usd">385070000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:TreasuryStockValue
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzQ1LTItMS0xLTU5MTI3_b6e398b0-00f0-4ac4-ac58-ab27561ee01f"
      unitRef="usd">1549000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzQ1LTQtMS0xLTU5MTI3_11226d7a-11d7-416c-9a68-c3c7bd2d2d6e"
      unitRef="usd">603000</us-gaap:TreasuryStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzQ2LTItMS0xLTU5MTI3_02b4a503-be2e-4731-bae6-ca916333cdc5"
      unitRef="usd">-4601000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzQ2LTQtMS0xLTU5MTI3_03774e0b-1e74-4f34-a2ad-41d2b5cb54d4"
      unitRef="usd">-4601000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzQ3LTItMS0xLTU5MTI3_844fa8d5-b7e0-4927-85cd-2d3a5bd85a20"
      unitRef="usd">-333097000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzQ3LTQtMS0xLTU5MTI3_ca265a6b-3298-4060-97fc-9046487535d6"
      unitRef="usd">-263716000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzQ4LTItMS0xLTU5MTI3_dcb5dd94-2881-4ad7-ae3b-70fd14a8aa78"
      unitRef="usd">230466000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzQ4LTQtMS0xLTU5MTI3_a49401a7-07ee-4083-933b-f23782e6d01a"
      unitRef="usd">148005000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzQ5LTItMS0xLTU5MTI3_1ecbb9cc-ecbd-407f-8e00-35b5c7d6be78"
      unitRef="usd">259468000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDMvZnJhZzpkNTNlMmY4MjdiOTk0YTMwODNlZTBkMDhmOGJhOTY4YS90YWJsZTo0ZmRiZWJhYWI5MWI0YzBiYTU4OTA0NDA5OTk2NTA2Yi90YWJsZXJhbmdlOjRmZGJlYmFhYjkxYjRjMGJhNTg5MDQ0MDk5OTY1MDZiXzQ5LTQtMS0xLTU5MTI3_fe584c46-d0d0-42f4-8e6f-b9ca066c04fe"
      unitRef="usd">186587000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzItMi0xLTEtNTkxMjc_04daaa4c-92e4-4715-9040-498d2e842c80"
      unitRef="usd">458000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzItNC0xLTEtNTkxMjc_6cda5271-5c9a-471d-b8f9-b32cbfa40654"
      unitRef="usd">40000000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzMtMi0xLTEtNTkxMjc_62642537-ad70-4924-b333-b2de2fdae05c"
      unitRef="usd">346000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzMtNC0xLTEtNTkxMjc_6702c0df-711c-4eaa-b874-6e173a681c6a"
      unitRef="usd">0</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzQtMi0xLTEtNTkxMjc_720e8d7e-d28a-4a91-8636-ddf7bf494f4f"
      unitRef="usd">112000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzQtNC0xLTEtNTkxMjc_200d2810-08e7-4f0b-bc74-2d946efcd4ff"
      unitRef="usd">40000000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzYtMi0xLTEtNTkxMjc_71d30870-bfce-4dcc-842b-aa877fff6fdc"
      unitRef="usd">49283000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzYtNC0xLTEtNTkxMjc_8b57c4e9-277c-40ae-b470-fec8640c6010"
      unitRef="usd">79406000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzctMi0xLTEtNTkxMjc_e50fee84-48ac-4682-9e1d-457eed164e23"
      unitRef="usd">26579000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzctNC0xLTEtNTkxMjc_acbcf422-0e93-4530-a2de-9613456d07fb"
      unitRef="usd">33907000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzgtMi0xLTEtNTkxMjc_ed9820d9-6121-4131-8c19-68c0a8593fc2"
      unitRef="usd">75862000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzgtNC0xLTEtNTkxMjc_89d5be54-a1af-41a5-90bc-6b929e63262f"
      unitRef="usd">113313000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzktMi0xLTEtNTkxMjc_7335aa25-174d-4d95-9f4e-01bf4c72a6d7"
      unitRef="usd">-75750000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzktNC0xLTEtNTkxMjc_a7b041e7-633c-4bf9-b11f-4c54b232b020"
      unitRef="usd">-73313000</us-gaap:OperatingIncomeLoss>
    <vrna:GainLossFromResearchAndDevelopmentTaxCredit
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzExLTItMS0xLTU5MTI3_f4649fa6-486b-412a-8896-4e08b070bde3"
      unitRef="usd">9634000</vrna:GainLossFromResearchAndDevelopmentTaxCredit>
    <vrna:GainLossFromResearchAndDevelopmentTaxCredit
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzExLTQtMS0xLTU5MTI3_8379b371-4738-4af3-8c8f-371817e05597"
      unitRef="usd">15630000</vrna:GainLossFromResearchAndDevelopmentTaxCredit>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzEyLTItMS0xLTU5MTY0_76ddb656-35a9-49e1-ae6f-d5aef45fc63e"
      unitRef="usd">-815000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzEyLTQtMS0xLTU5MTY0_d9bc4fc8-dcd3-4a9a-8efb-40262016ea2f"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:InvestmentIncomeNet
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzEyLTItMS0xLTU5MTI3_29021942-0d27-4cb1-b744-b8b883889814"
      unitRef="usd">2821000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzEyLTQtMS0xLTU5MTI3_81b54ac3-13ad-4675-957a-ebceac2d25bd"
      unitRef="usd">14000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InterestExpense
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzEzLTItMS0xLTU5MTI3_57f62e5f-7aca-4683-9b00-6ce8a66850f9"
      unitRef="usd">521000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzEzLTQtMS0xLTU5MTI3_281279d3-91e4-45a7-a88f-cd6dfbac7f0a"
      unitRef="usd">340000</us-gaap:InterestExpense>
    <vrna:UnrealizedGainLossOnWarrants
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzE0LTItMS0xLTU5MTI3_4907f05f-4424-418d-9c61-b172806e8497"
      unitRef="usd">0</vrna:UnrealizedGainLossOnWarrants>
    <vrna:UnrealizedGainLossOnWarrants
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzE0LTQtMS0xLTU5MTI3_08bf8ef4-c22c-490b-9cf1-8a3712729d83"
      unitRef="usd">2246000</vrna:UnrealizedGainLossOnWarrants>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzE1LTItMS0xLTU5MTI3_d1bf539a-fad8-485c-bb93-0b134dd1b5e5"
      unitRef="usd">-3817000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzE1LTQtMS0xLTU5MTI3_92497c84-a4f6-4cc1-a385-41fd80f8ab8f"
      unitRef="usd">176000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzE2LTItMS0xLTU5MTI3_77e09019-35d9-4c6a-9685-0efab40bda47"
      unitRef="usd">7302000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzE2LTQtMS0xLTU5MTI3_1b0e7220-1059-4aa5-8cc3-059f7a01de96"
      unitRef="usd">17726000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzE3LTItMS0xLTU5MTI3_464ad949-d9da-4558-88d7-a5997af639c1"
      unitRef="usd">-68448000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzE3LTQtMS0xLTU5MTI3_f4afa9d7-ceb3-4212-93d8-82786a964aad"
      unitRef="usd">-55587000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzE4LTItMS0xLTU5MTI3_d13eef67-8713-44b3-8d2c-f0991f45f0a8"
      unitRef="usd">253000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzE4LTQtMS0xLTU5MTI3_f4e30076-a8d6-4496-b556-4e2330b71bf3"
      unitRef="usd">-18000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzE5LTItMS0xLTU5MTI3_b1f13fbf-99d9-4b9c-ade9-675d4193b0cd"
      unitRef="usd">-68701000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzE5LTQtMS0xLTU5MTI3_795f12cb-4286-4e08-b821-ed78b19ea57f"
      unitRef="usd">-55569000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzIzLTItMS0xLTU5MTI3_0a7e9201-6ec0-4172-91fa-89b900474441"
      unitRef="usdPerShare">-0.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzIzLTItMS0xLTU5MTI3_36ba8915-9bcf-47d3-a672-087b4ae9afb2"
      unitRef="usdPerShare">-0.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzIzLTQtMS0xLTU5MTI3_6a5f1077-3559-4095-896a-c60a37b100f5"
      unitRef="usdPerShare">-0.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDYvZnJhZzo0OWU4YmIyMjlkZWQ0YTJlYjI1ZjRjNDg3YWU5ZDRjMi90YWJsZTplYzIxYzZiNTZlNzA0YjBmYTViY2U0NmJlM2IxMDhhMS90YWJsZXJhbmdlOmVjMjFjNmI1NmU3MDRiMGZhNWJjZTQ2YmUzYjEwOGExXzIzLTQtMS0xLTU5MTI3_e0a11042-d08d-4522-949a-20dd118a311c"
      unitRef="usdPerShare">-0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i914d9cdf65d04c2f90fe005e7472a193_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzItMi0xLTEtNTkxMjc_44105498-d4e9-47d1-92b7-0a2dad101498"
      unitRef="shares">488304446</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i914d9cdf65d04c2f90fe005e7472a193_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzItNC0xLTEtNTkxMjc_7764a667-7fd8-4d27-b866-66faf04b93c6"
      unitRef="usd">31794000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i628f4c337d8a4907b099660435d9a654_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzItNi0xLTEtNTkxMjc_1572d66f-7272-4304-a5a8-7043f7fc4b9d"
      unitRef="usd">366411000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib7f0ec0ed1784d75a7a6870bf8e210e8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzItOC0xLTEtNTkxMjc_b97862cc-69ed-403b-b22a-3ae2a270d6e4"
      unitRef="usd">-1700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9bcd9fdf0b49455fbda9ed3d6b4ffe6a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzItMTAtMS0xLTU5MTI3_201d1b5d-2d67-4246-9271-0f350c555467"
      unitRef="usd">-4601000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9f35aecd3e8247dab76bb02c4f16b0fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzItMTItMS0xLTU5MTI3_7e85dc61-54b0-45fc-8fef-3b4635e6cd12"
      unitRef="usd">-207050000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if80b5e08771841e98a3888a3388c32e2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzItMTQtMS0xLTU5MTI3_e7475005-db7c-4a66-bafe-1bb570ae660d"
      unitRef="usd">184854000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="if823f7d8c92d4955b417d2877d92cf1e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzMtMTItMS0xLTU5MTI3_5e3c24a6-8547-4b6a-a8b4-3817f2eb09cf"
      unitRef="usd">-55569000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzMtMTQtMS0xLTU5MTI3_943a29ed-94d3-490e-b7be-df9434a6a8cc"
      unitRef="usd">-55569000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i380ad8bec02d4cef80ab1e2a0293509c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzUtMi0xLTEtNTkyMjg_46c14e4b-7f0a-47fb-b6c2-ab30dd038f8c"
      unitRef="shares">873104</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i380ad8bec02d4cef80ab1e2a0293509c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzUtNC0xLTEtNTkyMjg_128aff55-f767-4be4-9c22-d9d203baca66"
      unitRef="usd">61000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i375548ad8ff84bd0982f3bccb9de8503_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzUtNi0xLTEtNTkyMjg_73ec496d-ffc7-42f8-9f5e-99444a294aee"
      unitRef="usd">672000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i442b161bf35c4276ac36992d05e23115_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzUtMTQtMS0xLTU5MjI4_8a351799-7539-4495-8001-e55f37366d9f"
      unitRef="usd">733000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i2541a30ef7e84fc1925bf03d916e97a2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzctOC0xLTEtNTk0MzI_e440f8ab-8953-493c-a67d-2c3c43d57988"
      unitRef="usd">1097000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="if823f7d8c92d4955b417d2877d92cf1e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzctMTItMS0xLTU5NDMy_594bf020-e764-47a0-be5d-e57b9f909fd4"
      unitRef="usd">-1097000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic8a8c7eae65b43e9a11fdf51f5b2d5d8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzgtNi0xLTEtNTkzNDQ_255de6fd-8512-4c24-9a9d-d99057676227"
      unitRef="usd">25425000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzgtMTQtMS0xLTU5MzQ0_73b0c6b2-c835-4ccd-93d8-a52bf4beba45"
      unitRef="usd">25425000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ic8a8c7eae65b43e9a11fdf51f5b2d5d8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzktNi0xLTEtNTk0MzI_fd158733-f343-4b1d-bc16-a3e420ca9ced"
      unitRef="usd">6850000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzktMTQtMS0xLTU5NDMy_44d6eff8-3574-4d67-a379-ebe02052fa0a"
      unitRef="usd">6850000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <vrna:AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation
      contextRef="ic8a8c7eae65b43e9a11fdf51f5b2d5d8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzEwLTYtMS0xLTU5NDMy_628fa5aa-389c-460e-96d7-10394d4d64ef"
      unitRef="usd">588000</vrna:AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation>
    <vrna:AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzEwLTE0LTEtMS01OTQzMg_cb69f546-c6ab-49d6-9c0c-4135fac49cae"
      unitRef="usd">588000</vrna:AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib56e759a9ec24aa88f41a41be62db95d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzEwLTItMS0xLTU5MTI3_6c0d1d42-75d3-4816-91ae-f4e58b0d3c8b"
      unitRef="shares">489177550</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ib56e759a9ec24aa88f41a41be62db95d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzEwLTQtMS0xLTU5MTI3_b6928d67-a0a2-4585-99a3-ea0aab2584fa"
      unitRef="usd">31855000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia773a9ee14f34d1a8dc7c9d57c7401e1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzEwLTYtMS0xLTU5MTI3_54f72f85-5eb3-46ba-a07b-3d3b02b8b33b"
      unitRef="usd">385070000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9ece18e799b840598f8450de9ee4fb80_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzEwLTgtMS0xLTU5MTI3_991d6998-fc2c-4ff8-bdec-bc5550e5e340"
      unitRef="usd">-603000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie8f5a4cc91e843d384ab12b09f91edb8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzEwLTEwLTEtMS01OTEyNw_5a86e3cf-6e11-4758-9e5c-f7cc3681f8eb"
      unitRef="usd">-4601000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i609c9125fe4c4df8b724395ec47768f6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzEwLTEyLTEtMS01OTEyNw_3013fe08-27f9-4ae3-9aeb-acbb31b8b46f"
      unitRef="usd">-263716000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzEwLTE0LTEtMS01OTEyNw_41cbaae7-a1f1-4dc6-9469-836b34848c2e"
      unitRef="usd">148005000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i2df52cddbf6047d99bc4c33dc209f75a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzExLTEyLTEtMS01OTEyNw_d9d1a12c-77f7-4fa5-a141-85aa9501f7e7"
      unitRef="usd">-68701000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzExLTE0LTEtMS01OTEyNw_589c6e08-e0f8-4d24-b4e9-1233d61517c6"
      unitRef="usd">-68701000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i079c0a66af1a4b4f8579073c30a06c55_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzEzLTItMS0xLTU5MjY2_78c38e91-9aae-4b31-886d-de81c2b022f0"
      unitRef="shares">114080000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i079c0a66af1a4b4f8579073c30a06c55_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzEzLTQtMS0xLTU5MjY2_e720ac5f-1006-46d5-927a-ebb3aa4e6852"
      unitRef="usd">6918000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ibab55600f3bc40aa902c283296c411ce_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzEzLTYtMS0xLTU5MjY2_66a128b9-6cd0-410d-b53b-89bb479a2a68"
      unitRef="usd">133279000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i5d11dce15ffe46c5a3f318667309b215_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzEzLTE0LTEtMS01OTI2Ng_ec36b814-d0f5-4980-a1da-5729f5a8b6c6"
      unitRef="usd">140197000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i2af5163aa9d84dad89a011496414bdd2_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzEyLTItMS0xLTU5MTI3_bb4ab586-afb9-4ef9-9fee-0f46ee74b925"
      unitRef="shares">80696</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i2af5163aa9d84dad89a011496414bdd2_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzEyLTQtMS0xLTU5MTI3_eed6d343-eb76-4e3f-a4fd-9029934f3ef1"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i111533997c354eed8392ec995f25323f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzEyLTYtMS0xLTU5MTI3_7e2def35-1837-4cd2-9a24-5d960966722c"
      unitRef="usd">62000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i979239b8c81f4ce297052fdb5fcfb029_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzEyLTE0LTEtMS01OTEyNw_7d83be96-dea0-49dd-829b-eb907940222c"
      unitRef="usd">67000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ie6d783db1d43419d8f15b7dc0a5bcb2d_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzEzLTItMS0xLTU5MTI3_93ac81fd-95e5-4618-b6e0-00d01df5fc2f"
      unitRef="shares">28000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ie6d783db1d43419d8f15b7dc0a5bcb2d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzEzLTQtMS0xLTU5MTI3_cf8219a5-2fda-4d4d-830b-1f61672091df"
      unitRef="usd">1748000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i1aae0c0ff8a846889a7cab3fe123941d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzEzLTgtMS0xLTU5MTI3_53515dbf-48f1-4d70-a5e7-d7060868cb7b"
      unitRef="usd">-1748000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzEzLTE0LTEtMS01OTEyNw_65200643-cae4-4c58-8d3c-e01765e9de35"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i1aae0c0ff8a846889a7cab3fe123941d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzE3LTgtMS0xLTU5NDkx_a3bf3a24-5dc1-48a7-8c65-24d2e5ab0f6f"
      unitRef="usd">680000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i2df52cddbf6047d99bc4c33dc209f75a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzE3LTEyLTEtMS01OTQ5MQ_732e802d-7945-41e1-8f9e-38fb820ee80e"
      unitRef="usd">-680000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie9ea6a1e50f743c7b2706c4f275812bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzE4LTYtMS0xLTU5NDU0_ced646b4-7f93-4bc6-845d-59b08232182f"
      unitRef="usd">1250000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i1aae0c0ff8a846889a7cab3fe123941d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzE4LTgtMS0xLTU5NDU0_f30dc5ee-ec02-48b2-b5c0-96fd3a75af67"
      unitRef="usd">122000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzE4LTE0LTEtMS01OTQ1NA_ebe4d095-5375-4ba3-b214-34493c350832"
      unitRef="usd">1372000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie9ea6a1e50f743c7b2706c4f275812bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzE0LTYtMS0xLTU5MTI3_f257b956-3211-46b5-b598-da182689181d"
      unitRef="usd">14121000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzE0LTE0LTEtMS01OTEyNw_961208eb-1211-4942-a380-30f7664f2e52"
      unitRef="usd">14121000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ie9ea6a1e50f743c7b2706c4f275812bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzE1LTYtMS0xLTU5MTI3_4eac42fc-8065-4e33-8163-f85302f544ce"
      unitRef="usd">4723000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzE1LTE0LTEtMS01OTEyNw_683ad21b-43e2-4ace-85ec-117ec0b05124"
      unitRef="usd">4723000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <vrna:AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation
      contextRef="ie9ea6a1e50f743c7b2706c4f275812bf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzIwLTYtMS0xLTU5MTI3_756bd2e0-4b5b-4cbd-9fbe-58ec8367df86"
      unitRef="usd">-128000</vrna:AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation>
    <vrna:AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzIwLTE0LTEtMS01OTEyNw_8051eb74-5b01-4e05-b361-bd650facb4f4"
      unitRef="usd">-128000</vrna:AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i91456de939c649aabb7986b2e37d0859_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzIxLTItMS0xLTU5MTI3_269b9a1a-1b52-444c-a64a-c262e9e1af28"
      unitRef="shares">631338246</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i91456de939c649aabb7986b2e37d0859_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzIxLTQtMS0xLTU5MTI3_0c9dda61-b8fb-4f7d-a37d-d89f759248d1"
      unitRef="usd">40526000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i25dfa9d20fe64551adbf52bf5cde91b6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzIxLTYtMS0xLTU5MTI3_e1688bc8-d2a7-407b-b50e-574f4fd2d6fe"
      unitRef="usd">529187000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ica49ccad51694417b0ecd16ca773ee2b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzIxLTgtMS0xLTU5MTI3_c5d3e2bb-ed08-4bfd-a799-570bb0bfa450"
      unitRef="usd">-1549000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i79d67ed1de10489aa0bb85ba9c0ec74a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzIxLTEwLTEtMS01OTEyNw_bdcc17be-74bc-4d3a-a587-52ea15066a5b"
      unitRef="usd">-4601000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9383bef872e64838b59e60f52963eea3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzIxLTEyLTEtMS01OTEyNw_09ed7493-89d5-4064-a075-56ffce9e2058"
      unitRef="usd">-333097000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMDkvZnJhZzpiZjU2Zjc5N2Q4ODE0YmJmODU5N2FkOGZjYjZhNGJhMi90YWJsZTo2ZTQ0MmZlZmQzNWQ0ZDJlOWJlZWU0MjZlMWY0ZTQ4NS90YWJsZXJhbmdlOjZlNDQyZmVmZDM1ZDRkMmU5YmVlZTQyNmUxZjRlNDg1XzIxLTE0LTEtMS01OTEyNw_e08935ec-8a04-4888-86d6-fe3f74ab66ef"
      unitRef="usd">230466000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzMtMi0xLTEtNTkxMjc_1f24ed5d-4ce0-4e0b-bd38-ea8bb12e4de5"
      unitRef="usd">-68701000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzMtNC0xLTEtNTkxMjc_3f9e62f1-abea-4211-b7ba-c02a97b9840e"
      unitRef="usd">-55569000</us-gaap:NetIncomeLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzUtMi0xLTEtNTkxMjc_6f2adc97-36c1-4036-9302-7d6fad619c63"
      unitRef="usd">-3817000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzUtNC0xLTEtNTkxMjc_f20598c9-cf3a-4509-b27e-e9836c7291d2"
      unitRef="usd">176000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzYtMi0xLTEtNTkxMjc_42d8e36e-f77d-448b-9b0f-c6af67b3a257"
      unitRef="usd">80000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzYtNC0xLTEtNTkxMjc_fc31ebcd-9595-4908-94cb-229191a11628"
      unitRef="usd">114000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzctMi0xLTEtNTkxMjc_80a0b479-7cf2-4dd5-ad1a-1feec9d99974"
      unitRef="usd">108000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzctNC0xLTEtNTkxMjc_73901c89-4cf5-4866-a6bf-1dce9d4e32e7"
      unitRef="usd">125000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzgtMi0xLTEtNTk1MzA_851a76cd-dc69-41b5-8af4-b1538b4c23a8"
      unitRef="usd">-815000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzgtNC0xLTEtNTk1MzA_d8190015-bdb4-43c6-9b13-9790f8ecf6f5"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzgtMi0xLTEtNTkxMjc_dbda9887-43a3-4fab-ad3d-370855140531"
      unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzgtNC0xLTEtNTkxMjc_d42acac5-6347-4f4e-97d5-b00ae42bab51"
      unitRef="usd">-2246000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ShareBasedCompensation
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzEwLTItMS0xLTU5MTI3_4540b060-250f-4225-be71-02cfb3667932"
      unitRef="usd">14121000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzEwLTQtMS0xLTU5MTI3_ad6581a9-d17b-4457-96dd-498dd3f545ce"
      unitRef="usd">25425000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzExLTItMS0xLTU5MTI3_02ffc5b7-34d1-4e74-bad5-ae2efe80ccce"
      unitRef="usd">636000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzExLTQtMS0xLTU5MTI3_9951f210-beb9-49d0-9e59-785f8e896303"
      unitRef="usd">629000</us-gaap:DepreciationDepletionAndAmortization>
    <vrna:IncreaseDecreaseInEquityInterestReceivable
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzEyLTItMS0xLTU5MTI3_3b436057-e674-40cb-a9b1-e1445fd18cec"
      unitRef="usd">0</vrna:IncreaseDecreaseInEquityInterestReceivable>
    <vrna:IncreaseDecreaseInEquityInterestReceivable
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzEyLTQtMS0xLTU5MTI3_a5cb6b1f-5fe9-407f-8d77-17809189c20e"
      unitRef="usd">15000000</vrna:IncreaseDecreaseInEquityInterestReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzE2LTItMS0xLTU5MTI3_30402302-5839-474c-ba11-4b1e44e1d3d7"
      unitRef="usd">-1538000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzE2LTQtMS0xLTU5MTI3_6b6cf190-0863-4043-abc4-cc88df64f0a7"
      unitRef="usd">-501000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <vrna:IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzE3LTItMS0xLTU5MTI3_e4254633-259f-4307-ab66-04f9924a2cfe"
      unitRef="usd">-3964000</vrna:IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent>
    <vrna:IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzE3LTQtMS0xLTU5MTI3_575cac2c-5751-44f9-be13-6bb2de7fae4f"
      unitRef="usd">6924000</vrna:IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzE4LTItMS0xLTU5MTI3_90399fa9-f016-49fb-ac7a-5810332d7ff6"
      unitRef="usd">1325000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzE4LTQtMS0xLTU5MTI3_be91bd09-3ca6-4598-9105-b6b0b19624f0"
      unitRef="usd">343000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzE5LTItMS0xLTU5MTI3_aeacbebe-9117-4422-b5d2-b4bce982a920"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzE5LTQtMS0xLTU5MTI3_040997d8-7978-4a35-9a35-b5a9a4891951"
      unitRef="usd">440000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzIwLTItMS0xLTU5MTI3_bbcab77e-9d7a-4983-840b-466d2bb8d1f4"
      unitRef="usd">-7146000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzIwLTQtMS0xLTU5MTI3_ea55bd19-7c47-4d54-9bb3-7b9dad67b7ec"
      unitRef="usd">9866000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzIxLTItMS0xLTU5MTI3_e8125572-1c4e-4711-8d13-cef1e6441eef"
      unitRef="usd">-8504000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzIxLTQtMS0xLTU5MTI3_47d02767-bc94-4bbb-a7bf-b314572cfc0f"
      unitRef="usd">11389000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <vrna:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzIyLTItMS0xLTU5MTI3_3b3ad075-b28d-4304-8360-928b21e97ada"
      unitRef="usd">-597000</vrna:IncreaseDecreaseInOperatingLeaseLiabilities>
    <vrna:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzIyLTQtMS0xLTU5MTI3_48e46e1f-3364-4c82-9207-81b390245d8f"
      unitRef="usd">-373000</vrna:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedTaxesPayable
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzIzLTItMS0xLTU5MTI3_cfc066ad-73d4-4b3d-b776-90d70b1c8597"
      unitRef="usd">136000</us-gaap:IncreaseDecreaseInAccruedTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedTaxesPayable
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzIzLTQtMS0xLTU5MTI3_2e2744ca-22ab-4e88-bdd7-86972ad9140f"
      unitRef="usd">147000</us-gaap:IncreaseDecreaseInAccruedTaxesPayable>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzI0LTItMS0xLTU5MTI3_37162e05-efc2-4380-a016-7f9983fa0081"
      unitRef="usd">1196000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzI0LTQtMS0xLTU5MTI3_69b9b126-458c-48be-bebc-027b19550ec9"
      unitRef="usd">-379000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzI1LTItMS0xLTU5MTI3_9b46d596-14e8-47fd-a8dc-a30f14f7a06f"
      unitRef="usd">-59862000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzI1LTQtMS0xLTU5MTI3_ca1143ba-f2fb-464c-981e-444905135166"
      unitRef="usd">-33254000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzI3LTItMS0xLTU5MTI3_71bdb539-6a7d-4caf-934d-7db120a1842c"
      unitRef="usd">29000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzI3LTQtMS0xLTU5MTI3_a70f4ce1-4bec-44e8-a0b1-95e9f7f4d7ef"
      unitRef="usd">12000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzI5LTItMS0xLTU5MTI3_98aa91c8-d22f-463b-bf61-707c0f07ad05"
      unitRef="usd">-29000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzI5LTQtMS0xLTU5MTI3_4db20a38-004b-4d77-bcc4-0dfc7ad1dd90"
      unitRef="usd">-12000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzMxLTItMS0xLTU5MTI3_c89add5d-76e8-403a-a87b-9c48ac5e97e0"
      unitRef="usd">149797000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzMxLTQtMS0xLTU5MTI3_f5072336-6b7e-4e42-9ad6-1476becd84ff"
      unitRef="usd">733000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzMyLTItMS0xLTU5MTI3_437565c1-841d-47ea-889e-ee2b134893b7"
      unitRef="usd">9533000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzMyLTQtMS0xLTU5MTI3_3eb0d110-f555-439f-bb70-4ab5f443046c"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzMzLTItMS0xLTU5MTI3_1d4cd6d7-63e1-46fd-9bd3-264b956c2fdf"
      unitRef="usd">10000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzMzLTQtMS0xLTU5MTI3_e49144f7-871e-4177-85e5-e81f7d112693"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzM0LTItMS0xLTU5MTI3_e3805715-0615-4100-802b-b2acd52ba10a"
      unitRef="usd">245000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzM0LTQtMS0xLTU5MTI3_a52ae838-fa8a-4faa-8531-ea950c902f93"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzM2LTItMS0xLTY5MTY3_9bece2ba-a636-4508-b178-011a4453a3a5"
      unitRef="usd">5000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzM2LTQtMS0xLTY5MTY3_6b2763c8-8df2-4463-8d0e-f04011058607"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsOfLoanCosts
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzM3LTItMS0xLTY5MTY3_3cd6a545-f285-4ecf-b69e-4bd00face73c"
      unitRef="usd">850000</us-gaap:PaymentsOfLoanCosts>
    <us-gaap:PaymentsOfLoanCosts
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzM3LTQtMS0xLTY5MTY3_b482e804-8068-495e-86bf-1929c5590b2a"
      unitRef="usd">0</us-gaap:PaymentsOfLoanCosts>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzM1LTItMS0xLTU5MTI3_3ec303d7-3f78-4613-ad5a-cae4d479abfd"
      unitRef="usd">4723000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzM1LTQtMS0xLTU5MTI3_f3f9351b-3322-4da1-bc52-c48b3f9b30f7"
      unitRef="usd">6850000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzM2LTItMS0xLTU5MTI3_add54e1a-516f-4cf4-b496-a5a50d5d0384"
      unitRef="usd">1372000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzM2LTQtMS0xLTU5MTI3_dc827a20-4e0f-468a-8125-42a92eb3f903"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzM4LTItMS0xLTU5MTI3_c819b3fc-6f34-4299-9948-ee5f3ddb3a55"
      unitRef="usd">140818000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzM4LTQtMS0xLTU5MTI3_f1154390-3283-426e-95a2-886b1cf0a9f9"
      unitRef="usd">-6117000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzM5LTItMS0xLTU5MTI3_5ebdf782-2857-4376-9ee2-4ed8c741b09b"
      unitRef="usd">-1480000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzM5LTQtMS0xLTU5MTI3_553720e9-7a55-4f9d-a98d-6b8bf4bc73b0"
      unitRef="usd">-223000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzQwLTItMS0xLTU5MTI3_cbb9fab3-68cb-4e44-a122-f03be82f34ca"
      unitRef="usd">79447000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzQwLTQtMS0xLTU5MTI3_c424077d-fee7-49a5-9c28-fad9caf00f26"
      unitRef="usd">-39606000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzQxLTItMS0xLTU5MTI3_450f994a-73e7-457b-84de-d5df15581ca2"
      unitRef="usd">148380000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if80b5e08771841e98a3888a3388c32e2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzQxLTQtMS0xLTU5MTI3_eb3b388a-bc37-4d4f-9c33-89cb8c5172ac"
      unitRef="usd">187986000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzQyLTItMS0xLTU5MTI3_1d443dbf-b083-401e-af25-6ef3d89b3a7a"
      unitRef="usd">227827000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzQyLTQtMS0xLTU5MTI3_36c2db9d-6e03-45a6-a02a-901ba3905028"
      unitRef="usd">148380000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzQ0LTItMS0xLTU5MTI3_6032a8c5-bc51-4eb0-9124-26d2c61bfe75"
      unitRef="usd">120000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzQ0LTQtMS0xLTU5MTI3_fd9b4e7c-89fa-402e-82db-97db81326f31"
      unitRef="usd">1000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzQ1LTItMS0xLTU5MTI3_4cdd2c60-d539-4436-b280-a173ade8c1d0"
      unitRef="usd">348000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTIvZnJhZzpkYjA2OTY2ZDQxZmM0ZTk1OWVjODNkZGQ3OGNlMTc2Ni90YWJsZTplYjMyM2JlNzc5YmY0Yzg0ODIzNjdhM2Q3MmU4MmViMy90YWJsZXJhbmdlOmViMzIzYmU3NzliZjRjODQ4MjM2N2EzZDcyZTgyZWIzXzQ1LTQtMS0xLTU5MTI3_71062625-5e56-4f64-aa07-a55b2777c499"
      unitRef="usd">215000</us-gaap:InterestPaidNet>
    <vrna:OrganizationAndBusinessDescriptionTextBlock
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzMzMzg_5824c86b-37bd-43e3-b851-c58da915fca4">Organization and description of business operations &lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Verona Pharma plc (the "Company") is incorporated and domiciled in the United Kingdom. Verona Pharma plc has one wholly-owned subsidiary, Verona Pharma, Inc., a Delaware corporation. Rhinopharma Limited (&#x201c;Rhinopharma&#x201d;), a Canadian company that was previously a non-operating, wholly-owned subsidiary, was dissolved in June 2021. The address of the registered office is 1 Central Square, Cardiff, CF10 1FS, United Kingdom.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company is a clinical-stage biopharmaceutical group focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. The Company&#x2019;s American Depositary Shares (&#x201c;ADSs&#x201d;) are listed on the Nasdaq Global Market (&#x201c;Nasdaq&#x201d;) and trade under the symbol &#x201c;VRNA&#x201d;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company has incurred recurring losses and negative cashflows from operations since inception, and has an accumulated deficit of $333.1&#160;million as of December 31, 2022. The Company expects to incur additional losses and negative cash flows from operations until its products potentially gain regulatory approval and reach commercial profitability, if at all.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company expects that its cash and cash equivalents as of December 31, 2022, will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months from the date of issuance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In August 2022, the Company completed an upsized public offering of 14,260,000 ADSs, each representing eight ordinary shares of the Company, nominal value &#xa3;0.05 per share, at a price to the public of $10.50 per ADS, which includes the exercise in full by the underwriters of their option to purchase an additional 1,860,000 ADSs. The aggregate net proceeds from the offering were $140.2&#160;million after deducting underwriting discounts and commissions and estimated offering expenses payable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In October 2022, the Company entered into a term loan of up to $150.0&#160;million (the &#x201c;Oxford Term Loan&#x201d;) with Oxford Finance Luxembourg S.&#xc0; R.L. (&#x201c;Oxford&#x201d;). This Oxford Term Loan replaced the Company&#x2019;s existing $30.0&#160;million facility with Silicon Valley Bank. See Note 7 for further details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In March, 2021, the Company entered into an open market sale agreement with respect to an at-the-market offering program (the &#x201c;ATM Program&#x201d;) under which the Company may issue and sell its ordinary shares in the form of ADSs, with an aggregate offering price of up to $100.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;During the year ended December 31, 2021, the Company sold 873,104 ordinary shares (equivalent to 109,138 ADSs) under the ATM Program, at an average price of approximately $0.86 per share (equivalent to $6.91 per ADS), raising aggregate net proceeds of $0.7&#160;million after deducting issuance costs. As of December 31, 2021, there remained $99.3&#160;million of ordinary shares, in the form of ADSs, available for sale under the ATM Program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;During the year ended December 31, 2022, the Company sold 80,696 ordinary shares (equivalent to 10,087 ADSs) under the ATM Program, at an average price of approximately $0.86 per share (equivalent to $6.86 per ADS), raising aggregate net proceeds of $0.1&#160;million after deducting issuance costs. As of December 31, 2022, there remained $99.2&#160;million of ordinary shares, in the form of ADSs, available for sale under the ATM Program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Additionally, between January 1, 2023 and March 3, 2023, the Company sold 20,321,384 ordinary shares (equivalent to 2,540,173 ADSs) under the ATM Program, at an average price of approximately $2.88 per share (equivalent to $23.08 per ADS), raising aggregate net proceeds of $56.9 million after deducting issuance costs. As of March&#160;3, 2023, there remained $40.6 million&#160;of ordinary shares, in the form of ADSs, available for sale under the ATM Program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company&#x2019;s commercial revenue, if any, will be derived from sales of products that we do not expect to be commercially available within the next year, if ever. Additionally, we may enter into out-licensing transactions from time to time but there can be no assurance that the company can secure such transactions in the future. Accordingly, we may need to obtain substantial additional funds to achieve our business objectives including to further advance clinical and regulatory activities, to fund prelaunch and launch related costs and to create an effective sales and marketing organization to commercialize ensifentrine. Any such additional funding will need to be obtained through public or private financings, debt financing, collaboration or licensing agreements and other arrangements. However, there is no guarantee that we will be successful in securing additional capital on acceptable terms, or at all.&lt;/span&gt;&lt;/div&gt;</vrna:OrganizationAndBusinessDescriptionTextBlock>
    <vrna:NumberOfWhollyOwnedSubsidiaries
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzE3Ng_b4ba8c58-705e-43e1-a106-190c53057fce"
      unitRef="subsidiary">1</vrna:NumberOfWhollyOwnedSubsidiaries>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzIxOTkwMjMyNjg2NTc_4550bdff-e665-4ea3-9c3e-69f1590e96f2"
      unitRef="usd">-333100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ie238e662ca594fb8b2c61e9a8e7cc2b7_D20220815-20220815"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzI0NzM5MDExNjM3NjIx_c87d2f10-f52f-426b-b263-29928d34712a"
      unitRef="shares">14260000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <dei:EntityListingDepositoryReceiptRatio
      contextRef="ice1cf713bbb6461a9be47f13e6cb343f_I20220815"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzI0NzM5MDExNjM3NzA1_c2826258-d8f6-40f1-b261-7bdb37d14835"
      unitRef="number">8</dei:EntityListingDepositoryReceiptRatio>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ice1cf713bbb6461a9be47f13e6cb343f_I20220815"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzI0NzM5MDExNjM3Njk5_d6f69e28-35fb-41f5-aa35-411d0b792465"
      unitRef="usdPerShare">0.05</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ieb1aa532b71f489d849b821859d2f380_I20220815"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzI0NzM5MDExNjM3NjMz_a51339ae-d0e9-4adb-9fb1-fe538d902d15"
      unitRef="usdPerShare">10.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i184e0ab9d5a54b338f38f20780281582_D20220815-20220815"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzI0NzM5MDExNjM3NjQx_c709f81e-ce3c-4be4-b837-77204ac88db6"
      unitRef="shares">1860000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i7bd8f835b5424f209ef20622393563fe_D20220815-20220815"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzI0NzM5MDExNjM3NjUy_c5e5770e-5c62-4d13-80ca-746212da8b29"
      unitRef="usd">140200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ia867c724f1754d6b8ce8489a52865172_I20221014"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzI0NzM5MDExNjM3NjY4_3d84a1e5-f414-4bbb-91a6-1e09980e1431"
      unitRef="usd">150000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ib6f1e5c7e48647c0920bd6e598622618_I20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzI0NzM5MDExNjM3Njg0_2fb246ea-1144-4d44-9331-aa6add372e25"
      unitRef="usd">30000000</us-gaap:DebtInstrumentFaceAmount>
    <vrna:SaleOfStockMaximumAggregateOfferingPrice
      contextRef="ic5b573c06bda4d9abf4c5788689f8267_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzIwMjU_a4340ccf-2cd8-470e-bdbb-f9d33d60537d"
      unitRef="usd">100000000</vrna:SaleOfStockMaximumAggregateOfferingPrice>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzI0MTg5MjU1ODIzMzY3_fb0a8734-641c-4825-9d72-fd3a3558eb58"
      unitRef="shares">873104</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i527c9fac13d64a47b9bf9214236f60e2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzI0MTg5MjU1ODIzNDAy_f98d3561-ec47-4d99-a65b-1124966bc4d3"
      unitRef="shares">109138</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzI0MTg5MjU1ODIzNDcy_1d2dc7f1-7176-4ad2-b1a8-b7f1988cd9a9"
      unitRef="usdPerShare">0.86</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i6695925fbed543f894ece49ef4cdea3a_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzI0MTg5MjU1ODIzNTAx_7184858a-fdab-4ff7-81a4-9d9cb8ff956a"
      unitRef="usdPerShare">6.91</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzI0MTg5MjU1ODIzNTYz_6e4f2ff9-b15a-4d3a-b5e2-228c6349f919"
      unitRef="usd">700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <vrna:CommonStockSharesAvailableForSaleValue
      contextRef="i6695925fbed543f894ece49ef4cdea3a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzI0MTg5MjU1ODIzNjM5_bac242d6-fa41-40cd-a45d-b8546212300e"
      unitRef="usd">99300000</vrna:CommonStockSharesAvailableForSaleValue>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzM4NDgyOTA3MDEwNTE_5b2371f5-973f-4f54-abfa-9b94a9e21110"
      unitRef="shares">80696</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i51dfe19fdb8b4c94be7f8c486773856a_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzM4NDgyOTA3MDEwNzA_3e697fdd-5279-4782-a0fd-07ec0d5d38ba"
      unitRef="shares">10087</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzM4NDgyOTA3MDEwODY_1ff9a70e-6492-4ab8-9702-f6a2ce04d0c9"
      unitRef="usdPerShare">0.86</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ic554433105b34f27be03700dabfb47f7_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzM4NDgyOTA3MDEwOTk_112c030c-19ed-4e21-8875-d67f99507c32"
      unitRef="usdPerShare">6.86</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzM4NDgyOTA3MDExMjE_e22bf46e-413e-4f10-8e19-9c304d42661f"
      unitRef="usd">100000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <vrna:CommonStockSharesAvailableForSaleValue
      contextRef="ic554433105b34f27be03700dabfb47f7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzM4NDgyOTA3MDExNTI_3b480fa9-9900-4351-8543-66567b53509b"
      unitRef="usd">99200000</vrna:CommonStockSharesAvailableForSaleValue>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i8aef53e83ae8405d96c0bb866c6a4b44_D20230101-20230303"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzEzMDYy_d97a1354-b612-4901-b86c-9e394ed10ac8"
      unitRef="shares">20321384</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i7a0e931dedec4d268138428467b28255_D20230101-20230303"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzEzMDc4_59ccf274-f257-4616-8de8-88e75af8571e"
      unitRef="shares">2540173</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i947febb528b2492baff336d20285fda1_I20230303"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzEzMDY2_5eadfad8-b989-484f-9127-e5c9985ebcb0"
      unitRef="usdPerShare">2.88</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="icff757a8f7aa4258a984848491ccbe0b_I20230303"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzEzMDc0_3310fbc0-8bff-411c-a408-592bec39cd85"
      unitRef="usdPerShare">23.08</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i8aef53e83ae8405d96c0bb866c6a4b44_D20230101-20230303"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzEzMDgy_3e0e26e9-6551-4f23-b2db-9cdd923d7fce"
      unitRef="usd">56900000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <vrna:CommonStockSharesAvailableForSaleValue
      contextRef="icff757a8f7aa4258a984848491ccbe0b_I20230303"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTUvZnJhZzowZGMwYjExOGQzMzY0OTY5OTQzNzE5MzAwYmFhMTkzZi90ZXh0cmVnaW9uOjBkYzBiMTE4ZDMzNjQ5Njk5NDM3MTkzMDBiYWExOTNmXzEzMDcw_cced559d-0f79-42ca-b64d-5cb91af1d670"
      unitRef="usd">40600000</vrna:CommonStockSharesAvailableForSaleValue>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzIzOTA2_29295754-e2dc-48bb-8746-3dae9e9e4d4d">Basis of Presentation and Summary of Significant Accounting policies&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Basis of presentation and consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The consolidated financial statements include the accounts of Verona Pharma plc and its wholly-owned subsidiaries Verona Pharma, Inc. and Rhinopharma through to its dissolution in June 2021. All inter-company balances and transactions have been eliminated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") and the following accounting policies have been consistently applied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;At the end of the second quarter of 2020, the Company determined that it no longer qualified as a Foreign Private Issuer under SEC rules. As a result, beginning January 1, 2021, the Company was required to report with the SEC on domestic forms and comply with domestic company rules in the United States. The transition to U.S. GAAP was made retrospectively for all periods from the Company&#x2019;s inception.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual and prepayment of research and development expenses and the fair value of share-based compensation. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from the Company&#x2019;s estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Business combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company applies the acquisition method to account for business combinations. The consideration transferred for the acquisition of a subsidiary is the fair value of the assets transferred, the liabilities incurred to the former owners of the acquiree and the equity interests issued by the Company. The consideration transferred includes the fair value of any asset or liability resulting from a contingent consideration arrangement. The excess of the cost of acquisition over the fair value of the Company's share of the identifiable net assets acquired is recorded as goodwill. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Identifiable ass&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;ets acquired and liabilities and contingent liabilities assumed in a business combination are measured initially at their fair values at the acquisition date. Acquisition-related costs are expensed as incurred and included in administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company considers all highly liquid investments purchased with original maturities of ninety days or less at acquisition to be cash equivalents. Cash and cash equivalents includes deposits held at call with banks, and in money market funds investing in U.S. and U.K. government debt and liquid securities from highly rated institutions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Equity interest&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;As part of the Nuance Agreement, the Company received an equity interest in Nuance Biotech, the parent company of Nuance Pharma (see Note 8). As Nuance Biotech&#x2019;s securities are not publicly traded the equity interest&#x2019;s fair value is not readily determinable. The Company therefore follows guidance from ASC 321-10-35-2 and uses the fair value measurement alternative and measures the securities at cost, which is deemed to be the value indicated by the last observable transaction in Nuance Biotech's stock, subject to impairment. The valuation will be adjusted for any observable price changes in orderly transactions for an identical or similar investment in Nuance Biotech, or if there is an indicator of impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Furniture and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Furniture and equipment comprise office furniture and computer equipment and are stated at cost less accumulated depreciation, which is calculated on a straight-line basis over the expected useful economic lives, generally &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzQ1MDg_ff010e70-9a6d-4e4c-a482-a7e0d106f1e3"&gt;two&lt;/span&gt; to five years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Goodwill consists of goodwill related to the acquisition of Rhinopharma. Goodwill is not amortized but periodically tested for impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company reviews long-lived assets for impairment annually or whenever events or changes in circumstances indicate that the carrying amount of assets may not be fully recoverable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Revenue recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company&#x2019;s revenue consists of revenue from the Company&#x2019;s strategic agreements for the development and commercialization of ensifentrine. The terms of the agreements typically include non-refundable upfront fees, payments based upon achievement of milestones and eventually revenue from the commercialized product. These agreements usually have both fixed and variable consideration. Non-refundable upfront fees are considered fixed, while milestone payments and revenue from the commercialized product are identified as variable consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under agreements within the scope of ASC Topic 606, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic 606. The Company&#x2019;s performance obligations include intellectual property rights, (which include the license, patents and developmental and regulatory data) and manufacturing and supply. Management are required to judge when performance obligations are satisfied and consequently when revenue is recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company allocates the total transaction price to each performance obligation based on the estimated relative standalone selling prices of the promised goods or service underlying each performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied. If the right to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the right when the right is transferred to the customer, and the customer can use and benefit from the right.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;At the inception of the arrangement, the Company evaluates whether the development milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company, such as approvals from regulators, are not considered probable of being achieved until those approvals are received.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Research and development costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Research and development (&#x201c;R&amp;amp;D&#x201d;) costs are expensed as incurred. Research and development expenses include salaries, share-based compensation and benefits of employees, and other costs related to the Company&#x2019;s R&amp;amp;D activities, including contracts with clinical research organizations and contract manufacturers. The Company is required to estimate its expenses resulting from its obligations under contracts with vendors and consultants and clinical site agreements in connection with its R&amp;amp;D efforts. The financial terms of these contracts are subject to negotiations which vary contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts. The Company&#x2019;s objective is to reflect the appropriate clinical trial expenses in its consolidated financial statements by matching those expenses with the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of the trials and other development activities. Judgment is applied in determining assumptions related to patient progression and the timing of various aspects of the trial used to measure progress. The Company determines prepaid and accrual estimates through discussions with applicable personnel and outside service providers as to the progress of clinical trials, or other services completed. During the course of a clinical trial, the Company adjusts its &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;rate of clinical trial expense recognition if actual results differ from its estimates. The Company makes estimates of its prepaid and accrued expenses as of each balance sheet date in its consolidated financial statements based on facts and circumstances known at that time. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in the Company reporting amounts that are too high or too low for any particular period. The Company&#x2019;s clinical trial prepaid and accrual expense is dependent upon the timely and accurate reporting of study recruitment from contract research organizations and activities carried out by other third-party vendors as well as the timely processing of any change orders from the contract research organizations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company has a share-based compensation plan under which various types of equity-based awards may be granted, including stock options and restricted stock units (RSUs). The fair value of share options and RSUs, which are subject to milestone or service conditions with graded vesting, are recognized as compensation expense on a straight-line basis using the graded-vesting method; f&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;orfeitures are recognized as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company uses the fair-value based method to determine compensation for all arrangements under which employees receive shares. The fair value of each option and RSU is estimated on the date of grant using the Black-Scholes valuation model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate. Expected volatility is based on the historical volatility of the Company&#x2019;s ordinary shares over the expected term of the options. The expected term of options granted is derived using the simplified method, which computes the expected term as the average of the sum of the vesting term plus the contract term. Historically the risk-free rate has been based on the appropriate U.K. government debt yield. After delisting its Ordinary shares from AIM on October 30, 2020, the Company used U.S. government debt yields.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Details of the assumptions used are set out in Note 9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;to the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Other income - United Kingdom R&amp;amp;D tax credits &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Other income relates to R&amp;amp;D tax credits receivable in the UK. As a company that carries out extensive research and development activities, Verona is subject to the UK R&amp;amp;D Small and Medium Enterprise (&#x201c;SME&#x201d;) Program. Qualifying expenditures largely comprise employment costs for research staff, consumables, a proportion of relevant, permitted sub-contract costs and certain internal overhead costs incurred as part of research projects for which it does not receive income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Tax credits related to the SME Program are received as cash and are recorded as other income, as they are akin to grant income, in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company accounts for income taxes in accordance with ASC 740, &#x201c;Income Taxes&#x201d; (&#x201c;ASC 740&#x201d;). ASC 740 prescribes the use of the liability method, whereby deferred tax assets and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. ASC 740 establishes a single model to address accounting for uncertain tax positions. ASC 740 clarified the accounting for income taxes by prescribing the minimum recognition threshold a tax position is required to meet before being recognized in the financial statements. The Company has no uncertain tax positions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Comprehensive loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company accounts for comprehensive loss in accordance with ASC 220, &#x201c;Income Statement - Reporting Comprehensive Income&#x201d;. Comprehensive income represents all changes in stockholders&#x2019; equity during the period except those resulting from investments by, or distributions to, stockholders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company has one operating and reportable segment, pharmaceutical development. The Company&#x2019;s long-lived assets are held in the United Kingdom.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Foreign Currencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Reporting and functional currencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The consolidated financial statements are reported in U.S. dollars, which is also the functional currency of our subsidiary. Transactions in foreign currencies are remeasured into our functional currency at the rate of exchange prevailing at the date of the transaction. Any monetary assets and liabilities arising from these transactions are remeasured into our functional currency at exchange rates prevailing at the balance sheet date or on settlement. Resulting gains and losses are recorded in foreign exchange loss in our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Treasury shares&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In the year ended December 31, 2020, the Company incorporated a trust to facilitate the acquisition of shares, by or for the benefit of employees and former employees. In the year ended December 31, 2022, the Company issued 28.0&#160;million ordinary shares (equivalent to 3.5&#160;million ADSs) to cover expected shares issued upon the vesting of share awards to employees. The Company issued no ordinary shares in the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company has the indirect ability to control the trust as trustees are required to act in accordance with the trust deed and because the Company controls the issuance of shares to cover awards. As a consequence, the trust is consolidated into the Company&#x2019;s consolidated financial statements. The shares that were issued to the trust that have not been issued to employees to satisfy vesting of share awards are included in the Consolidated Balance Sheets as treasury shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Fair value of financial instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;US GAAP defines fair value and requires companies to establish a framework for measuring fair value and disclosure about fair value measurements using a three-tier approach. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Our financial instruments include cash equivalents, an equity interest, other assets, accounts payable and accrued expenses and other liabilities. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgement and therefore cannot be determined with precision. The equity interest is held at cost subject to impairment, following &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;guidance from ASC 321-10-35-2&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;. The carrying amounts of the other instruments are considered to be representative of their fair values because of their short-term nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Concentration of credit risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Financial instruments that potentially subject the Company to concentration of credit risk consist of principally cash and cash equivalents, bank deposits and certain receivables. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company holds cash and cash equivalents with highly rated financial institutions and in highly rated money market funds and the Company has not experienced any significant credit losses in these accounts and does not believe the Company is exposed to any significant credit risk on these instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Lease accounting &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The company accounts for leases in accordance with ASU No. 2016-02, &#x201c;Leases&#x201d; (Topic 842) (&#x201c;ASC 842&#x201d;). The standard requires lessees to recognize almost all leases on the balance sheet as right-of-use (&#x201c;ROU&#x201d;) assets and lease liabilities, and requires leases to be classified as either operating or finance type leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Under ASC 842, the Company determines if an arrangement is a lease at inception. ROU ass&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;ets and liabilities are recognized at the commencement date based on the present value of remaining lease payments. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;As the Company's leases do not provide an implicit rate, the Company determines the incremental borrowing rate in calculating the present value of lease payments. The ROU assets also include any lease payments made prior to commencement and are recorded net of any lease incentives received. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company&#x2019;s lease terms may include options to extend or terminate the lease. When it is reasonably certain the Company will exercise such options the lease will be recognized as a liability and a corresponding ROU asset also recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Operating leases are included in Right-of-use assets and in Current and non-current operating lease liabilities on the Company's Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Recently issued accounting pronouncements, not yet adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326)-Measurement of Credit Losses on Financial Instruments. This guidance replaces the current incurred loss impairment methodology. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Under the new guidance, on initial recognition and at each reporting period, an entity is required to recognize an allowance that reflects its current estimate of credit losses expected to be incurred over the life of the financial instrument based on historical experience, current conditions and reasonable and supportable forecasts. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates (&#x201c;ASU 2019-10&#x201d;). The purpose of this amendment is to create a two tier rollout of major updates, staggering the effective dates between larger public companies and all other entities. This granted certain classes of companies, including Smaller Reporting Companies (&#x201c;SRCs&#x201d;), additional time to implement major FASB standards, including ASU 2016-13. Larger public companies will have an effective date for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. All other entities are permitted to defer adoption of ASU 2016-13, and its related amendments, until fiscal periods beginning after December 15, 2022. Under the current SEC definitions, we meet the definition of an SRC as of the ASU 2019-10 issuance date and are deferring adoption for ASU 2016-13. The guidance requires a modified retrospective transition approach through a cumulative-effect adjustment to retained earnings as of the beginning of the period of adoption. We are currently evaluating the impact of the adoption of ASU 2016-13 on our consolidated financial statements, but do not believe the adoption of this standard will have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Other accounting standards that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company&#x2019;s financial statements upon adoption.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzIzODk3_10b5b295-c9cb-48fb-a2a3-899c5ba125e5">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Basis of presentation and consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The consolidated financial statements include the accounts of Verona Pharma plc and its wholly-owned subsidiaries Verona Pharma, Inc. and Rhinopharma through to its dissolution in June 2021. All inter-company balances and transactions have been eliminated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") and the following accounting policies have been consistently applied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;At the end of the second quarter of 2020, the Company determined that it no longer qualified as a Foreign Private Issuer under SEC rules. As a result, beginning January 1, 2021, the Company was required to report with the SEC on domestic forms and comply with domestic company rules in the United States. The transition to U.S. GAAP was made retrospectively for all periods from the Company&#x2019;s inception.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzIzOTA4_1310afd3-d363-4c85-b091-cca25a40c9be">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual and prepayment of research and development expenses and the fair value of share-based compensation. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from the Company&#x2019;s estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzIzOTA5_25cbef5b-b5ea-417f-bf6c-6884438f9d2b">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Business combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company applies the acquisition method to account for business combinations. The consideration transferred for the acquisition of a subsidiary is the fair value of the assets transferred, the liabilities incurred to the former owners of the acquiree and the equity interests issued by the Company. The consideration transferred includes the fair value of any asset or liability resulting from a contingent consideration arrangement. The excess of the cost of acquisition over the fair value of the Company's share of the identifiable net assets acquired is recorded as goodwill. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Identifiable ass&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;ets acquired and liabilities and contingent liabilities assumed in a business combination are measured initially at their fair values at the acquisition date. Acquisition-related costs are expensed as incurred and included in administrative expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzIzOTEw_028f006c-ad2b-4f46-afed-9a10416df8cb">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company considers all highly liquid investments purchased with original maturities of ninety days or less at acquisition to be cash equivalents. Cash and cash equivalents includes deposits held at call with banks, and in money market funds investing in U.S. and U.K. government debt and liquid securities from highly rated institutions.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzIzOTEx_4909fab0-fe68-4f65-80bb-2dedcb7a51a1">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Equity interest&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;As part of the Nuance Agreement, the Company received an equity interest in Nuance Biotech, the parent company of Nuance Pharma (see Note 8). As Nuance Biotech&#x2019;s securities are not publicly traded the equity interest&#x2019;s fair value is not readily determinable. The Company therefore follows guidance from ASC 321-10-35-2 and uses the fair value measurement alternative and measures the securities at cost, which is deemed to be the value indicated by the last observable transaction in Nuance Biotech's stock, subject to impairment. The valuation will be adjusted for any observable price changes in orderly transactions for an identical or similar investment in Nuance Biotech, or if there is an indicator of impairment.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzIzOTAy_af158b7d-0fb8-4109-a5e8-ac8e468602f5">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Furniture and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Furniture and equipment comprise office furniture and computer equipment and are stated at cost less accumulated depreciation, which is calculated on a straight-line basis over the expected useful economic lives, generally &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzQ1MDg_ff010e70-9a6d-4e4c-a482-a7e0d106f1e3"&gt;two&lt;/span&gt; to five years.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i12dbdc5aaf3b4090a92274f569107ad3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzQ1MTQ_1fe556f8-e30d-44c8-af93-78c4c0864b22">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzIzOTAz_8c8dbc78-c3fd-4bb3-8458-698de3fc3524">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Goodwill consists of goodwill related to the acquisition of Rhinopharma. Goodwill is not amortized but periodically tested for impairment.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzIzODk4_ac2bf854-fbbc-4f3e-b5ad-29838c61f29f">Impairment of long-lived assetsThe Company reviews long-lived assets for impairment annually or whenever events or changes in circumstances indicate that the carrying amount of assets may not be fully recoverable.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzIzOTEz_d0bc2003-146b-4889-aa15-c2cf3c16dbe4">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Revenue recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company&#x2019;s revenue consists of revenue from the Company&#x2019;s strategic agreements for the development and commercialization of ensifentrine. The terms of the agreements typically include non-refundable upfront fees, payments based upon achievement of milestones and eventually revenue from the commercialized product. These agreements usually have both fixed and variable consideration. Non-refundable upfront fees are considered fixed, while milestone payments and revenue from the commercialized product are identified as variable consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under agreements within the scope of ASC Topic 606, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic 606. The Company&#x2019;s performance obligations include intellectual property rights, (which include the license, patents and developmental and regulatory data) and manufacturing and supply. Management are required to judge when performance obligations are satisfied and consequently when revenue is recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company allocates the total transaction price to each performance obligation based on the estimated relative standalone selling prices of the promised goods or service underlying each performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty has been allocated has been satisfied. If the right to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the right when the right is transferred to the customer, and the customer can use and benefit from the right.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;At the inception of the arrangement, the Company evaluates whether the development milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company, such as approvals from regulators, are not considered probable of being achieved until those approvals are received.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzIzOTAx_d10f8b66-02e9-4a58-859c-e82ce811b30a">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Research and development costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Research and development (&#x201c;R&amp;amp;D&#x201d;) costs are expensed as incurred. Research and development expenses include salaries, share-based compensation and benefits of employees, and other costs related to the Company&#x2019;s R&amp;amp;D activities, including contracts with clinical research organizations and contract manufacturers. The Company is required to estimate its expenses resulting from its obligations under contracts with vendors and consultants and clinical site agreements in connection with its R&amp;amp;D efforts. The financial terms of these contracts are subject to negotiations which vary contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts. The Company&#x2019;s objective is to reflect the appropriate clinical trial expenses in its consolidated financial statements by matching those expenses with the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of the trials and other development activities. Judgment is applied in determining assumptions related to patient progression and the timing of various aspects of the trial used to measure progress. The Company determines prepaid and accrual estimates through discussions with applicable personnel and outside service providers as to the progress of clinical trials, or other services completed. During the course of a clinical trial, the Company adjusts its &lt;/span&gt;&lt;/div&gt;rate of clinical trial expense recognition if actual results differ from its estimates. The Company makes estimates of its prepaid and accrued expenses as of each balance sheet date in its consolidated financial statements based on facts and circumstances known at that time. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in the Company reporting amounts that are too high or too low for any particular period. The Company&#x2019;s clinical trial prepaid and accrual expense is dependent upon the timely and accurate reporting of study recruitment from contract research organizations and activities carried out by other third-party vendors as well as the timely processing of any change orders from the contract research organizations.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzIzODk5_5acb3774-20e1-468c-93b0-5a74f614123f">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company has a share-based compensation plan under which various types of equity-based awards may be granted, including stock options and restricted stock units (RSUs). The fair value of share options and RSUs, which are subject to milestone or service conditions with graded vesting, are recognized as compensation expense on a straight-line basis using the graded-vesting method; f&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;orfeitures are recognized as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company uses the fair-value based method to determine compensation for all arrangements under which employees receive shares. The fair value of each option and RSU is estimated on the date of grant using the Black-Scholes valuation model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate. Expected volatility is based on the historical volatility of the Company&#x2019;s ordinary shares over the expected term of the options. The expected term of options granted is derived using the simplified method, which computes the expected term as the average of the sum of the vesting term plus the contract term. Historically the risk-free rate has been based on the appropriate U.K. government debt yield. After delisting its Ordinary shares from AIM on October 30, 2020, the Company used U.S. government debt yields.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <vrna:GovernmentTaxCreditsPolicyPolicyTextBlock
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzIzOTEy_63ed354e-c882-4ac1-beb5-ba762dc02395">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Other income - United Kingdom R&amp;amp;D tax credits &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Other income relates to R&amp;amp;D tax credits receivable in the UK. As a company that carries out extensive research and development activities, Verona is subject to the UK R&amp;amp;D Small and Medium Enterprise (&#x201c;SME&#x201d;) Program. Qualifying expenditures largely comprise employment costs for research staff, consumables, a proportion of relevant, permitted sub-contract costs and certain internal overhead costs incurred as part of research projects for which it does not receive income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Tax credits related to the SME Program are received as cash and are recorded as other income, as they are akin to grant income, in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</vrna:GovernmentTaxCreditsPolicyPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzIzODk1_c45632ac-5591-49bf-8592-627fe1573d10">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company accounts for income taxes in accordance with ASC 740, &#x201c;Income Taxes&#x201d; (&#x201c;ASC 740&#x201d;). ASC 740 prescribes the use of the liability method, whereby deferred tax assets and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. ASC 740 establishes a single model to address accounting for uncertain tax positions. ASC 740 clarified the accounting for income taxes by prescribing the minimum recognition threshold a tax position is required to meet before being recognized in the financial statements. The Company has no uncertain tax positions.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzIzOTE0_32c64ecb-406b-4429-b349-9dc285ce3785">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Comprehensive loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company accounts for comprehensive loss in accordance with ASC 220, &#x201c;Income Statement - Reporting Comprehensive Income&#x201d;. Comprehensive income represents all changes in stockholders&#x2019; equity during the period except those resulting from investments by, or distributions to, stockholders.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzIzOTA3_528f726d-6270-41f8-b4e1-a01629d05081">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company has one operating and reportable segment, pharmaceutical development. The Company&#x2019;s long-lived assets are held in the United Kingdom.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzE1NjE2_6d6a9e83-1c40-487b-a156-d82d026a8e4f"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzE1NjE2_bebe3fdb-3461-4b27-a078-dffd3405f91f"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzIzODk2_07ad4b3f-be23-4fa6-acd6-5a9e04d30de5">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Foreign Currencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Reporting and functional currencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The consolidated financial statements are reported in U.S. dollars, which is also the functional currency of our subsidiary. Transactions in foreign currencies are remeasured into our functional currency at the rate of exchange prevailing at the date of the transaction. Any monetary assets and liabilities arising from these transactions are remeasured into our functional currency at exchange rates prevailing at the balance sheet date or on settlement. Resulting gains and losses are recorded in foreign exchange loss in our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:StockholdersEquityPolicyTextBlock
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzIzOTE2_7357c90c-9e25-423e-a182-1cb78fee4bbb">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Treasury shares&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In the year ended December 31, 2020, the Company incorporated a trust to facilitate the acquisition of shares, by or for the benefit of employees and former employees. In the year ended December 31, 2022, the Company issued 28.0&#160;million ordinary shares (equivalent to 3.5&#160;million ADSs) to cover expected shares issued upon the vesting of share awards to employees. The Company issued no ordinary shares in the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company has the indirect ability to control the trust as trustees are required to act in accordance with the trust deed and because the Company controls the issuance of shares to cover awards. As a consequence, the trust is consolidated into the Company&#x2019;s consolidated financial statements. The shares that were issued to the trust that have not been issued to employees to satisfy vesting of share awards are included in the Consolidated Balance Sheets as treasury shares.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityPolicyTextBlock>
    <vrna:StockIssuedDuringPeriodSharesHeldInTreasury
      contextRef="ie6d783db1d43419d8f15b7dc0a5bcb2d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzE3OTMy_9538706d-a40c-480d-a1c8-4c598b3a4815"
      unitRef="shares">28000000</vrna:StockIssuedDuringPeriodSharesHeldInTreasury>
    <vrna:StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares
      contextRef="ie6d783db1d43419d8f15b7dc0a5bcb2d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzE3OTY2_26e8d226-e006-403b-a44f-c91c26177084"
      unitRef="shares">3500000</vrna:StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares>
    <vrna:StockIssuedDuringPeriodSharesHeldInTreasury
      contextRef="i1ffe1b3cbbcb48709153748921695a17_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzI0NzM5MDExNjc1MzU5_8a046c61-6ab2-4ba7-a498-2b9bb14d8d73"
      unitRef="shares">0</vrna:StockIssuedDuringPeriodSharesHeldInTreasury>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzIzOTE3_e3c18a80-7bc0-4d2d-8936-5886622d0ebf">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Fair value of financial instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;US GAAP defines fair value and requires companies to establish a framework for measuring fair value and disclosure about fair value measurements using a three-tier approach. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Our financial instruments include cash equivalents, an equity interest, other assets, accounts payable and accrued expenses and other liabilities. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgement and therefore cannot be determined with precision. The equity interest is held at cost subject to impairment, following &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;guidance from ASC 321-10-35-2&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;. The carrying amounts of the other instruments are considered to be representative of their fair values because of their short-term nature.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzIzOTE4_b57880bb-e3a6-42cf-ab4d-6b14bef299d6">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Concentration of credit risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Financial instruments that potentially subject the Company to concentration of credit risk consist of principally cash and cash equivalents, bank deposits and certain receivables. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company holds cash and cash equivalents with highly rated financial institutions and in highly rated money market funds and the Company has not experienced any significant credit losses in these accounts and does not believe the Company is exposed to any significant credit risk on these instruments.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzI0NzM5MDExNjc1MzU4_5744fb6f-e583-4f26-a8c6-c6b59d40792b">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Lease accounting &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The company accounts for leases in accordance with ASU No. 2016-02, &#x201c;Leases&#x201d; (Topic 842) (&#x201c;ASC 842&#x201d;). The standard requires lessees to recognize almost all leases on the balance sheet as right-of-use (&#x201c;ROU&#x201d;) assets and lease liabilities, and requires leases to be classified as either operating or finance type leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Under ASC 842, the Company determines if an arrangement is a lease at inception. ROU ass&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;ets and liabilities are recognized at the commencement date based on the present value of remaining lease payments. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;As the Company's leases do not provide an implicit rate, the Company determines the incremental borrowing rate in calculating the present value of lease payments. The ROU assets also include any lease payments made prior to commencement and are recorded net of any lease incentives received. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company&#x2019;s lease terms may include options to extend or terminate the lease. When it is reasonably certain the Company will exercise such options the lease will be recognized as a liability and a corresponding ROU asset also recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Operating leases are included in Right-of-use assets and in Current and non-current operating lease liabilities on the Company's Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMTgvZnJhZzo1OTk1ZTVkM2QzMTY0NjIxYTU0NTc2YWRhNWNjMDQzNS90ZXh0cmVnaW9uOjU5OTVlNWQzZDMxNjQ2MjFhNTQ1NzZhZGE1Y2MwNDM1XzIzOTA1_fd917c47-402b-494a-a5e8-4d76c33bc3e6">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Recently issued accounting pronouncements, not yet adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326)-Measurement of Credit Losses on Financial Instruments. This guidance replaces the current incurred loss impairment methodology. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Under the new guidance, on initial recognition and at each reporting period, an entity is required to recognize an allowance that reflects its current estimate of credit losses expected to be incurred over the life of the financial instrument based on historical experience, current conditions and reasonable and supportable forecasts. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates (&#x201c;ASU 2019-10&#x201d;). The purpose of this amendment is to create a two tier rollout of major updates, staggering the effective dates between larger public companies and all other entities. This granted certain classes of companies, including Smaller Reporting Companies (&#x201c;SRCs&#x201d;), additional time to implement major FASB standards, including ASU 2016-13. Larger public companies will have an effective date for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. All other entities are permitted to defer adoption of ASU 2016-13, and its related amendments, until fiscal periods beginning after December 15, 2022. Under the current SEC definitions, we meet the definition of an SRC as of the ASU 2019-10 issuance date and are deferring adoption for ASU 2016-13. The guidance requires a modified retrospective transition approach through a cumulative-effect adjustment to retained earnings as of the beginning of the period of adoption. We are currently evaluating the impact of the adoption of ASU 2016-13 on our consolidated financial statements, but do not believe the adoption of this standard will have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Other accounting standards that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company&#x2019;s financial statements upon adoption.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <vrna:PrepaidExpenseDisclosureTextBlock
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjEvZnJhZzo5YTgxODRhNmVkMWY0ODRiOTFkNGZjZGU0YjA3MDgwYy90ZXh0cmVnaW9uOjlhODE4NGE2ZWQxZjQ4NGI5MWQ0ZmNkZTRiMDcwODBjXzky_bd20446a-8ec0-4ba8-afa3-898d9b7df575">Prepaid expenses &lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Prepaid expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trial and other development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</vrna:PrepaidExpenseDisclosureTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjEvZnJhZzo5YTgxODRhNmVkMWY0ODRiOTFkNGZjZGU0YjA3MDgwYy90ZXh0cmVnaW9uOjlhODE4NGE2ZWQxZjQ4NGI5MWQ0ZmNkZTRiMDcwODBjXzkz_64eb3181-74ee-44c8-b722-02b207131458">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Prepaid expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trial and other development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <vrna:PrepaidResearchAndDevelopmentFeesCurrent
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjEvZnJhZzo5YTgxODRhNmVkMWY0ODRiOTFkNGZjZGU0YjA3MDgwYy90YWJsZTozODMzZTdhMjg1ZGE0MjBiYjkzNjg1YmY3ZmM1M2RhOC90YWJsZXJhbmdlOjM4MzNlN2EyODVkYTQyMGJiOTM2ODViZjdmYzUzZGE4XzItMi0xLTEtNTkxMjc_7b18741f-031d-4ebe-a47d-93a8fe4b8583"
      unitRef="usd">38000</vrna:PrepaidResearchAndDevelopmentFeesCurrent>
    <vrna:PrepaidResearchAndDevelopmentFeesCurrent
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjEvZnJhZzo5YTgxODRhNmVkMWY0ODRiOTFkNGZjZGU0YjA3MDgwYy90YWJsZTozODMzZTdhMjg1ZGE0MjBiYjkzNjg1YmY3ZmM1M2RhOC90YWJsZXJhbmdlOjM4MzNlN2EyODVkYTQyMGJiOTM2ODViZjdmYzUzZGE4XzItNC0xLTEtNTkxMjc_775692ea-35da-4afd-8fb5-1f5feff306dd"
      unitRef="usd">2169000</vrna:PrepaidResearchAndDevelopmentFeesCurrent>
    <us-gaap:PrepaidInsurance
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjEvZnJhZzo5YTgxODRhNmVkMWY0ODRiOTFkNGZjZGU0YjA3MDgwYy90YWJsZTozODMzZTdhMjg1ZGE0MjBiYjkzNjg1YmY3ZmM1M2RhOC90YWJsZXJhbmdlOjM4MzNlN2EyODVkYTQyMGJiOTM2ODViZjdmYzUzZGE4XzMtMi0xLTEtNTkxMjc_74728fc2-8ff0-4e65-8a01-ebfb4c74d233"
      unitRef="usd">2027000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjEvZnJhZzo5YTgxODRhNmVkMWY0ODRiOTFkNGZjZGU0YjA3MDgwYy90YWJsZTozODMzZTdhMjg1ZGE0MjBiYjkzNjg1YmY3ZmM1M2RhOC90YWJsZXJhbmdlOjM4MzNlN2EyODVkYTQyMGJiOTM2ODViZjdmYzUzZGE4XzMtNC0xLTEtNTkxMjc_787e718c-41a3-41c3-b3ca-8f8297e18b52"
      unitRef="usd">1555000</us-gaap:PrepaidInsurance>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjEvZnJhZzo5YTgxODRhNmVkMWY0ODRiOTFkNGZjZGU0YjA3MDgwYy90YWJsZTozODMzZTdhMjg1ZGE0MjBiYjkzNjg1YmY3ZmM1M2RhOC90YWJsZXJhbmdlOjM4MzNlN2EyODVkYTQyMGJiOTM2ODViZjdmYzUzZGE4XzQtMi0xLTEtNTkxMjc_07418532-d1a2-44ce-85ba-c840eb43cfda"
      unitRef="usd">434000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjEvZnJhZzo5YTgxODRhNmVkMWY0ODRiOTFkNGZjZGU0YjA3MDgwYy90YWJsZTozODMzZTdhMjg1ZGE0MjBiYjkzNjg1YmY3ZmM1M2RhOC90YWJsZXJhbmdlOjM4MzNlN2EyODVkYTQyMGJiOTM2ODViZjdmYzUzZGE4XzQtNC0xLTEtNTkxMjc_b89f8e4c-dfe2-48c0-8c6a-903e899818da"
      unitRef="usd">313000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjEvZnJhZzo5YTgxODRhNmVkMWY0ODRiOTFkNGZjZGU0YjA3MDgwYy90YWJsZTozODMzZTdhMjg1ZGE0MjBiYjkzNjg1YmY3ZmM1M2RhOC90YWJsZXJhbmdlOjM4MzNlN2EyODVkYTQyMGJiOTM2ODViZjdmYzUzZGE4XzUtMi0xLTEtNTkxMjc_17b1dc53-fd77-49e0-989d-770e808fbf4f"
      unitRef="usd">2499000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjEvZnJhZzo5YTgxODRhNmVkMWY0ODRiOTFkNGZjZGU0YjA3MDgwYy90YWJsZTozODMzZTdhMjg1ZGE0MjBiYjkzNjg1YmY3ZmM1M2RhOC90YWJsZXJhbmdlOjM4MzNlN2EyODVkYTQyMGJiOTM2ODViZjdmYzUzZGE4XzUtNC0xLTEtNTkxMjc_74e9a320-a9c6-4091-b078-f8c5ce98abf3"
      unitRef="usd">4037000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjcvZnJhZzpjYWRiMzlhODQ3ZWI0NGUzYWIzOTczYTVlYTU0MDU5OS90ZXh0cmVnaW9uOmNhZGIzOWE4NDdlYjQ0ZTNhYjM5NzNhNWVhNTQwNTk5XzkxMQ_c013619c-b2c1-4258-a270-fb9126cdc6cb">Property leases&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The right-of-use assets (&#x201c;ROU&#x201d;) relate to rented office space in London, North Carolina and Georgia with leases ending in 2023, 2024 and 2025, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In the year ended December 31, 2022, the Company entered into a lease arrangement in Georgia for office space and extended its existing London lease and recognized lease liability and corresponding ROU asset of $0.7&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In the year ended December 31, 2021, the Company extended its existing London lease. As a consequence it modified its accounting for the lease and recorded $0.6&#160;million lease liability and corresponding ROU asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;To calculate lease liabilities the Company used a weighted average discount rate of 4% and 8% for the years ended December 31, 2022 and December 31, 2021, respectively. The weighted average remaining lease term as of December 31, 2022 and December 31, 2021 was 1.5 and 1.8 years, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Minimum annual payments over the remaining lease periods as of December 31, 2022 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.926%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum future lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The total operating lease expense included in selling, general and administrative costs was $0.6&#160;million.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i562a8171ec384150b25fc8dac4d3d04a_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjcvZnJhZzpjYWRiMzlhODQ3ZWI0NGUzYWIzOTczYTVlYTU0MDU5OS90ZXh0cmVnaW9uOmNhZGIzOWE4NDdlYjQ0ZTNhYjM5NzNhNWVhNTQwNTk5XzM4NDgyOTA3MDA1MTA_577515aa-d384-4821-bfb6-4cf7ca6f3d50"
      unitRef="usd">700000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="id194ff6c8cf4476bad35353399857ce0_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjcvZnJhZzpjYWRiMzlhODQ3ZWI0NGUzYWIzOTczYTVlYTU0MDU5OS90ZXh0cmVnaW9uOmNhZGIzOWE4NDdlYjQ0ZTNhYjM5NzNhNWVhNTQwNTk5XzMyOQ_982aad5c-9481-4cbc-a9c7-3f3e154d4d15"
      unitRef="usd">600000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjcvZnJhZzpjYWRiMzlhODQ3ZWI0NGUzYWIzOTczYTVlYTU0MDU5OS90ZXh0cmVnaW9uOmNhZGIzOWE4NDdlYjQ0ZTNhYjM5NzNhNWVhNTQwNTk5XzI0NzM5MDExNjI4ODk2_31e86302-ff5b-4011-9676-afe2065109df"
      unitRef="number">0.04</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjcvZnJhZzpjYWRiMzlhODQ3ZWI0NGUzYWIzOTczYTVlYTU0MDU5OS90ZXh0cmVnaW9uOmNhZGIzOWE4NDdlYjQ0ZTNhYjM5NzNhNWVhNTQwNTk5XzI0NzM5MDExNjI4OTAw_8cf173c5-2d53-4ae2-914b-e43b4f656c2e"
      unitRef="number">0.08</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjcvZnJhZzpjYWRiMzlhODQ3ZWI0NGUzYWIzOTczYTVlYTU0MDU5OS90ZXh0cmVnaW9uOmNhZGIzOWE4NDdlYjQ0ZTNhYjM5NzNhNWVhNTQwNTk5XzU0OTc1NTgxNjgyMw_662dd611-7be5-4014-9178-208ed907b6eb">P1Y6M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjcvZnJhZzpjYWRiMzlhODQ3ZWI0NGUzYWIzOTczYTVlYTU0MDU5OS90ZXh0cmVnaW9uOmNhZGIzOWE4NDdlYjQ0ZTNhYjM5NzNhNWVhNTQwNTk5XzI0NzM5MDExNjI4ODkz_598985f9-43c6-4045-8f4e-0045880c51da">P1Y9M18D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjcvZnJhZzpjYWRiMzlhODQ3ZWI0NGUzYWIzOTczYTVlYTU0MDU5OS90ZXh0cmVnaW9uOmNhZGIzOWE4NDdlYjQ0ZTNhYjM5NzNhNWVhNTQwNTk5XzkxMg_1a9d0d77-803a-411e-bec8-744e9d8ffda8">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Minimum annual payments over the remaining lease periods as of December 31, 2022 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.926%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum future lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjcvZnJhZzpjYWRiMzlhODQ3ZWI0NGUzYWIzOTczYTVlYTU0MDU5OS90YWJsZTpjNmI5NTY1Mzc3NGI0MDZlOGZkNGNkMWIzYjVhOWRhMC90YWJsZXJhbmdlOmM2Yjk1NjUzNzc0YjQwNmU4ZmQ0Y2QxYjNiNWE5ZGEwXzEtMi0xLTEtNTkxMjc_515b1faa-76db-4eff-8328-d0928597856b"
      unitRef="usd">675000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjcvZnJhZzpjYWRiMzlhODQ3ZWI0NGUzYWIzOTczYTVlYTU0MDU5OS90YWJsZTpjNmI5NTY1Mzc3NGI0MDZlOGZkNGNkMWIzYjVhOWRhMC90YWJsZXJhbmdlOmM2Yjk1NjUzNzc0YjQwNmU4ZmQ0Y2QxYjNiNWE5ZGEwXzItMi0xLTEtNTkxMjc_0d6d684a-ba3d-4089-9851-0cac8763537c"
      unitRef="usd">215000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjcvZnJhZzpjYWRiMzlhODQ3ZWI0NGUzYWIzOTczYTVlYTU0MDU5OS90YWJsZTpjNmI5NTY1Mzc3NGI0MDZlOGZkNGNkMWIzYjVhOWRhMC90YWJsZXJhbmdlOmM2Yjk1NjUzNzc0YjQwNmU4ZmQ0Y2QxYjNiNWE5ZGEwXzMtMi0xLTEtNjYzNTE_1fe473ff-ce9d-4b7a-b1d2-9f0f3855d3f9"
      unitRef="usd">17000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjcvZnJhZzpjYWRiMzlhODQ3ZWI0NGUzYWIzOTczYTVlYTU0MDU5OS90YWJsZTpjNmI5NTY1Mzc3NGI0MDZlOGZkNGNkMWIzYjVhOWRhMC90YWJsZXJhbmdlOmM2Yjk1NjUzNzc0YjQwNmU4ZmQ0Y2QxYjNiNWE5ZGEwXzMtMi0xLTEtNTkxMjc_06d7b09c-15a2-4482-982d-aa6218dabf63"
      unitRef="usd">907000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjcvZnJhZzpjYWRiMzlhODQ3ZWI0NGUzYWIzOTczYTVlYTU0MDU5OS90YWJsZTpjNmI5NTY1Mzc3NGI0MDZlOGZkNGNkMWIzYjVhOWRhMC90YWJsZXJhbmdlOmM2Yjk1NjUzNzc0YjQwNmU4ZmQ0Y2QxYjNiNWE5ZGEwXzQtMi0xLTEtNTkxMjc_b907144b-9eb4-45fd-8e0b-bb675acab5dd"
      unitRef="usd">27000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjcvZnJhZzpjYWRiMzlhODQ3ZWI0NGUzYWIzOTczYTVlYTU0MDU5OS90YWJsZTpjNmI5NTY1Mzc3NGI0MDZlOGZkNGNkMWIzYjVhOWRhMC90YWJsZXJhbmdlOmM2Yjk1NjUzNzc0YjQwNmU4ZmQ0Y2QxYjNiNWE5ZGEwXzUtMi0xLTEtNTkxMjc_36d00d92-9269-4a81-b12a-45844f5c7d16"
      unitRef="usd">880000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseExpense
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMjcvZnJhZzpjYWRiMzlhODQ3ZWI0NGUzYWIzOTczYTVlYTU0MDU5OS90ZXh0cmVnaW9uOmNhZGIzOWE4NDdlYjQ0ZTNhYjM5NzNhNWVhNTQwNTk5XzU0OTc1NTgxNjgyOQ_e4c0a909-b306-41fb-9442-213911fbcc00"
      unitRef="usd">600000</us-gaap:OperatingLeaseExpense>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzAvZnJhZzpjMzM1ODVlMDhhMGY0Nzk3YTcxZTMyMWExOWJmNjkxMC90ZXh0cmVnaW9uOmMzMzU4NWUwOGEwZjQ3OTdhNzFlMzIxYTE5YmY2OTEwXzkx_50fc4ad1-8379-4e00-976b-8ba761e8020a">Accrued expenses&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trial and other development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees, listing and general corporate costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;People related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzAvZnJhZzpjMzM1ODVlMDhhMGY0Nzk3YTcxZTMyMWExOWJmNjkxMC90ZXh0cmVnaW9uOmMzMzU4NWUwOGEwZjQ3OTdhNzFlMzIxYTE5YmY2OTEwXzky_a67e5a3c-0010-4876-9358-b4ff3d059388">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trial and other development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees, listing and general corporate costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;People related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <vrna:AccruedResearchAndDevelopmentFeesCurrent
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzAvZnJhZzpjMzM1ODVlMDhhMGY0Nzk3YTcxZTMyMWExOWJmNjkxMC90YWJsZTo2MTc4NDY4OWNhYjA0OTI4YTUxZmM3Y2JkOTkwZjNiZS90YWJsZXJhbmdlOjYxNzg0Njg5Y2FiMDQ5MjhhNTFmYzdjYmQ5OTBmM2JlXzItMi0xLTEtNTkxMjc_f7114742-880a-4a1a-8b02-89658bfa476b"
      unitRef="usd">12314000</vrna:AccruedResearchAndDevelopmentFeesCurrent>
    <vrna:AccruedResearchAndDevelopmentFeesCurrent
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzAvZnJhZzpjMzM1ODVlMDhhMGY0Nzk3YTcxZTMyMWExOWJmNjkxMC90YWJsZTo2MTc4NDY4OWNhYjA0OTI4YTUxZmM3Y2JkOTkwZjNiZS90YWJsZXJhbmdlOjYxNzg0Njg5Y2FiMDQ5MjhhNTFmYzdjYmQ5OTBmM2JlXzItNC0xLTEtNTkxMjc_96caedb0-2da6-4a59-b6ef-782b407f321b"
      unitRef="usd">21336000</vrna:AccruedResearchAndDevelopmentFeesCurrent>
    <vrna:AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzAvZnJhZzpjMzM1ODVlMDhhMGY0Nzk3YTcxZTMyMWExOWJmNjkxMC90YWJsZTo2MTc4NDY4OWNhYjA0OTI4YTUxZmM3Y2JkOTkwZjNiZS90YWJsZXJhbmdlOjYxNzg0Njg5Y2FiMDQ5MjhhNTFmYzdjYmQ5OTBmM2JlXzMtMi0xLTEtNTkxMjc_7779ead1-71d2-48c4-a9a7-8b1286d105d2"
      unitRef="usd">1364000</vrna:AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent>
    <vrna:AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzAvZnJhZzpjMzM1ODVlMDhhMGY0Nzk3YTcxZTMyMWExOWJmNjkxMC90YWJsZTo2MTc4NDY4OWNhYjA0OTI4YTUxZmM3Y2JkOTkwZjNiZS90YWJsZXJhbmdlOjYxNzg0Njg5Y2FiMDQ5MjhhNTFmYzdjYmQ5OTBmM2JlXzMtNC0xLTEtNTkxMjc_c6d3e8a0-afe0-4240-9032-9a4229aaacef"
      unitRef="usd">919000</vrna:AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzAvZnJhZzpjMzM1ODVlMDhhMGY0Nzk3YTcxZTMyMWExOWJmNjkxMC90YWJsZTo2MTc4NDY4OWNhYjA0OTI4YTUxZmM3Y2JkOTkwZjNiZS90YWJsZXJhbmdlOjYxNzg0Njg5Y2FiMDQ5MjhhNTFmYzdjYmQ5OTBmM2JlXzQtMi0xLTEtNTkxMjc_340fcbec-1d8f-4480-8724-2c6c414692f1"
      unitRef="usd">74000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzAvZnJhZzpjMzM1ODVlMDhhMGY0Nzk3YTcxZTMyMWExOWJmNjkxMC90YWJsZTo2MTc4NDY4OWNhYjA0OTI4YTUxZmM3Y2JkOTkwZjNiZS90YWJsZXJhbmdlOjYxNzg0Njg5Y2FiMDQ5MjhhNTFmYzdjYmQ5OTBmM2JlXzQtNC0xLTEtNTkxMjc_6213187f-15d1-4c32-9f57-b2ef3ebdb127"
      unitRef="usd">1000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzAvZnJhZzpjMzM1ODVlMDhhMGY0Nzk3YTcxZTMyMWExOWJmNjkxMC90YWJsZTo2MTc4NDY4OWNhYjA0OTI4YTUxZmM3Y2JkOTkwZjNiZS90YWJsZXJhbmdlOjYxNzg0Njg5Y2FiMDQ5MjhhNTFmYzdjYmQ5OTBmM2JlXzUtMi0xLTEtNTkxMjc_e6636196-eb90-4565-843a-7f7f72aebcb2"
      unitRef="usd">13752000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzAvZnJhZzpjMzM1ODVlMDhhMGY0Nzk3YTcxZTMyMWExOWJmNjkxMC90YWJsZTo2MTc4NDY4OWNhYjA0OTI4YTUxZmM3Y2JkOTkwZjNiZS90YWJsZXJhbmdlOjYxNzg0Njg5Y2FiMDQ5MjhhNTFmYzdjYmQ5OTBmM2JlXzUtNC0xLTEtNTkxMjc_bd5eb446-1b04-442e-9a79-5a2da4298ec2"
      unitRef="usd">22256000</us-gaap:AccruedLiabilitiesCurrent>
    <vrna:WarrantAndRightsDisclosureTextBlock
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzMvZnJhZzowN2ZiZGVhY2JmZjg0OTU2YjI3ZmQwOGMzNzhkOGVhOC90ZXh0cmVnaW9uOjA3ZmJkZWFjYmZmODQ5NTZiMjdmZDA4YzM3OGQ4ZWE4XzE5NDc_bcbadc12-1056-48a3-97a5-5905182b73a1">Warrants&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;On May 2, 2022 all remaining warrants expired. No warrants were exercised or forfeited in the years ended December 31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In 2016, the Company issued 31,115,926 units to new and existing investors at the placing price of &#xa3;1.4365 per unit. Each unit comprised one ordinary share and one warrant. The warrant holders could subscribe for 0.4 of an ordinary share at a per share exercise price of &#xa3;1.7238 until May 2, 2022. The warrant holders could opt for a cashless exercise of their warrants, whereby the warrant holders could choose to exchange the warrants held for a reduced number of warrants exercisable at nil consideration. The reduced number of warrants was calculated based on a formula considering the share price and the exercise price of the warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;If, after a transaction, should the warrants be exercisable for unlisted securities, the warrant holders were able to demand a cash payment instead of the delivery of the underlying securities. Accordingly, the warrants were accounted for as a liability under ASC 480 &#x201c;Distinguishing Liabilities from Equity&#x201d;. The warrants were measured at fair value, classified as Level 3 in the fair value hierarchy, with movements recorded in other income/(expense) in the Consolidated Statements of Operations and Comprehensive Loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;At December 31, 2021, 31,003,155 warrants remained outstanding and entitled the investors to subscribe for, in aggregate, a maximum of 12,401,262 ordinary shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The warrants had no intrinsic value as at December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;There have been no changes in valuation techniques or transfers between fair value measurement levels during the years ended December 31, 2022 and 2021. There has been no change in fair value between December 31, 2021, and May 2, 2022 (expiration). The warrants were valued using the Black-Scholes model and the table below presents the assumptions used:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercise price in pounds sterling&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#xa3;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term to exercise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.33&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Annualized volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Calculated value of the warrants, in thousands of U.S. dollars&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The following table shows the movement of the value of the warrants (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;At January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,246)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;At December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</vrna:WarrantAndRightsDisclosureTextBlock>
    <vrna:ClassOfWarrantOrRightNumberOfExercisedOrForfeited
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzMvZnJhZzowN2ZiZGVhY2JmZjg0OTU2YjI3ZmQwOGMzNzhkOGVhOC90ZXh0cmVnaW9uOjA3ZmJkZWFjYmZmODQ5NTZiMjdmZDA4YzM3OGQ4ZWE4XzI0NzM5MDExNjMyMzI0_19c032ea-9f5c-4dd6-b1e9-79e53c0ddcfc"
      unitRef="shares">0</vrna:ClassOfWarrantOrRightNumberOfExercisedOrForfeited>
    <vrna:ClassOfWarrantOrRightNumberOfExercisedOrForfeited
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzMvZnJhZzowN2ZiZGVhY2JmZjg0OTU2YjI3ZmQwOGMzNzhkOGVhOC90ZXh0cmVnaW9uOjA3ZmJkZWFjYmZmODQ5NTZiMjdmZDA4YzM3OGQ4ZWE4XzI0NzM5MDExNjMyMzI0_894cec93-7ee2-435d-b470-b03564ede4d9"
      unitRef="shares">0</vrna:ClassOfWarrantOrRightNumberOfExercisedOrForfeited>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ie824d87e23bd49a6b8466e65062ab474_I20161231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzMvZnJhZzowN2ZiZGVhY2JmZjg0OTU2YjI3ZmQwOGMzNzhkOGVhOC90ZXh0cmVnaW9uOjA3ZmJkZWFjYmZmODQ5NTZiMjdmZDA4YzM3OGQ4ZWE4XzUx_f2b5bb4c-3a59-478b-a3fe-61dbac60e50d"
      unitRef="shares">31115926</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <vrna:ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights
      contextRef="ie824d87e23bd49a6b8466e65062ab474_I20161231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzMvZnJhZzowN2ZiZGVhY2JmZjg0OTU2YjI3ZmQwOGMzNzhkOGVhOC90ZXh0cmVnaW9uOjA3ZmJkZWFjYmZmODQ5NTZiMjdmZDA4YzM3OGQ4ZWE4XzExNA_00c0bddd-c5b1-4a6a-98eb-ba8f77b297b0"
      unitRef="gbpPerShare">1.4365</vrna:ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="ie824d87e23bd49a6b8466e65062ab474_I20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzMvZnJhZzowN2ZiZGVhY2JmZjg0OTU2YjI3ZmQwOGMzNzhkOGVhOC90ZXh0cmVnaW9uOjA3ZmJkZWFjYmZmODQ5NTZiMjdmZDA4YzM3OGQ4ZWE4XzIyMQ_7564ded8-b01f-4857-aa6f-1ce77dc394e0"
      unitRef="shares">0.4</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ie824d87e23bd49a6b8466e65062ab474_I20161231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzMvZnJhZzowN2ZiZGVhY2JmZjg0OTU2YjI3ZmQwOGMzNzhkOGVhOC90ZXh0cmVnaW9uOjA3ZmJkZWFjYmZmODQ5NTZiMjdmZDA4YzM3OGQ4ZWE4XzI3OA_e8412b84-94fa-4460-bca1-e359926c740d"
      unitRef="gbpPerShare">1.7238</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzMvZnJhZzowN2ZiZGVhY2JmZjg0OTU2YjI3ZmQwOGMzNzhkOGVhOC90ZXh0cmVnaW9uOjA3ZmJkZWFjYmZmODQ5NTZiMjdmZDA4YzM3OGQ4ZWE4XzY2MQ_b025399d-a07a-4722-8a63-cad96b205ef8"
      unitRef="shares">31003155</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzMvZnJhZzowN2ZiZGVhY2JmZjg0OTU2YjI3ZmQwOGMzNzhkOGVhOC90ZXh0cmVnaW9uOjA3ZmJkZWFjYmZmODQ5NTZiMjdmZDA4YzM3OGQ4ZWE4Xzc2Mw_f39095b2-de7d-4acf-946d-8496ee4dcddb"
      unitRef="shares">12401262</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <vrna:ClassOfWarrantOrRightIntrinsicValue
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzMvZnJhZzowN2ZiZGVhY2JmZjg0OTU2YjI3ZmQwOGMzNzhkOGVhOC90ZXh0cmVnaW9uOjA3ZmJkZWFjYmZmODQ5NTZiMjdmZDA4YzM3OGQ4ZWE4XzE0MDE_71c759dd-9a7d-43d3-8982-778f3fa1dd22"
      unitRef="usd">0</vrna:ClassOfWarrantOrRightIntrinsicValue>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzMvZnJhZzowN2ZiZGVhY2JmZjg0OTU2YjI3ZmQwOGMzNzhkOGVhOC90ZXh0cmVnaW9uOjA3ZmJkZWFjYmZmODQ5NTZiMjdmZDA4YzM3OGQ4ZWE4XzE5NDg_df4d6d1f-adf0-4889-96b3-8c5796532c06">The warrants were valued using the Black-Scholes model and the table below presents the assumptions used:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercise price in pounds sterling&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#xa3;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term to exercise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.33&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Annualized volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Calculated value of the warrants, in thousands of U.S. dollars&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzMvZnJhZzowN2ZiZGVhY2JmZjg0OTU2YjI3ZmQwOGMzNzhkOGVhOC90YWJsZTo1YTM3ZTBkNGMyN2Q0YTFmYjEwY2UzZTU0ZDQwNDBmYS90YWJsZXJhbmdlOjVhMzdlMGQ0YzI3ZDRhMWZiMTBjZTNlNTRkNDA0MGZhXzMtNC0xLTEtNTkxMjc_be93ba18-b259-4ba6-916f-96537868e7f1"
      unitRef="gbpPerShare">1.7238</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="ia8b9d9c7ed4d45b39aee6fc8c9e89a1e_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzMvZnJhZzowN2ZiZGVhY2JmZjg0OTU2YjI3ZmQwOGMzNzhkOGVhOC90YWJsZTo1YTM3ZTBkNGMyN2Q0YTFmYjEwY2UzZTU0ZDQwNDBmYS90YWJsZXJhbmdlOjVhMzdlMGQ0YzI3ZDRhMWZiMTBjZTNlNTRkNDA0MGZhXzQtNC0xLTEtNTkxMjc_f0821470-c8f8-41b6-bcc9-807186b29342"
      unitRef="number">0.0007</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzMvZnJhZzowN2ZiZGVhY2JmZjg0OTU2YjI3ZmQwOGMzNzhkOGVhOC90YWJsZTo1YTM3ZTBkNGMyN2Q0YTFmYjEwY2UzZTU0ZDQwNDBmYS90YWJsZXJhbmdlOjVhMzdlMGQ0YzI3ZDRhMWZiMTBjZTNlNTRkNDA0MGZhXzUtNC0xLTEtNTkxMjc_df6e980b-be73-4c75-8b1a-440b5fcd7fc1">P0Y3M29D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="ia06c5918648040c2b8e5e55554c67cb2_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzMvZnJhZzowN2ZiZGVhY2JmZjg0OTU2YjI3ZmQwOGMzNzhkOGVhOC90YWJsZTo1YTM3ZTBkNGMyN2Q0YTFmYjEwY2UzZTU0ZDQwNDBmYS90YWJsZXJhbmdlOjVhMzdlMGQ0YzI3ZDRhMWZiMTBjZTNlNTRkNDA0MGZhXzYtNC0xLTEtNTkxMjc_9c56781b-32bf-4996-8d07-de80fb4c537f"
      unitRef="number">0.516</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="ibc128abfb89243b6bb31d0ca13db2070_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzMvZnJhZzowN2ZiZGVhY2JmZjg0OTU2YjI3ZmQwOGMzNzhkOGVhOC90YWJsZTo1YTM3ZTBkNGMyN2Q0YTFmYjEwY2UzZTU0ZDQwNDBmYS90YWJsZXJhbmdlOjVhMzdlMGQ0YzI3ZDRhMWZiMTBjZTNlNTRkNDA0MGZhXzctNC0xLTEtNTkxMjc_c22a1bc0-d9c8-44da-87ee-18b376788705"
      unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <vrna:WarrantLiabilityCurrent
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzMvZnJhZzowN2ZiZGVhY2JmZjg0OTU2YjI3ZmQwOGMzNzhkOGVhOC90YWJsZTo1YTM3ZTBkNGMyN2Q0YTFmYjEwY2UzZTU0ZDQwNDBmYS90YWJsZXJhbmdlOjVhMzdlMGQ0YzI3ZDRhMWZiMTBjZTNlNTRkNDA0MGZhXzgtNC0xLTEtNTkxMjc_a566de86-f018-46f6-8790-efa318f37db1"
      unitRef="usd">0</vrna:WarrantLiabilityCurrent>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzMvZnJhZzowN2ZiZGVhY2JmZjg0OTU2YjI3ZmQwOGMzNzhkOGVhOC90ZXh0cmVnaW9uOjA3ZmJkZWFjYmZmODQ5NTZiMjdmZDA4YzM3OGQ4ZWE4XzE5NDk_49cd62f7-fc20-4478-aa4f-a33b09c14806">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The following table shows the movement of the value of the warrants (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;At January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,246)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;At December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="if80b5e08771841e98a3888a3388c32e2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzMvZnJhZzowN2ZiZGVhY2JmZjg0OTU2YjI3ZmQwOGMzNzhkOGVhOC90YWJsZTo1OTY0MGFkNmFhMGM0NDBmYjU0OGZmNjQyNmU2MzE3OC90YWJsZXJhbmdlOjU5NjQwYWQ2YWEwYzQ0MGZiNTQ4ZmY2NDI2ZTYzMTc4XzItNC0xLTEtNTkxMjc_14064eb8-5e8c-4bdc-a15d-0dc7b59bb17a"
      unitRef="usd">2246000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <vrna:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustment
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzMvZnJhZzowN2ZiZGVhY2JmZjg0OTU2YjI3ZmQwOGMzNzhkOGVhOC90YWJsZTo1OTY0MGFkNmFhMGM0NDBmYjU0OGZmNjQyNmU2MzE3OC90YWJsZXJhbmdlOjU5NjQwYWQ2YWEwYzQ0MGZiNTQ4ZmY2NDI2ZTYzMTc4XzQtNC0xLTEtNTkxMjc_a2d0b826-fe30-45ad-818c-2960df857b74"
      unitRef="usd">-2246000</vrna:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustment>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzMvZnJhZzowN2ZiZGVhY2JmZjg0OTU2YjI3ZmQwOGMzNzhkOGVhOC90YWJsZTo1OTY0MGFkNmFhMGM0NDBmYjU0OGZmNjQyNmU2MzE3OC90YWJsZXJhbmdlOjU5NjQwYWQ2YWEwYzQ0MGZiNTQ4ZmY2NDI2ZTYzMTc4XzctNC0xLTEtNTkxMjc_5626c211-3823-4ed5-92c7-72c654d74dc3"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzYvZnJhZzplMGZlM2Q3MGM0NDk0ZDkwOGE2ZWU2MTlmMTBlZTQ3OS90ZXh0cmVnaW9uOmUwZmUzZDcwYzQ0OTRkOTA4YTZlZTYxOWYxMGVlNDc5XzY3MDY_2a4f70d2-fd00-4809-9617-d27308013dff">Term loan&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In November 2020, the Company entered into a term loan facility of up to $30.0&#160;million (the &#x201c;SVB Term Loan&#x201d;), consisting of advances of $5.0&#160;million funded at closing and $10.0&#160;million and $15.0&#160;million&#160;contingent upon achievement of certain clinical development milestones and other specified conditions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The SVB Term Loan was categorized within Level 3 of the fair value hierarchy and the carrying amount of the debt approximated its fair value based on prevailing interest rates as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;On October 14, 2022 (the &#x201c;Effective Date&#x201d;), the Company entered into a loan and security agreement (the &#x201c;Loan Agreement&#x201d;) with Oxford Finance Luxembourg S.&#xc0; R.L. (&#x201c;Oxford&#x201d;) for an aggregate amount of up to $150.0&#160;million (the &#x201c;Oxford Term Loan&#x201d;). The Oxford Term Loan provides for an initial term loan advance in an aggregate amount of $10.0&#160;million funded on the Effective Date (the &#x201c;Oxford Term A Loan&#x201d;), and up to four additional term loan advances in an aggregate amount of $140.0&#160;million, which are available as described below and subject to terms of the Loan Agreement. The proceeds from the Oxford Term Loan will be used for general corporate and working capital purposes, and a portion of the proceeds of the Oxford Term A Loan have been used to repay in full the existing outstanding indebtedness owed to SVB.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The four additional term loan advances under the Oxford Term Loan consist of: a $10.0&#160;million term loan advance (the &#x201c;Oxford Term B Loan&#x201d;) which is available at the option of the Company from the Effective Date up to and including March 31, 2023; a $20.0&#160;million term loan advance (the &#x201c;Oxford Term C Loan&#x201d;) available during the period commencing on the later of January 1, 2024 and the date on which the Company receives positive ENHANCE-1 data in the Phase 3 clinical trial for ensifentrine sufficient to support the submission of a New Drug Application (&#x201c;NDA&#x201d;) with the United States Food and Drug Administration (the &#x201c;FDA&#x201d;) for ensifentrine through and including March 29, 2024; a $60.0&#160;million term loan advance (the &#x201c;Oxford Term D Loan&#x201d;) available during the period commencing on the later of October 1, 2024 and the date on which the Company receives final approval from the FDA for the Company&#x2019;s NDA for ensifentrine up to and including December 31, 2024; and a $50.0&#160;million term loan advance (the &#x201c;Oxford Term E Loan&#x201d;) available during the interest-only period at the Company&#x2019;s request and at Oxford&#x2019;s sole discretion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Each advance under the Oxford Term Loan accrues interest at a floating per annum rate equal to (a) the greater of (i) the 1-Month CME Term SOFR reference rate on the last business day of the month that immediately precedes the month in which the interest will accrue and (ii) 2.38%, plus (b) 5.50% (the &#x201c;Basic Rate&#x201d;). In no event shall the Basic Rate (x) for the Oxford Term A Loan be less than 7.88% and (y) for each other advance be less than the Basic Rate on the business day immediately prior to the funding date of such term advance. The Basic Rate for the Term A Loan for the period from the Effective Date through and including October 31, 2022 shall be 8.54205% and the Basic Rate for each Term Loan shall not increase by more than 2.00% above the applicable Basic Rate as of the funding date of each such term loan. The Oxford Term Loan provides for interest-only payments on a monthly basis until the payment date immediately preceding December 1, 2025, if the Oxford Term D Loan is not made, and December 1, 2026, if the Oxford Term D Loan is made. Thereafter, amortization payments will be payable monthly in equal installments of principal plus accrued interest. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Upon repayment, whether at maturity, upon acceleration or by prepayment or otherwise, the Company shall make a final payment to the lenders in an amount ranging from 1.30% to 3.00% of the aggregate principal balance, depending on the advances received under the Oxford Term Loan. The Company may prepay the Oxford Term Loan in full, or in part, in accordance with the terms of the Loan Agreement, which is subject to a prepayment fee of up to 2.00%, depending on the timing of the prepayment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Oxford Term Loan is secured by a lien on substantially all of the assets of the Company, other than intellectual property, but including any rights to payments and proceeds from the sale, licensing or disposition of intellectual property. The Company has also granted Oxford a negative pledge with respect to its intellectual property. The Loan Agreement contains customary covenants and representations, including but not limited to financial reporting obligations and limitations on dividends, dispositions, indebtedness, collateral, investments, distributions, transfers, mergers or acquisitions, taxes, corporate changes, deposit accounts, transactions with affiliates and subsidiaries. The Loan Agreement also contains other customary provisions, such as expense reimbursement, non-disclosure obligations as well as indemnification rights for the benefit of Oxford.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ib6f1e5c7e48647c0920bd6e598622618_I20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzYvZnJhZzplMGZlM2Q3MGM0NDk0ZDkwOGE2ZWU2MTlmMTBlZTQ3OS90ZXh0cmVnaW9uOmUwZmUzZDcwYzQ0OTRkOTA4YTZlZTYxOWYxMGVlNDc5XzU0OTc1NTgzNDM1NQ_4e846ba0-d856-4a8d-8dd7-76fd557145f3"
      unitRef="usd">30000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i30e7bb276e12407b8476499428f6f60a_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzYvZnJhZzplMGZlM2Q3MGM0NDk0ZDkwOGE2ZWU2MTlmMTBlZTQ3OS90ZXh0cmVnaW9uOmUwZmUzZDcwYzQ0OTRkOTA4YTZlZTYxOWYxMGVlNDc5XzU0OTc1NTgzNDQwOA_45b4cf18-cf62-45af-96c7-4bf7a63fe16c"
      unitRef="usd">5000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i90f55e89f14448548416cbd47cfb6cf9_I20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzYvZnJhZzplMGZlM2Q3MGM0NDk0ZDkwOGE2ZWU2MTlmMTBlZTQ3OS90ZXh0cmVnaW9uOmUwZmUzZDcwYzQ0OTRkOTA4YTZlZTYxOWYxMGVlNDc5XzU0OTc1NTgzNDQzNA_78b0ca62-6ea4-4b9c-8cad-1902ef1a9ab5"
      unitRef="usd">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ie69772c787fa46e283c35e0159c9ed3b_I20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzYvZnJhZzplMGZlM2Q3MGM0NDk0ZDkwOGE2ZWU2MTlmMTBlZTQ3OS90ZXh0cmVnaW9uOmUwZmUzZDcwYzQ0OTRkOTA4YTZlZTYxOWYxMGVlNDc5XzU0OTc1NTgzNDQ0Mg_bf4e8699-cfe1-438a-bdbe-3eac553374b7"
      unitRef="usd">15000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ia867c724f1754d6b8ce8489a52865172_I20221014"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzYvZnJhZzplMGZlM2Q3MGM0NDk0ZDkwOGE2ZWU2MTlmMTBlZTQ3OS90ZXh0cmVnaW9uOmUwZmUzZDcwYzQ0OTRkOTA4YTZlZTYxOWYxMGVlNDc5XzU0OTc1NTgyOTk4OA_36879990-beef-414a-8c86-8d4ea1a155d1"
      unitRef="usd">150000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i10a520855ec54e2da16ba70468d0a51b_I20221014"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzYvZnJhZzplMGZlM2Q3MGM0NDk0ZDkwOGE2ZWU2MTlmMTBlZTQ3OS90ZXh0cmVnaW9uOmUwZmUzZDcwYzQ0OTRkOTA4YTZlZTYxOWYxMGVlNDc5XzU0OTc1NTgzMDEwNw_e0cded6d-49b5-4f40-8fbb-6e56a91ee397"
      unitRef="usd">10000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <vrna:LineOfCreditFacilityNumberOfLoanAdvances
      contextRef="ia867c724f1754d6b8ce8489a52865172_I20221014"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzYvZnJhZzplMGZlM2Q3MGM0NDk0ZDkwOGE2ZWU2MTlmMTBlZTQ3OS90ZXh0cmVnaW9uOmUwZmUzZDcwYzQ0OTRkOTA4YTZlZTYxOWYxMGVlNDc5XzU0OTc1NTgzMDE3OA_15ca25bb-4f43-4671-97f1-4864a4c0b20c"
      unitRef="loanadvance">4</vrna:LineOfCreditFacilityNumberOfLoanAdvances>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i3541a8c38127458ba1aae3fdc52c63d5_I20221014"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzYvZnJhZzplMGZlM2Q3MGM0NDk0ZDkwOGE2ZWU2MTlmMTBlZTQ3OS90ZXh0cmVnaW9uOmUwZmUzZDcwYzQ0OTRkOTA4YTZlZTYxOWYxMGVlNDc5XzU0OTc1NTgzMDIzOA_d60f307e-98dc-4883-b9df-25998db69860"
      unitRef="usd">140000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <vrna:LineOfCreditFacilityNumberOfLoanAdvances
      contextRef="ia867c724f1754d6b8ce8489a52865172_I20221014"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzYvZnJhZzplMGZlM2Q3MGM0NDk0ZDkwOGE2ZWU2MTlmMTBlZTQ3OS90ZXh0cmVnaW9uOmUwZmUzZDcwYzQ0OTRkOTA4YTZlZTYxOWYxMGVlNDc5XzU0OTc1NTgzMDY3MA_aadfbd38-f588-4c34-92f0-c37abd8a1b80"
      unitRef="loanadvance">4</vrna:LineOfCreditFacilityNumberOfLoanAdvances>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ic244fa4c95204e0e8dcfaefb2e6b8237_I20221014"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzYvZnJhZzplMGZlM2Q3MGM0NDk0ZDkwOGE2ZWU2MTlmMTBlZTQ3OS90ZXh0cmVnaW9uOmUwZmUzZDcwYzQ0OTRkOTA4YTZlZTYxOWYxMGVlNDc5XzU0OTc1NTgzMDc0Ng_206993bd-59b8-4368-923a-4a1a66964b32"
      unitRef="usd">10000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i22eac3eaf4ba4678a0eb3d0971d09767_I20221014"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzYvZnJhZzplMGZlM2Q3MGM0NDk0ZDkwOGE2ZWU2MTlmMTBlZTQ3OS90ZXh0cmVnaW9uOmUwZmUzZDcwYzQ0OTRkOTA4YTZlZTYxOWYxMGVlNDc5XzU0OTc1NTgzMDkwNQ_01bd81f4-f60c-417e-8f44-b95f4c7be403"
      unitRef="usd">20000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i48aaa74363db4fc7b8d8426a1eff5049_I20221014"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzYvZnJhZzplMGZlM2Q3MGM0NDk0ZDkwOGE2ZWU2MTlmMTBlZTQ3OS90ZXh0cmVnaW9uOmUwZmUzZDcwYzQ0OTRkOTA4YTZlZTYxOWYxMGVlNDc5XzU0OTc1NTgzMTMzMQ_0f21561f-56a8-4e72-885f-34636a89d7c6"
      unitRef="usd">60000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="id04385f9e7774756bbf90a20930f80ec_I20221014"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzYvZnJhZzplMGZlM2Q3MGM0NDk0ZDkwOGE2ZWU2MTlmMTBlZTQ3OS90ZXh0cmVnaW9uOmUwZmUzZDcwYzQ0OTRkOTA4YTZlZTYxOWYxMGVlNDc5XzU0OTc1NTgzMTYwNg_0ec5b12c-d7f7-4db9-ba70-77ae5575f9b5"
      unitRef="usd">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ibbe1ef2d7eb14330b2e19597ed9f08da_D20221014-20221014"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzYvZnJhZzplMGZlM2Q3MGM0NDk0ZDkwOGE2ZWU2MTlmMTBlZTQ3OS90ZXh0cmVnaW9uOmUwZmUzZDcwYzQ0OTRkOTA4YTZlZTYxOWYxMGVlNDc5XzU0OTc1NTgzMjAzMQ_b34bc036-1948-4764-a687-386c47b79f6e"
      unitRef="number">0.0238</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ic419bc3e647a4ca9a2757dc9edc5107d_D20221014-20221014"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzYvZnJhZzplMGZlM2Q3MGM0NDk0ZDkwOGE2ZWU2MTlmMTBlZTQ3OS90ZXh0cmVnaW9uOmUwZmUzZDcwYzQ0OTRkOTA4YTZlZTYxOWYxMGVlNDc5XzU0OTc1NTgzMjA0NQ_22a6e600-70bf-4fe7-a059-6cb64e9cd50d"
      unitRef="number">0.0550</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i428494c244664464882b178b3d34c37f_D20221014-20221014"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzYvZnJhZzplMGZlM2Q3MGM0NDk0ZDkwOGE2ZWU2MTlmMTBlZTQ3OS90ZXh0cmVnaW9uOmUwZmUzZDcwYzQ0OTRkOTA4YTZlZTYxOWYxMGVlNDc5XzU0OTc1NTgzMjE0Ng_805f1301-c561-4225-bcf6-3390745df374"
      unitRef="number">0.0788</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i3d4b040098df4fc3a356ffafd5e4b830_D20221014-20221014"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzYvZnJhZzplMGZlM2Q3MGM0NDk0ZDkwOGE2ZWU2MTlmMTBlZTQ3OS90ZXh0cmVnaW9uOmUwZmUzZDcwYzQ0OTRkOTA4YTZlZTYxOWYxMGVlNDc5XzU0OTc1NTgzMjQxMQ_3745bb5c-65c7-49b0-b459-8688e1defefb"
      unitRef="number">0.0854205</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="i77e399a94d574a9c9520217f5ebd6515_D20221014-20221014"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzYvZnJhZzplMGZlM2Q3MGM0NDk0ZDkwOGE2ZWU2MTlmMTBlZTQ3OS90ZXh0cmVnaW9uOmUwZmUzZDcwYzQ0OTRkOTA4YTZlZTYxOWYxMGVlNDc5XzU0OTc1NTgzMjQ4NQ_563c09e1-850d-4f6f-9455-dc1370a27dc5"
      unitRef="number">0.0200</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <vrna:DebtInstrumentFinalPaymentPercentageOfPrincipalAmount
      contextRef="i7ad954ea881e4224a373e39507e05382_D20221014-20221014"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzYvZnJhZzplMGZlM2Q3MGM0NDk0ZDkwOGE2ZWU2MTlmMTBlZTQ3OS90ZXh0cmVnaW9uOmUwZmUzZDcwYzQ0OTRkOTA4YTZlZTYxOWYxMGVlNDc5XzU0OTc1NTgzMzA4Ng_5dc96197-eb6f-40ab-a751-31803f8301c1"
      unitRef="number">0.0130</vrna:DebtInstrumentFinalPaymentPercentageOfPrincipalAmount>
    <vrna:DebtInstrumentFinalPaymentPercentageOfPrincipalAmount
      contextRef="ife6bb65a13724831ab4e8d78c473f147_D20221014-20221014"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzYvZnJhZzplMGZlM2Q3MGM0NDk0ZDkwOGE2ZWU2MTlmMTBlZTQ3OS90ZXh0cmVnaW9uOmUwZmUzZDcwYzQ0OTRkOTA4YTZlZTYxOWYxMGVlNDc5XzU0OTc1NTgzMzA5Mw_cbff71f4-9832-4d69-a11d-36a9c7ec4444"
      unitRef="number">0.0300</vrna:DebtInstrumentFinalPaymentPercentageOfPrincipalAmount>
    <vrna:DebtInstrumentPrepaymentFeePercentage
      contextRef="i7d76374535984c8fbfde48cfb17a2b35_D20221014-20221014"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzYvZnJhZzplMGZlM2Q3MGM0NDk0ZDkwOGE2ZWU2MTlmMTBlZTQ3OS90ZXh0cmVnaW9uOmUwZmUzZDcwYzQ0OTRkOTA4YTZlZTYxOWYxMGVlNDc5XzU0OTc1NTgzMzM1OQ_baca5f6c-ff54-44b2-918a-0f6490db94b9"
      unitRef="number">0.0200</vrna:DebtInstrumentPrepaymentFeePercentage>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzkvZnJhZzowYmM2NDE1MGIwNGU0YjdiOGNjMDE5MDY3ZGQ0MzVmNC90ZXh0cmVnaW9uOjBiYzY0MTUwYjA0ZTRiN2I4Y2MwMTkwNjdkZDQzNWY0XzU2MzQ_f06e45a3-2e31-4674-a2df-79f63c63c0a3">Significant agreements&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Ligand agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In 2006 the Company acquired Rhinopharma and assumed contingent liabilities owed to Ligand UK Development Limited (&#x201c;Ligand&#x201d;) (formerly Vernalis Development Limited). The Company refers to the assignment and license agreement as the Ligand Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Ligand assigned to the Company all of its rights to certain patents and patent applications relating to ensifentrine and related compounds (the "Ligand Patents") and an exclusive, worldwide, royalty-bearing license under certain Ligand know-how to develop, manufacture and commercialize products (the "Ligand Licensed Products") developed using Ligand Patents, Ligand know-how and the physical stock of certain compounds.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company is obligated to pay a milestone payment on obtaining the first approval of any regulatory authority for the commercialization of a Ligand Licensed Product, low single digit royalties based on the future sales performance of all Ligand Licensed Products and a portion equal to a mid-twenty percent of any consideration received from any sub-licensees for the Ligand Patents and for Ligand know-how. Royalties payable are based on the future sales performance so the amount payable is unlimited.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;At the time each contingency is resolved, the Company will record the contingent consideration payment (or payable) in connection with the Ligand Agreement as an expense and will classify it within R&amp;amp;D expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In March 2022, the Company entered into an Amendment Agreement (the &#x201c;Amendment&#x201d;) with Ligand whereby the Ligand Agreement was amended to clarify certain ambiguous terms in the Ligand Agreement. Pursuant to the Amendment:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt"&gt;the Company agreed to pay to Ligand (i) $2.0&#160;million within five business days of the date of the Amendment and (ii) $15.0&#160;million upon the first commercial sale of ensifentrine by the Company or a sub-licensee, which amount is payable in cash or, at the Company's discretion, by the issuance of Company equity of equivalent value, as determined based on the volume-weighted average price of the Company's American Depositary Shares on the Nasdaq Global Market over the ten (10) trading days including and prior to such milestone event;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt"&gt;the Ligand Agreement shall expire on March 24, 2042 unless terminated earlier by either party in accordance with its terms;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt"&gt;upon termination of the Ligand Agreement, any Sub-licensee (as defined in the Amendment) shall have the right to enter into a direct license agreement with Ligand for the portion of the Program IP (as defined in the Amendment) that was sub-licensed by such Sub-licensee;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt"&gt;the milestone payment may be paid in cash or, at the Company&#x2019;s discretion, by issuing to Ligand shares in the Company of equivalent value; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:32.5pt"&gt;each party&#x2019;s right to terminate the Ligand Agreement is conditioned upon such party obtaining a final judgment of the English High Court declaring that the other party is in material breach of its obligations under the Ligand Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company accounted for the $2.0&#160;million payment at execution of the Amendment as selling, general and administrative expense in the consolidated statements of operations as the payment is related to a contract modification.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Nuance agreement &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company entered into a collaboration and license agreement (the &#x201c;Nuance Agreement&#x201d;) with Nuance Pharma Limited (&#x201c;Nuance Pharma&#x201d;) effective June 9, 2021 (the &#x201c;Effective Date&#x201d;), under which the Company granted Nuance Pharma the exclusive rights to develop and commercialize ensifentrine in Greater China (China, Taiwan, Hong Kong and Macau). In return, the Company received an unconditional right to consideration aggregating $40.0&#160;million consisting of $25.0&#160;million in cash and an equity interest, valued at $15.0&#160;million as of the Effective Date, in Nuance Biotech, the parent company of Nuance Pharma. The Company is eligible to receive future milestone payments of up to $179.0&#160;million triggered upon achievement of certain clinical, regulatory, and commercial milestones, as well as tiered double-digit royalties as a percentage of net sales of the products in Greater China. The Company will recognize these milestones when it is probable that a significant revenue reversal would not occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;As of December 31, 2022, the $25.0&#160;million cash payment and $15.0&#160;million equity interest had been received and the holding in Nuance Biotech was recorded as Equity interest on the Consolidated Balance Sheet. The Equity &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;interest is recorded at cost as the Company has elected to use the measurement alternative for equity investments without readily determinable fair values. The Company will evaluate this investment for indicators of impairment quarterly. The Company did not identify events or changes in circumstances that may have a significant effect on the fair value of the investment during the year ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Under the terms of the Nuance Agreement, at any time until three months prior to the expected submission of the first New Drug Application in Greater China, if (i) a third party is interested in partnering with the Company, either globally or in territory covering at least the United States or Europe, for the development and/or commercialization of ensifentrine or (ii) the Company undergoes a change of control, the Company will have an exclusive option right to buy back the license granted to Nuance Pharma and all related assets. The price is agreed to be equal to the aggregate of (i) all prior amounts paid by Nuance Pharma to the Company in cash under the agreement and (ii) all development and regulatory costs incurred and paid by Nuance Pharma in connection with the development and commercialization of ensifentrine under the Nuance Agreement multiplied by a single-digit factor range dependent upon achievement of certain milestones, subject to a specified maximum amount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Nuance Agreement will continue on a jurisdiction-by-jurisdiction and product-by-product basis until the expiration of royalty payment obligations with respect to such product in such jurisdiction unless earlier terminated by the parties. Either party may terminate the Nuance Agreement for an uncured material breach or bankruptcy of the other party. Nuance Pharma may also terminate the Nuance Agreement at will upon 90 days' prior written notice. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company reviewed the buy-back option and determined that because it is conditional on a third party the Company does not have the practical ability to exercise it and, accordingly, the contract is accounted for under ASC 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The transaction price at the Effective Date of the Nuance Agreement was $40.0&#160;million consisting of the $25.0&#160;million upfront cash payment and $15.0&#160;million equity interest. Developmental and regulatory milestones, and the manufacture and supply of ensifentrine drug product, were not included in the transaction price as management determined that it is not probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Commercial milestones and sales royalties were also excluded and will be recognized when the milestones are achieved or the sales occur in Greater China.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The performance obligations in the Nuance Agreement include the grant of the license (including the right to commercialize ensifentrine until the end of the term, the sharing of certain know how, and the sharing of certain clinical and regulatory data), and manufacture and supply of ensifentrine drug product. The Company has determined that the manufacturing and supply was not at a discount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company has determined that the license and the know how shared with Nuance Pharma constitutes functional intellectual property and that revenue relating to this should be recognized at a point in time. Consequently, the Company determined that it fulfilled its obligations to Nuance Pharma after it delivered the know how that will allow Nuance Pharma to file an investigational new drug application in Greater China. This know how was delivered in the year ended December 31, 2021, and the $40.0&#160;million revenue was therefore recognized as revenue in this period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;On the Effective Date, $4.0&#160;million of costs of obtaining the contract were recorded as a contract asset. As of December 31, 2021, the entire cost had been recognized in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;On April 13, 2022, the Company formalized the Agreement for the Manufacture and Supply of ensifentrine (&#x201c;Nuance Supply Agreement&#x201d;) with Nuance Pharma. The Company determined that the manufacturing and supply of ensifentrine to Nuance represents a distinct and separate performance obligation, for which consideration to be received is variable based on the quantities to be ordered by Nuance. Revenue earned with the manufacture and supply of the licensed product is, and will be, recognized as the supply is delivered to Nuance. The Company has determined it is acting as principal in relation to the manufacture and supply under the Agreement. In its capacity as principal, the Company will recognize the associated revenue on a gross basis. As of December 31, 2022, the Company has recognized $0.5&#160;million in relation to the clinical supply of ensifentrine to Nuance Pharma.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <vrna:SublicensePayment
      contextRef="i2014cf02dad94153af60f28551c0469c_D20220301-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzkvZnJhZzowYmM2NDE1MGIwNGU0YjdiOGNjMDE5MDY3ZGQ0MzVmNC90ZXh0cmVnaW9uOjBiYzY0MTUwYjA0ZTRiN2I4Y2MwMTkwNjdkZDQzNWY0XzI0NzM5MDExNjM4MzQz_9c7178d3-783d-4dcb-8dc3-90d9acc55747"
      unitRef="usd">2000000</vrna:SublicensePayment>
    <vrna:SublicensePayment
      contextRef="ifa2a4633d09c407a94ff8f3507d2318d_D20220301-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzkvZnJhZzowYmM2NDE1MGIwNGU0YjdiOGNjMDE5MDY3ZGQ0MzVmNC90ZXh0cmVnaW9uOjBiYzY0MTUwYjA0ZTRiN2I4Y2MwMTkwNjdkZDQzNWY0XzI0NzM5MDExNjM4MzU3_f94b9d65-9477-41d6-b2b0-a2b7d529eb56"
      unitRef="usd">15000000</vrna:SublicensePayment>
    <vrna:SublicensePaymentEquityIssuanceThresholdTradingDays
      contextRef="i2014cf02dad94153af60f28551c0469c_D20220301-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzkvZnJhZzowYmM2NDE1MGIwNGU0YjdiOGNjMDE5MDY3ZGQ0MzVmNC90ZXh0cmVnaW9uOjBiYzY0MTUwYjA0ZTRiN2I4Y2MwMTkwNjdkZDQzNWY0XzI0NzM5MDExNjM4Mzcy_baa9d696-753a-4e70-a95b-16334e00a243"
      unitRef="tradingday">10</vrna:SublicensePaymentEquityIssuanceThresholdTradingDays>
    <vrna:SublicensePayment
      contextRef="ia63bdd4aff86454a9544c5c56ab3a539_D20220301-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzkvZnJhZzowYmM2NDE1MGIwNGU0YjdiOGNjMDE5MDY3ZGQ0MzVmNC90ZXh0cmVnaW9uOjBiYzY0MTUwYjA0ZTRiN2I4Y2MwMTkwNjdkZDQzNWY0XzI0NzM5MDExNjM4Mzc2_bd6129e6-2633-473a-a184-a1ca5b91afb9"
      unitRef="usd">2000000</vrna:SublicensePayment>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i44405a18d6cc405cab4ed043524c8fde_I20210609"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzkvZnJhZzowYmM2NDE1MGIwNGU0YjdiOGNjMDE5MDY3ZGQ0MzVmNC90ZXh0cmVnaW9uOjBiYzY0MTUwYjA0ZTRiN2I4Y2MwMTkwNjdkZDQzNWY0XzU0MQ_11596286-a2fd-4f91-8e87-1ad618c4a5b2"
      unitRef="usd">40000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i44405a18d6cc405cab4ed043524c8fde_I20210609"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzkvZnJhZzowYmM2NDE1MGIwNGU0YjdiOGNjMDE5MDY3ZGQ0MzVmNC90ZXh0cmVnaW9uOjBiYzY0MTUwYjA0ZTRiN2I4Y2MwMTkwNjdkZDQzNWY0XzU1OA_a262d9ef-46d3-46f6-b86d-966d395fb4b6"
      unitRef="usd">25000000</us-gaap:AccountsReceivableNetCurrent>
    <vrna:EquityInterestReceivable
      contextRef="i44405a18d6cc405cab4ed043524c8fde_I20210609"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzkvZnJhZzowYmM2NDE1MGIwNGU0YjdiOGNjMDE5MDY3ZGQ0MzVmNC90ZXh0cmVnaW9uOjBiYzY0MTUwYjA0ZTRiN2I4Y2MwMTkwNjdkZDQzNWY0XzYwMw_f299a3a9-8814-4941-9be4-9f33da875d77"
      unitRef="usd">15000000</vrna:EquityInterestReceivable>
    <vrna:ContractWithCustomerFutureEligibleMilestonePayments
      contextRef="i44405a18d6cc405cab4ed043524c8fde_I20210609"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzkvZnJhZzowYmM2NDE1MGIwNGU0YjdiOGNjMDE5MDY3ZGQ0MzVmNC90ZXh0cmVnaW9uOjBiYzY0MTUwYjA0ZTRiN2I4Y2MwMTkwNjdkZDQzNWY0Xzc1OA_798d543b-97b9-4890-9608-6266ee4e15ae"
      unitRef="usd">179000000</vrna:ContractWithCustomerFutureEligibleMilestonePayments>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i2ed4c5f1e427439596625fc8558417f6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzkvZnJhZzowYmM2NDE1MGIwNGU0YjdiOGNjMDE5MDY3ZGQ0MzVmNC90ZXh0cmVnaW9uOjBiYzY0MTUwYjA0ZTRiN2I4Y2MwMTkwNjdkZDQzNWY0XzEwOTg_41e36a87-86a6-4637-95db-0494cb48e625"
      unitRef="usd">25000000</us-gaap:ContractWithCustomerLiability>
    <vrna:EquityInterestReceivable
      contextRef="i2ed4c5f1e427439596625fc8558417f6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzkvZnJhZzowYmM2NDE1MGIwNGU0YjdiOGNjMDE5MDY3ZGQ0MzVmNC90ZXh0cmVnaW9uOjBiYzY0MTUwYjA0ZTRiN2I4Y2MwMTkwNjdkZDQzNWY0XzExMTg_17766514-85a8-43fe-a7e8-b6da2ca8dbe3"
      unitRef="usd">15000000</vrna:EquityInterestReceivable>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i44405a18d6cc405cab4ed043524c8fde_I20210609"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzkvZnJhZzowYmM2NDE1MGIwNGU0YjdiOGNjMDE5MDY3ZGQ0MzVmNC90ZXh0cmVnaW9uOjBiYzY0MTUwYjA0ZTRiN2I4Y2MwMTkwNjdkZDQzNWY0XzMzMjI_ccf24bdd-6c36-49ea-8650-2eed789add5b"
      unitRef="usd">40000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i44405a18d6cc405cab4ed043524c8fde_I20210609"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzkvZnJhZzowYmM2NDE1MGIwNGU0YjdiOGNjMDE5MDY3ZGQ0MzVmNC90ZXh0cmVnaW9uOjBiYzY0MTUwYjA0ZTRiN2I4Y2MwMTkwNjdkZDQzNWY0XzMzNDM_5e2e2c79-036d-4e74-8439-4d50a9700be7"
      unitRef="usd">25000000</us-gaap:ContractWithCustomerLiability>
    <vrna:EquityInterestReceivable
      contextRef="i44405a18d6cc405cab4ed043524c8fde_I20210609"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzkvZnJhZzowYmM2NDE1MGIwNGU0YjdiOGNjMDE5MDY3ZGQ0MzVmNC90ZXh0cmVnaW9uOjBiYzY0MTUwYjA0ZTRiN2I4Y2MwMTkwNjdkZDQzNWY0XzMzNzE_c6365473-cae6-4371-9382-232bf79e1479"
      unitRef="usd">15000000</vrna:EquityInterestReceivable>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ib45dfb15713741578ce57657f76c641a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzkvZnJhZzowYmM2NDE1MGIwNGU0YjdiOGNjMDE5MDY3ZGQ0MzVmNC90ZXh0cmVnaW9uOjBiYzY0MTUwYjA0ZTRiN2I4Y2MwMTkwNjdkZDQzNWY0XzQ3MjI_3978242e-fbe8-409c-827d-2a5a8115cb3b"
      unitRef="usd">40000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:CapitalizedContractCostNet
      contextRef="i44405a18d6cc405cab4ed043524c8fde_I20210609"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzkvZnJhZzowYmM2NDE1MGIwNGU0YjdiOGNjMDE5MDY3ZGQ0MzVmNC90ZXh0cmVnaW9uOjBiYzY0MTUwYjA0ZTRiN2I4Y2MwMTkwNjdkZDQzNWY0XzM4NDgyOTA3MDc5MjM_3bd2129c-5c91-48be-b7ae-6a950f426a2a"
      unitRef="usd">4000000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="idbecaaa2e50f422788c7776146b6f738_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xMzkvZnJhZzowYmM2NDE1MGIwNGU0YjdiOGNjMDE5MDY3ZGQ0MzVmNC90ZXh0cmVnaW9uOjBiYzY0MTUwYjA0ZTRiN2I4Y2MwMTkwNjdkZDQzNWY0XzI0NzM5MDExNjM4Mzkw_8f91d9c8-435d-4eff-b765-027f14a0428b"
      unitRef="usd">500000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzUwMzI_2fc7c26a-d8dd-4ebc-9279-bdbf0e6f6c44">Share-based compensation&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company operates various share based incentive plans for its staff and issues ordinary shares or ADSs when share-based awards are exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company records share-based compensation expense related to share options and RSUs granted to employees and directors. The expense is included in research and development and selling, general and administrative costs, based on the nature of individual employees&#x2019; functions, and represents the relevant year's allocation of the expense. The costs of share-based compensation to employees are recognized in the consolidated statements of operations and comprehensive loss, together with a corresponding increase in equity over the vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Options are issued with an exercise price of the closing market price on the day before the grant and generally vest over a period of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzgyMg_06949a37-1fa3-4277-8388-a28ff5d09dc6"&gt;one&lt;/span&gt; to four years and the contractual life of all options is ten years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The following table shows the allocation of share-based compensation between research and development and selling, general and administrative costs (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%"&gt;EMI Option Plan and Pre-IPO Option Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The EMI Option Plan and the Pre-IPO Option Plan were adopted by our board of directors on September 18, 2006, and July 24, 2012, respectively. The total number of shares that may be issued under these plans is the current number of outstanding options over 114,000 ordinary shares, or 14,250 ADSs, for the EMI Option Plan and 1,860,000 ordinary shares, or 232,500 ADSs, for the Pre-IPO Option Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;No further awards have been granted under either plan since the 2017 Incentive Plan was adopted, and no further awards will be granted under them.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%"&gt;2017 Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The 2017 Incentive Plan was adopted by our board of directors and became effective on April 26, 2017, in order to grant share based compensation to certain of the Company&#x2019;s directors and employees. It provides for the grant of stock options, RSUs, and other share-based awards to Company&#x2019;s directors, officers, employees and non-employee directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In the year ended December 31, 2019, the Company modified the terms of all RSUs issued prior to January 1, 2019 to include a market based condition, which was also included in the terms of RSUs issued during 2019. The Company's stock price must be maintained above the equivalent of &#xa3;2 per ordinary share for thirty days for the RSUs to vest, in addition to the existing service condition. The RSUs vest five years after the date of grant irrespective of whether the &#xa3;2 market condition was met. This modification did not result in an increase in the fair value of the RSUs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Share option activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The number of options, the weighted average grant date fair value per stock option, and the weighted average exercise price are all shown below on a per ordinary shares basis. The Company&#x2019;s ADSs that are listed on the Nasdaq Global Market each represent eight ordinary shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The following table shows share option activity and includes the options outstanding from all three plans :&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.335%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.244%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of share options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted average exercise price&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted average remaining contractual term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate intrinsic value (thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at January 1, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,125,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,696,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,126,472)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,695,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,024,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(620,016)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,822,688)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,276,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,382,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The exercise prices relate to the equivalent price for an ordinary share, calculated as one eighth of the ADS price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The following summarizes the aggregate intrinsic value and cash receipts related to stock option exercise activity for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.241%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;($ in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aggregate intrinsic value of stock options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash receipts from stock options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Determining the fair value of share options and RSUs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The total fair values of the options and RSUs were estimated using the Black-Scholes option-pricing model for equity-settled compensation, amounted to $19.6&#160;million for instruments granted in the year ended December 31, 2022 and $3.1&#160;million for instruments granted in the year ended December 31, 2021. The cost is amortized over the vesting period of the options and RSUs on a straight-line basis using the graded-vesting method. The following assumptions were used for the Black-Scholes valuation of share options granted in 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Volatility is calculated using historical weekly averages of the Company's share price over a period that is in line with the expected life of the options and RSUs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Fair value of ordinary shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The fair value of ordinary shares has been based on the share price of the Company&#x2019;s shares on AIM on the evening before the date of grant up until October 20, 2020 when the company delisted from AIM. Post this the fair value has been based on the ADS&#x2019;s traded on Nasdaq on the evening before the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The risk-free interest rate has been based on U.K. Government debt yield for the relevant term at the time of grant up until October 20, 2020 when the company delisted from AIM. After this appropriate U.S Treasury yield rates were used.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Expected term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;As the Company does not have sufficient history to estimate its expected term, the Company applied the simplified method of estimating the expected term of the options, as described in the SEC&#x2019;s Staff Accounting Bulletins 107 and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;110. The expected term, calculated under the simplified method, is applied to all stock options which have similar contractual terms. Using this method, the expected term is determined using the average of the vesting period and the contractual life of the stock options granted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Expected dividend&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;There are no expected dividends.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;A summary of the weighted-average assumptions applicable to the share options granted in the applicable years is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.09% - 4.20%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.79% -1.32%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected lives, years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5-7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5-7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.50% - 84.27%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.35% - 87.68%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Grant date fair value (per share)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.34 - $1.33&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.62 - $0.78&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"&gt;Restricted stock units activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The following table shows RSU activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted average remaining contractual term (years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at January 1, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,992,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,030,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,002,584)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,673,352)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,347,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,877,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,006,264)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,676,608)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,542,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.476%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of RSUs outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted average remaining vesting Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Period in which the target must be achieved&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs subject to time based vesting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,028,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs subject to milestone based vesting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;513,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 - 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The intrinsic and fair value of RSUs that vested in the years ended December 31, 2022 and 2021, was $14.3&#160;million and $20.2&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;As of December 31, 2022, total compensation cost related to share options and RSUs granted but not yet recognized was $20.5&#160;million. This cost will be amortized to expense over a weighted average remaining period of 1.0 years and will be adjusted for subsequent forfeitures.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ic9abfa929c414b3a8a9f9e7a5436d4f3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzgyOA_4f62dcb2-e5ef-4c44-92d0-4ff3bd989bd3">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i6ef7ac44600e4b82bd5f7115b1d6d54d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzg3NA_10c50313-7650-4ee2-92d1-b14fb4dbd832">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzUwMjk_1612f5f4-bf9a-4a6b-a0d5-361c890553ce">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The following table shows the allocation of share-based compensation between research and development and selling, general and administrative costs (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i01712b818a734e4a92734201de78b797_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTo4ZWU3MTE3MGZlMDA0MDUzYTgwZjY4NWNlN2E0M2VmNC90YWJsZXJhbmdlOjhlZTcxMTcwZmUwMDQwNTNhODBmNjg1Y2U3YTQzZWY0XzItMi0xLTEtNTkxMjc_4dadab6e-0ded-4aff-b1fd-f0412772d226"
      unitRef="usd">5420000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7233af3af0bd4811889a59bfd4f27031_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTo4ZWU3MTE3MGZlMDA0MDUzYTgwZjY4NWNlN2E0M2VmNC90YWJsZXJhbmdlOjhlZTcxMTcwZmUwMDQwNTNhODBmNjg1Y2U3YTQzZWY0XzItNC0xLTEtNTkxMjc_ed9f984e-cb22-4aad-ab6e-2ba0cf491a3d"
      unitRef="usd">9654000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i119cc232d51e4fbb9e1d846ac2bd0d41_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTo4ZWU3MTE3MGZlMDA0MDUzYTgwZjY4NWNlN2E0M2VmNC90YWJsZXJhbmdlOjhlZTcxMTcwZmUwMDQwNTNhODBmNjg1Y2U3YTQzZWY0XzMtMi0xLTEtNTkxMjc_fb091897-654d-4cd6-9932-ac345b99c4a5"
      unitRef="usd">8701000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i26d09ecdd3a64d1a8904a12f454da71e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTo4ZWU3MTE3MGZlMDA0MDUzYTgwZjY4NWNlN2E0M2VmNC90YWJsZXJhbmdlOjhlZTcxMTcwZmUwMDQwNTNhODBmNjg1Y2U3YTQzZWY0XzMtNC0xLTEtNTkxMjc_d42e8c90-c4d2-407b-a96a-c6ba0f450ac6"
      unitRef="usd">15771000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTo4ZWU3MTE3MGZlMDA0MDUzYTgwZjY4NWNlN2E0M2VmNC90YWJsZXJhbmdlOjhlZTcxMTcwZmUwMDQwNTNhODBmNjg1Y2U3YTQzZWY0XzQtMi0xLTEtNTkxMjc_d415ce97-7767-40ec-814b-07d5e4e9f9e2"
      unitRef="usd">14121000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTo4ZWU3MTE3MGZlMDA0MDUzYTgwZjY4NWNlN2E0M2VmNC90YWJsZXJhbmdlOjhlZTcxMTcwZmUwMDQwNTNhODBmNjg1Y2U3YTQzZWY0XzQtNC0xLTEtNTkxMjc_30d2218a-d2c5-4e12-8b17-d12973dc058e"
      unitRef="usd">25425000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i2a6b7ded42314692aa873d8195ffbd32_I20060918"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzU0OTc1NTgxOTgwOA_402b15cf-e0ca-4a6a-be78-d9c06065b9d0"
      unitRef="shares">114000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized
      contextRef="i2a6b7ded42314692aa873d8195ffbd32_I20060918"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzU0OTc1NTgxOTgxNA_8ac9cf85-569d-4692-a837-3d696b037d24"
      unitRef="shares">14250</vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i20dbfdab854c46fdaca99b937c1a2004_I20120724"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzU0OTc1NTgxOTgxOA_2939ce67-12bb-4eb7-a363-58343ce68928"
      unitRef="shares">1860000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized
      contextRef="i20dbfdab854c46fdaca99b937c1a2004_I20120724"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzU0OTc1NTgxOTgyMg_7d4ddc17-70c1-44d6-8c58-d4c21d944317"
      unitRef="shares">232500</vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i7ce1126e308447edb0ce8f68eda07d48_D20170401-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzE0NDI_091dbc15-dd1b-42da-a001-d38df2ebda99"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i4854c977bffc4921b1f1611822527f5d_D20170401-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzE0NDI_5ea8ede0-4018-467a-ab57-d398a943f0a6"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="icd6f70b91dd0435991ce621ce894613c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzE1MjU_1283bd8d-8c81-4909-aba1-444f08eb8746"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i5476c2b57bb84c3c9a60aba57bb6d479_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzE1MjU_e74e8406-2d13-4bd1-b45f-654550c33be2"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired
      contextRef="i2fd6a66dcd33401c900f14a24e099e1b_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzIyMjM_b52cbb7a-c29f-401f-b6a4-d09151f7b7a4"
      unitRef="gbpPerShare">2</vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired>
    <vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod
      contextRef="i2fd6a66dcd33401c900f14a24e099e1b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzIyNDk_b63fd677-2572-4dc5-b73f-9530af31a516">P30D</vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i2fd6a66dcd33401c900f14a24e099e1b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzIzMzU_682b0cc4-314b-464f-80da-0c19d915602e">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired
      contextRef="i2fd6a66dcd33401c900f14a24e099e1b_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzIzOTA_465e2068-f70e-42ba-9928-c721e5fe5ab3"
      unitRef="gbpPerShare">2</vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired>
    <dei:EntityListingDepositoryReceiptRatio
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzI3NzQ_e5107e02-954c-4f59-9bb2-97f8fea445cf"
      unitRef="rate">8</dei:EntityListingDepositoryReceiptRatio>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzUwMzM_c16ec94b-5467-4583-8869-adefe0d8a7df">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The following table shows share option activity and includes the options outstanding from all three plans :&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.335%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.244%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of share options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted average exercise price&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted average remaining contractual term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate intrinsic value (thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at January 1, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,125,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,696,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,126,472)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,695,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,024,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(620,016)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,822,688)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,276,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,382,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The exercise prices relate to the equivalent price for an ordinary share, calculated as one eighth of the ADS price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The following summarizes the aggregate intrinsic value and cash receipts related to stock option exercise activity for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.241%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;($ in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aggregate intrinsic value of stock options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash receipts from stock options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="if80b5e08771841e98a3888a3388c32e2_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzEtMi0xLTEtNTkxMjc_8c5191ab-64c2-4391-9294-cc14b3889924"
      unitRef="shares">13125672</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="if80b5e08771841e98a3888a3388c32e2_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzEtNC0xLTEtNTkxMjc_025267b0-24d4-48ad-947f-8388ca58f5b7"
      unitRef="usdPerShare">1.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ic23d87e5f60a4b6cbb480b4fd31b6c15_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzEtNi0xLTEtNzI1NTk_58e940d3-4c86-4a24-9ba1-bd93eb5d1e42">P7Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzItMi0xLTEtNTkxMjc_1c9fafa6-2035-4f9c-a478-7c4ab27f311e"
      unitRef="shares">1696000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzItNC0xLTEtNTkxMjc_1f44f93c-223a-412d-b29c-78dbc386d36f"
      unitRef="usdPerShare">0.72</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzMtMi0xLTEtNTkxMjc_bb4e2225-271f-477d-92f7-1166b6a07f63"
      unitRef="shares">2126472</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzMtNC0xLTEtNTkxMjc_ce7f8c0f-e3de-471f-bcf4-2efefc7ed5ed"
      unitRef="usdPerShare">1.06</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzYtMi0xLTEtNTkxMjc_efc95e9c-c75b-4d77-a37e-84e8f6a476a0"
      unitRef="shares">12695200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzYtNC0xLTEtNTkxMjc_78b39277-2f85-4292-93de-7a7cb6f214da"
      unitRef="usdPerShare">1.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzYtNi0xLTEtNTkxMjc_75b2bc76-3dc8-42e1-9571-2739ae2e8ece">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzYtOC0xLTEtNTkxMjc_92efc256-5064-4305-b4f0-e1322618cf9e"
      unitRef="usd">950000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzctMi0xLTEtNTkxMjc_930a2512-d2ae-4ec7-b6d0-f9c9fba67b9a"
      unitRef="shares">9024000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzctNC0xLTEtNTkxMjc_be635205-aef1-47b5-a19c-f5845c639081"
      unitRef="usdPerShare">0.90</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzgtMi0xLTEtNTkxMjc_fe20d2b5-ebf5-4131-b77c-9a995b37abfc"
      unitRef="shares">620016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzgtNC0xLTEtNTkxMjc_cd86f403-479b-4575-b458-b5b240e63b6b"
      unitRef="usdPerShare">1.04</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzEwLTItMS0xLTU5MTI3_546c34db-b751-4634-8b45-b5c57dccfff8"
      unitRef="shares">1822688</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzEwLTQtMS0xLTU5MTI3_2bcecc3f-7127-43c4-a1ef-b348faf606b5"
      unitRef="usdPerShare">0.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzExLTItMS0xLTU5MTI3_5aaec7ff-bf5f-4524-b40f-9f736a2923f3"
      unitRef="shares">19276496</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzExLTQtMS0xLTU5MTI3_41cf6ab5-d122-465a-85bd-318e1ef9e85b"
      unitRef="usdPerShare">1.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzExLTYtMS0xLTU5MTI3_b381bbf1-4f9f-4c3a-97dc-c3c88d204b69">P7Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzExLTgtMS0xLTU5MTI3_2817ece7-dee4-4471-aab6-089be5d36792"
      unitRef="usd">39412000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzEyLTItMS0xLTU5MTI3_224a813f-fbd0-4755-b42f-5c2417ab42f1"
      unitRef="shares">10382256</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzEyLTQtMS0xLTU5MTI3_cb12c66b-0468-45a4-a4b1-95459484ed52"
      unitRef="usdPerShare">1.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzEyLTYtMS0xLTU5MTI3_3a5a4d3d-73e4-486b-8641-fed0fbf6db15">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToyMDljMzcxZTI0MmI0NGU1YTg0MjRiOWJmZGJmNjZmZi90YWJsZXJhbmdlOjIwOWMzNzFlMjQyYjQ0ZTVhODQyNGI5YmZkYmY2NmZmXzEyLTgtMS0xLTU5MTI3_e6105fb6-4473-4d8d-8d98-f9da331a6636"
      unitRef="usd">18543000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <dei:EntityListingDepositoryReceiptRatio
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzMwMDE_5070474b-cc55-4501-9ee4-9fb416f9b2e6"
      unitRef="rate">8</dei:EntityListingDepositoryReceiptRatio>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToxNzA0NzE1OTM1ZWM0NzQ4YjZiNDk3MWU4Zjg0YzY3ZS90YWJsZXJhbmdlOjE3MDQ3MTU5MzVlYzQ3NDhiNmI0OTcxZThmODRjNjdlXzEtMi0xLTEtNzUxNjU_8b78629f-8630-42e2-a59c-6384988c6037"
      unitRef="usd">2413000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToxNzA0NzE1OTM1ZWM0NzQ4YjZiNDk3MWU4Zjg0YzY3ZS90YWJsZXJhbmdlOjE3MDQ3MTU5MzVlYzQ3NDhiNmI0OTcxZThmODRjNjdlXzEtNC0xLTEtNzM5MDg_22af085a-be2c-4acb-91d1-92151b629f6d"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToxNzA0NzE1OTM1ZWM0NzQ4YjZiNDk3MWU4Zjg0YzY3ZS90YWJsZXJhbmdlOjE3MDQ3MTU5MzVlYzQ3NDhiNmI0OTcxZThmODRjNjdlXzItMi0xLTEtNzUxNjU_3f4202c8-af13-4588-8244-9c0efc4cd167"
      unitRef="usd">1372000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZToxNzA0NzE1OTM1ZWM0NzQ4YjZiNDk3MWU4Zjg0YzY3ZS90YWJsZXJhbmdlOjE3MDQ3MTU5MzVlYzQ3NDhiNmI0OTcxZThmODRjNjdlXzItNC0xLTEtNzUxNjU_40ce3e50-9ff2-4567-9852-80a42216820a"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzU0OTc1NTgxOTk1NQ_ea916f2e-75c7-4e5f-b259-a6d8c570c896"
      unitRef="usd">19600000</vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue>
    <vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzU0OTc1NTgxOTk0Ng_fbbd6606-a907-4a08-ade4-f5dd56f4304a"
      unitRef="usd">3100000</vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzUwMzQ_8cf31ba8-e5d9-42e3-84bc-22357c0915ef">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;A summary of the weighted-average assumptions applicable to the share options granted in the applicable years is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.09% - 4.20%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.79% -1.32%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected lives, years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5-7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5-7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.50% - 84.27%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.35% - 87.68%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Grant date fair value (per share)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.34 - $1.33&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.62 - $0.78&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i6ef7ac44600e4b82bd5f7115b1d6d54d_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTplMTk4YTBjYzRhM2Q0ZDgyODFjYjJkYjE3NTk5MTc5Yy90YWJsZXJhbmdlOmUxOThhMGNjNGEzZDRkODI4MWNiMmRiMTc1OTkxNzljXzItMi0xLTEtNTkxMjcvdGV4dHJlZ2lvbjo5ZWQ2OWJmNWU0ZTc0NDg0YmRhNzcyOTJjNmJkZGJkYV80_49815520-73cf-41fa-bc66-dc62548c5f4b"
      unitRef="number">0.0209</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i6ef7ac44600e4b82bd5f7115b1d6d54d_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTplMTk4YTBjYzRhM2Q0ZDgyODFjYjJkYjE3NTk5MTc5Yy90YWJsZXJhbmdlOmUxOThhMGNjNGEzZDRkODI4MWNiMmRiMTc1OTkxNzljXzItMi0xLTEtNTkxMjcvdGV4dHJlZ2lvbjo5ZWQ2OWJmNWU0ZTc0NDg0YmRhNzcyOTJjNmJkZGJkYV85_ca330215-46c4-4fc5-a3cb-0624aac27239"
      unitRef="number">0.0420</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i28bc6028d27549bdbe82ed5d76e8a4d3_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTplMTk4YTBjYzRhM2Q0ZDgyODFjYjJkYjE3NTk5MTc5Yy90YWJsZXJhbmdlOmUxOThhMGNjNGEzZDRkODI4MWNiMmRiMTc1OTkxNzljXzItNC0xLTEtNTkxMjcvdGV4dHJlZ2lvbjo2NTE5OTA0NDBjOWY0NzkzOGYwNmU1MzVhNWIyZDhiYV80_b3967105-0222-454a-88ad-9b85ebc51894"
      unitRef="number">0.0079</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i28bc6028d27549bdbe82ed5d76e8a4d3_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTplMTk4YTBjYzRhM2Q0ZDgyODFjYjJkYjE3NTk5MTc5Yy90YWJsZXJhbmdlOmUxOThhMGNjNGEzZDRkODI4MWNiMmRiMTc1OTkxNzljXzItNC0xLTEtNTkxMjcvdGV4dHJlZ2lvbjo2NTE5OTA0NDBjOWY0NzkzOGYwNmU1MzVhNWIyZDhiYV84_92d26efa-4540-4fca-94ce-763c8711cc3b"
      unitRef="number">0.0132</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ie22e6682054147c4961ab22e3d0b6106_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTplMTk4YTBjYzRhM2Q0ZDgyODFjYjJkYjE3NTk5MTc5Yy90YWJsZXJhbmdlOmUxOThhMGNjNGEzZDRkODI4MWNiMmRiMTc1OTkxNzljXzMtMi0xLTEtNTkxMjcvdGV4dHJlZ2lvbjo3Mjc5MTE3MjQ2ODA0NWFlOTA3NzAzZjBkMmI2MmI2OF80_03ede85d-d26c-4901-bf71-2989c06636fb">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ic9abfa929c414b3a8a9f9e7a5436d4f3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTplMTk4YTBjYzRhM2Q0ZDgyODFjYjJkYjE3NTk5MTc5Yy90YWJsZXJhbmdlOmUxOThhMGNjNGEzZDRkODI4MWNiMmRiMTc1OTkxNzljXzMtMi0xLTEtNTkxMjcvdGV4dHJlZ2lvbjo3Mjc5MTE3MjQ2ODA0NWFlOTA3NzAzZjBkMmI2MmI2OF83_1b4fdbdd-3ae8-448f-9e28-257acf6b4fcd">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i47d19bc9bec84458b044241464c4ca53_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTplMTk4YTBjYzRhM2Q0ZDgyODFjYjJkYjE3NTk5MTc5Yy90YWJsZXJhbmdlOmUxOThhMGNjNGEzZDRkODI4MWNiMmRiMTc1OTkxNzljXzMtNC0xLTEtNTkxMjcvdGV4dHJlZ2lvbjplNDc4NTQ3MjIyMDE0NDE5YTU2YjA1NDk2ODhlYTY4Nl80_5430f08c-5e4e-41a0-8eb8-4e19334e8209">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i659b636bd9904c8884a0708f012c5d76_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTplMTk4YTBjYzRhM2Q0ZDgyODFjYjJkYjE3NTk5MTc5Yy90YWJsZXJhbmdlOmUxOThhMGNjNGEzZDRkODI4MWNiMmRiMTc1OTkxNzljXzMtNC0xLTEtNTkxMjcvdGV4dHJlZ2lvbjplNDc4NTQ3MjIyMDE0NDE5YTU2YjA1NDk2ODhlYTY4Nl83_d16cd075-b756-43b1-bde6-1a421558b332">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i6ef7ac44600e4b82bd5f7115b1d6d54d_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTplMTk4YTBjYzRhM2Q0ZDgyODFjYjJkYjE3NTk5MTc5Yy90YWJsZXJhbmdlOmUxOThhMGNjNGEzZDRkODI4MWNiMmRiMTc1OTkxNzljXzQtMi0xLTEtNTkxMjcvdGV4dHJlZ2lvbjoxM2MzMGJhOWQzZjA0NWNiYmYzOWQ1YjljYTdkODZjYl80_c8d11c69-d94b-4f2f-a13f-36e08c40272f"
      unitRef="number">0.8250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i6ef7ac44600e4b82bd5f7115b1d6d54d_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTplMTk4YTBjYzRhM2Q0ZDgyODFjYjJkYjE3NTk5MTc5Yy90YWJsZXJhbmdlOmUxOThhMGNjNGEzZDRkODI4MWNiMmRiMTc1OTkxNzljXzQtMi0xLTEtNTkxMjcvdGV4dHJlZ2lvbjoxM2MzMGJhOWQzZjA0NWNiYmYzOWQ1YjljYTdkODZjYl85_42d24a7c-f75b-415f-bfdd-b7f38303995a"
      unitRef="number">0.8427</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i28bc6028d27549bdbe82ed5d76e8a4d3_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTplMTk4YTBjYzRhM2Q0ZDgyODFjYjJkYjE3NTk5MTc5Yy90YWJsZXJhbmdlOmUxOThhMGNjNGEzZDRkODI4MWNiMmRiMTc1OTkxNzljXzQtNC0xLTEtNTkxMjcvdGV4dHJlZ2lvbjo1Mzk5OTM0MjVkMDg0MTBmODMzYWE3MzRjYThiODI3M180_61993ab0-6032-4a99-b70c-e68fddae9552"
      unitRef="number">0.8535</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i28bc6028d27549bdbe82ed5d76e8a4d3_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTplMTk4YTBjYzRhM2Q0ZDgyODFjYjJkYjE3NTk5MTc5Yy90YWJsZXJhbmdlOmUxOThhMGNjNGEzZDRkODI4MWNiMmRiMTc1OTkxNzljXzQtNC0xLTEtNTkxMjcvdGV4dHJlZ2lvbjo1Mzk5OTM0MjVkMDg0MTBmODMzYWE3MzRjYThiODI3M185_7ca3f529-2a41-40a1-a96a-2ed3f7c9ce21"
      unitRef="number">0.8768</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i6ef7ac44600e4b82bd5f7115b1d6d54d_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTplMTk4YTBjYzRhM2Q0ZDgyODFjYjJkYjE3NTk5MTc5Yy90YWJsZXJhbmdlOmUxOThhMGNjNGEzZDRkODI4MWNiMmRiMTc1OTkxNzljXzUtMi0xLTEtNTkxMjc_28b70659-8b52-4255-be61-f23039b50a0f"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i28bc6028d27549bdbe82ed5d76e8a4d3_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTplMTk4YTBjYzRhM2Q0ZDgyODFjYjJkYjE3NTk5MTc5Yy90YWJsZXJhbmdlOmUxOThhMGNjNGEzZDRkODI4MWNiMmRiMTc1OTkxNzljXzUtNC0xLTEtNTkxMjc_0922309c-a53e-4990-8218-969fae5ba1b7"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie22e6682054147c4961ab22e3d0b6106_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTplMTk4YTBjYzRhM2Q0ZDgyODFjYjJkYjE3NTk5MTc5Yy90YWJsZXJhbmdlOmUxOThhMGNjNGEzZDRkODI4MWNiMmRiMTc1OTkxNzljXzYtMi0xLTEtNTkxMjcvdGV4dHJlZ2lvbjoyZWQ5NmI4NjdiNGQ0MDZjOWJkYmIwNmEyOGUxN2Q2M180_b9856461-7daa-497f-9f7a-d79f2cad1668"
      unitRef="usdPerShare">0.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic9abfa929c414b3a8a9f9e7a5436d4f3_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTplMTk4YTBjYzRhM2Q0ZDgyODFjYjJkYjE3NTk5MTc5Yy90YWJsZXJhbmdlOmUxOThhMGNjNGEzZDRkODI4MWNiMmRiMTc1OTkxNzljXzYtMi0xLTEtNTkxMjcvdGV4dHJlZ2lvbjoyZWQ5NmI4NjdiNGQ0MDZjOWJkYmIwNmEyOGUxN2Q2M185_31f61793-6677-4a07-a556-b7356ad3344d"
      unitRef="usdPerShare">1.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i47d19bc9bec84458b044241464c4ca53_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTplMTk4YTBjYzRhM2Q0ZDgyODFjYjJkYjE3NTk5MTc5Yy90YWJsZXJhbmdlOmUxOThhMGNjNGEzZDRkODI4MWNiMmRiMTc1OTkxNzljXzYtNC0xLTEtNTkxMjcvdGV4dHJlZ2lvbjoxMjdhMDljNGUwYTM0NTNkYmQ2MTE1YzJiMjcwNmVlY180_763c16c1-4952-4bcc-85d9-e29e1a2604e2"
      unitRef="usdPerShare">0.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i659b636bd9904c8884a0708f012c5d76_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTplMTk4YTBjYzRhM2Q0ZDgyODFjYjJkYjE3NTk5MTc5Yy90YWJsZXJhbmdlOmUxOThhMGNjNGEzZDRkODI4MWNiMmRiMTc1OTkxNzljXzYtNC0xLTEtNTkxMjcvdGV4dHJlZ2lvbjoxMjdhMDljNGUwYTM0NTNkYmQ2MTE1YzJiMjcwNmVlY185_972f40d7-66c1-47ce-8e21-c48fb0e88d12"
      unitRef="usdPerShare">0.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzUwMzA_6bc6e8bd-b3e7-4bb0-89f3-12d828ddb3ee">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The following table shows RSU activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted average remaining contractual term (years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at January 1, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,992,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,030,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,002,584)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,673,352)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,347,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,877,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,006,264)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,676,608)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,542,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.476%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of RSUs outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted average remaining vesting Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Period in which the target must be achieved&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs subject to time based vesting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,028,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs subject to milestone based vesting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;513,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 - 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i0887a875bbe3456c88ad04cb88647ce3_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTpmYjdkZjIyMzM5ZjU0NWRlYTIxNTgxMzM2N2MwNzRiNi90YWJsZXJhbmdlOmZiN2RmMjIzMzlmNTQ1ZGVhMjE1ODEzMzY3YzA3NGI2XzEtMi0xLTEtNTkxMjc_ef6efcf9-edd6-419c-bdee-686fea942ad1"
      unitRef="shares">61992360</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="if80b5e08771841e98a3888a3388c32e2_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTpmYjdkZjIyMzM5ZjU0NWRlYTIxNTgxMzM2N2MwNzRiNi90YWJsZXJhbmdlOmZiN2RmMjIzMzlmNTQ1ZGVhMjE1ODEzMzY3YzA3NGI2XzEtNC0xLTEtNzUxMjI_7c64fc0b-9994-4017-ad50-93879d5e4419"
      unitRef="usdPerShare">0.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ic01569d19cb64fe9a0f5cf16691732dd_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTpmYjdkZjIyMzM5ZjU0NWRlYTIxNTgxMzM2N2MwNzRiNi90YWJsZXJhbmdlOmZiN2RmMjIzMzlmNTQ1ZGVhMjE1ODEzMzY3YzA3NGI2XzItMi0xLTEtNTkxMjc_f96c9f42-7c7a-4c1a-a916-7e5595ccad14"
      unitRef="shares">3030928</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTpmYjdkZjIyMzM5ZjU0NWRlYTIxNTgxMzM2N2MwNzRiNi90YWJsZXJhbmdlOmZiN2RmMjIzMzlmNTQ1ZGVhMjE1ODEzMzY3YzA3NGI2XzItNC0xLTEtNzUxMjI_278a9114-a8d5-473a-b82f-104233d284db"
      unitRef="usdPerShare">0.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ic01569d19cb64fe9a0f5cf16691732dd_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTpmYjdkZjIyMzM5ZjU0NWRlYTIxNTgxMzM2N2MwNzRiNi90YWJsZXJhbmdlOmZiN2RmMjIzMzlmNTQ1ZGVhMjE1ODEzMzY3YzA3NGI2XzMtMi0xLTEtNTkxMjc_53897699-9ef6-40cd-94d1-3bf56879225f"
      unitRef="shares">2002584</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTpmYjdkZjIyMzM5ZjU0NWRlYTIxNTgxMzM2N2MwNzRiNi90YWJsZXJhbmdlOmZiN2RmMjIzMzlmNTQ1ZGVhMjE1ODEzMzY3YzA3NGI2XzMtNC0xLTEtNzUxMjI_c8c70d03-a179-4a91-8c8c-7936cf13873e"
      unitRef="usdPerShare">1.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ic01569d19cb64fe9a0f5cf16691732dd_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTpmYjdkZjIyMzM5ZjU0NWRlYTIxNTgxMzM2N2MwNzRiNi90YWJsZXJhbmdlOmZiN2RmMjIzMzlmNTQ1ZGVhMjE1ODEzMzY3YzA3NGI2XzQtMi0xLTEtNTkxMjc_1f3db49a-22b0-4a27-b303-d8b25ba2c36e"
      unitRef="shares">24673352</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTpmYjdkZjIyMzM5ZjU0NWRlYTIxNTgxMzM2N2MwNzRiNi90YWJsZXJhbmdlOmZiN2RmMjIzMzlmNTQ1ZGVhMjE1ODEzMzY3YzA3NGI2XzQtNC0xLTEtNzUxMjI_df736a27-e855-406d-bc4e-5fe04dc8b611"
      unitRef="usdPerShare">0.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i6b874456201746c6bb2d1caa6f13eeed_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTpmYjdkZjIyMzM5ZjU0NWRlYTIxNTgxMzM2N2MwNzRiNi90YWJsZXJhbmdlOmZiN2RmMjIzMzlmNTQ1ZGVhMjE1ODEzMzY3YzA3NGI2XzUtMi0xLTEtNTkxMjc_959c64d4-f9a7-493f-b56f-78cdfc661952"
      unitRef="shares">38347352</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTpmYjdkZjIyMzM5ZjU0NWRlYTIxNTgxMzM2N2MwNzRiNi90YWJsZXJhbmdlOmZiN2RmMjIzMzlmNTQ1ZGVhMjE1ODEzMzY3YzA3NGI2XzUtNC0xLTEtNzUxMjI_a93a78cd-d1ba-45a3-93c2-8d56e47e2506"
      unitRef="usdPerShare">0.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="ic01569d19cb64fe9a0f5cf16691732dd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTpmYjdkZjIyMzM5ZjU0NWRlYTIxNTgxMzM2N2MwNzRiNi90YWJsZXJhbmdlOmZiN2RmMjIzMzlmNTQ1ZGVhMjE1ODEzMzY3YzA3NGI2XzUtNC0xLTEtNTkxMjc_2e59def4-7c06-4765-b1b1-00891240fb4e">P1Y2M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i0cb073618a12467ebf16ed58054c7606_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTpmYjdkZjIyMzM5ZjU0NWRlYTIxNTgxMzM2N2MwNzRiNi90YWJsZXJhbmdlOmZiN2RmMjIzMzlmNTQ1ZGVhMjE1ODEzMzY3YzA3NGI2XzYtMi0xLTEtNTkxMjc_ecc4e9cb-aceb-46c6-9603-786b749ced91"
      unitRef="shares">12877864</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTpmYjdkZjIyMzM5ZjU0NWRlYTIxNTgxMzM2N2MwNzRiNi90YWJsZXJhbmdlOmZiN2RmMjIzMzlmNTQ1ZGVhMjE1ODEzMzY3YzA3NGI2XzYtNC0xLTEtNzUxMjI_3a71c31a-724d-43d5-9486-01fb43b5dc5d"
      unitRef="usdPerShare">1.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i0cb073618a12467ebf16ed58054c7606_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTpmYjdkZjIyMzM5ZjU0NWRlYTIxNTgxMzM2N2MwNzRiNi90YWJsZXJhbmdlOmZiN2RmMjIzMzlmNTQ1ZGVhMjE1ODEzMzY3YzA3NGI2XzctMi0xLTEtNTkxMjc_cc234585-53e1-479e-8122-90f2e869bf30"
      unitRef="shares">1006264</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTpmYjdkZjIyMzM5ZjU0NWRlYTIxNTgxMzM2N2MwNzRiNi90YWJsZXJhbmdlOmZiN2RmMjIzMzlmNTQ1ZGVhMjE1ODEzMzY3YzA3NGI2XzctNC0xLTEtNzUxMjI_dd5925a5-663f-42d0-a3db-122fde107012"
      unitRef="usdPerShare">1.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i0cb073618a12467ebf16ed58054c7606_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTpmYjdkZjIyMzM5ZjU0NWRlYTIxNTgxMzM2N2MwNzRiNi90YWJsZXJhbmdlOmZiN2RmMjIzMzlmNTQ1ZGVhMjE1ODEzMzY3YzA3NGI2XzgtMi0xLTEtNTkxMjc_45393270-7e13-4716-8e2a-8a8cb4be2a0d"
      unitRef="shares">15676608</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTpmYjdkZjIyMzM5ZjU0NWRlYTIxNTgxMzM2N2MwNzRiNi90YWJsZXJhbmdlOmZiN2RmMjIzMzlmNTQ1ZGVhMjE1ODEzMzY3YzA3NGI2XzgtNC0xLTEtNzUxMjI_226c9693-2c3e-4f9e-a09b-cd8aeb9ebd2c"
      unitRef="usdPerShare">0.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i0b5ab64a3a124f8683b6125306368d23_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTpmYjdkZjIyMzM5ZjU0NWRlYTIxNTgxMzM2N2MwNzRiNi90YWJsZXJhbmdlOmZiN2RmMjIzMzlmNTQ1ZGVhMjE1ODEzMzY3YzA3NGI2XzktMi0xLTEtNTkxMjc_8d2faa6b-966d-43cd-8cb6-5c4e66104f06"
      unitRef="shares">34542344</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTpmYjdkZjIyMzM5ZjU0NWRlYTIxNTgxMzM2N2MwNzRiNi90YWJsZXJhbmdlOmZiN2RmMjIzMzlmNTQ1ZGVhMjE1ODEzMzY3YzA3NGI2XzktNC0xLTEtNzUxMjI_70af3ddc-a29f-4efd-8dbd-7a6897283e15"
      unitRef="usdPerShare">1.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i0cb073618a12467ebf16ed58054c7606_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTpmYjdkZjIyMzM5ZjU0NWRlYTIxNTgxMzM2N2MwNzRiNi90YWJsZXJhbmdlOmZiN2RmMjIzMzlmNTQ1ZGVhMjE1ODEzMzY3YzA3NGI2XzktNC0xLTEtNTkxMjc_ce23c3cd-b729-4742-951d-8f8f00f12a9c">P1Y2M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i00a363abd6ea427e834a199f24664952_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTplMDMxNGIzNTQzODk0MTgxODc3MDlhNGJkYzQwNmYxZS90YWJsZXJhbmdlOmUwMzE0YjM1NDM4OTQxODE4NzcwOWE0YmRjNDA2ZjFlXzEtMi0xLTEtNTkxMjc_3710a35e-6de6-4509-883e-c0eff0b9482f"
      unitRef="shares">34028680</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod
      contextRef="i1754f1ba19694c9bb318a7a84afebbe8_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTplMDMxNGIzNTQzODk0MTgxODc3MDlhNGJkYzQwNmYxZS90YWJsZXJhbmdlOmUwMzE0YjM1NDM4OTQxODE4NzcwOWE0YmRjNDA2ZjFlXzEtNC0xLTEtNTkxMjc_b063e1a9-d3fa-4d44-aac1-3ad695f11ed7">P1Y2M12D</vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i280f6b8ea0fa434cb722279e0e05373e_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTplMDMxNGIzNTQzODk0MTgxODc3MDlhNGJkYzQwNmYxZS90YWJsZXJhbmdlOmUwMzE0YjM1NDM4OTQxODE4NzcwOWE0YmRjNDA2ZjFlXzItMi0xLTEtNTkxMjc_12574f48-8253-4a57-9dbd-d8515193219a"
      unitRef="shares">513664</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod
      contextRef="i4f452df8cc584b6c9688098f4a50632f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90YWJsZTplMDMxNGIzNTQzODk0MTgxODc3MDlhNGJkYzQwNmYxZS90YWJsZXJhbmdlOmUwMzE0YjM1NDM4OTQxODE4NzcwOWE0YmRjNDA2ZjFlXzItNC0xLTEtNTkxMjc_f0397238-a2c6-48e0-be4a-c5396b4ac904">P0Y</vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="i0cb073618a12467ebf16ed58054c7606_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzI3NDg3NzkwNzU5NDg_3a35dcdf-ba33-48f8-ba47-b6d557a4456a"
      unitRef="usd">14300000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="ic01569d19cb64fe9a0f5cf16691732dd_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzI3NDg3NzkwNzU5NTY_6d0244f7-76da-4d87-adce-05448bb821f2"
      unitRef="usd">20200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzU0OTc1NTgyMDUyNw_851b9006-03c1-46bd-84c4-d310f913fd76"
      unitRef="usd">20500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDgvZnJhZzo1NjYzNTExOTAxZmU0NmNmYTdkNGE0ZTExNzc1NjdmMi90ZXh0cmVnaW9uOjU2NjM1MTE5MDFmZTQ2Y2ZhN2Q0YTRlMTE3NzU2N2YyXzI0NzM5MDExNjMyMjQ4_6ac9b7b8-d8bf-4a70-860c-a62819c1e497">P1Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:DefinedContributionPlanTextBlock
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDIvZnJhZzpmZDg3MzE1ZjU5MGE0MWEwYTU5NWRmZjg0MjQyYWUyNy90ZXh0cmVnaW9uOmZkODczMTVmNTkwYTQxYTBhNTk1ZGZmODQyNDJhZTI3XzU0OA_6d120cc4-6c3c-4d1a-9a1a-df5af6314761">Benefit plansThe Company maintains a 401(k) defined contribution retirement plan in the U.S. and a defined contribution plan in the U.K. for its employees and executive directors. The assets of the plans are held separately from those of the Company in independently administered funds.&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The retirement plan cost charge represents the contributions payable by the Company to the plans during the year. Defined contribution costs during the years ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;December 31, 2022&lt;/span&gt; and 2021 amounted to $319 thousand and $274 thousand, respectively.</us-gaap:DefinedContributionPlanTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDIvZnJhZzpmZDg3MzE1ZjU5MGE0MWEwYTU5NWRmZjg0MjQyYWUyNy90ZXh0cmVnaW9uOmZkODczMTVmNTkwYTQxYTBhNTk1ZGZmODQyNDJhZTI3XzUwNg_12debe06-e6d3-4640-ba86-751df0a1818e"
      unitRef="usd">319000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDIvZnJhZzpmZDg3MzE1ZjU5MGE0MWEwYTU5NWRmZjg0MjQyYWUyNy90ZXh0cmVnaW9uOmZkODczMTVmNTkwYTQxYTBhNTk1ZGZmODQyNDJhZTI3XzUyMg_0813930a-2ea2-423f-87e1-288c2c6ae286"
      unitRef="usd">274000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90ZXh0cmVnaW9uOjc1MmU0YmUxMzczODQ3ODFhN2FlYzRhNTM5ZDk5NDI1XzE4NDU_86a5986d-a12c-40e7-a27f-cb95cba37423">Taxation&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Verona Pharma plc operates in the United Kingdom and Verona Pharma, Inc. in the United States and they are subject to income taxes in those countries. U.K. corporation tax is charged at 19% and the U.S. Federal Income tax rate is 21%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The components of (profit)/loss before income taxes are as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,868)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,850)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The components of income tax expense are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total current tax expense/(credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total deferred tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total income tax expense/(credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;A reconciliation of the U.K. statutory income tax rate to our effective income tax rate is as follows (in percentages):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.K. tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development incentive&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in deferred tax valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Effective income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Components of the Company&#x2019;s deferred tax assets and liabilities are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,903)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,903)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D asset&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Future exercisable shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(516)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48,476)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,252)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Movements in the deferred tax valuation allowance &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation allowance at January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in tax rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase/(decrease) in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,422)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation allowance at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;These relate to the difference in the tax base of the IP R&amp;amp;D asset and assumed contingent liability and the financial reporting base, which is nil under U.S. GAAP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Management has reviewed cumulative tax losses and projections of future taxable losses and determined that it is not more likely than not that they will be realized. Accordingly, valuation allowances have been provided over deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;At December 31, 2022 and December 31, 2021, the Company had U.K. net operating losses (&#x201c;NOLs&#x201d;) of $155.6&#160;million and $104.3&#160;million, respectively. The NOLs can be carried forward indefinitely to be offset against future taxable profits, but this is restricted to an annual &#xa3;5&#160;million allowance after which there will be a 50% restriction in the profits that can be covered by losses brought forward.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The Company files separate income tax returns in the U.K. and the U.S. All necessary income tax filings have been completed for all years up to and including December 31, 2021, and there are no ongoing tax examinations in any jurisdiction. No interest or penalties were recognized in the consolidated statements of operations or consolidated balance sheets. As of December 31, 2022, the Company has no uncertain tax positions.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90ZXh0cmVnaW9uOjc1MmU0YmUxMzczODQ3ODFhN2FlYzRhNTM5ZDk5NDI1XzE4NDY_9592f4b0-d88b-4493-ad70-896646024402">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The components of (profit)/loss before income taxes are as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,868)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,850)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTplZTBiMmMxNGVhNzc0YTRiOTA3ZTZmODkwNDVmOTkxNi90YWJsZXJhbmdlOmVlMGIyYzE0ZWE3NzRhNGI5MDdlNmY4OTA0NWY5OTE2XzItMi0xLTEtNTkxMjc_56f8e697-a1e5-4f37-b275-c4e601c67e28"
      unitRef="usd">3868000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTplZTBiMmMxNGVhNzc0YTRiOTA3ZTZmODkwNDVmOTkxNi90YWJsZXJhbmdlOmVlMGIyYzE0ZWE3NzRhNGI5MDdlNmY4OTA0NWY5OTE2XzItNC0xLTEtNTkxMjc_fb1262cd-7c29-4820-8840-842f9cc0c670"
      unitRef="usd">4850000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTplZTBiMmMxNGVhNzc0YTRiOTA3ZTZmODkwNDVmOTkxNi90YWJsZXJhbmdlOmVlMGIyYzE0ZWE3NzRhNGI5MDdlNmY4OTA0NWY5OTE2XzMtMi0xLTEtNTkxMjc_da6060bc-1f5f-4687-b943-a450521b4088"
      unitRef="usd">-72316000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTplZTBiMmMxNGVhNzc0YTRiOTA3ZTZmODkwNDVmOTkxNi90YWJsZXJhbmdlOmVlMGIyYzE0ZWE3NzRhNGI5MDdlNmY4OTA0NWY5OTE2XzMtNC0xLTEtNTkxMjc_a3ef6e4e-2092-4755-b966-b86adfc7d4c4"
      unitRef="usd">-60437000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTplZTBiMmMxNGVhNzc0YTRiOTA3ZTZmODkwNDVmOTkxNi90YWJsZXJhbmdlOmVlMGIyYzE0ZWE3NzRhNGI5MDdlNmY4OTA0NWY5OTE2XzQtMi0xLTEtNTkxMjc_f99dcfc2-e559-4745-bb11-7b12aeb395d0"
      unitRef="usd">-68448000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTplZTBiMmMxNGVhNzc0YTRiOTA3ZTZmODkwNDVmOTkxNi90YWJsZXJhbmdlOmVlMGIyYzE0ZWE3NzRhNGI5MDdlNmY4OTA0NWY5OTE2XzQtNC0xLTEtNTkxMjc_fba7fdf8-d6a2-4714-a387-499b5b937338"
      unitRef="usd">-55587000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90ZXh0cmVnaW9uOjc1MmU0YmUxMzczODQ3ODFhN2FlYzRhNTM5ZDk5NDI1XzE4NDc_abe5d335-bb00-4eb4-8d5b-f318c52e607c">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;The components of income tax expense are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total current tax expense/(credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total deferred tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total income tax expense/(credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTowYWE0NWJiYWRiODQ0ZTNhYWUwYmVlOTVhODEyNWMyYS90YWJsZXJhbmdlOjBhYTQ1YmJhZGI4NDRlM2FhZTBiZWU5NWE4MTI1YzJhXzItMi0xLTEtNTkxMjc_7f8b0b38-bf22-4849-857f-150167d3d079"
      unitRef="usd">253000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTowYWE0NWJiYWRiODQ0ZTNhYWUwYmVlOTVhODEyNWMyYS90YWJsZXJhbmdlOjBhYTQ1YmJhZGI4NDRlM2FhZTBiZWU5NWE4MTI1YzJhXzItNC0xLTEtNTkxMjc_fca14f52-71ac-43e2-a177-368d6a2828ba"
      unitRef="usd">-18000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTowYWE0NWJiYWRiODQ0ZTNhYWUwYmVlOTVhODEyNWMyYS90YWJsZXJhbmdlOjBhYTQ1YmJhZGI4NDRlM2FhZTBiZWU5NWE4MTI1YzJhXzMtMi0xLTEtNTkxMjc_7704ca2c-aee7-41d1-a2c4-b360ed7a634f"
      unitRef="usd">0</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTowYWE0NWJiYWRiODQ0ZTNhYWUwYmVlOTVhODEyNWMyYS90YWJsZXJhbmdlOjBhYTQ1YmJhZGI4NDRlM2FhZTBiZWU5NWE4MTI1YzJhXzMtNC0xLTEtNTkxMjc_62d5c5ff-7b4e-4bfd-bf31-a07ca72b2af5"
      unitRef="usd">0</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTowYWE0NWJiYWRiODQ0ZTNhYWUwYmVlOTVhODEyNWMyYS90YWJsZXJhbmdlOjBhYTQ1YmJhZGI4NDRlM2FhZTBiZWU5NWE4MTI1YzJhXzQtMi0xLTEtNTkxMjc_ac489c5d-6674-4dd2-b031-c4d67b386fba"
      unitRef="usd">253000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTowYWE0NWJiYWRiODQ0ZTNhYWUwYmVlOTVhODEyNWMyYS90YWJsZXJhbmdlOjBhYTQ1YmJhZGI4NDRlM2FhZTBiZWU5NWE4MTI1YzJhXzQtNC0xLTEtNTkxMjc_06b0a1c2-906b-47b1-b689-e17c01c01057"
      unitRef="usd">-18000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTowYWE0NWJiYWRiODQ0ZTNhYWUwYmVlOTVhODEyNWMyYS90YWJsZXJhbmdlOjBhYTQ1YmJhZGI4NDRlM2FhZTBiZWU5NWE4MTI1YzJhXzYtMi0xLTEtNTkxMjc_d56534eb-0c6a-4523-a0de-d1450cbc7d3d"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTowYWE0NWJiYWRiODQ0ZTNhYWUwYmVlOTVhODEyNWMyYS90YWJsZXJhbmdlOjBhYTQ1YmJhZGI4NDRlM2FhZTBiZWU5NWE4MTI1YzJhXzYtNC0xLTEtNTkxMjc_76255688-6814-43c2-81d4-2949a0192d86"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTowYWE0NWJiYWRiODQ0ZTNhYWUwYmVlOTVhODEyNWMyYS90YWJsZXJhbmdlOjBhYTQ1YmJhZGI4NDRlM2FhZTBiZWU5NWE4MTI1YzJhXzctMi0xLTEtNTkxMjc_cf215cc6-fb57-4fa0-a5b4-88763e60506b"
      unitRef="usd">0</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTowYWE0NWJiYWRiODQ0ZTNhYWUwYmVlOTVhODEyNWMyYS90YWJsZXJhbmdlOjBhYTQ1YmJhZGI4NDRlM2FhZTBiZWU5NWE4MTI1YzJhXzctNC0xLTEtNTkxMjc_952eb9ce-0830-4c74-853b-c3071f5facd5"
      unitRef="usd">0</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTowYWE0NWJiYWRiODQ0ZTNhYWUwYmVlOTVhODEyNWMyYS90YWJsZXJhbmdlOjBhYTQ1YmJhZGI4NDRlM2FhZTBiZWU5NWE4MTI1YzJhXzgtMi0xLTEtNTkxMjc_9e9d8051-101a-4649-887b-d83045b49e37"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTowYWE0NWJiYWRiODQ0ZTNhYWUwYmVlOTVhODEyNWMyYS90YWJsZXJhbmdlOjBhYTQ1YmJhZGI4NDRlM2FhZTBiZWU5NWE4MTI1YzJhXzgtNC0xLTEtNTkxMjc_e95caeaa-7062-4fe8-b52c-1fa13b494226"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTowYWE0NWJiYWRiODQ0ZTNhYWUwYmVlOTVhODEyNWMyYS90YWJsZXJhbmdlOjBhYTQ1YmJhZGI4NDRlM2FhZTBiZWU5NWE4MTI1YzJhXzktMi0xLTEtNTkxMjc_072754a3-0499-4837-934a-2a67e26b3c3b"
      unitRef="usd">253000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTowYWE0NWJiYWRiODQ0ZTNhYWUwYmVlOTVhODEyNWMyYS90YWJsZXJhbmdlOjBhYTQ1YmJhZGI4NDRlM2FhZTBiZWU5NWE4MTI1YzJhXzktNC0xLTEtNTkxMjc_daef3212-96de-4610-8505-b6045ecad0b2"
      unitRef="usd">-18000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90ZXh0cmVnaW9uOjc1MmU0YmUxMzczODQ3ODFhN2FlYzRhNTM5ZDk5NDI1XzE4NDg_a4efea69-96ad-430f-8c06-8260275cfb9a">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;A reconciliation of the U.K. statutory income tax rate to our effective income tax rate is as follows (in percentages):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.K. tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development incentive&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in deferred tax valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Effective income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTo4NTgzMWRmOTMyZGQ0M2ZmYTBlYWU1ZDRkMTg4YTM0MS90YWJsZXJhbmdlOjg1ODMxZGY5MzJkZDQzZmZhMGVhZTVkNGQxODhhMzQxXzItMi0xLTEtNTkxMjc_a32520ae-1443-465c-96fc-93b8b108dbe9"
      unitRef="number">0.190</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTo4NTgzMWRmOTMyZGQ0M2ZmYTBlYWU1ZDRkMTg4YTM0MS90YWJsZXJhbmdlOjg1ODMxZGY5MzJkZDQzZmZhMGVhZTVkNGQxODhhMzQxXzItNC0xLTEtNTkxMjc_cb03f2d6-7196-4564-93c1-3baef198845f"
      unitRef="number">0.190</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTo4NTgzMWRmOTMyZGQ0M2ZmYTBlYWU1ZDRkMTg4YTM0MS90YWJsZXJhbmdlOjg1ODMxZGY5MzJkZDQzZmZhMGVhZTVkNGQxODhhMzQxXzMtMi0xLTEtNTkxMjc_9cc21f68-91c0-4ac0-8545-28f1bdae00a4"
      unitRef="number">-0.018</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTo4NTgzMWRmOTMyZGQ0M2ZmYTBlYWU1ZDRkMTg4YTM0MS90YWJsZXJhbmdlOjg1ODMxZGY5MzJkZDQzZmZhMGVhZTVkNGQxODhhMzQxXzMtNC0xLTEtNTkxMjc_299ecfd7-db0c-43dd-be14-e677514899c4"
      unitRef="number">-0.075</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTo4NTgzMWRmOTMyZGQ0M2ZmYTBlYWU1ZDRkMTg4YTM0MS90YWJsZXJhbmdlOjg1ODMxZGY5MzJkZDQzZmZhMGVhZTVkNGQxODhhMzQxXzQtMi0xLTEtNTkxMjc_d64e7694-85db-416a-9caf-abf4930c45d6"
      unitRef="number">0.080</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTo4NTgzMWRmOTMyZGQ0M2ZmYTBlYWU1ZDRkMTg4YTM0MS90YWJsZXJhbmdlOjg1ODMxZGY5MzJkZDQzZmZhMGVhZTVkNGQxODhhMzQxXzQtNC0xLTEtNTkxMjc_b6d768d6-8d8f-4132-bf33-a5384295ea86"
      unitRef="number">0.109</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTo4NTgzMWRmOTMyZGQ0M2ZmYTBlYWU1ZDRkMTg4YTM0MS90YWJsZXJhbmdlOjg1ODMxZGY5MzJkZDQzZmZhMGVhZTVkNGQxODhhMzQxXzUtMi0xLTEtNTkxMjc_1286b7cc-3af7-4284-ba54-72076105a6c5"
      unitRef="number">0.021</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTo4NTgzMWRmOTMyZGQ0M2ZmYTBlYWU1ZDRkMTg4YTM0MS90YWJsZXJhbmdlOjg1ODMxZGY5MzJkZDQzZmZhMGVhZTVkNGQxODhhMzQxXzUtNC0xLTEtNTkxMjc_f9eeca54-2738-4ea7-8bb6-e260426075a1"
      unitRef="number">0.026</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTo4NTgzMWRmOTMyZGQ0M2ZmYTBlYWU1ZDRkMTg4YTM0MS90YWJsZXJhbmdlOjg1ODMxZGY5MzJkZDQzZmZhMGVhZTVkNGQxODhhMzQxXzYtMi0xLTEtNTkxMjc_50d42c29-fa81-471f-9e61-48cca6ef4822"
      unitRef="number">-0.116</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTo4NTgzMWRmOTMyZGQ0M2ZmYTBlYWU1ZDRkMTg4YTM0MS90YWJsZXJhbmdlOjg1ODMxZGY5MzJkZDQzZmZhMGVhZTVkNGQxODhhMzQxXzYtNC0xLTEtNTkxMjc_28c65552-6145-4342-8841-108568da3767"
      unitRef="number">-0.030</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <vrna:EffectiveIncomeTaxRateReconciliationCapitalAllowancesPercent
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTo4NTgzMWRmOTMyZGQ0M2ZmYTBlYWU1ZDRkMTg4YTM0MS90YWJsZXJhbmdlOjg1ODMxZGY5MzJkZDQzZmZhMGVhZTVkNGQxODhhMzQxXzctMi0xLTEtNTkxMjc_2a8d405d-cce9-42ae-910d-28fcaf0dc733"
      unitRef="number">-0.001</vrna:EffectiveIncomeTaxRateReconciliationCapitalAllowancesPercent>
    <vrna:EffectiveIncomeTaxRateReconciliationCapitalAllowancesPercent
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTo4NTgzMWRmOTMyZGQ0M2ZmYTBlYWU1ZDRkMTg4YTM0MS90YWJsZXJhbmdlOjg1ODMxZGY5MzJkZDQzZmZhMGVhZTVkNGQxODhhMzQxXzctNC0xLTEtNTkxMjc_145a3c29-8fb7-4cc3-8869-cc56c98e27ce"
      unitRef="number">-0.001</vrna:EffectiveIncomeTaxRateReconciliationCapitalAllowancesPercent>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTo4NTgzMWRmOTMyZGQ0M2ZmYTBlYWU1ZDRkMTg4YTM0MS90YWJsZXJhbmdlOjg1ODMxZGY5MzJkZDQzZmZhMGVhZTVkNGQxODhhMzQxXzgtMi0xLTEtNTkxMjc_88057f7b-b1e4-4b08-af2e-6489e268ad34"
      unitRef="number">-0.004</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTo4NTgzMWRmOTMyZGQ0M2ZmYTBlYWU1ZDRkMTg4YTM0MS90YWJsZXJhbmdlOjg1ODMxZGY5MzJkZDQzZmZhMGVhZTVkNGQxODhhMzQxXzgtNC0xLTEtNTkxMjc_14d8d0d2-6c5d-48ea-be13-023937f343cf"
      unitRef="number">0.001</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90ZXh0cmVnaW9uOjc1MmU0YmUxMzczODQ3ODFhN2FlYzRhNTM5ZDk5NDI1XzE4NDk_44351669-6012-446d-845f-15d194832312">omponents of the Company&#x2019;s deferred tax assets and liabilities are as follows (in thousands):&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,903)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,903)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D asset&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Future exercisable shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(516)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48,476)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,252)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Movements in the deferred tax valuation allowance &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation allowance at January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in tax rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase/(decrease) in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,422)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation allowance at December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;These relate to the difference in the tax base of the IP R&amp;amp;D asset and assumed contingent liability and the financial reporting base, which is nil under U.S. GAAP.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <vrna:DeferredTaxLiabilitiesContingentLiability
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzMtMi0xLTEtNTkxMjc_a705910a-9bac-49ab-a86f-e0b088e001fb"
      unitRef="usd">34565000</vrna:DeferredTaxLiabilitiesContingentLiability>
    <vrna:DeferredTaxLiabilitiesContingentLiability
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzMtNC0xLTEtNTkxMjc_d8317946-a78f-4f84-9783-02b25e98fc4d"
      unitRef="usd">8903000</vrna:DeferredTaxLiabilitiesContingentLiability>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzUtMi0xLTEtNTkxMjc_72c68c47-0a07-43ba-97e8-a9f06229bc0d"
      unitRef="usd">34565000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzUtNC0xLTEtNTkxMjc_698ef4b9-d9ad-4233-974f-5f56873e4ba5"
      unitRef="usd">8903000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzgtMi0xLTEtNTkxMjc_2321cc48-236c-40f7-ad27-0ef6dacdf427"
      unitRef="usd">38893000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzgtNC0xLTEtNTkxMjc_773ed204-ff16-44fa-8888-d083d16efa7c"
      unitRef="usd">26931000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzktMi0xLTEtNTkxMjc_72b54460-eee5-40f9-b932-8f794d0e797d"
      unitRef="usd">32700000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzktNC0xLTEtNTkxMjc_3a65d071-4601-424d-a3ed-62f4be6c761c"
      unitRef="usd">7992000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzEwLTItMS0xLTU5MTI3_53ad51b3-c57d-4d61-bc31-3764e66afc9b"
      unitRef="usd">11964000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzEwLTQtMS0xLTU5MTI3_d406205f-13e6-4e7c-947d-5c69978164c5"
      unitRef="usd">4228000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzExLTItMS0xLTU5MTI3_e8ee61be-b6d5-4078-bcff-fca3dc32cf4e"
      unitRef="usd">-516000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzExLTQtMS0xLTU5MTI3_9fd120a0-0a88-4ad1-95a2-6389952609dd"
      unitRef="usd">4000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzEyLTItMS0xLTU5MTI3_4b202e11-0975-41d4-a171-3df48280397a"
      unitRef="usd">83041000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzEyLTQtMS0xLTU5MTI3_4eb73552-1873-45b5-a143-c70b88e42d2f"
      unitRef="usd">39155000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzEzLTItMS0xLTU5MTI3_b340798d-5c9d-4e9c-95c2-ee8773e3ccf8"
      unitRef="usd">48476000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzEzLTQtMS0xLTU5MTI3_5150fd4e-d992-42c3-9268-4f786595819c"
      unitRef="usd">30252000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzE0LTItMS0xLTU5MTI3_fb5c7804-d7b1-4eb7-806e-7e26e7492faa"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzE0LTQtMS0xLTU5MTI3_5290556f-a39d-4ae9-a459-cc81ca9e8926"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="id9240e12e8374554928914a1dfb017fb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzE4LTItMS0xLTU5MTI3_725960e5-e5bc-48e1-b840-ee2f1addd49f"
      unitRef="usd">30252000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i6c61487d635a4696b64cde5303229764_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzE4LTQtMS0xLTU5MTI3_a596d6cb-b02f-45c0-a4ab-f08276044555"
      unitRef="usd">30321000</us-gaap:ValuationAllowancesAndReservesBalance>
    <vrna:SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates
      contextRef="i0a63b0b903ee4acab0480335043b47f5_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzE5LTItMS0xLTU5MTI3_db590d5b-4f15-43b7-be91-dfb43e996181"
      unitRef="usd">0</vrna:SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates>
    <vrna:SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates
      contextRef="i709ea29e7e7249da99a23ab89c643290_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzE5LTQtMS0xLTU5MTI3_eb1d1117-50ed-426a-bc9a-5cd01ab751ab"
      unitRef="usd">7353000</vrna:SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates>
    <vrna:SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance
      contextRef="i0a63b0b903ee4acab0480335043b47f5_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzIwLTItMS0xLTU5MTI3_929b90b5-dd4d-4b78-b644-b6a3e4753ac9"
      unitRef="usd">18224000</vrna:SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance>
    <vrna:SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance
      contextRef="i709ea29e7e7249da99a23ab89c643290_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzIwLTQtMS0xLTU5MTI3_e52d14e4-a049-4862-89c6-4c4e25bc71f7"
      unitRef="usd">-7422000</vrna:SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ic1b945830df8444a9ed8c6acd123c8b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzIyLTItMS0xLTU5MTI3_8ebf6627-0612-4d1b-86a4-06ca0994e03a"
      unitRef="usd">48476000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="id9240e12e8374554928914a1dfb017fb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90YWJsZTpjYjQ5YjY3OTI2OWM0MmUxOWFmNmNlMjllMTgxMjUzMi90YWJsZXJhbmdlOmNiNDliNjc5MjY5YzQyZTE5YWY2Y2UyOWUxODEyNTMyXzIyLTQtMS0xLTU5MTI3_691747d5-5fde-44ba-9a7f-09abd4140c20"
      unitRef="usd">30252000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90ZXh0cmVnaW9uOjc1MmU0YmUxMzczODQ3ODFhN2FlYzRhNTM5ZDk5NDI1XzExNDI_e9e8e664-f138-4d3b-ab59-19f0f3bbb7b5"
      unitRef="usd">155600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90ZXh0cmVnaW9uOjc1MmU0YmUxMzczODQ3ODFhN2FlYzRhNTM5ZDk5NDI1XzM4NDgyOTA3MDI3ODI_795be1a7-f3b4-4d50-bea5-9c7dd1f70176"
      unitRef="usd">104300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:IncomeTaxExaminationPenaltiesAccrued
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90ZXh0cmVnaW9uOjc1MmU0YmUxMzczODQ3ODFhN2FlYzRhNTM5ZDk5NDI1XzE2NjA_2f534f47-73df-4f5b-9031-d46ceaeb575f"
      unitRef="usd">0</us-gaap:IncomeTaxExaminationPenaltiesAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90ZXh0cmVnaW9uOjc1MmU0YmUxMzczODQ3ODFhN2FlYzRhNTM5ZDk5NDI1XzE2NjA_5bca1714-bb34-49eb-9415-e488a48feeaa"
      unitRef="usd">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:IncomeTaxExaminationPenaltiesAccrued
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90ZXh0cmVnaW9uOjc1MmU0YmUxMzczODQ3ODFhN2FlYzRhNTM5ZDk5NDI1XzE2NjA_5f6e1f60-5940-43a8-9f58-f918dfa6c637"
      unitRef="usd">0</us-gaap:IncomeTaxExaminationPenaltiesAccrued>
    <us-gaap:IncomeTaxExaminationInterestAccrued
      contextRef="id40f0f069eba45cba259ca5e4029e3c6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90ZXh0cmVnaW9uOjc1MmU0YmUxMzczODQ3ODFhN2FlYzRhNTM5ZDk5NDI1XzE2NjA_a58e6c3c-7c90-4618-bb89-af4628c24c74"
      unitRef="usd">0</us-gaap:IncomeTaxExaminationInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90ZXh0cmVnaW9uOjc1MmU0YmUxMzczODQ3ODFhN2FlYzRhNTM5ZDk5NDI1XzE2NjA_c214cc1e-765c-4616-9260-5ff0ecd14c2f"
      unitRef="usd">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:IncomeTaxExaminationInterestAccrued
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNDUvZnJhZzo3NTJlNGJlMTM3Mzg0NzgxYTdhZWM0YTUzOWQ5OTQyNS90ZXh0cmVnaW9uOjc1MmU0YmUxMzczODQ3ODFhN2FlYzRhNTM5ZDk5NDI1XzE2NjA_d00377b1-25cf-42f6-9552-998b04ea129f"
      unitRef="usd">0</us-gaap:IncomeTaxExaminationInterestAccrued>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNTEvZnJhZzo1MDgwNTRmOGYwYjM0MzQ1OGI1NmQwMjNiNjlhMzIxMy90ZXh0cmVnaW9uOjUwODA1NGY4ZjBiMzQzNDU4YjU2ZDAyM2I2OWEzMjEzXzU5MQ_4a08edb3-f552-4450-b2d4-1fbc792f6b5c">Net loss per share &lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;Net loss per share is calculated on an ordinary share basis. The Company&#x2019;s ADSs that are listed on the Nasdaq Global Market each represent eight ordinary shares. The following table shows the computation of basic and diluted earnings per share for 2022 and 2021 (net loss in thousands, loss per share in dollars):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68,701)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55,569)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss available to ordinary shareholders - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68,701)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55,569)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529,071,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473,188,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net loss per share - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.13)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;During the years ended December 31, 2022 and 2021, outstanding share options, RSUs and warrants of 53,818,840 and 63,443,814, respectively, were not included in the computation of diluted earnings per ordinary share, because to do so would be antidilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <dei:EntityListingDepositoryReceiptRatio
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNTEvZnJhZzo1MDgwNTRmOGYwYjM0MzQ1OGI1NmQwMjNiNjlhMzIxMy90ZXh0cmVnaW9uOjUwODA1NGY4ZjBiMzQzNDU4YjU2ZDAyM2I2OWEzMjEzXzI0NzM5MDExNjI1NjU5_9b78198f-0421-4e68-a170-d3def61ffcdf"
      unitRef="rate">8</dei:EntityListingDepositoryReceiptRatio>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNTEvZnJhZzo1MDgwNTRmOGYwYjM0MzQ1OGI1NmQwMjNiNjlhMzIxMy90ZXh0cmVnaW9uOjUwODA1NGY4ZjBiMzQzNDU4YjU2ZDAyM2I2OWEzMjEzXzU5Mg_f4d9611a-5472-4e52-8dad-07b5b64aef93">The following table shows the computation of basic and diluted earnings per share for 2022 and 2021 (net loss in thousands, loss per share in dollars):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68,701)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55,569)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss available to ordinary shareholders - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68,701)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55,569)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529,071,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473,188,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net loss per share - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.13)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNTEvZnJhZzo1MDgwNTRmOGYwYjM0MzQ1OGI1NmQwMjNiNjlhMzIxMy90YWJsZTpiMmQwM2UxNmU5MjQ0MDJiOTcxODljYjBhNGY0YjcwZC90YWJsZXJhbmdlOmIyZDAzZTE2ZTkyNDQwMmI5NzE4OWNiMGE0ZjRiNzBkXzMtMi0xLTEtNTkxMjc_a11c1af4-0489-4f88-b9b6-21f67f2fa074"
      unitRef="usd">-68701000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNTEvZnJhZzo1MDgwNTRmOGYwYjM0MzQ1OGI1NmQwMjNiNjlhMzIxMy90YWJsZTpiMmQwM2UxNmU5MjQ0MDJiOTcxODljYjBhNGY0YjcwZC90YWJsZXJhbmdlOmIyZDAzZTE2ZTkyNDQwMmI5NzE4OWNiMGE0ZjRiNzBkXzMtNC0xLTEtNTkxMjc_2880f779-4707-45c6-88b9-a5077f13da4a"
      unitRef="usd">-55569000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNTEvZnJhZzo1MDgwNTRmOGYwYjM0MzQ1OGI1NmQwMjNiNjlhMzIxMy90YWJsZTpiMmQwM2UxNmU5MjQ0MDJiOTcxODljYjBhNGY0YjcwZC90YWJsZXJhbmdlOmIyZDAzZTE2ZTkyNDQwMmI5NzE4OWNiMGE0ZjRiNzBkXzQtMi0xLTEtNTkxMjc_2835996a-5d87-489e-95ab-9c6f05792fc3"
      unitRef="usd">-68701000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNTEvZnJhZzo1MDgwNTRmOGYwYjM0MzQ1OGI1NmQwMjNiNjlhMzIxMy90YWJsZTpiMmQwM2UxNmU5MjQ0MDJiOTcxODljYjBhNGY0YjcwZC90YWJsZXJhbmdlOmIyZDAzZTE2ZTkyNDQwMmI5NzE4OWNiMGE0ZjRiNzBkXzQtMi0xLTEtNTkxMjc_c9c4110d-ae83-4712-b8f4-0c9d55bfc6da"
      unitRef="usd">-68701000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNTEvZnJhZzo1MDgwNTRmOGYwYjM0MzQ1OGI1NmQwMjNiNjlhMzIxMy90YWJsZTpiMmQwM2UxNmU5MjQ0MDJiOTcxODljYjBhNGY0YjcwZC90YWJsZXJhbmdlOmIyZDAzZTE2ZTkyNDQwMmI5NzE4OWNiMGE0ZjRiNzBkXzQtNC0xLTEtNTkxMjc_23c0bdf5-f9b6-466a-a002-d6085ea2c60d"
      unitRef="usd">-55569000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNTEvZnJhZzo1MDgwNTRmOGYwYjM0MzQ1OGI1NmQwMjNiNjlhMzIxMy90YWJsZTpiMmQwM2UxNmU5MjQ0MDJiOTcxODljYjBhNGY0YjcwZC90YWJsZXJhbmdlOmIyZDAzZTE2ZTkyNDQwMmI5NzE4OWNiMGE0ZjRiNzBkXzQtNC0xLTEtNTkxMjc_8e454b6e-d57a-4021-afb5-b488040896d2"
      unitRef="usd">-55569000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNTEvZnJhZzo1MDgwNTRmOGYwYjM0MzQ1OGI1NmQwMjNiNjlhMzIxMy90YWJsZTpiMmQwM2UxNmU5MjQ0MDJiOTcxODljYjBhNGY0YjcwZC90YWJsZXJhbmdlOmIyZDAzZTE2ZTkyNDQwMmI5NzE4OWNiMGE0ZjRiNzBkXzYtMi0xLTEtNTkxMjc_6a5d22a0-0456-4d4a-b582-33c00dccdf49"
      unitRef="shares">529071526</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNTEvZnJhZzo1MDgwNTRmOGYwYjM0MzQ1OGI1NmQwMjNiNjlhMzIxMy90YWJsZTpiMmQwM2UxNmU5MjQ0MDJiOTcxODljYjBhNGY0YjcwZC90YWJsZXJhbmdlOmIyZDAzZTE2ZTkyNDQwMmI5NzE4OWNiMGE0ZjRiNzBkXzYtMi0xLTEtNTkxMjc_dc4fc896-cb58-45be-a3f7-cb5fc6b6a4b9"
      unitRef="shares">529071526</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNTEvZnJhZzo1MDgwNTRmOGYwYjM0MzQ1OGI1NmQwMjNiNjlhMzIxMy90YWJsZTpiMmQwM2UxNmU5MjQ0MDJiOTcxODljYjBhNGY0YjcwZC90YWJsZXJhbmdlOmIyZDAzZTE2ZTkyNDQwMmI5NzE4OWNiMGE0ZjRiNzBkXzYtNC0xLTEtNTkxMjc_99d91f01-2053-4d8f-a781-b966cb4b3d30"
      unitRef="shares">473188457</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNTEvZnJhZzo1MDgwNTRmOGYwYjM0MzQ1OGI1NmQwMjNiNjlhMzIxMy90YWJsZTpiMmQwM2UxNmU5MjQ0MDJiOTcxODljYjBhNGY0YjcwZC90YWJsZXJhbmdlOmIyZDAzZTE2ZTkyNDQwMmI5NzE4OWNiMGE0ZjRiNzBkXzYtNC0xLTEtNTkxMjc_cd1ebf1d-0171-4853-b3c2-fa3a0ebb3bef"
      unitRef="shares">473188457</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNTEvZnJhZzo1MDgwNTRmOGYwYjM0MzQ1OGI1NmQwMjNiNjlhMzIxMy90YWJsZTpiMmQwM2UxNmU5MjQ0MDJiOTcxODljYjBhNGY0YjcwZC90YWJsZXJhbmdlOmIyZDAzZTE2ZTkyNDQwMmI5NzE4OWNiMGE0ZjRiNzBkXzctMi0xLTEtNTkxMjc_0a7e9201-6ec0-4172-91fa-89b900474441"
      unitRef="usdPerShare">-0.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNTEvZnJhZzo1MDgwNTRmOGYwYjM0MzQ1OGI1NmQwMjNiNjlhMzIxMy90YWJsZTpiMmQwM2UxNmU5MjQ0MDJiOTcxODljYjBhNGY0YjcwZC90YWJsZXJhbmdlOmIyZDAzZTE2ZTkyNDQwMmI5NzE4OWNiMGE0ZjRiNzBkXzctMi0xLTEtNTkxMjc_36ba8915-9bcf-47d3-a672-087b4ae9afb2"
      unitRef="usdPerShare">-0.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNTEvZnJhZzo1MDgwNTRmOGYwYjM0MzQ1OGI1NmQwMjNiNjlhMzIxMy90YWJsZTpiMmQwM2UxNmU5MjQ0MDJiOTcxODljYjBhNGY0YjcwZC90YWJsZXJhbmdlOmIyZDAzZTE2ZTkyNDQwMmI5NzE4OWNiMGE0ZjRiNzBkXzctNC0xLTEtNTkxMjc_6a5f1077-3559-4095-896a-c60a37b100f5"
      unitRef="usdPerShare">-0.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNTEvZnJhZzo1MDgwNTRmOGYwYjM0MzQ1OGI1NmQwMjNiNjlhMzIxMy90YWJsZTpiMmQwM2UxNmU5MjQ0MDJiOTcxODljYjBhNGY0YjcwZC90YWJsZXJhbmdlOmIyZDAzZTE2ZTkyNDQwMmI5NzE4OWNiMGE0ZjRiNzBkXzctNC0xLTEtNTkxMjc_e0a11042-d08d-4522-949a-20dd118a311c"
      unitRef="usdPerShare">-0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNTEvZnJhZzo1MDgwNTRmOGYwYjM0MzQ1OGI1NmQwMjNiNjlhMzIxMy90ZXh0cmVnaW9uOjUwODA1NGY4ZjBiMzQzNDU4YjU2ZDAyM2I2OWEzMjEzXzM4NDgyOTA2OTc4NTg_6dd2216b-5e1b-4faa-8ee3-cee0b45a616d"
      unitRef="shares">53818840</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if34cf15b770f40d7b36c8fcd3c9c63ca_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNTEvZnJhZzo1MDgwNTRmOGYwYjM0MzQ1OGI1NmQwMjNiNjlhMzIxMy90ZXh0cmVnaW9uOjUwODA1NGY4ZjBiMzQzNDU4YjU2ZDAyM2I2OWEzMjEzXzM4NDgyOTA2OTc4NjI_db6b3adf-586e-4ec7-a9da-9b1733147152"
      unitRef="shares">63443814</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNTcvZnJhZzo4N2Q5YjM5ZDhiZTM0ZjdkYmY4ZjY5YjYyNzZlY2I4NS90ZXh0cmVnaW9uOjg3ZDliMzlkOGJlMzRmN2RiZjhmNjliNjI3NmVjYjg1XzI0NzM5MDExNjI3MTc0_bc4e10e2-99d4-4f6a-be8b-9f3ea0f8c1d2">Commitments and contingenciesManagement is currently negotiating a matter with a supplier that has an estimated exposure of approximately $1.5&#160;million. Management does not currently consider it probable that a payment will be made and therefore no accrual is recorded at December 31, 2022. This matter is expected to be resolved within the next 12 months.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNTcvZnJhZzo4N2Q5YjM5ZDhiZTM0ZjdkYmY4ZjY5YjYyNzZlY2I4NS90ZXh0cmVnaW9uOjg3ZDliMzlkOGJlMzRmN2RiZjhmNjliNjI3NmVjYjg1XzIxOTkwMjMyNTY4MzE_608be0c0-c174-4a53-acda-94134e9a612b"
      unitRef="usd">1500000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i46f03490e9ee4cdfbbb33910795928d1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl8xNTcvZnJhZzo4N2Q5YjM5ZDhiZTM0ZjdkYmY4ZjY5YjYyNzZlY2I4NS90ZXh0cmVnaW9uOjg3ZDliMzlkOGJlMzRmN2RiZjhmNjliNjI3NmVjYjg1XzI0NzM5MDExNjI3MTc1_f384b627-9498-42b9-b9c6-b73c17bad2a1"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i5aed7afbd4034009bb514762c617a15a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM4NTU1YjBhMGU1NzRjZGNiNTQyOGEwMDQ0N2ZlMzIyL3NlYzpjODU1NWIwYTBlNTc0Y2RjYjU0MjhhMDA0NDdmZTMyMl80NDAvZnJhZzpiZjBlYjlmMzdiZmE0N2Y2OTZlYzZkNTkxNjY2MTE0Mi90ZXh0cmVnaW9uOmJmMGViOWYzN2JmYTQ3ZjY5NmVjNmQ1OTE2NjYxMTQyXzI0NzM5MDExNjI1MjUz_22c150d7-7cbd-4624-b5f5-ca64ace21360">Related party transactions and other shareholder mattersIn the years ended December 31, 2022 and 2021 there were no related party transactions.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>81
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MJ2]PI59]45H: VS/YS_'"NP37R ??S__ <UHF GH929D!Y0^B2AF!$:P!&]
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MK>QAK8F]AHD*2A,5V,W/2V*;6K5Z9G:YFZ]&8DZ-DRNU*K'2. 6-C-,8H D
M-F$1?4*_4G.*9I?R/,\_.3X-?',_<^J@7*D5U'I[A>#:%.4%]1*>'AE314WX
M[NBN:'^4EZKWRM.+BO];HCV51 E=0*AW= I3B"B*Z(L=Q==Y6?F<*\73?'-%
M"3QB] GP_8)SM=W1%]C]*\/P/U!+ P04    " #D16=6@)=)/#\"  #%!0
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MPU"0D 0>8#VFP8%IX&5Z(]F&\ARP)Y.C%',2W'F(N@2#-!W0&X,"2&(WN?!
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MO@Y0D$PP;I4+^:7+U&7,/^=C)<+)4*T<(!1,[$/<ZA7VZU6_&#LRAGBL32B
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MNQL+J#MUZDZUHV97!),@S?W=H?$7BAX82@9#R1L,,:VWV/G63=<YHV([QNQ
M1Q:'<3R-DNR1XJ>5R?0L/#U-TV!<=CK(3M\@&^>Q-E14-O47M*=/M0=9'(1!
MFCS2_K0RF0;!-#K+LD?:_8.!8X?])ZHV3&C"88W88'**5*H;H-W&R-;-H)4T
M.-'<LL9O#BA;@,_74IK[C1UKPU>L^ -02P,$%     @ Y$5G5N#TP.(1!0
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M3$I6UI<9T!2X-E#O-XS)YQO=0'<DM_P74$L#!!0    ( .1%9U82J/7IE D
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MZ3WYB90-^;%66R.:PEQ.6L!@-4WR_>]]ZGZ/!7Z/,O*;:MJU(5^:0A;G"B8
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M ?C_2JGV<&%_X/@JS/+_4$L#!!0    ( .1%9U8L3HO14PD  -H7   8
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M*<3*'-%T'[E1GEOR$AYH<V/(YM"\,)%"SZKN/Y'Y$^946]>3W2(@_HF$9TU
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MP3?!;#*,)#E;3UV%$,QM*2+I2*#(L*0(<;QSU5_4X:0_-+9C(QC<414LNF*
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M\U$$IAL<W<'I-HAUK1U)/VQKFK5H? #Y2ZW=_N OZ*?W_#=02P,$%     @
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M _JCVDZH<J9DJ"Y<:TITLFDHO)ZRN(-&@XEH5_818B25>'33C1\?$WZ9CT_
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M^:?XXOSJ6!P1\"A;[<0?RC:RTN[0ZN.%^#W3%)FMK*,]27^HAU/SX[1_I0N
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M=RAIU(&XN05.<LD;O57Z3"_W_$\]_!** ZNR7F$AXJ]O$.!-A)O[BWF&6N5
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M6DU23G9V<TUY%\H8:)!253&-J\@2KI-&Q8!QT6.D+V D*7Q1TE8&/LD2R^<
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M9:,=WG@(K;7*/R[0T':6C;+#P:W>U!P/\OFT41N\0_[2W'C1\AZETA9=T.3
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M_$:[  ;7XCH<O#W+P'<[J5.8FK0'5L2R59)8RQI''PWD?DW$!R4&Z/\8YK\
M4$L#!!0    ( .1%9U;0@(>O-P(  ',%   9    >&PO=V]R:W-H965T<R]S
M:&5E=#(Q+GAM;+542V_;, S^*X(&[#3$CR1MD<4&DG;#>B@0M'L<AAT4FXF-
MZN%)3-W\^U&RXV5 DEVVBTU*Y,>/)#[-6V.?706 [%5)[3)>(3:S*')%!4JX
MD6E T\W&6"607+N-7&-!E"%)R2B-XZM(B5KS?![.5C:?FQW*6L/*,K=32MC]
M$J1I,Y[PP\%CO:W0'T3YO!%;> +\TJPL>=& 4M8*M*N-9A8V&5\DL^7$QX>
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M:CRZGG)F.XEW#IHFR&IMD$0:S(I>1; ^@.XWQN#!\06&=S;_!5!+ P04
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M B,&>$7U4W WN8/@;VENWN'U0Z<FMY3W6TMWYU$=9L?A@UR\=RVH\&F#9[K
ME-]?#F2BS>7/VB1R*<3(UOA+/!1I%I/<.=VHQ:)S9;F,/LEICK,J]BD!@U:N
MZ]C(40X%>^;D+FE,.Q[SYY@K*,=R*G0HF!$*/A"N7K[/?@< ,O+2E8=S4O;"
M.[;RQ0V>Q1+>XSW5U)PZGM:CU[F9#SV20% HX*.OCN52NG<2KB+)W0X<.E?_
MPH(&-PYC8./PL [1(.3LI6*(^8PWP[QA=SHN$^:+%9.RNT3G=2#</3"D X;O
ML2L&#B#RE=F:W]GX->J>B,1QR/8^AX),[6W(&#+#L4F]DK]=.6>A7*X]DL0S
MX>!9R$_M5\OS/5/O3<575R2&+3["YEHWB-P ;J$N')!+M<//L(T:A_^OQ3"W
M(Q^N6\AUNI^>7[\($Z'%(&NQ@. EN3MODH&\?,D6]&<VT&(\'BX?W[]\6UY$
M*U^$$QF=#S7"9A\^ -^RT94H?SCJ6.KF5&"Z\\L%3->XS2' -XYKS6V<<:;H
MNP3TN9:B5$4BW'-/TO%WL699<&6/O_X6#5U6^6/@E"Y4[NH+Q,?.XN3RB7>3
M5QOY"@'O,C;]-'8=\\!C\5LR#EF34?*N9I&&K'&-K:9@A(E7ND)M J,5< Q[
M3@/^ J10,@R$XKMQ<1$'XSL(,29$1EVJ2:&9J5>&/ME',(G$_,W4&SR(X)8L
M'MV?25"ML\'HKGRO7E,]%X.05_SQPNB_? Q$E3Z,&$-F*MIMH+ .1APA'EB#
MG=GX.0'*4*@.(ZN!KP[KW["HND<4P<[X7F\V)I:\3*2%GL>J-W61=/(QD2P#
M0_('.,M!%PF;-5$?I&<K0#AY-!PAQQGR]DCJ?8%IRIH?+Q1[7]Z_#$X?LK1F
MB<#V5+3F'%!ROEYV2D<=O+YBN0PGYNKGB0V2%:$$GVZ/N$..Z]IZE%?,O?KL
M6XR:.K=B&G;Q:";2EY:GZ-CN8M-YO(F"1YM/RY_F+#D<KN5*]PWE3NB.9^WB
M!:,"!\/'1$-C3)098 G?1Y$E SEW[&6YS+$JJ"A^19+21:RG,W5KN$I.!:'X
M@%T,!6=)"3+&ADS<4RZ8^!R\%.X_()+"-O$(BG-$_<AP6!QKC5T&[$L7'YS,
MOT\94GNQ,1M< _X,"+QX*4T7W/$</KT(<VE*@L Q(:M\MIW$OW#!DJO)N'6A
M'EP>P\D)9E\3[WT%=40K4<4;T1.'B]!Y4E8:RVOS-PS%D<W#SGQB0I08)67B
M'Z]"1*J^<-FY].%E!C[J8Y9 SY/G\I4>TMW4M!X&76)1#J=9P:&&%+UL2XX\
M;8F%6T,T3PDQ%BBYKI7;KNE-CM401BNX_*6&<+AC'MF#['O5.P.(@U_EIN\B
MMCU_NCK^&K_\_9R_=YU>Y\^&OP7 PB)D8]8P]&K^[:,+CD7#'[W;T]>O5Z[O
MW8[^B8UWIL,7X/G:N3[\@0O$[Z$_^U]02P,$%     @ Y$5G5AKB!C.H @
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M&ER,AA[H=E*T@E5UTYTK9:G7FV-)PQ6U4Z#W0BF[%YR#?ERGOP%02P,$%
M  @ Y$5G5FDLK\&: @  K@4  !D   !X;"]W;W)K<VAE971S+W-H965T,C0N
M>&UL?91M;],P$,>_RBE,:)/0DJ;M6DH;J=U (#%1;0->(%ZXR:6QYH=@.^OV
M[3D[:2A2US>)'^Y^]S_;=_.=-H^V0G3P+(6RBZARKI[%L<TKE,Q>ZAH5[93:
M2.9H:K:QK0VR(CA)$:=)<A5+QE64S</:VF1SW3C!%:X-V$9*9EY6*/1N$0VB
M_<(=WU;.+\39O&9;O$?WO5X;FL4]I> 2E>5:@<%R$2T'L]7(VP>#'QQW]F ,
M/I.-UH]^\J581(D7A )SYPF,?D]XC4)X$,GXTS&C/J1W/!SOZ9]"[I3+AEF\
MUN(G+URUB*81%%BR1K@[O?N,73YCS\NUL.$+N]9VE$20-]9IV3F3 LE5^V?/
MW3D<.$Q?<T@[AS3H;@,%E3?,L6QN] Z,MR::'X14@S>)X\I?RKTSM,O)SV5K
M0_=KW L(I-PLG#^PC4![,8\=T;U-G'>D54M*7R$-4KC5RE46/JH"B_\!,<GJ
MM:5[;:OT)/$&\TL8#MY!FJ3I"=ZPSW48>,-7>%_;%'\M-]89>@Z_CR79(D;'
M$;Y$9K9F.2XBJ@&+Y@FC[.V;P57RX83 42]P=(J>W7+%92-AJ53#!'RCFV&.
MJRT$Y;!F+U0.SAZ3?1)\7/8^&FNCU1T=]!,:<!52S?FJ]O'#XP"2PW5A@9%-
M"70[*#=DNK\A8 ;]7JD%E3H]):X(HQO+5&$O9MYF"&=P-1G[X0C201B,83"!
M!^U(@NP4E8UKB-5%W>LZ@_?)A(["VAEP63<."^#*(27DX#R=7'04W1];"Q"<
M;;C@CJ-G3*<)'+NJ^*"&))IMZ!06<MTHUY93O]HWHV5;@__,VTYVR\R6*TOA
M2W)-+B?C"$S;'=J)TW6HR(UV5-]A6%%#1>,-:+_4VNTG/D#?HK._4$L#!!0
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M6-#[B=HYD'VEE-U-W ;=BSS[!5!+ P04    " #D16=6F20ERCH%   7#@
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M!BI1RNT];>I588J).-)@V X3U[,JON?.S.1V;>I<5"8$BJ")*U=4$8'KT]_
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M<T-I!.C_4@B]>S$&VKO@_&]02P,$%     @ Y$5G5KA*MA-@!@  .1   !D
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M\'$+N+#PFZB7V*:@Y1/&/<1XQBQ).077BP)(O1!^QJI!: *6C!+F^S[X'J[
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M4M\?@&XOJNW$-@MW.9PT%J^:;CC'N[W4M "_3YO&;B9DH/MOP=4_4$L#!!0
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MEAE^'T!9![1OI#2'C4W0?''F_P!02P,$%     @ Y$5G5F<1+3X*#   "I\
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M12C54'+F*NVF.<R-:I<6E4O!&9?\ *TX4YE$O[ 8XC: J_DU)(,#R470B_@
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M<N*<.U#@DJR9NN7;+]CYB0U?SIFT7]BVL>.Q _E:*EYU8*V@HG7[)T]='78
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M9:E=\,,I-72HG0%]'RME'R=N@ZI%3'\#4$L#!!0    ( .1%9U91P-9,?P(
M &@&   9    >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;(U56V^;,!3^*Q:K
MIE9:"R$AL(P@M8VF3FJEJ)?M8=J# R>)58.9?4C:?[]CH"A;2+H7\.V['/OX
M.-XJ_6S6 ,A><EF8J;-&+">N:](UY-Q<J!(*FEDJG7.DKEZYIM3 LQJ42]?W
MO+&;<U$X25R/S742JPJE*&"NF:GRG.O7*Y!J.W4&SMO O5BMT0ZX25SR%3P
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MK,@FE9_8[D^H%^1J7L1247ZB735VXAHHV@C)LMI8S2"C>?5-7FLAC@QL?,;
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MC:(DK!B709;ZM;G.4M58P27,-3%-53']-@6AMN,@#O8+#WQ=6K<09FG-UK
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M4!I#T=0,RR*"@YT!X$"K!E :A=(8BJ8F1E8-'/T, '.YF_3*G>U,NWH'K0A
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M!C6H2Q>*5@IA[CW 5@$-BC<'!"IV$N6S[/K7^NV$J^*9O+EK7K[:<(=Y0)E
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M2J'M3+\M[>P$[0+L^5HIW!LN03^-L]]02P,$%     @ Y$5G5NO9-0R> @
MV08  !D   !X;"]W;W)K<VAE971S+W-H965T-#(N>&ULK55=;]HP%/TK5E9-
MK;0VWP%U(5*!3:NV2E5IMX=I#R:Y$*N.S6P'NG\_VPD9T(#ZL!=B7]]S[CF7
M^";=</$L2P"%7BK*Y,@IE5I=NZ[,2ZBPO.(K8/IDP46%E=Z*I2M7 G!A015U
M \]+W H3YF2IC=V++.6UHH3!O4"RKBHL_HR!\LW(\9UMX($L2V4";I:N\!)F
MH)Y6]T+OW(ZE(!4P23A# A8CY\:_GB0FWR9\)["1.VMDG,PY?S:;VV+D>$80
M4,B58<#ZL88)4&J(M(S?+:?3E33 W?66_;/UKKW,L80)IS](H<J1,W10 0M<
M4_7 -U^@]1,;OIQ3:7_1ILE- @?EM52\:L%:0458\\0O;1]V 'YR!!"T@. 0
M$!T!A"T@M$8;9=;6%"N<I8)OD##9FLTL;&\L6KLAS/R+,R7T*=$XE3WB%VS[
M>8F^<2G1&/2; 4B'T?D4%"947NBSI]D4G9]=H#-$&'HL>2TQ*V3J*BW!$+EY
M6V[<E N.E/,#=,>9*B7ZQ HH]@E<K;TS$&P-C(.3C%/(KU#H?T"!%P0]@B9O
MA_LGY(1=/T/+%Q[ANV4YKYK^38G,*9>U;N?/F[E40K^RO_I:UC!&_8SF&E_+
M%<YAY.A[*D&LP<G>O_,3[V.?W?]$MF<^ZLQ'I]BS)T84%&BFL(+>EZ.!#RS<
MS)=U=AD.DV'JKG<M]&1%P]CKLO:TQ9VV^"W:OA*V+'C5)Z[!)SME!T'H)P?B
M7F<E7A0.^L4EG;CDI+A'KC#MTY2\:D4RC*+#AKW.BN-X>*C)W9D2%8BE'9X2
MY;QFJKEO7;2;SS=V+!W$QWIN-V/V'TTS].^P6!(F$86%IO2N!KI;HAFDS4;Q
ME9U%<Z[T9+/+4G][0)@$?;[@7&TWID#W-<O^ E!+ P04    " #D16=68?[
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M9&0-+13# N>I?&";;U :ZFN^B*7"_*)-$>NKX"@7DF4E6"G(""W^\;9,Q![
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MI,J0-_US,Y!L7;>@"R950UL_ID 3X-I O5\R)I\'^@/M?S&F_P-02P,$%
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MF.V8X?%'9GMD9YE!+1$HC4)I#$KC*)HIL\82\>R6R'[-?,*[7'9BY\(.ZHM
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MA&H;FS>P.TB)&>F]4:A;(V1NC>Z25#I+\PL*M!FI<U+WA-;TNVZOD+F]>K-
M]]I$]876=+9NHE"')NJ" AVT/N$A=/W6EL(\ZWN]JCLA%'Y4>3:V6)T7MR>T
M9ACJ[@J9NZN.Y7ETX=I^1/_DUOV3:VQ9?JPXOX'M%,596XS-([MZ;1^==V2$
MK8IC("ZW*MM<E <'U=/JJ.FF.& Y>3Z#U_/RP*B&*<^O[C!;)3D'*5E*2&<0
MR*K*RB.A\D;037&J\D2%H%EQN28X)DP9R/=+2L7KC9J@.IB;_@]02P,$%
M  @ Y$5G5G1_'/U"!   8A(  !D   !X;"]W;W)K<VAE971S+W-H965T-3(N
M>&ULM9A;C^(V%,>_BI6.JEEIAL2Y<"L@ =E5*^VN1D.G^U#UP20&K$UB:CLP
ME?KA]^1"""&)*$I?()=S_O;Y^=@Y]N3(Q7>YHU2A]S"(Y%3;*;4?Z[KT=C0D
MLL?W-((W&RY"HN!6;'6Y%Y3XJ5,8Z*9A]/60L$B;3=)G+V(VX;$*6$1?!))Q
M&!+QSX(&_#C5L'9Z\,JV.Y4\T&>3/=G2%55O^Q<!=WJAXK.01I+Q" FZF6IS
M/':QG3BD%G\P>I2E:Y2$LN;\>W+SFS_5C*1'-*">2B0(_!WHD@9!H@3]^#L7
MU8HV$\?R]4G]4QH\!+,FDBYY\(WY:C?5AAKRZ8;$@7KEQU]I'I"3Z'D\D.DO
M.N:VAH:\6"H>YL[0@Y!%V3]YST&4'&RGP<','<RJ0U,+5NY@51P 9;V#G3ND
MJ/4LE)2#2Q29300_(I%8@UIRD<),O2%\%B7COE("WC+P4[.OD%H!EQ+M*63#
MC@B*GM&2A_M8D71@'EVJ" OD!_2 ],Q"(A:AMX@I^00/X?KW'8\EB7PYT17T
M*5'6O;S]1=:^V= ^-M$7'JF=1!\CG_J7 CH$4T1DGB):F*V*+O5ZR,)/R#1,
M$[VM7/3X<-'Y5Z)H?EW3W^7MZKA.O5'8;1>>Q]L>PD[6[18,5C&P5JIG->A]
M)")BT5:B%QC853JP?\[74@F8:7_5C5,F9]?+)<O/6.Z)1Z<:K"^2B@/59C__
MA/O&+W40NQ1S.Q*[P&@7&.TV]=G7.%P#0+Y!7/@L@J7Q--#)A)F[JSJ4F20V
M4LUDY3W,AA/]4 ;4VNI_!92)]6N;NXC:*:)V6I,'HJ:"*"[&=>$Y769*EV)N
M1V(7S/H%LWY[IIQ6TG_10QVUS'M0&J3G_G!@X$IBU)@YCM,?79JYK7VY,])!
M$>G@MDC) ;X,9!U0I'AE?NQXX%,AX6,"7V7F-4$97&5N+90:LSHHK=V^$\JP
M@#+L$(K/@EA1OPG+\+9<J3&KP]+:\3NQC HLH]:5Q*41A[*E<2T9=;F6="GF
M=B1V00T;Y[+,:$VG;VG!2OUG<H"5>'LJ6!"4[E)!J06?]F)N/4()EKW^  G5
M6( L\B;+T\@Q1\8 .V:_DEDUIO; PL.A[0PJV=4>R+V@2O4K[@#4:;[=C K?
MCNK:M!%5:RCWHC+/J,Q65)]/=?[EJO1T0<?G04!$:3^0@#K7M[6PLF9'Y77(
MZ&&K"JK>S*Q":@WB7DCGLAFWEI/-D,YS[1Y$UFV(ZLVN$/T?%3$^E\2XO2:>
M1XJE*0,[=B2I%PNF&$PY^NX%,6SBT$;P$'FE3224SY5-YLT3\;JV=:QA,KN,
M*KMKR[YEVV!L5_%U5'QG^/32YANJYFUZB"$A_#A2V:ZU>%H<E,S3XX'*\P4>
M+[/CCK-,=OKRA8@MBR0*Z 8DC=X ZER1'6AD-XKOTRW^FBO%P_1R1PG4&HD!
MO-]PKDXW20/%L=+L!U!+ P04    " #D16=6EPYVHR0"  #"!   &0   'AL
M+W=O<FMS:&5E=',O<VAE970U,RYX;6R5E&MOTS 4AO^*91 :TE2G:;NAD43J
M!0022-6JP0?$!]<Y::SY$FRGV?X]MM-&9703Y$/BRWG?\YSD.%FGS;VM 1QZ
MD$+9'-?.-3>$6%:#I':D&U!^I])&4N>G9D=L8X"6420%29/DBDC*%2ZRN+8V
M1:9;)[B"M4&VE9*:QP4(W>5XC(\+MWQ7N[! BJRA.]B NVO6QL_(X%)R"<IR
MK9"!*L?S\<UB&N)CP#<.G3T9HU#)5NO[,/E<YC@)0"" N>! _6,/2Q B&'F,
M7P=//*0,PM/QT?UCK-W7LJ46EEI\YZ6K<_P.HQ(JV@IWJ[M/<*AG%OR8%C;>
M4=?'SE*,6&N=E@>Q)Y!<]4_Z<'@/)X+T.4%Z$*21NT\4*5?4T2(SND,F1'NW
M,(BE1K6'XRI\E(TS?I=[G2N66DKN_%MV%E%5(J:5XVH'BG&PZ&(%CG)AWV;$
M^61!0MC!>-$;I\\8KX"-T&1\B=(D3='=9H4N7C^Q(9YU $X'X#3Z3OX1>/D'
M\(I;)K1M#: ?\ZUUQG_UG^?@^R33\TG"2;BQ#6608]_J%LP></'FU?@J>?]"
M"9.AA,E+[L47;>T)]^,E^F =]QT&2%=H[7?Y5@ *8>?0>_/K:![.W+X8SY)P
M961_AFHZ4$W_BPK-&3,M%><0IG\A/$U.3EHRG.ZOU.RXLDA Y37)Z'J&D>E/
M3#]QNHE=NM7.]WP<UOXG R8$^/U*:W><A,8??EO%;U!+ P04    " #D16=6
MK*[ZW(X#  ![&0  #0   'AL+W-T>6QE<RYX;6S=6=%.VS 4_94HC FDB;0-
MI,UH*VV5D"9M$Q(\[ VYC=-:<IS,<5G+[^Q/]F7SC=,T*;Y0>!C-6D%LGYQS
MCZ]O'"R&N5IS>K.@5#FKA(M\Y"Z4RCYZ7CY;T(3D9VE&A4;B5"9$Z:Z<>WDF
M*8ER("7<ZW4Z@9<0)MSQ4"R3JT3ESBQ="C5RN[UJS#&7+Y$>#<Y=Q^A-THB.
MW+N3]S^7J;I\YYCKT8>CH\Y9Y^[T<A<Y*:%3U[,*7^PAC,IBHH%=],_OIMVZ
M<(5M#*/B_;U2\50N4.E!4[JX_5@+&>(Q1@LMM&(QGDE^O[-GGI[)%#JA?M?J
MS.CM0>\A] 8;(_MV\G&=C*6T?XX9;_([3T@@E=U,+I[70M8K'\_Q,$[%]BGU
M73.@XY*$.O>$C]P)X6PJ&;!BDC"^-L,]&)BE/)6.TMN#-M*%D?S!P%W3@YVC
MU$F82&41VT0POZ?E[3O I@<&&>>50=A%8& \S(A25(HKW2EN+@8?04[9OEUG
MVN%<DG6W=^%N"<5%!YFF,J)RNUNYFZ'QD-,8[$@V7\!5I9D'H%)IHAL1(_-4
MD,+#AE$VM.R,<GX#V^J/N*&]BFLK6CPLHFIJ0V73R)@.Z-?5C'9=-GR5KI.Q
M^U1]7NKIB*(/E4*O)8W9JNBOXLH IM[%U4F6\?4GSN8BH6;R>P<<#\F&YRQ2
MR1YT-"B5F1Z@TG7NJ51L5A_Y)4EV2U=J4TZK&/?<:Z'G?YOG.154$EXWK6O_
MD+/\:L?EGR%OX;G85G8=6TWZ_</W6/[9=>@F@S:8;,5R#]I@,FR!R?Z;[9HO
M,=EM@\E>&TSZ;3#9@K=B>1PZ;)/^8>Y 7GF$J)U3&J>4:M2!T^#(_0ZG3KX-
MZDR7C"LFRMZ"11$5CPXK6EZ1*:=-?7U_1&.RY.JV D?NMOV-1FR9A-5=UY"(
M\JYM^RM,KQM41U$=BXF(KF@T*;MR/BV:CF[HJ.4'"+O(5?&Q(QC'8'8$,"P.
MY@#C&!86YW^:SP"=C\$P;P,K,D Y Y1C6#9D4GRQ.'9.J#_VF8:A[P<!EM')
MQ.I@@N4M".#'KH9Y P86!R*]+-?X:N,5\G0=8&OZ5(5@,\4K$9LIGFM ['D#
M1AC:5QN+ PQL%;#:@?CV.%!3=H[OPZIBWK G&$?"$$.@%NTU&@1(=@+XVM<'
M>TI\/PSM"&!V![Z/(? TX@CF #Q@B.\7[\&=]Y&W>4]YVW^WC/\"4$L#!!0
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M96QS+W=O<FMB;V]K+GAM;"YR96QSS=D[3L- %(7AK41> )/[F/!00D5#B]B
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MWA'UCO^I=RZG7<K7GN\U/O\_J2[G>]/U\9?E]\G1JW+!.<!O^\<O4$L#!!0
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MZ_[)3SX!4$L! A0#%     @ Y$5G5@=!36*!    L0   !
M ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #D16=6&N[3F>\
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M=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ Y$5G5KM77KE+!@
M!1P  !@              ("!M!(  'AL+W=O<FMS:&5E=',O<VAE970S+GAM
M;%!+ 0(4 Q0    ( .1%9U851:ZSGP(  -$&   8              " @349
M  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " #D16=6X/3
MXA$%  ">$P  &               @($*'   >&PO=V]R:W-H965T<R]S:&5E
M=#4N>&UL4$L! A0#%     @ Y$5G5A*H]>F4"0  '64  !@
M ("!42$  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( .1%
M9U9?'6Y(Y0<  !8C   8              " @1LK  !X;"]W;W)K<VAE971S
M+W-H965T-RYX;6Q02P$"% ,4    " #D16=6+$Z+T5,)  #:%P  &
M        @($V,P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%
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M+GAM;%!+ 0(4 Q0    ( .1%9U8E;54K]P4  +\-   9              "
M@71C  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ Y$5G
M5IDKZ<)J"0  P!@  !D              ("!HFD  'AL+W=O<FMS:&5E=',O
M<VAE970Q-"YX;6Q02P$"% ,4    " #D16=62D:A<: .   %*0  &0
M        @(%#<P  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0
M   ( .1%9U;P"@XBQ@(  %P&   9              " @1J"  !X;"]W;W)K
M<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ Y$5G5NL07#0N!P  /!$
M !D              ("!%X4  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q0
M2P$"% ,4    " #D16=67;<W"9$,  !6(@  &0              @(%\C
M>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( .1%9U8+0$=3
MB ,  ! (   9              " @429  !X;"]W;W)K<VAE971S+W-H965T
M,3DN>&UL4$L! A0#%     @ Y$5G5HKO65>\ @  ) 8  !D
M ("! YT  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " #D
M16=6T("'KS<"  !S!0  &0              @('VGP  >&PO=V]R:W-H965T
M<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( .1%9U:ARG*&Z1P  !M=   9
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M970R-BYX;6Q02P$"% ,4    " #D16=6F20ERCH%   7#@  &0
M    @(&ARP  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    (
M .1%9U:X2K838 8  #D0   9              " @1+1  !X;"]W;W)K<VAE
M971S+W-H965T,C@N>&UL4$L! A0#%     @ Y$5G5N4[=BW@ @  ?08  !D
M             ("!J=<  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"
M% ,4    " #D16=69Q$M/@H,   *GP  &0              @(' V@  >&PO
M=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( .1%9U;X 0JFOP,
M  P1   9              " @0'G  !X;"]W;W)K<VAE971S+W-H965T,S$N
M>&UL4$L! A0#%     @ Y$5G5M4YTKRI @  !P<  !D              ("!
M]^H  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " #D16=6
MLJ(&S38#   N"@  &0              @('7[0  >&PO=V]R:W-H965T<R]S
M:&5E=#,S+GAM;%!+ 0(4 Q0    ( .1%9U91P-9,?P(  &@&   9
M      " @43Q  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%
M  @ Y$5G5N->]^BI @  &0<  !D              ("!^O,  'AL+W=O<FMS
M:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " #D16=6T[0R_<D#  "I$
M&0              @(':]@  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+
M 0(4 Q0    ( .1%9U:3-4G7&@0   L5   9              " @=KZ  !X
M;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ Y$5G5JI@D998
M @  C 4  !D              ("!*_\  'AL+W=O<FMS:&5E=',O<VAE970S
M."YX;6Q02P$"% ,4    " #D16=6G_,&ZI<(  !/70  &0
M@(&Z 0$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( .1%
M9U;+?=2T,04  +\A   9              " @8@* 0!X;"]W;W)K<VAE971S
M+W-H965T-# N>&UL4$L! A0#%     @ Y$5G5B%Q@G95 @  F04  !D
M         ("!\ \! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4
M    " #D16=6Z]DU#)X"  #9!@  &0              @(%\$@$ >&PO=V]R
M:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( .1%9U9A_L"U] (  &<)
M   9              " @5$5 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL
M4$L! A0#%     @ Y$5G5MYCF\M4 P  4PH  !D              ("!?!@!
M 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " #D16=6!G<3
MW%T$  #1$   &0              @($'' $ >&PO=V]R:W-H965T<R]S:&5E
M=#0U+GAM;%!+ 0(4 Q0    ( .1%9U:WZD "J@(  '<'   9
M  " @9L@ 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @
MY$5G5FVK>14H P  KPL  !D              ("!?",! 'AL+W=O<FMS:&5E
M=',O<VAE970T-RYX;6Q02P$"% ,4    " #D16=6NMD5P4L)   39P  &0
M            @(';)@$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4
M Q0    ( .1%9U82@_ A4@8  "@G   9              " @5TP 0!X;"]W
M;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ Y$5G5L^.F0?4 P
M#!   !D              ("!YC8! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX
M;6Q02P$"% ,4    " #D16=6\A4>U!<%  "D&P  &0              @('Q
M.@$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( .1%9U9T
M?QS]0@0  &(2   9              " @3]  0!X;"]W;W)K<VAE971S+W-H
M965T-3(N>&UL4$L! A0#%     @ Y$5G5I<.=J,D @  P@0  !D
M     ("!N$0! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4
M" #D16=6K*[ZW(X#  ![&0  #0              @ $31P$ >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( .1%9U:7BKL<P    !,"   +              "
M <Q* 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( .1%9U9/G+*&;00  /8B   /
M              "  ;5+ 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #D
M16=6?'[I&]0!  #&'P  &@              @ %/4 $ >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #D16=6*F32ILH!  ";'P  $P
M            @ %;4@$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     /0 ]
+ *(0  !65 $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>119</ContextCount>
  <ElementCount>318</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>46</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Shareholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity</Role>
      <ShortName>Consolidated Statements of Shareholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Organization and description of business operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Organizationanddescriptionofbusinessoperations</Role>
      <ShortName>Organization and description of business operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Basis of Presentation and Summary of Significant Accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Prepaid expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Prepaidexpenses</Role>
      <ShortName>Prepaid expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Property leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Propertyleases</Role>
      <ShortName>Property leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Accrued expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Accruedexpenses</Role>
      <ShortName>Accrued expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Warrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Term loan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Termloan</Role>
      <ShortName>Term loan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Significant agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Significantagreements</Role>
      <ShortName>Significant agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Benefit plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Benefitplans</Role>
      <ShortName>Benefit plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Taxation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Taxation</Role>
      <ShortName>Taxation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Share based compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Sharebasedcompensation</Role>
      <ShortName>Share based compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Net loss per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Netlosspershare</Role>
      <ShortName>Net loss per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Commitments and contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Commitmentsandcontingencies</Role>
      <ShortName>Commitments and contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Related party transactions and other shareholder matters</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/Relatedpartytransactionsandothershareholdermatters</Role>
      <ShortName>Related party transactions and other shareholder matters</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Basis of Presentation and Summary of Significant Accounting policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Prepaid expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/PrepaidexpensesTables</Role>
      <ShortName>Prepaid expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://veronapharma.com/role/Prepaidexpenses</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Property leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/PropertyleasesTables</Role>
      <ShortName>Property leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://veronapharma.com/role/Propertyleases</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Accrued expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/AccruedexpensesTables</Role>
      <ShortName>Accrued expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://veronapharma.com/role/Accruedexpenses</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/WarrantsTables</Role>
      <ShortName>Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://veronapharma.com/role/Warrants</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Taxation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/TaxationTables</Role>
      <ShortName>Taxation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://veronapharma.com/role/Taxation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Share based compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/SharebasedcompensationTables</Role>
      <ShortName>Share based compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://veronapharma.com/role/Sharebasedcompensation</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Net loss per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/NetlosspershareTables</Role>
      <ShortName>Net loss per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://veronapharma.com/role/Netlosspershare</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Organization and description of business operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/OrganizationanddescriptionofbusinessoperationsDetails</Role>
      <ShortName>Organization and description of business operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://veronapharma.com/role/Organizationanddescriptionofbusinessoperations</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Basis of Presentation and Summary of Significant Accounting policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Prepaid expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/PrepaidexpensesDetails</Role>
      <ShortName>Prepaid expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://veronapharma.com/role/PrepaidexpensesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Property leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/PropertyleasesNarrativeDetails</Role>
      <ShortName>Property leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Property leases - Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/PropertyleasesMaturityDetails</Role>
      <ShortName>Property leases - Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Accrued expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/AccruedexpensesDetails</Role>
      <ShortName>Accrued expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://veronapharma.com/role/AccruedexpensesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Warrants - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/WarrantsNarrativeDetails</Role>
      <ShortName>Warrants - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Warrants - Fair Value Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/WarrantsFairValueAssumptionsDetails</Role>
      <ShortName>Warrants - Fair Value Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Warrants - Movement in Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/WarrantsMovementinValueDetails</Role>
      <ShortName>Warrants - Movement in Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Term loan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/TermloanDetails</Role>
      <ShortName>Term loan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://veronapharma.com/role/Termloan</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Significant agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/SignificantagreementsDetails</Role>
      <ShortName>Significant agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://veronapharma.com/role/Significantagreements</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Benefit plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/BenefitplansDetails</Role>
      <ShortName>Benefit plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://veronapharma.com/role/Benefitplans</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Taxation - Loss Before Tax (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/TaxationLossBeforeTaxDetails</Role>
      <ShortName>Taxation - Loss Before Tax (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Taxation - Tax Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/TaxationTaxExpenseBenefitDetails</Role>
      <ShortName>Taxation - Tax Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Taxation - Reconciliation of Statutory Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/TaxationReconciliationofStatutoryRateDetails</Role>
      <ShortName>Taxation - Reconciliation of Statutory Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Taxation - Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Taxation - Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Taxation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/TaxationNarrativeDetails</Role>
      <ShortName>Taxation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Share based compensation - Share-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails</Role>
      <ShortName>Share based compensation - Share-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Share based compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/SharebasedcompensationNarrativeDetails</Role>
      <ShortName>Share based compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Share based compensation - Share Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails</Role>
      <ShortName>Share based compensation - Share Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Share based compensation - Weighted-Average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/SharebasedcompensationWeightedAverageAssumptionsDetails</Role>
      <ShortName>Share based compensation - Weighted-Average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Share based compensation - RSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails</Role>
      <ShortName>Share based compensation - RSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Net loss per share - Computation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/NetlosspershareComputationDetails</Role>
      <ShortName>Net loss per share - Computation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="vrna-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Commitments and contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veronapharma.com/role/CommitmentsandcontingenciesDetails</Role>
      <ShortName>Commitments and contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://veronapharma.com/role/Commitmentsandcontingencies</ParentRole>
      <Position>53</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:PropertyPlantAndEquipmentUsefulLife, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 -  vrna-20221231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="vrna-20221231.htm">vrna-20221231.htm</File>
    <File>consentletter-fy22.htm</File>
    <File>exhibit211q422.htm</File>
    <File>exhibit311q422.htm</File>
    <File>exhibit312q422.htm</File>
    <File>exhibit321q422.htm</File>
    <File>exhibit322q422.htm</File>
    <File>vrna-20221231.xsd</File>
    <File>vrna-20221231_cal.xml</File>
    <File>vrna-20221231_def.xml</File>
    <File>vrna-20221231_lab.xml</File>
    <File>vrna-20221231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>vrna-20221231_g1.jpg</File>
    <File>vrna-20221231_g10.jpg</File>
    <File>vrna-20221231_g11.jpg</File>
    <File>vrna-20221231_g12.jpg</File>
    <File>vrna-20221231_g13.jpg</File>
    <File>vrna-20221231_g14.jpg</File>
    <File>vrna-20221231_g2.jpg</File>
    <File>vrna-20221231_g3.jpg</File>
    <File>vrna-20221231_g4.jpg</File>
    <File>vrna-20221231_g5.jpg</File>
    <File>vrna-20221231_g6.jpg</File>
    <File>vrna-20221231_g7.jpg</File>
    <File>vrna-20221231_g8.jpg</File>
    <File>vrna-20221231_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="518">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="43">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>87
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "vrna-20221231.htm": {
   "axisCustom": 2,
   "axisStandard": 17,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 518,
    "http://xbrl.sec.gov/dei/2022": 43
   },
   "contextCount": 119,
   "dts": {
    "calculationLink": {
     "local": [
      "vrna-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "vrna-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "vrna-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "vrna-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "vrna-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "vrna-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 469,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 2,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 6
   },
   "keyCustom": 40,
   "keyStandard": 278,
   "memberCustom": 25,
   "memberStandard": 21,
   "nsprefix": "vrna",
   "nsuri": "http://veronapharma.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://veronapharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vrna:PrepaidExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Prepaid expenses",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://veronapharma.com/role/Prepaidexpenses",
     "shortName": "Prepaid expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vrna:PrepaidExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Property leases",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://veronapharma.com/role/Propertyleases",
     "shortName": "Property leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Accrued expenses",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://veronapharma.com/role/Accruedexpenses",
     "shortName": "Accrued expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vrna:WarrantAndRightsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Warrants",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://veronapharma.com/role/Warrants",
     "shortName": "Warrants",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vrna:WarrantAndRightsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Term loan",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://veronapharma.com/role/Termloan",
     "shortName": "Term loan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Significant agreements",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://veronapharma.com/role/Significantagreements",
     "shortName": "Significant agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Benefit plans",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://veronapharma.com/role/Benefitplans",
     "shortName": "Benefit plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Taxation",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://veronapharma.com/role/Taxation",
     "shortName": "Taxation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Share based compensation",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://veronapharma.com/role/Sharebasedcompensation",
     "shortName": "Share based compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Net loss per share",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://veronapharma.com/role/Netlosspershare",
     "shortName": "Net loss per share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://veronapharma.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Commitments and contingencies",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://veronapharma.com/role/Commitmentsandcontingencies",
     "shortName": "Commitments and contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Related party transactions and other shareholder matters",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://veronapharma.com/role/Relatedpartytransactionsandothershareholdermatters",
     "shortName": "Related party transactions and other shareholder matters",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Basis of Presentation and Summary of Significant Accounting policies (Policies)",
     "menuCat": "Policies",
     "order": "22",
     "role": "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Prepaid expenses (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://veronapharma.com/role/PrepaidexpensesTables",
     "shortName": "Prepaid expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Property leases (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://veronapharma.com/role/PropertyleasesTables",
     "shortName": "Property leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Accrued expenses (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://veronapharma.com/role/AccruedexpensesTables",
     "shortName": "Accrued expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Warrants (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://veronapharma.com/role/WarrantsTables",
     "shortName": "Warrants (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Taxation (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://veronapharma.com/role/TaxationTables",
     "shortName": "Taxation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Share based compensation (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://veronapharma.com/role/SharebasedcompensationTables",
     "shortName": "Share based compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Net loss per share (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://veronapharma.com/role/NetlosspershareTables",
     "shortName": "Net loss per share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i46f03490e9ee4cdfbbb33910795928d1_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://veronapharma.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i46f03490e9ee4cdfbbb33910795928d1_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "vrna:NumberOfWhollyOwnedSubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "subsidiary",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Organization and description of business operations (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://veronapharma.com/role/OrganizationanddescriptionofbusinessoperationsDetails",
     "shortName": "Organization and description of business operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "vrna:NumberOfWhollyOwnedSubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "subsidiary",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:NumberOfReportableSegments",
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Basis of Presentation and Summary of Significant Accounting policies (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:NumberOfReportableSegments",
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i46f03490e9ee4cdfbbb33910795928d1_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vrna:PrepaidResearchAndDevelopmentFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Prepaid expenses (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://veronapharma.com/role/PrepaidexpensesDetails",
     "shortName": "Prepaid expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i46f03490e9ee4cdfbbb33910795928d1_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vrna:PrepaidResearchAndDevelopmentFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i46f03490e9ee4cdfbbb33910795928d1_I20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Property leases - Narrative (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://veronapharma.com/role/PropertyleasesNarrativeDetails",
     "shortName": "Property leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i46f03490e9ee4cdfbbb33910795928d1_I20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i46f03490e9ee4cdfbbb33910795928d1_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Property leases - Maturity (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://veronapharma.com/role/PropertyleasesMaturityDetails",
     "shortName": "Property leases - Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i46f03490e9ee4cdfbbb33910795928d1_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i46f03490e9ee4cdfbbb33910795928d1_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vrna:AccruedResearchAndDevelopmentFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Accrued expenses (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://veronapharma.com/role/AccruedexpensesDetails",
     "shortName": "Accrued expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i46f03490e9ee4cdfbbb33910795928d1_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vrna:AccruedResearchAndDevelopmentFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "vrna:ClassOfWarrantOrRightNumberOfExercisedOrForfeited",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Warrants - Narrative (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://veronapharma.com/role/WarrantsNarrativeDetails",
     "shortName": "Warrants - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "vrna:ClassOfWarrantOrRightNumberOfExercisedOrForfeited",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "id40f0f069eba45cba259ca5e4029e3c6_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Warrants - Fair Value Assumptions (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://veronapharma.com/role/WarrantsFairValueAssumptionsDetails",
     "shortName": "Warrants - Fair Value Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "id40f0f069eba45cba259ca5e4029e3c6_I20211231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstandingTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "if80b5e08771841e98a3888a3388c32e2_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Warrants - Movement in Value (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://veronapharma.com/role/WarrantsMovementinValueDetails",
     "shortName": "Warrants - Movement in Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "if80b5e08771841e98a3888a3388c32e2_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfLongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Term loan (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://veronapharma.com/role/TermloanDetails",
     "shortName": "Term loan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i30e7bb276e12407b8476499428f6f60a_D20201101-20201130",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfLongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i46f03490e9ee4cdfbbb33910795928d1_I20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "gbpPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://veronapharma.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i46f03490e9ee4cdfbbb33910795928d1_I20221231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i2014cf02dad94153af60f28551c0469c_D20220301-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vrna:SublicensePayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Significant agreements (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://veronapharma.com/role/SignificantagreementsDetails",
     "shortName": "Significant agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i2014cf02dad94153af60f28551c0469c_D20220301-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vrna:SublicensePayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Benefit plans (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://veronapharma.com/role/BenefitplansDetails",
     "shortName": "Benefit plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Taxation - Loss Before Tax (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://veronapharma.com/role/TaxationLossBeforeTaxDetails",
     "shortName": "Taxation - Loss Before Tax (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentForeignTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Taxation - Tax Expense (Benefit) (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://veronapharma.com/role/TaxationTaxExpenseBenefitDetails",
     "shortName": "Taxation - Tax Expense (Benefit) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentForeignTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Taxation - Reconciliation of Statutory Rate (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://veronapharma.com/role/TaxationReconciliationofStatutoryRateDetails",
     "shortName": "Taxation - Reconciliation of Statutory Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i46f03490e9ee4cdfbbb33910795928d1_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vrna:DeferredTaxLiabilitiesContingentLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Taxation - Deferred Tax Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails",
     "shortName": "Taxation - Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i46f03490e9ee4cdfbbb33910795928d1_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vrna:DeferredTaxLiabilitiesContingentLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i46f03490e9ee4cdfbbb33910795928d1_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Taxation - Narrative (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://veronapharma.com/role/TaxationNarrativeDetails",
     "shortName": "Taxation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i46f03490e9ee4cdfbbb33910795928d1_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Share based compensation - Share-Based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails",
     "shortName": "Share based compensation - Share-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Share based compensation - Narrative (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails",
     "shortName": "Share based compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "vrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i46f03490e9ee4cdfbbb33910795928d1_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityListingDepositoryReceiptRatio",
      "reportCount": 1,
      "unitRef": "rate",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Share based compensation - Share Option Activity (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails",
     "shortName": "Share based compensation - Share Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i6ef7ac44600e4b82bd5f7115b1d6d54d_D20220101-20221231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Share based compensation - Weighted-Average Assumptions (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://veronapharma.com/role/SharebasedcompensationWeightedAverageAssumptionsDetails",
     "shortName": "Share based compensation - Weighted-Average Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i6ef7ac44600e4b82bd5f7115b1d6d54d_D20220101-20221231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "id40f0f069eba45cba259ca5e4029e3c6_I20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Share based compensation - RSU Activity (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails",
     "shortName": "Share based compensation - RSU Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "if80b5e08771841e98a3888a3388c32e2_I20201231",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i46f03490e9ee4cdfbbb33910795928d1_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityListingDepositoryReceiptRatio",
      "reportCount": 1,
      "unitRef": "rate",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Net loss per share - Computation (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://veronapharma.com/role/NetlosspershareComputationDetails",
     "shortName": "Net loss per share - Computation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted",
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i46f03490e9ee4cdfbbb33910795928d1_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyEstimateOfPossibleLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Commitments and contingencies (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://veronapharma.com/role/CommitmentsandcontingenciesDetails",
     "shortName": "Commitments and contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i46f03490e9ee4cdfbbb33910795928d1_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyEstimateOfPossibleLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i914d9cdf65d04c2f90fe005e7472a193_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Consolidated Statements of Shareholders\u2019 Equity",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity",
     "shortName": "Consolidated Statements of Shareholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i914d9cdf65d04c2f90fe005e7472a193_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfFinancingCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vrna:OrganizationAndBusinessDescriptionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Organization and description of business operations",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://veronapharma.com/role/Organizationanddescriptionofbusinessoperations",
     "shortName": "Organization and description of business operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vrna:OrganizationAndBusinessDescriptionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Basis of Presentation and Summary of Significant Accounting policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vrna-20221231.htm",
      "contextRef": "i5aed7afbd4034009bb514762c617a15a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 46,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r566",
      "r567",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r566",
      "r567",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r566",
      "r567",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region",
        "terseLabel": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r566",
      "r567",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityListingDepositoryReceiptRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'.",
        "label": "Entity Listing, Depository Receipt Ratio",
        "terseLabel": "Number of ordinary shares per ADS"
       }
      }
     },
     "localname": "EntityListingDepositoryReceiptRatio",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/NetlosspershareComputationDetails",
      "http://veronapharma.com/role/OrganizationanddescriptionofbusinessoperationsDetails",
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails",
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r566",
      "r567",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://veronapharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r177",
      "r178",
      "r293",
      "r319",
      "r535",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://veronapharma.com/role/SignificantagreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r276",
      "r277",
      "r278",
      "r279",
      "r345",
      "r491",
      "r503",
      "r529",
      "r530",
      "r551",
      "r553",
      "r561",
      "r603",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails",
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails",
      "http://veronapharma.com/role/SharebasedcompensationWeightedAverageAssumptionsDetails",
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r276",
      "r277",
      "r278",
      "r279",
      "r345",
      "r491",
      "r503",
      "r529",
      "r530",
      "r551",
      "r553",
      "r561",
      "r603",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails",
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails",
      "http://veronapharma.com/role/SharebasedcompensationWeightedAverageAssumptionsDetails",
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r276",
      "r277",
      "r278",
      "r279",
      "r342",
      "r345",
      "r375",
      "r376",
      "r377",
      "r490",
      "r491",
      "r503",
      "r529",
      "r530",
      "r551",
      "r553",
      "r561",
      "r599",
      "r603",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails",
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails",
      "http://veronapharma.com/role/SharebasedcompensationWeightedAverageAssumptionsDetails",
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r276",
      "r277",
      "r278",
      "r279",
      "r342",
      "r345",
      "r375",
      "r376",
      "r377",
      "r490",
      "r491",
      "r503",
      "r529",
      "r530",
      "r551",
      "r553",
      "r561",
      "r599",
      "r603",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails",
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails",
      "http://veronapharma.com/role/SharebasedcompensationWeightedAverageAssumptionsDetails",
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r177",
      "r178",
      "r293",
      "r319",
      "r536",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://veronapharma.com/role/SignificantagreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r250",
      "r251",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r552",
      "r560",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://veronapharma.com/role/PropertyleasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r250",
      "r251",
      "r516",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r552",
      "r560",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://veronapharma.com/role/PropertyleasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r180",
      "r181",
      "r182",
      "r183",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/Accruedexpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r16",
      "r559"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r253",
      "r254"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SignificantagreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://veronapharma.com/role/AccruedexpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/AccruedexpensesDetails",
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r28",
      "r29",
      "r30",
      "r154",
      "r500",
      "r511",
      "r515"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r27",
      "r30",
      "r106",
      "r483",
      "r506",
      "r507",
      "r575",
      "r576",
      "r577",
      "r589",
      "r590",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r11",
      "r559"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r384",
      "r385",
      "r386",
      "r589",
      "r590",
      "r591",
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Common shares withheld for taxes on vested stock awards"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r95",
      "r96",
      "r347"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r379"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total share-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r40",
      "r50",
      "r113",
      "r312"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Accretion of redemption premium on debt"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r34",
      "r312",
      "r465",
      "r579"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issue costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of loss per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/NetlosspershareComputationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r118",
      "r131",
      "r149",
      "r173",
      "r234",
      "r243",
      "r247",
      "r258",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r422",
      "r424",
      "r440",
      "r559",
      "r601",
      "r602",
      "r646"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r145",
      "r157",
      "r173",
      "r258",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r422",
      "r424",
      "r440",
      "r559",
      "r601",
      "r602",
      "r646"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r173",
      "r258",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r422",
      "r424",
      "r440",
      "r601",
      "r602",
      "r646"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total non-current assets:"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "Non-current assets:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r350",
      "r351",
      "r352",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails",
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails",
      "http://veronapharma.com/role/SharebasedcompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum rate investor will accept.",
        "label": "Base Rate [Member]",
        "terseLabel": "Base Rate"
       }
      }
     },
     "localname": "BaseRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Summary of Significant Accounting policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Building"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/PropertyleasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalizedContractCostLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Capitalized Contract Cost [Line Items]",
        "terseLabel": "Capitalized Contract Cost [Line Items]"
       }
      }
     },
     "localname": "CapitalizedContractCostLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SignificantagreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalizedContractCostNet": {
     "auth_ref": [
      "r267"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Net",
        "terseLabel": "Capitalized Contract Cost, Net"
       }
      }
     },
     "localname": "CapitalizedContractCostNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SignificantagreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostTable": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about cost capitalized in obtaining or fulfilling contract with customer.",
        "label": "Capitalized Contract Cost [Table]",
        "terseLabel": "Capitalized Contract Cost [Table]"
       }
      }
     },
     "localname": "CapitalizedContractCostTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SignificantagreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r52",
      "r147",
      "r532"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r47",
      "r52",
      "r55"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of the year",
        "periodStartLabel": "Cash and cash equivalents at beginning of the year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r47",
      "r112"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r173",
      "r205",
      "r206",
      "r213",
      "r215",
      "r222",
      "r223",
      "r258",
      "r281",
      "r283",
      "r284",
      "r285",
      "r288",
      "r289",
      "r317",
      "r318",
      "r320",
      "r321",
      "r323",
      "r440",
      "r531",
      "r572",
      "r580",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/OrganizationanddescriptionofbusinessoperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/OrganizationanddescriptionofbusinessoperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of stock warrant (in pound sterling per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/WarrantsFairValueAssumptionsDetails",
      "http://veronapharma.com/role/WarrantsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/WarrantsFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Number of shares called by each warrant"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/WarrantsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Stock warrants (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/WarrantsFairValueAssumptionsDetails",
      "http://veronapharma.com/role/WarrantsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Number of outstanding warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/WarrantsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r84",
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/WarrantsFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r24",
      "r123",
      "r135"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r64",
      "r273",
      "r274",
      "r517",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/Commitmentsandcontingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r589",
      "r590",
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Ordinary shares"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails",
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in pounds sterling per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://veronapharma.com/role/OrganizationanddescriptionofbusinessoperationsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r10",
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r10",
      "r559"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Ordinary \u00a30.05 par value shares: 631,338,246 and 489,177,550 issued, and 606,301,054 and 480,082,966 outstanding, at December 31, 2022 and 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r128",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of credit risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r105",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of presentation and consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetNoncurrent": {
     "auth_ref": [
      "r326",
      "r328",
      "r338"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent",
        "terseLabel": "Equity interest"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r326",
      "r327",
      "r338"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SignificantagreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r339"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Contract with Customer, Liability, Revenue Recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SignificantagreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r36",
      "r173",
      "r258",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r440",
      "r601"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "negatedTerseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/OrganizationanddescriptionofbusinessoperationsDetails",
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/OrganizationanddescriptionofbusinessoperationsDetails",
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r636"
     ],
     "calculation": {
      "http://veronapharma.com/role/TaxationTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal, State and Local, Tax Expense (Benefit)",
        "terseLabel": "United Kingdom"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TaxationTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r583",
      "r636"
     ],
     "calculation": {
      "http://veronapharma.com/role/TaxationTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TaxationTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r103",
      "r401",
      "r411",
      "r583"
     ],
     "calculation": {
      "http://veronapharma.com/role/TaxationTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current tax expense/(credit)"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TaxationTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r68",
      "r172",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r306",
      "r313",
      "r314",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Term loan"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/Termloan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r3",
      "r4",
      "r5",
      "r119",
      "r121",
      "r130",
      "r179",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r302",
      "r303",
      "r304",
      "r305",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r466",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/OrganizationanddescriptionofbusinessoperationsDetails",
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r114",
      "r116",
      "r290",
      "r466",
      "r547",
      "r548"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/OrganizationanddescriptionofbusinessoperationsDetails",
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument.",
        "label": "Debt Instrument, Interest Rate, Increase (Decrease)",
        "terseLabel": "Debt Instrument, Interest Rate, Increase (Decrease)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r23",
      "r179",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r302",
      "r303",
      "r304",
      "r305",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r466",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/OrganizationanddescriptionofbusinessoperationsDetails",
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r23",
      "r75",
      "r78",
      "r79",
      "r80",
      "r113",
      "r114",
      "r116",
      "r127",
      "r179",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r302",
      "r303",
      "r304",
      "r305",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r315",
      "r466",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Summary of Prepaid Expenses"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/PrepaidexpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r631"
     ],
     "calculation": {
      "http://veronapharma.com/role/TaxationTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit)",
        "terseLabel": "United Kingdom"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TaxationTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r103",
      "r583",
      "r637"
     ],
     "calculation": {
      "http://veronapharma.com/role/TaxationTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TaxationTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r50",
      "r103",
      "r402",
      "r410",
      "r411",
      "r583"
     ],
     "calculation": {
      "http://veronapharma.com/role/TaxationTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred tax expense"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TaxationTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r7",
      "r8",
      "r120",
      "r129",
      "r396"
     ],
     "calculation": {
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r397"
     ],
     "calculation": {
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r634"
     ],
     "calculation": {
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Deferred tax assets, net of valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r101",
      "r635"
     ],
     "calculation": {
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating losses"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r101",
      "r635"
     ],
     "calculation": {
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r100",
      "r101",
      "r635"
     ],
     "calculation": {
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "IPR&amp;D asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r101",
      "r635"
     ],
     "calculation": {
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Future exercisable shares"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r398"
     ],
     "calculation": {
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Less: valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r343"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Contribution cost"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/BenefitplansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanTextBlock": {
     "auth_ref": [
      "r343",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for defined contribution plan.",
        "label": "Defined Contribution Plan [Text Block]",
        "terseLabel": "Benefits plans"
       }
      }
     },
     "localname": "DefinedContributionPlanTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/Benefitplans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r50",
      "r232"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r349",
      "r380",
      "r381",
      "r383",
      "r388",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Share based compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/Sharebasedcompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r166",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r202",
      "r205",
      "r213",
      "r214",
      "r215",
      "r219",
      "r435",
      "r436",
      "r497",
      "r501",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Loss per ordinary share, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://veronapharma.com/role/NetlosspershareComputationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r166",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r205",
      "r213",
      "r214",
      "r215",
      "r219",
      "r435",
      "r436",
      "r497",
      "r501",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Loss per ordinary share, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://veronapharma.com/role/NetlosspershareComputationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net loss per share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/Netlosspershare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r453"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r392"
     ],
     "calculation": {
      "http://veronapharma.com/role/TaxationReconciliationofStatutoryRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TaxationReconciliationofStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r175",
      "r392",
      "r413"
     ],
     "calculation": {
      "http://veronapharma.com/role/TaxationReconciliationofStatutoryRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "U.K. tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TaxationReconciliationofStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r632",
      "r638"
     ],
     "calculation": {
      "http://veronapharma.com/role/TaxationReconciliationofStatutoryRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in deferred tax valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TaxationReconciliationofStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r632",
      "r638"
     ],
     "calculation": {
      "http://veronapharma.com/role/TaxationReconciliationofStatutoryRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "terseLabel": "Non-deductible expenses"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TaxationReconciliationofStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r632",
      "r638"
     ],
     "calculation": {
      "http://veronapharma.com/role/TaxationReconciliationofStatutoryRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "terseLabel": "Share options exercised"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TaxationReconciliationofStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r632",
      "r638"
     ],
     "calculation": {
      "http://veronapharma.com/role/TaxationReconciliationofStatutoryRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "negatedTerseLabel": "Research and development incentive"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TaxationReconciliationofStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://veronapharma.com/role/AccruedexpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "People related costs"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/AccruedexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r382"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Cost related to share options and RSUs granted but not yet recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Expected period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Share Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails",
      "http://veronapharma.com/role/SharebasedcompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r74",
      "r141",
      "r161",
      "r162",
      "r163",
      "r185",
      "r186",
      "r187",
      "r190",
      "r198",
      "r200",
      "r221",
      "r262",
      "r325",
      "r384",
      "r385",
      "r386",
      "r406",
      "r407",
      "r434",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r483",
      "r506",
      "r507",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails",
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r50",
      "r69"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "terseLabel": "Fair value adjustment"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Fair Value Valuation Assumptions of Warrants"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/WarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Warrant Activity"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/WarrantsMovementinValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r108",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Movement of the Value of the Warrants"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/WarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r108"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "At December 31",
        "periodStartLabel": "At January 1"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/WarrantsMovementinValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r110",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair value of financial instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r449",
      "r450",
      "r451",
      "r452"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "negatedTerseLabel": "Foreign exchange loss/(gain)",
        "terseLabel": "Foreign exchange (loss)/gain"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currencies"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r50",
      "r66",
      "r67"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 6.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Loss on extinguishment of debt",
        "terseLabel": "Loss on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r148",
      "r268",
      "r496",
      "r545",
      "r559",
      "r597",
      "r598"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r269",
      "r270",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r35",
      "r173",
      "r234",
      "r242",
      "r246",
      "r248",
      "r258",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r440",
      "r543",
      "r601"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r174",
      "r412"
     ],
     "calculation": {
      "http://veronapharma.com/role/TaxationLossBeforeTaxDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "negatedLabel": "United Kingdom"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TaxationLossBeforeTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r31",
      "r117",
      "r124",
      "r137",
      "r234",
      "r242",
      "r246",
      "r248",
      "r498",
      "r543"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://veronapharma.com/role/TaxationLossBeforeTaxDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "negatedTotalLabel": "Total",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://veronapharma.com/role/TaxationLossBeforeTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r174",
      "r412"
     ],
     "calculation": {
      "http://veronapharma.com/role/TaxationLossBeforeTaxDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "negatedLabel": "United States"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TaxationLossBeforeTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r271",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails",
      "http://veronapharma.com/role/SignificantagreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails",
      "http://veronapharma.com/role/SignificantagreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r175",
      "r393",
      "r394",
      "r400",
      "r408",
      "r414",
      "r416",
      "r417",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Taxation"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/Taxation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationInterestAccrued": {
     "auth_ref": [
      "r633"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of estimated interest accrued as of the balance sheet date arising from income tax examinations.",
        "label": "Income Tax Examination, Interest Accrued",
        "terseLabel": "Interest accrued"
       }
      }
     },
     "localname": "IncomeTaxExaminationInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TaxationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAccrued": {
     "auth_ref": [
      "r633"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of estimated penalties accrued as of the balance sheet date arising from income tax examinations.",
        "label": "Income Tax Examination, Penalties Accrued",
        "terseLabel": "Penalties accrued"
       }
      }
     },
     "localname": "IncomeTaxExaminationPenaltiesAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TaxationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r633"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.",
        "label": "Income Tax Examination, Penalties and Interest Expense",
        "terseLabel": "Interest and penalties recognized"
       }
      }
     },
     "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TaxationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r176",
      "r199",
      "r200",
      "r233",
      "r391",
      "r409",
      "r415",
      "r502"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://veronapharma.com/role/TaxationTaxExpenseBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Income tax (expense)/income",
        "totalLabel": "Total income tax expense/(credit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://veronapharma.com/role/TaxationTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r160",
      "r389",
      "r390",
      "r394",
      "r395",
      "r399",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r54"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Income taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedTaxesPayable": {
     "auth_ref": [
      "r578"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period of all taxes owed but not paid, including income, property and other taxes.",
        "label": "Increase (Decrease) in Accrued Taxes Payable",
        "terseLabel": "Taxes payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "auth_ref": [
      "r578"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current assets classified as other.",
        "label": "Increase (Decrease) in Other Current Assets",
        "negatedTerseLabel": "Other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "auth_ref": [
      "r578"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current liabilities classified as other.",
        "label": "Increase (Decrease) in Other Current Liabilities",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r578"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedTerseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedTerseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r115",
      "r126",
      "r164",
      "r231",
      "r464"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r168",
      "r170",
      "r171"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNet": {
     "auth_ref": [
      "r38",
      "r40"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Net",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r257",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Short term investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/PropertyleasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/PropertyleasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Lease accounting"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments.",
        "label": "Lessee, Operating Lease, Discount Rate",
        "terseLabel": "Discount rate (in percent)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/PropertyleasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Minimum Annual Operating Lease Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/PropertyleasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r476"
     ],
     "calculation": {
      "http://veronapharma.com/role/PropertyleasesMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://veronapharma.com/role/PropertyleasesMaturityDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total minimum future lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/PropertyleasesMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r476"
     ],
     "calculation": {
      "http://veronapharma.com/role/PropertyleasesMaturityDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/PropertyleasesMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r476"
     ],
     "calculation": {
      "http://veronapharma.com/role/PropertyleasesMaturityDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/PropertyleasesMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r476"
     ],
     "calculation": {
      "http://veronapharma.com/role/PropertyleasesMaturityDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/PropertyleasesMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r476"
     ],
     "calculation": {
      "http://veronapharma.com/role/PropertyleasesMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/PropertyleasesMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/PropertyleasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Property leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/Propertyleases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r20",
      "r173",
      "r258",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r423",
      "r424",
      "r425",
      "r440",
      "r542",
      "r601",
      "r646",
      "r647"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r15",
      "r122",
      "r133",
      "r559",
      "r582",
      "r595",
      "r642"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND SHAREHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r22",
      "r146",
      "r173",
      "r258",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r423",
      "r424",
      "r425",
      "r440",
      "r559",
      "r601",
      "r646",
      "r647"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r5",
      "r6",
      "r173",
      "r258",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r423",
      "r424",
      "r425",
      "r440",
      "r601",
      "r646",
      "r647"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total non-current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Non-current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r18"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/OrganizationanddescriptionofbusinessoperationsDetails",
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/OrganizationanddescriptionofbusinessoperationsDetails",
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r150"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Term loan"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/OrganizationanddescriptionofbusinessoperationsDetails",
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r23",
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/OrganizationanddescriptionofbusinessoperationsDetails",
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r275",
      "r573"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Loss Contingency Accrual"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/CommitmentsandcontingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "auth_ref": [
      "r276",
      "r277",
      "r280"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "terseLabel": "Loss Contingency, Estimate of Possible Loss"
       }
      }
     },
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/CommitmentsandcontingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "terseLabel": "Dividend rate"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/WarrantsFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/WarrantsFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/WarrantsFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/WarrantsFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "terseLabel": "Valuation Allowance [Roll Forward]"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r169"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by/(used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r169"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r47",
      "r48",
      "r51"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r32",
      "r51",
      "r125",
      "r136",
      "r144",
      "r158",
      "r159",
      "r163",
      "r173",
      "r189",
      "r193",
      "r194",
      "r195",
      "r196",
      "r199",
      "r200",
      "r211",
      "r234",
      "r242",
      "r246",
      "r248",
      "r258",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r436",
      "r440",
      "r543",
      "r601"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://veronapharma.com/role/NetlosspershareComputationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r193",
      "r194",
      "r195",
      "r196",
      "r202",
      "r203",
      "r212",
      "r215",
      "r234",
      "r242",
      "r246",
      "r248",
      "r543"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss available to ordinary shareholders - basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/NetlosspershareComputationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r204",
      "r207",
      "r208",
      "r209",
      "r210",
      "r212",
      "r215"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "terseLabel": "Net loss available to ordinary shareholders - diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/NetlosspershareComputationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/NetlosspershareComputationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r57",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r195",
      "r201",
      "r219",
      "r255",
      "r256",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r384",
      "r385",
      "r386",
      "r404",
      "r405",
      "r406",
      "r407",
      "r419",
      "r420",
      "r421",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r462",
      "r463",
      "r467",
      "r468",
      "r469",
      "r470",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r493",
      "r494",
      "r495",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently issued accounting pronouncements, not yet adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r234",
      "r242",
      "r246",
      "r248",
      "r543"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r643"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/PropertyleasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r472"
     ],
     "calculation": {
      "http://veronapharma.com/role/PropertyleasesMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/PropertyleasesMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r472"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r472"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Non-current operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r471"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r100"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TaxationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r156",
      "r559"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other income/(expense):"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r21",
      "r559"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities Disclosure [Abstract]"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r574",
      "r596"
     ],
     "calculation": {
      "http://veronapharma.com/role/PrepaidexpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/PrepaidexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/OrganizationanddescriptionofbusinessoperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedTerseLabel": "Oxford Term Loan issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfLoanCosts": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for loan origination associated cost which is usually collected through escrow.",
        "label": "Payments of Loan Costs",
        "negatedTerseLabel": "SVB Term Loan repayment costs"
       }
      }
     },
     "localname": "PaymentsOfLoanCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedTerseLabel": "Payment of offering costs in connection with the issuance of ordinary shares"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r167"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedTerseLabel": "Payments of withholding taxes from share-based awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of furniture and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r155",
      "r265",
      "r266",
      "r533"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://veronapharma.com/role/PrepaidexpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses",
        "totalLabel": "Total prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets",
      "http://veronapharma.com/role/PrepaidexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r534",
      "r544",
      "r596"
     ],
     "calculation": {
      "http://veronapharma.com/role/PrepaidexpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/PrepaidexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of ordinary shares"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Proceeds from issuance of Oxford Term Loan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r42",
      "r93"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of share options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/PropertyleasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r63",
      "r134",
      "r499",
      "r559"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Furniture and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r63",
      "r518",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Furniture and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/PropertyleasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Furniture and equipment, useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r484",
      "r485",
      "r486",
      "r487",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related party transactions and other shareholder matters"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/Relatedpartytransactionsandothershareholdermatters"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedTerseLabel": "Repayment of SVB Term Loan"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r97",
      "r138",
      "r654"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and development costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails",
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r12",
      "r81",
      "r132",
      "r510",
      "r515",
      "r559"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedTerseLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets",
      "http://veronapharma.com/role/OrganizationanddescriptionofbusinessoperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r141",
      "r185",
      "r186",
      "r187",
      "r190",
      "r198",
      "r200",
      "r262",
      "r384",
      "r385",
      "r386",
      "r406",
      "r407",
      "r434",
      "r506",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r336",
      "r337",
      "r340",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Significant agreements"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/Significantagreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r539",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r335"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Transaction price"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SignificantagreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r165",
      "r173",
      "r229",
      "r230",
      "r241",
      "r244",
      "r245",
      "r249",
      "r250",
      "r252",
      "r258",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r440",
      "r498",
      "r601"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r475",
      "r558"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets recognized with associated liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/PropertyleasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Consideration received from sale of stock"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/OrganizationanddescriptionofbusinessoperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://veronapharma.com/role/OrganizationanddescriptionofbusinessoperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares issued in sale (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/OrganizationanddescriptionofbusinessoperationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/OrganizationanddescriptionofbusinessoperationsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/AccruedexpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Components of income tax expense"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TaxationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Deferred tax assets and liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TaxationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Computation of Basic and Diluted Earning Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/NetlosspershareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of the U.K. statutory income tax rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TaxationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r91",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Allocation of Share Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Components of loss before income taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TaxationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r346",
      "r348",
      "r350",
      "r351",
      "r352",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails",
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails",
      "http://veronapharma.com/role/SharebasedcompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r86",
      "r87",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Share Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Weighted-Average Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Restricted Stock Unit Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r70",
      "r71",
      "r73",
      "r75",
      "r76",
      "r77",
      "r78",
      "r79",
      "r80",
      "r81",
      "r151",
      "r152",
      "r153",
      "r222",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r551",
      "r572",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/OrganizationanddescriptionofbusinessoperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Secured Debt"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/OrganizationanddescriptionofbusinessoperationsDetails",
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, General and Administrative Expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SignificantagreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r362",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding, ending balance",
        "periodStartLabel": "Outstanding, beginning balance",
        "terseLabel": "Number of RSUs outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r362",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Outstanding, Weighted average remaining contractual term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails",
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails",
      "http://veronapharma.com/role/SharebasedcompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "verboseLabel": "RSU Activity"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Further awards to be granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Stock option activity, additional disclosures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable, Weight average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r369"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of stock options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted",
        "verboseLabel": "Number granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails",
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r92"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding, Aggregate intrinsic value (in dollars)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r354",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance outstanding",
        "periodStartLabel": "Beginning balance outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of share options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r354",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, Ending Balance, Weighted average exercise price (in dollars per share)",
        "periodStartLabel": "Outstanding, Beginning Balance, Weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r350",
      "r351",
      "r352",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails",
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails",
      "http://veronapharma.com/role/SharebasedcompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised, Weight average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited, Weight average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted, Weight average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r353",
      "r372",
      "r373",
      "r374",
      "r375",
      "r378",
      "r387",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",
        "terseLabel": "Intrinsic and fair value, vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Contract life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected lives, years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r92"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable, Aggregate intrinsic value (in dollars)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable, Weighted average remaining contractual term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding, Weighted average remaining contractual term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r173",
      "r205",
      "r206",
      "r213",
      "r215",
      "r222",
      "r223",
      "r258",
      "r281",
      "r283",
      "r284",
      "r285",
      "r288",
      "r289",
      "r317",
      "r318",
      "r320",
      "r321",
      "r323",
      "r440",
      "r531",
      "r572",
      "r580",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/OrganizationanddescriptionofbusinessoperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r26",
      "r74",
      "r141",
      "r161",
      "r162",
      "r163",
      "r185",
      "r186",
      "r187",
      "r190",
      "r198",
      "r200",
      "r221",
      "r262",
      "r325",
      "r384",
      "r385",
      "r386",
      "r406",
      "r407",
      "r434",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r483",
      "r506",
      "r507",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails",
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r221",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r9",
      "r10",
      "r74",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Issuance of ordinary shares, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r9",
      "r10",
      "r74",
      "r81",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationShareOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r9",
      "r10",
      "r74",
      "r81"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Issuance of ordinary shares, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r74",
      "r81"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Restricted share units vested"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r26",
      "r74",
      "r81"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Share options exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r10",
      "r13",
      "r14",
      "r61",
      "r559",
      "r582",
      "r595",
      "r642"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets",
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.",
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "terseLabel": "Treasury shares"
       }
      }
     },
     "localname": "StockholdersEquityPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r460",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/OrganizationanddescriptionofbusinessoperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r460",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/OrganizationanddescriptionofbusinessoperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r460",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/OrganizationanddescriptionofbusinessoperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://veronapharma.com/role/OrganizationanddescriptionofbusinessoperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r25",
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Ordinary shares held in treasury"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r10",
      "r74",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "terseLabel": "Issuance of ordinary shares to treasury (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r25",
      "r82",
      "r83"
     ],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedTerseLabel": "Ordinary shares held in treasury"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r74",
      "r81",
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "terseLabel": "Issuance of ordinary shares to treasury"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r58",
      "r59",
      "r60",
      "r224",
      "r225",
      "r227",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember": {
     "auth_ref": [
      "r584",
      "r585",
      "r586",
      "r587",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation allowance of deferred tax asset attributable to deductible temporary difference and carryforward.",
        "label": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset"
       }
      }
     },
     "localname": "ValuationAllowanceOfDeferredTaxAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r180",
      "r184"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Valuation allowance at December 31",
        "periodStartLabel": "Valuation allowance at January 1"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r180",
      "r181",
      "r182",
      "r183",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r180",
      "r181",
      "r182",
      "r183",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "terseLabel": "Measurement Input"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/WarrantsFairValueAssumptionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Expected term to exercise"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/WarrantsFairValueAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r204",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/NetlosspershareComputationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r202",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/NetlosspershareComputationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://veronapharma.com/role/NetlosspershareComputationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vrna_A2017IncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2017 Incentive Plan",
        "label": "2017 Incentive Plan [Member]",
        "terseLabel": "2017 Incentive Plan"
       }
      }
     },
     "localname": "A2017IncentivePlanMember",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://veronapharma.com/role/AccruedexpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Professional Fees, Listing, And General Corporate Costs, Current",
        "label": "Accrued Professional Fees, Listing, And General Corporate Costs, Current",
        "terseLabel": "Professional fees, listing and general corporate costs"
       }
      }
     },
     "localname": "AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/AccruedexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_AccruedResearchAndDevelopmentFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://veronapharma.com/role/AccruedexpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Research And Development Fees, Current",
        "label": "Accrued Research And Development Fees, Current",
        "terseLabel": "Clinical trial and other development costs"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentFeesCurrent",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/AccruedexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to Additional Paid in Capital, Reclassification from Share-based Compensation",
        "label": "Adjustments to Additional Paid in Capital, Reclassification from Share-based Compensation",
        "negatedTerseLabel": "Equity settled share-based compensation reclassified as cash-settled"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_AmericanDepositorySharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "American Depository Shares",
        "label": "American Depository Shares [Member]",
        "terseLabel": "American Depository Shares"
       }
      }
     },
     "localname": "AmericanDepositorySharesMember",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/OrganizationanddescriptionofbusinessoperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_AtTheMarketSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-The-Market Sales Agreement",
        "label": "At-The-Market Sales Agreement [Member]",
        "terseLabel": "At-The-Market Sales Agreement"
       }
      }
     },
     "localname": "AtTheMarketSalesAgreementMember",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://veronapharma.com/20221231",
     "xbrltype": "stringItemType"
    },
    "vrna_BenchmarkAchievementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Benchmark Achievement",
        "label": "Benchmark Achievement [Axis]",
        "terseLabel": "Benchmark Achievement [Axis]"
       }
      }
     },
     "localname": "BenchmarkAchievementAxis",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/SignificantagreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vrna_BenchmarkAchievementDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Benchmark Achievement [Domain]",
        "label": "Benchmark Achievement [Domain]",
        "terseLabel": "Benchmark Achievement [Domain]"
       }
      }
     },
     "localname": "BenchmarkAchievementDomain",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/SignificantagreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_ClassOfWarrantOrRightIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Intrinsic Value",
        "label": "Class Of Warrant Or Right, Intrinsic Value",
        "terseLabel": "Intrinsic value"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIntrinsicValue",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/WarrantsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Issue Price of Warrants or Rights",
        "label": "Class of Warrant or Right, Issue Price of Warrants or Rights",
        "terseLabel": "Issue price of warrants (in pounds sterling per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/WarrantsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "vrna_ClassOfWarrantOrRightNumberOfExercisedOrForfeited": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Number Of Exercised Or Forfeited",
        "label": "Class Of Warrant Or Right, Number Of Exercised Or Forfeited",
        "terseLabel": "Number of warrants exercised and forfeited"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfExercisedOrForfeited",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/WarrantsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vrna_CommonStockSharesAvailableForSaleValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Shares Available For Sale, Value",
        "label": "Common Stock, Shares Available For Sale, Value",
        "terseLabel": "Remaining ordinary shares available for sale"
       }
      }
     },
     "localname": "CommonStockSharesAvailableForSaleValue",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/OrganizationanddescriptionofbusinessoperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_ContractWithCustomerFutureEligibleMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Future Eligible Milestone Payments",
        "label": "Contract With Customer, Future Eligible Milestone Payments",
        "terseLabel": "Future eligible milestone payments"
       }
      }
     },
     "localname": "ContractWithCustomerFutureEligibleMilestonePayments",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/SignificantagreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_DebtInstrumentFinalPaymentPercentageOfPrincipalAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Final Payment, Percentage of Principal Amount",
        "label": "Debt Instrument, Final Payment, Percentage of Principal Amount",
        "terseLabel": "Debt Instrument, Final Payment, Percentage of Principal Amount"
       }
      }
     },
     "localname": "DebtInstrumentFinalPaymentPercentageOfPrincipalAmount",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vrna_DebtInstrumentInterestRatePeriodOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Interest Rate, Period One",
        "label": "Debt Instrument Interest Rate, Period One [Member]",
        "terseLabel": "Debt Instrument Interest Rate, Period One"
       }
      }
     },
     "localname": "DebtInstrumentInterestRatePeriodOneMember",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_DebtInstrumentInterestRatePeriodTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Interest Rate, Period Two",
        "label": "Debt Instrument Interest Rate, Period Two [Member]",
        "terseLabel": "Debt Instrument Interest Rate, Period Two"
       }
      }
     },
     "localname": "DebtInstrumentInterestRatePeriodTwoMember",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_DebtInstrumentPrepaymentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Fee, Percentage",
        "label": "Debt Instrument, Prepayment Fee, Percentage",
        "terseLabel": "Debt Instrument, Prepayment Fee, Percentage"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentFeePercentage",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vrna_DeferredTaxLiabilitiesContingentLiability": {
     "auth_ref": [],
     "calculation": {
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Contingent Liability",
        "label": "Deferred Tax Liabilities, Contingent Liability",
        "negatedTerseLabel": "Contingent liability"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesContingentLiability",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_EMIOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EMI Option Plan",
        "label": "EMI Option Plan [Member]",
        "terseLabel": "EMI Option Plan"
       }
      }
     },
     "localname": "EMIOptionPlanMember",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_EffectiveIncomeTaxRateReconciliationCapitalAllowancesPercent": {
     "auth_ref": [],
     "calculation": {
      "http://veronapharma.com/role/TaxationReconciliationofStatutoryRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Capital Allowances, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Capital Allowances, Percent",
        "terseLabel": "Other differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationCapitalAllowancesPercent",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/TaxationReconciliationofStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vrna_EquityInterestReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Interest Receivable",
        "label": "Equity Interest Receivable",
        "terseLabel": "Equity interest receivable"
       }
      }
     },
     "localname": "EquityInterestReceivable",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/SignificantagreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Fair Value Adjustment",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Fair Value Adjustment",
        "terseLabel": "Fair value adjustment"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustment",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/WarrantsMovementinValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_FirstCommercialSaleMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First Commercial Sale",
        "label": "First Commercial Sale [Member]",
        "terseLabel": "First Commercial Sale"
       }
      }
     },
     "localname": "FirstCommercialSaleMember",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/SignificantagreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_GainLossFromResearchAndDevelopmentTaxCredit": {
     "auth_ref": [],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) From Research And Development Tax Credit",
        "label": "Gain (Loss) From Research And Development Tax Credit",
        "terseLabel": "Research and development tax credit"
       }
      }
     },
     "localname": "GainLossFromResearchAndDevelopmentTaxCredit",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_GovernmentTaxCreditsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government Tax Credits, Policy",
        "label": "Government Tax Credits, Policy [Policy Text Block]",
        "terseLabel": "Other income - U.K. R&amp;D tax credits"
       }
      }
     },
     "localname": "GovernmentTaxCreditsPolicyPolicyTextBlock",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vrna_IncreaseDecreaseInEquityInterestReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Equity Interest Receivable",
        "label": "Increase (Decrease) In Equity Interest Receivable",
        "negatedTerseLabel": "Equity interest recognized as revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInEquityInterestReceivable",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease Liabilities",
        "label": "Increase (Decrease) In Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Tax And Tax Credit Receivables, Current",
        "label": "Increase (Decrease) in Tax And Tax Credit Receivables, Current",
        "negatedTerseLabel": "Tax incentive receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_InterestRatePeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Rate Period",
        "label": "Interest Rate Period [Axis]",
        "terseLabel": "Interest Rate Period [Axis]"
       }
      }
     },
     "localname": "InterestRatePeriodAxis",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vrna_InterestRatePeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Rate Period [Domain]",
        "label": "Interest Rate Period [Domain]",
        "terseLabel": "Interest Rate Period [Domain]"
       }
      }
     },
     "localname": "InterestRatePeriodDomain",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_LigandUKDevelopmentLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ligand UK Development Limited",
        "label": "Ligand UK Development Limited [Member]",
        "terseLabel": "Ligand UK Development Limited"
       }
      }
     },
     "localname": "LigandUKDevelopmentLimitedMember",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/SignificantagreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_LineOfCreditFacilityNumberOfLoanAdvances": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Number of Loan Advances",
        "label": "Line of Credit Facility, Number of Loan Advances",
        "terseLabel": "Line of Credit Facility, Number of Loan Advances"
       }
      }
     },
     "localname": "LineOfCreditFacilityNumberOfLoanAdvances",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vrna_LondonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "London",
        "label": "London [Member]",
        "terseLabel": "London"
       }
      }
     },
     "localname": "LondonMember",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/PropertyleasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_MeasurementInputAnnualizedVolatilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input, Annualized Volatility",
        "label": "Measurement Input, Annualized Volatility [Member]",
        "terseLabel": "Annualized volatility"
       }
      }
     },
     "localname": "MeasurementInputAnnualizedVolatilityMember",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/WarrantsFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_NuanceShanghaiPharmaCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nuance (Shanghai) Pharma Co Ltd",
        "label": "Nuance (Shanghai) Pharma Co Ltd [Member]",
        "terseLabel": "Nuance (Shanghai) Pharma Co Ltd"
       }
      }
     },
     "localname": "NuanceShanghaiPharmaCoLtdMember",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/SignificantagreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_NumberOfWhollyOwnedSubsidiaries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Wholly Owned Subsidiaries",
        "label": "Number of Wholly Owned Subsidiaries",
        "terseLabel": "Number of wholly owned subsidiaries"
       }
      }
     },
     "localname": "NumberOfWhollyOwnedSubsidiaries",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/OrganizationanddescriptionofbusinessoperationsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vrna_OrganizationAndBusinessDescriptionTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization And Business Description",
        "label": "Organization And Business Description [Text Block]",
        "terseLabel": "Organization and description of business operations"
       }
      }
     },
     "localname": "OrganizationAndBusinessDescriptionTextBlock",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/Organizationanddescriptionofbusinessoperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vrna_OxfordTermALoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oxford Term A Loan",
        "label": "Oxford Term A Loan [Member]",
        "terseLabel": "Oxford Term A Loan"
       }
      }
     },
     "localname": "OxfordTermALoanMember",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_OxfordTermBCDELoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oxford Term B, C, D, E Loan",
        "label": "Oxford Term B, C, D, E Loan [Member]",
        "terseLabel": "Oxford Term B, C, D, E Loan"
       }
      }
     },
     "localname": "OxfordTermBCDELoanMember",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_OxfordTermBLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oxford Term B Loan",
        "label": "Oxford Term B Loan [Member]",
        "terseLabel": "Oxford Term B Loan"
       }
      }
     },
     "localname": "OxfordTermBLoanMember",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_OxfordTermCLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oxford Term C Loan",
        "label": "Oxford Term C Loan [Member]",
        "terseLabel": "Oxford Term C Loan"
       }
      }
     },
     "localname": "OxfordTermCLoanMember",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_OxfordTermDLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oxford Term D Loan",
        "label": "Oxford Term D Loan [Member]",
        "terseLabel": "Oxford Term D Loan"
       }
      }
     },
     "localname": "OxfordTermDLoanMember",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_OxfordTermELoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oxford Term E Loan",
        "label": "Oxford Term E Loan [Member]",
        "terseLabel": "Oxford Term E Loan"
       }
      }
     },
     "localname": "OxfordTermELoanMember",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_OxfordTermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oxford Term Loan",
        "label": "Oxford Term Loan [Member]",
        "terseLabel": "Oxford Term Loan"
       }
      }
     },
     "localname": "OxfordTermLoanMember",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/OrganizationanddescriptionofbusinessoperationsDetails",
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_PreIPOOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-IPO Option Plan",
        "label": "Pre-IPO Option Plan [Member]",
        "terseLabel": "Pre-IPO Option Plan"
       }
      }
     },
     "localname": "PreIPOOptionPlanMember",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_PrepaidExpenseDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Expense, Disclosure",
        "label": "Prepaid Expense, Disclosure [Text Block]",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseDisclosureTextBlock",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/Prepaidexpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vrna_PrepaidResearchAndDevelopmentFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://veronapharma.com/role/PrepaidexpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Research And Development Fees, Current",
        "label": "Prepaid Research And Development Fees, Current",
        "terseLabel": "Clinical trial and other development costs"
       }
      }
     },
     "localname": "PrepaidResearchAndDevelopmentFeesCurrent",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/PrepaidexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_PublicStockOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Stock Offering",
        "label": "Public Stock Offering [Member]",
        "terseLabel": "Public Stock Offering"
       }
      }
     },
     "localname": "PublicStockOfferingMember",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://veronapharma.com/role/OrganizationanddescriptionofbusinessoperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_RestrictedStockUnitMilestoneBasedVestingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock Unit, Milestone-Based Vesting",
        "label": "Restricted Stock Unit, Milestone-Based Vesting [Member]",
        "terseLabel": "Milestone-Based Vesting"
       }
      }
     },
     "localname": "RestrictedStockUnitMilestoneBasedVestingMember",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_RestrictedStockUnitTimeBasedVestingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock Unit, Time-Based Vesting",
        "label": "Restricted Stock Unit, Time-Based Vesting [Member]",
        "terseLabel": "Time-Based Vesting"
       }
      }
     },
     "localname": "RestrictedStockUnitTimeBasedVestingMember",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SEC Schedule 12-09, Valuation Allowances and Reserves, Change In Tax Rates",
        "label": "SEC Schedule 12-09, Valuation Allowances and Reserves, Change In Tax Rates",
        "terseLabel": "Change in tax rates"
       }
      }
     },
     "localname": "SECSchedule1209ValuationAllowancesAndReservesChangeInTaxRates",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SEC Schedule 12-09, Valuation Allowances and Reserves, Increase In Valuation Allowance",
        "label": "SEC Schedule 12-09, Valuation Allowances and Reserves, Increase In Valuation Allowance",
        "terseLabel": "Increase/(decrease) in valuation allowance"
       }
      }
     },
     "localname": "SECSchedule1209ValuationAllowancesAndReservesIncreaseInValuationAllowance",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/TaxationDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_SaleOfStockMaximumAggregateOfferingPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Maximum Aggregate Offering Price",
        "label": "Sale Of Stock, Maximum Aggregate Offering Price",
        "terseLabel": "Maximum aggregate offering price"
       }
      }
     },
     "localname": "SaleOfStockMaximumAggregateOfferingPrice",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/OrganizationanddescriptionofbusinessoperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Award Vesting Rights, Minimum Stock Price Required",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Award Vesting Rights, Minimum Stock Price Required",
        "terseLabel": "Minimum stock price required to vest (in pound sterling per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequired",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Award Vesting Rights, Minimum Stock Price Required, Period",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Award Vesting Rights, Minimum Stock Price Required, Period",
        "terseLabel": "Period to maintain minimum stock price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMinimumStockPriceRequiredPeriod",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Vesting Period",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Vesting Period",
        "terseLabel": "Weighted average remaining vesting Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingVestingPeriod",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationRSUActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period, Grant Date Fair Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period, Grant Date Fair Value",
        "terseLabel": "Fair value for instruments granted during period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of American Depositary Shares Authorized",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of American Depositary Shares Authorized",
        "terseLabel": "Number of American Depository Shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAmericanDepositarySharesAuthorized",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vrna_StockIssuedDuringPeriodSharesHeldInTreasury": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Held In Treasury",
        "label": "Stock Issued During Period, Shares, Held In Treasury",
        "terseLabel": "Issuance of ordinary shares to treasury (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesHeldInTreasury",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vrna_StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Held In Treasury (American Depository Shares)",
        "label": "Stock Issued During Period, Shares, Held In Treasury (American Depository Shares)",
        "terseLabel": "Issuance of ordinary shares to treasury as ADS equivalent (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesHeldInTreasuryAmericanDepositoryShares",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/BasisofPresentationandSummaryofSignificantAccountingpoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vrna_SublicensePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublicense Payment",
        "label": "Sublicense Payment",
        "terseLabel": "Sublicense Payment"
       }
      }
     },
     "localname": "SublicensePayment",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/SignificantagreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_SublicensePaymentEquityIssuanceThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublicense Payment, Equity Issuance, Threshold Trading Days",
        "label": "Sublicense Payment, Equity Issuance, Threshold Trading Days",
        "terseLabel": "Sublicense Payment, Equity Issuance, Threshold Trading Days"
       }
      }
     },
     "localname": "SublicensePaymentEquityIssuanceThresholdTradingDays",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/SignificantagreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vrna_TaxCreditAndIncomeTaxesReceivableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Credit And Income Taxes Receivable, Current",
        "label": "Tax Credit And Income Taxes Receivable, Current",
        "verboseLabel": "Tax incentive receivables"
       }
      }
     },
     "localname": "TaxCreditAndIncomeTaxesReceivableCurrent",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_TermBLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term B Loan",
        "label": "Term B Loan [Member]",
        "terseLabel": "Term B Loan"
       }
      }
     },
     "localname": "TermBLoanMember",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_TermCLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term C Loan",
        "label": "Term C Loan [Member]",
        "terseLabel": "Term C Loan"
       }
      }
     },
     "localname": "TermCLoanMember",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_TermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan Facility",
        "label": "Term Loan Facility [Member]",
        "terseLabel": "Term Loan Facility"
       }
      }
     },
     "localname": "TermLoanFacilityMember",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/OrganizationanddescriptionofbusinessoperationsDetails",
      "http://veronapharma.com/role/TermloanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vrna_UnrealizedGainLossOnWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrealized Gain (Loss) On Warrants",
        "label": "Unrealized Gain (Loss) On Warrants",
        "terseLabel": "Fair value movement on warrants"
       }
      }
     },
     "localname": "UnrealizedGainLossOnWarrants",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vrna_WarrantAndRightsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant And Rights Disclosure",
        "label": "Warrant And Rights Disclosure [Text Block]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantAndRightsDisclosureTextBlock",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/Warrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vrna_WarrantLiabilityCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Liability, Current",
        "label": "Warrant Liability, Current",
        "verboseLabel": "Calculated value of the warrants, in thousands of U.S. dollars"
       }
      }
     },
     "localname": "WarrantLiabilityCurrent",
     "nsuri": "http://veronapharma.com/20221231",
     "presentation": [
      "http://veronapharma.com/role/WarrantsFairValueAssumptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131252-203054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/subtopic&trid=2235116",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r562": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r563": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r564": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r565": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r566": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r567": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r568": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r569": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r571": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21459-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>88
<FILENAME>0001657312-23-000006-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001657312-23-000006-xbrl.zip
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MBQ_F=POF#[D4CKA>5.K>[/7!5_XS\.?Z =(=;W?$:YN<KNT4H1U$*U[R1:E
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M."V4E!--Q8,CIIM:9;HB]T:%S+!@+=5#E7\XE:JNY0&9.:H[_AM02P,$%
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M>38)?(?[=D!MCW[;PZY8MF6;(V[OT@Z^6B;;.R"3!,JE@Y2>;1B)@":%^WG
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M912T6<FRZQ?'7 WGFQ AC7S"3#NP/& N&I@LL#V3!J$3V2P QG,VWOSS'U%
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MFB24L<FLV#<%ES208<!<V_ZQY+VOG%V44+U_]*9HRS2MY:[Q:D[:V*TQBM^
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MF#3-7F4QK!CTN\D">J35/MQ5MZME[G<Z1]6Z&. M0T/R&9#N -UZ$VN"6,9
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M&O)W;8G5629VY=.HG3Q, HUU6UD7>C0U&JUY]+AYG>PR5&7S5L>L7AP9]R-
MHUX/H.%YZI$3&DL,BFG9LAI#O+LF&9ILLWD;4W$L5#=9>JE\.9/>YDWH+V8
MG"L+#KWM< '@WQ W30MO6(-""2MH!IT]BF,_ME3(-;]$A^O(S:XD&,<C/2B&
M-[NUK8MY$"I^I,^VQ;!IKH+,T([&EO S&(QIV1X8T/$^M TWJ[ !*C0P[2]5
M#%6H2D;IH(9SB+D*E'2*^34,ATL="@/&4.8HGZTV?]7JF8AGMU$+819#1\=W
M9RSF2JW&4NT]J&]553 &H[OG6L;8QQD;&H0:-,148';:^)[CF2FFO%XP5:BE
MIRG^_<!E&WAJ""-J-#T)(Y24TB2LDSE5KA%8 CWM+-2. X3LVH&G1%$]'0C
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M33B0)VS#B?6C.LAX3\E46.?DY;%,Y3,5+1BV'=3::&E-\R43I<+PP:Z@< 7
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M.C0[U?$OX:QVIFE06=#ES/L<K9-_21#YWWX@UO \3QFYU' >OJK9"8W(*'+
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MXD:2R&!SUA-&]]U9+9V$F BQXVX77%B[8 'E\<2JGD7^.(0:>>Y(?$C'-"Y
MXX(,;G_#*$5-1\E]8#D2V>W+ZARB.=3Y396K):&,3"MY [ ;VKR<]W:6)9G%
M)Y45-<:F+)CZ2/IF3)0[;E69V*I8PEK(1HNA=X?Q385U7-2U+%(P-YR;TS9
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M%0]GG\)7^ *HZ,A"W#^8/XA$"/A2L26Y$4ARIY$H%?Q4VS/N*3,O#*$D/H?
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MSE1>^4D%Y"H\]:**!X9EH\.BTYN1LL='WF_KLUGR"?M.\J#)0. )PY=X??B
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M9RZ4/2S(%S7)!"[@S2F:!M[+SH]7SPL['(>S)\.W!4KG<#C*UK7HBF3C9N9
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MI VKP%VM@0S@+I%+*"4N"-V@]?7]EG.(\F0'CGK]\ZLV1)=OP'T\ 9TY/0H
M$\]JP.3B[5O<OER;&21!^E>NGDEQII9F&WY/CV\P#*QS!;N%V[Z+],F^9[0@
MH#2ZS9%E=F0Y]4>:R:!0>SAQG;T@5W#/M0U%K]J_.I (^ .7,R.&YXN7=.7A
M[#4<*P9VZIC4IPM1^4;;**;Y6??L#1.MZI)'%(">0N598^ !*^L -TI/+Q_+
M+ )WE2E^E5#^CFER)\:F+S8VM!MPPK'[E_8*FZ(MTS[I3J=P$RZ'/;[B$9E'
M "HD;7NV:^EC.=("M'G&/2)MUYD1>;*!55^M\K)QL %ZB5*FD\T)YK)]LP,R
M *:=G'43ZR$H&!G9X.OC5(6[$XL(^LTFMU[9BK0CQ4*/I=V@;5TH6(TC4QRW
MD.R4]0V+RU3&GF7 IPF? !T7-""@MZ +FIN'].:&7-GJE3),INU-?)C'-9R8
MN:M8G+3&G5WM#SP+'*9P#DZH6Q[24"T+TN!K^8*G3QBPGX^93/@ P -RQ-&>
M6)F=;B%MOBGW$2=E(W%)(491ID<L70!1I3Q>B946.!=/2*E')MPG)P.",CW;
MP3Z[]]68"VQ+WN#L1=U<Y.2U_5@6BS-$.[JB%.3NLT4!UK6;L/3&K$V'LF<%
M,)?("3H&]EPGWRP/)("(_U8<$HRH67;*2OYE:I2SWK9F[DK@Y*F[M9!LL/(B
M4@7I(LT"ZJ'Z&N@L_U[?I(&=[?WF9<(&S['0**79X]"(*YNB7 028IB=EL:,
M.I-/EE CYL\F1D#Q*T=B!NP03=P ?Z#"JINFWX8B6"R3]H*\FH 21D-HFD@"
M#<8'9_,9)7]IH] WG%L/OX",60?XK!"_MX,>LB$5<,7NS&I74X1%B_%_8U2W
M-I;*FFX?4/;TA(H]2XC8&ZY=2] 6>P@J );OY"M,?\NDP9'?/:@Q_NAMMCMD
MN[^ZS7;_+MD:Y!\?K(&\&%$[[FL.D#&C:67_2$\NB07Z1V&-"P:-!&YV)]/O
MFN)=V07J7=<>XRG*R2[JYNT@'_XW6MMEO;D>JW%%S,S8XEP47A=DQ)+FF5.%
MFHO^^SWROO25DF-,=YY4IVON@_1Z47=K44G+V2\YF6!W0V$RIX$#IZKSA$B-
M0W-GLS/!L#JF,Q()FV!K/6O8</K+BYKA8I7] J@/3C)F]JB!S<>6P/!;@:@V
M6@V<P.)A\BH(?(_I67_^&SXVLS(T"4MC1=;%*3E>HD>4Z2RU,I.5<C#=.,=7
MA6+=:2P_TDONO"K.:PO:T^Q>P9C8W)U]A_ &.-Q<F]-%WS22M%"3@\_KWZ"I
MUF4.Y9ZQ0=:X=V BS/O\#@Y1RPD/TN'-N185JNV+A"U"JW3T(Y8$4+]Z Z#E
M@I_#6968+A2[H6!@GO=2[H#A%BYO9TUK_@>,)/?N\WEZJ QM("MAWA;>.!I>
MJ384IY/.Z[?RDL?%0HP^HZ]SJXK(D]\27Z((ECHA]M5>K?MV*?8 ^^XF1>9B
M66VLT<3J/M<*Q,?%.7=-.Z%;*;<<GWU=+'!XQ&-_+40'C>&/CA]^Z^&3@335
M^+9Q]<D$1,\>Q))IE\26Q\E<#CIN!B3BN+D7W+C\,GM<9["4&6B/2B6!Q9$0
M9]#PFTI+&]S\5=^I$T.V!YOT4]?;;EU>;EIM&%M?S%9K&K=V^633>8D[-6AP
M=)IK59F^2:FRP_O+8KUD*7?&/$^N3G.BV=QHMC?@:(I"&FF9\5G]@?V@!?<!
ML1/@5/<)VM[O(J7<#Z^B_QZ02"(B8^TN-V58(SZR2=XU6.>XH8>SDY9K\MEA
M4N4T4DK;H)0D#,.Y'CZ'KIT=G8#1%SO!*\R"4F4]*E$QTZ]P2DX+ 4U__]VW
MY W6^1))XM'3^&6HIRHKJ75=U7QPQQ@6^K%$"31J69'Q#>PA4ZS(_%A5>+Q-
MM-0W@GS@C2A0MRXK;P]:I>@D3?X N1<D&I2N4TIWD/DW$'YJ8627FQAW0?0;
M[\E7F=H#M@-)H3O/BB9;O.6H%:A;Q-W%+# IRZ_@U6YX$\3Q2A3FG[)8UUJC
M+@7WQP\<P:S)2+02SC=8Y+$DB\W/R-$0-6PL7IF6VH^_)799CBJT7?CB*6,_
M&\D3<=E%(R>7 1DQ)%L8EEU^)_P(975>K\^5C']$DJIU;7W'W+$1PQ'7(51D
M\((@0)5WN@-Z^98%K%BL@6^-3HN^.*O16D>4"=K/A6@Y[!0@?@&B.RWD- FP
M,>1U_0&-.NC&7$$^S0*1">K:U&;2+H%=6,V?.$H:"S'&WTK.CUDJ$'J*^$-7
MO60,#0HP%3BI%4"D;.3'7QX=+)'L2WLQD%JHA9,JTF48FA&I%2\3GFOYE((?
MUSL/D@WJC;N%IZ8Q8]0:[1V.\-ARE7.^),H2>G;FD#@P<;^;W4%9R5WF&.##
MC,3+:3'IX&GCJ2XIHXQDT'0CF&PC$/]8U<P>QI;8_Q*/\VL\353)]661SL(R
M2SYM4H9*-"58%9 K6Q+BRT9TM9:,VK<5 DM?U5XV_ET3[\!=S2L'/+/9HBO-
M'NXJ?)E<H7R9ODFF@O5DO\Q_&\<A7=2P9KRA&@0/I;[.! KC''0#OV3=Z)%L
MY. 3:A(H\Y7^-7(])_E<=Z&L=M:J@S=*"\E98 TGE$ESI44=^UFE-].F6KWG
M1$4PLY20X#5="_C+D4\?#3&JRXA;ZP#5'S1FOC.YIW<Q,@;XFT#78S3L3)'C
MJB6+QM T.S-FE!K[OWL7M[783_FF)<BF]G!>0EI5FLBE>:@[]#Q--@WR4)FF
MIZSOB $*64S<!(?BC2N"!N, DY -4:&X;'Q%G0&E=JW@=WW/Z&E@Z4R:[Y%4
M+M8QW=0(^(DUQ?,3_QPUI RM*JE@X!U+%NR&VQ0CW(6C\G*-[G@AY2ZY"M)(
MS!UQ%=24MQ7]_]3ZR!VW-^Z_1.?V%KH<SEZ?<58'I-_C)8CG1T=R&;[<I#ZW
M/TS9%5;&GN N9 +3O4:'\T/KV'ACG'/[(V*2UV.J5Y6+&V((UP--@Y+6Q<Q]
MYY*I@^:4'/R+S3IC9E0RFTSYM2J6C,M@"!['I\[B.B:=SB[:\'*Z7RW,O39"
M7T+U>3J$LEK2"H*/5(.NUJ0'-]2JB3WM4X1@Q)%UY<';<O%VGB_>9B M93@T
M.TGLB1B,AT3)+EB27-A#!JL0CCF_AV="=U*!KSPO-BLQ ^MDG?01OR:7YFJ_
MW._W"5;U;[JJ')D$>[2!>/8P]L/F4D@K]XAEDXSET-NJOD"[IEUPW%8]1'*-
MV WCY6AS^/\MVA.60MXCI=":DI-:=;$*8)* =;M1AS;D/5#C5MF_,@:XZJ\7
M^G,FQ5;P>>335M7'(-R>G.V\Y9>O"_V!#4;]B<XDG9538\'AS+MTME^:OZ_/
M*&[3U2Y=_?5MNOIWW4\<1JEQ%?<%UC3=@M.Z7F9&ZX8&64#N(O"/CH4+".AR
M,^^;%A9M)K2\]=K./? 6EBF3+ 6Z*<A/Y3*4EP21<)9$AYFE4@PNV.NS/_D;
M^:<8#];8J;@J9$99=R\#T58[EAZ8$4A^M&O;M/@)#QT\+&0AY78J[,::- U4
MSJ! 0=GC*CQ=,ZN*9)Q+B:5>9_R,3"':,^\4+ZU8*@EED(IIRB(^D0& $>#8
M!8(/SP<:,4B!*=5 -Y&V#@P8-(<YH%I6O,<D)1M&9V_@F3G<*.0M?:PM%HIN
MX%1T^OCDF1@4D#OD@],"UA?K'3@E37%+C9+$\1*Q*W_1HBG8Z*>!)C64FT=9
M:XLJPEX754#0080ZD/4\J1"A;])<Z,!+;=ENMJS9,D")FKK'#F\EC0W#RO(;
MPFJ&A>![$I?A<&9P.\0!\5S'VS)^O.L)[G*=$]LY>+U[8ZR*9!9FC]9"*T,P
M!JRE[V_,9E^MHP=N%S_ M19T-R1X"\JN)?'FG'EZ#^:[ _Q?ZS\#8RK]M=_T
MHJC,D<-ZT(.0U,"]4J!+V= G0_/WUP63EP&_UAAW47*)SVSQBB^4K2#IP2V;
MDNN9*T7ZX=)J!W41B,GLY,A*K- =VK)UA[)1*I]6*JQ'<HZ-!N3%U9[-_$"C
M.#HG(SKO;DB;/^=49%+HG-ISX=0R3S((:KDP><&1%=AYZV)Y&MQD6RM<-BO6
MT.VEK^K"29_>&)GC)QK3***^\CGV\&_ "D/!V6%+W!7!Z?B6>X7"0Y_RQQ[)
MQTY0*&JF^'ZC>]I&CY:X<AF990MN)NVM.B_LC]SH4P8)&!NIA(YKM$!$T.3]
MLE]S<VJ,2PQH=;'@JAG[$X(-<^U<:],6P+T@:.*(2 [R:/IV>E @^M!@W]*&
MQ=JC$;@#?$-MO:DP&2YSE<]-#5EC2E.CJINAYR*C"\^+;\-+SNN2EFI92,6Q
M\E(M"O9/AZ1;.5<*%0%!G0CU. 9PP\@P UWNG\3U8>H)3F$5:,CQ)^'\X$>*
MHP3BW%W<P^1%R0LT4! 5S/1Q,Y4\YS1"*,<\H:O6X*W?:_4&MAS)>Y+;LR[?
MS)11&[AU.-OGTF8Y%$*6UN$M9O_\Z/YAMSY@U/:,#NF#"+ ^!W#;,Y=@983Y
M(."H&0G0%-#9RWR3GWH=-1$ED2N4* 9+:,0PHME<H>BD8_ V1Q!H@_:XS&(W
M25V\^K><0+*X'*+U)*W(UFO:F,(4WFYGAO'JQ,]Q0'$._6[GRDSV85V1-9^\
M8D8K=QD3F35LK6TD;R%,JH_]8A"*\@W8^BHVU(7;8>5(D 38F>=U4]2,0,N3
M&R%TK,6F=3Y/JR=!%I(NL-,>(?]RA155N(Y9[:4")"RFF"'AH-K#IP\LYZ&B
MDHTG>^*DF@*5BL?6G^%3L*XF"D"K@T-./.KG* MT(X.M'O^21ZF8#ZRAP'D>
M^2+DC1"/K;)WX,SAWQC"2F!L0X=4<I,*657V06:WXC?+Z/#M\8(KO;PF7[BD
MC"=F! W\24D2S_LV&!ZML[]9DJ0%+')ZV".*QT=\YG"-@T<<)8%$(6.O!MQN
MDCRM2I!6Z^/E-?3VO%ERPM=B[OFNOC'%8790)+X.[T.*:&8O06BOX#TLW<F"
M*^3L5R=2E7+\S3</^=;_\.PE2'P6##=9^E+8<)D,/!_VEC?3+*%4P.8&RM\7
M>BS>L8-L<3T27IMMI[:&_(T;5BAU/K-PVAG;>540@ QR&E)XA*B\M%*+]OZR
M86WFQ6^_K37H"4]N[4399>]U4=5YVS6]1 GRN&PIB2N[L>YY",56K<36]PT.
M]Y).&R^:VC=6, 'YC)_[+7--J_T%AY 3KVH[H4>6_DT?=YE=&4TLIJ>M*J4M
M"FIP6:Q+5O<HB8O6)X3/>*7:;*PL8J!_RA:;=+!OG:)_O=LIP;+(;L>9 *Q.
MHR45D=IGG*"*TIX-#3D3PA+(YG<HZY9 A78%'9EXJIV,U^ME2".]M">^[M'2
MHBI8E*E^WI<8J01W8,07HS)GBS2DT4G?#C9,!*/^$Z>L5DJQPH'3/T5]FL[R
M#@DNLP5"Y6 -$D(T,\4!9@K >@OCL6OD7]M:Z+Y:B^>0"*LYFT=?NYN%455U
M=> R;!PUY#)A&MF=^ ?CI\.C*RC7]*,.BBU_Y6M!QY+'HBQE- /Y8UZ1&#LK
M=-SZK[:4/K?Q36%[W7</-N7R C7@=\4%0'4W]N.L;K?()^-Y (4!0DQ+>X'!
MG95;11P9P^/,^CVU0C9/_LW@5'5,3E]N-LR:ALXKN#**(&F36*/VS 9S%/=^
M 44Q?45E+]?E%OQ/%XC$8!",=K 8D'/H"<EFX],AQDN8#V< )J:3EJHFS/G[
M#%0VN:*RCG_ L/ZDFH06@"?<'OYI]FCRJ/O^X4;CHF[F-T<D[I=2/,#E^"#$
M5V*-!5 92Y+?(#@;V-5V1M5FU+6+X. @(QSS>7"3PN([1O1+$MA?M*ZUE?L>
MVM04ZX!ZESU<%^="QI5\S-Z_Z==2T:'3GXI.*/_)_FQ_3+P;+1+]XJV1*"0,
M/*?EBF\9<.A5&RNC1(0EP5,<&U&A=JSVR)Q)IQG40@6CPZS8@K4G%SK?YDI#
MKO2;VUSI[[(DTK"1\%^2T. X#'NE.SV:\4(-"NJ<CWB)0%2SVBKX10[ZVOXH
M"[U3H/$FK0I64!<:\*A?Q%T"&=(%T0ZS_Y($[.Q.?+#E<%W96;F\"W!$>UHW
MFA41L=;0]9=87%><<L4)4XBJ]E H#HN8:7NF*>F);*\;X%0ML,B -,B952[
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M9#2W;C0W\R7+LL-9.PJMUCL2;\J0\5E38!R>)8L:'BW1%U2(KV/C^9@/XV0
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MW$@G.DQYLE7JX731M-L&WC?LA-1(^%M@S"<[.FY'0K&FB83+7463$"-(6^$
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MP175"CR;_7Q@[GDN ,7@+!A:U)44<W :&(84V5#/)]:**+\X-A- *Z;,!P_
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MD%F!11^ T-8=VG=8OE/XP_+:4=Z*X@[(MP0GGV+ A?2X]5S!HJR3J'QA%Z5
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MQQ+J08454WP%5:/<]HECV\$Y20S-F8&2$?U.S'M>-ELPEBZ*G>*:A93'F"=
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M/$RFF?D%Z9;S\T7E1$=34Q7Y4OU6B+41.JS2NPOX.RT-/H0=C$4[)_O*!:
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MH?S:B,<;DK>D' T/#6>?K 0%>-P@2HMB%&4[<5AD';^KY,2H315U#IZ^V5N
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M(*>7#GOK$C#G*RZ[X_:VYI(F7S//V6S)E2NJND!7K4\+;U3UL6_'1 _A :F
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MU>6YY:>N9"A4O!,_=_K=)YMR>45-:(]%HHEH[0>MO#EQ15/2D(C-Z.DNRJV
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M;_U,AVEF24CP/ED)//A$,$RC-(2+#L"=X()6L4Y&"5IWD<KQWJOV$5CH5]$
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M]9J*EBK;F0*$--H9),>L8% 9Z^ADIJ,NI<NT5AE[H<>];V ,UQ3@"[P+G^_
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M?!AS=*M60ABA9QI=5=L%7G]>Q\9Z%,5KPR:OAN@W&/$-?F-C-4';6J/01ZV
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MRP"PWO6Q'>O!I"]NA:VB 2Y#&<<-O\Q:0:._-.QI)ZMS=_UP2OMPW,<&&5S
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M^3NA%+SNL(>_Q$QM)TF][BOWW=K4^BI=MG1Q68A;05SFUQ;)RR%2S1RNCLU
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M'/T?' ^=#A;2+6Q5B<AO?12:I9V-EH?!#N@S()_ A5P;KN;P.!5<EP>Z.#C
MGI>"/'R!'@BQ)UT#G_ H(A>G<K^K9QGD"9--X?JK.(^>/FZ2C-'2-,*8?5WM
M!#0+007(VX?@X'49/K[Z/\&'("A8T]2%^WPL7=GGOR_[#ZN_E'M!Q N#(FAQ
M!QJ*5PTI6JW>AL#(7TG5Z>TZ?RW'?4.#]&.]^1!N77@8LL06U8"X(!R>>VJ:
M([AMRINJV2$.;-]6E#5]%T*TR^[LY9Q/$H[\\+SARZ_*<!$:[M=U^=]GOBT:
MNE)"#M_;]S4)\9*S]3T%AVU$&"W<_L?_71ZNOGY=K-Z7?;GZ<5^5P1$3L6)Q
M;N*L]AHLX5*R& <#\;%C<C8_'EF%9SKI$Q&^<(,9,[!,K<@MC,FOPE<;]'!Q
MBK&*@Z%:('.;,;-=P=I31KU0(X:Z*R41*1^Q#[N;NOL_U%"^B]O3![I<J<7X
M87]IK@[Q++*#^8O'UW6ZP0Z[[A'OZI]++SD_EXT_[?IZ/,8Z!E_+IWX9E\&S
M!DML&"(2%6:2.1,U)NJ\-NU6\2P8M;$&S&E$E[3]KA>4<U(_%I$Z)6K#N)<4
MQ7BMQO**#B].75@JSE=YM4CR4%HF[M_2PGJQDI;55>U&,+4KM&=+%4R/"MQA
M(%WZ!:=Z3(-;,G%97?:@W@^,+WR#">1AKN[W,";E-BZ#9 HLL^M"=O&69(LL
M)>PU(C>"G#P,32AHM3!*:5CZ\+8_7B[/.Y\G2_,?K'PGADE*\9KUWJ8.'R^%
MXS!:]0,D.C$+SANQ[V1O1V/G\">R8>,I;K5SMX*#-=1PU!=;V(<4-Y%K_@[3
MON PKE['JHH2+\2[AT4>_K!Q$Z"?<;,9Z^[JTHQ5>4B6?BEV^>1Z=?Q ^A%T
M.'(%FCFA7)D)-#S3B"B@(8,+=?U'#,7[6RX*V+]HC:1:YHHHIT]LH\J]&Q+Z
MJQE>;\1MB#GY$(8^GJKRLK)%O/O [Y_QA-GUKYJ2Q^#33,L#BSW)M_[F];OA
M81C.^_+M9-G\X,-51(D( ,$!C-$6#ZT[:I0DNQ?\^DVD&9AT#**+LF0E"L==
M8>@PW&58?>&Z +,_]55D2UR?,/Q?3L_(4HB#=3__0J[X4&6;"$$!8\>/C^+X
M^P8S\KK:,*'W5R^(&O;ERR14\7'K=-XPE)<H1(,2HUW]_G\E<Z]VN>ZU:QK:
M.#OB)F88KYZ%EY?40$NY<.JNW3+]RR_U@6N>7[W\7S;[QQ$,LS3=U]TX-^OW
M7A"#$#NT;O)QNWBK3LM7"7<;CARREL!UCR/('P$E26+90X6S&N.=;@VN3"=#
M)LQ[9=.Q(("\Y-A=,HD*EB[0$D;N1;O$L,MH9:3V)1$4<*L8OL>N.>)<!-#R
M.&ZD'3;2T#&I A5_M1Z0O8=4"N)#0ZT;3Y2]H&Z;AGO5&% 65LGS_V7=\WLP
M,$LT()/#;1?\WG<<2L9$R"8ML\>C0ZSALXC[,_C0'^#]F'U).E&YBZ$+0:?F
MY'GYBRTKK'X9QXV3T9@JSE/(2UE1MC W!:O[&MD+1W7HK8WB#X&,%*Q_&'=P
M7!M,;&"D#C=8@+JPI92UHP>U3G7CNL#1+&6)'1_7TGPH\ =QB(PK, [J5D#V
MD6Z]I3W+GH^4.B+>GN+8Z'[13A/$3[(C'X@AO>=QJ.3:D0?)H5&D=5,Z;_8K
MY-=\TA5CU4T/.HW3.]HET RSF-W"Z;"PB-6,\S%**:N\27+QE>P9)47%X>OV
MDOX^;)JP0>'^T30"=:-+F$EX6VJL K<B[#HE&XY]*Y:Q[@6K\H Z%\\>F#^A
M7JE<36_:RX:D8)KRIH@1A+6?EYO-\7!D[R^<D V 3&'7[ZC:ACA,JG'T\^R'
MN="W^H(JAM(FV(8I$5KB=3G4X>P2=O>XAJA[2GKD$I41C?Y@!)B8>'UD_D]]
M*A4Z",<A&P&]*I)<!I9 ^UV\H37T#*,NX'R/T]>1OMNZ0@*)E7%%6)?I3D"2
M4F6P> 'YQWMLH\5]DD $;]LTMVS&7V]/&9GXW,:V[8;[29.*UJRGVTSHD4Z2
MY%.7=JB:1CZ+]WFJLEJ5]:L'4&7]+1O%F:U1 E52KKMK92EA>+6D%7DY@PLF
M;(,] 6HOH$(T(*8@2D5.;":;6O1K8(#D:^?VYP,Y;^[I5_Q%G%WO5&E&RKP[
MJ R(]ZRRD2RXM4^_/IFW-NJ;ZIDNUZ$XC%M*R+@*(&\N9I9@3\GCPM<?!;QS
M;N 5J#PW#-GP$TAQ+Z%!TN F(Z](V*UJO/*J;KEW6PNP?.83;>3T83#[$K%
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M=M(5Y!5JH4TUS9B"R-[GV&=ZMTQMBS6R7:['TJL="&+3LU\BOF;<:_5;.=F
MBP.4FA/! 4;_(4.W,Y*J&# 3C 3HN **5_8%:L#:./7)LV0E"2G'"(5%JN!Y
M:MBR'J2W'2XOL&RSU_5&+E$.9EUR/!D[C[*.IER1E$'Z65"[M0_R4E0TXDB<
M$!E*=2*BD %;F2'&&FIPB9;Q99"'XBK5J$?54>=V6P(Z>7<_:Y)F8B9U104
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MX,;P Z=^'OC_L>9D 8C:+?.6"J'([OI#7<1"W=*B_.[$5!W:W4"MF5,UL]U
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M 9^%4_%@X7G.T8C46#[*2:7WQI%0DXSJ4/V]"<:T6D-,\.-UX!U ['I.2(Z
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MN&+.1]!]<M#4<*-VQ]>[]N\J91IE$%Y3=5YC'ZN,%9\*.8JAMUH2FDPF@.6
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MNO'?V'-/R,,B&OR4A3:EUU/T"EEJ5Q(&-DWXO5(("U:DV@\(/A1_HES7NT,
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M._W!WMV)]P9*^5:\]6EO#X&S]UYL*!R?XC8]I CX;D?H2[A\O7W\2)C[BF.
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M^1R1JA2'2?:9)BVFH(7V[.62OA; V'-T:TCB&JEP,@1Q?2L-C&*,UI#QM6;
M'><08ULL,LJ4SN<!OXSFC:R<=0ZBJ1&]KDSB,HTO0_L8L'M1)F=4?%+&Y1NX
MM%DTD6@S$.R8\RS0,D>+783)Q!%UV"BL7"A;.0\X"1Q.*69NR6[B,@'P+#_C
M B2Q VBC;.Y>6.75E,*CBZ?96 95/0;NG"(ULIW'>\XTHK(&*INR2E6-$(PG
MT]JCB(S6Z$<EQHG;B/&Y\ )W-HXCJ6(OL5.+<RH_1@0*#&'>X#D5\41F*PE
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M&&)7<Y@6I7&.=G]!PU>T$!_N#00BE5;SRH](I\]2[,IG$ 0W6"+71@P\]?/
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M(]I].<G7;EN_B+);[WI7]J,ON=6VG9:/O_&]O7,A9H2;.\(=S7 4B8P1A!F
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MXC^EA5HR18+%T5MC#<GSSF76_<4RGJS["]7]F4B-<LQX1H%&.D3=U^D@B[&
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M^EY_%-O)KD/-W?0QSFRUOT:I)5@9QJMW?/82%FB]HY> 530 BF( '1: 6H.
M$90"(XV4)#KG$M&5-=R0J4YO]LB7TWQ?J599<^YAF)-_C0RCVA* B': <L&
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M='U3]\NO_N6WTO6/Q_D0$]\:322\^(HV<001S:_]RL0,6Y\2+A]^DQE7A2,
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M>!K]$TT"09)S0: R&&5W92DHS638=@OO''WVEG C$04.!@:HDA!HY#1@ JO
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M2,6EA'_@7\.98X'-DX[-'Q2;+P(Y:J[A/!71A@.;6^'!%.*<R,)H:5*:,V6
MS66^6<AE6V@]"\X>)!KU=Y@]#O[^HP;/%2[G';J9ZQ4J_%]W8]5?EZS77!.(
MS"=<%(DKG!/&>JTUYP5-\B(MF+0T:(*[CM%UFN 6-<'R:!%JA>!6>Z(3K#%)
MJ"/*LY1DSG,K"\U5CE"8+-^4[.G$W#H!V G SN-]G )P<3!+9IC5A06)EX
M3%5&5,(4*1*J%2^2-&'RUCS>!Q,;7 >)M=HV?C,].QLX[+Y6@Y[MC\U@-)Z6
MH9G4U-.6>_UAY!DXHGL?K]PZ;' Z>G8TU0,W?]KW/7GYIDM\C)[8:F7Q<FA&
MIZZ"9SE3?7L?[M9CMRD>H>5PZW4.D1 /D0Y? 1GNNTFG^F^F^I?' &0)9TJ:
M%$$B*!%.)Z2@3!"663PH[5V.K3?LL8TFZN3-HY,WM]X-WLF;6Y WB_T\MM#"
MY8;(PBL"3J0C$GP/4N162\I9YN%4GM%UD3:/L<S@,BMOXDKPO[_?PKO"&+^F
M 1ZA"2^UP1^=/+[YVS\.:7T'UF$DX$Y4?Y>H7H8+%,:B#9@0F_*"",$SHIE,
MB*(Y5]9)0VVR\8R+'^[(OC$+W&>%1"?&.C%VMT9G)\9^3(PM6)PY33*6L92D
M+LV(\)D@2B4Y46FJ69[G1A3%QC-&EP?=K:48"Q;IOR8*[@C_M?W/S_XO_%.O
MZE25Q_UA_? ,J+WZ"\8ULWE1\W$ZGO3]^<_G,8H\=GCB>LJ @P7//L<"UN%H
M G='*$2<V@E<<%RJ 5BCY:0J]1CC#,]A2!0@X&@-S ,7C2?PAP!&NM6<UN+.
M5 _/&:SN;#3NA[AXB=BE_<_N]R]].SFIN;_UK6HCD]E7E(853">7?Z6UP\8A
M,__\) '#-;T@^?QFM/_%]09Q8F0*?)"HQ*4Y*'RC4\&D2A(A<N\X8T>4IAOU
MMT[*^B7.U+$CNG3J$U$>WO$W-?BBSL<;_YJG1B"\]KZO^Y;]X\K14/5>G:CR
M5/7.!N92:EJ7%>\'IIF,>L_;G/&BX8PW#6=$8;;\[RH:N52@4#8O4<+O]R!2
MEC:#UIO1HSW2J_3W_O04;F1NP>^(*OIS.52_'93':MB_"'FU[:']8SJ&=8S'
M.VYLRGY "SR$9_TQ&)E/]ZZQWU8:>_3EPY][7]Y_W/UZ\.??%WL7[Q/0WNG!
MX=\7^Q>[Z=[%]I?WIR].]@X_77P C?WA/R>).?UGJ-X5TX./?WQZ?_%'?^]P
M5WS8V0-M_7>Z__%3NK^SQ_'ZO9T_^N_?P7T/]T]Q7/;>Q?%1*IDP,M.$Y]H2
MP1TG6J:4F%1:5=#4&R6B%=4?3IW=QJR^20JNJ,R*3#F1JUQZ;C(FJ789U?"E
MC1[LKSI#SBNG;N-9^Q1"E:"=[3^J"UT=2V]TYLIPU;A7Z_>*+)[-4SY\5BTI
MWC1*QZN6]4"5[Y*@Z_V"M90;SZ,ZWOBUUQ^##C:C\FQ4!I$2]GATVC?]0<#%
M"[67;\$NAM_^&]0W?+;56[[MB1KW+K6FQU,][MN^*L]O-S;P<O_%',O"@6M7
M'OAW)Z/!X/S@R]#9-_6C%Q&<8$<-%IA\ 2MN[(:-^9T\.6;>Y?O'1UIHS Y)
MDB>I0UZFX/XG&:%%8E*>I+DWP(VCH5LRGGM?PFZ3$6YW;W;4F_-4LME[.31;
MFSW5VP%;[ N:?S75P5VV>J]/^L/1622HO_JG@=Y^0110EOS>^BS\A?[^*][H
MN1HJ>-2P5QF70*IJTOL"E'A6NL_]T70\.(?+8+&DD@[#X\W+EXM?M/TQ:-?/
MD?+_/1VZ'CIS6[U@Q%I;!DD3ZY%+=]P?HPN'%<J^;QRR$NT]!QV,]NR;_YG"
M.V["(DO;]QY^>$&3'GWQ9G.1FRZU/1Z.F,'MJ40*[H+J&;@FN#5@L1^[GNY7
MQV?<-+@[/?2HSH ?38#?!&%AW6<W&)T%^$TL!A^=GB(4+[S=!?ZM/QR./@<3
M'C>_! V!-QHC1X?3F(").JEG\,(QG?7AO$?E.9XH=J*.PP2:T/K:A\-2<.%T
M>.HFO5-GPX*&" <<#[IZDP!!F_\^[FT'-0*[NN."=P#4T@LC#\8-A6[OO!G7
MI!E<FP'21G@Q7-V^&EOU/[T_!R,-C]I3Y2=X<OW=^.'LV_#V0$'6P0+!OPS?
M'Y^?ZM&@5WWAG]?[V]7E6[V'03WACK_!U@WZYAH&WE_]_YD"6T[.'\;;79LW
M4$N"MIV6*#5*AS\@<0]&8Z10//FA.XY4CO5=6-Y5S1%HF3=@\*"P@7^"%;09
MOH=WAG<#1WMZ.@US.H"C@-#[@2'^U]T7PJ>7]I6_=A,%NV)W58D-K./MV1IW
MXA*O5_69/3G-_!+^^^G+WL>]\_V/QPS6=R32--'6>^*R#(<5*HZ]3(YDA:<I
MGEGFV<8SSOG699E5H/!!L*6#(MMQQJ'-U.-T$U4=FY. /??US)E)\#L#V:(.
M#-$1D&*7$6UO-=5.P>0>]/H35,XC.\6[GH$;!W]5H(Y[QT BJ%*1+E!LJS,$
M:8;'X/U!MIN3EDK 6W@0)KH_ !FQV>M[[!6"^SPV7=KL/QHVN'>7 OQ<=IY@
MUL"!]S3HD"E:*7U4D7"<'I1+N&-C&86'#>LC!1\,I77\(YPY5IV6^+PR1AF"
MXH5%#4"Y3H*.&L(&]BCKG<(;GE3GCW_'2 4N#2RKJ0*A]1C.Z.6PMST]AB54
M>SQIG1D:HP,77:G>] QO:WMG4PV:#PU%5U9-_)=[2\&T6)#*CG$)/,^,2@OA
MM=3H([E"29<;PW1>>4J2IJ3^H2V>DT6A_ ;(YL"'T0>UUQ1-FI=P3(B >UC"
M_L2E74\\/SW'Z66R?[&7[NWL?MW_N,?W/[[\>F1D;IFG"?$I\XABJXEF&2>L
M0-W)14YQ*"45FRQ+5DZT[Z$EN=D+ J]TX,>,440"Q5Q*+L-P? OD8APU/J<<
ME'<F,JH*[43N*7>9T5QP'Y7XI51B7?^W77CNY/POL&/A\97E"Y+Y-4B8_MGD
M-8KU;SO43YL:+K;ID6$2$U*26.DS(A)/D1HHR;75/+=42)YN/ N"99D08!O[
M0W0UHCRHW<Y*S&R"6WO:1ST,"F#J>JC<^>_?,O->N3BG[58HA2UU_8!R'@V#
M/'FERH,RQ*/M/[BVV8,[25%)BD_ID<U\5C@F"4^])H+ZE"C%P::CU"8Z+YC(
M@#:2K60Y7=D#E1VI8C/8/6 .8?@!M#H22*-JOFWU7T(.3E.E4@X:A7HA"RM%
MH<$-EFD!<HW+Y)KDT%(OKW!Q'0TLT<#>Q9%**;A6RA&+B)M"87FDUY1XEW)I
MBX19S,G19&O%"+] !* L,*#5!V71#U!;F","&FBFSH%1[:=H_YV'OX>(PI>R
M/W%E+5#Z9361#NGG;%H:\"1#9K9EZM_,5*%2N$3IPJ8J%> [2J ;SY)<)@S(
M1K+.5+E_XOL;3)4\*;RDCAC'#1$@]HF6/"=YSA*AC)169X@$+;]EJ521T>/C
M$EU = (FZ)RU!B BV35F[Q<';L1-@A&@*:4'+8G9:@%$5#CX)V.,%SS-N'=7
MT!)&)2XE)LRD]FWEH :SYK.S!S>GIB<8EUB@IK?G1R9U:9XGCJ0FPVFDE!.9
M&$5RD3'*K *'I0B37;8N&]'7!":PS #.$&,$2#.-S,)?L =R- W^;A4D!K<R
MQ!?P=P>VZFF(?344USBU9^H<2VD>B?=Y8"8C=/.7W<]0I!#R%R#/50]^.>T-
M1BHD2Z=G*.1OPG]*9KG)@?5HG@J;:6F<!+- I4QFB)Q3!0,3*K[-=G_!2QSX
MY["P_N2%,B%NLZ>^]D^GIW^,RG+T!<[JN3J#3R;G'===C^O>BR,.]IFB+B5>
M4 $R7(,!055&J$N*0B:.BM!DD8(9>077A;1PE5\X^ H'8'N'2#I_ >DTJ8F0
M0JD^C:4GKO?7]*L[U:-I>=Q[LP7W+-COO==;?VTUZ8UX?7T/5!C]<6_Q$>CK
M#I0!NIVL2,"XK]$+O1'IZLS#SIC<"9F)W"0%2[3-7%I(T!\9E16T%^7)MTEW
MQ^G)R^%X4DXQ\ 7$Z[9/401U9'H],CU.CIC7X,XX12@5 A&X!"DXI^#P9&!E
M\IPY!G8NOYI*?24Z(B6^@9_AR'O@90[<>>\/-?RTU7OC7"_4!^4A1.FG)>8+
MX80GJC_X1MG@@Q+_>PKL]!#@I=^2_D.,[@Y[IS'?. :"!%.M="&"&[<0,Z4X
MS2=>K28$;D:JZQL="@;=<:E.YV3$]N%>[U7\>R,>8KXRNB/M19VJ\Q#]=4%)
MC]T@Y@$6 QQ5K0ER%2JK& @+J\2E-29F:UGH]7Z76C-@4.;<))FV2MA":2],
MFDN923")699'K).$+^>X6M4F+5.R4F7;]2(/JC4&W[<3%)<(BB][']\>*<%%
M8HPGS%A)!)J0VH(>\X7EW&9)RG.+/O"5PN$QL/;.-%!V#7>'\'? S(M)G06>
M'X\&]H8N^@\V,W0N^IWHS;W#XQ18@F*W!#R''WF=*)ES03)!P467+"6%S1GQ
MEBN>IM+I5&X\@RLV:2*NCB#_,LL7HL"\&<FD+#<%Z%\*3"F4R'6A?<&H8#SS
M6>)81S+W33+[.]OG1[Z0EJ<9)<X(!#LM"J*R5(/EQ4219=H(RU&<%IN4+_?S
M!:7[:ZOPJ*7F8ZP9-/%G5V)-5Z-^0ZK^:W"\!^??%73^/NBQ+NA\<PHQYT?4
M,FMR3TE.\PR#SHQHJB31\+="2@/F4(&)AQ58N+/$PZ(L^9Y3SS*L*$J]=C85
MW,M"@)X3A0-;S#K%57?JMW3JA]M?CQ#?6J92@>Y0F@CO<R*I C_,(@JR]T6:
MJ8UGV5:Q7#=49QI^W>R5JC\.%9JK [XWK#2[]9;*+KA[!\3S_N(H<\(SH!$0
M%*D"I<(5T:ECA#$)!R4*7] @,B[#3+TLM%N7! %9C"?CK=[VRAJF:.Z&^J/3
M4$AX(R+[/BDSHZW@ZK6RV]%(V?ZL^@.,)[\8E4AU(='=4=2U*.KC7GJDE6&"
MV0S<*$$).("6@.:WV#\4$@8\2=S&LZ+86IXS.$]20"\+9N[FZD""JD\LA(5"
M+&2EF?-TW$CVPV[D#[;O=#[!7;3FB?V=X_.#PVV^M[/[9?]P]RC5C.=87U+D
MW(/J3P51VBM2Z$*HPH'PHPEXD<EF5JPP^6[7B:36.UIXJZ46IA#:Y5X:(;,\
MYQ(LD(Y@[IU@+K:/N,N*W%M+P.<OB,!IT2KQEB2Y,XE-+9<:BQB3S40N:_Q[
M<B&_KVNA<R9N2A\'.^^/*)B""@.UF2@8>)!:@FA)&/&98L8EPB;FYWB0)DV%
MX)PFJ>9@H>;:)3Q/$O!PO!:YS[M#OZ5#/_QT!":R27AB""V<)0+4!I$R3XG-
M<E\4:9(;SM"!O.S0[\*!O'5HL<Z!O&W:^;KW<??(,::]R!P1E,,_6!\OP0S
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M-[W&'('M0%D8.P%QBP(3-@ P$:\-+ALA*'"%=H)Z7;O6[1'$K=EKK >OCB,
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MIPZ-+6\'&EMVT-@=-/:#@<9F=P>-7;L_?ZAQ?WS@7T6 HAHD^\T,7A,UW#1
M%[V",S&@4=8'+ONXME'IP>$G^N'PGT][#&S4P_<)@CB]/WR;P#W8^W>O3_;?
M[7^$YUWLOUFT4=^"+?O/8/_=WQ=@HWX%&Y7M?7QQ FN$]7XX^?#G+GW/]KZ
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MIL;OKR@0V72\:FOGZ28B1,?];0XWH'.Y@('7FA -1UE&7"*U<)-Y^SMVD<3
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MJ9'>E>P*T/GD FSA)QRT?9GL7^RE>SN[<)VA>Q=OTR.I$I&!_4DRI1D16N5
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M/^'#[2]'H+%HSDU*F$TY$<HQ4E"AB1-<"Y^EF6'@B"TW;/WO1G5&S+!+K.]
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M>-RL:JD3DIV07"NCN!.2/T5(+EK*VJ9."Y$1JA,!?BUSI%!Y05+%K!*LD,Z
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M#.3-Y&JJ_3[L]RL*+J4AS9DPD5L#Q$T9'"SS6!<D_9 KP7T@P?UVTGJ_CPE
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M<=UCO 2OW.?L4F^LO'(K'E<#="D2*Q)W^_B\T!MNGT3F+=<&46HQX#,MD&4
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M8908N[(N"%N5,]N,/C>B^ 0Y9L_"L'R/#L)D"QJ2]EYH[G*"H=;8Z 13#W2
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M@IC7$&%[<V3;ASG#_'91DZ^V>39(6;<YR=RV?15I6_9(VR/6,092L-T>53V
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MGJHT,^+RR&I$CW#6EFZWVH/K%-WSX9<;[9>!NM7CV.I]:ES$@*YBMU,!^\.
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MQOQ4"P@5I'?(89H0%QZ#GVH=2EA3)3$'$R1*B&+T%19[69R3\^;(M@]CZ>&
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M+\49MC2;0W5D?_:^F'K-!Q-QO <_OOH?4$L#!!0    ( .1%9U9W%2-@%QT
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M3Z9Z@XU(3%FPV8;:QK=U+]'&I\Z.=X;D.,#J2GO=FZKUOD+"YN1EX0Q-H1D
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M*AZX_357=?("3H=S&#T?C2:?ZYFM>BH]U8U*4_<[T68F)-0T0$XL9%&MK U
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M77&CKJ2^-TH$G6))W$+*0H$22H&OT=W9!2FYYHY[^WBI\$V,Z^&9L(FP.V#
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MWAT GP:/@ ;ON@\  0 >$=X_\._\&0^?@)"(F(24[ 8Y;D #-8"/1T" 3TA
M1$1(B#L;@CL/$-(0T=X64R.F>VQ+<L>+7CPBK8B4ZWY--X/1)(I;XH5W)-D-
M1B9F%E8>7C[^NP*24M(RLG+R#QZJ:VAJ:>L\>?K,V,34S-S.WN&EHQ/8V<?7
M[Y4_)" PZG5T3&Q<?$)ZQMO,K.QW[W,^%I>4?BK[_*6\MJZ^H;&IN:6UI[>O
M?P Z.#0\-3TS.S?_<V$1!D?\7M_8W-K>01\>'9]@3K%_SOZR"P\@P/MW_)_:
M18.S"Y^0D("0Y"^[\/#]_QI 0TAT6XR85NTQB:T7W1WQ"%+Z^VE%-=UD7!)&
M*(87WI,W&+DE83SHOTS[AV7_UPR+_)^R[#\,^Y==BP % 1YN\@AH !7@3".!
MOQ _X;!@D7Q ^0Y*,]+W4K=G_AJPS;%2=UO/&$K1&[9[-<"NM9/G\B-8"0Y:
MY.LWI^RL*_QU66W0LKRNM[Z]W>9"KR((:/XH\58P))EY:Y)\(=B"A?(EE1C$
MD_-/$7U%+C.4I\IX(S=NMWTZ<,;H /P?$_Y-J@DN/P4KP)'!3HFPW5N7FGJ/
M.?-7AE@?Z>@@'=5_)]VD4AM_=+0#(J\?=='$VGTTA10MGV@]O^-VT/*6Z46<
M07G1LPM^@HJ/G?>=&E87R1&,I:4CE4HIN<Z\6?0"UK*<FJ3-J0+DM",9;P*4
MPTVF5F]>,"L2K.4:4"5NS+ NE[QL$?L3-"+'M?[KYW=./R65&\#VUK\_V<?V
M:H1'?[(N['7@O:GZ<POH3/OEP.]&NI%#='B)H[)CM3-PHB.0E>BO=!51MKPB
MP-/?7^\]7+/I],I0BV6<1>I5^ W^ZJQ048@H7+H-W5$VN==P%[D OQIMC_7/
M<&UCXH/ %:7A/E&K.<!93H*]VAP];>,?_/ ?Q.)!.2$ _6/U?XD)&;J@3QX:
M'<JP8SX>ZQXZ$N2*0N:.:"Y6"GR!=8/Z4_)VASM)@WWF3E99&J,0>7KN X5%
MKB_O:3)E\X\/'?*/K06=&I*8 V?W$S:5.7?\6T5[\X*>3)5)SV>]$A^E*&)H
MK*U2Z\6GTH<WJRSL0CGNH,=C3Q*KZ7=4W'-6MKGB_M! &W3L40D2XY5 X"7]
M8U6B_RP,A^-(LTTUA#"KZ8:O]C'BUIT6O,9!:-HT=G>KFO C%'4-] ZQ1C^;
M0D9&_ S05;WU]C_;]@^QX8<L'EEA^]$[B&[CLZ\_MU\UB2]^]+9+'2+YD9;!
M%<1H#)VY^6&"9/;8) 44?;8:?H6/C>WMI)OEG3D)*CN"Y\A>Q"X^LD6HM7Q[
M)7BLF%41ME#0LR(T<6=N7U$='%1F:AGPXI;%K--"">&^9_+@6L0'"O0\&Q"T
MS( ^B)Q3O_R:/@8WSA1N:)M1?RG$Y)&;Y+@EN"?PKRC]/\@W17^/K\M8 HLF
MU)+\3KK98.. S.(2>M+ [B?(TK>0\DQPTV.ANL=:?.+B0<4J)'+X&M"?YFWZ
M^;Q#(VG4TTK+LW*H)X:H;9\]*(0.Y\&-KGIF%51QPP+# JN$N]J3I W(3!0R
M1FHH=/A&\7?SD7 9=@/"LPC:L/A"*O^/G28H@\@K;CXD:6O^%_"7^S76[=DY
MKY=>B_=F9)HHRG(!_-MIWZ&@IX9XZO3_%.^Y:X#VXK8_ H15K_1K?CGG+QZ2
M([L<LTY8>T!>QTF0]@%MI8<+-.@UP/KBU66Q0P.X]%QIM#^#N9>Z^"[KAYMY
M=2=2&*+_%)(I%W;8_HH+131O7O%6H%OR3/8<_#'/@C=#8FU$-%<*WJYU_U^A
MP=3-\RYT,IY@B'O$>?YS:;R"J@DHUOD,@UL<'__;15$7\_4:2#?[= W\=!:]
MI%'RZKJAK RQ^]YUL\*7\@74-']G8?UED-,+)]24! 7C&XZKS(70V;!#7<G5
M<TKU:^ C7RF6;&V<?!=$<KRT;-,;J'XY/2(+WJ^XD_F3S)2B[BX?00*PW\EV
MH3MUQ;-].I\C5;I<;^Q#^LXJFF*!A>0&M*D#HMD?Q@&9[[D&.'AJI_QRAX2Y
MFAMSE@R.WK]XRZ A]HUY..L7E1)EB&@QQ$<=M>>C6;AM'.CJT_F'=HHAWJS5
M\090G=6I^*/Q&JA7?SM&9CHU.LCN>4L2;P*2T:/"456?FTIC \FL7&3^@?RT
M?1;5LU5H'YX6GJ2*;,Y(V6A561B'OVI"X'UQ"N5IE6EB?"R$.14A>3>H/V?,
M545FR=&>@QG5O%+SMSGIOP:.Z6R$KX9!A\HN-AC*:V#QBRI3L".:#LHAC^WV
M6TLEWA4LZB;ZT>A%(_/&'G+(GJ-*;I\I2XX<"*@J[K:A"A7%!D'-K:!QBA:\
M7XKCM=N?S?)\<+O1AU\;'B#+%CA[D "JFRU(.HEO.+BY6I5=/N9OP%;^2$+F
MM%9.XX2+\\R1M_VTIX"Z/0S5!%<J>-WNY25U\K9.DP[JQ??A&?NWVGX^(Y(B
M1.0]*M6;V9@LM$=\NVC%5B+LTOM(OZFM*>-'RJ)5[GMFG[1QC1.DE4V<H@2B
MFOF"!^4;RH"^!0[,,;,8"?$3/IY4_/V]962 Y5T6]X>374L2I-LU<-N _!J8
MOU5P>4/^C*"[X/#V%@A#B7/XI*XJB"E8"+69J&@!'_EJ0.02JS63-;J9]7MY
M! ]RT4?DKT'.5G>W&Y%J:Z.WBDTY71OO%C1K?Q9P65.EWDK_LCD@=%JAK7FD
MF>(I04;^2,1BNR/F*2X<R[Z$_62TN001O;H&&I(;1K 6O:?\%6X?V].XN0I?
MJIJH1#8 WHLW"]!U\+$"OCC7=L.S9QEMI$!'^B1W=S=I#;X625)3V1,+&_).
M7FRO*O9C*.A"O<4%FOZ$T.=1=TF,55O&YLX.@GG,X$>''$,NJAJVWX%0P3=?
MV5)A;$@6D=5]()(+9#,FD?WQK/O<S6S[?=>J*OI<@5UB8#$L04J4Q7IG'I--
M\TOKE/$/>,%K-C%CB1VMRF8 +6##-O6H,$ZQ"UIW1/9U$RV::TIP.Y(0:3$/
M\DJD[;OH6J!BH:LT9KJ5EBX(O9!/#Z=</596U$'+^&+U!:<?"@(W5)R[_@@$
M>EQ&O,!Y]VA^SG.XKIOM,ZD9_3V2*M)1(/@:.)</?CI_H5>Y@G7I.TT-G5RZ
ME>L2'WO Y")0*Q'&M$+HF!8UKG,DFFH.2O#U8&5"Z]==%KF%*(W.Y>$OZPHL
M/IP*^5X%Z$LGB8+XCRO'%Z!7NEFEUX"UO\J9E. 33%U\;)RBW-WS9!?QU,]^
M?'\2 *0RS84*-KYH%R/?E:!H<EE:+/7^< ^WV-QY%\TTQM-F^+^?(AH"7K6A
M5:"AC-C9<G.U<IL=%Y<0'P_',L4*NQ#8%%OA^;E_,=ZOSYL=(4]@\<4MJ)0T
MR9O<";K,9BP&%#<H6/\$AX>Y=FJ$P;WRPW;S -\K_,E0*:KX,[W3)'>_N/JO
M\6;[42O%/?1<]Y[0BI&E ^?%E?;8U0%KT8;+4KK>K)7;,US32\:UR<(OFOES
MN0]SP0/B-_>>8^"=Q=7IP0'7 %^&"XZL50I> ZI-A3?/,>_0H'A%,>((']BR
M\Y%^S.]QMEVWVWH_I!GD0,:7@B3:TU>RP=JH_((0N^K>C]LCSO'NJZX0A[;%
MHD<56RPC8H1Y?128RM1%Z)6Z,,%55\$UH#[_\8+I_4NL!.R3JBICKMR)\?.P
M3 "2W3,>KRR-.NAO#F9!Z-W?.+M;I?=V<D5[HUU\#>GPYO<;?84W:N.E@=E0
MJD3Q8-E)-Z2D7XJ>AR&%K3CEB ?SVJ"F3SZ@Z,B]R:RL4G4-#*WC,JYMHLTE
MOKP'TL#-!]2W2_[^67M\?;WIAV,>^PS/"QF":P"?'J_2<2TUE>/VY$<T-=IJ
MM&V<.4>!<>9WI 9)VGD#A^EX$=<JP\\+?&S-5VSKSGFOLDB8S-/:I%&&7D[-
M- (B/T_@UMNT<2.R\4<YK"0]'G20#-6Z6=^NY)P]C(R7X*=NF?MR3Z[2NME)
M]]1]KX&;RL1JJ-/^P]UM.-G)W=(FB!E/$UG>CY(:-RC?^J43P6#N0 '=_I7*
M->#8'U3._:4\(&RAW-2BLCF##7KZRG4S #D6-#^7.32"?M#M":F'O+2AMA"I
M<J"^+*!0??/!530YHFY  E=['8" )B3)-<#-UZ>"05X#I6(FHTPK5,T>4<H@
M]%C:!M=/ ^%2Q.WN5#H)=7ZN_&K<@G+9#ENDNM(RB M#+ET#.B\J;!8.].MG
MKPC"''?N56"RG_SJES28G$TA+23U78TC1_-A/-#"?=$:E7:E!@P7SQ$;IO&T
M>%O?Z4XH%(Q-]O*N@3M97=> S1"N[.V.^.5)&&'O(I8]'K: "S3FZG<3U;-9
MCI#K&D\]]+;Z'+>"[HU_"1U:/;R+"[V3BX(SD?"[%_K8>;C2@P'D6FJ,@/&Z
MX[E0ME=Y?8;N9*9$3_DA.>B^-S#T'0V*59:]4)E:ZFM2%FSMC*10W+Y9Q//]
MM>-73<Y%S2H\@FW+:Z#GUGD( 291?;Z&OM+/#[RAX[4^MO3646EH^-*\\S,:
M4VQ;>J$T7]7@KU[/2,<5*TO5<N/UJ9 6$)@#P#KI+W2RX:N1#5;BETOZ\\)K
M]T:E<NOM8XT8[3G73:E]HKJ!4_SVNK7L5$5=!_0[)PZ1>3^%V0]Z+R965K3%
M^^4_1!+01;T53+O<J3GG,QN[$IJO?F:P *_1RFOS<"32_)UL9L-QG)A*<.%2
MCY;.D1;>U?Q\OS><+SD&_2?:[NH2".1#RB"L-'M;]6-+M^1+5_("_!1^:?/D
M]3Z\,A>9(#.Z2>;M=37>X(OH:P+=4"8TW0D5:&V9.7&(\!;99]7F;<D6X1+I
M^R"BA7DJ6WW/LX YS/D6F.MR/[E$C1[Z(8KMN3+5G$DW9M0/U.#6T)=/,+D9
M;U8)F_&ZRTY?[U9?,)AT?CY!PE)H<>&,[7*1[BC#9M;G4HEE46=[FPW\]GM*
M@Z_%+KZ2ITW<@",M.NB"UYT"9>&A7%8=.^/B2R5US?X)&BS)6?I5U9G,BA>]
MGTCE"L@4\:H@T]\G?FV!&$[<V-U^0TJGD'UM;OIP#?RQ8HJ;>TBVC%^LR..N
MA2%DL.TG;(8QNA)3&>+@3SG=,=II;G<K!JC3T@*)*,##9<<71ZXT/*C"YC]T
MG3%7?U1DP<4<1\0U\'S)XY*^X:@+Z7 -<,G$=NV.V5Q2F$QR4%P#:52JU\ W
MMZ:K!',@$9IAO12L.+\O^>5W4T?3]&8.F=WY\%9TC J-C6BP'!K4O\IAN2.O
M$G.A=U?HBW#_[ GT+)H%N'L[X7?^JZ2+8O194]]DQ0K=+/R- \> @^T.Q<M.
ME\N,3TL(]E?L7:'=-J\"7ZBJ8#RFPL4O#(+0B6L;U>" "DCZSA5YS!_NH!81
M9 E7!@LM\!3QD\U7T0O)NIKBWFYR+F^-;>HUH=UN@L^/\?+^*4R7X7AQ>:]"
M^36'(#GF\\P>#.M3MCTU&'.X^=C,-C%YZ3'()X1X367M6<8:NS(<BE%%$V8+
M#(H@#QSC[D&'FIQ4XN\[$8Q?<"%6$SF$)ZO:96"Z>9J/.]+M?+Q"YT'M*4KE
M'\6XWG"Q$*+4N-$I/GNK9*#^%2J48]R):,)\:\H2BPQG9\&X?3*=C[BR_IHN
M<$]K>,U$])P'[S(#[I/R"+-6@*7(W%IE7VMNQMZ&2]93V-,\W/0X971:N ;0
M$TX$ Q_1I_U4R?G\K=]04I,3]3^)$>O#+ZB+8(\R^(5,UU"=L021SOF5<)7$
M+L*&I0=P86L]Z^'?Z5W@9I?/? 2WWDK )I)2#?I,3,[YG!M5%N0Q:2TFAD=3
MFV#%(<;E=BJ,UN8EVKRKP;C(%M2+E#%X_V95[W/%-VC!NSO%,:Z!P=]#)?&F
M=^=9Q_NK7YN'X+:.>1;GK/N'3S-+@][?=NK9-^-:9<T:M$TAOJE$&=P-LZ'$
MUIEB:[P^;K7"ZM&TX]ZUSKS[IB.M[D>W?AA:[G=OLFWFG-EAO.ORI]<Z\]UI
MWA@H3@U0^8JHJJ2057-@#7#ETPRGQ28G]6JFD$IWSO> -5CE,D\J=J9=4W@\
MKG+#(A5)NO_[W9[X0)O_8%OGAH;87.K"5YMY14V8F_-1'VOI2LEN8,W Z1.6
M&WC,W!3Y)%RE?C9L7;_CL1E7S7Q7R3IP%0?0'[XSZ&4TU56"#G#D08JK=6N_
MPGYV?PZ3^[J@+'=AE0M;R?/XM'5?>EYTHE4Q@=E"_4- ;E"Z&L A^U=UE(&!
M_BC>2CUGEJ+:E!)%*GAXD?0/.KZ3[Y4N((O^OL<2 6V60_P*G""^4";$'I5O
M;<-!6)VJCSE:%[^GQ\J$O-.2(M8_'W8KOTX--G%#$< 'RA"0@WH0O5:=<R--
M?''S(L.G1 4+[R3*89VDTU\2@T/C4\K4V&*;*6$_816$>X>?G3_K8%*DQWNM
M[6L Q,;1QQ'3:A.C0BA\=0OR:=,BT2K7*!T^B<R1$^ZQ\RG>'T-D'(;6X^UD
M'J;^M??9[%UE%SE>9K+JH.[W<<=DA;K?#ME*KLGF9!#JHW;9V?E#AQBR4%F\
MLP(S\5IR%*2XA)."8F_P$X3UY9-BC]Q*1^'DU8QZBF^*<G2%%1ZGL:O^ADL]
M>Y"JJA_TLK4 %[,(XE+$W7U%&?A[]8%B0HT@EXZB1Y.1!()VR;V<D?))FY\,
M&E97+<"!?OTG%T-$E?5N0E,MW]4?IQO ;+A"QZ2]=U181T]*U-TJ*_=Y,]9A
MSV)FV;QF8SD&PD6QYW";I&!V]-+CIMAGG6WUM6U4Q#G3XGUPK5X!!A D%.6U
MI_35HY=5$RK8%6<N\A5ND?QB_E%+>_+^4ZNRMS4$+9F%QCWXQ'*/Y^=:</N_
M\-5&]6^V;_SR^*F#+K).3CH B,% =7)K=LQ)-PQ$6.AF^9J)R8(PAC>LC?7V
MH(@:"3>;/85C&<\7"!]B++-8)IX'K?Y[2A-4(/Q:_D,R]W.*#_VI0H@).F3.
M1D/;5K#2N8E>2'5R(\KEJU#R[>\/7]R0PP!?0XA"HOR"W!QLA9&_T+TN%"_-
M>%_A/0.&7H2(J7+(H4014JNIUF%4V'>:E]6$O*95+ZPB-^ZIND9\]TJ;!J(F
M[ K$)B]LX04$5Q-OMCIOHT5J LHLG%_.PMN[LIXZE0P7U]91AYH87PAT[?TA
MP<1"BP,^]1B-,5>5"1#C:WPO3QV=,;X&D$]@=N#J;>6[C4:TARJU8[WU\<.@
M+T::%_CA2J*8>+3;?'0GB^M4=5EMUXP((N9N9:G3;W6;O#@'SM16>L3YSP/3
M3F8/^NVP6DQ9U:I+:]+BZ&Q]3A*3C(R>T)L!L9JGG9XWJO;"&EW&%4TJ+(.=
MT=!P2=*\][<,$G3G'@QKK4KUAI(S]X<0H>5)*T,IL>DKRX1>ZB4_XA(GGVJH
M$J *J60NWROJPD%THO'[BNI?5YQU;YF7J( _-"=='3=.&+#\\4EIYL@<#S;
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MQ805K4G1;'[5)$ QG>IQP7"SGB.F9%+RDDL_JU<CPW!&I-"L2CAK2^A5R36
MEP'^M;(4UA.NM)BP>4$.+T)X$/V$1 O9?[.8??%-"Y80[=TR.*"VE ;5:8/K
MO5KJY6"9D6K[G8;<XP3G<0UL +XLG/;'A93R@INZ!8N+"SQWQKL/1T OLQ_3
M% QJK(ZU=<44L/N*QK5F8PP6>*<:C&(>-F7VQ?.SY:6(I>,BRFLW2I6C2#U
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M1^%R#\AC!%R8!R]9QG1VM^.^M,8-L*LCDUOH.O^>E+B^!C;ZM]MSPYIC?VO
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MM!K\)6L?BU*RMZQ:&MWR>W5QX,_9_I2H(44V7&W)NUYY7#!4UK=1>ZXYXC*
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M&N,OC3*PY?L(9=+(]1&>=P:R,D_E(E3F%3(A)2NK*_DF0^)2['\VV*FN]3N
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MEPD$@B6?\FM9\7TV+.;J, (+<AGP5>'^=!V *=3H3J#A32Y=4.SBA'L7MVO
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MI:QC_1\?KH'DGB+ZJT+K5JFTH[2MI")-1UTX#9>B?GW421KSXYG]F4LJH(W
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M6VL_C_.YD'J&(]PKYK:_1C7%6SD]TM10'<:@S79L&8TM)"$3N2O'^% EQ#T
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M["HT*<H%1'^KE]2Q./*Z69-7W\NS&OJ6HPUF13(J: , ^RYJ'D1=2PESY,N
MD;K&Y&#40TU921#7:/9LHJDZ#O 28\_B1UN7P",@)VFO9$7+,YPH5#'\3K4O
MFZ:^=K(",RGCDU5^E/VIB((3+]8@J&N7Q5:.ZR&]2-JD'Z_SE^]^J)JZ3IU\
MW.%V_$J? OD>O<$:DO/2M((:2\.P,?'P56=CH^G9J",[^S9QM19@^+H<'+8D
M>QV.8=PSTJL@2_"UM:D>I;UTC!EGT'J))O&@U@3*;MWQGQNCO*IL?3Z;>?Q=
M_?*KFW6C=>5A",<#Y8JJH%9C?M(]/@K)2]Y>M',O>KD_LY17!RHJ 1.,'L3]
M^_J>G"!"/_K2U*VKQ:^RM<A>BRAJ]*EO H13.R@8.;3.3^_JMM: %B]'R\_6
M-XUUPDW!O3>:BD)E!^P'\ S0,ZW 9[M)V6N7BP_D\[1YDRQB2:_3@S9IHXPO
M0)73+\7&0Z<^07$RYX5*9N9NL8,VA@5J83 %$;WS[1NQAY0<7JO(I'A&FTE[
M*"R5-=WM'*CLF_938VV "2%R;'O^CU3'2??%_+FF^)U.//>/W1N2EIK2NMD5
M_QF2"H]+BJY#N7HP;*D#C.$Q,.>&";M4O1%+VX^.7-\;]."-- +H=\:)2IV5
M^*=!,IPR5'#EB_>^5^O\WH7G;54"<I^C4<M)TYY2YY%[>SA?$9T/(U]\LS/V
MLFP$PM^KCQF_I>[XE"/^.R@!!>0@=AEB.%9]<#H/V*O?1\9TX'6%T2TJ\W!\
MDIG]J3&]A'1. L@!C'7Y3Q6[84J(M=: ,A2DKX.FL:%C1@8L,R9R6R)3UZ2B
MR?&Q!4B/2]4U+#>8@K0,[[L'@&SG$DRA5H,O:^HZ&IM\!1H'W5R<]72'UUY$
MEK9FW X"2.N/'I26":G1TQ(>!2.?\WD<?OMV[H!I1#<3SK(%.^9J4%0,N'-/
M-T"2Q;1)E^_[RR+^^.#5SW8N)DK4XS9[X_  '7[V;/T=U)YK?5"!WR+>&&XH
MS]N0WD.XO0"-\6)5@FVI4NF3DK/P1SL<T8GXPG'J!6<^(&RHAO[TI9I^W]J+
MIL8<\SDQGG[[G*=3U&-#\=D:)DDK&.N&!SSLQ(4&:$VB=;>D1Q77?X=HS\SY
M*IW3M/51!&5B*^]&,S,>0LIS9^H.,YB&^E*NWXL(Y>T-=06#.;1GQ!/41*.1
M1N-7WFMB!CO/6T<^23A\M@9F?M8$1J/))B\?78XJ7ANF.5D@^B#P=BE+2?TW
MR5GKTQ*"_$H?+ZL<RD&X*"TR/.BKD5<-697^8^6631Z]:AR"5JY"/HF^.140
M32#) [:DCY7X_H F]5#*MUR%"+>]6,FJ7E5@#TU\*EL#Z#X>?[?MBN$)V:R*
M:WM2L@^!WX*)Y:\J61]JX"%[;O'WJ\%'#CT9RD&)JH\/4G7=CZ&=$]4(U((Z
M]4R/SL:F.0(:S]^[[O\]8?I*A.;*W&QH4_+87.52F%[OD5)(J9"!&I<91^4\
M27MU#\"YFW [-'T U+\3^_XBR,$8$1+]?C/6>L1 3NZ?Z^?D'<;-)YP\=8 A
M[-)K612Z$EK<:\8U)>,*L]YX5@$I;FDP-M5XVYKZFXX[QV7RAB<V$QEY\6!6
M@J<\[@%?C2JK[5+7'DU?$&$]N]5I-*I95=;NZ"8'B7_,YFZ,OA"@6H I_D)V
M?G$?<715KIN;=A)9/'E#\FMX!QBSX$B2&:P!,4'N/;18@JDMF*)-?TN#R-[G
M),JB8+_%+'^'18JI+MMF9J"[,%&=>NLOEB;5.:6/ONGFJ,6@D7HU%=2XY\J,
M;9H1:T<1,C?GD>IFG?KO[?'R:>:MOOD# JU_D0%OFK[>Y%N/A9D6+^U-#Q>1
M""V_:VRBJAG<\0[=CB<IK T47-X?<Y<2C_5G/I3*13C%V&]"R [$(;XL46L5
MY5>N8/Z\];_/LY4"9G)T?P1*"A#:94O.BJI\1FJ$N]\1J9'G\%.WWZIUI[IN
M\>8^G6BM79>XKFSX_\XZ___Q_\?_V\#F*?M>?ORTN=F%^46^"D=V9.[GG"']
M,7_&NT*/58U!*8_*BD+;JS70C$!,C0FGUB-J2NS$_M^)K?&-+"1>G75*D0%P
M%I2&ESW1<<L<L^%3J2.9(?^,E^8H\BIFY%@"W#Y@\;27PM:,;?)$=/1YWWDW
MQ(_J#PSSV;1T\8GQARL"&YP#<XI[@-T]H$>X)*!'\F^6\=&47]R?@75QV^5,
MY#P+]+(2 K=&<^4@HC7N 432(YCI6VUO:5C%FM[L *PJJ?(TP&@PO!^,^.[_
MIR6VL5.<$NISS$_J3<7)7QE J^7_13\=_3QA_"AO*[H65K.&MYM[*Z(4]V<"
M.$VM/PPBDJ-%A6QJA/&*/D>K.XB,TF[W?G3@$"+O1@]*$.=Y![0/RTH ]#4V
MCM>P[RI$8RBB"K,;=[X'@9^OR5R @XA##FQP]@EYMM)D+#U QXPRD%3,B!2\
MFFKW[YD\Q<-C^0\YZ'MO=JU)W55<F+*+6=5-T$H^ :!+-;W_!%"^)X/+@Q3>
MFTNA%1#%O:G(L&(7)-VF^@_K=#=.([\RNEMZL =A:'PTF>56_0<879.I?3\K
M/\H/4F%R(,?0.5VI-:;RFACPNX1-K_MU_3 '3KQ$+EFI3546V!I"(Q[F"#.$
M@\D[$V\>I]S:@YHX_EDS7^'IW .Z8@SN,AR<+N\!%-"RP:4$B!C&LU'C>T+*
M1]Z0/; G'L#7/$I&]3\[% CM&#$E3<L&_>W)<N>)KTKC7/O(!MKLWZ(:D6[]
MGGR54(TN']C2TS.J/_%U<2$A=6GDC3*?'V\S7HZSHM[+N&R8:O36J#MBEND?
M/6-8..B>25AQ>I^PG_YO604IT'<:*'989-_";<?*HJ*1LKA*F>*0PV]YVRPI
M;>*#>(:S#R$^\&H9#Q.Y>ZTS73 MP/^83#0S;97(2SN>;(='JXUG"Q15=P]@
MPHQNF4ZF];>/SCS.C_^8_P'U^>,!P0TKB8O^/8#XI+XJR&+P9O=K/5&6WMHH
M/^\&,2[YJR_<N?1CGK&YL;ZL!3@'I3Q_[P'X,)G9#@&88*H1TBO*X[E" 012
MN%06PFPE>%V(R[*=+7S]2PZY)X(A?/"X#G*$T)J#&UN!G-[#'<-_QZU8\<>O
M?(Z)FZ^ ./4 /R8%6"_B%&Z,MD3<#4;!O#9-]>S33EBE+<,4>AP'N5SC\:&$
M><Y ,^@,BF<SR[H'(X/4"/(8?>6H/J(<YIV;L%#]FBC0<WN;Y_G8"D*I.9?L
MQ\^JE#8<N/'Z$IGVG,<Z\V'+%T^]6H*-VMIXO.@&=>H7W*7Y.$7JWG(MK#BI
M>B@(\@H23FDW+Q4;[LO$:<\34+;Z*(%!"?'KMIB9M6D_D$RC#M60&L#$+\=:
M&3VR70*&B,LJ1ZC$"4 ZA%N:R9:\^GS6P^LZ23M"RM9M8T3.O6.LG1]8I0AK
M25&)*\3,N!C]?.+D'F 3586EXO&3A)]\V<J0:EPB4&7$87GF'N!5Z-%9EQ)B
M#X_#0O&\^95HRU?^;F+@_)<U&[<'&U9.+C7615947;I?:_/**&6BAEN0]OP(
MB%J.9@6EVN7I+Y[4;U1X&J&E_.9<YOO[-F=V#N(,=<'AK5]5N1W,A_IFCU&0
MW(.6*$AK2TU,4<!IQPMC) <XYC]K[IDZGARLD[B3B)V_KJ]MRC[;[EMWT+?4
M)=3 ,E1WB[TTWVCL+SN-Z%QJ8'U<TU ]6[>C)[A<QMU"^?*?02)A0L@XDO!O
MISWH'W4=V0TFX([.@*H997O["@4QO@?H%D$C!W"SJL]B]JH[MP\2014 G\$!
M@:]>8-(Z:;(C>V4!CQCUK>'Z8.>W&WX[2P54P^\#E7CEP@4VK/L=K3?=?3;F
M'8X<U]5?>%N-LKQ^)/-G6UA<0V"^W;46C.;M7.J0>"FT+T>I-MB29B%SB[/[
M@G53:N@N^2LC))9 @IW)A.*B*9>LZ&=5=L#G :LI&8WFK_< Y< SWV.?"L3L
M F:>5>!?'(\GF:P+MR9P\D)_H'1)*0+SY##E(2<>JQ"5]EC7!@C=39/ZSC]E
M[F5])K%C@ 67[.%\FUO5*IK_+NN( W'5<=,W+TRDJF;A;+7X.%&S:WN7H!5K
M_ /T/\M=S?"0QGTW)ZFW*E">=]/U48>F<KM'<GX%XL35JAW'DXUL$@X_<1*6
M2E"J5[!P<X15QJ9]%:T][1K[3$4BTFDK7FAPYYGET.V1/ <7='>J%/9!*Z>>
M+I"ZVC5?'2].&Y/!)8)U44AS=CU8!6H?[Z=!I!0'E!B@(!K*HV>V0>^F6P=
M^4(AO<\ F:3J9&^W9*0WC[EZ<BA$)/WIS:$1!N,NS/IS/K_BKO,RL0$1\8NX
MEX!@?.$%G..W__4/W5,W(/V.]IM>5Z=7?PM#&Z]<0H9O&:5.*+W35ILS)!:D
M+$K^Z^Y;/D14]WP A4< A8U7^MU53M[R"E-&F>]3PFLA24N3:MP/>+(O;[P
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M 3U&$R-)#ZE3"_3#Y6JAM-$/_'!!!A-)1.V-BQ>:15#A,6[Y,V]]/:6U09\
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MF,C6P@]+X2,:4V4'3+J,S3$>,D4O!"NS030$62%^^M,(OP"H$X)U=21QW>;
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MK=<-B$\2I1?!RBF !TNT$>_7@!0ZU5_ ,HJ+-[DX7[_[?LQM_AG_YXO8'&,
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MZ-6910]]>$7O.]ZQ[\H%K3D4.U YQ#=79*RZ'XPZKR^L(\ 6:_/=1EY!$)B
MK[9G1L?XKLSCU\SW@#X.F3LB4UKK$R>>-4CN'6C)>DGK>DV6^BP/J#MZH_\=
ME?*;BKL(_W=24$7$EU2L5Y"/Z&A'B@XS4?;J^0OPF.NYE3C'.]OC9&>N5>GR
M%XEO3V=G\F^DVJ;J@'@^33-9US96D(:&A,&T+0#F'*T+KYN!#3H#9I\@VN0_
MH,OL_\'^,;(??S.0=S<P7I_,]\"+#MO/YWMMNHB^&_=9(U.%ZMU(>;SJ;OO
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M9__)1B;/U*6TK3TXV"F(2O#O 3.53]C1XW([])^UC8'S'^B6!IKY9L8SA.[
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MHJJX\GWP=5N]&7+ZC]QML.R+,D6H1$.'_SHE>D[>1>VK-(2JX%"]Z&0SC0T
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MXND[.A2:#B?^1(NTB6=LP99RD \BM?6Z(TWICONAP)U HZ0'"_Z68BO*_'%
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M273\CMYVV\[,M9\Y^K32_8YT[#;/W^X>@*MU)Q7D>J&%0EW?&=G<:DE)@?*
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MG@C/<E.I*@Q6)+?.^HJ5>+# *8'8\:XL79RBC\C!=/<-91U&\N.%%3__*==
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MUK\_X'US(BY)GA49C%TS^C$>3\<W!A/K=R,3TN/-G9R6K*K1P7S[$ \VP!/
M>33'D$=;S*%46S27YPB!5L'^'<W$1EOFJ^1=*\."MXLGOPKH%RE[,5>GJU=0
MYZZWWPH<O.]P6B&(BQ)^8UH-\%B]FGMB];H[P[-62ZBH*.5:L%3T?SJ'1&"\
M%G23'$3RX.6LV_< Q3JWT5WX3)Q@+H;1/<!"JW#6CAAN[[ZT-(1.Z?^%FH@T
M6EF&3S)]/FSDM:M91)7MQ=TSQ,7W@B58E'.0T\4)Y"66KN<+%6;"++J5R:N
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MJ*(, ,5_ !M?,R9*AS%0Y?4G%S#E7F:B4#Q=NQ+@5!AC_%A#T.ZQ.?3S;R9
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M "V7;@=PC'NTT=B;:F9'5![?U=0LH)4,?7;FQ2[/UDH5YSX'U1(:;?5&/ZB
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M)@[0#8U(G33UG.@JS*A.3X_,?1L'4$3ZX84-B@^9#L @]T#<R*G(VE[PHZ_
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M;M?!2E@AB&S':N;D--F__M<!]F?D].]ZB;G^*_3V0J,5QE[[#F18S@0':!.
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MM[4HOBZB8/V[3ZO>4R?6):;B0S<-1,QZD2@Q^-VRO@D]GG&[%)6+DLI&SG.
MW'- CW98O2P3)K'8X7PR7;2^P$(ZFBR1\WW+Y+0&$_[#1S7GWP87P<;9V^]5
M@<LDB@MWO>OB>$K)V1+KA>4%\-1OKL1]Z3N?:E#/L?H=,&HD.;Y)5S5ND[PS
M^N3KB_1WO=R %?<>D?69E$:$'^N][02@[#WL9#-VK/'^_H762W%!4<(NNN5
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M4M\:GA -Q.6U#/QDG:'HRG^L!')G*[-A7:@/N#1.NY09JP!K(H?N91J=;/G
M&M.DU"IG*/U25^\&BR- 0[D;#_$3)B[QEOWO[/V<-1S-NLU7>&\6BZ:WZ ,\
M77V#M][(6FB>CM".S:EM:$A62.^O'_I2]W(:/65/<AU"!H985BU+/3S" 8A
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M%[,#!CWQNWX,B/_U<ZG+'1D8;OTGDK#_:O]J__N&A_O]OP!02P,$%     @
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M9N9F9GORE/,9)RT3#S\/!Q\[!R?'7X-@X.+A$> 3D!,2DG/04]-S_)_&;1M
MBG?/"ZL-$X,9N$>*@4F*<=L%@    QOC'_CW' 'C'B86-@XN'CX!X5V'Z@?
M/0Q,S'M8F-C86%AW3_WNG@-8I-ADCWAE<1YJF.(RNY#S!<5EX+&\*&^G>#N&
M9.4W<_V 3T!)14U#R_:8_<E3#@%!(6$14;&7K^3D%125E#7?:6GKZ.KIFUM8
M6EG;V-JYN7MX>D&\?8(_AH2&??H<'I_P)3$I^>NWE,RL[)S<O/R?!1655=4U
MM77U#1V=7=T]O7W]O\8G)J>F9V;GX(B5U;4_ZQN;6]NHPZ/CD],S]/G%7W9A
M )@8_X[_TB[2.[ON86%A8N'^91?&/:^_.I!B83_BQ2&3U< U=7G(S!>$1_XB
M+J.\'9^%_RV2PLQUC("250#!AOK+M']8]G_,L __ERS[EV'_81<<(,+$N-L\
M3%) &KB0#W^2?N]_*GA.3DP3N]P\3J"!VIK/.8G(-Y,:\<ZB$O>G-F#(T0"B
M@$VK6Z"?$'8C;!00>0NLO9RY!7;IW&Z!S)06W>LT*#&BE7Y'?ZHTO*H]@*&Z
MR?7EY;G9K,H#_U6BC>B6+Q@'I](,+?1V8B'-4;!/5P,1W[2I$W:%,=W*VVAX
MEUU]9S)T?L"OL-!>I@7ZVY1BK$E'\%\)K[1/K3"F:C%#W=)D3@MOI-"5B)$P
M*J'I&R:5F:1M?E85,.#71L^HA"EZMO\$LS:SJ=+D.A.*G5[E$E%8_$9'SC-&
M[;/%X2'_A^X/&VDR[!2C$)*5VI ;YO/R32J^G-]/6U3$L^<X2EP:@5AY11JL
M599)=5QK.5=&$70&(B#LYP,4\0[AMV1W[:2M=>6=G>A WWA^P^BP2R4TO_'T
MGD"C+Y<=841_/-[KZ;$]:T^"K#]Q,6_%U7&U4+@KR6$MM.UV\%L GI.R6YO@
M9$OM3<W-M\3_!+#PD%9>0LY\JCJ@A#B.&(Y9V-J7/JBR'Z@.Q7^+MRN+!<KQ
MUND]0.NX#F3+H8!MY )'H_Y 3L'^T[AZI?<Z-.TGQSL&FE 99$!':4@+=6/M
MA ?Y6.GR2TNG>RR_,B:&!O:=^;S(G-4>!_(V^5TJ;MZ0H"AZ(G*VR'9T**/-
MZQ/V[N&-]6KA@BF9D!!,P2U&;-1+]$B[F-<GUC(QEQ9Y%_OQ\Q# +'V_;=@E
M+16O-*[E 51NK(ET-56A2^II94-S_#JN+GR:U4N)H9,?NEO7AV4MNO%[9I86
M-_R9QRV "T<G"NO-_IZ_SA)F>]?S8ZU\& <X22=.X>P35(,[M8EYH&J#+S4U
MM,R(3I,&_MP"J_O9,>DE&^TF#Z"BJY?XCE!AOPUJQ8?MS+M)SXY_YY5OQ,4Z
M>Z\$BMEQ#K4BH)"G$I;"H?MY#57UM4DVUG7U4>8?'G_B?3]H(-TFTR;*>O\D
MRN-2#8*SI"Z$>ESLP;CKETNG17KM/$P'0M("IQQ90K4Y!MN\6T?;GB[&?>UO
MY_8?**Y%!I+_2 CO-V&TT43CK/;0^@V8V&J?'CCW+/B[/K!,!I.&KE*+E"8L
MK;P)OP6J%*[88\!0]]*JSTTP+HF;1[-21I=NC;#F\4"IR<PZT'VH*?(6^ RE
M*(04P.?5:R;<OPFI;72UF'84DE'HU=$U^VK[Y>UA+ON6$BWN1$DN-#=G#P#A
M-E]4Q"OV[PD0N?5XB]P+E*13;ZT9KYI/?:F>:%I=_3DW17[S4Q;KS8LZ&,:5
M);*V2])N0WGT9IYBDO3;BX6.!\J!@7J*YJ-Q[>T;>?IYV5?OD&%=3IB0I&6X
M'6?.K/[SR<SZ0$[J5)"X)^_(K^+1-1?#UC8#4&BOR30W%)NQ7'+M04&_6X%]
MA_RNOV+':H,UJW6>I!S@FTBQ[@D#71&[E?[>TC0RG!,LZ!O_;=3%\EG9P]C
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M@*&\UYGIR(#0]\B-B./"_ADU'&KK*@(+/!*\S3_>QM]&WOQVVV;$1:.R(;=
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ML*"A9HH]<1]#0KC: HU[^K5L%/K0-AL"4VZI:YY /'@I6-)1R1'Y^'J0(!;
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M9*YB2WD:-:VA9B2.TXE20=ICCJTVJ53J2-7L"ZL$ER(X'M<?#/WG@Q',R_P
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MCTYU 9,O(6M.SS_1@9!1\_06UI=3OJO)5W'29 $S6+? V$^]TP!DHU2[TY^
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MQNJ#3@":0G#:^.$@$B WAR;WWZZFAI^GXYR<YM9]ZKM*'/I.2A/^X%Z)V$G
M/4!:(@KF2(.0_@8WWMR7,H/^6+41E5#+OQ)Y<J+*U![N1!17.?;CI\Q:$\NK
M+8ZVV?M=^WEK(MGN7I7*]**&Z$)T$.<F8DWJ!%3L7*;H!0'+]J[CMDE6PO.>
M!A\8PMWVS9M2=@]4#8X_.1+<Q(E2,L@QJ'O)9);[TLR?_Q#FB\CBZ)B74I;
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MJ>VH4B]%OO5NJ@1%C1^\=I2XD_.WN?^1\D$PECRWU]"^X=)\4 $X;EQ2W6.
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MCU@D8$(2L%>?@P>"?K)% N?,X) [)+"/!/[V*T_:SEN<K#\3O0Y  FRZJHJ
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M>T\&&)1\-=Y!)N^*GP=M+FLTN;B+)PK@,L:AIQ2LR25@B0\&FD&V@JH+B@X
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MA^$1'J4ES_HSH<G5-V_DDS&_%5)W PE]QEV6>)D:>]+!1W5JA*"3$16R@&.
M-"OUR"U#<<'N>!^J)@;9I90&E JRL0_"J:7AJ,)-</X:P+RQ<L#H<M-3?21A
M_\^EU%<9Q^;+O1HV5WVEK[!4%=T0A<[>9<E*B;85?.]*G&$'^\F+74'!,#'[
MH%/X2T]F]T&*8IY.OR ID3_1U Y'3>+.Y,./*VAI:BS=C4NV\3(;CSRE:N-
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MQV.3;HFW0/2:3L]F%2WI@[&*""]6/2/E-W;V*<E>J2E[%,!FS]U' B'*\4?
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M=?#HC_@'<=G\;678U;97OS\/J23^PW*>G=T#," $A"(D()OCP!-$I-9W-RB
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M)U6VB&##M)(;,ZMRAKMXVMN[8%HAL]R!81/]SU=<!=_HF3YF#LL]0GZ\[=&
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MKB3]X#&F 8-ADQ'+-=C+DIE!4Q%N#M-/47INC9+:-4MN!<[EL$"3-:VBCCW
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M^B[#-F[!@PY-#E[MZJ(1KX*LCGT[\EZTW]FVAD-)]=;GIZH,H$F.[E\7/G?
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MVG4J;/*5OP[YQ0[DKD>/YXF)$])<&<:DBV.E"^X94_';VV?%^;Z@/RLNI8!
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MCO7K$#(#6WVUJ2_/>SY6\"_^VNL);+;:?,$73 \/OP>"O9$FMQB"3M>WO/<
M;=E)+R.I4!8AJNKD=55=)?CQ7&U^U"#]KQ+78/1"J6+2.TK>4,CVR.N_%+<6
M!.F&-O+?MX.-U6Z(\_9D@+1F3J^I#P3/PK>V1 WS'*DP30GX;SW+C;/Q8LC!
MCB,]=Y2MH^YB;-'39P^4S_?)V_%H ^3H9??M1%XAW@VG%,E[LD6VJ/SD>OG5
MP5,2GRR=.!B7)/-R-3JAMLPN%11\JIIAHM]P+115%)QJ%'DM]]A-0V4C.J"R
M!A+&0#[C;GTZ)*/]Y.H=-WGK5,GT"#N]1Y@FR(\Z&W>>,:C$#==(9WG8((Q4
M&]K0EC5DR6J1O!FPBL=^D)[EJJ>S0G#@=@]@[?K1CPLMN:H%OEY\TE#3J)#0
MP1)[^:)$3*;+@$8IC.LLPUQOPL$\X^G8MC(/C0*:7@IZ0 -+7#"][%;M#GHD
M)&B>!8H_=2,E-)W+ =?"<3K:3)?Z/?QH-9%#"4VVW1!MOEZ($%]OSYA][&QW
M(\.QQJU!F9@*XP-_4=VJXIL'>*;1MW;&X<"&NU.(!TU(*-OTZ8'!^]'RPP2=
M0S6.37-*"46RIJJJ>"S G[#U?1/B:1H(-LA-X]TJ!ZMNC;[\F+@Q*!B?EVDU
M?$@@YY@;+4I5.O3FCIM3I672D7R>5IG!D^(Y+OD[+MEAL?:?IVHZ^-ZR$V?>
M@G'<9[CO#W/T9 F*]J@P@;AT!F<UX.VT)+=Y*2KPY33/7_L45+%(G#,W)8X,
MJSC"(%$4-XVVC0=3#!#2+((3^[2FN+::+;R;17F ND8+HZ+A?)5AOM'(]=3=
MG;\.G1!L.]*EN??L \LQOI)FEF;2L*E'/Z>C:0/ZYHCL)]\A\\4;X;'#&[9R
ME)=J&LRFW$35]Q/\B6<82S1] 'T#;@+5+S9Z>'F./Y^D*LR D>P>L+@'K/M=
M&,_?%! 48,6W.R9R'?R7!N,S>2,4Q+S$;F7!(S6S.,?6@2C8+H-G0]%*[D*^
MF)/3G V+^F+WSZ]Q6O9.[ Z-2TW WCFB)EB%#=I@DQ\7H_7^=$>4"KVBE.-?
M\4-:O&PRMSM:TA0T25'9$D'3<HR!M^]<A'.H#H"*R=>SJ%O8UJ*<WE>T(K:S
M,)ZQYGT:Q*AZ;134*R>\ZO! \C+H'B#XAK;_ND.[F@B@9CG_:5_NX,[)7BX(
M3W8\^&$T-H+Q>:SOYX<.\NWZ.U(D71M.S1#%F%I=K9,S_39-R<@&T?#KY8\B
M:C/2!GBN,3#R%(1YYS+36 NYFQ#<LV6P&3M^R:HID5*6O"_>C/F"5>4:/NBX
M-.TOI45[+1$QF*;JW<#:6#//PZ2"+BD1K.L5K<L<EYE3HAOH(X7@C:QI"]-:
MW%L#5=4FDB!;%P="\; ^]BO? RK',Q<6#&@R^A>I 'MYVAV7S!?" U)[:>9$
M!V(W(:K?BRJM ^L#ETW;"]/-67.70A:(Z)].B9>"29,6XN(FV[\I9JG@P\N9
M<\/LZ%,[Y73(F6Y&HJ[U<T0AM!ZA$]OQPNZB[H!W/@Q("(W;_+X9\AO<^XF0
M?'>9:H)I[$;(RM*NT' O+B>)LO[MY?@;O0A*WA76&-AG69H:W2%FA3I4!.P>
M"&,0F+%J\7VKV-ADQ#H-&]7+(TZ2+2(0:\<J+S>V6X#2V,YX;7<Q$N[I?_MA
MUQS!_KNJ7M?T^?OK](_^XN&<6U1NWI!0!@"YW<UMMG4*3W6X;9]@4PU1K^Q[
MQ)R3$_CYHL+KZFRKUNTZ&%6[/H*+@O22C+CF]\# M;01UIO6B5N;_H-UXSA[
MV+L!4L.RTF$Y+78P[H3A?-@1-8K?UT0K?%!YAK6JIC' M[KG4=NB[N-8@G$I
MYSX,YY<KU9LU'CK& K6!H 2LT$-FM?WW!QK9%IDJZX79A$;Q+\.%XW6T7SY,
M25YEIU<1HL]?JKU-U_40(39<>/U]+962(+K@.YXH\Z(N*U)>?EKH'L#M<X(=
MC"TKN6R5=BZI$/MC.!MRH&^=]26")8I34.HP$Z)=&8*C[!GN_'CO)7&R.I5R
MUB $DR416=^5F);'H?$;$(,"X!5)>0[2%:$XKW=6DRK&: @70Q?D4I0U%=.2
MP\*J?5_^"&6W"J':E2'A<1+JDCSWF,%M^]V40JY2^TY7A_F6A?UV9FBTS#MU
M%V)=8(EB+GYHAJ[J2$"HN<U&AK9'ICO$@*9&?,<!?G_SV !IEOC;Y^7ZR#6?
MA+A(VHW>R!N!>O+]+#))@U*P2"=D7II^C%:GT>:EPW$S:U6L>NJ>?Z6&+!45
M?-I?0IQSV(_J'N@^M/%1 ZW7(J7V1SV?+O\.+;6?2A;&D &+#$A;H8660"*T
MA-N0S!W&6,VIX-,H+96"MG!J/(BUMF$1"8$'8H[A+EL#JUS36 91MG!'[!3A
M)XS021/L>UEA8)<FX6EA1;&E/)7\C"7=!P6_>?)U[3,#.ZIC=07-EG]8T&"G
MH!D:\&>QV6C-]X7# M3KM^6&INBSUN44*)L?4DD14";P@T&MMMJQ_4S,RN?#
M/@M\'/&=(O9QLU8+4BI",NVWTO2<O2;$)=ROH_"A)7'?$^698R6'51E4+@31
M]M\9]]Z-:%=%G[QN#CB>-DS>KH]5C@D,#*;&BE6"O6<D<G-X:XS(?;\CPWJB
M3JH@LL"P\HNI>LL2T\#)J)6 ,PI%"<LBLO:2_(H*%NM<E,TAK)&,DS25V!*P
M;\?H&'2DJ[NY&L4J&3.FO%:&IO/>8&<^-K^-=M=RFN$-Q.8[DF$;NE!UV\YD
M1W'$_A4I_T:2HJB=)MIE+.1L>21'GI5]2N_;\IGM2\F\B3S/)G3+:1E<ZXLY
MNP>PEW:G]17RA#UT<V^935J"54KW&WL?9<N(?)=T/6/.0?D6*#CDJ/A .=)Z
MWIHTQ!O)Y>M$QO+5"9DDD$'<0()H4V/&C*"<V9NW*.2: VF/XM;ZJU'[[ZH2
M+S-RM>.F5%6/,PU8UA>HZ705KF7VZJ^2.L\BWC;%'ZI)G]L)ILHG6FAA]TNG
M54CYDZ'M3NJ&+.W4R9#=28+37B(U&QO&:VC9M8;'V*RG6-RUQF\*$OM%SWN5
MR'N)BU'%Y[ZCI;Q<[C+$/Q+6*A]VZ\2V3/3;T:@T'YZ,G0?&1?[\M>8OG9O3
M4K^Z--,%$ZZV6E6CN99KDV<\#PK.W<)I-^K T04!/D.C%]0'QOG_[N'@_S">
M6<9'[1Z(CRJ\!Q9X;TD2!G3S4?!V*/.TCPT$\F-WV;UFV;CO9-UP30@KH/T,
ML_$>0.D8\]P#V4IWKWON@9Y13/4@R(;+6!O\CO"6JO:T%>SQ&7'4(VS,.L%3
M5M,:*P<BBQ>9?R+QSI#$F5;JH7<4X,Q(U[81AOIZU\!V%_7J%_+AT%&W$PE8
M"Y^Q:[XWBR"FN*=PR58\_ZL^AQ*56!@Z+!DJ*TJU:K50CHJ!%8]0^4A,U=#S
M*S]I:HW2$FDP^XGM[JB,<<H0W.0%G)C@]8,(P^[85 I4[,CGC;M'^\'*053Z
M/W#7,W*A$CH,&4C,K9F^5((,.R26.M+6%J0X?3Q,JYQ+<0\P/X]GB\G(COP0
MX0XWHK\'NB*6M ;[IEU7>AP8PS:C#O*_5 O*F2E<]F)IM?B_D2N*0XGTS@?G
MPZRF61 '^3$A1R2:#@4X$*\<D1?M5?X%<5]ZQ=A @ ;&]%52N*3+V@C1PH[T
M8Q/"W53RT4IY\F^N_:ZB&L,C6P\>!,BB.:L;AG]?-V$TL:8YCX!)R7>?T^!/
M-D$6W.DM2^71@V=)J%8X<)^;GU@!;J6N,!,*L&M/ZG3N:N&I38E[H\Z6MY'&
M0/"R[W>]T5Z"U5F,P&CO<+]R&"%)AJL24B?BITW,FH0J9@54]6<&=_F3CP2R
M'*I/Z4C$S[8+'M--!ZV'W2C 5AAVJNT\[IY$O)Z@,7 P7B:/&%9A^LJ^U\9N
MR:$H"T1W_IQ;!A]U,6+4.%$LP!.CG IL$JNBR/3*$[A_O@0$"WA8.$](L*G7
MZ>%CNFK(CZ6PC$\CW:Z[.%)GN0OS<F8L?)UZU"J>M(G]'\84@:/4#1/81;3C
M#:[-JMV!N=)=UWNF^LPKP:\'9ABXR0DN%:?S='''9X:CF'7E:T9VW<9B%8CZ
M+V</QYD=V&WK4P,-2L8Y!!RB!74O/WG%RZV5@-4-9DINO(O (MT7A47]#[]Y
M!27F5'!Q<W'U//I5?'R()\HA1EU@MTPPS=WRP7(M!GVHH,L3/^3<H2<QFTY>
M$JW^*34:QX#WZH:+CB0G3$UGIOLJ)MQ'%V0G7>G[0#]/F.D+1043%[&JSV]5
M$E4B*?]L@MY_8R:=X)'3@STM'X_ WF(7N]L,AF_VJ4^&MCW3DK=I/0XZZ+:E
MIY;'% #/>R!\7YIUSROHX,=7N]6(5DQ#[.]3ZXV>U!Z11[C'F:X3=9R0=B_Z
MF1!)<O/\/8HFRXSNIUH(&T5Y^[1\T*5D5W.N1>#HUV@^(WPRM'7]F,YR:CU#
M<)8J(K@Z3PYV1/;FQ"AB=D.$8MFT.T"JC?,!#B,?G7G!V]DYL$FW-&,;HBP#
MUJHUSXAGHU.*^=V!'UVH'^>+J4<Z_6(Z_P5\O/D5.WI/N30):F" D1CLW46S
M'(<5=*/@<2&"N?<,?ZH^)0I.Q<CY *#+#*PL-3* ^=7F@@-?SD!IC7='C7=3
M]7?Y#?8&MJAA)DW=!4/-;5 LJ*]6.'#2A@MF[/;#1;PI<XM8XO_K?FFJA9LL
M&IIP1=A:@&AG<$X<<)L9#QC?<$K 0 $MWJM+=EIWBVE=\;M>I?LS%R;FGO/N
M"7UH(NP:C>AEZJU>I?^<2]:E19IT7-Q)H-Q]LW<%#+I SDA^J4'^ON-?)9^T
M24<9IN8T9<G=FG4KQ_8/6#E&,'!(R7=>_<1B3/@(+K\C&=G?@< P[WJOG=*N
M5PYB1 :/$7Y'2</[Z^540XYCL@R@U;9'J)S!/DKQOT[LM UK85#H:[NC&TN#
MRH;9SJSS/<#)0W82-8>>_K'$YR5"N'"-6U<.21CDY. @M/3(RMO%J\0TA0[X
M=>U)+Q[S]HQ^DPQM2YS07U+OAP&JO)N2!IIQ#^"4M=&4O.V@]4V<,#M0,&J/
M%[=(D,+"2B\/O4%;:U6[85M3DWDWT0;C&_W -\(ZZ7!N4+5;]WH?^#QH#CCW
M%9#OUFA@I:/>MM\]16R6A[G/';D5KU#!RZHH+./LUV:?A_4-:UN<S!3\L..%
M703</4&9]\Z7%92HP3RYW!>JW7^6%B]2:_K;8]>S XX?,KJ1QK7_N33*A%@2
M]R>JN3L3?](-'O$^9]1=NZ51;RY0'$N1Z7D!VX:4LQC<Z(!, XMM[11YFJ3)
M%I#4Q6LQ1NS<-)K>:)^)E=2[Z#4%"9&FGFJ1P/QQ=9@&&\2-F)LV@C+J);)U
MKG-5N3E=R)+/:\HR6*X1HJ'J^M98[X$(*(.M^&N!O>E")U^G8I8@.=D'OX+0
M+OTU.];+7%,]4A#7W<L$**<?UM+8,]P?IDAN#/=$ZETL'8FK+-X]-, Z1!N%
M>47.Y(_]*Q;]^A)!&7:#OXHO\PJA6/JCOU!!\.MR72%ZLN/2I>3WQ895/'?T
MU--4=O21%O15>A-%I$[MVCU 94N1Y'5744@69AI9(4\# $:+F>2>S"COK5;,
M?] &XF_\C7\CT._G_A-02P,$%     @ Y$5G5@BV=),/Z0  ]&$! !4   !V
M<FYA+3(P,C(Q,C,Q7V<Q,2YJ<&?LNP=4E%VS+OB2021*SDI4<LXT04!$1$%R
MDB1)<FJ@H0F2DX" H!)$)(/DG"0J A($)---D-Q-;*#IGO[^\Y]SYIXY<^_,
MW+-F9JW[%:M6U][O?JMVU:Y=^]F+;NP<=A6@?JBEHP7@X>$!KW%_ ':-&J,)
M=GD! 'IZP#T  $@!0CQ% !\GT> :#V-= $*<C(>3+=]_^.L3N , U-,[;  )
MKN\FKJV"8X!MYQ_O_DU_T]_T-_U-?]/?]+\H&;O8^WGZN-AR&?HY!MKZ^.&Z
MB%X3_ -3T.&P0_EKPG^3N]+3_B$3R,L#0'KZO\O_CB](\_[2^3>^^)O^IK_I
M;_J;_J;_M4E"3$)204Q"05R:2UQ<05)<05KB/^W#(1' !; '_ !/P <GV0)<
M@"&NY0@$XF0?X"]@@ETCYW;V\_-2$!7U\!6Q=?"T<Q2Q]W07!=MZB8J+B(D"
M2B"PEZV]FZ,?EYVCDXN',O]A>S<_EXN#,K^)M)Z8GI>&H[/+@V ?1\/@Q\_L
M@]WLY1WX02H4-Y3 "F!W+W='/ULNL/M+#U\%L/*=?VA7P,E_=8O>45'R<7BA
M8'!?ZY\C<"WE._^<2V!@H$B@I(BGCY.HN+R\O*B8A*B$A#!NA+!OD(>?+5C8
MPY?[GPKN._K:^[AX^;EX>G#]U;:U\_3W4[[C[^_BH/#"]H6TG8.#M+"=K:2#
ML+BX@ZVPK8.DN+"#I*2#K+2XG,0+<;L[_S3O8/]OUKW\?5[^P[:#O:CC2T=W
M1P\_7UPTQ$7OB/[7VL2%Z-^,_J?AQ_F(&Z.@X>-HZ^=X'\<J?RVTL)B$L+CT
MLW]=:!%Y>2DET?\P3DGT/TST_X-HJ2@YV"O8_S4G3Y]_,6_HZ/T_M]HO753^
M([S^%T]Q#_Y%P)G Y1\9&9F2Z/_>^O\Q'*+_3#^<]&_)BGN3Z_\%^MO(WT;^
M-O*WD;^-_&WD;R/__S+R[X#7T0.'<@-Q<!:[ &@ )$1$Q$2$),1$Q*0D)*0W
M:,AQ&.,&/17U31HF>A9F)GHF1E8._MNL[+SLC$QW1.[P"MP5%!)DX1*5%+TG
MP7]/\-Y?2O!(2$EOD-V@(R>GN\?&Q';O_S9A>P :4GQ7PA "O#L /@T> 0T>
MMA_@!  \(KQ_T+_>$?#P"0B)B$E(R6Z0XP8T4@/X> 0$^(0$1$2$A+BGH;CG
M "$-$>UM<37B6T]M2>YXTTE$I!62<JO7]M(;3"!X).U\(LEN,# R,;/P\O$+
MW+TG)2TC*R>OH'%?4TO[@<Y#PV=&QB:F9N;V#HXOG)Q=7'W]_ ,"P4'!4:^B
M8V+CXA/2,]YD9F6_S<G]6/2I^'-):5EY77U#8U-S2VO;U[[^@<&AX6_?)Z>F
M?\W,SOV>7X/!US<VM_YL[R"/CD].S\Y1%Y=_^84'$.#]*_VG?M'@_,(G)"0@
M)/G++SS\P+\&T! 2W18GIE5[2F+K?>N.1 0IG7I:86TO&;>D 8+>SF?B!@./
MU!HO\B_7_N'9_S7'(O\?>?9OCOV[7_/ 30(\W.(1T  @X%(K0:  _Q^\KB+H
MEIL:T\7H%MR5Z'WFMFN:69AMUS7I\ 3\7&TU[V-7&"(_N4L%#!L,&2=WQ;\D
M#U(JL_CV)=7M.9OM-$=LS4/@\FL"(A]_$1+(H3)EA_R2<74K)+3RPC@D8.\E
M9"+I>K^3(J01H'NJ^2]L$@[Q!]&M#,Y#K,FL'%RT",6;,CH(9.#MHW>G4&'G
M(ZF#G<G2K$M4:T<[8=QSYV<LIBW=<ZK&F7>6^$CAS,3AL@(UJ4J,J\G0LXB9
MQ@\V5DA!\T03_9PUR7 ;;]+X5O52\MWMV=S+V?N34_<1F/SB@=MI0E5%S;2R
M)G.%@9R^23^)=@0^AM_X!]=P($"#RC8#6("I492L*\?1W=;.P_=>MHO%]]#P
M+;DM;J4G)%\F-.F IY8E_;-('BBE_PN$0;N;BOD%_NT<\0[/WYB9I;EK^0$O
M+%"_ U%C":C$@-P-]WX@KY/][3!@SW=A!.BUL$-K9<6?)+7_4/2O;.V$_(UV
MS2.*Q5 3=<I2^!!-3$7(X@N7'.Q?=)U)-N?W27NN?@H32UW[ 47D-TYTRU(^
MO[+E\R9F=,Y0.ECJ/O1->D)2\-]H_#]C&RG,S$3;$MA<;X4GWN<3P719:LWU
M^67N.6?,]PI$S=<(58(KEI^KE)OT?.$*YO\6FW_RO4XT\:Y>:S,!GZD50,*N
MQNZV(?K;?[T#51\B/%WW$.D\F>ED]^#Z1*/[:C!<I?%CER^J @N0QW@F?A0E
MH["5^F)W16YZP#"T093T"9(?$A!X=E9CB<J$LW8#:(6VV;7&F*.=Q?X\B]IG
M0F/E^FSP#%7V:/I!B  RI1 ^#BSL7C9V-C;,WGI8P?[%O= H(>73>X1;_3]3
M]U_Y0G](UGQED#/5%\6W8.S&+C+I(IPF82YU]":'K8 [A,&80*4OQ6VYBQ&M
MK!_311M*[W^K3"I;U&OJ+:2F@\Z=O/4+\8KUIY\DCIJ^W=2%(:DQ8;PI=^['
M/FP5,/JB0?HV):REAN0Z8\32K8NO)4\[_:FG1_N'>#DA++ J0+!=+KC%[H9A
MY%GAO#$'=1OZ)'QYH6*]9GMFU7<(Q5-4V-H<\Y[O=(-M)8HH,2+ZC'Z=G)$'
MT]LVV:>F+44>;%7_U+6?#U=\*+AA$PTB/J7B7)@#[UH@I<*OVW\<?8HO25^S
MA[Z5BNZU?-U7>'I64UX*?$P0^!]S1S <SE&#6X=+$&"^G:7^P[+2P'+8<MCD
MVS$9$Q?!Q>R7GWB:]#DPK5^WOLX7@4.-&I^ZW*TW'KS9_GBLPW_(6H#@<0("
M%#Z"U.RP*-.%!\QH9:R+"58<,K_SV3^*.D[RN.H6W;:^4"6B,WF#F2070"GZ
M*E$B.QB]5-9]/CDVG6&!X'!E\P1DS>\@?#1_:P9/QWSEV/K[];TDJ)KU".ZU
MI_]ES$8R)'IQ)XP'"U2388$B@P[RU=A!=H*UZMBRW[M-P9G]V8&"0B_&!.8
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M*C+/=]3BNM"SPWYU)4YL99N#=Z;*K]/@MI#8 /3> %M\M-\-5J:KJM2SY.#
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M9[EZ"W"VE'1ZF(N#XR7)'<)7TE8CY;LFY+ 0SF7=@ Q/NV[G00)X_E(::K8
M16XV=7J(YSP[_^B;<+O98+XH0J+TYJL KDC2L\KN))LC;24]+& MC!X (%MK
MGBP02^10C"/B\-7G:4^/.Q^J14YO!S99)14(A;E](<4SYL(G&V>G#(WM41B/
M4^& </QJ[$[(5G@U:YPM8B#8"OG]<,V(QC3CPYB^/'>^FBFH+A"=8([;+5!^
M3&)UU%EN@HL*9;MZI8$@BL5 @>@B1K\)UAU/A[?99MR,A,)#K_=G8Z4]]]A%
MEO4*^KS.)K2"7RV'MS>1CGMH/XHPVN_B13] R<.=3Z <EJ,5OVW-'VQECTK<
M?ZPT7 R2 2MQR'&%!W%D7HFY!IB R'F^1&I>67W8BX&!8'@(HZY7WOEG^L5>
M6*#QP_6;^958(5M_MP5G_G1_=B.V@D<8 30T&0@V&80F,*I0H7QMR\%6\)!D
MQTQWD1P-(>\ZSV- Z5:2O9)OWER-Z$\T#;)B((^S$2F3#Q\Z.J36I^-<N%7T
M_$R@XDNHI'6K&P(V-( %"#J4UVKH!H0,^DH6ZCJ<:"T>XNJ@\N #[A)S)"<-
M;@=P]C1D6")FNHZ=O]V[2%^H-6+F$GU'[A@DQWS1EI)30.6$)$F0_@MSXMV>
M;OPLNWPGAFDML,4+/AXP:)K:0<<Y1+!KK;$62@#G[]^G1F7K(1<L^GA2(CGW
M=:K&GJVFBO#.=_T>"-%^Y<\JFIQ/_!.5]<W(,TK-GTTOG$=K[>?9.C&[]U0N
M,I\.PHRL^9K9CN0,/[W8_-*D(33(*/XX+47'[ZI.@"V_?Y\.[Q!*?M)-Y\)Q
M0]>&;?E;2$7H1_5)';'L]3$ZX@,QR7&EF=F$2FEVPZ\*Q3&Q@6?"6ILS#ZJJ
ME093O[^NIF\6X'E^SC9+CU"$29_WVQ"/>U<.1CWYDC^<:SKXZZT[H8HB1T'$
M$#/3&$GQ3Y(^<;#]P#'$387="IQ*1QZ3>/5D6>^\WR%C$_[CJHAYJ/GA)>=#
MQ&R*TBV$S4 5C).V$]-4JQ?D%D2_6-_@QJ8:37$GZGV1=Y+OH;4]8;SGE0O#
MAU?/=SP*FIF%\<@OTD$*E_J#T*/;NUC@C*(55_+T5#GO@A5AC ,VM[:;EUD1
MG6.%Y:ZR!D+CP>?,Z<M<,IG&/@QBC^6'Y;>M2U99J>(N.?NHV$;@[!I&>H_)
MS2C?>XI -I/3&4/_K'_AJGTZG9K5FO^;'Z.>)X %JF56+NDR3TB2L,"ZQBSN
M5LWJBP4^YH8KV9PY(SWCE PKP$FH1+/.Z8ZWS\6%^P<RR9S&& O&2/0?=L*I
M""%.2-E$:?F&5+JAHFWB  9O\O-7%\^3.!<+E>!*[T^KG<YP5X'7)0F@W>1F
M3#2OU3N8:(J*$.11%Z*Y[]J8G>!1G1GSP<,HGK2B5Q(>O?*\,?3>LQFJ;#&M
M,*I$$%&'GD,;%HA[,0UK(;YO5L.Q0QYM&&.S#!E9*"!)L^Y#[EPJ&YZ%M$US
M$6H&"/.K!N^[T,3^<>OKD@<+VB"B9Q*6N9'^A_'6IWSBG9,MU/1W6TU\FZWZ
M/BO<.,-I/W)MZC[=*H'*_<$#.2FB3FHB@F,*);)2)@\V XUVU >35-$58W[L
MGK":P6M?PU"2 <&/0TY-^O7:0;SE=VJ?EW>99T&>K[\_.ZMY?)W#K=-%.<I6
MSL[Y](.9J0/U4PG!3"1T[W>92W!2[FP?A;5NT)/LE-%-YT])E]H"UP3VUSO
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M+=AX: #TFW->XG'^;X7W"N\Y=/':3)O=*5[[=(L/,ZF<X+U#FA(@4@>8F;%
MO ,6N,2K%H015$()E&Y[^VG/V;9..G0)270]6/BP_%O0NKCF3],R-V(?DPPY
M*FZ\;E_X_O,UNU$,&6&DY"GQ1T^*[0RP'D0^A&3^9,*U*9EMB!=N=$-"2W[5
M1WR<FPXO#'8P,S^HVUX&2YB1DE":E".M2$K7@3,=6@==J4"_D2'.KSNPP/:C
MABO12!7VIBR>]NG3?4.]B"B-3S8[PL+OP?)/N'N&F=AHM>EGP29],M94B%]-
ML<4=XVXO)R6D]L@A1U*Q<H"_;XJ"73@_DCC:'@:ELO[3UN#.^V%/2UZ]B90]
M3CF.B^9 ,+QM&FV&Z-A.K-P10V7W92QIVGGP)G[O:EP.*.1AKXM8"1]L[Z9%
M^0P-!-.U&9<ZF?(X>IT=O5W7,KY96:E K5IM\A %*C+=.<M-*:M$1?5+F [S
M-B2:3>OU>\G]^=Y"P-WDFP#4P/AU;>9O_6_LO6=85%V7)GP0I)0H(#D42I0L
M.0=1@HB  00$5$"24)*+6 3)24! R3D'R<$B9Y&<)%,%$@6JB 4451_/]#?7
M]/OV._WTU]=\/=/3SX_]J]:U]JFU]EKKOL_9>^WV_<=;$:[YINUTL+">*8[]
M0IS,@@I]8$T?5[)XLH_M\/>HS\3QU 'OY99=RPMZ3(E'X<X%[?:EN9M<I2VN
M90NE^7?*EL[[.@M68MMVKSJ;H7+EI40%DM.SRFSK-\6?E.==!MX)"<?[=D)1
MQ+/8(8#3/9,BID>1/*+[X\]!NBS'/-MDBQXO\GL_KXPT,KQZAOJN3L16&X7
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MMR1=CL3(G<\#'P!=@SFLY#^Z<^C&_K*X!<^#W,O+NEL"/D9S#L.#!1IC3;&
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MJ*COF6*'? *3'\DF?@R"?X19(>.?VG,?'= Q<<6+3!V22 SY4.!XNWH^59A
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MZGZZ:YZ_ A_EN7J[(#^(/3HXO[_I:R,YGD6K+4'3HDNV_G@1RG^\[$3S8.4
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M$"_2[%R-K"Z9Z;K?2=Q^E"JBW9TXU]J 8\7S^M''H39A :J"'C#A\5WHA&"
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MUDR>5."N7M5VURE'..^#/+N*)V.=FA"'R^17#Y90]3&%E9+$X'']QTJ@<=:
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MO*$SY]YB@9&9"M07"++=G1RTRCX@G(0G@GZ1P^P+)?QP+% CCKJ#\:1IW\6
MF#\083JZA&^*.=XYU6W_*MO(1^/3/(+C;97?FXDII<O>])D)?^)D#/9/&#Y3
MF]F(82KY788=]6[&OJ.1!06J*S>_0L]?B<U8U6?-4D2V2C ,SFJ&%WKR(;H<
MKDE3%:@IM1+/>J"3DTLG6-/7OWJ(4_XE.;AERJ4YAP7DU:_3:"\D\1F!X_YG
M;NWA&H$HY-( %&-8L>.*!0;NXHSM;>A1'.P]HM;<>[@9B<VA%-K#>;6PJ<.9
M%>N*AP3F>WO._O(#?1VSFFL.IM!F??HA71=\UV^?7 #?V#NTV( *,D"Z01]+
M/&(8+UI66B&X7&?>)Y/O9&Z1Z>S.'BU=% ':IZQ)5HSXD&;;5$/OJ6X,_K_V
M,J5<;#G>&I<X3X7?"TR^7$7M0H<3PQ:D'F.-SXQ@VWX+.5DJFC5SZ=MVWPO+
M>99"WEE-[8)9L=J+X<-XX[PQA/-L!2E6=@ZI[<>\Y]2'2AZ(A@<:7!;,[AO=
M)0%<PA>F \HI^TT4TF=+'"M>$_D_$C#IJQUH/U)P2N=ZB)<^[MGUC5EQS2)9
M%#S37#/E"89_67&C+B[6NE!)74N=,]F*;;?^^=,'.ZZ/*]MOZWP!?K-H_>Z:
MTA_.?_N;\&_"OPG__T?XWY?7>EF\[FG- D-?NV)G?N8@8WOP>UG.U5J[^&@[
MOB>G;XD\#AI2$QV;TY&M':&:6HZ>V725B#1/AAM5\A\OS?0OY%GBT!=[<\++
M21AM\XUO'Y+@_>[1 W\^#U#LS@3\"5KTM?/YKCFI#KXR@;%U\L"4O-P@*L/+
MC3="$^@,<(/OZ^ZUO#O8T/E[XKDCZMP8],1<.<''$@0?";=RD8+TA(851]*K
MWFLVSQ/>L5(S3PPADGZ(E=M@@<, ]<0?J/S]=N'_&)EYHX28LYT4^'N#=.-$
M8-JW./B V,A[S60)HQ'V?R3TEGL=1!R2#/3['65E86S[6;P^KBK_J'T7_:7V
MG4SHE]IW]FF:PX#\SO^*F?\/D)&^<A><*5'UGC"7UR&]F==M,7)+CH9=U,&;
M.B#T2.T%7"' N%\M1NWG7D<*,M@#!G$9C3TQNUH=1;=)9MJW\DO/MT"Y7^K=
M^W]XZ_N#-9-#_UO6QSPQB,^'V8]<?4*:,#T)1W(&F+_8\QL%EP.QO>OE24D-
M^I;G/<>7DTIMGVQ=)G*)$;@RL>E/,SF]I)]!D:11$J,9$!44- "+YAPO-2K7
M?EP.R?L$;.Y^>X8AQTGY$PWA_Q/7GVU"GW,WA_U@LJ5KRH&CU?Z9*#E1 ;%7
M4-/ 5&(:N[FYO^_[%+HX&C?7.WH%C&)DROS\ -0<YF0P!6AZWH.>V6BYWEYU
MP54Q-= XU8.>F><6'!6U0_DSLO(7*$5]IU0T=Y>% Y%&%A?3:F&-F"&]'6](
MN%C0<6B@(]]OS_S/5@$/O87^.BF[;^JG\_YA'<+?:G*V920T(YK,+*P&5'R#
M2#H%NM,BA*G/"KNC99P7^<V9-!7$\ZU(H[>8Y9_TT/6_.<%@E=MVW%+$Q>C.
MX'.))[BZ_["M(5_T99SNO4EB\:W$[4LL+:94Y?TB9MO\3J;KS&A :1#01B'+
M<4L(-]2\%6TW<>4M[.*R<3]?J]6M4'J!FTWIWW('?$A6GJ=4-E6)7\ U:QAW
M",IR@&QP>>7,BMB'N5Q\,ZCN];#!L:LR@O@NPUOR8-<%]D:69<& <@:T>-=Z
MZ]6&FA5GVS8B]=2\O%7OVI,%/:IJ^OG/AHII91%EKKO@9'^SQ@Y0_,_T;?J;
M[F^ZO^G^1^GV6RCG_K2%\N^4IO_;!*4Z]/UE&E/K&1K.^LSSP<9O1\C+RWS]
M2K1D/L92/#WW<D%)5BQD. 4%JR#NUBW2.R)+GYT>,6CL'3I.S<#8['1FJLK]
M*AK%.A)G[MQ0S3FVADS-&GO$M:3D51/EU<KI=W.3K)0G0\V Y[*Q(?/)XC33
MY6%4P_CBJW$3>QVI&UUKY@0)O+.J7X>U,ECJ3\J,"-11"PM1BRGAI^PW3HEJ
M[_U  M'S$\K_<K[A3M#Y+S2Z6LQ5I.G$)T@,?]*VYE42?^L/MR$_U.I(TL%_
M"&EOXX]OUNP*D!X?*/0J93*E7RZ_<J[K0^_I+7?M5^T1Q8.QY9_KG!'H<PSL
MH&^CKP$^&U8!OO)^IU8\\HES#L8[T!@+'%O! GN-<DZ-5VQ3\L>CJ5KVSY\J
M.A@8O,,_@06.NT.^Y:%DOI7JC]'*<7NO/FO+3,V(;%F9J!>K:QM:W&@S+_U)
MHR)>&?/H'VY##U41>HC<[(SZ(\6%"2?"^(R*_X##9H*;W$K]QUHI_=$1(FB7
MF>K5&$@Z'Y3D!Q$,VRX_@\UK7QZL\N%)OGYE,J.!PNWPVTQ#T?Q(OG>E5J,+
M1]DSE.\H>-\B?4WT_%$#'TX8LK"!*NXR<D<NW=^^**^@4$/JT[&61J7%4'7/
MQZ??4VL;G(I[F0V]B6I_HXN:42\58#=E/GGUO*"DZ=<[?(^G@J:-IH<2V#+.
M# 6)VLU$C!##B,S-*4IU23L^GY/T,^P>#VG$Q;5[Q]'0$RHWJ\ 'XT32S)(X
MBYU+W,HZ\RPC5XH!AY51S(*D?1B7^1Z9QP5<W/&EX'4(WK=Z$J9F04'5MOOF
M3AI<H]:R2T>)4S0O\1"P>@V4P'%1*6B]URT98JKO'DPEJI\K6M4]>20VCR3)
MH'0E9E0_+"K'#5E8Z;2A/- ^NDNA'^Z8=\60CDLBR(,GWEI:\<?$DBZC ,0?
M:=KT1V6$_KQ)ZQ_I;MZ!+Q?%J_WO2]W^^A$R<!X.9:_! [>YPE\[#W0AI+HY
MU@:=ND-E_-J^W)?19_9X3PBT =0;%-/D_ZCP(45K_7K_QZ@(>ARUUX^;H..7
M?MP"L5;,N2VIU>U,9WHB'J@QA]K*9?WODJ+.'Q?^)\6#2KCI/P_*%^=YJ2+1
M3H[E, 2-5X/Y>9M)N0V-_HJ*QEQN](G\.5Z5DI+"G@_J"P\QG12M<])VK!%:
M\\O^WX\Q23Q\C F%VMUN"X=8QJ6;/4RK%E;GG,_?G+"]='97B-_,#UAU+J<T
M4Q-QC'^->EJW.AM'UST9F/1NY[0T<PLU'E_$O0;7 .(Q-2'ZN:X_>RSZ_]3%
M7KMN%3"0$AD,S4OR:<JZY_>5]177E7=<+ ',H4,/OS!4UNE(GN5-P'")OQ$<
M.0UM=KH 93=PQR_Z^7%Z?_SBG[K>[$M_MW@@(4Y]-(;TC@><#7"@D)+I6ULZ
M:>HX$!1BR\5IF4AV;>=&A%2,0!_@8>T:U.O^Q^?5UH-0MI"5%;%[\-GJS$AP
MY$N)]DNX<?"^ER5V#:GF,KGK;K)%O7S"JNL6WOFK-SHIJXKQ!@Q6*A>O6*.F
M=S7$TW&5_PDYV.)RTNG9Y8K*M=@_KAY9I.R[_33JEBM;* XT$-!.+!W>F> O
MB*13GBTG6/9^P?/I^=M"&MB-C_UC,K#A9$3R?]Q__]=U#Q5?Q4"W'*7%[;M6
MM(YCIE[-[*@3_?[C8@C"!)W9YL[@+%JS##-"Y.L1?GO?;ZI)SB0O199'L!A-
MPFL0MHE'Q;"50&IP>(-:1(_TFYU9QZRRQNL23P*+SMRKSR;OM1$:FS8IV<J8
MR_Q7MVR-&W3)X6=,-K9A=EJ#1XLU-,?EX3SJDOA?/189M(N92-N$1Q$*TH!+
M134ICID$<:?^(VVIC4S_ZQ$J$9<VE4JF+[_J?6;20'OWA(C!>!GC_\.;WP::
M<4HH:-4LP&V8[S2DBVHP!OBF[G",9EI;B^6Q.T[)B@>5&9C?49?.='[$G15E
M^K6'GN/+K:,\NQ&.'"Z3+N:,FU-/>P#S7QKFX9#\R>;36CU*^-'FS,[M$[JO
M$KG;4U'*YS*&@UH=1Y^=W$EO\5N+^EI*#:I=E#13KU%1N4C0ZTR])C<'^P<K
MFY1C2ERW*"0KIQ%I-[Z9_+<<?_0WU=]4?U/]IZC83"/S1C[[9G\8S.*Y6OLH
M[ENB,2[BLF@V:5]6Y^]%&<=)24SC6/."$!I!+N>"%"]?$U2N=+H7]#XWK$J,
MS*\7?/TCU7.CT*=.(#3U-RV,S!VH7C U">0<"KW1,+53%Q/XB6#:@_2^;$T\
M,?1)*7Z::2&'0;F!(%77Y18YFW-?SK%6?+*)EV1/_VZ)>=<M<&41XT&<3G+O
M>R9\"V4B(YHN2<WBXGII_'C:L0X+.<X>6"XZ#);_ION;[F^Z_Z-T]K?KG]>&
M7/6G,WE]F_S>!7J WEOD-S*K1.]$C8M+R6JY410':=5K3+&'/8R[EGQ=G.!>
M!A:P(#'I_/TN$W]??U\_N:C5RB\B,='.&R4^'U,'M&4#D>TN-"*3!H9RC:->
MJ!X(,AIU!^/SB!8+X)V"+ZNL1M;K;;&[?C_$XQ2"5!)B4#5!2J(])'NL\-F'
M5ZGAU;)T3IUYHF0> $FHW((6Q3+"$SJ9X.R&J8X8V>8WG]<$+N3PHB;M]W#Y
M&F2A@GN'%W.:'5+@4F'7-.2TN#$8TSL":,(NA]TM_HARH8Q /*_+=>%X/)3>
M\+K]@=I:P@F,WXH_)*"DX/7HDV68Q+$23*TOT? MJPZ1"P]YKWG;L>78.MH+
MM1%D)]5*B(0I]O#I\-8,J&VT)65=W:3LS&\>K&>4)M:(\72]5$FHV.4ATN=P
MT\I0^SG>+1Y%LY0WY@,ROI.@-)D5B#C%#3[8T6F6_BJ8N,C$^DW;R3__3+:8
M^)AIJ?Z8S49F\,D!R0BX5>.'5\D&<EX)-1X2%LG$BU55V>9W1>I?[TC+4;0_
MF>>_D-#1)Y147'%,%:_XGB5P^3G=!*W(Z*-%&TF&%FF7]8;:6-69635=2F3
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M1/1O'4WU8._,('U'&1D\MP0I33^]##N*P:7^39Q#.;6([GNF(.KZM ^R8T\
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ME=2D=GU,,@:ZG3 VD#B[D]3RY\9(BT09 '< H(BE0@1@=3&H_GPGX80 \2?
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M,@LNOEB+5V#>Z\"#_NN4V9:O!]2V3)>VF^C[T>F(MR\'2Y\,CSZO%L.%Y=,
M$S;8:-&^?E?%]7Y>I*V;\!4P1?9>8_K$PD.FH42VJJA5">G.@A5 <#4@1>,>
M3VSJ9U!B'E:0";,:CDO]L!#\\?K\('/?@ORKQ=QCKQZ"BY(0N2N@DGYZ?%$(
M_2LC7E$H-'\S*[+NT(0U;8^'F-$R%Q'&AR<4\AOF8"P&0[X8;-'Y4X4I.[4V
MR!59IT<)R'(%W.TAE ^<KL'=:L?470&1NT78I&O1SQ,Q!0EL)/'O7]VFVD=[
M:7HI"76YMU['&"R'-TTJBGYNVWWS>DAH+@R#:M$@LG?L6(WR@+PQJ,6Q84OP
M>2?3/:T3X)3>_"E[($.#"=9 33UMNB]1URC7)_\35'COICK(D2]BPT)@(Z]6
M)U'R"J#=]&ONZB_5YDV=&OE.8?."V=PJTKK6_27@6<NEP:U[E !+07\27#HN
M:Z%B^ZJYHURIM@!I70E\"LJ'<6 R>JE"D52]T8F%S0U?362:Z,P<7\V!O$HC
M%1CRVI:4[F0DM,M!,PPQ-5A-A'#J@L[U6AW_U6ML:A:M3V6^?Q8[R:KZNK7'
MUOG>P;]OVC]7N&C_^&BA%L6= #-"FR_UGBS>:ZY'DS:4;+"5I\<;:ZY0K?6Q
M:MY9DUF750(!9T]!H9#>O+@K@$HJ3@+#V^FV7<F^.\@@U*8J3J\>\K2[DCKD
MW88%2PBO4R:HJTVTUYRL)>;9&9)#XR[/ 65*#5'$SQ5!G);GY4WL?4QHOS%,
M'RR&B8KQ=2<N<$B5K4>@5;V^\OP)/IN*[DVB,L7:'YO6C[FMQ3K6]M5K\"<I
M&)Z^_[YBC_U,]/XGF _FA1F-0H9>VQ@;^,ID= 2Y12S1CO10_"% KN>1GRNN
M@X\S*2X$8Q>!TD/O];+H)?^XD6L?;IGY*TF5QZ-8CACS<^7ZSY/0&OX^G8C-
M(H!W\M;]Q"O !W_8[+O/)O^&]PKQUY*[166Q-/Y>:&C_&7R,0O.&@:.P'S!\
M6EAGQ+?/%A^;6AJM.7,RZRE'2+5U;%E9P:@F1J1^KB+V!"5$B@%%W25F>\I?
M8#)WOZX#TG5S"/X$5I=QKD716)=$;K*0<3&5V$3U4Z.%!HMNP@EMY)'6%4+9
M5>3M,XY52CI73D/]W=/%8H%]R&MN;I'6YU6B48J.KHSU)3Q"KM[T#$:FO@F3
M%U/+RXDT3XBF,OK@<>8B:.:>,BV))ZV)G"*:#FX?F!9E4MZV",5_5?*363^L
M@F#B=65V7*X_>.I=:53/<P7DPIO%\RHO3D^&G2]_=81V!1=R>/G\N'X%N)J'
MW37#66%KD,(ABU= M['KU(?\!=,BZ>):N#03Y=R+UO)H@5R_9"&)XX2T?J(>
M55&Z/.RGV9TY=9:([#M1$('1)6S9YH*(9)Q:32+_BX?AC'JJA&&% #E:=';Z
M\CX7*WX+GW"?D3\E28K0P$36B5+F^'Y;KJLF%<O2MCR7HZ5).\EY[+L^5=LN
MC'-O1Z^_F>@"D]1H[GA^>.;()G$C(8O=^A%WP"GK*)%LIUQ_$4SFY1(Y3O#%
M*\BW"A#W4:_02IDGDA7N,/?GD//QG-:T[90;JJ$9_G0@T?C^*W((/ZQP53%E
MH@+PER_IH4GB(HP2MNZ=^G(K<U]02*JM155B3"-Z[<GA:4(0/ I\8P/,A_7D
MCC=J'[2IWQ,>;QH,^^3_10E]O_]S?T6 6P-Z&N4>>QAP&$J/G7B0I]U(-!S#
M0^0W10G>:<[-YVHK+8E5O/X%)W61[MO&M+_/'E/4GFB0.NVWD'17A2,L-/HH
MGU(N1 JG@XU#!I2'L!I2J/,-\:I1/@/_6):L$M'UQ@9Z3S5:Q+,E)>Y)4=U9
M0NIGIV<<_Y3OOD-\<<:TZ4?_@=@Z/ECH-\26N(:+=&I1">XF_^:Z]5Z E=3^
MP4[:+0C;>JBS'I$^NAN081$AD%U)&+R\%0:.19_@XN0M+@)ZKX!\\B\H)16#
M<1S[%W.HT^C.;+EG:,'<MFC;(.!!-L Z:O[+O7MI_^Y&Z-$Z\V78G>A$14OK
M91VRA:W9S-J4N3!Z!EE'LT1&M4\Z(=UX!B>]>04<IZ=+MR1.;V.LP2]T#5/E
M+K=LR[R7,_HJG'L7;^9U78I%B3:4:Z--^<V?2_"<%OIL9-N@00MRC 8/,#I]
M2S'-_L?]D2,)B)T[]K8-Z;94K4*T(?M-LC?B=XCDD(TTKSP7N\\?2QK7?I$Z
MTX0UB/?=JQ(T6.P.[Y13 OU\2J*3M ]=QL*',!^O@!BKA87Z*(CG%<"UI@Q9
MS1L^>1@:FC?5%H1@@UFZTQK))+)SL9OPK<3/>ODEB5X8C$Y,8RK5CNNO@.22
MR"M@*V'T,I(SF XQ184(OOWVU:<1>C*ED/O*;'K[%CN<5\#-(:TKH$K!_8+M
MZ*@8EG&N%CKH-1&Z-3)W!:BV <&L&%!_LWTWG$*CW.ECL=6B65TUA^0^77+^
M,8=-;H>_+*C+Y9('YX/!T6]Q44V,3S]1L]4EIG5U\2.%9?"U+YZ>Z27-SFJT
M_T(X#+KS%P\1X&[6<(5R6!]4.6'UIRK0:5U]'1_CSD6 .?F <" -L]0"/LVG
M$<(:G2L[&9?$6J,;>B@,=_;L,K;1"_QVO+=&%)MH#_DQ*8D>8HLUEU*P)QC\
MQL;':,C]TY:"I/.;@J:&!NGDKW,G9C)OA4_>)9F&=34N):0\6*IU&V:XW1S@
M2OQ*I#U@+JF?W7GR"G 2I4AXWB&=B;O]X3 H7ET9?V$21^BL(" 2RER1J%$6
M-<1>9&!>3+G=TT=)'^QY@ C^,+)$&M":K6R5R$7>Y5UH6N_E[5^2%BR;$)>,
M[3)/Y^9%V5A7%]E31N_DS8#+/<ZMA&8,9W]B^W6<+%JX-M[-O2JA8G'BA#>\
M_E9PO:P[EL01^OT7F#5DLOE6C5.>_80O'QT/])$:U\.()>Y0+F28O$["%4"/
M,_D(>S@&$UTV>V@\;_8@U^DB][;_X-U(W1!?%VM6U/FOW:G!N_K?U#QOY^HI
M5]U^*O.5HQY$)) KM"X:/:6&Y-Y10'(S:G_2Y&32W]=880*Z:2[ERZ\ 70OU
MGZ"DD)]@)0PDS&>!;:OKY.E<OS__-VV;<!N>L&>-"U< X2C7N[4,.$>( #;I
M<4THJ>-T ;N08>KE)=4]4]9=0AJQK!7!6!-^ ,1M2CUW7$ET2<O)@LK; <./
M![?JL(QL:FB=[G;C.VY1J@JJXD^JTO"5HB*TQX+^.<(BRJU5M 1/I-[4"1:F
M'K6/2'=5<.V^CGR>"@)'M<Z98)AWF!%M8%=K0_W$/H(US6J*VWK,[0\(.VC,
M?VV%,K<+S>'$QBKB]0M.7K3?%<[WXV$0D5%(F;'QD)/;&:R2PQ#"O*=;"<J<
M,MN.DXH<13^-"@^'Q<!^W]B/L>7F2WZ\SGU/;E>0J 9K@E%[@<U GQM#EZ.X
MZ3;&))UX.C0X4^*UB3@HJU->>?:7$*US6EF\\8+9A_MZY[&K*5(P,^$TZIY8
M^)]8^%29*_V52#;NIUGPG:$KP'E*(,Y0=*?8S3 ,4GN(&=Q]&16FE(4PP:G4
M34@%5<4]*W>)3W QJNA0_V78!-8!?+9&&=<"2_I&N;#GO1EL:EU4"DP_"?41
M'U53)CG<K04&8G64 TZVE9*0$T_@9#!MUSC0Y4B&0N!.__ 5D+C6;H_EM$9=
MJ)U;T41S\8X?QES_'O1YSUH_0.T'0Z5E"$ANQ9>KEF#&,8^MG0<+ZF-J5NMM
MN7%<D[+VV#*!_Z$ EY6D!5_X/(UV_G0ASAE;(]H=3-_K ^5IFCQ2NE313.-0
M;QQ*!F-.HTB#SU^B\3G C='I3W 5C6\U*E@8<F!]^9OUZ<=O>4WD]K*<]S?,
MKH >>,08[#XZY)V-*/V$_KCE-7>/%^^75I]^[ZZ\]O3^II(<;YCB^/_X>GPF
M]"#US()Z8]P)R[SG?-W,4II&,G]I__BTIM_IU 7:@!SMF,LR$:7] A^+"/"H
MZ [X.5"(M7X+&_ <T]'973:8:&?$,%;%P81*MNK)-T@.>?74S@<"&<'+KR#D
M0$VYT[$Q=8)_Z69-15M.D:I1D3M"=V?^F*BI*GL%.XJ106HW>=NCJ]29TO&U
M4_J 0^>&*=HF(-2O"+6;%*(M81Y]KM[Z!6V,?6@H9-I1[;K;TKD^=T-?9[MZ
M*AH1N=E9L\/W/&V4:"^T3*OIN%][(?@/4=(X6 FZWLEUUXP969E[,YYNO2'Y
MVRA;;F++O43X_=$*WRN 6]$3N43N*$_=MIS@<+]XB311WP1:;&#U$?72[-JJ
MO_^VT(>+"OTA_RA#E_, 9@"UQ]+^Q'Y.KA^U9Q:.SEZ\>_'6Q>=+H36T^:&_
M='Y25B 5)OQR/PRNFD_=C8#$V6+RNJF$C.#O-0,'QA::]$P'XE^D H -,!\X
MG0&[BTU!Z7#C[":%,XQ$$7$&C8W[).5\)PJQ75E=;I<WE;P>9"Z',,$>NE/B
M>#"+[VU_WPNWJ^Y<46R,?'-F)XT3FKX"[*K(0E_"9.5[?P2Y'0TJ[JKQ,@[$
MAT D@EF>DMKW["7*M^7%@R+ [$;%N^75 1(CU@>>HKB#A$#;H+2.3I;ES)4C
M[A@(^R7'D.MGZ-J(0@+8D7 [DSTXNGT!'3QU@\,-E^ !)M5A6(#9-D9WG=5]
M>H>\MMZDUSA)*YX^Q&RN>VE%L+,U'$0*1S>@U.)]HL=A>B@EZK7.#Z9]R>'I
M(+YWX3I;RIRAB6!^\[PP5+\YQ3L>>T.;B_V[N8:.Q-I%7#)"V<&/ AB3^D??
MS)Y$68WC9*R]/SL/\0WZ!KF6E/](65]YD< 0GNAER+:'N[\\5T48\ET>'GUT
M>[DY=X&B-GG=<L&C7"R9AK5TJ?JU@^*U"G4ZE?KBVGJY&P_?LQX/XH8!?VZ2
M(S@#-!J!)Q31"3FY%Y6K"3)S;PQ5&RT^*!,I1!QSEE5AJ.H_!B!RM.<>Y@C7
MW=ZYF3CN;U5PVXA,C9]0]1KHXX:QY%/0D#D?FKF?FWS#GPV%'=EZ&OO+."!U
MU*#1JU3.^EO7*V"P8U3[W=+E*)SAR)W+<)/-(H;53?1P58-^Y^GM3&E^RS"6
M>3*.Q/RS5]K]?? WL_ZO<7S^A0^V?"LW?TK5U;T-E?B<S"A^CR-\L/\DB:B)
M-;1FNEMACQ@:LJ<WC;SG%/CUB<F]TPJD:3+[6(Q+RAS%$F^84B 26N%:W-B4
M8A7%+\J?Z/$YWR8U"!!"X4_C)<96(Z295;!_MW%E21'6C3W"TLY5))= 07#>
M[%5*ZGU0;MCG*EUL)]),I:]=J ZKN[SQ>-2GLRZH>-4R*6K&<X;F0UN(WNXC
M+WBM>]3A%4"&I>G,O)7$G>'L<%"Z7I;S65/FBP#_A0/1'QJB06_1[B7JP5#)
MM 5PALO$$%^&(T=/R_MO*ZE>7H%3.R^QO$A6&-5'_N>JV\VN[:OZQ$D+PNY/
M0='8)2,L(@!%]7BTH_E99U'G#<V@J%@21X!(^$,6*/N0I=>C(90%+(J3G:XH
MP%PTF_;*#*^8FG05/ 115:LKLW(GBHO+5<[UA+*VZE;!'C2B[;MRQ*>0:[]R
M!-I:5FRI.3[S Z70P9$@Z@_[\,1,_QX%T>W;8'ZGLY#\F^=J,X75RHKQ 4'=
M5E(C7N]7F[ER.I2Z40(]PO;=>92U20Q0<21_XJ5#]?X#_HO)%(DR +H-D5^6
MA,1RL\*\$4$^:+?8:DTW5I$C^T2>=8W4$*US:Q9B&Z"_I$K^"F#08S]61X]Y
MB-<'6CXY.[T#29&:"!FVV%=UA6_MAUZ0A\E"HJ\ =IR[+>;.=)<%'9_1XMJ&
MR_R@6_*PNU R+2[L]C/UG9\KW!;&V#J,_!PB+\JZA;9XL=AO34'!SH64;T_!
M.J<L9>++#<_LI.O88E>*D*E,>A)N>-L$;)ZKY(?>I;*>^VR]8Q92-8U"(N!:
M46%!;GC\>!3?$CD\.9]*E :[A,^1V(]LQQ%V&6R65OK77=TYG@$!%*TQ+'X#
MUD>50<L)O<-+._QNOF3@87_)C&H=$.[ J](HX%".\<@^BOX[A&SC6K'+.?GO
M!\+'P4NB+^>2NMKML"ZE>76[E9\)2S>-WP.4@(R&,K?^3VU2'<)8##QA41J>
MBIQ ]$=HI%E,BW%L1W,]%)Z\/O,5)%#]*BA"F<L1$X%L>-/ZJ,)L'BKPHOTK
M>C?FSJS4:L)$EX@=;/]Q2B,LVF$]4@!;MGA):V9A >-#7TQ5^$JMSD^MKN0&
M/$D\];N1KI@K9JZ":>C4YR*XR)-4HM$F^!'X0\<3/,^Z>D^K:70U3 $ .1WE
M11C0PKM$J1ZF]HT+QZ:&AUL.[BAS/<=L=<LW1(7P;L"O^[0X[-W=R25M3!BE
M&V2G:HDV*[\G+D\;7%K2PQT[Z]^G0[5A3H.N>YWBU)PP[\X#3^%-G*^$4NO\
MT [R4F,9[#60*4%> 3OWSD1C;MG]/"R+>]TP<4*;R#.PL=GCIH3IOV\FT[\7
MR<5:A[XY&BNIP![,>ZXMMFMB2Z<FS_QB]H5GHQLQW6"?' K@@B_G48E&X*X7
M.UR3R75Y2=?:V'?,GW[#CSVFX[#,G#_I>4;76>J?ZQ=Y+\[OYMED6-7_]LMI
MO7?C('R@2NDB!V?R&5J&2,)IK:8&)4AOE/?L<]2^833R"DIFYU86^N5 M#X:
MQLW4JH6B8=ED$XT[TJF_[KAN0N3.\,B(A92;MU*#*C>TY=GE3VXF1;7E*^"Z
MXZQ:Q)'H-_7T3\BCR%:O%0429?\R:W:=)\&8'5/M8L<K@+S_^&M=^@VK;RUP
MH\+.CGTWKRJLD$1\:+50"7HZ&HYPA:8A$]O$8WB;8@XKQ&96"!L%NR>X7@A<
M$@<[$,W 0,A##'-7FVC/],1MN^H#47Z 8$V5_+N'++?XM]Z C X+;N@2DB;V
M*"XG2._ QT2VW<33F9Z KV% Y@ZIK)[;Y8<J*71&4M$8W#Z4!>IG8-/"?)N8
M#$>;P6K$S-4E1_.K;"Z$&OK,G1Q&2?EF\(N3W[Y%.^@'Z\2)]2:#*%?13Q ?
MRCW1_.:4HLLE/5;3IN%YS\[UA=,'JBG3>PQ4^Z64P6M;V_*(48P]?G6[M:Q^
MX-2_FK0(19U7/R+?TXU_G<K]]MY61%ZQ!S?)#LXB&$51Y@XX!X:DE XZ]!:U
M*R^Z6+ZMKK0.\8[XZ4%3'#@:$T(+L\!,Y3$FQ<,L"\Q,.@4S^1.%&V%TV>5D
M@=PAM01;LWL]G#3WL8&*EIX2&B4:A%INM+ #9J" 8-,;ZYW[#B$-H6N7Q3TT
M2=#I.+[F^*F?1X^VFW01$@V[ F")$@W[C*+]9J3G77E$,,[\^1\UP;'KWS\@
M1OH\V5T5#WXV;&EA+0IQEI/MG!L34+X^><[<1,6>J%G#%X-TU/ZD5X":FW?:
M)/I^/G4A@AM_Z3;!O&ZGQ%P4F&S^]HVR9'[;]Y#584&>*$R=CU,LT3D:VWL%
M"*@5A$Z[0O#W5O(MG (:TI>,>_$54Q5;=R%RN:D0F;LUJ*^?_'JN@ZQL@C/Z
M,:)=P5@S]/S1C-&<F5+V-(4]@[_8NL_=X3 4,<<K[TD?/&^X OH@\<:]T3$5
MBISH<;4TTX.PYG06>BN61!X]VQNY7OT<+RF/^O,W#,[67[6SF&Y!:(]4?]6Q
MF_BW-.U_3+SWWO3-<ZNP )3GIDXQ[!<BP>0YE@Z3&11ZW43-^WI#AJ^']?P>
M178,TGJTB1-]?\7SJ++$\A.VNRN#Z;G\_$9S\1<=\5OG UO=MW'W2</ WA,A
M_#!W;-K-7U= N'!^_==7%G?["4U<5>(CA2%W/50]D_*KS+$JH:CS':%GW/0(
MATI$CG4#E5M*NEF3W7=8^36^DH]5S)/M;# =K(RO=RF4_5GZ^6/309[Z3@6U
M@)<NKY1WFSIVA:; UW"F&4C]O #GTME^US+'S00AE12.@=\$88H1*0,G+(<
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M@?4M(K&YNC<L=Z111$#LKD,^S;N*=FJ8"=8;J;&.#?;)N#>T3_%&()+H$_2
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M#Z:BCA&<[N@\ EF,@#1NINC.S;)YG>YMA9E@,C&1[Y5#$<5.GH<:FU[F\R]
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M^ZX0\6U*+9 GFTH-]-/XSB0V4)^5<$B\D <E6)4+FWX^*EL^./'\]-'K)V$
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M-'Q\7&X1C9LA)KAK@K[.@A[3W%R0\%\8NL(;E9!CT/5C@NT/5"=%]'>:[1-
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M@T>HU->UXWN[Z4B6@,L7'@I%V\@A+VO^5C\=S;*K4//,TA:7AYUW7F")L^_
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M>)>X23+[>8,Y&2LK[/UHLZ3[#"<<D%NI)"-SCV.D[_>1A%#24I :,S+XB88
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M^);F15=:%\O5$TV6Q5F>E#8TCJ:(W8-'K<%\T,7X<]I<WQ&&SSG2NCM[WU:
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MG$CZGCL7+"OO]4500%JX1U8M7!G'QZE5?LQ%$5.R5C.]H4O2^-KW)L:,.WN
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M]PHW?\[#77\DPSO;OGR(^XR5TCU'/JH-9PZIAQ0=7L3=)*1F2+*3$K1V)%O
MBC<]K4,*H=N_E^&;M0Q\5E79;GI"@"3_&GIRWDQ#C6,9DS\K6:]CR#,Q]^C5
M]VY-A6S",0=^ZDZ.(8- J3:OJP4&6%!BD2>6@U[OAK2PXR-E($44^?Z0D/QC
M.I'0$BG)6BH6,!YZZKZ]::TTIW"3?]\FR>!>Y8](MYR.&4)(<+7:&*N!U6.@
MV7ON3J+^^.JH8:3(NAY*#G$*QF"7AD4\! ZV>6?K1>3,U4R5K-,&_P:34'=A
M/V'X"H\>9<$]XO#O8Q4#D8G*B]-SUM!$8G?(9UVKR$@(,0L+D#O<U!2-W)DF
MRHLH-IYXG7#6P[O#/9&,"+)\OI8Q./+#CJS[8.;%XEJ_SQB$9M_,/<Z3TI_0
M1@VFF DV,P*9.+KF@"U:3Z&'5C=:ID'C+#TA,B1":INDWP,PLK!*4K>4NL0P
M=P1=/LG[.@/KPM)E']%Z.K]8##[;O?[A=<#R(; CGC&&E3VGENA",2PW51Y
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M7;CA.I!W/Q@@L-I,&_!U$I:[8&<24OAL#UVQ3* -;CK$(L//@M![Q:*3Y1:
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M AI79!F_R!$]\N,=&\4A4KK_2EQ[+1(-A][/SC18N AU3;%CY2NK6T#@DUO
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M4<%KZ_=AG9('S'7CX;/!^/W^OXR>B]9[@* 6TCV@45G[C\H2,4<!=QYUN/<
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M4DA_&EFY+LB(>*V<L["I]C8WNU,W=\M!.=8:7;^RJE*2\B4<')8/' R9_)>
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M,FPPS4[:XI43IRFXT]N,1WS)H"J'>"J899/X%T@^POBRD9$1XCD4)6P7A?>
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MKM6A(OX@V*AQ#&(I.NLX0> F@W[Y\M+3^#J!JQ_5QC9Q PO&V_,H_ Z3-$"
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M W?:V/5SF"2KQ)Q*]( .OQ= !T [!K"Y@RNKE_&+)TXZEH8XU6C(UGS+TN+
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MVH0))R,<10-\';3DQG]D*WQ$^J&@+-B506U8^B5<<H_KC PM88SB[ RA( >
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MRL3T_I6"J,L:NII2^$DZCGL_U/7&(77:=SL1SUC'BGSA=N/EE5 M&\J:$+\
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MDW6\Y,XIF4;8^N4[LU^+Q<'NU&:]_^J/!246H\QJV^ 21\:@?)S=1-HZRU@
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M'[^=V^T'!) WSSV%QT"$-)K;*59ZFLS<1<-D*?5-WCGT2T8W.[ FE&^8/Y=
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M7V<Q,RYJ<&?LN@54E%WW-WP--2 @W3&4@H0HW8-!6:!(" (B)5+20PZ"A-2
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M73VO6MNZ/;>[:N/F(@VS?B5]_>HU:4 -"GME;>-DYR7PW,[!T55==+^^653
MT59=U$3^_K7[KV[9O7#4]?>P,_1_\-C&W\E&V584JD%_00VF G-YY6+G92T
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M#4E=H^0$NSZ REI*KT"G?0G,#&POZX9PEXB  V&D,7V_E]"_N'H6;^6Z+^?
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M(N#X++ (]C@I_#GXPYGD*]6LMJ::,;EM%XA>Q9BSH5WE1QH*B8_+;#=?GUT
M#H?>9(/AR\;S+Y/@KD3@)1%X(>*$*#_3L&SKQNY^W#O9M,S08@4M6['^==L"
M<[=!2Z-QV>+F0MO>SGYM51W]JEKFG$SHXRPD.,OI(ZIY)]^G[HT'IMN\2J%P
MVBE(299+Y\LI;?4!=++I0VZ(FF(+]&<Q@1J]FQHUU;&I,JWZOII=Z6II[!MV
MZ6[Z*:HZJQ@X6+]3HE'&;7=QYU/!Y[?5.\&^:0U?!WU+KU<O-"I$ W^:N&$\
M!+;%,*%A: 6\(K#V<^K0@5KQGG+7_,#8]M.A3D3H /J6Z?=&#4%"WUTE.B'I
M<K_9M\XI0Q]J=J[O6A9H 9YPA@9A(D M^EJ."-#CJTGQ]?P0/JI6)A%\9J9?
M7UL>A]GR-Z%'ZR\9!MY#VZJ,P9*P<K=>I!2!?ZLML&7^K.^WW LP*1W1Y&RZ
MB-K'"5G2C\E!*H/*=ABI27V(M$-:/-;#_2Q])I=4/[ KV3OX%6D>#*F=ZU"Q
MKRP >:^^J:YC%DUA8[M>>\MA+VFLT6/&EY1-GHB2&T\=9;SXV6=.<]DYB,OP
M;&KBL0%8"D7*U81$U'9[\[298II@(FXVYFW4HBR22VD)H +X2+G?!6UXXLLO
M@Z8[)P(1WF+.TJY-3AD!^6[B.EV*$4^3!Y4YE=6F:A]J0J1?6/V(^'X:'7B_
M['>K,\^:A;JEB?L&[;=P#0STSH8+W.YW!1'@Z"QR;!)5F*RJ=I\S-V],35^2
MH+HPU.#9_328[8B2%=01:(SQ"+Z,L9S5)DP0^A@MI:8R2-7#AVG*5?&J!L$S
M:^+NLG1;-L:HRO\C9!8ZT^SV3G&>5#[Z9CAM]JL\ZV?S_2^Q@EH#33'VBRQ'
MJGQR3I!I)R</!^D3*U6_F<=T;D^]Y?;#(?3095-8\.$]PB1A'&LT-:.V^--/
M-5CKJ8VGP]ZZ\K[%/"MH'<I.8&GN5/(JC*C%OT\/N-,1E#1T>'>G&UUZO>)\
MW;?R)4X:!<9)P*FK(O'Y^/RZU3TU(B#<BVW55MASVR-U4SLO<A@HJ_!I],UQ
MUF@0V@?)GU/=!?IBHY04/+_@MOPQF&W_,:EF,"UG3^<WJ",M5#MD8/6[;@X^
MU?<93AQ2UQBGNP+'8O'T 7%_Z+UMU!L\_.Y+.L=<GI^EX1Q418Y^(3F\:DOS
M3SA.T%)Q+/ 6$: QF0UNVUET( P>G*YR!9^FNY_^')YR0%LM&T5V[/(O7+EZ
M/S[/UG1FGF(.<';5MI0I()]C.@8WD5*>807^O=JCTWJWRETA'A)>+(D<2$03
MEHT@F&,O_X*=3"?Y@9I1M7LGWR7%?W+M!D[YR?@JM8L!Z->S?/>#6+0 #PTQ
MU.V%2Y@GHF&SQEBU'V:MKJ<KLSZ!53<'5O<@ =:<\UT!*[7P< A%\[*ITU1=
M*DX$,I/]L@H+33V1%G7KYU$^Y%%7>=YH%@V(Y3;Y858662LA7'<_8>ZH/W>Y
ML#(I8_QKUCD@_E;1/5;O;G'S3T<Y#)<GO0*@W(01CG3+J, ^=1TS.VF.FQF'
M$F&;[55!$KN_<W6M=7,-$G/#C?@ /DH8H@416MU$4Y?4$2QN.F7T3EI\9H(3
M.OT>O]*OM.#OGD#EIXR<$P-RH_^[\@$18,5,=2VBJI):LVC"-(=.GC4[5GIG
M9'_\"G0%9S;ZY3 8Y#;,$J3A>$,B@,LL/:!QRQFVR7C,OFX0_UN^IVI^E>OF
M:I7KNNL.4FTEY.J(Y754)-(^'^GB[&@I.;8K=[9O[11WU=S.^VZXMOCVH:Q=
MQ&C JX+XM!-_0*P4LEP6Y\W !6_3PQ=05D"GS?HG&8,R35WCKH=.VZ2LO[NF
M_M45YU1HCG,O1SV_X>R%S>1<;,@W'V"FX7MU<<>E[>+T:<[%A6B)L/$&W\(G
M..]1-1:^QJ]C^UY5#>_LC0]OA8D!O$A(/5_]<<[%@VB)'@W10/MFE$[<KER)
M](/0D[9)L5+OKYE\Z0O*(M1D"9KT85DW!E=/<QBL<C-8O\I=D;S'KVCPJ_T3
M^%,I9.4TKE(?!+NL;G*SJK*V,>5$PO9N3J>&\XFQ898ZJ<GSUG)?I&OP)L7;
M?KC&M+>KY+&Y7OK4PY\ 0LA.+9;_E8[:T1\?>:<5Z%M7' 1U:#Q5\3LG9>O7
M)=CHLM[-N]\.0.!F$KC/BAX:EJ?Q=J-W3(]KR[WKZ\BZ5WAQ>/!U%-=NTE.K
M*(W+EM#H551!.YX#"W]2S=60HA=89"YYXKNWN(,H$&$$U)FC#Y7E$;$J:O:'
MAJC3B,HBN[.L*=W:=-601O0:KC@HTFQS-]#F8A%J!<[FF#*F_=5!K<_-ETM'
M3VB.B]=',"'L*.=B2C2:U#_ 4I&06#5INS+'1 RWA/FX-/=3J94:4/0!2+CP
M6'X*8T-@MSII(0)O^@A,^CN+4C_QR2?9JG"WX^RK*FLAJMQ_M3L2L5,:@NT7
M:T4C T6?$P30%#:G5:BJW\Z'.,.^$3!66-+_>5$@'WKA$YJAI:3DY<E)U2FM
MKPB/E%&HB\%GWNNB4,42P/?]O_X#UQB,N%I0CG%?N5M_)8LV)NCREFE^W/>1
MNK:.:^I1PO*)*-^'#1--C!L<=9GC4ZF/6A9L#VM] W5;F+O?O0*; ;N%N0W5
M'?SRZ('NSKYL*MAE!@:&GXXQP0=;VU"!'R2W#[* =9?)@;8>FV3 ._>)P#<X
M$4BJG'EI%KZ6M(1MU-X4"-A6!6?=1F@8ZB:F"#ADUD*>&E 6X24>3#QG>IG"
M7ET>_];S0@]XJ672J#DD$.)X+66JS9^765H'<3_<-%C0*0RCBHXT0$_LG)M$
M%[M4X/5R.%*TI[EL:L,NF<;USX6J^ZTCWD^5&I")?Q-[##+2!LB!"V8K&JRP
M,0/T8OC52G4SVA>7(PW2)XRGGSS^9D.Q]]QSJ(0]2W[\JH;2(NSZ4A5W4%6L
M]*A!R5H:752-J(_"\I S=ACLIL76VHDLT=:/'\.(S<[$J:B+6;ZMJOYH.T<E
M^]&E=3.6)..GQ89<9-*06\"HKDA5(6P*9N<=V9]33>YE\C9^3VXRH%:BN,J3
MX)F@E,-@G9MH*A/QB%I8(/ZX!6>-'BQ?DJ;YO0CS&9S<.S]]%-TK7&=\Y3"O
M6LMN70QL>01:''F:VF[%JX/<!VM]DQ.:/!=U"L#>8WR6&7RP= !:BCU1VJ*'
ML ::!"PA(F;*HKP*2];J?QXT5-0:OQ@\2[QX,\'_^OYDB,J,>&FJU^F,>N;<
M)Z/UUY>>-8+L*)"'I0SFF RX[TH1@A:G,L)A.2%)!)#G6XX-17>%\9.NQ=,0
M+YOF1]0 ?YR6W_NZQ4[\15F_(IAG>]WJMZ7&IK?N<KX7&GN8_USG#ROQ^HD9
ME$"$5R]<&Q4(O/5ER(^5X\7#L*[8.TJ[$8\N,@P/@Q]J^7%$5!*!V*8KJ(GX
MVH+N)=/=LESFKJ22I5<,A12QA,MU^[3PMA["I!OF/GR9G51ZXTD!6G&V8*\M
MN^9>S?-S,1_P/OK+ETTRJJ,(8DZ'OPB<J-+DW&GAY&@WIB'1M&M@GH;"6OWN
M;;WEQ:B9^>IX 91;AP7_[/T):2$9TX7?ND-.OB%ZY+[B,#66,UM;\M$7N7\5
MR7_E6@3+(J9KJL.,0H-]U+G,Z^N>PM;AG"[;[LI<LPS]=E)H=YX7KP%87XO5
M *3E9]%4^4UQ]Z[W9X5/'EX3P[=S^W\MZ ;U'3IOUB<-F1W?^9\H^ ]%X$58
MV\FZJ177IH)9H,$\VYC9I.;:"[^SC'57?[AOV0U-/G76AYJ4;$/ZR/LJBRN7
MJL,L)9(*YTQYCA*$SFY>ZR?YJ:^=OG/ U"U-RK\$_\$FZGXDZ>[N&?@;N^@_
M6]SA1?-:0KEG-TR4Z7P=H%<VZ $ON7]+"X:7DY^%ZEFIVCSJY@^Q;]!O28=&
M:4A@O'%6WS"+'=RW+)[^DBRNR$BD4T 7N8!2W89ZU ,,P-4CEA9H"=,IX:D&
MOJ4X%I,,_6SSQ,Z% F:$G XSV6P0UX\' <^,]^*6\.:MDRK%YU9OY;.9AB[E
M!:6,6=2S@)0HRH9"'K.$O""OR/W>P.6[<G?QPJP^TD)C]L&D:7.VV\O61&UD
M-86L]U-(@Y//__D?B"1^-5W9]O^2AKZUG)^56?AT9M;J)<NE\6N_C$0-K $E
MWFMG&6';ED7_>8LR<)9H]O("(M"FN+Q_T3)3X;##[-V,_$&A?:A@7.<-@O2'
M8)T",^ H6B(15?#:M4&J2,]K01I-54GQG7-AUJ2.Y5O3JN#X$EL+A0W^VW8A
M"12L-Y#.2+7-=^92:3Y;_SLGWTUKYV=:@K;/ >D43DN=>]DO@8U_][=B!NYY
M3'IWV^'04I#*U*-)MF$M-R_LPU3H]5Z[/PPGD4<E0>I[G\=<LA^^%:Q_83#$
MZR#^[IDK< JLA4@^U&(%_L&6CH6!]R<JRY@M-B!T7DJ5:<4\=GL%OHJI#J3^
M<+YG=6AL+/;XR]"*=#2!)W8!%MENQE___&-_$W^649;\WLV[ISU'K*#-"F.C
MLK=>]=DT6BO:-5B-M$N%]3*#"LX(UYWO.YJ[3RD1'=*\L T];]1ZNP_[N:9'
MPE8ZKC3&,RSTD1+!V7WJ/%2,?$*L3&R\P0_-T3(2L\^'L;D[[N4-W>18X$^_
M-RM]FJZL+'S ?[QIIE!N4[9155>:^*I:P<3]K6 R/ KR1^<F@T"H&-DNVRIW
M9%RPP,MLMF,2',!<9: 745$ST!W=ZG.OQ?5,U%S_Z.WLQ7=%7I\_\!:*]THA
MA@BTGVL1HGBE.O=>2V:4W!"@LDU-X5+:43^W)9\4^_;VZPWOW-(":Z&GYGUN
MZ^U"V2E:$K7ZP]$'4"I8^PH1B,=)4S7GM2]]D+K*-\&\Z=H1YL2F/*.[I?Z"
M?'JC[$H3)AD)(9=[A+N#JBP??1*J5[3A*5?>IL_U8G:-7/2K1OOE1HVN\]E'
MWT-/];-48\RC.A+O\]A9Z/8(#%,<_>>Z:Z*.U.=V7* <L1X_AI7:A3H5[AJY
M)#X)TWBE:T_.RW\\/ S2\N0F0:!8.\S;K]-;_O??:[#'S\G''7F0R_W I1GS
M#(*E<<(Y?Z;T_\-_V<P-FV/NC+H>TR;LTG]F4'M-9?KMJTWL:<LW#3;TI>P8
MW#\0R!!?R19'W%56B1#.,@%FE;"Y8:K&?X^ ?V'8X-=BQW3(KNG5RA+ML0=5
M&MS4E^LSG]_LLJ1:$W (ZZX,D">)Y&VFK^^:2GF7J(P]K.+GOBA8_]I.L\WR
MXB2%0])0(^ O8L78P*762\=_==@V1?M"5/K'2Q^R $#Q<E4EY(QR'C[%002&
M[S_O1&%;$^XEW5CFHU*V>=:S^>4FE^X?QILH)Z>'1"#!8@KO#L=3#(,'^3E0
MX0NU6(4-__W('UE"J-WYSMV8G+./DOV6T,#7":H)8$_+W24K#C/8>FL*]W$\
MZU.=M[G@RUPZ%R,W_/UC^8^["8/P@]M>9>>[[D0@+_U'Q001"+^/+KTON2)-
MB^GLK\I\-WE:%T U"! !1S J':A%00@.V5BNO>;\QVB%DB\;S97&B;[%6^QU
M0=]1O8;R<WW,9/:IY)Z,LL8$<B+0?T@$;-2GCKYE71[UFG<Z^38J)9^I,650
MI<$E:5T?;G?S]NC2[C/M%^3#\&4;C# A4OJO2UBC# 3QAE](\]'*_9FI]FHS
M_@*'K^9?PD5<I#+;^J-;!N^\^QR[%(9PM\P@(4ID*^3H,H8$IBA?P='R:R;<
M5Y-S")--?)7#1WWJ"O-'5T1>%.].LMI??F4:#C@ =-@+P,EL1E3QKEUM;8(.
MG9AMXFQN(9?H =O*(D/#50TA&$=7EL"D\*QTG.A[\U3@0PY" HP_^.O*JZ'Y
M(O]Q7P8D,N_FZ..^;YAWJW*S+][']?/B\+ _@<VHZT9>]+XKBI$-JM9YOW%"
MG8UQ=9K9Z$>S'JPVHJM;_L-4B)8RQH%BG%R8_KA'74JXA&.J[OSC[C8XL@9B
M))^)U8;W*H\1@1UY%R+P<TIY*<[0##6U2Q[$\390+5 1'/M)IO.%FW"MH3MG
M[[/-;FC#TM)J=Z47O,(!EY0));0;+V+5@4=H,U+*_HII=D**@5.7AYA_3&^+
M*YF*$F@0.5MZ)\$[$@68E5N!3&@NPP27X5!5PK%$ =HJHCC0>MD<3_OXZ>S"
M;4,?&1O7;\AY78H@B;:]!IT@Z1T\$D*)22XO@UD+5R:)IN4<&O8E^,<^<QAS
MW-?DKW4KAC $LH29&G 5JVFD7BC I$FUDJ,%+K1A0+EQJLM&7_(U;)LG\]^=
M[]DK.W)]#.\E E[DQY<K]BIZO;.G<9N3+16G&CQ,'7GU&>X5P;!OV:#*%]YN
M8=RB[[8L1_@G[2 M/>L -ED<S@T<F76BLW%1_D0 '^8*/S(TGGB.&2+<5H<3
M6JNAYU<*R8>:Z#'(MG2K-GJR(4.T1IR#-^M5D5"D0;3BK;7KJW?)E.0W572B
MCO09:>+#BAW//X3QN_TN?><FK=RU^QFII#3TJ4P!H[B$N/ RFUJ.=D"_G5M^
M=?Q[[;N .(TK?$,?VE/$]99,/F_R\XZH:5SFOAA7L!D:Z-?\O%(WL-^!I^KU
M1UNDQI<0N<)2B!6J&B%/[[&V?0N#P".L!:TN=V,OTN"*Q<"GL1[3 EE![F8$
MYI$&O;QVCR9QM!5.Q$/WES5\9V-7+0'4T\92K^9]E$.?<5]CL+5 P?C[;,9;
M,\?8A^$RM5L#\9_/TP_TI^$$/=;L?UQVO''G1 4]]%\6@!,5V_Y-\H:':1:/
MDS4UY]Q;>I?LLXTJI;2G=$=+*_EN/J0O^2PE-PI9UB)Y/BMH?5T74[Y"39B"
M1LL-4>^=Y7W_.39ZEN#S1"0AQ'R\L#M?L258!BV$P1JB(/&$/HT"!V=I*7G:
MQP>C6\R:O98#*;OQL:JVDV-JCFCAKA-A(Y15I)>%M-Z')">-9K4O=]\,+=)P
MS(,742+&X' BL'R9"$3D0%'I1,"6"+P@^:N*.SYI[4S#*OTZX6?F]&" 5P[]
M?BR$47Z('%/0^C6W6VJ.^TVUA&=!._//^62FJ&%F&JNT\[+MT<]!/$CV/%OO
M&RLEHKKUUDWJS.K*=E'^PH/3SB<B= [YQIA\(G I8]D*'VP)W[@V56( YD&U
M=S-C]MM<_. OJ\SRD_NF7[+_@NDE<74%,-[8C]=^(&O:)(1&O)4G I"!I>Q(
MA(N#0C9SW[=MCNM^14XU=@]9\J#J^&[.RX4X%IY /;0@1[@5RYRUSHW#2@A5
MCX8*)MV!"""&=D\NZEM)>&59+<>NA,BJ^6N(8'1:SG]/RDO N5Y,I7MW5G:,
M_"[)'TB#3=_.,$BVI<#-MZS'.Y5B>(B B'X[_+B5"!PY32YVP,\N94D0@>]2
MZX0H_X[_^G@8#+>\=KY RG<3Z263M5^G-ZOVEROB[!IJ3!]^Z&.Z0,LH&_)
M/2Y '=:^46?<B#5^656WED;*I041HUK1!_/V6M:2FM?HJ =IN$[E0!O#@9HH
MEXD.GY,%J>$OZ28TO.Y;!C]564( ^G=Z2#9H+!'X<VN*E)]X/(E ;GI.6 L_
M?65-_,ILFQFK[.UEY#MU!3;;9Q[4@A[4:FL%_R5,#<#A9AC7(QP%RBT^4*YF
MJN$Z;^H%4DFQ<EMK3N,ZYNP]=^/;7@B46KD+X8!9MEN,SBI,E=.0O:.Y-9*
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MGE%-!M&Z<! 5D1) BM2@@* TD2H$0I$F8E2D2%60&JJT4$/O'4%%!!20#J)
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MCB/%W8\\>-.%GM?_"B6$IMT'I,Y6R\ _=LU818 A'A6PL?=B%?B6";KL- "
M45<P5)5KW#AIFCRV<*%QW&A2YQ!& >JCDIUW?7SKL$PTZ7)+,.UR(S(IP)'%
MQ%85WYN8X2W 'S['K K\/UF"K.IC\#W$SS$X'1FS>&HF%"1D)4^R3EP\^HIC
M'[<[!Z3X+?E;ZD!71*AK"$B\AODP&%I D&Z;K-:OV@HU&_C@*_:PWU"5)F%5
M5Q 'V/!$"U00MI<7._2U'S7AS]8^5FUR?/^3_F?DSENTD,:=&PP)J2EJ[27D
M>YN-0Q'!4@Y6+#([]URT'R,?)&VH%R;8^HI23SF(S,D_2O[J=PZ(X9-M))S=
M2L:@+FQPA41QYRHN;^W>9;\UBQ0L>5E*S:)['_S2/\1[D57E-N%'9RX["5((
MU^Y#_1CWVEA-ACJ,<4@_W/_"LN(*>,5(Q0L4N%^>B%@&=;M%YMP:K6Q&>'_=
M,M4J0'NW9.O%O&5NT;AHQ$A]X9X)R. %@G.U$;>'WKNL6S#=6NA1M)F9H_\-
M4W0;_/MITCJ;P;)D_%ZPTO8I*))T^[,3.\KV;>UT4PPU71V5>)A/:<A<&NV0
MJD<*,'^OV0VC?V^GPAMRS>'(]PYKC3P'7FOKRD66\K:$,.#P5#1Y&.ESO"!+
M\/6V!1O+'3RTO/W9??/F!VO^*!ZF($W_'"3.IBU88*)@_'" ?G[Q84S:(S=A
M=0S335P2S?P3!=ZR7RK*CG*-\G'!7)M9A@U1@Y/0FU?:[6;*!/DE= 7Q6YZJ
MO/;)S8AEY6M'8;C<*)F^PVB=\9NAE7G[ C:W_0HT#IA,W/,_L\4NY\8BF"K(
M$*=6!EPJLD4[3J%\Q_6F&@_],%K@T5 B&H"Z5-V[M$1-TRUC0S0FL$8*7A=W
M]]CTD)(Q%4!TNEOQ%H'L:11VCE@Y280\NF!N_#F@RXJ.9%^-,^Z"E2D_5M;7
MT)1M?AA*?7FFUY UM>%A2B<XV(5"XX:8%TG:+;CDL,.*:YVICGGQB08F60H3
M*]?G2E]?=']\ES4]S-_0+4YG@&@"YW!*)\9;AH\N6\-2\551,JB+@0Z3M= 8
M%8Z6R6:IT@&A+NE9<&SURLN5**,G.D)O2P0J@T2H1U1828;XRY_Q5['M*I+C
M,BVN;H)]L-+-9P+H&X;TQB(74A..GEWA#\]11G1!]L6V<@_7)<DAL.Y@(*IS
MW@I=YKT$!6QE.<V:]F*-6W*>%:/IOMWV?90R,.C9CJU4KK*ZU"Q;4AJF6_,6
MH$2*"E$1&?4RBVEED4SXBTH[5L<#^D/>E/YDUH+HLB'V?EAB\4AT7WD@:+A"
MAJ=E*H%>7>%IZRO0KWZ4Q2K3F6DU&4#P@; %,E"(K0J;VVY!K$64.BKMHQGN
M)1!C[MN& F[E"!#*OLYLJQO]P"6\T;F1XD%]DF"HT@K+/ >$$)]</@>$-D.
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MFRIW+KN*&$P1FK@3R(:A&Y#6:TF3$I\L*=6)9>6\%+9*?MHVJ'._%V!73>+
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M$?P>+ZP8P-3+5G$<I\>)?T@601B_RKW7R0,UVN)WK7G?O>G-O;-Z^3Z/3S?
M*_?2+95+A.EE5/1!M9E?@:-S)]_F@01-V8,3R.[5/D(N)J;9GOA$ W/RT7[6
MJ^BYYX@@^^AWJ2/Z4L35'OQQA/=>>*L2;BK^$,@\3\C(6N%TW16P]?C!F9#I
M*_R&G3JU37;62D<"X7P. ,YI9,99*/0F)I6ZV+7GT5==@E=NN87R*>!46AK%
MK3KKY*7*WX ^_FR_%'2DHOWUZ@15^=PFJ#JH\46#%JHE;63Z\16M#]/1RQR.
M1[=J( X(N@6"C16"BQ L1Y2K=KR56UI:<H?N:]M 4D@"HBW%5S9_Z1Q /0=?
M/])#CE2$)!U^S5SK[]LO4QSLHC^].]=PG,>XMV0?*3- @WF<[N'BPMPXOM,]
M,-&NUJI/BA0>IJ?WPLY-*>&/54>;(3BSY_KL/=S7=P]U7.V2V&8J;G=DHM52
MRL;X6G0KS=H0W"L$#TP]6(@2 8Q.>$M'XF<D_)7%J 3\6:7Q5_<KP@*@Q,58
MLO DR9X(<6JLJ\[3^]+F;:+YEB5\388:I+3^U03Y4BJI18=:A2=X.(=U.) [
MC^!Z )VTW%\0K/.-NY)@&]NC=H\Z*4C:<KV4H@P:&49G85GD=U\'-]?$C-^E
M=O0W"+C3JPGP)Q"Y< @ >22'!8<,\0H"/AFK+9%P=HEX!F9Z\"0U)^(7(X3*
MLKJ<!,9!NZJ+"-%=7*(+>K)OK3D"8JUM8U8G=!+;!LU/#[=5.<":&,I@ @UP
M+2TU4]N( NZ,W.#<-^7I;WM_6WCV0!7N8XNKF GZKV"%Y F^6]5C>7H!9@Z5
M^5$B/6RL.B%4EJARIU8.PHVE*Y:\<KO*-[F3[R@%:*PK.-))W4]%<PX9564'
M"N#--(95[F^W2C?7CH,>CS\@/W^J%66[L-7I+L'Q)1N3" A*UC0:<UN>D"G3
M5Y^WL&X*%=9,>17V/0J0;,[UX_^[5M__;H.O[ZC]N_\(0J3]=^]F2P O?&\'
MG+!XY7EI&L?3B&KJO!FL,%[@((\>&&U5 XJ4V:,G>'8<;)[V67;3L^O?5&-.
M0-&E!/9C5::/2L\!-9<_N94'6N,N?_ OK*BR2UIXR7@OV3UN\;,,7/0H!1<=
M16+(=YB:\4$*#41FNS\<;J=5_Y7'0ON6)TBUA'SWD62K7*!84R2/MO)$<VR#
M7WM]PL$NU5H()\[&L!EGU[+L%MEZ(U#?6:A^;+I183:3[L_/.E7(0GE5.&C?
M)9?I'+"=N$=.C=NB\",0W<*TWM= 3=RXL[<X;Y>OM:QP( ^IB[%3"$J4W!!]
M1Y"DCSZ"$4("D5VIEA%*T/[@7D7_X<N2[=#$8!Z"QU)3BX#Y]PGA^H]/ @IA
M"OFOK]HDJ@H5&&1_WME\!E?J]E&1/_LF1M(HU/1@*%P[!XA+&!JI?6]/6;DM
M4)IS)CH,L7VBW=&B+< Y:2NP>'QW2D' D^C-?J6+JC[;"S1=/[3>#7 F!3>F
M=_/=Q45WEMUR7IP7GU@8.S808B73K56?7OTYPBX9!:KU'DR_2A<DW/4TE-XF
MTD"X_SW?:!G_D5/7R/_#WGN'-1E]ZX(?@H#TWCL(*@+2>P(B301L]":"TJ2W
M4(,@(%U 0$"*]-Y[E19$I/=0$WI/D!(AA.%WRIPS=\YY[CUS[\PS,X]_K+^R
MOR_ON[/W6N_:V7LOK&R9OQUF$!E'M<W!TXHZ-O;($339XGV-\(G1\VJA_RE(
M&X(U/S% 'G8OTT(XM:K0;S9C1+!:DN7CCVH6U2[V?6NJWL9C%D1C97F"Y++@
M^#J-TR!1"/Z3]N?3,[7JS@^(F-6;5)U'TQ)78*4^*T-^O<ND_@\Q:;-:KH6U
M'JZ-]QGG$M\%0=M?=G#O"B*A$<M$)ZV0.:O.A&F7IHN\!37#0/HQW.AU;E>3
M\@03A2B:W3&6_WC0:Z^#D?WSD3WL<=:IQ>A3(GI4EE'S*/AM%MN.%(55<RPB
M0?I%<.AJC#2E:RLXU)NS5B"T;E<DW*H7;!-SPOX0J>3$K Q95:GBR>SA2HQM
M/J4?QA*@1K"WH3<4C'*&OJ0\:TVXD_]&7@^;!U_"O"*W\0=C$HNPE'4MJ*Q>
M3DK[AW#YL 0X<@YO=U(86;*C\8.[->L[_C3H+L9/<[R#"3+Q;,(#(^1T0DHE
MO!;J]6?^%ER#S=K9R??K[U&#3U@>S#XB"\""PU6F[WO:5>1F:I+">VCYF=;<
MQN^.(,P:&E?;+9"4W5"V)4[RA6UC/GV2^[=;GO,W.VDUR#GB.S^);<L,B<"H
MHN=[0'@8*$5XF>'.A)FZ0@)C?1C_$]$?ZWDOLKJ#0%'I, [.FO'CBTL+@YKQ
M;Y.6M"8Q#]>Y;&ZJ6)'Y<#T8%H^>3)Y9XD '?KT"K%HF).?Y/A,=Y<5N2'KV
MD*WRNJR<QY*[/[<U)\-,(1Q9S:8E? [*O31.[5P%>_@LOPA:/\)L#K*///Z!
M=K"] FZ &':D,TG&>H44NS_$Y"?HT<K V:.J9?!\K6^XR(\2X5WHVK.\+?;[
MQ^FN;:K;2VV) 3_H&".8;FHT'?0&,\YRK(+V5]HYH)00QD=CA^SF2!B,Z?8]
M-^E[@.M^VA\3A$TO]"9&]V4K6B2ZW+/<IO=,K)8T*4Q 0WGG95U0BN(P(1%^
M1V Q"AI9YN^(D =3V3TS5;'SZ1S42B+E@N^%<]'(%1^.!TEM_:=W)O]G5K1K
M,"/G%.[C9VG)G^_N3*K)_O4)?<$K\3K:A=&;.X(#G8AWF&5<!$7M=<9][?5B
MQJX)VL"N@&,-SRPL"2?6*4CQ;>21,\8$)'T%Y*B470$K3Z^ 50]H]QRZ\Y*&
MW>:Z[\*O -9L2J.<MG0<P\AUGK/U:1>,H0-C%CE1#?[.5\"C<*,KX/NW*P"V
MA3]M6\E_!836KD+/^>1&<#<I<=+J6*$LUBM@C'L:BKH#1;< )VG_[\25#H.2
MGD"IL>]0,]'O*O:LJL9S0P4B#5P%Z9(6]O$T9"F(^#PJ7_Q_E]]?7']Q_<7U
M%]=?7']Q_<7U%]=?7']Q_<7U_RM<O-WP]M-6Q*"CNOY8X9CPND@'#'&F 'E-
MJ$/T%&]+;KK]?_IO@;_VO]I,1WI%6.;]P2BSI4Y/(GCT;1I!2_X>\5J 3HI"
M9F +0A@D9R\8BC%#BX$_GGOE'6T[YUEL-X)4^SXG^D2GLM%X58BI1%L%%[26
M_ ?K VV46I=YDON^LF]&00P[OGFB4C,)XSN:#S._[P<%N<*#%(\BCY;9L-;-
M*/4/6-F218R^CXADW>#VD>F7S*G@XCN:T0ENL["QR[L=M)A*Y#(U)FU9:Q+$
M:'\N07O_P]*B0H[,3]BO;U%*V4[W&"O1WMM*',6J+A:DH#OJZ'N#+VS&AQ/]
M"A:("^H<XB2"U,DS2F/UPD2QDK='>C]U,@OYXUOFLS8Z6-29FT?%Y$PZWL?3
M+O1FE8_KN(/?_$][?MH2D2+]'Q5NKA*-(D;YII+AQ!OM3;&[@Q=2I]]O>K&A
M7AZI>>.9AR Y:7IR(#Q70&\R.FI6Z%W:D83!+/_3UC!6(F9VM!+K2P,1U"[,
MJA]'7(<FKKH@@G.H7H S-O9GUP-/Q[ZN*@H*? ?3,?:#[J&%HULTJW'=60._
M8_I3-[$'S?-UCA>I,%UCX+"HDGWF"K 5A"AHN7[#"'3#XZ*$RPW+AFPU3$-"
M&NUE7U$R?^=(W36K[!EAEXX]CFI-/3898M@97MW[#3>[7'?\UAKD&G9P$_"L
M,_CB[X(>KD:PXS^N0>5UL[L;=9CXV=RIK%>3IF*B<C-BC,?J%:Y> 1')4+)C
M1RE%-<$8&X/V&X)^#B[T!VP \S#1SUN\V0I?\;;PEIZ9&ZU 8ZHQZ3#\;AP/
M:NHLS-/G:1N56;6S.-  LGY(@<<;S<81$* 31"(X$,B-#9AHHPV03,[ZMN0@
M!A_F:DGG)X7D<66)_+HWYT^V0F;52=AZJ=N+L@,1I_2F2$UHDND';V<'$;I_
MHAB;$/CZE'"1'I& &W?.WVD8P^1^]^V(*ESD7#33V6-/B?NB-E;T2GR8::9)
MY;XW%=]H$V3MZ8^>W!MBY  H\BB.%#-O,=EI1TF+,3["@&(L+3?FYXF?OO/O
M&EZ1YCR)F8P?\OWWWNG90EX-?)"]K>"6$4G>-^797I=9!38.G^Q;=RI%,;=7
M8ZSZ?$&U!9@:SRS3T4/XTH8R2\$ZW_[MEX"L@3D1:J;PO[#Q4<79Q]%[XS(!
M>1>;2O;\CPZK56R)ZVB<RI!KRV$OZRZ441L1=POB9$%EG_R)[RRU5<O0,0FW
M)?Q]_>,FX $V!;SI#!@1%A]I,3DC9@TL9-,@[E&<5@R_7VA7_.>Z5X\)I1K&
MI:UBFV#BB:60*Z _C2/.N\0>2N'XK:XVM"!-%Z.1*Z^GIGM#./ SWO9+?>D/
MGG-8;02YN$G+Q+Q. NYFUEZYP)=G)DE_JL3C0T8]R]/^>6I76"&N@.CP6*RP
MYWNK4S;302?+WVTC3;/#>Q3MO@:Z2C?I^VR7N"?KEZ-83D+K84.4#QLBES0^
MV/M?-(/<YM%?>6*:F-9^FY7_4U^;*MLYW^Y;&.LB<VA>2PHNB7NN"SPE^&S
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M]7W,;O2;UJQV)0[-_!WCS5"P3;L?[-.")F$E<M&0NSDZR3I.)-GBH<D0<$I
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M47 >Q R)TD0S!DDTC#G3[+\KMZQONI?GXU:FV:RCM!UOC+OWCP+C_*C8XIR
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M,8D&=:WI_:@^ABSHZ2ZQ6ECX#\N,[,8OTBML;K+9E!K-P?+IFMGIEZ9%/ZZ
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M-5 4+G3H0?^G,N/OSPF=:K[XAQ*%\1^NBDC0XM+V368KW*7MBFC+8Q6@QBW
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M!_+/A 6_K[PPP0C(?B1DYVGI?WQJP,B":_ILB9/'$WD4QH["5?W+\:HU<F4
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M=#A#_XQ%<63UGO33QLP_T!W*ZGZ$R+CA$3GW;TS97@T(W_[P_2^JA'F/TR_
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M/;<LD![<,-!=*RP+/[67F9!&VJ Z?PCW<M>#S;]4M"@Z,<R*EFE>7NOU87D
M%3H $N:)?1@W&CPXQK.PV(M.>Q;$MXW?M[RH)J\K6=J'MBP#N3BXK%<PF(&N
M-/*'A.<XOGC^]-1+/OFAQB_MVNLS1O#3=&A[0>F9>9L5_D+6#[H>M?^VF]5_
M6MZZ=9),D>']51/5)09^YK9YOZ.XKZNC0'OE\L5/(F^9H8P->J4?.K O5O;-
M5?[F]#?)Q__+&J.=8QOS>.VFTJQH%(F:WF'4T(?O I.?)(M/$3Q:XPB\\H3W
M3M;.I*_$*TM5Y5>? TK>_K<SGF:C46U,:-,^79/VR)KV^MKO[W&N7U5])(E9
M<0T+V-DW%WN,D[HV2N(@1S$&GP#*.YRKTQK_>'K"_(::/<LH:2KKK/A_W,?
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MLL&S$7!RA!B%-*/O7")YZQ; (,?FV$[2(O"^V#YEQHO2;#F"UCQ/.'1NN,-
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MF@4"SMC)?&PNNKE+/2XFXD(Q>C+L70*UIKNDY]N2EU\R'Y[,5,L)V%^Y6Y(
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M9_/,(+&-%=LDC*6R7DQ6YCCL=GIWT<-%\5'(R#!SK+6YUI@_[5W5Z6;6?5#
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MM")KY5F?OTC_31P72;QUG+T&O;U0A \7Q#0/+_6?#V,<M@_-9^@)NF%ZJ)^
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M74%L_C8DA<5FOY?5>>N;HO)2J-35B6C^L:+;F.&B":C>2B#YM;_%#B[?LG:
M*O4%\]P'-XR'*XD/9KO7^Z86^0;-H;A4J^3/*QK W?KWD>*)AL2;UM@7SZN;
M:2<*-C^WK+YGIQ1LJZZ)T)W:WZMD>L\X\4CL@6Q7"8C\BECOAN2*XE"51D9
M-^[617<;;\.X2^5!I?4C;M-(6_4@6D[^#EZ:[END R=5_XEO4=W%;D15= H7
M*^:7[<8>!I:.!DE6O2KIHKQ5I<ND,"8U8[H]:YAF]%BZS@MK9OX#&F4=]7J#
MVXJ)VR:2W</PAE&<V^@KKD&4ETJHWYX#E2Z72KP>?QP3E16-7\I8T_#2''T<
M*Y:LLZ1 >N':(M )-$"7_[LC38E/$7L/B.3?1_8]>5@_Z*[">S Z+H-0^1XD
MPZ&-&BUFBA$Y^0_'9994>F4?'F.EHLU5)>YWN%:HSY[(RI:>!(9?@Q;P--53
M4@G4CDRL53F>IT-.]D1:WW/<K#J5%VKMV/Q!QU7+T2#,1[T[L)]SAL@F'%6"
MLY2IWSM-9(1N](R-O.85ZH6VYR@)B7+%U4M4RE5__(D>XU: 8./$B>"OU>B[
M'&4#K/>$9XUI,FE)_FE>%/XO]MXZ+*KWZQL=!$&0[@8EI26D2Z1$!$6ZE) 8
MAHX!ANXN 04))962&+IG:.ENF*%S!HD1!GCY/G7>]SKG.N=Y_CS7]?OCGG_6
MGKWWO>_/BL_>ZUY+8\_#(N+.6-V08P+HHFRGCZ$!:MH^1C/]-V-MC3'6E+SF
MWVB?=I?BH4=W^/$GUU]W?-\]V6FGQX3X%X,#YNN-)>(]M)W+-6T2W=T+TA))
M9<ZVVF1B 8.HT<C3XP<8YU&5<6O[@X-)1V?ICYRIQDGNFIS70(/_YDZ3_[W:
MW_^;W7#E61>J+77P7B"+D?/Q_0EV7LJ_&:5]T\/9'TZMR8-7BQ.2BR-UUE6E
M<V=&#UU@/@L9;>M7A[+F31,5XE_,*P5 LQ<^/Y6(DB(!][MZE??\6(&21JC,
M.)Z9RBJ(+'(Q1VAE)Q(HFR##7Q<=\?"J!D[#;,<<G^KVC^[]QO!WGN>2-+1Y
MMC9-005?NBC< G2;V0=<KQN9[S-(X18[7L1!Q&R1;$26.XS?O.K;XCG$[8C#
MR0=A2R($J(J[B0UZ688M'$>?2HFO4F)NCG6U)&,J +\T4KQ%ME0-?B?4T>#]
MZO4(!=:VH?(6%1[OYO)=.8_^,M9V.+?D5[#[K+S<(6?-(@(LN)O: )9K&_(*
MBO99]+[.>Q6@>)!KN++,'G#UI^^5-5N")(R55(=T"9.H*:PPT[Q5Q/6')[UV
MD/2;MYW;\F05BY^AEBK E94"X_838ZC9/#;9*YFVH[9@+U"1.OTX=ZS?H_4U
MX4?;(>N0T(#@TN\88(7EWN6K&Q%T16^3;<%RT6%1_B2R@=MFI"]E*A4SFC_J
M=_J2%U EAI$J>>%"C7D6E&I.99BRKF/J< OPI0I4E/"S-31]*#[%V:&E07NB
M ==QY[BGKN1.W? 6AR?)#P!'J8?? M9)QHHGVQ?/1Y^=^U>)#9Z@MZ1!C0.[
M7^WD9NC" JF,P?P(_%J$H-!U0F411:*\%"P$E$FZ:.G#WR+%I":VTG8O%O!G
MX(8- ^^12*B"#YU.<G.]\G! :[E'^_U<HB1UZ]7@U-=A=9AA([NYMXSQ@:&J
MJ3K%6Z0TAT8%84YRZ S9^22D18[^T>F5['E(505[T[.)F#6Q%VR#R38$9DGI
MD3H<N?;W2B+K(NZH6H1G&ZLHT9R)JDO*JM7]463\#!L\"4<83D:V.*]>VI[N
M;^>9:= PWK,E_@J'(&'H:ZC_)>OT[!TUV2P)YY@,9%T$FVI."7FB08[)JOZ@
MB'1C5\CHJPR\E+&-V)Z)&U;'442;F#DZ*:YX=G,"+^]]A( U5&-^%BA[R./;
M-^9OZ*\*L,*,WKR0#[KI:E"\?%(VB*5#K9K.M%/MG!NT2W?4C$&U%9ZU3 Z7
MNS>2-GDF6@\^&4 2_#@ +FQ%\F?[LC<F<$7J/^%TY[7UXL C]PN5U0.!0 >@
MQ]":4'X@6/??G0 S@-H5<'KG<(!!9 )G+$S=S1;9;M=Y#NMM;V=NJ$^PHT_?
M$^/Y+CW-6?7/^S;\;N:&=2\-/(.$KU"AWS63;)X2WM^[LWB<@WF>P7#0>]D_
MI_NY1[$ 1*L@:H7EWBS<>R'WAT(3733GJKLS$F?QZ8&KAI3T!@H?![<>**:!
M<4" 2"=(>%YC8@)8PYP[51P],0G=:J0O GVW6=J/=WO\5/]IWGYGLH^.6LV%
M8^\"06FL;)E9]R\+D?H[9Z\?N&L_E_295"PW;#\G 1>V4)_W 9)U$>,LT5+6
ME?1,RS-22NU!MUH.@=Q&JJOT/Y'#28#PVDI3/L8<(O\-J]Q>-\D=7;3$W<.Y
MI$/ZX:,3K-%[Z'VJJF=69O<RT1U6EY/"/S@<')Y.I!J;/Y_+(DQ.Y2*X@F?P
M7",G6E[RXHY$P03MC%JK;P'A^[T>F#"=R6W3:*>WW;(O4E6OBM\69O:9N?*/
MV_\W6C8D(E:86AP$C[X;?TA_*><L2L^:'YL:"^BZ.S,;C.T4Y]<MH.->$D89
M^_06H,1$=H7B]_N7]%_2?TG_)?V7]%_2?TG_)?V7]%_2_W]*0P=[9[5KM;0>
M<#0T),D^3G M2TL+.>.<.OT?9!G1=#H&,0>R[%Q"9[)+,=&J/G9BRG)6@^OU
M,E]%!GN5N_!<@26HCCAQ2X:=[7>HZ>-%)W@"7?:F7)!(KQHS[I)W/DGL_Q&3
M5]*M&\*+,#GY*WO (A81D^5L-X;&/SX)/Q=KH6X7S1Z3%0"??RM8K,_?!M2:
M/#YT<CGCEP6VP.* OB7O4CUV8E^;ENX:64AB(@HQ!%?"5U8KET&'LGFU*N<:
M88?.TDZ_D+GS"E,XT__G%^FW+3-U;0HW,[VW@+>U]2VM4O4-65Z:/ K1A9O-
MB9]PO/^'FZ+_S[$)T41+=MU0MC\S.6^@IG/,7GGP/=4GP>UK36_Y.VN"KUXT
M305 /Y?HNE*H/.4YT^*3VAI[4_:UM20K,NO^_(=3ABP5$&.4>M39$\]K/<L8
MH?=27QY%:F(+=K8DWG?$T 29H"MS"KD_LX?NZS=-A_@SF<O3;.3<B[1C^O*.
M%X\Y52;)!+!36A[PL$?&+EI.]AIJQZ_BF/O^JUE5QLPAPZ/IKJLB#>E#C%ZK
M&(+?A<;^C>,Y[87NPNOA#8G?'QAM".XIB;Z>V1,+52.]#P"^>>?59C&K-.8"
M!9XO@FQQ1Y^P>)>.$'30D$5* '/\NR^]*_RMK_,D#IM'0)!5$3B]K;(3J:L:
MF%Y.%[_HWS#SSV2,_IE,C&>;H64D?Z,&U6,5SN^4_K*/TU7.'@?+,O(Q:;7X
M7TE5'I3<L3,;,NIJD3L>S1XJ$UN$(*.TOZ&9R'Z+)OU&$O$]I]VFY,<IP+TO
MK!-O##^'9@1LAR"(P'Z0&P/[&R3N(7":-5@E8U596UCTJ_NWZ;=JH99Q[83C
M7MD5_&^F-[06)0GEW.;,7E+\(I7DM/%4J,-9>&.\P-I1C$E2C3.8X'$HMUVN
M,7X,KJU+5^0/5F<_HQF&H>,Z)1EK=JO!J7,C)W]?;DGC"=R$6K4;WP+:2W&A
MWZM;-1'7!-VT*4N8)+W('FZK:G[;W+<RX:KWLTMWR-[H8BS[%)C07ST:(J%&
MQR9+"/MS<7?U 391*6(95K>%8,F=2@_8BI Y$+[R:*Q2X*;/_[O98YH_/C'?
M4GS4>=>LY38\XKTDQL?^O0TDS6_PGUZ5+D;Y]#]&V:M01_)Y/,J__I!NM8.U
M;?K=U2E= IU_/\YB_TU-=>J*[/Z0OUWS)Y5[PWS?OHP^HJ;Z(TD0,@PPNKMK
M+42%<+=WO0_C[U1.GX:4>95-N-D72UEEW/RU/Z;_F=UA#5SAFY23]BDR=4Q]
MF>HX&V?KR!'=OLN4+[4C/PQP&O\O93)LFG(J/Q)<:VT-):S,&VI(--8W^=CK
M7<JS);5]+UC@OY\G\AY3U;O"BE*-E\Q],I7:S;!Q@N"63,FISJ7!D9=%LLC;
MX_K%CDQCE0MW9,0<FT>^W4^/#8;\S;:7WB%PU\G?JL9*HH6[%02G\G3&)#X?
M"5/X9/L^2J7CWZ-5?0O;S0+LV5<JFF/2[_Z=?E98;Y*^X6>B=ID^74B$-BJ+
M_Y&<07"$A?-:$7 :=$1#](LQ0%B)<9LO=TBL ,6BT%\A\_X'*95J6U9@MB3<
M+,#\]R]47QZIVR\\'B14[]T\E^*T\:<R8GV*?H^JJ/SZJ%;R8B$':_ LX[NE
ML'_39MS[=7UE3F1#&\#SWZNOO\HP6HO8RE5-Y)VJ;:FG4=I(U5%6(OO>V":+
MN B1,+<2%.V#Z\K_GO!U<XY]D6@P(E(C&FZ=]]S#O A ;2B-<(EFI4-!4%T(
M%A-9TYC>G36-%6-ZOP/5CWT$7ZUCQU"W@!CQ(!H'K1]@?]W(F_'$55&.L4MR
M7[W^M6![W->QB&),SQI3@''=/$33B4<34NS&'$D3I")B*1"TJC\!E+E)6S_D
M.I-WT6VHJ7GUT2&/2'.'X(=\\,88?L(=".T0BN'8#P%<F5%GX4TM,3[0UA1-
MXFSPW]#^GQH;[O*..E00)51'V'8D&?G>^,+2:TGU>VHG_;!9*_YG4G)(9ET"
M=56KW< GDZWJZTU>081+766]%*U%B=K9&[B/F#AX=5C4U/STY.@0V4&,8 68
M15UT9X-;*DK,6:2_L.R;% /LGEA(;F,^R<)_^A#^SRWH9"@FIP2C>, UO)7'
M=;R 77):6/0^Z)/N,TLJ\CS]=WCIS[ZI 6F>;K8V2 Z0?SE\4;;UDRIXTR.Y
M"2G/+WM#62%\0Z6#46T=4(0J])TOY^HYG32 KI;%<J=P:O^K%:NU*J)"U(5A
M=-U^X]->LG'<K K%'(< G6RS':?;#7Z]_?_UVKVLN,!6Z)M@N$^R_ 9OC993
MS8]4">=X0VD ,M2QYW]84O?_/B!AQ7M!\WD,K=ZW %3E+6!=9O6G65+M==[P
ME>2E"A9S4MCKYTESL/"[G3-JS6I?D:S."V7Q@W1_H Y<;CW2:21#;=_W6XDL
M)_\KSDICMN)#K#G*$'Y,"\RE0$$CKMNK V0+,S/?D%L[?)D*YGY.RM3FK<">
MB>B+#B0W<_@#]IZ9A/LEP$Q^UV>^^:[LJ#2T6>24L>E**,6YYJ9$OT*#J48H
MQBJ(HK:RUQU,M6JA4#J+1VG]ZBN=:[U%4VN44AP$I$$M!NWL^Y94H%;] -8<
MQ#$11N]E0G -8_K4$Z[!0V;L'G9;<7D7DV6BWNU" 7F*2<AW;+_? -)[E34M
MZ%4G2<BJ@[.!,^?ZFAGG*PW'M_(*G_6DI(- ;G#4NPFLQ/HM@&IAWY"$T]"O
MNT^D]JVF+L4<^3OR5GYBWLL[^*T%)1A>=.#^4Y E=N')L:=#/%LS$^WZ9_8D
M]H"ENF!FMY4RC+ N9K4JR!J<ZW_X&$2EF\N3IGTRSB(XWVE'\!%LEO(G[4"'
MABZXG128C&5 6X9!M!B-S!PE(PZ+C U40:&B22>ISS/B75W=%@I1YDE])!3B
M2<0Z'PI-=YHAX[V7*2FL:@T&#$JX:1?N!1L$2ZSVN(H]>318PTK(BVFL_-H_
M.QZ"NNM-Q"/I6F:X$\7<'J>6$WRNP"K%WS],];U7U_H([6$Y&TB+63"=!RDV
MM(KA'G;4$:&UTP-2<08;GE;W_]7HHTE#)(7?"(VU<P!9V5&9D5A%1 N+U<><
M"J]HJ^3. RU)2E'D%L]]TY3X1/Z2<3FJ.YN@CWPH:*@\=N>G#>O!AT[BX$<A
M0=/)/W^W4C5^I;6./Z/&T5M7:$,;]@X7@./T.B:_HT9'B='T8]J^=:)?U*B2
M5HC?T^R.G2DXH"S88F9S":<?8=P\2AS.Q\V_?&QL)IK0YLGH:%8:A.43<)*V
M 7?8PMI9I[#\J#RU<>B^2\WJHN^-DX)5^_)D/W+KK?)?(U82\"T@%,* KEH?
MC10ZQ$H7[Z9>MW_\(\B3Q9VZ'$S$;;!"O6$=JK.\&: DZQ(51(E]@\P+]^LY
MS"DJSWTR:9ZOS$[1\ZCST2(G0$DP)5FTK39V32(O-H@"^]#?KA1H(8KJB 9M
M-!(JI)=H$:>^D,E9I# &X^&FBL7/ZA=@:69/1X.S9B,GSCG1^-6B2T,Q.ID1
MMM?C@7^)W/ULJR>SUB1<PNX6"EKUT,3A3@G#P?[:,F[ZAC4BZEZ^O9(#0G]:
MIC82_5D[&6\!#.5R-K< -CDY@3.@U$;3%\5?QLE6D^D$OZ_G1T?31FX4^0X4
MV#$-?8'XXZV$=KX5INT5 7X?IH78&Q)2W=I<\3?HZ9UL^+(ZT'F=-_PS$,WU
M)&HPX\+#81753]4-6:K:JZ(U>5^".2+Q;%C!YP7HAUTW,NC*I#6MLC:^>:@I
MTU:>7N2"I\;:_:F$EKQD&G_*P#H<R22Y *2V'B(3R[\:F>!@Y^]R;]0WR#,D
MW%=W;M/H/M' R(2FDUNB\9HE*QBIB?G50=;.I647Y.'E/&EBL9!O/O?V%M#]
M\UERTK1R_T4A>C:XU:T0:^02K4AB7=O>U-Q@Y'S@_%7H@%<'87M?X\5.9RB?
M#@[F86]628\BQDB1<F9DY&1EJ<O.VGZ]M?6'A>O=%4>QKS2=YS9P,U''"8%/
MP4=7<!F[")?3G<CL "&7RO6$E]P:B7@X#Q2]FFQY<HU\3H5#.L@E[NY.[1#[
MHOH6X+#;H+9@S*'[_4VP"KD402DRD:^JR_(^\(9\"F+)$RT0\=-1)CAK.KS_
MQO'>+4!R\+4":FUM',7?97(+"!,_)E=':%%\O,B*R@'\2=7>3>QX)'7):H]S
M"V!M]:C /(0QJA6L[T>$:GIQ);J.%_Q-"?_XY ]N_)K['2BUT;&3W<U'115:
M!4N.>C#B+/-HOIB/6H&G&G-O3KZ-"BPEUJTN$'3)W (2(6S%\V +N,525R!7
MJIBH>OC)DIV0TIYZFZ<EG=R3GYC)]<IOWW?T"@W3Q)W+. Z-GS=:A9^/*'S!
MW5=B%?-!:R%XPB0.1<T]>A48T%P5TQ,]"GG%0\1)1!MVWG #O;"N 89];<SP
M!R0/YN_ZNEV9<1_7[X'KT-]AM%]+%>R.1@(AN3[HOP8!%]TZ,8SM>85]/*%R
M\D4DS\!3MP"[OQ1+9E6^G&F^R_&>_=+R9"XZF-&U()I]!4Y47ZP<">C^UK?O
M@T:+PX^+C[\8Z_SNI(#=$R63\P?HHF\!<!TZ#"XLD %U.'SS13).PGS(Z^<P
M5#!?%T,V^#.I59H_F!KESB_9>0N@EC,MP;Z:E!-&C%+8*_!!IS]%'WO&%*0=
M'(<^3V.L<@LENNB7,XB"*T;>B*)GPM;SR(>!17=0TRLZ K:)ZC(NZ%JZ*M'7
M?'U_C[!K8#M1)^J&&MV%[LTN!<=UMI.A9O(^VCA8OJYNH!I\Y40'?.+>\90@
MM!7WE)UU]7]OI_X_& 0LB%':>0P?PL$*55S[T\R\;UOK65KQWY\;),%:[#NN
M^1Y?>=E>KBLP691$W=P#EUE,' M:;&D*0R4:H%P9O2KT\X1X]X@.W[H36/:V
M!%A:HL\SR\U5K==:S+T[ZT$\T&G*Y>XUM\>#,MMR/Q1?#J ,86UJ+'0]QXB.
MVL5E3+.Q"6+B]U'B- N#=R32 [+-'2P== ^3:8'RZ6Y3^/,:X^'A523X?<72
MD:3T1=I2AOG)J\=_O_3Q,+"GXX9,- ]=M,Y*N#SXIPO5I8?CS--Y;:9Y@1CB
M%;/!"&.?Y"]O/[/_.A^V<C@/HCH-NL-Z-XG+>AE39.QR^?O9Q,*X!^&A/[<$
M?+-#4WIEDKI;'M1I6W99/A0X9</OS+S,*2<$$J?6]#'*LN5ZXUU/<V7;#\A+
MW^'4DC,)5+QG@M]L0B*^5^.8RT6K_IM;*\:#-)O"LO4P?34Q+/Z/!6P]B68.
M6&OA\,O(?->P^7V"W>3QXW>IG!\^<5B+IK,S@WCH^VA^ _-(BJ 8H%TAQN=:
M[.VO*?9IENTT:T<Z0G;?APT7>5_M0DX2PSBTNOV>50@G0E=I]F4\'"Q=&AJ@
M#36IGAE*U4<"1[KI&_4 /!19!< 6XO<E":8Z&58C5/;#9%YC:(I?@_X6L$-?
M(1S;SCXMQ[56!EPEI=%**37IK$YNL5%S)?9]_SQ4:D145I\LB;9F -5L_GQ%
MC'^7KO[BB@"-EXR/#:/"Z+LD4D'OGMPB?X*0#8G;#V/YNG+1)@<< X6"9/M[
M>;'0I&@V,H%RK'XE.+)/?S)PFMDO-Y,EM(>E66/N]UN;IH77"M:CEHX'V.>W
M '*UG^H1CU"3NU?XI$42W4,='0\*K8OY$]#<*<CCZ/H,"WHT651Y7<!3YX),
MO2GK#N/470[I16KK;7,X[A_/B^-Y<-1Z9EBKX<\<+;@,LV1#!%X@L'_MD(6
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MEB&J,P=A'D63:2@IJ2+\5U:5G#9%F=;>=*O',KA[$(\E/EYA 9'66.35^JP
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M&CWHV-PR<4<%E_)6"I6>@WS&D*/$7<%/MG+ 76*\ZD"=^RI,"FYK-[SQ^_)
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M?D%KM]-]J+$S7PP1;8C527\>L,S4,KS\#985DHV=MY YLQ! /<J<"I=%*YS
M:V=A'&V_GYT*L;VM*#/$"79Q6QQ7_CHHU(TG "D_I)\8,"<6&X"(H]V,Y<:*
MEKMQTJ^\^?)%]_L87VR276^F#GJ\;_Z/J^JBS H"X3GF!C,P!:0ZQ*_8Z&_)
M)F?X&S?.;;D)O%)FC+WZQKV^:NJG9UI(./&0,I5]U:&NP&W*9.V5ZW$3GBLG
M&N0'<)]H%+W80B>)?+X#P&DR^H!?AFE^W$X9SMMI3#)("=:,J]QT1'8 W&2)
M:DIF981@\JV2UFLI&00?N U-P\F5!D5[WA>'V]SGJ5SP2WAJK'ET'OGYISO
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M/JGVG8^,P]!4'LBP3K6_A4O=2/E[OX[?> Z+WS+MW_SHGR>XL15GFRK':!7
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M\.9G(I4$NGF<\T=F&,F&PI3!GF7*@370*$W>[4V.#+KT5USE@!'\EJN3(0<
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M <'AF&>2X9?/-R9[2QY UC[;@JIV&Z51*@-:XAM47A7 ;YOJ="$<\T"&'6:
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MX2!WU$M1:E#-C=[&&I4UQL'D*ZZ>0@&/5ABA1V4"&8!HNZL3*=F,.MA8;B?
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M61XPV,M:'*? 95@!!>1Z<Y*$DT$*9?O\$>IU#1D>,84TS^=O!;?7 #>"[ Q
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MCY<<4K<>8@Q*1,=G<QQL?6KV>O>+POP>49OG? 9\<97I4JW4:U,#@C[NG%=
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M;?_+"=-_^G]":2'AR2$B8K\NC3;USR"5:'QID83[IIJ<&L3LOG. IK?G.0#
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MKX6GOTWLVK(=9>=28'?)&58[?;CA)#S@2=M'CQL$O"+DV&ZG97(SJNB"T6*
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M"I- /%C1<45_TGX__P-9B^]I'GL?/MG11C)^3"'IK)UIK6G]N5?.J/B9-MV
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M52+BXU/8_+?#E&#=EJD[V2;GX;DW7ZQ.P;)R^?4^;_4+Z:Y:DN-G(;$!/HJ
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MM#SMP'Y\(?TR";*W!+;FT'['>U+EO>KL80[-RW0[HH5E.?45(2$?6ADR6#=
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MY6%>'M#")X<12J=+]60^O;1NDZ&[FBBHX:3'?V/OK<.B^I['\8L@(0W2L*"
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M&N\SM#9#VRC0;'_ET!S_6@+:WZ\(6\Q<W'!;9>1(^%@)^EAZS844";UR<B
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MQM4 MO-^AMG[R*DY/TIKV&;,9]3KY1V896%QU7>8^_*'>O9\DF\$9$H ">[
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M!V&W"6$BP(20C6'%:9:ZVDC$[$5/#^&D',^]%U5W5#IEGQ-G$Y_)W_GL7MB
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MC[5;!JUT'>C=?HVE< /T;6%NZG%M5:*M;EW9&V <?!NI=H2WHQ<9D6/7I#=
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MMONBHH>33V/Z<&6<7Z N';=Q$U2TKZV+*SC]4<3F\9?@Q1D*B4?YL<7&.RB
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M_>L80Y^A2?07>W1\4R=IWC)C.MVPQ=WDGGN#H14#@8O9LVGC% &SP9?SSC&
M9C+PO;!<U9[,>F*ORM+K0;B59Y'NG)QC$64M9O#2XOK(0)S,/?X(M\I!.6II
M5HS5_/$K/>=5>IQYZS:Z<2KO3QL>='.[T-<&5D2?S(B%\1PH<0+#UN-: "6
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MQ7S 7NI9N;;]^_HD/^PI_I+&FA]<RSU\(&T0+V79,N^A[N8+3*V/":_X?JY
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M)'A@>(-"=TM29BZ[CTMG.?8K9KZ??U9PQ'6"#&0%]#,%::" +I:?>=?0=5'
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M'L18?I"Y/_=9QTKC]YSD]'[]B5-:!?7/50W'7"ZS9.PUW[J'WDKO\LH3?NF
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M UPA:'%J4 <[ -#1 6X# $ *$!'( 81XC0X_>!#E !#A=0*\;I:3^^=?X 8
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MWAU9^%3CFG&BC_*S6G>415)?K$>TOWW1!D+X8F^NH#*4L(*Z9Y0!::=!Y5?
MT[0E7.O&;M/RUX4N)10<3VRD)_"_1(^":MNN@-]5^2_ZAGT/X2[-!326LS"]
M HR 5E-VC\E;'\E^VGZ^@MQ?)(\(MD 2V9YH@T[F/.Z&[_LP-0>NB%5KEU\<
ML$+C(J8DC@'*8J\],\L]A9<98-)T.Y!W=1%E;&#A%!YF-635OK.=#-K>45X#
MS5M>>YRE51S!(T7#Z?XQ;X%41D;@3=(KX*2&$OL891_O&MB/6/)?WMDEBF;C
M%G@NBS!_DM_5HJ"A_WE2_,RU0;O9:>\Z1W&>+VFTPF!-HB(OU&(!$=1W00H3
MXTOI2')][52]D45ON;^_H_[D^)>;IT7%A>'\SA'40"UKQ,;Y-D4FU?YP<O6]
MZ,RO[=\ISU-VE;E:L?X8!Z[!D#8]-C?WM/K<#-PY65*_1 /2L9T*DXU(P)Y'
MEJ6\9(\H-&Q7#2Y;)&'C;MX1[ @$S\-(T<(Q]J6[AI]_^J^DEXMG--7=&+P)
MW*GF^-:I0 !<&-5#M^[5CL,!1UG)_.8?<]MCG/P+=^X)$*7$YXDI<[IV))%C
MP-T96?L5B!6F*Z!+S=?5I7;QD9#%DE#A"U-6&4JM.+ZMA**0/%CK200FXCWF
MP/S/H+%.)QQ'Y-;M*SY,V4O+SN-2#WQJH5P]=:+W.71+'>TQ6C*)J$*D> 8;
M.;6YCZ'9CU;F09WS+*'R ;8?,"_Z?TFF_DP919^-W33[=OM-Q@O_V^@<=V6P
M*E9\-I!IY564+L:=*FEA[U=2MKBL8_>M<%$0W#!!VS8VQV8]_J2ZM0<NCMH*
M6]6":5>:.B"5'_ E9+C)IJFD*P57!K!T<%-B'*B+JJ&O-24?I2?:6WG>B2BR
MS(F72U;<@Y47["IRH<=ZOHWX(O?KA!K>AI0<KFE9#LMTW8.;I)85_9R:W@Q6
MK!A7A&!H>N9#C;>7^1K3=]07. WXDED4XS9OKU^0;\NK(IW!75G/I^55@[@B
M"MU9TY4U[ZCPN-%(7X.K8"IHNKRF?E7#F2V&F[XI_M@+770Z/'G3[M7-$PD\
M!R-/:IZ@&XL\D?ESAPO&TPLCK9I5N>O6J;_J*M7@Q?2ZT^,D9?FQ@626U/W5
M6DC!^U,;*46)1HM5O+>ZB>])22I$B'7G,\O3($=4G+S M N+YE^Z5/D\[HT&
M,&I6M*)J*# @U)LNG RJ:K,)&>T",:'8JD^<>S31]Y$WX13VSFEC#.8^^44I
M89G\$\8>3=^/H]-(GR>KFCPD$F5V]&,:.#,^5']"EZIK ISK(J^ A'I+<BB'
M_N<9B9N?VV?J=YOK5U,&^K3N0UEMB6XM_ASDK:FM8<80H*6Z<-23WC68A]Y?
MA&H@PKPB9\DC(EY/Y3>>UG[C;M@)XH!!BJ!Q".?]KQ_GSN83LY]/_ACB]Z:M
M<Q;8H"38E@VS,+I0@$F@\A-A<A6+F%*M"Z_OL]J<.B>9UO,EHNITP?+GXR3C
M)@<]2N28%]]'URQGD+7:<VT+02*LF2R)RD#>VM%'__[>?- V<[H4>U/T\P@)
M4GKDDJ$,U[(41]K0[?3'*OO$?DI[SSXL+&#LN\8(G9CKM%W9UW.NJZT)7'8^
MNP)HE.P3Q/HLB&K1)#$-7[7W?,<C0X1R)7O9$\HJS8T;F31  "7!9+ "!?)W
M(!EZK#M T=FZ5^2GH=BHL/BELKJ-T?-*TA^=5J'05;21(OU/'!U*M^L+Q$O'
M=>_\6;IVW%=]XRQ^'X/:Z'NB'R77VA^N;S8'S?-VG^ X, R(W)L_XN,^K*B\
M2J4+734=HJ#;>;"%KCJ(,('YYG_._V%FZWI'@CA@22;5%A<:+)<@A\P(]7:D
MV-V%T/UHJ,[_9#9R_>5WT8O&^&8V >OGE+\_,H,YX%RO3$)_F&#>+XS:S<.]
M]'O"KP#X#LMQ33:<$"8_ >?!).F%]:@C]IRLM,)I!S\]Z$DYHALE42!5/!['
MC0>1RTNM!O!JSV %7?EC==V</S2*R7_L=WC>\84/_#9L5(9+9(!D)GC=QD,P
M#2W5LW(-H[B^ (VS;&SX C"'J&K?V/J@1V"%B45XK7 N8UQ/]#^CN0]$<5P*
MSGL_OIQAQ_A9MZJOT2BX6W"@AI0BF^IVV$M[O[[P$[;).#6LS!#:9/CVX( ^
M54N =5&6WC\6.._NN@+HVGC79$P@5([IIW5_+#[OUK@IEYL(HCN(K4/6L&-\
M.R7US#%%3V*[;KVK-$W++>:MGGELO,8KS6ECU!\HV8Z*BFQ[_6%7B53BUK#D
MA=WM;[>C;0VW*8-%]&7#\K"K2'@(9@3U1A]3RIQ0MIUQTI@A6<OTTN4;D2U,
M4O7VFY2D1P&URMQ%[W?]7:/KH1(Z](=RWSB"'QJH0YTXN=M"27G"!BJ.![%B
M*%VLX 'ALVTA[Y,O1?:I#J&(9W/K>]QA(1C[^98A /-^K"O+-4[)04>[V[]R
M]N[<XJX4NFY!-.;:E* P!:%L&4EB9HU=QHD!R@$T\%VB1^'T&T70'[W0A"TL
M7Q!JPF0,>UWID NW!+\0.&__NJF5?YPOL+3T_>N#*1R[TH7^MPO3D0N6>>LC
M;/LG>[N#;#E%)VMQ@E\,.WF<&.U5'5$J3X/7 9(CUK612.-Y=1]RGU ZK4%R
M75 #K XQ1H?1-L"<ED.C^M_TN[_7]O:4=U9H_<:9R7>?\K76;<9X0NF.D0!W
M9#O)2PNIR:(IF*[UR:[F!X;B0,_^*/(A:KV0[9$^]Q%8!JJTLX4F)E#28IM]
M)FK>:P ^\YE&]GY?7Q=VJ+,9?XHGTH,8X.Q0SRY)_\1\/^>2;=\W@UQ-/^I_
M\FKQF;GV.'!K6!23G]4@A+^L3J-Q)958?4>_PCPVOGASDZ_#KG(#9/R$C8^D
MO-?RS8RF3-J[P*!%J"(5MS.#=V3ZS:Q)<,.H?&F@\5;@(\U]'=C&A2)4H!LG
MC78IM44F*.U]1QF?U9;F\KVV'-;+*2*$W@Q6&.M/AH)ZE8B%](Y?RBLA=F/"
M'&;U3-Y-\.FOO^ D5"' F5$>[QHJ$F$<N[G!*._I//KOV>:FV>^;I/JNA8L5
ML#Y5WP9<#5)U%2(%]@@*?\Z#.Z1_C]Q>&:C[U!+BC%P>^603;QLC$.J?%;=J
M6$X3&61ONN?Q1%2H.,/7)?.BEQ%6M%M/TQ>L8-"3)X;:"K^N!=.J-/F)?/A6
MRW+K7VXT2QJ8)0H2VQ!=_Y7$0CO[QV?>\ 4=-ACA(ZD"DF =V &JKDL4ZXX)
MJ=@-E&C+>OWZ\6<S/N?Z5AGGE'(<(X%I:0'7D:7*2_ U& /"E<'$$<X]N?ZY
MK<&(+"Z3S^#+@U35]"U*?SIE]F5^3 Q"B611J#WZ^)LI1Z0RDIF_>-XSK$%%
M>O6D4ILF,9^J@:.^L0E]GX(W!^1.-%Z#' W10+YJ3X)SPV2GO7W12CUL3SW9
MNZAF+E1H*<;_T"_.T_5'0>+8@SHQ7OQ!42P7WB^W'I^@&WI2!MD&!+R"X\/"
M3K^^!/VZ[YTJ 9V3O4O\[)$*]_M/\MIK[108&2,<O;G+]\XY%^/<.,WNZ1L;
MT:>]?DE=!^QF+Y4^_\[:FSV_GW7?LY]P0&LIJN>5[@=CFN>"(S@JK()N/#?O
M=WFMM>S6N#FK-%@O/9-CIJD <=3MC\"J=1D(>!&L&(D:ZW4EAO8_87>-DNAI
M:[MM?,]Y(S[YFA;'M%W%/-8&Q740PSLN=#SIK24<.-1X8"L+EO)9"O\,4$/7
M)S'6")JP-@ZD2A7&]5'JT+KRN/.%ZD"X")N2#!^W'/=F&^@D K6(H\14V2.K
M;L&:&UA,F^>HZ3=O2 4&\;Y.5WQ+< R.;M,H@1JHYANCB>?J/P67I>K'8^YT
M:@P5X \#\5-4:?QO&HZ?=988"\R*2?>MB/5#OB2:X+GN,H%(+@7'OB ',)M*
M$*JN.]E8:;!&UB*8VI.\P F,88PY,RK%\J+RL=?S*<5S18U/S-N"'%K6\B5U
MWX7]9K7$4 $^:6/0_'XX"^I%(5JRP?GYJ!3?0^T!O'M#>UXC&R1R'PDQJ+3/
MN*B\='(N_I(,BO]XR_J<_(P"41,I@%E"&^*N@-XF_4&76)<#^<9Y2SZB&%U4
MS>'3CL[-8+FD>1(D2P3,&=4X"!.I[ [@,^EYB"9^N?[TT(ZC49HJ/F549,2?
MYM?6%<"G\> *J)X%G\M4C"K*PVZ@@L)@(.I:1*ZBJ6!::^*UWN%4P8IK@]<'
MMT*FF*:P0F@V5,:OC^<[/'YW4G\B#;?-ACL)3A;5 '_[&-P-C';G9](VK>J%
M9P^-W,(R^?NM:PF<7B,+46,]!]>@7;N_X%RS>]75FGS*0Q.:'=Y=S?I!!)8"
M6/DW'5DKT1(*]FO,37*#O)&)A&]JO_@,VOO$: %N )'W;\:Q&'H,C1::.:T<
M"YZN9NS/Y']<]T=3BC&CK8.R=4Z^98L"/G=I&*!KW8%4M&"&5^,_KP"'I?48
M$,/-17L -,5[5+ED@!P+J3>7'+W01S/5WUU1SF#>89K72(A\VM:@OPIV$QQH
M=Y ):E1DQLB993+99\Y$@[LWNSA#]M*8/!&03AHB3!PB/;L*&MKU^F+OGI2/
M3TNJ"#/;6V)2Y=4_=O-_*G,W( YBN&G0.O5'V_Z7N5VF IEW?43$'2XWC8"(
MTS[!ZS@9F)2.ZB\=9+:U\%YK^JV'0:<HX>'7FW"+.A13*#;H"@B_N:\UFGOY
MX7MO2D?*^XVW#(G-?5!LQ;2B))81E1&!XQBK@5KTF7)DD]V@3ZJ7C[LM%[XN
M(RWS'-H_&:P8V]#2!*^/W1F"[@MM*J.U&2*-# 9X$DDKV^F@[=TXAB:M-HV*
M^9]#5X";SDVV*V!);Q!+["?UZQ@I-84CV)F/0#OP3 B[9!HI\&JFOB!!CIS-
M9N!OT9&Q?J68EL3R-;G!#XU-*@I#1;2FGE8W+/=YMDJM#K* <\A]S"#J"N@Q
M^FE;@DG_4<TGIR>0J"F5KVSSE.B"?+>!2WU*:\J^?;K4]+6VEZBVX&\U+JV3
MFEQ%*1@EZB!*GD$J1A[L*A1G_#G@P]SP87%*'?&B5&I'J,INO%V3(@TF\:BO
M'8!I%#OJ9V?>$2JMT[+A2X\IY%=1T&+C50Q^3%+R<X6QC:'"V-+R&31QI,KK
M,G33@4*]-F.IWK9C4(X#L"]Y_ FSA-K5GV8>FNUE7O:4G#EZG\XG<'GZN+T*
MMH1B0&PFH$EZ_..Y;TC1.%J3/^2)U DUY$MZE^@FLZUR6AUU$H;10[2#?K);
MU"!,_>[HOPYSEJC-W#"4T[Y&/,B#+>9V'_B9J*Q8,;"0$V\M4\WP!+. VM5H
M<W1<831E>Y*\8A_[K(/WLFPF:M?LK>CN_,&O"/")2KJSWN]:^C,_871QJQGU
M^KNTJ/(:)LQ3I2[?AJQ^I$6^!R3/=7$Y\P-M. ]0?+^C?-2/)PG?DQEOYRF@
MQJ)_RXU8J\U8M];6WCL5+7:1+V!Q'TJF4<FQECABB</Q;&>-[3%\V#TY'Y[$
MN"SOC]J]L2DT^C9G?&;KZ_;MAU]O -UJ#2%43 ?E4F2%> $15_#TRW:>2#%G
MDV]\ZN9QC> @66MK:M/9M+.%JFE/!!S!4[OPGNO!,LAQ2S-0_?X=J?2E08$<
M?&?VX<^PXYOX(NWI!B$&0Q9F$Q/7MMR"5(D8MT>/CDF 6WRQ=KEHW4[9JNI"
M3VNDH%'3E)[%OMUB#.N+>]AA0.8VE$U!04VC%"N#:@]O@U3-05UU+BC9T^JJ
MALX.M=O7;<$!B=+64TR'09TK45M(C5AA\=>YZJ^%)%D59[RN*XEG/YH!N,4R
MY)/=Q':5P688(Z1N>)NSGT)-I$3T0;70%"SE3%2]T^/:+]GX^)2!X\H1[37[
M[JJ;"$0;6JT\A<.1E#<5!JY\U=V@BMI:/8E#31E.NXH[+GPK?$WI3MPZ9W*W
M./WL+>5ZVAJG\X&93Q5J=M4RS)TDUBY\B2Y5N$$FOG^QV(E&L?4E: (KAI;K
MS+O;<@&)\KYPK$@EHQ6MU[_+Y5;-F-]A".E+XMA>9D4)EWQ8V=&Q+]_Q8:C.
M*^>,R.U:BWQ\[[ [50U6NZ:-[_Q?(_D_%*'J'J>_IG!G&G;J4KL[7.E1T!+)
MNV&0%WAJ<FYT$HK*B_N(E9INN+B 2!E,[G74YX]X'S9I%F +(A1>ARES.Z(H
MD$D1\ER(7$,(RZZ'J:79,AFM/,/#9X0 ]5-C[Z7IV:D*>6<G8:F(Z ^7PVZ$
M:S**.4;#EG5;W6!2Z%KG>=IIK'A2DYE*H%4";DK\M<$W@WC>D.FLA<LRF)5W
M\4\3RW"O0792"*_84IH A#VW+/,W'WW0$B/!3Y85SD!.A]/([VN]DB,\TC=)
M;3.5#NKUVZN\YV^V%V/>Z)BKJDP+'5,82A\]=^L JVX')$D<7@$17E= ,/,R
M?4-<SWG/;%9/RK4O.6K^>4_";3X2*1=39_)LL95= ?8!UA>":SJ;<>^7OGD6
M619O1ZHT#1L?3@P9<4I.[)TF  $:U= H3=3W'->&2_45W482;IM#XL4 $H^
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M"*))M4]KX(YO\S70U]WSEA%>' $<*HT7POG.K4-1P_8+7^+R,V,$-E_XX8_
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MA]A)]&S#1<"J661YL6G,WJ$WN?GRDV)(SU>M[T1[<.Y&W\S#GA4 GZ87I&&
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MXYQ-^J2"!2[R)48A3BA6GT\7:4ZH;8=SWE:ST:9'%WKJ8WL>[HG'O)OO&JZ
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M/P ]HFZ^GGX:IA^2H=C)LWPD&!O?=P44DW9PQ@)8S2?G/6?@ 1':18+UU'Q
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MS';:[/,M@&T)OAQ]+R"=YE1VWN->S_W#)X_F"C#$%Y?A?4Y[?%BO@(B$#U=
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M!& XOJ?E<+H>]X"?O-Z_*65^S*53^83XJO,X^'R6O6[> A& BQNL1;Q**L0
M.)_C=!_?[T<4^0TMB:;@E/<F$^F_)=XGE"?W4]1.!XJ&*\"78%<&\^RN;9R]
MM'X[R\$L)K<DW2>FD^;Y@/^+9@=BSS1E6'PXAUN6S;:>KEX@=B@%PD+XXR=)
MD22,=V>JP$'L5D>,%JW(/#WLO@1<C]]5K'.(;T/H%1BC-$$KP5#KZ(V[?(L7
MP7O$KB716C?'!CVQ2W^N2Q61^I;1^<D'S/5 N<9<O'3_1P96E/%1QW=:FPY$
M-G2P+TMM8SU+^/TO*]^*"S<MN@2/2H61+PI6?^?MH/;TT('%#D3^69$;GX(F
MZ3 UG9D9E),SC4_G-0*7>_6>'IW*I,-'ZY91%X]G*@OF1$:6K*I:4W@>\]?<
M!9UF-3'';*67PAY,;95J1MS\/D"^8]Z.?K8 W![$MBK!Y)[*363C1I]*'8?A
M#5R]@*=L,,+>>3;5._(*!+#;MT]PLK?8\]NMS=*NWK\J]S6$$1Z=[G? DG4R
M#JB?EX6];#RM&T3O=.E_4HW1A 226>L>0F B$I@.+T<")*TX&VU8EYZPX_Q"
M:]+YJ]_SE4P0YA,S[K<Z5^*:C\]#.J%1P U=KR'SE"]3899<KW<,/VE+ \:7
MS%IO%@HV3Q$ E-P,GUD'P^S+J_8AVV2*)E\Q)X>+QXS?VJB5V/)@6Y)?57/"
MZ_DRD0"!&*5 #)40JD[^^$Q .9O\6@M-Q]P>I&4D2V CK/P[O&RI:SX=;>5@
M6J<X7C66]EF]=O^BT4H8SKC<6*9E;B[ZW4OXF/G6/<-OH;Z5^N*(X=$3.VN'
M5]_?ME'SV%-TC0OXD^3#W _'6JD"W/#BJEJ-;-.J.]3:H^1]8YXGY;0QKC^B
M$GU317;IF=8=OK'TD%Z;!W0KB<U2;<<8DM=D=_@6<4'UC3[K7H@_Z 19EL@@
M^1%YVLC1#DG#&MRTNL%'#:.ENA\)A..4W@=ZEBV,KX"=XB1) XZJ5KY>K43M
MUY^0[].2QZLFZ\^:UBN_<P/7^U4<,8!5/E+C7<9AM/F>EB*![E*Z6E]Q"T2_
MV'-^ K^Q#KM;HY$.P>O+XY6%G3Y->+B#&W,G79BC3;<JMT)PPIU JN0O)!!'
MDHOG,]W.YDFE=XH_^:>: +)\B-WW@0^75'J_2K9?7,K%(-1WZ[2\FQ(CY&("
M4-R(?;6D],7F.??E07TF:__'&L1S7*\W(@M3LW^O+OOGC7\GL>4%_[UZJ&$H
M_-L2,9+3B$282^^B(!*0=-AEY;GT8[Q["KM4"=C:=D$"1MSSQ?WX>NLGD<'!
MJHOZIW"M!%\Z^-%&#K8GE10LY3ZNDNG.N556_E-,WS=+=T.EP"U<GH%J7>"B
M&M=7@98>GK^)AX'#LH0$3.4ZH %6*WO.^53\L1T^LW]*[GA.W_C*;,63>+H>
MO%A"$&P&3(M-=4 !+HP="/^?"[X=K6QFA\\==0Z1?,H^\K,<%?6-$G4^\CV\
MGW\S6#&B#J>(;'MK=(2DD37']XE'@!=N;&]LKQR]H-:OKS<("0\K!PP*U-".
M B NT!L&@P-#]-GJ*O:NI(MG7^OX:[8WTM]3'*)[J6%4>K@_V-J?)_Y$=+1#
M-+WN5ORB#2A?%%L<4H6ID]X<A&2S3B !2RLDL-D#SWAYS@>=%'$.F/J^=;U
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M(&$BN3+Q2%$\'**14AP*W6QL?;D1K/S-4G_HZVA Z[771KQRZ]P:'EQEH$<
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M6(AU]'(_YM&;5!XJA\>$GB+&<7Y6J(;_9:<>G=/%I2OI7H6W"A3HMPR07$5
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M9$,O&^*L<OH/";3>.Z(*6PQ&&]\-!V 34@;J'^+56TC+=U=D')FUWHAX!2;
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MI1K18?4PKW!0K\<-.R*K<LC%5%B2M>>Q#-;++OIOD@.S3__:47Q<!.VTHR>
M0.3M#7^D>5F78RK44?>898Z_5$U64_;-=;C-D>^GS0Q.-,\/5[V4%5I$NCJ?
MN9E^ELM[".5VFF!HTMQHSA&C;!K!YOPQ'VA?*T(<1HN'$#4L7D<"Q+\\%[I3
M#>FGOS>&3</>Q')H:$K6_\*52A(J/9EN*,G%>W-ZU;^&ZRMTBNTM!C8O4W5B
M:EY&KXWB5ZX8S34O4,\LA1[HB-'=%X@\VU0ET+9J$'('TXS='3U6YL7_C#T
M)#$QTTF %EAR,:NJ"*?'0=]0B</X$X,OZ+%/#3F1 ([6>OP-FF<($D!Y^#-;
M<] Z-0R>=4[: W$"7Z&;\<]I[R5I>O1:/>1)YF9?[A?$Q12'K#;;!$\/SW<S
MD,36\4^E+G\@[W[DYR@,>^7]3VQ%0$V$Q^<="B'"BY8.^)& 52J-R?BNS&IY
M@^ .-O2<8!(WRX_U"[P6=J4[[R;LI]X%8_RY)D(*:6M*5%,@5F>K&3O'QWHQ
MKSZ;L([2YSU&C!);"M=3G:O&F9OKKZ0.E8+6S7- DU'O(PHU)MIY=-)S>I9H
MI*:[,=WL;&9^DW4C*' .6AQX.>885YXX8Z@)H4X8@BJ^!XI<]=#B++A61T$N
M:P/*#P7XR4CG2XEKHXW^=)?3FSM1&Y=(=<;F\60K/@W7%GO6",_/!\TC<.8*
M?LZPVT,+GF\.\H9)9>B@--)Q#GJOGPG^M>W[ZWH:D-;/64KRUI=^I1!>EB'1
MK+$&:>IC.06S>/+N]5)C9V_3S(DP0XIV6$>H9<-L?MC<\<E>6[QJT)5<\0"K
MO9X;/2!UU=FOT"_'_./?*,[_P>.-'A*(H+3(.A50@HG,7]F5VKA7NA$/EF^7
M!3WKH5FJO2W:QWL/=]/8-&1! LE#,,O[(#,D,,G)NF3U+];SLU7U_L'>,*$3
M=PS:B+EAOPSWE0QP]=H*$F [S5J\;CA>.K>K$N[N@&4'=!>J-ESGP)*\'/W2
M)OJ7[>)I+3-N1_U.!#PF<GA&$$^!/S:L8W=<2.#)R=TK[?9?NP'=<@UKOQ'^
M_+9+=#=K/%>-_2<"XJTKNUX!77I&V $;C$C@,^D(@HA3X%9N))K6TB!;R<>E
MY2JC^>1<S(%G=&"D(5#H\.]W*I)QZ7+ZHG8S)]SCJOW9K.4LA^F<6:AYUD\I
MS._/_+^9!%!>I)\'!*T^GD/0PI^?OSM% 0OPV' Z=U@F-/_FZL]/PG@C;9CX
M'V_F^*]JZ/K?-4AR*E[4,G*]".*+;8U! FW9EV1?GZ_?+\XE.S&CII%3B/RI
M?+HKXN&V:>6J77E'5ZSLYN;&$@?Z:O99--.H[SE;5=E)'#%1S)FW<:#+? Y!
MO8Z(J!/U?*IJ%6=$3L\/^8S4>9UP,?=I132-Y7?VC%]8&RT9WHF3VU#BUE8<
M9'/XL(9\*L@R86W!I"1@?*IC)AN[,FC.FGE,'T:-33F:TZ.EO'Y/2X<'M[]5
MS>AI+M#]S.\=.DIK?HD:&>!%7=6R*+_'(:M7A<%GXH!]:/AZOAZJJ/4C30;<
M.IGSMA[<F/KFQ:=G[(R5.SS/8[X\125TKQ%<5T.MO-/95"38:%,U-& [R*9O
MC%O679)Y/F8R\]+*Y:5SK>OBXMN=(&ILK0!#)]R4367OI>YTL<J\H2*YO!5I
M-S_?J_<*#]&\%/-'V1N7MLL&LR>A&*6=U7+_*>)]FF2MZPHIT,UL(*T.>&H;
M!<U39P--H)PFB%FLT^[-5RZD@!"L\U!QZS5L3PO(_8QLZ_2J3[1$>8,<EK/D
M.,^#[\WD00W+'RQ12W1KXIK0 0E <Q QNL"^576V52Y>7LF_?K#!'Z2!@6_@
MW@N,"$LY=/VK> 0E=B.>=-^?>X9Q5H3/'WQ9,VKL14+AN([.@(VR/W(]/^:9
M]KOTK_WA/SP(RFS'S?.GEY!_=J=<E:7>Z65LGF>RZJ3EK?+8_>]3J0\0FB.'
MW53,Z:;N$F$]5.$X;A3J!65#IU/%WG2:V+TP.TZW++'5W36CNL9TBJI$6L&P
MN\%A%:G;;!;4FE.!2#;?EWE#I8=2U@3:C(Y+10<6+E,$SMS>V;G $T9 63VY
MO]G6GVC:;0-G9J""$;U_BD#IO'6HC0%56-J4,:E+XG%R4/J>B(YEY2%XVC-<
M,5IVK@[D]\+H]Z6=PM;B&8-7<N"/YJ:7H>J-QF2(ZPJL-_85"-H[M@4^SSSP
MCVG(XK("<>7S/M1?==:\G\M^4YBOS'*<M,HJ ]XJH9L1?"-'MQ@_6V?<:$3R
M&G^V?5PMVV+9R+>050_FKG#\&!+,:M\HCF,@N8D7!5GMR%=*\WYG[3Z/Y85E
M'^:5JF 0++AQ&:XFOTX4E[O@]4_K5*/P!D?^H7DDO[7@UB:LY"6[/W]V+*@8
MKT8>,Q]PQQ;P.&!R9P,)W%%*(H$^K21?!1CBVV8UI+H[G:/-[K)-;$_6@9^.
M*]E]K?[UCCS#KIJG:'D#$@CS_<L<I280JLM(X'08^./JFLJ7Q*\EBY+R91O?
M)T3;PU\8%I?CQ5Z(!*+J%$%?M0M^C)7TQL4(!1?^Q*NI;'P6!UD5?&90TY]'
MX)()O$9S; 9W<88W']>XE=FTTYV?<&QSCW$NV9/YT!9CT:/"B%%FK/TY8*M-
M[G:NJOC6NK&=4KM4BHL[COE 5EGO0];>9CC+1\7^HE]Q1?-L=7B:[2&9X*YP
M*I)'9>M%29*X2=_U98>5=V5CS66HP\9C+UG[([K-;C].FS]Y'".<."=GLWJ*
M$?YG@GA?BY*_Q>ZR'"NKW5;,] 6T@MQW6)*Z1(02&$4"H?$/F$C=*HX$0N3%
MX65+,Q=4[+K]PBNOSE8OI_6O/4BG*Q+;G_RUUW4PYDW4.1* 6TZ$B?]A0P+;
M]Q-(@+IJJP=!-R/"GJ>W#R$!_[)E!WNI7<?<>G"9GG,QGO6>63VBT>IKIYZL
MZJL";^)PJC2:$6(Z<)I&#B=)V')A4&#DF&I 1;PVL&X'*]E\-;[K+X]V/0^C
MD27S,)U$PTGR"[6$%V\8A?B"RE\4;]K10<&1F*$/]SBU@<*(S1 T%R]X\M&U
M.E@<SU79<.'C])WXMJ'NNUK)AX=,91J2X#B-'T @0;/4+$.EP/#J>?#HJ"-
M,U3E@2 5#Q;?=X8A 03.0Z*Q69Z737YLMQULOD(=]7Y!<)#AL5;F0R8BYOM
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MTJSZ=ZZ0_>6PLQ5&,D'1Y(ZTRR,Y#= $N='BS*"QW Z2B*9E3:H+R1*59K,
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MY\ 7M(G@I9^)@A?M45V^PON1S-VW82RP_?P+C<7F87>I7M:QOA3X; ;'!1P
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M<Z%722MC4.? FF'@?S9N >J:!]Y&W;<'[80D]>=LB[<2G2O>L6.) ABQBJP
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ML43\G&/7@CB3W9EJ(]F"M&ZP.ETW=V'!)O'P%]>29)<=%*1BH"=0JH ]B8%
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M6+= W2<R-BZ\KZF^6,.%EE!B3(/U/I[*(I4"ZW?%Y-9=9E'+HD/TX:21%"Q
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MY5HM.C@^_K@LADS54(/P>K.Z<Q7'F"NTFCGWQ8Y7P$FHJB< :_PPTSU>WA-
M5A"0*3)LCHD*-5>C4D(2=*\4O+R,HS"@0VT%#\LGQU42*A+1&XCVD@G%TX(-
M?C,-^DE0E]9_'W0/J#9Y]C;!Y0.P@O_-K>777*[OB,B(+B \% $#3J,/?ICW
MEW$D@-N[;'%UPYN5]>0!-+A]FT28!\=?<XAH3LS8D.KE-QJ(KRN7V_(\GE5,
M9, -4P[,<)=^]\5L8==,P!*2;RB(JO?;HRIX-X#K0^[H0#TK% *+&>_YPF%2
M_ *'YGFQ^Z8?Y#=V>)<"45070^D9<L01WMUJ-.7D?GC@)K"#+;F:#MZF0FY'
MP>-I@P9>%\#.:+UB"F79D^Y>"//[6--D -.8WHHRAFXR%@W"1*(E^8C"NUX[
M6]MZ[:$\5B/UEO#34\5"LC%-XK^W,1!A9ULF$,KS07JX'?EG1_CM?"T0>D=%
M]QQ]21JM8=LZTS+]D(I]FEG&NP74,1P[RO_M?CSA22I4*!-$6UKE;.',:\W'
M.B#?";$K=MAHA[2Z*6V-LD<VH;SV[Q&I.8CM*^7F^'<-R])SGGN^D?[H.J_F
MB;8)51DU&+K/\E%-I:A]4Z17Y,;@-N%#0'SD'8<G.?3O4@A?"P5L1"I.3EU1
MQ/TL&G"W$7(&?ATI;2%O@-=^3.^:F%>JX'T\J$'L?:6)BBP'>H<[]0RQRKDP
M;@5Y/ &L%16L;KZU;0IWX-!3V6 [.YLMVD([%FK8EWBD![VX.6Y@OPHU7DR$
MC'>YK(G1T-/;5,]A$_"-Q$?6FXV"1*)J]G-5,HEKR$,MJQPEXC:9QT[7L,M%
M*WM84 7<C$)!SU &:A$WYKH&MDN\J; M# YKYN0>G0@F3OR[XU SA8(?@3Q(
M@\$=$I3MX%^&Q4L'3[5 9Q']U!.MF@\?JKT4%8'Y_2;[[-&W\0R@S)5BK) G
MP/-"I'Z6+;[KAGU\C1R8BR$F55/Q]D6C^ UD[EFW^XBT8/U*LPS6C]3?0C^C
MG:J-[W\?G4VI*FN^-0DWS\,,P9[S178B9D?2I$40T\,K)5:IQG%Y?KQY?N0?
M/WZV0R85WX10!W;EM@Q-[P71VHD?AS^:[OU!5U._7E5TY'T"J/0L%PD47O'V
MGF ^\Z<\^ UX.Z-PA8<*&@W$0>#'EYQ  ^Y[J\'3Y?:421K?:@K3T 9:]]K+
M%2Y]LYU&F;&C EE0W8]*<* YQHFQ[KTTQ5>V)9LE,[6;!OG#%SBR8WHLN?N;
M-JG=R"#CE$?.;;JT05]=\:/TU04UN%BN*-Q"=HW!T#W[ZZCHA=IJ%]]^-]DP
MH^ 3($SG7<N*X!75^V -ME-Y!ZOK"0'^-E[ISRY2V.W"0GQ8I[^9PFX9*(D
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MKMC0Q+D.C&!<].X(,5*[5.4<,Q'-B5,W:L8P1GB.+'WD-X^S9M37XK,STB>
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M#WV-VC9$;HVO-X1\9LF(.5S%Y%V\''L0"8,_ROO\=GO))]HVX*NIGUC*8%3
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MWP$'!3?R=T /^E*SU$#B<"O 210R[?'HG;W&1]W("=ZKB6!D(UZJM2)C-]_
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MLO!QT'0IE&5HJ)'7 M%P&>OIZ.I2O<P@*?&TMKI[G3D0<)/D&M3P$?DK^NZ
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M>,2^B;)A#N&Y T3IW&:$WP&(M3%*\F?7PC>A=X"JE:FK?-FKOS8J5@%5_7<
M$D6@F8LU<*Y[H5"\XCP@*Y#N3^:8P\\/7RMX"7:' $%6-/T[^4J+( O^VY>(
M7FA):09+17O]9ZUT2QNR)T4X?SG)O40#:7(J0EY!;J1(&+,3;@@\?^QX::5U
M[>T9Z"+=V/DU*9,)Y#>_A0;\DPEM4ZPWZB D*2:&].P3Q-.Y<8)VW\O\N9V^
MD?$3LG-[#N71WV?5 8H"SL:LG',^=P!&M-#?@:P@<#\QTZXP9YZYRH6QZM/K
MQH#-C,M[R@0E,Y:E'Q#AARFL 0G]D"#/ALX9<&O2SY6A>2%1+ES'86D\;TB-
MG":J['QDT,I]0#(+;V6G_CF$#N./[X3__*GD'<"?5ZXC\4V$K-D1!RBJM#U+
M^HT-^.0)EK&<E57X'GL!V9//!D/>@&>;L<YD[-J(%0\_K"(,R>!.@9H#Q7/2
MU(_I,OO84;O)9S;#!935&!8+M)N,3]Q1#>C9Z^<MH;,J(#KG2L0V5[V^*!]N
M3Q$8H8<NJQB"KXFIHL(_"H<HL-8/B>]7""'RWGF(TF!'H^IM[[#F&$M[G7KA
MO?B_#S!/K"<0I.[]ZVQ(WZV&JMV,3\_C=]_&:R ?I/VVQ0OYAO/7OFJWA\G-
MMT=.>R:$IF(-70HUB=_7<$H7;UF),#NB=R72[$5P?1QYIJQ@'?\;3(!8DG<I
MV\BIYIGU91':7'&FE2*C[T7<?D^L(_A&%MT^BA'<-T?H^6[JX=@$?%1OS2QR
M5:TK;J',E.;ALM5.*=O%RATC$,LSB.;L$?9DPS,[29<?*)G10*$MTCLF#3C=
M:J\A@!M'U:(ICX>>EC8UUU,2[[C14:[(OQ5(+.YY07;)IO7W#D!U\VKQK"[:
M?.WW!O!,VP:X%V0U:-SQI3U9?3!-M'B,\#+M >?6&/UV+N"<A<VD 7(:;&6B
M47!(:^(9QY']5NA, =E+@8[OM+;9[*'972>^S0]1JG9>?ZO*\LV)^4GM+F]:
M'%&L7'KX</482L5LQJ&Q8'B=J&W:)V$Y"Z^'#K4:*( =]TE50*%BNW0A4+VH
MC8TEY*4>'KI*:X8LSK=2IU+Y&  *7Q>/B&CX-"+#FY&6HF*L!!-#R5LSM7:
MD?>O]NGH=.XY95VD:95_]W_ &D9#?;K=0XVS8F#)FH"B,\@8SNJF0X5'_49B
MOH>3I"]U6)?,F^#@6[KI/^E]AV#ISH'Y'#.&/,5&U#:<6"-$^B):CC!VIL#2
M*'HMS%*K^I6;A7P$SF6[O#Y!IX&E>[Q\.$]2K1G:__D,#R1$Q1^G_9KD5;4F
MGO(F.+V52*QW<_MD/,!BY&0/P]..A,0VRX"5:OO<A+(6CF@#MF/D_$<>1I !
M#3Y<,0/\?(Q(O?9?-LZ4M<V(+RP(9[AGVE\\Q.$QQ;WN)Z3'R_^&8-D?ZP:@
MJX9E(5'OYXSG[.:;M]N^:=9:.7_X\U+TV>4+8HIOPNL(Q:5"H&,1>%(O_JJE
MKGQC:!.(MX;.FM#-J3D2_G7JUR"></$IN.^OR.%-+&\)4BKY?8COCU5+J,6J
MZ=JR[B*D14KY@6L)B^%U$%O=,\)"LOSX[1L7^+7[_8#@:]T]:/!(ND]+"Z@5
M-V1.IK^<]\/9'>#,R)T$G3$HFU_!'1,'9O/\KI1N'^\#UBYGOH?S<@\?<ME(
MG:S,Q<J'6U$$/M&+RVVIJG2FQ> A0S <S7,\+L%?(=W)BY*982?J;2R_'9;"
M\*A8CH>N S#TJP$C.C.U0E%12Z!YGTNND])FVSY+5GK*DL^(Q(_?X@&G0?PY
MJ)2D:C#W)E,!]66X:]1#]=8X-G<H<2K%T[YA?S(/#YGJ-7<X]V1>:,E.D$-,
MV4*(7KACJWO)D$=#2:4'_9@8"8")G06,*!S%PVW#5C_B (R5S2!$D1%%&R,5
M<[8D.#0+[>J?8D9NNZ%_Z^/T[3U14DD.[!;9,^GF6P3+P.KPL$(I/\,/V3$2
MD/;\C;7\<%HVD>;H@TF/P$*@85%;*/;B"[5=!#$A<K"QLZ[0&N.CK1FWEX35
MTPC6=]6$!-, ;W0\" 9D*2#?I[NB;?BA\]T%&B30M#3Q>+R&R2==AB[&$O6-
MY)T^@9594%G<*2F93XPY1'Q-U@S_I5QG&]S^"I]3PF1$D4.1&LG34/NP2M/.
M^>1YS?18(KOB2FPM$RQ[0!BXCN:9L$%9Y[G6[9L?$(?Z!Y8/\K[=BABO9.+P
M^$$FLW\ (*A4$?<G_U&OD3Z,\.IX\GA@GF*QL0[\&E8C='T05!#;_%6N&C':
MUITL-75=\J%.#AWE5D"D2+5'&X8O!M6NVN,G_6'_LG]A"_ DH2.1DUQF0(1S
MMH.%>!,2*9YT3T$1,7 N^WE(*3PP^-Z$>&W87_?7F6.GPWRX[<G/<R72>4W4
M&(Q?I:J72T0II<ASN 1RETS%-VNXO?%F3ATK[Z]-)B/*%$SU'N:?PM /\7Y4
M% @HAIV!3S2+A_""\G-(:DU7BFG("O,]VWM'6H(ROM5]ZJ9#3K;(^WK#K9BT
MNT0"DG?EKU<<UXIUR7#KQY,U-Z<)6FL6.LU#*QP25PXVM@F8)!%R37/TQZ:>
M(4^1[TZJ]0,ZGZ6K21OJZ%)JGN-4C2LR/M&+L:$\%,_)#R<UGPIF33WXD^WP
M^4]DQD(8C.UE4(8%VP-%-K2*-5KD^Z\JM(-61SZ<X*\;ZXS\]BTB\3+";5)N
M*T(AU,Q*A8.D6I10!N\E).U&Y.\-"TIN,)Q,=3";T0C4X6RNGSDA3B&BC_I]
M3H)@>Q:<>S8.X"N*!_!O'T-+BK3="4'#\B7@+]UJ:JOJ^7(H&^7%L)I"QZL;
M@Z':74G9;YXBCK,GRSR$>A[TS(R OP7$ <>;X'SNYE9DNA,M%#1Q27OH4@0F
M&VI;Z1FGGVJOD&>X _#2H#@Q;;L]5[K\S4U(X4\^^Z.UIU@<<6QI?=*RL_51
M-XX%6&[;C@_BF!,0/&/*>[8^#N5?*2R"_WEHE&Y;3,00,6'K(38;(;^BD\9^
M6PI6%RAX+!SSVI_=(6)_BB6 9G@?FA^W*4@!UD&F#*/D_>DT$ /X=FW1?_)Z
M[9*%>RBV>9E1R=)UP3JB_0JZ.EIR_+[=62+4V=J4<58$'-H(+N"+!>D0?MB^
MJ^&>WQ59#FVAK@[4;+@Q8Q],@FG&Z=L_F@V;R2?TUTF$&L'X]-;D]*A;-DY\
M+PK.'P%O'VF=!OI,/ #Q23RHKOG=U6JLX6;-+?J\YB*R113GB,#<H-24U'#O
MS?BJ,RDPU6U0>^O+W[ROJ+SV;89A1]P^@=,J;:5$C'@]2CCQ+(7H5[ WRY\,
M\PWN9O^T)^YP7XYXI$C:QESR'0"V_A%F(4SC$I02<V,5# \U@$4S[;K5O6T_
M@6PM23W$*?B<B&TI52T+/H*<5E%O%D^K!+7$90S!K9J1!;:]\[E^F64[YT4K
MFO6@A@B?>"A-DOIF(1'@;\KR%$8C.?,.8%6K=.IB3!<A^*X3#43L:]O]S+!R
MGE$K].61Q_E@/5'FE,6HFKZ\*VF\*%FN:2I89#JC*</U.$)&?N9UJ:F3/EC6
M+K/K\TN-V0Z+P88J.=\W  ;>]D*@-%H%;D6GCWY:XB1I7O/C*JDE:\M%_ O#
M&R*_]+%YDOK?R5XBKS!3S@2]=<!4 -=JQ@?(+8_YD8"\3)&3O]BJ4ZYD@8/"
MZ.#)"O2'*]\=P#&".$S"06_NO4\"X8%/E5PPDT;3GY65YPW#.5S?'D?@:_+N
M.>).AOWW\V:OE!R4+A_*FMSZM=T!9FJLTUQ+3<VL+%>7ERU65JWJ@W/>Q!F5
MVCXA3A4=)-M*DGM1/RN0-:79V-( >J;5YTHY'*\YQF&(,[85(8^K/2LL4;=<
M-V+,:/C^@L"L/8TST6N">::3#[?62&/(9K9:GJX&C?\ !$R GDKZT[[AKY(Y
M*Z>:&'\-=X3*7W R_PZ"M)EB/6DH3)9CYVY'G2Y>FX42<)Y<,\7:?N2BJ(>/
M?F/U?(\2[:T9/+N2-&$Z^(X7XK>Z%<&%K"UX71*@HMDP4YJ.T(N<Y6K)?965
MKE#LPDK 97N*A2EW6G3RL0&Z3SA*0H]V;/.6<477XDM)I 8LZW+I;]P[/#YK
M-8+O^RN0WM[>3>.P*M@MDY4IQ'+VO2]W[)9(X/L,/,65#T. @#M W^[I*;H*
M<7EZZ_;7LEY#8-S9Q"NP49>&7F25V@T0K:^\4\RP;V9^7E840/S<G2J$$P76
M8QF:E4;VY;AQM#MX,+Q-.!X,'!N1?YO,OU[C4R,[#-MNK >UYB!,<S6^&]JK
M3BYPD:2*>LC95ZK ;( 6SF6O6J=]1D'WO-QF)R4^%UAM.IP5DDKG_8ABF7LK
M&JE?T!'*/U0+5A6.4^0,*--!*:4(R;.\+M)(@RY#+55=N'8C7PQK4F=-,9-%
MI(RL\(L9(!>CJJU4?:L<.WS/!I7VMCJ:-5D4HSX\C)"?. ]R?#=W\YJ[9/5B
M\1C.L,Y4E9'C1EZ9F9:,;_:!1)? .C/\//$.D,Y9>0> N(3?,H-V)3M",Q,S
MNC)_T!Y[\N:(J5!^ST3B;_7^WL3)V'G4D9SSNMJT*ZONK6NH"\?]S8XHNZ1Z
M+]%J0FE.<1QXOA 2-%EQK806&^R@7ZE!.[QH[&GQ9>"FI9^HZUDCO0/@C 2-
MH^G*>>-O[%"<^G.0@PWH> ;[[I_FZ%=75(O=T?'K](+IZX3ITIS*<91\1)7X
M]R*D<9G?5#A9L\R(TW[9"5*(SG5@'W]_^))-C$7*%5=!S\8<<)+R45$6.16-
M8;! AP\&U63%5>[,3I'^*?G=S[NVU?0.7TF*=$5^J_J&;XX=I=.: @JLR?%1
MHG86+6GLH/G[?8!? P=SCD!_M,ZH"# 9@ [!K?:P)3'<Z\N*Q,(WKPY$*<.'
MAR #6ND%3OW8POM&]( @(L!EV4 V73Y/QH#2 U_V*=X84-R*$;<&I84%\U"!
MT9OK\$W^L]J8$7,?R8)F>;J..T L2)C4J:,TZ3S82FOXCRV^42H5L1P_X(F4
M+2(=#&D>*-KU@S9?E71_=:#][M')TYE\WZS$6MH!E\M#FK>^0H)4<L2XR47'
M>'S]?!ES*B4B$+MA9*L*"*R+EI>!W4>GV(6[( ZU!SO^Y#5WOZ S_VSR3/J+
MZQL_=LYCLA]A$KP#;)>/L-I#Z8"7 )/@?'Q:!]R!4HKNY*HFY]9=1.4U/F?:
M;R;*77E1W]C1WM[4V-K:UFE[(3I$6?6BUY:.W2Z6Y1? TX:YYW<<.@/3QHM)
MTMH.\1'S1F8HG=+\>\V'BS4H]+53Q;*V0X5Y7Z#+D\%42S4N=18/0Z3SH],D
MR?V# J>Y0_MKXAC07W;C:SF<B+&TDU2Y1'V";S>^N-=2?3',*;1+B1A*$Q94
M_"ST#G">C*0I.0.;2,X): J(L?OXBK4\?=7'.MRU=?VB?H'V_GRU:]U]\(3\
M0SA-QGB:-PC"#HO6)?QM7]PQ??KU4&O%H&OVH-:])ARQON?B$_CZ^*2=P:8_
M0E[[/!$9$]VL%#7F7X0.UIJK#6]^J"<[.RY=X&0RNEI))LULK#YXZQRHB!\B
MAW3[&@V&'%0;EE4*&!P2S(F*AF_P=,?,G^;)F3=)YDX6N)1;T)+8=D;9/5-7
M 7U@J#R&U1!95/'GB%O);,_-O)PT;GZV.-[CH^;Y&;>>?@@0<@9/B2J@YT+[
M\J15HF-4NF=\.E]S^=&B/O LF?PQ?+BF^9[$:_5"?K: ^@[0KWU-M^?YXKK6
M)ZNU/EO!K^0GC]@=((2&[4-=R2C)CR>C\N3!B_**Y,B%[AS/TC[8X6-^IE)2
M3^<L@^I7Y$_OIPK11Q(80"/D"Q"D<3K^L*/6\/(-IR"%*DUWW_*E[C$!J*%R
M75LD-<L/JN2/NR89_9@'72C6"$@!M82KW]$ZAK]+<=+U#7%4^CNYSX>F?Y-E
M42-!9\LUKD>"YM  SJRU[+?/=XAH3ME1\9-S\ORP0\K-J6)'6?L"D7WN$BPL
MW1CB*K.^+MLW]X_L<>RA8Z.Q42E3K34WGWKKZP>77GNKG-@Y!8@D_'T' ,Y6
M_DM8]W@EYSCW9LVD7[D!H=^U(WYP#=DSY0!10E[MS'8ZP?A5WYT83Q^1M9>8
M.1NH^3^TMO@Q7C:/3T"]XV,E!#WA[PR5G.3_8GLM_TK]7M4/LZDL>I*H*3EU
MAD+"&Y4[P,/)BCN M=<=8 <?++RY_:GFQOU:8J^#=')!2FJ._AWGK>5W_>(P
M$OS01OX=&4[-MXY_C'P\C#*C57#G*8R:?_'JSKR/RD]Y[5(&C19@!T6]4=9[
M!5)F* 1F=3/O9P>-'-[?3' UYTEX-=.\>]K9>_LB=<0'/U2W/Z) WZ7.]?'B
M!*(G41"L#;^UZ.^!ACMTU.=.G@D6@Y5_D)O-1QI^PTF[L7)9F1O(Y0I:<1'9
M@08Y)^5!)IPCO=,^7O]TVQVQSN2I*G(R/^SHJ]G-"DI\["_@[[?[^.-^-)X^
M >DF*6Y_5K[X@H0@U;#4.N\"9C352F'AU%_1T*ZQV(N];SQ?#&W"C52!$T2+
M*^%;.<D>U>!G^I(>#O72_>0P*W:0=EQN"S-,)/,"TAPRNJ65[BQN.,R<7EL0
MBA4\7KP?%\X-,)(!<\"JODI7'\DKE&B[$C>G*9\;-*K]]/I)78O#FZZ.K;U*
MN,NKZ(S><!K?)*%U%1>XYG%/$W6M/.I/1PPNPV7"VSW"0[WI;NZ EVS+B^O]
M.M:X%4+)YVS+.RNU).MFRO(-?VWS_=_2'UNOD8BL]*>N#*>I,D8]5R6J)% &
M[/#+*I$XDN^).5,X!CE;3Q)F_7'EI-0 ZO]*_'8]31"YQW;BF(]E[;I1I=.2
MJBYTW!V NQ/F?NLW'W[ZPG>'%'9(<QI[6C9SP*0;^Y$E!Z1"1.Y%^,*57OYT
M_]6J4Q9==DMKMI_QW)I9EN3<!&53K^GK>!$&RPB<$7, Z@[ @OZJBHH97))G
MJMXW#\N!K5','AM+M3H1=G_Q9FE;5?O#8L%P0TA=P+@^93P7P@17$#,./R!F
M,26N45?/L3G8&13.K>Z,&3=,W-S\9E)FC6;J#\H\:,U-B3JUZ*Q(WN4MT(M;
MFZIXTRY1[%"\V^'W17Q-2;<9U( 3 8J\KQ'!R_L;ESG=>R0(<")71X*F,_RJ
MF?(*75?M#-=>8IV<M;)_,#CGAO,D@56/B^1\RN"5]=ZY(NEMJ=OQC9XO2U0R
MJ(C+V#^;A))]9[^=.)]@C3==-L7 .KL,K3X0I+K<,0M6*C%=97VQN&@PO(W!
MJP0&@2H=H=;MSH*@&LDY@PA)&,TJ\7^%F7V$O >Z6 NE=Z@)6SYE2@MV<2FU
MM #-JSP9A5G%JN\LD;1S)KLL^1X*2DR1.9N_2 ()'W*WV)^216G>.GY\.G-H
M#\I=T6J(MA!W/,R7>V?\P>+X,;FB?O"'Q;II@I]L^&$/34.X75WZ"LC?%FBE
MRPUX--&;*S-7%M^CIHJDT$HE9"]X?Y4)21 73L0\0/E]V+PL;4]G>E+D]%ID
M^$3:FYZI?B-(41.7@;[VV!BY%5?W'K,ZTWRK/7%=\!ZDV7(KA1M?H#O;?,BZ
M<@#5B:I)Q/UA7%^M?<EW#ZNK8 5#PJ1U'WQN>0=SNVH3JAW/]]\&.E7\9/=
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M6#PS%6?!U5\XIE1OG3M\UY'Y!M#Y^-$;:DI\#^DQFM]L_\%QWMWXJ-H\Q!V
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M&W/0]=!,0O"QW_4/9(M[Y]YH8.0#> 3<WV(]>,HL=5V'VHS+^TE-]P)O<8;
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MC!1G3+S:P 4LQDY^C/G)+8'4%&RX&JF\H0Y1;[ZHGEL:X!;H.BDN<6!FI]C
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M(%GJ@%BT6\%G*4;5V,?65][/Q=V&X>,<R;T7XF1-%J)# H8R_Z$S8/&DEZ-
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M1Y* S"B%]G$)'W9>Q%T;..F4WI>X+?JC=O7\PM5;ERD+V=$!N8DJ,!M_G>K
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M+@76_FN]07]VQ&I<(,26&6]S@3"WKJ:IZ;7#DVGC_GNV ^C!NVMLJ]@) FU
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M.^> M^0Q![<PH=*ZJXQL1P<T6L<,69V'9A3;\ 5V901.>Z6VQVVOK"E-M24
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MJ\C.2M^(G3F.M0!VD[]"4I[R;]0PX^/59MSO+TJ>U1T6^"8X#P>^%0CL?7*
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MW5BV=X'&Z.I1 *I7&D(5KM89&A!C]N$CS_O7%B^_X:Q1  [S@3%PA4W$PC/
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M6Z+ O5=VZ:,^)M8]CZJ8OA11:IN$"AJ%$D/LV.B++A9FY-0E,?$:*/CTB:
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MY&6S:+1W6W=S@)Y;L*V>3,?OGR9>3P1PL[;=;LD!Z&..CK]IS;>@LJ=E/^J
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MNZ8/?S\1FZW0+\FYGA[87CV4L]K25SZYA<UE!VPUQ2V.Z.L_0%(E>ZWN"RT
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M6<QTL!WVC%BK&JIB#DW,U4Q(4.G@;JW?;>Z+6O<R-JYL @&I2<[L'[\8U-P
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M<R%P-%++W?!^UI+!-EMU+J6W:FR<Z8UEX_G1A$_V"7ZPH E&7#B%=6\.=5U
MA)GDHWU=.8(#_@(>!"Q+ZHM-UD@XR*WW74K/(!\?QIYN=O7> V!>G&&RZ"XW
MH,P;0WW!8U<2O36&<5JLX):5XP,T,RV AQBA!'\1PI]O:K2JND_I)BT9M"H;
MVD)])<7<%U8BY61$['/YV\Y,PP?:]SM%UO4:WY>8JCK :!6TWH+9T>D:]'Q_
MQ6L>X6C4V5@[--9E4_<^Q;/",0'MNNMUEBFALL ]N_7BM8BS+(T:X*;0'B@&
MI"@X;M;N0/HQ<?F$(N>2T->Q*U'+:DN%2:+%MK*'MZK-@&;MF*RL) S'_<%U
M26W_/(<<IME&:">$O:@5JM#TZB4SJUBJ#?BV)*]44OL$I')L6QPO'5'IB6==
M/O83YZO"H5-0JL/K5HUR,5855R*CG<H\U/;5YB;3 8/LU^%H!NF)&Z>0Y:,_
M-H,K]8K-W28[<9^W72*,_'QR8_TP2ASW&<;?OS#K<Z? +0RJ7!8F3Y(1D[39
M1'[#=BB]BIMZ,]=@^LPF?0=5F,*]RH?+$0=ZR@5+P"T;Q-@Y*YR65+:OW*>=
MS(32HX7CQ5^Z3K/CC@_34_2"8_CVL(6VC%CO!N+[IQ[#.?73BY =(KZ^^.[=
MQID*=0F]O*U+ITWB%%71?937MVLD'7X>W.JJ]3&.&M[1WB7*[@9WZ6*/[>.!
M2]C[,@RK01O&TB0C%:PQL$$/A(*J>("8S K+\UK.8/<6MY'>_0&MXP= 7$,U
M*3Q<YWLEZ3J/X)'*:#GI^JMX,DD;?J[\35MPT/ O$Z+0\YMXG"NJ#;-Z?[ (
M5=.'IQW, R2QK%D#N'DXAA&/1V-L<GQ1:FG^3C\.C=>1QWWEK[0HOY][5PM6
M5-A80^CYDPQFX;EL93=#^S*,.;G$#797R6S!-#P%R&F,YZ,GI6%R#=*IB';6
MBY^U,9;&.9QJ0_U>/N$1Y[&4X'0>P="@*D:91WPI*CPS6<?D.\P?A'ZV=8<=
M22J>D&V03)O(5Z(K"LW12;GK+7$<4647EBF0"5U!%V(F6H<' /FYZ1,;E>@)
MTGDN4"3+9Z-Q!%,]%J8&=N'+S?GJ I$,LR"$(ZV,'X$6BCJ#@RIV,C$=<YI=
M["=(HL;KB)KUTDSDR4;F(?#-\3VBPA1](L\]9B14Q_($@V.\_BG;3ZG'1L>"
M%VG21!W2/%DZBTV9SBRX<%V2TJ'U&.O%EB5VH=8NT:NA&VR-FCJ6(?6S#TL6
MEQ)=AOS-[[X?_IH3VRP6 _RN4-YJK8]R0-@V)"(I@ZU"-R$?"P1V=I4NJUP&
M D@$I7%,>^U+_<NWC^SB^0Q[;-XF*6-"P>&A\EQN22_9\H1*2AW;4C^GG@SE
MK>UK"09T9JH+G[#4[)].B"?FY!',GU=!-VXHKYP-/^6+AP8]GQ]] !3)]PZ1
M8ZS^3S<&_E[_'TV I?]M*=M!5^EG)%6M*8KK,9/E,=$PDBCOI_"?<BF>\ 4#
M8A]BJ%K].>*]ZO%YU,K>)>25UNL$A4<O.NKXOWYA"9X<JBME0P T(;C?P=.\
M@NW#5>=XG-\POSN*AP[,;^9K<];*/IG4QV9FS+,R9?OJ XDN52XU[)-LGG[%
M+*+?G&PZ#L+V&O V3=>7/,1\Y.JKP[OIC\5+M+8O(J)M;(@>NN,]I(3)<]'T
MTGVQ(<4/P_3K"!EP'F(9(U6F&14/TX[+^X;%<>P<[/?B_?JF]=_II!V5N--\
M5OAG/,[TWFDIS""Y=[/1W6@H].7)X45!)9QR;<#(H\GKV$#0S4@RM5W$19^*
M,'W$0N[1,KZ;6;(\P/VOE/\MI=BW2A \9/ \V;MNA*'\C:VQ:/I(W&,8DH7"
M_&4,(4"HJ )N_1K5B*>ROVM'E6KYD8IR3FMIN'Q^N:C EE4-2V?+;;JQ0OK5
M7,,:B8'042SL(M,S_0?OSSK+[U$U?0 X<\SO/%S:\& /*17=7*U4N@K?]D^O
M6I*&-%H:;F0T9/\$LVEL 0,-R.+$W?2-^]HTD1YCZS:1D&3R!(,_-E]ZZ4+U
M- )#!TD403%N4=.5YF17?2^/G;(;YR(;']<$[[FYD,?%]+1B_CC$!@).7;$1
M )/[@1K&I^(["P^ #2LG^?1<WX!RHF[GY<.;(;%!_[WH*Y&7 41[M" #>S5D
M42JTQ0\M#3\5WI%HMK$YZZ4^U&\D<.Q[W5;3U)T[FJF9>W!149LYGNS@U K8
M#&5C T9URI#0O37ZMMCQ^IC\=-Q9A).'/YA(,]YH</J6(A]-]>4(M;IAB"+#
M=/'VE9I+H1G4Q*SJQ>@9-K$'3C>7YA'J$87ED#=G3+Z:V;:T%%\V'&+]_8NA
MHL(9BWUA=/#%@@SU)O5&DY,'@<"4SJP0G:\&3Z,U3:>7G:5P_WRKEA*UF2A0
M:D]44M[!;6.IFP@,PVM74:K:<B\8XP )!!+"LO*G&+-0" !LT26H@8!E@^:=
M4Y4F]WP'Y;3Y%&L'=HYU4-;@YY'!6>HIZ@KH>NQS:3+EZC[\;WLOGD?FT)5I
MB5V4Z0J\JB25)?]!J:6 )8[/%G&K70!_/<@Y1;S&G=U1%Z$Y^N)GC?&78!D,
M@^1O &66QEU@Y/%.:)7%5<E&-X4C)<EBYFQS?9WKZ(2@4HA?..8F%[G%CW5L
M"B34B#L\PL/[-\)J[9!2'_#$:G6D'9/OIQ(H09RV4QZ@J4JE'M]/!G5PB56
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M[&AO--NXV)]!ZITD5SX,7[EVX[M'@WL25YZL&9@!33*9I'[Q751L@/-!>+4
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MJ*WGLW@4_SE-;(>![S$C[?%*;FC#R#N//VQ)',[%;=82CY:*W ]$@3$YT@B
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M85P:5K8#=[U44;^MU^=MO--(TVCG-'30GYN)_[=<^(>%_P502P,$%     @
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M_GVPXM_D^5^ OXW\;>1O(W\;^=O(WT;^-O+_+2/_07CM7/ LUQ=/9W$+@ 9
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MJV]H[.SJ[NGMZQ_X-3XQ.34],SLW#X,CUM8W-O]L;:,.CXY/3L_0YQ=_^44
M$!+\&_Z;?M'B_;I&1$1(1/*77P37?/\J0$MT_:8D,=U=0Q(K=WI>J1!2AGM)
MN54=9'S21DA&:X\Q<B9^&9@ ZB_7_N'9_SG'0O^'//MWQ_[#KWF DI  WWF$
MM  (N-"*OIUS[;\0X<^N45GDVK>Q$J.,'U9+)F%$W)?;P4I*PIDX(#QA->&"
MHQF$ \)T0.AO<VU3U7O"!O(7!5?EJ1D(>69I$??8SS2?HC@V@D7'7LYK1U5;
MWA IS]EA8LOH5/\P9\Z_;.$9NR?(VK&S]5R62FM0MRKY[%ESW8_J&"Z[GM^E
M' [)P* D8)NH5A@L,O;4J]SUP4RYR8[&Y.Z)L)<GNYZ]VT_>[T"J@"YK!PD7
M_)LV@H9RJ/2+D#BM@WCQ^X>WAER_2I,1=.AGUKD0<<3:1P-S>=&]WU$)$;+Z
MFEY7TMW^^NL[=$SSRQ=W^!6(LC](J@">QSE4&;?+]#5Z6QG'Q=>JIB!Z7V>7
M>A*DEC>PM]<>!FL]^TB;>/>"#5C(*YU=F=M.DUQV2'>S,/DES7%Z2$;;Z]Y%
M&=9??*)O\W!T%SM3[BB7X5V[FN6]N$/GHDJ\P6,?U@.8Y14[*.TG59HV7S"5
MV)5HL+_U$]FGLWO>Z_8@)2QL/'^RQEQ9ZX?3D#5VNG-*YXGJY"#=-7^JW^HY
M%%[/]*6?3]24WO3[NC*_S500_7[O]<O'29,N1EJ.<PJL*N3 [3+V;$[P@U^;
MNV=9=\:<-SFMTQ^_-ST4S9AD*PAS<"XI/ZGZKC/_O(E>_$-QPV+/42PEQV=4
M-%"CZ0E%5F%H<8!&>B0.0#J0X !&(U/P9<=9NJ')'/JG1A;<GK:'P>2#R*&D
M GF.G"[_*H$ZYW6&9_H&SR>J3:5]R[:9&@._ORH,:$CC)SIF_QB2 =3]MRHU
M97.I*G22VPCD-JQN>^>=/.V="I7E?WS]U^V\8/+_0_G66)C+E))OX2@OM$?U
MF48EAF6045-$G:N>@< Q>K69!!79E4WK75HNK1[V^*7SJZ-EO8_/;E2LUK-8
M>Z9LF>\!#(::_Z489_[! 1S-XA7@;6ZR65/'2,,TOU<B2-[>.!;K.>6CA _'
MQ(T@1H@&LC+4KBZFAZW[N=1B; ^K=M)'>];.:^HCGCV 5_73YW6/+5]V^=I+
M&;@JD?&FR2U6Y-O>" @5,@%NYT7_9U)OR8TQ0YYU!0PZF0>QGPLT1@TRSUD9
M4Q)TL(I(O"%LS"O98OM@,AQI\\VT3\30TE3;+>EWCI)P\2N6:^H\7'ZR'O^=
M\.!%.'4">PNL_!3U!.UJ,%.^.97TB:JQU.J39\.S_OGN5T@R%;;M8B O^C9>
MUC'Z*+Y.->I)YUT5W?(N&V^WW.1;VI[5GXF=<_982=+:5T=)##7E%.G>I.E\
ML9!__&O;@X7K'1?\B_IU!L/_M8+O@<$.)?MNFNAT$ZXZV46YW9^_N,:FS*3J
M.'Y\[[.8.CV!W%F%HA^VP6P7<4!G PY(G#DXQ0$E., X._/*=7#K0)WK1'RW
M:'6C+ZELY_U.ZPM3T ?K.ASP1MB&NSW02.'<U*=V0"W4UG);. T9A3[' 62]
MB1"[#:B-'P[8,E7KB?MXL Y9<C=/W\./87[!;M#I'@XHD'Q,,H0#2%7L/9$C
MO1G>IP4-,LXNG'6<?:D;4F305;$XM,M)96&0O$XRA@9%F235J-K\MJSH9DBJ
MQ-U*NN_H +R9OMV.PFVVIZ8G<70!19J$G_*DF,!]);TL :'*$Q@!% !./_5&
M&;RK\8M9<6#BLBN5]A2M]V[' <%R)*.5N3DTZE=I-]]@&99_VM!M'S8B)GY%
M026<!IJE:3-/FS_=[571]E])^04M""#9;<,W/-K@DDP?!^04@#DW,?Q0Y)C)
M".8FZ) 3N]1Z*7C1UK*AFWV2+;BT-!VLME*9T$IZ3Q0'.- (Z ISI!>3'82[
MFT,QM@?GV-\5XJN"\VVPG!SL. Y(&#EN Q5=#,4U%7%Z3D0#E^1P<+ES07V]
M.X?D33^.XV>$_-AG*,[E] "4G"4W>)5,;M:Y40<UMP[< >UVEY^37\B?1J(L
M,7Q0<I?R5X%U_ETQMU&3-UD3K^1"VY W+3R1GGV65!!19!Y"$R56R]L\E64#
M)9G=A C3B(BMQX8= F#! S9@N\UNA"Y.#W:R$<ZWX<R[]L'L.-KL.P[HZ\[^
M6(H#JM?T!3NN!L=5[S&Y%K) I81[0/8X@+8/EAV;.!N3*QI?S-4U!'QK&+9^
M1<,GDD-Y*#]3CQUO.]1R@>X<TER1!ZMHKZ;'%:&=$<4B)UUK;RYV)5E9$WYE
M1EAGJ@4G%XW2;UGL76I^QM!.D:[Y3>. "UFG =F$R*X>Z$_MB&;#KUUMAF-[
M&R\G:3),O3/T5XS>,7'UM)1TP4DPMRQ_#+?D._YDGJH6_R&V86WR1K_;,3Y0
M9^#),=%)#LW3JTSK-UB*.6D;.O-'75O-"5L6IH@5+G0,@KE;$ZD=LL]%Q3?T
MQI?O@VEBPXK(.^B@!$'G&2)4A[ %;>"N6KE;XNMNGUVM85?<_$+A/"0Q8;IY
M\_2IJ2>*[ZF4\U%OVO)S?\10@@_H ;!?#K6CH13+*O&K=#Q<MME($[_#-W(9
MKHL/86GC%$:>YAW(?LE)O?9347R?>G/L@\'JMGVSE/@Y_IE LY5NZ+E EC .
M^"ZZB8WR!\XM5UT[KVC@=L,UU"V>Q:97X3??Z'\H_K1H)K?7/W?YE:4OJ&:/
M#;0[!G.FZ,[PJ;(J=:*ZE>W-..G^&R7Q.JX+< L+U00+=AJ@7UHZ3H%@SW!
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M&K/AH3CA)\F9UT,?1]YZ'2S7MME>>1QJS50K\HO;T_5YT]%CRP>$9B\P;:F
M![[-UB] ;^_ '^XE&$\QV(_RPYM&XI<9D;?JX)?**W3H27 05OAIO"GT1TU'
MVHW?=PG\G@Q2'BJY[W2!:; &MW:P72:5V!#W)T%3W_,P]\=?<P<>%SPYIAM(
MN"+%K]')3JT,: <8%>^$T113GT'TDN@>%\)3)N0I=1<_@@CU<%)-&,RG-U9V
MHH<G<J8:3H',7UQ3/?G?7\%8V%%]!7Y]>Y)O;J&5\Q:#Y4U7NE+^E%,&8YN<
MV%>S.Q)(P)6PJ=86N)Y>S&5IB8!ZG <J_RY'\?R-L 65%'6N*9AK5"L]JK0Y
MB'5ZM25-LB%W?JR?Y.&N&SL7NL=+GEGBY8*NNZ^,VUVZM.27+X1R.'4%@X77
M2"'*.(#\X+1X0B;NQB_GKY-[TYS#\G[20OM$9^T^7.BSBM+30E3JGRDO?-)@
M\A Y=_79?"F<G^QC%6G1I%BG^[9V3@[-RW1$4=<;U]9?V#MU4O;LR60O00??
MPZ$F>\=[#P:-)V"MXQ6PYNI/OMHJU)P< ;26XJ9;V3^[@QB9Y)5.?L\7I41,
MIE&T8U\K?7L[%WM,%&C@/WKUP;NI9EIVB6APX\4YA4],RCNW#C+"JQPMZ!(#
MP?&4T51-G/R]B>5+D]:Z[]6/V)S>7[NM&F$ =6RRY .WGEXB0'M4W.%KS<DK
M#^N:TX:O<](IA+&:$?:>TE81X8 ?- ^ LX]J2ACYAE93!8@![:>/O!OSK_*S
MU%#Z;>5^W'N.T;)0RGINR=!5^FW"6Z!/E09AIP%H7T=GV]IQ%[Z&VB1^TQ"_
M.Z_M> XI&#<Y@RNEKLK;UN[ H!<(/''+U5;G*K)!:7<$W4 &A3C :6Z8FIK%
M22UXD5;*O+\LN!QDL6Z+%RY'SL2J@! 4\HW(Z5+78DW6:P:W$_L-]'^Y&:,8
M-[CHK[)5K@>N!JIM/OG9U-S:^C/:3VQY;VKL"R%GKH[9-7"_VGFE#)K"R1LV
M,L_^>!26M*S M#_L\4B>="%4^_(72 FX '6OT*H(K%Z&UZ%N-3C;N ULD)IZ
M#M1E^10+<G ME;+KXS<)Q+-F/5,#!M.R"G7+:@T1BNRS?$WN\F<H'-"U$FD2
M48$51(<+W93,YUFRK*8-;N@L-LK/TNW5AYRA//I@(FSF9=F4!R^VA3WH FP=
MEJ5IGP_N)](F=F@10FD1HX0[+:[=;,:1,I%3LDVSN[N/@R=:'\0>;^V\ "%K
M('0J$LLW76^H-[[X4MZ]&R_?#P@\>[!O$Y9%4"D1K^N- V9S6B[/?VC;=KS\
MV1[ZYQTF34)X&$N&X:M&9Q:MC%1LU]5>^&3+]9>7LQ!+*84.I5&2D'\-28F?
MQ0\/;!P"!U" P[IFE/93RSK$/KW1J6](E-&C)13T09*N)@PW["3\M9:_EAR
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M)^H.S46G*U<:J\PIC^"Z' LDW)UI7PEQ%MPLD;^L <$K?6@[G]S!R_61$7O
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M'%Z+9<6HC4N+P!'$ESZ/4+@/+^.-GG<GT4YT-WWY"%TL;<$YG,@:9@U=3X$
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M%CC$6"PD^K3P@92I.IF#R'6%!A1=6$U*D>#=C&Y1.TNWZ/LO8]@"G%E'&5P
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MZ>E'0K!74J#7?@_ 9^@O/R97YQ<3S&,4KUC8YEBI\/2G,0%&T?IZP6. <S7
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MOB@OM%V^>Y@<],]E@ZP(PY\U0DWLDZN[+$U1RLO94RSE\-S_@3SBVIRL6I_
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M/+?#,04<PP]$AZ#M2E"4RVA-\<R3&W0JDFN-+%U-Z'DD77"RQK6BT#*W!P;
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MIDZLU7H*.(,EN;*M:HSQ;@WPT4Z-D$R#XZGDN,66S0B][LBX;_;Z^%]UI5T
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MT9*Q(Z&M]U?_0W&A%4P5=R1_OIVB\@K<PQF6T(_A\5DNN-WC]0AFB6^)5:L
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M'N(: UF89ET0_A?>ZK#TC9GJ/L1!'10S]WY=U^Y52)ULA\AZ@47F4]8CYWM
M4*-H1:$-;_F4T=OC4>*HV8L1V3?^<D2\W\<ER,0_R'UO-ETO)4:BUP<*9Z2_
M!KD/9MXXW\DVW&IT7) 4Q*QA2'>E,INWO0]>8\,=7)H#-M<<,%TH93W'['I.
M+!(TY$?4E\L09$483C^;8_%ZSTNF-@4_))FFE$"6EGB!_P6R*-'9.LD;N YW
M9E)EANUN[2NM1+Z8U2/FIU3@C.$#<<^XNB]K_(#(&":"WJ?2 _M:K=C?%=\=
MAW3%CKS8&E,,X.R*7S]]IT_1DBN]1O[DIWQ3JKO-D=&+P9D?^(,41$\D][BP
MR)^6QDJ2@YOM)0($<B1"(\;?H /$40'Q_^,UW:MB=%97^77?><@IYM]\M)2X
MK=2NF31K!#%Y\HWC<OX$Y<#Z-*)9FG+\!9?1E7,M6K$5[;#F++$MKO3$@*#A
M0E6$,GRGD[RBLHTK?T>%(]U,M-.T?4/,A7W@6=/\OAA5DX_4X7.\D(_\."\E
M 5%5042BF%;@''^1H3[^RO5EU)X<\T:*2H(JWL7F.-&[%+;&W;)X%I[>]^H4
MZM)8BTT$(X3V#$T'KC.*1YA[6K&1 Z)Y5507)E1^0FTR /L,^-F5KY?<JZ!)
M"P\GU#G0O#RK#= MLL3Z/6>!CO]08.VS$8?(U4;>9FA?3\.-:N'NA980<%?\
M7:I5DS8X_MR/4X^26:)"BJGW7/TBE!@PJYFU0Y!!5ITQJ>KA.\HV5<>"%XGR
ML7_SNP;@G1L!%=D9;Z$$&7O,.Z_R&]#TC60Q4!4Q*>;);JI:?6CAY^&0#-/^
MC6=@>/0 N/*6UR='VFG:QUM?&J,37<Y9>\IX*W;POV"+0!;XA<YH(QV&[<8E
M*!3%/WIKY+FWM?,E\0--DH2 BR_CY\T36%T'-FQNCZZD3>HD'-OXQ?E?+=7+
M-MYFE45ZE\>$F%JH9B>YH(@5#AE?:GOH MU"RGD6_;1FC#WRFZ>!'(+Y;Z7H
MK, X 'A4KKZ&H6>I@.E_\UZN)P6%Q9)YWTE+BP[S(E_H0R#Q"VWB/UZ6S5WT
M>"QWU5.J79H5N[]?&WT]>62+F9T)V:W#9E(HB,W&W,'[(O3EB6H=4HM8. #V
MN<P.'!/B^^S86XRRK6KF-&U(MCX)A!R.Q@>)]4@HZT99^(HNE]1=EW+6I[LN
MC+:,>[G<!034?MDYGT@'O:XWCXG?HD%X<=@[PR!=7^ 4-()2L1<.8!FY(U\D
M9Y2!Q?.677#O+E&WN=;529A^XL2MF*8S272(]M@U"---\D0L#PD%LQE]W]0%
M\X3J]=1[6(\'E*P84X?'%G[!+NW#@^NS8O4V71='U3,7>I^-9GXQ[.)2;+ [
MJ?M+C2B%!)^;F?M74+!4@)B!0Z_'@:I\P,G/'L/C+^:-A]GEO!LQ.7I W06E
MKQ+U?,OODSBK%T]*ZY.D0/0#^#\>GE0LJ[<:VA.G;:@[=PQ5;<W31^4HS2UU
MH0J(M7&]Q,V[<)U)C(#(X+>^X&W"*\Z6"=XS&$-$Y<+EQN(WGJ%K+U (SD.P
M3//Z1*''"=BO)S1P.R+&/^110TYS;R67W;GAG03S*?#:':1YI4$D3Y*"H;*?
M_)&5,@MI6ABJ"X_/\D?##T0DA;]=:&E-@$"].AX.8:C)]ISIW<R1VUF[P-K_
MV2IS;8[U4>P]3X(87'.@S_3T[8\,)2=I,[9NU\#F"5;+;G\A=$<_DCVF+$QX
MI;&RHSN*Y4O#+NW&C$P'H:2&*3 &\QICRH;UX/8WG,/WI"&#R^QR6255.V*,
M-9?Y6>*9A>"H@F0>,9N*.%;['B+W-I=O/_#[#3]M1U(FEDZ89V%B]4++#*B/
M@\&K.][B)8M[_.I#5ABU5]8!M SR"MXG(K%9'ZAL?K63DX;_<"ZU^'%JQ0(:
M:+X.M5F/UG54_;PJP39:3%SZ\%!*=I>6;)B]0U-<_<R1K%(??GXX<O"-04)J
M4=!],$0C6*/V!)-H>HB-M/O\'D!4;FMK5N4E<,J-IFJ7-X0G['WLG<CP'O6V
M8V#%9^D,:I%*7I'@5[RH6YM[_6I%;_C9"Z9J:U1=62Y^1(03CW(2P$D;P0Z)
M+-BT9%>,:!P<5[Q7P^,8$GT^T\EOEWA(;FB-X<_OG9WR^0F<R*R/G7NJ;;[Q
MZF7M]7:D[B&H)Y!OYQDJ3J:(X!Z2D!88#VY;J!5,>,-F0ZNN+PSR$B9E:?+8
M4L:%)9J\CS$GBMA"MG)L('/9T+P'X/?.&N+=H"'HU6)YN3 (0B-0E.[8:,(/
M]CEYT#1A>JU49DF*?34@.O0N$_40=M=(,]9NDW@GL*>1/\^_VR&"9>1&N4S6
ME^'R_:&HN&[2_*MK9S<GF5S]1FKW:6U$8^H.JI,&_)U/#ZI?T[T1]G#!J N[
MX78J[J[R@/QL#:/?PUC@B@H](,4HC>UPBHM<68^[&X$I^:']R,X0?6>3J?O3
MU@;7U>NRMH:6JZ=!P7'%NO\UR%8;VF(4#OA9B6;A /1^Z7%#7F"P:T 6WYUV
MR5B;-/&4W;&4.)I84]XGW(VK2*-7P7KZ'D >0]MC@-P:Z[LE^B[+.#J*%9?Y
MKME'O@):XW*+.=L-5-0QJ*TJCA=\K:/SE":.3$@H'@6!*WII"F[8ZJ%,B2ZO
MV >Z5AH=>!F?FQ\<\@PPQ!,E8AI');E<?U.D3"XFMW_>BI>L<SS:X?6\\L=&
M<UO-)':7L9TIC1)*)&)8@A.G]['\_-U.C]M#-^584<:T0W/'A9(>3UIRL2P9
M5K,;@,*>NIT.#$#% DH-+:#)D2$A9P=BKN,SWP;L&UUK"FJCMK[.5>Q4%\RH
M-Y%EMF5D&5?E^ NH!E_9MKPKNBP&%WZ4$7N(8@2=\NC?C$,]BH"RM]_A 6]/
ML+YY/A7#R1:#4VP-\_%Q<R&\CA%.% _MN,+1=\TWX65CW^LI3%W0ZQPG?DLE
MA(1@JH#PA+L/*4%QTJ;6AV%2^6O,$*0VZ%V8#[XL\DD6VIO_-%)C^(\B1-WT
M+N\>T'++E(6&'U.Z,T,2!1WRL*5WD<A*HHU,F+N>Z?G'\@YT\4M9'K]?)Y07
M\W\L&(HTOP?\W! _@MP#2$9@%Q&;Q]HAM%/EM9!IL]0]%IUR+3NF)L'V7Y#,
M32")69CSK6K'L7N\H)2.HL4YQ%5\;XI]:W02@3(?P'%#2R)^\POK^J"M-^8W
M!&-O8=A"AL@D1\76!-V$P<2&%'6\'6>*DN5>WR:I N9#[-[7]P'\,3>(,_<>
M,!I[#VB=_V-%ST=CN7M )O4]P*?N<CK]_8FRN%1;RT<6!1L;NB(R$]P2^=$Z
M?(U.H>:K>T# J8\!C%8Q8I^I@E[G PIQ+"Z [HO3GCG<\K]8)[Y*-'X/V.[W
M6[:YXRV7^7>8U_OS/OPJ#:TM"8,0<%A!RGD"& ^W#SZA7?2Y]>%*6U7 R?A-
M/SNMKI$W3H.."1F%''(+P.PO;SD#EG%RP$@OJ^/G0ED-0H\7=M:$I\ML5T-R
M>X0[Z95A@^MN"IRJZ3-%]X/\5@T1^YRX:@8CXQ&%(6NHPAGC!]U&RH@S0YP2
M2R&50/1&O&0;VV0V7X+5:;W>B=!7-E B?B3E'FTJDR J4LK_'US,/,2YA'L
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M9$IUYBV&$=-3Z2!U47Q'$-F1';JG'\ *D>MT&V\OLC!&'Q%BP_O+9'L>?)C
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M5>@ED6PV,ZPE&T7"$BNVUICS,>4R%JOEJ%W*]9-ESOI"T-YM,9\ROM XQ;C
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MP%1@>0NMZ_9]"R8-RB=LA2X+L[K]4MM^N#A.<^8!C4(_^MB2!(+/F\2V7E-
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MJUF+08;Q](+ NI\,7Y.W.UIR[L*RGF#D$HPI25VB/?0Q\^FSWEWJ4ZU&N0?
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MHI4!^_R9FC?@8KG=,4U&,>=.*;RWLSB$O-#?L,E>6V8P>[.P+KABJ][< WT
M1HV6_^$6"(O_!0*L4U<;*)EV%N:&"A68QANL':V* B7@CTU,1YI9@GW.W1=9
M7]>G:P1H[VGEW%X'3K*L!BC2>Q1$RXJ\?^]R?@RK]/J[P?-^[!"K-7-,.QXJ
MR9HD_?KA-V9DM*18:=4JA(*MF_J%E%*HQ'=2F)M?TM"_,MJ;J[>XI6S?^YRD
MYA^&?#CJ7P&?Y[,(O-<_IQZ *O:6RJ[=&3)S&,="[Y/8PM4<VDF36VA,WWK2
MZ E3&/&71LX"B[/4 D\P WE+K:8L#H*"NCWY4@SRVT%] /YXJ+-C?X%&'V$I
MHEK=XXR#/?0-/ES/":9VVL>[F$M%G R0(^?1K!2@HZ/7%MFX*+^M'H.<YQ^2
M0AT9'1NY1QAB%]!UH<UJ1@=.)[&S*( Q<O;?R0AR_+;/K9@G6LQ36 U&/9N>
M4AKX>#L0.FVA1TI!X)1/RI#BO)5<8#%-)A%P87'+D5A3']'5P/#8O4!!G(&F
M,'5"ULDW)1IC6,Q6_?[O>.X=[.!R*[&:*B#K<Z1 ;K&"<W=8B"01LE59Q'K@
MMOP[.GH _H1'%5E_@?[4)/G_NA_3Z1X5?@B]=5;1$.32(<_/$."N:OQ(D<Y%
MP[Y99!*+H2(E1#'9S#/.A^/=KEXO'2_J-+[,TL8PSD5.:X:L8T!1/=3JU$<Q
M^0#\G4);S&MW@:R>554:"1I*45@T/9-L18$7'YIW:.DU\17/A7/?_1@M\UM;
M^A-[+?R.O<A9 9GW*138YT\]H[3_>,<M__".'?X*(9G+CW]V4!1C<VAPK*EY
MI32J0&1DI_EMHX*PSTB..=9RT_1O_UWT]O_M_O%_?E+#@D,F\JU8?FDXD0 B
M(?QV,]QVGBD4:%'E:(%%75DN_F<:Z51CG9^CT+7D#PEO"67I0@4-7+/C>YDM
MNWTJ*)!=T '"T4^<:ZFDH@)$S9#XRMEXLA<QI.')7S S@06-6+11 ?-PLT*7
M=)G)4D<<XD]C7D.,L'B[T[NT/;50H?@UEQF(JE&V=:^(\COG4C[X8==O*U?)
MZJZMX&E(:]5WGJ^W,C\_0F-TMG@TTV,!:LSWTI-R[D550:^:9O-B<-$1;3@N
MH0\BCP.Q+R1YML_+//<,U+*G3A"WYM:FNBA;O3/#PW>Q5X:Q/XLEWW=(Q;\_
MM5;YQP5>*?.HX=3%<? ]$QP6_V/P 9@3;LZT=GR1$PC.5/_NST4^&."; J2D
MV*'S(AWRJB/9,C4^  10CQ=Y5K$:(!N+%_9L,5*$P\.,7'[%>ZTF2"E!)!2
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MPPS&&1KEBLVXM74[_ (G;+"_&4= 1[P"5-":2CNCL'5[0,\;ZVJJFVBT%Y=
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M/])K84D"_@L>QY;&Z+?D=,KQD3]WK+^H<A##I /XE,$0XX>Q*]$^*Z!M55#
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M:PU1Z>HD=40G0%3UVV-]QZ^$."!FZPHT&4;ICWW%@QWP&KOGT<!';W%FEU)
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M4#5UR*_UV2LVXI,BATT1:Q];$D<0 $)7I-J^P-H I4D5T-Q6(F5&F2G(2#2
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M[99&FAE&@O+$95G?UO &'PI)\Z5@**75BB#I.=ESH2G*C5SS-A&/@ZZKZ\J
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M63Y\2Q]F0HRQ3I^=YQ!S93QTWK8<M6*+%0>9$!JC;<",!"7B"=P!_B@* 2-
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M@BHAY8\H:7((?WD[*,?Q/"/21J:E6& DJWX"<DOIY/>U9VI J"O.:,VXCKI
M0HF&K_=SAJ5 R35 B#GHB,4_QH41F*)M$7/[Q+^3?7OG<!;(HQT"%.S'OKC"
MMGGRT5NFS2<LW2L^>07D&^V[K/=,K:)V,JS0F:*Z)$C(X01K+PN4@\\52P=(
MA !0[VN49%J.F;9;G:+_-\ZKA-[]K*IJZ;6ZFH\-4:P$S%^=J9* GN<)&;/;
M9.1=H1Y%4D6[/!'3VU?VNY!<SL+^;S@@Y.#:TM!T,U(ZN+&<8A$H*L-R.-$Y
ML9).X!J.@!D/A^QZTK+^$V@,;?[#)X,>8(MCY%]"C^$_%J'I6E,&T,,[@/]A
MR@.S7[:<E)^ G@@9\J8E[5TN$,R54W\9FXUS:D'=>N;)OZQIVB2%"Y,J\2[I
MX9$]H:!6>G^._J(YODM$57FM:R]J'S>##$$BYJ919,H>([]I4*9P;"#42'+$
M3EY*2_I;BKN<ZA%7<.WG*('' 8%4;RZ2&24Y?(\Y8;9Q-3Y[M*EF[A)-!3!?
M*^;N<I_RJQU7*8EEN9?Q%HXR(D6;@SS78]DZ0GV5'I!$NHN/I+KR:D\:\,,1
MQ:YA$_(4\0H$"I0)K&UX4J<UY V"Y%Z>JZUB8&UMK)_(&ZY ($1CUG$J-*P=
MN=6)7F1.>S+W61!)S\GC2E9 QW4>9!]>AA0YI5';K++C9**YIT",RE8KUEUE
M!E=UST2I^M+*"?L8Z,1^X%L3T/MEQHWX5>7J"DQ"M@?H&>*XI[VMQ9HIL$'W
M0&+-Z6@"P7K5OH+R[AXK1OE=S&_O !4+RR^HDGGE+8G[0V%Q>B0H?%L'0#MA
M=2)=3.@;[&KVNX3?3)7/M)8[2MG.6C^9+G[/S?^\9^ TE:SR-=2_/6NWXY$&
M=WQ@T^QKH@#02N@3<<\<JIX9JFA#YRU\3R'$H*-]?*= ZG,?T')]_8#DK**_
MXA6HPT77MK)SK,)7&<:34.V1$0?[:F1*(@G!"<ARY)HA7=.)1ZW^L+)0CW.S
M/G+#W))I:L/<;SO0SKWT<VNKW@P DPYNQ*R(;';H8*CC"HT(?'BY^6+B^"+S
MT,J*JI9U (7V:S$E!T#M0(.W!]XHL1]*],PA'LG?J\-E,A]7 XYW'O[5P)/[
M)K.AI%F2$V9F1!^THO7" "<[RL *F\:'+)PPL*+=[3'.0]U2(]"B)4=]E5!^
M9CV4+"[-Z:&].XWI>&%#I@Z)+N>^/>67TA1'ZMAH"N-(*;YM45)JO,UF5,E2
MJ_SS?,6I$YU0V8W)0]@!QH)M8D$4RH)7-^.H'0 !&(UK*V>;6YJ#(M_3_F!2
M ;6Z6+T!$,<SR@OK_3"L)]>]M?X"TE3T@"-1TB]XFY=/NJU7BA\Y$9V>@N1>
MZ&@:AS);$CF_TAKY$,$9(D?FY;<BC;8=-''^)E<^]UIH3'XME&DBQ95^OJZ\
M;8-=L1:,L2I*JO>WDY7^=)*K L3SD['7X1DG3$SAG 5W'5='/&GDP@ZQPVS;
M'A8/CN=7&7*Z006^%E[XE9J$\ ?ZYPYW /'Q D8:*&[TKO--1IITI$[<'A8'
MWQ&A!GG]3,BZFB? 4\*%[.3VX'IKH7F!_ O Z%Q NG98$"?=G&>4L9I;75F,
M@;YO[R7 T]4K!..U[J9?H?TBS+1BBM3R52%0P<^<9FRO@-9+MILJY/9E,&?
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MDM+0,[Q=O$*+[UJ8E@,Y5,LDY#I_%4-'CO Z8FL=L/@!B^0/A& V%C"#.]B
M1[NWC =^A32U;F[AW +!--5CD&IK7(]MXJ [  [W7"FD!2^E]_0.$+X%)<GZ
MO+Q"0UD^)-*7?0N'0[3G^!V@/'5MA83L'9ZSTXBG>A;LC#$J<2B$R#D2.PH
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M9)TH &"8W!]J"HTW?^ (QBSO#S(CY,3_T4.XF/Y>7B?1L6'S_RS*0N6._G$
M5'[8!-Y]K&E*UB,SFC\"1W^,U?Q',SY?=I\M@DF1 Z1G[+5)[;,E=4]%A/0
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M>I#<,FGXRN=,*KBK.-4O$Z7$!\?GC!X??[DM3 ^G^B\<1__KZ',YOAP=?^2
M_L\BEVG0PS'^7_:25(W66:O:^63)Z2= '2OJ#YJF1C5\>%_UM'T41)E.PP'
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MH3PCGYH@@9G^9SG))V1(C4F;(Y2#3:H3BQVXDH[7$E?<*=;H*_<O)_?\8JW
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M)0#NIE&ZG?B_6&J=H$X#$+5+A!]+[ZN.?*PE>XW?^?&\#RMT?=?!RSCF(9G
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M^PU@[_[V>_7G4,&ZW4$XM#F&H;EBC7&GEDB1Y! #B'T?6[YG3F/STC!K-_0
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M#::(%X=._3"W=ONUVO!+0T?KB%?M3J)^ #FFOK/JFV!* L.;<9"K<Q:Z-?G
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MMCFL65^7\4Q\"B3W&'"%'?ZQ2$7!1D'R:J)-.\>7L[8"XZ 9*^' 0S@(:#(
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M+[E8N5=:R,G-EX4@$@^9Q4O#DQ]@+A%ZWW.^V2?^:!W;[Q!<[@98;*BLK<T
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M"J_!':EW6XV9:_4U+1[F;4LQE-@ "0'<_&[R2(FGOUJ'&W1.NVI89[PZI.]
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M,@Q^?JPX8,4V[ , %'VGA2I9:C=NYNR'8,+9+^?[O'28A+:;M@#=-"NSQ'J
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M-1@3%1%?#A6%MHD3>W3.G]0M8DEN4H7HV(B#!'QY$%A@4#01P=]%P$[ZU32
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M?^?I]%/S[_A,^)V *D^2+.0[R18%_D^9<7UQKL4 &92PTG48_GE(_G)YP+*
MR@<]I,R%P$_3KI>5$6G_[<[K%]'&MLB]'17-]K64&_G,TZGMV$1X=<;0[_/D
M9F#L"XZWR(F_8O:7&?\9,Z:W.M(H;08B[7-,AYJ)=+C'#6N)26([*@D<">[Q
M$?FG OZ,]!8BCZ98>,98-FQJV"9R< 2PJ7G@SO1^7V6.)XJ$#D!*]*:HZO]P
M"(JSQB#C=\HKG[8J>+^?H UF;L)RAB&?E.09]@E&^:N?H2,X&OX;4$L#!!0
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M'&T:_&(^2B)E5,3;DG@S$%+HF"*J(JUW-4H,)Q@"$0HWQM,*E<?I_U$@2SV
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M&TC_7$K=*C*D95<"6 -]6N+LNP(V/=#6:$S9_?V,V5GU5_ 7B9^R71OLW&/
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MRUX:M+_YOLR(XK@REWG=_\XL;2."-8S1JI[)Z<TASJN;F7WZG<P=QQ[LE$Y
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MY!ZC3QKXH7+?YCL6.BLK%A4'\5XY_F_(^(JXIC"#>VUY?M3Q,)H!!G6N]VL
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M$Q-%"-8=<A7\8;=!5/[ZP8J),=D]$X+*S'X&F(X G9 .76J7FWPL_;[$=I
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M#;8\'/M:=B^,.7*#>1VVU?+ )KD[I'.'D5PHR0N$J+<MJ<$-C".54/L9^WF
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M/D404(#G7E=P4@(/,73'+>3HH)LF-&6/.]&\4#\HH]^J=H2L//9J]G>*&W/
M0.1'DAY8[<%R74SU"+")MO9^%J'1,+H1?C.H0./Y8K=^H:&M81&OW5+4EI:^
MOE?C0CO&DPE-8(#F"8;QVY7",7&TEFE#)[A[:U7)(J?+59[%&8F7#<.*$@X
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MV#B<.6 P<G6@"R';<Q]OFV/>BHGI$=:?M<!1A]>4A=)\E9@S@,8YA=T"K>6
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M5JF']>9_>Z5[S=%02OOR#XG!#"$]2K,Z!J:'U"^7^Q0W#(?^G\6I \1 .BE
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M^G$+!#65W@(=J5*<EPRIIP=[,>6A5W6'L%9A"TBK>,5!Y&F)LJ?="E@..=V
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M+:;')5YE5/*>3]$>K3(TC3+PC#@ PT[3:GL#)5.8K-J_DR449QH2?\",LXP
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MN*?SD3K77'9'T'['H&W*U[1PR__9B!M];1G=KHEM\NRJ]M,0#N*Y/I88&@O
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MZY.5D1SMB1:C52HC6W@:OD"T=\&;]F]Y#]+)6ONH+%!"[A1D+N?4*LS87\%
MT N1TTJO<S:T!7N6BK(H^;3$>T3J?&Y@K@@X+2 "=Z8],._FI<:_$&9ZAW,M
M7\C:/=,U75FV?!\Q,FV=>*0B_)9U=]VQ&5-S;N"A"/@&KX 8=DQYD%*V3$D]
M4-'RX&=5.@8_/\J0.#5':1K#GY$,F5WUA>2AJEHM_6R')R >U/SK *1)AR2W
MD\KN:(]@>>%-+?T[WX?V^<;T%7'&?H7/&=!&@<T\)5N'E,Y=7U@KLC+IQ)R-
MIEK?/R0EBI*8),V3!&Y?,NJ?6!W+J*J0?.3X?EZNC)SP[6\!*EY'.IJ%-OH.
M-5 O#QN[1+>ARFA!^S5W 0-?Z-WRL"Z37@;S+P,4@(V^<OAZR>M6[P^)A?55
M8D'$U^6IJ&Y* SD<)!(MW2T;'(70R5LKZNQ=1F-'R?<O*MA%"?GKNJ!YZE#0
M!P[+5]MOKE(1."DK22]J7=:DW#)07^$>+ZX7@N5(OVWOD\V+;8_2T_NH4.#T
MD_KA,RF0KLFX<ZU[F/F2(]U69?RI9/N.A^.]=[O>_1WMUKJ.?6M2M.C,I3IS
MAO6ZN\#=[*PLF_/^6,,=.KK)DX*'U@)?#+6BN[F>4G= T@-NE9=5COY<+O]6
M%3XQ37N5YEZ:@B(KH-T,>ISXKV61_R/W4W_34AJ6 0<,]>. &'HPQB% ACN\
M,'N;KK8QSN:KS<'91,+[3(1J>=&1&WD.T:7[5Q8CQ@Y4HI5,#9X\'/^X2 JX
MT0;[K,!);6JP0TBQ:#ME1)\?4VJ?.S2E'K6"6&]?UJ2!],X!5>&JI;!%4FO"
MQO1&5=1KM!RJ0MHCEXH8.C)CG5J'YM/90A*#:DT6=CCX^QRD3V3C-E,O8\6F
M;;&L-:'+/.&%-PS14"^PK4*5&<<+^[,X/=D3; XX"_")HZ4H7*LXKAVT<*;]
MSG_Z,KCMZSEUA_I_>?Z+9?)M/<'2/LWVA%%4B=6ZL9'80]W ^R>JX/JT0_BF
MB@Q[KB)IP-W<9N 9@9HB8&$K2S]4X8L#;#9/Q'^#A4/<^,]61 ?Z$ EM=VXE
MJ-*?B^3$<B?[<%J!'ZE<\%:E!T@XHN0Q)CDNZ:B]]2>LM\9V=?P6#!:'+[X@
M>7_# ?!">L6)(8_26J@'Q\+W%='983D6<0S?5SY/)-6;BETID/>3RAOMX$5;
M6);I*);'4USGV3?H28FLD\[JQRNRJ1*TX^,4\O(C;A8<3T;Y]H5Q /@:+PX0
MDJ,KW"O<9[\^K4F#3('?" %]_ I]5XU27[K#)6QHJ)ZMB0-D[ 1,V<'D*T>Y
M34O$2+94'' 3Q&9K3:)R?#OF)\CN,[4<:S]MF]?"#=?!X_A:RBJ&K365DX.J
M28\^90R?C$8;5@E$!'7W1 ]:YWLP71BJ_ K-Q_N^%/5U<6=*.GO"O/RCT_"\
MTE#<>3S@7S%JN"TF&>%OF>KEZ)HZ'Z3G?(:G_=;_60CR2$F>=^60_&Y??J^,
MGAP38S77L-P.P4]0SB)3.5(6E:RICX3ED3\&>$N+I9&I[R;5D)G>,AL1=AA!
M!]?CVK"U<'%HZ'W);]P:-+>?=+G/+LR)$$QZ0A4EB0,IWB1P[ST[Z)=I,6FT
M*^T>Z6[Q:A;X*?=3HM"H!]&QZH%EJ:AY;00W5A5?T8K4UK=[P$)TYMDY+\-K
M]'?Y6O\A=QWO/Z6W^]NVDD:6>E3D2C$92K/-D6Q;O_+40%Q)GUW*.K67=$".
M\^47ADXOMHJ=>5&D16J0[QV/0C-"G@^7'EZZV%ISN"[*EHF5YZEXX2N$B%L/
MRYJ#^G/."(95;%V>R. 66EOU?0]7?-@IX_*#%#@$A325N0T$+QONU?LFBA7G
MB&9P:LGS%>G;;\I?Z\Y@EH]J.#<HFL$((KB*I(NO6.>PDL<+-6'?4+@]T2)6
M;PKVE;&!EUI+OL0W\%1G4[?^9RW%2[M!G)%^U'*@+-EPH!T)#^;S=5R2&J2R
M+9V5M_$J^^YCJ??>SLTYJ#DJ3\JU6&H8;%E,LBF)3<V?VC9:F;4YU9Y3*!V\
MJO3R6?,]:L*(*"=%[XM_)QRF7MVX*YKL'<0'O0.U*0;U54;9Q#&Y8[<OO>KZ
MH74Y3UDQFE3E2]PO/"!2KD7"GX\10FC@,8P__2BG^PX[Y.UG'- <2W)<Y(.E
MB8I^/A@L_7 93&F/+OFQK?'BG,9WU<>RX6Z^+5-D?*PYUUZ^EZ.%#9UTW[M/
M^A*CG 3Q+X">FW[J@-<IA@-$ZPH[(T3MJ$^\]_OAEBS>UX7'+2O'&=CK>) [
MK8P)P8(@V\[P!N<,6[5S19[OT!&.:*[(EV%QP\T6%@_(J1Y12 9(__!U1APG
M$2&5XHI1]F5!;C+W%8W1]QVZ3XL25%!AB[L>UB/U:MG&4J[PW;O%>,@C1'%N
MH"1G<;?YFM(5F9W$<2PS2MADUDV3W"96RNT]Y.X#'!!8Q'R<1C%SH='V>'2U
M:5S0_F?!2B?Z5P4F_ZJ 2L$[1Y"G[,$V+P1,9^TR^]NR1/H[G> 4)1Z")\0]
MG)\!WBZLD"\W8C]8E@8JF1IJ.<Y'!^*XN"RXZF,CKLFT%!TV(!P]2$1H)H7B
MFR^&U\NZQ@7O=^;8V>LO1C,F])L$E@S,_1AXT 'XO]$VM<&C78Z.6GHV893;
M5S[HQ*%"G*,Y!WJ&F%%YHJ+<+(+M\J3%-0@J:'YB0P+J@YE1*=P* WK.+0.D
MC.Z4=,=TEBIL;[;=[7UUY7ST?[U'X9]"SL.O3T^;;$U\A7F</)W4*H]FB=B+
M=J".!B_^=@DK6FS(QF4O(S)C.1ZC'(I^]%V)?9M;G/IMV,EU6IX9$8)B0^_3
MT)^^RB_B3[&N]N1!U@+\6=;907)7**/JO[9PS%ZG?%CXN ,967&\\=H-8G^+
M.^8$8OE4AU'!8?=B:#6R9NMSA&7 K6%?5HN,[<BO/3ZYVXF!;UNK)"-[XM(C
MWC].6WIR/>TS^6?RHZ*@:A#QYLF)T9@+3UM=,=7C6S?G>GR(\G)8BGMXA0:+
M%GKK_N- ]SJ&! >P[TY>A%2874@8&Z@:_U.\YJT_*E\\: ]N2;D]7CCMQ]OF
MW7!T=UTL9KK3D.;>=F9>=/26F27& ,FU_BEMQIH-9(<G"SH7(>V$WY_A@(*/
MYT2ZDR4W3XH26AN92Q&AP04B_$+.CA;7Y'ZT1->6I;J_4#T?(DGRU%PB.DTA
M&V8V089&W'3):393C\+,=#GX5GR'B*W:HZNE(_2_PPA\+[V\;LMD/Y%S&RLU
M]\@*G$%P;I"!=U_)\-;!2S8HM/B;\HBH2/[T7N7EYL1-NZ-"*0V&T9_\]LJ9
MU_)@M_0WTZCXD?"?.&#)C!E5>M@N68@MH9A;'Q3BSPXS9Z;6>B;R\DA[H= >
MI;D$"O;E6?IT1%N.G2Q+7"MZ:CO<(45LH7?S.4!X1<KJP7J=]VW"@:)&$D_Y
M70JW-+QK]G38K3D\\MEXL[&I:M;]!(P(PV@.>2%.H^Q%<PWVIG=.C+'WNPZ9
MCFIO$_:#EV21\Z%=X5B6.>/V)N\=N1I(X8)*%(,_=Y%-$[,OF9_S":3!L-RG
MY+3PV)IM*G;[J?T%M"G/.QZ>#17#*I7D&"VTX0GK7IHA_<$SZTL0*;2ZTJRQ
MS:G6W*,YSB"Y;1AUAZ:IAQ="JB7&6'0B\O)I:#$SUM05.EGU_(CQ+OCN:^RU
M_3 C>EEFY)%D@?S>-"JH6WQ#!/8 DTLXLEDL@N<.&\N4^/+)LJGZ73^N15R,
M#-9MD>$!2"%D%"ONR;ZW:+3-]&:::\/'WG1J]Y-_9F0&GC_(I9>9M1M)6AL8
MC=B*'=I,O*\_-)YI^IP7GO41\VD X"'DKH:CK,$AX"-AV&KP( Y@_L4Y_H6A
M][^Y+A7N?7K^5;E,N[2J3B/I#Z8A[(7(;YE\Y?4UD_]SVUZ?%6^KP29-X+G!
M\]^91G$%A-(7O!)I.PER$WP\EXX&FIV5$Y#BOZ%C-R5GY;'>'#.]"PE])OTT
M!&VP5H]E"C!6'DLX;DZ8OS7"]>-\R3D\<6:YZXUE0D]=4X)&:KW!Q#XU2$<)
M;/1SFSE)#?JC/K_/LX@#W'*7&!2=1GKN7Y6UW5>G-E8H2"R,A4LV'8AZUZC+
M+X6^=J/C%WAM3[9Q:]>%@&1RE3T7![16IG2E4GFVF8XB3U_$.SM?OZ ./?ZU
M;+[4V(84_(7<_,P4)H;<T!9ED#H_Z4;AX^([J%BD<KOD!UV4Y7J':TB(4A1*
M\8ZY&/C-=>(;37YM+"NY),-'!E&^C*@XCX+N%,:)-U7B0IU&TS_OO-!6YKVU
M&_7=^TAZ1;;KS[-[*1)COFHV>2JN^3T_7=%0J,U4X<]X]X_,R0D\7!!BB?!O
M6O<[X,;4)G->@^W\NOHC&$5SI](=ZJWAAMAVD1D;+E7F7?/=1X[\AM]NMFAY
M@L&Z@7*LX"#!XF/!*T9SMJ5],FT]]PZS AZ-*G$[LR3=$PN1*R 6#A+N=YP0
M?&,Y)N K6<54J\ER.#O[/7I68(HC."?ZB[YINX+6LP.AUY G?Y=KY7^>-C*]
ML:(Y3=A::2HZ^M/BVP1Y(^M$#MKPZ8MI]+/J*BFPU^ @>XISLPRJ&(+P"/_Y
M"U> KVUI&^-Q15.?6AP>5[C+O\^,RO,Y2J.HE70K6*#>Q@$(.,I ;\(77@ZS
M,E3W6-V?6O>R-G/XR6+%,$#AV[,"FGZ%;F^DK1L^6J!*OK5/WQ>SY48E%"]\
M&J<<7\WIG.(<VP%X5T: EZ"^JK*W$DY3:!'?^RGC,UFKJLR9-TZ?;.9,DHP9
MY(]3D"F6(-9?6V5LW3L3<W>^DO[;ZJ('3PU/C$^,[<6_//OX]Y>7^FFGB;8C
M1A6:[LFVHR?+4A,MR*6V&DGT6!;[>+6DS3?\:NN&] 1/A*^ZQ0HK=(FR*9L$
M IW32];#'ESK+LAA;;L$)NT:<BUFLIT717VQ62Q4?EP1M:,+]?F2VWDF-__L
MD./E  -YQ#5%=S-$KL!/OD;6'UL&E?LDP0[3R[L;?(5BZY0= $F^PV)T"\L0
MD?\]U!+X=<5,'62!K'-"+.:GUX)15=2RXH!XEYV_.\NJZTH*KV-[$XUI&V3D
M"'S5T]_Q^@Y3Y,=&-=<:-=<HPN%I)2+R<__ZB#-L$X*Y?7(RA3N\$T9N#($:
M.'JQ?<F%J)P.Q<R\L46K* Y>#M&LDBC*T$;9+S=(M3.1A/G2YV[=R7]JC=PR
M<#^/Z;9?UP-Y/::8\T\FJ4XC\[^-Z@.%B,PQ"I0S<DP</_%@LCC^J?_.X=K[
MWV)5W -4I#21_GK=J,-ET9QVP:F%CA%%FQ/>?EGH4X<TR)MJ.?7O"C1QL@:Z
MK[N/BEYWX !2C.*R*@9<K.:5MFUZ:_1%#&^NJ!K[B?CC[^T4 =?%]FZRO$2\
MNI*]@.&=K "]P=Y"H(M#1"YT#>))5,J30*73CSBBF2\')?CN.JA(#$AJ$<TS
MHO*][/-1T+9Y#CP<?V=? +EKDS!JG'&VIN4T#*_Y''659YW%1:,)U9\K?=[?
M%>Q+ZU&T6<M23('-K/IZ1?]APA0C435ABI2/+E\CLV>;-C(A5%#:HM#&0%(S
M^,".KI->M0@"$'\ Q6GVYJQQ.@]9B:I@A)#SP:"WY68D4"-V%*R=7EB3UZQ#
M<-K>=XBVU;ZWJA?H\W9/H])&3+[EP^@M)5&X_+9P ME4R&5YGC"N67WS]1$>
MQ2!@(8L(V.NCN4L3^HE2# K^4')ZAX(?N_&<*Q7V?X;OE)P,+@=1MYM/ED-9
MY<R!6;FBOB/.E_ZTA?CN6YY*5 ZYRN1(O,.T$)S%XSXG>1;!B0,JF%>I=Z/5
MT20=^U2PKNS"+ZC*.5C0":&5DW+:G0.KV<FL83DVF]_G0)7.?%T6[3T4NA9J
MJB),9P0G5/"VM5:=<%GY=;UFN74*Q[?JZ,:?_(()=W! @"SS45%*30-L:>&-
MM&;U3@KKM]KHVOXUH@]X0#])@<<FJHI>.9@[9T>PI.9&T<ER<K\^&V[Z^#X<
M8)>) YAD)Y&PM@7D88ZUJ4"EV7+%QRGC;Z<4!_Y/"+9<#1)S.OMY--S>=2:R
MU2S9"+_F.HZ5)L(!9>Q6' NT4YLI_(C3, ZJ-*B^9"@CKZ-DF>"X2S0J')C\
M3S%HZG63#HOLAWPG=WP+<PW;.?S?#KHP\253W7XJ<:K=O6,TGE0TF O9&I:-
MID]R<N37'BMR)C-6*A-?8G1)^9%&<;<7J93JG(<RT"XI2^I)\62D_AY,HA$<
M>I?JD?)-IO$",,/,S#8;;>.H@^-N0>1/_NLR?<";E0SRB*^;<C_5 >=Y:D2Y
M&)LD4U0L<7SB,W$VO?Z*Q>@LRA+LQC.&WOM-_;$MIZ);%>O^5T8=X6]'U-:'
M^/EWLVNJ0R8?-Z(?NG^XW<Q\P_:V[K;J\U&6<XO_-%9_9M$_I@+^ .B^C+X5
MMO9I0F)83;BD64LRQH?4S:NJP^_1OF&2.LKC2Z]Y$_(J]\F3'?L7.:=X2G.I
M17NG.^V*+&L[5AP9GX-D.X/\#'5/35-:C(SO=3HT'Y^111&Y%FOEU5HF0S-M
MW&O=DTG;H-#K;>3083TE(/_)?TH5]4SDU4:/H2Z.>3]F3%N]NUQ(NYMB+]T=
MIR%8Q4JB[BQQ([*K8$N[=%!6/9&S::*1M6CI#>J2IY@LJ:<W LLI7<+/S+&T
M79$X8%,=28(EW< !R]#]\]]!H0@J\HOSLEGHSE<%/"AL.PWZ[>(6+/4X7PS,
M(DTKTUPQ[K!W1(8'?@+3'1DSW\YC2.$##:3Y"S831LDU56,%N_NW9,RKPU[J
MHJC# <ODO*WSAJ9ID20T9!.VD57>QXZU5<EWVSB'MX (YXW]\MK4$Q3KL<S)
MW$MX!!>HL3"2!VLE6[F@2B7#*"2><&U!E\GTJN>./S[' ;?DV!)^C0(N''#]
M2$!:>9'7SY0+/6D*:J XD^<9@$FF#*[ 7YLNV;O5.&*D/!<.]@NFI,EE<RXK
M;\BQA2GJC(HF"QM5'1[Y*8U@06=;4,GNIL18@W].Z_7O7D7TR\IM:IHL/\)V
M(]QKVWG?.C#X%H&K41MLH;F8EKW<-$JSYA2BT7J*##*H''?]!T(W=P,*7F\J
M1=;0XZ*_7E(L@)2-7091F=HRC>,Y]C%S(?6Z5WV=WR/F!W9#GW]JWSU[13!P
M?],YZFJQ=K%4#<KBJ[%GRH81['J7F_"L=&6;UFCPY(^QSV_>BB1I$73J/939
M)/R*L-\MREHB(^N7/<">3%M81ODI/AY8\4(WYYX31EPC8&1)KOV:_=#'/KN#
M+L>[:E(M^93LRELP)_S#C0ARRH8R_4U\R38*?)].Q]>X/;=(LXUIL7*?B%W8
MJ[J6$4R$L#B\<A:JL"_'2D';N^4/'CV&H*_$MVE5EHTS*8RZ,8X(7=ZYR7,U
M5* NSO!#;>ZS'-:R<2V23BP8);525_SV/'F,B6[3K=!VYR?%23=)<G7?O<5&
M@U/K_D/S;,E%@T*,+(I^S?.&YKN.VM"W?*)<A[X[S/:0:QWHB9GR6[R]BY_9
M,B<S_S&W$YMN(88 T3\?F"O_[/Q-8D1\*5=!0NV'[^_NZ%S[1K1*W"+-)L6$
MQ $H"TUF'#!D@._%*&HP#F L+LS]+R]2DU8FFJ8^=W9S?FYN;R^Z<I9P7YXT
M0V-A_A7Q4W1BQ;\X]1/UCOW^GS,[[-7]CDOT@6YGY)/^;!5!*P_HZ>1F5)@G
MA:)CC_O=/VB1),):RY%*H8>>@LO<7\FAI_:B'R?.[X-K&98^^ DK8SB;:##@
MSH;%"W#[/4%(,BFB<]'[3.>@ZX?!+]_D88-L:E5:LY=^>)&QE-^YTCUAET*8
M>EIC]CU\3V3.3'W"/K@S.M=HH04'R/!;&M(?ZMA"ZGA-'DT5[N]^J0UL/-)5
M8M4<8^,-'6N\BF(_V=AU9W*M9=U S&Z>4MCV'9$=P-'K 5+GO'A#0H:*3'-9
M@H$$OI)>S&A2&X6Y''^2A8W 49J^'FG(Y870!'JGXOEZQ''K[.N=MQHL_MP!
M,@+A2R*ID6S$XP*R_0*EM2:+$E![';$*-]DWU61G3+N[>\_J BTK$A\L.\?%
MB)$7'K$'</[-+>VZ3V-WU%6./K737]J;FNJC_:XF*9*?ZMD&]YV(?.F9.#"/
M5H[B[>LHC70L6+O^K9LO0:@V1_OTTR-8<QT><WNOR=ZT\;\QYFIMUAG;9D]1
M7[>;X^5^_[&2[$/,R]>1F?=D0VIK>R;K!3-0G_@G(65HS2GCGJO7Z^V9J8,>
MZE ]!E:D"6R\Z!IW24+M<4 I'<<JU(#)V-MO)G7O#-KW^F(WFLK<--:X/R$$
MP[\$[6RJP@&*B;=G7-3]>'>-70[JHD>G:V_O<22..[#;(R5)]+4TUCAN!BZ$
M S'A*\>G]<C44#UI@<G*TC:?&]\34NU&C*S'UH94U\( CHA<]IKDN\?'@]=M
MYFD_;]<:T\%S61\Q'.=_,K7Y@I9MKE)\4\C6]Q[5>QB@3'2-2K^(9[FXW0RE
M;TI;.0$KQ0'E&/1X^8'_\.KN;!2ZRMYQSYQAW\"?;7YNSM/2NKCH9;T84^1<
MA,']F$$^K0'D%TNP5V7NY=J8JYPQZB]\H2A8'D8989(=_676L,69,BWAM\FH
MWF"%5W> O)(!8_??SZH:HN6FS78FL,QC(IZN?3XS,SLY8U9C<BJ^4]S5I _E
MJ/AN2(5XHPUJVI;M25<NE"IRU+!KTZ!5Z 8H&%:&S6Z\6SY1K^1J(J]845-?
M45-NZ6'#Q!U/'FS=&KTNL!0C 1PO-Y0ZODZELD1C;XR&HM_JGE'+L?# 8397
M,+0KT(M+( J![/@44X%1G1^<"TQ-<P<S#'-1.5G6OE?&-".SD>+P8X:3;8/S
MP))(<0>Z$V07,Y\M;-'W,WD<<36,V?^[=V?6"ME.$XE:^M:T2(K95*%E]4=I
MSTAYJU/[\3:VG.(ETZ\(W25L/F*EQ<-;J<;92J9]^O4<KV'=_<M"G6G7>W,>
MR,^,!,A<_W<L2UI]2?D8__0\=H(Y%[*O+/U\#$L2GA(.++J!@_POCPG(CMIG
MLK+_])M)OFM9\?+\LA3L<18.N$(2Y2KK>P?)M+?,A:ZLO:B=(S[OO=>&H-UR
M_=UPZ"'E'ZZTLY&432R9-;BDS2]>*.CX=M8,TF%'XE.8T9Q.*'E]<9U]M&+E
MUR2>4&9G>'3;!D^V$-S[9/M ,RJ5M&(PK.F'V0]Q([^F$X]IZ87*[JVZ[P?(
M*EOQ4TJ7J#' ]RYJ"X]^Q3L,),4Q'$U3*8JQ)F<+#H=5]J[J=;X56*Q+ROB.
MVR$\ &:9;*4\F5.#E*U@K0=96E2E/FJ,EWJ;/9LI9G1/J%R\F-/9-!A?GXT.
M$/EAFF=>5WME_LBH2950+TE:HNQ3= 7@;4&[#D-4"98+QBY3!55$4ACLFT[G
M-E2PK8U&[T0P[=3+K,#)/0L)$"<U%K[M5KU16IR@)Q+/\<AV_O_:X[_8[S02
MGIVSKJHZ9:(X"E'SY*Q_TU)_0-BZ)Z:Z?4^S>M=$QJGJ&U26+P8"[?=1&SF"
MOJOYN1@RP)6RO-DYP*CV78R7X$9,7H32Q$;$$'$1?,EGA\)V4+<!R762/?RT
MSYY3G#2)<2[=4<@],,)+X=G>4FT$RU%%Y!*_L,JPK[!C%LJM;^O$D>]J[:-5
MR=Y6Q9XCIS96XGL2M&5RC.=126X^+H[\E15^.9P\@A2E<GU@CI!#CE>2YFN\
M8VCS\'%?4>Z2Y7RU=X(DW)$PXCR>ZLD5'S?AF:_/FN^+)ZXKM'YP(Q5GTQA.
M54P/D)Z40YS43YA2#KGQ<_U<1-2GJU80)_*$[_>&J)@?!)4XUWVG],A;O/1
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M_<-#JZ*9F;D-F_+&_OHO3745R-BC?G>YH/L/B$O<< ")IT>'D!V2\IU%KG/
MX2.RXF$L D/AW(3(R1S"PD(;!29\'\#KK \NBL9@,W? [4,DV=JF5A=52$B;
M-)2-==37P+K!020,.RC!ELVS!"\=;Y!:,7OC(! <7R6Z$%*,GMYQ[[=3QES!
M5)\G D=,O(,"6&F,:$E#RLA*>\]Z"X<"UB2YK6A-0L(B(H21]>'-DZ*NMOE;
M(QB]M)D=28K!Z2-T\OR3>0CW;H$6IH  =#^Z>U>.Z<F_FT5T;>>+L9I73D^V
M9[_](@YX$ZKE)TD_XA'MJKZ0S&C?=I/0.<B)<G@W5:OH/BPD_M4\?[L1MLZ.
MHR$1RY!6*_=>7>A]W>W;SJF2&AO[3, <8N ==^"7PHC35/N/L\;&?<YK5T[K
M1Z4+@XD6+1\)I8P7ZHGTW<C>*C$271O?@H.;ZIQ&9%6EWP,K$EM#I%7_3B[B
M_S^\X?]T64$G#4Z\59-47^_2LUL_4=*JU,[2<PG<#(97\BJ556RZ,1[%)(JD
M\S9)TI%KR#Z\FP *)P9% M:3/"NW7:7Z=15+D2S4Y<+2G0_FM](.#'6E:3D>
M;$5,&NJ)4O!HC&>H'$/((&/R-?KKM._O'!,$=@#.\Y=&, S(:=M$VG*ZR0[.
M)X%N))\[Z][:\8K[6DGLFZQ9_D"Y*(P**'8F9=B<Q 8\47.TC:ZDTGXO;/3W
M"R__IR3W(_]V,B>2]^J(J(7V!49I2)[GX*.H??G&D,F?PLR1!2;LBKYVSW9Z
MHP<(3HM.=IIE&>J'7'>OV[/?RMY*N.IBX\A<#Z7)_RS>^Y!GW6[CP>"#HO!P
M8.5X\ V6!,E=>]Y9L802*%XU*7W\,MH#&5&:#VA(1:>09*GG8H01_L5+22"J
M;4E.W:W:5[OE85GO13B&5)AA,F<;A*+C^#[4YBN!>.>I*'UOFK;,&MEX5&G?
M!<4!GF(>#JN8J4%1MG>(KI9YMN%C"D'EH:7*BK$EJ,\W3G>OC&</=7YVE 1Y
ML_'FIP=(-(@OD024)]M.ZHUBQ.TIUM+36[A/GR7)D<ZHT?(WG[V=2W%)L87=
M\!5 6$6X<8U)*Z:U>;@#NI+=2&&"46<EYI+1SY,014!O5*2.E?ZWUQHC]B_*
MRJI,2AZ2[CYA'"3<5L78CO^=.O5$^7DU)_@IB@K-[?T<YE[4!+_41=UC+\2C
M(@K/OJ6J<'/D?'VB^.N*V!R!+"=^V<'L[^8']1-3WX);3*H[I0RJ\ 4!M4MI
MADQ#MK#WZQ [6+0[/-=ZZV;HZ> %1G(/O8"X>^I]F["_/C7BW..\KOC*CE!4
MHYU+RZUS^S-K_/@?7=9/Q0&W-$.@[J\+IAV*;_BKM+EYJ^,1W0*BQKQLQ02A
M_*[\NUOTT>#]6SB 4'=P39]?5M)7JC:V%W:-/[.MP,-]I-5@V]#Y?#)MW*>.
M3 J%J4.K".BBRY18_)4"[I?C &:4@5[7B6.82%(Z+(3WQU03WWH5[>O<E[<^
M'%QYT/_KB$W3)5LOM-F;H\]5^N%3+\Q1V10OQ)MAEUL[RE^.BQA([XT>/X@E
MP1)U!LBPAQ\ZHO02C^&8@$8>ST1RO^'<^Z:!.,"/0/F$OF-7"F]2S=-V&+8N
M,K(9A(\/(@%O==KUA9D%^O)]% 9A&5Q@7GSBGOML<+2?!M8Z-FD'6Y5"=+4C
MS/>9B=2:P;3LOW8Y'KJAD(NY3[E+N',R'DC,Y-J4W2+!7LJN$L$!X?Y$8\@3
M33J;!S)TD*PP^")*A&!"6\O(;-JL:_WIW,-7J?,A<BN'M#+_DC'^/V=,-N'Z
M?YJP_+^4=SIV&:JR7\YX,_&,CZ:?S"]=/H"T-X)$^_0MV623?URA(=L==5E-
MRN^UWTL5+5^^\VF7?>8[/O,#!]#-CQ$4_Z/I$%\$G]$[-/T4S<,!6ZW+M8__
M:4O+_V<6_4IO49:)_)W%H/L4S[?92!#9^:F[@A0VXIPX@*92.QZ#3)S#L[J3
M_46#MKI/TC^."*S$;?CV+-X4#_&:'^6"E]2S4B7IHWQ-LLTSH5_/HJE0A%0[
MIK&*@%<5YE;J]2,<<'89HZ96SGIKK-P3OK[MH;V!L1QMFC!$J1E&N!Y8I,S+
M'\\=3&8.R['9X]$?85<\Z( )!?%^XA:K,?:E9FZ/YAD\"X2H<WUG=D:)<NR0
M%) ]--T2H/&_JZ'X:WRV/O6U0[GEOK^%5,]4'EDS)8<MV/+R=C25TP?5\^3)
MO]QW*[A:V+[CG/G1ZNVE[W5J7J_7SUS@CWB'BH]D>/2(;+U-XA9E_(<=8JP.
MB1O=4*,(><@X!FKO@MAOK2S9:GJF^-%(]7*IU_S+-YC@A.2L!X2@.,"'OJTX
MO!;4OK +^LEL\F@!+=5[Z#_#Q+TO["^VZXY=&G">KK-%"DZ-+IV&8:[BF0P(
MP^5M]4-VYL2L# =D*@I<I#CL5_='.)I6[YC._%UKZ/OG+%,P*\3,RUCIEXS.
M;\8%.NSI< @Q=&NU.W0NC8YY#Q$'T_;,+D#I4FG*ZQC=:/SN8SL/M*WC>^O(
ME6;O"*A:VO5>D!:)1=80?:;@;9=$/T69MU=)UAE#H*<[C@+Q0PHED*[;+HR1
M06'B1>,]EL]>S5+>^WW!S\;TUN1T5QL;5\WX]/*,61/$R[4RB"M\_H'\Q^]V
M-*H-[D5JPH3QB\YPM31*QP[0@9"G,+9-![;5>/"K[T)H]T]"0_;Y1'8BY7]*
M?H[MHZB10ZO']1(F6)C5;S_@* 0A/FS/8<B6\5[7O@!\QAT@^9@W"6]V\Y_L
M+\*N4:%MS'% CPBLU2#W%&'PE@1#.H@#8FX39J;7-*'4!-$HX78\>R( HRY
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M.6)AEB#('1R "@?C?UIA@ZY3%68N8!3_U"(921OHZ#K'CB.^E6XH8_@$R7#
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M":WQ&53\3_0T_]7X.?4W4$L#!!0    ( .1%9U9HE;Y9OSL! 'ZI 0 4
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M5!RO*T3VBLV5X!_'.T2)#<5?;5D?7$N\]I<?3;^PL;TN+SPQR&R%4P ]2CS
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MP[_#9J9#\=]98/+H/;PQ'.VW#._Y? Z\V)NK[B@\<@J1[#R#?/D=,(VM::W
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M' @19-(<#E7N6;[@A9# MXK&*[[/?UQT,/2</,_XCT>L9&K.=FIDYB^G3^=
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MG!-"8:DCWN0<$+6). ><<M.(D^6=GCFW"TEGT>308-1'36*P-BI*T\+F+(]
MSQD#N33A(_72(G%VCG>C+3A T%S_Q\@0ZS2--LTJW*V]/:T)GSLJX=/1(C(
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MG-5QU0<& B)!2;1S;R0#$1R_Z*^T W&VLCA".IL(\WSAA[5V50:WNXJWOZ)
MI2<W",ETQM6,,1RHIHE^-Q.Q0R#+1.W :4QVC;)CV0+L^4N'=!8%#/UU3#&&
M$?7BW-D>B8QL>I=KT#G-Q,H8O%D)5 O7YM>:JVPNI!Z1*KHW$@<O65"$0Z+
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M(VC-,T5ZW&8]-EERHM<>O8!O8=>"[:LQ&=L (DWD_1ZO2P]7\C1EG:J@XRI
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MJ4PRF!R.T$"TQ..2HFN+.QM0N%WOK5?G[3PKV(T)<B5 9C1CA"TSMGW>K='
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M:>):-W^X?4L["[)&7,YUAV@WMS:F[E\>?'.;?'!0$/8RS'73D<)50;:?:V
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MET[3@1TA2D='H<W.NY*UJ+@G$_,J*=6(69Y".3B%3!5=V/!D!9A%;&MQZ.G
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ME5SI/RT XWB 43\!".7N63ML'\.ZPOS/OCT!X&6 J]<LD_Z;YD>&5\KW2D\
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MLQ$ 2Q6N]TLS$X;8#S%()BK A2S&L>UE.F$,;YIS*S#'H8#=3-;Y!?"=,L@
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MY5S:RK]KJ-O; R.#*DLH+UA,)7%@V;BK+?=XWXRMO!I>IDW<6"142W=4P !
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MA5UQUI-\&88P M%>$;G<3/4,I$[.=B9D_''Y_"D)"J\-QMWS7RGA*@4Q!??
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M?WQ*UB1XR2 V%[]UAF]]]8%A6H1]4UE/T06L)/B"PNMDD%2'MOO%EWQNG%<
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M]"W*#\5'LI);'K8",@KMI/56J)ZLW[?/FPV.+M_XNF[]8Q:3@R?(@?C)8IU
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MOIEB_-+8:=^_!\:-=@LNJ3D25LF#).]#IE]^9"FPQ4<)_EXFC>]^@IU1A:E
M#6BVSHOKECB#C8FAJA]"4;*K5S^&J;%MJ+F,3]]2LMY[$QLA]\GSV:2+<1 C
MSJ=]4 BEFA?^Q[$I_=9/%Y\.&W?P5YIE<GB@.$NQ8^1EE.W&CQ">I/M:P6FW
ME.ZI+-+8@$!J2IE6?'NQE'<-I?;^M9HY><T [>@VKKI.1#:6L,\H_*W6_7@
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MS.PTAY@LRSQNK1_720N)("])S^* <+>07A><4["F[ZL*F$NYG,^]P_J#83W
M/WJ;WTP3+;C;A&Z_ :B,78KG0-4TP)WPRNJ:)R-[X=%QO\W4&U.L-<.^ONC+
MP#OVH<+< -H38?3!G1]H"-!;'DTEOK\J#F7J#FD) G4K]:F?+2ZMB!K)N>AQ
MA-@)\GZ#/1VVC,"M&5FJA-*3!9OQB0NA5(GPPSX278$'I9@^-W/^Y97 0=P
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MSGZK?" PY1>8LT>,(A:9_LA3/%%F#%)]QC)),F*$UUX1JC@E%B,JNI=Z>"R
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MV];ML13:!':Q\P+3#\3=&M#?F=D)'$01DK)TCXRLLS ^;_Y>2V+F#]^7^QV
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M;_ZC+_[!/_@'_^ ?_(/_M2'\2%A$\I&PI) 8J]#=;U%)89'_Z;T[)0+8 N:
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MM(7:SE!12(_3T-IG_V):W 91V1@T'H([2BDRWQZ^:L>OSZ%*&0R>4(7V/6T
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M#[;T.U-LW>P[1N>8ALGJC_5!P7K3163_DI&N?58%V889MZZ2TKW/EU^AB%N
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M,EN$SM'+ $5 9_IKZTUA.Z?M>$FWHZ@ \9AXVWN)$:FW32:W@-1#D45-9J(
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M1'].&9Y1K%4!1N9_^?ODM\7#9 [?N83;T;+)E]RO%4MQ2=VZF+%@E+/Z N5
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MF!H;B*C*44:W;+C)4[DARZ B$T4XOK\HW_Q&SFP#RZ=$R9_B)S5)IXFM>M4
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M%;[\I223.#[$,3_VFCUKCW+8\FA^SQ9"=- :8?(>;AZD80W635I.P7^LZW1
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M9D=Z$CXRY=A80#1)8%;>$@?N!=W&/685CN1N#G>L0&)_)(;'W64$0#XN;PL
MHHW)(#DG@6 L]8 U!53]EXOGXEVK;A]7EK011-3S'\K*CPM-(XS9V$!^Q@S+
M&+X5<SF9(K=2^<1%A=KYP1LLW'=BORM"2616DNYTKT8#1ZT"$<WX)E2)(@LU
M^_W6;.W'7#0:S =-:;]-P"(LI%GMM]2=8'0$O0DHSXJN4K]?/=.RS32)HB["
M+3=#C!=+EDK,29SE[Y-#-1"-AKKB['L5@=KZ-*NDE84E=9[H@261@Y0CSD\
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MAM"A]2T-5"4+@K@*G)X69T_CVYB*K=8L$/AZ(UO0//33[7>7]43'%PSK9E=
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M[*_F00NVN.[*/0 _U:W(@'\>L/H%H7"MXNL=N9#A&=RBPG2:^\/[3^M6.ZZ
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M:M)8B_=%:7J]LJO7289YG[\YC3I5-[WU@>A\[C0"E .*48.,A>%T!A1YL%=
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MOK&M)ZSF8@,WC' )@WL,^&*+&C +QMEXP:R3]W>-01D,27[/?B$KY9"!GNC
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M-W%)CH_1KZ]%1)]KUK=VMK1"NL(*N6CROFUXW\ J;UEK7J^-GYK,:>/X:4,
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MV+-P++CDP\:ME,\/R3Q'NX3#U2 "@TDLAKH1#-:QKCCX66:N./.A.,-\2S>
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M<6>#,YT.^*3\F NAI@[-W!V1YCXM3IR92A\V:OA3F,%$5S9=,N-UV\>C>S>
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M@;$/F,O'E1"5X  X)3K2HG=@K(X*?&@$)5:;VJ_S%YTPU9W<KS"U013=  1
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MCNJ#=18FMH8MEYG\YXQ .>SQ%,P2XW[KX;[]81?RK:?2%FFX,K3.9%N*+Z5
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M6RG$9>)%#>+=5ZC#]-TG[8X//.K:16)/AWFG_GM,'.!//AXA"2-GCF8P\J.
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MMJDN$YU4;(CR:AI\W:0:XR"P.\ST%)UJ3)=Y=.DD6-\ZD>_.]ID\5E4;DE\
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M8(S_" 8P65VAL3C/B_Z&DD2RG$S:Y[3E^QW"YR_1@+$1Q$HFJ?L'2@&%!UU
MHQCO@OX&\2,>4%LKNB>!.?V#9(6FGHI2*C"D3$SZ73\_(A2RKOJ4&%0\XC<=
M07]B_<3ZB?43ZR?63ZP_P,IABVV(.8IH0Q,?4H&ZWRS<D,/?W[']1Q0H=>)?
M %!+ P04    " #D16=6J$B4IZ-? 0 FS0$ %    '9R;F$M,C R,C$R,S%?
M9S@N:G!G[+H'4)3/TC?ZP )+7D#).0F2<TZ*)!$!%9 LDG.&)2?)&004D9P$
MR4ERSI(1)+. Y(4ENN1O_9_SGO-^[WUOU4UU[ZWZ_KW5M3W/,SL]/=W3\^NM
MN?MYMPH0/5544030T-" !-0'N(,1W2I K2T 0$T-X    !O 0),$T%$2,:KQ
M--P:P$#):"C9(./SGV^ "0"(IG=I ##J&3ZJ+8-B@&;WK]_^37_3W_0W_4U_
MT]_TORAI6YNZ.;I8FS"\=#/W-'%Q0SW"3 #]A2GNH[!#20+&O^2VI,2_9)"H
M"  D)?U;_C>^P,[\,^;?^.)O^IO^IK_I;_J;_M<F 3X!00D^ 0E^809^?@D!
M 0DAX?_V&0J) -: *> &. (N*,D$8 !>HEKF@"=*=@'^ ),[&!ZSE9N;DP0O
MKX,KCXF9XUMS'E-'>UZHB1,O/P\?+R E"W4R,;4U=V-X:VYI[2#-=MC<SL9@
M;2;-IB.LQJ?F)&]N9:WL[6+^TOOY*U-O6U-Q,S99&0)<*:@$U-[)WMS-A %J
M;^?@*@&59OIK= F4_.<Q+Y.,E(N9A<2+)XK_[(%J23/]<RZ>GIX\GH(\CBZ6
MO/SBXN*\? *\ @+<J![<KEX.;B90;@=7YG\.\,3<U=3%VLG-VM&!X4_;Y*VC
MNYLTD[N[M9F$A8F%\%LS,V'NMR:"9MS\_&8FW"9F@OS<9H*"9J+"_&("%OQO
MF?ZIWLST7]J=W%WL_M)M9LIK;F=N;^[@YHI:#7Y>)M[_9W6BENA?2O_;Y4?9
MB.HC(>]B;N)F_@3%,G\<S<TGP,TO_.H_',TC*BPLQ?M?^DGQ_I>)_G^P6C)2
M9J82IG_FY.CR#_4OS9W_[WG;SEKFO\+K?UB*>O$/ :4"%7\X.#A2O/]9^_]V
M.7C_&7XHZ5_!BOHEP_\+]+>2OY7\K>1O)7\K^5O)WTK^_Z7DWX#7W &%<CU1
M</9N 9 'P)B86)@88"Q,+&PP&!N7& ^%,7!)(43XQ!2D5)04I!3DU'1LC-2T
MK+3D%$P\3*SL#SFY.*D8> 5Y.038.#@Y_@R"!L;&QL7!O8^'=Y^#AH*&X_\T
MW74 Q-CH$1BL(#0F )T8#42,=M<#T , &B;:7_0?-0(:.@@#$PN,C8.+A^I0
M1P2@HX% Z!@@3$P,#-1;/]1[ (,8DX21_Q'6/4T3,)/S?8&@Q!QLYL=5G:0O
M)A L@F]=@G%PR<@I**E8'["Q/^00$A81%1.7D'^BH*BDK/+TY2LM;9W7NGJF
M9N86EE;6-JYN[AZ>4"_OD'>A8>$1D5%)R>]34M,^?$S/S<LO*"PJ_E)275-;
M5]_PK;&IJ[NGMZ]_8'!H<FKZQ\SLS[EYV-KZQJ_-K>V=W:/CD].S\]_(B\L_
M=J$!(+3_H/_6+F*47>@8&" ,\!^[T- ]_W0@QL!DY,<B>:0)-G&^QR00A'W_
M<6).52<.L^ +!.E;EPE<,A8A&.O1']/^LNS_F&'!_Y<L^Y=A_[9K'L 'H:&<
M!R(&9(%+Q:BN(\M87]E5/QGJP_O&-V'+7KX?5@:3U,:"G=^]\ 899%T+T7?3
M7U*V'S_>N@-BQ\'Y$T;V=P !&-%_&^9XG=!X!ZR[YZPY1M_>0[2_.STD-C18
M-)S;_2BB8H]SP@;Z@GOE!*8<E8@"#JR^JF,C&U2/&L+*SD8(-FQ5A@%6M?(8
M0MS*,_ 44_TVD!O%_I\XS[QL1R]E.G7>H\C24TJU23G[FY(9K8"<.'H@KZ;"
M?> O?B1&*86+,+[G_X-*)J5,S3Q[6V"/Z/$O@JFE"-(!L2&"F*=7&7[LH.7B
M"IDCT3YI<&<FY82[.HG^4J]SZ<+7HY_Z',,<Z"7*+"E&HF@9,>?E#=U&3%,M
MNK!F:5>%Q(+JEL<3-3PS%*S*S%481/[OT;XHW-= ^XLUPPTF'=P?3,'/5,4=
M7Y'96AT0YP.F;%;BZ\PGI=/ OR;XW[*79:]Z;.(U_PS<;4Z(;3I]<]J N6P\
M O(QS?I"_ZIQK!7P_DRJJC =4'=*3: Z=.P_9T_;G];L,;)+3=DQ*CA+ZA&(
MRYZ+XA*1^<UDKV+IT,(OEM(;5H;PW&^*B:^(<#@(Y3#?6RYZCV/N<M[K7>:>
M;+D':SQK]=:)FR$A)R[?\F!#>^7)=@=4Z"X#R/@<7^7)<EY?V?,/MR,,<58\
M>3A,) (XG<S@S/ ZP/V]I@)P_S^SEM_CVX6G4P[N!(^UPF9F'J1;4^<RQ21?
MX*[Y@H_2NE:(SDH_<\I?V>EH*)KC>6(_XD!',V>,?ZP$!F=^M@*U_=O#H[-G
M2[+=$IB;-5_5-N9T^S>?(@=/ <*-)("N,%#(JIP3]KLW@/!:130R&^^;1<V\
M6=@!0\RK#2QJW2 :[ZWY'.2G(V,EI*FIW?P[@>45PX,KZ7P6] YW"]/?.@F2
M2=Z$A(!D$^=P&YFOE7&D@$V?/>2*;D4UU#S5H^4DC2"SG6D]U!2I=8CE:X](
MBVM1?Q":6[=KB&D96?X&.SETKS*,K4CLC5@V1/Y_#DL4%\_;>FO=[*=Z2'S^
M/#)MV[@:!J.=<,%Z&I(@H+3UNIWHVBH+<DTKT\X=LM*/GYCW. E#5M!^5%EZ
M()LP-PIV2WJM= >$?H)=+>D*I4XQU[?8:KUTWKSXH&"W9;-^&"=^.>LLAWE?
M\Q],ND'L"Q7T?7,'O".5$A^8IAI8_G0''"2GSOVZ)/S43G>V=_J/H#*27;T#
MXFW7#B,UH$_I"51M1D_R&WBAU$/'$Y\.WFVQ.D^;2N_]_"^6_.&6D[797A-$
M_9A:QO;*?):C%Q'O?,OG3X\SFZG%ERYUU%?'B$6C?2D+;<>LN$:N91P36$]$
MT)]C[>.?GMY':_S7AOC?8TVJY??SV5,Z+VM$M\3JR'$V,_"SDL5700MU1MGH
M49R\/6W,4[YLL(561_T/W>96.?EO!%18 .! A0%2!MAH&EAVKT09T2-3"-:M
MT \>VD5%9C=', ?.S7?;\C&L_AZCB=K_DSA@;0]]5>-A<;'FQ6,%*L7][DYO
MYI.QSVD+@C9H3H70%B<,^KO;*1KB?2'F:P^F[H":T 5E,HCD2(>2V2B\-"-%
MNK0(-1OVOYC0IT\&:[S%J[#3=$U?I[$AV%A"6"5=2@1[]%5<S^P8?2U;MSH.
MDKJ[27HLM+:B<L39;6+H#K!.51NZ)]9=!<IZ>IG; CZON@,25>506PR5-2?<
MT'B[5H)O04>R7:WD6C-NBNFW!V36EOJ#XTDL;PC'KY0 CS)(S+Q.MQ]YYRWM
MA-2;]++6LI(6;].=%:FJ$@S\@BQF#-*]6;H?/WP)[H D-EC[)<K;E\)[8^VV
M[--(X^Y)XI.RC2A(-KO@=2C@*4-W! EIH[\FK9PY';;=<X38D3"X0<0%1$1E
M" 7T5T#,!:^,YYD[9!&Q=X#MH)<KG875BX$>@NX4X. G16#+V5O.K)9Z\H"J
MI+Z?73O\@V,E3\ON@.I9_BL!I&AW)L.$>^F-CT+U] %CH[*I:$*D%KD#5'MH
M2_HH'3AUQ+^=H ,=\61SS6_N*:?45-6)S0C9X=^<66C> >A,)399M6.!;G"5
M,D:)S.R2!;61@NH/EY?-7Y@707 CQJ.QKB;9<'\!>9,\W7YK<T_\>]*U\C8/
M+3@ZY;8)%U>]TW]G1:S@MI!#NCX[[=S23.T739U>E-L?, 1RE4SD.*==C7S^
M)LY6!GCZDQXYQ*ZK$0@[$BYS_RCE5Q3CF/BV^[4HP8L^")SS59WF6A>1U;WS
M8L6HU:,U4;3L\U=_LV8_Y57VTT%*N)'T%>?N"]UM?R%/5EBMJD]HO/3Y2/,)
M=GN*E^4[U.$PV,:X#$U;B_V\69M,_N$1ABV#5R3%,N6T'8B!E[G(1(Y>!>EX
M'HU@BS@3^XH_VV10(S.PH!FJ29$9XE*#AEQKU6[C0>:MJ0/(T=%)]?"V>RV3
M%?!?O9UQ0^QOH1%BF&\MJ*NQ",&4FVU%2!,OKP!$37<#5;*DH7",+;.89"3(
MX;G/JJL<D>\S9%"!KS1BTFA/PTB==B-L1KA6P0)?,^[YII%8Q0=_L._S\5LJ
M&ZK>OE9K/^?SG[EQS)94_(8%T9:N%<5G.\:ZT&&E*>$LW)4'%45ZQE_)CH=)
MEN2J(Q89NWE6G?QZ?=>O^* ^"K-G],3EK?FO;6SQM3<9?>R2,5C:G+_16(**
M"@ __FS;F64&1&M<,WHM64/]L$ON6S0%DZQ/8%"\]TF9SWDB@C#2=Z9RQ*]4
M0&0F^7F0'I_?QSEY/T4%D]LIB<5E:J1[ 31 0:NJ;IJ5KTF_6(%(,>^W'&&4
MBA'8O%]>NPW'EQU1=,TI+:LU(^3#K7?U*F:$):V2*U>8!?X*']L $*=)SO36
M #NOQD<MWT,&'F(%^7<="R_/>#[\-40^31@CN\1&NU==$2/#M8V#2%X7;NU_
MMV%K=?WMC%.Y^][&KX]/+;\8Y#G?S/3ZI6'D^EAM@M"?X*/!$].!$^.8]ONU
M8^C;:50*TZ(5Q3;S?EUS@PY1+T3GM523.H*^Q05F$D!Y.R%11M1(:[JJ!\U%
MQ@9+RQ]Z!.85J$D5"%)8/RL/,A>ZQIL8/_5]-2[DIPY;B7"LXW[0=W PIM1L
M:QL)3U)A8'K D$><(@X<+;>8GIL@1D,J=OR9_'R>3-6)A%EAV/M8T_2BZ8R*
M@F)6-< Z1UU[L+XBVVRU]3%XM-=FX)C%I4WY'<!=GZK-A7OI<^E>WK72ZT^"
M=$:$R/^PASMRN^$P1,SW5%TD%:<\"PD06U1AR5A_T%)Z7A\F%O_NF17YK^9G
M:(' L1,_,GW[EJ&CQK_?V[7AM=MG[MFXB]" 9"I@&S6\E2R&+E1[S"!==9)7
M[Q%F4D\A+%C\1:^GR:O$3B[!BUD%V&%D)NT1)*C@R$:=)RN_XWOUH&^P0*AS
M)IKX+M ICL)F67-W (PMM,41IB:O=Z3PM6&,=D]/ ?B\]@2/2N0P(5CE1#+#
MV7"K-SZ,9-X75YT02KCLQ3AUJ+"N%\;+,I'TZWV #V8GJ/Q>8S;8T'_:']30
M9)5;/U.>0(.36Q?#^/LBG^!21\?SR*>[OAU_[6@VL5@M?X3W?41"\?OZX_!?
M%B#@R^%\"PA6U ,)NWP>#@F_]EO]],@93T"E1#CI^;[JO:L.Q;-^]31I"=Q+
M8Z7Q%N9B),=H]].IT[T[@+#RQ#[;:@9*^+I>SBZ^17W\J!?P_8QH7E.,7JV(
MTFN/=(_6WX'S,GYF5+6:R-?V2NQDS( TY=.I/VC[AK",VK]VA''*$NTDC&&6
MP9*'XU:!59:8C$#EW?PSX1/P_N\<:ZK9WB6;,=W)_3J\UZ<72PQ-#2J:%.I$
M&)SH:$!BUF/;/4D"F;&G57'#SVJ#1V<8GCCI]S _&1SL"@0VDN7(.+]?ZQ]=
M==P2_V"=*FILFG98M4]6*NJA'S;YH2K(L>$)9&BG]<43&R*-80_JBJW+)Y:$
M;!UIHIQ,3V@8W_@0420>1EW$PW2B;FF@>C,'Z_U&=,TS9P_->ICW*\<PG-\$
MX,?)O'5-#@G$@N@!EY8==P!E"^/ZWDKE#OE+_944KOJTJH@-)W%)IZ=5=(%;
MK?1$;;Q6*P2.<.ZZ&U[MCP[KO 2]^9I"=H^Z>?04),/!1<[&?- 0O0G'-G9K
M?R:D2>[*#EG5,-Z'92#J@<Y&L>*;^S'H@GM[QKJ^"@CA^!YZK,7MV073-#KS
MLD&:3G8:T:EBYO%TH,Y\78WNJ@-OG:+ ?3+VDQ'_&]'<8M;W@<[?B'0H=_G3
M!Y!>1R]5D.]GPQ]/"=M"N3I(#(QZJ11?G\II_4SMEQ:CU\Q*KATCMU6!J=Q2
ME)U]]1!M*@%Y3_D?""^%43=YF0>W*>7L-;4-(G3>"=T!(.CSJ<>3:;^=>,S>
MQZ=;0Y8]?K,=4] 6@R*/Z.'DJP$$>^3>9MTO6AMK/JY^T%O YRPE-4DS'\66
MBI/F,,;U'_<''UE4$'[$;VBR_]$=L6KXF%0A,5X!_VO'O7&SF$Q.T=ZFADYU
MT&X:WUZZ8K)GR5,X%X([>&FD,6[M=26C"IL8BWO%9QDVVV6BF6LMK!S$[Z??
M)N"I1 ]B<U\'O>?OSLTC$EO8F4+EX1]<59UX(U+1-)I?+#WM.((&63*#6_(,
M;@JDT/*6ZVI)5G9[J6U53!R^?CRW-!_X34DZ>CMEQ-4^=8V9LWT^V6*JS_7[
M>8NC\@\<^7T]!:D 3](ZA"U,]ETVTK%@U[L\VK34>-=CSY5K=F:/3V.QI*22
M > ?V,@8!_NM&M-:RQ*UR,SWO4M3<4BNQ6_0?/<&IA7_^!&%R8!,W0BT>WTL
MV)?ZRW#ATN+B+GFER%SVU!J)E^5X#:E!W+HX*6_\;3^B?W4L@L>7V9SL4YT@
MU4)L#LO'2>Y5#V8GV5#?*41%KRQ$2O!\88S>2C3]UW5%!/G^A#J^=4R2MA+E
M6[]''2!:-<!/>#4^UI_P:#.WR2/-5;H\>_4#W#&/N.4#I:0RJTJ_&%@,X_Q+
MBQ\J1P00.F;7S*ZW)?E$^&[/S !7:2SN7%@NLIK&7- %P_$Z>NJ?R&280VA
M/FNC"I6@0W&PFUV8@N(;\+.@N,S-5M[SAB#MPZXTT.% FC)TOY!)]I19CBYV
M+6 >TDE'_B/LLS,K_'05(KG/S_D5(P;VH9*2<H/'>:K,2PFN*F&\2W=O>A6?
MH;G2,T:L^TV*@Y(#A8[MJB,J/W8T573;T_W6JFEL;)^V,VE*VC:4$* DDB%]
MM!#43!,RV6@\/R0<=0=T5?7E:#)\TP)58DD \'@X9%46;R?=([7"IWC0T?:^
M"ZT$J=4Z(]"W:0ZFW]_0R49RKD'"?0.*I%?"#GW7<="A+"^2NM35A@(^#.R-
MD8;F^+(B6-K U35I79=NP3Y" L\1(>)<(=R;-PC7,7#<CY/#;K$#7YPKU?)0
M<R>S(,>BJ8*QZ[KHS3Z_8]*VW$"9\*/9/F-<7YD?Y&HSR\?Z,Q%J&WJ=+:'B
MP$9"R^KO<ENUFZ)K3#]H@H%"Z<YV#T1F=PZ7=]:TZH;39PWOF@=QFRU<0:^[
MD[2RR/"Z]T?[O'FB3E"]%!V6]RK$^V)E;2NZC0J:IEH7WY%)F_QL.J<12V6]
M)F[^(>-\1_FTPW/X.W,_KVQ(<8OY$40!M5U-CEB1WUJG#EABF6R!)/)E'&U*
M<XPW[B.^I8B -<5(Q!W03U7?4*9GK$[ZJ[F;J#:6<M8MZCK,G:+K,OT2LMKV
MV71-/5"&-J1'1*0IG^-!CTX"5[&(.D?%4$?<_3>H)/E]GBRQ CJE'6*(2M?L
MIE._\SU3=P1*O:($0*"0D)E Z:R^6S:$<8P,=G<9LIQ D19/,]&W@A4\S^3T
MG?0;"^@XLY%F=1J%@;]>TT*"'1RDP%C9W.;-9NE^JHZ?!4OBGB^+!/X$@=II
M1WCGP<^K*Y$$?K8FU@1EK2TSM\_X%(F9;W9C,&D("QO;@_6^M]'>I-?!WR[)
MJYER+QZ%C#?U%+C",S3 >="%-52E*(7I?&YH<U/0MO!M3K?H(T=<GB<#3\ \
M4^6UY)4"$J]'(EBWM7<SF2NVCC /-Y?_#O#2#;Q6KF"XR435>==R1Q;-Y=!&
MV3J]_F%7TK'1&E5^%\/.JY\_H5+FK:4%-WG^%% ?%40&W0/$^6?[@C&,'0S$
M?!]SW"N[53@-%I@FQNQ>9G"@]%AO&]>4+SFLL6[$:N2<75?K._&A757'^J[<
MM6VD^CQ]!UMWUORQT>(3*HM0KGD&!YIBL$>O:>A6<(\..&\WS8CM)M8=>D:)
M/VF].\X5/\AY/Y+)7Q[PP]2X^7A-#&LGMI;H*ZC8/F]*Z6WMDB>?G_K^Y$6C
M+..%RI@+.VBRA?/J,9*YU_N[A)FZ7^'BHE@</1Q;BTQ1^KY #:#^*$/GBT[_
M'5!K^<ZM HP\5&M$+.7KN8G6M]G*.XAP/(U3_ 4*77<$?1,^.]7__G#+GL2>
M^OQTS%<#@RJUP#)OIV:7JN"[1WWJMI%N@1T'^X'MP*&L#2_:@J&0AOZ>: 3D
M7J=-$/4VG8+C9$.;%-11YTBIZ],P-[IHYJ9XWN>R]:NIW,Q7A%L)/P\;9EJ8
M86GQ_G3;$A)0GS5(,+?1YD-:L^F-:I4-\;?.3)7+S?Z'PYDA07+T"DKKO/C(
M,9AV0<4PZ70F?=*,>Y,*(\>F,(9*(*30"USG)(MFYT]-&_"Z$7'?N^=WPN-2
MUM$O-3C451?,>'$[&8F9&6>D2VJVL!R$JG9XYYZ#V\/:YKY _2IV^;S4ON=*
MW_7CEL3Z./L#S+(N<*%YM]\6 K9?:(#+D;/KHB&^.-XS$G6G:>2[:#ZJ8M>#
M]YB9G0>T9'I"1EQ*KS2@#];56Z",TV4'N4'+RYS#[GB"H:POV4=B,O S=.*0
M5%=JXP%6T8.W#YCZF98,'%/A+HD&9*R&-=?23MXN147"/_PG;UD0'JWF^0^"
M_(IV];J>/4LCXZE>H_TV/]I"_\D!ZSF?MR=P($.)+%J3U[>Y94=^I.Z&34_-
M'\\+!9.:@PB?YMZ>H G^;G^I-^^(2HH$C[LUFGWVHMF_/C,EUP1^8_Y^HQBE
M*B)RT@%BEK;5Z910N&GOB)5].M.-EY<OY,+2JJE+;9.XGX_OHS-Z!]3$OSM5
M)T7NWLH26Q_9$.OI>DTHB#QU7"Y-:J4.AHK?1]MO<H0+K]+*O]17":C=)_YD
MU=A4KTD^G>+!X)-H6-2C>RVV0N"NXJN[J9ZC0N(%M\.KTG;''HY7Y'"%IQ]!
MYBT[_.E1)0&][KA0J9J "H_>O%EMQ),D]$_OX9HQL46)>\O-AO)^_?N^[;;=
ME>-,S,D3C^$W0#;N'8!5A/2"W0'8T$\]=/CAKU-I99A9ST9SB;YO1TS:RWVC
M $F'/1<77LLB:6/>OA5'5A4BPR15ZR>YR9;%N<OSU/GS5/ DX/BOMIP/C4JO
M.!<>>:W&D^@MR].<GQA^=>GEP%*YWQ_\%8)!Y/2HG'FM/C3?>J76([[0^E(K
MI>Q=TL_PVN ED@<$# 3O06#F"IIQ<#-4<JT]S)_9*OVB<JIBK7*R[-52OSLN
MB,6AVEQ+\Y,LE^54<3GU:FA\UXZ4EY]HT-N9HFF&>FLR0U7+- SSX$0Z/A=/
M4RZ</J^M+!-U BOO!]'%O;G;,U1VGD1\'^W@2<0/[@<U6U'N!DA<M)]KW &)
M)WIW0*7C[8^GP*5D;Z8(*J4'G?YH/>+)H\UP4([DTU-1WB\6EV[<%ASQ^E$$
MEUSU&7G!R;Y_EFV>H)A4]]5'A0T4Q.APF[*A VOC\9]:F9/8J.8.7E&S2<3J
M^\G=73\1%]I2D_RSJJ+@)<PS*#<.,[K+^YG%4LIZ(K>6&>;S1\M8ZP,'5FB^
M[D?4W:CB8!]>+J4D-'A>;QXLQL@S^@K=+UQS.JZN0^'J)91,-8CZ]5YBCMB)
MT3QWWDHDS@UG\]%-45!JWX(.,I(@9.'GX6NZ"]5 8X?5+Z-K'H1\ZC0Z@==*
M1UN=K99=L_.>8=>\OVR>96VGU7O;:0_%83,DX5:]'.B;.MV1HU?^B>Q6^.%+
MSQ996]I>;^W<<?*1\84^-HY)[3'%&X17.:?:3<XU6O&"#3G$S]F<-"KGP2Y#
MF?C;#BXK' M97BGGQ,,XR7,#G5:DUYHJV+=K%OK*(;!%[AYRU5]K,Z"F(;36
MD<Q7I;'NB/2=Y_EYDUL:?S>/AU>P\C2);(3)0D@OX&,?#Q=?I1Y1L3>G*LNP
M6_#_X6S7]OJWI$$E/8(*+N5Z1*^ @(3"W6_4>!RY'+:4341PD\AX8G97!-D7
MWDEM?:N@O"FX!L&6\+KFC1JS=\B\S3:1>D_KG;%3%:R6PK3D*.F,C5IF\ZYE
M)[_6':+ D5QXCX1?9F[B:Z]$5'0-%;\2R ,Z8,$9EHOCX-$5#!D6JRP"]Y'G
M5T:U;=_(M8?QC4UC*=,(DC^/MCAQ+LGPVJ:V<=]\Y#W;4S:/POL&+PI]T.&.
MM<D_BD/9YS.;ZO_=&RN^ AEM&&\X:><NME87FZ<Z;/:!D<=%[HV3[9R,E)[^
M:_^QIE\%L2W:,^-E)0KX[,3$"M]?HRD!/KC AJREF@4OQ!?W"*O*U='9E2"N
M2.I8P2XGGZ/RL3Z00(BE;O1CQ5<:.0P;BY2HF_F<LV C\IMLW&N?US36DV>U
MB-JPB4168D/6/&+2\=UEODNQF]];<W.3A$?!-%$G 3AS[5V.\U'2C(.JU-')
MUM2B1YUB-[,RWU^R_5 #?,9Z>&.,Z)"VQ?.ZMO5-L3VSSI3)^YI]5Z]H7!MG
M:>X #OB^0^AYEJ-'U2#)&,D0\WM@@,(2 UU1T6NSS>Q(*_Z:FWZ^BYO-\E/1
MCJ*8 \Z&E\;U,>@L\:,LL;&F!@;Y[$R3?<QL4VB/QTPEHY=%2G )^ZZ*-.>@
MHZSU"J"WJSC/6++41TUO$_S#M[WB^]#/.R!P5O9*&YJT._9HPE?6[GN"#8F*
M]""8NL?G<<6WX7MG6N7A,'"7+*[>M<ADQ5DL2;]6^P_N%P>Z%6]TZR,!<RU\
M;(W[<1E;0FCK30]*B_;:ZV++O^0]K=$UW&VS>\&1LHCKWMD)%M\SUD&&]WBK
MA[KIUMG[GTMRLON?QB<GS\G15,F$I%^\'5.J'I>UW19:XL%HJ U_^?*^9@P'
M5K0'<'I18CQOW//2AOY^6:WDH(4:[[,P)M-HC-3D352=3#8O1WGZ6PAMEQXQ
M+8-^Y9FX84MGM.]7M/_EU_HL]6_36Y#1EVQDB.J13#16:8Z1DI>YV) JY>$B
M\33Q(IV"[[#?^AT0K)-Y+_GQU#5><?X(6A1>2E4('.THU)3]?:/X5IL?9\"Y
M9IIFD*]*D2'+Q'P(QE%^Q"NPY(^(L6*\K-\*@$L[#O';FQ)>8BQ2AS,@;QPB
MT'K2'T AQ8DXT8Q6G\UO\ADTN?>5;-Q1$H>#4 7OASKE&.EJ.\X=L+''V[YW
MHGD'S*<<!!#%=W,3'@F/18@TF34D*3)%PYW\<E5(53I>(Z"83>LTQU:@C,J;
M8E],+X^$,:RJMS%>Z6L__D#R&O^4%616O[=.Z#6)KPZ+)U5J6L2B2M&[A/<N
MZ-\6AW WXF[V?JU$&_$C3=;4R-BE(+#^*7>Q<I!?(34[/!>*D'^(.\<FJ3QT
M*VT[?XNS<P3]=.Y:.RG\8G+!H-_=9FZ7:&@]OA!ZNA8H41$><%](-C*U8<J*
M;[GSG/Q)JF2/@N,'$NSYD?ZA ([O1\9]8X1(I;X)I-YE_ZNF:9;CX$_*N6;?
ML]S,\\%2<4M[??Z NCNJW+NL>"<L7W?P0E^;HL/:A#4EO$H#>0= M;( 5"AV
M#=T4N\>3*&=:9!4LU@TU;HB,+>G?RK([(M&R(7E2*FM^]%T20ND5$15YU;7R
M#3X;J:836DI<?J%>P?ZH + ]9.C\RN+5/Z_W0ZJ]''2 *AULAV2M*HCKOQPE
MNOF]4)E5F23#GA=STB?A&&0N%J..J@2Q(16,9Z3\$/HO$>\NZ9)1M3Y>80/_
M_&)!#+I9,CTG)4;!0L:]C*U6P$\ZUS;=,>+4QT_G27/<\1#,4TG(,N1GR"(1
ME.&8P+E-!+FPNH)N7)_UQ5#=R__#"3<7,XE4P"')XQ!XQI5.XC7:$=876%98
MILRW=$H,;ZTFH_E>#B+\0G'7V:KC]1$3_[%,[$IDZ#JMZ>LCO0!KI3<D.E&N
MB4*3-41C-ZLB_/TN2N.!ZD=C:UEA_BQ0=:7;3E'B);VEQB2\;X^5(UZ6/^)X
MQ%P%-[I!>-XJ;X4%[/4&?*Q@O"E$P?@E<->E8EZ.U0R5V:'WFX2YA:^/IG.D
M0CM6*XJ\SPY#VH^5I 3O "/.ZQ' 0U246$]OV-5I@3$4/TE$L$YN4,I')][(
M?]H(O>Z3&9&M:'16.V8)VAT0WY0UV>I_/(.W1PGG)5)Q=*96X""1,S,)%I".
MA?HWKT,"VTB3#,6LJ+2+N)[D1YL7](N#*?K3.]#]8[RR"0\[VBFN68^P$'-6
MLX*=_D3?:EJBAQ/?NS-C?.G/%B]OUID1@H-5/[V8<62LK@FT4"FT+VG+BMP&
MOS2F@LJ_F.21M8(S777.3.W,O[K\&F 9K 'JBP/<.[@ <9.83 (/^MK#",<Z
M6;J=-M(X>=J4VH<\WQ$GRLJ+_M&!T@++M6C;:5EUD,"R"GR^[J]&2AE>"+UL
M^<-P=\?)9@++M8IP-UYTZV6>-O*\9]-1$2*//@H,O49O7 ^5/M*T"L"ZQLNS
MXMLI@[5*7"3Q51L:+G E#?W\U4"D/+B/#:ISE:W%BC<ON@:E#G5A!,^JI\[9
MKVDF1-$P@*1.I;W',?<.Y^]U4@6$GL)M+%L#X,3,CTQIE&?17BC&U/#<E."\
MC&E@/NHW7SVDM,X40[3HG2<T$.L.?,^#*Q,'O0S)()'X/0*%=!B'W-X_2@LN
M=V^_KS<<(&C8VN+L=4CRI*3$]9A(A;4YPTFL/'P].Q[6T&DHV95)*K"@:V0H
M1:CZJR6O24EMR<L"N(Q!E;T2CD2W$\MHX[SIDYS1(X83]<T[E:79LH<U[(XE
M29S9"*7>,6SDK:MMSHJ$,<>AB*?FA4OB8EQ.U>V@6#ED5:FK'7<$,3FF/U,;
M+:UW]0K"++S/R=&3,Z>EP=>Q:I;9* TEW;@#**_Y(5UCT62>;20>U7%6D[=S
M1%FG7J"$5P$U*:/2A!(:X!_+7$=QX:N?:7;]6=KT55T6B-[4#*PL:=$D7S?/
M?N2%JZUJ?SL>B?M6FN%5.,_=;L0RMF.P G^8;>O//.XKN68H,Z,?C>>C+<K?
M4] V:L#IR."QCG'>,:97M-H>00^64BA:L%I^B+#XF&M(^CJVLTZ>.L-4QB5P
M+TM[U?MW-B3;'4)J=:D4&AY19UM7/?7LH>A',8; #E)J[P/QJ[R,V;3AJQ=(
M$LD\$MT]EVP[KT%[NDEIKP016?SIK%KC4&%CHFN12E39;@-N"G_^[9Z*/< U
M0M:5\Q[2VB";R%;G5=2=%1& 9SIN+P2A@?+TS:^Q$,L4VB4Y"OWVM/.*\O]X
MC5J J4R:V?UK3=B"M.TSDFC5@>N!EHV?/P=IXKM*D?V]VC(XB,];$>Y6Y:RU
M-7.;K-6ERIY-V1UOP=JTEUJMZ 0<L]TS?$B?P=MAY5=Z7KRM4BW.(<F)45D:
M4W;N/CA<[OJ2/GLJSIOZBSW5BDB&F%)T0FSP+CMH71WLJSPA)7LTI754<%-P
MVN2W-+(QWG_?RL)8?- @&.8:UKEQ*WQ:T-"G3CB"6$0NZ_L])F WH/:KP*UM
M#NH8*B5"DW(_-,)#%#V>%*:?EWP])4S ,;3;)>X8K*?N$$\2FA#:11P4-!7'
M.7\KM.WMD(7 ,ZZ:W+>WXS9Y71!'_9I,2/M>'@FI'$AJ:]<*R#H/1B@TO,N>
M_96*8/T^J8#Y(5*MYQ,AGOU28$O<ZZCHUT>_@]H8?,E_N,=:$*A(26]QUPU8
M>8S0!"5\,<R/HTS.2%R8:2DZ]T5JPN)IK+PS*]8^63NV1"?:DW[[N*9P 2)C
MQ6:Y_KD7QSG5Q@*55$)X[O]:(R!_$CHYQ/= *W&8J,_-H?4Y(?_I?> P4-L(
M*_[1#YX6$%GQP"PGP<C,EYJ1A)(#P'Z5?65;_*QPS[BV*$C(_K$/7U/!:8*R
MJ:NM3;,+#OBP^C=I]!7['3 H.R.[SQYP^D)KC,0V"^2+Y\.3%9"[(]HPL-(:
MS"WNL/$RTU,2'6TK05\(;1PINMX??&U;JE PI^9IXB>^@"^*>'>BGFUN87!U
M;\15MN[M0Z1)H;+2]Z8>&T@VWTC6!F?'M6XYTO(%\K-YR;7,5+F0#R,+/F,B
M*>ZSBF&.4CY0J+3W5M3OP_F*6Q6+3W> 27'[Z9-3M E?M%0Q&;1M076F_ONV
M;J,'/[70-U^HL&5_;=4_3T<0?O0]GUE_-=U%@C_C,?PK21JO*?D,1/IIU9Y<
MXXA\/X N.2_#:$G/\*MJAJ.L3<+[L2LYTFO;@5MJ:$-7&T;ZB3PR>?5UA85M
M[(B[JU72B ,?5C=-R$$,V0##,51* SSMCXX,S_-5G+2<%L)H5B[[1:S,DXLM
M;RJVF@!ESBDO:90-M^Q,AKJHCH5'VM)]\A1/U:K'?#Q<]P@3PNY4>KSJO9Z1
M6?V/>S,7O\]K/NIT&]&^"VD\^.7D\X8!? <\)CTEM;2YI9MP/XT4AC-UOWRM
MPE\&KWY&E/EMD5 P2(XFOF/E@LF?^@XHA]P!>48M=\!Y-?,ML31@F54_X'P'
M !6>594UD_NF-5/<##5U$6_%N->)<_&W0BE R5IU 1"KILLGZ>>))E^^LGR8
M.9][@*UNX "F[,B&T#>GY-S$I"1_F60V\L,/I!__P3LG>:O '7#;GGP'*,PV
MR 3E#>;< :8RR6_GC<;;340&WG1(!AX?-5!2[LS$LLE-G&*;13^>M',;^&4_
MR?JY^C'-Z2 NEAK@6W.E*-'>KPH4L7)SA_C0\\<?,[7%(].8>A%%O<^N07E+
MO&MOW\B^U*.*?^<K6KH2#=?OOM0Z^PG@17]BWTA F]HT9XN:;*YM:*])G;E<
MYOQD_3Z_\GO0I(+THY>=='V!,@XWR=EQN[-]'B<$$T.I$>O3Q&+"O7,J:_1S
M"VNUU4NOZY9BHL;#Q%^U-+ 0#?WL< X5VP(SYXSX.>=#7>51]?OGFY \ZTO+
MK(:1*](2^4W[45%[D-A@GY^:?DM5[;1];%N.+<$TOLO;3+[= % O 'V?5>?X
M+K38JE;-NJB??9"D/&!Y67W'J!<V8H ,Z;HTJK2_';G)L28=?]=VR"41!A*C
M7+W4DC1&1RKV.0O'A];J6RNI,$[E*M)'Z"T#'(%Y@!, ER,]PS-NL$[3_E1_
MDTL>[5FXJAB@ASR$B<;/KL[&N)?*WM])LTLJ;O@6A?F2ZX5B/PT_$*??GE-1
MP\GV"E$17C<<FJ4W[C:B:$ZAR[._GA)XBADDA+:Q0EXKWL;GRS#9H@+35TU-
M7XJ=)DMF)QF\Y_N5+S]VA:.24@I=(D/G'J+A_%T=0OW=5+<_]^3AIH2/@/ZP
M38D!C\K/W?UO\RJ48\_PG<>F1<X1\_KY9)7]^/RQ7VAL2%]Y V*D'XN1JMWI
MO>.-/ZYE"U9&)53=S6F^RI)AC(.'B7_N!=2J]W:6!%@.6N=TF$;I4B35GV^[
MUOCSF=E5=1PLAPB?[9;DALJ1OGH#\ '%\#+[_;+)Y5%L..Q1:!P+;NDI*.C%
M.)C[2.8EI"O@?B7E:+)+RU5?]^5L@O^@TBVK#!OM]57 #>;>MF2SJL^5N+UC
MV5IC_<>GJO@#M"POITFEB/=M4A-A(Y#N6\]SPMBBG4S_%=%][2^0CPUB2[7X
MZVR49T)H)W< W$7Q$#OF6.8G:OOX<^8@@]CCS\4K7PAN6E/IQ3N8R$ZV^N@@
M9D(K:M4JK)H\"L>#F43K(_GEO->=Q$;!ZD^3UA]-\IR:3?+4ECZLG=92J$Z:
MHR+5NLIFI):CH%B/T0 GW YE':L*\UX1J-X!N0SEAVO&/3Z\8>FDF47%NB/>
M::)O%X9#@ZN#8WH;5]<=^/OU=H3*R)^.V^O-RD]QG2YXNC(K6#I4YO$#9(QR
ME!T@F:Z"]BDN8?T YE?5#:WAXL<'3+KDLHH8&N"A%5(93E_1H]_A15=L8<+8
M9\?@Q  6_B<:P3(GG%7.,3'$%^X5KV\^"7U^J8)\AE6%7XE7NL/#;?J>Z FK
M!BADG$R'>9KF=_GY6,?MO:ER[75U1%NLK<!Q=6=13XPL46/9/("<ZFIC<0P.
MH!$.G[7C,0^DA+,J=YS@/X--*F $NM:I:W96E%S?6Z>&T$&-:'U4@G?Q=#]/
MD,&U#.#V^3#=, &(=VLIU%%^]KNEX43MC7+_;YDYFV3[2P<PJ<-0WY1:K:JA
MQ RU*A2I_":&B7><$!-P72&18O%U1OQ^-<Z<^#9SDV]<TDV7.*3<+U(#4B5\
M(MK-&T65U6FHI(G8BJK53ZU+<A31]R=YS=(W.03!I\ \C$,#S^Y3Y91822@V
M4O6766OK1?$J-#>HR%U34 ''G 'S/MWIA66FA=OS=*7<O;]Z/+8=6KZ])W_3
MR*H[%O T_CP.F;I,.T[>U23T2UCZA=1B$YU)@SB&#SE#?+:CIE%=(5*]NTFH
MS2(^V]J#Q%(2;I<7L;6;_9+7EQ[V6?V%1%P>;.G! 3+EP:X/Q<;[%(!W5$<*
MX-^) B[6^V31\R9NT7[N:I\W2STJ5'1T)P&/,(EACM\!LWQ8LDN.>O [P'(E
MLAI:T^4"]='\(-*0WQUAI#CX+3RWZHS#J6C!^L!VKB!*' :UC#6+4N#8WDMY
M V4(F=9^_FGU$-^J(?=$";&9;.*679PYT\>> 9IVT,(*E'F,=%^[$>R@)Q;6
M'XND(IW)\SO)(XMD25_VN["8W\#/]+?;\-C3]+5"1A=>*Q^1AM[&%BWI+NCI
M4YN+2CX*^-"P9! 4NUQ4YA== D59OC2T:*N'E5;\/ ^/>RG#I9)>&V.*5PIE
MN^+R,H%\=Y/:M$A'!'-FG^CKH#Z/X'8>)PEO7."$-\X?:#V:[?9[@#KO8A97
M=AYN]N.Z3#W9;NZZ;!C*)T1*[XW=DM^.'R$%NQ.ACGT2AAM'.Q=1./#'%R79
M=T"IFTN[9Z'K5(QS\AD-7[\CAM-"7Z("U3OEB<<EQ10 VCB:KG?6NQ;Q,K4M
M6SKZR3.<@'943BJ[J!1"VTK-9*N\R?:G0Q8I3>Z7NR%)2=@MFIDWTPZ_,+H
M^-&9ZE@M.K#^'GOC5?_6+U9T[!/E5#/6H!''WRR1_71O+<,P?%97B?S\FZ9.
MAPD>3.M;:VN?:^]-<EJE"M$'!W)(J\M/NG][HC?ZT;)8L97D8(D5A'AC!>H/
MARO!2A<6;*7I'_\H^M:8PO3(]5=7HP5@5BI^N&,P!G=D%Y6Y'TZ3:UCO7TC\
MYXY;V\XR,6(YGN^3,N(\Q81='&)K3O-,EE3SQ>XMU7C=>60=G/SY]#S1$\7S
MB0?LD+\.\)T=.<H50MF-5.C+VX[Z@$M&SHYV6U'3-5G"'%GVVO=!VZHQ=P"C
M\?,%_4>6MJ1E&?R=CKC8:U$LN(G%%+C93@ (P!W[T<*?;7O<_Z Y9Z<I(_'A
MZ^7C2?$HT#1ZQZH&.,SZ#JB]C<Z'RLSTV8-?^;T=_<%@M?&S2B@JR,788U5
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MS<AR$7=G$N>"E:DG,5R#>;@Z!2V$3N+@O*)RCR0 $ZFWI2$Z*T,UL=EBL>C
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MX+?@M7I&<Q1?*:P.V9Y?"RJS%I&(T SD@2<90)!$PH0?_X"M9*\FD9!"Z^,
M_\E1L4\G&NR@D0)DT!V ZPC3";&_UBI:7%P:LZM4P7\N->#!(,: 4!XJ%^ <
M:..^5D6ZK\.IE"9\A0/LU[ 2=7E_A;&["(B"?^X;,S-8YO1+Q\]0Q246[A%A
MN]O+S%PR9BBYHP_E24/?V(2&!U]S%QA$Q_)VZRF\WQM(7>YB_^G/D8W:Z B(
MRO2I8\BE>7T=?NJ)X#"7TQ"V66Q&RH"TX"S=V<Y]33EZVK8ZV<[#>=57TW6V
M#POK;4O#V0.Q4G$BS<W8@KWH(YBCSBKH?!]/_0_VWCNJR6[;%WXHTB%*[Z"
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MKOMV+43^1-%XU/FN[\F4"BSPUA>8+#9"&^<35J2DOC!9>N!RT?ZAV)1Y^J3
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MX_?JX5&0[<.WF^+DXY_<B=;&BI?EK;'>'OW8L6?_T/?)QW*2L##W.T$ZXE#
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M /O]"@9E"E'1-M31FR;6-3YLI$,@PSBRUY^#1V9&5[.*C59)*%KXO93<I8Q
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M>;+2!J&;A:9K1^CZ"[A8T?3+9A!>$0$%*V4=RU0!GM^K5)1L:!Z7EC3#3B)
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M_E3_1VGYHBPNX<AQ:TV\.'(F>WGO<HACYGV$B+ZP!VFSN.3'XA M^QXL9;Q
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MM?C"QAJ'Z8%'D=ILX:A9Z!9O9=%D[>QO+.[-!2TM>IBO;D&[!VH>UPAP/;;
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MS7!VZE,:Q02ITY?EM3O9V@U6'W6SR-HM4G*I;=B/^C#^S204B5B=Z.EC=2J
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MI;?!7)1U/J:E_@B)??*XKSU7:L!^'K-Y)?F.2T^"HFZH3SA\2[Q;B0=R4M3
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M&RN-\XJP/9ONMTA@5JMCC"#BIC2FCWHF*[8MHG+@2.[XZ-$$'_>T.MGM2'@
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M:YN>;5=H+C9"LVEU:[F3GN#L35QSXNSH+8?9GIZ8Z3G)S&<%[[136Y!#)Q'
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M:L-'88C;SQ[-0(A)C\O Y58N@V_'X/B2:J>@-J"U%SEPP_Z6"B0\5Y/).-A
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MXP$%JSZ88_JN8'$BTW<7JJTKM&.BVTP6]X OI*P$BI:A0=2& ""2J5SB^(Z
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M$!3=*RFJ:@<"9H9).S['"8=H+D9$?G.=%YU]=%;$EFD5*_1JZKE=T/I"]U>
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MOL(_7_]EFP>CIHT5L<2I12M]B1N$\D0(3'EV8'L/5$T= ,Z0:1$VGFC(N$M
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MU_DQR4B>(7B:O<BRX6;:5#?L&>C$8 ]MW[O+9(0Q1TP(7MB)"^=E18$QOGC
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MJ@*ZD9@*]9C8.0_""5P1 R[].)\O=C#BE2/GOC807?X&G8,<0^*X<*VQ'=W
M3*45]HXFY.N;1"&XQ#3]AW&BC50;,J1RJ9ZM03'29B:E5D6V^'$SUB?%D+?9
MI&"5';( /B*X3QT!3H5NG#=9H<#!7WQ1G>CC[0:#HK4DN*R93M<]KUXV^^KG
M];&P!?;K,L["R\+&1V)^$H(Q$]%8)Z&GNF'HPJ*K[T(*=7=F?:"\"=//6;.,
M'+?TEN3&9'0$PPMC2#Z]0Y"%]A"U^W<(T6;.N4MT-9A5%UJ2).XIZRL1Y)CE
M?;3K]((HCS"XG9H(MHT,C EL^6$K9(9N>CM2!-(E(-^ 2%[IS >)0TA,/X*N
M7VTHPF=Y-U:D)4?%N.&*S5LBY&8V%76)/+%L(=7=^3EUI5%5N$-"P])UMC'N
M,<54=>O3P)%<\[I\\-BTN]XQ,.R.8?Q'%&Y/CF3NK$]6IV;YG)*ME\"FC\""
M'G]R[4VEL!AZP&$/%;LRMM3_5MY1A/DP>HINQ\F(9\T(.%^HO+,C"<)3E0?A
M)_OP]MV-E/MW[CT:'1+?\]K@NT530LI9['/R%(PELS3!YJ96WN,N /SW>4?J
M\LVLPU=7W=]WR4]W3J!3(W51++,\X<D(@2>-6,[34R5C8D2X[I0=E3V%S\8#
M(G0V6+\/.LN$G]*A]>9HX;U1(RO%\MB3-UE.P]YI,9QAUM81O <.J X=F2KJ
MV3WH-,R-M4-QL9QCY<DJACB[*>A%",<SZN^!$./+2,W!26[NBO=&LK-D1;A;
M9 P&/: W%N@2QT'5J]@D5N;M4S,N+!(28:]16?JT318[-F>I^8U2&MT.>OA'
M\. FI%=\*-BJ+M^Z7_-DL.80'AINU,<-+MYZC"31(_LW^K=U";.UB9".E6K8
MBBHR5=*'\F770;2R-+MO8QKQ5+Y=?@1J%&7[!MU::"<(NV$77DJP-0@?,W5+
M77/LX<#)V'H\3Z&-[;!0<?@RA9,4TKX]UL75FK((2:4ERY2"YJO:9DYKSX N
MYKLWQ@-HV4_-7= A@+1?OV-@&](/ ^31U7'6'TNLY[JD==XA+'D3I681)G>[
M3#(O36K[(OEV]#$=1#&:U!W+K#;[>)=8WL?EG-U,/_KT>;#K*1"@];$7M(Z(
M*-;7:W#E)W2X8OIZV-L'X[@X1G9U8-+%M;^<O1.%Z@R_WNIHK;W!+81JFJN9
MH+O]^^+"RD>=F0Z2 F/LS\"K0^ -V0]S\CW2WPK&="$4/#7U$U,#RK SX:<Y
MT-CSA3.4F$='&?K[\(T<.,VHVO#E"^-4?H#N!=U,F7GC-+>PA$&JO'2E5"L[
M0Q"QZ!0C,WMW>@LA2\ W90Y$NHCES]"B:_2B%+#:I*Z"?\F^REG&G%TQONSM
MO*5^33ZQ4T^9DRR7(9G.'F%--$]"@=5.OM@TSY-%:2+YNNE'\2C[_6_+;4OQ
M/PKS\=6GNV=.=VJ2A//4U-8,Y?7']+)1G7RI[:YD0J1W0-1R^*KE!N_'\T<J
MK$U,]AB74V:378XVD>ESX1?D74X5-^Q'WB0_!*IS_?-F!_"A->U,8)DL<1!3
MPJ4:^?(SY;9P9*/%AOXM9B$3\LT*BB3'S-T&[^G'LH[F]C01B+"GRG-B3LHW
MNV]['Y^.!_JAN/C"Z^[P-MC ]DAR<RCBGDCFS2T*Z;+XZW]!I-%P>L*(7N6@
MY)R8(''T/I&UWJ.0]^.9K;CN0NZJ(+0&]:DZ6MY/AXQ'<)$H%.GCMD)FH$7:
MJC&V)MZBG5K>&'DN>Z?S4G^:[DT1M>]M9I\LR+744O&.P>Z5PXM72V*3S#:L
M)5V=A&X1]I62?&WH9,/+T<[]_E^W^!XA9/XU<3$W)\?J:BA.>X^ 8/J\^(4E
M:X:V<DPOK19.E_,Y)88W>5Y+SL:%EP*$7,XU4=[#)L-R;38TX_5;AU;6?>=3
M3HJS,6O>UIE9[VGQJ=6#+$IF@H(6650^M/1H?OH"*JQL/]12CQL?"ZRPPB7]
M'9WXZNXX+H?YG1-F W<K'IO9ET$<6&=;[P2V'BG#:WD+C''I^L@*\8'&Z"98
M(1NE7-NK(:M,M3CYW]1Z3M)B K%3FL&JXD<_!$@-%,X'2L1/KEZP#"W,T5W*
MY:L32:HIXP'P^6?\H$0;S\WT*[5:VQ5;'7Z86)@I;-:C$DODS<N-Y\+?* 34
MWI$?BU\$':I6"RC<)?%\89006("RG%8BSV*H\/6J9 =(\:+]3PHH J?FT=2'
M,JA"F67#V]S1 &K>FA!V,<\U![YA9"6Y+>3V!<:E%V-<$4RO6\=9H!:G)@1]
M=I*#=8 \1].KR#52_]GG2[S**#O<$3JV+%37K#'YUN.O.E&*(<^5X6('80)4
MY$CHIEM^#H[)+1R1AR_&JQ5()2>K35M#<K1L,UZZQSO6\<>/J?OSS=7%.ON)
M@0#)H@O:LWQHAL>JOLG0."TGJ!"2-QS'KQE#@D!L>H>+]^9T.G&;V38'6A&)
M'C9SF/TBJ*Y.#9M>6$92_7Q%TIB26-HQ8Z<A-RS+NJ%3)Z*^/H)Y-4*'"TYV
MT=1%>>DYG)/6J9]X+/>/"(UQ_3&;,WWN04A">?%1A0JJ!C$Q<IX.4/]7E5C^
MT@M^H1>T@VZ>FR4$*9Z%"9XV*I+KP^E&"2S$,0AP 3C3]<NQ5E>M[^/T&REG
M!5HRK\Q_O(41]NFZS00@X%!^UJ1BU[\01NG!2_P9MG9TUD':3*,&Z69C.Q (
M9^]9USVT34\9)O?K!676P&W5%90UJ8)-5E-XQ6-AE[D3Y%GR_DA44CA"Z83&
MO+@5K?,+ 4@']7I^#^ HN Z)R1;L"7R:=8#P*\8*Q=>8O\+'>&FL0>IGG--+
M'\#>Y8(_8'TG7 GC)IUS&W<E3;+ES]07OT(,ZX=RO(GXFBQHI*VUK['\DQ^A
MX&_2!G;82)F[YPFU5XLE!3U&G",65AX@*4$/(H[OB"::3O@S4N=V1&=\W+1I
M[Z=8/,EU5:>XR8TW)_5M$;=B"VQ;@Q@KI/QB^0;LJ$PQ3#=8;@S)4JEK878_
M(E0Z#B(X9A;TI4FZG,9.OHHY[<H%&35K/E6J 5LMBI9/N*(3)2A-L.Q7/S,-
M5IK(D^EJGDLWJ7;8F':09M3'>VZ VML+OT,!7S%VR*S/C2F^.?Z*@YRG?67M
M^0P!XCN%?/+RXO[&F?)B1WT%8\N[9]53U4-*\K70E@!]?NJ8U%UL!KE*8CP\
M#<$C$GI*CE('E/YHQ05 =9*95'5\<8;-KIBLLE)/AT_[<1$242^C--%3_T>F
MCU\4$QXA?CK7+/ JV-74G([[ZG 5UP06D$5%HLYX+,43,VZ.I>B<N'UH3U->
M"=DU37P9;EK\N*GTW4>_BAO$-SUK2:A"I)0?$X?/:"#.MN0Q+\'!2<///[9I
M,,6N =][G,2& +%WE-H*F*>&NPTIWS,\F''O 2NY8]#19]3G^Z@DW? 5)@'!
M@G-OI?%+,B[>L>"4;O(FZ'S8V ^03QJH3#7]H,883EW( +Q!5!9(S8X3%R73
M"L.4LA7OOU:L'\^)?%9,_])J9J/GTY,!<\U%+<8#D^$77Y%)9A6S7//;#CVR
M#':82_S)U]H&U\BEXVG"?61$)N#>_:=*29SV0KP9NR39GO%W$7D+AIT9- VI
MDQ1JKY.!=5,LI7>;>6&RX^F3]!/+Y=61=ROB"F^C\R'J1&T6"" ,+-0#C>UT
MM&"Y\<0I>?/RZN?RO&D@*?S9$[NEIO W-<NDPLXC.KFI^$<;M7.IPLCR80>[
M[6>08>YKN5AY5+[+KWWT_"6> 5<3AE8_><*["-P3J3ORYU%&]L3PN'RD)2<.
M64NYTACFZR2$ G"C&,/?&\L@)N0CQTSC^;8KY6 J[QP*Q<QC;N&*;6=3#9!W
MF@!N0\HPKA*#J1V[TK5JW*]6^)]DR=X7?RR!1"<[.(YY7)VJ[HI0)F@DJ8/K
M UBZDK1U#K;Z-0Q3HNKY;O"4$6\Y=<JG3&*@.X.I!KQ(4N)PVPYM9!0]&0\T
M-24^-^^H<';D=4W0]REM.P(M^G"92*&?RP7+4^<A>=8XNYH"0871DLS1DG85
M8AO3J'7?^Q *[%(JM#0,,;^[Y"]B4G8+3,;G?3Z1MDF59_;Z5H'@]&0B%0K7
MC!QPPV*;-_]-UQTL$SI\:%5?&]E.&VF;Q]0LOE+N0;QM=>(NW>&T?6S%<>$E
MY\-#+/1M/[&?$TU4]+E"XXO+I&0WD>JH>P#%H/H>D-A\()7>NO? <8/H"OI4
MZ[;WM.AAF.\=KQBY?G,3@4:,KHX$>7,3"DTHPR=JJ=#G>'!M ,8;M?H1N=6M
M([H29WO0DXL]7<L<\<A&JG6< -%)6->RK0&1"D.3:RFC5(::3: ?$O)-53K6
M<*&UIV)*B3:IL''[M'(U,]%75[3^]Y'!8'A.O>F;IY[3M]B)6[?']O= ]_8]
M\)Y-YQ[(.-6[!UI8[H&+!0#<D^%N_W)<8Q&3YE5YY;6:,_-KG1XR7\OY#$I+
MHJ4Z.M)2L1]%.C4?LO>F=I#J<V:LE;OG8((#+E_4*\+]VOP<E+@'];U%)PZ-
M</3=UW1=M''%>,2>]W_]= \4[8MQ\_[6 (0R=37E?/C"<  )P*ONN0?:"4M\
M1R]+?9<([H$;NZ@+\;.R*TKND>O5I7L@8A39*!KET8DGM@Y32$(;2?*TLI[\
M6H1M3BVSL6VT=V,0]DW5CX+6W]#]8,(;>,-QU7I>=.$F:RL]],2G_%NW^2E<
MK\^UF]V(]V;EK\,A_7L+P8IC3<(Y>[Q*.5:)KJE9 AZU'+JZ(*?>XIX$,R"Y
M7-@K]%W"2@FZ1%VB#Z'D.'0GCP@B+_\R)'M+E%T9=6NJ_NLRIH)]ZM$#&-<2
MW16<^X'Q*C*4N[=:=ZY_ J,\L^YA#'[I\MB?S0?8AT/FX^]!"EVUO8$KF&TZ
M0([DAO+B$IM>4ETF 1:WANGX?WYS,=@0V=VX1Y4D(BJ8*PF\K/UA@H<=5/]&
M@GS%N1=$X=%7'/4O/OSNX+]LPV9;@"W8Y9K0%]/*TS:EY!OB78=-#'.;*<8!
M@K"23D7VMHYBH-V1I:<^) DCHGFMJE9&/8FH#PV@!YSUNM(Z;N7:AYETE<C
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M1)Z08^F7,*/Q VYLE";E[[.P63T(O_'\ZHOYR</?1A!PX]+$_!VGK+Z+BGM
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M0NAN:1ERA6,(IP^#/<U"!+_6MAL 1M5T)>W(JXS.@7!;-40*(.B"J)208V^
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MZ$CR5?P3(ZOP![ @Z1K8JV4M\$G0/1-/89-G"NFF1N500'00/>6/;Y-PO]T
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MM%[V)#S\J%F6KU$\0$HOQ!)Q7],P3>[NA3+JP%^44VBD43]AVG!(I"-6PY^
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M-([GV)2&\F,&9(LKBRM4GS>#,-J\DN0Q4G! 7V]Q.G1+VA3,:<B'\DU1<<Z
MW)GI[6GGZ;4D2O<Z$X<  YD(9;\?X(Q/Z*' <==HD.P(G2Z3_\OR$ >H]!<Y
M(LS7:CE'L',Q55FRQ>6:A5N*I?W3,L#,2#U?JOE9F8&%,&>BD:,@O<5> 8%
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MYO3LK5"2>)S35S\&Z^6'\:%%!7,N7-K#?..U#>,9-14EU2-Q'&,"+Q:+O4>
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MI$.YJH1<K[O&710^##K39"0B<_:=ZVD+*O.?(K.6W,?7T(S;7WE J00GBFZ
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MAD77K[%#7N4K3JP/=*]BGX@R?_[0X?E+GC\MVCS4C<JVE2]*V[@J(H7ON8-
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M6'>:M<+L89A&5E3@.*QK<RK])]3OG9JN0)'SOFB-WPBB)+BX5^?"82M+17B
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M7Y^ " !<&-_@!ZA)SQA(8QT2 _P;__CNW_0W_4U_T]_T-_U-_XN2E9=+$"3
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M5A[OMJ\1'FX8A?OG[.^P0$/-<%;/_-]Y3R0%N_G)K\U>,#:B"*#1IB'%C8[
M&3O>"[-#-_6(LY%0>;B2 )_RS/:CBK:#=7DE:0;F"6(XUEOI\*:+$!"T!W)5
MX-K2P;U8 \Z]>=':KBC40P"'TBZ)'6]S;='P_N CT1.JDL;J+S"8,=2.:!8
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M>ICT):DA.<+DUFZ:7Z3QG9Y@53#G_A+6O#G"-XDG8^ZI2A7_RJHXA0>W&$3
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M4Y$0WK*(=_D@\Z'@\2\*0]J'+77]JOWU!^WGX1/%4005:-T-? QS3.L5&^G
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MNU_S'R[SA4'PFF@P&[Y\LB>?/MVU-5',N$Z)YK4]K>3:=]UM-3$7GAV''4,
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M,@Y;245YF&2%28><ZI&3)BD<I&52T<Z=I3BU[I8J#4&^(H=P5L)'VE?OXYV
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MFL\=)MN3=/SN.CN\[B>$I<=74--FV&0CE45VR8G?N^ ^*D<1Z:^9BPRW/(5
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M!#B@Q]Y#>N-HZGUX50(5FW[5>-B758U3]C,__-+/+QXX'#RH@+5M:3LX$QL
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M"+#/O9=@D-?<,J'-[TX/GIJ*A1MB8KR/>BJZ6M[6,?^(!GIC6#4 '0SL"N#
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MI<@ "9EA8FCX<0G8$#DPGP#SXDM(V6;:UB^5B9DO).L;FE%A<$BYTU-&A4J
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M5!,;_(_Q:O+O.^O-]-7)AHWINM,DXQ_"58Q_I[9ADH+I3\@_X<]]H?E"963
M6LODP/(R/3,JN$E- VV)&'JPJM8T7C4[ISFQX<XPTJ" E;NY@9=)>YP.W$IF
MQQR6?)()N06H(_=XYVVI=7-+]IG:1@6#\&E7'9B$^K8_"[4@O<:[?Z #E'5!
M-JL-M;$4^GC*W$006OT&6+*7\<]:FRLQGI0/EHR3G30IN;_>!H*;]ZPQ%C%1
M!<$'D@IE\/82>--%<.F(M5^H /&S!_I,&0T^3&9QYM([YJ0R5?:20@598WG-
M-=,OQM6PLD7+_65%)7V5Q2[T;?*\WE5Z?Z*1^J2&P[49EJOVG?7Y#R51&9-1
M[ *M5\'6!T]4,UUBQ1[S\Z<&8V<5C/Z[3E0>8_@"Z+_G9?OR%B _!DGT;;0_
M6OJJ&3^SM&CB/7' &34I36&J8K1@;S%9,KP*/JN>.2OUJ%EK=]PB]+AC->OB
M/D%"/L2"PA>21H'4R<7,B5I]]/!-ML-RNZ +E](,561"=9Z-@V$WPB;^'1WY
M(C\&&QL5?7[#!3MF%P_;E*14T8R-T7!F7#MMI88;"$(N>C#\V41:VFXSZX#S
MF9<\_'6E^&">+;4DOUA]765E1)&U@67A%@8@ +8A'7_H=@%*+[(#G>);'SR5
MW(^1:S^]@(G]\)(:/[2CIA%CK4BK$V&?6PC^A&D_O-+K 5BS:P)YK\P5NV2\
M"="O2":N$FJR'1+Z>6$_\M;GRV*SC/J4G8NG8,,$=W9]L%P\9(8:&6FL!+L2
M*UV<,]\1+B\MYF ^^F:0L/&D#V^!M$ZH %RJD#EOLBON&N">5SFO5(,TEC7#
M_][6^7"P'9OVLS/&_HE^0F>96F%#OQ5W+5NH&4-5"5$POHM&CE>CQ/LC8"ZR
MH$N=J<L5J2PX:%6HTC0WX%AW/N/!>Z&);:H(V,S[YVMNUUNK**[BYA@N"8QN
M 5M*S2^;*L_\[]:0YX=;@,47\VL<6-'HGQ;(WT'!TIX_9\%DZ?Y1E?5])P^W
MJP20PDT;^=*%EI1S_)_"32<8\+&[5UJ#P_PEY4H_CQO)A'$_]T=[JE3"$Q^\
M_[T&7P.DU&*VR WS'<&*!X:_-BJE6_Z(+20287B5_FV'';/MZAGR2]<(TKC[
M0JF>VN:&$79PA208: MDWZ'Z6H[Q7?30%XBIA13I@0)7[*3)&B=*0"6"ZU'L
M4,;T)T);>C1NK4GE'%$>_BJT]#G;#>R8'9)@9&WW]"<(@P'RN1ZL=I&J(GP*
MRA;S1H"5Z/"[KQQ+Y3'F!#W\(B.HA>E*'FU8MITN>/-KPH6S)VCO^7[TP>K1
MC 3V6^,$)@:(GR]PACV3.+V):OG.HUQXGR59LOE?,66U6Z.8+WZYUFQL&$Q&
M#M4;_ES#'![KWS<RDT&"N]1N 9%AJ\1X-@F?>G,,F5U9CYQG/W4)G^#7/?3Q
MN*H9.SK=-MM4!$!&_#_30QJ-T2$\43?/\(' K?UD>$_'6">^@YSV)WP X&/O
MK][GJI+ZSU8R[GM]1 .)"N[<&LZ,C7ZR]UXW3#OVS0.!R*PV*RQ:C'8]P 5L
M7% 3^SXR>J4=[;1B SJT#]HH]A&!\Y12,)/WW/-W9W3J7XO5J':\!3Q>)?T\
MFD$8Z_5;7OE#_ZJ#@_+JU]8\3Y 3/1N2/![1^M":>CB+:U+$@[ 7SJ7>^"-$
M(CZ\Y<WZIP"_J()T:\Q85%F T"&IES/R<WX-1I-4=E:Z<7Z2M&&M (!4(OH9
M!:-EAJVZ6KO16<7E2YL6]L:?/0%Y!NX.&INL].IE/;\.+L?C4GUP-IKUP@$]
M*' PE^2'%>,%3*VZ^MKJ9EU#YBJ'GP!:80S&*-=EU&CR42OZ@P:6SZA^%P/Z
M$?8M@*H,E.W+82/^H>5+]LRVJW%0=623Z^BAF,0C^5*-4D!91@OGECF5]),P
M9RMD6KCU64/ B U+\[P:\P\1#HH%OAORD07:] 7.K0%VS+YJ<*@9-U*D?6E?
MALSZPC0CS&P;)+@O3&(F8E)(A<]$XAHL*7*N3.;311W2/9&)]GR#[$G*;=XU
MLI]R[N_3VN35!LQW8K@S^!0=3C=^.<3?@F>$V@DUR_?;"Q&*&8*88V9*)!J^
M)LTU%@Q%(,40U868G5<2R,V>&UYTC,6J3'C/^. E)]#0)L&>$EMOOIG*%Z/%
M[H#Y*[:<%J3VS!IY/115^<-&Q&AAHY)_2*JYT52VB'D_%H.5[^A :L9QJ=D3
M^AACQ9SX\V-(W,IAYURSN;P?=A3XW:-FZ-K6&8HQ14)I$9<=6X])JENQ$**/
MN 5T"P6HH/8\P,%59/%FV\_3# _N'3W BD[W5@$<!_AR+A9F$N.C-_Q!/!T^
M^)*\_F(NSQ!:),=K<UW"I<HF5ALCUP)"^QZ@0&J]>)L"./><IXHV3N*8KKS?
M;[RV*K1/+OQ*H0F5^W-A80?&&\IT^2)\#)X)>,>")[Q)NY9>,+E9^"\+?F'T
M0 X[TDE;*[WUNVIF^/I)J31)#G2#)P$NS"@_F)!&IR/:4 A-\PJ9=QH_-I+H
M)!60&1U]*+(PY&S&-U;JLD2H;E70Q+<0QI2,R\IF*R[ZP3):7EQ7G<2<0LW)
M'IX*9YX._'RZ3S<HC*W;UVL$V/F#B1_7"\H\--AVNR&;.)E*[CBSH:=3^97U
MUI#!\\&K V:2F=["TAZX1+'AA'K4E%$'C>*;.BL&@2CA^),V;*$"18![9(B_
M/=A+RU)H.M"Y3O RHTJPU8ZD:T\<1T>&D:U4%E'C<HA6!5M,5NDBKYN[]#M4
M$)-Z[PU6E2@?*,KP,4D%N59I/F"YSC& D&^,K?$+4GMF.5T9R N88+='XQIH
M(#<5IHP0UU:=TI.-CO1N&<O#?/MF<?_%_.!_FD^@/4/.YP]^C]7%EC"5H[JR
M?<F.V?.9S4NJO!9X;:Z.3$AS ;-F/%5_^D-IM#_U=].IZ$FI0N<-^S$X=L)\
MJLJ@Y.20^#LT?+[+2.DK"#]F*GA16<O\)7^P=@D&=B$3]"V0'A.9W^I(>S$2
M<G+9;VE:>-2&BUG*CAF'!(=)ZA:C/XY5@61>DH^RUVI4S?.ZL@O'^9V4)LJB
MWM2*ORYR0K#O[S&HQ8^OKWZRQ%!RN^>^;>;$ULFE\S*^=846>1H$72_-!S\_
MQ5FCPJ&,H=+VL S_7+322FOD)8HRG:[X8?0"_#39!O2NFL $M/D5TI=)=-W"
M K%@XI<Z_H$1NT$!(#99S7-Y.!#7$=O1OAJCP(G9CMT,L2]&8=G S?+R;9/3
M\BN +KD_Y_JM[$.UM>O@\S KBU5W4!/3/;:0TR#(7AL1X_+#-&O,T<(R"F1J
M30-B^^RBIG$57V)NURWM?9RF-<*[X&M+FJ*SN')$Z<E2,+7Z;+R0E))G<+6.
MBS0^ ]\DA7WS8R=9^FA%]\7:U7UP!W+.%.(_H1P^;A/H'GZ2:)'^TE^LVT6/
MGA=Y5N25X/&Y#"@UZ*_'_)7<SJ4MD_#'WQ2L<"[.&-GJ0<$^(+HN;M[^I\$/
M*D]N ?@V'G909MZJJ#?92:DMW5*Z3J.>>#/9OI).O3+$AWMEK"WC/-4*%H)J
MI.VV(E76Q,^B\OA&/6"\W'.&P%VH_##A:_:5FY'QE1#;?GL,A ;;(8&+I/Z8
M;E@A1%EUDD=Z=ET*.D;IOF\\Z$8?&)7M*Y9!@.X9Z%%;D$J^\92PI)[K [U_
MAVN>)NZ#>^/2>@O [8F[!4@>W@*0>!I(: J=-$R]2@W(KL<>EUUX;=LSMB7#
M 3@NDK0 EBZI;>S47IAFFWBG8]!5<I^M;E@Q16DLG)4&J*&>NX[NZ%UT[VFK
MYHN( /PVGU!A8_IZODO41^8LJCHX[Q9"$8V@<^'C.=P<UQLT=M:-"Y8,X95D
M\JN:.$-%P<IGQ]Q4G]_UUIWT6LCBDS>6J>-.6E1/K%7 F87[.6G\&$PR5H8E
M]%4_N!->1X@D0!NH1E4B=W#ZRB1],!?#$A8'ADZVN^2Q)^W K[3Z&8K9M!<7
MI'8]EE:NFZ'^1NVENT6TCGNZQF=XHB>9^'&08M+^,SKNHXMI<DZA24:0MO@R
MO3']5"7($^S^/M'UJ+AMM]Z$GL_, @3\ 5&9A<^:[(PO&AU$S)FXQQF;/J'4
MT\X,%-N,TUG<_LPST?04-2R(PJI]A]A@GST*'<;GP3SP@]%5RM*M)X:>>+_<
MAY:XT+AOF*2%+L=BFWA,?WV[Y!QP4D:-<@MU$:JMG9A3KXYA_JH*<LM]%=C
MSER(%6SN8S=E*F/:K+8@<O/(L]*R:(?43EPP9H-%5MKJHY3JZ7DFL4-V?30^
MY"?H+4M+L76-6RPVWV]P@YBK\#3< ^D(FV[P +#G-Y9H5?:U:RD9AK7=JZ^7
M],R>&Z%L<H>"\GVX.>M7GSV.W-, ?_Z&,:&EU>Y(.(DK5%7T_#5_:02.Q9ZB
MZC_<]/<7P7K_Z,X5(,QIKC@M\R!*TS>+B M5<X.:@2'7@]3ZD8'7G'/ _U 9
M]F<CU^GUII+BPLS/;F($$&=6;<Z_J$-3ZG9$Z2PT#Z-#45QK!-\"]M[>_72V
M\%[&%>/#NV?T(\!7-/W*?WMC^N$Q1O\MH .#^)K@CW:W[4W??/[F)GY:[PZ3
MAU8U"QA/.'^9*^.^!;SAQQ=]8==CSN4FP_BP#ELR1I9R">FK< M08 MK18)9
M&/[V!@1<?#)^Q9<GG%=JZITP9FK)4Y&:8!F$\8;DDX:%T9M_/+26+.T_\>(Z
M+/&,0>OQ_KW4"1^E?->2 >NM*X"0FV -4I_EQ9<R?W-=OPQ^+!)Q1?.AK-JO
MW'AHG='&JX/,]!N)@_C^R.O3.[[/=H=<L61.^"$IMX '1WJ$T?Y/?<)A-1ES
M-T\PG U8CO7??%5QDNRTL6^$]-'G7L#R_CZ#C75G'<H8;P%9*=TR:-&$:+3^
M5Y_1(43&%:V:Z1U9[;O[CJ: FV#PXUO ,L)(9L5,[DZ#(N$^2$<NETE-;*9;
M -X1\055D\XM("#,^A80Y(Y]3;#X[.Y#NZIA=VJ*ON+LD]GZB-*X(6+)N2%;
M8S@1@!3< K!)8'>,[9/,_S_V/SLVD*+'##,8UM9PVH:B"&/ALZDE(C$U4E+J
M>N70=HI=5Z;R=^$OS?M+Q 00*S7,ZE33USZ^>I%6Z#]%O_X:\\&.+#D$7W$)
M4CM8@?F%DP5%;2R("$*E!M;T,R"\0@=95@]"++RMSNC,W-\+M-VYB(@ZW&/O
MO50'@?%F9>,@JW%65:%G@MUMK#O/R @@8CN0[D_T="C[2D<$^TE>I,NU#+-J
M\9R2A<%K40)HIT]3[I^C3P_<0GW6#"=O ;OCYM=8,!:D\HW*6<@MP&3N3@]"
MT^B0&\4TC9MFEKOW5?]DCN6S%FWM<SK4>B(@2W?Z_V;>_A FCH9X!RJ5=JSW
MU$;L]\HGGBNK<=[Q-[O$*PX;"U7H(L5E5!Z1Z'*$SE8FL60C6J9@"2X'=(/N
M_)R;L^J+S&=HP#K!PBN"7C&/[7GQ6 )7]JDY^_<.2)0N7^0*#N ^Q[<J&OHC
MT'-L'NXE4F8 *>V8[\[?\@#M3\+(M[TYOD.'^SH)?SD.M\F>LF8@RD)1&MFS
M7\08-1X:"K5Y1O)9=D2V*Y2..]S!2?$+UD.-RLE'VC?C^'DZ7RM?T&*BPP>F
MFFBR;1NX-M+.*+G(#YA(U8!XS.'$69AP7\D=-\,3TX_J$EV+O+63SH,:5;_U
M$QDQ>[%IW,GF=M*9IYY;CNZ=#.(<EE4SLYV/_[9MU'%D]@5F3-_@&T"B=O>I
M%UN+YX?60[_\GL-]M6DSYZL\_>..!GU,_%!H0R'.$&)T@^_#Q_WDTOE'U^..
MU(33DTS"I!O&Q2VSIQ."2Q1&-@T>M@0[/Y4]FW/@03_;_'P=(RZ2=TY&'EE?
M_"HCCR\R-NT+<&+6?L#H@6AYBV*I#9<4*NE]7C$S.YC3\3%@/XZSKV] $Z,I
MK<O^2ARFE6\[?7XQ-5RP GX\/^1DF>->>Y\I4M9[^XB6'<OEJA!S*YE3$"BL
MY_$A]Z+ZNCHKG>6M5;PE@0K6*FN&59D-=>"-8G#Q!Q=N@?5.AZB9TS9!C,__
M67+.'_,9 3\Q%OV)EBSEN?3C,7N+9.'R< &114C/-/8D_=3FQ4A'8['G2/7,
MT#7T7L\[@]*>[4R-B_>S@)AA?F6CTW!VS*$KJ>5(T\]]O9I-$US/'\4.X[HV
MY3C^_O(VYB)YVV>%;NH6L/6Q\1;0"C2ENR-9P$62Z<,JFD:(I*(39\-;I2V
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M:[6MY]!^/MKE>UKNV%1EEE."=)Q&?S10+.$ZN"K9$U"BL?= 9)<C6T+R%KY
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MD6=+IIPEH/0OMRIY%WFF.W%<[6#U1:E$V>29H*"RTWL';XL\<:Q,?,4OC3<
M'CC1Q_K\NO<&4/(1V._Y(&;W(.ZQ<9STG:9[_V%>AQJ6>U67G+M)[CX69A1I
M4&OA=/<K];#TH#L_Q/L6DJDMMU]0</F=6@.WFH8MV;%X3*5R<<1V Q#+7W+>
M )A^(U:2!]\S+I5=/_Q6=/ _?(J6 #VA-P=]C\WLQN2(KD0D&@=; MLCMD_O
MHQLWNX[*G_^)^;I[^\A;@[FO@\)O -];8 C[51)0N-1^CL=VA4RZ <++FB*
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MR9D @9]G"35C?<[QVK/Q'I<B>.QK?UU7V[]Z_,&ZE6YW(!8O$S*(_&;8=VX
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M^Z@ET+_ZZDQZU7,$,^>5%MW=B6,NM<ZZ([#.H,L%FD743*2Q_51\B(29"@7
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M8=E^MG<#]-:)<2]1X^/8D.OD@(CU%N:?5HA5G<SD,X TI.B\3F,CZ(\&9&^
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M>0.R/_V/?_]O_^U?_P\ _M>K3^^"UTN^>92+=7"WDG0M1? ]7W\-_BYD\8]
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M5G^^77Q>+_D_OB[G0G^W]__<Y.OG3\OY_,UR]9VNQ"Q.PA#KM0PHE84 4R(
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MW3T.9"%160@!IQ(#K-<2D+&, QA3C"+,$696O@V]>I_:,O'Y_BYH1O8F"",
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M,@?OVO!T)G 'A#PQKDV/HU*D P3'G.;RJOL&^LXD.ET]?Y(/QB6614JH3&2
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MMP+&VS+?WMO(R[V5ZJ?+OMUK/?+I_)V:78JY&OID-AC%.>L5)B22C&*@(I0
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MNRL_\(2\;=?8>94]5-#3LEHW.NHZ>JC(\<)Y]%L?X4:.]53.OSRA+^LD3&:
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M?EPMO^5"BE?/OQ4F-=X;O6-:\'SQ<,O7^;<JKT^*N9")4D#JR0XPE@A0%E&
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M54E]4\+:D]":^_"C]+.?I+DVT?*:P'43.KJA<TT,C^&,0Q@B4OHO1LH$AE/
M$DB!E)A3$D4T54Y;GQ?086I+T9X*>QFNFZSIJT:-@._T"+1<C\%/SY*N7 _
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MR1TQ3\3ET/&HQ.4.R#%Q]6BA'W']5L@/ZKY8YX_FQ'\F(:*)PAE RH3R4X4
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M5M6J67_+YZ!#X6G)'4;&49?I06$^7MJ'[:SO9>\WN=CH;6_*9<:B, 5ARD*
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M@2?S^GP?HYJZK6H>FYWM#_>;[]L\#N],7H<F7O?YO1:_3F_)(!-9"@G@BD&
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M3PV_*EOEEG*;1$FX]0'3F$D7?NV0,356;=4$M9[ *@HJ3=THH0O.;B(-!-+
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M)\-A1^/O/]G1\&1QG^%P8_:!WO*!V;Y%M%4;[.D-]F)J9VW(F5$_W"S0 [-
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MSD"EIF7>FLP#DN\5*$(QY24QX]+:%6-/..C:]?T(H]Y@W-MP;#OY*DE)BJ6
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M.<]1C"G),DB1[>B2Q0H2K@5D3&H<)9JPW.M([8*<J2U$C@J @C^LIJ!2U?,
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M_/HE^"R^*OEHJYS&"8SH#&SM 5N#9J UJ/J6*I/\UJL^ ^2V:AT(]J$WZF]
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MR;X5F[IXP0S</=BBT^ /:QNHC//<N0H]]&X,_XP#.C3C=\?YAQI+;\H?"/%
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M$*ZF6G9>/%YJ99_^1ZF4O1_V7$TU+3[KUBAM'T@E,PJS0@$J8 $0XQD@%"'
M<HZ$8FE,L7):0IV)F!KK-6UF;^RP>0%)RS733?@,O5!RA,9]>=1I?:@UT;F
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MJLH=L%"!L/:"QPUE=0;D+!C5_0Y^Y/73IIR+<O'4;EZE7!*2<PKB6)FU1:Y
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MY4<^$G^)@3D_9'\1+3P.$;R#D'XQNSW5-A.E_NFUUFBW0)OQ-!48DQA %#.
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M\+]^>__FEQ>+='Z&\_4OSY<8UIA_^7.Z_OS+/S*N_OE+62[.?OG'8OG/Z=<
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M2\QOMEJYE[D-9VLRI;CYS18:?S:?GX?9>_RR6*XGWAA?BK+ 4R0;Z)V!Z(L
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M_#Z=?_KW,#O'24S!"N5JUX)2'6RO( C%@>>HE8[H>7FH#/,8[!Q$6 ]8.@D
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MQMYO3K)FJB"%6T;G0(>!MQ L><<NV%2L%]K?+$4]&;<#L#%N,#W8-<C8"N_
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M[X'PX#)7X'?6HPDVD*ON:I\DB1 "DU"P*!]+L8:UGNMQ*&WC&J A,'2[,<(
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MO2M[8T*HS8 D9,.)(>$2>#HOH#BFI;4)9?.+U!\2->[HK('0V%8576!KA41
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MIN[>&2))FZPW8)1QH *=^$[7TCO!?.%).>-;Y^L.I>TPA/UT5PQ#:*8#Q'W
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M6+H,'HL'4X(.1=$VP=8U5#^FJI_"SB-5OQA4#X]'EM\B:XZ?ZIH?VR3[]FI
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MSMCG./<Q=CE0HQ9\G^0?U;:6$ZT]B[S04FUS;4Q%WSD>,G 74>L0C#>W(/?
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MV )PS374#_JN1'>+&Y3.8G3D8(3: M!Z!=&A ^^92TR0V'+S<[!'*>K7-6N
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M9GDR,BYH=&U02P$"% ,4    " #D16=6$/Y_D?@"  "_"0  $@
M    @ 'N @  97AH:6)I=#(Q,7$T,C(N:'1M4$L! A0#%     @ Y$5G5LC
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M:70S,C)Q-#(R+FAT;5!+ 0(4 Q0    ( .1%9U;82^/=BVH# &E1&P 1
M          "  0<A  !V<FYA+3(P,C(Q,C,Q+FAT;5!+ 0(4 Q0    ( .1%
M9U9C% 9VM@\  %JG   1              "  <&+ P!V<FYA+3(P,C(Q,C,Q
M+GAS9%!+ 0(4 Q0    ( .1%9U9W%2-@%QT  $0: 0 5              "
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M '9R;F$M,C R,C$R,S%?9S$S+FIP9U!+ 0(4 Q0    ( .1%9U:?#YGYH\<
M *14 0 5              "  9*1"@!V<FYA+3(P,C(Q,C,Q7V<Q-"YJ<&=0
M2P$"% ,4    " #D16=6 ,475!I" 0"[C0$ %               @ %H60L
M=G)N82TR,#(R,3(S,5]G,BYJ<&=02P$"% ,4    " #D16=6.#/MC/)D 0"?
MOP$ %               @ &TFPP =G)N82TR,#(R,3(S,5]G,RYJ<&=02P$"
M% ,4    " #D16=6/Y) ^C[= 0!A60( %               @ '8  X =G)N
M82TR,#(R,3(S,5]G-"YJ<&=02P$"% ,4    " #D16=6'<.V"#Y8 0 %I@$
M%               @ %(W@\ =G)N82TR,#(R,3(S,5]G-2YJ<&=02P$"% ,4
M    " #D16=6:)6^6;\[ 0!^J0$ %               @ &X-A$ =G)N82TR
M,#(R,3(S,5]G-BYJ<&=02P$"% ,4    " #D16=6=ZO"5FW8  !4( $ %
M            @ &I<A( =G)N82TR,#(R,3(S,5]G-RYJ<&=02P$"% ,4
M" #D16=6J$B4IZ-? 0 FS0$ %               @ %(2Q, =G)N82TR,#(R
M,3(S,5]G."YJ<&=02P$"% ,4    " #D16=6BUND3Q(@ 0! <P$ %
M        @ $=JQ0 =G)N82TR,#(R,3(S,5]G.2YJ<&=02P$"% ,4    " #D
M16=6E;'#+OO4  !:#@D %0              @ %ARQ4 =G)N82TR,#(R,3(S
M,5]L86(N>&UL4$L! A0#%     @ Y$5G5G.K6F!5?   ZH@% !4
M     ( !CZ 6 '9R;F$M,C R,C$R,S%?<')E+GAM;%!+!08     &@ : *\&
(   7'1<    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
